Prophylaxis of disease caused by bacterial pathogens of man by TITBALL, RICHARD WILLIAM
Prophylaxis of disease caused by bacterial pathogens of man 
Richard William TITBALL, BSc, PhD 
Submission for the degree of DSc 




-UNIVERSITY OF PLYMOUTH 
Item No. Gf n-oS o oo ?-S'i-
Date 2 4 JAN 2002 
Class No. T 516 . 165 111 
Cont. No. X7-o 4-3 & 7 6o/ 
PLYMOUTI-I LIBRARY 
Prophylaxis of disease caused by bacterial pathogens of man 
Richard William TITBALL, BSc, PhD 
Submission for the degree of DSc 
List of contents 
Summary 
Declaration 
List of publications included 
Clostridial toxins 
C. perfringens toxins. 
C. botulinum toxins 
Francisella tularensis. 
Antibiotic prophylaxis and therapy. 
Approaches to a new vaccine 
Yersinia pestis 
Antibiotic prophylaxis and therapy. 
Existing vaccines 
A new sub-unit vaccine against plague. 
Orally and intranasally delivered sub-unit vaccine. 
Live attenuated mutants as vaccines. 
The search for new virulence determinants which might be exploi 
to devise new anti microbials or vaccines. 
Burkholderia pseudomallei 
Antibiotic prophylaxis and therapy. 
Approaches to a new vaccine 
Contribution of the author to published works 
Prophylaxis of disease caused by bacterial pathogens of man 
Richard William TITBALL, BSc, PhD 
Summary 
This thesis reports research undertaken which will lead to improved pretreatments 
and therapies for disease caused by Clostridium perfringens, Francisel/a 
tularensis, Yersinia pestis and Burkholderia pseudomallei. 
C. perfringens is thought to be the most widely distributed bacterial pathogen and 
is the most important Clostridial species associated with enteric disease in 
domesticated animals. During warfare C. perfringens has been a significant 
causes of mortality. Between 1 and 1 0% of wounded personnel developed gas 
gangrene during the 1st and 2nd world wars. The ability of the bacterium to cause a 
range of diseases is due largely to the differential production of toxins. The first 
reported cloning and nucleotide sequencing of three of the four major toxins (a, ~ 
and £-toxins) is documented in this thesis. The regulation of expression of a-toxin 
in C. perfringens has been investigated and methods for the expression of 
recombinant proteins in E. coli have been devised This information has been used 
to develop improved PCR-based diagnostic tests, and to investigate structure-
function relationships. A high resolution crystal structure of a-toxin (phospholipase 
C) is reported. Using molecular and biophysical techniques, the functions of the 
two domains of the protein have been determined. Residues that play roles in the 
interaction of the toxin with host cell membranes have been identified using site-
directed mutagenesis. This work has also provided a major insight into the 
structures and functions of related phospholipases C (the zinc-
metallophospholipases C) from other bacterial pathogens. This pioneering work 
with a-toxin is recognised by invitations to write reviews and book chapters on this 
subject and on bacterial phospholipases C. C. perfringens ~-toxin has been shown 
to be related to pore forming toxins such as Staphylococcus aureus a-toxin. This 
finding suggests, for the first time, the mode of action of 13-toxin. The interaction of 
C. perfringens E-toxin with host cells has been investigated and progress made in 
identifying the cell-surface receptor for the toxin. Genetically engineered toxoids 
have been devised which induce high-level protection against a and E-toxins. 
These vaccines are currently being developed by industry for veterinary use. 
Similar approaches have been used to devise a recombinant vaccine against 
Clostridium botulinum toxin F. The wider applications of toxins as therapeutics 
have also been investigated, and a novel cancer drug delivery system based on 
targeted lysis of drug-containing liposomes by a-toxin has been devised and 
patented. 
F. tu/arensis is the etiological agent of tularemia, a disease of man that is found in 
most countries in the Northern hemisphere and most frequently in Scandinavia, N. 
America, Japan and N. Russia. In this thesis the efficacy of antibiotics for the 
prevention and treatment of experimental tularemia is documented. Two surface 
antigens (lipopolysaccharide and FopA) have been evaluated as sub-unit 
vaccines. Of these, lipopolysaccharide shows potential as a protective antigen. 
However, because of the paucity of information available on this bacterium, a 
wider approach to vaccine development, involving the determination of the 
genome sequence of a fully virulent strain of F. tularensis has been undertaken. A 
preliminary analysis of the genome sequence is reported here, which has allowed 
the identification of targets for the development of a rationally attenuated mutant 
for use as a live vaccine. 
Y. pestis is generally recognised to have caused three major pandemics of 
disease, and credible estimates indicate that together these resulted in 200 
million deaths. WHO figures indicate that there is a continuing public health 
problem from plague, especially in Africa, Asia and South America. In this thesis 
existing vaccines and antibiotics have been evaluated for the prevention and 
treatment of plague and found to have limitations. A number of approaches to the 
development of an improved vaccine have been investigated including rationally 
attenuated strains of the bacterium and isolated surface antigens. A sub-unit 
vaccine against plague has been devised based on recombinant forms of the F1-
and V-antigens. This vaccine provides high level protection against both bubonic 
and pneumonic plague. This recombinant sub-unit vaccine has been patented 
and is currently in phase I clinical trials in man. This vaccine has been formulated 
for single oral or intranasal delivery, using microencapsulated or Salmonella-
based delivery systems. Methods for enhancing the stability and efficacy of these 
vaccines have been investigated. Reviews on plague and plague vaccines have 
been written, confirming the status of the author as a world leader in this field. The 
work to devise an improved vaccine has also provided insight into the molecular 
basis of pathogencity of Y. pestis. A phoP I phoQ regulatory system has been 
discovered in the bacterium, which plays a key role in survival of the bacterium 
within macrophages. The V-antigen has been shown to be surface located to 
play a key role in the translocation of effector proteins into host cells. The 
biogenesis of the F1-capsular antigen has been investigated at a genetic and 
biophysical level. In order to underpin future work with this pathogen, the genome 
sequence is currently being determined. This work has already provided major 
new in sights into the evolution of this pathogen. 
B. pseudomallei (formerly Pseudomonas pseudomal/e1) is found primarily in S. E. 
Asia, N. Australia and other tropical areas of the world. Melioidosis has recently 
appeared in temperate zones, including mainland France and the UK possible as 
a consequence of increased international travel. Acute disease can be treated 
with antibiotics but the bacterium can persist in the host and subsequent disease 
episodes can occur. In this thesis ciprofloxacin and doxycyline have been are 
evaluated and shown to have significant limitations for the treatment of 
melioidodis. In the longer term there is a requirement for an effective vaccine 
against melioidosis, and work is reported here to devise the genetic tools which 
will be necessary for the genetic manipulation of the bacterium, with a view 
towards the identification of virulence determinants. 
Declaration 
I declare that; 
a) I am the author of this thesis and the publications submitted. 
b) The work reported in this thesis has been carried out by myself. 
c) none of the work reported in this thesis has previously been submitted for a higher 
degree . 
..... ~~c(A./ .... ~··········· ··· ?~(!'~ ciZoo) 
Richard W. Titball, BSc PhD date 
List of Publications included 
Clostridial toxins. 
C. perfringens toxins. 
1. Titbaii,R.W., Hunter,S.E.C., Martin,K.L. , Morris,B.C., Shuttleworth,A.D., 
Rubidge,T. , Anderson,D.W., and Kelly,D.C. (1989). Molecular cloning and 
nucleotide sequence of the alpha toxin (phospholipase C) of Clostridium 
perfringens. Infect. lmmun., 57:367-376. 
2. Bullifent,H.L. , Moir,A. and Titbaii,R.W. (1995) The construction of a reporter 
system and use for the investigation of Clostridium perfringens gene 
expression. FEMS Microbial Letts., 131 :99-105. 
3. Bullifent,H.L. , Moir,A. Awad,M.M., Scott,P.T. , Rood,J.I. and Titbaii,R.W. (1996) 
The level of expression of a-toxin by different strains of Clostridium perfringens 
is dependent on differences in promoter structure and genetic background. 
Anaerobe, 2:365-371 . 
4. Titbaii,R.W., Yeoman,Y. and Hunter,S.E.C. (1993) Gene cloning and 
organisation of the alpha-toxin of Clostridium perfringens. p211-226. In; 
Genetics and Molecular Biology of Anaerobes, Sebald,M (ed.) Springer-Verlag 
Inc., NewYork. 
5. Titbaii,R.W., Leslie,D.L., Harvey,S. and Kelly,D.C. (1991) Hemolytic and 
sphingomyelinase activities of Clostridium perfringens alpha-toxin are 
dependent on a domain homologous to that of an enzyme from the human 
arachidonic acid pathway. Infect. lmmun. , 59:1872-1874. 
6. Titbaii,R.W., Fearn,A.M. and Williamson,E.D. (1993) Biochemical and 
Immunological properties of the C-terminal domain of the alpha-toxin of 
Clostridium perfringens. FEMS Microbial. Letts., 110:45-50. 
7. Basak,A.K., Stuart,D.I., Nikura,T. , Bishop,D.H.L. , Kelly,D.C. , Fearn,A. and 
Titbaii,R.W. (1994) Purification, crystallisation and preliminary X-ray diffraction 
studies of alpha-toxin of Clostridium perfringens. J. Mol. Bioi. , 244:648-650. 
8. Ginter,A., Williamson,E.D., Dessy,F. , Coppe,P., Bullifent,H., Howells,A and 
Titbaii,R.W. (1996) Molecular variation between the a-toxins from the type 
strain (NCTC8237) and clinical isolates of Clostridium perfringens associated 
with disease in man and animals. Microbiology, 142:191-198. 
9. Basak,A.K., Howells,A., Eaton,J.T., Moss,D.S., Naylor,C.E., Miller,J and 
Titbaii,R.W. (1998) Crystallisation and preliminary X-ray diffraction studies of 
a-toxin from two different strains (NCTC8237 & CER89L43) of Clostridium 
perfringens. Acta. Cryst., 054:1425-1428. 
10. Naylor,C.E., Eaton,J.T., Howells,A., Justin,N., Moss,D.S., Titbaii,R.W. and 
Basak,A. K. ( 1998). Structure of the key toxin in gas gangrene. Nature Struct. 
Bioi., 5:738-746. 
11. Naylor,C.E., Jepson,M., Crane,D.T., Titbaii,R.W., Miller, J., Basak,A.K. and 
Bolgiano,B (1999) Characterisation of the calcium-binding C-terminal domain 
of Clostridium perfringens alpha-toxin. J. Mol. Bioi., 294:757-770. 
12. Titbaii,R.W., Naylor,C.E. , Miller,J., Moss,D.S. and Basak,A.K. (2000) 
Opening of the active site of Clostridium perfringens a-toxin may be triggered 
by membrane binding. lnt. J. Med. Microbial., 290: 357-361 . 
13.Jepson,M., Howells,A. , Bullifent,H.L. , Bolgiano,B., Crane,D., Miller,J., 
Holley,J., Jayasekera,P. and Titbaii,R.W. (1999) Differences in the carboxy-
terminal (putative phospholipid binding) domains of the Clostridium 
perfringens and Clostridium bifermentans phospholipases C influence the 
haemolytic and lethal properties of these enzymes. Infect. lmmun., 67:3297-
3301 . 
14. Flores-Diaz,M. Alape-Gir6n,A. , Titbaii,R.W., Moos, N. , Guillouard,l. , Cole,S., 
Howells,A,M., von Eichei-Streiber,C., Florin,l. and Thelestam.M. (1998) UDP-
Giucose deficiency causes hypersensitivity to the cytotoxic effect of Clostridium 
perfringens phospholipase C. J. Bioi. Chem., 273:24433-24438. 
15. Titbaii,R.W. and Rubidge,T. (1990). The role of histidine residues in the alpha 
toxin of Clostridium perfringens. FEMS Microbial. Letts., 68:261-266. 
16. Alape-Gir6n,A. , Flores-Di az,M., Guillouard,l. , Naylor,C.E. , Titbaii,R.W., 
Rucavado,A., Lomonte,B., Basak,A.K. , Gutierrez,J.M., Cole,S.T. and 
Thelestam, M. (2000) Identification of residues critical for toxicity in 
Clostridium perfringens phospholipase C, the key toxin in gas gangrene. Eur. 
J. Biochem., 267: 5191 -5197. 
·17. Walker, N., Holley,J., Naylor,C.E. , Flores-Diaz,M. , Alape-Giron,A., Carter, G., 
Carr,F.J., Thelestam,M., Keyte,M., Moss,D.S., Basak,A.K. , Miller,J. and 
Titbaii,R.W. (2000) Identification of residues in the carboxy-terminal domain 
of Clostridium perfringens a-toxin (phospholipase C) which are required for its 
biological activities. Arch. Biochem. Biophys., 384:24-30. 
18. Logan,A.J., Williamson,E.D., Titbaii,R.W., Percivai,D.A. , Shuttleworth,A.D., 
Conlan,J.W. and Kelly,D.C. (1991). Epitope mapping of the alpha-toxin of 
Clostridium perfringens. Infect. lmmun., 59:4338-4342. 
19. Tempest,P.R. , White,P., Williamson,E.D. , Titbaii,R.W., Kelly,D.C., 
Kemp,G.J.L. , Gray,P.M.D., Forster,S.J., Carr,F.J. and Harris,W.J. (1994). 
Efficient generation of a reshaped human mAb specific for the a-toxin of 
Clostridium perfringens. Protein Engineering, 7:1501-1507. 
20. Williamson,E.D. and Titbaii,R.W. (1993). A genetically engineered vaccine 
against the alpha-toxin of Clostridium perfringens protects mice against 
experimental gas gangrene. Vaccine, 11:1253-1258. 
21. Bennett,A.M, Lescott,T., Phillpotts,R.J., Mackett,M and Titbaii,R.W. (1999) 
Recombinant vaccinia viruses protect against Clostridium perfringens alpha-
toxin. Viral. lmmunol., 12:97-105. 
22. Titbaii,R.W. and Williamson,E.D. (1993) Clostridium perfringens vaccines. 
International patent publication number WO 93/23543. 
23. Carter, G., White,P., Fernie,M., King,S., McLean,G., Titbaii,R. and Carr, F.J. 
(1998) Enhanced antitumour effect of liposomal daunorubicin using antibody-
phospholipase C conjugates or fusion protein. lnt. J. Oncol., 13:819-825. 
24. Titbaii,R.W. and Carr,F.J. (1996) Pharmaceuticals and assays using enzyme 
subunits. International patent publication number WO 96/25952. 
25. Titbaii,R.W. (1997) Clostridial Phospholipases. p223-242. In; The Clostridia: 
Molecular Biology and Pathogenesis. J.I.Rood, B.A.McCiane, J.G.Songer and 
R.W.Titball (eds.) Academic Press, London. 
26. Titbaii,R.W., Naylor,C.E. and Basak,A.K. (1999) The Clostridium perfringens 
a-toxin. Anaerobe, 5:51-64. 
27. Jepson,M. and Titbaii,R.W. (2000) Structure and function of Clostridial 
phospholipases. Microbes and Infection, 2:1277-1284. 
28. Titbaii,R.W. (1993). Bacterial phospholipases C. Microbiol. Revs., 57:347-366. 
29. Titbaii,R.W. (1998) Bacterial Phospholipases. J. Appl. Microbiol., 84: 127S-
137S. 
30. Titbaii,R.W. (1999) Membrane-damaging and cytotoxic phospholipases. In. 
The Comprehensive Sourcebook of Bacterial Protein Toxins, Alouf,J.E. And 
Freer,J.H. (eds.). Academic Press, London. pp310-329. 
31 . Titbaii,R.W. and Rood,J.I. (2000) Bacterial phospholipases. In: Handbook of 
Experimental Pharmacology: Bacterial Protein Toxins, Aktories,K and Just,l. 
(eds.). Springer Verlag, 529-556. 
32. Hunter,S.E.C. , Clarke,I.N. and Titbaii,R.W. (1992). Cloning and nucleotide 
sequencing of the Clostridium perfringens epsilon toxin gene and its expression 
in Escherichia coli. Infect. lmmun., 60:102-110. 
33. Havard,H.L, Hunter,S.E.C. and Titbaii,R.W. (1992) Comparison of the 
nucleotide sequence, and development of a PCR test for the epsilon toxin gene 
of Clostridium perfringens type Band type D. FEMS Microbial. Letts., 97:77-82. 
34. Payne,D.L. , Williamson,E.D. and Titbaii,R.W. (1997). The Clostridium 
perfringens epsilon-toxin. Revs. Med. Microbial., 8:S28-S30. 
35. Shortt,S.J., Titbaii,R.W. and Lindsay,C.D. (2000) An assessment of the in vitro 
toxicology of Clostridium perfringens type D E-toxin toxicity in human and 
animal cells. Human Exp. Toxicol., 19:109-116. 
36. Oyston,P.C.F. , Payne,D.W, Havard,H.L. , Williamson,E.D. and Titball, R.W. 
(1998) Production of a non-toxic site-directed mutant of Clostridium perfringens 
E-toxin which induces protective immunity in mice. Microbiology, 144:333-341. 
37. Titbaii,R.W., Williamson,E.D., Havard,H.L. , Oyston,P.C.F., and Payne,D, 
(1997) Clostridium perfringens vaccines. International patent publication 
number WO 97/34001 . 
38. Hunter,S.E.C., Brown,J.E. , Oyston,P.C.F., Sakurai,J. and Titbaii,R.W. (1993). 
Molecular genetic analysis of beta-toxin of Clostridium perfringens reveals 
sequence homology with alpha-toxin, gamma-toxin and leukocidin of 
Staphylococcus aureus~ Infect. lmmun., 61:3958-3965. 
39. Leary,S.E.C. and Titbaii,R.W. (1997) The Clostridium perfringens r3-toxin. 
p243-250. In; The Clostridia: Molecular Biology and Pathogenesis. J.I.Rood, 
B.A.McCiane, J.G.Songer and R.W. Titball (eds.) Academic Press, London. 
40. Garmory,H.S., Chanter, N., French,N.P., Bueschei,D., Songer,J.G. and 
Titbaii,R.W. (2000) Occurrence of Clostridium perfringens r32-toxin amongst 
animals, determined using genotyping and subtyping PCR assays. Epidemiol. 
Infect., 124:61-67. 
C. botulinum toxins. 
41 . Holley,J., Mauchline,M., Minton,N. and Titbaii,R.W. (2000). Cloning, 
expression and evaluation of a recombinant sub-unit vaccine against 
Clostridium botulinum type F toxin. Vaccine, 19: 288-97. 
42. Byrne, M.P., Titbaii.R.W. , Holley,J. and Smith, LA. (2000) Fermentation, 
purification, and efficacy of a recombinant vaccine candidate against 
botulinum neurotoxin type F from Pichia pastoris. Protein Expr. Purif. , 18:327-
37. 
Francisella tularensis. 
Antibiotic prophylaxis and therapy. 
43. Russeii,P. Eley,S.M., Fulop,M.J., Beii,D.L. and Titbaii,R.W. (1997) The efficacy 
of ciprofloxacin and doxycycline against experimental tularemia. J. Antimicrob. 
Chemotherapy, 41 :461-465. 
Approaches to a new vaccine. 
44. Leslie,D.L. , Cox,J., Lee,M. and Titball, R.W. (1993) Analysis of a cloned 
Francisella tularensis outer membrane protein gene and expression in 
attenuated Salmonella typhimurium. FEMS Microbial. Letts., 111:331-336. 
45. Fulop,M., Manchee,R. and Titbaii,R. (1995) Role of lipopolysaccharide and a 
major outer membrane protein from Francisella tularensis in the induction of 
immunity against tularemia. Vaccine, 13:1220-1225. 
46. Coulson,N.M., Fulop,M. and Titbaii,R.W. (1994). Effect of different plasmids on 
colonisation of mouse tissues by the aromatic amino acid dependent 
Salmonella typhimurium SL3261 . Microb. Pathog., 16:305-311 . 
47. Fulop,M., Leslie,D. and Titbaii,R. (1996) A rapid, highly sensitive method for 
the detection of Francisella tularensis in clinical samples using the polymerase 
chain reaction. Am. J. Trop. Med. Hyg., 54:364-366. 
48. Karlsson,J., Prior,R.G., Williams,K. , Lindler,L., Brown,K.A. , Chatweii,N., 
Hjalmarsson,K. , Loman,N., Mack,K.A. , Pallen,M., Popek,M., Sandstrom,G., 
Sjostedt,A. , Svensson,T. , Tamas,l. , Andersson,S.G.E. , Wren,B.W ., 
Oyston,P.C.F and Titbaii,R.W. (1999) Sequencing of the Francisella 
tularensis strain Schu 4 genome reveals the shikimate and purine metabolic 
pathways, targets for the construction of a rationally attenuated auxotrophic 
vaccine. Microb. Comp. Genomics, 5:25-39. 
Yersinia pestis. 
49. Leary,S.E.C. and Titbaii,R.W. (1998). Plague. British Medical Bulletin, 54:625-
633. 
50. Russeii,P., Nelson,M., Whittington,D., Green,M., Eley,S.M. and Titbaii,R.W. 
( 1997) Laboratory Diagnosis of plague. Brit. J. Biomed. Sci., 54:231-236. 
Antibiotic prophylaxis and therapy. 
51 . Russeii,P., Eley,S.M., Beii,D.L. , Manchee,R.J. and Titbaii,R.W. (1996) 
Doxycycline or ciprofloxacin prophylaxis and therapy against experimental 
Yersinia pestis infection in mice. J. Antimicrob. Chem .. 37:769-774. 
52. Russeii,P., Eley,S.M. Green,M., Stagg,A.J ., Taylor,R.R. , Nelson,M., 
Beedham,R.J., Beii,D.L. , Rogers,D. Whittington,D. and Titbaii,R.W. (1998) 
Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis 
infection. J. Antimicrob. Chem., 41:301 -305. 
Existing vaccines 
53. Russeii,P, Eley,S.M., Hibbs,S.E. , Manchee,R.J., Stagg,A.J. and Titbaii,R.W. 
(1995) A comparison of plague vaccine, USP and EV76 vaccine induced 
protection against Yersinia pestis in a murine model. Vaccine, 13:1551-1556. 
54. Titbaii,R.W. , Eley,S., Williamson,E.D., and Dennis,D.T. (1 999) Plague. p734-
742. In; Vaccines, Plotkin,S.A. , and Orenstein,W.A. (eds). W.B Saunders 
Company, Philadelphia. 
A new sub-unit vaccine against plague. 
55. Leary,S.E.C., Williamson,E.D., Griffin,K.F. , Russeii,P., Eley,S.M and 
Titbaii,R.W. (1995) Active immunisation with recombinant V antigen from 
Yersinia pestis protects mice against plague. Infect. lmmun., 63:2854-2858. 
56. Anderson,G.W.Jr., Leary,S.E.C. , Williamson,E.D., Titbaii,R.W., Welkos,S.L. , 
Worsham,P.L. and Friedlander,A.M. (1996) Recombinant V antigen protects 
mice against pneumonic and bubonic plague caused by F1-capsule-positive 
and -negative strains of Yersinia pestis. Infect. lmmun., 64:4580-4585. 
57. Hiii,J., Leary,S.E.C., Griffin,K.F., Williamson,E.D. and Titbaii,R.W. (1997). 
Regions of Yersinia pestis V antigen that contribute to protection against 
plague identified by passive and active immunisation. Infect. lmmun., 65:4476-
4482. 
58. Pettersson, J., Holmstrom,A., Hiii,J., Leary,S., Frithz-Lindsten,E., von Euler-
Matell A, Carlsson, E., Titbaii,R.W., Forsberg,A and Wolf-Watz,H. (1999) The 
V-antigen of Yersinia is surface exposed before target cell contact and involved 
in virulence protein translocation. Mol. Microbial., 32:961-976. 
59. Miller,J., Williamson,E.D., Lakey,J.H., Pearce,M.J. , Jones,S.M., and 
Titbaii,R.W. 1998. Macromolecular organisation of recombinant Yersinia pestis 
F1 antigen and the effect of structure on immunogenicity. FEMS lmmunol. 
Med. Microbial. , 21:213-221 . 
60. Williamson,E.D., Eley,S.M., Griffin,K.F., Green,M., Russeii,P., Leary,S.E.C., 
Oyston,P.C.F., Easterbrook,T. , Reddin,K.M., Robinson,A. and Titbaii,R.W. 
(1995) A new improved sub-unit vaccine for plague:the basis of protection. 
FEMS lmmunol. Med. Microbial. , 12:223-230. 
61 . Williamson,E.D., Eley,S.M., Stagg,A.J ., Green,M., Russeii,P. , Titbaii,R.W. 
(1997) A sub-unit vaccine elicits lgG in serum, spleen cell cultures and 
bronchial washings and protects immunised animals against pneumonic 
plague. Vaccine, 15:1079-1084. 
62. Williamson,E.D., Eley,S.M. Stagg,A.J., Green,M., Russeii,P and Titbaii,R.W. 
(2001) A single dose sub-unit vaccine protects against pneumonic plague. 
Vaccine, 19:566-571. 
63. Green, M., Rogers,D., Russell, P., Stagg, A.J ., Beii,D.L. , Eley,S.M., 
Titbaii,R.W., Williamson,E.D. (1999) The SCID/Beige mouse as a model to 
investigate protection against Yersinia pestis. FEMS lmmunol. Med. Microbial., 
23:107-113 
64. Williamson,E.D., Vesey,P.M., Gillhespy,K,J., Eley,S.M., Green, M. and 
Titbaii,R.W. (1999) An lgG1 titre to the F1 and V antigens correlates with 
protection against plague in the mouse model. C/in. Exp. lmmunol., 116:1 07-
114. 
65. Titbaii,R.W., Williamson,E.D., Leary,S.E.C., Oyston,P.C., and Bennett,A.M 
(1996) Vaccines for plague. International patent publication number WO 
96/28551. 
Orally and intranasally delivered sub-unit vaccine. 
66. Williamson,E.D., Sharp,G.J.E., Eley,S.M., Vesey,P.M., Pepper,T.C., 
Titbaii,R.W. and Alpar,H.O. (1996) Local and systemic immune response to a 
microencapsulated sub-unit vaccine for plague. Vaccine, 14:1613-1619. 
67. Oyston,P.C.F. , Williamson,E.D., Leary,S.E.C., Eley,S.M. , Griffin,K,F. and 
Titbaii,R.W. (1995). Immunisation with live recombinant Salmonella 
typhimurium aroA producing F1 antigen protects against plague. Infect. 
lmmun., 63:563-568. 
68. Titbaii,R.W., Howells,A.M., Oyston,P.C.F., Williamson,E.D. (1997) Expression 
of the Yersinia pestis capsular antigen (F1-antigen) on the surface of an aroA 
mutant of Salmonella typhimurium induces high level protection against plague. 
Infect. lmmun., 65:1926-1930. 
69. Bullifent,H.L. , Griffin,K.F., Jones,S.M. Yates,M., Harrington,L. and 
Titbaii,R.W. (2000) Antibody responses to Yersinia pestis F1-antigen 
expressed in Salmonella typhimurium aroA from in vivo-inducible promoters. 
Vaccine, 18:2668-2676. 
70. Leary,S.E.C. , Griffin,K.F., Garmory,H.S., Williamson,E.D. and Titbaii,R.W. 
(1997). Expression of an F1N fusion protein in attenuated Salmonella 
typhimurium and protection of mice against plague. Microb. Pathog., 23:167-
179. 
71 . Bullifent,H.L. , Dhaliwai,K. , Howells,A.M., Goan,K., Griffin,K., Lindsay,C.D., 
Tunnicliffe,A. and Titbaii,R.W. (2001) Stabilisation of Salmonella vaccine 
vectors by the induction of trehalose biosynthesis. Vaccine, 19:1239-1245. 
72. Titbaii,R.W., Williamson,E.D., Leary,S.E.C., Oyston,P.C.F. and Howells,A.M. 
(1995) Vaccine Compositions comprising live bacterial vectors for protection 
against Yersinia pestis infection. International patent publication number WO 
95/18231 . 
73. Titbaii,R.W., Williamson,E.D., Leary,S.E.C. (1995) Vaccine Compositions. 
International patent publication number WO 95/24475. 
Live attenuated mutants as vaccines. 
74. Oyston,P.C.F. , Russeii,P., Williamson,E.D. and Titbaii,R.W. (1996) An aroA 
mutant of Yersinia pestis is attenuated in the guinea pig, but virulent in mice. 
Microbiology, 142:1847-1853. 
75. Oyston,P.C.F., Dorreii,N., Williams,K. , Li,S.-R. , Green, M., Titbaii,R.W. and 
Wren,B.W. (2000) The response regulator PhoP is important for survival under 
conditions of macrophage-induced stress and virulence in Yersinia pestis. 
Infect. lmmun., 68:3419-3425. 
76. Williams,K. , Oyston,P.C.F., Dorreii,N., Shu-Rui,L. , Titbaii,R.W. and Wren,B.W. 
(2000) Investigation into the role of the serine protease HtrA in Yersinia pestis 
pathogenesis. FEMS Microbial. Letts., 186:281-286. 
The search for new virulence determinants which might be exploited to devise new 
antimicrobials or vaccines. 
77. Payne,D., Tatham,D. Williamson,E.D. and Titball, R.W. (1998) The pH6 
antigen of Yersinia pestis binds to 131-linked galactosyl residues in 
glycosphingolipids. Infect lmmun., 66:4545-4548. 
78. Leary,S.E.C., Griffin,K.F., Galyov, E. E. , Hewer,J., Williamson,E.D., 
Holmstrom,A., Forsberg,A. and Titbaii,R.W. (1999). Yersinia outer proteins 
(YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a 
murine model of bubonic plague. Microb. Pathog., 26:159-169. 
79. Payne,D., Tatham,D. Williamson,E.D. and Titball, R.W. (1998) The pH6 
antigen of Yersinia pestis binds to 131-linked galactosyl residues in 
glycosphingolipids. Infect lmmun., 66:4545-4548. 
80. Leary,S.E.C., Griffin,K.F., Galyov, E. E. , Hewer,J., Williamson,E.D., 
Holmstrom,A., Forsberg,A. and Titbaii,R.W. (1999). Yersinia outer proteins 
(YOPS) E,K and N are antigenic but non-protective compared to V antigen, in a 
murine model of bubonic plague. Microb. Pathog., 26:159-169. 
81 . Prior,J. , Hitchin,P.G., Wiliamson,E.D., Reason,A.J., Morris,H.R., Deii,A. , 
Wren,B.W. and Titbaii,R.W. Characterisation of the lipopolysaccharide of 
Yersinia pestis. Microb. Pathog. 30:49-57. 
82. Prentice,M.B., James,K.D., Parkhiii,J., Baker,S.G., Stevens,K., 
Simmonds,M.N., Mungaii,K.L. Churcher,C., Oyston,P.C.F., Titbaii,R.W., 
Wren,B.W., Wain,J., Pickard,D., Hien,T.T. , Farrar,J.J., and Dougan,G. (2000). 
Yersinia pestis pFra shows biovar-specific differences and recent common 
ancestry with a Salmonella enterica serovar Typhi plasmid J. 
Bacteriol.183:2586-2594. 
Burkholderia pseudomallei. 
83. Ellis,J.F. and Titbaii,R.W. (1999) Burkholderia pseudomallei: medical, 
veterinary and environmental aspects. Infect. Dis. Rev., 1: 17 4-181. 
Antibiotic prophylaxis and therapy. 
84. Kenny,D.J., Russeii,P., Rogers,D., Eley,S.M. and Titbaii,R.W. (1999) In vitro 
susceptibilities of Burkholderia mallei in comparison to those of other 
pathogenic Burkholderia spp. J. Antimicrob. Chemotherapy, 43:2773-2775. 
85. Russeii ,P., Eley,S.M., Ellis,J., Green, M., Beii,D.L. , Kenny,D.J. and Titball 
R.W. (2000) Comparison of efficacy of ciprofloxacin and doxycycline against 
experimental melioidosis and glanders. J. Antimicrob. Chemotherapy, 45:813-
818. 
Approaches to a new vaccine. 
86. Mack,K. and Titbaii,R.W. (1998) The detection of insertion sequences within 
the human pathogen Burkholderia pseudomallei which have previously been 
identified in Burkholderia cepacia. FEMS Microbial. Letts., 162:69-74. 
87. Mack, K. and Titball, R. W. ( 1996) Transformation of Burkholderia pseudomallei 
by electroporation. Anal. Biochem., 242:73-76. 
Contribution of the author to published works 
Clostridial toxins 
C. perfringens toxins. 
Titbaii,R.W., Hunter,S.E.C., Martin,K.L. , Morris,B.C., Shuttleworth,AD., 
Rubidge,T., Anderson,D.W., and Kelly,D.C. (1989). Molecular cloning and 
nucleotide sequence of the alpha toxin (phospholipase C) of Clostridium 
perfringens. Infect. lmmun., 57:367-376. 
This paper reports the first cloning and nucleotide sequencing of the gene 
encoding the C. perfringens a-toxin and was the result of the first genetic 
manipulation experiments performed at CBD Porton Down. The work was 
conceived and planned by myself. I carried out most of the experimental work 
reported in this paper, including the cloning of the gene encoding the alpha-toxin. 
T. Rubidge and D. Kelly were senior managers at CBD Porton Down. D. Anderson 
(post-doctoral scientist) synthesised oligonucleotides used in the study. K. Martin 
(senior research technician) provided technical assistance with nucleotide 
sequencing. S. Hunter (post-graduate scientist) carried out restriction mapping of 
the cloned gene. A Shuttleworth (post-doctoral scientist) provided antisera for 
immunological studies. I analysed the data and wrote the manuscript. 
Bullifent,H.L., Moir,A. and Titbaii,R.W. (1995) The construction of a reporter 
system and use for the investigation of Clostridium perfringens gene expression. 
FEMS Microbiol Letts., 131:99-105. 
This paper reports some of the work carried out by H. Bullifent, a PhD 
student working in my laboratory under my guidance. I devised and directed the 
work. The data was analysed by H. Bullifent, A Moir (external PhD supervisor at 
the University of Sheffield) and myself. The manuscript was written by myself. 
Bullifent,H.L., Moir,A Awad,M.M., Scott,P.T., Rood,J.I. and Titbaii,R.W. (1996) 
The level of expression of a-toxin by different strains of Clostridium perfringens is 
dependent on differences in promoter structure and genetic background. 
Anaerobe, 2:365-371 . 
The paper reported that the levels of a-toxin mRNA in three strains of C. 
perfringens paralleled the levels of a-toxin in culture supernatant fluid. I devised 
and directed the work. Experimental work was carried out mainly by H. Bullifent, a 
PhD student in my group. A Moir (University of Sheffield) was the external PhD 
supervisor for H. Bullifent. M. Awad and P. Scott working in the laboratory of J. 
Rood (Monash University, Australia) provided vectors for use in this study and 
carried out some studies on the level of expression of other exotoxins enzymes in 
the three strains of C. perfringens. The data was analysed by H. Bullifent, J. Rood 
and myself. I wrote the manuscript jointly with H. Bullifent. 
Titbaii,R.W., Yeoman,Y. and Hunter,S.E.C. (1993) Gene cloning and organisation 
of the alpha-toxin of Clostridium perfringens. p211-226. In; Genetics and Molecular 
Biology of Anaerobes, Sebald,M (ed.) Springer-Verlag Inc., New York. 
I was invited to contribute this chapter by M. Sebald, and wrote the 
manuscript with additional input from H. Yeoman and S. Hunter who were both 
PhD students working in my group at CBD Porton Down. 
Titbaii,R.W., Leslie,D.L. , Harvey,S. and Kelly,D.C. (1991) Hemolytic and 
sphingomyelinase activities of Clostridium perfringens alpha-toxin are dependent 
on a domain homologous to that of an enzyme from the human arachidonic acid 
pathway. Infect. lmmun., 59:1872-1874. 
I conceived, planned and directed this project. Experimental work was 
carried out by myself, D. Leslie who had joined my group as a post-doctoral 
scientist and S. Harvey who worked as a research technician in my group. D. Kelly 
had overall managerial responsibility for all microbiological work. Data was 
analysed jointly with D. Leslie and I wrote the manuscript. 
Titbaii,R.W., Fearn,AM. and Williamson,E.D. (1993) Biochemical and 
Immunological properties of the C-terminal domain of the alpha-toxin of 
Clostridium perfringens. FEMS Microbial. Letts., 110:45-50. 
This paper reported the expression and purification of the carboxy-terminal 
domain of a-toxin. I conceived, planned and directed this project. The molecular 
biology and biochemical experimental work was carried out by myself and A 
Feam who worked as a research technician in my group. D. Williamson carried out 
cell culture studies. Data was analysed jointly with D. Williamson and the 
manuscript was written by myself. 
Basak,AK., Stuart,D.I., Nikura,T., Bishop,D.H.L., Kelly,D.C. , Fearn,A and 
Titbaii,R.W. (1994) Purification, crystallisation and preliminary X-ray diffraction 
studies of alpha-toxin of Clostridium perfringens. J. Mol. Bioi., 244:648-650. 
I had the idea to determine the crystal structure of alpha-toxin and 
established a collaboration with the Institute of Virology in Oxford (A Basak, D. 
Stuart, T. Nikura and D. Bishop). The protein used in these studies was prepared 
by myself and A Feam who worked as a research technician in my group. We 
devised an improved method for purification of recombinant a-toxin. Crystallisation 
was carried out by A Basak and T. Nikura under the guidance of D. Stuart. Data 
was analysed jointly with A Basak and we jointly wrote the manuscript. 
Ginter,A , Williamson,E.D., Dessy,F., Coppe,P., Bullifent,H., Howells,A and 
Titbaii,R.W. (1996) Molecular variation between the a-toxins from the type strain 
(NCTC8237) and dinical isolates of Clostridium perfringens associated with 
disease in man and animals. Microbiology, 142:191-198. 
A collaboration that I established with A.Ginter (Centre Economie Rurale, 
Belgium) was aimed at determining whether C. perfringens alpha-toxin played a 
role in sudden death syndrome in Calves. The project was jointly conceived with A. 
Ginter and I planned and directed the work at CBD Porton Down. A. Ginter and P. 
Coppe provided strains for analysis. The gene cloning was carried out in my 
group, by myself, H. Bullifent and A. Howells, a PhD student and a research 
technician respectively in my group. Nucleotide sequencing was carried out by 
myself, H. Bullifent and A. Howells and by F. Dessy (CER Belgium). Biochemical 
analysis of the recombinant proteins was carried out by myself and A. Howells. D. 
Williamson carried out peptide mapping and vaccine challenge studies. The data 
was analysed jointly with D. Williamson and A. Ginter and the manuscript was 
written by myself. 
Basak,A.K., Howells,A. , Eaton,J.T. , Moss,D.S., Naylor,C.E., Miller,J and 
Titbaii,R.W. (1998) Crystallisation and preliminary X-ray diffraction studies of a-
toxin from two different strains (NCTC8237 & CER89L43) of Clostridium 
perfringens. Acta. Cryst., 054:1425-1428. 
This work built on the previous crystallogaphic studies with A. Basak who 
had now moved to work in the group of D. Moss at Birkbeck College. For this work 
I proposed that we used recombinant a-toxin produced by an isolate of C. 
perfringens from a case of sudden death in a calf (CER89L43), · because this 
protein was more resistant to proteolysis than the NCTC8237 protein. The project 
was conceived, planned and directed jointly with A. Basak. Purified recombinant 
protein for these studies was prepared by myself, a post doctoral scientist (J. 
Miller) and a research technician in my group (A. Howells). Crystallography was 
carried out at Birkbeck College by A. Basak, J. Eaton and C. Naylor who worked in 
the group of D. Moss. I was a joint PhD supervisor for J. Eaton and N. Justin. The 
data was analysed jointly with A. Basak and we wrote the manuscript jointly. 
Naylor,C.E., Eaton,J.T. , Howells,A. , Justin,N. , Moss,D.S., Titbaii,R.W. and 
Basak,A.K. (1998). Structure of the key toxin in gas gangrene. Nature Stroct. Bioi., 
5:738-746. 
In this paper the crystal structure of C. perfringens CER89L43 a-toxin was 
reported. I conceived the project and the work was jointly planned and directed with 
A. Basak and C. Naylor. The protein used in these studies was prepared by myself 
and A. Howells who worked as a research technician in my group. Crystallography 
and structural determination was carried out at Birkbeck College by C. Naylor, J. 
Eaton, N. Justin, and A. Basak who worked in the group of D. Moss. The 
crystallographic studies were supported by a BBSRC grant, on which I was a 
collaborator. I was the joint PhD supervisor for J. Eaton and N. Justin. The data 
was analysed jointly with A. Basak and C. Naylor and the manuscript was written 
by C. Naylor, A. Basak, D. Moss and myself. 
Naylor,C.E. , Jepson,M., Crane,D.T., Titbaii,R.W., Miller, J., Basak,AK. and 
Bolgiano,B (1999) Characterisation of the calcium-binding C-terminal domain of 
Clostridium perfringens alpha-toxin. J. Mol. Bioi., 294:757-770. 
This paper reported calcium ion binding sites located in the carboxy-
terminal domain of C. perfringens a.-toxin. The work arose from a collaboration 
which I established with B. Bolgiano at the National Institute for Biological 
Standards and Control. Protein for these studies was provided by J. Miller, a post-
doctoral scientist working in my group. Crystallography was carried out at Birkbeck 
College by C. Naylor and A Basak. The optical spectroscopy was carried out in the 
laboratory of B. Bolgiano by D. Crane (NIBSC) and M. Jepson who was a PhD 
student working in my group. Data was analysed jointly by C. Naylor, M. Jepson, B. 
Bolgiano and myself and we jointly wrote the manuscript. 
Titbaii,R.W., Naylor,C.E. , Miller.J .. Moss,D.S. and Basak,AK. (2000) Opening of 
the active site of Clostridium perfringens a.-toxin may be triggered by membrane 
binding. lnt. J. Med. Microbiol., 290: 357-361 . 
I was invited to speak at the 9th European Workshop on Bacterial Protein 
Toxins, Nice France, 27th June-2nd July 1999. This manuscript was a summary of 
my presentation. The work reported develops the hypothesis explaining how the 
Clostridium perfringens a.-toxin binds to host cell membranes. The manuscript 
was written by myself. 
Jepson,M., Howells,A , Bullifent,H.L. , Bolgiano,B., Crane,D., Miller,J., Holley,J., 
Jayasekera,P. and Titbaii,R.W. (1999) Differences in the carboxy-terminal 
(putative phospholipid binding) domains of the Clostridium perfringens and 
Clostridium bifermentans phospholipases C influence the haemolytic and lethal 
properties of these enzymes. Infect. lmmun., 67:3297-3301 . 
The work reported here was conceived, planned and directed by myself. 
Experimental work was carried out mainly by M. Jepson (a PhD student in my 
group) and A Howells Ounior scientist in my group). J. Miller, J. Holley and H. 
Bullifent (post-doctoral scientists in my group) also carried out some of the 
experimental work. The data was analysed jointly by M. Jepson, B. Bolgiano and 
myself and I wrote the manuscript jointly with M. Jepson. · 
Flores-Diaz,M. Alape-Gir6n,A , Titbaii,R.W., Moos,N., Guillouard,l., Cole,S. , 
Howells,A,M., von Eichei-Streiber,C., Florin,!. and Thelestam.M. (1998) UDP-
Giucose deficiency causes hypersensitivity to the cytotoxic effect of Clostridium 
perfringens phospholipase C. J. Bioi. Chem., 273:24433-24438. 
The work reported in this paper arose from a collaboration that I had 
established with with A Alape-Gir6n (Karolinska Institute). The mutant cell line had 
previously been isolated by the Karolinska group working with M. Moos and C. von 
Eichel Streiber (lnstitut fOr Medizinische Mikrobiologie und Hygiene, Germany). 
The C. perfringens a.-toxin, isolated amino and carboxy-terminal domains of a.-
toxin, C. bifermentans phospholipase C and the hybrid phospholipase C were 
purified by A. Howells a research technician working in my group under my 
direction. Cytotoxicity assays were performed by M. Flores-Diaz, I. Florin and A. 
Alape-Gir6n working in the laboratory of M. Thelestam at the Karolinska Institute. I. 
Guillouard working in the laboratory of S. Cole (lnstitut Pasteur, Paris) provided 
site directed variants of a-toxin. The data was analysed mainly by A. Alape-Gir6n 
and myself and the manuscript written by us both. 
Titbaii,R.W. and Rubidge,T. (1990). The role of histidine residues in the alpha 
toxin of Clostridium perfringens. FEMS Microbial. Letts., 68:261-266. 
This experimental work was conceived, planned and carried out solely by 
myself. T. Rubidge managed the laboratory in which I worked. I carried out all of 
the data analysis and wrote the manuscript. 
Alape-Gir6n,A. , Flores-D i az,M., Guillouard,l. , Naylor,C.E. , Titbaii,R.W. , 
Rucavado,A. , Lomonte,B., Basak,A.K. , Gutierrez,J .M., Cole,S.T. and 
Thelestam,M. (2000) Identification of residues critical for toxicity in Clostridium 
perfringens phospholipase C, the key toxin in gas gangrene. Eur. J. Biochem., 
267: 5191-5197. 
The work reported in this paper arose from a collaboration that I 
established with A. Alape-Gir6n at the Karolinska Institute. The work undertaken 
used C. perfringens alpha-toxin, the amino-terminal domain and C.· bifermentans 
PLC prepared by myself. The site-directed mutated proteins used in this study 
were provided by I. Guillouard working in S. Cole's laboratory. Cell culture and 
biochemical analyses were carried out by A. Alape-Gir6n, M. Flores-0 i az, A. 
Rucavado, B. Lomonte and J. Gutierrez. Molecular modellling was carried out by 
C. Naylor and A. Basak at Birkbeck College. The data was analysed jointly with 
A. Alape-Gir6n and the manuscript written by A. Alape-Gir6n with appropriate input 
from the other authors. 
Walker,N., Holley,J., Naylor,C.E., Flores-Diaz,M., Alape-Giron,A., Carter,G., 
Carr,F.J., Thelestam,M., Keyte,M., Moss,D.S., Basak,A.K., Miller,J. and 
Titbaii,R.W. (2000) Identification of residues in the carboxy-terminal domain of 
Clostridium perfringens a-toxin (phospholipase C) which are required for its 
biological activities. Arch. Biochem. Biophys., 384:24-30. 
This manuscript reports the results of a project which I conceived, planned 
and directed. Random mutagenesis was carried out by F. Carr and G. Carter at 
Biovation Itd. The pool of random mutants was screened by J. Holley (post-
doctoral scientist in my group) and myself. Mutants that we selected for further 
study were purified by J. Miller (post-doctoral scientist) and M. Keyte (research 
technician) working in my research group at CBD Porton Down. N. Walker 
(graduate scientist) in my research group carried out biochemical assays. 
Molecular modellling was carried out by C. Naylor and A. Basak at Birkbeck 
College. Data was analysed by C. Naylor and myself and I wrote the manuscript 
with N. Walker. 
Logan,AJ., Williamson,E.D., Titbaii,R.W., Percivai,D.A, Shuttleworth,AD., 
Conlan,J.W . and Kelly,D.C. (1991). Epitope mapping of the alpha-toxin of 
Clostridium perfringens. Infect. lmmun., 59:4338-4342. 
As part of the research programme at CBD Porton Down, a panel of 
monoclonal antibodies were generated by A Shuttleworth (post-doctoral scientist) 
and D. Percival (post-graduate scientist) working in D. Williamson's group. I 
established a collaboration with W . Conlan at the University of Southampton and 
A Logan carried out peptide-based epitope mapping at Southampton. I also 
worked with A Shuttleworth to chemically cleave a-toxin and to identify fragments 
of the protein reactive with monoclonal antibodies. The data was analysed by A 
Shuttleworth and myself and the manuscript written jointly. 
Tempest,P.R. , White,P., Williamson,E.D., Titbaii,R.W., Kelly,D.C., Kemp,G.J.L., 
Gray,P.M.D. , Forster,S.J., Carr,F.J. and Harris,W.J. (1994). Efficient generation of 
a reshaped human mAb specific for the a-toxin of Clostridium perfringens. Protein 
Engineering, 7:1501-1507. 
This paper reported that a monoclonal antibody, which neutralised 
phospholipase C, haemolytic and lethal activities, was "humanised" by transferring 
thr COR regions into a human antibody framework. I conceived the project most of 
which was carried out at the University of Aberdeen by P. Tempest, P. White, S. 
Forster working under the direction of F. Carr and W. Harris. D. Williamson (senior 
immunologist) provided the original hybridoma cell line. G. Kemp and P. Gray 
carried out molecular modeling studies. D. Kelly was the head of the microbiology 
group at CBD Porton Down. The data was analysed jointly, and the manuscript 
was written mainly by P. Tempest and F. Carr. · 
Williamson,E.D. and Titbaii,R.W. (1993). A genetically engineered vaccine against 
the alpha-toxin of Clostridium perfringens protects mice against experimental gas 
gangrene. Vaccine, 11:1253-1258. 
This paper reported that immunisation with recombinant carboxy-terminal 
domain of a-toxin provided protection against experimental gas gangrene. I 
conceived, planned and directed the project. I purified the proteins used in this 
study and prepared toxin and bacterial challenge doses. The animal experimental 
work was carried out by D. Williamson (senior immunologist). I analysed the data 
and wrote the manuscript. 
Bennett,AM, Lescott,T., Phillpotts,R.J. , Mackett,M and Titbaii,R.W. (1999) 
Recombinant vaccinia viruses protect against Clostridium perfringens alpha-toxin. 
Viral. lmmunol., 12:97-105. 
The work reported in this paper was conceived and directed by myself. The 
cloning work to construct recombinant vaccinia viruses was carried out by A 
Bennett, a PhD student working in my group. Animal work was carried out by T. 
Lescott (post-graduate scientist) and R. Phillpotts (senior virologist). M. Mackett 
was the external PhD supervisor for A Ben nett. The data was analysed by myself, 
A. Bennett and R. Phillpotts and the manuscript written jointly. 
Titbaii,R.W. and Williamson,E.D. (1993) Clostridium perfringens vaccines. 
International patent publication number WO 93/23543. 
This patent describes the use of the carboxy-terminal domain of C. 
perfringens a-toxin as a vaccine. The patent arose from the work reported in 
Williamson, and Titball (1993). Vaccine. 11:1253-1258. The patent is currently 
being exploited by industry to provide an improved vaccine for veterinary use. 
Carter,G., White,P., Fernie,M., King,S., Mclean,G., Titbaii,R. and Carr, F.J. 
(1998) Enhanced antitumour effect of liposomal daunorubicin using antibody-
phospholipase C conjugates or fusion protein. lnt. J. Oncol., 13:819-825. 
During an ASM meeting in 1994 I had dinner with F.Carr (Biovation Ltd, 
Aberdeen) and we devised the idea of using the alpha-toxin as the basis of a novel 
anti-cancer therapy. An experimental plan was developed by us when we returned 
to the UK. This paper reports the construction of an a-toxin-antibody conjugate 
which retained biological activity. Most of the experimental work was carried out by 
G. Carter, P. White, P. Fernie, S. King and A Hamilton at Biovation under the 
direction of F. Carr. The purified a-toxin for these studies was provided my myself. 
The data was analysed by G. Carter, F. Carr and myself and the manuscript 
written mainly by G. Carter. · 
Titbaii,R.W. and Carr,F.J. (1996) Pharmaceuticals and assays using enzyme 
subunits. International patent publication number WO 96/25952. 
This patent across from the previous publication, and reflects the original 
idea developed by F. Carr and myself. The patent describes the use of targeted 
liposome lysis for drug delivery and diagnostic applications 
Titbaii,R.W. (1997) Clostridial Phospholipases. p223-242. In; The Clostridia: 
Molecular Biology and Pathogenesis. J.I.Rood, B.AMcCiane, J.G.Songer and 
R.W.Titball (eds.) Academic Press, London. 
The idea for this book came from the 1st International meeting on the 
Molecular Biology and Pathogenesis of the Clostridia, which I was involved in 
organising in 1995. The book was not simply the proceedings from this meeting, 
but rather we invited world experts (who may or may not have attended the 
meeting) to contribute to the book. I wrote this chapter on the Clostridial 
phospholipases. 
Titbaii,R.W., Naylor,C.E. and Basak,AK. (1999) The Clostridium perfringens a-
toxin. Anaerobe, 5:51-64. 
I was invited to write this review article by M. Sebald, the Editor in Chief 
for Anaerobe. I wrote the manuscript with additional input from C. Naylor and A. 
Basak (Birkbeck College). 
Jepson,M. and Titbaii,R.W. (2000) Structure and function of Clostridial 
phospholipases. Microbes and Infection, 2:1277-1284. 
Marie Jepson was asked to write this review whilst she was in the third 
year of her PhD with me. We drafted the outline plan for the review and she 
wrote the first draft which I modified for the final submitted version. The 
manuscript pulls together the work she had carried out during her PhD and 
places it is the context of other reported work. We were rewarded by one of the 
figures in the review being used as the cover image for this issue of Microbes 
and Infection. 
Titbaii,R.W. (1993). Bacterial phospholipases C. Microbiol. Revs., 57:347-366. 
This review summarised the state of knowledge of the bacterial 
phospholipases C and considered the molecular biology, biochemistry, mode of 
action and applications of these enzymes. I believe that this review stimulated 
renewed world-wide interest in these enzymes. The manuscript was written by 
myself. 
Titbaii,R.W. (1998) Bacterial Phospholipases. J. Appl. Microbiol., 84:127S-137S. 
This paper arose from an invited talk at the Summer Conference of the 
Society for Applied Microbiology, Norwich UK, 14th-17th July,1997. I wrote the 
manuscript. 
Titbaii,R.W. (1999) Membrane-damaging and cytotoxic phospholipases. In. The 
Comprehensive Sourcebook of Bacterial Protein Toxins, Alouf,J.E. And Freer,J.H. 
(eds.). Academic Press, London. pp310-329. 
I was invited to write this chapter for the 1999 revision of this book, a 
definitive text on bacterial toxins. I wrote the manuscript. 
Titbaii,R.W. and Rood,J.I. (2000) Bacterial phospholipases. In: Handbook of 
Experimental Pharmacology: Bacterial Protein Toxins, Aktories,K and Just,l. 
(eds.). Springer Verlag, 529-556. 
This manuscript was written by Julian Rood and myself. I wrote the sections 
on structure-function relationships and roles of phospholipases in pathogenicity. 
Julian Rood wrote the section on regulation of gene expression. 
Hunter,S.E.C., Clarke,I.N. and Titbaii,R.W. (1992). Cloning and nucleotide 
sequencing of the Clostridium perfringens epsilon toxin gene and its expression in 
Escherichia coli. Infect. lmmun., 60:102-110. 
This paper reported the first cloning and nucleotide sequencing of the gene 
encoding £-toxin from a type B strain of C. perfringens. I conceived, planned and 
directed the project. S. Hunter was my first PhD student and this paper arose from 
her PhD thesis. I carried out some of the biochemical analyses of the toxin (e.g. 
SOS-PAGE, IEF). I. Clarke was her external supervisor at Southampton 
University. Data was analysed jointly with S. Hunter and the manuscript was 
written jointly. 
Havard,H.L, Hunter,S.E.C. and Titbaii,R.W. (1992) Comparison of the nucleotide 
sequence, and development of a PCR test for the epsilon toxin gene of Clostridium 
perfringens type Band type D. FEMS Microbiol. Letts., 97:77-82. 
This paper reported the nucleotide sequence of the E-toxin encoding gene 
from a type D strain of C. perfringens. The type B and D E-toxin encoding genes 
were sufficiently similar to allow a PCR test to be devised which detected the gene 
in a range of type B and type D strains. I conceived, planned and directed this 
project. H. Havard joined my group as a new graduate and carried out this work 
under my supervision as her first project. S. Hunter, a post-doctoral scientist in my 
group, assisted with design of primers and nucleotide sequencing. Data was 
analysed jointly with H. Havard and the manuscript was written by myself. 
Payne,D.L. , Williamson,E.D. and Titbaii,R.W. (1997). The Clostridium perfringens 
epsilon-toxin. Revs. Med. Microbiol., 8:S28-S30. 
I conceived and directed this project to identify the cell recaptor for E-toxin, 
and this work was carried out by D. Payne, a post-doctoral scientist who worked in 
D. Williamson's group. The project made progress in identifying the recaptor on 
brain synaptosomes by Western Blotting and preliminary biochemical analysis of 
the recaptor was successful suggesting it was a sialoglycoprotein. Data was 
analysed jointly with D. Payne and the manuscript was written by myself. 
Shortt,S.J., Titbaii,R.W. and Lindsay,C.D. (2000) An assessment of the in vitro 
toxicology of Clostridium perfringens type 0 E-toxin toxicity in human and animal 
cells. Human Exp. Toxicol., 19:109-116. 
This paper reported that only 2 cell lines (MOCK and G-402 cells) of 17 
tested were susceptible to the effects of E-toxin. On the basis of Western blotting 
the toxin appeared to bind to range of cell surface proteins in the susceptible cell 
lines. I conceived and directed this project which built on the previous work by D. 
Payne. The experimental work was carried out by C. Lindsay · a post-doctoral 
scientist in the Biology group and S. Shortt, a sandwich course placement student. 
Data was analysed jointly with C. Lindsay and the manuscript was written jointly. 
Oyston,P.C.F., Payne,D.W , Havard,H.L. , Williamson,E.D. and Titball, R.W. (1998) 
Production of a non-toxic site-directed mutant of Clostridium perfringens E-toxin 
which induces protective immunity in mice. Microbiology, 144:333-341 . 
This project to construct and test a vaccine against C. perfringens £-toxin 
was conceived and directed by myself. Recombinant DNA work was carried out by 
P. Oyston and H. Havard, a graduate and post-doctoral scientist respectively in my 
group. Cytotoxicity studies were carried out by D. Payne. D. Williamson (senior 
immunologist) carried out animal challenge studies. The data was analysed jointly 
by myself, P. Oyston and D. Payne and the manuscript written jointly by the three 
of us. 
Titbaii,R.W., Williamson,E.D., Havard,H.L., Oyston,P.C.F., and Payne,D, (1997) 
Clostridium perfringens vaccines. International patent publication number WO 
97/34001 . 
This patent describes the use of a site-directed mutant or C. 
perfringens £-toxin as a vaccine. The patent arose from the work reported in 
Oyston et al., ( 1998) Microbiology. 144:333-341. The patent is currently being 
exploited by industry to provide an improved vaccine for veterinary use. 
Hunter,S.E.C., Brown,J.E., Oyston,P.C.F., Sakurai,J. and Titbaii,R.W. (1993). 
Molecular genetic analysis of beta-toxin of Clostridium perfringens reveals 
sequence homology with alpha-toxin, gamma-toxin and leukocidin of 
Staphylococcus aureus:. Infect. lmmun., 61:3958-3965. 
This paper reported the first cloning and nucleotide sequencing of the gene 
encoding ~toxin from C. perfringens. The work arose from a collaboration I 
established with J. Brown (senior bacteriologist) at the US Army Medical Research 
Institute for Infectious Diseases (USAMRIID). He had obtained purified J3-toxin 
from J. Sakurai (Tokushima Bunri University, Japan) and determined the N-
terminal amino acid sequence. I designed oligonucleotides for probing C. 
perfringens DNA and S. Hunter (post-graduate scientist) isolate·d the 13-toxin 
encoding gene from the same plasmid library she had used to isolate the E-toxin 
gene. Nucleotide sequencing was carried out by J. Brown, S. Hunter and myself. 
The deduced amino acid sequence of J3-toxin showed sequence similarity with the 
alpha-toxin, gamma-toxin and leukocidin of Staphylococcus aureus. P. Oyston 
(post-doctoral scientist) , who had recently joined my group expressed the 13-toxin 
gene in E. coli and showed that the recombinant protein oligomerised. Data was 
analysed jointly with S. Hunter and J. Brown and the manuscript was written by 
myself. 
Leary,S.E.C. and Titbaii,R.W. (1997) The Clostridium perfringens f3-toxin. p243-
250. In; The Clostridia: Molecular Biology and Pathogenesis. J.I.Rood, 
B.A.McCiane, J.G.Songer and R.W. Titball (eds.) Academic Press, London. 
The idea for this book came from the 1st International meeting on the 
Molecular Biology and Pathogenesis of the Clostridia, which I was involved in 
organising in 1995. The book was not simply the proceedings from this meeting, 
but rather we invited world experts (who may or may not have attended the 
meeting) to contribute to the book. I wrote this chapter jointly with S. Leary. 
Garmory,H.S. , Chanter,N., French,N.P., Bueschei,D., Songer,J.G. and 
Titbaii,R.W. (2000) Occurrence of Clostridium perfringens f32-toxin amongst 
animals, determined using genotyping and subtyping PCR assays. Epidemiol. 
Infect., 124:61-67. 
This paper reported that the ~-2-toxin gene was positively associated with 
isolates of C. perfringens from cases of enteritis in piglets, but not in isolates from 
cases of disease in foals or lambs. I conceived, planned and directed this project 
which was supported by a grant awarded to me by MAFF. H. Garmory who joined 
my group as a new graduate carried out most of the experimental work under my 
supervision. C. perfringens strains for analysis were provided by N. Chanter 
(Animal Health Trust Cambridge), N. French (University of Liverpool), D. 
Bueschel (University of Arizona) and J. Songer (University of Arizona). N. French 
also carried out statistical analysis of the data obtained for lamb isolates of C. 
perfringens. Data was analysed jointly with H. Garmory and the manuscript was 
written by H. Garmory and myself. 
C. botulinum toxins 
Holley,J., Mauchline,M., Minton,N. and Titbaii,R.W. (2000). Cloning, expression 
and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum 
type F toxin. Vaccine, 19: 288-97. 
This paper reports the construction and evaluation of a recombinant 
vaccine in E. coli which induced protection against botulinum toxin F. The project 
was conceived and directed by myself and was undertaken in collaboration with N. 
Minton and M. Mauchline at CAMR Porton Down who constructed the synthetic 
gene encoding the FHc fragment of the toxin. the recombinant protein was purified 
and evaluated by J. Holley (post-doctoral scientist), who worked in my group at 
CBD Porton Down. The data was analysed by J. Holley and myself and we jointly 
wrote the manuscript. 
Byrne, M.P., Titbaii.R.W., Holley,J. and Smith,L.A. (2000) Fermentation, 
purification, and efficacy of a recombinant vaccine candidate against botul inum 
neurotoxin type F from Pichia pastoris. Protein Expr. Purif., 18:327-37. 
This paper reports the expression of a recombinant recombinant vaccine in 
Pichia pastoris which induced protection against botulinum toxin F. The project 
was conceived in discussion with L. Smith at USAMRIID. The synthetic gene was 
constructed at CBD by J. Holley (post-doctoral scientist) and myself. The gene was 
expressed in P. pastoris and the recombinant protein purified and evaluated by 
M. Byrne and L. Smith at USAMRIID. The data was analysed jointly by L. Smith 
and myself and manuscript written jointly. 
Francisella tularensis. 
Antibiotic prophylaxis and therapy. 
Russeii,P. Eley,S.M., Fulop,M.J., Beii,D.L. and Titbaii,R.W. (1997) The efficacy of 
ciprofloxacin and doxycycline against experimental tularemia. J. Antimicrob. 
Chemotherapy, 41:461-465. 
In 1995 I initiated a programme of work to determine the efficacy of 
ciprofloxacin and doxycycline against a range of bacterial pathogens. This paper 
reports that both antibiotics offer protection against murine tularemia. I directed the 
work which was carried out by P. Russell, a post doctoral scientist in my group 
assisted by D. Bell a technician. M. Fulop and S. Eley helped to set up the animal 
model of disease. The data was analysed by P. Russell and myself and the 
manuscript written by P. Russell. 
Approaches to a new vaccine 
Leslie,D.L. , Cox,J., Lee,M. and Titball, R.W. (1993) Analysis of a cloned 
Francisel/a tularensis outer membrane protein gene and expression in attenuated 
Salmonella typhimurium. FEMS Microbial. Letts., 111 :331-336. 
lt had previously been reported that individuals who recovered from 
tularemia had serum antibody against the 43K outer membrane protein (OMP) of 
F. tularensis. I considered that an immune response to this protein might play a 
role in protection. The work was conceived, planned and directed by myself and 
carried out by D. Leslie a post-doctoral scientist in my group assisted by J. Cox 
and M. Lee who were sandwich course placement students at CBD Porton Down. 
The data was analysed jointly by D. Leslie and myself and we jointly wrote the 
manuscript. · 
Fulop,M., Manchee,R. and Titbaii,R. (1995) Role of lipopolysaccharide and a 
major outer membrane protein from Francisella tularensis in the induction of 
immunity against tularemia. Vaccine, 13:1220-1225. 
I conceived, planned and directed the work reported in this paper jointly 
with M. Fulop who worked in R. Manchee's group. I carried out the molecular 
biological work reported in the paper and M. Fulop purified LPS and carried out 
animal challenge studies. The data was analysed jointly by M. Fulop and myself 
and we jointly wrote the manuscript. 
Coulson,N.M., Fulop,M. and Titbaii,R.W. (1994). Effect of different plasmids on 
colonisation of mouse tissues by the aromatic amino acid dependent Salmonella 
typhimurium SL3261 . Microb. Pathog., 16:305-311. 
During work to express various microbial antigens in attenuated S. 
typhimurium we noticed that the presence of some plasmids appeared to limit the 
ability of the bacteria to colonise host tissues. I directed this work to investigate this 
effeect. The experimental work reported was carried out mainly by N. Coulson, a 
PhD student in my group. M. Fulop assisted with some of the animal experimental 
work. The data was analysed jointly by all of the authors and the manuscript was 
written by N. Coulson and myself. 
Fulop,M., Leslie,D. and Titbaii,R. (1996) A rapid, highly sensitive method for the 
detection of Francisel/a tularensis in clinical samples using the polymerase chain 
reaction. Am. J. Trop. Med. Hyg. , 54:364-366. 
I proposed that the nucleotide sequence of the F. tularensis 43K OMP was 
used as the basis for the development of a diagnostic PCR for tularemia and 
directed the work reported in this paper. The in vitro work was undertaken by D. 
Leslie a post-doctoral scientist in my group. M. Fulop undertook the in vivo work. 
The data was analysed by all of the authors and the manuscript written by M. 
Fulop. 
Karlsson,J., Prior,R.G., Williams,K. , Lindler,L. , Brown,K.A. , Chatweii,N., 
Hjalmarsson,K. , Loman,N. , Mack,K.A. , Pallen,M., Popek,M., Sandstrom,G., 
Sjostedt,A. , Svensson,T. , Tamas,l. , Andersson,S.G.E. , Wren,B.W., .Oyston,P.C.F 
and Titbaii,R.W. (1999) Sequencing of the Francisella tularensis strain Schu 4 
genome reveals the shikimate and purine metabolic pathways, targets for the 
construction of a rationally attenuated auxotrophic vaccine. Microb. Comp. 
Genomics, 5:25-39. 
In 1995 I suggested to F. tularensis research community in Europe and 
the US that we should work together to sequence the genome of a virulent strain 
of the bacterium. In 1996 the project commenced with collaborators from CBD 
Porton Down, NDRE Umea (Sweden), University of Uppsala (Sweden), Waiter 
Reed Army Institute for Research (USA), London School of Hygiene and Tropical 
Medicine, University of Belfast and St Bartholomews and the Royal London 
School of Medicine and Dentistry and Imperial College. DNA for this project was 
prepared by K. Mack (post-doctoral scientist in my group at CBD Porton Down) 
and the sequencing library was constructed by K. Will iams in B. Wren's group 
now at the London School of Hygiene and Tropical Medicine. Sequencing was 
carried out by R. Prior and N. Chatwell (research technicians at CBD Porton 
Down), M. Popek (research technician in L. Lindler's group at WRAIR), I. Tamas 
(research technician in S. Andersson's group at the University of Uppsala), J. 
Karlson and T. Svensson (graduate scientists in K. Hjalmarsson's and A, 
Sjostedt's groups at NDRE). N. Loman and M. Pallen provided data analysis 
capabilities and constructed the www site. The data was analysed mainly by 
myself, L. Lindler, S. Andersson, G. Sandstrom, K. Brown and P. Oyston. I wrote 
the manuscript, incorporating these inputs. 
Yersinia pestis 
Leary,S.E.C. and Titbaii,R.W. (1998). Plague. British Medical Bulletin, 54:625-
633. 
This paper provides a general review of plague throughout the world today, 
the Surat outbreak of disease and changing patterns of disease. The use of 
antibiotics and vaccines to prevent and treat disease is summarised. I was invited 
to provide the review for an issue of the British Medical Bulletin dealing with 
emerging pathogens. The manuscript was written jointly by myself and S. Leary. 
Russeii,P. , Nelson,M., Whittington,D., Green,M., Eley,S.M. and Titbaii,R.W. 
(1997) Laboratory Diagnosis of plague. Brit. J. Biomed. Sci., 54:231-236. 
This paper reviewed different methods for the diagnosis of plague and 
reports work undertaken at CBD to develop a PCR diagnostic test. The work to 
devise PCR based tests was conceived and directed by myself. Experimental work 
was carried out by post-doctoral scientists P. Russell and M. Green and post 
graduate scientists M. Nelson, and S. Eley. D. Whittington provided technical 
support. The data was analysed by P. Russell and myself and the manuscript was 
written by P. Russell. 
Antibiotic prophylaxis and therapy. 
Russeii,P., Eley,S.M., Beii,D.L. , Manchee,R.J. and Titbaii,R.W. (1996) 
Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia 
pestis infection in mice. J. Antimicrob. Chem., 37:769-774. 
In 1995 I initiated a programme of work to determine the efficacy of 
ciprofloxacin and doxycycline against a range of bacterial pathogens. The work 
reported here was conceived and directed by myself and experimental work 
planned by P. Russell. Experimental work was carried out by P. Russell (post-
doctoral scientist), S. Eley and R. Manchee (senior microbiologists). The data was 
analysed jointly by P. Russell and myself and the manuscript written by P. Russell. 
Russeii,P., Eley,S.M. Green,M., Stagg,A.J., Taylor,R.R. , Nelson,M., 
Beedham,R.J., Beii,D.L., Rogers,D. Whittington,D. and Titbaii,R.W. (1998) 
Efficacy of doxycydine and ciprofloxacin against experimental Yersinia pestis 
infection. J. Antimicrob. Chem., 41:301 -305. 
This paper reports the effectiveness of ciprofloxacin and doxycyline for the 
prevention and treatment of pneumonic plague in the mouse model of infection. 
The project was conceived and directed by me and experimental work planned by 
P. Russell, S. Eley and myself. This is a landmark paper for my group, because 
the work reported here was the first time we had aerosolised Y. pestis and caused 
a pneumonic infection in exposed mice. Experimental work was carried out by 
scientists in my group; P. Russell (post-doctoral scientist), S. Eley (senior 
microbiologist), M. Green (post-doctoral scientist), A. Stagg (senior research 
technician), R. Taylor (post-doctoral scientist), M. Nelson (post-graduate scientist), 
R. Beedham (post-graduate scientist), D. Bell (research technician}, D. Rogers 
(research technician) and D. Whittington (research technician). The data was 
analysed by P. Russell and myself and the manuscript written by P. Russell. 
Existing vaccines 
Russeii,P, Eley,S.M., Hibbs,S.E., Manchee,R.J., Stagg,A.J. and Titbaii,R.W. 
(1995) A comparison of plague vaccine, USP and EV76 vaccine induced 
protection against Yersinia pestis in a murine model. Vaccine, 13:1551-1556. 
This paper marks the start of the plague research programme, which I 
conceived and planned at CBD Porton Down. The initial phase of this programme 
involved establishing a murine model of disease, and evaluating the existing 
vaccines in this model. The experimental work was carried out by scientist in my 
group; P. Russell (post-doctoral scientist), S. Eley (senior microbiologist), A. Stagg 
(senior research technician) and S. Hibbs (research technician). The work was 
directed by myself. The data was analysed by P. Russell, R. Manchee and myself 
and the paper was written by P. Russell and myself. 
Titbaii,R.W., Eley,S., Williamson,E.D., and Dennis,D.T. (1999) Plague. p734-742. 
In; Vaccines, Plotkin,S.A., and Orenstein,W.A. (eds). W.B Saunders Company, 
Philadelphia. 
This book chapter provides a detailed summary of the properties of existing 
vaccines against plague and prospects for new vaccines. The book is aimed 
primarily at clinicians and researchers and provides details of vaccination regimes, 
contraindications and side effects. I was asked to write this chapter by S. Plotkin 
and I did this with additional inputs from S. Eley, D. Williamson and D. Dennis 
provided. 
A new sub-unit vaccine against plague. 
Leary,S.E.C., Williamson,E.D., Griffin,K.F. , Russeii,P. , Eley,S.M and Titbaii,R.W. 
(1995) Active immunisation with recombinant V antigen from Yersinia pestis 
protects mice against plague. Infect. lmmun., 63:2854-2858. 
This paper reported a method for the production of Y. pestis V-antigen in 
E.coli and evaluation of the recombinant V-antigen as a vaccine against plague. 
The Y. pestis vaccine programme at CBD Porton Down was conceived and 
directed by myself. All of the authors on this paper worked in my group. Gene 
cloning and protein purification was carried out by S. Leary (post-doctoral 
scientist), Animal challenge studies were carried out by P. Russell and S. Eley 
(post-doctoral scientist and senior microbiologist respectively). Antibody and T -cell 
assays were carried out by K. Griffin and D. Williamson (post-graduate scientist 
and senior immunologist respectively). The data was analysed mainly by S. Leary 
and myself, and we jointly wrote the manuscript. 
Anderson,G.W.Jr., Leary,S.E.C., Williamson,E.D., Titbaii,R.W., Welkos,S.L. , 
Worsham,P.L. and Friedlander,AM. (1996) Recombinant V antigen protects mice 
against pneumonic and bubonic plague caused by F1-capsule-positive and -
negative strains of Yersinia pestis. Infect. lmmun., 64:4580-4585. 
During a visit to the US Army Medical Research Institute for Infectious 
Diseases (USAMRIID), I discussed to possibility of a collaborative project to further 
evaluate the recombinant V-antigen we had produced at CBD Porton Down. The 
prject plan was developed by A Friedlander and myself. S. Leary (post-doctoral 
scientist) and D. Williamson (senior immunologist) in my group, produced 
recombinant V-antigen and provided details of our immunisation schedules. 
Challenge work at USAMRIID was carried out by G. Anderson, S. Welkos and P. 
Worsham. The data was analysed by A Friedlander and myself and the 
manuscript was written mainly by G. Anderson. 
Hiii,J., Leary,S.E.C., Griffin,K.F., Williamson,E.D. and Titbaii,R.W. (1997). Regions 
of Yersinia pestis V antigen that contribute to protection against plague identified 
by passive and active immunisation. Infect. lmmun., 65:4476-4482. 
This paper reports the results of studies to map the antigenic regions of V-
antigen. This work was conceived and directed by me and experimental work 
which was carried out by my group at CBD Porton Down. J. Hill and S. Leary 
(post-doctoral scientists) carried out the gene cloning and protein purification work. 
K. Griffin and D. Williamson (post-graduate scientist and senior immunologist 
respectively) carried out the animal challenge work and immunological analysis of 
samples. The monoclonal antibody used in this work had been generated under 
contract. The data was analysed by J. Hill, S. Leary and myself and the manuscript 
was written jointly by us. 
Pettersson, J., Holmstrom,A , Hiii,J., Leary,S., Frithz-Lindsten,E. , van Euler-Matell 
A, Carlsson, E. , Titbaii,R.W., Forsberg,A and Wolf-Watz,H. (1999) The V-antigen 
of Yersinia is surface exposed before target cell contact and involved in virulence 
protein translocation. Mol. Microbial., 32:961-976. 
During a visit to the National Defence Research Establishment (NDRE) in 
Sweden, I discussed, with A Forsberg, the possibility of collaborative work on the 
V-antigen of Y. pestis. Specifically, since antibody against V-antigen provided 
protection against experimental plague, I suggested that the V-antigen (part of the 
type Ill system) might be located on the surface of the bacterium. The project plan 
was developed by A Forsberg, H. Wolf-Watz, S. Leary and myself. Cell culture 
studies were carried out by J. Pettersson (University of Umea), AHolmstrom 
(NDRE) and E. Frithz-Lindsten (NDRE) and J. Hill (post-doctoral scientists in my 
group at CBD Porton). Electron and confocal microscopy was carried out by A van 
Euler-Matell (Karolinska Institute) and E. Carlsson (University of Umea). The data 
was analysed by A Forsberg, H. Wolf-Watz, S. Leary and myself. The manuscript 
was written mainly by J. Pettersson and A Forsberg. 
Miller,J., Williamson,E.D., Lakey,J.H., Pearce,M.J., Jones,S.M., and Titbaii,R.W. 
1998. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and 
the effect of structure on immunogenicity. FEMS lmmunol. Med. Microbiol., 
21:213-221. 
The work reported here was conceived and directed by myself. J. Miller, a 
post-doctoral scientist in my group carried out the purification and preliminary 
analysis of F1-antigen. M. Pearce (post doctoral scientist in the bio-detection group 
at CBD Porton Down) carried out CE studies with monomeric and multimeric forms 
of F1-antigen. J. Lakey (University of Newcastle carried out CD studies). Animal 
challenge and immunological analyses were carried out by D. Williamson (senior 
immunologist) and S. Jones (post doctoral scientist) CBD Porton Down. The data 
was analysed mainly by J. Miller and myself and we wrote this manuscript jointly. 
Williamson,E.D., Eley,S.M., Griffin,K.F. , Green,M.. Russeii,P., Leary,S.E.C., 
Oyston,P.C.F., Easterbrook,T., Reddin,K.M., Robinson,A and Titbaii,R.W. (1995) 
A new improved sub-unit vaccine for plague:the basis of protection. FEMS 
lmmunol. Med. Microbiol. , 12:223-230. 
This paper reports that immunisation of mice with a mixture of recombinant 
Y. pestis V and F1-antigens induced an immune response which provided high 
level protection against bubonic plague. The work was conceived and directed by 
myself, and was carried out in collaboration with A Robinson's group at CAMR 
Porton Down. Work at CBD Porton Down was carried out in my group; 
recombinant F1- and V-antigens were produced by S. Leary and P. Oyston (both 
post-doctoral scientists at CBD Porton Down) and K. Reddin and T. Easterbrook at 
CAMR Porton Down. Animal challenge work was carried out by S. Eley (a senior 
microbiologist), P. Russell and M. Green (both post-doctoral scientists) at CBD 
Porton Down. Immunological analysis of samples was carried out by D. Williamson 
(senior immunologist) and K.Griffin (post-graduate scientist) at CBD Porton Down. 
The data was analysed by D. Williamson and myself, and the manuscript written 
mainly by D. Williamson. 
Williamson,E.D. , Eley,S.M. , Stagg,AJ., Green,M., Russeii,P., Titbaii,R.W. (1997) 
A sub-unit vaccine elicits lgG in serum, spleen cell cultures and bronchial 
washings and protects immunised animals against pneumonic plague. Vaccine, 
15:1079-1084. 
This paper reports that immunisation of mice with the F1N-antigen sub-unit 
vaccine provides high level protection against pneumonic plague. The work 
reported here was conceived and directed by me and was carried out entirely by 
my group at CBD Porton Down. Animal challenge studies were carried out by S. 
Eley (a senior microbiologist), A Stagg (senior research technician), and P. 
Russell (post-doctoral scientist). Immunological analysis of samples was carried 
out by D. Williamson (senior immunologist) and M. Green (post-doctoral scientist). 
The data was analysed by D. Williamson and myself and the mansucript written 
mainly by D. Williamson. 
Williamson,E.D., Eley,S.M. Stagg,AJ., Green,M., Russeii,P and Titbaii,R.W. 
(2001) A single dose sub-unit vaccine protects against pneumonic plague. 
Vaccine, 19:566-571. 
This paper reports that protection against pneumonic plague can be 
achieved after a single immunising dose with a recombinant F1-V-antigen vaccine. 
The project was conceived and directed by myself. Animal challenge studies were 
undertaken by my group at CBD Porton Down; D. Williamson (senior 
immunologist), S. Eley (senior microbiologist), A Stagg (senior research 
technician), P. Russell and M. Green (post-doctoral scientists). The data was 
analysed jointly by D. Williamson and myself and the manuscript written jointly. 
Green,M., Rogers,D., Russell, P., Stagg, AJ., Beii,D.L. , Eley,S.M., Titbaii,R.W., 
Williamson,E.D. (1999) The SCID/Beige mouse as a model to investigate 
protection against Yersinia pestis. FEMS lmmunol. Med. Microbial., 23:107-113 
To investigate the role that antibody against F1 and V-antigens played in 
protection against plague, we used SCID/Beige mice. The work repo'rted here was 
directed by myself and carried within my group at CBD Porton Down. D. 
Williamson (senior immunologist) and M. Green (post-doctoral scientist) carried out 
the SCID/Beige mouse reconstitution and the immunological work reported. 
Animal challenge work was carried out by A Stagg, S. Eley, P. Russell (post-
doctoral scientist), D. Bell, and D. Rogers (both research technicians). The data 
was analysed by M. Green, D. Williamson and myself. The manuscript was written 
by M. Green. 
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as part of the plague sub-unit vaccine programme I had established at CBD Porton 
Down. The work reported here was conceiv~d and directed by myself. S. Eley (a 
senior microbiologist) and M. Green (post-doctoral scientist) carried out animal 
experimental work. Immunological analysis of samples was carried out by P. 
Vesey (sandwich course student), K Gillhespy (research technician) and D. 
Williamson (senior immunologist). The data was analysed by D. Williamson and 
myself and the manuscript written mainly by D. Williamson. 
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Vaccines for plague. International patent publication number WO 96/28551 . 
This patent describes the use of recombinant F1- and V-antigens from Y. 
pestis as a novel sub-unit vaccine against plague. The novel finding is there was a 
synergistic protective response when a mixture of the F1- and V-antigens were 
used in the vaccine. The patent arises from the work described in publications 
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Williamson,E.D., Sharp,G.J.E., Eley,S.M., Vesey,P.M., Pepper,T.C., Titbaii,R.V'I. 
and Alpar,H.O. (1996) Local and systemic immune response to a 
microencapsulated sub-unit vaccine for plague. Vaccine, 14:1613-1619. 
Under my direction, the plague vaccine programme moved towards 
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microencapsulated vaccine containing recombinant F1- and V-antigens. The 
programme of work involved a collaboration with 0. Alpar's group (G. Sharp, T. 
Pepper) at Aston University who microencapsulated the sub-units. Animal 
challenge studies were carried out by D. Williamson (senior immunologist) and S. 
Eley (a senior microbiologist) in my group. Immunological analysis of serum 
samples was carried out by P. Vesey, a sandwich course student at CBD Porton 
Down. The data was analysed by D. Williamson and myself and the manuscript 
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was carried out in my group at CBD Porton Down by H. Bullifent (post-doctoral 
scientist) and A Howells (research technician). Cell culture studies were carried 
out by C. Lindsay (senior scientist in the biology group at CBD Porton Down). 
Animal studies and immunological analyses were carried out by my group at CBD 
Porton Down by K. Griffin (post-graduate scientist) and H. Bullifent. Trehalose 
biosynthesis studies were carried out by K. Dhaliwal, K. Goan and A Tunnacliffe at 
Quadrant Biotechnology Ltd. The data was analysed by H. Bullifent, A 
Tunnacliffe and myself, and I wrote the manuscript. 
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In this paper the construction and evaluation of an aroA mutant of Y. pestis 
is reported. The project was conceived and directed by myself and planned with P. 
Oyston (post-doctoral scientist). The work was undertaken in my group at CBD 
Porton Down. The mutant was constructed by P. Oyston. The mutant was tested 
in animals by P. Oyston, D. Williamson (senior immunologist) and P. Russell (post-
doctoral scientist). The data was analysed by P. Oyston and myself, and we wrote 
the manuscript jointly. 
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London School of Hygiene and Tropical Medicine) who had an interest in two-
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Shu-Rui and N. Dorrell in B. Wren's group. Within my group, P. Oyston (post-
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and carried out stress response studies. M. Green (post-doctoral scientist) and P. 
Oyston carried out the macrophage survival studies. K. Williams, in B. Wren's 
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The work reported in this paper was conceived and directed by myself, 
and most of the work including purification and determination of the biological 
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was her external PhD supervisor. P. Hitchin and A. Dell (Imperial College) and A 
Reason (M-scan) carried out mass spectrometry studies. D. Williamson carried 
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compared with the sequence of the S. enterica serovar Typhi plasmid. The S. 
enterica serovar Typhi genome sequencing project was conceived by G. Dougan 
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pestis strains. Sequencing at the Sanger Centre was carried out K. James, S. 
Baker, M. Simmonds, K. Mungall and C. Churcher. Analysis of the data was 
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ciprofloxacin and doxycycline against a range of bacterial pathogens. The work 
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ciprofloxacin and doxycycline against a range of bacterial pathogens. The work 
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scientist), S. Eley (senior microbiologist) and D. Bell (research technician) The 
data was analysed jointly by P. Russell and myself and the manuscript written by 
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A fragment of DNA containing the gene coding for the phospholipase C (alpha-toxin) of Clostridium 
perfringens was cloned into Escherichia coli. The cloned DNA appeared to code only for the alpha-toxin and 
contained both the coding region and its associated gene promoter. The nucleotide sequence of the cloned DNA 
was determined, and an open reading frame was identified which encoded a protein with a molecular weight 
of 42,528. By comparison of the gene sequence with the N-terminal amino acid sequence of the protein, a 
28-amino-acid signal sequence was identified. The gene promoter showed considerable homology with the E. 
coli u 55 consensus promoter sequences, and this may explain why the gene was expressed by E. coli. The cloned 
gene produ~t appeared to be virtually identical to the native protein. A 77-amino-acid stretch that was close to 
the N terminus of the alpha-toxin showed considerable homology with similarly located regions of the Bacillus 
cereus phosphatidylcholine, preferring phospholipase C and weaker homology with the phospholipase C from 
Pseudomonas aeruginosa. 
Clostridium perfringens is the etjological agent of a wide 
variety of diseases of animals. In humans there is a signifi-
cant association of type A strains of the bacterium with 
wound infections, leading to gas gangrene. This is the 
disease caused by C. perfringens that is most studied in 
humans. The bacterium also causes a wide variety of other 
diseases such as necrotizing colitis in birds; necrotic enteritis 
in humans, calves, lambs, and pigs; and enterotoxemia in a 
variety of animal species (24). Strains of the bacterium can 
be classified as types A, B, C, or D, depending on the 
spectrum of toxins produced (24, 39); of these toxins the 
alpha-toxin has received the most attention. It was the first 
toxin for which an enzyme activity (phospholipase C) was 
implicated in conferring toxic properties on a bacterial 
product (20). 
Although many different bacterial phospholipase C en-
zymes have been isolated, few are as toxic as the alpha-
toxin, and this toxicity is thought to reflect two features of 
the protein; the enzyme exhibits a high turnover rate for 
phosphatidylcholine and sphingomyelin, which are key com-
ponents of eucaryotic cell membranes (28). Also, unlike 
many other bacterial phospholipase C enzymes, alpha-toxin 
is readily able to interact with cell membrane phospholipids 
rather than monodispersed phospholipid suspensions (13, 
30). These features combine to provide an index of phospho-
lipase C toxicity: the ability of the enzyme to promote the 
hemolysis of erythrocytes (39). · 
Over the past 50 years, a wealth of data has accumulated 
concerning both the physiology of toxin production by the 
bacterium (39) and some of the biophysical properties of the 
protein (24). It has been suggested that the toxin plays a key 
role in the pathogenesis of C. perfringens-mediated gas 
gangrene infections when it promotes local cell membrane 
disruption (15, 39). In support of this, prior immunization 
against alpha-toxin can prevent the establishment of the 
disease (15). The alpha-toxin may also play a key role in the 
pathogenesis of other diseases such as necrotic enteritis of 
fowl, in which extensive damage to intestinal villi occurs. 
• Corresponding author. 
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However, the difficulties associated with completely sepa-
rating the alpha-toxin from the multitude of other potential 
toxins produced by the bacterium make these data difficult to 
interpret (29). These problems have also limited the use of 
the enzyme as a phospholipid-specific membrane probe (6, 
41). We thought that the molecular cloning of the alpha-toxin 
gene into a suitable host bacterium would enable some of 
these problems to be resolved and, in addition, would enable 
us to examine the relationship of the protein structure to its 
function and antigenicity. Eventually, this will enable us to 
use immunogenic peptides or genes which encoue toxoids to 
induce protection against alpha-toxin and some C. perfrin-
gens infections. 
MATERIALS AND METHODS 
Enzymes and chemicals. Components for the preparation 
of growth media were obtained from Oxoid Ltd. (London, 
England) or Difco Laboratories (Detroit, Mich.). Restriction 
endonucleases, T4 DNA ligase, DNA polymerase I, Klenow 
fragment , and bacterial alkaline phosphatase were obtained 
from Boehringer Mannheim Biochemicals (lndianapolis, 
Ind.) and were used according to the instructions of the 
manufacturer. All other chemicals and biochemicals were 
obtained from Sigma Chemical Co. (St. Louis , Mo.) or BDH 
Ltd. (Poole , England), unless otherwise indicated. Chroma-
tography materials for DNA or protein purification were 
purchased from Pharmacia Fine Chemicals (Piscataway, 
N .J .) , unless otherwise stated. 
Bacterial strains and cultivation. Clostridial strains were 
cultured anaerobically at 37oC in a liquid medium containing 
Trypticase Peptone (3%; BBL Microbiology Systems), yeast 
extract (0.5%; Difco), glucose (0.5%), cysteine hydrochlo-
ride (0.05%), and sodium thioglycolate (0.1%) that was 
adjusted to pH 7.5 by the addition of Na2HP04 (TPYG 
broth). For the isolation of DNA or extracellular proteins, 
cells of C. perfringens NCTC 8237 were cultured in 6-liter 
volumes ofTPYG medium for 18 h, and the cells and culture 
fluid were separated by filtration through a 0.22-j.l.m-porc-
size membrane (Millipore Corp., Bedford, Mass.). 
Escherichia coli HB101, JM101, and CSH26 were stored 
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as glycerol stocks (22) and cultured on Luria agar (L-agar) or 
in L-broth (22) at 37°C. When necessary, the growth media 
were supplemented with ampicilJin (50 f!.g/ml). E. coli Jm107 
was maintained on a glucose-containing minimal medium 
(37). To induce and detect 13-galactosidase production, iso-
propyl-13-o-galactopyranoside (320 fl.M) and 5-bromo-4-
chloro-3-indolyl-13-o-galactoside (320 f!.g/ml) were incorpo-
rated into the solid growth medium. 
Detection of alpha-toxin activity. Alpha-toxin activity was 
detected by determining its effect on egg yolk lipoproteins 
(increase in turbidity) or sheep erythrocytes (hemolysis). 
Egg yolk emulsion (Oxoid) was centrifuged before use 
(10,000 x g, 20 min, 4°C), and the supernatant was incorpo-
rated into the solid growth medium (10% [vol/vol]). Defibri-
nated sheep blood was centrifuged (1,000 x g, 5 min, 4°C), 
and the celJ pellet was washed three times in phosphate-
buffered saline (Oxoid) before it was finally suspended to its 
original volume in buffer. The washed sheep blood cells were 
then incorporated into the solid growth medium (5% [ voU 
vol]). 
Alpha-toxin activity in liquid samples was detected by a 
microtiter tray assay. The samples (100 fJ-1} were serially 
diluted across the microtiter tray in 100-fl.l volumes of 
dimethylglutaric acid-NaOH buffer (40), and after the addi-
tion of diluted egg yolk emulsion supernatant to each well 
(100 fl.l; 10% [voUvol] in 0.9% saline), the microtiter tray was 
incubated at 37°C for 1 h. The phospholipase C activity of 
the original sample was expressed as the dilution which 
resulted in a 50% increase in the turbidity of the well 
contents and was expressed as egg yolk units per milliliter. 
For precise determinations, the optical densities at 620 nm of 
the microtiter tray well contents were determined with a 
plate reader (Flow Laboratories, Inc., McLean, Va.), and 
.the 50% endpoint was calculated. Hemolytic activity was 
also determined by a microtiter tray assay. Freshly drawn 
citrated blood was washed three times by centrifugation in 
phosphate-buffered saline and was suspended in borate-
buffered saline (0.2 M sodium borate, 7.5 g ofNaCI per !iter, 
1.8 g of CaC12 per I iter [pH adjusted to 7.6 with boric acid]) 
at 1% (voVvol). Microtiter tray dilutions of samples were 
made as described above in borate-buffered saline, and 
0.1-ml volumes of erythrocyte suspensions were added to 
each well. After incubation of the plates for 1 h at 37°C, the 
endpoint of this assay was considered to be the dilution 
causing 50% hemolysis of the erythrocytes (hemolytic units 
per milliliter) . In some experiments the hemolytic titer was 
also read after incubation for an additional 1 h at 4°C. 
Isolation and purification of DNA. DNA was isolated from 
the clostridia by the method of Marmur (23) , but it was 
modified to include a final digestion stage with proteinase K 
(50 f!.g/ml) for 18 h at 37°C. DNA extracted from C. perfrin-
gens type A strain NCTC 8237 was additionally purified by 
centrifugation through a gradient of cesium chloride without 
ethidium bromide (22) and was finally dialyzed against three 
1-liter volumes of 10 mM Tris hydrochloride buffer (pH 8.0) 
containing 1 mM EDT A (TE buffer) for 24 h at 4°C. The final 
preparation possessed an optical density at 260 nm/optical 
density at 280 nm ratio of 1.9. 
Small-scale plasmid DNA isolations were performed by 
the method of Holmes and Quigley (11). For the isolation of 
larger quantities of chloramphenicol-amplified plasmid DNA 
(22) , the method of Godson and Vapnek (8) was used; the 
DNA was then centrifuged through a cesium chloride den-
sity gradient (22). 
Construction of a C. perfringens genomic library. The DNA 
that was isolated from C. perfringens type A strain NCTC 
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8237 was partially digested with the restriction endonuclease 
Hind Ill to obtain fragments mainly in the size range of 3.2 to 
12.8 kilobase pairs (kbp) (mode, 5 kbp). The DNA fragments 
(1 fl.l) were mixed in a 1:1 molar ratio with an equal volume 
of Hindlll-digested plasmid pUC18 (100 f!.g/ml) , which was 
treated with bacterial alkaline phosphatase (50 U/fl.g, 30 min, 
65°C), and 0.1 U of DNA ligase was added (2 fJ-1}. Following 
the addition of 1 fl.l of 4X ligation buffer (22), the ligation 
reaction was allowed to proceed for 18 h at l2°C. After 
transformation into competent E. coli JM101 cells (Strata-
gene) , 3.1 x 1W ampicillin-resistant colonies were isolated 
per fl.g of plasmid. 
Maxicell analysis of plasmid-encoded polypeptides. Recom-
binant plasmid pT5C100 was transformed into E. coli CSH26 
cells that were made competent by the calcium chloride 
procedure (22). Plasmid-encoded proteins were radiolabeled 
with [35S]methionine (1), and the polypeptides were exam-
ined after sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE). 14C-labeled molecular weight 
marker proteins were obtained from Amersham Corp. (Ar-
lington Heights, 111.). 
Nucleotide sequencing. The cloned DNA fragment encod-
ing alpha-toxin was digested from its plasmid vector with 
Hind Ill and was isolated from agarose gels (0. 7%) by elec-
troelution. After suitable restriction endonuclease digestion, 
fragments were ligated with digested bacteriophage 
Ml3mp18 or M13mp19 and transfected into E. coli JM107 
cells that were made competent by the calcium chloride 
technique (22). Recombinant phages were detected after the 
transfected cells were coplated with E. coli cells from a 2-h 
culture in L-broth onto L-agar plates containing isopropyl-
13-o-galactopyranoside and 5-bromo-4-chloro-3-indolyl-~-o­
galactoside. 13-Galactosidase-negative plaques were picked, 
and after growth in E. coli JM107 for 6 h, the single-stranded 
M13 DNA was isolated by the method of Sanger et al. (37). 
Nucleotide sequencing was performed by the dideoxy chain 
termination method by using modified T7 DNA polymerase 
(Sequenase; USB Corp\ in accordance with the instruc-
tions of the manufacturer. Extension products were sepa-
rated by electrophoresis in 6% polyacrylamide gels contain-
ing 46% (wt/vol) urea (Aldrich Chemical Co. Ltd.) and were 
visualized after exposure to X-ray film (Hyperfilm l3max; 
Amersham). Some sequencing reactions required the use of 
oligonucleotide primers other than the standard Ml3 primer 
(USB Corp.). These were prepared by using a DNA synthe-
sizer (System 1 +; Beckman Instruments, Inc., Fullerton, 
Calif.) and were then purified by ion-exchange chromatog-
raphy (0.4 to 1.5 M NaCl gradient in 10 mM NaOH; Mono-Q 
fast-protein liquid chromatography [FPLC]), preparative 
polyacrylamide gel electrophoresis (20%), and centrifugation 
through columns of Gl5 Sephadex (22). The final DNA 
sequence was interpreted with a microcomputer system 
(DNAStar) and was compared with nucleotide sequences in 
the GenBank data base by using the NUSCAN program. 
The alpha-toxin amino acid sequence was compared with 
sequences in the DNAStar Protein Information Resource 
(PIR) data base by using the PROSCAN program. Hydrop-
athy profiles of selected proteins were generated by using the 
PROTEIN program. 
Fractionation of E. coli cells. E. coli HB101 cells containing 
plasmid pT5C100 were cultured for 20 h at 37°C in M9 
medium (25) buffered with Tris hydrochloride (0.05 M, pH 
7.4) and containing proteose peptone (0.2%), glucose (0.2%), 
CaC12 (100 mM), and L-proline (1 mM). The cells were 
harvested by centrifugation (10,000 x g , 20 min, 4°C) and 
were treated to extract the proteins that were located in the 
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periplasmic space or cytoplasm or membrane-bound pro-
teins, as described by Minton et al. (26). 
Purification of alpha-toxin. C. perfringens NCTC 8237 
culture filtrate was concentrated from 6 liters to 500 ml by 
ultrafiltration through a membrane with a molecular weight 
cutoff of 10,000 (Millipore) . The alpha-toxin was then pre-
cipitated with ammonium sulfate (50% saturation) for 1 h on 
ice, collected by centrifugation (10,000 X g, 20 min , 0°C) , 
and redissolved in a minimal volume of 10 mM Tris-1% 
glycine buffer (pH 7.5; TG buffer). The material was applied 
to a gel fi ltration chromatography column (2.2 by 60 cm; 
Ultrogel ACA 44), and the column was eluted with TG buffer 
at a flow rate of 0.2 ml/min. Fractions (7 ml) containing 
alpha-toxin were pooled, incorporated into a flat-bed elec-
trofocusing gel (pH 4 to 6.5 ; LKB lnstruments, lnc., Rock-
ville, Md .) , and electrofocused at 18 W for 6 hat 10°C. Gel 
fractions were obtained by eluting proteins with TG buffer, 
and the alpha-toxin was fi nally separated from carrier am-
pholytes by elution from an FPLC gel filtration chromatog-
raphy column (0.5 mllmin; Superose 12) with buffer (10 mM 
Tris, 5 mM CaCI2 , 2 mM ZnS04, 0.9% NaCI). The final 
preparations were stored at -20°C. In some experiments the 
alpha-toxin was purified by using two successive ion-ex-
change chromatography steps (flow rate, 1.5 ml/min; 20 mM 
triethanolamine hydrochloride buffer [pH 8]; 0.25 to 1.0 M 
NaCI gradient; FPLC Mono-Q column). The cloned alpha-
toxin was extracted from the periplasmic space of cells 
cultured in 2-liter volumes of brain heart infusion broth and 
then purified by either the electrofocusing or the ion-ex-
change chroma tography protocol described above. 
Protein assays on purified toxin samples were performed 
by the method of Bradford (2), with bovine serum gamma 
globulin fraction used as the standard protein . The assay 
reagent was obtained from Bio-Rad Laboratorie (Rich-
mond, Calif. ). 
Amino acid sequencing. The N-terminal amino acid se-
quence of the purified C. perfringens alpha-toxin was deter-
mined with a gas-phase sequencer (470A ; Applied Biosys-
tems) equipped with an on-line phenylthiohydantoin (PTH) 
analyzer (120A; Applied Biosystems). 
SOS-PAGE. Proteins were normally separated in poly-
acrylamide gels (7 .5 or 10%) by using a discontinuous buffer 
system (18) and stai ned with Coomassie brilliant blue R250. 
When maxicell-encoded polypeptides were analyzed by 
SOS-PAGE, the gel was subsequently dried and exposed to 
X-ray film to detect radiolabeled plasmid gene products. 
Molecular weight determination by gel fi ltration chromatog-
raphy. Samples of purified native or cloned alpha-toxin were 
applied to an FPLC column (Superose 12) and eluted with 50 
mM triethanolamine hydrochloride buffer (pH 8.0) contain-
ing 0.9% NaCI at a flow rate of 0.5 ml/min. The molecular 
weight of the alpha-toxin was determined by comparing its 
elution volume with those of proteins with known molecular 
weights (13-amylase, 200,000; bovine albumin , 66,000; car-
bonic anhydrase , 29,000; cytochrome c, 12,400). 
RESULTS 
Isolation of recombinant plasmids encoding C. perf ringens 
alpha-toxin. C. pe1jringens type A strain NCTC 8237 (ATCC 
13124) was the strain selected for cloning experiments be-
cause it has been the strain of choice for many previous 
studies on alpha-toxin. Chromo omal 0 A from this strain 
was isolated and purified, and after digestion with Hindlii it 
was ligated with suitably digested vector plasmid pUC18. 
After transformation of the resultant recombinant plasmids 
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FIG . l. Production of C. pe1jringens alpha-toxin {phospholipase 
C) by E. coli clones T5Cl00 and T6Cl534. (A) C. perfringens type A 
genomic DNA was cloned into E. coli JMlOl by using the plasmid 
vector pUC18. When the resultant clones were grown on agar 
containing egg yolk emulsion, two clones were isolated which were 
surrounded by a zone of turbidity (characteristic of phospholipase C 
activity). {B) When the alpha-toxin-producing clone T5Cl00 was 
cultured on agar containing egg yolk emulsion , which was previ-
ously swabbed with C. perfringens type A antiserum , complete 
inhibition of activity occurred. 
into £ . coli JM101, approximately 2,000 ampicillin-resistant 
colonies were isolated , of which 86% were found to be 
13-galactosidase negative, suggesting that these clones con-
tained plasmids with DNA inserts. When they were cultured 
onto L-agar containing ampicillin and egg yolk emulsion, 
two colonies containing recombinant plasmids pT5C100 and 
pT6C1534 were found to be surrounded by a zone of opacity , 
which is characteristic of the action of a lecithinase on this 
growth medium (21) (Fig . lA). Colonies of both clones were 
also found to be surrounded by a zone of hemolysis when 
they were cultured on agar containing sheep erythrocytes. ln 
contrast, £. coli JM101 containing pUC18 alone did not 
produce similar reactions. When clone T5C100 or T6Cl534 
was cultured onto solid medium which was previously 
spread with C. pe1jringens type A antitoxin , the zones of 
opacity (egg yolk agar) or hemolytic reaction (sheep eryth-
rocyte agar) were not observed around the colonies (Fig. 
lB). Normal serum did not cause a simiJar neutralization of 
these effects . 
Analysis of alpha-toxin-encoding recombinant plasmids. 
Phospholipase C (alpha toxin)-encoding recombinant plas-
mids (pT5ClOO and pT6C1534) were isolated , digested with 
Hindlll , and analyzed by agarose gel electrophoresis. Plas-
mid pT5C100 was found to make up pUCl8 and a 3.1-kb 
insert, while pT6Cl534 additionally contained inserts of 1.5, 
1.2, and 1 kb. When the insert fragments from pT6Cl534 
were recloned separately into pUC18, only those recombi-
nant plasmids containing the 3.1-kb DNA insert were found 
to encode the alpha-tox.in. The size of the zone of opacity 
surrounding these colonies on egg yolk agar was judged to be 
similar to the s ize of the zones of opacity surrounding 
colonies of either T5Cl00 or T6Cl534. The polypeptide-
coding potential of the 3.1-kb DNA insert in plasmid 
pT5ClOO was determined in a max.icell transcription-trans-
lation system. Plasmid pUC18 was found to encode a poly-
peptide with a molecular weight of 27,000 corresponding to 
the vector-encoded 13-lactamase. Plasmid pT5C100 was 
found to encode a polypeptide with a molecular weight of 
41 ,000 (mean of two determinations) and several polypep-
tides with molecular weights of 27,000 to 29,000, which may 
represent different forms of 13-lactamasc. 
Physical mapping of the alpha-toxin-encoding DNA. The 
3.1-kb Hindlll DNA insert from recombinant plasmid 
pT5ClOO was examined for the presence of restriction endo-
nuclease digestion sites, and a physical map of the DNA 
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- -FIG. 2. Physical map of the 3.1-kb alpha-toxin-encoding DNA 
insert from plasmid pT5ClOO. (A) Restriction endonuclease diges-
tion sites. (B) Alpha-toxin-positive and -negative subclones gener-
ated in plasmid pUC18. (C) Subclones generated in bacteriophage 
M13 ror DNA sequencing. (D) Strategy used to determine the 
nucleotide sequence of the alpha-toxin gene. 
fragment was constructed (Fig. 2A). The presence of a 
unique , asymmetrically placed BamHI site enabled the ori-
entation of the insert to be determined easily in recombinant 
plasmids generated by the ligation of the alpha-toxin-en-
coding insert with pUC18 vector plasmid. Expression of the 
alpha-toxin gene was shown to occur with the DNA insert in 
either orientation. In addition , when these clones were 
cultured on egg yolk agar, with or without isopropyl-f3-
o-galactopyranoside added (to induce the lac promoter), no 
change in the size of the zone of opacity surrounding the 
colonies was observed. These results indicate that the 3.1-kb 
DNA insert contains the alpha-toxin structural gene, to-
gether with its gene promoter, which is active within the£. 
coli host. 
The physical map was also used to indicate restriction 
sites which could be used to generate subclones of the 3.1-kb 
alpha-toxin-encoding DNA; after partial digestion with 
Sau3A, the resultant fragments were ligated with suitably 
digested vector plasmid pUC18. A number of constructs 
were obtained (Fig . 2B); however, only recombinant plasmid 
pT2.2 (containing a 2.2-kb DNA insert) was found to encode 
the alpha-toxin. In later experiments , the coding region was 
further delineated by generating a 1.8-kb Hindiii-EcoRI 
subclone of pT2.2 (Fig. 2B). 
Nucleotide sequence determination of the alpha-toxin-en-
coding DNA. The nucleotide sequence of the 2.2-kb DNA 
insert which encoded the alpha-toxin was determined after 
suitable restriction fragments were subcloned into bacterio-
phage Ml3 (Fig. 2C). The sequencing strategy involved the 
use of synthetic oligonucleotide primers, when appropriate , 
to determine the nucleotide sequence of both strands within 
the gene promoter and protein-coding regions (Fig. 2D). 
Examination of the nucleotide sequence (Fig. 3) revealed 
several open reading frames ; however, all but one of these 
were much shorter than the predicted alpha-toxin-coding 
region. In addition , results of our maxicell experiments 
described above indicated that a single polypeptide was 
encoded by the DNA insert. An open reading frame extend-
ing from base 943 to base 2137 would encode a protein with 
a molecular weight of 45,480. The open reading frame was 
terminated by two consecutive T AA stop codons, with a 
third in-frame stop codon apparent 3 bases downstream. 
Comparison of the putative coding sequence with the 
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experimentally determined alpha-toxin N-terminal amino 
acid sequence revealed homology starting at nucleotide 
1027. This may indicate the start of the mature alpha-toxin 
polypeptide. The amino acids encoded between the start 
codon and nucleotide 1027 could form a signal sequence 
directing transport of the alpha-toxin across the cell mem-
brane. The proposed signal sequence would consist of a 
short charged N-terminal stretch followed by a hydrophobic 
core, which in turn would be followed by an amino acid 
stretch, fulfilling the criteria for a signal sequence cleavage 
site (47). Several other observations confirm this suggestion; 
the native alpha-toxin is known to be exported into the C. 
perfringens growth medium (40), and we found that the 
cloned protein is translocated across the £ . coli cytoplasmic 
membrane into the periplasmic space. 
lf the alpha-toxin is synthesized as a precursor and is 
subsequently processed, then the calculated molecular 
weight of the mature toxin would be 42,528, which was in 
good agreement with our experimentally determined molec-
ular weight of the native or cloned alpha toxins (43,300). 
Some differences were seen when the deduced amino acid 
composition of the protein was compared with the experi-
mentally determined amino acid compositions reported pre-
viously. In particular, Mitsui et al. (27) failed to detect 
proline or cysteine within the alpha-toxin (Table 1), whereas 
we predicted that there are significant numbers of the former 
amino acid in the mature protein. The proportions of amino 
acids in the alpha-toxin, as determined by Krug and Kent 
(16), are comparable with our deduced composition. The 
acid hydrolysis step used by both groups of investigators (16, 
27) would have promoted the destruction of tryptophan 
residues and prevented detection of this amino acid. 
The coding region was found to contain 34% G+C resi-
dues , which is close to the reported C. perfringens G+ C 
content of 24 to 27 mol% (3). As expected from this result, 
there was a marked preference for adenine or thymine in the 
first or third position of codon triplets . 
The nucleotide sequence was examined for the presence 
of promoterlike sequences. Five consecutive G residues 
located 9 bases upstream of the proposed translation start 
point at position 943 could form a stable hybrid with the 3' 
end of the£. coli 16S rRNA subunit (38), and such a duplex 
would be energetically favorable (ilG = - 10 kcal) (43). This 
spacer sequence extending downstream to the translation 
start point showed many features that are normally associ-
ated with such a sequence: the region was rich in purine 
residues and contained no guanine residues at positions - 1, 
- 3, or -7 before the translation start point (48). 
Upstream of the proposed Shine-Dalgarno region starting 
at base 863 there was a heptanucleotide stretch homologous 
with the £. coli a55 RNA polymerase -10 consensus recog-
nition sequence (TATAAT) (36) . At 17 bases upstream from 
the proposed -10 recognition sequence, a pentanucleotide 
stretch showing 50% homology with the reported ~s -35 
consensus sequence (TTGACA) (36) was found . In addition, 
the nucleotide stretches adjacent to the proposed -10 and 
-35 recognition sequences showed considerable homology 
to the a55 consensus sequence for these regions (36). Several 
other clostridial genes have been shown to possess £. coli 
a55 promoterlike sequences (50); some, like the alpha-toxin 
- 10 sequence that we have proposed , are completely ho-
mologous with the TAT AAT consensus sequence, with 
much weaker homology with the -35 sequence. The 17-
nucleotide spacing between the putative - 10 and -35 rec-
ognition sequences of the alpha-toxin gene is similar to the 
optimal distance for strong gene expression in E. coli (36) 











GGGAGATTAATACTTGAAAAAAATTAACGGGGGATATAAAAAATGAAAAGAAAGATTTGTAAGGCGCTTATTTGTGCCGCGCTAGCAACTAGCCTATGGG 1000 SD.'"" llkrkicka1icaa1ats1wa 
CTGGGGCATCAACTAAAGTCTACGCTTGGGATGGAAAGATTGATGGAACAGGAACTCATGCTATGATTGTAACTCAAGGGGTTTCAATCTTAGAAAATGA 1100 
9 a s t k v y a !w d 9 k i d 9 t g t h a • i v t q g v s i 1 e n d 
TCTGTCCAAAAATGAACCAGAAAGTGTAAGAAAAAACTTAuAGATTTTAAAAGAGAACATGCATGAGCTTCAATTAGGTTCTACTTATCCAGATTATGAT 1200 
1 s k n e P e s v r k n 1 e i 1 k e n • h e 1 q 1 g s t y p d y d 
AAGAATGCATATGATCTATATCAAGATCATTTCTGGGATCCTGATACAGATAATAATTTCTCAAAGGATAATAGTTGGTATTTAGCTTATTCTATACCTG 1300 
k n a y d 1 y q d h f w d p d t d n n f s k d n s w y 1 a y s i p d 
ACACAGGGGAATCACAAATAAGAAAATTTTCAGCATTAGCTAGATATGAATGGCAAAGAGGAAACTATAAACAAGCTACATTCTATCTTGGAGAGGCTAT 1400 
t g e s q i r k f s a 1 a r Y e w q r g n y k q a t f y 1 g e a • 
GCACTATTTTGGAGATATAGATACTCCATATCATCCTGCTAATGTTACTGCCGTTGATAGCGCAGGACATGTTAAGTTTGAGACTTTTGCAGAGGAAAGA 1500 
h y f g d i d t p Y h p a n v t a v d s a 9 h v k f e t f a e e r 
AAAGAACAGTATAAAATAAACACAGCAGGTTGCAAAACTAATGAGGCTTTTTATACTGATATCTTAAAAAACAAAGATTTTAATGCATGGTCAAAAGAAT 1600 
k P q y k i n t a g c k t n e a f y t d i 1 k n k d f n a w s k e y 
ATGCAAGAGGTTTTGCTAAAACAGGAAAATCAATATACTATAGTCATGCTAGCATGAGTCATAGTTGGGATGATTGGGATTATGCAGCAAAGGTAACTTT 1700 
a r 9 f a k t g k s i y y s h a s • s h s w d d w d y a a k v t 1 
AGCTAACTCTCAAAAAGGAACAGCGGGATATATTTATAGATTCTTACACGATGTATCAGAGGGTAATGATCCATCAGTTGGAAAGAATGTAAAAGAACTA 1800 
a n s q k g t a g y i y r f 1 h d v s e g n d p s v g k n v k e 1 
GTAGCTTACATATCAACTAGTGGTGAGAAAGATGCTGGAACAGATGACTACATGTATTTTGGAATCAAAACAAAGGATGGAAAAACTCAAGAATGGGAAA 1900 
v a Y i s t s 9 e k d a g t d d y • y f g i k t k d g k t q e w e m 
TGGACAACCCAGGAAATGATTTTATGACTGGAAGTAAAGACACTTATACTTTCAAATTAAAAGATGAAAATCTAAAAATTGATGATATACAAAATATGTG 2000 
d n p g n d f m t g s k d t y t f k 1 k d e n 1 k i d d i q n 11 w 
GATTAGAAAAAGAAAATATACAGCATTCTCAGATGCTTATAAGCCAGAAAACATAAAGATAATAGCAAATGGAAAAGTTGTAGTGGACAAAGATATAAAC 2100 
i r k r k y t a f s d a y k p e n i k i i a n g k v v v d k d i n 
GAGTGGATTTCAGGAAATTCAACTTATAATATAAAA~TAAAAGTAAAAAAATAATTATTGGTTTTGGTGGTATTTACAAAATAAAAGCTT 2192 
l' w i s g n ~ t y n i k atp iiii' iiii' 
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FIG. 3. Nucleotide sequence of the 2.2-kb alpha-toxin-encoding DNA fragment. The experimentally determined amino acid sequence of 
the N tenninus of the mature alpha-toxin is boxed. Possible Shine-Dalgamo (S.D.) and -10 and -35 recognition sequences are underlined. 
stp, Stop codon. 
and is similar to the reported spacer lengths in other clostrid-
ial genes (50). 
A 31-base poly(An stretch observed upstream of the 
proposed -35 box was found to contain a tandemly repeated 
sequence TA TTCAAAAAT and may play a role in the 
expression of the alpha-toxin gene. Similar AT-rich se-
quences have been observed upstream of genes that have 
been isolated from other gram-positive bacteria (31), and the 
function of such sequences may be to prevent interaction 
with histonelike proteins (32), which enhances the accessi-
bility of the gene. 
The nucleotide sequence downstream of the translation 
stop codon (position 2137) was examined for the presence of 
possible transcription termination signals. This stretch was 
found to have the potential to code for a number of short 
stem loops; a 6-base-pair stem loop centered at nucleotide 
pair 2173.5 may represent a [rho]-dependent termination 
signal; alternatively, a 4-base-pair stem loop centered at 
nucleotide pair 2164 and followed by a short poly(T) stretch 
may function as a [rho ]-independent termination signal. 
Alpha-toxin sequence homology with other phosphoUpases. 
No significant homology was detected between the mature 
alpha-toxin and the reported nucleotide or amino acid se-
quences of the Staphylococcus hyicus lipase (9) or any of 
the eucaryotic A2 or C phospholipases in the PIR (amino 
acid sequence) or GenBank (Los Alamos National Labora-
tory; nucleotide sequence) data bases. A significant level of 
amino acid homology has been found between the nontoxic 
phosphatidylcholine-preferring phospholipase C of Bacillus 
cereus (14) and the alpha-toxin; this homology appears to be 
maximal (34%) in an area containing histidine residues (D. 
Leslie, N. Fairweather, D. Pickard, G. Dougan, and M. 
Kehoe, submitted for publication). The phospholipase C of 
Pseudomonas aeruginosa showed little overall amino acid 
homology with the alpha-toxin, but a 77-amino-acid stretch 
was identified which was 26% homologous. The stretches of _ 
maximal homology among the B. cereus phospholipase C, 
the alpha-toxin, and the P. aeruginosa enzyme were all 
found close to the N terminus of the proteins and were 
located approximately in the same region (Fig. 4). 
Further examination of structural homologies was under-
taken by comparing the hydropathic potentials of the mature 
alpha-toxin and B. cereus enzymes predicted by using the 
methods of Hopp and Woods (12) or Kyte and Doolittle (17). 
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TABLE 1. Comparison of the predicted and 
experimentally determined amino acid composition of the 
mature C. perfringens alpha-toxin 
No. predicted from No. experimentally determined by: Amino acid DNA sequence• Mitsui et al. (26)b Krug and Kent (16)' 
Ala 26 30 30 
Arg 9 10 9 
Asn 26 29 
Asp 35 55 36 
Cys 1 0 2 
Gin 10 11 
Glu 23 40 26 
Gly 25 35 29 
His 9 15 8 
lie 22 20 22 
Leu 16 20 17 
Lys 36 40 39 
Met 8 5 9 
Phe 15 15 16 
Pro 9 0 9 
Ser 25 30 27 
Thr 25 25 28 
Trp 10 NDd ND 
Tyr 26 20 26 
Val 14 15 15 
Total 370 375 388 
• Calculated from the nucleotide sequence of the cloned alpha-toxin gene. 
b Data from Mitsui et al. (27), which were determined experimentally from 
purified C. perfringens alpha-toxin. 
< Data from Krug and Kent (16). which were determined experimentally 
from purified C. pufring~ns alpha-toxin. 
4 ND, Not determinable. 
The alpha-toxin was predicted to possess a 13-amino-acid 
N-terminal hydrophobic region (fig. 5A), while the nontoxic 
B. cereus enzyme possessed an N-terminal hydrophilic 
region (Fig. 5B). 
The site of accumulation of cloned alpha-toxin in E. coli. 
The alpha-toxin-encoding recombinant plasmid pT5ClOO 
was transformed into E. coli HBlOl, and a resultant clone 
was used to elucidate the site of accumulation of the cloned 
alpha-toxin in E. coli. The results (Table 2) indicated that 
most of the alpha-toxin produced was translocated across 
the cytoplasmic membrane and then accumulated within the 
periplasmic space of the bacterium. When proteins found in 
the periplasmic space were extracted and examined by 
SDS-PAGE, a major protein band was observed which 
migrated with the same mobility as the purified alpha-toxin 
(fig. 6). 





FIG. 5. Predicted hydropa thic potentia ls of C. perfringens alpha-
toxin and B. cereus phosphatidylcholine-preferring phospholipase 
C. The hydropathic potentials of alpha-toxin (A) and B. cereus 
phosphatidylcholine-prefening phospholipase C (B) were predicted 
by the method of Hopp and Woods (12). Hydrophobic (positive) and 
hydrophilic (negative) values are plotted on the x axis for each 
window of six residues. The probable signal sequence cleavage sites 
(alpha-toxin) or proenzyme activation cleavage sites (B. cereus 
enzyme) are indicated with arrows. The possible membrane-span-
ning N-terminal sequence in the mature alpha-toxin is underscored. 
Purification of the native and cloned alpha-toxins and 
elucidation of their biophysical properties. The native C. 
perfringens alpha-toxin was purified by a combination of 
selective ultrafiltration, ammonium sulfate precipitation, gel 
filtration chromatography, and flat-bed electrofocusing. The 
cloned alpha-toxin was isolated from the periplasmic space 
of E. coli and then purified by the column chromatography 
and electrofocusing steps outlined above. The C. perfringens 
native alpha-toxin purified in this way was separated into a 
major form of the toxin with a pi of 5.48 and a minor form of 
the toxin with a pi of 5.6. In contrast, when the cloned 
alpha-toxin was fractionated by a similar technique, the form 
of the alpha-toxin with a pi of 5.6 was the major form that 
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FIG. 4. Region of maximal homology between the phospholipase C enzymes of C. perfringens (alpha-toxin), B. cereus (phosphatidyl-
choline-prefening enzyme), and P. aeruginosa. (A) Location of regions of maximal homology (shaded) in the phospholipases C enzymes of 
C. perfringens (a-tox), B. cereus(BcPLC), and P. aeruginosa (PaPLC). (B) Alignment of amino acids within the region of maximal homology. 
PaPLC, P. aeruginosa phospholipase C, amino acids 52 to 129 (35); a-tox, C. perfringens a lpha-toxin, amino acids 69 to 145; BcPLC, B. 
cereus phospholipase C , amino acids 69 to 146 (14). Double points indicate frequently substituted amino acids, and single points indicate 
rarely substituted amino acids. 
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TABLE 2. Site of accumulation of cloned alpha-toxin 
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• E. coli cells contained plasmid pT5ClOO (pUC18 and a 3.1-kb DNA insen 
encoding C. pufringtms alpha-toJtin). Cells were grown for 20 h in a Tris-
buffered liquid medium and were Lhen treated under the conditions described 
in the teJtt so that proteins would be released. The cell fractions were 
subsequently assayed for marker enzyme activities. The periplasmic space 
marker protein was alkaline phosphatase (44), the cytoplasmic marker protein 
was f3-galactosidase (25). and Lhe membrane-associated marker protein was 
NADH oxidase (33). 
was detected (Fig. 7). The specific activities of the forms of 
the alpha-toxin with pis of 5.48 and 5.6 were similar within 
an experiment, although variations between experiments 
were observed. The alpha-toxins with both forms of pi 
retained their identities when they were reexamined by using 
analytical electrofocusing, both in the presence and the 
absence of 6 M urea. In some experiments, minor protein 
bands with pi values of 5.15 and 5.3 were observed. 
The molecular weights of both the native and cloned 
alpha-toxins were estimated to be 43,300 after the samples 
were examined by SDS-PAGE (Fig. 6) (mean of 13 determi-
nations). No difference in the mobilities of the pi 5.48 or pi 
5.6 forms of the native alpha-toxin was observed. When the 
molecular weight of similar alpha-toxin samples was deter-
mined by gel filtration chromatography, a much lower mo-
lecular weight was obtained (25,600; mean of three determi-
nations). 
The purified cloned alpha-toxin (100 fJ.g/ml) was found to 
cause the hemolysis of murine erythrocytes (640 hemolytic 
units per ml) when tested at 37°C in a microtiter tray assay. 
The toxin showed no activity against horse, sheep, rat, or 









FIG. 6. SOS-PAGE (10%) of proteins extracted from the pen-
plasmic space of£. coli and pUC18 (lane 2) or £ . coli and pT2.2 
(lane 3), purified forms of cloned alpha-toxin with pis of 5.6 and 5.48 
(675 ng; lane 4) , the purified form of native alpha-toxin with a pl of 
5.45 (610 ng; lane 5) , the purified form of alpha-toJtin with a pi of 5.6 
(500 ng; lane 6), or C. perfringens extracellular protetns (lane 7). 
Lane 1 contains molecular weight markers, as follows: bovine 
albumin, 66,000; ovalbumin, 45,000; glyceraldehyde-3-phosphate 
dehydrogenase, 36,000; carbonic anhydrase, 29,000; trypsinogen , 
24,000; trypsin inhibitor, 20,100; and a-lactalbumin , 14,200. 
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FIG. 7. Laser densitometer scan of analytical isoelectrofocusing 
gel (pH 3 to 9 ; Phast system; Pharmacia) stained with Coomassie 
brilliant blue R250. The bar on the x axis indicates an optical density 
at633 nm ofO.l. (A) pi marker proteins; (B) purified native forms of 
alpha-toxin with mixed pis; (C) purified cloned forms of alpha-toxin 
with mixed pis; {D) purified native alpha-toxin with a pi of 5.6; (E) 
purified native alpha-toxin with a pl of 5.48. 
rabbit erythrocytes. Some previous investigators (24) have 
found that the hemolysis of erythrocytes by the alpha-toxin 
is greatly increased if the erythrocytes are cooled to 4°C 
following the 37°C incubation step. We did not obtain a 
similar result with the purified cloned alpha-toxin; no in-
crease in hemolytic titer was detected after any of the 
alpha-toxin-treated erythrocytes were cooled to 4°C for 1 h; 
in this respect our results are similar to those reported by 
Molby (28). 
It has been reported that C. pe1jringens alpha-toxin is 
inactivated when it is heated to 60 to 70°C and is partially 
reactivated on further heating to l00°C (39). We obtained a 
similar result with the cloned alpha-toxin (36 fJ.g/ml , 2,560 
egg yolk units per ml); after the cloned alpha-toxin was 
heated to 60°C for 10 min in phosphate-buffered saline, only 
12.5% of the initial phospholipase C activity was detected; 
however, after incubation for a similar period at 90°C, the 
enzyme retained 50% of the initial activity. A similar pattern 
of inactivation was observed when the hemolytic activity of 
the samples was determined against murine erythrocytes. 
Initially, the immunological identity of the purified native 
or cloned toxin was assessed by an Ouchterlony double-
diffusion technique. Alpha-toxin samples (forms with pis of 
5.48 or 5.6) were allowed to react with C. perfringens type A 
antiserum, and a single line of identity was observed be-
tween all of the samples tested (Fig. 8) , indicating that some 
or all of the major epitopes are shared by the native and 
cloned toxins. 
DISCUSSION 
A segment of the C. perfringens genome which encodes 
the alpha-toxin gene was cloned into E. coli by using a 
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FIG. 8. Immunodiffusion reactions of C. pe1jringens type A 
a ntiserum (center well) against crude C. pe1jringens culture filtra te 
(welll): purified C. perfringens alpha-toxin with a pi of 5.48 (well 2): 
o r alpha-toxin with a p l of 5.6 (well 3), purified cloned alpha-toxin 
with a pl of 5.48 (well 4), a lpha-toxin with a pl of 5.6 (well 5), or 
bovine serum albumin (well 6). 
plasmid vector. Expression of the clo ned gene appeared to 
be mediated by the associated promoter sequences. The 
pUC18 vector lac promoter appeared to play no role in the 
expression of the cloned gene. Examination of the nucleo-
tide sequence of the cloned gene revealed potential u 55 -10 
and -35 recognition sites (36) ups tream of the protein-
coding sequence and a 31-base poly(AT) stretch upstream of 
the proposed - 35 sequence. 
The translation termination point of the alpha-toxin ge ne 
was marked by repeated stop signals, a feature that is rarely 
observed within procaryotic genes and the significance of 
which is no t known. The short s tem loops identified down-
stream of the translation stop codon may act as transcription 
termination points; a lternatively , the transcription termina-
tor was located downstream of the frag ment that we cloned 
and sequenced. Nucleotide sequence data for other clostrid-
ial genes suggests that [rho ]-independent transcription stop 
signals are often used in this ge nus (4, 7) . 
Although the location of the proposed alpha-toxin pro-
moter sequences would require experimental confirmation , 
we believe that the sequences we have suggested here and 
their relative positions would cooperatively result in gene 
expression. This was confirmed by the experimental results 
to some extent. Alpha-toxin is known to be one of the majo r 
extracellular products of C. perfringens (40), and we dem-
onstrated expression of the alpha-toxin gene in E. coli. With 
the exception of C. pe1jringens bacteriocin (7), all other 
reported clostridial genes that have been cloned into E. coli 
have been expressed. The biased AT-rich codon usage was 
suggested as the reason for the lack of expression of the 
bacteriocin gene in E. coli, but we found that the codon 
usage in the bacteriocin and alpha-toxin genes is a lmost 
identical. 
The alpha-toxin appeared to contain a typical signal se-
quence , and on expo rt of the protein the act ive toxin was 
released into the culture supernatant. The pho phatidylcho-
line-preferring phospholipase C from B . cere us exhibits 
considerable amino acid sequence homology with the alpha-
toxin (L eslie et al. , submitted), and this protein possesses a 
signal sequence, although it is exported into the growth 
medium as a proenzyme requiri ng proteolytic cleavage of a 
14-amino-acid N-terminal fragment for activation (14). 
Our observation that C. pet/ringens alpha-toxin can exist 
in two major forms with different pis is well documented 
(24), but we were unable to confirm the suggestion of Smyth 
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and Arbuthnott (40) that 6 M urea can induce the conversion 
of these two forms to a single species. It is unlikely that the 
forms with different pis are artifacts induced by the elect ro-
focusing , because the two forms with different pis retained 
their identit ies when they were individually refocused . The 
minor bands that we observed with pi values of 5.15 and 5.3 
may be comparable to the minor forms of the toxin observed 
by Takahashi e t al. (42) . Microheterogeneity of bacterial 
toxins is a common observation and may result from a 
posttranslational modification, such as deamidation or phos-
phorylation of the protein. Our observation that the major pi 
form of the toxin is different when the gene is expressed in E. 
coli may indicate that such modification systems are not the 
same. 
The calculated molecular weight of the mature alpha-toxin 
(42,528) is in c lose agreement with our experimentally deter-
mined value of 43,300. Previously reported molecular weight 
values determined by SDS-PAGE have been within the 
range of 41 ,000 to 90,000 (28), a lthough more recent reports 
have indicated molecular weights closer to the former value 
(5, 16, 42 , 49). Our results, indicating that the apparent 
molecular weight of the protein was much lower when 
determined by gel filtrat ion chromatography, are also in 
agreement with previously reported resul ts (24) and may be 
due to the hyd rophobic interaction of the protein with the 
agarose-based support matrix. 
We have predicted that there is only one cysteine residue 
per protein molecule , suggesting that intramolecular disul-
fide bonds cannot be involved in promoting structural s ta-
bi lity, and it is of interest that the pho pholipase C from B. 
cereus has also been reported to lack any disulfide bonds , 
yet it is also conformationally very stable (34). The obser-
vation by Krug and Kent (16) that alpha-toxin can exist in a 
minor form as an active dimer may reflect the formation of 
intermolecular disulfide bridges between the single cysteine 
residues in the protein. 
Interpretation of the significance of the aligned homolo-
gous regions of the alpha-toxin with the B. cere us and the P. 
aeruginosa pho pholipase C enzymes was made difficult by 
the observation that there was no direct homology between 
the B . cereus and P. aeruginosa enzymes. One explanation 
is that the proteins represent stages in the evolution of the 
smaller B. cereus phospholipase C. Alternatively, conver-
gent evolution may be responsible for the homologous region 
of the P. aeruginosa enzyme and the alpha-toxin. 
In contrast with the P . aeruginosa enzyme, which has not 
been reported to contain bound metal ions, the B. cereus 
phospholipase C has been found to contain two zinc ions that 
are essential for its activity (19), and alpha-toxin has been 
reported to contain two zinc ions (16). The histidine res idues 
which are found in the homologous regions of the alpha-
toxin and B. cereus enzyme may be involved in the binding 
of structura lly or catalytically important zinc ions. The 
absence of zinc ion redox chemistry would mean that the 
conformation and activity of the a lpha-toxin are conserved 
under the reducing conditions required for the growth of C. 
perfringens. The P. aemginosa phospholipase C did no t 
contain a ligned histidine residues within the homologous 
region. 
One difference between the alpha-toxin and the B . cereus 
phospholipase C is that although the C. petfringens enzyme 
is toxic , the B. cere us enzy me is not. This may re flect the 
reported abi lity of the alpha-toxin to damage a variety of 
eucaryotic ce ll membranes (28, 39). The purified cloned 
alpha-toxin that we tested represents the first preparation 
which is known to be completel y devoid of o ther C. pe1jrin-
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gens membrane-active proteins such as a and 8 toxins (24). 
The cloned alpha-toxin was capable of promoting the hemo-
lysis of murine erythrocytes, which have previously been 
reported to be the most sensitive to hemolysis by alpha-toxin 
(24); but our observation that rabbit, sheep, and human 
erythrocytes are insensitive suggests that previous studies 
indicating that alpha-toxin can promote lysis of these eryth-
rocytes when tested in a microtiter tray assay may, in fact , 
reflect the contamination of these preparations with other 
toxins. Our initial observation that weak hemolysis was 
detected around E. coli cells containing the alpha-toxin-
encoding recombinant plasmid which were cultured on 
sheep erythrocyte agar may reflect the increased sensitivity 
of this detection method . 
The ability of the alpha-toxin to interact with eucaryotic 
membranes may represent an important difference when 
compared with the interaction ability of the B. cereus 
phospholipase C. To examine this possibility, the hydro-
pathic potential of the alpha-toxin was estimated; a poten-
tially membrane-spanning hydrophobic stretch was found at 
theN terminus of the mature protein (Fig. SA). Hydrophobic 
N-terminal sequences are thought to be important for the 
interaction of phospholipase A2 from pig pancreas (46) and 
human serum amyloid A protein (45) with lipid interfaces. 
The alpha-toxin N-terminal amino acid stretch could be 
involved in the binding of the alpha-toxin to cell membranes 
by becoming embedded in the lipid bilayer. The later mobil-
ity of membrane phospholipids would ensure that the bound 
enzyme was continually presented with substrate. When the 
hydropathic potential of the nontoxic phosphatidylcholine-
preferring phospholipase C of B. cereus (14) was estimated , 
the N terminus of the mature protein did not possess a 
hydrophobic region (Fig. 5B). 
These results provide a basis for further studies concern-
ing the mode of action and immunogenicity of the alpha-
toxin. We have generated monoclonal antibodies against the 
alpha-toxin, and they will be of use in determining the 
location of epitopes on the protein (manuscript in prepara-
tion). A study of the roles of specific amino acids in the 
activity of the protein is also in progress. The cloned gene 
product may be of use to other investigators as a phospho-
lipid-specific membrane probe and for the evaluation of the 
role of this toxin in pathogenicity. 
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Abstract 
A reporter system was constructed to enable the study of gene expression in Clostridium perfringens. The system was 
based on plasmid shuttle vector pJIR410, which contained the C. perfringens erythromycin resistance gene. The vector was 
modified by the introduction of a DNA fragment comprising the open reading frame of the C. perfringens chloramphenicol 
acetyltransferase gene and flanking transcriptional terminators. The presence of a unique restriction site, engineered into the 
extreme 5' end of the open reading frame enabled a promoter region to be inserted to form an in-frame transcriptional fusion 
with carP. The system was tested by inserting the promoter region of the alpha-toxin gene of C. perfringens. The production 
of chloramphenicol acetyltransferase in C. perfringens was monitored during growth and the pattern of expression was 
shown to reflect levels of plc mRNA and alpha-toxin in the parent strain. 
Keywords: Clostridium perfringens; Recombinant DNA; Chloramphenicol acctyltransfcrasc; Shuttle vector; Toxin 
1. Introduction 
Clostridium perfringens produces a wide spec-
trum of toxins which play a role in the pathogenesis 
of many diseases in man and animals [1]. The genes 
encoding some toxins have been isolated and their 
nucleotide sequences determined [2-7], but the 
mechanisms regulating their expression are not well 
understood. ln view of the wide range of toxins 
which may be produced by the bacterium, and the 
association of these toxins with different diseases [1], 
it is likely that toxin production is regulated in vivo. 
Recently it has been reported that two different 
• Corresponding author. Tel.: +44 (1980) 613 301; Fax: + 44 
(1980) 613 284. 
regulatory proteins bind to the alpha-toxin gene ( plc) 
of C. perfringens [8] and also that the expression of 
plc in an Escherichia coli is negatively regulated by 
DNA bending of upstream sequences [9]. The theta-
toxin gene (pfo), when expressed in E. coli. is 
positively regulated by an upstream sequence [ 10]. 
To further characterise these, and other mechanisms 
of gene regulation, it will be necessary to perform 
studies in C. perfringens. 
Techniques have been described for the introduc-
tion of plasmid DNA into C. perfringens by electro-
poration [11] and several E. colijC. perfringens 
shuttle vectors have been reported. The aim of this 
study was to construct a reporter system, based on 
one of these shuttle vectors (pJIR410; [12]) and the 
chloramphenicol acetyltransferase gene (catP) of C. 
perfringens. This reporter system could be used to 
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investigate the activity and regulation of a variety of 
gene promoters in C. perfringens. 
2. Materials and methods 
2.1. Chemicals and enzymes 
Chemical and enzymes were obtained from the 
Sigma Chemical company or from BCL Limited 
unless otherwise stated. 
2.2. Bacterial strains and growth 
C. perfringens NCfC 8237 was cultured in TPYG 
broth [3). 100-ml volumes of TPYG broth were 
inoculated with cells from 5 ml of an 18-h culture. 
The cultures were incubated at 37"C in an anaerobic 
incubator (80% N2 , 10% C02 , 10% H 2 ; Don Whit-
ley Scientific). Growth medium for Strain 13 con-
taining plasmid pHBl also contained erythromycin 
(50 J.Lg ml- 1 ). At intervals the optical density of the 
culture (600 nm) was measured. 
2.3. Preparation of DNA 
Large-and small-scale plasmid isolations from E. 
coli were performed as described by Sambrook et al. 
[13). Oligonucleotides were prepared using a Applied 
Biosystems DNA synthesiser (model 392). 
2.4. Nucleotide sequencing 
Both strands of DNA were sequenced using the 
dideoxy chain termination method using T7 DNA 
polymerase (Sequenase Version 2 .0, United States 
Biochemical Corp.) according to the manufacturer's 
instructions. 
2.5. Electroporation of bacteria 
C. perfringens strain 13 was transformed using 
plasmid DNA which had been isolated from E. coli 
DH5a . Electroporation conditions have been de-
scribed previously [11). 
2.6. Enzyme and protein assays 
Extracellular alpha-toxin activity in culture super-
natant fluid was measured using a microtitre tray 
assay with egg yolk emulsion [3). Chloramphenicol 
acetyltransferase (CAT) activity was determined as 
described by Rodriguez and Tait [14). Total protein 
was measured using the method of Bradford (Bio-Rad 
protein assay). 
2. 7. mRNA isolation and quantitation 
Total RNA was isolated from 100-ml cultures of 
C. perfringens using a simplified version of the hot 
phenol method described by Janzon et al. [15). Be-
fore analysis, the RNA was denatured by the addi-
tion of formaldehyde and forrnamide [13). For slot 
blots, 1 J.Lg and 3 J.Lg total RNA samples were 
loaded directly onto a Nylon filter (Hybond N, 
Amersham) and fixed by baking. The RNA was 
detected using an Sspl- Hindiii restriction endonu-
clease fragment labelled with [a- 32 P)dCTP 
(Amersham; 6000 Ci mmol- 1 ) to a specific activity 
of > 108 dpm J.Lg - 1 [13). The probe corresponded 
to the plc structural gene [3). Pre-hybridisation and 
hybridisation were carried out at 42°C in buffer 
containing formamide [13). For the quantitation of 
mRNA levels, autoradiographs were scanned using a 
laser densitometer (Pharmacia-LKB). These experi-
ments were performed twice. 
2.8. Construction of reporter system 
The E. coli transcriptional terminator sequence 
rrnBT1 was isolated from pKK232-8 (Pharmacia) 
after digestion with EcoRl. The DNA fragment was 
used in two ways: firstly, plasmid pHL Y3 was gen-
erated after cloning the rrnBT1 cassette into pBiue-
script II SK - cstratagene) which had been restricted 
with EcoRl (Fig. 2). Secondly, after cloning the 
rrnBT1 cassette into £eaRl-digested pGEM7Zf(-) 
(Promega) it was excised as a Kpni / Xhol fragment 
which was cloned into suitably digested plasmid 
pHL Y1 to generate pHL Y2. After digestion of plas-
mid pHLY2 with Smal and Kpnl the fragment of 
DNA which contained catP and the downstream 
rrnBT1 was isolated. This was ligated with plasmid 
pHLY3, which had been digested with EcoRV and 
Kpn l, to generate the reporter cassette contained 
within pBluescript II SK - (pHL Y 4). Digestion of 
pHLY4 with Smal and Kpnl allowed the isolation of 
a DNA fragment encoding catP, · flanked by the 
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rmBT1 transcriptional terminator sequences. This 
fragment was cloned into pJIR410 which had been 
digested with Puuil and Kpnl, to generate the shut-
tle reporter vector pTCATI. A DNA fragment which 
contained the plc promoter was generated using the 
PCR with primers containing appropriate restriction 
endonuclease sites at the 5' ends (5'-CATATGATC-
GATATGCATAGTIGTAGCCATGGCTGCATAC-
CTICACTIATI-3' and 5'-ACGCGTATCGATITI-
TICAAATACCAI I I I IATATCCCCCGTIA-3'). 
Plasmid pTCA TI was transformed into E. coli 
DH5a [16] and C. perfringens strain 13 by electro-
poration [13]. 
I 
the C. perfringens plasmid plP401 [17] and codon 
usage effects should not limit gene expression. The 
gene product can be easily quantified [14]. The 
polymerase chain reaction (PCR) was used to am-
plify the open reading frame of catP, from vector 
pJIR418 [12]. The DNA fragment encoding CAT 
was cloned into pBluescript II SK- to generate 
plasmid pHL Yl. The upstream oligonucleotide 
primer used in the PCR (sequence: 5'-ATGGTATI-
TGAAAAAATCGAT-3') was designed to introduce 
a unique Clar restriction endonuclease recognition 
site located 15 bp downstream of the 5' terminus of 
the open reading frame. The introduction of the Clal 
site did not aJter the amino acid sequence of CAT. 
When creating promoter fusions using this restriction 
enzyme site the DNA nucleotide sequence of catP 
upstream of the C/a[ site must be regenerated. When 
the nucleotide sequence of carP was determined 
(Fig. 1), a number of differences were found on 
comparison with the previously reported sequence. 
These differences have also been reported by other 
workers [12]. 
3. Results and discussion 
3.1. Cloning and modification of catP from C. per-
fringe/Is 
The catP gene was selected for the construction 
of a reporter system as it was derived originally from 
8 . 
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ACnTGUAGT,TACCnGTACATACAGCATGACCGnAAAGTGGATATC.ACACAAATWGGA.U•CJGGI,ATG..U.ACTATATCCTGCMTGCTTIAnATAnGCAATGAnGTAAACC 
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GCCA ntAG.AG TTT AGGACGGC.U TCM TCAAGA TGGTG.U nGGGG.A TAT A fGA TGAG.A TGA TACCMGCTA TAC.U TA nTCACM TGA T ACTGAAACA TTTTCCAGCCTTTGG.ACTG 
IHSffiTAJMQDSELGJYDE"JPSYTlFHNDTETFSSLWT 
AG TGT.v.GTC TGACTn AAA TCA TTTTT AGCAGA TT ATGAMG TGA T ACGCAACGGT ATGGMACM TCAT AGM TGG.UGGAMGCCAM TGCTCCGGAAMU. TTTTT M TG TATCT A 
EC<SDF<SFlADYESDTQRYGNNHRREG<,NA,ENIFNYS 
T6ATACC6T66TCMCCntGATGGCTTTUTCT6MTTTGUGAMGiiATATGAnATTTGAnCCTATTTTTACTATGGGGAMTAnATAMGAA~TMCMJJ>.nATACnCCT 
' "IPWSTfDGFNLNLOICGYDYLJPJFT"GKYYICE ONICIILP 
nGGCAA TTCAAG TTCA TCACGCAG TA TG TGACGG.A TTTCACA TTTGCCGTTnG TAAACGAA nGCAGGA.A TT !aT AM T AGn M CnCAGGTTTG TC TGl.U.C T A.AAAACJ.AGT A TT 
LAlQYHHAYCOGFHlCRfVNELGELlNS. 
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TAN><AMAACCCTIGGGT"ACCTCGAGGMnC -cmbi,- GAAnCGGTACC 
Fig. I. DNA nucleotide sequence of the reponer casseue within pTCA lT. The DNA nucleotide sequence of the reponer casseue within 
pTCAlT, and the deduced amino acid sequence of CAT, is shown at A. Clal restriction endonuclease recognition sequences are underlined. 
The previously reponed nucleotide sequence [ 17), where different, is shown below the main sequence. The DNA nucleotide sequence of 
rrnBT1 is not shown as the orientation of the transcriptional tenninators was not detennined. The creation of a promoter fusion is illustrated 
at B. The fidelity of the nucleotide sequence of the entire promoter region (P) and ribosome binding site (SO) is conserved to the ATG 
translational stan codon. Oligonucleotides used in the ampl ification of the promoter should reconstitute the first 15 bp of the catP open 
reading frame and should include Clal restriction sites for cloning purposes. 
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Fig. 2. Construction of I he C. perfringensjE. coli shuttle reponer plasmid (pTCATI). 
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3.2. Construction of pTCAIT reporter plasmid 
Plasmids pHLY1 and pTIR410• were used for the 
construction of a reporter shuttle vector (Fig. 2; 
pTCATI). Plasmid pJIR410 • , which was derived 
from pHR410 [12] by the removal of a Clal restric-
tion site, contained the E. coli origin of replication 
from pUC18, the origin of replication from the C. 
perfringens plasmid piP404 and the C. perfringens 
ermBP gene, which encoded erythromycin resis-
tance. A single copy of the E. coli transcriptional 
terminator rrnBT1 was introduced upstream and 
downstream of catP to prevent expression of catP 
from other sequences within the shuttle vector and to 
stabilise the plasmid. 
A reporter system using lux has been described 
previously [18], but expression of a gene derived 
from Vibrio fischeri (54-60% A + T) may be con-
strained in C. perfringens (73-76% A + T). The 
reporter system described here also included tran-
scriptional terminator sequences, a feature which was 
absent in the catP reporter system constructed by 
Matsushita et al. [19]. The terminator sequences 
should prevent read-through from other plasmid en-
coded genes. In addition, the use of the C/al site for 
fusion of the promoter and the reporter gene ensures 
that the authenticity of the nucleotide sequence of 
the promoter, ribosome binding site and the region to 
the start of the coding sequence is retained. Other 
reporter systems described [18,19] incorporate the 
Shine-Dalgarno site and associated regions which are 
native to the catP gene. 
When creating promoter fusions using the C/al 
restriction enzyme site, the DNA nucleotide se-
quence of catP upstream of the Clal site and the 
Clal recognition sequence can be incorporated into 
oligonucleotides used for PCR amplification of pro-
moter regions to ensure that the complete catP is 
regenerated. 
3.3. Cloning of the plc gene promoter into the re-
porter plasmid 
The reporter system was tested using the promoter 
for the C. perfringens NCTC 8237 plc [3]. The 
location of the transcript start site for this gene has 
been determined [20]. An 0.8-kb fragment containing 
the promoter was amplified using the PCR and cloned 
upstream of catP into the Clal site in plasmid 
pTCATI. The authenticity and orientation of the 
DNA fragment cloned into pHB1 was confirmed by 
determining the nucleotide sequence of this frag-
ment. The plasmid was transformed into C. perfrin-
gens strain 13 by electroporation. Thjs plasmid was 
isolated and transformed into E. coli for the retro-
spective confirmation of its structure by examinjng 
the restriction endonuclease digestion profile. 
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Fig. 3. Comparison of alpha-toxin and CAT production from the 
C. perfringens NCfC8237 alpha-toxin promoter. C. perfringens 
strain 13 containing plasmid pHBl (a) or strain NCfC8237 (b) 
were cultured in TPYG broth. At intervals the optical density (600 
nm) of the culture ( .a. ) was measured. Extracellular phospholipase 
C (0) or CAT-specific activity <•> produced between consecu-
tive time points was calculated. The level of plc mRNA within 
cells of strain NCfC8237 (e ) was determined at the times 
shown. 
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3.4. Analysis of expression of the plc/ catP tran-
scriptional fusion 
The pattern of expression of catP from the strain 
NCTC 8237 cpa promoter was determined after 
electroporation of plasmid pHB1 into strain 13. At-
tempts to transform strain NCTC 8237 with plasmid 
pHB1, using a variety of techniques, were not suc-
cessful and other workers have found that plasmid 
DNA could be transferred only into some strains of 
C. perfringens [11]. The production of CAT in C. 
perfringens strain 13 containing pHBl was measured 
during growth of the bacterium (Fig. 3) and com-
pared with the production of alpha-toxin by strain 
NCTC 8237. It is known that CAT and alpha-toxin 
are both stable in cultures of C. perfringens and 
therefore it was possible to calculate the amount of 
enzyme produced between consecutive time points. 
The maximum level of CAT activity was detected 
after 3 h of growth, which corresponded to the late 
exponential phase. In strain NCTC 8237, the plc 
mRNA levels increased throughout the exponential 
phase of growth, reaching a maximum level after 3 
h, which corresponded to the late exponential phase 
of growth. The level of production of alpha-toxin 
exported into the culture medium reached a maxi-
mum after 3 h. These results indicate that the strain 
NCTC 8237 plc promoter, within the genetic back-
ground of strain 13, reflects the level of intracellular 
plc mRNA or extracellular alpha-toxin in strain 
NCTC 8237. 
The use of the reporter vector will be simplified if 
Clal restriction endonuclease sites are absent in the 
promoter to be cloned; the recognition sequence for 
the Clal enzyme is absent in the upstream regions of 
the genes encoding C. perfringens perfringolysin 0 
( pfo; [2}), enterotoxin gene (cpe; [4]), beta-toxin 
(cpb; [5]), iota-toxin (/a, lb; [6]) and epsilon-toxin 
(etxB, etx.D; [7]). 
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Introduction 
The control of expression of the a-toxin gene (cpa or plc) of Clostridium 
perfringens has been studied in three strains shown to have high 
(NCTC8237), intermediate (strain 13) and low (NCTC8533) phospholipase C 
activity in the culture supernatant. The phospholipase C activity was shown 
to be related to cpa mRNA levels. Primer extension studies were performed 
to locate the cpa promoter regions in strains NCTC8237 and 13. Differences 
in promoter sequences could account for the differences in a-toxin 
production between strains 13 and NCTC8237. In contrast, the differences in 
a-toxin production between strains NCTC8237 and NCTC8533 were 
unlikely to be due to promoter differences because the upstream promoter-
containing sequences were identical in these strains. The recombinant 
plasmid carrying the NCTC8237 cpa gene was introduced into strains 13 and 
NCTC8533. The level of production of the a-toxin was 16-fold higher in 
strain 13, indicating the presence of strain-dependant regulatory systems. 
© 1996 Academic Press 
Clostridium perfringens produces an array of toxins and 
the differential production of these toxins can be used 
to assign strains to one of five biotypes (Types A-E [1]). 
Type A strains of C. perfringens are widely distributed 
in the environment and have been associated with gas 
gangrene in man [1], necrotic enteritis in chickens [2] 
and enterotoxaemia in piglets [3] and in calves [4]. The 
etiology of these diseases has been ascribed mainly to 
the effects of the a-toxin (phospholipase C [5,6]) and 
type A strains of the bacterium often produce high 
levels of this toxin in vitro [7]. Type B-E strains of C. 
perfringens produce low levels of the a -toxin and the 
ability of these strains to cause disease in animals is 
largely ascribed to the production of the E-toxin (types Address correspondence to Dr. Richard W. Tttball 
1075-9964/96/060365 + 07 $25.00 / 0 © 1996 Academic Press 
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B and D strains), ~-toxin (types B and C strains) or 
L-toxin (type E strains) [1]. 
The a-toxin encoding gene (cpa or plc) has been 
cloned from different type A strains of the bacterium 
and the nucleotide sequence determined [8,9]. The 
level of production of a-toxin by a type A strain 
(NCTC8237) and a type C strain (NCIB10662) has been 
shown to be related to the level of cpa mRNA and it 
was proposed that a protein which bound within the 
cpa coding region acted as a positive regulator of gene 
expression [10]. However, the differences in cpa 
upstream sequences in these strains did not allow the 
effects of promoter strength and genetic background 
to be differentiated. The deletion of a region upstream 
of the putative -35 promoter region in strain 
NCTC8237 was shown to result in an increase in 
a-toxin and cpa mRNA levels when the gene was 
expressed in Escherichiia coli [11] and it was proposed 
that these studies provided insight into the regulation 
of cpa gene expression in C. perfringens. 
Interpretation of these studies has been hampered 
by the unknown locations in the cpa transcript star t 
points and gene promoters in different strains of C. 
perfringens. We have set out to determine the positions 
of transcript start points in strains of C. perfringens 
producing high (NCTC8237), intermediate (strain 13) 
and low (NCTC8533) levels of a -toxin. This has 
enabled us to determine, for the first time, the effect of 
host cell background on the level of a-toxin expression 
in C. perfringens. 
Materials and Methods 
Chemicals and enzymes 
Unless otherwise stated chemicals and enzymes were 
obtained from the Sigma Chemical company (Poole, 
U.K.), BDH Ltd (Poole, U.K.) or Boehringer Mannheim 
Diagnostics and Biochemicals Ltd (Lewes, U.K.) 
Bacterial strains and growth 
Clostridium perfringens strains NCTC8237 (type A), 
NCTC8533 (type B) and Strain 13 (type A; [12]) were 
maintained Brain Heart Infusion agar (Oxoid) and 
were normally cultured in TPYG broth [12]. 100 mL 
volumes of TPYG broth were inoculated with cells 
from 5 mL of an 18 h-culture which had been collected 
by centrifugation (5000 X g, 10 min, 4°C) and resus-
pended in fresh TPYG broth thereby avoiding the 
carryover of a-toxin in the inoculum. Cultures were 
incubated at 37°C in an anaerobic incubator (Don 
Whitley Scientific; 80%Nu 10%COu 10%H2). Cell 
numbers were estimated by measuring the optical 
density of the culture at 600 nm (OD600 nm)· Phospholi-
pase C activity (egg yolk units/mL;Eyu/mL) in 
culture supernatant fluid was measured as described 
previously [8]. The 8-toxin in culture supernatant was 
measured using 1% vI v sheep erythrocytes in phos-
phate buffered saline (PBS pH 7.2; Oxoid Ltd) [13]. 
Escherichia coli OM101) containing the plasmid pT2.2 
which encoded the C. perfringens NCTC 8237 cpa gene, 
was cultured as described previously [8]. 
Strain NCTC8533 cpa cloning and nucleotide sequencing 
Strain NCTC8533 genomic DNA was digested with 
EcoR1 and cloned [14] into suitably digested pBlue-
script SK + (Stratagene Inc). Escherichiin coli JM101 
cells containing the cloned cpa gene were identified as 
colonies surrounded by a zone of turbidity on agar 
containing egg-yolk emulsion [8]. Single-stranded 
DNA was prepared from the 2.26 kb cloned DNA 
fragment using helper phage M13K07 and the nucleo-
tide sequence was determined [14]. 
A 1.8 kb EcoRl-HindW DNA fragment, encoding the 
NCTC8237 cpa open reading frame and 800 bp of 
upstream sequence, was isolated from plasmid pT2.2 
[8] and cloned into the shuttle plasmid pJIR418 [15]. 
The recombinant plasmid was used to transform E. 
coli DHSa. The purified plasmid [14] was then 
introduced into C. perfringens strains 13 and 
NCTC8533 by electroporation [16,25]. Recombinant C. 
perfringens were cultured in TPYG broth as described 
above. After 4 h of growth the cultures were centri-
fuged (10 000 X g, 20 min, 4°C) and the supernatant 
fluid was tested for phospholipase activity and 
8-toxin. Total DNA was extracted from the cell pellet 
using the method of Marmur [17] and the relative 
copy number of plasmid DNA was determined using 
the PCR to detect the chloramphenicol acetyltransfer-
ase gene [16] with similar quantities of template 
DNA. 
RNA isolation and analysis techniques 
Total RNA was isolated from 100 mL cultures of C. 
perfringens or E. Coli using a version of the method 
described by Janzon et al. [18]. Total RNA (1 ~tg or 3 ~J g) 
was denatured by the addition of formaldehyde and 
formamide [14], loaded onto a nylon filter (Hybond N. 
Amersham), and fixed by baking (2 h at 80°C). The cpn 
mRNA was detected using an Sspl-Hindlll fragment, 
isolated from plasmid pT2.2, which corresponded to 
the cpa structural gene [8]. The probe was labelled 
with a-32P dCTP (Amersham; 6000i/ mmol), usin~ 
random priming to a specific activity of > I08dpm / 1t~ 
[14]. Pre-hybridisation and hybridisation vvere carried 
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out at 42°C in buffer containing formamide [14). For 
the quantitation of mRNA levels (mean of two 
determinations), autoradiographs were scanned using 
a laser densitometer (Phamacia-LKB). These experi-
ments were performed twice and a similar pattern of 
mRNA levels was observed each time. The data 
presented are derived from one of U1ese 
experiments. 
Primer extension 
Transcript star t sites were determined using a mod-
ification of the primer extension methods of Graves & 
Rabinowitz [19) or Debarbouille & Raibaud [20]. 
Briefly, 15 11g of total RNA was denatured by boiling 
and annealed with 2.5 ng of oligonucleotide (ORF; 
position + 124 to + 114). The primer extension reaction 
was carried out by adding 0.5 ~-tL of dGTP, dCTP and 
dTIP (1 mM), I ~-tL of 355-dATP (Amersham; 600Ci/ 
mmol) and 9 units of avian myeloblastosis virus 
reverse transcriptase. After incubation (42°C, 10 min) a 
chase reaction was performed by adding 0.5 ~-tL of each 
deoxynucleoside triphosphate (1 mM) and further 
incubation for 5 min. The sizes of products of the 
reaction were determined by comparison with 
sequencing reactions performed using the same 
primer. 
Results 
Selection of bacterial strains 
Three strains of C. perfringens which produced high 
a-toxin activity (strain NCTC8237; type A), inter-
mediate a-toxin activity (strain 13; type A) and low 
a-toxin activity (strain NCTC8533; type B) were 
selected for study. The cpa gene from strains 
NCTC8237 and 13 had previously been isolated and 
the nucleotide sequence upstrean1 from the structw·al 
gene reported (GeneBank accession numbers: X13608 
for strain NCTC8237 and L43546 for strain 13) [8,12]. 
To determine the upstream sequence in strain 
NCTC8533 the cpa gene was cloned into E. coli. 
Bacteria containing recombinant plasmids encoding 
the a-toxin (pRB2) were identified as colonies sur-
rounded by a zone of turbidity on agar conlaining 
egg-yolk emulsion [8). The nucleotide sequences of 
the strain NCTC8533 open reading frames and 800 bp 
upstream of the translational start codon were identi-
cal with the reported strain NCTC8237 nucleotide 
sequence [8]. 
Mapping and structure of the cpa gene promoter 
We have previously reported the 5' end of the mRNA 
transcript in C. perfringens strain NCTC8237 [21]. The 
experimental evidence supporting this report is pro-
vided here. A single and identical transcript start point 
was identified from cpa expressed in C. perfringens 
NCTC8237 and in E. coli carrying the cloned 
NCTC8237 cpa gene (Figure 1) indicating that the same 
promoter sequences (Table I) were utilised . The faint 
bands observed below the transa·ipt start point were 
considered to be due to premature termination of the 
extension reaction. A 68 bp region separated the 
transcriptional and h·anslational start points. 
The strain 13 cpa mRNA transcript start site was 
shown to be identical with the transcript start site 
recently reported by Ba-Thein et al. [22) and the 
h·anscript start site in strain NCTC8237. Differences 
between the strain NCTC8237 and 13 promoter 







Figure 1. Determination of the cpa transcript start point. Primer 
extension analysis of cpn genes expressed in C. perfringens 
NCTC8237 (A); E. coli carrying the cloned NCTC8237 cpa gene (B); 
or C. perfringens strain 13 (C). Sequencing ladders generated using 
the same primer with single stranded DNA generated from the 
NCTC8237 cpn gene (A and B) or strain 13 cpn gene (C) are also 
shown. The letters above the lanes indicate which dideoxynucleo-
tides were used to terminate the reaction. 
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Table 1. Comparison of the C. perfringens strain NCTC8237, strain NCTC8533 and strain 13 promoter sequences with the consensus 
sequences recognised by the Gram-positive and£. coli major form RNA polymerase 
Species 
C. perfriugens NCTC8237 TAITCAAAAATAITITAAAAAATAITCAAAAATTTAGTGAGCTTATGGTAATTATATGGTATAATITCAGT 
t 
C. perfringens NCTC8533 TAITCAAAAATAITITAAAAAATAITCAAAAATTTAGTGAGCTTATGGTAATTATATGGTATAATITCAGT 
C. perfringeus strain 13 TAITCAAAAATAITITAAAAAATAITCAAAAATTTAGTGAGGTTATGGTAATTATATGGTATAATITCAGT 
Gram-positiveconsensusf181 Ta AAAAA TTGAcA a A aT IG TATAAT AAtAt 
£.coli consensusll81 a t TTGACat t t t g TA tAAI 
The transcript start point was immediately following the 3' end of the C. perfringens strai n NCTC8237 sequence which is compared with the 
consensus Gram-positive and the £. coli promoter sequences. Nucleotides which are more than 75% conserved (in upper case), 50-75% 
conserved (in lower case) in the consensus sequences are indicated. The locations of the likely -10 and -35 regions in the C. perfriugeus 
NCTC8237 sequence are emboldened whilst the upstream repeats are shown italicised. The position at which the upstream region was 
truncated in experiments by Toyonaga et nl [111 is shown arrowed. 
regions were found. A substitution (C~G) was appar-
ent in the -35 region, a substitution (T ~A) preceded 
the Shine-Dalgarno region and there was a deletion of 
an adenine nucleotide preceding the ATG translational 
start codon. Mapping of the cpa transcript start site in 
strain NCTC8533 was not possible because of the low 
levels of cpa mRNA produced. A -10 Pribnow box was 
identified seven nucleotides upstream of the transcript 
start point in both strain NCTC8237 and in strain 13. 
In both strains, the -35 region was located 17 
nucleotides upstream of the -10 region. 
The nucleotide sequence upstream of the -35 region 
was A-T rich and a direct repeat (TATTCAAAAAT) 
was observed in sn·ains NCTC8237 and 13. Expression 
of the B. cereus PC-PLC and P. aeruginosa PLC-N genes 
is regulated by environmental phosphate levels and 
sequences upstream of the Pseudomonas aeruginosa 
gene show homology with the E. coli pho box [23]. 
There was no apparent pho box (consensus CTcTTCA-
TA ATA ATCTGTCA eT; [24] close to the a-toxin pro-
moter region. 
Levels of expression of the a-toxin cpa gene are reflected 
in mRNA levels 
Clostridium perfringens strains were cultured in a liquid 
growth medium and at intervals the cells were 
harvested, the total RNA isolated and hybridised with 
a P32 labelled gene probe corresponding to the cpa 
open reading frame. The cpa mRNA levels were 
measured as a proportion of total RNA, which was 
assumed to be constant over the exponential phase of 
the growth cycle and the production of a-toxin was 
calculated by relating the increase in phospholipase C 
activity between time points to mean cell density over 
that period. 
In strain NCTC8237 we have previously found that 
increases in cpa mRNA levels were paralleled by an 
increase in a-toxin activity during the exponential 
phase of growth [16]. This data is included for 
comparison in Figure 2(a). The level of production of 
cpa mRNA by strain NCTC8533 [Figure 2(b)] and 
strain 13 [Figure 2(c)] was lower than by strain 
NCTC8237 and paralleled the lower production of 
phospholipase C by these strains. The level of phos-
pholipase C produced by strain NCTC8533 was below 
the lower limit of detection of the assay used. 
However, bacteria cultUl'ed on BHI agar containing 
10% (v I v) egg yolk emulsion were surrounded by a 
narrow zone of turbidity. The strain NCTC8237 and 
strain 13 a-toxins have been reported to have similar 
specific activities [12] indicating that this was not the 
reason for the lower a-toxin activity in culture 
supernatants. 
After 4 h growth, the levels of 8-toxin (perfringoly-
sin 0) were measured in the culture supernatant fluid. 
The level of 8-toxin was highest in the strain 
NCTC8237 supernatant fluid (494Hu / mL; mean of 
foUl' determinations). The supernatant fluid from 
strains NCTC8533 and 13 contained 24 Hu/ mL and 
207Hu / mL respectively (each are the means of foUl' 
determina tions). 
The level of expression of the cloned cpa gene is regulated 
in different strains of C. perfringens 
To determine the effect of different genetic back-
grounds on the production of the a-toxin a 1.8 kb 
EcoRI-Hindiii DNA fragment from pT2.2, encoding 
the cpa gene and 800 bp of upstream sequence, was 
cloned into plasmid p)1R418 [15], to generate pJIR542. 
This plasmid was then used to transform C. perfringens 
strains 13 and NCTC8533 by electroporation [25]. 
Strain NCTC8237 was refractory to transformation 
under all of the conditions tested [16]. The level of 
a-toxin in culture supernatant fluid after 4 h of growth 
was 16-fold higher in strain 13(pJIR542) (0.023 units / 
mg protein; mean of three determinations) than in 
strain NCTC8533(p)1R542) (0.0014 units / mg protein; 
mean of three determinations). When the DNA from 
these strains was analysed, using a PCR assay for the 
plasmid-encoded chloramphenicol acetyltransferase 
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gene, the copy number of the plasmid was judged to 
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Figure 2. Relationship between a- toxin production and cpa mRNA 
levels. The cpa mRNA levels are expressed as a densitometry signal 
(Pharmada-LKB laser densitometer) per unit total RNA, (e ). 
Extracellular toxin activity (as egg yolk units per 00600 ""' unit) 
produced between consecutive time points (0 ) was determined 
during the growth (.&.) of C. perfringens strains NCTC8237 (a); 




Figure 3. PCR amplification of cloned chloramphenicol acetyl-
transferase genes. C. perfringens strain NCTC8533 (lane 1), C. 
perfringens strain 13 0ane 2), C. perfringens strain 
NCTC8533 + pJIR542 (lane 3), C. perfringens strain 13 + pJIR42 (lane 
4), 1:16 dilution of C. perfringens strain NCTC8533 + pJIR542 (lane 
5), 1:16 dilution of C. perjringe115 strain 13 + pJIR542 0ane 6). Lane 7 
contained molecular size markers (in kbp). 
Discussion 
Previous workers have shown that C. perfringens strain 
NCTC8237 a-toxin was produced during the exponen-
tial phase of growth of the bacterium [7,13) which is in 
accordance with our finding that cpa mRNA levels 
reached a peak dwing this growth phase. It has 
previously been shown that cpa mRNA levels are 
related to the level of a-toxin production in a type A 
(NCTC8237) and a type C strain (NCID10662) of C. 
perfringens [10]. We have shown that production of the 
a-toxin by a type B strain of C. perfringens (NCTC8533) 
and a type A strain producing lower levels of a-toxin 
are also related to cpa mRNA levels. 
The C. perfringens strain NCTC8237 and strain 13 cpa 
promoters rud not have any atypical features and 
showed significant similarity with other Gram-pos-
itive and E. coli promoter sequences (Table 1). The 
possibility that differences between the strain 
NCTC8237 and strain 13 promoter sequences were 
responsible for differences in the level of cpa gene 
expression awai ts investigation. The cpa gene 
upstream sequence in strain NCTC8533 was identical 
to that from NCTC8237. The effect of the genetic 
background on the level of cpa gene expression was 
demonstrated by showing that the NCTC8237 
( = NCTC8533) cpa gene was expressed at different 
levels when cloned into strain 13 or into strain 
NCTC8533. It has previously been shown that a two-
component regulatory system, consisting of the VirR 
and VirS proteins partially regulates a -toxin gene 
expression from a single promoter in C. perfringens 
strain 13 [22,26,27], although the precise molecular 
basis of this regulation has not been determined. The 
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expression of 8-toxin is also known to be regulated 
mainly by the Vir / VtrS system [22] . The differences in 
the levels of 8-toxin produced by strains 13 and 
NCTC8533 were similar to the differences in the levels 
of production of a-toxin from the cloned cpa gene in 
these strains, which suggests that the differences in 
alpha-toxin production were due to differences in the 
VirR/ VirS systems in strains 13 and NCTC8533. 
Alternatively, we cannot rule out that these differences 
were due to the absence of a cpa-specific regulatory 
gene in strain NCTC8533. 
We have shown that a similar cpa promoter 
sequence was recognised in E. coli and in C. perfringens 
NCTC8237. This finding enables us to conclude that 
the region which was deleted by Toyonaga et al. [11], 
with a resultant increase in phospholipase C produc-
tion in E. coli cells expressing the cpa gene, was 
upstream of the -35 region of the promoter. This 
region is also implicated in the regulation of gene 
expression in C. perfringens. Saint-Joanis et al, [9] have 
previously determined the a-toxin transcript sta1"t 
point in C. perfringens strain 8-6. The strain 8-6 
promoter -10 and -35 regions were identical with 
those in strain 13 but the level of cpa mRNA in strain 
8-6 (a heat resistant strain) was maximal during the 
stationary phase of growth [9]. Our finding that cpa 
mRNA levels in strain 13 were maximal during the 
logarithmic growth phase suggests that regions out-
side of the -10 and -35 promoter sequences regulate 
the pattern of gene expression. The 11 base pair 
repeated sequence located upstream of the -35 region 
in strain 13 was disrupted in strain 8-6. It is possible 
that this difference in promoter upstream region was 
responsible for the different pattern of gene expression 
in C. perfringens strain 8-6. 
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14 
Gene Cloning and Organization of the 
Alpha-Toxin of Clostridium perfringens 
Richard W. Titball, Helen Yeoman, and Sophie E.C. Hunter 
14.1 Introduction 
Clostridium perfringens is widely distributed in 
the environment. In the soil, the bacterium is 
well adapted to survival by producing an array 
of hydrolytic enzymes capable of breaking 
down organic materials to yield essential nu-
trients (McDonel, 1986). It is not dear why 
many of these enzymes are also potent toxins. 
At least 12 toxic proteins have been shown to 
be produced by C. perfringens (McDonel, 1986), 
but most are considered minor toxins of ques-
tionable significance in the pathogenesis of 
disease. 
The pattern of production of the four major 
toxins can be used to type strains of C. perfrin-
gens into one of five groups, and of the major 
toxins, the phospholipase C (alpha-toxin) has 
received the most attention. The alpha-toxin 
was the first bacterial toxin shown to possess 
enzymatic activity (MacFarlane and Knight, 
1941), and the biophysical properties of this 
toxin have been studied extensively by num-
erous workers. Even so, varied results con-
cerning such fundamental properties as the 
molecular weight of the toxin have been re-
ported (Mollby, 1978; McDonel, 1986). Studies 
on the precise mechanisms of toxicity have re-
quired cautious interpretation because many of 
the alpha-toxin preparations used for these 
studies were probably contaminated with other 
C. perfringens toxins and enzymes (Mollby et 
al., 1974). 
The toxin is produced by most strains of C. 
perfringens and in especially large amounts by 
type A strains (Mollby et al ., 1976). The associa-
tion of type A strains with gas gangrene in hu-
man has lead to the suggestion that this toxin 
plays an important role in the pathogenesis of 
this disease (MacFarlane, 1955; Willis, 1969). 
There is some experimental evidence in sup-
port of this; the toxin is known to be cytolytic 
for erythrocytes (MacFarlane and Knight, 1941; 
Titball et al. , 1989) and human fibroblasts (Moll-
by et al., 1974; Thelestam and Mollby, 1975) 
and to be capable of inducing inflammatory re-
sponses, smooth muscle contraction (Fujii et 
al., 1986; Fujii and Sakurai, 1989), and platelet 
aggregation (Sugahara et al., 1976; Ohsaka et 
al. , 1978), all of which would promote anoxia in 
tissues and facilitate growth of C. perfringens. 
Prior immunization with a formaldehyde tox-
oid has been shown to protect mice not only 
from alpha-toxin but also from infection with C. 
perfringens (Kameyama et al., 1975). In contrast 
to this evidence, attempts to correlate the level 
of alpha-toxin production in vitro with vir-
ulence of different strains of C. perfringens 
have not been successful (Mollby et al., 1976, 
Mollby, 1978). 
Gas gangrene in humans is a serious but 
usually treatable disease in civilian popula-
tions, but during conflicts infection of battle-
field wounds remains an important cause of in-
capacitation and death. For example, during 
World War I it is estimated that 100,000 Ger-
man soldiers died of the disease, and attempts 
to treat the disease with antiserum met with 
variable results (MacPherson et al., 1922). In 
addition to gas gangrene in humans, it has been 
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suggested that alpha-toxin plays an important 
role in several other diseases including necrotic 
enteritis in chickens (Al-Sheikhly and Truscott, 
1977). 
To investigate the mode of action of the 
alpha-toxin and to determine factors that reg-
ulate expression of the gene in vivo, we have 
examined the molecular genetics of the encod-
ing gene. In particular, the relationship of gene 
structure to the function of the protein has been 
investigated, and homologies found between 
the alpha-toxin and other procaryotic and euc-
aryotic lipid-metabolizing enzymes have pro-
vided further insight into the mode of action 
of this toxin. This approach has also permitted 
the precise determination of some biophysical 
properties of the toxin, and gene donir.g has 
provided a source of alpha-toxin that is free of 
other C. perfringens toxins and enzymes. Alpha-
toxin prepared in this way could be used for 
toxi.nological $tlldies and may find increasing 
use as a reagent for the selective modification of 
eucaryotic membranes. In future applications, 
this approach should facilitate a greater under-
standing of the role of this toxin in the disease 
process and permit the development of pro-
phylactic and therapeutic reagents against 
alpha-toxin and C. perfringens type A infections. 
14.2 Gene Cloning, Location 
and Detection of Homologous 
Nucleotide Sequences in Other 
Bacteria 
Gene cloning 
Molecular cloning and the nucleotide sequence 
of the alpha-toxin were first reported by Titball 
et al. (1989), and following this, several other 
workers reported the results of similar experi-
ments (Leslie et al., 1989; Okabe et al., 1989; 
Saint-Joanis et al., 1989; Tso and Siebel, 1989). 
A high alpha-toxin-producing type A strain of 
Clostridum perfringens (A TCC 13124 = NCTC 
8237 = CN 1491) was used as the source of 
DNA in all studies except for the work of Saint-
Joanis et al. (1989), who used strain 8-6, a 
mutant derived from the heat-resistant type A 
strain NCTC 8798. The isolation of intact DNA 
caused problems for some workers because of 
the high level of deoxyribonuclease also pro-
duced by C. perfringens (Okabe et al., 1989). 
DNA fragments encoding the alpha-toxin were 
cloned into Escherichia coli using plasm.ids 
(pUC18, Titball et al., 1989; pEMBL8+, Tso 
and Siebel, 1989; pACYC184, Leslie et al., 
1989) or bacteriophage lambda vectors (gt10, 
Okabe et al., 1989; NM1149, Saint-Joanis et al., 
1989). Recombinant E. coli containing the 
alpha-toxin gene were isolated at a frequency of 
0.2% to 1%. Expression of the gene was de-
tected by examining the growth medium sur-
rounding colonies or plaques for egg yolk 
phospholipid hydrolysis (Titball et al., 1989) or 
hemolysis of sheep erythrocytes (Leslie et al., 
1989; Okabe et al., 1989; Saint-Joanis et al., 
1989; Tso and Siebel, 1989). No instability of the 
cloned DNA was reported and the produced 
alpha-toxin did not appear to be detrimental to 
the host, possibly because of the low levels of 
phosphatidylcholine and sterols and the pre-
ponderance of odd-number branch-chain fatty 
adds found in procaryotic cell membranes (Tso 
and Siebel, 1989). 
Chromosomal location of the 
alpha-toxin gene 
It has been reported that C. perfringens plasm.ids 
play no role in the genetic control of alpha-
toxin production (Kramer and Schallehn, 1978), 
and it is now known that the alpha-toxin gene 
is chromosomally located in strain CPNSO 
(Canard and Cole, 1989). The location of the 
gene, dose to the putative origin of replication, 
would explain the low incidence of alpha-toxin-
negative mutants because this region would be 
expected to be highly conserved (Canard and 
Cole, 1989). In addition, the observation that 
the gene was flanked by ribosomal RNA oper-
ons suggests that this region may be readily ex-
changed between strains by recombination. 
By combining the reported restriction en-
donuclease maps of the cloned DNA fragments 
from strain NCTC 8237 (Leslie et al ., 1989; 
Okabe et al ., 1989; Titball et al., 1989; Tso and 
Siebel, 1989) a map of the alpha-toxin gene and 
flanking DNA has been constructed (Figure 
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FIGURE 14.1 Genome organization adjacent to 
alpha-toxin gene; locations of cloned and nu-
cleotide sequenced fragments. (A) Restriction en-
donuclease map of alpha-toxin gene (cpa) and 
flanking DNA from Clostridium perfringens strain 
NCfC 8237. Locations of fragments that were 
cloned (B, pTSCIOO, Titball et al., 1989; C, pPLC8, 
Tso and Siebel, 1989; D, pDAZ1, Leslie et al., 
1989; E, pKM1, Okabe et al., 1989) are depicted 
14.1A). The homologous region from strain 8-{) 
is also shown (Figure 14.1F), with the location 
of the second unidentified open-reading frame 
identified only in this strain (Saint-Joanis et al., 
1989). 
Conservation of sequences 
resembling the alpha-toxin gene in 
other phospholipase C-producing 
clostridia 
We have examined in detail the degree of 
conservation of the alpha-toxin gene between 
strains of C. perfringens using a DNA probe cor-
responding to the alpha-toxin gene (Ssp1 to 
Hindill fragment; Figure 14.1G). The probe was 
hybridized with DNA from a selection of phos-
pholipase C-produdng clostridia and other bac-
teria under conditions of high stringency (Table 
14.1). homologous 3.1-kb Hindiii fragment was 
with single line. Regions that were nucleotide 
sequenced are shown as double tines. Locations of 
restriction endonuclease si~es, cpa gene, and un-
identified open-reading frame (ORF 2) within 
DNA fragment from C. perfringens strain 8-6 (F, 
pTOXS, Saint-Joanis et al., 1989) are also shown. 
Location of the DNA fragment used as gene probe 
to detect alpha-toxin gene is also depicted (G). 
detected in DNA isolated from C. perfringens 
types A to E, including one strain that failed to 
produce detectable phospholipase C on growth 
in liquid or on solid media (R476). In addition, 
sequences homologous to the alpha-toxin gene 
were detected in DNA isolated from one strain 
of C. bifennentans (LPHL 2825), C. nauyi type A, 
and C. barati (formerly C. parapeifringens). 
Homologous sequences were not detected in 
DNA from any of the other phospholipase C-
producing bacteria tested. The possibility that 
phospholipase C genes, which are closely re-
lated to the alpha-toxin gene, occur in other 
clostridial species was confirmed by the recent 
report that the C. bifermentans phospholipase C-
encoding gene was 64% homologous with the 
alpha-toxin gene (Tso and Siebel, 1989). Pre-
vious studies have shown that the phospholi-
pase C produced by C. barati was nontoxic, and 
there are differing reports concerning neutra-
lization using anti-alpha-toxin serum (Naka-
214 Richard W. Titball, Helen Yeoman, and Sophie E.C. Hunter 
Table 14.1 Detection of DNA homologous to the alpha-toxin gene in phospholipase C-producing 
bacteria 
Origin of DNA (species and biotype) 
Clostridium peifringens type A NCTC 8237 
Clostridium peifringens typeB NCTC 6121 
Clostridium peifringens typeC NCTC 3180 
Clostridium perfringens typeD NCTC 8346 
Clostridium peifringens typeE CN 5083 
Clostridium peifringens R476 
Clostridium bifermentans LPHL 2825 
Clostridium novyi type A NCTC 6737 
Clostridium barati ATCC 27639 
Clostridium absonum ATCC 27555 
Clostridir1mnouyi typeD NCTC 8350 
Bacillus cereus B 33 
Pseudomonas aemginosa NCTC 2531 
Staphylococcus aureus NCTC 6571 
•Minus (-)indicates no probe-reactive fragment detected. 
mura et al., 1973; Willis, 1977). The gamma-
toxin (phospholipase C) produced by C. novyi 
is hemolytic and lethal, and it has been shown 
to be partially neutralized by anti-alpha-toxin 
serum {Willis, 1977). Unlike the alpha-toxin, 
the C. novyi enzyme was able to degrade phos-
phatidyl inositol and phosphatidyl glycerol. It 
would appear that the phospholipase C's from 
several clostridial species are closely related 
genetically and im.munologically but differ in 
toxicity and substrate specificity. The precise 
nature of the proteins and of their encoding 
genes awaits determination. 
14.3 Open-Reading Frame 
Nucleotide Sequence 
The nucleotide sequence of the gene encoding 
the alpha-toxin from strain NCI'C 8237 has 
been determined independently by four 
groups (Figure 14.2) (Leslie et al., 1989; Okabe 
et al., 1989; Titball et al., 1989; Tso and Siebel, 
1989), and, with the exception of one residue 
(Serl7 to Thr1 7; Tso and Siebel, 1989), the de-
duced amino acid sequences are identical. 
Comparison with the deduced sequence from 
strain 8-6 revealed several differences (Saint-
Size of probe-reactive fragment 










Joanis et al., 1989) that were clustered more fre-
quently in the signal peptide. 
The low GC ratio of C. perfringens DNA (24-
27 mol%; Buchanan and Gibbons, 1974) is re-
flected in the codon usage of the alpha-toxin 
gene that is biased toward codons in which A 
or U predominate. This is particularly notice-
able for amino acids having six codon 
synonyms: the codon AGA for arginine is used 
almost exclusively, and there is a marked pref-
erence for the codons UUA for leucine and 
UCA for serine. The extent of the A or U bias is 
highlighted by the fact that 79% of codons end 
in these bases, comparing well with an average 
of 84.5% for other C. perfringens genes. This fig-
ure is similar to that reported for C. acetobutyli-
cum (87%; Young et al., 1989a), C. pasteurianum 
(81%; Young et al., 1989b), and C. perfringens 
plasmid-borne genes (86%; Gamier and Cole, 
1988), but not to that reported for C. thermocel-
lum (60%; Young et al., 1989a). Thus, the codon 
usage of the C. perfringens alpha-toxin gene is 
similar to the codon usage of the majority of 
clostridial genes. However, it differs substan-
tially from the codon usage found in other bac-
teria such as Escherichia coli and Bacillus subtilis 
(Table 14.2). 
In particular,. a number of codon synonyms 
that are frequently found in the alpha-toxin 
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A1'GUAAGUAGA1TI'GTAAGGCGCTrA1TI'G'I'GCCGCGCTAGCUCTAGCCT&'roGGCTGGGGCATCAACTWG1'CTACGCTTGGG&".'GGUAGATIG 
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FIGURE 14.2 Open readjng frame nucleotide 
sequence of alpha-toxin. 1, NCTC 8237 consensus 
sequence; 2, Tso and Siebel 1989. Strain NCTC 
8237; 3, Saint-Joanis et al. 1989, strain 8-6. Ex-
perimentally determined N-terminal amino acid 
sequence of alpha-toxin, isolated from Clostridium 
perfringens culture supernatant fluid, is shown 
underlined (fitball et al., 1989, Okabe et al., 1989) . 
gene are found only rarely in E. coli genes. 
For example, the codons AGA (arginine), UUA 
(leudne), UCA (serine), ACA (threonine), 
GGA (glydne), and AUA (isoleucine) are found 
in fewer than 10% of cases in E. coli genes, but 
at least three fold more frequently in the alpha-
toxin gene. It has been suggested that this dif-
ference in codon usage may present a barrier to 
translation of some clostridial genes, espedally 
large genes (Gamier and Cole, 1988; Leslie et 
al., 1989). However, the alpha-toxin gene was 
effidently expressed in Escherid1ia coli. 
A wide range of values (30,000-106,000) 
have been reported for the experimentally de-
termined molecular weight of the alpha-toxin 
(McDonel, 1986), but recently reported data 
from Sodium dodecyl sulfate-polyacrylarnid gel 
electrophoresis (SOS-PAGE) analyses are sirni-
lar to the values of 42,474 (Saint-Joanis et al., 
1989) to 45,528 (Titball et al., 1989) for the ma-
ture toxin calculated from the deduced amino 
add sequence. 
14.4 Transcriptional and 
Translational Signals for the 
Alpha-Toxin Gene 
Promoter sequences 
Putative promoter regions have been identified 
for many of the clostridial genes cloned and 
sequenced to date. Localization of the promo-
ter, by primer extension or SI nuclease map-
ping of the transcript start site, has been re-
ported for only a limited number of these. 
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Table 14.2 Codon usage of the Clostridium perfringens alpha-toxin gene 
Alpha toxin Clostridium Bacillus Escherichia 
Amino acid Cod on gene (%)• perfringens (%)b subtilis (%)C coli (%)c 
Arg CGA 0.0 0.0 9.1 2.3 
c 0.0 0.0 17.5 35.0 
G 0.0 0.0 11.1 3.2 
u 0.0 21.2 25.2 58.1 
AGA 98.0 75.8 27.7 1.2 
G 2.0 3.0 9.4 0.3 
Leu CUA 26.6 9.4 6.3 1.8 
c 0.0 0.0 9.8 6.6 
G 4.3 1.2 21.8 69.1 
u 16.0 20.0 26.1 8.6 
UUA 53.2 69.4 22.4 5.8 
G 0.0 0.0 13.6 8.2 
Ser UCA 48.1 32 3 18.7 8.3 
c 3.8 5.6 12.0 25.6 
G 0.0 0.0 10.0 11.4 
u 11.3 32.3 24.4 26.5 
AGC 11.3 5.6 24.1 21.6 
u 25.5 24.2 10.7 6.5 
Thr ACA 37.0 55.3 43.3 5.9 
c 0.0 7.1 14.1 50.6 
G 1.5 0.0 27.9 19.7 
u 61.5 37.6 14.8 23.8 
Pro CCA 67.4 55.3 19.1 19.9 
c 0.0 5.3 9.8 6.0 
G 0.0 0.0 37.5 65.1 
u 32.6 39.4 33.6 9.0 
Ala GCA 39.6 47.7 27.1 22.9 
c 6.2 10.8 20.0 18.8 
G 8.0 0.0 25.4 30.5 
u 49.6 41.5 27.5 27.9 
Gly GGA 68.5 59.2 31.5 4.6 
c 0.0 11.8 29.6 40.8 
G 11.5 1.3 13.5 6.8 
u 20.0 27.7 25.4 47.8 
Val GUA 48.8 42.5 24.5 22.9 
c 6.3 2.7 24.7 12.9 
G 5.0 4.1 19.4 26.8 
u 40.0 50.7 31.4 37.5 
ne AUA 50.0 51.0 10.6 0.5 
c 12.7 6.9 39.4 62.2 
u 37.3 42.1 50.0 37.3 
Lys AAA 72.9 70.2 75.4 76.7 
G 27.1 29.8 24.6 23.3 
Asn AAC 32.6 26.9 46.9 75.8 
u 67.4 73.1 53.1 24.2 
Gln CAA 90.0 93.7 54.2 26.6 
G 10.0 6.3 45.8 73.4 
His CAC 22.2 26.7 31.4 61.1 
u 77.8 73.3 68.6 38.9 
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Table 14.2 (Continued) 
Alpha toxin Clostridium Bacillus Escherichia 
Amino acid Cod on gene(%)" perfringens (o/o)b subti/is (% )< coli(%)< 
Glu GAA 59.6 93.2 69.5 73.4 
u 40.4 6.8 30.5 26.6 
Asp GAC 14.2 20.5 36.2 49.0 
u 85.8 79.5 63.8 51.0 
Tyr UAC 14.8 9.8 38.2 59.4 
u 85.2 90.2 61.8 40.6 
Cys UGC 33.3 28.6 54.3 58.0 
u 66.7 71.4 45.7 40.6 
Phe uuc 40.0 14.3 36.0 56.5 
u 60.0 85.7 64.0 43.5 
Met AUG 100.0 100.0 100.0 100.0 
Trp UGG 100.0 100.0 100.0 100.0 
:From Titball et_ al., 1989; Leslie et al., 1989; Tso and Siebel, 1989; Okabe e t al. , 1989; Saint-)oanis, 1989. 
From Roggenhn et al., 1988; Tweten, 1988; van Damme-)ongsten, 1989. 
<from Ogasawara, 1985. 
The alpha-toxin gene promoter has been 
mapped experimentally in strain 8-6 (Saint-
Joarus et al. , 1989) and NCTC 8237 (Yeoman et 
al., in manusaipt). Differences in the position of 
the transaipt start site were observed (Figure 
14.3). The promoters from each strain con-
tained identical Pribnow boxes, which matched 
both the B. subtilis Ea-43 and E. coli ECT7o con-
sensi. However, differences between the pro-
moters were seen in the -35 region; in strain 8-6 
the final nucleotide was G, whereas in strain 
NCTC 8237 it was a C (see Figure 14.3). In both 
strains the -35 region corresponds to the B. sub-
tilis Eo-43 consensus in the second, third, and 
fourth bases. Percentage conservation studies 
have indicated that the first four bases of this 
region play the most important role in poly-
merase recognition in gram-positive bacteria 
(Graves and Rabinowitz, 1986). 
In addition, the "extended promoter re-
gions" that may play a role in polymerase 
recognition in gram-positive bacteria (Graves 
and Rabinowitz, 1986) are also apparent. The 
degree of conservation is particularly marked 
for a TG motif around the -15 region. A simi-
larly located TG motif may enhance gene ex-
pression in E. coli from promoters with weak 
-35 homology (Keilty and Rosenberg, 1987; 
Ponnambalam et al., 1988). 
Ribosome-binding site 
A large number of putative clostridial Shine-
Dalgamo regions have been reported. The free 
energy of interaction of these ribosome-binding 
sites with B. subtilis 165 rRNA have been calcu-
lated (Tinoco et al., 1973), ranging from -10.5 
to -23.5 kcal per mole. The free energy calcu-
lated for the alpha-toxin mRNA-165 rRNA 
complex was -10 kcal per mole, suggesting 
that the initiation complex is less stable than 
those predicted for the other clostridial genes. 
In view of the high level of alpha-toxin produc-
tion in C. perfringens, it is therefore possible 
that the control of gene expression is not ex-
erted at the level of translational initiation. 
Like most clostridial genes the translational 
initiation codon of the alpha-toxin is ATG. This 
is located 9 nucleotides downstream of the 
5hine-Dalgamo purine tract and corresponds 
well with the clostridial consensus of 8 nu-
cleotides. 
Transcriptional stop signals 
The termination of transcription of some clostri-
dial genes has been investigated by S1 nuclease 
protection studies (Beguin et al., 1986; Graves 
and Rabinowitz, 1986; Gamier and Cole, 1988). 
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FtGURE 14.3 Upstream regions of alphn-toxin gene: compnrison with 
Escherichia coli Ea70 and Bacillus subtilis Err43 consensus promoter sequ-
ences. Nucleotide differences between strains of Clostridium pctfringcns 
(NCTC 8237: Titball et al., 1989; Okabe et al., 1989; Leslie et al., 1989; 8-6, 
Saint-Joanis et al., 1989). Dots ( ·) refer to absent nucleotides; transcript 
start points, as found by Yeoman et al. in manuscript and Saint-Joanis et 
al. (1989) are indicated by arrows. Suggested -10, -35, and upstream 
A • G 
repeat sequences are shown underlined. Promoter region consensi of 
gram-posi ti ve and gram-negative genes are also shown; "extended" 
promoter regions postulated to play role in polymerase recognition are 
indicated (Graves and Rabinowitz, 1986). Bold capitals represent more 
than 75% conservation; capitals, 50%, lower case letters, conserved in 
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These transaiptional terminators appear to be 
rho independent, with characteristic areas of 
dyad symmetry in the DNA, as long as 19 
nucleotides and capable of hairpin loop forma-
tion. An inherent or subsequent poly-T tract, 
when transoibed to poly-U, leads to mRNA 
release. 
Sequence data reported for the alpha-toxin 
gene included a stretch of 44 nucleotides down-
stream of the triple translational termination 
codons (Leslie et al., 1989; Okabe et al., 1989; 
Saint-Joanis et al., 1989; Titball et al., 1989). 
There are no obvious rho-independent trans-
oiptional terminators in this region, and ex-
amination of the nucleotide sequence down-
stream of the previously published region has 
revealed the presence of a possible rho-
dependent terminator located 54 nucleotides 
downstream of the translational stop codons 
(Yeoman et al ., in manusoipt). 
Regulation of gene expression 
Determination of mRNA levels in a heat-
resistant strain of C. perfringens (Saint-Joanis et 
al., 1989) showed that the alpha-toxin gene was 
expressed constitutively and that production 
was about threefold higher in the stationary 
phase than in the logarithmic phase. This pat-
tern of gene transoiption may not be typical, 
because previous reports have indicated that 
maximal toxin production occurs in the logar-
ithmic phase, with a reduction on entry into 
the stationary phase (Smyth and Arbuthnott, 
1974). 
Several reports have indicated the impor-
tance of factors such as iron and phosphate 
concentration for microbial gene expression 
(Pritchard and Vasil, 1986; Calderwood and 
Mekalanos, 1987; Guddal et al., 1989; Goldberg 
et al., 1990). Murata et al. (1965) demonstrated 
a possible relationship between environmental 
iron levels and alpha-toxin production by C. 
perfringens, but they were unable tp show that 
environmental phosphate levels also affect 
alpha-toxin production. Environmental phos-
phate concentration has been shown to reg-
ulate production of the phospholipase C's of 
both Pseudomonas aeruginosa (Pritchard and 
Vasil, 1986) and Bacillus cereus (Guddal et al ., 
219 
1989), and it is possible that alpha-toxin is reg-
ulated in a similar manner. 
It has been suggested that phospholipase C 
and alkaline phosphatase function cooperative-
ly as part of a phosphate-scavenging mechan-
ism within P. aeruginosa (Liu, 1979). This may 
also be the case for the C. perfringens alpha-
toxin, as the protein shows structural motifs, 
such as central, catalytically essential zinc ions, 
that are common to both the B. cereus phospho-
lipase C and alkaline phosphatase. These reg-
ulatory mechanisms may only operate in some 
strains of C. perfringens, and the reason why 
alpha-toxin is produced at much higher levels 
by type A strains has also yet to be elucidated. 
It is possible that global regulatory mechanisms 
operate in some biotypes. 
14.5 Export and 
Posttranslational Processing 
The N-terminal amino acid sequence of the 
alpha-toxin isolated from Clostridium perfringens 
NCTC 8237 culture supematant fluid has been 
experimentally determined by two groups (see 
Figure 14.2) (Okabe et al., 1989; Titball et al., 
1989). In both cases the results indicated that an 
N-terminal, 28-amino-acid peptide, with the 
characteristics of a signal sequence (Sarvas, 
1986), was removed on export. Other observa-
tions confirmed this possibility; the cloned tox-
in was found predominantly in the periplasmic 
space of E. coli, and minicell analysis of the 
cloned gene products revealed an additional 
polypeptide corresponding to the precursor 
form of the toxin (Leslie et al ., 1989). 
The acquisition of three catalytically essential 
zinc ions probably occurs intracellularly, soon 
after protein synthesis, because the apoprotein 
is highly susceptible to proteolysis (Sato et al ., 
1978). The sequential acquisition (or loss) of 
zinc ions may be responsible for the appear-
ance of several forms of the toxin with similar 
biological properties after isoelectric focusing 
(Krug and Kent, 1984), but we have been 
unable to demonstrate interconversion of the 
different forms after toxin incubation with 15 
mM EDTA or 190 mM zinc ions. The difference 
in the main form of the protein expressed from 
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the gene in C. perfringens (pi, 5.48) and E. coli 
(pi, 5.6) suggests that an active mechanism 
may be responsible for the observed heter-
ogeneity. Phosphorylation of the alpha-toxin 
does not occur in E. coli (K. a Horics, unpub-
lished observations), and the possibility that 
dearnidation of the protein leads to charge dif-
ferences has not been investigated. 
14.6 Functional Analysis of the 
Alpha-Toxin 
Biological activities of the alpha-toxin 
Many of the early functional studies of alpha-
toxin used protein preparations of dubious pur-
ity (Mollby, 1978; McOonel, 1986) and need to 
be interpreted with caution. The problem of 
obtaining alpha-toxin free of other C. perfringens 
toxins has now been circumvented by gene ex-
pression in E. coli. Toxin purified from this 
source was similar to the native protein (Titball 
et al., 1989) and was able to hydrolyze phos-
phatidylcholine and sphingomyelin (Saint-
Joanis et al., 1989), cause mouse erythrocyte 
lysis (Titball et al., 1989), and kill mice (Tso and 
Siebel, 1989). These results contrast with those 
found in Bacillus cereus, a nonpathogenic aerobe 
in which the separate phosphatidylcholine-
preferring phospholipase C (PC-PLC) and 
sphingomyelinase act synergistically to cause 
hemolysis (Gilmore et al., 1989). 
In addition to the cytolytic activity of the 
alpha-toxin, it is now apparent that limited 
membrane damage by the toxin may elicit more 
subtle actions on cells and organs. Fujii and 
Sakurai (1989) have reported that alpha-toxin 
treatment of cells lining the rat aorta resulted in 
activation of the arachidonic acid cascade, lead-
ing to the production of thromboxanes which 
then caused an inflammatory response. The 
phospholipase C of Pseudomonas aeruginosa has 
also been reported to increase the levels of 
arachidonic acid metabolites from human gran-
ulocytes and mouse peritoneal cells (Meyers 
and Berk, 1990), resulting in inflammatory re-
sponses. The inflammatory responses elicited 
by these toxins could be reduced by using iJ!-
rubitors of enzymes in the arachidonic acid 
pathway. 
Treatment of rat aorta cells with alpha-toxin 
has also been reported to cause an increase in 
intracellular inositol-1,4,5-triphosphate, leading 
to increases in calcium levels and the activation 
of the calcium gate (Fujii et al., 1986). The re-
sultant contraction of the aorta wall may be of 
significance when considering the role of 
alpha-toxin in the pathogenesis of disease. 
Homology with other lipid-
metabolizing enzymes 
Significant insight into the molecular arclti-
tecture and function of the alpha-toxin has been 
obtained by comparing the deduced amino 
acid sequence with those of other phospho-
lipid-metabolizing enzymes. The most fre-
quently reported homology is that between the 
N-terminal two-thiri:is of the alpha-toxin and 
the entire smaller, nontoxic PC-PLC (Leslie 
et al., 1989; Titball et al., 1989; Titball and 
Rubidge, 1990) (Figure 14.4). The possibility 
that the N-terminal two-thirds of the alpha-
toxin represents a structural and functional 
homolog of the PC-PLC has recently been 
confirmed by expressing a truncated alpha-
toxin from a recombinant plasmid (pBISb), 
which contained the gene lacking the 3' coding 
region. The purified alpha-truncate, which ter-
minated at proline249, was able to digest egg 
yolk phospholipids as efficiently as did the 
alpha-toxin but did not hydrolyze sphingo-
myelin or cause the lysis of mouse erythro-
cytes. It was also at least 10 fold less toxic (Tit-
ball et al., 1991). 
Calculation of the hydropathic potentials of 
the alpha-toxin and B. cereus PC-PLC did not 
reveal any marked similarity (Titball et al., 
1989). It has been suggested that some regions 
of the alpha-toxin (Asp30 to Leuso and AJal45 to 
Pro165) could form surface-seeking amphi-
patltic alpha helices (Saint-Joanis et al., 1989). 
These regions have no obvious functional 
counterparts in the B. cereus PC-PLC, although 
they would correspond to the structural helices 
A and 0 (Hough et al., 1989). It is possible that 
these regions promote the interaction of alpha-
a-toxin 
B cereus PC plc 
a-toxin 
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FtGURE 14.4 Alignment of the amino acid sequences of alpha-toxin d ine residues with box; PC-PLC and tyrosine residues with HASL, point 
Bacillus cereus PC-PLC and arachidonate-5-lipoxygenase. Aligned histi- of truncation of alpha-toxin gene in plasmid pBlSb, arrow. 
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+ of sphingomyelin. The removal of this domain 
in the alpha-tnmcate could explain the in-
creased hydrolysis of the synthetic substrate 
1-+--+---!~+--+---i-~~----i--i-_;._-i + p-nitrophenol phosphorylcholine because of 
B 
FIGURE 14.5 Hydropathy profiles of alpha-toxin, 
Bacillus cereus PC-PLC, and arachidonate-5-lip-
oxygenase. Hydropathy profiles of alpha-toxin (C, 
residues 249-370) and HA5L (B, residues 1-113) 
calculated using algorithm of Kyte and Doolittle 
(1982) are superimposed (A). 
toxin with membrane phospholipids (Moreau 
et al., 1988). 
In view of both these results and the tandem 
location of PC-PLC and the sphingomyelinase 
genes in B. cereus, it is tempting to speculate 
that the alpha-toxin represents a fusion of these 
two elements. It has been suggested that the 
C-tenninal domain of alpha-toxin is a structural 
analog of the B. cereus sphingomyelinase (Saint-
Joanis et al., 1989), but neither the encoding 
genetic elements nor the predicted proteins 
show significant sequence homology (Saint-
Joanis et al., 1989). 
In contrast, there is a significant degree of 
amino acid sequence homology (29% identity) 
between the C-tenninal domain of the alpha-
toxin and residues 1-113 of a eucaryotic lipid-
modifying enzyme, arachidonate 5-1ipoxy-
genase (HA5L) (see Figure 14.4). In addition, 
the hydropathy profiles of these regions 
showed a high degree of similarity (Figure 14.5), 
and a region of alpha helix was strongly pre-
dicted in the aligned region of both proteins 
(alpha-toxin 310-325, HA5L 60-70). The HA5L 
has not been reported to possess sphingo-
myelin-hydrolyzing activities but it is required 
for the generation of leukotrienes from ara-
chidonic acid (Samuelsson, 1983). It is possible 
that the N-terminal region of HA5L is involved 
in the recognition of hydrocarbon chains; the 
C-terminal region of alpha-toxin may perform 
a similar function by facilitating the recognition 
the increased accessibility of the active site. 
Characterization of functionally 
critical amino acids 
The role of some amino acids in alpha-toxin has 
been investigated by several workers using 
chemical modification techniques (Table 14.3). 
Of these, it appears that histidine residues are 
essential for the phospholipase C activity of the 
toxin (Titball and Rubidge, 1990). This result 
can be explained by examining the tertiary 
structure of the related B. cereus PC-PLC, be-
cause histidine residues that are involved in 
binding the three zinc ions (Hough et al., 1989) 
are conserved in the alpha-toxin (Figure 14.4), 
which also required zinc ions for structural sta-
bility and activity (Krug and Kent, 1984). The 
histidine residues can only be modified after 
pretreatment of the alpha-toxin with EDT A, 
which could remove the zinc ions exposing his-
tidine imidazole groups to the diethylpyrocar-
bonate modifying agent (Titball and Rubidge, 
1990). 
Tyrosine residues appear to be essential for 
the hemolytic, platelet-aggregating and lethal 
activities and to a lesser extent, for phos-
pholipid-hydrolyzing activity (Sakurai et al., 
1989). It may be of significance that within 
the C-terminal domain of alpha-toxin, which is 
known to be essential for hemolytic and lethal 
activities, five of the seven tyrosine residues are 
aligned with the HA5L residues (see Figure 
14.4). It is possible that these C-tenninal tyro-
sine residues play an essential role in the recog-
nition of substrate hydrocarbon chains. 
The single cysteine residue within the alpha-
toxin appears to play no direct role in the activ-
ity of the protein. Superimposition of this 
residue onto the crystal structure of the B. cereus 
PC-PLC (Hough et al., 1989) indicates that it 
would be located distally to the active site. In 
this orientation, disulfide bridges could form 
with other alpha-toxin or theta-toxin molecules 
without masking the phospholipase C active 
site. 
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Table 14.3 Chemical modification of alpha-toxin 
Effect on biological activity 
Residue modified EY pNPPC Hly PtA Lty 
Histicline• + + NT NT NT 
Cysteine _b,c,<, -< -< -< -< 
Arginined NT NT NT NT 
Tyrosine/ ± + + + 
Tyrosine + cysteines ± + + + 
Tyrosine+ cysteine!'+ histidine + NH2 + + + + 
•Modification with EDTA + diethylpyrocarbonate (Titball and Rubidge, 1990). Inhibition ( + ), partial inhibition{±), or 
noninhibition (-)of egg yolk phospholipid (EY) hydrolysis, p-nitrophcnol phosphorylcholine (pNNPC) hydrolysis, 
mouse erythrocyte lysis (Hly), platelet aggregation (PtA), or lethality (Lty). NT, not tested . 
bModification with p-hydroxymercuribenzoic acid (pH M CB) {I :I to 1000:1 molar ratio pHMCB:alpha toxin cysteine 
residues, pH 6, 1 h, 22•c, ± 2mM EDT A). 
<Modification with iodoacetic acid. Method as for p-hydroxymercuribenzoic acid modification,.. 
dModification with phenylglyoxal (PF) (10:1 to 100:1 molar ratio PG:alpha-toxin arginine residues, pH 8, 1h, 22•c, ±2 
mMEDTA). 
•Modification with N-ethylmaleimide (Sakurai et al. , 1989) . 
!Modification with N-acetylimidazole (Sakurai et al. , 1989). 
&Modification with tetranitromethane (Sakurai et al. , 1989). 
hModification with maleic anhydride (Sakurai et al., 1989) . 
14.7 Antigenic Analysis of the 
Alpha-Toxin 
By using gel double diffusion techniques with 
polyclonal anti-alpha serum, it has been shown 
that the E. coli cloned alpha-toxin shares many 
or all of the epitopes found on the native pro-
tein (fitball et al., 1989). Individual epitopes 
have recently been investigated using mono-
clonal antibodies against the alpha-toxin from 
strains NCfC 8237 (Shuttleworth et al., 1988) 
and BP6K (Sato et al., 1989). In both cases of 
antibodies capable of neutralizing phospholi-
pase C hemolytic and lethal activities were 
reported, but these activities were not coneu-
tralized to the same extent (Sato et al., 1989), 
suggesting the presence of different functional 
sites in the alpha-toxin molecule. This is partial-
ly confirmed by our results showing that the 
alpha-toxin is composed of two domains (see 
Section 14.6). 
All the monoclonal antibodies generated by 
Logan et al. (in manuscript) reacted equally 
well with the alpha-toxin or alpha-truncate (see 
Section 14.6), suggesting that the immunodo-
minant region of the protein is located between 
amino acids 1 and 249. Only the toxin-
neutralizing monoclonal antibody (3a4D10) 
reacted with alpha-toxin after Western blot 
analysis. The exact binding site of antibody 
3a4D10 has been mapped more precisely after 
chemical cleavage of the alpha-toxin at the sing-
le cysteine residue (2-nitro-5-thiocyanobenzoic 
acid cleavage) or partial cleavage at methionine 
residues (cyanogen bromide cleavage). The 
results indicated that the antibody recognized 
a region of the protein between Cys197 and 
Met238 (Logan et al., in manuscript). Further 
characterization of the recognized epitope is 
currently in progress using peptides corre-
sponding to this region. 
14.8 Conclusions 
A resurgence of interest in the toxins of C. per-
fringens has occurred. The cloning and nu-
cleotide sequencing of the alpha-toxin gene has 
facilitated the precise determination of several 
fundamental biophysical properties of the pro-
tein. The role of alpha-toxin in disease is still 
not fully elucidated, and the regulation of gene 
expression in vivo is not understood. The 
failure to correlate in vitro alpha-toxin produc-
tion with virulence should be investigated at a 
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molecular level. We have recently cloned the 
gene encoding C. perfringens epsilon-toxin and 
determined its nucleotide sequence (Hunter et 
al., in manusaipt). Parallel studies on the con-
trol of toxin gene expression may reveal the 
nature of regulatory systems. 
Considerable progress has been made in 
understanding the molecular architecture and 
function of the toxin. It is apparent that the 
alpha-toxin is composed of two domains. One 
of these constitutes a phospholipase C capable 
of digesting phosphatidylcholine. The C-
terminal domain is required for sphingomyelin 
hydrolysis, hemolysis, and lethality of the pro-
tein. The exact role of this domain has yet to be 
elucidated, and although this region appears to 
be essential for sphingomyelin hydrolysis, it 
seems unlikely that this domain is endowed 
with a catalytic site. 
ln the case of the two characterized phospho-
lipase Cs of Pseudomonas aeruginosa, it has been 
shown that the N-terminal two-thirds of these 
proteins show extensive amino acid sequence 
homology and that the C-terminal region may 
be responsible for the sphingomyelin specificity 
of the haemolytic enzyme (Ostroff et al., 1990). 
The C-terminal domain of the alpha-toxin may 
contain regions able to interact with membrane 
phospholipids. The elucidation of the function 
of the C-terminal domain of alpha-toxin would 
not only provide further insight into the 
molecular basis of toxicity but could also indi-
cate the function of the homologous domain in 
HA5L, a eucaryotic enzyme of importance in 
the pathogenesis of cardiovascular and in-
flammatory diseases of man. 
By fusing different domains from the alpha-
toxin, B. cereus PC-PLC or Clostridium bifennen-
tans phospholipase C the molecular basis of 
toxicity could be further investigated. If the 
phospholipase C-encoding genes from C. novyi 
and C. barati are also structurally. related, then 
comparison of these proteins with the alpha-
toxin could reveal the molecular basis of sub-
strate specificity. The functions of some amino 
acids in the alpha-toxin can be tentatively 
assigned from comparison of their homologues 
in the B. cereus PC-PLC. A more precise deter-
mination of their functions will be possible 
using site-directed mutagenesis. 
Expression of these native or modified phos-
pholipase C genes in E. roli could provide a 
source of enzyme, free of other clostridial exo-
proteins, that could be used as phospholipid-
specific probes for the investigation of eucaryo-
tic cell membranes. 
The development of a vaccine based on the 
alpha-toxin could proceed in a number of direc-
tions. The finding that a neutralizing antibody 
binds to a discrete region of the alpha-toxin 
suggests that a peptide vaccine could be effec-
tive. Alternatively, a vaccine based on an inac-
tive N-or C-terminal domain of the alpha-toxin 
may enable a number of epitopes to be pre-
sented in the form of a nontoxic polypetide. It 
has been d emonstrated that an antiidiotype 
vaccine is capable of protecting mice from C. 
perfringens epsilon toxin and infections caused 
by C. peifringens type D (Percival et al., 1990), 
and it is possible that this approach could also 
be applied to the generation of an alpha-toxin 
vaccine. 
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Studies of Alpha-Toxin of Clostridium perfringens 
A. K. Basak 1'2 , D. I. Stuart1•3, T. Nikura2, D. H. L. Bishop2, D. C. Kelly\ A. Fearn4 
and R. W. Titball4 
1Laboratory of Molecular Biophysics 
Rex Richards Building, Oxford University, South Parks Road, Oxford OXJ JQU. U.K. 
2NERC Institute of Virology 
Mansfield Road, Oxford OX2 6SR, U.K. 
30xford Centre for Molecular Sciences 
New Chemistry Laboratory, Oxford OXJ JRE, U.K. 
'Chemical and Biological Defence Establishment 
Porton Down, Salisbury, Wiltshire SP4 OJQ, U.K. 
Alpha-toxin of Clostridium perjringes, cloned in Escherichia coli, has been purified and 
crystallized from ammonium sulphate using the hanging drop ,vapour diffusion method at 
20°C. The crystals diffract ,to a minimup1 Bragg spacing of 2. 7 A, belong to the space group 
R32 (with a= b = 153.3 A, c = 95.4 A, et= p = 90° and y = 120°) and contain a single 
polypeptide chain in the crystallographic unit. · 
Keywords: toxin; X-ray diffraction; purification; crystallization; structure 
The bacterial zinc-metallo phospholipases Care an 
important group of enzymes, some of which play 
significant roles in the pathogenesis of disease 
(Titball, 1993). The enzymes have differing substrate 
specificities and toxicological properties (Titball, 
1993). The Clostridium perfringens phospholipase C 
(alpha toxin) is the most toxic phospholipase known 
and plays a major role in the pathogenesis of gas 
gangrene in man (McDonel, 1986; Williamson & 
Titball, 1993). In contrast, the Bacillus cereus 
phosphatidylcholine-preferring phospholipase C 
(PC-PLCtJ is non-toxic (Otnaess et al., 1977). 
A comparison of the deduced amino acid sequences of 
these proteins has revealed significant homology 
(Leslie et al., 1989; Tso & Siebel, 1989) and has also 
shown that some members of the zinc-metallophos· 
pholipase C group possess an additional C-terminal 
domain which shows amino acid sequence homology 
with arachidonate-5-Iipoxygenase, a eukaryotic lipid 
metabolising enzyme (Tit ball et al., 1991 ). The 
function of this domain is not fully understood but 
studies with the alpha-toxin of G. perfringens have 
shown that removal of this domain abolished the 
haemolytic and lethal activity of the protein and 
markedly reduced the ability of the enzyme to 
hydrolyse sphingomyelin (Titball et al., 1991 ). The 
t Abbreviation used: PC-PLC, 
phosphatidylcholine-preferring phospholipase C. 
0022-2836/94/500648-03 $08.00/0 
648 
phosphatidylcholine hydrolysing activity of the 
enzyme was unaffected. The truncated alpha-toxin 
possessed similar properties to the B. cereus PC-PLC 
which does not possess a C-terminal domain 
(Johansen et al., 1988). These studies have resulted in 
the suggestion that the C-terminal domain of the 
alpha-toxin plays an important role in the recog-
nition of some phospholipids and facilitates inter-
action of the protein with the eukaryotic cell 
membrane (Titball et al., 1993). 
We have developed methods for the purification of 
the alpha-toxin in a form which permits crystalliza-
tion of the protein for the subsequent analysis of the 
structure. These studies will, in the longer term, 
permit the comparison of the structure with the 
B. cereus PC-PLC structure (Hough et al., 1989). Such 
studies could provide insight into the molecular basis 
of phospholipase C substrate specificity and the 
mechanisms by which some enzymes are able to 
interact with cell membranes. 
The cloning and expression of the alpha-toxin 
encoding gene (cpa) into plasmid pUC18 in 
Escherichia coli have been reported (Titball et al., 
1989) and the alpha-toxin produced in E. coli was 
shown to have similar biophysical properties to the 
toxin produced from G. perfringens. The bacteria 
were cultured with shaking (150 revs/min) in 
25 x 250 ml Erlenmeyer flasks containing 100 ml of 
brain heart infusion broth containing ampicillin 
(Sambrook et al., 1989). 
© 1994 Academic Press Limited 
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Extraction of alpha-toxin 
After growth for 24 hours at 37°C, the bacterial cells 
were collected by centrifugation (5000 g, ten minutes 
at 4°C}. resuspended in 300 ml of 10 mM Tris-HCl 
buffer, (pH 7.4) and centrifuged as described above. 
The washed bacterial cells were resuspended in 240 ml 
of 10 mM Tris-HCl buffer (pH 8.0) containing 0.58 M 
sucrose. After· incubation for 15 minutes (at 0°C) 
lysozyme was added to a final concentration of 
40 Jlgfml and 0.1 M EGTA (pH 8.0) to a final 
concentration of 4 mM. After incubation for ten 
minutes at room temperature, phenylmethylsulpho-
nylfluoride (PMSF) was added to a final concentration 
of l mM, and ZnS04 and CaC12 added to final 
concentrations of 1.4 mM. After further incubation 
for 30 minutes at room temperature the suspension 
was centrifuged for ten minutes at 10,000 g (4°C) and 
the supernatant (crude extract) removed for 
subsequent purification of the toxin. 
Purification 
The alpha-toxin ·was purified from the crude 
extract using a two-step process. Firstly, the extract 
was mixed with 15 m! of DEAE-Sephacel (Pharma-
cia), stirred gently and allowed to stand for 18 hours 
at 4°C. The supernatant fluid was discarded and the 
DEAE-Sephacel resuspended in 100 ml of 10 mM 
triethanolamine-HCI (pH 8.0). After centrifugation 
(2000 g, ten minutes at 4 °C) the pellet was 
resuspended in a minimal volume of triethanolamine 
buffer and packed onto a column. The column was 
washed with same buffer containing 5% (wfv) betaine 
(5 ml, pH 8.0) and then successively with the same 
buffer containing 0.1 M NaCI (10 ml), 0.2 M NaCI 
( 15 m!) and 0.3 M NaCI (20 ml). Fractions (5 m!) were 
collected and tested for phospholipase C activity 
· (Titball et al., 1989). Fractions containing the 
alpha-toxin were pooled, diluted 1:5 in 50 mM 
triethanolamine buffer (pH 8.0) containing 2 mM 
CaCI2 , 2.4% (vfv) ethylene glycol and 5% (vfv) 
ethanol and passed through an FPLC Mono-Q 
(Pharmacia) ion-exchange column. The unbound 
material was collected. The protein was stored at 
- 20°C, with 50% (vfv) glycerol. 
Protein concentration 
Concentration of the protein using a Centricon 
concentrator resulted in a very low recovery of the 
protein. However, when the protein was concentrated 
using acetone precipitation at - 20°C the recovery 
was approximately lOO%. The stored protein, with 
50% (vfv) glycerol, was diluted with 1.5 x volume of 
acetone at - 20°C and the mixture was kept at - 20°C 
for one hour. The protein was then pelleted by 
centrifugation at 10,000 g for ten minutes at - 20°C 
and resuspended in 10 mM Tris-HCI (pH 7.5) to a final 
concentration of 10 mgfml. 
Crystallization 
Crystals were grown using the hanging drop vapour 
diffusion technique (McPherson, 1982) with am-
monium sulphate as the precipitant. Initial exper-
iments showed that a range of ammonium sulphate, 
between 38% and 46% saturation at pH 7.6, 
produced crystals of dimensions 0.1 mm x 0.1 mm 
x 0.1 mm after 15 to 20 days. The optimal conditions 
for reproducible crystal growth were found to be 10 Jll. 
protein drops containing 10 mgfml protein in 50 mM 
Tricine-NaOH buffer and 24% saturated ammonium 
sulphate at pH 7.8, added to 6 Jli of reservoir solution, 
containing40% saturated ammonium sulphate in the 
same buffer. The crystals were well-defined truncated · 
rhombs, the biggest crystals (0.3 mm x 0.3 mm x 
0.3 mm) grew in two to three weeks at 20°C. 
X-ray analysis 
Initial characterization of the crystals was 
carried out using radiation of wavelength 0.90 A at 
station 9.5 of the SERC synchrotron facility at 
Daresbury, U.K. The diffraction limit was found to be 
approximately dmin = 2. 7 A for the crystal tested at 
Daresbury. Subsequently, diffraction data were 
collected at this synchrotron station (to 2.8 A 
resolution) and in house using a Marresearch imaging 
plate system with X-rays supplied by a Rigaku 
rotating anode generator operating at 60 kV, 70 mA 
(to 3.5 A resolution). Data were collected with 1° 
rotation per image and processed using the 
programme suite DENZO (Otwinowski, 1993) to 
yield a data set composed of 10,227 reflections (95% 
complete to 2.8 A) with a merging R-factor of 8. 7%. 
In the highest resolution shell (2.9 to 2.8 A) 55% of 
the data had I > 2u(J). 
The crystals belong to space group R32 with unit 
cell dimensions of a = b = 153.3 A, c = 95.4 A 
a= p = 90°, y = 120°. Assuming one molecule per 
crystallographic asymmetric unit the solvent content 
would be expected to be 52% (Matthews, 1977). 
Attempts to solve the structure by molecular 
replacement have been unsuccessful and a search for 
suitable heavy-atom derivatives is currently in 
progress. 
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Hemolytic and Sphingomyelinase Activities of Clostridium 
perfringens Alpha-Toxin Are Dependent on a Domain Homologous 
to That of an Enzyme from the Human Arachidonic Acid Pathway 
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Chemical Defence Establishment, Salisbury, Wiltshire SP4 OJQ. United Kingdom 
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TheN-terminal domain of Clostridium perjringe11s alpha-toxin, homologous with the nontoxic phospholipase 
C of Bacillus cereus, was expressed in Escherichia coli and shown to retain all of the phosphatidylcholine 
hydrolyzing activity of the alpha-toxin, but not the sphingomyelinase, hemolytic, or lethal activities. The 
C-terminal domain of alpha-toxin showed sequence and predicted structural homologies with the N-terminal 
region of arachidonate 5-lipoxygenase, an enzyme from the human arachidonic acid pathway which plays a role 
in inflammatory and cardiovascular diseases in humans. 
The alpha-toxin of Clostridium perfri11gens (CPA) was the 
first bacterial protein shown to possess both enzymatic 
activity (phospholipase C) and toxic properties (10). The 
single polypeptide toxin is considered to be the major toxin 
of biotype A strains (12, 21), which are often associated with 
gas gangrene infections in humans, and it has been suggested 
that CPA plays an important role in the pathogenesis of 
disease (6, 21). Some experimental evidence supports this 
hypothesis; the toxin is myonecrotic and the tissue damage 
associated with gas gangrene can be partially reproduced on 
administration of the toxin to animals (6). Also, prior immu-
nization with a crude toxoid vaccine has been shown to 
protect mice from C. perfringens infection (6). 
In contrast to CPA, the phospholipase C of Bacillus cere us 
is considered to be nontoxic (13). The toxicity of some 
phospholipase C's may be attributable to their ability to 
interact with, and degrade, not only phosphatidylcholine but 
also sphingomyelin, which are key components of eukary-
otic cell membranes (13). This property can be determined in 
vitro by measuring the hemolysis of erythrocytes (13, 21). 
Sublytic concentrations of CPA can cause the contraction of 
smooth muscle (1, 2), thromboxane release from cells (2), 
and blood platelet aggregation (23) and can elicit cardiovas-
cular (22) and other effects which may contribute to the 
pathogenesis of gas gangrene. 
The N-terminal two-thirds of the deduced amino acid 
sequence of CPA is approximately 29% homologous (9. 16, 
24, 26) with the non-toxic (13) B. cere us phosphatidyl-
choline-preferring phospholipase C (PC-PLC), and many 
functionally important residues are conserved (4, 9, 25). As 
CPA and PC-PLC share many properties, including thermo-
stability (7, 15) and the requirement for catalytically essen-
tial zinc ions (4, 7), it is possible that this region of CPA is 
responsible for phospholipase C activity (9, 16, 24, 26). We 
have constructed a plasmid (pB15b) containing a DNA 
fragment predicted to encode the region of CPA (residues 1 
to 249 [CPA 249]) homologous with PC-PLC and seven addi-
tional amino acids, encoded by the pUC18 vector, before 
termination (Fig. 1). CPA 249 , purified from 12-h cultures by 
the method described previously for CPA (24), purified 
Esclu'richia coli-cloned CPA (24), and PC-PLC (type XIII; 
* Corresponding author. 
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Sigma) were analyzed by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and Western blotting (immuno-
blotting), using anti-CPA primary monoclonal antibody 
30<4D10 (20, 24). The immunological identity of CPA249 was 
confirmed, and its molecular weight was estimated to be 
27,700 (predicted, 29,389). PC-PLC did not react with 
30<4D!O. 
The specific activities of purified CPA and CPA249 against 
egg yolk substrate were similar, but CPA249 was approxi-
mately 4.5 times more active against the synthetic substrate, 
p-nitrophenol phosphorylcholine. PC-PLC hydrolyzed both 
substrates more rapidly than either CPA or CPA249 (Table 
1). Only CPA caused hemolysis of mouse erythrocytes 
(Table 1). Similarly, CPA249 and PC-PLC were nontoxic for 
mice at doses of 10 11-g/mouse, while CPA caused five deaths 
(n = 6) after inoculation of 1 11-g of protein. 
The ability of the each enzyme (10 11-gl to hydrolyze 
purified phosphatidylcholine (from egg yolk) or purified 
sphingomyelin (from bovine brain) (both at 0.25 mg/ml) after 
incubation for 2 h at 37°C was assessed by thin-layer 
chromatography (16). CPA digested both phospholipids but 
CPA249 and PC-PLC hydrolyzed phosphatidylcholine much 
more efficiently than sphingomyelin. No hydrolysis was 
detected with periplasmic extracts from E. coli containing 
pUC18 (Fig. 2). 
It has been suggested that both phosphatidylcholine and 
sphingomyelin hydrolyzing activities are necessary for a 
bacterial phospholipase C to be hemolytic and lethal (13). 
Other workers have used a panel of neutralizing monoclonal 
antibodies (19) or chemical modification of the toxin (17) to 
show that the phosphatidylcholine hydrolyzing activity of 
CPA was partially independent of other biological activities. 
In the related bacterium B. cere us, phosphatidylcholine and 
sphingomyelin hydrolyzing activities are associated with 
separate proteins (5. 27) which can act synergistically to 
cause hemolysis (3). The genes encoding these enzymes are 
tandemly located and coregulated (3). leading some workers 
to speculate that the alpha-toxin gene represents a fusion of 
these two elements 0. 16). However, neither the nucleotide 
nor the predicted amino acid sequences of the C-tt:nninal 
third of CPA and B. cereus sphingomyelinase show signifi-
cant sequence homology. Consequently, it was decided to 
investigate amino acid sequence homologies between the 
C-terminal portion of the protein (removed in PLC24.) and 
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FIG. 1. Alignment ofCPA (24), B. cereus PC-PLC (5), and HA5L (11). The middle line shows identical residues and frequently (double 
points) or rarely (single point) substituted amino acids. Plasmid pB15b encoding CPA249 was constructed by ligating the products of a partial 
Sau3A digest of the 3.1-kb insert of pT5C100 (24) into suitably digested pUC18 vector plasmid. The point of truncation of the alpha-toxin is 
shown by an arrowhead with additional pUC18 vector-encoded amino acids found in CPA249 . 
protein sequences in the PIR (Los Alamos National Labo-
ratory) data base. We found a significant degree of sequence 
homology (29% identity) between residues 255 to 370 ofCPA 
and residues 1 to 113 of a lipid-modifying enzyme, human 
arachidonate 5-lipoxygenase (HA5L) (11) (Fig. 1). Compar-
ison of hydropathy profiles (Fig. 3) suggested that the 
C-terminal domain of CPA may be structurally simjJar to the 
homologous N-terminal region of HA5L. Five of the seven 
tyrosine residues in the C-terminal domain of the alpha-toxin 
are aligned with tyrosines in HA5L. Tyrosine residues have 
been identified as essentjal for hemolytic, platelet-aggregat-
ing, and lethal activities of CPA (17). 
Our results, and the lack of homology between the CPA 
C-terrrunal domain and B. cereus sphingomyelinase, suggest 
that this domain is unlikely to exhjbit sphingomyelinase 
activity. Rather, it seems likely that phosphatidylcholine and 
sphingomyelin hydrolyses both occur at the same site in 
CPA. With B. cereus PC-PLC it was shown that the sub-
strate range could be artificially enhanced to include sphin-
TABLE 1. Specific activities of CPA 
Egg yolk phos- Hemolytic Lethality 
Sample• pholipid hydro- pNPPC activity (UI (LD$0 [IJ.g]/ Jyzing activity (U/mg)c 
(Uimin/mg)b min/mg)" mouse)' 
Alpha-toxin 52 .3 6.4 236 <1 
Alpha-truncate 43.4 29 0 > 10 
PC-PLC 1,917 57 0 > 10 
E. coli control 0 <0.1 0 Not tested 
• Purified CPA, CPA249 , B. cereus PC-PLC, or a crude periplasmic extract 
from £. coli containing pUC18. 
b Egg yolk phospholipid hydrolyzing activity; units as defined previously 
(24). 
< p-Nitrophenol phosphorylcholine (pNPPC) hydrolyzing activity (25); 1 U 
catalyzes the hydrolysis of 1 nmol of substrate in 1 min. 
d Hemolylic activity against S% (vol/vol) mouse erythrocytes; units as 
defined previously (24). 
' Intraperitoneal inoculation into a group (n = 6) of 23-week-old BALB/c 
mice (18 to 22 g). LD50, SO% lethal dose. 
gomyelin by substituting cobalt for zinc ions in the native 
protein (14). This was attributed to subtle alteration of 
active-site architecture. 
HA5L is required for the generation of leukotrienes from 
arachidonic acid, a phospholipid catabolite (18). Why a 
domain from such an enzyme confers toxicity on a bacterial 
phospholipase is not clear. Possibly, the N-terminal region 
of HA5L and the C-terminal domain of CPA are involved in 
recognition of structural components common to arachi-
donic acid and sphingomyelin. The requirement by CPA, 
HA5L, and B. cereus sphingomyelinase, but not PC-PLC, 
for calcium ions for substrate binding supports this (13 , 27, 
28). Alternatively, the C-terminal domain may distort the 
active site, permitting sphingomyelin hydrolysis. 
These results demonstrate that a potent bacterial toxin is 
composed of a domain representing a functional homolog of 
1 2 3 4 5 1 2 3 4 5 
FIG. 2. Hydrolysis of phosphatidylcholine (a) or sphingomyelin 
(b) by purified B . cereus PC-PLC (lane 1), CPA (lane 2), CPA2• 9 
(lane 3), or a crude periplasmic extract from E. coli containing the 
vector plasmid pUC18 (lane 4). Lane 5 contained only phospholipid. 






FIG. 3. Superimposed (A) and individual hydropathy profiles of 
residues I to 120 of HA5L (B) and residues 250 to 370 of CPA (C) 
calculated by the method of Kyle and Doolinle (8) (nine-residue 
window). 
a nontoxic prokaryotic enzyme and a domain sharing homol-
ogy with a eukaryotic enzyme which, although inherently 
nontoxic, catalyzes the formation of mediators of some 
human cardiovascular and inHammatory diseases (18). Fur-
ther analysis of the C-terminal domain of CPA should also 
contribute to the elucidation of structure-function relation-
ships in HA5L. 
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Abstract: The C-terminal domain of the alpha-toxin (cpa ~,.~ 7 _ 370 ) of Clostridium perfringt.!ns has been expressed in Escherichia coli-
and purified. Antiserum raised against cpa 247 _J 70 reacted in an identical manner to anti-alpha-toxin serum when used to map 
epitopt:s in the C-tcrminal domaiil, suggesting that cpa 2.n-J?o was immunologically and structurally identical to this region in the 
alpha-toxin. The isolated cpa 247 _ 370 was devoid of sphingomyelinase activity or haemolytic activity and was not <..-ytotoxic for mouse 
lymphocytes. Haemolytic activity was detected when cpa 247 _ 370 was tested with the N-terminal domain of the alpha-toxin 
(cpa 1_ 24q), confirming th~t cpa 247 _ 370 confers haemolytic properties on the phospholipase C activity of the alpha-toxin. Haemolytic 
activity was not detected if cpa 247 _ 370 was tested with the Bacillus cereus phosphatidylcholine phospholipase C. nor if cpa 1_ 149 and 
cpa 247 _ 370 were incubated sequentially with erythrocytes. 
Key words: C/ostridi11m perfringens; Alpha-toxin; Phospholipase C 
Introduction 
A wide variety of Gram-positive and Gram-
negative bacteria produce phospholipases C which 
have different biophysical properties. They hydro-
lyse phospholipids with varying efficiencies and 
only some of these enzymes have haemolytic and 
lethal properties [1]. The phospholipases C have 
been proposed to play important roles in the 
pathogenesis of diseases, ranging from activation 
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of the arachidonic acid cascade to the hydrolysis 
of lung membrane surfactants. The alpha-toxin of 
Clostridium perfringens is the most toxic phospho-
lipase C characterised to date [2], and has been 
the subject of considerable investigation since it 
was first described by MacFarlane and Knight in 
1941 [3]. In spite of these studies, it is still not 
clear why this enzyme is toxic whereas other 
members of the zinc metallophospholipase C 
group, such as the phosphatidylcholine-preferring 
phospholipase C (PC- PLC) from Bacillus cere us, 
arc not. Some insight into this question has been 
gained from the observation that the N-terminal 
two-thirds of the protein (to amino acid 249) 
showed sequence homology with the entire B. 
cercus PC-PLC [4]. A truncated form of the al-
pha-toxin (cpa 1_w,l retained phosphatidylcholinc 
hydrolysing activity but was no longer haemolytic 
or lethal, and showed markedly reduced sphin-
gomyelinase activity [5]. This has prompted some 
workers to suggest that the C-terminal domain 
encodes a sphingomyelinase activity [6], which 
acts synergistically with the phosphatidylcholine 
hydrolysing activity, conferring haemolytic and 
lethal properties on the alpha-toxin. The aim of 
this study was to investigate the biochemical and 
immunological properties of the C-tcrminal do-
main of the alpha-toxin, in order that the molecu-
lar basis of toxicity could be examined in more 
detail. 
Materials and Methods 
Enzymes and chemicals 
Unless otherwise stated, enzymes used in this 
study were obtained from BCL Limited. Chemi-
cals were obtained from the BDH Chemical 
Company or the Sigma Chemical Company. C. 
perfringens alpha-toxin; or the N-terminal domain 
of the alpha-toxin (Cpa 1_ 249) were prepared as 
described previously [5, 7]. The phosphatidyl-
choline-preferring phospholipase C (PC-PLC) 
from B. cereus (type XIII, suspension in 3.2 M 
(NH 4 ) 2S04 ) was centrifuged and the pelleted 
material resuspended in borate-buffered saline 
[7] before use. 
DNA cloning 
Oligonucleotides (30-mers) for use in the PCR 
were designed from the nucleotide sequence of 
the alpha-toxin gene (cpa) of C. perfringens NCTC 
8237 [7]. They were synthesised (Applied Biosys-
tems 392 DNA Synthesiser) with 6 additional 
nucleotides at the 5'-ends, which contained re-
striction endonuclease sites. The NCTC 8237 cpa, 
cloned into a plasmid [7], was linearised and used 
as the template DNA (40 ng) in the PCR. A 
DNA fragment, which would encode amino acids 
247-370, was generated after 20 amplification 
cycles (LEP Prem thermal cyder), purified by 
agarose gel electrophoresis [8] then digested with 
Smal and Hindlll. The DNA fragment was li-
gated [8] with Smal-Hindlll digested pBiuescript 
SK + (Stratagene) and transformed into E. coli 
JM 109 cells [9]. A recombinant plasmid (pCTH I) 
was isolated and used for all subsequent nu-
cleotide sequcncing and subcloning steps. To ex-
press cpa 247 _~711 , plasmid pCTH I was digested 
with Smal and Hindlll, the DNA fragment puri-
fied as described above, and the Hindlll site 
blunt-ended using KJenow fragment [8]. The DNA 
fragment was ligated [8], with Sma I digested 
pGEX-3X expression vector (Pharmacia) and the 
mixture transformed into E. coli JMI09 [9]. 
Transformants were screened using the PCR as 
described above, and a colony isolated which 
contained recombinant plasmid (pGEX3X-13). 
Nucleotide sequencing 
Single-stranded DNA was generated from cells 
containing pCTHI by eo-infecting the cells with 
the helper bacteriophage MI3K07 [8]. The sin-
gle-stranded DNA was purified and used as the 
template for dideoxy-termination sequencing re-
actions using a 35S-dCTP [8]. The reaction prod-
ucts were separated by electrophoresis and visu-
alised by autoradiography [8]. 
Expression and purification of GST-cpa 247 _370 and 
cpa 247-370 
E. coli containing the plasmid (pGEX3X-13) 
was cultured in 10 X 100 ml volumes of BHI 
broth, in 250-ml Erlenmeyer flasks, at 37°C with 
shaking (ISO rpm). Fusion protein expression was 
induced by the addition of IPTG (I mM final 
concentration) to cultures which had reached an 
OD600 of 0.6. After a further 5 h of growth, the 
cells were harvested by centrifugation and resus-
pended in 3 ml of phosphate buffered saline 
(PBS, Oxoid). Lysozyme solution (80 1-L I, 10 
mgjml) was added to the suspension and, after 
incubation (10 min, 22°C), 30 I-Ll of Triton X-100 
was added. The cell suspension was frozen 
(- 20°C), thawed, and sonicated for 12 X 30 s 
(Braun Sonicator, maximum power, 25 mm probe) 
on ice. After centrifugation (10000 X g, 30 min, 
4°C) the supernatant was mixed with 2 ml of 
glutathione-Sepharose gel (Pharmacia) previously 
washed three times with PBS + 0.1% Triton X-
lOO. The mixture was stirred for 18 h at 4°C, 
packed into a chromatography column, and the 
column washed with 20 ml of PBS + 0.1% Triton 
X-100 followed by 10 ml of Tris buffer (10 mM, 
pH to 8.0 with HCl) containing 5 mM reduced 
glutathione. Fractions (2 ml) were analysed for 
the presence of the fusion protein by SDS-poly-
acrylarnide gel electrophoresis (Pharmacia Phast 
System, 10-15% gradient gels) and staining with 
Coomassie Blue R250. To generate cpa247_ 370 the 
GST-cpa 247 _ 370 fusion protein (2 mg) was cleaved 
for 18 h (22°C) with factor Xa (BCL; 30 J.Lg) 
according to the manufacturer's datasheet. The 
mixture was applied to a 1 ml mini-column of 
glutathione-Sepharose and the column eluted 
with 3 ml of PBS. Fractions (1 ml) were analysed 
for cpa 247_ 370 as described above. 
Cellular effects in vitro 
Solutions of various concentrations of 
cpa247_ 370 (0.44-1.75 J.Lg j ml) were added to a 
primary culture of naive mouse lymphocytes 
seeded, in a microtitre plate, at a density of 
1 X 107 j ml in Dulbecco's minimum essential 
medium conta ining 10% foetal calf serum. For 
comparison, equimolar amounts of alpha-toxin 
(1.25-5 J.Lg j ml) or the N-terminal fragment, 
cpa 1 _ 249 (0.83-3.3 J.Lg j ml) were added to sepa-
rate mouse lymphocyte cultures. Incubation was 
continued at 37°C in an atmosphere of 5% C02/ 
95% air for 20 h, at which time a sample was 
removed from each well and the viable cell count 
determined using an acridine orangej ethidium 
bromide vital stain. All counts were corrected, as 
follows, to give the percentage of viable cells: 
mean viable cell count in duplicate-treated wells 
divided by mean viable cell count in duplicate 
control wells (medium only) X 100. In a parallel 
assay, the holotoxin was cultured with mouse 
lymphocytes in the presence of a 1: 10 dilution of 
a mouse polyclonal antiserum to the alpha-toxin 
[10]. 
Enzyme assays 
The hydrolysis of egg-yolk phosphatidylcho-
line, p-nitrophenylphosphorylcholine (pNPPC) 
or haemolysis of mouse erythrocytes was mea-
sured using microtitre tray assays [5,7]. The hy-
drolysis of N-omega-trinitrophenyl-laurylsphingo-
47 
sylphosphorylcholine (TNPAL) was measured us-
ing a modification of the method described by 
Gatt et al. [11]. Briefly, the reaction mixture (200 
J.Ll) contained Dicab buffer [7], 0.3 J.Lmol sodium 
deoxycholate, 20 nmol TNP AL and 0.34 nmol 
of the test enzyme. After incubation for 2 h at 
37°C, 0.75 ml of isopropanol: heptane: 5 M 
H 2S04 (40: 10: 1) was added followed by 0.45 rnl 
of heptane and 0.4 ml of water. The optical 
density (330 nm) of the heptane phase was read 
against a reagent blank. The hydrolysis of puri-
fied egg yolk phosphatidylcholine or bovine brain, 
bovine erythrocyte or chicken egg yolk sphin-
gomyelin, with separation of reaction products 
using thin-layer chromatography, was carried out 
as described previously [7]. 
Epitope-mapping 
Hexapeptides, overlapping by 1 amino acid 
residue, were synthesised between residues 247 
and 370 of the alpha-toxin, using the multiple-
peptide synthesis technique [12] (Cambridge Re-
search Biocbemicals). Polyclonal mouse antisera 
raised against the alpha-toxin or cpa 247 _ 370 , were 
reacted with the peptides immobilised on 
polyethylene pins and binding was detected using 
a peroxidase-conjugated anti-mouse IgG (Sera-
Lab Ltd.) using a standard ELISA format. 
Results and Discussion 
Cloning, expression and purification of cpa247 _370 
A DNA fragment corresponding to the C-
terminal domain of the alpha-toxin (cpa 247_ 370) 
was generated using the PCR and cloned into 
pBluescript. Single-stranded DNA was generated 
from this plasmid and the authenticity of the 
DNA fragment checked by nucleotide sequenc-
ing. The DNA fragment was subcloned into plas-
mid pGEX-3X and an in-frame fusion formed 
with the vector-encoded glutathione-S-trans-
ferase. The fusion protein, expressed from the 
tac promoter, was produced at high levels and 
purified from cell extracts using glutathione-Se-
pharose affinity chromatography. To generate 
cpa 247_ 370 , the fusion protein was cleaved with 
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Fig. l. Purification of cpa247_370. Track I, molecular size 
markers (shown arrowed, molecular sizes in kDa X 103); track 
2, whole cell extract from £. coli expressing the GST-
cpa 247_370 fusion ; track 3, purified GST-cpa247_370; track 4, 
GST-cpa 247_370 cleaved with factor X 8 ; track 5, purified 
cpa247-no· 
second glutathione-Sepharose column. Using this 
procedure cpa 247 _ 370 could be produced which 
was pure when judged by SDS-polyacrylamide gel 
electrophoresis (Fig. 1). 
Immunological properties of cpa247 _ 370 
It was of interest to establish whether the 
isolated and purified C-terminal domain of the 
Table J 
alpha-toxin (cpa 247_ 370) was immunologically sim-
ilar to the corresponding region of the entire 
a lpha-toxin. To investigate this, cpa 247_ 370 was 
used as an immunogen in mice [13) and the 
resulting antiserum reacted with overlapping pep-
tides derived from the primary amino acid se-
quence in the C-terminal domain of the toxin. 
The results indicated that the pattern of reactivity 
did not differ from that obtained when antiserum 
to the whole toxin was reacted with these pep-
tides [10). This data suggested that cpa247 _ 370 did 
not contain any new and significant sequential 
antibody-binding regions and that cpa 247_ 370 was 
correctly folded and structurally indistinguishable 
from the C-terminal domain resident within the 
toxin molecule. The unaltered immunoreactivity 
of the isolated cpa 247_ 370 is confirmed by our 
previous finding that anti-cpa 247_ 370 serum was 
equipotent with anti-alpha-toxin serum in neu-
tralising the phospholjpase C and haemolytic ac-
tivities of the toxin in vitro [13). 
Biochemical properties of cpa247_ 370 
We have previously shown that the N-termmal 
domain of the alpha-toxin (cpa t-249) retained 
phospholipase C activity but was devoid of 
haemolytic and lethal activities [5]. These results 
suggested that the C-terminal domain of the al-
pha-toxin either possessed these activities, or that 
Comparison of biological activities of alpha-toxin (cpa) and cpa247_370 
Biological activity 
Phospholipase C-pNPPC hydrolysis • 
activity 
Sphingomyelinase-TNPAL hydrolysis b 
activity 
Sphingomyelinase-TLC assay c 
activity 




















0.079 U/ min 
< 0.001 Uj min 
1003 Uj min 
< 0.01 Uj min 
hydrolysis detected 
no hydrolysis detected 
1.05 Hu j min 
< 0.007 Huj min 
Alpha-toxin (cpa) or cpa247_370 were tested for phospholipase C activity, sphingomyelinase activity, haemolytic activity or lethality. 
• p-nitrophenolphosphorylcholine (pNPPC)-hydrolysing activity. 1 U catalysed the hydrolysis of I nmol of substrate. 
b N-omega-trinit rophenyl-laurylsphingosylphosphorylcholine (TNPAL)-hydrolysing activity. 1 U catalysed the hydrolysis of I nmol 
of substrate. 
c The hydrolysis of bovine brain, bovine erythrocyte or chicken egg yolk sphingomyelin was also assessed after separating the 
reaction products by TLC. 
d Haemolytic activity. I haemolytic unit (Hu) caused 50% lysis of 100 JLI of a 5% (v j v) mouse erythrocyte suspension. 
it conferred these act1v1t1es on the -terminal 
domain. In Bacillus cereus, the genes encoding 
the phosphatidylcholine- and sphingomyelin-hy-
drolysing enzymes are tandemly located and eo-
regulated [ 13]. These two enzymes, acting syner-
gistically, cause haemolysis and this has prompted 
other workers to suggest that the alpha-toxin 
a rose from a fusion of these two elements [6] . If 
this were the case then it may be expected that 
the C-terminal domain of the alpha-toxin would 
possess phingomyelinase activity . To examine 
this, purified cpa 247_ 370 was tested in a variety of 
enzyme assays. The results (Table 1) indicated 
that cpa 2-17 _ 370 did not possess sphingomyelinase 
activity and did not cause haemolysis of mouse 
erythrocytes. In contrast, activity of the alpha-
toxin was detected in all of these assays (Table 1). 
Our finding that the C-te rminal domain appeared 
to be immunoreactively indistinguishable from the 
holotoxin, and therefore folded simila rly, sug-
gested that such an activity should have been 
detected if it were encoded by cpa 247_ 37o· 
Cellular effects of cpa 247_ 3 70 in vitro 
When tested at concentrations in excess of 
1.25 ,ugj ml, alpha-toxin was toxic for mouse lym-
phocytes. These cytotoxic effect were apparent 
after an exposure time of only 1.25 hours (results 
not shown), becoming maximal after 20 hours 
(Fig. 2). The cytotoxic effects increased with a 
clear dose-response relationship up to a concen-
tration of 2.5 ,ug toxin per ml tissue culture 
volume. The cytotoxicity was inhibited by the 
addition of a mouse anti-alpha-toxin serum, which 
had previously been shown to neutralise the 
phospholipase C and haemolytic activit ies of the 
toxin in vitro [10]. In contrast, neither cpa 1_249 
nor cpa 247_ 370 was toxic to mouse lymphocyte at 
concentrations equimolar to those tested for the 
alpha-toxin. These results support our previous 
observation that cpa 247 _ 370 had no toxic side-ef-
fects when I 0-,ug amounts were tested by in-
traperitoneal inocu lation in BALBj c mice, 
whereas 1 ,ug of the alpha-toxin caused death 
within 24 h [ 13]. 
Complemenrarion of cpa 1_ 249 and cpa 147 _J7o 
Individually, cpa 1_2-19 and 147_ 370 we re non-
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Fig. 2. Cytotoxic effects of a lpha-toxin. cpa 1_2J9 and cpa~.7 - nu 
o n mouse lymphocytes. Mouse lymphocytes were incubated 
with the alpha-toxin (O ), cpa 1 _ 24~ (c.), or cpa 2J?-J7II ( e ) for 
20 h. The number o f cells rema ining viable was dett:rmin.:d 
microscopically a fte r staining with e thidium bromide and acri -
dine orange. The results are expressed as a percentage of 
viable cells in control wells. 
we re treated with cpa 1_ 249 and 247_ 370 toge the r, in 
equimolar amounts, hae molysis was d etected (T a-
ble 2). It is possible that thi was due to the 
separate e ffects of these components on the red 
blood cell. In this case, it would be expected that 
sequential treatment of red blood cells with 
cpa t - 249 and cpa 247_ 370 would lead to cell lysis. 
To investigate this, cells were incubated with 
either component, washed, and then incubated 
Table 2 
Complementa tio n of cpa 1_249 and cpa247-370 
Sample • 
cpa 
B. cereus PC-PLC 
cpa 1- 24'1 
cpa 247-J70 
cpa 1- 249 + cpa247-370 
B. cercus PC-PLC+cpa247-370 
Haemolytic activity h 







" Alpha-toxin (cpa : 0 .172 J.L M) or 8. cereus PC-PLC. cpa 1 _~49 . 
cpaH7-J7o (0.5 J.LM) were tested fo r haemolytic activity 
aga inst mo use e rythrocytes (5% v jv) in a microtitr.: tray 
assay. Whe n prote ins we re mixed togethe r before tes ting. 
the ir final concentrations we re also 0.5 J.L M. 
" I haemo lyt ic unit (Hu) caused 50% lysi of 100 J.L I of a 59-
(v j v) mouse erythrocyte su~pension . Result~ arc expre~ eo 
as haemolytic unit; p.:r min per nmol o f protein . 
50 
with the second compone nt. The results showed 
that both components were required imultane-
ously in the reaction mixture for haemolysis. 
Comple menta tion of the B. cereus PC-PLC and 
cpa 147_ 370 could not be demonstra ted, which 
might be expected if cpa 1_ 249 a nd cpa 247_ 370 acted 
separately o n the e rythrocyte membrane. These 
results support ou r previous uggest ion that the 
C-terminal region confers haemo lytic activity on 
the N-terminal domain of the molecule, which 
has intrinsic phospholi pase C activity. 
Ta ke n together, these results suggest that 
cpa 1_ 249 a nd 247_ 370 can associate to form a 
molecule with the prope rties of the alpha-toxin. 
Our finding that this activity was lower in the 
re-associated mixture than for an equivalent 
amount of the whole toxin suggested that bond-
ing between these do ma ins was weak. T he 
de monstra tion that cpa 247 _ 370 can complement 
cpa 1_ 249, if only to a limited extent, provides 
furthe r evidence that cpa 247_ 370 was correctly 
fo lded and reta ined biological act ivity. However. 
we cannot discount the possibility that on binding 
to cpa 1_ 249 a conformat ional change took p lace 
which resulted in the formation of enzymatica lly 
active cpa 247_ 370 . 
We have previously shown that cpa 247_ 370 is a 
potent immunogen, which induces a s trong pro-
tective response aga inst the alpha-toxin. The data 
reported here indicate that the vaccine based on 
this fragme nt [13] would be devoid of any de-
tectable sphingomyel inase, haemo lytic or cyto-
toxic activity, a nd should therefore be free from 
detrime nta l side-effects. The exact funct ion of 
the C-te rmina l domain of the alpha-toxin remain 
open to question . It is possible that cpa 247 _ 370 
facilita tes the interaction of the phospholipase C 
moiety of the alpha-toxin wi th the cell me mbra ne. 
Furthe r investiga tio n of the prope rties of 
cpa 247_ 370 a re required to explore this possib ility. 
The results reported here will faci litate a 
greater molecula r understanding of other zinc 
meta llophospholipases C. The C-terminal domain 
of the C. bifermentans phospholipase C, which 
shows seque nce homology with cpa 247_ 370 [1 5], 
may have simila r prope rties. T he low toxicity of 
this protein seems attributable to the low turnover 
rate of the e nzyme rather than a difference in the 
C-termina l doma in [16]. In the case of the Pseu-
domonas aeruginosa p hospholipases C, which ap-
pear to be structu rally unrelated to the zinc met-
allophospholipase C ( 17], it remains to be ex-
plored whe ther the toxic propertie of some 
members of this group are a lso dependent o n a 
C-termina l domain. 
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INTRODUCTION 
Molecular variation between the ex-toxins from 
the type strain (NCTC 8237) and clinical isolates 
of Clostridium perlringens associated with 
disease in man and animals 
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The oc-toxin produced by the type strain of Clostridium perfringens (NCTC 8237) 
was shown to differ from the oc-toxins produced by most strains of C. 
perfringens isolated from man and from calves with respect to reactivity with 
a neutralizing monoclonal antibody {DY2F5D11). The difference in antibody 
binding correlated with three differences in the deduced amino acid sequence 
(Aia174 to Asp174; Thr177 to Ala177 ; Serm to Pro335) of the oc-toxins. Using 
octapeptides synthesized on the basis of the amino acid sequences from these 
regions of variability, it was shown that the Ala174 to Asp174 change had the 
greatest effect on reducing the binding of monoclonal antibody DY2F5D11 to-
the oc-toxin. These differences did not affect the enzymic or toxic properties of 
the protein. However, the phospholipase C activity of the oc-toxin produced by 
strain NCTC 8237 was more susceptible to inactivation by chymotrypsin. The 
changes in amino acid sequence did not affect the ability of a C-terminal 
domain vaccine, derived from the oc-toxin of strain NCTC 8237, to induce 
protection against the oc-toxin from a bovine enteric strain of C. perfringens. 
Keywords: phospholipase C, oc- toxin, Clostridium perfringms 
Clostridiu111 p etfringem produces a wide array of toxins and 
the differential production of these toxins is associated 
with different cliseases (McDo nel, 1986). The ex-toxin is 
p roduced by almost all strains of this bacterium (Moll by et 
al., 1976). The type strain of C. pufringens type A. (1 CT C 
8237 or A TCC 13124) produces high levels of the a-toxin. 
Most of the studies carried out over the past 20 years have 
used puri fied a-roxin deriYed from th is strai n (McDo nel , 
1986). Mo noclo nal antibo dies have been generated against 
the a-toxin (Sa to et al., 1989; Logan et al., 1991) and the 
bio physica l properties of the roxin have been determined 
(M cD onel, 1986). The :x-rox in has phospho lipase C 
activ ity which contributes direcrh· to the haemolytic and 
letha l acti\·ities o f the pro tein (Titball , 1993). More 
recentl y, it has been demo nstrated that the o: -toxin is able 
to elici t a variety of subtle effects o n eukaryo tic cell 
metaboljsm, including activation o f the arachidonic acid 
cascade and stimulation of protein kinase C activity (Fuj ii 
et al., 1986 ; Fujii & Sakurai, 1989). These effects mav also 
contribute to the toxicity of the pro tein. 
The gene encoding the a-toxin (cpa) from strain NCTC 
8237 has been iso lated and characterized by several g ro ups 
(Leslie et al., 1989; Okabe et al., 1989; Titball et al., 1989; 
T so & Siebel, 1989) (the gene encoding ex-toxi n has also 
been termed plc by some workers). The pro tein (Cpa) is 
known to comprise two do mains ; theN-termina l do main 
possesses phospholipase C acti vity (Titba ll et al. , 1991) 
w hile the C-terminal do main lacks any detectable enzymic 
o r cvrotoxic activ ity (Titball et al., 1993). Immuniza tio n 
with the C-terminal do main fused to g lutathio ne S'-
transferase (GST) induced an immune response which 
p rovided pro tectio n aga inst the a-tox in (\X'illiamson & 
Titball , 1993). 
Abbreviations : EYU, egg-yolk un its; GST, g luta th ione $-transferase; HU, 
haemolytic units. 
The GSDB accession numbers tor the nucleo tide sequence data reported in 
this paper are : L43545 (strain CER B9L43 cpa gene); L43546 (strain 13 cpa 
gene); L43547 (strain CER 89L 1105 cpa gene); L4354B (strain CER B9L 12 16 
cpa gene). 
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The a-rox in has been proposed ro p lay a major ro le in rhe 
pathogenes is of gas gang rene in man and has anracted 
most attentio n in thi s context (\XI ill iamson & Titball, 
1993; N ino mi ya et al., 1994). The toxin has also been 
proposed to p lay an impo rtant role in se\·e ral di seases of 
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animals including enreroroxaemia and sudden dearh in 
certain breeds of calves (Cygan & Buczek, 1993) and in 
piglets (Johannsen 1'/ rli., 1993) and in necrotic enrcritis in 
chickens (Long & Truscott, 1976; Baba et al., 1992). The 
inrragastric administration of a crude preparation of the 
a-toxin causes disease in piglets with similar symptoms to 
C. pnfringens type t\ infection (Cygan & Buczek, 1993). 
The aims of this work were w compare the properties of 
the a-toxins produced by isolates of C. pnfringem from the 
intestine or from soft tissues of man and cattle with those 
of the a-toxin from the type strain CTC 8237 and ro 
determine whether a genetically engineered vaccine de-
rived from the a-toxin of strain CTC 8237 (Tit ball el al., 
1993; '\ illiamson & Titball, 1993) would provide pro-
tection against the a-toxins from other strains. 
METHODS 
Chemicals and enzymes. Unless otherwise stated, all chemicals 
and enzymes were obtained from Sigma or from BCL. 
Bacterial strains. Eighty-three strains of C. pnfringens were 
kindly provided by G. Daube (Faculte de Medecine Veterinaire, 
Universite de Liege, Belgium; Daube, 1993) or B. Limbourg 
(Federation de Lurre Contre les Maladies du Betail, Erpent, 
Belgium). The strains had been isolated from the small intestine 
or colon (seventy strains), liver (four strains), kidney (six 
strains), perironeal fluid (two strains) or muscle (one strain) of 
cattle which had died from suspected enterotoxaemia. Of these, 
C. perfringms strains CER 89L110S, CER 89L43 (small-intestine 
isolates) and CER 89L1216 (muscle isolate) were isolated from 
cases of sudden death in Belgian Blue calves. The bacteria were 
cultured on TGY medium (Trypticase peptone, 3%, w /v; 
glucose, O·S%, w/v; yeast extract, O·S%, w/v; adjusted ro pH 
7·S with 10 M NaOH) supplemenred, when required, with egg-
yolk lecithin (Calmels, 1982). Strains CTC 8237 (Stevens el al., 
1987) and 13 (Lappoime & Fredette, 197S) were o riginally 
isolated from cases of gas gangrene in man. Twelve strains of C. 
perfringms which were isolated from cases of gas gangrene or 
soft-tissue infection in man were kindly provided by M. Sebald 
(lnstitut Pasteur, Paris, France) or J. Bazier (PHLS, Cardiff, 
UK). Nineteen strains of C. perfringens, isolated from human 
stools, were kindly provided by G. Daube (Faculte de Medecine 
Veterinaire, Universite de Liege, Belgium). The bacteria were 
cultured anaerobically at 37 °C in TPYG broth (Tirball et al., 
1989). For the isolation of D A, strains of C. perfringms were 
cultured in SOO ml TPYG broth for 18 h, and then separated 
from the culture fluid by filtration through a 0·22 J.lm pore-size 
membrane (Millipore). Escbericbio coli strains JM1 01 and JM109 
were stored and cu ltured as described by Sambrook et of. (1989). 
Production of polyclonal antisera. Formaldehyde (0·5 %, v /v) 
was mixed with a -toxin from strain CTC 8237 for 3 d at 37 °C 
and the mixture was then dialysed against PBS, pH 7·2 (Oxoid). 
Freund's incomplete or complete adju,·anr was mixed with rhe 
a-tOxoid and used to immunize a New Zealand White rabbit 
(100 llg per dose) or a guinea-pig (50 llg per dose). Three 
intradermal immunizations were given at monrhly intervals. 
The antisera (termed COL25 and COB13, respectively) were 
obtained I 0 d :tfrer rhe final immunization and the immuno· 
g lobu lins were purified using a Protein G affinity chromato· 
graphy column (Pharmacia). 
Production of monoclonal antibodies. Mice (BAI.B/c) were 
immunized inrraperiro neally with 10 J.lg toxoid with Freund's 
complete adjuvant (tirsr immunization) or with Freund's 
incomplete adjuvanr (second immunization). For the third 
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immuniz:11 ion, I ~~g tX-LOXOJd was in jected subcutaneously with 
our adju\·ant. r ou r days later, the spleen cell ~ were isolated and 
fu sed wirh myeloma cells (cell line SP2/0AG14) using PEG 
4000 (Koh ler & M ilstein, 1975). Hybridoma cells were screened 
for the production of anti-a-toxin antibodies using an ELl ,\ in 
microtitre tray wells coated wirh phospholipase C (2·5 llg ml- 1). 
Positi,·e hybridoma cells were cloned by limiting dilution and 
the mo noclon:tl antibodies were isotyped . Of rhe monoclonal 
antibodies raised, three were lgG I amibodies (DY2FSD11 , 
DY8H2E12 and DY8C7HI) and one was an lgG2a antibody 
(DYSH5H3). Only antibody DY2rSOII neutralized the phos-
pholipase C activity and the lethal efl"ecr of rhe a-roxin. The 
generation of monoclonal antibody 3a4D1 0, which was effective 
in neutralizing phospholipase C activity, has been described 
previously (Logan t l al., 1991 ). l\lonoclonal anribodies ,\C1-
l C6F4 (neutralizes phospholipase C and lethal activities), r\C7-
7C9A 10 (neutralizes phospholipase C and lethal activities) and 
AC9-12G8B 11 (neutralizes lethal activity) (Saro el of., 1989) 
were kindly provided by H. SatO (National Institute of Health, 
Tok yo, Japan). 
ELISA detection of a-toxin. An E L! SA was used ro detect the 
a-toxin. Either polyclonal antibody COB13 (10 llg ml- 1) or 
monoclonal antibody DY2FSD11 (10 J.lg r:ll- 1) was used ro 
capture a-toxin and peroxidase-conjugated polyclonal anti-a-
toxin antibody COL2S was used for detection. After devel-
opmenr of the assay (1 h, 37 °C) the difference between the A 450 
of tesr samples and control wells (coated wirh control guinea-
pig serum) was calculated and divided by the A 460 difference 
when a reference sample was tested (strain NCTC 8237 culture 
filrrare, SO J.lg a-roxin ml-1). A va lue of above 0·2 was considered 
to be positive. 
Purification of a-toxin and GST-Cpa;z47_370• The a-toxin was 
purified from the periplasmic fraction of E. coli (Titball et al., 
1989) containing the cloned cpo gene from C. pufringens strain 
CTC 8237 or from strain CER 89L43. The toxins were 
purified using barch ion-exchange chromatography followed by 
column ion-exchange chromatography (Basak et al., 1994). 
GST - Cpa247 370 fusion protein, which had been produced in E. 
coli, was prepared as described previously by Titball el al. (1993). 
Measurement of phospholipase C, haemolytic and lethal 
activities. Phospholipase C activity was measured by a micro-
titre tray assay using egg-yolk phospholipids as the substrate 
(Titball el of., 1989). The end-point in these assays was 
determined as the reciprocal of the dilution of the roxin resulting 
in an OD592 of 0·6 and the activity was expressed as egg-yolk 
units (EYU). Neutralization of phospholipase C activity was 
determined after mixing SO ng roxin with 7 J.lg antibody wirh 
incubation for 1 h at 20 °C. To determine the effect of trypsin 
(60 ng or 600 ng bovine pancreatic trypsin ml- 1 final con-
centration) o r N-tosyl-L-phenylalanine-chloromethyl·ketone-
treated chymotrypsin (60 ng or 600 ng ml-1 final concentration) 
on rhe phospholipase C activity of the toxin (600 llg ml- 1) , the 
toxin and protease were first incubated together in 0·1 M 
Tris/HCl buffer, pH 7, for I hat 37 °C, then the phospholipase 
C acri,· ity was determined as described above. In some 
experiments, rhe roxin was first incubated with ZnCI2 ( lOO-fold 
molar excess) for 30 min at 20 °C before incubation wirh the 
proteases. Haemolytic activity wa measured by a microtirre 
tray assay using S% (v ;,·)washed mouse red blood cells (T itball 
tl al., 1989); the 50% haemolysis end-point was determined and 
acth·iry was expressed as haemolytic units (H ). The lerhaliry of 
the a-roxin was determined after intraperitOneal injection of 
dilutions of the toxin (50 Ill in saline) into 18 20 g iemale 
BALB/c mice (Cha rles River Laboratories). Protection afforded 
by antibody DY2FSD11 was determined by mixing a-toxin 
( I J.lg ) with antibody (7 pg) in PB and after incubation for 1 h 
at 20 °C, the mixture was injected (i. v.) into 20- 2S g outbred 
female mice (B & K Universal Limited, Belgium). 
Isolation of DNA. Chromosomal DNA was isolated from C. 
perfringens main CER 89L43 and strain 13 using the method of 
Marmur (1961). The DNA was purified by centrifugation 
through a gradient of caesium chloride (Sa m brook et al., 1989). 
Chromosomal DNA from C. perfringensstrain CER 89Ll216 or 
CER 89L110S was isolated according to the method of Van 
Damme-Jongsten et al. (1989). 
Amplification and cloning of the cpa gene from C. per-
fringens. A DNA fragment which wou ld encode the strain 
CER 89L43 cpa ORF and the gene promoter was generated 
using PCR. The oligonucleotides used were designed from the 
strain NCTC 8237 cpa gene nucleotide sequence (accession 
number X13608). The oligonucleotides S' TGC AGC CAA 
GCT TTT AG A TAT GTT T AA TTG AAA TTTG 3' and S' 
ACG TCG GAA GCT TTA TTT TGT AAA TAC CAC CAA 
AACC 3', which incorporated Hindlll restriction endonuclease 
sites at the S' ends, were used for amplilication of the strain CER 
89L43 cptt gene during 3S cycles of PCR (9S °C, 1S s; 4S °C, 
1S s; 72 °C, 30 s; Perkin Elmer 9600 Gene Amp PCR System). 
For the amplification of the cpa gene from strain CER 89L 1216 
or CER 89L 110S the oligonucleotides S' AAC CAT GGA AAG 
AAA GAT TTG TAA GG 3' and S' ACT GAA TTC ATT 
TTA TAT TAT AAG TTG AAT 3', which incorporated, 
respectively, Ncol and EcoRI restriction endonuclease sites, 
were used during 30 cycles of PCR (9S °C, 60s; 42 °C, 60s; 
72 °C, 60s; Koch-Light NBS TC1 ). The reaction products were 
purified, digested with appropriate enzymes and ligated with 
suitably digested plasmid pUC18 (for the strain CER 89L43 cpa 
gene) or pjLAS02 (for the strain CER 89L1216 and strain CER 
89Ll10S cpa genes). For the cloning of the strain 13 cpa gene, 
total genomic DNA was digested with EcoRI and Hindlll 
resrriction endonucleases and cloned into plasmid pBluescript 
SK(-) (Stratagene). 
After transformation into E. coli strain Sure cells (Stratagene) or 
E. coli strain JM109 by electroporation or transformation 
(Sambrook et al., 1989), bacteria containing the cpa genes were 
identified by the presence of a zone of turbidity or a zone of 
haemolysis surrounding colonies on L-agar containing ampi-
cillin and egg yolk or ampicillin and sheep red blood cells, 
respectively (Titball et al., 1989). 
Nucleotide sequencing. Plasmid D A was prepared, using a 
small-scale method (Sambrook et al., 1989), from rwo trans-
formants containing the cloned PCR-amplified cpa gene from 
strain CER 89L43. The plasmid DNA was used as the template 
for Taq (BCL) cycle sequencing reactions using a Molecular 
Biology Workstation (Applied Biosystems Catalysr). The re-
action conditions used were according to the manufacturer's 
instructions except that an annealing temperature of SO °C was 
selected. Sequencing primers were designed from the nucleotide 
sequence of the strain NCTC 8237 cpa gene (Titball et al., 1989). 
The reaction products were separated and analysed using an 
auromated nucleotide sequencer (Applied Biosystems 370A). 
For the strain 13 cpa gene, single-stranded DNA was generated 
from the pBluescript recombinanr plasmid by eo-infection with 
helper phage KO? and sequenced as described previously 
(Hunter et al., 1993). Three plasmids encoding the strain CER 
89Ll10S cpa gene and three plasmids encoding the strain CER 
89Ll216 cpa gene were purified using a Nucleobond column 
(AX-100-1, Macherey-Nagel) and sequenced using a T7 sequ-
encing kit (Pharmacia). 
SDS.PAGE and Western blotting. The proteins were mixed 
with sample buffer (4 %, w/v, SDS and S%, v/v, P-mercapto-
ethanol), incubared (S min, 22 °C or 100 °C) and analysed by 
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SDS-PAGE (Pharmacia Phase system, 10- 1S%, w/v, gradient 
gels). In some experiments the separated material was trans-
ferred onto a polyvinylidene difluoride membrane (lmmobilon 
P; Millipore) and the membrane was blocked with aS% (w /v) 
solution of dried skimmed milk in PBS. The membrane was 
probed with a 1:1000 dilution of a mouse anri-o:-toxin mono-
clonal antibody (DY2FSD11, 3o:4D10, AC1-1C6F4, AC7-
7C9A 10 or AC9-12G8B11) or polyclonal antiserum (COL2S) 
and bound antibody was detected using gold-labelled anti-
mouse lgG antibody or gold-labelled anti-rabbit IgG antibody 
(Janssen Scientific) as appropriate. Bound antibody was visual-
ized using silver enhancement according ro the instructions of 
the manufacturer. 
Epitope mapping. Mapping of the binding of the monoclonal 
antibody DY2FSD11 to the a-toxin was achieved as described 
previously (Logan et al., 1991 ). Briefly, overlapping octa-
peptides were synthesized on the basis of the deduced amino 
acid sequence of the a-toxin (strains NCTC 8237 and CER 
89L43), and the binding of the monoclonal antibody to the 
immobilized peptides was measured using an ELISA (Logan et 
al., 1991). 
In vivo protection studies. GST - Cpa247 370 (Titball et al., 1993) 
was used to immunize female BALB/c mice, as described 
previously (Williamson & Titball, 1993). The mice were 
challenged with 1 J.tg or S J.lg o:-toxin purified from E. coli 
expressing rhe cpa gene from C. perfringms strain NCTC 8237 or 
from strain CER 89L43. The challenge dose was administered 
inrraperitoneally in SO J.tl saline. 
RESULTS 
Monoclonal antibody DY2FSD11 does not detect the 
a-toxins produced by most strains of C. perfringens 
isolated from cattle and from man 
In view of the possible association of the a-toxin with a 
variety of diseases in man and animals (see Introduction), 
and the potential use of GST- Cpa247_370 derived from C. 
perfringens strain NCTC 8237 as a vaccine to prevent these 
diseases (Tit ball et al., 1993; Williamson & Tit ball, 1993), 
we set out to determine the immunological cross-
reactivity between the a-toxin from strain NCTC 8237 
with the a-toxins produced by other strains of C. 
perfringens. The reactivities of monoclonal antibody 
DY2FSD11 with culture supernatant filtrates from 115 
strains of C. perfringens which had been isolated from 
cattle or man were examined using ELISA. The results 
(Table 1) indicated that the a-toxins produced by most 
isolates (100/102) of C. perfringms from the gut of cattle or 
from gas gangrene or the intestine of man did not react 
with monoclonal antibody DY2FSD11. H owever, the cx-
roxins could be detected in each case using an ELISA with 
polyclonal antibody COB13. Two of the bovine enteric 
strains (CER 89L43, a-toxin did not react with mono-
clonal antibody DY2FSD11; CER 89L1105, cx-roxin 
reacted with monoclonal antibody DY2FSD11 ) and one 
gas gangrene strain (strain 13, a-toxin did not react with 
monoclonal antibody D Y2FSD11) were selected for 
further study. Approximately half of the isolates (6/13) of 
C. perfringem isolated from soft tissues of cattle produced 
cx-rox.in which reacted with monoclonal antibody 
DY2FSD11. One of these strains was selected for further 
study (CER 89L1216, a - toxin did not react with mono-
clonal antibody DY2FSD11 ). 
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Table 1. Reactivities of the ex-toxins produced by bovine 
and human strains of C. perfringens in an ELI SA using 
polyclonal antibodies and monoclonal antibody 
DY2F5D 11 raised against the ex-toxin of type strain NCTC 
8237 
Culture supernarant Auid was resred in an ELISA using 
polyclonal anti-GHoxm (COB 13 ; pAb) or monoclonal antibody 
D Y2FSD11 (m Ab) as the capture ant ibody. Figures ind icate the 
percentage of the coral number of strains rested (u) char produced 
ex-toxin which reacted with the respective antibody. 
C. perfringens 
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Fig. 1. Western blot analysis of the ex-toxins from strains NCTC 
8237 and CER 89L43. Cell lysates from E. coli expressing the cpa 
gene from the C. perfringens strain NCTC 8237 (lane 1) or strain 
CER 89L43 (lane 2) were separated by SOS-PAGE and Western 
blotted against (a) polyclonal anti-ex-toxin (COL25) or (b) 
monoclonal antibody DY2F5D 11 . Lane 3 contains molecular 
mass markers (kDa). 
Characterization of monoclonal antibodies to C. 
perfringens oc-toxin by Western immunoblotting 
Monoclonal antibody D Y2FSD11 and four previously 
reported mo noclonal antibodies (3ex40 10, AC1-1C6F4, 
AC7-7C9A10 or AC9-12G8B11 ), which were able ro 
neutralize the phospholipase C o r lethal activities of the 
strain CT C 8237 ex-toxin, were tested by Western 
blotting against whole-cell lysates of E. coli containing the 
NCTC 8237 o r CER 89L43 cpa gene. Monoclona l 
antibodies AC1- IC6F4, AC7-7C9A10 and AC9-12G8B11 
and the polyclonal antibody COL25 (Fig. 1) reacted with 
a whole-cell lysate of E. coli containing the CTC 8237 o r 
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CER 89L43 rpa gene. J\t(onoclonal antibody DY2FSO 11 
reacted with a whole-cell lysate of E. coli containing the 
NCTC 8237 cpa gene and weak ly with E. coli containing 
the CER 89L43 cpa gene (Fig. l ). The molecular mass of 
the reactive band (41 kOa) IS similar ro the deduced 
molecular mass of the strain CTC 8237 !X-toxin 
(42·5 kOa; Titball el al., 1989). 
Differences in the deduced amino acid sequences of 
oc-toxins from nucleotide sequencing of the cpa 
genes from strains CER 89L 1105, CER 89L 1216, CER 
89L43 and 13 
The nucleotide sequences of the cpa genes from C. 
pe~fringem stra ins CER 89L1105, CER 89L1216, CER 
89L43 and 13 were determined. The deduced amino acid 
sequences of mature ex-toxins which reacted with mono-
clonal antibody D Y2FSD11 (strains NCTC 8237 and 
CER 89L 11 OS) were identical. Three changes (Aia174 ro 
Asp174 ; T hr177 tO Ala177 ; Ser335 tO Pro335) were found in 
the ex-ro>Uns from strains which failed ro react with 
monoclonaJ antibody D Y2F5011 (strains CER 89L1216, 
CER 89L43 and 13). One additional difference in amino 
acid sequence was found between the ex-to>Un of strain 
CER 89L43 and those of the four other strains (lle345 ro 
Vala4s)· 
Epitope mapping of the reactivity of monoclonal 
antibody DY2FSD11 w ith oc-toxin 
To define which regions of the protein were responsible 
for the differences in bind ing of monoclonal antibody 
D Y2FSD11 , the Geysen epitope mapping technique was 
used. Overlapping octapeptides, which spanned the 
regions of sequence difference between the C. perfringen.r 
strain NCTC 8237 and strain CER 89L43 ex-toxins, were 
synthesized and tested with monoclonal antibody 
D Y2F5011. The results (T able 2) indicated that at 
sequence position 174, peptides containing alanine, rather 
than aspartate, preferentially bound monoclonal antibody 
D Y2FS D11 . The substitution of alanine for threonine at 
position 177 had no significant influence o n the binding of 
the antibody. Furthermore, binding was fully restored by 
re-substituting alanine for aspartate at position 174, whi lst 
leaving the alanine at position 177. 
In the C-terminal domain of the ex-toxin (amino acids 
250- 370), antibody D Y2F5011 bound preferentially tO 
the sequence 332T AFSDA YK 339 and binding was reduced 
when proline was substituted fo r serine at position 335. 
Comparison of the phospholipase C, haemolytic and 
lethal activities of the oc-toxins from strains NCTC 
8237 and CER 89L43 of C. perfringens and the 
susceptibilities of these oc-toxins to chymotrypsin and 
trypsin 
T o examine whether the ex-toxin produced by C. pe1jringen.r 
strain CER 89L43 had similar biochemical properties to 
that produced by strain NCT C 8237, the ex-toxins were 
isolated and purified from E. coli containing the cloned 
,\(olecular variation of C. perfringens 0:-LO'I:in 
Table 2. Reactivities of octapeptides derived from variable regions of C. perfringens 
:x-toxin with monoclonal antibody DY2FSD11 
(herlapping octapcptides spanning the regions of amino acid seguence differences between the 
:Hoxins of c. pnfrlll,~ti/J strain ere 8237 (monoclonal antibody DY2F5D 11 reacti\·e) and Strain 
CE.R 89L43 (monoc lonal antibody DY2fo50 11 non-reactive) toxins were S}·nthesized using the Geysen 
technique, incubated with monodonal anribody DY2F51)11 and antibody binding was measu red. For 




CER 89L43/NCTC 8237 hybrid 








101 T EAFYT D 178 
171 TNEDFYAD 1' 8 
171TNEDFYTD 178 
171 T EAFY AD 178 
332T AFSDA YK339 
332TAFPDA YK339 
• Amino acid differences between the peptides are shown m bold type. 
ELISA Am (SEM)t 
Cl-619 (0·09) 
0· 391 (0·04) 
0·378 (0·03) 
0·658 (0·09) 
0·653 (0·0 ) 
0-474 (0·04) 
t Values shown (ELlS A reading) are the means of three separate experiments with the standard error (sE~t ) 
shown in parentheses. 
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Fig. 2. Effects of chymotrypsin and trypsin on the 
phospholipase C activity of strain NCTC 8237 and strain CER 
89L43 ex-toxins. Purified strain NCTC 8237 ex-toxin (hatched 
columns; 60 1-19 ml- 1 final concentration ; 657 EYU ml- 1) or CER 
89L43 ex-toxin (open columns; 741-19 ml- 1 final concentration ; 
739 EYU ml- 1) was incubated for 1 h at 37 •c with chymotrypsin 
(60 ng ml- 1 final concentration, A; 600 ng ml- 1, B), trypsin 
(600 ng ml- 1, C) or chymotrypsin and trypsin (both 600 ng ml- 1, 
D). Results shown are the means of three separate experiments 
with SE bars. 
CER 89L43 rpa gene and the cloned NCTC 8237 cpa gene. 
SOS-PAGE analysis of the ex-roxins revealed a single 
protein band in each case w hen th e gel was stained with 
Coomassie brilliant blue. The phospholipase C specific 
activity (when tested against egg-yolk phospho lipid) and 
the haemolytic specific activity (against mouse eryth ro-
cytes) of the strain NCTC 8237 !X-toxin (3·2 x 105 EYU 
mg- 1 and 1·4 x 105 HU mg- 1) were similar to the specific 
activities of the strain CER 89L43 ex-toxin (3·1 x 105 EY 
mg-1 and 1·5 x 105 H U mg-1). Bo th toxins were le thal 
when 0·1 ~tg was administered intraperitoneally into mice. 
Purified ex-toxin was incubated with chymotrypsin or 
trypsin and the phospholipase C activity was measured. 
The results (Fig. 2) indicated rhar treatment with chymo-
trypsin (600 ng m l- 1) reduced (ro 47 %) the phospholipase 
C activity of the strain NCTC 8237 ex-toxin but had only a 
limited effect (95% retention of activity) on the strain 
CER 89L43 ex-toxin. Preincu bation of the toxin with a 
1 00-fold molar excess of Zn2+ did nor affect the pattern of 
inacti vatio n by chymotrypsin (data no t shown). The 
phospholipase C activity of the ex-toxin from either source 
was not affected by treatment with trypsin. The combined 
treatment with chymotrypsin and trypsin did not enhance 
the deg radative effec t of chymotrypsin a lone. Neither 
chymotrypsin or trypsin alone showed any activity against 
egg-yolk phospho lipid. 
Ability of GST - Cpa247_370 to provide protection against 
ex-toxin from bovine strains of C. perfringens 
A fragment of the ex-toxin, produced as a G T fu~ion 
protein by genetic engineering (G T - Cpa247 3 , 0 ; 
\X!ill iamson & Titball, 1993), was used tO immunize 
groups of mice. The mice were subsequently cha llenged 
intraperitoneally w ith the purified ex-wxin from C. per-
f ringens strain CTC 8237 or s train CER 89L43. The 
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Table 3. Protection afforded by immunization with GST --<:pa247_370 against intraperitoneal 
challenge with the ()(-toxin from strain NCTC 8237 or CER 89L43 
Immunization group ~-Toxin for challenge 
S1rain Dose 
No immuniz.:uion NCTC 8237 I ~g 
CER 891.43 I ~g 
Formol roxoid of NCTC NCTC 8237 I ~g 
8237 2-roxin C:ER 891.43 I ~g 
GST-Cpa,,. 370 NCTC 8237 I ~g 
NCTC 8237 S1-1g 
CER 89L43 I ~g 
CER 89L43 S1-1g 
results (Table 3) indicated that mice were egually well 
protected against I J.lg or 5 J.lg ()(-toxin. The challenged 
mice showed no signs of intoxication. In comparison, 
both of the control groups of six mice died after challenge 
with I J.lg ()(-toxin of the NCTC 8237 or CER 89L43 
strains. 
DISCUSSION 
The microhererogeneiry of bacterial toxins is a widely 
reported phenomenon, but the effects of such variations 
on the properties of toxins have not been investigated in 
detail (Wadstrom, 1978). This is the first comparative 
report of rhe molecular generic, biochemical and immuno-
logical properties of the ()(-toxin produced by the type 
strain of C. perfringws with those of the ()(-toxins produced 
by strains of C. perfringws isolated from the gut or soft 
tissue of cattle or man. The bovine isolates of C. perfringms 
rested in this study were isolated from animals which had 
died from suspected enterotoxaemia. The contribution to 
this disease of the C. perfringws isolated from abscesses in 
soft tissues in these animals is not known. However, the 
symptoms of disease associated with colonization of 
tissues (Darke et al., 1977; Hub! et al., 1993) do not 
typically include symptoms of enterotoxaemia. Therefore, 
it is possible that these abscesses were not directly 
associated with the cause of death in these calves. In 
contrast, the strains of C. perfringens isolated from tissues 
in man were associated with m·ert symptoms of infection, 
including gas gangrene. 
Strain NCTC 8237 (ATCC 13124) has previously been 
used b1· most groups for the production, purification and 
characterization of the ()(-toxin. Our results indicate that 
the amino acid seguence of the toxin from this strain is not 
typical. Monoclonal antibod1· DY2F5D11, which was 
generated against the ()(-toxin of strain NCTC 8237, failed 
to react with the ()(-toxins produced bv 93% (107/115) of 
the isolates of C. perfi"in,gms tested. The three amino acid 
substitutions responsible for rhis altered reactivity were 
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found in each of the three ()(-toxins from the monoclonal 
antibody DY2F5D11 non-reactive strains which were 
characterized in this study. It is possible that intermediate 
or other forms of ()(-toxin exist. However, the reponed 
amino acid seguence of the ()(-toxin from a type C strain 
(NCIMB 10662; Katayama et al., 1993) is identical to that 
of strain CER 89L43 reponed here. The amino acid 
seguence of the strain 8-6 ()(-toxin (Saint-Joanis et al., 
1989) contains an additional five amino acid substitutions. 
The finding that the Ala174 to Asp174 change caused the 
greatest reduction in the binding of monoclonal antibodv 
DY2FSD11 may be explained by considering the change 
from a neutral to an acidic residue ar this position. The 
finding that the Ser335 to Pro335 change also reduced 
binding of monoclonal antibodv DY2FSD11 would 
suggest that the epitope recognized was discontinuous. 
The combined effects of the amino acid changes at 
positions 174 and 335 could result in the marked reduction 
in binding of the antibody to the tx-toxin from strain CER 
89L43, which was observed in \\iestern blotting experi-
ments. 
The amino acid seguence differences between the tx-toxins 
derived from the C. perfringens NCTC 8237 and CER 
89L43 strains did not affect the phospholipase C, hae-
molytic or lethal properties of the toxin. Two of these 
substitutions (t\lam to Asp 174 and Thr1, to Ala 177) are 
located in a region predicted to be a Aexible surface-
exposed loop, linking two helices (Lys170-£\ia 177 ; R. 
Titball, unpublished results). Two further amino acid 
substitutions (Ser335 to Pro335 and lie345 to Val 345) are 
located in the C-terminal domain of the tx-toxin, Aanking 
a region predicted to be surface exposed (Asp336-Asn" 2 ; 
R. Titball, unpublished results). Of these substitutions, 
the Thr 177 to A la 177 and lle,., 5 to V a 13., changes can be 
considered to be conservative substitutions. The substi-
tutions at positions 174, 177 and 335 arc located adjacent 
to aromatic amino acids, the preferred site for ciea\·age 
with chymotrypsin (Cunningham, 1965). Our results 
would suggest that at least one of the substituted amino 
acids, close to a chvmotrypsin cleavage site, inAuenced the 
ability of the protease to cleave the ex-toxin. It has 
previously been shown that excess Zn 2+ protected the ex-
toxin from inactivation b~· chymotrypsin and trypsin 
(Sa to el al., 1978). Our finding that the ex-toxin from strain 
NCTC 8237 was nor susceptible to trypsin inactivation 
but was still susceptible to chymotrypsin inactivation 
when excess Zn 2+ was present in the reaction indicates 
that the protein was not in a zinc-limited form. The 
chymotrvpsin stability of the ex-toxin produced by enteric 
isolates of C. perfringens would be entirely consistent with 
rhe proposed site of production of the ex-toxin in cases of 
sudden death in calves (Cygan & Buczek, 1993) and 
piglets (Johannsen e/ al., 1993) and in necrotic enteritis in 
chickens (Long & Truscott, 1976; Baba e/ al., 1992). 
In a study of calf diarrhoea, which resulted in up to 36% 
morralit1· in newborn calves, it has been demonstrated 
that C. perfringms type r\ was present in high concen-
trations in the intestinal contents and that immunization 
with an ex-toxoid protected animals from disease (Cygan 
& Buczek, 1993). ln view of the diAiculties associated 
with the elimination of all contaminating proteins and 
toxins from preparations of C. perfringws ex-toxin (Moll by, 
1978), it is difficult to unequivocally associate protection 
against disease with the ex-toxoid used. In addition, the 
identity of the toxin material used by Cygan & Buczek 
(1993) for preparation of the toxoid is not clear. 
We have previously reported that a fragment of the a-
toxin (Cpa24 ,_370) derived from the NCTC 8237 strain of 
C. perfringms and fused to GST, induced protective 
humoral immunity against the toxin and against an 
experimental gas gangrene infection in mice (Williamson 
& Titball, 1993). The observation that the a-toxins 
produced by human and bovine strains of C. perfringms 
were not identical, and had different reactivitl' with the 
DY2FSD11 monoclonal antibody, suggested that this 
vaccine might be deficient in inducing protective humoral 
immunitv to most bovine isolates of C. perfringms 
producing the a-toxin. However, we have demonstrated 
that mice vaccinated with GST -Cpa247 _370 were equally 
protected against challenge with a-toxin derived from 
either strain NCTC 8237 or strain CER89L43. The results 
reported here will facilitate further studies to determine 
the role of the a-toxin in the pathogenesis of disease 
associated with the presence of C. per(ringens in the 
intestine of man and animals and the investigation of the 
efficacy of a genetically defined vaccine in the prevention 
of disease. 
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Abstract 
l11e a -toxin of Clostridium perfringens is the major virulence 
determinant for gas gangrene in man. The gene encoding the 
a -toxin has been cloned into £ . coli from two strains of the 
bacterium (NCTC8237 and CER89L43) and subsequently 
purified to homogeneity. The two strains of a-toxin differ by 
five amino acids, resulting in the toxin from NCTC8237 being 
sensi tive to chymotrypsin digestion while that from CER89L43 
is resistant. The a-toxin from each of these strains has been 
crystallized in two different fo rms by the hanging-drop vapour-
diffusion method at 293 K. CER89L43 form l crystals belong 
to space group R32 and have two molecules in the crystal-
lographic asymmetric unit and a unit cell with a = b = 151.4, 
c = L95.5 A, a= f3 = 90, y = 120• . The crystals diffracted to dmon 
= L.90 A. l11e characteristics of the NCTC8237 form I crystals 
have already been reported. The form li crystals from both 
strains belong to space group C2221 with one molecule in the 
crystallographic asymmetric unit and, for strain CER89L43, 
have cell dimensions a= 61.05, b = 177.50, c = 79.05 A, a= f3 = 
y = 90•, while for strain CTC8237 the cell dimensions are 
a = 60.50, b = l 75.70, c = 80.20 A, a= f3 = y = 90•. The crystals 
diffracted to maximum resolutions of L.85 and 2.1 A for the 
CER89L43 and the NCTC8237 strains, respectively. 
l. Introduction 
The a-toxin of Clostridium perfringens has a place in the 
history of microbiology as it was the first bacterial toxin shown 
to have an enzymatic (phospholipase C) activity (MacFarlane 
& Knight, 1941 ). l t is one of a number o f toxins produced by 
C. perfringens and plays a significant role in the pathogenesis 
of many diseases in man and animals (McDonel, 1986; Will-
amson & Titball, L993). The a-toxin, a two-domain protein, is a 
member of a fami ly of bacterial zinc-metallophospholipases 
which include the C. perfringens phospholipase C, the 
C. bifermemans phospholipase C and the C. novyi phospholi-
pase C. The Bacillus cereus phosphatidylcholine-preferring 
phospholipase C (PC-PLC) and the Listeria monocytogenes 
phospholipase (PLC- B) are single-domain proteins (Titball, 
L993) with homologies to the N-terminal domai n of a -toxin. 
All of these phospholipases are inactivated by zinc-chela ting 
agents and are relatively the rmostable, but have different 
substrate specificities and toxicological properties (Titball et 
al. , 1993). An al ignment of the deduced amino-acid sequences 
of these proteins reveals that they fall into two groups, 
depending on the presence or absence of the C-terminal 
domain (Titball, 1993). This C-terminal domain of a-toxin 
shows sequence homology with arachidonate-5-lipoxygenase 
(HASL) , a e ukaryotic lipid-metabolizing enzyme (Titball et al . . 
1991). The function of the C-terminal domain is not clear and 
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studies with a truncated form of the C. perfringens a-toxin 
have shown that the phospholipase C activity resides in the 
N-terminal domain. However, the isolated N-terrninal domain 
is non-toxic and has a markedly reduced ability to hydrolyse 
sphingomyelin (Titball et al., 1991), while the phosphati-
dylcholine-hydrolysing activity remains unaltered. The 
isolated N-terminal domain also possesses similar properties to 
the B. cereus PC-PLC. These observations lead to the 
hypothesis tha t the C-terminal domain could enable the 
enzyme to inte ract with membrane phospholipids, hydrolysis 
of which results in the toxic effects of a-toxin (Titball et al. , 
1993). 
The cloning and expression of the gene encoding the toxin 
into E. coli have already been reported (Titball et al. , 1989). 
The a-toxin produced in E. coli was shown to have similar 
biophysical and enzymatic properties to the toxin produced by 
C. perfringens. Previously, Basak et al. (1994) reported the 
purification, crystallization and preliminary X-ray diffraction 
studies of C. perfringens a-toxin produced by E. coli containing 
the cloned a-toxin gene from strain CTC8237, which was 
isolated from a case of gas gangrene in man. Recently it has 
become apparent that a-toxin produced by strains of C. 
perfringens isolated from the intestine of diseased animals is 
more resistant to proteases such as chymotrypsin. The primary 
amino-acid sequence of this form of a-toxin shows several 
differences compared with the amino-acid sequence of the 
NCTC8237 srrain. We now report the purification of a-toxin 
produced in £. coli containing the cloned a-toxi n gene from a 
strain of C. perfringens (CER89L43) isolated from a diseased 
calf (Ginte r et al., 1996). 
2. Methods and results 
2.1. Cell culture and protein purification 
2.1.1. CER89L43 a-toxin. E. coli containing plasmid pL43-2, 
which encodes the C. perfringens CER89L43 a -toxin (Ginter et 
al. , 1996), was cultured in brain heart infusion broth containing 
ampicillin (50 1-1g mr1) at 310 K for 24 h with shaking 
(170 r min- 1) . The culture was harvested by centrifugation at 
9000 r min- 1 for 45 min a t 277 K. Cells were resuspended in 
ice-cold 20 mM Tris-HCI, pH 8.0, containing 0.58 M sucrose, 
LO mM EGTA, 0.5 mg ml- 1 lysozyme, 0.5 mM ZnCl2 and 
I mM CaC12 (all buffers contained 0.5 mM phenylmethylsul-
fonyl fluoride (PMSF)). The suspension was stirred, on ice, for 
15 min, followed by centrifugation at 15000 rev min - 1 for 
30 min a t 277 K. The supernatant was then filtered using a 
22 f!m filter. The a-toxin was purified from the filtrate using a 
two-step process. The crude extract was loaded onto a D EAE-
Sephacel (Pharmacia) column and bound protein was eluted 
using a gradient of 0-1 M NaCI m the same buffer (20 mM 
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Tris-HCl, pH 8.0). Fractions containing a-toxin were analysed 
by SOS-PAGE and Western blotting, and tested for phos-
pholipase C activity (Titball et al., 1989). These fractions were 
then concentrated and loaded on to a HiLoad 26/60 Superdex 
200 column which was equilibrated with PBS, pH 7.2. The a-
toxin was eluted with PBS and the fractions containing pure a -
toxin were analysed as before and then dialysed overnight 
against 10 mM Tris-HCl, pH 8.0, at 277 K. The protein was 
stored at 253 K with 50%(vlv) glycerol. 
2.1.2. Strain NCTC8237 a-toxin. The protein was produced 




Fig. I. (a) Crystals of a -toxin (strain CER89L43), rhombohedral form, 
with dimensions of approximately 0.6 x 0.6 x 0.4 mm. (b) Crystals 
of a -toxin (strain CER89L43), onhorhombic form, with dimensions 
of approximately 0.6 x 0.4 x 0.3 mm. (c) Crystals of a-toxin (strain 
NCTC8237), onhorhombic form, with dimensions of approximately 
0.5 x 0.4 x 0.3 mm. 
containing plasmid pKSa3 (Basak et al. , 1994). Filtered crude 
extract was first loaded on to a DEAE-Sephacel column 
equilibrated with 20 mM Tris-HCl, pH 8.0. at a How rate of 
1 ml min- 1 and bound protein was eluted with 0-1 M NaCl 
gradient in the same buffer. The eluted protein was analysed, 
concentrated using a stirred ultrafiltration cell with PM 10 
membrane and dialysed overnight against the same buffer at 
277 K. Concentrated protein was filtered and loaded on to a 
HiLoad MonoQ HR 10/10 column (Pharmacia), which had 
been previously equilibrated with the same buffer. The protein 
was eluted with a continuous NaCl gradient from 0-0.5 M, 
again in the same buffer. Fractions containing pure a -toxin 
were analysed as before and stored at 253 K with 50%(vlv) 
glycerol. 
2.2. Crystallization 
Protein from both strains was concentrated using solvent 
precipitation, as described by Basak et al. ( 1994). Crystals were 
grown using the hanging-drop vapour-diffusion method 
(McPherson, 1982) at 293 K. 
2.2.1. Strain CER89L43 a-toxin. Two different forms of 
crystals were grown. 
Form I. The optimal conditions for reproducible crystal 
growth were found to be 4 j.!l of protein solution containing 9-
10 mg ml- 1 protein in lO mM Tris-HCl, pH 7.5, and an equal 
volume of well buffer containing l.7 M NaCl in sodium 
acetate, pH 4.6. Well defined truncated-rhombohedra1 crystals 
(Fig. la) with maximum dimensions of 0.6 x 0.6 x 0.4 mm 
grew in 3-4 weeks. 
Form II. These crystals were grown using I M sodium 
acetate as precipitant in 100 mM Na-HEPES, pH 7.6, with 
0.05 M cadmium sulfate. The protein was mixed with well 
buffer in a I: 1 ratio and left to equilibrate with reservoir 
solution. Rectangular plates with maximum dimensions of 
0.6 x 0.4 x 0.3 mm (Fig. 1b) grew in 2- 3 weeks. 
2.2.2. Strain NCTC8237 a-toxin . The optimal conditions for 
crystals of this strain were very similar to those for form II 
crystals of the CER89L43 strain. These crystals, however, 
could not be reproduced as reliably as those from CER89L43. 
The biggest truncated-rhombohedral crystal was 0.5 x 0.4 x 
0.3 mm (Fig. le) and grew in 4-5 weeks. 
2.3. X-ray analysis, data collection and processing 
Initial characterization for crystal forms I and II of strain 
CER89L43 was carried out using an in-house MAR Research 
90 mm-radius image plate mounted on a rotating-anode X-ray 
generator operating at 40 kV and 90 mA. The form land form 
li crystals diffracted to dmin = 2.7 and 2.6 A, respectively. 
Subsequently, higher resolution data sets were collected for 
both crystal forms using the CCLRC synchrotron facility at 
Daresbury. 
2.3.1. Form I. These crystals diffracted to a Bragg spacing of 
1.90 A (Fig. 2a) at station 9.5 of the CCLRC synchrotron 
facility at Daresbury. Analysis of the data sets indicate that the 
crystals exhibit R32 symmetry with unit-cell parameters 
a = b = 151.38, c = 195.3 A, a= f3 = 90, y = 120°. Assuming two 
subunits in the crystallographic asymmetric unit, Vm = 
2.5 A3 Da-1, which corresponds to a solvent content of 50% 
(Matthews, 1977). No signi ficant peaks were seen in the self-
rotation function at x = 180•; however, there was a peak in the 
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native Panerson consistent with two molecules in the asym-
metric unit related by a translation of approxima te ly 0.5z. 
2.3.2. Form If. The diffraction limit for this crystal form was 
1.85 A (Fig. 2b) at station 9.5 of the CCLRC synchrotron 
facili ty at Daresbury. Analysis of the data reveals that the 
crystals are orthorhombic with unit-cell parameters a= 61.30, 
b = 177.30, c = 79.20 A, a = {J = y = 90•. Reflections h + k = 
2n + 1 and 001 = 2n + 1 a re absent, indicating that the space 
group is C222 1• Assuming one molecule in the crystallographic 
asymmetric unit, the solvent content of these crystals is 50% 
(Matthews, 1977). Da tasets for both crystal forms were 




2.3.3. New crystal form of NCTC8237 strain. All data were 
collected from a single crystal cryo-cooled to 100 K at station 
9.6 of the CCLRC synchrotron faci lity at Daresbury. The 
crystals diffracted to a maximum resolution of 2.10 A 
(Fig. 2c). Analysis of the data indicated that the crystal 
belonged to space group C2221 with unit-cell parameters 
a= 60.49, b = 175.68, c = 80.19 A, a= fJ = y = 90°. Assuming 
one subunit in the crystallographic asymmetric unit, the 
solvent content or these crysta ls is 50% (Matthews, 1977). 
These data were processed with MOSFLM (Leslie et al., 1986). 
Scaling and merging were performed using the programme 
SCALA (Collaborative Computa tional Project, Number 4, 
1994). 
(c) 
Fig. 2. (a) Oscillation photograph of a-toxin (CER89L43) rhombo· 
hedral crystals diffracting to 1.9 A at the edge. (b) Oscillation 
photograph of a-toxin (CER89L43) orthorhombic crystals 
di[fracling to 1.85 A at the edge. (c) Oscillation photograph of 
a-toxin (NCfC8237) orthorhombic crystals diffracting to 2.0 A at 
the edge. 
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Table L. Native data for different crystal forms 
Resolution Complete-
Strain Nrct (A) R ..... , •• (%) ness (o/o) 
CER89lA3. 56901 40-1.95 5.8 (19.3 fror;t 90.9 
form I 2.02-1.85 A) 
CER89lA3. 30175 40-1.90 6.5 (15.7 fror;t 87.5 
form 11 1.96-1.90 A) 




Well diffracting crystals of a-toxin were grown in two very 
d ifferent cond it ions, from two different strains. These crystals 
were stable in the X-ray beam and diffracted to L.S-2.0 A 
resolution at the CLRC synchrotron faci lity at Daresbury. 
Native data sets for all crystal forms were collected. The details 
of the native data for the different crystal forms are summar-
ized in Table 1. 
We are at present working on crystals from the CER89L43 
strain, and the search for heavy-atom derivatives of both the 
crystal forms is in progress to facilitate the determination of 
the three-dimensional structure of a-toxin. 
We acknowledge the support of the protein crystallography 
project team at CLRC D aresbury Laboratory for their support 
and help in data collection. We also acknowledge Mr G. Wright 
for his help in data collection. 
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Structure of the key toxin in gas gangrene 
Claire E. Naylor1, Julian T. Eaton 1, Angela Howells2, Neil Justin1, David S. Moss1, Richard W. Titball2 and 
Ajit K. Basak1 
Clostridium perfringens a-toxin is the key virulence determinant in gas gangrene and has also been implicated in 
the pathogenesis of sudden death syndrome in young animals. The toxin is a 370-residue, zinc metalloenzyme that 
has phospholipase C activity, and can bind to membranes in the presence of calcium. The crystal structure of the 
enzyme reveals a two-domain protein. The N-terminal domain shows an anticipated structural similarity to Bacillus 
cereus phosphatidylcholine-specific phospholipase C (PC-PLC). The ( -terminal domain shows a strong structural 
analogy to eukaryotic calcium-binding C2 domains. We believe this is the first example of such a domain in 
prokaryotes. This type of domain has been found to act as a phospholipid and/or calcium-binding domain in 
intracellular second messenger proteins and, interestingly, these pathways are perturbed in cells treated w ith 
a-toxin. Finally, a possible mechanism for a-toxin attack on membrane-packed phospholipid is described, which 
rationalizes its toxicity when compared t o other, non-haemolytic, but homologous phospholipases C. 
Over 50 years ago pioneering studies in microbial pathogenesis 
showed that the potent a-toxin of Clostridium perfringens was 
an enzyme, namely phospholipase C (PLC)'. This was the first 
bacterial toxin to be identified as an enzyme. Further studies 
proved, however, that not all PLCs are toxic (Clostridium novyii 
PLC, for example, is toxic, while that BacillrH cereus PLC is not), 
and that therefore enzymatic activity alone is not sufficient for 
toxicity. While it has long been thought that the key difference 
between toxic and non-toxic bacterial phospholipases C is the 
a 
b 
haemolytic function of the former, there has been little advance 
in understanding the relative toxicities of the various enzymes. 
The structure of a-toxin, in combination with the known 
structure of the non-toxic B. cereus PC-PLC enzyme2, provides 
an opportunity to investigate factors influencing toxicity in a 
more detailed manner. 
Studies of a-toxin have shown that it is the key virulence 
determinant of C. perfringens in gas gangrene. Specific mutants 
of C. perfringens that do not produce a-toxin are unable to 
cause disease, and vaccination with a genetically engineered 
toxoid has been shown to induce protection against gas gan-
grenel·4. The toxin is also implicated in the pathogenesis of sud-
den death syndrome in young animals5. Recently other 
bacterial phospholipases C, including those from Listeria 
monocytogenes5 and Mycobacterium tuberculosis5, have been 
implicated in the pathogenesis of a number of diseases. 
The C. perfringens a-toxin is a zinc metallophospholipase5. 
Phospholipases within this group show approximately 30% 
identity over 250 residues. Haemolytic bacterial phospholipas-
es C (C. bifermentans PLC, C. novyi y-toxin, C. perfringens a -
toxin ) possess an additional C-terminal 120 amino acids, 
which can confer toxicity6. The crystal structure of the non-
Fig. 1 a, Cartoon representation 
of the a-toxin chain. The sequence 
is shaded from blue at residue 1 to 
red at residue 370. Three black 
spheres indicate the zinc ion posi· 
tions in the active site. Secondary 
structural elements are named. 
b, Stereo a-carbon t race, same 
view as for (a), with balls marking 
every 10 residues, and the chain 
numbered at regular intervals. 
All figures, with the exception 
of Fig. 5, have been drawn with 
a modified version of 
Molscriptlt.l>, and subsequently 
rendered using Raster3Dll.J.I. 
'Department of Crystallography, Blfkbeck College, Malet Street. London, WC 1 E 7HX, England. 1Defence Evaluation and Research Agency, CBD Port on Down, 
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Fig. 2 Sequence alignment of a-toxin with 
homologous or structurally similar proteins. CB-
PLC is C. bifermentans phospholipase C"; PC-
PLC, 8. cereus phosphat idylcholine-preferring 
phospholipase Cl"; HASL, human arachidonate 
5 lipoxygenase17; Synap, Synaptotagmin 1'1 and 
1 LO, soybean lipoxygenase-P•. Secondary 
structural elements for a-toxin are shown 
above, and for PC-PLC and Synap and 1 LO, 
below, alignment: cyl inders indicate a-helices; 
arrows, P-strands. Dark gray boxes indicate con-
served zinc binding residues, clear boxes with a 
black outline; conserved aspartat es possibly 
involved in Cal• binding. 
In this paper we describe the three-
dimensional structure of a-toxin, deter-
mined by X-ray crystallography. In 
addition to the anticipated structural sim-
ilari ty of the N-terminal domain to 
B. cereus PC-PLC, the (-terminal domain, 
which has no sequence homology with 
any proteins of known structure, is shown 
to have a strong structural similarity to 
eukaryotic C2 domains. This domain is a 
Cah -dependent phospholipid binding 
domain fou nd in eukaryotic second mes-
senger proteins, but has not been recog-
nized previously in prokaryotes7• In this 
case, it is interesting that this domain has 
been identified in a prokaryotic protein 
that, as a toxin, may indirectly cause 
changes in the activation state of eukary-
otic host proteins possessing C2 domains. 











Crystals of C. perfringens a-toxin, can be 
grown in n...,o fo rms8: one in space group 
C222 1 with cell dimensions a= 61.3 A, b = 
177.3 A and c = 79.1 A and one molecule 
in the asymmetric unit, which diffracts to 
1.9 A; the second in space group R32 with 
cell a = b = 151.4 A and c = 195.5 A, this 
form has two molecules in the asymmetric 
un it and also diffracts to 2.0 A. Both crys-
tal forms have a solvent content of approx-
imately 50%. The structure was solved 
using a combination of molecular replace-
ment and single isomorphous replace-
ment (SIR) phasing. The structure was ~144 
refined in space group C2221, for which 
higher resol ution data are available, to an R-factor and Rrrec of 
20.8% and 25.5 % respectively, fo r all data between 25.0 A and 
1.9 A. 
toxic B. cereus PC-PLC, which does not possess the ( -terminal 
amino acids is known5 and residues involved in the coordina-
tion of catalytically essential zinc ions in PC-PLC are con-
served in a -toxin. Both enzymes are able to hydrolyze 
monodispersed phospholipids and the toxicity of C. perfrin-
gens a -toxin is thought to be related to the ability of this 
enzyme also to interact with phospholipids in eukaryotic cell 
membranes5• Membrane phospholipid hydrolysis results in 
the perturbation of cell metabolism leading to activation of 
the arachidonic acid cascade and protein kinase C4• Increasing 
evidence indicates that other bacterial phospholipases C, 
which play important roles in diseases such as those caused by 
L. monocytogenes and M. tuberculosis, also affect host cell 
metabolism in this way5. 
Overview 
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The structure of a -toxin is shown in Fig. I. All residues of the a -
toxin structure could be placed in the electron density with the 
exception of a five-res1due hydrophobic loop at the surface of the 
protein (residues 84-88). This loop has been modeled and ener-
gy minimized using X-PLOR9. The protein falls into two 
domains: an a-helical N-terminal domain (residues 1- 246) con-
taining the active site, and a P-sandwich (-terminal domain 
(residues 256-370) , which has been implicated in membrane 
binding10. A flexible linker (residues 247-255), containing a 
739 
articles 
Fig. 3 Stereo superposition of 
Bacillus cereus phostidylcholine-
preferring phospholipase C on 
a-toxin. 
series of highly mobile residues (average B-factor for the linker is 
46.6 A2 ), connects the two domains. 
N-terminal domain 
TheN-terminal domain is the catalytic domain; the C-terminal 
domain alone is unable to hydrolyze phospholipid6. As predicted 
from a sequence alignment (Fig. 2), the overall fold of a -toxin is 
similar to that of PC-PLC (Fig. 3): 190 Co: atoms can be aligned 
with a root-mean-square (r.m.s.) deviation of 1.49 A, and as far 
as possible we have retained the helix names used for PC-PLC. 
There are some secondary structural differences: a six residue 
insertion relative to PC-PLC (a-toxin residues I 79-184) has 
formed an additio nal helix (labeled F1), while a 16-residue dele-
tion in 0:-toxin (between residues 2 I 2 and 213) removes PC-PLC 
helices G and H1• 
Active site 
Zinc ions had been identified as essential for the catalytic activity 
of o:-toxin5 and at the end of refinemen t the presence of metal 
ions in the active site was indicated by difference Fourier density. 
The metal ions and their Ligand coordination in 0:-toxin are 
shown in Fig. 4. One ion (labeled Znl in Fig. 4) is most Likely to 
be Zn2+, but unusually low B-factors for the other two, coupled 
with bond distances that were very long for Zn2+ ion binding (an 
average over all ligands of 2.54 A for these two, compared to 
2.32 A for Zn1 ), indicated that they are most Likely Cd2+ ions 
(Cd2 and Cd3 in Fig. 4). Since CdS04 
was present at 0.05 M, the fact that cad-
mium ions, which can replace zinc 
without loss of activity (R. Titball, pers. 
comm .), were found in the active site 
was not surprising. These metal ions are 
bound to residues that are conserved 
between a -toxin and PC-PLC and have 
been identified previously as zinc-bind-
ing both by comparison with the PC-
PLC structure2 and by mutagenesis 
studies10• The metal ions have geome-
Fig. 4 Stereo view of the active site, showing 
metal ions as grey spheres. Zinc and cadmium 
ligands are shown as ball -and-stick, with the 
remaining res idues are drawn as black 
bonds. Waters are red spheres. Metal-ligand 
interactions are shown as dashed lines. 
740 
tries similar to those in the PC-PLC active sites and their lig-
and-metal distances are within the expected range 11 : 2.2- 2.3 A, 
for zinc and 2.4-2.7 A for cadmium. Accessibility calculations 
have shown that the active site region is available to solvent. Fig. 
5, which shows the electrostatic potential surface of the mole-
cule, highlights the positive potential created by the metals ions 
at the base of the active site cleft. Within the cleft, Cd2 is 6 A from 
the protein surface, closer than the other two metal ions. This ion 
is also more mobile than the other metals (it has aB-factor of25 
A2 compared to I8 A2 and 19 A2), and is bound to His 148, a 
residue previously suggested to bind a zinc ion involved in catal-
ysis rather than maintaining st ructural integrity5. We therefore 
believe that Cd2 occupies the site normally occupied by a catalyt-
ic zinc ion. 
Substrate binding 
Some researchers12 have suggested that o:-tolcin may have both 
inactive and active conformations, and that the conformational 
change in the active site is triggered by the binding of calcium 
ion. In this structure, the open active site cleft and the accessibil-
ity of the active site zinc and cadmium ions (in particular Cd2, 
which we have associated with catalytic activity) suggest that the 
enzyme is in the correct conformation for membrane binding 
and enzyme turnover. Byberg et a/. 13 have constructed a model of 
a phospholipid (with shortened tailgroups compared to the in 
vivo substrate of the enzymes) bo und to the active site of PC-
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Fig. 5 GRASP39 electrostatic potential surface of a-toxin (shown with the 
active site cleft and membrane-binding surface uppermost). Active site 
cadmiums were included, but surface cadmium ions removed, for thecal-
culation. The positive oxyanion hole for the phosphate head group is vis-
ible at the base of the cleft, as indicated by a modeled sphingomyelin. 
Some residues thought to be important for membrane binding have 
been indicated. The electrostatic potential is scaled from red for -20.0 to 
blue for +20.0. 
PLC. This model, with the phospholipid tailgroups extended, 
was oriented in the a-toxin structure using a transformation 
matrix that optimally superposed the active sites of PC-PLC and 
a -toxin. As seen in Fig. 5, the modeled phospholipid can be 
accommodated in the a -toxin active site cleft without major 
stereochemical clashes with the protein. All of the residues with-
in 5 A of the phospholipid head group are either identical or con-
servatively mutated between PC-PLC and a-toxin. The modeled 
tailgroups fit into hydrophobic grooves on the enzyme surface. 
One tailgroup requires at least one cis-double-bond about 
halfway along its length to interact maximally with the surface. 
This model is in accordance with the finding that phospholipids 
with unsaturated fatty acyl chains are the preferred substrate for 
a-toxinH. The other tailgroup should ideally include a double 
bond at approximately carbon atom 6 of the chain for good 
hydrophobic contact with a-toxin: for example, the ceramide 
moiety of sphingomyelin (Fig. 5). In our model, this tailgroup 
interacts with the C- terminal residues 295-305 and is therefore 
consistent with both the observation that the presence of the C-
terminal domain enhances sphingomyelinase activitf and the 
fact that PC-PLC, which has no C-terminal domain, cannot 
hydrolyze sphingomyelin. 
C-terminal domain and calcium ion binding 
The C-terminal domain (residues 255-370) is an eight-stranded 
antiparaUel P-sandwich with an immunoglobin-like fold. 
Calcium ions are known to activate a-toxin, and recent circular 
dichroism (CD) results have shown that calcium binds specifi-
cally to the C-terminal domain and induces a conformation 
change (B. Bolgiano, pers. comm.). Several attempts were made 
to obtain the crystal structure of calcium-bound a -toxin. 
However, calcium is insoluble in the crystallization buffer for 
form I crystals, and soaking form li crystals with even micro mo-
lar quantities of a calcium salt causes them to shatter. No calcium 
ion sites have, therefore, been identified unequivocally. However, 
a CdZ+ ion (Cdl3) , which is ligated by six oxygen atoms in an 
nature structural biology • volume 5 number 8 • august 1998 
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octahedral arrangement, has been identified in the C-terminal 
domain of the protein and is ligated by Asp 336 (001); Asp 269 
(0); Gly 271 (O); Ala 337 (0) and two water molecules (Fig. 6). 
This metal binding site has ion-ligand distances of 2.3-2.5 A. 
Two of the ligands to this site (Asp 269 and Asp 336) have been 
identified recently by GuiUouard et a/. 15 as important for calci-
um-mediated activation of a -toxin. We have therefore identified 
this site as a putative Ca2+ binding site. Although the side chain of 
Asp 269 is not currently interacting with the ion, it is situated 
such that a slight alteration of side chain conformation would 
allow its side chain to become a ligand. We speculate that it is not 
interacting with the ion in the structure due to the rigid ligand 
geometry required by a Cd2+, but that it would interact with a 
CaH ion. Asp 269 is not conserved in Clostridium bifermentans 
phospholipase C (Fig. 2), where it is mutated to tyrosine. 
However, in the PC-PLC sequence, Ala 337 is mutated to aspar-
tate, and this residue is positioned such that its side chain could 
interact with a Ca2+ ion at the Cdl3 site in a manner similar to 
that proposed for Asp 269 in the a-toxin structure. 
In addition to Cd 13, a number of other Cd2+ ions have been 
identified bound to the surface of the protein in non-specific 
sites, due to the relatively high concentration of cadmium ions in 
the crystallization buffer (0.05 M). Two of these ions (Cd9 and 
Cd12) are close to the Cd 13 site, and interact with three other 
highly conserved aspartate residues (273, 274, 293). But since 
their sites are completed by ligands from symmetry related mol-
ecules, and these interactions can have no biological significance 
(the molecule is active as a monomer), definite identification of 
any other CaH binding sites must await further crystallographic, 
or biochemical data. 
Relationship to other proteins 
Three-dimensional structural alignment using the program Dali 
(http://www2.ebi.ac.uk/dali/) with proteins in the Brookhaven 
Protein Data Bank (PDB) shows that the C-terminal domain is 
structurally similar to several other P-sandwich domains. It is 
most similar to the C-terminal domain of pancreatic lipase16 
(HPL, PDB entry lGPL, 86 Ca atoms superpose with an r.m.s. 
deviation of 1.92 A), and the N-terminal domain of Soybean 
lipoxygenase-1 17 (LO l, PDB entry 2SBL, 76 Ca atoms superpose 
with an r.m.s. deviation of2.1 A). The C-terminal domain of a-
toxin also resembles the structures of two C2 domains in the 
PDB: those of synaptotagmin [18 (PDB entry l RSY, 60 Ca atoms 
superpose with an r.m.s. deviation of 2.4 A) and the C2 domain 
of phosphoinositide-specific phospholipase COI 19; (PI-PLC, 
PDB entry l DJI, 60 Ca atoms superpose with an r.m.s. deviation 
of2.2 A). All of these proteins have additional catalytic domains, 
which show no structural analogy either among themselves or 
with the a -toxin C-terminal domain. 
The C-terminal 120 amino acids of HPL, lLO and a-toxin 
have identical topologies (Fig. 7a,b), while the remaining two 
domains are different (Fig. 7c,d) . A PI-PLC-like topology can be 
generated from a-toxin by interchanging a-toxin strands 6 and 8 
during folding; the connectivity is unchanged (Fig. 7c). 
Synaptotagmin l's connectivity is a circular permutation of the 
strands in PI-PLC, as illustrated in their topology diagrams 
(Fig. 7d). Despite the differences, all eight strands in a-toxin 
superpose well with their equivalents in synaptotagmin I and PI-
PLC, and residues from every strand were used in the calculation 
of r.m.s. deviations between the structures. 
C2 domains are CaZ+ and/or phospholipid-binding domains 
containing approximately 120 amino acids; they occur in a wide 
range of eukaryotic signa ling proteins, and are involved in a large 
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Ca2+ is ligated by conserved aspartates on equivalent loops. 
Specifically, Cal in synaptotagmin is ligated by Asp 172 
and Asp 178 in loop ~2~3, and by Asp 230 and Asp 232 in 
loop ~5~6. Site 11 in PI-PLC is ligated by Asp 653 in loop 
~ 1 ~2 ( topologicalJy equivalent to ~2~3 in synaptotagmin, 
Fig. 7c,d), and Asp 706 and Asp 708 in ~5~6 (equivalent to 
~6~7 in synaptotagmin). In either case, main chain car-
bonyls in both loops also contribute to the metal ion bind-
ing. Inspection of the structure-based sequence alignment 
for a-toxin and synaptotagmin I shows that, although 
there is no exact alignment of proposed calcium binding 
residues between a-toxin and synaptotagmin I (Fig. 2), 
these residues occur on loops ~ 1~2 and ~5~6, which are 
topologically equivalent to the calcium ion binding loops 
for PI-PLC and synaptotagmin I (Fig. 7a,c,d). Ca2+ is 
therefore ligated to a-toxin in a manner highly reminis-
cent of Ca2+ binding to PI-PLC and synaptotagmin I, in a 
spatially equivalent position. 
Implications of the structural analogy w ith C2 
domains 
The evidence presented suggests a functional and structural 
analogy between eukaryotic C2 domains and the C-termi-
nal domain of a-toxin, although there is no evidence of any 
common evolutionary ancestor. This is the first prokaryotic 
example of a C2-Like domain. Phosphokinase C (PKC) con-
tains the first identified C2 domain and, recent evidence 
has shown that the diacyl glycerol product of a -toxin attack 
is able to interfere with the pathways that PKC regulates. 
This suggests that a-toxin uses its C2-like domain fold to 
bind membrane in a manner similar to those of the proteins 
whose function it disrupts: a-toxin may cause haemolysis 
by mimicking proteins in the cells which it attacks. 
Fig. 6 Model for membrane binding. Phospholipids are shown as red spheres for 
headgroups and gray cylinders for tailgroups, except for one short-tailed lipid 
pictured in the active site as a space filling model. a-toxin is shown with residues 
shaded from gray for those distant (> 15 A) to blue for those closest(< 5 Alto the 
membrane, the active site metal ions are shown as black spheres. Some residues 
expected to be important for membrane binding are illustrated, and the proba-
ble calcium binding site is shown in more detai l in the insert. 
TheN-terminal 120 amino acids of human arachidonate 
5-lipoxygenase (HASL) is homologous to the C-terminal 
domain of a-toxin (there is a 34o/o identity over the 120 
amino acids). The structures of two lipoxygenases are 
known: that of rabbit 15-lipoxygenase22 ( 15LO), which has 
a 39o/o identity over its entire sequence with HA5L, and soy-
bean L-lipoxygenase (ILO)i7, which has a 30o/o identity with 
the C-terminal domain of HA5L. There is little sequence 
range of processes including lipid-second messenger generation, 
activation ofGTPases and phosphorylation controF. It has been 
suggested that C2 domains do not exist in prokaryotes because 
calcium regulation of second messenger systems is uncommon 
in these organisms7, however a relationship between a-toxin and 
C2 domains was postulated by Guillouard et al. 1s, and compari-
son of the sequences aligned by equivalent strands7 reveals that 
the pattern of non-polar/polar conservation seen in C2 domains 
is 80% retained in the sequence of a-toxin C- terminal domain 
(Fig. 2). 
We have already described a likely calcium ion site (Cd 13), lig-
ated by conserved aspartates and main chain carbonyls from two 
loops. When a-toxin and PI-PLC C2 domains are optimally 
superposed, Cd 13 is 2.4 A from the calcium ion site labeled as 
site II by Essen eta/. in PI-PLCZ0. After optimal superposition of 
a-toxin on synaptotagmin I, Cdl3 is 8.5 A from the site labeled 
Ca1 by Shao eta/. in synaptotagmin !21• Site II in PI-PLC and Cal 
in synaptotagmin, though differing in detail, have been 
described by Essen et a/.20 as equivalent, because in both cases 
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homology between the N-terminal domains of 1LO and 
HA5L, and there is no similarity between the sequences of 
110 and 15LO and a-toxin. 15LO and 110 have identical 
topologies and the topologies of 110 and a-toxin are the same 
(Fig. 7a,b). The lipoxygenases are all members of the leukotriene 
synthetic pathway, which is disrupted by a-toxin. 
The similarity between the N-terminal ~-sheet domain in 
1LO and 15LO and C2 domains has not previously been noted, 
however these two proteins are cytosolic and show no Ca2+ 
dependence. Instead of interacting with membrane, they inter-
act primarily with lipoxygenase-activating lipoprotein. An 
inspection of the sequences of lLO and a-toxin aligned by 
structure (Fig. 2) shows that none of the residues identified as 
involved in calcium binding is conserved, and that large inser-
tions occur in these loops (Fig. 7b). 15LO also has large inser-
tions in the Ca2+ binding loops, and all but one (Asp 336) of the 
conserved residues are mutated. In this they bear a strong simi-
larity to human pancreatic lipase, described earlier as sharing 
the same fold as a -toxin C-terminal domain, 1LO and 15LO. 
HPL also binds a colipase23 protein, and not calcium; HPL does 
not have the aspartates we have identified with membrane 
binding. 






Fig. 7 Comparison of a-toxin (-terminal domain with other similar folds. a, ex-toxin (-terminal domain is shown in blue with human pancreatic lipase 
(HPL) superposed in yellow. Positions of possible caz. binding sites shown as spheres. b, The N-terminal domain of soybean lipoxygenase-1, note 
large insertions, and the C2 domains of c, Synaptotagmin I and d, PI·PLC. The position of calcium bound to these domains is indicated by grey 
spheres. A topology diagram for each fold is shown to its upper right, positions of calcium binding residues on these are indicated by red circles. 
In contrast, HASL is calcium dependent and membrane 
binding24• In its sequence (Fig. 2) four of the five Asps that we 
have associated as possibly involved in Cah binding are con-
served. Of the Cdl3ligands, only Asp 269 is mutated to pheny-
lalanine, and in HASL, as for PC-PLC, residue 337 is an 
aspartate, and could replace Asp 269 in the binding site. There 
are no large insertions in the calcium binding loops. 
Understanding of HASL is therefore also likely to benefit from 
comparison with C2 domain mechanisms of action. 
In the light of these structures, a -toxin C-terminal domain 
(and HASL) can be seen as an intermediate between two dis-
tinct groups of ~-sandwich structures. While it has the same 
topology as the lipoxygenase group, the function of a -toxin is 
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quite different from the ~-sheet domains in these proteins. The 
function of a-toxin is identical to that of the eukaryotic C2 
domains, although its topology is different. 
Membrane-protein interactions 
Two mechanisms have been suggested for the binding of C2 
domams to membranes'. The first proposal is that calcium 
and/or contact with the membrane catalyzes a large conforma-
tional change which exposes a hydrophobic surface for mem-
brane insertion. The second suggestion is that calcium ions 
mediate interactions with the phospholipid headgroups, creat-




Inspection of the a-toxin 
structure revealed two extreme-
ly exposed hydrophobic 
residue~; Trp 214 and Phe 334 
have surface accessible areas of 
151 A2 and 164 A2 respectively. 
The plane deftned by these two 
residues and Cd 13, indicates 
the approximate position of a 
membrane binding surface 
(Fig. 6), with the open active 
site close to, and facing 
towards, phospholipid. This 
suggested penetration of Phe 
334 into the membrane is mir-
rored by a proposed penetra-
tion of the membrane by a 
hydrophobic loop in the C2 
domain of the recently solved 
structure of cPLA225• The posi-
tion of the membrane binding Fig. 8 Stereo view of 2F.- F, omit map for the metal ions in the catalytic domain, together with the final eo-
surface was refined by including ordinates. Map contoured at la. 
a number of additional atoms 
(the C~ from Ala 146, Trp 214, 
Asp 269, Tyr 275, Asp 336 and Phe 334 and Cd 13) in the plane 
definition. Tyr 275 had previously been suggested to be a mem-
brane binding residue by Guillouard et a/. 15• Using this refined 
plane, membrane interacting residues are defined as those that 
have an atom with a deviation of 5 A or less from the plane. In 
Fig. 6 these are highlighted in blue (residue numbers 59-65, 
78-83, 135, 139-154, 204-205, 208-217, 268-275, 293-301, 
329-337, and 364). A sequence comparison shows that, whereas 
the overall identity between C. bifermentans PLC and a -toxin is 
50°,o, for these loops the two sequences are 75% identical. 
Furthermore, while the overall identity between PC-PLC and a-
tmcin is 30%, for the putative membrane binding residues in the 
N-terminal domain (PC-PLC has no C-terrninal domain and 
cannot bind membrane), the sequence identity is 16%. 
The previous paragraph describes a protein capable of interact-
ing with a membrane surface, both by burying highly exposed 
large hydrophobic residues and by forming a complex with calci-
um and phospholipid headgroups. This interaction could insti-
gate conformational changes elsewhere in the protein: a highly 
hydrophobic, disordered surface loop (residues 84-88, WYLAY) 
is bordered on one side by active site residues and on the other by 
calcium-binding and domain interface residues (Fig. I). The loop 
is not present in PC-PLC, which does not possess a membrane 
interacting C-terminal domain (Figs 2, 3 ). Its highly hydrophobic 
nature suggests involvement in phospholipid tailgroup binding. 
Given its position between the active site and the C-terminal 
domain, another possible function of this loop could be to com-
municate calcium and/or membrane-binding to the active site, 
thereby initiating any conformational changes required to acti-
vate enzyme. 
Haemolytic activity 
Finally, the toxic properties of individual zinc metallophospholi-
pases C have been correlated with their abilities to cause lysis of 
erythrocytes>. This model allows us to suggest a molecular expla-
nation for the presence or absence of this function. Two examples 
are given below. 
PC-PLC has no haemolytic activity26• This protein lacks the C-
terminal domain present in a-toxin, which is important for 
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membrane binding, and which we have identified as a C2-like 
domain. In addition, sequence identity with the a -toxin N-termi-
nal domain is low ( 16%) in the putative membrane binding 
loops. Two of these binding regions have been completely 
obscured: PC-PLC helices G and H1 replace the exposed Trp 214, 
and the loop including residues 78-83 has been deleted (Fig. 3). 
We propose that this enzyme is not haemolytic because it has 
none of the membrane-interacting regions identified in a -toxin. 
C. bifermentans PLC is weakly haemolytic. It shows 47% 
sequence identity with a-toxin, a figure that rises to 75% dose to 
the active site and membrane binding regions, suggesting it 
should be strongly haemolytic. However, in the a -toxin-mem-
brane model there is a loop (residues 329-337) raised above the 
membrane binding surface of a-toxin (Fig. 6). This loop contains 
a larger than average number of mutations between the C. per-
fringens and C. bifermentans sequences in particular Tyr 331 (C. 
perfringens) is changed to lie (C. bifermentans) and Phe 334 (C. 
perfringens) to Ile (C. bifermentans). The reduction in size of these 
residues, and consequently in the hydrophobic contact area 
between C. bifermentans PLC and phospholipid, should reduce 
the free energy of membrane-protein complex formation relative 
to a-toxin, thereby reducing its activity and therefore toxicity. We 
would suggest then, that these residues may be crucial to the toxi-
city of a -toxin, and that the lack of conservation in other related 
proteins could explain the relative inefficiency of other PLC 
enzymes present in the environment. 
Conclusion 
The structure of a-toxin has revealed both an expected homology 
to B. cereus PLC, and a structural analogy to the C2 domains of 
intracellular second messengers in eukaryotic cells, and the ~­
sheet domain found in Lipoxygenases. Thus, a -to;<in may be 
viewed as an intermediate between these two topologies. 
However, because of its calcium binding function and mem-
brane-binding functions, we have identified the a-toxin C-termi-
nal domain as the first example of a prokaryotic C2-like domain. 
Finally, modeling the membrane binding of a-toxin has allowed 
us to suggest possible reasons for its potent toxicity, in compari-
son to other, highly homologous, but harmless, enzymes. 
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Table 1 Data collection and processing, structure solution and refinement statistics' 
max. res. No~ Nunoque Camp. Rmerge2 MFID3 FOM4 






1.9 202,958 30,175 91 6.5 
1.98 257,576 56,901 87 5.8 
2.8 86.712 19,688 92 9.2 13.4 0.33/0.26 1.21/0.88 
Nrefle<tion\ Naroms 
working test protein other 




Deviations from ideality 
bond lengths (A) bond angles 




Ramachandran plot Average B-factor (A2) Waters 
main side N B.,, (A2) 
28.1 29.8 174 33.9 
1Coordinate error as given in SIGMAA40 
'R....,,. = r,.,J:, ll,(hkll-ITliml/r..,r,l,(hkll 
'MFID= ~/ iF.l. (F)/(E) =[r. IF,. 12/l:,.IE I' I'''· = l:,. iE i' {IF,, hobsl-IF,, l<c:tlcl }' . . 
'FOM = IF(hki)~ .. I/1F(hkl)i. F(hkl)..,.,= r,.P(a)F,.,(a)/l:,.P(a). where, I= intensity, F =structure factor. F =structure factor amplitude, p =protein, H = 
heavy atom, PH= protein and heavy atom, P =probability and a.= phase angle. 
SJn most favored regions. 
Methods 
Crystallization. C. Perfringens u-toxin strain CER89L43 was 
expressed in Escherichia coli and purified to homogeneity as 
described•. Two different crystal forms were grown by hanging drop 
vapor diffusion at 20 'C. Form I grew in the presence of 0.05 M 
CdSO,, with 0.1 M Na-HEPES. pH 7.5 as buffer and 1 M Na-acetate as 
a precipitant, while form 11 crystals grew in 0.1 M sodium acetate 
buffer at pH 4.6, using 1. 7 M NaCI as a precipitant. Form I crystals 
are in spacegroup (222, with unit cell dimensions a= 61.3 A, b = 
177.3 A, c = 79.1 A, u = fl = y = 90', and one molecule in the asym-
metric unit. The solvent content of the crystal is 50%. Form 11 crys-
tals belong to spacegroup R32 with cell dimensions a = b = 
151.4 A, c = 195.5 A, u = fl = 90', y = 120'. There are two molecules 
in the crystallographic asymmetric unit and the solvent content of 
these crystals is also 50%. 
Data collection. The high resolution C222, native data set was col-
lected on stations 9.5 and 7.2 of the synchrotron radiation source at 
Daresbury Rutherford Appleton Laboratory, on a 300 mm 
MarResearch lmagePiate. All other data sets, for both the crystal 
forms, were collected using an in house 180 mm MarResearch 
lmagePiate mounted on a Siemens rotating anode generator operat-
ing at 40 kV and 90 mA. All data were processed with the DENZ027 
program suite. Scaling and merging were carried out with 
SCALEPACK, from the same suite. Subsequent data manipulation 
used the CCP4 program package". Statistics for each data set are 
given in Table 1. 
Molecular replacement. Initial phasing for the C222, structure was 
provided by the placement of a previous, incompletely traced model 
of C. perfringens u-toxin, strain NCTC8237 (Basak er a/., unpublished 
data) into this crystal form using X-PLOR' (Initial R-factor and R1re, val-
ues following rigid-body refinement were 50% and 53% respectively). 
Following refinement of this model, also using X-PLOR, R-factor and 
R • ., values fell to 46% and 43% respectively. Two copies of this model 
could then be placed in the R32 crystal form. using AMoRe29 (correla-
tion coefficient 0.49 and R-factor 46%, after initial rigid body), related 
by a translation of half the c-axis, with no rotational component. 
Details for both molecular replacements are given in Table 1. 
SIR phasing. The protein was derivatized with ehtylmercury chloride 
(EMC) by soaking the R32 crystals for 24 hours in the crystallisation 
buffer containing 2 mM EMC. Heavy atom positions were identified 
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from Patterson difference maps, and confirmed by a difference 
Fourier map, using the R32 molecular replacement phases. Quality sta-
tistics for the derivative are shown in Table 1. 
Density modification. Cross-crystal averaging (between the (222, 
form model phases and the non-crystallographically averaged R32 
form SIR phases) and solvent flattening were performed prior to 
model building. The solvent flipping option within DM30 was chosen. 
During an average round of refinement the R1,., fell from 25% to 9% 
during this process. 
Model building and refinement. The improved phases meant that a 
much improved model could be constructed (in the (-terminal domain 
only 29 Cu atoms had been approximately correctly positioned in the 
previous 'best' model), and refinement of the C222, crystal form pro-
ceeded smoothly through rounds of manual rebuilding and refine-
ment using X-PLOR9• A bulk solvent correction was made (B = 110 A>, k 
= 0.43) allowing all data (25.0-1.9 A) to be included in later rounds of 
refinement. Waters were included in the later stages at stereochemi-
cally sensible positions with a difference density peak of at least 3.5cr. 
A number of very strong difference peaks were seen (>10 times the 
r.m.s. electron density in a Fourier synthesis) subsequent to complete 
tracing of the chain, both in the active site and at the surface of the 
protein. After consideration of the crystallization buffer these peaks 
were identified as cadmium ions. Model validation statistics are shown 
in Table 1; four disallowed residues occur and all four are in a highly 
mobile region immediatily preceding the modeled residues 84-89. The 
average B-factors for the main and side chain atoms have remained 
nearly identical. despite the loosening of restraints at the end of 
refinement. 
Coordinates. The refined coordinates have been deposited in the 
Brookhaven Protein Data Bank with accession number 1CA 1. 
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Alpha-toxin is the key determinant in gas-gangrene. The toxin, a phos-
pholipase C, cleaves phosphatidylcholine in eukaryotic cell membranes. 
Calcium ions have been shown to be required for the specific binding of 
toxin to membranes prior to phospholipid cleavage. Reported X-ray crys-
tallographic structures of the toxin show that the C-terminal domain has 
a fold that is analogous to the eukaryotic calcium and membrane-binding 
C2 domains. We report the binding sites for three calcium ions that have 
been identified, by crystallographic methods, in the C-terminal domain of 
the protein close to the postulated membrane-binding surface. The pos-
ition of these ions at the tip of the domain, and their function (to facili-
tate membrane binding) is similar to that of calcium ions observed 
bound to C2 domains. Using the optical spectroscopic techniques of circu-
lar dichroism (CD) and fluorescence spectroscopy, pronounced changes 
to both near and far-UV CD and tryptophan emission fluorescence upon 
addition of calcium to the C-terminal domain of o:-toxin have been 
observed. The changes in near-UV CD, fluorescence enhancement and a 
2 nm blue-shift in the fluorescence emission spectrum are consistent with 
tryptophan residue(s) becoming more immobilised in a hydrophobic 
environment. Calcium binding appears to be low-affinity: Kd"" 175-
250 11M at pH 8 assuming a 1:1 stoichiometry. as measured by spectro-
scopic methods. 
© 1999 Academic Press 
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Clostridium perjringe11S biotype A is an important 
pathogen of both humans and other animals, 
primarily because of its production of o:-toxin. The 
bacterium is found in soil and its entry into 
wounds may result in clostridial myonecrosis 
(Hatheway, 1990; Titball, 1993), a disease which, 
unless treated, is ultimately fatal as a result of sys-
temic toxaemia and shock (Stevens et al., 1988). 
The growth of the bacterium in damaged tissues 
results in the production of a toxic phospholipase 
C (o:-toxin), which plays a key role in the spread of 
the infection by suppressing host immune 
responses (Bryant & Stevens, 1996), by triggering 
the release of inflammatory mediators (Fujii & 
Sakurai, 1989; Gustafson & Tagesson, 1990) and by 
causing changes in intracellular calcium levels 
(Fujii & Sakurai, 1989; Williamson & Titball, 1993). 
All of these effects are dependent on interaction of 
the o:-toxin with host cell membranes and this can 
be measured in vitro as haemolysis of erythrocytes 
(Williamson & Titball, 1993). 
The holotoxin is a zinc-metalloenzyme produced 
as a single plc gene product, containing 370 amino 
acid residues with a molecular mass of 42,500 Da. 
Alpha-toxin is composed of two domains: the N-
terminal region contains 246 residues and carries 
the site for phospholipid hydrolysis, and the C-
terminal domain, which consists of the remaining 
124 rcsidues and contributes to the toxin's lethal, 
haemolytic and sphingomyelinase activities. For 
maximal activity, o:-toxin requires calcium as well 
as zinc ions and the optimal concentrations for 
ions have been reported as 5 11M and approxi-
mately 5 mM for Zn2+ and Ca2+, respectively 
(Miles and Miles, 1947; Sato et al., 1978). According 
to Moreau et al. (1988), calcium is essential for 
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binding to lipid membrane and zinc is responsible 
for substrate hydrolysis. 
TI1e isolated C-domain, which is devoid of enzy-
matic or toxic activity (Titball et al., 1993), has sig-
nificant amino acid sequence homology (30% 
identity) to an enzyme, arachidonate 5-lipoxygen-
ase, involved in the arad1idonic acid pathway 
(Titball et al., 1991). bnmunisation with the C-term-
inal domain affords full protection from disease in 
mouse models, indicating that the protective epi-
topes are included in this domain. The advantage 
of using the C-terminal domain as a vaccine com-
pared with the conventional formol-toxoid has 
been reported (Williamson & Titball, 1993). 
The crystal structure of cr-toxin has recently been 
solved (Naylor et al., 1998; Figure 1), and has 
added extensive knowledge to the mode of action 
of this lethal toxin. The N-terminal domain of this 
two-domain protein is entirely helical in character 
(66% cr-helix), and contains the active-site zinc 
ions. In this structure, the active site is solvent-
accessible, with a channel large enough to admit a 
phospholipid molecule leading to it: the structure 
is referred to here as the open form. The position 
of the active site and a number of highly exposed 
hydrophobic residues allowed the identification of 
the likely membrane-binding surface of the toxin. 
ln a second structure of cr-toxin Q.T. Eaton et al., 
unpublished results), the active site is obscured by 
the movement of a loop of residues (135-155); there 
is additional change in the loop of residues (60-90) 
that contacts the C-terrninal domain. It is this 
second structural form that has been predomi-
nantly studied here, and it will be referred to as 
the closed structure. 
The C-terminal domain (247-370) consists of two 
four-stranded P-sheets, and is structurally related to 
the eukaryotic phospholipid-binding and calcium-
binding c2 domain. c2 domains are typically eight-
stranded anti-parallel P-sandwiches found in many 
signalling and vesicle fusion proteins, and fre-
quently interact with membrane or phospholipid 
(Sutton et al., 1995; Grobler et al., 1996; Guillouard 
et al., 1997). Several possible calcium-binding sites 
have been identified in the C-terminal domain of :x-
toxin, involving a number of conserved aspartate 
residues. All these sites are at, or close to, the mem-
Ccr•-binding in C. perfringens Alpha-toxin 
brane surface of ilie enzyme. Cadmjum ions found 
in these possible sites in the open form were postu-
lated to be acting as calcium ion analogues, and it 
was suggested that the presence or absence of Ca2+ 
caused the conformational shift between open and 
closed, thus causing the previously observed acti-
vation of the enzyme (Moreau et al., 1988). How-
ever, the relatively high concentration of cadmium 
ions (50 mM) meant that further work was required 
for definitive identification of tl1e calcium-binding 
sites, and to link tlus binding witl1 ilie observed 
conformation change. 
Here, we have set out to identify the calcium-
binding sites in cr-toxin, and to identify the changes 
induced by calcium ion binding, using crystallo-
graphic and spectroscopic methods. Calcium ions 
have been observed bound to cr-toxin, at sites clo-
sely related to the cadmium-binding sites seen in 
the open form, in a crystal structure of the closed 
form. The changes caused by calcium binding to 
ilie C-terminal domain of C. perfringens cr-toxin in 
solution are analysed by optical methods. Using 
far-UV circular dichroism (CD) we have also 
probed the effect of Ca2+ on the secondary sh·uc-
ture of the C-terrninal domain. By using the comp-
lementary techniques of near-UV CD and intrinsic 
fluorescence spectroscopy, we have investigated 
the effects of calcium binding on ilie aromatic chro-
mophores within the C-domain. We have also 
used UV absorption spectroscopy to assess the affi-
nity of the C-domain for calcium by measuring cal-
cium binding in the presence of ilie chromophoric 
chelator, 5-NBAPT A (5-nitro-1,2-bis(2-aminophe-
noxy) ethane-N,N,N',N'-tetra-acetic acid). 
Results 
Structural results 
The studies utilised C. perfringens, strain 
NCTC8237 tX-toxin; previously reported structures 
have been of cr-toxin from C. perfringens strain 
CER89L43. The two sequences differ by five amino 
acid residues. The mutations are (shown 
as CER89L43 -+ NCTC8237): Val167-+ Ala, 
Asp17-l-+ Ala, Ala177-+ Thr, Pro335 - Ser and 
Val345- Leu. We have crystallised the CTC8237 
Figure 1. Stereo -x-carbon trace of a-toxin, as reported by Naylor et al. (1998). Zinc ions in the N-terminal domain 
are shown as cyan spheres. A likely calcium-binding site in the C-terminal domain is drawn as a royal blue sphere. 
C<i'' -binding in C. perfringens Alpha-toxin 
strain under the conditions used for the previously 
described eER89L43 closed form (1.8 M Nael in 
100 mM sodium acetate, pH 4.7). The structure of 
the native closed form of a-toxin from strain 
NeTe8237 has been solved to 2.6 A, and refined to 
an R-factor of 22.0% and an Rr...., of 24.7 %, as has 
that of the calcium-bound closed form a-toxin from 
strain NeTe8237 (to 2.2 A), which has been refined 
to an R-factor of 18.3% and an Rr= of 25.7%.-The 
crystals grown in the absence of calcium, and data 
collected from them, will be referred to here as 
NeTe native, while those grown in the presence of 
calcium, and the data from them, will be called cal-
cium-bound. 
The native structure of a-toxin (strain NeTe8237) 
is essentially indistinguishable from the original 
eER89L43 closed form structure O.T. Eaton et al., 
unpublished results). The e• atom rms deviation is 
0.29 A, when residues 59-66 are excluded, with the 
structures optimally superposed. There is little evi-
dence for a change in the relative orientation of the 
two domains: with rms deviations of 0.28 and 
0.23 A for all e· atoms in the isolated N and e-
terminal domains, respectively. In addition, there is 
little or no disruption of structure in the region of 
the five amino acid substitutions between the 
NeTe8237 native and eER89L43 closed forms 
(though there was clear difference density in each 
case supporting the expected amino acid differ-
ence). This is illustrated by a comparison of the rms 
deviation for all atoms in all residues between the 
two optimally superposed structures (0.67 A), and 
the all-atoms rms deviation for those residues 
within 5 A of a mutation: for V167 A this is 0.81 A; 
for D174A, 0.62 A; for A177T1 0.54 A; for P335S, 0.72 A; and for V345L, 0.54 A. This similarity is 
seen also in the rms difference in B-factors, with the 
exception of residue 335. For all residues, the all-
atoms rms change in B-factor between the two 
structures is 17 A2. A compelling explanation for 
the large difference in B-factors between the two 
structures is not apparent, but could be due to the 
fact that the NeTe data were collected on a frozen 
crystal (rms B-factor 18 A2), whereas those for the 
eER89L43 closed form were collected from room 
temperature crystals (rms B-factor 29 A2). We can, 
however, still compare therms B-factor for the resi-
dues proximal to a mutation with the rms B-factor 
for the whole toxin. The rms B-factor for residues 
within 5.0 A of V167A is 16 A2; forD 174A, 17 A2 
for A177T, 17 A2; and for V345L, 16 A2 However 
for P335S, the rms difference in B-factors has risen 
to 23 A2 : placing serine at residue 335 has made the 
local structure relatively more ordered than when 
this residue was proline. Residue 335 is in a tight 
turn at the putative membrane-binding surface of 
the e-terminal domain of a-toxin. The <j>-q> angles 
adopted by residue 335 are allowed for both proline 
and serine; however, it is possible that the greater 
conformational flexibility of the serine residue 
reduces conformational strain in the turn, thereby 
resulting in a relatively more ordered local 
structure. 
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The calcium-bound structure is similar to both 
the eER89L43 closed form structure Q.T. Eaton 
et al., unpublished results) and the NeTe8237 
closed form structure. The e· atom rms deviation 
(excepting residues 59-66) is 0.21 A between ea-
bound and NeTe native, and 0.29 A between ea-
bound and the eER89L43 native structure. As for 
the NeTe native structure, there is no indication 
of any disruption in the region of the five strain 
differences. However, all comparisons will be 
made between the NeTe8237 native and calcium-
bound structures, unless otherwise stated, so 
avoiding confusion of residual strain differences 
with changes due to calcium binding. The calcium-
bound structure is shown in Figure 2(a) and (b): 
since the overall fold of all three closed structures 
is identical, the other two are not illustrated. The 
differences between the open and closed forms are 
also highlighted in this Figure. 
In the initial difference Fourier electron density 
map, three calcium ions were identified in the puta-
tive membrane-recognising surface of the e-term-
inal domain. The binding sites for these ions are 
highlighted in Figure 3. The three sites are close 
together, in an approximately straight line, along 
the /utative membrane-binding surface (ea1 is 
8.2 from ea3 and 15.1 A from ea2, while ea2 
and ea3 are 7.3 A apart). They are not as tightly 
clustered as the calcium ions that have been 
observed bound to eukaryotic e2 domains, which 
are typically separated by 3-6 A (Essen et al., 1997; 
Perisic et al., 1998; Shao et al., 1998; Sutton & 
Sprang, 1998). 
eal is identical with the site identified by 
Naylor et al. (1998), in the open form of the 
eER89L43 strain (the cadmium ion, ed13, seen in 
that structure, and ea1 are just 0.2 A apart, when 
the two domains are optimally superposed). 
Table 1 lists the ligands to ea1, they include resi-
dues that have been identified by Guillouard et al. 
(1997) as important for calcium binding (these 
experiments were carried out on strain 8-6, a 
mutant of strain NeTe 8789; there are ten amino 
acid differences between this strain and 
NeTe8237, none of them in areas thought to be 
important for activity). The other two calcium ions 
are bound to previously unidentified sites: how-
ever, all the protein ligands for both these new 
ions (ea2 and ea3 in Table 1) are conserved 
between the phospholipases e of Clostridium bifer-
mentans and Clostridium novyi, and the two strains 
of C. perfringens referred to here. The sites have 
their co-ordination spheres completed by water or, 
in the case of Cal, a carboxylate oxygen atom from 
a symmetry-related molecule, and are at the puta-
tive membrane-binding surface of the protein. It is 
proposed that when a-toxin binds to a membrane, 
the calcium ion co-ordination will be completed by 
phospholipid headgroups, thereby enhancing the 
binding of protein to membrane (and also increas-
ing the affinity of calcium for the complex, com-
pared with either protein or membrane in 
isolation). 
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Figure 2. (a) Side-view of the closed calcium-bound 
enzyme, drawn as a secondary structure cartoon. The 
loop that orders on binding calcium is shown in ball-
and-stick, while the conformationally mobile loops (resi-
dues 60-90 and 130-150) are shown in flesh colour. The 
conformation of residues 60-90 and 130-150 in the open 
form of the enzyme is shown in semi-transparent cyan. 
The positions of calcium bound to the C-terminal 
domain are shown in royal blue, while those of 
cadmium bound to the open form of the enzyme are 
shown in semi-transparent cyan. (b) View onto the 
membrane-binding surface of the calcium-bound 
enzyme (representing a rotation relative to (a) of 90 
towards the viewer around a horizontal axis in the 
plane of the paper). Colours as described for (a), except 
that the closed form residues 60-90 and 130-150 are 
drawn in flesh. A phospholipid molecule is drawn in 
semi-transparent grey spheres, modelled into the open 
form active site. The closed form residucs 130-150 clash 
with the phospholipid, and would prevent it binding. 
These three calcium ions, together with their 
ligands, were used in a least-squares fitting algor-
ithm to define a plane that was assumed to 
approximate the plane containing the phosphate 
headgroups of phosphatidylcholine when alpha-
toxin has bound to a eukaryotic cell membrane. 
The zinc ions of the active site are just 2 A or less 
from this plane, indicating that if the toxin binds to 
membrane vin these calcium ions, it wiJl be opti-
mally positioned to bind phosphatidylcholine in its 
ca2+ -binding in C. perfringens Alpha-toxin 
active site, without requmng the energetically 
w1favourable step of withdrawing the phospho-
lipid from the membrane. 
There was no significant conformational change 
in the C-terminal domain upon binding calcium: 
the rms deviation for the C" atoms of residues 247-
370 is just 0.17 A between the NCTC native and 
calcium-bound structures, with the C-terminal 
domains optimally superposed, and 0.79 A for all 
atoms in the domain. In addition, there is no evi-
dence of conformational change in the region of 
the calcium ions: the all-atom rms deviation is 
0.6-l A, 0.58 A and 0.66 A for residues within 5 A 
of Ca1, Ca2 and Ca3, respectively. 
The N-terminal domain, similarly, did not 
undergo any large conformational change: specifi-
cally there is no change from the closed to the 
open enzyme form upon binding calcium ion. The 
rms deviation for N-terminal domain C" atoms 
(excluding residues 59-66) is just 0.20 A, when the 
two N-terminal domains are optimally superposed. 
However, there is a small conformation change in 
one loop region. In both the previously reported 
CER89L43 closed form and the NCTC8237 native 
closed form reported here, residues 59-66 have 
been too disordered to observe in the electron den-
sity map. These residues are clearly visible in the 
calcium-bound enzyme, and are illustrated in 
Figure 4. The side-chain hydroxyl 0 11 of Tyr62 has 
formed several hydrogen bonds to C-terminal 
domain residues (specifically, to N62 of Asn294, 
and 0 and N of Thr306). There is no direct H-bond 
between the N and C-terminal domains in the 
open form, and only a small number in the closed 
form, therefore this hydrogen bond is a significant 
change in the interdomain interactions of the toxin 
molecule. In addition, Asn294 ligates Ca2 via its 
main-chain oxygen atom (Figures 3 and 4). It is 
assumed that the change in electrostatic potential 
in the region upon calcium binding induces the 
formation of the hydrogen bond, and thus the 
ordering of the loop containing Tyr62. His68, in 
the same N-terminal domain loop, ligates a zinc 
ion in the active site. The formation of this single 
hydrogen bond between Tyr62 (N-terminal 
domain) and Asn29-! (C-terminal domain) may 
therefore be said to link calcium (and so mem-
brane) binding in the C-terminal domain to the 
active site in theN-terminal domain. 
Far-UV circular dichroism 
The far-UV CD spectra of native a-toxin, strain 
NCTC8237 and its C-terminal domain (247-370) are 
shown in Figure 5. The spectrum of native ~-toxin 
shows a typically ~-helical rich protein with nega-
tive Cotton effects at 208 and 222 nm together with 
a positive band at 192 nm. When data between 178 
and 260 nm were analysed by the Varslc1 soft-
ware, estimates of 43% ~-helix (159 residues), 12 % 
~-sheet (44 residues), 16 '}o tu m (59 residues) and 
29 % other (108 residues) were obtained. This is in 
good agreement with the crystallographic data for 
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Figure 3. Calcium ion binding. The C-terminal domain is shown as a secondary structural cartoon, looking down 
onto the membrane-binding surface. Calcium ions are shown in blue, and their ligands are drawn in ball-and-stick. 
Note the proximity of Trp360 to Cal. 
the NCTC8237 native structure described above, 
which gives a secondary structure content of 45 % 
-x-helix (165 residues), 2.0% 310-helix (8 residues), 
18% P-sheet (67 residues), 16% turn (59 residues) 
and 19% other (71 rcsidues). Since the open form 
of the enzyme (Naylor et nl., 1998) differs in two 
loop regions and not in its ordered secondary 
structure, its secondary structure is almost identical 
with that for the closed form. 
The far-UV CD spectrum of the C-termlnal 
domain alone showed lower intensities, indicating 
a P-sheet-rich structure. There were positive signals 
at 186 and 232 nm, with a negative signal at 
200 nm together with a shoulder at 220 nm. Sec-
ondary structure prediction by Varslcl estimated 
8% a.-helix (ten residues), 36% P-sheet (44 resi-
dues), 20% turn (25 residues) and 36% other (<M 
residues). This is in agreement with the C-terminal 
domain (residues 2-!7-370) of the closed (and open) 
form crystal structure, which has a secondary 
structure content of no 'l or 310-helix, 54 °'o P-sheet (67 residues), 18 % turn (21 residues) and 28 % 
other (35 residues). In both cases, the P-sheet con-
tent of the protein is somewhat underestimated by 
the CD spectrum, compared to the crystaUographic 
structure. 
Near-UV circular dichroism 
The near-UV CD spectra of native :x-toxin and 
the C-terminal domain are shown in Figure 6. The 
Table 1. Calcium-protein ligand distances 
Cal Ca2 
spectrum of the native holotoxln shows bands 
indicative of a high absorption by Trp residues 
with intense positive bands at 287 and 295 nm 
(Strickland, 1974). The aromatic contribution in the 
holotoxin amounts to 11 Trp and 26 Tyr with no 
cysteine. The C-terminal domain consists of three 
Trp and seven Tyr residues, and the near-UV CD 
of this domain is different with a negative band 
between 265 and 300 nm, and a less intense CD 
band arow1d 292 nm compared with the holotoxin, 
possibly due to a different environment for one or 
more of the tryptophan residues. 
Fluorescence spectroscopy 
The tryptophan fluorescence emission maximum 
is indicative of the degree of exposure of Trp side-
chains. The fluorescence spectra of the holotoxin 
measured using A..,x = 280 nm, is almost completely 
dominated by Trp fluorescence due to efficient 
energy transfer. When excited at 280 and 295 nm, 
the holotoxin yields emission maxima of 343.5 and 
342 nm, respectively. These figures are indicative 
of predominantly solvent exposed Trp residues. 
The Amax values for the C-terminal domain alone 
were 3-!3.5 and 346 nm, respectively; showing that 
Trp residues are generally more solvent-exposed 
than with the full ~-toxin (Figure 7). In the 
fluorescence spectrum of the C-domain there was 
a 10-15 % contribution from tyrosine, using 
A.ex = 280 nm. 
Cc1J 
Residue Atom Dbt. (A) Residue Atom Dist. {A) Residue Atom Dist. (Al 
ruop:!69 0 2.18 Asp293 o··' 2.39 Thr272 0 2.56 
Gly271 0 2.28 Asn294 0 2.10 Asp273 0"2 2.59 
Asp336 01>2 2..!7 Gly296 0 2.19 Asn297 0'' 2.07 
Ala337 0 2.21 Asp298 o•l 2.25 Asp298 0 1.92 
Glu32 0.2 2.62 Wat ow 2.83 
(symm.) 
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Figure 4. Tyr62 hydrogen bonding to Asn294. Residu~s from the t:-J-ten:'inal domain are dra~n in ball-and-stick 
with grey bonds, those from the C-tcrminal domain are m ball-and-shck w1th yellow bonds. Ca2 IS shown as a blue 
sphere. 
Calcium-binding studies 
Titration wii.h co!ci!.!.!!l in the oresence of a chro-
mophoric chelator is a proven a~curate method for 
observing macroscopic Ca2+-binding constants for 
calcium-binding proteins (Linse et al., 1988, 1991). 
The effect of calcium on the absorbance spectrum 
of the chromophoric chelator 5-NBAPT A showed a 
large diminishing intensity at the absorbance maxi-
mum of 430 nm with calcium addition, due to cal-
cium chelation (Tsien, 1980), with a Kd of 20.25 J.!M 
using 10 mM Tris-HCl (pH 8.0) and 150 mM NaCI, 
in agreement with that obtained by Rand et al. 
(1997). Titrations with 5-NBAPTA and the C-term-
inal domain of ~-toxin (Figure 8), showed some 
competitive binding to the C-domain and indicated 
a calcium affinity with a Kct of 175(±50) 11M, 
assuming a 1:1 (Ca2+ to C-domain) stoichiometry. 
These results agree with previous workers, who 
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Figure 5. Far-UV CD spectra of Clostridium perfringens 
:x-toxin and its C-terminal domain. Samples of ex-toxin 
(9.1 llM) and C-domain (39 llM) were in 10 mM Tris-
HCI (pH 8.0). Spectra were recorded at 25 C using a 
path-length of 0.01 cm and band-width of 1 nm. Each 
spectrum is an average of 16 scans and has had a buffer 
base-line subtracted. 
suggested that only low-affinity ~~Jci~m b~din.g 
was in evidence as shown by equilibnum dtalys•s 
(Guillouard et al., 1997; Young et al., 1991). 
Far-UV CD results showed a distinguishable 
titration effect when a calcium chloride solution 
was added to C-terminal domain in siht. With an 
approximate starting calcium concentration .of 
100 J.!M, further additions of Ca2+ produced a s•g-
nilicant decrease in CD intensity at 200 and 
220 nm. At 500 J.!M Ca2+ there was an increase in 
absorption at 232 and 220 nm, the latter being a 
marker for helicity within a protein (not shown). 
These changes in spectra indicate that, in solution, 
small changes in the secondary structure of the C-
domain upon calcium binding can be observed. 
Small changes were also observed in the far-UV 
CD spectrum of the Ca2+-binding C2 domain (C2A) of synaptotagmin I (Shao et al., 1996). 
Near-UV CD results from the C-domain with 
calcium ions resulted in little change between 0 
and 50 J.!M added calcium. Upon adding higher 
concentrations of calcium, there was a significant 
increase in absorbance of the Trp band at around 
292 nm (Figure 9(a)) indicating that one or more 
Trp residue is affected by calcium binding. There is 
a large increase in absorbance between 100 and 
500 J.!M (Figure 9(b)) and upon adding more than 
5 mM calcium there was no further increase in 
absorbance, indicating that saturation had 
occurred. Line-fitting analysis estimates that the 
site is of low affinity (Kd ~ 250(±50) 11M, assuming 
1:1 stoichiometry), as previously postulated 
(Moreau et al., 1988; Guillouard et al., 1997). 
Fluorescence emission results suggest a titration 
effect similar to that of the near-UV CD with Little 
effect detected until 50 J.!M Ca2+ is added, when 
there is a strong fluorescence enhancement indicat-
ing a changed environment for at least one Trp 
residue (Figure 10). Based on the fluorescence 
maximum (A..,, = 280 nm, Aem = 343.5 nm) of the 
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Figure 6. Near-UV CD of Clostridium perfringens a.-
toxin and its C-terminal domain. Sample and spectral 
conditions were as for Figure 5, except that a path-
length of 1 cm was used. 
C-domain, it is likely that this exposed Trp makes 
a significant contribution to the fluorescence of the 
domain and is responsible for changes ur.on cal-
cium binding. Upon adding 100 J..!M Ca + there 
was a further fluorescent enhancement and a blue 
shift of 2 nm, suggesting that a Trp had relocated 
to a less polar environment. Binding of calcium to 
the domain increased the fluorescence by as much 
as 50%. When calcium-free protein is used, the 
initial titration of calcium yields a small quenching 
of the fluorescence emission followed by enhance-
ment after 250 J..!M added calcium. The fluorescent 
enhancement seen with the C-domain is of the 
same order as that observed upon Ca2+ binding to 
the C2 domain of phospholipase A2 (Nalefski et al., 
1997). The possible identity of the Trp with an 
altered environment is not immediately obvious, 
since, as has already been described, there is little 
change to the structure of the C-terminal domain 
on binding calcium. Of the three tryptophan resi-
dues in the C-domain, Trp290 and Trp325 are bur-
ied in the middle of /3-sheets. The third, Trp360, is 
exposed on loop /37-/38, on the postulated mem-
brane-binding surface (Figure 3). 
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Figure 7. Fluorescence emission spectra of Clostridium 
perfringens o:-toxin and its C-term.inal domain. Samples 
of ex-toxin (0.23 1-1M) and C-domain (1 11M) were in 
10 mM Tris-HCI (pH 8). The sample at 25(± 1)°C was 
excited at 280 nm and 295 nm using a 4.25 run band-
pass and a 1 cm path-length cuvette. The intensity of 
emjssion (cps, counts per second) was measured at 
4.25 nm bandpass. Spectra are displayed with buffer 
baselines subtracted. 
Further fluorescence experiments with other 
divalent cations did not result in the large fluor-
escence enhancement together with a blue-shift in 
the same manner as calcium (Table 2). The effect of 
Cd2+, Cu2+ and Zn2+ is likely to be due to intrinsic 
quenching due to heavy-metal binding to trypto-
phan. EGT A (500 J..!M) was added to the calcium-
added C-domain, with the result that the intensity 
of the fluorescence decreased to less than the start-
ing intensity. Fluorescence titration of ex-toxin 
yielded a small degree of quenching upon addition 
of calcium but no fluorescence enhancement or 
blue-shift upon high loadings of calcium as was 
observed with the C-domain alone. It is likely that 
the observed effect on the C-domain tryptophan 
residue(s) was obscured by the large fluorescence 
of the eight additional tryptophan residues in the 
N-domain. 
Table 2. Effect of divalent cations on the fluorescence emission spectra of the C-domain of o:-toxin 
C-domain prep• Divalent cation addedb Emission A.max (nm), ex 280 nm Fluorescence intensity 
Ca/Zn prep 345 
Normal 345 
Nom1al +Caz .. 343 50% enha ncement 
Norma l +Na2 .. 344 Quenching 
Normal + Mg-2 .. 345 
Normal +Mn2t 345 
Normal +Ni2+ 344 
Normal +Cu2 .. 345 Quenching 
Normal +Zn2+ 342 Quenching 
Normal +Cd z .. 340 Quenching 
Normal + EGTA 344 Slight quenching 
• Ca2~ and Zn2+ are added to the g rowth medium of £. coli to a final concentration of I mM (Basak 1'1 al., 1994) in the Ca/Zn 
preparation, but a re omitted in the procedure used to purify the Normal C-domain preparation. 
b A final concentration of 500 fiM of the indica ted diva lent cation (chloride fo rm) or EGTA was added separately to the Normal 
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Figure 8. Calcium titration of 5-NBAPTA in the pre-
sence <•> and absence (I) of C-domain. The titration of 
5-NBAPTA (50~) in 10 mM Tris-HCI (pH 8.0), 
150 mM NaCI with calcium chloride was performed in 
the presence of 33 1-1M C-domain. For the C-domain 
titration, the absorbance at 430 nm was normalised to 
that with 5-Nl3APTA alone. 
Discussion 
Alpha-toxin is the main virulence factor pro-
duced by the bacterium Clostridium perfringens 
associated with gas-gangrene or clostridial myo-
necrosis (Awad et al., 1995; Williamson & Titball, 
1993). Alpha-toxin is a phospholipase C, which is 
capable of binding to mammalian cell membrane, 
and cleaving membrane-bound phosphatidyl-
choline (or sphingomyelin) to produce phospho-
choline and diacylglycerol (or ceramide). The result 
of this reaction, possibly via the reaction product, 
diacylglycerol (which is a leukotriene precursor), is 
to suppress host immune response (Fujii & 
Sakurai, 1989; Gustafson & Tagesson, 1990), trigger 
the release of inflammatory mediators (Fujii & 
Sakurai, 1989; Williamson & Titball, 1993) and to 
cause an increase in intracellular calcium (Titball, 
1993). Continued exposure of the eukaryotic cells 
to the ex-toxin finally causes cell lysis due to the 
depletion of membrane phospholipids. Calcium 
has been shown to be essential for ·specific binding 
of ex-toxin to phosphatidylcholine on membrane 
surfaces, prior to phospholipid cleavage (Moreau 
et al., 1988), and as such makes a vital contribution 
to the toxicity of C. perfringens ex-toxin. However, 
the low affinity of calcium for the protein (in the 
absence of membrane) has, up to this time, made a 
thorough investigation of the effect of calcium on 
ex-toxin and its mechanism of action difficult. This 
study has shown binding of calcium ion to the 
C-terminal domain of ex-toxin in both crystalline 
and solution forms. Three-dimensional structures 
of the holotoxin both in Ca2+ -free and bound 
forms were determined by crystallography. A 
detailed optical spectroscopic investigation, using 
CD, fluorescence and UV absorption, of the 
changes induced in solution on addition of calcium 
ion to ex-toxin, and the ex-toxin C-terminal domain 
Ca2' -binding in C. perfringens Alpha-toxin 
280 290 300 310 320 
Wavelength (nm) 
(b) 1 .~J . . . ..... . .. 
.. ~ I 
.' 1 ~





0.001 0.01 0.1 1 10 100 
[Ca21, mM 
Figure 9. (a) Effect of calcium on the near-UV CD 
spectra of C-domain. Calcium chloride was added to 
63.8 ~ C-domain in calcium-free 10 mM Tris-HCI 
(pH 8). The amount of calcium added was, from bottom 
to top trace: 0 ~~ 152 ~' 250 1-1M, 531 ~ and 
909 JJM. The spectra are an average of four scans using 
1 cm path-length, 1.0 run bandwidth and were corrected 
for buffer baseline absorbance. (b) Change in near-UV 
CD signal (t.t.£ 290-310 nm) as a function of calcium 
concentration. 
was also carried out. These results suggest specific 
low-affinity binding by one or more calcium ions 
to the C-terminal domain of ex-toxin. 
Overall agreement between crystallographic 
and spectroscopic results 
The secondary structure content of ex-toxin as 
determined by crystallography and far-UV CD is 
in reasonable agreement. It is noticeable, however, 
that the far-UV CD predicts some ex-helix in the 
C-terminal domain, and also the ~-sheet content 
(36 % of the C-terminal domain total) is well below 
that seen in the crystal structure (57 %). The open 
form crystal structure shows a small quantity of 
310-helix in the C-terminal domain (approximately 
2.5 %; this region is random coil in the closed 
form), which is not easily distinguishable from 
ex-helix by far-UV CD (Andersen et al., 1996), and 
may account for the estimated helical content of 
C;i!• -binding in C. perfringens Alpha-toxin 
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Figure 10. Fluorescence titration of the C-terminal 
domain of Clostridium perfringens ex-toxin with calcium 
following excitation at 280 nm. Calcium chloride was 
added to :<::0.6 11M C-domain. Final Ca2+ concentrations 
were from bottom spectrum to top: 0, 0.1 mM, 0.5 mM 
and 1 mM Ca2+. Spectral parameters were as in the 
legend to Figure 7. 
the C-terminal domain in solution. The apparent 
loss of ~-sheet in the CD measurements could per-
haps be the result of "fraying" at the ends of 
~-strands, as proteins are more mobile in solution 
than in a crystal. In addition, some changes in 
structure may be expected when the C-terminal 
domain in isolation is studied, due to the loss of 
theN-terminal domain, with which parts of the C-
terminal domain would normally have stabilising 
interactions. 
Correlation between spectroscopic and 
crystallographic observation of calcium binding 
Both the spectroscopic and structural analyses 
reported here show that the C-termina1 domain of 
the ex-toxin is the binding site for calcium ions. 
Since other workers have shown that calcium ions 
are essential for the binding of the ex-toxin to lipid 
monolayers and bilayers, our findings logically 
implicate the C-termina1 domain in the membrane 
recognition event, which is essential for the detri-
mental effects of the ex-toxin on host cells. 
Our X-ray crystallographic analysis suggests that 
three calcium ions participate in membrane phos-
pholipid recognition with no significant confor-
ma tional change upon Ca2+ binding. The 
spectroscopic analysis, on the other hand, shows 
the binding of a single calcium ion to the C-term-
inal domain wi th low affinity (Kd ~ 175-250 11M). 
Part of the explanation for this difference might lie 
in subtle differences in the conformations of the 
isolated C-domain and the C-domain within the 
holotoxin. It is possible that the C-terminal domain 
in isolation may be slightly unfolded (perhaps 
because of the exposure of the hydrophobic inter-
domain surface), and that binding calcium ion 
specifically, by inducing the correct formation of 
the binding site, induces correct protein folding. 
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The change in conformation detected by CD and 
fluorescence measurements could then be inter-
preted as a completion of domain folding or s tabil-
isation of the CaH -binding loops, as seen with 
synaptotagmin C2A domain (Shao et al., 1996, 
1998) . 
This hypothesis would s till mean that the spec-
troscopic data show specific binding of calcium to 
the C-terminal domain for the first time; however, 
it reinterpre ts the significance of the posited con-
formational change. Also, assuming the binding of 
the first calcium ion (presumably the tighter bind-
ing Ca1, already observed as Cd13 by Naylor et al., 
1998) induces complete domain folding, then opti-
cal detection of Ca2 and Ca3 binding would not be 
possible, as no conformation change is predicted 
for the folded C-terminal domain. These two sites 
would be optically silent. In these circumstances, 
the change in tryptophan fluorescence could be the 
result of further folding. For example, in the cor-
rectly folded structure, two tryptophan residues, 
290 and 325, are buried, but could be exposed in a 
partially folded domain. 
An alternative explanation exists, however. The 
side--chain of Trp360 is just 4-5 A from Ca1 
(Figure 3). The change in the environment of a 
tryptophan residue could simply reflect the change 
in its environment on calcium ion binding. This 
tryptophan residue is more than 15 A from Ca2 
and Ca3, and neither of the other two is closer 
than 10 A to any calcium ion. Being exposed, 
Trp360 would be expected to be sensitive to a 
change in its environment on binding of the proxi-
mal calcium ion, Cal. 
Finally, it is likely that two of the sites are of 
lower affinity (probably Ca2 and Ca3), since there 
is an absence of competition with calcium chelator 
5,5'Br2BAPTA (Kd ~ 1.4 x 10- 6 M) (Rand et al., 
1997) for these ions. One ligand of Ca3 (Asp293) 
has very recently been identified by site-directed 
mutagenesis as necessary for calcium binding (N. 
Walker & R. W. Titball, DERA, Porton Down, 
personal communication). Lower affinity binding 
would be more difficult to observe by solution 
methods. 
Implications for enzyme mechanism 
In previous work, where the open (Naylor et al., 
1998) and closed Q.T. Eaton et al., unpublished 
results) forms of the enzyme have been described, 
it has been suggested that the key factor in con-
verting between these two forms was calcium ion. 
Calcium has been shown to activa te the enzyme, 
and the spectroscopic data presented here have 
shown that it binds to the C-terminal domain. 
Cadmium ion was present in the open, but not the 
closed form crystallisation conditions. Cadmium 
can compete with calcium and other divalent ca t-
ions in microbial uptake systems (Hughes & Poole, 
1989), and can act as a calcium ion analogue, par-
ticularly in the high concentrations (50 mM) pre-
sent in the open form crystallisation conditions. 
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Two loops were shown to move in the N-terminal 
domain between the open and closed form: one, 
consisting of residues 130-150, covered the active 
site in the closed form; the other, conta ining resi-
dues 60-90, made up part of the active si te, and 
was close to the C-terminal domain. It was postu-
lated that this second loop would signal calcium 
and/or membrane binding in the C-terminal 
domain to the active site, by an unknown means. 
The structural results presented here show cal-
cium binding, but the enzyme has remained in an 
essentially closed conformation. Clearly then, the 
difference between open and closed conformers is 
more complex than anticipated . However, we have 
identified a possible signal between the N and C-
terminal domains in residues 60-90. We suggest 
that the first stage of ex-toxin activation following 
calcium-binding is the ordering of residues 59-66 
and, in particular, the formation of a hydrogen 
bond between Tyr62, in the N-terminal domain, 
and As.n294, in the Ca2 binding site, thus signal-
ling to the active site that calcium has bound. This 
structure would be equivalent to the calcium-
bound intermediate identified by Young et al. 
(1991). In this case, why did ex-toxin, having 
received the signal, not then change to the open 
conformation? First, if the open conformation 
(which was observed in a different crystal form) is 
placed in the closed conformation's R32 unit cell, 
then residues 130-150 clash with residues in sym-
metry-related molecules. Thus the open confor-
mation cannot be observed in the experimental 
conditions used here. This leads to a second ques-
tion: why does the crystal form at all, if binding of 
calcium has forced the protein into an 'open' con-
formation? The answer to this is probably that the 
enzyme is active between pH 7 and 9 (open form 
crystals are grown at pH 7.5), and the closed form 
crystals used in this work are grown at pH 4.7. 
Thus, we would now hypothesise that the confor-
mation change between open and closed requires 
both the correct pH and calcium binding to the C-
terminal domain. That pH does play a role in Ca2+ 
bindin~ has been found by comparing Kd values 
for Ca + -C-domain binding at pH 4.7 and 8.0. At 
pH 4.7 (the pH of closed form crystals), the affinity 
of Ca2+-binding as determined by near-UV CD 
was slightly lower (Kd ~ 400 J.lM) than at pH 8.0 
(Kd ~ 200 11M). Also, a closed form structure 
solved from crystals grown at pH 7.5 is consider-
ably more disordered in the loops that change con-
formation between the open and closed forms (Dr 
A. K. Basak, personal communication) suggesting 
pH plays a role in determining their conformation. 
Differences between calcium binding to the 
closed form and cadmium binding to the 
open form 
Cadmium was present in the crysta llisation con-
ditions for the open form at high (SO mM) concen-
tration and, in addition to Cd13, which was 
observed bound to the open fo rm in the same site 
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as Cal in this work, a total of nine other cadmium 
ions were observed bound to the surface of the 
enzyme (Naylor et al., 1998). Cd13 was the only 
ion identified with calcium binding in the earlier 
work, as this site was supported by site-directed 
mutagenesis data (Guillouard et al., 1997). The high 
concentration of cadmium ion made distinguishing 
between specific and non-specific binding imposs-
ible for any site not supported by additional data. 
One of the other cadmium sites, Cd9, is just 3.1 A 
from the site described as Ca2 here, while another, 
Cd12, is 3.4 A from Ca3, when the two C-terminal 
domains are optimally superposed (see Figure 2(a) 
and (b)). However, if these sites are specific, and if 
cadmium is an analogue of calcium, we would 
anticipate that Cd9 and Cd12 should be as close to 
the true calcium-binding sites, identified here, as 
Cd13 is to Ca1 (the latter two are just 0.2 A apart). 
Inspection of the two sites shows that, in each 
case, binding has been disrupted by the close 
approach of a symmetry-related C-terminal 
domain (Figure 11). Instead of their co-ordination 
spheres being completed by water (as for Ca1, 
Ca2, Ca3 and Cd13), they are completed by aspar-
tate residues from the symmetry-related molecule. 
The ligands for Cd9 are 0 51 and 0 52 from Asp293 
in one molecule, 0 51 and 0 52 from Asp63 in the 
symmetry-related molecule. Cd12 is ligated by con-
served aspartate residues from both molecules: 0 61 
from As.n297, in the molecule and the symmetry-
related molecule, and 0 61 and 0 52 from Asp273 
again in both the molecule and the symmetry-
related domain. These residues are involved in 
binding Ca3 in a single molecule of the structure 
reported here. The close approach of aspartate resi-
dues from the symmetry-related molecule is evi-
dently sufficient to seriously disrupt the natural 
calcium-binding sites. 
Conclusions 
Specific binding of calcium ion to the C-terminal 
domain of C. perfringens ex-toxin has been observed 
spectroscopically and crystallographically. Spectro-
scopic data have suggested a change of environ-
ment for at least one tryptophan residue in the C-
terminal domain, which is explicable in the light of 
the crystallographically observed calcium ions. The 
crystallographic data have shown that calcium is 
not sufficient to induce a conformation change 
from an open to a closed form. However, they 
have shown that calcium binding does create a 
hydrogen bond between the N and C-terminaJ 
domains (Tyr62 to Asn294), thereby allowing the 
binding of calcium to the C-terminal domain to be 
communicated to the active site. 
Materials and Methods 
Materials 
Recombinant ex-toxi n, strain NCTC8237 and C-term-
inal domain (247-370) from NCTC8237 used in the spec-
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Figure 11. Distortion of calcium-binding sites in the 
open crystal form. The C-tenninal domain from one 
molecule is shown ns a secondary structure cartoon, 
whilst its symmetry mate is shown as a grey trace. Cad-
mium ion ligands are shown in ball-and-stick for the 
original molecule and grey bonds for the symmetry 
mate. Note how Cd13 is undisturbed, but both Cd9 and 
Cd12 have their binding sites completed by the sym-
metry-related molecule. 
troscopic studies were purified according to the methods 
of Basak et a/ {1994) and Titball et al. {1993). General lab-
oratory chemicals of the highest available quality, and 
those used for the binding studies, were supplied by 
either Sigma (Poole) or BDH (Poole). 5-NBAPTA was 
obtained from Molecular Probes (Leiden). Chelex 100 
was supplied by Bio-Rad (Hemel Hempstead). Tris buf-
fer was supplied by Fisher Scientific, UK. 
Crystallisation 
C. perfrm~ells :x-toxin strain NCTC8237 was used to 
grow R32 (closed) form crystals as described by Basak 
et al. (1998). The protein was concentrated to approxi-
mately 10 mg ml for crystallisation by precipitation in 
acetone, and resuspended in 10 mM Tris-HCI (pH 7.5) 
containing 5 mM ZnC12. Calcium chloride to a final 
concentration of 50 mM was then added to the protein 
solution that was used for growing calcium-bound crys-
tals. Crystals were grown by the hanging drop vapour 
diffusion method, with wells containing 1.8 M NaCI, 
in 100 mM sodium acetate at pH 4.7. Crystals grew 
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after approximately two weeks, with dimensions 
0.3 mm x 0.3 mm x 0.2 mm. Both calcium-bound and 
calcium-free forms appeared isomorphous with the pre-
viously grown R32 closed crystal form of the CER89L43 
strain a. T. Eaton et al., unpublished results). 
Data collection 
Data for both the native and calcium-bound crystals 
were collected from crystals flash-frozen following 
immersion in mother liquor containing 25% (v /v) gly-
cerol as a cryoprotectant as described (Carmen & 
Mitchell, 1997). CaC12 (20 mM) was also added to the 
solution if the crystals had been grown in the presence 
of calcium ion. All data were collected at station 7.2 of 
the synchrotron radiation source at Daresbury Labora-
tory of the CCLRC (A.= 1.488 A) using a MA Research 
30 cm Imaging Plate, the NCTC native crystal diffracted 
to beyond 2.6 A, while the calcium-bound crystals 
diffracted to a minimum of 2.2 A. Initial indexing of the 
diffraction patterns indicated both crystals were of space-
group R32 with two molecules in the asymmetric unit 
and cell dimensions, a= b = 149.5 A, c = 193.8 A, 
VM=2.42 A1/DA, for the NCTC native, and 
n=b=149.9A, c= 192.9A, V"'=2..l2 A3/DA for cal-
cium-bound crystals. This confirmed their isomorphism 
with the previously described :x-toxin strain CER89L43 
closed form crystals. Data for both crystal forms were 
integrated with DENZO (Otwinowski & Minor, 1997). 
and subsequently scaled and merged using SCALA 
(Evans, 1993), part of the CCP4 program suite (CCP4, 
1994). Statistics for the two data sets are shown in 
Table 3. 
Structure solution and refinement 
The CER89L43 closed form structure a. T. Eaton et al., 
unpublished results) was used to generate initial phases. 
The same reflections were selected for cross-validation in 
both the NCTC native and calcium-bound datasets as 
had been selected for cross-validation in the CER89L43 
closed form. A rigid body refinement was immediately 
carried out (Brunger, 1992) using reflections between 8.0 
and 3.0 A for each dataset. Following this, the R-factor 
and R1, • .., were, respectively, 35.2 and 36.0% for the 
NCTC native and 34.4 and 39.2 °'<> for the calcium-bound 
structure. Initial maps were generated using SigmaA 
weighting (Read, 1986), and NCS-averaging and solvent-
flattening options in the program DM (Cowtan, 1991) 
from the CCP4 package. There was density in the initial 
difference Fourier maps supporting the presence of the 
expected five amino acid sequence differences between 
the CER89L43 and NCTC8237 strains. Models were 
fitted to each dataset, by manual rebuilding followed by 
automatic refinement using XPLOR. A bulk solvent cor-
rection was applied, using the Auto-sol routine available 
in XPLOR 3.8, to both sets of data, allowing all reflec-
tions to be used in refinement. For the NCTC native, the 
solvent parameters were: k = 0..!, 8 = 21 A2; for tht:! 
calcium-bound structure they were: k = 0.37, 8 = 19 A2• 
Non-crystallographic symmetry (NCS) restraints were 
used throughout, though these were relaxed where clear 
evidence in the calculated electron density map indicated 
a difference between the two molecules. There was no 
evidence for differences between the two NCS..related 
molecules in the region of the calcium-binding sites. 
Even after restraints had been lifted, the rms deviation 
for C" atoms within 5.0 A of a calcium site was 0.03 A 
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Table 3. X-ray diffraction data scaling and merging statistics for both NCTC8237 native and calcium-bound crystals 
Crysta l Res. (A) Nmc<l!~>Urt.."'.. Numquc 
NCTC 30.0-2.6 98,122 25,328 
Native 2.7-2.6 1-!,192 3939 
Calcium-bound 50.0-2.2 134,096 42,803 
2.3-2.2 16,154 585-l 
for the NCTC native (NCS restraints had been kept tight 
for this lower-resolution structure), and 0.2 A for thecal-
cium-bound structure (NCS restraints had been loosened 
somewhat in the final stages of refinement). The differ-
ences that occurred in both structures in the C-terminal 
domain were due to the flipping of the C-terminal car-
boxylate group between two possible hydrogen bond 
donors. Water molecules were added in both structures 
at stereochemically sensible places, where there was a 3cr 
peak in difference electron density and a lcr peak in the 
2F, - F, map. Statistics for the final model for each data-
set are given in Table -l. 
Protein Data Bank accession codes 
Coordinates and structure factors have been deposited 
in the Protein Data Bank with identity codes 1QM6 for 
the native and 1QMD for the calcium-bound structure. 
Sample preparation for spectroscopic studies 
Protein concentration was determined spectrophoto-
metrically. Theoretical absorption coefficients of 
A~"~m = 2.3 cm- 1 (mg ml- 1) for holotoxin, and 1.87 
cm- 1 (mg ml - 1) for the C-terminal domain based on 
U1e extinction coefficients determined for individual aro-
matic amino acids were calculated (Mach et al., 1992). 
Molecular masses of -!2,500 Da and 14,400 Da were used 
for the ::t-toxin and C-terminal domain, respectively, and 
aromatic contributions amounted to 11 Trp and 26 Tyr 
for :x-toxin and three Trp and seven Tyr for the C-
terminal domain alone (Titball et al., 1991). Samples for 
spectrophotometric experiments were typically diluted 
in 10 mM Tris-HCl (pH 8), 150 mM NaCl buffer (Sigma, 
Poole) which had been passed down a Chelex 100 
column to provide calcium-free buffers. Calcium-free 
buffers were pH adjusted (to pH 8.0) with concentrated 
hydrochloric acid . Ca2+-free protein was p repared (for 
calcium titrations) by treating ':!-toxin with 5 mM ECTA 
(Sigma, Poole), prior to desalting on two PD 10 columns 
Table 4. Refinement statistics 
N rc0L.'f>hnt\.'o R-factor (%) 
Work Free Work Free 
NCTC 2-!,872 1291 22.0 24.7 
ea-bound 39,611 2116 18.3 25.7 
'Yo most Rmsd 
favoured in 
Ramachandran Bond (A) Angle (deg.) Main 
NCTC 89..1 0.009 1.3 17.6 
Ca-bound 88.6 0.022 2.6 31.5 
Completeness 
Redundancy Rm,•r;;< ("'<>) I/ cri (01,) 
3.87 12.1 8.8 90.5 
3.6 33.6 -!.2 87.9 
3.1 5.9 1-l. l 97.8 
2.8 15.2 6.5 92..1 
(Pharmacia, Sweden) of 10 ml volume and eluting with 
Chelex-treated calcium-free buffer (10 mM Tris-HCl 
(pH 8), 150 mM. NaCI), according to methods outlined 
by Martin et al. (1996). Typically, residual calcium levels 
in supposed calcium-free buffers were of the order of 
1-2 ~1M as determined using 5-NBAPTA. 
Circular dichroism 
CD spectra were obtained using a Jasco J-720 spectro-
polarimeter Oasco, Japan) at 25(±1)°C unless noted 
otherwise. The results have been corrected for pathlength 
and protein concentration and are expressed as molar 
CD absorption (Llc) in M 1 cm- 1• For near-UV, the 
molar protein concentration (mol/1) is used; for far-UV, 
the mean residue molar concentra tion (moll- 1 x no. resi-
dues) is used. The bandwidth employed was either 1 or 
2 nm and the response time was one second. Spectra 
were recorded between 178 or 180 and 260 nm for far-
UV using 0.01 cm demountable and 0.05 cm cylindrical 
quartz cells, and between 250 and 320 nm for near-UV 
using 1 cm pathlength quartz cuvettes (HeUma GmbH, 
Germany). Data were collected at 0.5 nm intervals, aver-
aging fo r 9, 16 or 25 scans. Spectra were corrected 
by subtracting a similarly averaged 10 mM Tris blank. 
The instrument was calibrated using ammonium d-(+)-
camphor-10-sulphonate Oasco, Japan) as a reference 
standard. 
The software programme Varslc1 was used to com-
pare the amount of secondary structures from CD data 
between 178 and 260 nm with a 33 protein basis set. 
Variable selection with singular value decomposition, 
results in values for five secondary structure elements 
(Mana va lan & Johnson, 1987; Bloemendal & Johnson, 
1995). 
Fluorescence spectroscopy 
Fluorescence spectra were obtained using a Spex 
Fluoromax single photon-counting spectrofluorometer at 
N .liOffi'!> Cruickshank ESU 
Protein Water Other All Free 
6012 91 -l 0.30 0.3-l 
6028 315 10 0.27 0.23 
Average B (A! ) All C' rmsd 
between A and B 
Side Other chains (A) 
19.5 16.7 0.113 
35.6 32.1 0.256 
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25 °C in 1 cm quartz cells (Hellma GmbH, Germany) 
with a sample that typically gave 0.05 absorbance unit at 
280 nm in a spectrophotometer. The instrument was cali-
brated using the 397 nm water Raman emission after 
excitation at 350 nm, and by the 435.8 nm mercury emis-
sion line. Excitation wavelengths of 280 nm and 295 nm 
were employed with a band pass of 4.25 nm on both 
excitation and emission monochromators. Data were col-
lected at 1 nm intervals between 260 nm and 500 nm 
with an integration time of one second. Fluorescence 
spectra were corrected by subtracting the corresponding 
base-lines and A.max values obtained are typically accu-
rate to ±0.5 nm. 
Calcium binding studies 
The calcium-free C-terminal domain of ex-toxin was 
titrated in the presence of the chromophoric chelator 5-
NBA.PTA as described (Linse et al., 1988, 1991; Martin 
et al., 1996) using a Cecil UV /Vis CE6603 spectropho-
tometer. All experiments were performed at 25 oc using 
cuvette temperature control. Calcium titrations were per-
formed by sequential additions of 1-5 J.il of freshly pre-
pared 0.005 M, 0.01 M and 0.1 M calcium chloride 
solution to a millilitre of 50 J.iM chelator (in 10 mM Tris-
HCI (pH 8.0), 150 mM NaCl) in a quartz cuvette. Protein 
concentrations were of the order of 33 J.iM. Kd determi-
nations were done using the program EqFit (Stephen R. 
Martin, National Institute for Medical Research, UK). 
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Opening of the active site of Clostridium perfringens a-toxin 
may be triggered by membrane binding 
R. W. Titball 1, C. E. Naylor2, J. Miller1, D. S. Moss2, A. K. Basak2 
1 Defence Eva luation and Research Agency, CBD Po rron Down, Salisbury, Wilts, UK, SP4 OJQ 
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Abstract 
On the basis of amino acid sequence homologies with other phospho lipases C, the a-toxin o f Clos-
tridium perfringens was predicted to be a two-domain protein . Using truncated fo rms of a-toxin 
the phospho lipase C active sire was shown to be located in the am ino-termina l domain. Crysra llo-
graphic stud ies have confirmed th is o rgan isatio n and have a lso revealed that the carboxy-rermina l 
domain is structura lly similar to the phospholip id-binding domains in eukaryotic proteins. This in-
format ion has been used to devise a model predicting how a -toxi n interacts with membranes via 
calcium-mediated recognitio n of phospho lipid head groups and the interactio n of hydrophobic 
amino acids with the phospho lipid ra il group. The binding of a-toxin to membranes appears to re-
sult in the opening of rhe active sire a llowing hydrolysis of membrane phospho lipids. 
Key words: Clostridium perfringens- a tox in - crystal structure 
Introduction 
C. perfringens is a G ram-positive anaerobe which is 
found in the gut, in soil and in decaying organic mat-
ter (Willis, 1969). The bacterium is capa ble of produc-
ing a range of exotoxins and the differential produc-
tion of these tox ins is used to type different st ra ins of 
the bacterium into one o f five biotypes (A-E). Whilst 
biorype B, C & D stra ins are associated with disease in 
anima ls, biotype A stra ins are associated with gas gan-
grene in ma n (McDonel, 1986). This disease is the con-
sequence of the entry of either vegetative cells o r spores 
into tissues which a re sufficiently anoxic to allow 
growth of the bacteria . In rea lity this means tha t only 
wounds which a lso resu lt in da mage to the loca l blood 
supply or wounds which occur in individua ls w ith pre-
existing damage to the vascula r system support the 
growth of the bacteri um (Will is 1969; MacLennan, 
1962). 
Since the early 1940s a -toxin has been implicated as 
the main virulence determinant produced by biorype A 
strains of the bacter ium associa ted with gas gangrene. 
H owever, it was not until relatively recently that the 
role of this toxin in disease was proven by two inde-
pendent groups. ln a n elegant study reported by Awad 
et a l. ( 1995 ), an a-toxin-negat ive mutant o f C. per-
fringens was constructed and shown to be incapa ble of 
causing gas gangrene in the murine model of disease. A 
second piece of evidence pointing towards the key ro le 
of the toxin in disease was o btained by showing that 
immunisation o f mice w ith a genetically-engineered 
and non-toxic derivative o f a -toxin induced protection 
aga inst experimenta l gas gangrene (Willia mson and 
Titball , 1993 ). 
In additio n to the ro le of a -tox in in gas gangrene, 
several studies have suggested that the toxin plays a 
role in enterotoxaemia in various an ima l species. In the 
case of nec rotic enre riri · in chickens, the disease a p-
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pears to be associa ted with overgrowrh of the bacteria 
in rhe gur wirh the production of a -toxin which ha a 
letha l effect (Baba er a l. , 1992). Interestingly, rhis dis-
ease is becoming much more frequent in counrrie 
w hich have withdrawn the practice o f adding growth-
promoting antibio tics to feeds tuffs. T here is ome evi-
dence tha t simila r overgrowth of the bacterium a nd 
production of the roxin in the gut can result in the 
death of ca lves and piglets (Cygan and Buczck, 1993; 
Ginter er al., 1996). 
A landmark in the history of microbiology, and rhe 
study of diseases ea used by C. perfringens type A, vvas 
the reporting in 1941 that a-roxin was a phospho li-
pase C (MacFa rlane and Knight, 1941 ). This was the 
first re port tha t a bacteria l roxin was an enzyme and 
certainly expla ined the potency of the a-toxin. H ow-
ever, subsequent studies have shown that many o ther 
bacterial phospholipases Care no t roxic. M oreover, a-
toxin is active rowards eukaryotic cells and this can be 
measured as the haemolytic activity whereas many 
o ther bacterial phospholipases C are non-haemolytic. 
These findings have opened opportunities for compar-
isons of the properties of roxic and non-toxic enzymes, 
more recently at the molecular leve l. It is the compar-
ison of the mo lecular architecture of tox ic a nd non-
toxic phospholipases C w hich is the subject of thi s 
chapter. 
Structure-function studies 
The d etermination of the nucleotide sequence of the 
gene encoding a -toxin (cpa} revealed that a 3 70-amino-
acid protein was encoded (Tirball et al., 1989), preceded 
by a signal sequence which directed export from the cell 
(Les lie et a l. , 1989). The a-roxin has since been shown 
to have amino acid sequence homology with a number 
of other Gram-pos itive phospholipases C (Table 1). Al-
though the haemolytic and toxic properties of these en-
Table 1. Properties of zinc-metallophosphol1pases C. 
Zinc-metallophospholipase C 
C. perfringens a-toxin 
Clostridium novyi y-tox1n 
Clostridium blfermentans 
phospholipase C 
Bacillus cereus PC -PLC 
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> 10 !19 
> 10!19 
' the toxicity of pure y-toxm has not been determmed but the tox1oty of cul-
ture f1ltrate IS attnbuted to the toxtn. 
zymes a re differenr, a ll arc inacrivared by zinc-chelaring 
chemicals such as EDTA o r o-phenoanrhro linc and rh is 
g roup of enzymes has collectively been termed rhe zinc-
mera llo phospholipa es C (Titball, 1993 ). In rhe case of 
rhe C. per(ringens CL-toxin, calcium ion have a lso been 
shown to be essential for biological activity but rather 
tha n playi ng a ca talytic role, these ions are rhoughr ro 
play a ro le in binding ro membrane phospho lipids (M o-
reau er a l., 1988). 
A detailed comparison of rhe deduced amino acid se-
quences of these zinc-mera llo phospho li pases revea ls 
rhar they fall into two sub-groups (Tirball , 1993). The 
B. cereus PC-PLC and L. monocytogenes PLC-B form 
a sub-group which lack a C-terminal polypeptide of 
approximately 120 a min acids whilst the other en-
zymes appear ro be o rganised like the C. per(ringens 
a-toxin a t the primary structural level. There is an ob-
vious correlation berween the presence of rhe carboxy-
rerminal polypeptide and rhe haemolytic/toxic activity 
of these phospholipases C (Table 1) suggesting that the 
carboxy-termina l polypeptide plays a key role in these 
activities. 
To determine the significance of this observation, 
genes w hich would encode the N-terminal 250 amino 
acids or the C-terminal 120 amino acids were ex-
pressed in Escherichia coli a nd the recombinant poly-
peptides purified and characterised (Tirball er al., 
1991, 1993). The purified -terminal polypeptide re-
tained the phospholipase C activity of the a-toxin but 
was non-haemolytic and non-toxic (Titball er al., 
1991 ), behaving as a structural and functiona l homo-
logue of the B. cereus enzyme. The possibility that the 
carboxy-termina l doma in possessed these activities 
was disproved, in fact this polypeptide appeared to be 
devoid of any enzymatic o r cytotOxic activity (Titball 
er al., 1993) . However, a mixture of the N- and C-
terminal polypeptides was haemolytic (Titba ll et a ll. , 
1993). These studies provided the first clues that 
a-toxin is a 2-domain protein, and that both the phos-
pholipase C activity and the carboxy-termina l poly-
peptide are required for toxicity. 
Crystallisation 
When rhe cpa gene was expre sed in E. coli the signal 
sequence directed export into the periplasmic space of 
the bacterium (Titball er a l. , 1989). Initia l studie 
howed rhat the a pparent molecu la r weight, the iso-
electric po int and the enzyma ric, haemolytic and lethal 
properties of the recombina nt protein were identica l tO 
the properrie of a -toxin purified from C. perfringens 
culture supernatant (Titba ll et al., 1989). Also, the 
terminal amino acid sequence of the recombinant pro-
tein was identical to rhe 1 -terminus of the prote in 
Conformational change-; of . per(rnzgL'IIS a-roxin upon mcmbr:\nc bind ing 359 
derived from C. per(ringens (Tirba ll er al., 1989). These 
findings indicated that recombina nr a-roxin would be 
suitable for cry tallographic stud ies. Over the past five 
years we ha ve obtained different crystal forms of re-
combinanr a-toxin (Basak er al., 1994, 1998) derived 
from the cloned genes originally isolated from C. per-
(ringens NCTC8237 (the type strain ) and C. per{ring-
ens CER89L43 (Table 2). The deduced amino acid 
equences of the proteins derived from these strains 
show a mino acid sequence differences at 4 positions 
(A174D; T1 77 A; S335P; 1345V), bur these changes do 
not affect rhe enzymaric, haemo lytic or lethal activities 
(Ginter er al. , 1996). 
As expected, the crysta l structure of the C222 1 form 
of the C. per(ringens CER89L43 a -toxin revealed a 
two-domain protein (Naylor et al., 1998). The amino-
terminal domain was composed of 9 a-helices and 
contained three zinc ions. The carboxy-rerminal do-
main was composed of 8 ~-strands in an immuno-
globulin-like fold. The two domains were linked by a 
flexible peptide and by a loop extending from the 
amino-terminal domain which contacted the carboxy-
terminal domain . The topology of the amino-terminal 
domain was similar to the previously reported crystal 
structure of the B. cereus PC-PLC (Hough er al., 
1989), confirming that rhe amino-terminal domain of 
atoxin contained the phospholipase C active sire. Like 
a-toxin, the crystal structure of the B. cereus PC-PLC 
revealed three zinc ions located in the active sire cleft. 
The carboxy-terminal domain of a-toxin showed an 
unexpected structural ana logy with the C2 and C2-like 
domains of eukaryotic phospholipid-binding proteins 
such as synaproragmin, soybean lipoxygenase-1 and rat 
PI-PLC and a lso with human pancreatic lipase (Naylor 
et a l., 1998). These C2 domains are thought to play a 
key role in phospholipid recognition, which for some of 
these proteins, involves calcium ions as binding ligands. 
The structural similarity of the carboxy- rermina l do-
ma in of atoxin with these C2 doma ins suggested a 
common mechanism for the calcium-dependent recog-
nition of membrane phospholipids. 
Open and closed active site forms 
The R32 structure revealed similar overa ll ropology ro 
the C222 1 st ructure but loops surrounding the active 
site cleft were in a di fferent conformation . These struc-
tural cha nges were more o bvious when the electrosta t-
ic surface potentia l of rhe differenr forms of the 
a -toxin were compared . This ana ly ... is revealed that the 
active sire was in an open form , accessi ble to the phos-
pholipid ubstrare in rhe 222 1 crysta l rructure and 
inaccessible in the R32 c rystal structure. The signi fi-
cance of this finding is appa rent when the crysta lli sa-
Table 2. Crystal forms of C perfrmgens a-toxin. 
Ongm of toxm crystal space dm<n molecules/ 
form group asymmetnc 
Unit 
C perfrmgens NCTC 8237 la R32 2.95A 2 
lb R32 2.6A 2 
C perfnngens NCTC 8237 11 (2221 2.1A 1 
C perfrmgens CER89L43 I R32 1.95A 2 
C perfringens CER89L43 11 (2221 2.1A 1 
tion conditions and the crystal unit cells are consid-
ered. The crystallisation buffer yielding C222 1 crystal s 
conta ined cadmium ions, and cadmium ions were 
found bound to surface-exposed regions of the protein 
including some in the C-rerminal doma in. The similar-
ity in charge and molecular size of cadmium and ca l-
cium ions suggested that the cadmium ions might be 
bound in place of calcium ions. At this stage it is nor 
possible to identify wherher some or a ll rhe bound 
cadmium ions are biologically significant. However, 
Guillouard et a l. (1997) have recently identified 0269 
and 0336 as being important for ca lcium-mediated 
activa tion of a-toxin , and we have shown rhar one of 
rhe bound cadmium ions was co-ordinated by rhese 
amino acids and by G271 and A337 (Naylo r er al., 
1998). 
Membrane binding 
and cytotoxic properties 
The C222 1 crysta l structure showed rhar the necessary 
oc tahedral co-ordination of one of rhe cadmium ions is 
provided by rwo protein molecules and that this might 
mimic the interaction of a-toxin with phospholipids in 
ce ll membranes, where phosphate groups would pro-
vide additional calcium co-ordinating ligands. A mod-
el of a-toxin bound to the outer leaflet of the cell mem-
brane (Fig. 1) suggests that calcium ions p lay a key role 
in binding ro phospho lipids. In addition, two hydro-
phobic residues which are exposed to rhe solvent phase 
(\X/2 14 a nd F334 ) are appropriately positio ned to 
interact w ith hydrophobic ta il groups, and a loop in 
rhe carboxy-rerminal domain (residues 329-337) is 
a lso positioned to play a role in membrane binding. 
This model explai ns why zinc-merallopho pho li-
pases C w hich lack a carboxy-rermina l doma in and the 
exposed hydrophobic amino acids ( uch as the B. cer-
eus PC-PLC) are non-haemo lytic, since they presum-
ably cannot bind to and subsequentl y hydrolyse mem-
brane phospho lipid . 
O ur model a lso poses the questio n of why the C. bi-
/ermelltans phospholipase C, which does possess a 




Fig. 1. Model of the interaction of C. perfnngens a-toxm with a cell mem-
brane. 
carboxy-terminal domain, is only weakly haemolytic. 
One explanation is that the enzyme has a low turnover 
rate, but recent studies indicate that the turnover rate 
towards phospholipid in some forms is similar to that 
of a-toxin. To investigate whether differences in the 
carboxy-terminal domain were responsible for the dif-
ferent properties, this domain of the C. bifermentans 
enzyme was replaced with the corresponding domain 
from a-toxin. The resultant hybrid protein was pur-
ified and shown to have increased haemolytic activity 
when compared with the C. bifermentans phospholi-
pase C (jepson et al. 1999). This indicates not only 
that the carboxy-terminal domain plays a key role in 
haemolytic activity but also that subtle differences in 
the precise structure of this domain influence haemo-
lytic activity. The molecular basis of these differences 
in the properties of the carboxy-terminal domains of a-
toxin a nd the C. bifermentans phospholipase C have 
not been determined. However, the 329-337 loop re-
gion of a-toxin, which our model predicts will be in-
volved in membrane recognition, is not identical in the 
C. bifermentans phospholipase C. Amino acid subst i-
tutions in residues which are thought to be important 
for membrane interaction (including T33 1 L and 
F334I) could be responsible for the different properties 
of the carboxy-termina l domains. 
Discussion 
Over the past five yea rs majo r advances have been 
made in understanding the molecula r basis of toxicity 
of the C. per(ringens a-toxin. H owever, many key 
questions sti ll rema in unanswered; is the model ex-
plaining the interaction of a-toxin with membranes 
correct a nd if so what is the molecula r mechanism 
which a llows opening and closing of the active site? 
Can thi information he used to devise novel phanna-
ceutica ls which block the toxic effects of a-toxin? 
Fina ll y, it is becoming apparent that other bacterial 
phospho lipases produced by a wide variety of bacterial 
pathogens play key roles in the pathogenesis of disca c. 
Can the information obtained from the srudy of a-
toxin be used to aid our understanding of the mode of 
action of these enzymes and to devi e nm·el trategies 
for combating these disease ? 
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Differences in the Carboxy-Terminal (Putative Phospholipid Binding) 
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Phospholipases C Influence the Hemolytic and 
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The phospholipases C of C. perfringens {alpha-toxin) and C. bifermentans (Cbp) show >50% amino acid 
homology but differ in their hemolytic and toxic properties. We report here the purifica tion and characteri-
sation of alpha-toxin and Cbp. The phospholipase C activity of a lpha-toxin and Cbp was similar when tested 
with phosphatidylcholine in egg yolk or in liposomes. However, the hemolytic activity of alpha-toxin was more 
than lOO-fold that of Cbp. To investigate whether differences in the carboxy-terminal domains of these proteins 
were responsible for differences in the hemolytic and toxic properties, a hybrid protein (Nb1C.,.) was constructed 
comprising the N domain of Cbp and the C domain of a lpha-toxin. The hemolytic activity of Nb1C.,. was 10-fold 
that of Cbp, and the hybrid enzyme was toxic. These results confirm that the C-lerminal domain of these 
proteins confers different propertie on the enzymatically active N-terminal domain of these proteins. 
In 1941 MacFarlane and Knight (9) reported a breakthrough 
in the understanding of the biochemical basis of bacterial dis-
ease by showing that the alpha-toxin of Clostridium pelfringens 
was a phospholipase C enzyme. This finding prompted a num-
ber of studies to characterize the phospholipases C from other 
species of clostridia in the anticipation that they, too, would 
possess toxic properties. However, this possibility was soon 
disproved by Miles and Miles (J 1), who showed that Lhe Clos-
tridium bifermentans phospholipase C (Cbp) was, by their cri-
teria, nomoxic. Attempts to explain this difference focused on 
the lower phospholipase C and hemolytic activities of the C. 
bifelmenrans enzyme, and MacFarlane ( 10) proposed that the 
toxicity of the C. pelfringens and C. bifermentans enzymes cor-
related with hemolytic activity rather than with phospholipase 
C activity. The molecular basis for these differences have been 
speculated upon but not examined in derail until more re-
cently. The alpha-toxin is now known to be composed of rwo 
domains ( 16). The isolated N-rerminal domain possessed the 
phosphatidylcholine phospholipase C activity of the holotoxin, 
but was devoid of hemolytic and lethal activities, and showed 
reduced sphingomyelinase activity (24). The isolated C-termi-
nal domain was devoid of any detectable biological activity but 
appeared to confer hemolytic, lethal, and sphingomyelinase 
activities on the toxin (22, 24). Studies with site-directed mu-
tants of the toxin have confirmed that N-domain mutants with 
abolished phosphatidylcho li ne phospho lipase C activity a lso 
show loss of hemolytic and le thal activities (5, 13), confirming 
that the phospholipase C activity of the toxin is necessary for 
a ll of the biological activities. 
The crystal structure of alpha-toxin ( 16) reveals that the C 
domain is organized into a ~-sandwich, termed a C2 domain. 
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The C domain of a lpha-toxin has a topology similar to that of 
the ca lcium-dependent phospholipid binding domains of some 
eukaryotic proteins, namely, pancreatic lipase, synaptotagmin 
I, human arachidonate 5-lipoxygenase (HASL), and pho pho-
inositide-specific phospholipase Col ( 15). These eukaryotic 
proteins share little overall sequence homology with alpha-
toxin, but aspartic acid residues involved in calcium binding in 
the C2 domain of HASL are conserved in the alpha-toxin C 
domain (16). Using site-directed mutagenesis, Guillouard et al. 
(6) showed that Asp269 and Asp336 (Fig. I) were essential for 
alpha-toxin activity and suggested that these residues a re in-
volved in calcium binding. Naylor e t al. ( 16) have designated 
the area coordinated by these key aspartic acid residues and 
other residues (Gly271 and Ala337) as a calcium-binding site in 
the C domain of alpha-toxin. 
A comparison of the deduced amino acid sequences of the 
C. perfringens and C. bifermenrans proteins revealed 51% over-
all homology (26), and the amino acid sequence alignment 
suggests that Cbp is also a rwo-domain protein (23. 26). This 
alignment a lso revea ls differences in key residues involved in 
calcium and phospholi pid binding within the C domains. These 
differences in the C domain of Cbp could result in diminished 
calcium binding and therefore reduce the ability of the protein 
to interact with membranes, resulting in its lowered hemolytic 
activity. We have set out to compare the properties of the 
C. perfringens and C. bifermentans phospholipascs C and to 
construct a hybrid fo rm of the C. perfringens and C. bifermen-
tans proteins, with a view towards determining whether the N 
or C domains of these enzymes a re responsible for the differ-
ences in activity of these enzymes. 
IATERIALS A D METHODS 
Chemicals a nd enzymes. All chemicals were oblained from Sigma (Poole. 
United Kingdom) or BDH (Poole, Uniteu Kingdom) unless otherwise slalcd. 
Materials for protein purification were obtained from Pharmncia Biotech. Ma-
terials for DNA purification were obtamcd from Boehringcr Mannhcim (Lewes. 
United Kingdom). 
















FIG. l. Alignment of the deduced amino acid sequences of C. perfringens nlpha-toxin (Cpa) and C. bifemremons phospholipase C (Cbp). Symbols: .t. . region (Ser250 
and Val251 ) at which a unique Aatll restricuon sile (Asp-Val) was imroduceu: •. aspanic acid residues thought to be involved in calcium binding in the C domain of 
alpha-toxin. 
Isolation of DNA. Esclrenclrro coli containing plasmids pi<S<t3, pCBPLC3. or 
paPROM27 were grown in L broth containing ampicillin at 37"C overnight (20). 
Plasmid DNA was isolated from the cell pellet by the Qiagen procedure. 
Ex1>ression of the C. bi/ermentons phospholi pase C gene (cbp). The C. bifer-
mentOIIS phospholipase C gene was amplified by PCR (20) with plasmid 
pCBPLCJ (encoding cbp) as the template DNA and oligonucleotides NbifUP 
(5'-GCTTGGGGCCCAAGATTAGAGGATATTA-3') and CbiRev (5'-TGCT 
CTAGATTATTTATTTATGTAATAAGT-3') for PCR amplification of the 
DNA fragment. The DNA fragmem obtained after 35 cycles of amplification 
(95•c, 15 s; 500C, 15 s; n•c, 30 s: Perkin-Eimer 9600 GeneAmp PCR system) 
was purified, digested with the appropriate restriction endonucleases, ligated 
with plasmid vector paPROM27 containing the alpha-toxin promoter, and trans-
formed into£. coli JM 109 cells by electroporntion (20). Colonies containing the 
cloned cbp DNA fragment were identified by PCR with the oligonucleotides 
NbifUP and CbiRev. 
Nucleo tide sequencing. Extension reactions with dithio threi tol chemistry and 
containing 500 ng of template DNA and 4.8 pmol of primer were prepared by 
using AB! 800 Molecular Biology Labstation Catalyst overnight at 500C. Se-
quence analysis was carried out wilh an Applied Biosystems 373A sequencer. 
The nucleotide sequence of the cpb gene. encoding the C. bifemremons phos-
pholipase C, has been deposited in GenBank (accession number AF072123). 
Cloning of the and C domains. DNA fragments, which encoded the N 
domain of alpha-tolcin or the C domain of Cbp were amplified by PCR (20) with 
ei ther oligonucleotides NbifUP and NbiREV (5'-CGGGGTACCTATGACGT 
CTCCTGTATTTCC-3' ) or oligonucleotides CaUP (5'-TGCTCTAGACCAGA 
CGTCGAAAGAATGTA-3') and CaREV (5'-TGCTCTAGATTATTTTATAT 
TATAAGTTGA-3'). The template DNA for these reactions was ei ther plasmtd 
pi<S<t3 (encoding alpha-toxin) or plasmid pCBPLC3 (encoding Cbp). The DNA 
fragmems obtained after 35 cycles of amplification (95•c. 15 s; 5o•c. 15 s; n•c. 
30 s; Perki n-Eimer 9600 GeneAmp PCR System) were purified, digested with the 
appropria te restriction endonucleases, liga ted with plasmid vector pBiuescript 
KS( +) (Stratagene), nnd transformed into£. coli JM109 cells by e lectroporation 
(20). Colonies containing the cloned DNA fragments were identified by PCR 
wi th the oligonucleotides described above. 
Purification of phospholipase C. Phospholipase C was extracted from the 
periplasmic space of E. coli cells as described previously (25). The phospholipase 
C was purified by using two successive fast protein liquid chromatography 
( FPLC) ion-exchange chromatography steps. The crude extract was initially 
applied to a FPLC anion-exchange chromatography column (3.2 by 25 cm; 
DEAE Sephacel) and eluted with a 0 to 100'0 (0 to I M) sodium chloride 
gradient at a Row rate nf 0.2 ml/m. Fractions ( 10 ml) were collected. and those 
cnntaining phospholipase C were concentrated by stirred-cell ultrafiltration 
(Amicon) under nitrogen pressure through a blocked membrane. The concen-
trated sample was buffe r exchanged into 10 mM Tris-HCI (pH 8.0) anu applied 
to a second anion-exchange chromatography column (MonoQ HR !0/10). Pro-
tein was eluted with a 0 to 100% (0 to I M) NaO gradient at a flow rate of 0.2 
ml/m. For Cbp, the protein was further purified by using a gel filt ration column 
(FPLC; Superose l2) and eluted in phosphate-buffered sa line (0.1 M sodium 
phosphate, 0.9'( !wt/voiJ NaCI; pH 7.2) at a flow rate of 0.2 ml/m. Fractions 
containing phospholipase C were collected manually, pooled, and concentrated 
by stirred-cell ultrafiltration. The concentra ted sample was buffer exchanged into 
10 mM Tris-HCI (pH 8.0). and the final preparations were stored at -200C. 
Protein content was determined by using the bicinchoninic acid protein assay. 
Purified products were analyzed by sodium dodecyl sulfate-10 to 15'"'o polyacryl-
amide gel e lectrophoresis by using a PhastSystem and were judged to be >95% 
pure (Fig. 2). Gels were stained with Coomassie blue R250. The yields of purified 
alpha-toxin, Cbp, and hybrid N";C., were !0, 5, and 15 mg. respectively. 
CD specrroscopy studies. Secondary structures of the purified proteins were 
determined by using circular dichroism spectroscopy (CD) in a Jasco J-720 
spectropolarimeter at 25 :t 1•c. The bandwiuth was either I or 2 nm with a 
response time of I s, and data were collected at berween 178 and 260 nm for 






FIG. 2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of puri-
fied phospholipases C. C. brfmnelllnlls Cbp (lane I), hybrid N",C" (lane 2), C. 
perfringens alpha-toxin (lane 3), and molecular mass weight markers in kilodal-
tons (lane 4) are shown. 
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TABLE I. Comparison of the pho pholipase C activities toward 
different substratcs and the hemnlytie activities of C. perfringens 
alpha-ICixin, C. bifennentmrs Cbp. and hybrid N~,C .. " 
Sp act ( U/mg/60 rn Y' 
Enzyme Egg yolk SPH P\ 
cmulsll1n pNPPC I lcmoly,is liposornes hposomc\ 
Alpha-toxin 64.445 238.000 256.000 290.000 119.400 
Cbp 42,552 10.000 1,933 28.90 1 57,803 
Hybrid Nh,c« 35.705 45.600 21.560 93,586 I 01.022 
"The results arc the mean of five detcrminations (standard deviations .!. 0. I' i. 
SPH. sphingo myelin; P . phosphatidylcholinc. 
far-UV by using 0.01-crn dcmoumablc and 0.05-cm cylindrical quartz cells. Data 
were collected at between 250 and 320nm for ncar-UY by using 1-cm patblength 
quartz cuvcttes (He IIma GmbH) at 0.5-nm intervals. with averaging for 9, 16. or 
25 scans. Varselec I software was applied to the CD spectrum between 17R and 
260 nm, with a 33-protein basis set. to calculate secondary-structure compo;ition. 
Biological activities of the phospholipases C. Phospholipase C activity was 
measured by egg yolk assay emulsion in a microtiter assay (25) or by using a 
modified version of the protocol by Ku rioka et al. (8), with p-nitrophenylphns· 
phorylcholine (pNPPC; 40 mM in water). The absorbance was read at 414 nrn 
(pNPPC) or 540nm (egg yolk) on a Titcrtek Muhiscan MCC/340 Platereader 
(Life Sciences). Liposomcs composed of either phosphatidylcholinc (Lipoid) or 
sphingomyelin encapsula ting carboxylluorescein (CF) were prepared according 
to the method of N:ogahama et al. (14). The liposomes were probe sonicated as 
an additional step after drying and hydration of the liposomes. Phospholipase C 
(100 ~J-1 ), at various concentrations, was incubated with liposomes (100 !J.I) m 
37"C for I h. Fluorescence intensity was measured with a luminescence spec· 
tromcter l..S-5B (Pcrkin-Elmer. excitation at 485 nm, emission at 520 nm). A 
100% CF release was determined by incubation of liposomcs with I 'ic Triton 
X-100 at 37"C for I h. Hemolytic activity was dctem1ined by using mouse 
erythrocytes (5% [vol/vnll) in a microtiter tray assay as described previously (25). 
Toxicity in mice. The toxicity of the pbospholipases C was determined by 
intraperitoneal injection of 50 I-ll of purified toxin (in saline) into groups of four 
BALB/c mice. The mice were monitored for 18 h after injection. 
Complementation of the C domain. The isolated C domain of alpha-toxin was 
incubated with mouse erythrocytes whic.h had been preincubated with phospho· 
lipase C. and the hemolytic activity wa determined as described above. 
RESULTS 
Cloning and expression of C. perfringens alpha-toxin and 
C. bifermentans phospholipase C. C. perfringens NCTC 8237 
alpha-toxin was expressed in E. coli as described previously 
(25). The plasmid-cloned gene encoding the C. bifermentans 
phospholipase (26) (cbp) was nucleotide sequenced, and even 
differences between the previously reported sequence (26) 
were found . These differences resulted in six amino acid se-
quence changes (Tyr31 -+Ser31 , Ser9~-+Ala94, Arg95-+Giu95• 
As"'>6-+Thr96, Ser97-+Gin97, and lle252-+Asp252). The level of 
expression of the cloned C. bifennentans phospholipase C gene 
(cbp) from the native promoter in E. coli was low. To increase 
the level of cxprc sion, the cbp open reading frame was am-
plified by PCR and cloned downstream of the C. perfringens 
alpha-toxin promoter. Nucleotide sequencing of the cloned 
fragment confirmed the au thenticity of the cbp gene. 
Construction of a C. petfringens-C. bifermentans hybrid phos-
pholipase C. Previous studies have shown tha t the C. petfrin-
gens alpha- toxin is composed of two domains (N and C do-
mains) linked by a potentially flexible region (16). An 
alignment of the deduced am ino acid sequences of the a lpha-
toxin and Cbp (Fig. I) suggc tcd a similar o rgan ization of these 
proteins. and we con idcred that by modifying the tinker region 
( e r2.,0-Val2., 1 in alpha-toxin or A PmrA n25 t in Cbp) to en-
code Asp-Val in both proteins we would be able to introduce 
a unique A(//11 restriction site into the coding DNA. To intro-
duce this site, the regions of DNA encoding the N domain of 
Cbp or the C domain of a lpha-toxin were amplified by PCR 
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with appropriately tailed PCR primers. The change in the 
amino acid sequence did not affect the pho pholipase C or 
hcmolytic activit ie of alpha-toxin or Cbp (data not shown). To 
construct the hybrid pho pholipasc C, the DNA fragment en-
coding the N domain of Cbp was fused with the C. petfringens 
cpa promoter sequence. The DNA fragments were ligatcd at 
the Aatll site to genera te a gene encoding a hybrid C. petfrin-
geiiS-C. bifermemans pho pholipase C (hybrid N",C"). 
CD spectroscopy study of the enzymes. Purified alpha-toxin, 
Cpb, or hybrid N0 ;C,. were analyzcd by using circular dichro-
ism spcctroscopy. Secondary-structure composition was deter-
mined with Varselec I software applied to the CD spectrum at 
between 178 and 260 nm with a 33-protein basis set. The a lpha-
toxin was shown to consist of 43% a -helix, 12% J3-sheet, and 
16% turn, which is consistent with the crystal structure data 
(44% a -helix. 18% J3-shcet. and 4% turn (15a]). Cbp contained 
40% a-helix, 15% J3-sheet, and 15% turn. Hybrid Nb;C.,. consist-
ed of 43% a -helix, 15% J3-shcet, and 15% turn. 
Phospholipase C: hemolytic and lethal activity of the a lpha-
toxin and Cpb. The specific activities of a lpha-toxin o r Cbp 
were determined by using a varie ty of assays. The activity of the 
alpha-toxin or Cbp towards sphingomyel in liposomes was in-
creased 127- and 146-fold , respectively (mean of three deter-
minations), when the assay were carried out in the presence of 
2.5 mM Ca2+ . Enhancement of activity towards murine eryth-
rocytes in the presence of 2.5 mM Ca2 + was a lso observed 
(data not shown). All subsequent assays were carried out in the 
presence of 2.5 mM Ca2+ ions. 
The alpha-toxin was more active in a ll of the assays com-
pared with the o ther enzymes (Table 1). However, the ratio of 
a lpha-toxin activity to Cbp activity depended on the form of 
the substrate. When phosphatidylcholine in egg yolk or in 
liposomes was used, a lpha-toxin was twice as active as Cbp. 
When tested with sphingomyelin liposomcs, alpha-toxin was 10 
times as active as Cbp. When a syn thetic substrate with the 
phosphorylcholine head group linked to p-nitrophenyl (pNPPC) 
was used, alpha-toxin was 24 times as active as Cbp. The he-
molytic activi ty of alpha-toxin was 132 times that of Cbp when 
tested with mouse erythrocytes. When administe red intraperi-
toneally into mice, 10 f.l.g of Cbp did not cause any deaths over 
a period of 18 h, whereas I f.l.g of alpha-toxin resulted in the 
death of a ll of the mice within 2.5 h (Table 2). 
Phospholipase C: hemolytic and lethal activity of hybr id 
Nb1C ... The replacement of the C domain of Cbp with the 
corresponding region from alpha-toxin yie lded an enzyma ti-
cally active protein (Nb;C.,.) which, on the basis of CD analysis, 
was correctly folded. The hybrid phospholipase C had proper-
ties tha t were intermediate between the two parent enzymes 
(Table 1 ). The specific activity of hybrid biCa was broadly 
simila r to alpha-toxin and Cbp when tested with egg yolk phos-
TABLE 2. The toxicity of C. perfiingens alpha- toxin. C. bifennentans 
Cbp, or hybrid N,,c .. when administered intraperitoneally 
to BALB/c mice and monitored for 18 h 
D<l>C o. or death>~ 
Enzyme aumini>rered total no. of 
(~J.g) mice 
Alpha-toxin 6/6 
Cbp I 0/6 
10 016 
Hybrid Nh,c .. I 0/6 
10 6/6 
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phatidylcholine or with liposomes composed of phosphatidyl-
choline. The activity of hybrid N";C., was greater than the 
activity of Cbp when as ayed with liposomes composed of 
sphingomyelin. The hcmolytic activity of hybrid N";C., was 
increased 10-fold compared to Cbp but wa lower than the 
activity of the alpha-toxin. When ad ministered intrapcri tonc-
ally into mice, hybrid N1,;C., phospholipase was intermediate in 
toxicity between Cbp and alpha-toxin (Table 2). 
Complementation of the C domain. Guillouard et a l. (6) 
reported that mutation of residue Thr272 to Pro272 in a lpha-
toxin results in the abolition of phospholipase C and hemolytic 
activity. They further reported that hemolytic activity was re-
stored when the isolated C domain of alpha-toxin was added to 
a solution of this mutated protein. When purified C domain of 
the alpha-toxin was added to a solution of alpha-toxin (78 
hemolytic units [HU)) or Cbp {14 HU), there was no signifi-
cant increase in the hemolytic activity of either of these en-
zymes (86 and 13 HU, respectively; all data are the mean of 
two determinations). 
DISCUSSION 
Phospholipases produced by pathogenic bacteria have been 
shown to play a variety of roles in the pathogenesis of disease 
(12, 21, 23). In the case of alpha-toxin, the enzyme has been 
shown to activate the arachidonic acid cascade and protein 
kinase C in eukaryotic cells (4, 7, 18, 19), and the toxic effects 
(1) might be a result of this perturbation of host cell metabo-
Jjsm. These changes in host cell metabolism are a result of the 
accumulation of diacylglycerol within the host cell, and the 
ability of bacterial phospholipases C to hydrolyze membrane 
phospholipids, yielding diacylglycerol, provides an obvious role 
for these enzymes in this process. Within cell membranes the 
phospholipid head groups are packed together, shielding the 
ester bond which is the target of the alpha-toxin (2). Therefore, 
it has been suggested that alpha-toxin is able to insert into the 
cell membrane (16). Hemolysis is often used as an indicator of 
activity towards membrane phospholipids. 
The C. bifennentans Cbp has been shown to be nontoxic and 
weakly hemolytic when compared to alpha-toxin (26), and pre-
vious studies have suggested that these properties can be ex-
plained by the correspondingly reduced phospholipase C ac-
tivity (23, 26). Our findings indicate that the phospholipase C 
activity of Cbp towards some substrates, such as egg yolk pho -
phatidylcholine or phosphatidylcholine liposomes, is close to 
the activity of alpha-toxin. Several studies have suggested that 
the ability of some bacterial phospholipases to cause hemolysis 
is due to their ability to hydrolyze both phosphatidylcholine 
and sphingomyelin {17, 23, 24), and it may be significant that 
Cbp was 10-fold less active than alpha-toxin toward sphingo-
mye lin in liposomes. However, this difference in substrate pref-
erence does not provide a full explanation for the > I 00-fold 
difference in the hemolytic activity of Cbp and alpha-toxin. Our 
finding that purified alpha-toxin was a t least 10 times as toxic 
to mice as Cbp lends support to the suggestion that hcmolytic 
activity provides an in vitro indicator of toxicity. 
Crystallographic studies show that alpha-toxin is compo cd 
of an active site domain (N domain) and a calcium-binding 
domain (C domain) , which arc linked by a flexible peptide 
{16). Removal of the C domain from alpha-toxin abolished 
hcmolytic activity (but not the phospholipase C activity), and 
antisera against the C domain neutralized hemolytic activity 
(27), cyto toxicity towards UDP-glucosc-deficient cells (3) , and 
le thality (27). lt is possible that this domain plays a role in the 
recognition of membrane phospholipids. Naylor et al. ( 16) 
have constructed a model indicating how urface-cxposcd hy-
INFECT. IMM UN. 
drophobic side chains (TyrJJ I and PhcJJ .. ) and calcium ions 
coo rdinated by the phospholipid phosphate group and the C 
domain a llow alpha-toxin to become inserted into membranes. 
Our finding that the activity of alpha-toxin and Cbp were 
similarly stimulated by Ca2 + ions and that, with the exception 
of Asp269 {Tyr in Cbp), Ca2 "' -binding ligands are conserved in 
both alpha-toxin and Cbp indicates that the differences in 
cytolytic properties of the c proteins arc not due to differences 
in Ca2 + -mediated recogn ition of phospholipids. However, 
Tyr33 1 and Phe33., in the C domain of alpha-toxin arc replaced 
in Cbp by residues, which arc unlikely to play similar roles (Lcu 
and lie, respectively) . 
The data we have reported here provide the first evidence 
that the function of the C domain of alpha-toxin and Cbp are 
not identical. Replacement of the Cbp C domain with the C 
domain from alpha-toxin enhanced the hemolytic activity of 
the enzyme 10-fold, which would be expected if the C domain 
plays a key role in membrane phospholipid recognition. How-
ever, structural motifs in the N domain are also thought to play 
a ro le in the recognition of membrane phospholipids (Trp214). 
This would explain why replacement of the Cbp C domain with 
the alpha-toxin C domain did not fully restore hemolytic ac-
tivity. Although Guillouard e t al. have shown that the low 
hemolytic activity of mutated forms of alpha-toxin could be 
complemented by adding the wild-type C domain of alpha-
toxin, we were not able to demonstrate a similar effect by 
adding the alpha-toxin C domain to Cbp. 
The finding that replacement of the Cbp C domain with the 
C domain from alpha-toxin increased its activity toward pNPPC 
was unexpected because this substrate lacks a hydrocarbon ta il 
group. In previous studies with the alpha-toxin it was shown 
that removal of the C domain increased the activity of the 
enzyme toward pNPPC, a result which was att ributed to the 
enhanced accessibili ty of the active site (24). Although the 
overall conformation of Cbp appeared to be similar to that of 
alpha-toxin. it is possible that the different C domains modify 
the accessibility of the active site to pNPPC. The determina-
tion of the structure of the Cbp might answer this question. 
The findings reported here suggest a similar phospholipid-
recognizing role for the C domain in other hemolytic zinc-
metallophospholipases C, such as the C. novyi gamma-toxin. 
Whether other bacterial phospholipases such as those pro-
duced by Mycobacterium tuberculosis and Pseudomonas aent-
ginosa possess similar phospholipid-binding domains awaits 
investigation. However, the overall amino acid sequence ho-
mology between the alpha-toxin C domain and the calcium-
dependent phospholipid-binding domains of synaptotagmin, 
phosphatidylinositol phospholipase C, and pancreatic lipase is 
low {15, I 6) . and the identification of domains with similar 
functions in other hemolytic bacterial phospholipases C may 
not be possible on the basis of sequence homology alone. 
Neverthele s. it seems likely that these hemolytic enzymes do 
possess specialized features which a llow membrane phospho-
lipid recognition. 
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A Chinese hamster cell line with a mutation in the 
UDP-glucose pyrophosphorylase (UDPG:PP) gene lead-
ing to UDP-glucose deficiency as well as a revertant cell 
were previously isolated. We now show that the mutant 
cell is 105 times more sensitive to the cytotoxic effect of 
Clostridiumperfringens phospholipase C (PLC) than the 
revertant cell. To clarify whether there is a connection 
between the UDP-glucose deficiency and the hypersen-
sitivity to C. perfringens PLC, stable transfectant cells 
were prepared using a wild type UDPG:PP cDNA. Clones 
of the mutant transfected with a construct having the 
insert in the sense orientation had increased their UDP-
glucose level, whereas those of the revertant transfected 
with a UDPG:PP antisense had reduced their level of 
UDP-glucose compared with control clones transfected 
with the vector. Exposure of these two types oftransfec-
tant clones to C. perfringens PLC demonstrated that a 
cellular UDP-glucose deficiency causes hypersensitivity 
to the cytotoxic effect of this phospholipase. Further 
experiments with genetically engineered C. perfringens 
PLC variants showed that the sphingomyelinase activ-
ity and the C-domain are required for its cytotoxic effect 
in UDP-glucose-deficient cells. 
Clostridium perfringens phospholipase C (PLC1), also called 
a-toxin, is the major virulence factor in the pathogenesis of gas 
gangrene (1-3). It is lethal, cytotoxic, hemolytic, necrotizing, 
and induces platelet aggregation (4, 5). This toxin displays 
lecithinase and sphingomyelinase activities, but the molecular 
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mechanism by which it induces an extensive destruction of 
tissues remains unknown (3). 
Structurally, the C. perfringens PLC is a single-chain zinc 
metalloenzyme comprising two domains joined by a hinge re-
gion: a catalytic N-terminal domain of240 amino acid residues 
and a C-terminal domain of120 residues (4, 5). TheN-terminal 
domain has extensive amino acid sequence similarity with the 
nonlethal Bacillus cereus phosphatidylcholine (PC)-hydrolyz-
ing phospholipase C (PC-PLC) (6). The crystal structure of_th~ 
B. cereus PC-PLC was used as the basis for site-directed mu-
tagenesis studies, which indeed showed that the critical amino 
acid residues for Zn2 + binding and catalysis are conserved 
between both enzymes (7-9). The C-terminal domain of the C. 
perfringens PLC, which has no counterpart in the B. cereus 
PC-PLC (10, 11), mediates interactions with membrane phos-
pholipids in a calcium-dependent manner (12). 
A Chinese hamster fibroblast mutant cell line (Don Q) that is 
106 times more sensitive to C. perfringens PLC than the paren-
tal cell (Don wt) was previously isolated (13). Don Q is 104 
times more resistant to Clostridium difficile glucosyltrans-
ferase toxin B (TcdB) (14) than Don wt, due to a UDP-Glc 
deficiency (15) caused by a recessive point mutation in the 
UDP-Glc pyrophosphorylase (UDPG:PP) gene (16). A sponta-
neous revertant cell (Don QR) was isolated from Don Q and 
showed to have the same sensitivity to TcdB as Don wt and a 
partially compensated UDP-Glc level (15, 16). 
UDP-Glc deficiency occurs in cells cultured under hypoxia or 
in low glucose-containing media (17-20). Since these conditions 
are two of the hallmarks of ischemia, it is likely that a low 
UDP-Glc level occurs also in ischemic tissues (16). The aim of 
this work was to determine whether a cellular UDP-Glc defi-
ciency affects the sensitivity to the cytotoxic effect of C. per-
fringens PLC as well as to map which parts of this toxin are 
needed for its cytotoxicity. 
EXPERIMENTAL PROCEDURES 
Cell Cultures-Diploid Chinese hamster lung fibroblasts (Don cells, 
ATCC number CCL 16; Flow Laboratories, Irvine, Scotland; referred to 
here as Don wt), a mutant of this cell line (13) (referred t.o here as Don 
Ql, and a spontaneous revertant of this mutant (16) (referred to here as 
Don QR) were cultivated in flasks (75 or 175 cm2; A/S Nunc, Roskilde, 
Denmark) or in polystyrene 96-well culture plates (Nunc) in Eagle's 
minimal essential medium (Flow) supplemented with 109< feta.l bovine 
serum, 5 mM L-glutamine, penicillin (100 units/m!), and streptomycin 
(100 JLg/ml) in a humid atmosphe re containing 5% C02 at 37 •c. Trans-
fectant cells were cultured in the same medium in the presence of 
geneticin (0.4 !J.g/ml) (Life Technologies, Inc.). 
Production and Purification of Toxins-Wild type recombinant Clos-
tridium. bifermentans and C. per{ringe11S PLCs, mutant variants (HllS, 
This paper is available on line at hltp://www.jbc.org 24433 
24434 Cellular UDP-Glc Deficiency Causes a-Toxin Hypersensitivity 
H68S, and D56N l, and fragments of C. perfringens PLC were expressed 
in Escherichia coli and purified as described previously (8, 21, 22). The 
production oflhe N-terminal C. bifernumtans-C-terminal C. perfringens 
hybrid PLC will be published sepa rately.2 C. diffi.cile TcdB and nonre-
combinant C. perfringens PLC were purified as described (23-25). The 
B. cereus PC-PLC was from Calbiochem (San Diego, CA). 
Protein Determination-Protein concentrations were determined in 
96-well plates us ing lhe Bio-Rad DC protein assay and bovine serum 
a lbumin as a standard. 
Cytotoxicity Assays-Cells were seeded in 96-weU plates (500 to 1000 
cellslweU), cultivated to 90% connuency, and exposed at 37 •c to serial 
10-fold dilutions of the purified toxins: C. difficile TcdB (500 JLg/ml) or 
phospholipases C (recombinant C. bifermentans phospholipase C, B. 
cereus PC-PLC, wild type nonrecombinant or recombinant C. perfrin-
gens PLC) (214 JLg/ml) in 200 ILl of medium/welL Cell viability was 
measured 24 h later using a neutral red assay as described (16). All 
cytotoxicity assays were performed at least three times with 4-6 rep-
licate samples in each experiment. The sensitivity to C. perfringens 
PLC was also determined in the Don wt cell line after a 24-h pretreat-
ment with 2-deoxyglucose ( 15 mg/ml), 2-deoxygalactose (8 mglml), or 
o-galactosamine (6 mg/ml l. 
Choline Incorporation into Membranes-Cell cultures were incu-
bated with 0.4 JLCilml [methyl-3H]choline (Amersham Pharmacia Bio-
tech) for 90 min. The cells were then washed three times with Hanks' 
balanced salt solution and incubated in fresh medium at 37 •c. After 
0.5, 2, 4, and 6 h of incubation, the cellular lipids were extracted with 
chloroform-methanol (26). and the choline incorporated into mem-
branes was measured by counting the radioactivity in the lipid phase 
using a microtiter plate 13-counter. The cpm were related to the amount 
of cellular protein determined in paraUel cultures. 
Stable Transfection of Bovine UDPG:PP to Don Q and QR Cells-The 
bovine UDPG:PP cDNA cloned in pUC18 (27), kindly provided by Pro-
fessor K Tanizawa (University of Osaka), was digested with EcoRI 
(Fermentas AB, Graiciuno, Lithuania). The 1.69-kilobase insert was 
separated in an agarose gel, cut out, eluted using the QlAEX kit 
(Qiagen, Hilden, Germany), and suhcloned in pCDNA3 (lnvitrogen 
Corp., Carlsbad, CA) at the EcoRI site. The ligation product was used to 
transform E. coli JM101 using a gene pulser electroporation instrument 
(Bio-Rad). After isolation of transformants, plasmids were digested 
with Acc651 and Kpnl (Fermentas AB), and the fragments were sepa-
rated in agarose gels to determine the orientation of the insert. The 
Chinese hamster Don Q and QR ceU lines were transfected with the 
pCDNA3 vector containing the UDPG:PP insert in the sense and in the 
antisense orientation, respectively. Transfection was performed using 
Lipofectin (Life Technologies, Inc.) as described previously (28). Stable 
transfectant clones were obtained by minimal dilution and selected by 
cultivation in the presence of geneticin (500 JLg/ml). 
Neutralization of C. perfringens PLC Cytotoxicity -The monoclonal 
antibodies (mAbs) 3A4D10 and 3A4F2 against the holotoxin were pro-
duced and purified as described previously (29). Polyclonal antibodies 
against the recombinant C-terminal domain of C. perfringens PLC were 
generated as described (30). The capacity of these antibodies to neu-
tralize the cytotoxic effect of the recombinant C. perfringens PLC was 
determined by preincubation of this toxin (0.12 JLg/ml) with serial2-fold 
dilutions of the antibodies (initial concentration 1 mg/ml) for 1 h at 
37 •c. Then 200 ILl of the mixtures were added to cells and incubated for 
24 h, the cells were washed twice with phosphate-buffered saline, and 
cell viability was determined using the neutral red assay as described 
(16). 
RESULTS 
Don Q Is Hypersensitive Specifically to the Cytotoxic Effect of 
C. perfringens PLC- As previously shown, Don Q and wt cells 
exhibit the same sensitivity to phospholipases A2 , B, and D, 
whereas Don Q is hypersensitive to the cytotoxic effect of C. 
perfringens PLC (13). To determine whether Don Q is hyper-
sensitive to all PC-hydrolyzing phospholipases C, the sensitiv-
ity of Don wt, Q, and QR to two other phospholipases C was 
studied. The B. cereus PLC showed the same cytotoxicity to the 
three cell lines (Fig. lA) whereas the C. bifermentans phospho-
lipase C was not cytotoxic to any of the cells (data not shown). 
Thus, Don Q seems to show a specific hypersensitivity to C. 
2 A. Howells. M. J epson, H. L. Bullifent, J . Holley, J . Miller, D. Moss, 
and R. Titball. manuscript in prepara tion. 
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FIG. L Dose response of Don wt (A ), Q (e ), and QR (0 ) cells to 
treatment with B. cereus PC-PLC or C. per{ringens PLC. Cells 
were exposed for 24 h at 37 •c to serial 10-fold dilutions of B. cereus 
PC-PLC (A) or C. perfringens PLC (8 ). Cell viability was determined 
using the neutral red assay as described under "Experimental Proce-
dures. • The results are expressed as the percentage of neutral red 
uptake in control cells incubated with only medium. 
perfringens PLC, a hypersensitivity that has been lost in Don 
QR (Fig. lB). 
The C. perfringens PLC Hypersensitivity of Don Q Is Not Due 
to a Decreased Synthesis of PC-Hypersensitivity to C. perfrin-
gens PLC has previously been found in a mutant cell with a 
lowered capacity to synthesize PC (31-33). To determine 
whether the C. perfringens PLC hypersensitivity of Don Q is 
caused by a defective synthesis of PC, we measured the incor-
poration of [3H]choline into the membranes of Don wt, Q, and 
QR (Fig. 2). Since no significant differences in the [3H]choline 
incorporation were detected among the three cell lines, the 
hypersensitivity of Don Q to C. perfringens PLC does not seem 
to be due to a defective PC synthesis. 
The C. perfringens PLC Hypersensitivity Is Due to Cellular 
UDP-Glc Deficiency-Since Don QR has partially compensated 
the UDP-Glc deficiency (16), the results in Fig. 1B suggested 
that a hypersensitivity to C. perfringens PLC is linked to the 
low level ofUDP-Glc. Accordingly, it was observed that Don wt 
cells had an increased sensitivity to C. perfringens PLC after 
treatment with sugar analogues (Fig. 3) known to cause a 
cellular UDP-Gic deficiency by trapping the uridine nucleotide 
pool (34, 35). 
To conclusively clarify the link between UDP-Glc deficiency 
and C. perfringens PLC hypersensitivity, stable transfectant 
cells with bovine UDPG:PP cDNAs were prepared. Don Q cells 
were transfected with a construct having the UDPG:PP insert 
in the sense orientation and Don QR cells with a construct 
having the insert in the antisense orientation. Transfectant 
clones were designated Q Sense (QS) and QR Antisense CQRA), 
whereas clones transfected with only the vector were desig-
nated Q Control (QC) and QR Control (QRC), respectively. 
Since the resistance of Don Q to TcdB is due to its UDP-Gic 
deficiency (15) and this resistance has been lost in Don QR (16), 
we used the sensitivity to TcdB as an indirect measure of the 
cellular UDP-Gic level in the transfectant clones (Fig. 4). Don 
QRA clones were resistant to TcdB, showing that transfection 
with the antisense construct indeed had induced a UDP-Gic 
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Fro. 2. Incorpor ation of Jabeled choline in t he membrane lip -
ids of w t ( A.), Q (e ), and QR (0 ) cells. Cells were incubated with 
(methyl-3 H]choline (0.4 1-'Ci/ml) for 90 min, the choline was removed, 
and normal medium was added. The lipids were extracted after 0.5, 2, 
4, and 6 b with chloroform-methanol as described under "Experimental 
Procedures," and the radioactivity incorporated into membranes was 
measured in a 13-counter. The cpm were related to the amount of 
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FIG. 3. Dose response of Don wt cells p retreated with su gar 
analogues to treatmen t with C. per{ringen s PLC. Cells were 
treated with 2-deoxyglucose (0 ), 2-deoxygalactosamine ~. or D-galac-
tosamine (6) as described under "Experimental Procedures" and then 
exposed for 24 h at 37 •c to serial 10-fold dilutions of C. perfringens 
PLC. Cell viability was determined using the neutral red assay as 
described under "Experimental Procedures." The results are expressed 
as the percentage of neutral red uptake in controls incubated with 
sugar analogues but without toxin. e, control. 
deficiency. Correspondingly, Don QS clones were more sensi-
tive to TcdB than QC clones, demonstrating that the UDP-Glc 
deficiency indeed had been compensated by the transfection. 
This conclusion has been further substantiated by 1H NMR 
measurement of the UDP-Glc concentration in lysates of the 
transfectant cells.3 
The sensitivity of the transfectant clones to C. perfringens 
PLC was then measured (Fig. 5). Don QRA clones were as 
hypersensitive to the cytotoxic effect of this toxin as Don Q. 
Correspondingly, Don QS clones had regained the same rela-
tive resistance to C. perfringens PLC as displayed by Don wt 
and QR. These results therefore demonstrate that a low level of 
UDP-Glc really causes hypersensitivity to the cytotoxic effect of 
C. perfringens PLC. 
The Sphingomyelinase Actiuity and the C-domain Are Re-
quired for the Cytotoxicity of C. perfringens PLC-Using Don Q 
as a model system, we undertook a mapping of which parts of 
the C. perfringens PLC are needed for its cytotoxic effect. Pre-
vious studies with mAbs demonstrated that mAb 3A4D10 neu-
tralized the enzymatic activities of C. perfringens, whereas 
mAb 3A4F2 did not (29). The cytotoxic effect of C. perfringens 
PLC in Don Q was abolished by mAb 3A4D10 but not affected 
by mAb 3A4F2 (Fig. 6A), suggesting that the catalytic capacity 
of C. perfringens PLC is required for its cytotoxic effect on 
UDP-Gic-deficient cells. This was further substantiated by 
3 M. Flores-Dfaz, A. AJape-Gir6n, M. Moos, P. Pollesello, C. Cordula, 
T. Bergman, C. von Eichel-Streiber , I. Florin, and M. Thelestam, manu-
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FIG. 4. Dose r esponse of transfectant clones to t reatmen t with 
C. diffi.cile TcdB. Different clones of Don QR transfected with the 
UDPG:PP antisense cDNA (designated QRA2C5 (0 ), QRA2B4 (0), and 
QRA2B2 (6)) and their control (QRC (e )) (A) and clones of Don Q 
transfected with the UDPG:PP sense cDNA (designated QSG3 (0 ), 
QS20 (0), and QSB9 (A.)) and their control (QC (e )) (B) were exposed for 
24 h at 37 ·c to seriallO-fold dilutions of C. difficile TcdB. Cell viability 
was determined using the neutral red assay as described under "Ex-
perimental Procedures." The results are expressed as the percentage of 
neutral red uptake in controls incubated without toxin. 
studies with enzymatically inactive C. perfringens PLC vari-
ants. Replacement ofHis-11 or His-68 by Ser or Asp-56 by Asn 
resulted in a loss of the enzymatic activities (7-9). All these 
three C. perfringens PLC variants were 104-105 times less 
cytotoxic to Don Q than the recombinant wild type PLC (Fig. 
6B). These results therefore demonstrated that the catalytic 
capacity of C. perfringens PLC is required for its cytotoxic effect 
on UDP-Glc-deficient cells. 
A truncated version of the C. perfringens PLC containing the 
249 N-terminal residues retains the lecithinase activity but 
lacks the sphingomyelinase activity (10). This truncated toxin 
had a cytotoxic potency 106 times lower than the wild type 
enzyme (Fig. 7A). Tbis result therefore demonstrated that the 
cytotoxic effect ofthe C. perfringens PLC requires the C-termi-
nal domain and the sphingomyelinase activity. The data also 
showed that the lecithinase activity is not enough to confer 
cytotoxicity. 
The C-terminal domain, containing residues 247-370, is de-
void of both enzymatic activities of the holotoxin (30). However, 
polyclonal antibodies against the C-domain of C. perfringens 
PLC prevented the cytotoxic effect of the holotoxin in Don Q 
cells in a dose-dependent manner (Fig. 7 B), demonstrating that 
this domain plays an important role in the cytotoxicity exerted 
by this PLC. In addition, the cytotoxic effect was potentiated 
about 102 times when the truncated PLC and the C-terminal 
domain where added simultaneously (Fig. 7A). However, the C. 
perfringens C-terminal domain did not potentiate the cytotoxic 
effect of the B. cereus PC-PLC (data not shown), excluding the 
possibility that a simple complementation of the lecithinase 
with the C-terminal domain would suffice to confer full cyto-
toxicity. Accordingly, when the C-terminal domain of C. per· 
fringens PLC was fused with the N-terminal domain of C. 
bifermentans phospholipase C, this recombinant enzyme (des-
ignated hybrid D) showed a cytotoxic potency 103 times lower 
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FiG. 5. Dose response of transfectant clones to treatment with 
C. perfringens PLC. Clones of Don QR transfected with the UDPG:PP 
antisense cDNA (designated QRA2C5 (0), QRA2B4 (0), and QRA2B2 
(6)) and their control (QRC (e )) (A), and clones of Don Q transfected 
with the UDPG:PP sense cDNA (designated QSG3 (0), QS20 (0), and 
QSB9 (&)) and their control (QC (e)) (B) were exposed for 24 h at 37 •c 
to serial 10-fold dilutions of C. pe1[ringens PLC. Cell viability was 
determined using the neutral red assay as described under "Experi-
mental Procedures." The results are expressed as the percentage of 
neutral red uptake in controls incubated without toxin. 
than that of C. perfringens PLC (Fig. 7C). These results indi-
cate that a specific interaction between the two domains of the 
C. perfringens PLC is required for full cytotoxicity. 
DISCUSSION 
C. perfringens PLC is hemolytic, necrotizing, and lethal, in 
contrast to most other bacterial phospholipases (3) and is con-
sidered the major virulence factor in trauma-induced gas gan-
grene (2, 36, 37). This disease is of increasing significance in 
elderly and diabetic populations, especially in those who have 
undergone lower limb surgery, where impaired blood supply to 
tissues can lead to hypoxic conditions suitable for multiplica-
tion of anaerobic bacteria (38-40). C. perfringens PLC induces 
localized intravascular neutrophil accumulation and platelet 
aggregation, thus reducing the blood supply to tissues and 
further promoting the anaerobic environment required for 
spread of the bacteria (36, 41). 
A UDP-Glc deficiency has been reported in the skeletal mus-
cle of diabetic animals (42-44). This deficiency could be a 
consequence of the defective transport and/or phosphorylation 
of glucose in cells from diabetic subjects (45-47). A UDP-Glc 
deficiency also occurs in cells cultured under low glucose con-
centration or hypoxia (17- 20), two of the hallmarks of 
ischemia. 
The isolation of the UDP-Glc-deficient mutant cell line Don 
Q and its intriguing hypersensitivity to C. perfringens PLC 
were previously reported (13, 15). The reason for the low UDP-
Glc level in this cell is a mutation in the UDPG:PP gene (16). In 
the present work we show that Don Q is specifically hypersen-
sitive to C. perfringens PLC and not to other phospholipases C 
that degrade phosphatidylcholine. Since the revertant cell line 
Don QR has partially compensated the UDP-Glc deficiency and 
lost the C. perfringens PLC hypersensitivity, a link between a 
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FIG. 6. Neutralization of C. perfringens PLC cytotoxic effect 
with mAbs and comparison of the cytotoxicity of recombinant 
C. perfringens PLC and enzymatically inactive variants. A, Serial 
2-fold dilutions of mAbs 3A4D10 <•> and 3A4F2 (0 ) against C. perfrjn- . 
gens PLC were preincubated with recombinant C. per{ringens PLC 
(0.12 !Lglm)) for 1 h at 37 •c. The mixtures were then incubated with 
cells for 24 h . 8, cells were exposed for 24 h at 37 •c to serial 10-fold 
dilutions of recombinant C. perfringens PLC (& ) and the mutated var-
iant PLCs HUS (0), H68S (X), and D56N (0 ). Cell viability was 
determined as described under "Experimental Procedures." The results 
are expressed as the percentage of neutral red uptake in controls 
incubated without toxin. 
gens PLC was hypothesized. Such a link was further supported 
by the finding that cells treated with sugar analogues, which 
induce UDP-Glc deficiency (34, 35), were more susceptible to 
the cytotoxic effect of C. perfringens PLC. Transfection of 
mutant and revertant cells with t he bovine UDPG:PP cDNA 
in sense and antisense orientations affected their UDP-Glc 
levels and indeed changed their susceptibility to C. perfringens 
PLC. Therefore, these results conclusively demonstrate that a 
cellular UDP-Glc deficiency causes hypersensitivity to C. 
perfringens PLC. 
Although a detailed three-dimensional structure of the C. 
perfringens PLC is not yet available, two separate domains 
have been identified: the N-terminal domain, which catalyzes 
phospholipid hydrolysis, and the C-terminal domain, which 
mediates interactions with membrane phospholipids (4, 5, 12). 
Ca2 + is required for the interaction of the toxin with mem-
branes, whereas Zn2 + plays a structural role. Crystallographic 
studies have revealed that the B. cereus PC-PLC has two 
tigh tly bound and one loosely bound Zn2 + ions, which are 
required for the enzymatic activity (48). These Zn2 + ions are 
coordinated to several residues conserved in the C. perfringens 
PLC, which suggests that these two enzymes have the same 
catalytic mechanism. It has been previously shown by site-
directed mutagenesis that the substitution of His-11, His-68, 
His-126, or His-136 in the C. perfringens PLC dramatically 
reduces its lecithinase and sphingomyelinase activities (7, 8), 
whereas their significance for cytotoxicity has not been studied. 
These His residues are very likely involved in the coordination 
of the loosely bound Znh ion, which is required for C. perfrin-
gens PLC binding to membranes (7, 8). On the other hand, 
Asp-56, which is exposed on t he surface within the active site 
cleft of the B. cereus PC-PLC, is also conserved in the C. 
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FIG. 7. Comparison of the cytotoxicity of r ecombinant C. per-
{ringens P LC a nd its fragmen ts. Neutralization of C. per(ringens 
PLC cytotoxic effect with polyclonal antibodies and cytotoxicity of the C. 
bi(ermentans PLC and a hybrid PLC are shown. A, cells were exposed 
for 24 hat 37 •c to serial10-fold dilutions ofrecombinant C. perfringens 
PLC (.t.), the truncated C. perfringens PLC <•>. the C. per(ringens 
C-domain (6), the combination of the two last (0 ), or glutathione S-
transferase (X). B, serial 2-fold dilutions of polyclonal antibodies 
against the C-terminal domain of C. perfringens PLC (El) were prein-
cubated with recombinant C. perfringens PLC (0.12 J.Lg/ml) for 1 h at 
37 •c, and the mixtures were incubated with cells for 24 h . • . control 
without antibody. C, cells were exposed for 24 hat 37 •c to serial10-fold 
dilutions of C. bifermentans phospholipase C (6) and theN-terminal C. 
bi(ermentans-C-terminal C. perfringens PLC hybrid (e ). Cell viability 
was determined using the neutral red assay as described under "Ex-
perimental Procedures." The results are expressed as the percentage of 
neutral red uptake in controls incubated with only medium. 
perfringens enzyme. Replacement of Asp-56 in the latter en-
zyme abolishes its lecithinase and sphingomyelinase activities 
without affecting its membrane-binding capacity (8, 9). 
Neutralization experiments with m.Abs and polyclonal anti-
bodies suggested that both the catalytic capacity and the C 
domain are required for the cytotoxic effect of the C. perfrin-
gens PLC. The enzymatically inactive C. perfringens PLC vari-
ants HllS, H68S, and D56N and the truncated enzyme having 
only the first 249 residues had a markedly reduced cytotoxicity. 
The cytotoxic effect was partially restored when the truncated 
phospholipase and the C-terminal domain were added simul-
taneously. In contrast there was not any potentiation of the 
cytotoxic effect when the B. cereus PC-PLC and the C. perfrin-
gens C-terminal domain where added together. Moreover, the 
hybrid PLC, having the C. perfringens C-terminal domain and 
the C. bifermentans N-terminal domain , displayed a cytotoxic 
potency much lower than that of C. perfringens PLC. These 
results showed that the lecithinase activity is not enough to 
confer cytotoxic activity to C. perfringens PLC and suggested 
that a specific interaction between the two toxin domains is 
needed for full cytotoxicity. ln addition, the data demonstrated 
that both the sphingomyelinase activity and the membrane-
interacting C-terminal domain are crucial for the cytotoxicity of 
C. perfringens PLC to UDP-Glc-deficient cells. 
Treatment of cultured cells with C. perfringens PLC has been 
shown to activate endogenous phospholipases A2 and C, hence 
generating messengers such as leukotrienes, diacylglycerol , 
and inositol 1,4,5-triphosphate (49-52). Therefore we have con-
sidered the possibility that t he cytotoxicity could be mediated 
by the activation of those cellular enzymes. However, we have 
not been able to protect Don Q cells from the cytotoxic effect of 
C. perfringens PLC by pretreatment with (i) inhibitors of the 
arachidonic acid pathway (mepacrine, indomethacin, nordihy-
droguaiaretic acid), (ii) inhibitors of cellular phospholipases C 
or D (D-609, ethanol, neomycin), or (iii) the diacylglycerol 
lipase inhibitor U-57908 (1,6-bis(cyclohexyloximinocarbon-
ylamino)hexane). 4 Therefore, the cytotoxicity of C. perfringens 
PLC on UDP-Glc-deficient cells seems to be independent of the 
activation of endogenous phospholipases. The interaction be-
tween this toxin and the plasma membrane in UDP-Gic-defi-
cient cells may be favored by a putative alteration in the 
composition of the membrane glycolipids or glycoproteins. The 
C. perfringens PLC induces activation of protein kinase C and 
stimulates Ca2 + infl ux into the cytosol, hence modulating a 
variety of cell functions (4, 50). The role of these effects in the 
cytotoxicity of the C. perfringens PLC are currently being in-
vestigated in our laboratories. Regardless of the molecular 
mechanism of cytotoxicity, our results demonstrate that a 
UDP-Glc deficiency sensitizes cells to the cytotoxic effect of C. 
perfringens PLC. In addition the data raise the possibility that 
the low UDP-Glc level occurring in diabetic tissues and cells 
under ischemic conditions predisposes to the extensive tissue 
damage induced by C. perfringens PLC during gas gangrene. 
Concluding Remarks- This work demonstrated that cells 
with a low UDP-Gic level are hypersensitive to the cytotoxic 
effect of C. perfringens PLC. Using genetically engineered vari-
ants of this phospholipase, we showed that the C-terminal 
domain and the sphingomyelinase activity of C. perfringens 
PLC are required for its cytotoxic effect. Since Lowered levels of 
UDP-Glc have been reported to occur in tissues of diabetic 
animals and in cells grown under low glucose concentration or 
hypoxia, we hypothesize that a UDP-Glc deficiency in the tar-
get tissues plays a role in the pathogenesis of gas gangrene. 
Furthermore we suggest that the Don Q cell line can be used as 
a model to elucidate the molecular mechanism of cytotoxicity 
induced by C. perfringens PLC on ischemic tissues. 
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1. SUMMARY 
The a-toxin (phospholipase C) of Clostridium 
perfringens has been reported to contain catalyti-
cally essential zinc ions. We report here that 
histidine residues are essential for the co-ordina-
tion of these ion(s). Incubation of alpha toxin with 
diethylpyrocarbonate, a histidine modifying re-
agent, did not result in the loss of phospholipase 
C activity unless the protein was first incubated 
with EDT A, suggesting that zinc ions normally 
protect the susceptible histidine residues. When 
the amino acid sequences of three phospholipase 
C's were aligned, essential zinc binding histidine 
residues in the non-toxic B. cereus phospholipase 
C were found in similar positions in the toxic C. 
perfringens enzyme and the weakly toxic C. bi-
fermentans phospholipase C. 
2. INTRODUCTION 
Clostridium perfringens is the bacterial species 
most frequently associated with gas gangrene in 
Correspondence to: Richard Titball. Chemical Defence Estab-
lishment, Porton Down. Salisbury. Wiltshire, U.K. 
humans. The ability of the infection to spread 
from an initial focus within damaged tissue, to 
surrounding tissues, is almost certainly related to 
the action of exoproteins produced by the 
bacterium on host cells [11,14). Of the array of 
potential toxic products the alpha toxin, char-
acterised as possessing a phospholipase C activity 
[10,11], is thought to play a major role in the 
pathogenesis of disease [3,11). 
It is not clear at present what the structural 
determinants of toxicity are in the alpha toxin. A 
comparison of the primary structures of the alpha 
toxin and the non-toxic phosphatidyl choline pre-
ferring (PCP) phospholipase C of Bacillus cereus 
has revealed some homology between these two 
proteins [7,16]. The smaller B. cereus enzyme was 
22% homologous with the N-terminal region of 
the C. perfringens protein and both phospholipase 
C's are zinc metalloenzymes [5,8]. Histidine re-
sidues have been reported to play a key role in the 
activity of the B. cereus PCP-phospholipase C [2] 
and it is possible that histidine residues also play 
an important role in the activity of the alpha 
toxin; we have examined this by chemical modifi-
cation. An understanding of the relationship be-
tween structure of the alpha toxin and activity 
should facilitate the development of genetically 
engineered toxoids that can be used as vaccines. 
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3. MATERIALS AND METHODS 
3.1. Purijic01ion of toxin 
Alpha toxin was purified from E. coli Jm101 
containing the C. perfringens (NCTC 8237) a-toxin 
gene cloned into the vector plasmid pUC18 as 
de cribed previously [15]. The final toxin prepara-
tion appeared as a single coomassie blue R250 
staining band after SDS-polyacrylamide gel elec-
trophoresis (Pharmacia Phast 10- 15%). From the 
deduced amino acid sequence the toxin was 
calculated to have a molecular weight of 42 528 
and to contain 9 histidine residues [16]. The pro-
tein content of the purified alpha toxin was de-
termined using the method of Bradford [1], with 
bovine serum gamma globulin as the standard 
protein. 
3.2. Detection of tox in activity 
Alpha toxin activity was determined by measur-
ing the phospholipase C activity of the toxin 
against egg yolk emulsion in a m.icrotitre tray 
assay [16]. In some experiments, p-nitrophenol 
phosphoryl choline (p-NPPC, Sigma, 40 mM in 
250 mM tris-HCI buffer pH 7.2 containing 60% 
vjv glycerol, 2 mM ZnS04 , 5 mM CaC1 2 ) was 
used as the substrate for phospholipase C activity 
(4]. To quantitate a-toxin activity the optical den-
sities of microtitre tray well contents were de-
termined at 620 nm (egg yolk assay) or 410 nm 
(p-NPPC assay), after incubation for 1 h at 37 ° C, 
using a Flow microtitre plate reader. The activity 
of the sample was calculated as the reciprocal of 
the dilution resulting in an OD increase of 0.1 
unit. 
3.3. Protein modification with diethylpyrocarbonate 
All incubations of toxin with protein modifying 
reagents were performed in duplicate at 22 o C. 
Alpha toxin (50 ~tl, 1.84 ~tM in 100 mM acetate-
acetic acid buffer pH 6.5) was first incubated with 
deionised W<)ter (25 ~tl) or EDTA (25 ~tl, pH 6.5, 
final concentration 0.2 mM) for 15 mio and then 
further incubated with deionised water (15 ~tl) or 
divalent cation solution (as chloride salt, 15 ~tl , pH 
6.5, final concentration = 0.37 mM). Diethylpyro-
carbonate (DEPC, Sigma) in anhydrous ethanol 
(10 J..d) was then added to the toxin samples with 
further incubation for 1 h. Ethanol only was ad-
ded to control samples. The stoichiometry of 
DEPC to alpha toxin refers to the molar ratio of 
DEPC to histidine residues in the protein. 
Prior to the determination of phospholipase C 
activity, ZnC1 2j CaC1 2 solution (10 J.d to saturate 
previously added EDT A and provide a 2 mM 
excess of these metal ions) was added to toxin 
samples after incubation with DEPC and the mix-
ture further incubated for 60-min. In some experi-
ments, hydroxylamine solution (11 ~t l , pH 7.0) was 
also added at this stage. 
All experiments were performed at least twice 
and the results presented are typical mean values 
obtained from duplicate samples in a single ex-
periment. 
4. R ESULTS 
4.1 . Tox in inactivation by diethylpyrocarbonate 
Alpha toxin was not inactivated after incuba-
tion with diethylpyrocarbonate at DEPC: histi-
dine molar ratios of 0.1 , 1 or 10 however, some 
inactivation of the toxin (21 %) was found after 
incubation with DEPC at a molar ratio of 100 
Table 1 
Protective effect of divalent cations on EDTA treated a-toxin 




Toxin + EDTA 
Toxin + EDTA + DEPC 
Toxin + EDTA+ZnC1 2 + DEPC 
Toxin + EDTA + CoCl 2 + DEPC 
Toxin + EDTA + MnC1 2 + DEPC 
Toxin + EDTA + CaC12 + DEPC 














a-toxin (0.92 11M) was incuba ted with EDTA (0.2 mM), then 
where appropriate with ZnS04 or CaC12 . After DEPC ad-
dition (mola r ratio DEPC; histidine = 10) the samples were 
finally incubated with 2 mM ZnS0 4 + 2 mM CaC12 and then 
assayed for phospholipase C activity against {a) egg yolk 
emulsion or {b) p-nitropheno l phosphorylcholine. 
(Fig. 1). When the toxin wa first incubated with 
0.2 mM EDTA the inactivating potential of the 
DEP was increased considerably; after incuba-
tion with DEPC at molar ratios of 0.1, 1, 10 or 
100 the residual activity detected was 104%, 59%, 
8% and 1.5% respectively. Incubation of the toxin 
with EDTA only, without the further addition of 
DEPC, resulted in a small decrease in a-toxin 
activity (87% of original activity). In all experi-
ments, the toxin was incubated with 2 mM zinc 
ions and 2 mM calcium ions before determining 
phospholipase C activity. 
The inactivation by DEPC of EDTA treated 
toxin could be prevented if zinc, manganese or 
cobalt ions were added to EDTA treated toxin 
preparations to saturate the EDTA and provide a 
2 mM excess, before DEPC treatment (molar ratio 
= 10). Similar concentrations of calcium or mag-
nesium ions did not protect the toxin from DEPC 
inactivation (Table 1). 
The chemical modification of histidine residues 
by DEPC is known to be reversible by the incuba-
tion of modified groups with hydroxylamine [9,12]. 
To examine this, EDTA treated a-toxin was in-
cubated with DEPC (10 or 100 molar ratio) and 
then further incubated with 10 mM, 100 mM or 
500 mM hydroxylamine. The results (Table 2) 
10 100 
DEPC : o< TOXIN MOLAR RATIO 
Fig. l. The effect of diethylpyrocarbonate ( DEPC) on alpha 
toxin activity. 0 --0= 0.92 J.IM toxin incubated with 
DEPC. t>--t>. = 0.92 J.IM toxin treated with EDTA (0.2 
mM) and incuba ted with DEPC (molar ratio 10). 
263 
Table 2 
Reversible effect of hydroxylamine on DEPC treated a-toxin 
Molar DEPC : llydroxylamine a-toxin activity 
histidine concentration detected after DEPC 
ratio and hydroxylamine 
treatment(%) 
10 : I None 8 
100 : 1 1.5 
10 : I 500 mM 112 
100 : 1 42 
Alpha toxin (0.92 p.M was incubated with EDTA (2 mM) and 
after DEPC treatment (60 min, 22 o C) incubated with hydrox-
ylamine (60 min, 22 ° C). Results are expressed as a percentage 
of the activity determined after incubation of the alpha toxin 
with EDTA only. 
indicated that complete reactivation of the 10: 1 
molar ratio DEPC treated toxin occurred after 
incubation with 500 mM hydroxylamine. Alpha 
toxin treated with DEPC at 100: 1 molar ratio was 
partially reactivated by 500 mM hydroxylamine 
suggesting that DEPC induced imidazole ring fis-
sion or modification of amino acids other than 
histidine occurred under these conditions. 
When these experiments were repeated and the 
alpha toxin activity determined against p-NPPC 
substrate similar results were obtained for all ex-
periments except those involving hydroxylamine 
reactivation of DEPC treated toxin. This result 
may reflect our observation that hydroxylamine 
(500 mM) inhibited the p-NPPC assay. 
5. DISCUSSION 
DEPC is known to be a reagent which reacts 
preferentially with histidine imidazole groups [9]. 
Our results indicate that C. perfringens alpha toxin 
was inactivated on incubation with DEPC only if 
the protein was first incubated with EDTA sug-
gesting that a divalent cation may normally pro-
tect susceptible groups from modification. 
Under some conditions DEPC may react with 
thiol groups, tyrosine residues or a or £ amino . 
groups [9]. Inactivation of the EDT A treated al-
pha toxin by DEPC was observed when the 
stoichiometry of histidine reagent to residues was 
less than 10 : 1 suggesting that histidine residues 
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Bacillus cereus pc phospholipase C ' 
C.perfringens a-toxin > 
C. perfringens a -tox i n 3 
~. bifermentans phospholipase C • 
HKEGVNmiVNRAIDIH- __ -SRNTTLVKQDRVAQLNEWRTELE.NGI2EYYDHSTF1 PDN X IDGTG IVTQGVSI LENDHSXNEPESVRI<NLEI Ll<DNMHELQLGS JIOO\ YD--LY POT Kl DG'!'G I VTQGVSILENDLSXNEQESVRI<NLEILXENMHELQLGS XNAYD--LY POT XIDGTG IVTQGVSILENDLSKNEPESVRXNLKII..NE'lUiDLXLGS PNAYD--LYQ POT 
GXT-------YIPFAX-QAKETGAKYFX-LAGESYKNXDKKQAFFYLGLS.UR~~WO~~~TKLS 










W- - DYSGRE--AII<NSQVCTAGFL YRFMNEVSHGNTGDNI SLTNEF'HIVLKTADNXYAGTDOHVYFGFETNEG 
XTQEWEMDHPGNDFMAGSKOTYTfXI.J(DEHL-KIDOIQNMWIRKRXYT.AFPDA YXPENI!tVIANGXVVVDKDI 
X'l'QlWEMDHPGHDFMTGSKD'I"t'lTT(L)(ENL-KIDDIQNMWIRICR.XYT.AFSDA.YXPENIKIIANGXVVVDKDl 
KXFEWKLDNAGHDFERNQVDHYILKTI<DGEEVDINNI SHYWIRKERLTSI SDDWELSNFJa.IANGXVIQQQDV 
HEWISGHSTYHI-X •• 
HEW! SGHS'l'YHI -X. 
NXVFTGNETYYINK . 
Fig. 2. Zinc ion binding residues in the Bacillus cereus phosphatidyl choline preferring phospholipase C; alignment with C. 
perfringens a-toxin and C. bifermentans amino acid sequences. 1 Deduced amino acid sequence of the phosphatidyl choline preferring 
phospholipase C from Bacillus cereus (6). 2 Deduced amino acid sequence of C. perfringens alpha toxin [16). 3 Deduced amino acid 
sequence of C. perfringens alpha toxin [17). 4 Deduced amino acid sequence of the C. bifermentans phospholipase C [17). 
are the target for modification. Confirmation of 
this was obtained by demonstrating that the DEPC 
modified enzyme could be reactivated by further 
incubation with hydroxylamine [12]. In addition 
this result indicated that multiple reaction of 
DEPC with histidine residues leading to fission of 
the imidazole ring did not occur. 
The inactivation of EDT A treated alpha toxin 
by DEPC was observed when the enzyme was 
tested against both micellar (egg yolk emulsion) 
and monodispersed (p-NPPC) substrates indicat-
ing that the modified histidine residues play a 
similar role in enzyme activity irrespective of the 
precise form of the substrate. 
Previous workers have shown that the alpha 
toxin contains zinc ions [5) and is inactivated on 
incubation with EDTA [4). The toxin can be re-
activated on further addition of zinc, cobalt or 
manganese ions "whilst other divalent cations 
showed limited or no reactivating ability [4). Our 
results show that zinc, cobalt or manganese ions 
can protect the EDTA treated toxin from DEPC 
modification, indjcating that these ions can be-
come integrated into the protein and then protect 
rustidine imidazole groups from mollification. The 
differences in phospholipase C activity against 
rrucellar or monodispersed substrates after re-
placement with manganese ions may be due to a 
change in substrate specificity following a change 
in the arcrutecture of the active si te. A sirrular 
change in substrate specificity on replacement of 
zinc ions has been reported for the B. cereus 
enzyme [13]. 
The B. cereus PCP phospholipase C has been 
shown to contain three zinc ions partially co-
orrunated to rustirune residues [2]. Comparison of 
the amino acid sequences of the toxic C. perfrin-
gens alpha toxin [16,17], non-toxic B. cereus 
PCP-phospholipase C [6] and weakly toxic C. 
bifermentans phospholipase C [19] reveals consid-
erable homology between these proteins (Fig. 2). 
Recently, the crystal structure of the B. cereus 
phospholipase C has been determined and the 
location of arillno acids co-ordjnating the three 
zinc ions in the molecule elucidated [2]. All of the 
B. cereus enzyme zinc co-ordinating ligands are 
conserved in the C. perfringens alpha toxin and 
the C. bifermentans phospholipase C and of these 
five are histidine residues (Fig. 2). The role of 
rustidine residues in the activity of the C. bi-
fermentans phospholipase C has not been de-
termined, however, it is likely that all three phos-
pholipase C's contain zinc ions within the active 
site-co-orrunate partially by rustirune residues. 
These results provide further evidence that the 
phospholipase C activities of these proteins reside 
in regions with sirilllar tertiary structures. The 
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toXJclty associated with the alpha toxin may be 
due to additional features of this protein. 
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Identification of residues critical for toxicity in Clostridium perfringens 
phospholipase C, the key toxin in gas gangrene 
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Clostridium pe1jringens phospholipase C (PLC). also called a-toxin, is the major virulence factor in the 
pathogenesis of gas gangrene. The toxic activities of genetically engineered a-toxin variants harboring single 
amino-acid substitutions in three loops of its C-terminal domain were studi ed. The substitutions were made in 
aspartic acid residues which bind ca lcium, and tyrosine residues of the putative membrane-interacting region . The 
variants D269N and D336N had less than 20% of the hemolytic activity and di played a cytotoxic potency 
103-fold lower than that of the wild-type toxin. The variants in which Tyr275, Tyr307, and Tyr331 were 
substituted by Asn, Phe, or Leu had 11 -73% of the hemolytic activity and exhibited a cytotox ic potency I 02- to 
105-fold lower than that of the wi ld-type toxin. The results demonstrated that the sphingomyelina e activity and 
the C-terminal domain are required for myotoxicity in vivo and that the variant D269N, D336N, Y275N, Y307F, 
and Y331 L had less than 12% of the myotoxic activity displayed by the wi ld-type toxin. This work therefore 
identifies residues critical for the toxic activities of C. peifringens PLC and provides new insights toward 
understanding the mechanism of action of this toxin at a molecular level. 
Keywords: bacteria l toxins; muscular diseases; molecular models: skeletal muscle; cell survival. 
Bacterial phospholipases C (PLCs) are a heterogeneous group 
of virulence factors with diverse roles in the pathogenesis of 
several diseases [ I] . PLCs have been classified into three 
groups according to whether the preferred substrate is PtdCho, 
sphingomyelin (SM) or Ptdlns [2]. T he PtdCho-preferri ng 
bacterial PLCs include Zn2 + -meta lloenzymes from Bacillus 
cereus, Listeria monocytogenes and several Clostridium spp. 
[2]. They di splay different abilities to hydrolyse SM and 
show 30-60% amino-acid sequence identity f2). However, 
the PLCs from clostridia possess 11 5 additional residues at 
the C-terminus [3). The Clostridium peifringens PLC, which 
displays platelet aggregating, hemo lytic. cytotox ic, myotoxic, 
and lethal activit ies, i the most toxic among clostridial PLCs 
[ 1-3]. This enzyme, a lso called a-toxi n, is the major virulence 
factor in the pathogenesis of gas ga ngrene [4,5], and has also 
been associated with other diseases of animals and man [6]. 
The three-dimensional structure of a-toxin shows two domains 
joined by a short hinge region. The N-terminal domain contains 
the active site and consists of 10 tightly packed a helices. similar 
to the nontoxic Bacillus cereus PLC [71. The C-terminal domain 
is a [3-sandwich composed of two four-stranded sheets 17]. 
Corre.l'prmdntce 10 M. Thcksi:tm. Microbiology and Tumorhiology Center. 
Karolinsb Institute!. Box 280. S-17t 77 Stockholm. Sweden. 
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E-marl : monica.the testam<il\mh:.~i .se 
Abhrevimious: PLC. pho>pholipa'c C: SM. sphingomyelin: CK. cre;Hine 
kinase. 
Enzyml'.l': phospholipa>c C (EC 3. I A .3): crc~t inc ~in;r>c tEC 2.7.3.2). 
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analogous to C2 domains of intracellular eukaryotic proteins 
involved in vesicular transport and signa l transduction [8]. The 
C-terminal domain is needed for the Ca2+ -dependent inter-
action with aggregated PtdCho [9] , and for the disruption of 
artificial membranes [I 0). but its function is not completely 
under rood. 
Crystallographic studies have revealed that a-toxin might 
exist in two conformations: an open form with the active site 
acce sib le, and a closed form wi th the active site covered by the 
loop encompassing residues 135- 150 [ 11 ]. It is suggested that 
the binding of the C-terminal domain to the target membrane 
causes the uncovering of the active s ite, thus a llowing turnover 
of the phospholipid sub trate [ 11]. The Ca2 + -binding region of 
a-toxin is located in three loops of the C-terminal domain 
which encompa s residues 265- 275, 292- 303 and 330-339 
[ 11]. Residues surrounding the Ca2 + -binding li gands at the tips 
of those loop are thought to constitute a membrane-interacting 
surface [7]. This surface has been hypothesized to be important 
for toxicity [7], but its role in the toxic activitic of a-tox in has 
not been experimentally tested . 
The N-terminal domain of a-toxin. which, isolated, retains 
the lec ithinase activity but lacks the sphingomyelinase activity. 
is not hemolytic 112] and has a cytotoxic potency I 06-fold 
lower than that of the holnloxin [ 131. Furthermore, the 
C-termina l domain, which. isola1cd. is devoid of both enzym-
atic activities o f the holotoxin. is neither hernolytic nor 
cytotoxic 112, 13]. Thus the interact ion between the domains 
is required to confer fu ll hemolytic and cytotoxic activities to 
a -toxin. 
Although the PtdCho-pre ferring PLCs from different Clos-
tridium ~pp. are highly simi lar in amino-acid sequence, they 
519:! A. Alapc-Giron et al. (£111: J. Binclwm. 2o7) 
dis play ~trikingl y different toxicities 131. The Clostridium 
b(fermenwns PLC, wh ich a lso shows a Ca2 .. -depe ndent capa-
city to dio.;rupt li po. omes. has a hemolytic acti vi ty 102-fold 
lower and ha. a cy10toxic potency I 05-fold lower than that 
of a-toxin 113. 141. However. a hybrid protein containing the 
N-tenninal domain of the C. bifemtenwns PLC and the 
C-terminal domain of a-toxin displays hcmolytic and cytotoxic 
acti vi ties significantly higher than those of the C. bifennentmls 
PLC 11 3. 1-1] . C hemical modification o f the exposed tyrosine 
residues in a-tox in did not affect it~ enzymatic activity toward 
p -nit rophe nylphosphorylc holine, but resu lted in a signifi cant 
reduction o r its platelet aggregating. hemolytic and le thal 
activitie . suggesting a role for tyrosine residues in toxici ty 
[ 15]. Of the six tyrosi ne residues in the C-terminal domain o f 
a-toxin only three are conserved in the C. b(fennentans PLC 
[9. 14]. Thus. the differences in the tyrosine residues of the 
C-terminal regions between these two enzymes are suggested to 
be at least partially responsible for the reduced toxicity of the 
C. bifermentrms PLC [9, 14]. 
The substitution of Asp269. Asp336. Tyr275, Tyr307 and 
Tyr33 1 in a-toxin causes. at most, a 209c reduction in its 
enzymatic activity toward aggregated PtdCho [9], but the 
importance of these residues in toxicity has not been 
determined . The present work was conducted to c larify the 
role of those residues in the hemolyt ic . cytotoxic and myotoxic 
activities. 
MATERIALS AND METHODS 
Production and purification of toxins 
The wild-type C. bifermentans PLC was expressed in Escheri-
chia coli and purified [ 14]. The a-toxin from the strain NCTC 
8237 and a truncated version containing only the 249 
N-terminal residues were produced and purified [ 12, 16]. T he 
wild-type a-toxin from strain 8-6 and the variant D56N were 
produced and purified [ 17,18]. The a-toxin variants D275N, 
D336N, Y275F, Y275N, Y307F, Y331 F, Y33 1 L, a nd Y367F 
were generated by site-directed mutagenesis and a ll mutants 
were fully sequenced to verify that only the desired mutations 
were pre ent [9]. These variants were produced in £. coli strain 
K38/pGP 1-2 using the T7 polymerase expression sy tem and 
purified from periplasmic extracts (9]. Homogeneity was 
verified by SOS/PAGE and protein concentrations were 
determined using the Bio-Rad DC protein assay and BSA as 
a standard. 
Ant ibodies and EUSAs 
The m Ab against a -toxin 3A4D I 0. 3A4F1. DY2F5, 9F3A6, 
A5A ll were produced in pristane-primed mice and purified 
[ 19.20]. lmmulon 11 microtiter plate. were coa ted overnight 
with 0.5 mg of each variant in 0.05 M carbonate buffer. pH 9.6. 
T he re mai ning binding sites were blocked with 2% BSA in 
NaCliP, (blocking solution) for 30 min. After aspiration the 
amibodies serially diluted in blocking sol ution were added 
and incubated for l h at 37 °C. After five washes with 
NaCl/P,/0.05% Twee n 20. 100 J.!-L of anti-mouse lgG-alkaline 
phosphatase conjugate (Dako, Copenhagen. De nmark) were 
added per well. After a 1-h incubation at 37 °C, plates were 
washed five times as above, then I 00 f!-L of p- nit rophenyl-
phosphate substrate solution ( l mg·mL -I ) diluted in l M 
diethanolamine buffe r. pH 9.8, was added per well , and 
absorbances at 405 nm recorded a fter 30 min. 
© FEBS 2000 
Molecular modeling · 
Amino-acid substitutions were introduced into the structure 
of wild- type C. petfringens a-toxi n [71 using the graphics 
package, o [211. The models were subsequently subjected to 
restrai ned energy minimization util izi ng the XPLOR package 
[221. but no change in protein conformation was observed, on 
either a global or a local level. Therefore. the structures 
produced by ·o', prior to energy minimization were used. 
Figures of the models were drawn by BOBSCRII'T [23] and 
rendered with Ri\ST ER 3o 1241. Surface potentials were 
calcu lated with GRASP [25]. 
Hemolytic, cytotoxic and myotoxic activities 
The hemolytic activity was determined in agarose gels con-
taining 5% sheep erythrocyte . 0.2 M odium borate. 50 mM 
NaCl, 30 mM CaC12, at pH 7.6, as described [ 16]. Briefly, 
different amounts of wild-type a-toxin in 15 JJ-L of aCl/P; 
were placed in 4-mm wells and after 24 h incubation in a humid 
chamber at 37 °C the diameter of hemolysis was measured. A 
linear dose-response cu rve was obtained using 0.1-0.7 JJ-g of 
wi ld-type a-toxin and therefore 0.35 JJ-g of each variant was 
used. All experi ments were performed three time . with 
duplicate samples each time. 
The Chinese hamster cell line Don Q [26]. was culti vated in 
polystyrene 96-we ll plates (Nunc. Roskilde. Denmark) in 
Eagle's minimal essential medium (Life Tec hnologies. Paisley, 
UK) supplemented w ith I 0% fetal bovine erum. 5 mM 
L-glutamine, penicillin ( 100 U·mL - I) and streptomycin 
( lOO f!-g·mL - 1), in a humid atmosphere containing 5% C02 
at 37 °C. Cells grown to 909c confl uency were exposed at 37 °C 
to serial tenfold dilutions of the purified PLCs (2 14 fJ.g· mL - I) 
in 200 JJ-L of medium per well a nd cell viabili ty was measured 
24 h later using a ne utral red as ay [26]. All experiments were 
performed three times, w ith four replicate samples each time. 
Myotoxicity was estimated by measurement of the creatine 
kinase (CK) release to the plasma after injection of the PLCs in 
the right gastrocnemius muscle in groups of four Swiss-Webster 
mice, as described [27] . Animals were housed. fed and handled 
according to the principles and practices approved by Vicer-
rectoria de lnvesti gacion, Universidad de Costa Rica. The CK 
activity was detennined using either a calorimetric or a kinetic 
assay (Sigma, kits 520 or CK- 1 0). Pl asma C K activity was 
max imal at 3 h after injection of the wild-type o:-toxin and 
therefore sub equent measurements were performed at this 
time. A linear dose- re ponse curve was obtained using 
0.5- 2.5 f!-g of wild-type a- toxin. and therefore 1.5 J.!-g of each 
variant was used. Mice were sacrificed by cervical di location 
24 h after injection and the injected gastrocnemius mu cle was 
d issected and immersed in Karnovsky's fixative solutio n (2.5% 
glutaraldehyde, 2% paraformaldehyde, 0. 1 M phosphate buffer. 
pH 7 .4) for 2 h. The ti ssue was post fixated with osmium 
tetroxide, dehydrated and embedded in Spurr resin. Sec tions of 
I J.!-111 were prepared, stained wi th to luidine blue and observed 
under the li ght microscope. 
For intravital microscopy experiments male mice ( 18-22 g) 
were a ncsthetized with an intraperitonea l injection of sodium 
pentobarbital (2 mg per I 00 g body weight). placed on a wate r-
heated bed (at 37 °C) a nd the crema ter mu c le expo ed [28] . 
Solutio ns of 1.5 JJ-g of PLCs in 20 f.l.L of NaCliP; were applied 
to the exposed muscle, wh ich was immediately covered wi th 
6-JJ-m Mylar® shee t to prevent dehydration. Control experi-
ments were performed in muscles treated with 20 f.l.L or 
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Fig. I. Schematic representation of the 
C. perfringens a-toxin s tructure. The ligure is 
shad.:d from red for rcsidues farthest from the 
membrane to blue for residues likely to be 
inserted tntO the membrane. The plane of the 
membrane is determined by the three calcium 
ions in the C-terminal domain (which are 
thought to coordinate the pho pholipid 
headgroups of the target membrane). Mutated 
residues are shown in green ball-and-stick. A 
phospholiptd molecule has been modeled in the 
active >ite in transparent ball-and-stick. 
NaCI/P; alone. The alterations induced by 1he toxins were 
recorded during 25 min. 
RESULTS 
Choice of substitutions and molecular modelling of at-toxin 
variants 
The residues of o:-toxin selected for mutagenesis were Asp269, 
Asp336, Tyr275, Tyr307. and Tyr331, which are located in the 
putati,·e membrane-binding region of the C-terminal domain, 
except Tyr307, which is part of the interface between the 
N- and C-terminal domains (Fig. I). The selection was based 
on structural comparisons of the C-terminal domain of o:-toxin 
with that of the weakly toxic C. bifermentans PLC and C2 
domains from eukaryotic proteins [9]. Tyr367, which is distant 
from the putative membrane-binding stuface and the :'.J and 
C-terminal domain interface (Fig. I), was mutated as a control. 
The ino·oduced residues were chosen on the basis of their 
propensity to adopt the same secondary structure as those of 
the corresponding wild-type residues [29). Asp residues were 
substituted by Asn to evaluate the role of the carboxylate 
groups, whereas Tyr residues were replaced by Phe to 
determine the role of the hydroxy groups. In addition, Tyr275 
and Tyr331 were substituted by Asn and Leu, respectively, to 
mimic loca lly the structure of the C. bifermentwls PLC. The 
mutant o:-toxin valiants were recognized identically as the wild-
type toxin by the mAbs 3A40 I 0, 3A4F2, DY2F5, 9F3A6, 
ASA 11 in an ELlS A (not shown), demonstrating that despite 
substitutions several ep itopes remain intact. 
The hemolytic and cytotoxic activities are reduced by 
aspart ic acid and tyrosine substitutions 
The va1iants D269N and D336N had less than 19 and I I % of 
the hemolytic activity, respectively (Fig. 2A) and displayed a 
cytotoxic potency I 03 -fold lower than that of the wild-type 
o:-toxin (Fig. 28 ). The variant Y275N had only 11 % of the 
hemolytic activity (Fig. 3A) and displayed a cytotoxic potency 
105-fold lower than that of the wild-type o:-toxin (Fig. 38), 
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Fig. 2. Hemolytic a nd cytotoxic activities of the wild-type (Wt) 
C. perfringens a-toxin a nd varia nts with single subs titutions in aspartic 
acid residues. (A) Hemolytic activity. Sheep erythrocytes in agarose gels 
were exposed for 24 h at 37 •c to 0.35 1-1-g of each a-toxin variant and the 
diameter of hemolysis was measured. The results are expressed as the 
percentage of hc::tnolytic activity, constdenng t 00% to be the diameter of 
the hemolytic halo induced by the wild-type a -toxin. (B) Cytotoxic activity. 
Celts were exposed for 24 h :u 37 •c to erial tenfold dilutions of each 
a-toxin variant: wild-type toxin ( .A ): D336N (x); D269N (0). Cell viabili ty 
was detennined using the neutral red assay as described in Materials and 
methods. The results are expressed as the percemage or neutral red uptake 
in relation to controls incubuted wi thout toxin. 
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Fig. 4. Myotoxic activity of the C. bifermentans PLC, the wild-type 
(Wt) C. perfringens a-toxin and genetically engineered a-toxin 
variants. Groups of four Swiss-Webster mice were injected with 1.5 IJ.g 
of each variant in the right gastrocnemius muscle and plasma CK activity 
was measured 3 h later as described in Materials and methods. In panel B, 
the results are expressed as percentage of the plasma CK increment, 
considering I 00% as the CK activity of mice injected with the wild-type 
a-toxin. 
showing that the phenolic ring of Tyr275 is crucial for the 
hemolytic and cytotoxic activities. Furthermore, the variant 
Y275F had 73% of the hemolytic activity (Fig. 3A) and 
exhibited a cytotoxic potency I 02-fold lower than the wild-type 
a-toxin (Fig. 38), demonstrating the importance of the hydroxy 
group at 275 for those toxic activities. Similarly, the variants 
Y331 F and Y331 L had 36 and 30% of the hemolytic activit1', 
respectively (Fig. 3A), and displayed a cytotoxic potency 10 -
to I 04 -fold lower than the wild-type toxin (Fig. 3C), showing 
the importance of the hydroxy group at 331 for toxicity. The 
Fig. 3. Hemolytic and cytotoxic activities of the wild-type (Wt) 
C. perfringens a-toxin and variants with single substitutions in tyrosine 
residues. (A) Hemolytic activity. Sheep erythrocytes in agarose gels 
were exposed for 24 h at 37 •c to 0.35 IJ.g of each a-toxin variant and 
the diameter of hemolysis was measured. The resu lts are expressed as 
the percentage of the hemolytic activity. considering 100% the diameter 
of the hemolytic halo induced by the wild-type a-toxin. (B-D) Cyto-
toxic activity. Cells were exposed for 24 h at 37 •c to serial tenfold 
dilutions of each a-toxin variant: wild-type toxin (A). (B) Y275F (x); 
Y275N (0). (C) Y331 F (x); Y331 L (0). (D) Y307F (0). Cell viability was 
determined using the neutral red assay as described in Materials and 
methods. The results are expressed as the percentage of neutral red uptake 
in relation to controls incubated without toxin. 
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Fig. 5. Myotoxic activity of the wild-type (Wt) C. perfringens oHoxin 
and variants with single substitutions in residues of the C-terminal 
domain. Groups of four Swiss-Webster mice were injected with 1.5 J.lg of 
each variant in the right gast rocnemius mu~cle and plasma CK actr\'ity was 
measured 3 h later as de cribed in Materials and methods. The results are 
expressed as percentage of the plasma CK increment. considering I OO'k as 
the CK activity of mice injected with the wild-type a-toxin. 
variant Y307F had about 38% of the hemol ytic acuvny 
(Fig. 3A), and displayed a cytotoxic potency 103-fold lower 
than that of the wild-type a-toxin (Fig. 3D), wherea the 
control variant Y367F had identical hemolytic and cytotoxic 
activities as the wild-type a-toxin (not shown). 
The myotoxicity of a -toxin requires the sphingomyelinase 
activity and the ( -terminal domain 
Although it is known that a-toxin causes extensive myonecrosis 
[30,31 ], there are no previous studies which report the 
relationship between the structure of the protein and its 
myotoxic activity. The wild-type recombinant a-toxin injected 
intramu cularly induced in 3 h a 35-fold increase in plasma 
levels of CK activity as compared to control mice injected with 
NaCI/P; (Fig. 4A). rn contrast, the C. b(fermemans PLC only 
produced less than a twofold increa e in the plasma CK level 
(Fig. 4A). Micro copic assessment of muscle damage in tissue 
samples obtained 24 h after toxin injection showed good 
corTelation with increments in plasma CK activity (not shown). 
Asp56 is a zn2+ ligand in the acti ve site (Fig. I) and its 
replacement does not affect the membrane-binding capacity of 
the holotoxin [32], although it completely abrogates the leci-
thinase and sphingomyelinase activities 118.32]. Intramuscular 
injec tion of the enzymatically inacti ve variant 056 118.32] 
failed to induce a significant myotoxic effect. and only caused a 
slight increase in C K plasma activity (Fig. 48). indicating that 
the catalytic capacity of a-toxin is required for its myotoxic ity. 
A truncated a-tox in contai ning only the 249 N-terminal 
residue. retains the lecithinase activi ty but lacks the sphingo-
myclinase acti ity 11 21. This fragment induced a 50-fold lower 
inc rease in CK pla~ma activi ty than the holotox in (Fig 48) 
Thus. the data demon~tratc that the lecithinase activity fiN se 
is not sufficient to confer myotox icity and show~ that the 
C-tenninal do mai n is required fo r full myotoxic activity. 
The e ffects of a -wxin on the mouse cremaster mu\c le and it~ 
microcirculati on were studied by intravita l mic roscopy. Hyper-
contraction and conspicuous morphologica l alterations o r the 
muscle fibcrs. likely due to the membrane-damaging e iTect of 
a -toxin. were already evident 1- 2 min after toxin application. 
The toxin a lso caused a progressive reducti on in the blood now. 
About 2-5 min after toxin exposure thrombi began to form . 
lirst in the walls of the venules and then in arterioles, giving off 
numerous emboli . These intravascular aggregates grew pro-
gressively in . i7e and number. disturbing the local blood now 
and finall y leading to a com ple te halt of the circulation within a 
15-20-min period. In contraq. none of the described event~ 
were observed in preparations treated with the enzymatically 
inactive variant D56N or the truncated a-toxin. 
The myotoxic activity is reduced by substitutions in residues 
of the putative membrane-interacting surface 
The variants D269N. D336N, Y275N and Y331 L were selected 
for studies of myotox ic ity in vivo becau e they had the lowest 
hemolytic and cytotoxic activities among the variants used in 
this study. These variants howed less than 12'*" of the myo-
toxic potency of the wild-type toxin, as judged by the increase 
in the CK plasma activity observed after intramuscular 
injection (Fig. 5). Furthermore. they induced negligible tissue 
damage in the mou e c remaster muscle. 
DISCUSSION 
We have studied in vit ro and in vivo the toxic activities of 
several genetically engineered a-toxin variants whose lecithin-
ase activity has been previously characterized [9] . These vari-
ant harbor s ingle amino-acid ubstitutions in re idues located 
within the proposed membrane-interacting region of the 
C-terminal domain . As the substituted residues are located at 
the surface of the protein and most substitutions were con er-
vative, it was expected that they would not interfere with 
correct folding of the protein. Accordingly, all the variants were 
identically recognized by several mAbs as the wild-type tox in 
and restrained energy mjnimization did not result in an alter-
ation of the conformation of the protein . Furthermore, previou 
pulse chase experiments have hown that these variants have 
the same thermodynamic stability as the wild-type a-toxin and 
behave in an identical way in gel filtration, ion-exchange 
chromatography and nati ve gel electrophoresis [9]. Thu . . 
although a detai led analysis of the different side-chain-s ide-
chain interactions that arise in each variant must await the ir 
three-dimensional structure determination, several lines of 
evidence indicate that all of them have a s imilar confonnati on 
to the wild-type a-toxin. 
The results obtained with the variants D269N, D336N and 
Y307F showed that A ·p269. A p336 and Tyr307 are crucial to 
confer full hemolytic and cytotoxic activities to a-toxin. in 
agreement with the hypothesi proposed by Naylor et al . [7]. 
A~p269 and Asp336 a re Ca2• ligand in a-toxin I ll] and the 
corresponding residues are also known to bind Ca21 in severa l 
C2 do mains of eukaryotic proteins [7,9]. Tyr307 makes a 
hydrogen bond to A p298, which is also a Ca2 + ligand [I I] and 
therefore could also be required for a proper interaction of 
a -toxin with the target memhrane. In addition. Tyr307 i~ 
part of the interface between the C-terminal domain and the 
N-terminal domain. and so cou ld be involved in ignaling 
between the major membrane binding surface and the active 
s ite. Thus, the lowered hemo lytic and cytotox ic activities of the 
variants D269N. D336N and Y307F are like ly ex plained by a 
reduced capacity to interact wi th the membrane of the target 
cell s (and, in the case of Y307F. a lso by a reduced capac ity to 
communicate such interaction to the active site). 
Altho ugh substitutio n o f Tyr275 or Tyr33 1 with Phe reduced 
the capac ity of a-toxin to hydro lyse aggregated PtdCho only by 
5 190 A. Alape-Gir6n er al. (£111: J. Bioche m. 267) 
20 and 5*. respecti vely 191. these substitutions affected the 
he molytic a nd cytotox ic act ivities to a larger exte nt. Further-
more, the Y275N and Y331 L sub titutions also caused a 
dramatic red uction in the hemolytic . cytotox ic and myotoxic 
activities o f a-tox in. underscoring the importance of Tyr275 
and Tyr331 for toxici ty. Since these tyrosine residues <~re A~n 
a nd li e, respectively. in the C. bifermellfllllS PLC. these ~ubst i­
tutions could explain . at least partiall y, the lower hemo lytic . 
cyto toxic and myotoxic ac ti vities of this enzyme in comparison 
with a-tox in . 
C. perfri11ge11s a-toxin induces the upregulation o f adhesion 
molecules in leukocytes and e ndothelial cells as well as the 
production of platelet activating fac tor [33,34]. Thus, throm-
botic events are thought to reduce the blood supply in tissues 
infected with C. perfrillgells, promoting the a naerobic e nviron-
me lll req uired for bacterial growth [31 ,35]. In this work , we 
observed i11 vivo that a-toxin. be ides damaging the muscle 
fibers, also induces the formation of intravascular aggregates 
which dramatically affect the microcirculat ion of the mouse 
cre master muscle. The myotoxic ity as well as the capacity to 
induce thrombotic events i impaired in the mutant variants 
D269N, D336N, Y275N and Y33 1 L. These results give a 
sta rting point for further i11 vivo studies aimed at developi ng 
genetically engineered vaccines for gas gangrene, a disease of 
increasing significance in the e lderly and diabetics, especially 
in those w ho have undergone lower limb surgery [36,37]. 
The C-terminal domain of a -10xin resembles C2 domains of 
eukaryotic prote ins, which despite a high sequence diver ity are 
structura lly similar [8). The binding of Ca2+ to C2 domains 
commonly promotes a rever ible binding to membranes and 
might cause conformational change which lead to membrane 
penetration or trigger local changes in surface potential, hence 
inducing a selective interaction with proteins of the target 
membrane [38,39]. Electrostatic and hydrophobic interactions 
make variable contributi ons to membrane binding depending o n 
the residues flanking the Ca2 + ligands in the loops [40]. Thus. 
the side-chains of residues surrounding the Ca2+ binding sites 
define the specificity of each C2 domain for different phos-
pho lipid types. In the case of a -toxin, it binds and disrupts 
artificial membranes with PtdCho or SM but not those with 
PtdSer, PtdEtn or PtdGro [41]. However, our understanding of 
the molecular interaction involved in the binding of a-toxin to 
membranes is incomple te, particularly regarding the re lative 
conu·ibutions of electrostatic and hydrophobic interactions. lt 
is not known whether Ca2+ ions only anchor a-toxin via a 
bridging mechanism. or whether they trigger membrane pene-
tratio n, a nd/or protein- protei n interactions. Tyrosine and tryp-
tophan residues have been suggested to play a critical role in 
the interaction of peptides with the interfacial region of lipid 
bil ayers [42]. Indeed, everal lines of evidence indicate that 
tyrosine and tryptophan residues. because of their amphipathic 
s ide chains. are ideally suited to reside in the complex 
e lectrostatic environment of the bil ayer interface: (a) phenolic 
and indolic ring analogues seek out a shallower locations than 
aromatic rings, and pre ferentially partition at the boundary 
between the acyl cha in and the polar region of phospho lipid 
bilayers 143]: (b) me mbrane proteins arc enriched in tyrosine 
and tryptophan residues near the hcadgroup of the lipid bilayer 
144]: (c) the capacity o f the me mbrane-interacting o li gopeptides 
gramicidin. to modulate the bilayer sll1JCture (induc ing hexagonal 
phase formation) depend~ on the presence of tryptophan residues. 
whic h can be replaced wi th tyrosine. but not with phe ny lalanine 
H5J : (d) tyrosi ne and tryptophan residues are critical for the 
anchoring of pancreatic colipasc. and cytosolic and secreted 
phospho lipases A! to micellar lipids j46- 4Sj . Further struc tural 
© FEBS :woo 
~llldies of the a-toxin , ·ariant~ '' ith \Ubstituti ons in Tyr275 and 
Tyr:n I will he lp to elucidate the exac t role of these rc~idues in 
the interact ion of a- to~ in wi th pho\pho li pid bilaycrs. 
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A panel of random mutants within the DNA encod-
ing the carboxy-terminal domain of Clostridium per-
fringens a-toxin was constructed. Three mutants were 
identified which encoded a-toxin variants (Lys330Glu, 
Asp305Gly, and Asp293Ser) with reduced hemolytic 
activity. These variants also had diminished phospho-
lipase C activity toward aggregated egg yolk phospho-
lipid and reduced cytotoxic and myotoxic activities. 
Asp305Gly showed a significantly increased enzymatic 
activity toward the monodisperse substrate pNPPC, 
whereas Asp293Ser displayed a reduced activity to-
ward this phospholipid analogue. In addition, 
Asp293Ser showed an increased dependence on cal-
cium for enzymatic activity toward aggregated phos-
pholipid and appeared calcium-depleted in PAGE 
band-shift assays. In contrast, neither Lys330Glu nor 
Asp305Gly showed altered dependence on calcium for 
enzymatic activity toward aggregated phospholipid. 
Asp305 is located in the interface between the amino-
and carboxy-terminal domains, whereas Asp293 and 
Lys330 are surface exposed residues which may play a 
role in the recognition of membrane phospholipids. 
() 2000 Acnde m ic Press 
Key Words: bacterial toxin; C. perfringens; a-toxin; 
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Clostridium perfringens is the etiological agent of 
gas gangrene (clo tridial myonecrosis) in man, a seri-
1 To whom correspondence and reprint requests should be ad-
dress('d. F'lx: ... 1980 613284. E-mail : RTITBALL@DERA.GOV.UK. 
ous ilisease which can occur after the entry of the 
bacterium into anoxic tissues (1). The bacterium is 
ubiquitous in the environment and traumatic injuries, 
with the associated ingress of soil or other organic 
matter containing the bacterium, are the events which 
most frequently lead to infection (1, 2). Gas gangrene is 
less frequently a consequence of surgical procedures, 
especially those involving the lower bowel which allow 
bacteria in the gut to infect host tissues (2). The spread 
of bacteria from the initial site of infection is a conse-
quence of the production of toxins which damage the 
surrounding healthy tissues thus allowing bacterial 
invasion. 
Although C. perfringens produces a wide range of 
protein exotoxins, the a-toxin, a zinc-metallophospho-
lipase C, is the major virulence determinant in gas 
gangrene. It has been shown that a- toxin negative 
mutants of C. perfringens a re no longer able to cause 
gas gangrene in mice (3), and immunization with an 
a-toxoid vaccine provides protection against disease 
(4). The a-toxin is hemolytic, cytotoxic and elicits a 
variety of effects on host tissues. The contraction of 
smooth muscle (5), especially that lining blood vessels 
(6), and the aggregation of platelets (7) might reduce 
the blood supply to tissues and promote the anoxic 
conditions r equired for bacteria l growth. The mistraf-
ficking of neutrophils such that they do not enter in-
fected tissues appears to be a consequence of the up-
regulation of adhesion molecules in endothelial cells 
exposed to a-toxin (8, 9). The toxin might also cause 
generalized tissue damage by activating the arachi-
donic acid cascade leading to the production of inflam-
0003-9861/00 $35.00 
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matory mediators (6, 10). The hemolytic, myotoxic and 
cytotoxic activities of a-toxin are believed to be a con-
sequence of its interaction with host cell membranes 
and the subsequent hydrolysis ofphospholipids. There-
fore, the lysis of erythrocytes is often used as an in uilro 
measure of the ability of the a -toxin to hydrolyze phos-
pholipids in cell membranes (11). 
The crystal structure of the C. perfringens a- toxin 
(12) reveals an amino-terminal domain (residues 
1- 246) and a carboxy-terminal domain (residues 256-
370) joined by a short hinge region (residues 24 7-255). 
We have previously shown that the phospholipase C 
active site is located in the amino-terminal domain of 
a-toxin (12, 13) and others have identified r esidues in 
this domain which are essential for enzymatic activity 
(14-16). In contrast, the function ofthe carboxy-termi-
nal domain, which adopts a C2-like fold, is not com-
pletely understood. C2 domains in eukaryotic lipid me-
tabolizing enzymes are often involved in phospholipid 
recognition and therefore the carboxy-terminal domain 
of a-toxin is believed to interact with phospholipids of 
the target membrane (12, 17). This is supported by our 
finding that removal of this domain abolished the he-
molytic activity but not the enzymatic activity toward 
the water soluble substrate pNPPC2 (13). 
Crystallographic studies r evealed that alpha-toxin 
might exist in two conformations: an open form with 
the active site accessible and a closed form with the 
active site covered by the loop encompassing residues 
135 to 150 (18). The binding of the carboxy-terminal 
domain to the target membrane is proposed to position 
the active site facing toward the bilayer and to cause 
its uncovering, thus allowing turnover of the phospho-
lipid substrate (18). 
We have set out to identify residues in the carboxy-
terminal domain which play a role in the biological 
activities of a-toxin. The r esults from this work provide 
new insights toward understanding the mechanism of 
action of this toxin at a molecular level. 
MATERIALS AND METHODS 
Chemicals and enzymes. Chemicals were obtained from Sigma 
(Poole, UK) or BDH (Poole, UK) unless othenvise stated. Materials 
for protein purification were obtained from Pharmacia Biotech Ltd. 
(St. AI bans, UK ). Materials for DNA purification were obtained from 
Boehringer Mannheim (Lewes, UK). 
Random mutagenesis of the carboxy·terminal domain coding re· 
gion. Plasmid pT2.2 (11) was digested with Hindiii a nd Nhei and 
the DNA fragment encoding amino acids 209 to 370 of a-toxin was 
isolated and cloned into pia mid pUC18 (Pha rmacia Biotech Ltd.). 
This cloned fragment was used as the templa te DNA for random 
mutagenesis in a PCR (94•C, 7 min ; so•c, 1 min ; 70•C, 4 min 
followed by 25 cycles of94•C, L min; so•c , 1 min; 7o•c . .J min). The 
PCR mixture (100 J.d) contained 10 ng of template DNA, 25 pmol of 
' Abbr·eviations used : CK. creatine kinase; pNPPC, para -nitrophe-
nylphosphorylcholine: PBS. phos phate-buffered saline. 
pUC universal fonvard a nd reverse pri mers , 1 mM dGTP, dTTP, 
dCTP, and dlTP and 200 JJ.M dATP in 10 mM Tris- HCI, pH 8.3. 
containing 50 mM KCI, 0.5 mM Mn CI,. 6.1 mM MgCI2 , and 2.5 U of 
Taq polymerase (8CL Ltd., Lewes, UKl. The PCR product was di-
gested with EcoRI and HindliJ and cloned into pUC18 (191. A pool of 
recombinant pl asmids were digested with Hindlll and Nhel and the 
released DNA fragment isolated (19). Plasmid pT2.2 (1 1) was di-
gested with Hindlll and pa rtia lly dige ted with Nhe l to release the 
Nhel-Hindlfl fragment which encoded a mino acids 209 to 370 of the 
a-toxin. The remainder of the plasmid a nd a -toxin encoding DNA 
was purified, ligated with the mutated HindUI-Nhel DNA fragment 
and transformed (19) into Escherichia coli stra in DH5a. 
Construction of site-directed mutants. Site-d irected muta nts 
were constructed using an overlapping PCR method with plasmid 
pT2.2 (11) template DNA. For each mutant two PCRs were carried 
out using one primer containing the modified nucleotide sequence 
and one primer flanking the C-term inal Nhel-HindiJI DNA frag-
ment (upstream flanking primer; 5'-GCAGAGGAAAGAAAAGA-3': 
downstream flanking primer 5' -GTTTTCCCAGTCACGACGTTGTA-
3'). The following primers were used: Lys330> Glu, 5'-TAGAAAAA-
GAQAATATACAGC-3' and 5' -GCTGTATATT~TCTI'TTTCTA-3' ; 
Asp293> Ser, 5-GGAAATGAGCAACCCAGGAA-3' and 5'-TTCCT-
GGGTTGCTCATTTCC-3', where modified nucleotides are shown 
underlined. 
The PCR products were used as template DNA for PCRs with the 
upstream and downstream primers. The PCR products were digested 
with Nhei a nd Hindlll , cloned into plasmid pT2.2 which had been 
digested with Hindlll a nd partially digested with Nhei and trans-
formed into E. coli DH5a. Transformants were plated onto L-agar 
containing ampiciLJjn (19) and 5% (v/v) mouse blood (11). After cul-
ture for 18 hat 37•c the diameter of the zone ofhemolysis surround-
ing colonies was measured. 
Nucleotide sequencing. Nucleotide sequencing was conducted us-
ing the Sequenase Version 2.0 DNA sequencing kit (Amersham Life 
Science, Amersham, UK) with [a-35S]dCTP a nd conditions recom-
mended by the supplier. 
Purification of mutated proteins. Methods for the isolation of 
a- toxin from the periplasmic space of E. coli expressing the cloned 
a -toxjn gene have previous ly been reported (11, 20). The extract was 
loaded onto a HiTrap Q column (Pharmacia Biotech Ltd.) and eluted 
with a 0 to 1 M NaCl gradient in 20 mM Tris-HCI, pH 8.0. Fractions 
containing a-toxin were dialyzed a t 4•c against 20 mM Tris-HCI, pH 
8.0, loaded onto a MonoQ HR10/10 column (Pharmacia Biotech Ltd.) 
and e luted with a 0 to 1 M NaCI gradient. Fractions containing 
a-toxin were concentrated and loaded onto a HiLoad 16/60 S uperdex 
200 column (Pharmacia Biotech Ltd .). The a -toxin was eluted with 
PBS (pH 7.2) and fractions containing purified toxin were stored at 
- 1o•c. The bicinchoninic acid (BCA) protein assay method [Pierce & 
Wa rriner (UK) Ltd., Chester, UKI was used to determine protein 
concentration. 
S DS- PAGE. Protein samples were analyzed by SOS-PAGE us-
ing 10- 15% Phast Gels (Pharmacia Biotech Ltd.) or 12% gels (Bio-
Rad Laboratories Ltd., Hemel Hempstead, UK). The gels were 
stained with PhastGel Blue R a nd scanned using the Bio-Rad Gel 
Doe system (Bio-Rad Laboratories Ltd.). Toxin concentrations were 
adjus ted according to their percentage purity, for activity assays. 
Biological activities. The hemolytic activity, phospholipase C ac-
tivity toward egg yolk phospholipid, and pho pholipase C acti\'ity 
toward p-nitrophenylphosphorylcholine (pNPPC> were determin ed 
as descri bed (1 1, 13). Cytotoxicity was measured us ing Chinese 
hamster fibroblasts or· the muta nt cell li ne Don Q whi ch were seeded 
in 96-well plates (500 to 1000 cellslwe li>. When the cells had grown 
lo 90% confluency they were exposed in three replicate samples to 
seria l 10-fold dilutions of the toxins. After 24 h cell viability was 
measu red using a neutr·al red assay; cells were incubated for 2 h with 
200 J.LVwe ll of neutral red (50 mg/ml in culture medium). Incorpo-
26 WALKER ET AL. 
rated dye was extracted from the cells with 100 J.LI of acet ic 11cid: 
ethanol:wate1· (1:50:49), before reading at 540 nm in a microtiter 
plate reader . Resul ts arc expressed as percentages of neutra l red 
uptake in controls wells incubated without toxin. Myotoxicity was 
measured as creatine kinase CCKl CEC 2.7.3.2) released to the plasma 
3 h after injection of 1.5 1-'g of wild-type a-toxin or the mutant 
varia nts (in 50 J.Ll of PBSJ in the right gastrocnemius muscle in 
groups of eight Swiss-Webster mice. CK activity was determ ined 
using a kinetic assay (Sigma, CK-10). 
Calcium binding assays. The ability of the wild-type and mu-
tated toxins to bind calcium was determined using a calcium-depen-
dant band shift method (21) A reaction mixture of 15 J.LI containing 
toxin at 250 J.Lg/ml, 10 mM EDTA wit h or without 20 mM CaCI, was 
incubated for 5 min at room temperature prior to separation by 
na tive PAGE through an 8-25% Phast gel (Pharmacia Biotech Ltd .). 
Th e gel was s ta ined with PhastGel Blue R. 
Molecular madeling. The refined coordinates for the calcium-
bound "closed" form of C. perfri ngens a -toxin, strain NCTC8237 (pdb 
code 1QM6l were used as the start ing coordinates for structural 
a nalysis of the mutations. The amino-acid for each site-directed 
mutant was replaced in "0 " (22), and then 200 steps of energy 
minimization were carried out with the X-PLOR refinement package 
(23). 
RESULTS AND DISCUSSION 
Random Mutation of the DNA Encoding the Carboxy-
Terminal Domain of er-Toxin 
The approach used here allowed random mutagene-
sis of the carboxy-terminal domain of er-toxin, while 
r et aining the wild-type amino-terminal domain. The 
method involved isolation of a DNA fragment which 
encoded amino acids 209-370 of er-toxin and random 
mutagenesis using the PCR with diTP, limiting dATP 
and MnC12 • When a representative sample of the 
cloned mutated DNA was sequenced, 65% of the cloned 
fr agments contained mutations at an average fre-
quency of 2 per 100 nucleotides. Approximately 1500 
clones were screened for reduced hemolytic activity by 
measuring the size of the zone of hemolysis surround-
ing colonies on agar containing mouse blood. The 
screening method employed would have allowed the 
screening of over 6600 mutations within the carboxy-
terminal domain coding region . 
Selection and Purification of S ite-Directed Mutants 
Three mutants with reduced hemolytic activity were 
selected for further study. D293S contained a single 
mutation (Asp293Ser). However , the plasmids isolated 
from the r emaining two mutants (CTM34 and 
CTM206) contained several mutations (Table I ). To 
determine which of these muta tions was responsible 
for the reduced h emolytic activity it was necessary to 
constr uct genes each containing one of the mutations 
found in CTM34 and CTM206. These genes and the 
wild-type toxin were expressed in E. coli and periplas-
mic extracts from each clone assayed for hemolytic 
activity and protein content . The mutated proteins 
Lys330Gl u and Asp305Gly were identified as having 
TABLE I 
Mutations Identified in Clones with 

















r educed hemolytic activity. The periplasmic extracts 
were then purified using a previously reported protocol 
by low-resolution ion-exchange chromatography, fol-
lowed by Mono-Q ion-exchange chromatography. The 
yield of each purified mutated protein was between 1.2 
and 16 mg/1 of culture at a purity of greater than 70%. 
Hemolytic, Cytotoxic, and Myotoxic Activities 
The variants Asp293Ser, Lys330Glu, and Asp305Gly 
showed a reduced hemolytic activity toward murine 
erythrocytes (Fig. la). They also showed reduced cyto-
toxic and myotoxic activity (Figs. lb and le). These 
findings are in agreement with previous studies show-
ing that the carboxy-terminal domain is essential for 
hemolytic, cytotoxic and myotoxic activities of er-toxin 
(13, 24- 26). Furthermore, they demonstrate the im-
portance of the residues Lys330, Asp293, and Asp305 
for the biological activities of this toxin. 
Enzymatic Activity toward Egg Yolk Phospholipid 
and pNPPC 
Asp293Ser, Lys330Glu, and Asp305Gly showed re-
duced enzymatic activity toward egg yolk phospholipid 
(Fig. ld). Only the variant Asp293Ser showed a signif-
icantly reduced activity toward pNPPC, while the vari-
ant Asp305Gly displayed an increased activity toward 
this water soluble substrate (Fig. l e). Previous studies 
have shown that the enzymatic activity of a -toxin to-
ward egg yolk phospholipid is partially dependent on 
the carboxy-terminal domain (13) and our results r e-
veal that Asp293, Lys330, and Asp305 play a role in 
the hydrolysis of this substrate. This finding might 
reflect the ability of egg yolk phospholipid to adopt a 
micella r structure which involves the packing of phos-
pholipids in a form similar to tha t found in mem-
bra nes. 
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FIG. 1. Biological activities of wild-type a-toxin and variants with single amino acid substitutions in the carboxy-terminal domain. Results 
shown are the mean of at least three independent determinations with standard error bars shown. Hemolytic activity toward murine 
erythrocytes (a), cytotoxic activity toward a Chinese hamster fibroblast cell line (b), myotoxic activity after intramuscular injection in 
Swiss-Webster mice (c), and enzymatic activity toward egg yolk phospholipid (d) or enzymatic activity toward pNPPC (e). 
Substitution of Aspartate 293 with Serine 
The carboxy-terminal domain of a-toxin is believed 
to play a key role in the calcium-mediated recognition 
of phospholipids (18). Crystallographic studies (18) in-
dicate that three distinct calcium ion binding sites 
(Ca1, Ca2, and Ca3) are present in the carboxy-termi-
nal domain of a-toxin (Fig. 2). The significance of Ca1 
and Ca3 for the biological activities of a-toxin has been 
already demonstrated (17, 18). The side chains of the 
aspartic acid residues at 269 and 336 are involved in 
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FIG. 2. Secondary structure representation of a-toxin. Shaded from red for residues predicted to be 5 A or more outside the membrane to 
blue for residues predicted to be 5 A inside the membrane. The amino-terminal domain (N) contains three zinc ions within the active site cleft. 
A modcled phospholipid is shown bound to the active site in a semitransparent representation. The three calcium ions (Cal, Ca2, and Ca3), 
bound to the carboxy-terminal domain (C) are shown in dark blue. The start and end points of the lid covering the active site cleft and 
connecting loops are labeled. Residues mutated in this paper (Asp293, Asp305, and Lys330) are highlighted and labeled. 
the coordination of Ca1 (18). The substitution of these 
residues with asparagine significantly reduced the he-
molytic, cytotoxic and myotoxic activities (24). The mu-
tant variants Asp269Asn and Asp336Asn display an 
altered calcium dependency in the enzymatic activity 
toward aggregated phosphatidylcholine (17). The main 
chain of Thr272 is involved in the coordination of Ca3 
(18). The mutant variant Thr272Pro had dramatically 
reduced hemolytic and platelet aggregating activities 
and displayed reduced enzymatic activity toward ag-
gregated phosphatidylcholine (17). 
Asp293 is one of the proposed calcium coordinating 
residues in the Ca2 site (18). The possibility that 
Asp293Ser had an altered affinity for calcium ions was 
investigated by measuring the calcium dependency of 
this variant for the hydrolysis of egg yolk phospholipid 
and by monitoring changes in mobility of calcium free 
and calcium-bound proteins (band-shifting) after na-
tive PAGE. 
The rate of hydrolysis of egg yolk phospholipid by 
wild-type and mutated a-toxins in the presence of 1.25 
or 6.25 mM calcium ions was determined as previously 
described (17). The enzymatic activity of wild-type 
a-toxin (Fig. 3) was not affected by altering the calcium 
ion concentration. In contrast, the activity of 
Asp293Ser was markedly stimulated by increasing the 
calcium ion concentration from 1.25 to 6.25 mM (Fig. 
3). A similar response of the enzymatic activity to in-
creases in calcium concentration occurs in the variants 
Asp269Asn and Asp336Asn (17) which also harbor sub-
stitutions in calcium-binding residues (18). 
To confirm that Asp293Ser had reduced affinity for 
calcium ions, the ability of the protein to bind calcium 
was determined using a calcium-dependent band shift 
method. The results showed that wild-type protein un-
derwent a band shift when free calcium ions were 
present (Fig. 4). In contrast, the mobility of Asp293Ser 
was not affected by the presence of calcium ions. 
Our findings that the variant Asp293Ser had re-
duced hemolytic, cytotoxic and myotoxic activities as 
well as an altered calcium dependency for enzymatic 
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FIG. 3. Comparison of the effect of calcium ions on the phospho-
lipase C activity toward egg yolk phospholipid of the wild-type and 
mutant Asp293Ser toxins. 0, wild-type toxin + 1.25 mM Cah; • · 
wild-type toxin+ 6.25 mM Ca2 '; 0, Asp293Ser + 1.25 mM Ca' ' ; e, 
Asp293Ser + 6.25 mM Ca2'. 
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FIG. 4. Band shift of wild-type and Asp293Ser toxins in the pres-
ence of calcium ions. Calcium depleted (lanes 1 and 3) and calcium 
bound forms (lanes 2 and 4) of the wild-type (lanes 1 and 2) and 
Asp293Ser (lanes 3 and 4) toxins were analyzed by native gel elec-
trophoresis. The positions of protein bands visible after staining with 
PhastGel Blue R are indicated by arrowheads. 
Ca2 site. The variant Asp293Ser also had reduced ac-
tivity toward pNPPC, which lacks the hydrocarbon tail 
groups of phospholipids, suggesting that the calcium 
bound to the Ca2 site plays a role in the recognition of 
the head group of the phospholipid substrate. 
Substitution of Lysine 330 with Glutamic Acid 
The substitution of lysine 330 with glutamic acid 
markedly reduced the hemolytic activity and the egg 
yolk phospholipid hydrolyzing activities without affect-
ing phospholipase C activity toward pNPPC. These 
findings show that this substitution affects the inter-
action of a-toxin with aggregated but not monodisperse 
substrates. Lysine 330 is one of a number of positively 
charged residues on the proposed membrane binding 
face of the carboxy-terminal domain (also including 
Lys328 and Arg329; Fig. 2). The Lys330Glu protein did 
not show altered dependency on calcium ions for activ-
ity toward egg yolk phospholipid (data not shown), 
indicating that Lys330 does not play a role in calcium 
binding. Lysine-rich regions in the C2 domains of eu-
karyotic proteins such as synaptotagmin have been 
shown to play a role in the recognition of the phospho-
lipid head group (27, 28) and in the binding to lipo-
somes (28). The mutation of residues within this ly-
sine-rich region reduced the ability of synaptotagmin 
to bind phospholipids (29, 30). Although there is no 
significant amino acid sequence identity between the 
C2 domains of synaptotagmin and the carboxy-termi-
nal domain of a-toxin, our previous work has shown 
that there is significant structural similarity between 
these domains (12). Our findings that mutation of 
Lys330 reduced the hemolytic, cytotoxic and myotoxic 
activities and enzymatic activity toward egg yolk phos-
pholipid suggest that the lysine rich region of a -toxin 
might play a similar role to the C2 domain of synapto-
tagmin in phospholipid recognition. 
Substitution of Aspartate 305 with Glycine 
The variant Asp305Gly showed reduced hemolytic, 
cytotoxic, and myotoxic activities. Furthermore it also 
displayed reduced enzymatic activity toward egg yolk 
phospholipid. Analysis of the 3D crystal structure of 
the wild-type protein revealed that this residue is not 
located on the membrane binding face (Fig. 2). Al-
though Asp305 is located close to the Ca2 binding site, 
the Asp305Gly protein did not show altered depen-
dency on calcium ions for activity toward egg yolk 
phosphatidylcholine (data not shown), indicating that 
Asp305 does not play a role in calcium binding. Molec-
ular modeling studies predicted that the substitution 
would not cause local changes in the structure of the 
carboxy-terminal domain. Surprisingly, the mutated 
protein was more active toward pNPPC suggesting 
that the active site in the amino-terminal domain of 
a-toxin was more accessible to substrate. 
Asp305 is located in the loop involved in hydrogen 
bonding between the amino- and the carboxy-terminal 
domains (Fig. 2). Since there are few direct contacts 
between the two domains, these hydrogen bonds are 
likely important in communicating membrane binding 
to the amino-terminal domain and causing the active 
site to open. The Asp305Gly substitution could desta-
bilize the interaction between the two domains hence 
opening the lid and making the active site more acces-
sible. This would explain the increased enzymatic ac-
tivity of the variant Asp305Gly toward the monodis-
perse substrate pNPPC. 
In conclusion, we have identified three mutated 
forms of a-toxin with reduced biological activities. Two 
mutations affected residues located in regions of the 
carboxy-terminal domain which are believed to be in-
volved in membrane phospholipid recognition and the 
third affected a residue located in the interface be-
tween the amino- and carboxy-terminal domains. Fur-
ther structural analysis of these mutants could help to 
clarify the exact role of the mutated residues in the 
interaction of a-toxin with eukaryotic cell membranes. 
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A panel of monoclonal antibodies specific for the Clostridium perfringens alpha-toxin was produced by the 
fusion of X63.Ag8-653 cells with splenocytes from mice immunized either intrasplenically or intra peritoneally 
with an alpha-toxoid. The toxin-binding activity of each monoclonal antibody was evaluated. The monoclonal 
antibodies were also screened for their toxin-neutralizing potential in vitro, as determined by the inhibition of 
phospholipase C and hemolytic activities. In vivo inhibition of toxicity was assessed by the survival of mice 
challenged with preincubated alpha-toxin-antibody mixtures. Only one monoclonal antibody (3A4D10) was 
protecti ve in vivo and neutralizing in both in vitro assays. Since 3A4D10 could inhibit both activities, the 
evidence suggests that these are colocated in the same area of the toxin molecule. This paper identifies a 
significant continuous linear binding region for 3A4D10 at positions 193 to 198 in the primary amino acid 
sequence of alpha-toxin. 
Clostridium perfringens type A is the most important 
causative agent of gas ga ngrene in man. C. perfringens is 
also the etiological agent for diseases such as equine grass 
sickness , necrotizing colitis, and enterotoxemia of horses. 
The organism produces a multiplicity of toxins of which the 
alpha-toxin is the most widely studied (13). It was the first 
bacterial toxin to be identified as an enzyme; as phospholi-
pase C (PLC), it catalyzes the hydrolysis of phosphatidyl-
choline to phosphorylcholine and 1,2-diglyceride (12). It has 
also been shown to have lethal. necrotizing, hemolytic, and 
cytolytic activities (3). 
Unlike many other bacterial PLCs, the toxin is readily 
able to interact with cell membrane phospholipids (7, 16) and 
is thought to play a key role in the pathogenesis of C. 
perfringens-mediated gas gangrene infections by promoting 
local cell membrane disruption (11, 22). In support of this , 
alpha-toxin a ntiserum has been shown to prevent the estab-
lishment of experimental gas gangrene in guinea pigs (3, 4). 
The effectiveness of alpha-toxoids in disease prevention has 
also been demonstrated (8, 9) . 
Biochemical tudies have indicated that the toxin is a zinc 
metalloenzyme in which zinc plays an important role in the 
stability and activity of the enzyme (20, 21). Calcium ions 
have also been shown to be essential for enzymatic activity 
and are thought to be involved in the binding of the toxin to 
the lipid interface (17). The gene coding for the toxin has 
been cloned, and the nucleotide sequence has been deter-
mined (18, 25 , 27). The toxin cloned by Titball et al. (25) was 
found to have a molecu lar mass of 42.5 kDa and appeared to 
be ide ntical to the alpha-tox in produced by the donor strain. 
Molecular masses of between 30 and 90 kDa have been 
previously reported for alpha-toxin depending on the method 
of analysis used (14, 23). A truncated form of the alpha-toxin 
which shows similar phosphatidylcholine-hydrolyzing activ-
ity to the native toxin but does not possess sphingomyelinase 
• Corre ponding author. 
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or hemolytic acttv1t1es has been recently produced by 
recombinant DNA technology (26). This supports the previ-
ous suggestion that both phosphatidylcholine and sphingo-
myelin hydrolyzing activities are necessary for a bacterial 
PLC to be hemolytic (15). 
Despite extensive interest in the biochemistry of alpha-
toxin , its structure-activity relationship has not been fully 
clarified. To further analyze this relationship, we have 
produced specific monoclonal antibodies (MAbs) and used 
them to map epitopes in the primary amino acid sequence of 
the toxin. 
MATERIALS AND METHODS 
Animals and reagents. Female 8- to 10-week-old BALB/c 
mice were obtained from Charles River Laboratories , Mar-
gate, Kent, United Kingdom. C. perfringens alpha-toxin was 
obta ined from three sources: as PLC (type 14) from Sigma 
Chemical Co. (Poole, Dorset, United Kingdom). as purified 
from cultures of C. perfringens type A strain NCTC 8237 
(25), and from Escherichia coli containing the cloned C. 
perfringens alpha-toxin gene (25). The truncated alpha-toxin 
(Cpa249) was expressed from a recombinant plasmid encod-
ing residues 1 to 249 of the alpha-toxin and purified before 
use (26). All other biochemicals were obtained from Sigma 
unless stated in the text. 
Production of toxoid and immunization strategy. An immu-
nogenic toxoid was produced by incubating the toxin with 
formaldehyde by the method of lto (8). BALB/c mice were 
immunized by one of two regimes. (i) A conventional immu-
nization schedule with an intraperitoneal (i.p.) priming dose 
of 0.3 1-1-g of toxoid in 50 1-1-l of pho phate-buffered saline 
(PBS) and then booster dose on days 7, 14, and 28 with 30 
1-1-g of toxoid in 50 ~-tl of PBS was used . Spleens and sera were 
taken 3 days after the final boo t to maximize yields of 
activated B lymphocytes and erum a ntibody levels . (ii) 
Alternatively, a single dose schedule, in which 20 1-1-g of 
toxoid in PBS was injected directly into the spleens of 
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anaes theti zed mice was used (24). Spleens were removed for 
fusion on the thi rd postoperative day. 
Production of hybridoma lines. Standard techniques to 
prepare hybridoma cell lines and to maximize their yield of 
antibod y by growth in ascitic mice (2) were u ed. Ascitic 
fluids were clarified by centrifugation at 1,000 x I? (15 min at 
4°C) prior to storage at -2ooc. Ascites were purified by 
ammonium sulfate precipitation and then Sepharose-staphy-
lococcal protein A adsorption (MAPs system; Bio-Rad. 
Hemel Hempstead , United Kingdom). The immunoglobulin 
concentration of the MAbs purified from ascites was calcu-
lated from the A 280 of the samples. lsotyping of MAbs was 
performed by enzyme-linked immunosorbent assay CELl SA) 
with specific antimouse isotyping reagents (Bio-Rad). 
ELISA. Hybridomas secreting toxin-specific MAbs were 
detected by using a standard ELISA format in which either 
alpha-toxin or Cpa249 was coated to the solid phase. 
PAGE. Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) was performed on gradient or 
homogenous gels. Gels were stained by using a silver stain-
ing technique (Bio-Rad) , and immunoblotting was carried 
out by transferring proteins from the acrylamide gels to a 
polyvinylidene difluoride membrane (lmmobilon P; Milli-
pore, Harrow, United Kingdom). The gel and membrane 
were placed in close contact within a gel holder cassette a nd 
immersed in transfer buffer (25 mM Tris, 192 mM glycine, 
20% [vollvol] methanol) for 1 hat 37°C, with protein transfer 
occurring by diffusion. The blots were then probed with a 
1:1,000 dilution of each purified MAb or with crude poly-
clonal antisera. Specific binding was visualized by using the 
Auroprobe BL + detection system according to the manufac-
turer's instructions (Cambio Ltd. , Cambridge. United King-
dom). 
Detection of alpha-toxin activity in vitro and in vivo. In vitro 
alpha-toxin activity was detected by using microtiter-plate-
based assays as previously described (25). Briefly. PLC 
activity was determined by its effect on egg yolk lipopro-
teins . Dilutions of toxin in 0.9% saline were placed in 0.1-ml 
volumes in the wells of a microtiter plate. An egg yolk 
emulsion (Oxoid Ltd., Basingstoke, United Kingdom) was 
centrifuged before use (at 10,000 x g for 20 min at 4°C) and 
diluted 1:10 in 0.9% saline before 0.1 ml was added to each 
well of the plate. After 1 h at 37°C, the A 510 of the samples 
was read. PLC activity was indicated by an increase in 
absorbance with the development of turbidit y. 
Hemolytic activity was determined by using freshly drawn 
citrated mouse erythrocytes suspended in borate-buffered 
saline at 5% (vol/vol). Volumes (0.1 ml) of erythrocyte 
suspension were added to equal volumes of toxin diluted in 
borate-buffered saline. After incubation for 1 h at 37°C, the 
transmission of light through sample wells was measured at 
540 nm. Increased transmission indicated hemolysis . 
In both assays, the neutralizing ability of the MAbs was 
assessed by preincubating cloned alpha-toxin with a 1.4-fold 
molar excess of purified antibody for 2 h at 37°C prior to 
addition of the egg yolk emulsion or erythrocyte suspension. 
Large molar excesses of antibod y (70-fold) were also tested 
in the hemolysis assay. 
To assess in vivo neutralization , groups of six BALB/c 
mice were given a single i.p. injection from mixtures of 1 JJ.g 
of cloned alpha-toxin preincuba ted (2 h at 3rC) wi th a 
70-fold molar excess (250 JJ.g) of purified 3A4Dl0 or a 
representative MAb, 20109, not fou nd to be neutralizing in 
vitro. A control group received an equal volume of cloned 
alpha-tox in alone. 
NTCB cleavage of alpha-toxin . NTCB (2-nitro-5-thiocy-
TABLE I. In vitro inhibition of PLC and hemolytic activities 
Inhibition (mean :!: SE) 
Treatment Hemolysis PLC !A.,0 )" (Aqo)" 
M Ab 
2DID9 (lgGll 0 .60 :t 0.01 l. I 7 :t 0.003 
A687 lgGI 0.81 :t 0.02 1.16 :t 0.003 
3A4F2 lgGI 0.60 :t 0.002 1.20 :t 0.01 
3A4D10 lgG1 0.07 :t 0.001'' 2.01 ± O.Oid 
Polyclonal a nt iserum 0.14 :t 0.001'' 1. 92 :t 0.06' 
Controls 
Toxin alone 0.48 ± 0.02 1.25 :t 0.06 
No toxin 0.07 ± 0.01 2. 18 ± 0.01 
"Cloned alpha-toxin (1.56 .,.glmll was preincubated with a 1.4-fold molar 
excess of each M Ab or a 5-fold excess (wt/wt) of polyclonal antiserum prior 
to the assay. 
• Cloned alpha-toxin ( 1.56 IJ.g/ml) was preincubated with a 70-fold molar 
excess of each M Ab or a lOO-fold excess (wt/wt) of polyclonal antiserum prior 
to the assay. 
' Differs significantly from toxin control (P > 0.1). 
J Differs significantly from tox in control (P > 0.5). 
' Differs significantly from toxin control (P > 0.5). 
I Differs significantly from toxin cont rol (P > 0.5). 
anobenzoic acid) fragments of alpha-tox in were prepared by 
using a modification of the methods described by Jacobson 
et al. (10) and Horiguchi et al. (6). Lyophilized alpha-toxin 
(Sigma type XIV) was dissolved in 0.05 M Tris Hcl , pH 8.0, 
containing 4 M guanidine hydrochloride and 0.2 mM dithio-
threitol at a concentration of 1 to 5 mg of toxin per ml. The 
sample was incubated at room temperature for 30 min , after 
which time NTCB was added to a final concentration of 50 
mM. Incubation was continued for 15 min more before the 
sample pH was adjusted to 9.0 by the dropwise addition of 
0.1 M NaOH. After incubation at 37°C for 6 h, the sample 
was dialyzed for 18 h against 0.05 M Tris Hcl , pH 8.0. 
Following dialysis, insoluble aggregates were removed from 
the sample by centrifugation (at 2,000 x g for 1 h). Samples 
were stored at - 20°C until required. 
Fine epitope mapping. Overlapping hexapeptides were 
synthesized throughout the primary amino acid sequence of 
alpha-toxin by using a modification of the multiple-peptide 
synthesis technique originally described by Geysen et al. (5) . 
supplied in kit form (Cambridge Research Biochemicals 
Ltd., Northwich , United Kingdom) . The binding of 3A4Dl0, 
the other MAbs, and polyclonal antisera to the immobilized 
peptides was assayed by ELISA in accordance with the 
manufacturer's instructions. 
The peptides corresponding to amino acid residues 193 to 
198 (ARGFAK) and 196 to 200 (FAKTG) of alpha-toxin were 
synthesized on a Milligen/ Biosearch 95100 synthesizer by 
using conventional tertiary butyl oxycarbonyl chemistry. 
Hydrogen fluoride cleavage was used to remove the peptide 
from the resin, with anisole and dimethyl sulfide as scaveng-
ing agents . 
Inhibition assay. In a variation on the standard ELISA. 
concentrations of the hexapeptide ARGFAK and the pen-
tapeptide FAKTG , ranging from 200 to 0.1 JJ.g/ml , and 
3A4D10 (1.5 JJ.g/ml) were added simultaneous ly to plates 
coated with alpha-toxin (5 JJ.g/ml) . The plates were then 
incubated for 2 to 3 h at 37°C. After washing three times in 
PBS-Tween. the standard ELISA procedure (for conjugate 
and substrate addition) was followed . 
Statistical methods. Paired t tests were used to determine 
the stati stical significance of the results obtained. 
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TABLE 2. Survival times of BALB/c mice after i. p. injection 
with preincubated toxin-MAb mixtures 
BALB/c mice 
No. of mice surviving at time postinjection" 
Toxin controls 
ToJtin + 3A4D10b 







" A total of six mice were used in each trial. 
40 h 7 days 
3 3 
6 Cloned alpha-toxin (1 JJ.S) was preincubated with a 70-fold molar excess of 
each MAb prior to injection. 
RESULTS AND DISCUSSION 
Antibodies. Hybridoma cell clones were screened for MAb 
production , and only those positive after a third recloning 
were expanded in vitro and in vivo. Twelve cell lines , of 
which two (3A4Dl0 and 3A4F2) were derived from intra-
splenically immunized animals, were produced. 
MAbs from all clones and mouse polyclonal antisera , 
derived from spleen donors, were equally reactive with 
native toxin , formol toxoid, or cloned toxin when tested by 
ELISA, but they did not cross-react with the PLC produced 
by Bacillus cere us. Isotype analysis of the MAbs secreted by 
lhese cell lines indicated that 10 were immunoglobulin Gl 
(lgGl), 1 was IgG2a, and 1 was IgG2b. All clones contained 
the K light chain . 
In vitro and in vivo inhibition of toxicity. When first 
generated, all 12 MAbs were routinely screened for their 
neutralizing potential against alpha-toxin, but only 3A4010 
was found to be neutralizing in vitro and/or protective in 
vivo. Subsequently, three representative MAbs were reeval-
uated and compared with 3A4Dl0 (Table 1). 
In vitro , 3A4Dl0 inhibited PLC activity when used at a 
1.4-fold molar excess to toxin . None of the MAbs preincu-
bated with the toxin at a molar ratio of 1.4 inhibited its 
hemolytic activity; but when the molar ratio of antibody to 
toxin was increased to 70:1, 3A4010 neutralized thi s activity 
also. Polyclonal antisera also neutralized the PLC activity 
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proximate ratio of 100:1 (wtlwt) of polyclonal antiserum to 
toxin was required to inhibit hemolysis. 
In vivo, mice challenged with toxin preincubated with 
3A4010 exhibited a significant increase in time-to-death 
(with five of six animals surviving for > 16 h) when compared 
with control animals challenged with toxin alone or with a 
mixture of toxin and an equivalent concentration of the 
nonprotective MAb 20109 (Table 2). The deaths observed 
after 16 h may be due to dissociation of the antigen-antibody 
complex. 
Our observation that higher ratios of antibody to alpha-
toxin were required for neutralization of hemolytic and lethal 
activities than were required for neutralization of PLC 
activity are consistent with our previous observations that 
the lethal activity of the toxin correlates with its hemolytic 
activity . The molecular basis of this difference in neutraliz-
ing ability is not clear. However, our observations coincide 
with those of other workers (19), who have reported the 
requirement of different stoichiometric ratios by any one 
antibody to inhibit, respectively , the PLC activity or in vivo 
effects of alpha-toxin. 
Analysis of cleavage fragments with MAbs. Cleavage of the 
alpha-toxin at the single cysteine residue (169) by using 
NTCB (Fig. la) generated two fragments (NTCB1 [22.4 kDa] 
and NTCB2 [24.7 kDa]) with different mobilities in SOS-
PAGE (Fig. lb). On Western blotting (immunoblotting) , the 
larger NTCB2 fragment was preferentially recognized by 
polyclonal antisera and was the only fragment recognized by 
3A4010. None of the other MAbs bound either fragment. 
Both the polyclonal sera and 3A4D10 recognized uncleaved 
alpha-toxin . 
Reactivity of MAbs with Cpa249• MAbs were screened for 
their binding capacity to Cpa249. All recognized the toxin and 
Cpa249 equally , indicating that the N-terminal domain of the 
toxin which Cpa249 represents has a comparable tertiary 
structure to that of native alpha-toxin (26). Thus, the 
epitopes for these antibodies are located between residues 1 
and 249 of the alpha-toxin , and the epitope for 3A4010 lies in 
the region of 169 to 249. As 3A4D10 was the only MAb to 
show any neutralizing ability in vitro and in vivo, it was 
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FIG. 1. (a) NCTB cleavage site at single cysteine residue in alpha-toxin ; (b) SOS-PAGE and immunoblot analysis of NTCB-cleaved 
alpha- toxin. The cleavage mixture was electrophoresed and silver stained (lane B) or transferred to nitrocellulose and probed with 3A4Dl0 
(lane C) or polyclonal antiserum (lane D). Molecular masses of protein standards (lane A) are shown in daltons. 
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FIG. 2. Reactivity of MAb 3A4D10 (1:1,000 dilution) (a) or polyclonal antiserum (1:600 dilution) (b) against overlapping hexapeptides 
spanning the entire amino acid sequence of C. pe1[ringens alpha-toxin. Peptide numbers correspond to the N-lerminal amino acid of each 
peptide . 
Fine epitope mapping. 3A4D10 reacted strongly and con-
sistently with a single region, Y ARGFAKT, located at 
positions 192 to 199 in the primary amino acid sequence of 
the toxin molecule (Fig. 2a). The maximum signal was 
achieved with the hexapeptide ARG F AK. 
The epitope profile achieved for the polyclonal antiserum 
is shown in Fig. 2b. Four dominant epitopes were identified 
in the sequence contained in the NTCB2 fragment. An 
additional six binding sites were found in the sequence 
contained in the NTCB1 fragment. 
Inhibition assay. Free ARGFAK significantly reduced (P 
> 0.5) the binding of 3A4Dl0 to solid-phase toxin by 
threefold , although both 3A4D10 and toxin were in approx-
imately 200-fold molar excess to ARGFAK. Thus, the pep-
tide could substitute for the epitope recognized by 3A4D10 
in the tertiary structure of the toxin molecule, indicating that 
ARGF AK is a significant linear binding sequence for 
3A4D10. The peptide FAKTG did not influence the binding 
of 3A4D10 to plate-bound toxin , suggesting that either one or 
more of the amino acids A, R, or G is essential for antibody 
binding. 
Of all the MAbs tested, only 3A4D10 identified the toxin 
after Western blotting of the denatured protein . This finding 
supports the concept that ARGFAK constitutes a short 
linear epitope for 3A4D10. The incidence of continuous 
epitopes on native proteins is low; the majority are discon-
tinuous a nd therefore conformational (1). Peptide scan meth-
odology is used only to identify minimal linear amino acid 
sequences recognized by MAbs. Therefore, the possibility 
that the ARGFAK sequence reported here is part of a 
conformational epitope exists. 
The ARGFAK sequence was not a dominant B-cell 
epitope in the conventional immunization regime used to 
generate polyclonal antisera. It may be that the acute intra-
splenic immunization procedure used to generate 3A4D10 
promoted this region as an epitope. 
Sato et al. (19) have claimed that the inhibition of different 
toxin-neutralizing activities is not linked , with one MAb able 
to neutralize lethality but not PLC activity. Consequently, 
they suggested that different sites in the toxin contribute to 
the PLC and lethal activities of the whole molecule. How-
ever, this hypothesis was eroded by their finding that any 
MAb which strongly inhibited PLC activity also afforded 
some protection against toxin in vivo. It is possible that 
phosphatidylcholine and sphingomyelin hydrolysis may oc-
cur at the same or overlapping site(s) in the alpha-toxin 
molecule. As both are thought to be required for the hemo-
lytic activity of the toxin (15), our results suggest that 
3A4D10 binds either directly to this site or to a site sterically 
related to it , preventing the ingress of enzyme substrates . 
The results presented here support the model previously 
hypothesized (26) that the C-terminal region (250 to 370) 
confers sphingomyelinase, and therefore also hemolytic and 
lethal , activity on the N-terminal domain of the molecule. 
Thus , the MAb reported by Sato et al. to inhibit lethal 
activity without affecting PLC activity could map to the 
C-terminal region. We have not produced any MAbs to this 
region , although we have demonstrated that it contains 
epitopes. 
3A4Dl0 neutralizes both PLC and lethal activities. That 
polyclonal antisera neutralize lethality without involvement 
of the linear ARGFAK sequence could be explained by a 
conformational change in the active site resulting from 
multiepitope attachment to the whole molecule . 
In conclusion , we have demonstrated that 3A4D10 inhibits 
the PLC, hemolytic, and lethal activities of alpha-toxin and 
binds to a significant linear region at positions 193 to 198 in 
the primary amino acid sequence of the molecule . Strategies 
for the presentation of an immunizing peptide derived from 
this region of the protein are under investigation. 
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We have used the technique of antibody reshaping to 
produce a humanized antibody specific for the a toxin of 
Clostridium perfringens. The starting antibody was from a 
mouse hybridoma from which variable (V) region nucleo-
tide sequences were determined. The complementarity-
determining regions (CDRs) from these V regions were 
then inserted into human heavy and light chain V region 
genes with human constant region gene fragments sub-
sequently added. The insertion of CDRs alone into human 
frameworks did not produce a functional reshaped antibody 
and modifications to the V region framework were required. 
With minor framework modifications, the affinity of the 
original murine mAb was restored and even exceeded. 
Where affinity was increased, an -altered binding profile to 
overlapping peptides was observed. Computer modelling 
of the reshaped heavy chain V regions suggested that amino 
acids adjacent to CDRs can either contribute to, or distort, 
CDR loop conformation and must be adjusted to achieve 
high binding affinity. 
Key words: antibody/molecular modelling/peptides/reshaping/ 
toxin 
Introduction 
Recent technical innovations have greatly enhanced the pro-
spects for providing human mAbs for human health care 
(Borrebaeck, 1988; Winter and Milstein, 1991 ). Major advances 
have been made in the development of genetic engineering 
techniques to convert rodent mAbs into rodent- human 
chimerics (Morrison et al. , 1984), and in protein engineering 
approaches to reshape human mAbs whilst retaining the antigen 
binding domains from rodent antibodies (Jones et al., 1986; 
Riechmann eT al., 1988; Tempest eT al. , 199 1). For first 
generation chimeric antibody technology, the variable (V) 
regions from both heavy and light chains of murine antibodies 
were combined by genetic engineering with human constant 
regions to generate antibodies posse sing -20% of murine 
antibody-derived amino ac id sequences. This leads, in prin-
ciple, to a reduced human anti-murine antibody (HAMA) 
response and allows the provision of human effector functions 
(Bruggeman eT al., 1987). However, chimeric antibodies have 
repeatedly been found to induce a HAMA response in vivo 
which prevents their extensive use in human health care. The 
second generation reshaping technology for the production 
of ' humanized' mAbs has created the potential for human 
antibodies with only -8% of murine antibody-derived amino 
acid sequences. These offer excellent prospects as molecules 
which will elicit minimal HAMA responses. The original work 
of Jones et al. ( 1986) found that direct insertion of the 
complementarity-determining regions (CDRs), as defined by 
Kabat eT al. ( 1987), into human heavy V region framework 
was sufficient to transfer antigen binding from mouse to 
human. Affinity of the final antibody was, however, slightly 
reduced. In subsequent studies, it has been confirmed that 
simple transfer of CDRs is usually insufficient to restore 
antigen binding affinity; additional amino acid substitutions 
must be made in framework regions (Riechmannet al., 1988; 
Gorman et al., 1991 ; Kettleborough et al. , 1991; Tempest 
et al., 1991 ; Foote and Winter, 1992). The extent of additional 
framework changes necessary to restore adequate antigen 
binding affinity has been analysed in some studies (Kettle-
borough et al. , 1991; Carter et al., 1992), but the number and 
position of such changes are uncertain for each individual 
humanized antibody. Since it must be assumed that the more 
alterations introduced into framework regions the greater is 
the likelihood of a HAMA response, it is important to build 
up a body of data which defines the minimum necessary level 
of such substitutions. Here, we present data showing that 
reshaping an antibody by CDR grafting, accompanied by very 
minor but strategic alterations to framework regions, can 
completely restore and indeed increase bincting affinity. 
The a toxin of Clostridium perfringens, a zinc-metallo 
phospholipase C, is a crucial determinant of pathogenicity, 
making a significant contribution to the development of gas 
gangrene (Williamson and Titball , 1993). We have shown 
previously that the murine m Ab 3a4D I 0 specifically binds at, 
or near. the active site of the enzymatic activity associated 
with the toxin (Logan et al. , 1991 ). 3a4Dl0 has been selected 
as the foundation for engineering humanized derivatives. 
Materials and methods 
Cell lines 
The 3a4D I 0 mouse hybridoma cell line (Logan et al., 199 1) 
secretes an antibody against C.perfringens a toxin. The cell 
line chosen to express the recombinant antibodies was Y82/0 
(Kilmartin et al., 1982) which is a non-immunoglobulin (lg) 
secreting rat myeloma. Both lines were grown in Dulbecco's 
modified Eagle's medium containing I 0% fetal calf serum 
(Myoclone Plus. Gibco), 30 j..tg/ml penic illin, 50 j..tg/ml trepto-
mycin and 2 .5 J.lg/ml amphotericin 8 at 37°C in an atmosphere 
of 5% C02. 
0/igonuc/eotides 
Oligonucleotides were synthesized using an Applied Bio-
systems 381 DNA synthesizer and purified using OPC columns 
(Applied Biosystems). For cDNA synthesis, the primers used 
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were VH I FOR (5' -TGAGGAGACGGTGACCGTGGTCC-
CTTGGCCCCAG-3') and VKIFOR (5'-GTTAGATCTCC-
AGCTTGGTCCC-3'). 
For amplification of heavy and kappa chain V region cON As, 
additional primers used were VH I BACK [5' -AGGT(C/G)(A/ 
C)A(A/G)CTGCAG(C/G)AGTC(A/T)GG-3' I and VK3BACK 
(5'-GACATTCAGCTGACCCA-3'). 
For COR grafting, mutagenic primers were VHCDR I (5'-
CTGTCTCACCCAGTGTATATAGTAGTCCTGAAGGTGA-
AGCCAGACACGGT-3 '), VHCDR2 (5 '-CATTGTCACTCT-
GCCCTGGAACTTCGGGGCATATTCAGTATCAACATT-
CTCAGGATCAATCCATCCAATCCACTC-3 '), VHCDR3 (5'-
CCCTTGGCCCCAGTAGTCAAAGGGGTAATCAGA-




ATCAGCAG-3') and VKCDR3 (5'-CCCTTGGCCGAA-
CGTCCGAGGAAGCTCCCTACTTTAGCTGGCAGTAGTA-
GGT-3'). 
Additional oligonucleotides for site-directed mutagenesis of 
the human VH framework were VHNA (5'-GTAGTCCAATG-
CATTACAATAATAG-3') and VHNIK (5'-ATATAGTAGT-
CTTTAATGTTGAAGCCAGACA-3') and its reverse 
complement. 
RNA isolation/cDNA synthesis 
Cytoplasmic RNA was isolated es entially as described by 
Favaloro et al. (1980). Poly(A)+ RNA was selected from total 
cytoplasmic RNA by affinity chromatography on oligo(dT) 
cellulose (Maniatis et al., 1982). 
Reactions for cDNA synthesis contained 5 Jlg mRNA, 
0.4 JlM VHIFOR or VKIFOR, 250 J.!M each of dATP, dCTP, 
dGTP and dTTP, 50 mM Tris-HCI pH 7 .5, 75 mM KC I, I 0 
mM OTT, 3 mM MgCI 2 and 27 U RNase inhibitor (Pharmacia) 
in a·· total volume of 50 !!I. Samples were heated at 70°C for 
10 min and slowly cooled to 42°C over a period of 30 
min. Then I 00 U murine Moloney leukaemia virus reverse 
transcriptase (BRL) were added and incubation continued at 
42°C for I h. 
Amplification of V H and V K DNA 
For amplification of VH, DNA- primer mixtures contained 5 Jll 
RN A-cON A hybrid and 0.5 J.!M each of VH I FOR and 
VH I BACK. For amplification of V K• ON A-primer mixtures 
contained 5 Jl] RNA-cDNA hybrid and 0.5 J.!M each of 
VK1FOR and VK3BACK. To these mixtures were added, in 
a final reaction volume of 50 Jll. 50 mM KC!, 1.5 mM MgCI2, 
lO mM Tris-HCI pH 8.4, 0.02% (w/v) gelatin and 2.5 U 
Taq DNA polymerase (Perkin-Elmer Cetus). Samples were 
subjected to 25 thermal cycles of 94°C for I min, 60°C for 
I min, 72°C for 2 min and ending with 5 min at 72°C. 
Amplified V H and V K cON As were cloned into M 13 and 
sequenced. 
CDR grafting 
Oligonucleotide site-directed mutagenes is of the human VH 
and V K genes was based on the method of Eckstein (Taylor 
et al., 1985a,b; Nakamaye and Eckstein, 1986) as described 
previously (Tempest et al., 1991 ). Acceptor human V regions 
were modified versions of NEWM V H (Poljak et al., 1977) 
and REI VK (Palm and Hilschmann. 1975) genes. In NEWM 
VH, Thrl07 and Thrl08 residues were included as residues 
typical of human V H subgroup 11. In the version of REI V K 
used, Lys39. Phe71. Vall 04. Glu I 05 and Lys I 06 were included 
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as residues typical of human V.,;, subgroup 1: Leu4 was used 
to accommodate a restriction site. 
Framell'ork mwagenesi.1 
Residues Ala93 and Arg94 were changed to Asn93 and Ala94 
by site-directed mutagenesis u~ing the VHNA oligonucleotide. 
Residues Thr28. Phe29 and Ser30 were changed to Asn28. 
11 e29 and Lys30 via PCR-directed mutagenesis (Ho et al .. 
1989) using the oligonucleotide VHNIK and its reverse com-
plement. 
Antibody expression 
Reshaped antibodies were expressed in vectors pSVgpt and 
pSVhyg (Orlandi et al., 1989). The reshaped V H gene. together 
with the Ig heavy chain promoter. signal peptide and appro-
priate splice sites. were excised from M 13 by digestion with 
Hindlll and BamHI. They were cloned into pSVgpt which 
contains the Ig enhancer sequence, the SV40 origin of replica-
tion, the gpt gene for selection and genes for replication and 
selection in Escherichia coli. Finally, a human IgG I constant 
region (Takahashi et al. , 1982) was added as a BamHl fragment. 
The pSVhyg vector for expression of the kappa chain gene is 
essentially the same. except that the gpt gene is replaced by a 
hygromycin resistance gene. The reshaped V K gene was excised 
from M 13 by digestion with Hindlll and BamHI, and cloned 
into pSVhygHuCK which is equivalent to pSVhyg but with a 
human kappa chain constant region (Hieter et al., 1980). 
Transfection into rat YB2/0 myeloma cell and ELISA detec-
tion of reshaped antibodies from transfected cells were as 
described previously (Tempest et al., 1991 ). Antibody was 
purified using protein A-agarose. 
EL/SA analysis of binding to a toxin 
The wells of a microtitre plate were coated overnight at 4°C 
with I Jlg a toxin (Sigma) per well. After blocking and 
washing, the reshaped antibodies were applied for I h at room 
temperature. The wells were then emptied, washed and the 
immobilized antibodies incubated for I h at room temperature 
with either peroxidase-conjugated or biotinylated goat anti-
human IgG antibodies (Sera-Lab), both diluted I: I 000. When 
using biotinylated second an tibodies, detection was with perox-
idase-labelled streptavidin (Sera-Lab) for 30 min at room 
temperature. The substrate for peroxidase activity wa o-
phenylene diamine. 
Affinity measurements 
a Toxin (50-200 Jlg) in I 00-200 111 PBS was reacted with 
500 j..lCi 1251 in the presence of 0.2 mg/ml chloramine T for 
2 min at room temperature. The reaction was stopped by the 
addition of 50 Jll PBS containing I 0 mg/ml tyrosine, 2 mg/ml 
sodium metabisulfite, I 0% (w/v) glycerol and 0.1 % (w/v) 
xylene cyanol. The mixture was loaded onto a Sephadex 
G25 column and six drop fractions collected. The fractions 
containing iodinated a toxin were pooled and dialysed exten -
ively against PBS. 
For affinity measurements. constant amounts of antibody 
( 1.0- 2.5 Jlg) were incubated with varying amounts of iodinated 
a tox in (0.5- 16.0 j..lg) for 2 h at room temperature. The 
immune complexes were collected by incubating with protein 
G- agarose for I h at room temperature. The protein G-agarose 
beads were removed by centrifugation: the amounts of free 
antigen remaining in the upernatant and. after rapid washing, 
of 1251-labelled antigen associated with the protein G, were 
measured in a gamma counter. A control experiment was 
perfonned in parallel using an irrelevant human IgG I antibody. 
Control experiments confi rmed that binding of both mouse 
and human lgG I antibodies to protein G was quantitative. The 
results were graphically represented by plouing the amount of 
free antigen (Ag) against the amount of bound antigen (Ab·Ag) 
using a Sips plot whereby the slope of the line. as filled by 
the least squares method, was equal to I. The equilibrium 
constant (K) was calculated as the reciprocal of the free antigen 
concentration when ha lf the antibody combining sites were 
occupied (i .e. when log 10[Ab·Ag]/!Ab1] - I Ab·Agl = 0). 
Therefore, the reciprocal of K could be obtained from ex tra-
polation to the abscissa. For the purposes of the calculation, 
it was assumed that there are two antigen combining s ites per 
antibody molecule and one binding site per toxin molecule. 
Fine epitope mapping 
The binding of antibodies to overlapping peptides ( ix to nine 
residues) based on the primary ami no acid sequence of o: tox in 
was assayed by ELISA using immobi lized peptides as described 
previously (Logan et al., 1991 ). 
Modelling antibody structure 
Modelling of COR-grafted 3o:4D I 0 antibody was undertaken 
us ing the QUANTA molecular modelling package (written 
by R.E.Hubbard, Univers ity of York, UK) and a homology 
modelling system that has been developed a an application 
of an object-oriented database of protein structure data (Gray 
et al. , 1990; Kemp, 1991 ). The model of the VH domai ns wa 
based on lg NEW [Poljak et al., 1974; Brookhaven Protein 
Data Bank (PDB) entry 3FAB; Bemstein et al., 1977] . For 
modelling of the hypervariable loops (HI-3), the HI region 
of the 3o:4D I 0 antibody is the same length as that in the 
known structure of NEW, whereas the H2 and H3 regions are 
all longer in 3o:4D I 0 than in NEW, so insertions were made 
in the models. 
For the V H domain, the residue corresponding to position 
7 1 was Val, suggesting that the H2 regions will adopt canonical 
conformation 2, as defined by Chothia et al. ( 1989). Therefore, 
the H2 region of HyHEL-5 (Sheriff et al. , 1987; PDB entry 
2HFL) was retrieved from the database and incorporated into 
models of the VH domains. For the eight residue H3 region, 
the McPC60 H3 region was cho en having nine residues 
(Satow et al. , 1986; PDB entry I MCP). This H3 region was 
retrieved from the database. After breaking the polypeptide 
chain in the most extreme part of the loop, local <1> and 'V 
angles were adjusted to overlap and then delete one residue. 
At positions in the structural framework where the residue 
to be modelled wa identical to that at the same position in 
the known s tructure being used as the basis for the model, the 
side-chain conformation was taken directly from the known 
structure by retrieving the coordinates of the known side-chain 
atoms from the database and copying these into the model. 
Other side chains were placed using the molecular graphic 
package. Side-chain torsion angles were adjusted interacti vely 
to minimize steric overl ap. 
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Results 
V region sequence analysis of murine antibody 
The orig inal hybridoma secretes the m Ab 3o:4D I 0 (lgG I, K; 
Logan et al .. 199 1) specifi c for C.pet:fringens o: toxin. This 
antibody has been characteri zed ex tensive ly and binds to the 
hexapeptide ARGFAK located between residues 193 and 198 
in the mature toxin (Logan et al., 1991). 
Cytoplasmic R A was prepared and cDNA from the Ig 
mRNA deri ved using primers specific for lg heavy and light 
chain V regions. VH and VK cDNAs were then amplified using 
the PCR and cloned into M 13. Amplified DNAs from two 
separate c D A preparations were sequenced in both directi ons 
from at least I 0 independent c lone . One type of V H and two 
species of V K sequence were isolated. However, one of the 
V K sequences was expected to be unproductive becau e it had 
the invariant Cys23 replaced with Tyr and also had a reading 
frameshift within CDR3. This sequence has also been isolated 
from other hybridomas in our laboratory and e lsewhere. and 
originates from the fusion partner used in the production of 
the murine hybridomas. The deduced amino acid sequences 
of 3o:4D I 0 V H and V K are shown in Figure I. The V H and 
V K sequences are members of murine subgroups IIC and III , 
respectively (Kabat et al., 1987). Nucleotide sequences of V H 
and VK have been deposited in GenBank with accession 
numbers L25353 and L25352, respectively. 
Transplantation of CDR sequences into human frameworks 
The human frameworks chosen to accept the CDRs were 
derived from modified versions of NEWM for VH and REI 
for V K• and were within M 13-ba ed templates with irrelevant 
CDRs, as described by Riechman n et al. ( 1988). 
Oligonucleotides were synthesized to encode the 3o:4D I 0 
VH and V K CDRs flanked by short sequences derived from 
NEWM and REI, respectively. They were grafted into the 
human frameworks by site-d irected mutagenesis. As well as 
introducing the three CDRs, one additional alteration was 
made in FRI of VH· In the VH of NEWM, Ser27 is unusual 
compared with Phe and Tyr most often found in this position 
in human VHs. Since the side chain of residue 27 normally 
locates in COR I and the original murine V H had Phe in this 
position, there was the possibility that the side chain of Ser 
might not pack the ame way as with the aromatic ring of 
Phe. Accordingly, Ser27 wa mutated to Phe27 to give the 
basic COR transplanted VH (HuVH, Figure 2). Comparison of 
the murine and human V Hs a lso revealed in 3o:4D I 0 the amino 
acid Ala at position 94 instead o f the more usual Arg. The 
majority of murine and human V Hs have Arg94 which is able 
to form a salt bridge with the re latively conserved AsplOI in 
CDR3 (Chothia and Lesk, 1987). Since the murine antibody 
lacked Arg94 but had Asp I 0 I, a second antibody construct 
was made with the murine Ala94 replacing the human V H 
6 0 10 so 9 0 1 00 11 0 
COR2 CORl 
HuVH ~VRSGASVRLSCTASGF"Nt X DYY rB WVJlQRPDOGL.EWIC WIDPENVDTEYAPltP'QO AATMTADTSSNTAYLQLSSt..TSVDTAVYYCNA LDYSOYPP'DY WGQQTI'VIVSS 
1 0 20 lO eo so 60 10 so 9 0 100 
COR! COR2 CORl 
HuVk QliUUl2SPASLAVSLGORATISC RTSJtSVST.OYSYMB WYOOilPOQPPQLLIY U.S.It.LES GVPARFNGSGSG11)f'TI..NIHPVE££0A.ATYYC OQSULPRT F'GGGTJJ...£1 
Fig. l. Deduced amino ac iu ' C4UCtll"C' of variable region' of murine 3a40 10 amibody. Region<. of V11 and VK which were e ncoded by the PCR primer' used 
for amplification arc underlined. 
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MuVH OVQLQESGAEI...VRSGASVRLSc.-I"ASGrNI K DYYIB WKORPDOGLEWIG WIDPENVDTEYAPKPOO KATKTA.D'TSSNTAYLQLSSLTSVDTAVYYCNA LDYSDYPP'DY W(iOGTIVIVSS 
NEWM rr .. mework ·-···-·· PG-·- PSOTLS ·T· ·V- -STFS 
· - R- P- GR · · · -- ·-··li· 
HuVH ·· R· P· GR - --- - · ···· ···-- ---- • ··- RV- -LV-- - lt-OF'S·R· --V - AA··-··· ·A.R ···------ -
HuVHNA 
lhJVHNI KNA -- R- P- GR-· -··· ---- - - -- --- --- -·- RV--LV--- K·Of"S - R---V · A.A······ ··· ··· ----- - - ·• • ••• • •·•• 
1 0 20 ) 0 4 0 50 60 70 1 0 90 l OO 
cr>Rl CDR2 CORJ 
MuVK DIOLTQSPASLAVSLOQRATISC RTSJtSVSTSOYSYMB WYQOKPGOPPOLLI Y L.\.SXLES GVPARFNGSGSGTOF'TLN1HPV££EOAATYVC OOSllELPRT f"GGGTKLEI 
REI F-r.amework - •. -j\· -I<A- K-- • • -- · S · ·S· ·- · · · - .E-I'T-SSLQP- -I -·--- . -0 ·. -l!i; · !i 
HuVJt --------9- - SA-V· D· V· · T· - • • • · • ·- •• • • •• • -·- - -- • KA-K---- · · · S· · S·- - -- - -- - F"T·SSLQP· -1 - - --- ··0 · · -Ja: -- K 
Fig. 2. Comparison of amino acid sequences of V regions of murine (MuVH. MuVK) and reshaped (HuVH. HuVHNA, HuVHNIKNA. HuVK) Ja4D IO 
heavy and light chains. The sequences of the acceptor human NEWM and REI frameworks arc included. with modified amino acids underlined (sec Materials 
and methods). CDRs are in bold type. Dashes indicate identity to the murine residues. Numbering is according to Kabal et al. ( 1987). Nucleotide sequences 
have been deposited in GenBank wi th the following accession numbers: MuVH. L25353: MuVK, L25352; HuVH. U05281 ; HuVHNA. U05282; 
HuVHNIKNA. U05286; HuVK. U05283 . 
Arg94; this al o included the neighbouring Asn93 residue 
replacing the human VH Ala93, a position which in some 
antibodies (e.g. Alzari el al., 1990) is known to contact antigen 
(HuVHNA, Figure 2). A third VH construct was made with 
the human residues Thr28, Phe29 and Ser30 changed to the 
murine Asn28, Ile29 and Lys30, in addition to the Asn93 and 
Ala94 mutations (HuVHNIKNA, Figure 2). Thi mutant was 
constructed because theN-terminal residues adjacent to CDRI 
are structurally a part of the first loop, although they are not 
within the stri ct hypervariable definition of Kabat et al. ( 1987). 
The reshaped V K (Hu VK, Figure 2) was constructed by the 
replacement of CDRs only. 
Expression of reshaped antibody 
The three reshaped VHs (HuVH, HuVHNA and HuVHNIKNA) 
and the reshaped V K (Hu VK) were cloned into the expression 
vectors pSVgpt and pSVhyg and cotransfected into rat myel-
oma YB2/0. Gpt+ transfectants were selected and screened for 
antibody production. Clones were expanded and antibody was 
purified from supernatants by protein A affinity chromato-
graphy. Yield of antibody was 2- 10 J.l.g/ml/106 cells. Herein-
after, reshaped antibodie are designated by the humanized VH 
variant residues, i.e. Hu, HuNA and HuNIKNA, which com-
prise HuVH- HuVK, HuVHNA- HuVK and HuVHNJKNA-
HuVK chains, respectively. 
Binding of antibodies to a toxin 
Figure 3 show the relative binding of the reshaped antibodies 
Hu, HuNA and HuNIKNA to a toxin as measured by ELISA. 
The antibody Hu exhibited very low binding to o. toxin, whi lst 
antibodies Hu A and HuNIKNA exhibited superior binding 
efficiencies. Absolute binding affinities cannot be compared 
between murine and reshaped antibodies by this as ay, since 
immunoconjugate of different specificities are used. Direct 
comparison of binding affinities of murine and reshaped 
antibodies by equi librium binding assays, where quantitative 
binding to protein G was obtained, is depicted in Figure 4. 
This gave estimated equilibrium cons tant K values of 1.3X 109 
M- 1 for Hu A compared wi th 0. 19X 109 M- 1 for the original 
murine 3o.4D I 0 antibody (Mu), with this 5- to I O-f old differ-
ence repeatable in other experiment . From a limited analysis 
as shown, Hu I K A exhibi ted a similar K value (2.0X I 09 











0.2 0.8 3.t 12.5 50 200 
ANTIBODY. ng 
Fig. 3. ELl SA analysis of variant reshaped Ja4D t 0 antibodies for binding 
10 immobilized C.peifringens a toxin. 
Binding of antibodies to synthelic peptides 
Earlier studies have shown that the murine 3o.4D I 0 bind to 
the epitope ARGFAK representing residue. 193- 198 of o. 
tox in (Logan et al. , 199 1 ). Figure 5 compares the relative 
binding of murine and Hu A antibodies to a series of 
overlapping peptides around the ARGFAK epitope. It can be 
seen that the re. haped antibody displayed an altered specificity 
of binding to peptides, including the ARGFAK sequence, in 
comparison with the murine antibody. This altered specificity 
may be related to the higher affinity of the reshaped antibody 
as shown in Figure 4, although with the use of different 
detecting an tibodies no direct comparison of peptide binding 
affinity is pos ible. 
CompLIIer modelling of reshaped antibodies 
Computer models of the HuVH, HuVHNA and HuVHNIKNA 
V H domains were constructed and the interactions between the 
grafted CDRs and the frameworks analysed in an attempt to 
explain the effect~ of the retained mouse residues in the 
-0.5 
f • <(.0 .ci~ -1 • <(~ ~ .0 <( 0~
Ol 
..Q 
-1.5 • Mu 
• HuNA 
• HuNIKNA 
-10 -9 .8 -9.6 -9.4 -9 .2 -9 -8.8 -8.6 -8.4 -8.2 -8 
log,0 [Ag] 
Fig. 4. Equilibrium binding assays of variant reshaped (HuN A. HuN!KNA) 
and murine (Mu) 3a4D I 0 ami bodies for binding to 125!-labelled a toxin. 
[Ab·Ag], [Ab, I and [Agj are concentrations of bound antigen, total anribody 
and free antigen. respectively. Lines were fitted by the least squares method 
and the extrapolation of lines to the abscissa jave an estimate of the 
reciprocal of affinity constant, K. Values of R- for the fitted lines were 0.90, 
0.93 and 0.96. respectively, for Mu, HuNA and HuNIKNA. 
humanized VH framework. The model (Figure 6) depicts the 
positions of residues 28-30 and 93/94 in heavy chains of the 
Hu antibody (top) and the HuNIKNA antibody (bottom). This 
suggests that the side chains of residues 28 and 30 are on the 
surface of the molecule and are likely to contribute to HI loop 
confonnation and possibly direct.ly to antigen binding (Amit 
et al., 1985). The dipeptide 93/94 is immediately before the 
CDR3 region defined by Kabat et al. ( 1987). The model 
indicates that the side chain of Arg94 reaches the ex ternal 
surface between the HI and H3 regions and may interact with 
Asp96 or Asp I 0 I in the H3 region. Retention of this Arg 
may distort the amigen binding conformation of H3. Hence, 
replacement of this Arg by Ala permits the H3 region to 
assume its correct conformation and restore binding affinity. 
The relevance of Asn93 for increased binding affinity was not 
tested, al though the model suggests that this residue is in the 
interior of the VH domain and may be replaceable by Ala93. 
Discussion 
The heavy and light chain V regions of antibodies consist of 
a relatively conserved framework of P-pleated sheets from 
which emanate six loops, defined as HI, H2, H3, L I, L2 and 
L3 by Chothia and Lesk ( 1987). The CDRs, as defined by 
Kabat et al. ( 1987), generally include these loops, but can 
additionally include residues within the P-sheet framework. 
Residues flanking these CDRs may lie in one of the surface 
loop regions (as with VH positions 28-30 which are within 
HI ), or may be located where they can interact with or affect 
the conformation of the CDRs (as with V H position 94). Thus 
it is anticipated that in some cases a humanized antibody 
constructed by grafting only the Kabat-defined CDRs from a 
mouse mAb may not retain the binding affinity of the progenitor 
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Fig. 5. Binding analysis of reshaped HuNIKNA (A) and murine (Mu) 
(B) 3a4D I 0 antibodies to overlapping synthetic peptides from the region of 
C.pe1jringens a toxin recognized by 3a4D I 0 antibody. 
demonstrates that strategic mutations outside the CDRs can 
restore and even enhance binding affini ty. 
Two different methods have been adopted to combine CDR 
grafting with framework changes and restore binding affinity 
during reshaping of human antibodies with murine CDRs 
(reviewed in Mountain and Adair, 1992). For the homology 
matching approach, Queen et al. ( 1989) firstly selected the 
human framework sequences which most closely resembled 
the sequences from the original murine antibody and grafted 
the CDRs into these. Next, they replaced most of the human 
framework residues which differed from those in the original 
murine antibody with the residues from the latter. This involved 
the replacement of seven residues in the heavy chain and two 
residues in the light chain frameworks. For the fixed framework 
approach, as practised in our laboratory, we have consistently 
used the NEWM heavy chain variable region framework and 
REI light chain variable region framework. irrespective of the 
amino acid sequence similarity with the donating murine 
antibody. In this example, there was only 64 and 75% sequence 
identity between the heavy and light frameworks, respectively. 
Our approach is to introduce strategic changes into frameworks, 
selection being on the basis of the likely conformation of the 
CDRs. It can be seen from the present data that this approach 
can restore and indeed sometimes increase binding affinity 
over that of the original murine antibody. Our experience with 
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Fig. 6. Computer models highlighting part of the VH region of the Hu antibody (top) and the HuNIKNA antibody (bonom). highlighting the variant amino 
acids between the two antibodies and their juxtapositions with HI (red}, H2 (green) and H3 (yellow). 
a number of different reshaping studies has shown that one 
can effectively restore binding affin ity to a range of antibodies 
with a minimum number of changes to framework residues, 
the overall amino acid equence identity between murine and 
human frameworks being of much less relevance than the 
conformational interactions between CDRs and individual 
framework residues. Indeed, by using the same NEWM and 
REI human frameworks for different reshaping studies, we 
have found that the alterations required to restore binding 
affinity are conserved between different humanized antibodies. 
For example, in the humanized VH chain based on NEWM, 
altered mouse residues at positions 28-30, 48-49 and 91-94 
are usually tested individually and in combination, with a high 
proportion giving restored antigen binding. Other alterations 
are also often tested individually (e.g. position 71 ), al though 
some mouse residues can give reduced affinity in specific 
antibodies. 
A major aim in reshaping human antibodies for therapy is 
to eliminate any possibility of HAMA response in vivo. In 
addition, human(ized) mAbs are preferable to rodent antibodies 
in investigating the repertoire of human immune response as 
a research tool. It is thus the aim to have the very minimum 
of mouse residues u·ansferred. In th is study, it would be 
j udicious to select the HuNA derivative as a potential thera-
peutic in preference to HuNIKNA, since any improvement in 
affinity of the latter is unlikely to significamly alter the 
therapeutic dose required in vivo and does not justify the 
introduction of additional murine residues. We believe that the 
approach of using the same human frameworks fo r COR 
grafting, with the introduction of the abso lute minimum of 
non-human residues, goes some way to reducing the possibility 
of HAMA response in vivo, although the success of the 
approach will onl y be proven by clinical studies. 
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A genetically engineered vaccine against 
the alpha-toxin of Clostridium 
perf ringens protects mice against 
experimental gas gangrene 
E.D. Williamson and R.W. Titball* 
Fragments of the alpha-toxin of Clostridium perfringens have been produced using genetic 
manipulation techniques. Antibody which cross-reacted with the alpha-toxin was induced 
after immunization with fragments representing the N- (Cpa1 _149) and C-terminal 
(Cpa247-37o) domains of the toxin. Smaller fragments of the alpha-toxin did not induce 
cross-reacting antibody. Anti-Cpa1 _249 serum neutralized phospholipase C activity but not 
haemolytic activity of the toxin. Anti-Cpa247 _370 serum neutralized both the phospholipase 
C and haemolytic activities. Only immunization with Cpa147 _370 induced protection against 
the lethal effects of the toxin. Immunization with Cpa247 _370 also provided protection in 
a mouse model against at least 10 LD100 doses of C. perfringens type A. This result 
confirms the essential role of this toxin in the pathogenesis of gas gangrene. 
Keywords : Gas gangrene vaccine; alpha-toxin vaccine; C. perfringens vaccine 
Clostridium perfringens is ubiquitous in the environment 
and has been found in soil, decaying organic matter and 
as a member of the gut flora in humans and animals1 . 
Different strains of C. perfringens can be assigned to one 
of five biotypes (A- E) depending on the spectrum of 
toxins produced2 . Biotype A strajns are of particular 
importance as the aetiological agents of gas gangrene in 
humans. Gangrenous disease is of increasing significance 
in elderly and diabetic populations, especially in those 
who have undergone lower limb surgery, where impaired 
blood supply to tissues can lead to anoxic conditions 
suitable for multiplication of bacteria 1 . The disease can 
also arise in patients who have undergone surgery of the 
gastrointestinal tract when contamination of damaged 
tissues with gut contents can result in the establishment 
of disease. A more periodic increase in the incidence of 
gas gangrene has occurred during armed conflicts when 
deep tissue wounds have become contaminated with soil. 
The failure to treat such injuries promptly resulted in the 
death of several hundred thousand soldiers during the 
First World War 3. 
The pathogenesis of gas gangrene can be largely 
attributed to the production of potent exotoxins by the 
bacterium 2 • Of these, the alpha-toxin has received 
particular attention as the major contributor to the 
Chemical and Biological Defence Establishment, Porton 
Down, Salisbury, Wiltshire, SP4 OJQ, UK. ·ro whom 
correspondence should be addressed. (Received 15 October 
1992; revised 21 January 1993; accepted 8 February 1993) 
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disease4 ·5. The toxin may act peripherally to the initial 
focus of infection by damaging and reducing the blood 
supply to tissues, thus promoting the conditions required 
for spread of the infection. In the later stages of the disease 
the toxin may act systematically, causing death5• A crude 
C. perfringens toxoid vaccine was demonstrated to 
provide protection against experimentally induced gas 
gangrene as long ago as 19376 and subsequent studies 
suggested that the effective component of this vaccine 
was derived from the alpha-toxin4 •7 •8 . However, since 
most of these studies used preparations which were 
almost certainly contaminated with other C. perfringens 
proteins, the studies were by no means conclusive. In 
spite of these favourable results a vaccine has not been 
developed for use in humans and current treatment for 
gas gangrene usually involves the removal of the affected 
limb or tissues. 
We have previously isolated the gene encoding the 
alpha-toxin9 and examined structure- function relation-
ships of the protein 10· 11 . As part of these studies we 
determined the location of some antibody epitopes 1 2 . 
These studies have enabled us to explore the possibility 
that a genetically engineered non-toxic derivative of the 
alpha-toxin could be developed. Such a vaccine would 
be relatively safe and simple to produce. To this end, we 
report here the production of genetically engineered 
truncates of the alpha-toxin and their evaluation as 
vaccine candidates. In addition, since these truncates are 
free of the heterogenous components present in crude C. 
perfringens toxoid vaccines, these studies have allowed 
us to assess the role of alpha-toxin in gas gangrene. 
Vaccine, Vol. 11 , Issue 12, 1993 1253 
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MATERIALS AND METHODS 
Animals 
Barrier-bred , female, 6-week-old Balb/ c mice, free of 
mouse pathogens, were obtained from Charles River 
Laboratories , Margate, Kent , UK, and were used 
throughout these studies. 
Chemicals 
All chemicals used in this study were obtained from 
the BDH Chemical Co. (Poole, UK) or the Sigma 
Chemical Co. (Poole, UK) unless o therwise stated. 
Bacterial strains, plasmids and growth media 
Escherichia coli strains pop2136 and JM I 05 were 
maintained as glycerol stock cultures 13 and subcultured 
as required onto L-agar or into L-broth 13 . When 
appropriate, ampicillin was added to a final concentration 
of 50 Jlg ml - 1 . Broth cultures were normally aerated by 
shaking at !50 rev min- 1 in a New Brunswick (Hatfield, 
UK) environmental shaker. C. perfringens strain NCTC 
8237 (biotype A) was cultured in 100 ml volumes of a 
liquid medium containing trypticase peptone (BBL, 
Oxford , UK; 50 g 1- 1 ) , yeast extract (Difco, East 
Molesey, UK ; 5 g 1- 1 ) , proteose peptone (Difco ; 5 g 1- 1 ), 
glucose (5 g 1- 1 ), cysteine hydrochloride (0.5 g 1- 1 ), 
thioglycollicacid (1 g 1- 1), Na2HP04 (2.26 g 1- 1), KH2P04 (1.4gl- 1 ), MgCI 2 . 6H 2 0 (0.2g l- 1) , ZnC12 (6mg l- 1 ), 
adjusted to pH 7.3 with NaOH (TPYG broth). The broth 
was inoculated with sedimented cells from 10 m! of an 
18 h culture, and resuspended in fresh TPYG broth. The 
cultures were incubated at 37°C in an anaerobic 
environment (80% N 2 , 10% C02 , 10% H 2 ) in 
an anaerobic incubator (Don Whitley Scientific, Shipley, 
UK). The a bsorbance (A600) of cultures was monitored 
and viable counts were made by plating cells onto BHI 
agar (Oxoid, Basingstoke, UK) .. A standard curve was 
constructed to permit extrapolation of viable cell 
numbers from the absorbance of the cultures. 
Plasmid pB15b encodes theN-terminal domain of the 
alpha-toxin (Cpa 1_ 249 ) expressed from the cpa gene 
promoter 11 • Plasmid pB3X13 14 encodes the C-termina l 
domain of the alpha-toxin (Cpa2 4 7_ 370) fused with 
glutathione-S-transferase in the expression vector pGEX-
3X (Pharmacia-LKB Biotechnology, Milton Keynes, 
UK). Proteolytic cleavage with factor x. (BCL) was used 
to generate Cpa24 7_ 370 alone 14 • Plasmid pEX3, which 
encodes a cro- lac Z polypeptide followed by a multiple 
restriction enzyme si te polylinker, was supplied by BCL 
Ltd. The plasmid was propagated in a bacterial strain 
(pop2136) which carried the cl ts857 repressor. 
Manipulation of DNA 
All enzymes used for the manipulation of DNA were 
supplied by Boehringer Mannheim Ltd, Lewes, UK 
unless otherwise stated and were used in accordance with 
the manufacturer's instructio ns. Plasmid was isolated 
using methods described by Sambrook et al. 13 a nd when 
required was further purified by caesium chloride density 
gradient centrifugation 13• To generate recombinant 
plasmid pL30-I , plasmid pT2.2, encoding the alpha-
toxin9, was first digested with BamHI and Hindiii 
restriction endonucleases. A DNA fragment, encoding 
residues 99 to 249, was isolated after electrophoresis 
through a n agarose gel onto DEAE cellulose filter paper 
(Schleicher and Schuell , Den Bosch, Netherlands) from 
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which it was then eluted 13 . The insert DNA was mixed 
in a ra tio of 3: I with p EX3 plasmid which had previously 
been digested with BamHI a nd Hindlll before DNA 
ligase ( I U) was added to the mixture (tota l volume 
20 Jll). The mixture was transformed into competent E. 
coli pop2136 cells15 . Colonies expressing the cro-P-gal-
alpha-fragment fusion protein were identified by 
examining the protein profiles of cell s, from small scale 
cultures, after SDS- polyacryla mide gel electrophoresis. 
Plasmid pL30-I-I was generated by self-ligating plasmid 
pL30-I , which had been digested with Sma I and EcoRV 
to eliminate the fragment of the a lpha-toxin encoding 
residues 99- 178. 
Production and purification of candidate vaccine 
polypeptides 
E. coli pop2136 containing manipulated plasmids 
pL30-I or pL30-l-l was cultured in 300 m! of L-broth 
containing ampicillin until the A600 of the culture reached 
approximately 0.6 units. To induce expression, the 
culture flasks were placed into a water bath at 42°C for 
30 m in and then shaken (190 rev m in- 1 ) for a further 2 h 
a t 42°C. The bacterial cells were collected by 
centrifugation (5000g, 5 min, 4°C), resuspended in 30 ml 
of0.01 M Tris buffer (pH 7.6 with HCI) and recentrifuged. 
The washed cell pellet was resuspended in 30 m! of Tris 
buffer and 650 Jll of lysozyme solution added (2 mg ml - 1 ) 
followed by 1.5 m! of0.1 M EDT A solution (pH 8.0). After 
incubation for 10 min at 22°C the cell suspension was 
sonicated for 15 s (maximum power, Braun Sonicator, 
Aylesbury, UK). The cell lysate was centrifuged for 
10 min (15 OOOg, 4°C), the supernatant fluid removed, 
a nd the pellet resuspended in 10 m! of Tris buffer. After 
recentrifugation the pelleted material was resuspended in 
a minimum volume of 15% (w/ v) sodium dodecyl sulfate 
solution and stored at - 70°C. 
E. coli JM105 containing plasmic pB15b or pB3X13 
was cultured in Brain Heart Infusion broth or L-broth, 
and the proteins were purified as described previously1 1.14. 
Purification and chemical toxoiding of the alpha-toxin 
Alpha-toxin was obtained from one of two sources : as 
alpha-toxin (Type XIV) from the Sigma Chemical Co. 
or isolated and purified from E. coli containing a 
recombinant plasmid (pT2.2) encoding the C. perfringens 
NCTC 8237 alpha-toxin gene9 • The purified cloned toxin 
or the relatively crude type XIV toxin were treated with 
formaldehyde as described previously12 to generate 
formol-toxoids. 
SDS-polyacrylamide gel electrophoresis (SOS- PAGE) 
and Western blotting 
Peptide or polypeptide samples were electrophoresed 
through SDS- polyacrylamide 7.5% or 10- 15% gradient 
gels (Phast System; Pharmacia) and the gels stained with 
Coomassie blue R250. When required , duplicate gels 
were diffusion-blotted onto polyvinylidenediftuoride 
(PVDF) membrane (Immobilon P , Millipore, Harrow, 
UK). The membranes were reacted with alpha-toxin 
antibody, either mouse polyclonal or monoclonal (mAb) 
3a4DIO (Ref. 12). Bound a ntibody was detected using 
gold-labelled goat a nti-mouse anti body (Jannsen Life 
Science Products, High Wycombe, UK) with silver 
enha ncement. 
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Toxicity of candidate \'accines 
Candidate vaccines were screened for unpredictable 
side effects by intraperitoneal (i.p.) inoculation of 10 J.J.g 
amounts into groups of six mice. None of the candidate 
vaccines tested were toxic at these doses and mice showed 
no signs of acute or chronic side effects for up to 
2 weeks after inoculation. 
Immunization with candidate \'accines 
Groups of six mice were immunized with 0.36 pM 
Cpa1_24 9, Cpa247_370, GST - Cpa247_370, GST or the 
formal toxoid or with 10 J.J.g guanidine hydrochloride-
extracted Clo-/3-gal-Cpa fusion protein. Animals were 
primed i.p. with the respective protein antigens in an 
incomplete Freund's adjuvant (IFA) emulsion and 
boosted as required until specific antibody titre to 
alpha-toxin plateaued or for a maximum of six additional 
doses. 
Measurement of antibody titre 
Antibody titre was measured by a modified ELISA 
procedure in which the toxin or homologous antigen was 
coated to the solid phase and the test serum serially 
diluted in duplicate on the plate. The titre of specific 
antibody was estimated as the maximum dilution of 
serum giving an absorbance reading 0.1 units over 
background. 
Neutralization of biological actil'ities of the alpha-toxin 
in vitro 
The neutralization of the phospholipase C and 
haemolytic activities of the purified cloned alpha-toxin 
by polyclonal antisera or by mAb 3a4D 10 was assessed 
in micro titre plate assays as previously described 12 . The 
quantities of toxin and antibody used for these 
experiments were determined by measuring the protein 
concentration using a Coomassie blue dye-binding 
assay 13. The inhibitory effect of any antiserum on the 
toxin's phosphatidylcholine-hydrolysing activity was 
determined by pre-incubating at least a 1.4-fold molar 
excess of the antiserum with a constant amount of cloned 
alpha-toxin (activity 7.9 egg yolk units (EYU)) 
for 2 h at 37°C prior to the addition of the egg yolk 
emulsion. Similarly, the ability of the antiserum to inhibit 
the haemolytic activity of alpha-toxin was determined by 
pre-incubating a 28-fold molar excess of any antiserum 
with a constant amount of cloned alpha-toxin (specific 
activity 35 haemolytic units) for 2 h at 37°C prior to the 
addition of a 5% (v / v) suspension of mouse erythrocytes. 
Toxin challenge 
Groups of six immunized animals were administered 
a bolus of purified cloned alpha-toxin at one of two dose 
levels (5 J.J.g or 50 J.J.g). The toxin was injected i.p. in 50 J.J.l 
of saline. Dose time was recorded for individual animals. 
Groups of six age-matched controls were incorporated 
in the experiment and received 5 J.J.g of cloned alpha-toxin 
under exactly the same conditions as their immunized 
counterparts. Animals were closely observed over an 8 h 
period for the development of symptons and, where 
appropriate, time to death was carefully recorded. 
Organism challenge 
Groups of immunized animals were administered 
viable C. perfringens NCTC 8237 organisms by 
intramuscular (i.m .) injection at a single site into 
a hind-limb. Vaccinees received doses of 109 organisms. 
Concurrently, groups of age-matched control animals 
received doses of viable organisms in the range (107 - 109), 
under the same dosing conditions as their immunized 
counterparts. Animals were closely observed over a 24 h 
period for the development of symptoms and time to 
death was recorded as appropriate. 
RESULTS 
Generation of candidate \'accines 
A number of candidate vaccines were designed to 
encompass a region of the alpha-toxm (Cpa193_198) 
recognized by the phospholipase C-neutralizing mAb 
3a4Dl0. Additional regions flanking Cpa193_198 which 
may be required for the correct presentation of this region 
were also included. The crystal structure of the Bacillus 
cereus phosphatidylcholine-preferring phospholipase C 
(PC-PLC) has been determined, and theN-terminal 250 
amino acid domain of the alpha-toxin is considered to 
represent a structural homologue of this protein 11 . Using 
these additional data and secondary structure predictions 
(data not shown), we were able to ensure that the 
fragments of the alpha-toxin would include complete 
helices. A BamHI- Hindiii fragment from cpa, which 
would encode a 20.5 kDa fragment of the protein 
containing six prediced helices (Figure 1), was expressed 
as a fusion with cro-P-galactosidase. The recombinant 
plasmid containing the cpa gene fragment fused with 
cro-/3-galactosidase encoded a protein with a molecular 
weight of approximately 143 kDa (cro-f3-gaJ- Cpa99_249). 
A recombinant plasmid which would encode a 9 kDa 
fragment of the alpha-toxin, containing three predicted 
helices fused with the vector encoded protein (cro-f3-
gal-Cpa1 79_249; Figure 1), was generated from plasmid 
pL30-l. Insoluble fusion proteins cro-f3-gal- Cpa99_249 
and cro-f3-gal- Cpa179_249 were purified from whole cell 
extracts and analysed by SOS- PAGE (Figure 2a). 
Polypeptides which corresponded to the N-terminal 
domain of the alpha-toxin (Cpa1_249), the C-terminal 
domain (Cpa147_370) or Cpa247_370 fused with glutathione-
S-transferase (GST - Cpa247_370) were prepared as 
described previously11 •14 and their purity checked by 
SOS- PAGE (Figure 2a). 
The immunological identity of these proteins was 
checked by Western blotting using mAb 3a4D10 and 
polyclonal antisera as the primary antibodies (Figures 2b 
and 2c ). All of the proteins reacted with the corresponding 
antibodies. However, cro-f3-gal-Cpa99_249 reacted less 
well with polyclonal antisera than the shorter cro-f3-
gal - Cpa1 79_249 fusion protein. Purified cro-{3-galacto-
sidase protein alone did not react with any of the antisera 
tested. The GST - Cpa247_370 reacted well with poly-
clonal antisera but the purified Cpa247_370 fragment 
reacted only weakly. This difference in reactivity was not 
attributable to non-specific reaction of antibody with the 
GST. 
Antibody responses to candidate \'accines 
The appearance of circulating antibody directed 
against either the alpha-toxin or the homologous antigen 
was monitored by ELISA in vaccinees. No significant 
antitoxic response was detected in mice immunized with 
the fusion proteins cro-/3-gal- Cpa 1 79_249 or cro-
f3-gal - Cpa99_249, although significant antibody titres 
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Figure 1 Candidate vaccines generated during this study: (A) C. perlringens alpha-toxin showing the locations of epitopes (hatched) " and the predicted 
locations of helices (C- H). The location of the ARGFAK peptide recognized by the PLC-neutralizing mAb 3a4D10 is arrowed. (B) Cro-p-gai- Cpa., .. ,..; 
(C) Cro-p..gai- Cpa,,. .. ...,; (D) Cpa, .. 2..; (E) glutathione-S-transferase- Cpa," .. ,.; (F) Cpa,., .. 170 
a. 
1 2 3 4 5 6 7 8 9 10 
211• 
106• 
119•• .-. 80• 
so• 98• -
33• 81 • 
28 • 64• 
19• 
b. 




33• - 81• 28• ~ 
19• 64• 
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Figure 2 Analysis of candidate vaccine proteins by (a) SD5-polyacryl-
amide gel electrophoresis, (b) Western blotting using polyclonal 
alpha-toxin antiserum or (c) mAb 3a4010. Lanes 1 and 7 contained 
molecular weight markers (arrowed, kDa x 10'); lane 2, alpha-toxin; 
lane 3, Cpa, ,..: lane 4, Cpa,., .. .,.; lane 5, GST -Cpa,., .. ,.; lane 6, GST; 
lane 8, cro-p-gai- Cpa., .. .,.: lane 9, cro-p-gai- Cpa,,. .. .,.: lane 10, cro-p-gal 
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Table 1 Groups of six mice were immunized with the candidate 
vaccines and the anti-toxin response over time was measured by ELISA. 
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were observed against the cro-P-galactosidase moiety 
(>25.6 x 103 ) (Table 1). 
In mice immunized with Cpa 1_ 249 , Cpa24 7_ 370 or 
GST - Cpa247_ 3 7 0 , a strong antibody response against the 
alpha-toxin was detected at day 21 of the schedule, 
increasing in response to booster inoculations, to reach 
a plateau as the animals became hyperimmune. The 
fusion of GST to Cpa247_ 370 reduced the titre of specific 
antitoxic antibody. However, the magnitude of the 
antibody response elicited by the toxin truncate Cpa 1_ 249 
against the holotoxin was equivalent to that induced by 
the crude formal-toxoid, and Cpa247_ 370 was also 
efficiently immunogenic, promoting these genetically 
engineered truncates as attractive alternative vaccine 
candidates. 
Properties of antibodies raised against candidate 
vaccines 
The abilities of sera from animals immunized with 
Cpa 1_ 24 9 , Cpa24 7- J ? o or GST - Cpa24 7_ 3 70 to neutralize, 
in vitro, the biological activities associated with the 
alpha-toxin were compared. 
Antisera to Cpa24 7_ 370 or to GST - Cpa247_ 3 7 0 were 
as effective as formal-toxoid antiserum in inhibiting the 
phospholipase C activity of alpha-toxin in vitro 
(Table 2). A molar ratio of 1.4:1 antibody :toxin was 
required for either serum to inhibit 7.9 EYU per 
ml. Similarly, the haemolytic activity of alpha-toxin 
(35 haemolytic units per ml) in vitro was inhibited equally 
effectively by sera raised to the formal-toxoid, to 
Cpa2 4 7_ 3 7 0 or to GST - Cpa24 7_ 3 70 although, in all cases, 
a 28-fold molar excess of antibody over toxin was 
required to achieve inhibition. Cpa 1_ 24 9 antiserum, when 
used at 2.8-fold molar excess to toxin, also inhibited 
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Formol-toxoid + (1.4:1•) 
Cpa, _, .. + (2.8:1) 
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'Neutralization of 7.9 EYU 









•The stoichiometric ratio of antibody to toxin required to achieve the 
effect is shown in parentheses 
Table 3 Protection against challenge with purified cloned alpha-toxin 
afforded by immunization with candidate vaccines. Animals were 
challenged intraperitoneally with 5 11g or 50 11g of purified alpha-toxin 
Dose of Mean time to death 
alpha-toxin ±s.e.m 
Immunogen (llg)' Survivors (h) 
None 5 0/6 1.83±0.0 
Formol-toxoid 5 6/6 
50 6/6 
Cpa, _,., 5 016 4.80±0.27 
Cpa,.,_,,. 5 6/6 
50 6/6 
GST -Cpa,.7 _370 5 6/6 
GST 5 0/6 2.53±0.21 
'5 11g alpha-toxin =5 MLD 
phospholipase C activity (7.9 EYU per ml), but even 
at 28:1 molar excess it did not inhibit the haemolytic 
activity of the toxin. 
Protection against toxin challenge 
When challenged with 5 Jlg of purified Cpa (approxi-
mately 5 mouse lethal doses, 5 MLD), all of the 
age-matched control mice died within 2 h (Table 3). 
Similarly, the GST-immunized controls died rapidly 
(mean time to death 2.53±0.21 h). All of the mice 
immunized with Cpa 1_ 249 succumbed to the 5 MLD 
toxic challenge with a mean time to death of 4.8 ± 0.27 h . 
However, mice immunized with the formol-toxoid, 
Cpa24 7_ 370 or GST - Cpa247_ 370 were protected against 
a 50 Jlg (50 MLD) challenge with 100% survival and 
showed no signs of intoxication. 
Protection against organism challenge 
To investigate the possibility that the formol-toxoid , 
Cpa247_ 370 or GST - Cpa247_ 370 could also induce 
protection against experimental gas gangrene, groups of 
·vaccinees were subjected to a live organism challenge. 
All age-matched control animals died with fulminating 
gas gangrene, characterized by oedema and cyanosis of 
the affected limb within 10 h of a challenge of 108 or 
more organisms (Table 4). The mouse LD 100 (MLD100) 
was therefore set at 108 organisms. When subjected to 
challenge with 109 organisms (10 x MLD 100), the 
Cpa247_ 370 and the formol-toxoid vaccinees were com-
pletely protected and all survived, whereas the age-
matched controls all died with a mean time to death of 
6.83 ± 0.44 h. At this challenge level, the GST - Cpa24 7_ 3 1o 
group showed some breakthrough in protection , with 2 
out of 6 succumbing to the gas gangrene syndrome within 
24 h. 
DISCUSSION 
In this study the C-terminal domain of the toxin 
(Cpa247_ 370) has been identified as an effective vaccine 
against the C. perfringens alpha-toxin. Immunization 
with Cpa247_ 370 was protective against challenge with 
50 x MLD of purified alpha-toxin. This level of 
protection was equivalent to that afforded by the 
formol-toxoid . Our results also demonstrate that 
immunization with a subunit vaccine, derived solely from 
the alpha-toxin, protected experimental animals against 
a 10 x LD 100 challenge with C. perfringens type A by the 
usual infective route (i.m.) for the organism. 
This vaccine offers several clear advantages over the 
formol-toxoid: it is much more easily prepared and, 
because it is free from formaldehyde, other toxoided C. 
perfringens toxins and partially toxoided materials, it is 
likely to be safer in use and less reactogenic. In this 
respect we did not observe any adverse side effects during 
the immunization schedule used. A need has previously 
been identified for an efficacious C. perfringens type A 
vaccine which could be used safely in 'at risk' groups 
such as the elderly and in patients who have undergone 
intestinal surgery2 • 
This study also confirms for the first time the major 
role suspected for the alpha-toxin in the pathogenesis of 
gas gangrene caused by C. perfringens type A. Previous 
experiments which attempted to demonstra te this 
correlation used toxoid prepared from C. perfringens 
alpha-toxin which were almost certainly contaminated 
with toxoids of other C. perfringens toxins. 
Several other vaccine candidates have been evaluated. 
Using our knowledge of the predicted structure of the 
protein, fragments of Cpa were expressed as fusions with 
cro-p-galactosidase (cro-p-gal-Cpa99_ 249 and cro-P-
gal-Cpa 179_ 249). These fusion proteins elicited a strong 
antibody response, but none of this antibody cross-
reacted with the alpha-toxin, suggesting that the 
Cpa fragment was not in the correct conformation or 
that the p-galactosidase moiety dominated the antibody 
response. The insolubility of these fusion proteins may 
have further distorted the conformation of the alpha-
toxin fragment and in support of this suggestion we have 
observed that the antisera generated reacted weakly with 
partially denatured toxin (data not shown). Other 
workers have found that cro-P-galactosidase fusion 
proteins elicit variable responses. DeLorbe et a/. 16 found 
Table 4 Protection against challenge with C. perfringens NCTC 8237 
afforded by immunization with candidate vaccines. Animals were 
challenged i.m. with the organism in 100 Jtl or saline 
Challenge dose Mean time to death 
of C. perfrlngens ± s.e.m. 
Immunogen (viable cells) Survivors (h) 
None 107 6/6 
10' 0/6 9.17±0.8 
101 0/6 6.83 ± 0.44 
Formoi-toxoid 101 6/6 
Cpa,.,_,,. 101 6/6 
GST - Cpa,., 310 101 4/6 20.00±4.0 
GST 101 0/6 6.5± 1.07 
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that bovine papilloma virus I (BPV-1) Ll protein, fused 
to cro-{J-galactosidase, reacted with anti-Ll sera , but 
more importantly that a nti-cro-fJ-gal-Ll sera reacted 
with authentic BPV-LI and was neutralizing. In contrast 
BPV-L2 fusions did not show total immunological 
identity with authentic L2. The effectiveness of this carrier 
may be dependent on the presentation of important linear 
epitopes. 
The results presented here indicated that Cpa 1_ 249 was 
a strong immunogen which induced high titre antibody 
against both self and the holotoxin suggesting that 
Cpa 1_ 249 adopted a similar conformation to the 
N-terminal region in the native toxin . In vitro, the 
anti-Cpa 1_ 249 serum neutralized phospholipase C but 
not haemolytic activity, and immunization with Cpa 1_ 249 
was not protective against in vivo challenge with toxin. 
Both fusion proteins (cro-fJ-gal - Cpa99_ 249 and 
cro-fJ-gai - Cpa179_ 2 49 ) and Cpa 1_ 24 9 contained linear 
epitopes including the ARGFAK peptide, located in the 
N-terminal domain of the toxin, which we have shown 
to be recognized by mAb antibody 3cx4Dl0 (Ref. 12). 
Since mAb 3cx4D10 neutralized both phospholipase C 
and haemolytic activity in vitro and afforded limited 
protection against toxin in vivo 12 it would be expected 
that these candidate vaccines would induce a protective 
antibody response. However, polyclonal antibody 
against the alpha-toxoid did not contain high levels of 
an antibody with a similar reactivity to 3cx4D I 0 (Refs 11 
and 12) and it seems likely that antisera generated against 
cro-fJ-gai- Cpa99_ 249 , cro-fJ-gal- Cpa 179_ 249 or Cpa 1_ 249 
were also deficient in an antibody with this specificity. 
The smaller Cpa247_ 3 70 fragment , derived from the 
final third of the alpha-toxin molecule, was also 
immunogenic, inducing antibody that reacted equally 
well with self and with the holotoxin, suggesting that this 
fragment of the alpha-toxin was correctly folded. 
Cpa2 4 7_ 370 was clearly the most effective candidate 
vaccine tested. Antiserum against this fragment not only 
had phospholipase C-neutralizing activity but was also 
a potent inhibitor of the haemolytic activity of the toxin . 
Clearly, protection against haemolytic activity. rather 
than phospholipase C activity alone, is critical for 
achieving protection against the lethal effects of the toxin . 
Cpa 2 47- 370 was more effective in protecting against 
organism challenge than the GST - Cpa247_ 370 fusion. It 
may be that the GST carrier distorted the conformation 
of the fragment of the alpha-toxin. 
The poor correlation between the presence of 
phospholipase C neutralizing antibody in sera and 
protection could be explained if the toxin underwent a 
conformational change on binding to cell membranes. A 
conformational change on the binding of snake venom 
phospholipase A2 and Rhizomucor miehei lipase to 
membranes has been reported 17 · 18 . It is conceivable that 
the antibody directed against the N-terminal domain of 
the a lpha-toxin, although phospholipase C-neutralizing 
in cell-free systems, may not prevent toxm bmdtng to 
target cells. A change in the conformation of the 
N-terminal domain of the toxin after it bound to cell 
membranes could reduce the affinity of any phospholipase 
C-neutra lizing antibodies. This may also expla in the 
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reason for the breakthrough of in vivo protection 
observed with mAb 3cx4DIO. 
The ease of production of Cpa247_ 370 a nd its 
effectiveness as a gas gangrene vaccine should prove 
attractive to other workers. The vaccine would have a 
utility in certain groups within the population known 
to be at risk from gas gangrene. Further evaluation of 
this vaccine is now required to determine its safety in 
humans a nd efficacy in preventing the natural occurrence 
of gas gangrene. 
REFERENCES 
Willis, T.A. Anaerobic Bacteriology, Clinical and Laboratory 
Practice, Butterworths, London, 1979 
2 McDonel, J.L. Toxins of Clostridium perfringens types A, B. C, D 
and E. In: Pharmacology of Bacterial Toxins (Eds Dorner. F. and 
Drews. J.) Pergamon Press, Oxford, 1986, p. 477 
3 MacPherson, W.G., Bowl by, A.A., Wallace, C. and English, C. Official 
History of the War. Volume 1. Medical Services Surgery of the War, 
HMSO, London, 1922. p. 134 
4 Kameyama, S., Sato, H. and Murata, R. The role of a-toxin of 
Clostridium perfringens in experimental gas gangrene in guinea 
pigs. Jpn. J. Med. Sci. Bioi 1975, 25, 200 
5 Smith, LD.S. Virulence factors of Clostridium perfringens. Rev. 
Infect. 0/s. 1979, 1, 254 
6 Penfold, W.J. and Tolhurst, J.C. Formol-toxoids in the prophylaxis 
of gas gangrene. Med. J. Aust. 1937, 1, 604 
7 Robertson, M. and Keppie, J. Gas gangrene. Active immunisation 
by means of concentrated toxoids. Lancet 1953, 11, 311 
8 Boyd, N.A., Thomson, R.O. and Walker, P.D. The prevention of 
experimental Clostridium novyi and C. perfringens gas gangrene 
in high-velocity missile wounds by active immunisation. J. Med. 
Microbial. 1972, 5, 467 
9 Titball, R.W., Hunter, S.E.C., Martin, K.L., Morris, B.C., Shuttleworth, 
A.D., Rubidge, T. et al. Molecular cloning and nucleotide sequence 
of the alpha-toxin (phospholipase C) of Clostridium perfringens. 
Infect. lmmun. 1989, !iT, 367 
10. Titball, R.W. and Rubidge, T. The role of histidine residues in the 
alpha toxin of Clostridium perfrlngens. FEMS Microbial. Lett. 1990. 
68, 261 
11 Titball, R.W., Leslie, D.L, Harvey, S. and Kelly, D.C. Haemolytic and 
sphingomyelinase activities of Clostridium perfrlngens alpha toxin 
are dependent on a domain homologous to that of an enzyme from 
the human arachidonic acid pathway. lnfect.lmmun. 1991, 59, 1972 
12 Logan A.J., Williamson, E.D., Titball, R.W., Percival, D.A., 
Shuttleworth, A.D., Conlan, J.W. and Kelly, D.C. Epitope mapping 
of the alpha-toxin of Clostridium perfringens. Infect. lmmun. 1991. 
59. 4338 
13 .3ambrook, J., Fritsch. E.F. and Maniatis, T. Molecular Cloning: A 
Laboratory Manual. Cold Spring Harbor Laboratory Press, New 
York, 1989 
14 Titball, R.W., Fearn, A.M. and Williamson, E.D. Biological and 
immunological properties of the C-terminal domain of the 
alpha-toxin of Clostridium perfringens. FEMS Microbial. Letters 
1993, 110, 45- 50 
15 Hanahan, D. Techniques for the transformation of E. coli. In: DNA 
Cloning: A Practical Approach, Vol. 1 (Ed. Glover, D.M.) IRL Press, 
Oxford, 1985. p 109 
16 DeLorbe, W., Pilacinski, W., Lum, M., Cooney, W., Marshal!. R., 
Reed. D. and Muscoplat, C. A recombinant vaccine for the prevention 
of bovine papillomatosis. In: Vaccines 87. Modern Approaches to 
New Vaccines (Eds Channock, R.M., Lerner, R.A., Brown, F. and 
Ginsberg, H.) Cold Spring Harbor Laboratory Press, New York, 1987 
17 Blow, D. Lipases reach the surface. Nature 1991, 351, 444 
18 Brzozowski, A'.M., Derewenda, U., Derewenda, Z.S., Dodson, G.G., 
Lawson, D.M .. Turkenburg, J.P. et al. A model for interfacial 
activation In lipases from the structure of a fungal lipase-inhibitor 
complex. Nature 1991, 351, 491 
VIRAL IMMUNOLOGY 
Volume 12, Number 2, 1999 
Mary Ann Lieben. Inc. 
Pp. 97-105 
Recombinant Vaccinia Viruses Protect Against 
Clostridium perfringens a-Toxin 
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ABSTRACT 
Recombinant vaccinia viruses that expressed the nontoxic C-domain of Clostridium perfrin-
gens a-toxin were constructed. The J2R (thymidine kinase [TK] gene) and B13R (serpin 2 
[SPI-2] gene) loci were used as insertion sites for the clostridial DNA, and expression of the 
foreign protein was measured in each case. A double recombinant that encoded the a-toxin 
truncate at the B13R locus and the protective antigen of Bacillus anthracis at the J2R locus 
was also constructed. Although differences in expression of the a-toxin C-domain were 
recorded, all of the vaccinia recombinants protected mice against a lethal challenge with a-
toxin demonstrating that a recombinant vaccinia virus can be used to provide protection 
against a toxin challenge that is known to be solely antibody mediated. 
INTRODUCTION 
Vaccination has been shown to be an extremely effective way of preventing diseases. Between 1960 and 1990, the number of diseases that could be prevented by vaccination increased from 15 to 33 (21). The 
improvement of existing vaccines and the development of new ones is an area in which much research is 
concentrated. Modem vaccines should be logistically easy to store, transport, and administer; require min-
imal doses; and be able to stimulate a protective immune response rapidly. ln addition, simultaneous im-
munization against multiple diseases increases vaccine coverage rates and reduces the cost of vaccination 
programs. Vaccinia virus provides a vector system for the development of recombinant vaccines with the 
aforementioned attributes. It has been used successfully to construct candidate vaccines that protect against 
many viral pathogens, including rabies virus ( I), hepatitis A virus ( 13), and, recently, Japanese encephali-
tis virus (20). Few bacterial antigens have been expressed in vaccinia virus, however, presumably because 
processing of bacterial antigens in this eukaryotic system may result in immune responses different from 
those induced by native proteins. We were interested in examining the ability of recombinant vaccinia 
viruses to protect against a bacterial protein toxin, a -toxin from Clostridium pe!fringens. We also wanted 
ro compare foreign gene expression from two different sites in the vaccinia virus genome as a preliminary 
step to the development of a vaccine expressing multiple antigens. 
Several hundred thousand soldiers died as a result of gas gangrene during World War I ( 17). The patho-
genesis of this disease is largely due to production of exotoxins by the bacterium C. perfringens ( 18), and 
1 Defence Evaluation and Research Agency. Salisbury, United Kingdom. 
2Paterson Institute for Cancer Re earch, Christie Hospital, Manchester, United Kingdom. 
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the most important of these is the a-toxin. Groups currently at risk from gas gangrene include the elderly 
and diabetics, especially those who have undergone lower limb surgery, as impaired blood supply to the 
tissues can lead to anaerobic conditions that allow the bacterium to multiply (29). Current treatment for gas 
gangrene usually involves removal of the affected tissue or limb. The a-toxin has also been associated with 
some cases of sudden infant death syndrome in human beings ( 19). There is no vaccine for human use 
against C. perfringens infections. 
The a-toxin may also play an important role in several diseases of animals, including enterotoxemia and 
sudden death in certain breeds of calves (6). An effective vaccine for veterinary use would have important 
economic significance. 
Analyses of a-toxin truncates have identified a C-terminal domain fragment which induced protection 
against the lethal effects of the toxin and protected mice against at least 10 lOO% lethal doses (LD100) of 
C. perfringens type A (27,28). The protective truncate, referred to here as CPAT, corresponds to the C-ter-
minal third of the protein (amino acids 247-370) and was expressed in Escherichia coli as a glutathione-
S-transferase (GST) fusion protein. We inserted DNA encoding CPAT at two different sites in the vaccinia 
virus genome, measured the amount of CPAT produced, and examined whether immunization with the re-
combinant viruses would protect mice against a lethal challenge with a-toxin . 
MATERIALS AND METHODS 
Construction of recombinant vaccinia viruses. A fragment of I 192 base pairs encoding the CPA T fu-
sion protein was removed from the plasmid pGEX-3X-13 (27) using the restriction enzymes Ssp I and Eco 
RI and was inserted into shuttle vector plasmids for subsequent insertion into the vaccinia thymidine kinase 
(TK) or serpin 2 (SPI-2) genes. The vector plasmids had been digested with Sma I and Eco RI. The con-
stitutive 7.5 K vaccinia promoter was located upstream of the CPAT coding region in each case, and the 
E. coli guanine phosphoribosyl transferase (Ecogpt) gene driven by the vaccinia 19 K promoter was used 
to provide dominant selection of recombinant viruses (9). CV-I African Green monkey kidney cells were 
infected with the Western Reserve (WR) strain of vaccinia and transfected with the plasmids to construct 
vCPATrrK- or vCPAT/SP2- . A double recombinant vaccinia virus, vDOUB, that contained DNA en-
coding CPAT at the vaccinia SPI-2 locus and the protective antigen (PA) from Bacillus anthracis at the 
TK locus was also constructed. To construct vDOUB, the shuttle vector plasmid pSCII-PA (I I) was used 
to insert PA into the vaccinia TK gene. The recombinant virus, vPA, was selected by blue plaque pheno-
type in the presence of X-gal due to the expression of the lac z gene in the shuttle vector. The CPAT cod-
ing sequence was then inserted into the SPI-2 gene of vPA, and double recombinant viruses were obtained 
using dominant selection for Ecogpt expression. 
Analysis of virus growth and protein expression. An evaluation of the time course of virus growth 
was performed, and infected cell samples were assayed to determine the virus titer and CPAT content. Con-
fluent monolayers of CV -I cells were infected with each virus at a multiplicity of infection of 5 and incu-
bated at 37°C. Infected cells were harvested at 4, 8, 12, 24, and 48 hours postinfection by scraping into 
phosphate-buffered saline (PBS) containing 0.1 % bovine serum albumin and were subjected to three rounds 
of freeze-thawing. Aliquots were used for titration of virus or were resuspended in Laemmli buffer and used 
for Western blotting with mouse polyclonal antiserum to CPAT. Horseradish peroxidase-conjugated sec-
ondary antibody was used, and development was achieved using 4-chloro-1-naphthol as substrate. The con-
centration of CPAT on Western blots was determined by laser densitometry analysis of immunoreactive 
bands using an UltroScan XL (Pharmacia Biotech, St. Albans, Hertfordshire, U.K.) and was compared to 
the signal intensity from samples containing predetermined amounts of CPAT that had been blotted in an 
identical manner. 
Immunization of mice and toxin challenge. Recombinant viruses ( I 08 pfu) were administered to groups 
(n = 20) of female 7-week-old Balb/c mice by scarification on the hind-quarter (Table I ) . Control groups 
were immunized with PBS (n = 15) by scarification, with 108 pfu of vaccinia strain WR (n = 20) by scar-
ification, or with I 0 p.g of purified CPAT by intraperitoneal injection (n = 20). Half of each group of mice 
were given a repeat vaccination 5 weeks later. The animals were challenged by intraperitoneal injection 8.5 
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TA13LE I. PROTEC110N AGAINST CLOSTRIDIUM PERFRJNGENS 
a-ToXIN UsrNG REcoMBlNANT V ACCIN!A V !RUSEs" 
Week 0 Week 5 
Group inoculum booster Protection 
lA PBS 0110 
18 P8S PBS 015 
2A WR 0110 
28 WR WR 0/10 
3A vCPAT/TK- 10/10 
38 vCPAT/TK- vCPAT/TK- 10/LO 
4A vCPAT/SP2- L0/10 
48 vCPAT/SP2- vCPAT/SP2- 7/10 
5A vDOUB 10/LO 
58 vDOUB vDOUB 10/10 
6A CPAT 8110 
68 CPAT CPAT 10/10 
"Groups of Balb/c mice were vaccinated with 108 pfu of virus 
(groups 2, 3, 4, 5) by scarification on the hindquarter or with 
lO p.g of CPAT (group 6) by intraperitoneal injection at 0 and 
5 weeks. All animals were challenged at 8.5 weeks with three 
50% lethal doses (LD50) of a-toxin and monitored for a further 
2 weeks, at which time the experiment was terminated. 
weeks after the first vaccination with 0.16 J.L& of a-toxin, a dose that was uniformly lethal within 4 days 
and approximates three 50% lethal doses (LD50). Humane end points were used in recording the effects of 
toxin challenge. Animals were bled from a tail vein at 4 weeks, at 8 weeks, and at termination ( 10.5 weeks), 
and the levels of IgG to vaccinia and to CPAT in the serum were measured by enzyme-linked immunosorbent 
assay. 
Statistical analysis of data. Serum antibody levels were compared by the two-sample t test. Contingency 
tables were analyzed by Fischer's exact test. P values of less than 0.05 were taken to be significant. 
RESULTS 
The recombinant viruses expressing CPAT from the vaccinia TK or SPI-2 loci and the double recombi-
nant virus expressing CPAT from the SPI-2 locus and PA from the TK locus were found to grow at simi-
lar rates in vitro (Fig. la). Therefore, samples from identical time points could be analyzed for CPAT con-
tent CPAT was expected to be 39.6 kd in size, corresponding to a 26 kd GST fragment fused to the 13.6 kd 
a-toxin truncate. A protein of about 39 kd was detected by polyclonal antiserum to CPAT in Western blots 
(see Fig. lb). It ran at the same position as the corresponding protein, which had been expressed in E. coli 
using the tac promoter and purified from cell extracts using GST-sepharose affinity chromatography (27). 
A smaller band of about 33 kd was observed when higher concentrations of infected celllysates were loaded, 
and this was presumed to be due to proteolysis. The prokaryotic gene had been checked for the presence 
of early termination signals, but none were found to be present, indicating that the smaller band did not oc-
cur as a result of premature termination. Similarly, examination of the bacterial DNA sequence indicated 
that the band was unlikely to be a result of incorrect initiation. 
At 48 hours postinfection (see Fig. le), samples of vCPAT/SPr contained nine times less CPAT than 
samples of vCPAT/TK- (2.27 ± 0.09 ng and 21.3 ± 0. 14 ng, respectively) and seven times less CPAT than 
samples of vDOUB ( 17.54 ± 0.24 ng). There was a slight difference in levels of CPA T produced from the 
vCPAT/TK- and vDOUB recombinants (a ratio of 1.2: 1). To address whether the difference in expression 
levels was due to a mutation at a second site in the viruses, revertant viruses were constructed in which the 
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FIG. l. Virus growth rate and expression of CPAT during a time course of infection in CV -I cells. Confluent mono-
layers of CV-I cells were infected with each virus at a multiplicity of infection of 5. (A) Growth of recombinant vac-
cinia viruses. Each point is the result of three replicates, and the error bar shows the SEM. (B) Western blotting using 
polyclonal antiserum to CPAT. Samples were electrophoresed through 8% sodium dodecyl sulphate (SDS)-polyacry-
lamide gels. The positions of protein markers run in parallel are indicated; the corresponding molecular weights (kd), 
from top to bottom, are 106,80, 49.5, 32.5, and 27.5. CPAT standards (A): lanes I through 8 contain 0.1, 0.5, 0.8, I, 2, 
4, 8, and 10 ng of CPAT, respectively. vCPATrrK- (B), vCPAT/SP2- (C), vDOUB (D): lane l contains uninfected 
CV - I cells; lanes 2 through 6 contain infected CV - 1 cells harvested at 4, 8, 12, 24, or 48 hours. (C) Comparison of CPAT 
production by vaccinia virus recombinants harvested at 48 hours postinfection. The error bars represent the SEM. 
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FIG. 1. (continued) 
inserted foreign DNA was replaced by the wild-type vaccinia sequence. The resulting viruses were found 
to have the same phenotype as vaccinia strain WR (plaque morphology and growth rates, data not shown). 
There is some evidence to suggest that the genomic DNA flanking a foreign gene affects its expression. 
Davison and Moss (7) measured the expression of /3-galactosidase using the 7.5 K promoter at the vaccinia 
TK locus in the same and opposite orientation as the TK gene. An increase in expression of three- to five-
fold was observed when the /3-galactosidase gene was in the same orientation as TK. In vCPA TffK- , the 
inserted DNA is in the same orientation as the TK gene; thus: the transcription signals present upstream 
may enhance the performance of the inserted 7.5 K promoter at this site. The DNA inserted at the SPI-2 
locus is in the opposite orientation to the surrounding DNA, however; thus it is unlikely that the inserted 
promoter will be affected. Orientation of the inserted DNA may account for the slight difference in ex-
pression levels between vCPATrrK- and vDOUB (where CPAT is inserted at the SPI-2locus). CPAT is 
also inserted at the SPI-2 locus of vCPAT/SP2-, however, and the marked reduction in the expression level 
of CPA T from the virus cannot be accounted for by the orientation of the surrounding DNA. Davison and 
Moss (7) demonstrated that single and multiple nucleotide substitutions in the 7.5 K promoter had a dra-
matic effect on /3-galactosidase expression. Nevertheless, nucleotide sequencing of the 7.5 K promoter re-
gion in the three recombinant viruses gave identical results and showed that the authentic 7.5 K promoter 
sequence was present in each case. The reason for the reduced level of CPAT expression from vCPAT/SP2-
remains to be elucidated. 
To determine whether the recombinant viruses were able to induce protection against a-toxin, mice were 
vaccinated by scarification on the hindquarters (see Table 1). All animals responded to the vaccinations as 
indicated by IgG to vaccinia virus in serum samples (Fig. 2). IgG levels to vaccinia were comparable in 
mice immunized with vCPAT/SP2- and vCPATrrK- (P > 0.5) but were significantly lower in mice im-
munized with vDOUB (P < 0.01 for all comparisons), in which both the SPI-2 and TK vaccinia loci are 
inactivated. Inactivation of the vaccinia TK gene has previously been found to attenuate the virus when de-
livered by the intracranial and intraperitoneal routes, although by intradermal scarification, TK- recombi-
nant viruses replicated locally to a level similar to that of wild-type virus (2). Inactivation of the vaccinia 
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FIG. 2. lgG response following immunization with vaccinia virus recombinants. Treatment groups were as follows: 
(I) PBS, (2) WR, (3) vCPATffK-, (4) vDOUB, (5) vCPAT/SP2-, and (6) CPAT. (a) lgG response to vaccinia virus 
following a single vaccination dose. (b) lgG response to vaccinia virus following two vaccinations. (c) lgG response 
to a-toxin following a single vaccination dose. (d) lgG response to a-toxin following two vaccinations. Error bars rep-
resent the SEM. 
fection model (14). SPI-2 has a 92% amino acid identity with the cytokine response modifier A protein of 
cowpox virus (strain Brighton Red), however, and like the cytokine response modifier A it inhibits the inter-
leu.kin (IL)-1,8-converting enzyme (ICE) and apoptosis mediated by ICE-dependent pathways in cell culture 
( 15). Therefore, it may have an effect on immunogenicity of the virus in vivo. The three recombinant viruses 
replicate to similar levels in single-step replication curves (see Fig. la); however, inactivation of both the SPI-
2 and TK loci in vDOUB may have resulted in reduced replication in vivo and lower antivaccinia titers. 
After a single vaccination, there was no significant difference in lgG levels to CPA T between the three 
recombinant virus groups at the 4-week, 8-week, or terminal time points (see Fig. 2c). After two vaccina-
tions, the terminal titers to CPAT for vCPAT/TK- , vDOUB, and the purified toxin truncate reached a sim-
ilar level and were significantly higher than for vCPAT/SP2- (see Fig. 2d; P < 0.001 for all comparisons). 
The lgG response to vCPAT/TK- and vDOUB was much greater at termination after two vaccinations com-
pared to that in mice given a single dose (vCPAT/TK- , P < 0.001 ; vDOUB, P < 0.01). There was no sig-
nificant difference in terrninaJlgG titer to vCPAT/SP2- after one or two doses, however. 
Mice that had been vaccinated with PBS or vaccinia strain WR exhibited toxic effects and were euthan-
atized within 4 days of challenge (see Table I). A single dose of each of the vaccinia recombinants gave 
100% protection as did two doses of vCPAT/TK- or vDOUB. No toxic effects were observed in any of 
the protected mice following challenge with a-toxin. The only group not completely protected by a re-
combinant vaccin ia virus comprised mice given two doses of vCPA T/SP2-, which had a lower level of 
IgG to CPAT at termination in comparison to the other groups. Three mice in this group exhibited toxic 
effects and were euthanatized within 9 days of challenge. Production of significantly less CPAT by the SPI-
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2- recombinant was therefore associated with lower antibody titers and reduced protection. One dose of 
the SPI-r recombinant protected 10 of 10 mice, but two doses protected only 7 of 10 mice. Although the 
reduction in protection after the second vaccination is not significant (P = 0.1 ), the mice that were eutha-
natized had exhibited abnonnal symptoms of a-toxin poisoning. Control mice exhibited mucosal hemor-
rhage, mild paralysis, and weight loss after challenge, whereas 3 of the vaccinated mice also had extensive 
periorbital edema and hemorrhage. These signs may have been caused by immune complex fonnation fol-
lowing a type lli hypersensitivity response, which characteristically causes small vessel vasculitis. 
Prior reports indicated that the use of vaccinia virus as a vector for recombinant vaccines in human be-
ings could be hampered by the immune response to the vaccinia itself (4,8). In individuals previously vac-
cinated against smallpox, existing immunity to vaccinia virus may restrict replication of a vaccinia-vectored 
vaccine. During the smallpox eradication campaign, the response to revaccination depended on both the 
time lapsed since the previous vaccination and the site of inoculation. The response ranged from absence 
of reactivity, to an accelerated reaction, to a major response indistinguishable from that of primary vacci-
nation (10). We have shown that mice given rwo doses of vCPATrrK- or vDOUB had higher JgG levels 
than mice that received a single dose; however, mice inoculated with vCPAT/SP2- showed no difference 
in terminal IgG titer after either one or two doses, and these mice were not fully protected after two doses. 
This result may have implications for the design of recombinant vaccinia-based vaccines in that careful 
choice of vaccinia genome insertion site may affect the immune response produced by the recombinant 
virus and the outcome of vaccination. It is interesting to note that all vaccinia recombinants protected 10 
of 10 mice after a single vaccination, whereas despite the higher antibody titers achieved, two doses of pu-
rified CPAT were required in order to achieve full protection (see Fig. 2). The difference between the num-
bers of protected mice (8/10 vs I 0/10) was not statistically significant, however, and repetition using larger 
group sizes would be necessary to confinn this effect. 
A major advantage of vaccinia as a vector is the capacity for coexpression of foreign genes from a sin-
gle virus. This property has been used to study the interaction of simultaneously expressed antigens of im-
munological importance (5) and for the construction of multivalent vaccines (22). Zhou et al. (30) inserted 
the L1 gene of human papillomavirus type 16 into the SPI-2 locus of a TK- vaccinia virus and found in-
creased levels of antibodies to L I compared to those in virus with an insertion at the TK site alone. Our 
results confirm the utility of the SPI-2 locus in addition to the TK locus for insertion of foreign DNA into 
the vaccinia virus genome and demonstrate that protective vaccination may be achieved when both sites 
are used in the same vector. 
Few antigens from nonviral pathogens have been expressed in vaccinia virus, and those that have been 
are generally associated with diseases in which cell-mediated immune mechanisms play a major role in pro-
tection. These include Plasmodium species antigens (16,23,24,26), Toxoplasmosis gondii 23 K protein (3), 
and glyco-lipoproteins of Mycobacterium tuberculosis (3 I). Expression of B. anthracis PA by vaccinia virus 
resulted in protection of mice against anthrax ( 12), and this is the only other reported example, as far as 
we are aware, of the use of vaccinia virus recombinants to induce protection against a disease in which the 
symptoms are caused by a bacterial toxin. 
We have shown that vaccinia virus recombinants protect mice against C. perfringens a-toxin when ex-
pressed from two different sites in the vaccinia genome and when expressed from a double recombinant 
vaccinia virus. We have also shown that different amounts of CPAT were produced by the recombinant 
viruses and suggest that this may have affected the degree of protection afforded, particularly after two 
doses of vaccine. 
REFERENCES 
I. Brochier, B .. F. Costy. and P.-P. Pastoret. 1995. Elimination of fox rabies from Belgium using a recombinant vac-
cinia-rabies vaccine: an update. Vet. Microbial. 46:269- 279. 
2. Buller, R.M.L.. G.L. Smith, K. Cremer, A. Notkins, and B. Moss. 1985. Decreased virulence of recombinant vac-
c inia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 317:813- 8 15. 
3. Cesbron-Delauw, P.R., G. Torpier. J.-Y. Cesbron, P. Leite, F. Darcy, A. Capron, B. Guy, G. Lenzen, and J.-P. 
103 
BEN ETT ET AL. 
Lecocq. 1989. A strategy for cloning potential protective antigens of Toxoplasma gondii. pp 301-304. In R.S. 
Lemer, H. Ginsberg. R.M. Chanock. and F. Brown, eds. Yaccines 89. Modern approaches to new vaccines in-
cluding the prevention of AIDS. Cold Spring Harbor Laboratory Press. New York. 
4. Cooney, E.L., A.C. Collier, P.O. Greenberg, R.W. Coombs, J . Zarling. O.E. Ardetti, M.C. Hoffman , S.-L. Hu, and 
L. Corey. 1991. Safety and immunological response to a recombinant vaccinia virus vaccine expressing HIY en-
velope glycoprotein. Lancet. 337:567-572. 
5. Coupar, B.E.H., M.E. Andrew, and O.B. Boyle. 1988. A general method for the construction of recombinant vac-
cinia viru es expressing multiple foreign genes. Gene. 68:1-10. 
6. Cygan, Z .. and J. Buczek. 1993. Nonenterotoxigenic anaerobe C. perfringens A as a cause of calf diarrhoea. Me-
dycyna Weter. 49 :~69-471 . 
7. Oavison, A.J .. and B. Moss. 1989. Structure of vaccinia virus early promoters. J. Mol. Bioi. 210:749-769. 
8. Erickson. A.L.. and C.M. Walker. 1993. Class I major histocompatibility complex-restricted cytotoxic T cell re-
sponses to vaccinia virus in humans. J. Gen. Virol. 74:751-754. 
9. Falkner, F.G., and B. Moss. 1988. Escherichia coli gpt gene provides dominant selection of vaccinia virus open 
reading frame expression vectors. J. Yirol. 62:1849-1854. 
10. Fenner. F .. O.A. Henderson, I. Arita, Z. Jerek, and 1.0. Ladnyi. 1988. Smallpox and its eradication. World Health 
Organisation. Gene\·a. 
11. lacono-Connors, L.C., C.S. Schmaljohn, and J .M. Oalrymple. 1990. Expression of the Bacillus anthracis protec-
tive antigen by baculovirus and vaccinia virus recombinants. Infect. Immun. 58:366-372. 
12. Iacono-Connor , L.C., S.L. Welkos. B.E. Ivins, and J.M. Oalrymple. 1991. Protection against anthrax with re-
combinant virus-expressed protective antigen in experimental animals. Infect. lrnmun. 59:1961 - 1965. 
13. Karayiannis. P .. S. O'Rourke, M.J. McGarvey, S. Luther, J . Waters, R. Goldin, and H.C. Thomas. 199 1. A re-
combinant vaccinia \·irus expressing hepatitis A virus structural polypeptides: characterization and demonstration 
of protective immunogenicity. J . Gen. Yirol. 72:2167-2172. 
14. Kettle, S., .W. Blake. K.M. Law, and G.L. Smith. 1995. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1 ) 
encode Mr 38.5 and ~0 K. intracellular polypeptides that do not affect viru virulence in a murine intranasal model. 
Virology 206: 1 36- 1~7. 
15. Kettle, S., A. Alcami. A. Khanna, R. Ehret, C. Jassoy, and G. Smith. 1997. Vaccinia virus serpin BI3R (SPI-2) 
inhibits interleukin-1,8--<:onverting enzyme and protects virus-infected cells from TNF- and Fas-mediated apopto-
sis, but does not prevent IL-1,8- induced fever. J. Gen. Virol. 78:677-685. 
16. Langford, C.J.. S.J. Edwards, G.L. Smith, G.F. Mitchell, B. Moss, O.J . Kemp, and R.F. Anders. 1986. Anchoring 
a secreted plasmodium antigen onto the surface of vaccinia virus infected cells increases its immunogenicity. Mol. 
Cell. Bioi. 6:3 191 -3199. 
17. MacPherson, W.G .. A.A. Bowlby, C. Wallace, and C. English. 1922. Gas gangrene, pp 134-150. In Official His-
tory of the War. vol. I. Medical Services Surgery of the War. His Majesty's Stationery Office, London. 
18. McOonel, J .L. 1986. Toxins of Clostridium perfringens types A, B, C, 0 and E, pp 477-517. In F. Oomer, and J. 
Orews, eds. Pharmacology of bacterial toxins. Pergamon Press, Oxford. 
19. Murrell, W.G .. B.J . Stewart, C. O ' Neill, S. Siarakas, and S. Kariks. 1993. Enterotoxigenic bacteria in the sudden 
infant death syndrome. J. Med. Microbiol. 39:11 4-127. 
20. Nam, J.-H., L.S . Wyatt. S.-L. Chae, H.-W. Cho, Y.-K. Park, and B. Moss. 1999. Protection against lethal Japan-
ese encephalitis virus infection of mice by immunization with the highly attenuated MY A strain of vaccinia virus 
expressing JEV prM and E gene . Vaccine. 17:261-268. 
2 1. National Institute of Allergy and Infectious Oisea e . 1992. The Jordan report. Accelerated development of vac-
c ines. National Institutes of Health, Bethesda. 
22. Perku . M.E .. A. Puccini. B.R. Lipinskas. and E. Paoletli . 1985. Recombinant vaccinia virus: immunization against 
multiple pathogens. Science. 229:728-73 1. 
23. Smith. G.L., G.N. God on. V. ussenzweig, R.S. ussenzweig, J . Barnwell, and B. Moss. 1984. Plasmodium 
Juw wlesi sporozoite antigen: expression by infectious recombinant vaccinia vi rus. Science. 224:397-399. 
104 
RECOMBINA T V ACClNIA PROTECTS AGAINST ALPHA-TOXIN 
24. Smith, G.L.. K.-C. Cheng, and B. Mos . 1986. Vaccinia virus: an expression vector for genes from parasites. Par-
asitology. 92(suppl): I 09- 11 8. 
25. Smith. G.L., S.T. Howard, and Y. Sang Chan. 1989. Vaccinia virus encodes a family of genes with homology to 
serine protease inhibitors. J. Gen. Virol. 70:2333-2343. 
26. Tine, J.A., D.E. Lanar, D.M. Smith, B.T. Wellde, P. Schultheiss, L.A. Ware, E.B. Kauffman, R.A. Winz, C. De 
Taisne, G.S.N. Hui. S.P. Chang, P. Church, M.R. Hollingdale, D.C. Kaslow, S. Hoffman, K.P. Guito, W.R. Bal-
lou, J.C. Sadoff, and E. Paoletti . 1996. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candi-
date for Plasmodium falciparum malaria. Infect. lmmun. 64:3833-3844. 
27. Titball, R.W., A.M. Feam, and E.D. Williamson. 1993. Biochemical and immunological properties of the C-ter-
rninal domain of the alpha-toxin of Clostridium perfringens. FEMS Microbial. Lett. 110:45-50. 
28. Williamson, E.D., and R.W. Titball. 1993. A genetically engineered vaccine against the alpha-toxin of Clostrid-
ium perfringens protects mice against experimental gas-gangrene. Vaccine. 11:1253-1258. 
29. Willis, T.A. 1977. Anaerobic bacteriology, clinical and laboratory practice, 3rd ed. Butterworths, London. 
30. Zhou, J., L. Crawford, L. McLean, X. Sun, M. Stanley, N. Almond, and G.L. Smith. 1990. Increased antibody re-
sponses to human papillomavirus type 16 Ll protein expressed by recombinant vaccinia virus lacking serine pro-
tease inhibitor genes. J . Gen. Yirol. 71:2185-2190. 
31. Zhu, X., N. Yenkataprasad, J . Jvanyi, and H.M. Vordermeier. 1997.Yaccination with recombinant vaccinia viruses 
protects mice against Mycobacterium tuberculosis infection. Immunology. 92:6-9. 
105 
Address reprint requests to: 
Dr. A.M. Bennett 
DERA, CBD Porton Down 
Salisbury 
Wiltshire SP4 OJQ 
UK 
Per WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau 
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCI) 
(51) International Patent Classification 5 : (11) International Publication Number: WO 93/23543 
C12N 15/31, 15/55, 15/62 
A61K 37/54, 39/08, C12N 5/10 
C07K 13/00, C12P 21/08 
A1 (43) International Publication Date: 25 November 1993 (25.1 1.93) 
(21) International Application Number: 
(22) International Filing Date: 
PCT/ GB93/ 0!039 (74) Agent: P B LOCKWOOD ; DIPR IPRlb, Room 2002 
Empress State Building, Lillie Road, London SW6 ITR 
20 May 1993 (20.05.93) (GB). 
(30) Priority data : 
9210717.6 
9215655.3 
20 May 1992 (20.05.92) 




(71) Appliant (for all designated States except US): THE SE-
CRETARY OF STATE FOR DEFENCE OF THE UN-
ITED KINGDOM OF GREAT BRITAIN AND NOR-
THERN IRELAND [GB/GB]; Whitehall, London 
SWIA 2HB (GB). 
(72) Inventors ; and 
(75) Inventors/ Appliants (for US only) : TITBALL, Richard, 
William [GB/ GB]; WILLlAMSON, Ethcl, Diane [GB/ 
GB]; CBDE, Porton Down, Salisbury, Wiltshire SP4 OJQ 
(GB). 
(54)1itle : CLOSTRIDIUM PERFRINGENS VACCINES 
A I I I 11 I 
24 44 65 83 





(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, 
DE, OK, ES, FI, GB, HU, JP, KR, LK, LU, MG, MN, 
MW, NL, NO, NZ, PL, PT, RO, RU, SO, SE, SK, UA, 
US, European patent (AT, BE, CH, DE, OK, ES, FR, 
GB, GR, lE, IT, LU, MC, NL, PT, SE), OAPI patent 
(BF, BJ, CF, CG, Cl, CM, GA, GN, ML, MR, NE, SN, 
TO, TG). 
Published 
With international search reporr. 
Before the expiration of the time limit for amending the 










1 1 I 
c lL-------------~JlL_ ________________ _LI~IL-~1 ________ ~1 
(57) Abstract 
The present invention provides novel peptides and vaccincs containing them capable of inducing production of antibodies 
directed again~t Clostridium perfringens alpha-toxin (CPa} in an imals to which they are administered a nd thereby providing pro-
phylaxis against infection by Clostridium perfringens and/or the alpha·loxin itself. Particularly the present invention provides 
such a vaccine that is relatively sa fe and si mple to produce, e.g. by genetic engineering means. Preferred peptidcs comprise thee 
amino acid sequence of Closrridi11m perfringens alpha-toxin from amino acid 247 to 370 but lack the epitopes necessary for phos-
pholipase C and/or sphingomyelin hydrolysing activity found between amino acids I to 240 of that sequence. Further provided 
are antisera and antibodies raised to the peptides and vaccines of the present invention, and part icularly monoclonal antibodies 
and hybridoma cell lines for their production. 
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Abstract. We have developed a new two-step method for 
targeting cytotoxic drugs to tumour cells. The method firstly 
involves the binding to tumour cells of antibody-phospho-
lipase C immunoconjugates or fusion proteins. Further to 
washing or clearance of the immunoconjugates, liposomes 
are introduced which are specifically lysed at the tumour 
s ite by PLC to release their cy totoxic contents in the vicinity 
of the tumo ur cells . For two a lterna ti ve human cell lines, 
a synergis tic inhibition of cell prolife ration was seen for 
combined treatment with a specific immunoconjugate and 
daunorubicin encapsulated liposomes. For tumour xenografts 
in mice, the combined treatment resulted in an inhibition of 
tumour growth although with no eradication of tumours at 
the doses used. The two-step antibody-PLC/Iiposome approach 
offers broad possibilities for the precise delivery of payloads 
of cytotoxic drugs to tumour sites. 
Introduction 
Liposomes have been used extensive ly as carriers for anti -
cancer drugs in attempts to reduce their toxicity (I ,2) and to 
selectively direct these drugs to tumours in order to improve 
the therapeutic index compared to free drug (3,4). Whilst this 
strategy has resulted in reduced toxicity for some drugs such as 
actinomycin D (5) and other anthracyclines (6-8), an increase 
in tox ici ty has been reported for others such as methotrexate 
and cytosine arabinoside (9, I 0). Liposomes can also extend 
the half-life of drugs in vivo ( 11 ) and can improve the chemical 
stability of some drugs in the c irculatio n ( 12). Incorporation 
of certain components suc h as proteins or polysaccharides 
( 13) or sphingomyelin into the liposomal vesicle can create 
liposomcs with extensive half- li ves in the circulation although 
this can also limit the re lease o f therapeuticall y significant 
levels of drug. 
Correspondence to: Dr Frank J . Carr, Biovation Limited, AURIS 
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The selective localisation of certai n drugs entrapped in 
li posomes at tumour sites is c learly complex and cannot easily 
be controlled. Moreover, liposomes arc commo nl y taken up 
by tissues of the reticuloendothelial system such as liver and 
this can impart new toxicities to existing drugs without such 
localisatio n. To improve the localisation of liposomes at 
tu mour si tes, preparations of I i posomes incorpo ratin g 
monoclonal antibodies ( 14, I 5) have been investigated in an 
attempt to harness the exquisite specificity of such antibodies 
for the targeting of liposomes. However, such liposomes have 
enjoyed limited success in improving localisation to tumours. 
There is therefore a requirement for new methods for achieving 
the selective localisation of liposomal drugs to tumours si tes 
in order to improve upon the therapeutic index of cancer drugs 
and to reduce their toxicities. 
This report describes a new approach towards selecti ve 
targeting of liposomes to tumours using a two-step approach 
involving monoclonal antibodies. The approach is based on the 
ability of enzymes such as bacterial phospholipase C (PLC) 
to degrade the li posomal membrane ( 16) in order to release 
the encapsulated drugs. In the approach described, monoclonal 
anti bodies fused to PLC are first allowed to locali se to the 
surface of tumour cells by virtue of specific antigens such as 
carci noembryonic antigen (CEA) ( 17) and the ep idermal 
growth factor receptor (EGFR) ( 18). Then a liposomal drug 
is added whereby the tumour cell -associated PLC causes local 
degradation of liposomes resu lting in release of the drug at the 
tumour si te. The results from two tumour cell types suggest a 
broad therapeutic potential for thi s approach with potential 
benefits for a range of liposomal drugs in a range o f cancers 
and other di seases. 
Materials a nd methods 
Liposomes. Daunorubicin containing liposomes (DaunoXome">) 
( 11 ) were a gift from Ncxstar. These arc small un ilamellar 
li posomes o f mean 45 nm diameter composed of a 2: I molar 
ratio of distcaroylphosphatidylcholine and cholesterol. Dauno-
rubicin concentrations were measured by nuorescence using 
a Perkin-Elmer LS-3 nuorescence spectrophotometer with 
excitation and emission at 476 and 588 nm respecti vely. For 
daunorubicin release studies in solution, free daunorubicin was 
separated fro m liposomal d aunorubic in by Sephadex G-50 
ge l permeatio n and the flu o rescence of preparations was 
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measured before and after gd permeation in order to determine 
the re lat ive amounls of free and entrapped daunorubicin . Fnr 
daunorubicin release studies in tissue culture, samples were 
subjected to Sephacryl S-300 gel filtration to separate free 
daunorub icin from protein and liposomc-associatcd dauno-
rubicin. 
Phospholipase C. Purified Clvstridiu111 pelfi·inMens PLC was 
purchased from Sigma and was assayed by lecithin hydrolysis 
as recommended by the supplier. PLC was diluted immediately 
prior to use in OMG buffer (0.2 M 3.3 dimcthylglutarit: acid. 
5 mM calcium lactate, 0.2 mM ZnS04 and I mg/ml bovine 
scrum albumi n at pH 7.2). For studies of the effect of PLC 
on liposomes, Daun oXomes were dil uted I: 10 in borate 
buffer (0.2 M sod ium metaborate, 120 mM NaCI , 12 mM 
CaCI2·2 H10 , adjusted to pH 7.5 wi th boric acid) to give an 
approx imate daunorubicin concentration of 0. 1 mg/ml. For 
studies in mice, DaunoXomes were diluted in 250 mM lactose. 
50 mM glyc ine and 280 )lg/ml 2 )lM CaCI 2. 
Cell lines. Huma n HL60 and A431 cell lines were both 
obtained from the European Collection of Animal Cell Cultures 
(ECACC) and these were grown in OMEM containing 10'* 
FCS. 
Antibodies. The monoclonal antibody 6.2 specific for CEA 
was obtained from the Scollish an tibody production unit 
(SAPU) and the monoc lonal an tibody and corresponding 
M ab 340 hybridoma ( 19) specific for EGFR was a gift from 
Or Lind a Durrant, Uni vers ity o f Nottingham. Mab 340 
hybridoma was grown in OMEM containing I 0% FCS. Anti-
body binding to A431 cells was assayed by incubating I 00 Jll 
of cell suspensions at 5xl0~ cell s/m! in RPMI 1640 medium 
with dilutions of antibody and I 00 Jll 1251 EGF (Amersham, 
I 00 )lCi/)lg, 50 )lCi/ml) at 37"C for I h. Cells were then 
centrifuged and washed twice in ice-cold PBS prior to counting. 
Results were expressed as concentrations of antibody which 
produced a 50% inhibition of maximum mr EGF binding 
(ED50). 
Preparation of M ab 340-PLC conjugate. Protein concentrations 
were assessed using a bicinchoninic acid (BCA) protein assay 
kit (Pierce & Warriner). Chemical conjugation of PLC wi th 
monoclonal antibody was achieved using the heterobifunctional 
cross- linkcr. sulpho-maleimidobenzoyl-N-hydroxysuccinimide 
(s-MBS, Pierce & Warriner). 0.5 mg purified Mab 340 in PBS 
was acti vated by reaction with a lOO-fold molar excess of 
s-MBS for 30 min at room tempera ture. Free tinker was 
removed by ge l filtration using a Sephadex G-25 column 
(Pharmacia) equilibrated with PBS. The protein was eluted in 
I ml fractions and the protein detected by BCA assay. Fractions 
containing activated antibody were pooled and I mg of PLC 
(S igma) in PBS added. The mixture was reacted for 30 rnin at 
room temperature. Unconjugated PLC (43 kDa) was removed 
from the mixture by dialysis against PBS using spe<.:trapore-CE 
dialysis canridges (Pierce & Warriner) with a molecular weight 
cut-off of I 00 kOa, and further purified and con<.:en trated by 
passage through a mi t:roconcentrator also wi th a molet:ular 
weight cut-oil nf I 00 kOa (Amicon). The presence of conjugate 
was verified b~· SOS-PAGE. 
Plnsmids. Plasmid pCR I \\':IS oht:tined lrom ln,·itrogen ant 
pP M 1-his was a girt l'rom Or Peter M olloy. U 111 versity ot 
Aberdeen. This is a vector containing a ~i ngil:-chain Fv (st:Fv] 
comprising. on a 1/indll ll £coR I fragment. a foe promoter/ 
operator. a pe!B leader. a \ ' H and VL joi ned hy a fungal 
cellulase linkcr and a downstream hum:tn C...: n>n'>tant region 
nanked by a his, purification tag. 
Cell pmlifi•mlion osso.' L A~~a~ s were performed ustng 
s ub-conf'lue nt HeLa or A·B I t:dls plated the preceding 
day in 96-well microtitre dishes. Cell s were grown in 
OMEM containing 10% FCS. and antibody treatments were 
administered in the same medium supplemented with I 00 J..IM 
ZnS04 . Treatments were carried out in duplit:a tc. Brief'ly , 
cells were washed using PBS . then 40 Jll per well of each of 
the antibody-PLC conjugates or controls in PBS. Cells were 
int:ubated at 37"C for I h and then washed using PBS. Cells 
were then int:ubated with dilutions of OaunoXomes in a final 
volume per well of I 00 )..11. In all cases DaunoXome dilution 
was in OMEM/1 0% FCS medium containing I 00 )..I M ZnSOJ. 
OaunoXomes were added to the washed cells and incubated 
at 37"C for 3 h. Cells were then washed and fresh medium 
added. Cells were incubated for a fu rther 12 h before 
assessment of cell proliferation. Proliferation was assessed in 
a colourimetric assay using a CellTiter 96n1 non-radioactive 
cell proliferation assay following instructions provided by the 
supplier (Promega). Microtitre plates were read at 540 nm. 
Production of a recombinant PLC-340 single c!tain alltibody 
molecule. mRNA was isolated from Mab 340 cells using 
Trizo!TM (Life Technologies) and was used to make cDNA 
using a Pharmacia Ready-To-Gon1 cDNA synthes is kit. 
Variable heavy and light chain cDNA was amplified using 
primer sets specific for the mouse heavy and light chai n 
variable regions (20). The PCR products were cloned into 
pCRII , transformed into£. coli strain TG I and six individual 
c lones sequenced in both direct ions using the applied bio-
systems automated sequencer model 373A. The sequences 
were compared with the Kabat database of proteins o f 
immunological interest to identify the variable region gene 
fami lies used and to confirm their uniqueness. Variable heavy 
and light chai n sequen<.:es were subcloncd into vector pPMI-his 
and recombinant clones fully sequenced to confirm in-frame 
insenion of a seFv. This scFv was further modified by insertion 
of a 2 kb fragment from plasmid pT2.2 (2 1) <.:On tai ni ng the 
PLC gene from C. pe1ji·ingens together with the 5'UTR leader 
and putative promoter. The PLC segment was cloned using 
PCR mutagenesis to include a linker peptide fused via the 
tinker from the PLC C-terminus to the N-terminus of the 
340 scFv (22). 
The scFv- PLC fusion protein wa~ expressed in small -
scale culture and released from the bacteria by a freeze fracture 
process. Briefly, followi ng culture. recombinant £. coli cells 
\\'ere co llected by cent ri rugal ion and gently re-suspended in 
I ml of ice cold 30 mM Tris-HCI/20!fr sucrose pH 8.0. Cells 
\\'ere incubated on ice fo r 10 min and recovered by centri -
fugation in a mit:rot:cntrifuge for I min. The supernatant was 
collet:ted for ana lys is hy ELISA, and the cell s re-suspended 
in I ml ice cold 5 mM MgSO.,. Follo\\'ing incubation in it:e 
for 10 min. the cclb were again collected by centrifugation. 
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The cell pellet was re-suspended in 0.5 ml PBS and the cells 
fractured by repeated cyc les of freeze-thaw. The scFv-PLC 
fusion protein was purified from the supcrna tant using a 
HiTrap chclating affinity co lumn (Phannacia). The presence 
of ·cFv-PLC fusion protein was measured by ELISA using a 
goat anti-human K HRP conjugate (Amcrsham). 
Effect on grmrtlt of' tttntollr xenogra.fis in 1111de mice. Sx I 0'' 
A431 ce lls in 100 ~I PBS were inoculated subcutaneous ly 
into both flank of 4-5 week old female athymic nu/nu mice. 
At the time o f inoculation, groups of 5 mice were treated i.p. 
with 100 ~g Mab 340-PLC conjugate in PBS (or Mab 340 
control) and for 2 consecuti ve days thereafter. 48 h later, mice 
were treated i. v. with DaunoXomes at 5 mg/kg daunorubicin 
(or dilution buffer contro l). The treatment was repeated 
weekly and animals were either sacrificed when tumours 
reached a diameter of about I cm or were observed for up to 
49 days. Tumours were measured across 2 diameters three 
Limes weekly and the mean values used for analysis. 
Results 
PLC-mediated degradation of daunorubicin-entrapped lipo-
somes. In order to test for the release of entrapped daunorubicin 
from liposomes, DaunoXomes were incubated with various 
concentrations of PLC for I h and the release of daunorubicin 
was measured by Sephadex G-50 separation and fluorescence 
of the excluded liposome fraction. The results, shown in Fig. I, 
indicated maximum release of daunorubicin at I nM PLC. 
Effect of anti-CEA-PLC immunoconjugate on proliferation of 
HeLa cells. The concept that antibody-targeted PLC could 
potentiate ce llular inhibition by local release of e ntrapped 
daunorubicin was next tested using HeLa cells and an anti-
CEA antibody conjugated to PLC. The conjugation of the 
antibody with PLC was achieved using the heterobifunctional 
cross-linker s-MBS a nd the conjugated antibody-PLC was 
separated from free antibody and PLC by dialysis through a 
I 00 kDa cut-off membrane. 
A non-radioactive cell proliferation assay was used to 
test the effect of immunoconjugates in combination with 
DaunoXomes on cells. Inhibition of cell proliferation using 
this assay was shown 10 correlate with the survi val of HeLa 
ce ll s with an IDSO and LDSO of approx imatel y 5 ~g/m l 
daunorubicin for proliferation a nd cell survival respectively; 
for anti-CEA-PLC immunoconjugate ( I h treatment), the 
1050 was approx imate ly 50 ~g/ml. Cells were first incubated 
with anti-CEA-PLC immunoconjugate for I h and then with 
DaunoXomes for 3 h; a fter an 18 h incubation in medium, the 
proliferation assay was performed. Fig. 2 shows the results o f 
such an experiment using a non-inhibitory concentration of 
immunoconjugate (5 ~g/ml) where a 3-fold increased inhibition 
of cell proliferation was observed as a result of pre-incubation 
of cells wi th imm~noconjugate prior to DaunoXomc treatment. 
Fu rthermore. the data also shows that a non- inhibitory 
concentration of 5 )..l.g/ml free PLC had no potentiating effect 
on ce ll inhibition . However. the data al so shows that pre-
incubation of cells w ith anti-CEA antibody alone ( i.e. with 
no PLC conjugated) actually has a protective effect on cells 
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Figure I . Me~surement of free daunorubicin rele:~sed from DaunoXomes 
following incubation with PLC or controls of B-galactosidase or anti-CEA 
antibody. Free daunorubicin was measured as the reduced fluorescence in 
the liposomal fraction after Sephadex G-50 t:xclusion. Oat:~ points are means 
of 3 ueterminations. 
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Figure 2 . Cell proliferation assay of HeLa cells showing the effect of 
DaunoXomes alone and in combination with 5 ~J.g/ml ant i-CEA-PLC 
immunoconjugate. 5 ~J.g/ml PLC and 5 IJ.g/ml anti -CEA. Proliferation was 
mc:~sured by conversion of MTS into a fonnaum dye. Data points are means 
of3 dctcrminations with SDs < 10%. 
These results are consistent wi th a model that anti-CEA-
PLC immunoconjugate binds to the HeLa cell surface causes 
lysis of DaunoXomes thus releasing daunorubicin at the cell 
surface which is then able to exert an e nhanced inhibitory 
effect on cell proliferation. Parallel fluorescence studies 
(Table I) confim1ed an increase in levels of free daunorubicin 
in the medium of cell s treated with anti-CEA-PLC but not 
PLC a lone. The results of f-ig. 2 al so demonstrate tha t 
pretreatment of cell s w ith anti-CEA antibody alone has a 
pro tec tive effect from subsequent DaunoXome treatme nt 
whereby the a ntibod y a l leviates the inhibition of cell 
proliferation. This result suggests that antibodies bound to 
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Table I. Release of daunorubicin from cultures. 
Pre-treatment 
None 
5 ).l.g/ml PLC 










Release of daunorubicin into tissue culture medium following I h 
pre-treatment of HcLa cell s with either PLC or anti-CEA-PLC 
conjugate and 3 h treatment with DaunoXomes. 
tumour cells may prevent the fusion of DaunoXomes with 
the cells and thus the effecti veness of DaunoXome or other 
liposomal formulations may be reduced by anti-tumour anti-
bodies. 
Effect of anti-EGFR-PLC immunoconjugate on proliferation 
of A431 cells. In order to test the generali ty of the resu lts 
obtained with HeLa cells above, a different tumour cell line 
was studied. The A431 squamous cell carcinoma cell line has 
high levels of s urface e pidermal growth factor receptor 
(EGFR) and a high affinity anti-EGFR monoclonal antibody 
(Mab 340) was available to target thi s receptor on A431 
cells. As shown in Fig. 3, pre-treatment of cells with a non-
inhibitory concentration of anti-EGFR-PLC immunoconjugate 
prior to treatment with DaunoXomes gave rise to a I O-f old 
increased inhibition of cellular proliferation which was not 
observed by pre-treatment with PLC alone. As previously, 
pre-treatment w ith antibody alone alleviated the inhibitory 
effect of DaunoXomes on cell proliferation. Assays on the 
immunoconjugate preparation (Table 11) indicated an 8-fold 
reduction in binding of Mab 340 after conjugation and a 
3-fold drop in PLC activi ty after conjugation suggesting that 
larger increase in inhibition of cell proliferation could be 
achieved with more active antibody and PLC components in 
the immunoconjugate. 
Generation of allli-EGFR scFv-PLC fu sion protein . As 
chemically cross-linked immunoconjugates are difficult to 
prepare, tend to be heterogeneous and lose both antibody 
binding and PLC acti vi ty, it was des irable to create a re-
combinant form of the anti-EGFR-PLC conjugate for future 
studies. Starting from the hybridoma cell line producing 
Mab 340, RNA was isolated and immunoglobulin variable 
regio n DNA fragments were amplifi ed by PCR. Variable 
heavy and light chain frag ments were then cloned into the 
vector pPMI-his to produce single chain Fv immunoglobulin 
fragments (scFvs) wi th heavy a nd light chain segments joined 
by a fungal cellulase linkage and with a C-terminal poly-
his tidine tag for purification. The gene e ncoding the scFv 
was the n c loned do wnstream from the PLC gene including 
the PLC promoter and leader sequences. The anti-EGFR-
PLC scFv fu sion protein was secreted into the peripl asmic 
space of E. coli and purified using a nickel chelate column 
taking advantage of the polyhistidine tag. Fig. 4 shows 
that pre-treatment of A43 I ce lls wit h the an ti-EGFR-PLC 
01 0 5 25 7 5 10 20 
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Figure 3. Cell proliferation assay of A431 cells showing the effect of 
Dau noXomes alone and in combination with 5 11g/ml anti-EGFR-PLC 
immunoconjugate, 5 11g/ml PLC and 5 11g/ml anti-EGFR. Data points are 
means of 3 determinations with SDs <I 0%. 
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Figure 4. Cell proliferation assay of A431 cells showing the effect of 
DaunoXomes alone and in combination with 5 11g/ml anti-EGFR scFv-PLC. 
Data points are means of 3 determinations with SDs <10%. 
Table Il. EGFR binding and PLC activity in immunoconjugate 
and scFv fusion protein . 
EGFR % relative 
binding PLC activity 




immunoconjugate 78 35 
Anti-EGFR scFv 
Anti-EGFR scFv-PLC fusion 29 24 
Competitive binding to A431 cells of anti-EGFR and anti-EGFR-
PLC conjugate/fusion proteins followi ng I h incubation with 1151 
EGF and relative activity of PLC in the anti-EGFR-PLC conjugate/ 
fusion proteins. 
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Figure 5. Growth of A43l xenografis in nude mice treated with anti-EGFR and 
DaunoXome dilution buffer (a), anti-EGFR and 5 mglkg/wk DaunoXomes (b) 
or anti-EGFR-PLC immunoconjugate and 5 mg/kg/wk DaunoXomes (c). 
The upper box (>I cm) depicts mice which were sacrificed and the lower 
box (<0.04) depicts no observable lumours. 
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Figure 6. TimescaJe for growth of A431 tumours in nude mice treated with 
anti-EGFR a lone or nnti -EGFR plus DaunoXomes or anti-EGFR-PLC 
immunoconjugate plus DaunoXomes. The data represenls mean and slandard 
error tumour size from all mice with tumours . 
scFv fusion protein gave an enhanced inhibition of cell 
proliferation although at a reduced level of 3-fold compared 
to the anti-EGFR-PLC immunoconjuga te which gave a 
I 0-fold potentiation. As shown in Table II, thi s reduction 
mainly renccts a loss in binding affinity and avidity of the 
monovalent scFv compared to the original monoclonal anti-
body 340. 
Effect of a111i-ECFR-PLC illllllttnoconjugate on A43 I tunwur 
xenograjis in mice. The trea tment protocol in mice was 
des igned to localise anti-EGFR-PLC immunoconjugatc at the 
tumour s ites prior to introduction of DaunoXorncs. Thus, 
injections of immunoconjugate were g iven i.p. on days 1-3 
with DaunoXomcs administered i.v. on day 5. The results 
in Fig. 5 show the progression of tumour growth for the 
ind ividual mice from diffcrenl groups and the graph of Fig. 6 
plots the overall growth of tumours in surviving animals. 1l1esc 
data show, at 50 days , that treatment with the combination of 
anti-EGFR-PLC immunoconjugate and DaunoXomes stops 
tumour growth in 5 out o r 6 mice with established tumours 
compared to 0 out of 13 for contro l mice treated with Dauno-
Xome alone or Mab 340 and DaunoXome. From Fig. 6, mean 
tumour diameter in immunoconjugate-treated animals declined 
from about 0.6 to 0.4 cm between days 29 and 50 whilst 
tumours in control animals grew to> I cm. Whil st all control 
animals with tumours displayed them in both nanks, 3 out of 
5 of the anti-EGFR-PLC immunoconjugate treated animals 
displayed tumours in o ne flank on ly. The data therefore 
indicates that the combina ti on of anti-EGFR-PLC 
immunoconjugate and DaunoXomes have an inhibitory 
effect on tumour growth although, at the doses used, tumours 
are not eradicated. 
Discussion 
There has been considerable effort to harness the specificity 
of monoclonal antibodies for treatment of cancer by attachment 
of drugs to such antibodies. However , thi s approach has 
been limited both by the difficulty in achieving therapeuti c 
concentrations of antibody-bound drug at the tumour site and 
also by the poor specificity of antibodies in vivo. One approach 
to improve the therapeutic concentration of drugs at tumour 
sites has been to auach antibodies to liposomes loaded with 
cytotoxic drugs ( 15,23-27); however, this approach has been 
limited by several difficulties including aggregation and pre-
mature clearance of immunoliposomes. Another approach to 
improve the therapeuti c concentration of drugs at tumour 
sites has been to conjugate an enzyme to an antibody which 
localises at the tumour si te and then to add a pro-drug which 
is enzymatically converted into an active moiety upon contact 
with the enzyme (28). However, the range of available pro-
drugs are limited and the introduction of an e nzymatically 
cleavable bond in an exis ting drug can reduce the potency of 
the drug following cleavage. 
The approach de monstrated herein represents a more 
general approach to localising drugs at tumour sites. The results 
presented show that antibodies either chemically conjugated 
to or fused to phospholipase C can localise to tumour cells 
and can produce a synergistic inhibition of cell proliferation 
upo n subsequent addition of l iposome entrapped drug. 
Further, initial experiments in mice indicate that antibody-
PLC immunoconjugate potentiate the antitumour effect of a 
liposome e ntrapped drug in vivo. 
Antibody-PLC fusion molecules have previously been 
used as immunotoxins for tumour cell s (22) whereby PLC 
acts upon the target cell membrane itself in order to produce 
a toxic effect. However, the high levels of PLC required to 
achieve cytotoxic effects may cause toxicity to normal cells. 
Structural data for PLC obtained after completion of thi s 
s tudy suggests that the ac ti o n o f the enzyme on ce ll 
membranes (and probably liposomes) is through the insertio n 
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o f two reg io ns o f the prote in into the membrane which 
positions the active s ite adjacent to the phospho li pid head-
groups in order to initiate the membrane degradation process. 
In o rder to achieve an immunotoxic effect from antibody-
PLC imrnunoconj ugates. PLC must be ab le to inse rt itself 
into the cell membrane. Where the target an tigen is on the 
ce ll s urface, the c iTicicncy o f PLC insertion into the 
membrane may be limited in an immunownjugatc where the 
PLC is effectively distanced from the cell membrane by the 
antibody component. The use o f ant ibody-PLC immuno-
conjugates in conjunction with liposomes potentially allows 
for the use of non-tox ic concentrations of PLC and potentially 
prov ides PLC mo lecules tethere d to ce ll s urfaces in 
orientations amenable to lysis of liposomes. 
The data presented in this report provide the lirst evidence 
for the PLC-mediated lysis of liposomes speci lically at tumour 
cell sites and the resultant e ffect of re leased daunorubicin in 
inhibiting both the proliferation of tumour cell s in culture and 
in animals. It is clear from the work so far that the observed 
potentiation of the inhibitory effects o f liposomal daunorubicin 
is limited by the quali ty o f the antibody-PLC immuno-
conjugates and fusion molecule which are not optimised but 
provide a start point for achieving a much larger potentiation 
effect. Areas which require particular optimisation arc the 
binding affinity of antibodies and the acti vity of PLC within 
antibody-PLC conjugates o r fusion proteins. The recent 
availability of PLC structural information will now assist in 
re-designing conjugates and fusion proteins in order to improve 
the performance of these proteins. The effi c iency of lipo-
somal lysis by PLC might also be improved us ing modilied 
liposomal membranes, and optimised timing and doses of anti-
body-PLC and liposo mes might achieve improved inhibitory 
or cytotoxic effects in studies with tumours. In addition , it 
appears desirable to use antibody-PLC molecules with low 
serum half-lives in vivo such as the fusion molecule in order 
to reduce the levels of circulating PLC when liposomes are 
injec ted. For pharmaceutical use of antibody-PLC proteins in 
man, it may a lso be necessary to humanise the ant ibody 
(29) or PLC components in order to prevent the generation of 
antibod ies against these components which may limit the 
effectiveness of therapy. 
The two-step approach of using antibody-PLC to localise 
to tumours followed by the introduction o f liposomal drug 
may have many advan tages over ex is ting immunotox in or 
liposome encapsulatio n approaches to prod uce antitumour 
effects. Firstly, the two-step approach a llows the introduction 
o f a non-toxic antibody- PLC immunoconjuga te excess o f 
which, a fter localisatio n to the tumour, can be cleared from 
the circulation before subsequent addition o f liposomcs. This 
may reduce no n-specific s ide e ffec ts experienced with anti -
bodies previous ly due to non-specific localisatio n at non-
tumour sites. Secondly, the two-step approach may allow the 
use of li posomcs wit h long serum half- li ves which arc usuall y 
re fractory to uptake in various tissues (and therefore non-
toxic) but which arc susceptible to lysis by liposomcs. Thirdly, 
the use of liposomcs r otentially allows large payloads o f drugs 
to be delive red rrccisc ly to s ites o f antibody-PLC localisation 
in order to deli ver much higher doses than otherwise rossiblc. 
Fourthly, the use of liposomcs potentia lly allows the de li very 
of highly toxic molc~.:u lcs to s ites of antibody-PLC localisation 
without tox i ~.: or immunogenic side effects usually asso~.: iatcd 
with such molecules. The data he rein demonstrates, for the 
first time , the feas ibility o f the two-step antibody- li rosomc 
approac h and indica tes tha t the approach meri ts further 
study. 
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Clostridial Phospholipases 
RICHARD W. TITBALL 
Defence Evaluation and Research Agency, CBD Porton Down, Salisbury, Wiltshire, 
SP4 OJO, UK 
1. INTRODUCTION 
In 1941 MacFarlane and Knight 1 reported a breakthrough in the understanding of 
the biochemical basis of bacterial disease by demonstrating that the main extra-
cellular product of Clostridium perfringens, the a-toxin, was a phospholipase C 
enzyme. The finding that bacterial enzymes could possess toxic properties 
stimulated activity to identify toxic enzymes produced by other bacteria. The 
phospholipases C from Clostridium novyi were shown to be toxic.2·3 However, 
the possibility that all phospholipases C were toxic was soon disproved. Miles 
and Miles4 showed that the Clostridium bifermentans phospholipase C was, by 
their criteria, nontoxic and later Otnress et a/.5 showed that the phospholipase C 
of Bacillus cereus was nontoxic. The basic tenet, that bacterial enzymes could 
act as potent toxins remained intact but clearly, enzymatic activity alone, was not 
sufficient for toxicity. 
With a clarity of vision MacFarlane6 reviewed the phospholipases C produced 
by the clostridia and developed a key hypothesis; that the toxicity of the C. 
pe1jringens and C. bifermentans enzymes correlated with hemolytic activity 
rather than with phospholipase C activity . This chapter aims to review the 
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properties of the c lostrid ia l phospho lipases and to revis it the suggestion of 
MacFarl ane, with particular reference to the a -tox in of C. perfringens. 
11. THE CLOSTRIDIAL PHOSPHOLIPASES 
All of the c lostridia l pho pho lipases which have been characterized have phos-
pho lipase C acti vity (Table 14. 1 ). The acti vity of these enzymes can be de tected 
as a zone of turbidity surrounding colonies o f bacteri a cultured on a solid 
medium containing egg-yolk, indeed this forms the bas is of the ' Nagler reac-
tion' , a di agnosti c test for C. perf ringens. Muc h of the pioneering work with 
these enzymes was carried out in the 1940s. The subseque nt decline in interest in 
these enzymes has been rever ed over the past fi ve years and significant progress 
has been made in the understanding of the relationships of clostridial phospho-
lipa es C. 
A. C. perfingens a-toxin 
The C. perf ringens a-toxin is the best studied of the clostridial phospholipases. 
The toxin has been shown to play a key role in the pathogenesis of experime ntal 
gas gangre ne. 19- 21 Like the other clostridial phospholipases C characterized, the 
enzyme is exported into the growth medium, and the deduced amino acid 
sequence of the protein reveals a typical signal sequence.7 The a-toxin produced 
by stra in NCTC8237 (the type strain) has been purified by several groups of 
workers.7- 10·22 E stimations of molecular weight, determined by gel filtration 
chromatography, 8·23·24 are generally in agreement with the predicted molecular 
weight from the deduced amino acid sequence, indicating that the protein exists 
as a monomer in solution. Not surprisingly , several groups used stra in 
NCTC8237 as the source of the gene encoding the a -toxin (alternatively te rmed 
cpa or plc) for gene cloning and sequenc ing analys is.7· 12·25·26 More recently, the 
cpa gene has been isol ated fro m a variety of other type A stra ins of C. perfrin-
gens and biotype B and C strains. In all biotypes, the gene has been shown to be 
present as a sing le copy on the chromosome, c lose to the orig in of replica-
tion.27·28 The deduced amino ac id sequences of these toxins are not identi cal: 
three amino ac id substitutions (Ala- 174 to Asp- 174, Thr- 177 to Ala- 177 and Ser-
335 to Pro-335) are found in the deduced amino ac id sequences o f the a -toxins 
from strains 13, CER89L43 and CER89L 12 16,29 strain 8-630 and stra in 
NC IB I 0662.31 Zinc-satu rated fo rms of the a -toxins fro m these stra ins are 
more res istant to chymo tryp in than the a -toxin fro m strain NCTC8237 .29 
Recently, a -toxin produced within the gut ha been as oc ia ted w ith a varie ty 
Table 14.1. Phospholipases C produced by the clostridia 
Clostridium species Biotype Name Mol wt pi Su bstrate specificity Ion requirements Hemolysis Lethality 
C. perfringens A-E a-Toxin 42,5008 5.4-5.67-9 PC,SPM,PS,LPC8·10 Zn2+, Ca2+8 +b +7 
C. bifermentans Phospholipase C 42,776c NR NR Ca2+13 ±12 12 
C. novyi A y-Toxin 30,000d 7.015 PC,SPM,LPC,PE,PS, Zn2+ Ca2+ , , +e +f 
PG 14,15 
A PI-PLC 30,00015 5.6, 6.015 Pl15 Mg2+14 15 NR 
None9 
B, D P-Toxin NR pc17 +i + 17 
32,0005 NR 
C. sordellii Phospholipase C NR NR NR NR NR NR 
C. paraperfringens Phospholipase C NR NR NR NR +/-j 18 
C. absonum Phospholipase C NR NR NR NR t /-k NR1s 
Hemolytic activity was considered to be complete(+), weak(±) or non-hemolytic (-). Enzymes were considered to be toxic if the lethal dose was less than 10 ~g/ 
mouse. NR = not reported. 
a Calculated from deduced amino acid sequence of strain NCTC8237 mature protein without metal ions.7 
b Sensitivity of erythrocytes from different species; cattle and mice > rabbit, man, sheep. Sheep erythrocytes show hot-cold lysis.11 
c Calculated from deduced amino acid sequence of strain ATCC638 mature protein, without metal ions.12 
d Determined by gel filtration chromatography.14 
e Horse erythrocytes were more sensitive to hemolysis than sheep erythrocytes.6·14 
1 Toxicity of C. haemolyticum culture filtrate attributed to y-toxin.16 
9 Zn2•, Ca2+ and Mg2• tested.15 
h Determined by gel filtration chromatography (h). 
i Hemolytic for sheep erythrocytes.17 
i Strains of C. paraperfringens reported to vary from nonhemolytic to hemolytic on human blood agar.18 
k Strains of C. absonum reported to be hemolytic on human blood agar.18 
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of diseases of animals and humans including enterotoxaemia and sudden death in 
certain breeds of calves32 and piglets33 and in necrotic enteritis in chickens.34·35 
The intragastric administration of a crude preparation of the a-toxin caused a 
disease in piglets with similar symptoms to C. perfringens type A infection.32 
The a-toxin has also been associated with some cases of sudden infant death 
syndrome in humans.36 It seems likely that the enhanced chymotrypsin re is-
tance of the a -toxin produced by some strains of C. perfringens may be impor-
tant for the development of these diseases. 
B. Clostridium bifermentans phospholipase C 
Comparisons of the properties of the C. bifermentans phospholipase C and the C. 
perfringens a-toxin were the subject of many investigations during the early 
1940s, although some of these studies require cautious interpretation because the 
enzymes used were almost certainly, by modern criteria, impure. Although the 
enzyme was immunologically related to the a -toxin, cross-neutralization studies 
showed that neutralization of the homologous enzyme by antiserum was at least 
10 times more efficient.4 The specific activities of the C. bifermentans strain 
ATCC638 phospholipase C, measured using purified phosphatidylcholine or 
sheep erythrocytes, has been reported to be 50 and 45 times, respectively, lower 
than the comparable activities of the a-toxin. 12 Miles and Miles37 found that the 
toxicity of the C. bifermentans enzyme varied from strain to strain; the most 
potent enzyme was at least nine times less toxic than C. perfringens a-toxin. 
This observation raises the possibility that the phospholipases C produced by 
different strains of C. bifermentans are not identical. In the author's laboratory it 
has been found that DNA from two different strains (LPHL2825 and LPHL2534) 
reacted differently with a gene probe derived from the a-toxin open reading 
frame (Table 14.2) or oligonucleotide probes from within this region (unpub-
lished data) also suggesting that different forms of the C. bifermentans enzyme 
exist. 
C. C. sordellii phospholipase C 
Clostridium sordellii can be distinguished from C. bifermentans by the absence 
of mannose in the cell walls of the latter's and the abi lity of C. sordellii to cause 
gangrenous disease in man and enterotoxaemia in sheep and cattle. There are no 
reports of work to characterize the phospholipase C produced by C. sordellii. 
However, the results of Southern blotting experiments suggest that the C. 
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Table 14.2. Southern hybridization of the Clostridium perfringens a-toxin probe with Hind Ill digested 
DNA from clostridia 
Clostridium species Biotype 
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sordellii is not identical to the C. pe1jringens a-toxin, or the phospholipase C 
from all strains of C. bifermentans (Table 14.2). 
D. Clostridium novyi phospholipases C 
1. Clostridium novyi y-toxin 
The C. novyi )'-toxin, produced by type A strains of the bacterium, is immuno-
logically distinct from the C. novyi B-toxin and the C. peifringens a-toxin.38 The 
relationship between this enzyme and the C. perfringens a-toxin awaits clarifi-
cation. However, Southern hybridization studies indicate that a sequence with a 
high degree of homology to the C. peifringens a-toxin is present in DNA from 
C. novyi type A (Table 14.2). This observation, together with the demonstration 
that this enzyme, like the a-toxin, requires zinc and calcium ions for activity, 14 
suggests that the )'-toxin is related to the C. peifringens a -toxin. The substrate 
specificity and hemolytic activity of the )'-tox in are not identical to those of the 
a -toxin and the further characterization of this enzyme could provide new 
insights into the molecular basis of substrate specificity. 
2. Clostridium novyi ~-toxin 
The B-toxin which is produced by type B and typeD (formerly C. haemolyticum) 
strains of C. novyi is tox ic 17 for mice, but the precise LD50 dose is not known . 
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The toxin is stable a t 37°C but not at 60°C. 17 The relationship of thi s toxin to 
other clostridial (or bacterial) phospholipases C awaits investigation . 
3. Clostridium novyi PI-PLC 
Taguchi and Ikezawa 15 reported the purification of a phosphatidylinositol hydro-
lyzi ng enzyme (PI-PLC) by a type A train of C. novyi which could be separated 
from they-toxin by isoelectric focusing. The enzyme did not require Zn2+, Ca2+ 
or Mg2+ ions for activity and was not inhibited by EDTA or o-phenanthroline. 
The C. novyi PI-PLC may be related to the type I enzymes produced by 
Staphylococcus aureus, Bacillus cereus, and Listeria monocytogenes (PLC-A) 
which share s ignificant amino acid sequence homology. 39 Like the e enzymes, 
the C. novyi PI-PLC may be able to cleave the phosphatidylinositol-glycan-
e thano laine anchor for membrane proteins, which leads to the release of enzymes 
<;uch as alkaline phosphatase and acetylcholinesterase.40 The role of the C. novyi 
enzyme in disease has not been reported and, although the L. monocytogenes 
enzyme ha been shown to play a role in mediating escape from the phago-
some41.42 it should be borne in mind that the latter is considered to be an 
intracellular pathogen . 
E. Clostridium absonum phospholipase C 
The production of a phospholipase C by C. absonum has been reported by 
Nakamura et a/. 18 The enzyme has not been characterized, but antiserum against 
the C. perfringens a -toxin is partially neutralizing. Our finding, that an a-toxin 
gene probe did not react with C. absonum DNA under conditions of high 
stringency (Table 14.2) would suggest that the C. absonum phospholipase C is 
only distantly related to the C. perfringens a-toxin. 
F. Clostridium paraperfringens phospholipase C 
The C. paraperfi·ingens phospholipase C is neutralized by a tenfold excess 
(compared with neutralization of the homologous enzyme) of antiserum against 
the C. perfringens a-toxin. 1 x The finding that C. paraperfringens DNA reacted 
w ith an a-toxin gene probe (Table 14.2) also suggests a high degree of 
homology be tween the C. paraperfi'ingens phospholipase C and the C. 
perji·ingens a-toxin. 
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Ill. GENE CLONING AND SEQUENCING REVEALS A FAMIL V OF 
PHOSPHOLIPASES C 
The comparison of immunological crossreactivities, and the reactivities of gene 
probes with DNA from phospholipase C producing clostridia suggested that the 
enzymes produced by these bacteria were related, but not identical. The fir t 
confirmation of this possibility was the finding that the deduced amino acid 
sequence of the C. b~fermentans phospholipase C was 51% identical with the 
C. perfringens a-toxin. 12 The identity was greatest in theN-terminal regions of 
the proteins (Figure 14.1). The genes encoding other clostridial phospholipases 
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Figure 14.1 Alignment of the deduced amino acid sequences of the Clostridium perfringens a-
toxin/ Clostridium bifermentans phospholipase C. 12 Bacillus cere us PC-PLC43 and the Listeria 
monocytogenes PLC-8.44 Residues known to be involved in the coordination of zinc ions in the 
Bacillus cereus PC-PLC49 are shaded. From Microb Rev 57: 347-366, with permission from the 
American Society for Microbiology. 
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phosphatidylcholine preferring phospholipases C (PC-PLC) from B. cereus43 and 
the L. monocytogenes PLC-B4 have been isolated, and the encoded proteins 
shown to have sign ificant homology with the C. perfringens and C. bifermentans 
enzymes. 7.25.39,44 
IV. THE a-TOXIN COMPRISES TWO DOMAINS 
A comparison of the amino acid sequences of the zinc-metallophospholipases C 
revealed that the PC-PLC and PLC-B proteins lacked a 120 amino acid region 
which was located at the C-terminus of the clostridial enzymes. This fi nding 
raised the possibil ity that the C. perfringens a-toxin and the C. bifermentans 
phospholipase C were composed of two domains. The crystallization of the a-
toxin has been reported by Basak et a/.45 and a preliminary low resolution 
structure has revealed that the a -toxin is composed of two domains (unpublished 
data). The precise determination of the structure will allow a detailed compari-
son of the structure of the N-terminal domain with the B. cereus PC-PLC and 
should provide insight into the possible role of the C-terminal domain. 
A. The N-terminal domain of the a-toxin has phospholipase C activity 
T he observation that theN-terminal region of the a-toxin showed homology with 
the phospholipases C from B. cereus and L. monocytogenes suggested that theN-
terminal 250 amino acids of the C. perfringens and C. bifermentans enzymes 
possessed phospholipase C activity . This was confirmed by Titball et a/.46 who 
showed that a fragment of the a-toxin (N-terminal domain; Cpa 1_ 249) retained 
phospholipase C activity but did not possess hemolytic or lethal activities and 
had a much reduced sphingomyelinase activity. This result is in accordance with 
the observations that the B. cereus and L. monocytogenes enzymes were non-
hemolytic and nontoxic phospholipases C.5.47.48 The relationship between theN-
terminal domain of the a-toxin and the B. cere us PC-PLC is fu rther confirmed by 
comparing the locations of amino acids known, from the crystal structure, to be 
involved in the coordination of catalytically essential zinc ions in the B. cereus 
PC-PLC .'~9 Additional evidence for the role of zinc ions in the a-toxin is derived 
from studies in which zinc-chelating agents, such as EDTA and o-phenanthro-
line, have been shown to inactivate the phospholipase C activitl and the 
chemical modification of histidine residues by diethylpyrocarbonate inactivates 
the enzyme only after pretreatment with EDTA,50 which would expose otherwise 
protected imidazole groups. The precise function of individual histidine residues 
within the N-terminal domain has been determined by generating site-directed 
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mutants of the toxin. 51 Replacement of those residues predicted to play an active 
site role (His6x.126. 136.148) with glycine abolished phospholipase C, sphingomye-
linase, hemolytic and lethal activities. Of these residues, His 148 appeared to bind, 
with high affinity, a zinc ion(s) which played a key role in catalytic activity . 
Modification of His46.207. 121 _24 1 did not affect the activity of the alpha-toxin. A 
His 1 1 mutant would also be expected to have a reduced activity but this mutant 
was unstable and could not be characterized. 
Therefore, it appears likely that the molecular architecture of the N-terminal 
domain of the a-toxin is similar to the B. cere us PC-PLC,49 a seven-helix protein 
which forms a twisted barrel structure and contains three zinc ions within the 
putative active site region (Figure 14.2). The C. perfringens a-toxin has been 
shown to contain two zinc atoms8·5 1 and this apparent discrepancy may be 
explained by considering that the third zinc atom in the B. cereus PC-PLC is 
weakly bound (this may be the zinc ion removed by EDT A treatment of the a-
toxin)5 1 and is present only under zinc-saturated conditions.8 Histidine residues 
at positions 68, 126 and 136 appear to play a role in the binding of this zinc ion 
Figure 14.2 Schematic representation of the crystal structure of the Bacillus cereus PC-PLC. The 
alpha helical regions of the protein are shown as cylinders (identified with the letters A to G) and 
zinc ions are shown as filled circles. Redrawn from Hough et al. (1989), with permission from 
Nature.49 
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and replacement of this ion with other divalent cations such as manganese, 
cobalt or cadmium has been demonstrated. 51 The z inc ions within the a.-toxin 
may erve three functions; by extrapolation from the B. cereus PC-PLC and from 
the data provided above it is likely that they contribute directly to the catalytic 
activity of the enzyme;g they a lso appear to play a role in stabili z ing the protein, 
particu larly against the effects of proteases;52 and finally zinc ions may play a 
role in the binding of the a.-toxin to cel l membranes.51 
B. The C-terminal domain of the a-toxin is responsible for hemolytic 
and lethal activity 
The finding that the His68. 126 , 136 , 148 mutants of the a.-toxin were devoid of 
enzyme, hemolytic and lethal activity5 1 along with the finding that only the 
phospholipase C activity could be attributed directly to theN-terminal domain46 
suggested that the phospholipase C activity of the a.-toxin was essential for 
hemolytic and lethal activity of the toxin. However, it is clear that phospholipase 
C activity alone is not sufficient for hemolysis and lethality. Of particular interest 
was the finding that theN-terminal domain of the a.-toxin (Cpa 1_ 249) had reduced 
sphingomyelinase activitl6 since it had previously been shown that the sphin-
gomyelinase activity of B. cereus was due to a separate enzyme from the PC-
PLC and that these enzymes could act synergistically to yield a hemolytic 
complex (cereolysin A-B).43 The observation that the PC-PLC and sphingomye-
linase genes formed an operon, with the sphingomyelinase gene located 3' to the 
PC-PLC gene might have indicated that the a.-toxin gene arose from a fusion of 
the B. cereus genes.30 Therefore, it was suggested that the C-terminal domain of 
the a.-toxin possessed a sphingomyelinase activity which acted synergistical ly 
with the phospholipase C activity in theN-terminal domain to yield a hemolytic 
and lethal toxin. To investigate this possibility further, Titball et al.53 isolated a 
fragment of the a.-toxin (Cpa247_370) which was devoid of any detectable enzyme 
or toxic activity.53 While this resu lt might have indicated that the Cpa247_370 was 
incorrectly folded, this seems unlikely since the fragment was immunologically 
s imilar to the holotoxin. In addition, the mixing of Cpa 1_249 and Cpa247_370 
partially restored hemolytic activi ty, presumably as a result of the binding of 
the individual domains in solution. This experiment clearly demonstrated that 
the C-terminal domain of the a.-tox in is responsible for conferring hemolytic 
(and possibly lethal) properties on the a.- toxin . 
The function of the C-terminal domain of the a.-toxin awaits clarification. The 
deduced amino acid sequence of Cpa247_:n o does not show s ig nificant homology 
with the deduced amino acid sequence of sphingomyelinases. However, sig-
nificant homology has been reported wi th the N-terminal reg ion of human 
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arachidonate-5-lipoxygenase (HA5L),4 <'> an enzyme which is involved in the 
conversion of arachidonic acid into leukotrienes.54·55 This sequence s imilarity , 
which includes five aligned tyrosine residues, may indicate the similar functions 
of these polypeptides in the binding to fatty acyl chains. In this respect it is of 
interest to note that the chemical modification of tyrosine residues in the a-toxin 
has been reported to abolish hemolytic activity.56 
We may now consider why the C. bifermentans pho pholipase C, which has a C-
terminal domain, is nontoxic and only weakly hemolytic. 12 This apparent anomaly 
can be explained by considering that the C. bifermentans enzyme has a low turn-
over rate 12 and, taking this difference into consideration, the toxicity and hemolytic 
activity of the C. bifermentans enzyme are in line with expectations. 
V. THE MOLECULAR BASIS OF TOXICITY 
A. Activation of intracellular pathways 
1. The arachidonic acid cascade 
The observation that the C. perfringens a-toxin caused hemolysis led to the 
suggestion by early workers that generalized membrane damage would lead to 
edema, shock, hemorrhage and local tissue necrosis.6 There has been a report of 
massive hemolysis, attributed to a-toxin, in a case of C. perfringens septicemia57 
but such gross effects of the toxin are considered to be exceptional. More 
recently, various workers have shown that the a-toxin is able to elicit a variety 
of subtle effects on cells, which leads to tissue dysfunction, shock and death 
(Figure 14.3). The hydrolysis of membrane phospholipids leads to the accumula-
tion of diacylglycerol58•59 within cells which can activate the arachidonic acid 
cascade.58·59 The subsequent generation of leukotrienes and thromboxanes 
would result in inflammation, edema, platelet aggregation, muscle contraction 
and increases in vascular permeability.55·60 All of these effects have been 
reported to be induced by the a-toxin61 - 64 and the production of thromboxane 
A2 in rat aorta cel ls treated with a-toxin has been demonstrated by Fujii and 
Sakurai.8 
2. Protein kinase C 
The activation of protein kina e C by diacylglycerol resu lts in the activation of 
intracellular pho pholipa es,<'>5 estab li sh ing a positive feedback loop and poten-
tiating the effects described above. Indeed, the production of arach idonic acid 
metabolites in cultured intestinal cell s treated with a -toxin has been attributed 
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Figure 14.3 Biochemical pathways which are activated after treatment of cells with Clostridium 
perfringens a-toxin. Eukaryotic phospholipases which might be activated are shown starred. PLA2 
=phospholipase A2; PI PLC = phosphatidylinositol phospholipase C; ER= endoplasmic reticulum; 
PIP2 = phosphatidylinositol biophosphate. 
mainly to activated cell phospholipases A2 .66 Sakurai et a/.67·68 have shown that 
treatment of rabbit erythrocytes with a-toxin leads to generation of diacylgly-
cerol, inositol triphosphate and phosphatidic acid. While the diacylglycerol may 
be generated by the hydrolysis of membrane phospholipids, the formation of 
inositol triphosphate and phosphatidic acid would indicate activation of the 
phosphatidylinositol cycle.69 These changes in rabbit erythrocyte membranes 
were accompanied by a decrease in phosphatidylinositol bisphosphate levels 
which would suggest that membrane phospholipases C were activated (since 
a-toxin is considered to be unable to hydrolyze phosphatidylinositol). In addi-
tion, treatment of erythrocyte membranes with pertussis toxin, which is known to 
ADP-ribosylate GTP-binding proteins involved in membrane phospholipase C 
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activation, resulted in the abolition of phosphat idic acid formation. 6x These 
re ults suggest that the activation of membrane pho pholipases may contribute 
to degradation of membrane phosphatidylinositol. The activation of membrane 
phospholipases is usually mediated by agonist binding to a cell surface receptor. 
The binding of the a.-toxin to this receptor might lead to membrane phospho-
lipase C activation. 68 Alternatively, it should be borne in mind that the products 
of phospholipid hydrolysis (e.g. phosphorylcholine and diacylglycerol) can lead 
to the activation of membrane phospholipases.69 
3. Calcium mobilization 
The hydrolysis of membrane phosphatidylinositol-4,5 bisphosphate, by the a.-
toxin or by the activated endogenous cellular phospholipases, would result in the 
generation of inositol I ,4,5 triphosphate,65 which is known to stimulate the 
release of intracellular stores of calcium. Inositol 1,3,4,5 tetraphosphate, derived 
from inositol 1,4,5 triphosphate, is thought to lead to the activation of calcium 
gates, with the influx of calcium into the cell. 65 These changes in intracellular 
calcium levels lead to a variety of effects on cells, including smooth muscle 
contraction. It is likely that the contraction of the rat aorta and the rat ileum, after 
treatment with a.-toxin, were induced by the activation of calcium gates since 
calcium entry blockers such as verapamil and nifedipine blocked the contrac-
tion.63·64 The activation of calcium gates might also be responsible for the 
marked changes in frog muscle membrane potentials after treatment with a.-
toxin, which were reported by Boethius et al.70 It seems likely that the prolonged 
exposure of smooth muscle to the a.-toxin would lead to the loss of contractile 
abi lity and this may explain why the a.-toxin has such a potent cardiotoxic 
activity leading to reduced heart rate, blood pressure and cardiac output.71 The 
specific effects described above, which would lead to muscle contraction, inflam-
mation and reduced cardiac activity may have an overall effect of reducing blood 
supply and promoting anoxia in the tissues adjacent to the focus of gas gangrene 
infection. This would promote the further growth of C. perfringens and may, in 
part, explain why the infection can spread rapidly through tissues. 
B. The a-toxin is able to hydrolyze membrane phospholipids 
Central to any of these mechanisms of toxicity is the abil ity of the a.-toxin to 
cleave, or to induce cleavage of, membrane phospholipids. In thi s respect, the 
measurement of hemolysis can serve as an indicator of membrane phospholipid 
hydrolysi s. The phospholipases C produced by the clostridia, and the B. cereus 
PC-PLC, show different hemolytic activities and can serve as models for 
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Figure 14.4 Model of membrane-integrated phosphatidylcholine, showing the interfacial area 
(boxed) wh ich would be accessible to phospholipases C and the site of cleavage (arrowed). 
Charged regions on the phospholipid head group are also depicted (redrawn from El Sayed et 
al. (1985) with permission from Elsevier Science).73 
examining the molecular basis of membrane interaction. It has been proposed 
that hemo lytic phospholipases are able to enter me mbrane bilayers ma inta ined at 
high lateral pressures,9•72 suggesting that the he molytic enzymes possessed 
mechan isms for promoting membrane insertion . The architecture of the mem-
brane bilayer indicates that the head group of phospholipids would be exposed 
and accessible for cleavage by phospho lipases C (Fig ure 14.4). However, phos-
pholipid recognition by the B. cereus PC-PLC involves not only the head group 
but also the fa tty acy l chains and the associated ester bonds,73 both of which 
would be buried in the tightly packed membrane bilayer. 
Other factors, such as membrane phospholipid composition may a lso influence 
the hemolytic pote nti a l of phospho lipases C . T he d istribution o f phospho lipids in 
the membrane b ilayer shows a high degree of asymmetry with phosphatidylcho-
line and sphingomyelin the ma in componen t of the oute r leaflet.74 These 
phospho lip ids a re the preferenti a l sub. trates for the a -toxinx whereas the non-
hemolytic B. cereus PC-PLC is unable to hydro lyze sphingomyelin.4 x.?s It should 
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also be noted that a mixture of the B. cereus PC-PLC and sphingomyelinase 
h I . 4:\ causes emo ys1s. · 
The role of calcium in promoting the interaction of the a-toxin with membrane 
phospholipids has been reported by a number of workers. Calcium ions are 
known to be essential for phospholipase C activity76 and for haemolytic activity 
of the a-toxin. 10 The role of calcium ions appears to be different from the role of 
zinc ion (which play a structural and catalytic role in the protein) and has been 
investigated by Moreau et al.9 using phospholipid monolayers. In thi s system, 
calcium ions were shown to play an essential role in promoting the binding of the 
toxin to lipids. It has been proposed that calcium ions reduce the overall negative 
charge on the phospholipid and thus permit binding of the a-toxin ; the finding 
that other cations are also able to promote lipid binding provides credence to this 
hypothesis. 77 The calcium ions may bind to the phosphate group of the phos-
pholipid 11 thereby neutralizing the charge in this region and permitting binding 
of the a-toxin. However, other workers have suggested that calcium ions bind to 
the a-toxin first and may induce a conformational change in the protein prior to 
lipid binding.78•79 This hypothesis would suggest the presence of a calcium-
binding site within the a -toxin but the location of this site has not yet been 
determined. 
VI. CONCLUSIONS 
A number of the clostridial spectes produce phospholipases C and, in some 
cases, these enzymes have been characterized. However, a number of funda-
mental questions remain unanswered; what are the relationships of the C. novyi 
enzymes to the C. perfringens and C. bifermentans enzymes? Are the enzymes 
produced by different strains of C. bifermentans dissimilar? Many of these 
enzymes appear to be related and the cloning and sequencing of the genes 
encoding these enzymes will permit more detailed comparisons to be made. 
The properties of these enzymes are different with respect to substrate specificity 
and toxicity. Increasing opportunity exists for the rational comparison of the 
structure and function of these enzymes. Indeed, the range of clostridial enzymes 
which are available provides the researcher with a unique opportunity to explore 
structure-function relationships. These comparisons will provide new insights 
into the molecular basis of substrate specificity and the mechanisms by which 
proteins interact with membranes. Many of these insights will be applicable to 
other prokaryotic and e ukaryotic phospholipases C. For example, there is an 
increas ing awareness of the role of eukaryot ic phospholipases C in the etiology 
of a wide range of inflammatory diseases. 
With respect to the a -toxin of C. perfringens, many questions remain 
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unanswered. The suggestion by MacFarlane6 that tox1c1ty of the clostridia l 
phospholipases C correl ates with hemolytic rather than phospholipase C activity 
appear well founded but the molecular basis of toxicity is still unclear. C learly, 
the protein must interact with the cel l membrane but the molecu lar basis of this 
interaction is not known. The determination of the crystal structure of the a-
toxin will aid studies in this area. By whatever mechanism the a-toxin interacts 
with the membrane it is possible that acti vation of cell membrane phospholipa es 
C, in addition to the inherent phospholipase C acti vity of the a-toxin, lead to 
membrane perturbation and activation of PKC and the arachidonic acid cascade. 
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Introduction 
The gene encoding the cc-(cpa) is present in all strains of Clostridium 
perfringens, and the purified cc-toxin has been shown to be a zinc-containing 
phospholipase C enzyme, which is preferentially active towards phospha-
tidylcholine and sphingomyelin. The ex-toxin is haemolytic as a result if its 
ability to hydrolyse cell membrane phospholipids and this activity 
distinguishes it from many other related zinc-metallophospholipases C. 
Recent studies have shown that the ex-toxin is the major virulence 
determinant in cases of gas gangrene, and the toxin might play a role in 
several other diseases of animals and man as diverse as necrotic enteritis in 
chickens and Crohn's disease in man. In gas gangrene the toxin appears to 
have three major roles in the pathogenesis of disease. First, it is able to cause 
mistrafficking of neutrophils, such that they do not enter infected tissues. 
Second, the toxin is able to cause vasoconstriction and platelet aggregation 
which might reduce the blood supply to infected tissues. Finally, the toxin is 
able to detrimentally modulate host cell metabolism by activating the 
arachidonic acid cascade and protein kinase C. The molecular structure of 
the ex-toxin reveals a two domain protein. The amino-terminal domain 
contains the phospholipase C active site which contains zinc ions. The 
carboxyterminal domain is a paralogue of lipid binding domains found in 
eukaryotes and appears to bind phospholipids in a calcium-dependent 
manner. Immunisation with the non-toxic carboxyterminal domain induces 
protection against the ex-toxin and gas gangrene and this polypeptide might 
be exploited as a vaccine. Other workers have exploited the entire toxin as 
the basis of an anti-tumour system. 
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Clostridium perfringens is a Gram-positive anaerobe 
which is ubiquitous in the environment, being found 
in the soil, in decaying organic matter and as a 
member of the normal gut flora of many animals [1]. 
The ability of the bacterium to form highly resistant 
endospores means that it is able to per i t in these 
environments, and especially within soil. All strains 
of the bacterium possess the gene encoding the ex-
toxin (cpa), and the differential possession of other 
toxin-encoding genes is used to identify strains as 
biotypes A toE [1,2). The ex-toxin is the best studied of • Corresponding a uthor. Tel.: lnt +~41980 61 3301 ; fax: lnt +441 980 613284; E-ma il: rtitcall@dera.gov.uk 
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the C. per[ri11gens toxins and it is the molecular biology 
of this toxin and the role of this toxin in disease of 
man and animals that is the subject of this review. 
The a -toxin is a phospholipase C 
The cx-toxin was shown to be a phospholipase C by 
MacFarlane and Knight in 1941 [3); Indeed, this was 
the first time that any bacterial toxin had been shown 
to have enzymatic activity. The action of the CJ:-toxin 
on egg yolk lipoprotein, resulting in an increase 
in turbidity, is the basis of a diagnostic test (the 
Nagler reaction) for C. perfringens. The preferred 
substrates for ex-toxin are phosphatidylcholine and 
sphingomyelin whilst phosphatidylethanolamine, 
phosphatidic acid, phosphotidyserine and phosphati-
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Figure 1. Site of cleavage of phosphatidylcholine by a:-toxin. 
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phospholipid (Figure 1) yields a charged head group 
and a water-insoluble diacylglycerol group (or a 
ceramide group in the case of sphingomyelin hydro-
lysis). Both monodispersed and membrane-packed 
phospholipids are susceptible to hydrolysis by ex-toxin 
[4-6). The activity tov.;ards phospholipids in lipo-
somes can easily be measured using liposomes 
containing an entrapped fluorescent dye, such a 6-
carboxyfluorescein, and monitoring the increase in 
fluorescence in solution as the dye is released [4]. The 
activity towards erythrocytes can be measured as 
haemolysis and it is significant that erythrocytes 
derived from different species vary in their suscepti-
bility to lysis. In part this might reflect the phospho-
lipid composition of the outer leaflet of the cell 
membrane, i.e. those which are rich in both phospha-
tidylcholine and sphingomyelin are most sensitive to 
lysis [7]. The direct hydrolysis of membrane phos-
pholipids by ex-toxin [8] appears to provide a simple 
explanation for the lysis of erythrocytes. However, 
recent studies have suggested that at least some of the 
membrane damage might be caused by endogenous 
phospholipases C in the erythrocyte membrane [9], 
which are activated by the PKC pathway (see below 
for details) . All of this underlines the complexity of 
the interaction between :x-toxin and eukaryotic cells. 
For all of these activities both Zn2+ and Ca2+ ions 
are required. The finding that purified ex-toxin 
contained two Zn2+ ions [5] suggested that they were 
bound to the protein and the finding that treatment 
of the protein with EDTA abolished enzymatic 
activity [5,10] is consistent with the zinc ions being 
essential for catalytic activity. In contrast it has been 
suggested that Ca2+ ions are essential for the binding 
of the enzyme to the phospholipid [6,11], perhaps by 
neutralising the charge on the phosphate group [5,6]. 
Gene cloning and analysis 
The gene encoding the :t-toxin (cpa) is chromosomally 
located, close to the origin of replication and adjacent 
to rrnA genes [12,13]. This region is one of the most 
stable within the bacterial chromosome [12] and this 
might reflect the essential nature of :x-toxin for the 
lifestyle of C. perfringen~ . In contrast, many of the 
other major toxin genes are known to be plasmid 
borne [12,13). Cloning and nucleotide sequencing 
of the cpa gene from <1 t~· pe A train (NCTC8237 = 
ATCC13124) which was known to produce high levels 
of ex-toxin was reported b~· five independent groups 
[14-18]. The cloned gene was expressed in E. coli, 
colonies of which were surrounded by a zone of 
turbidity on egg-yolk agar and a zone of haemolysis 
on agar containing erythrocytes [14,171. Nucleotide 
sequencing revealed a sing le open reading frame 
which included a putative prokaryotic signal se-
quence [14] . The presence of a signal sequence is also 
suggested by the findings that et-toxin is exported 
from C. perfringens 1191 and that it accumulates in the 
periplasmic space of E. coli expressing the cloned cpa 
gene [14). Confirmation of the presence of a signal 
sequence was obtained by Leslie et al . [16) who used 
mini-cells to show that in addition to the predominant 
mature form of the protein (Mr = 42 528) there was a 
higher molecular weight form which represented the 
protein before post-translational processing. Recom-
binant ex-toxin isolated from the periplasmic space of 
E. coli expressing cpa has been shown to be identical to 
the :x-toxin purified from the culture supernatant fluid 
of C. perfringens [14]. The ease with which the 
recombinant protein can be purified [14,20] along 
with the freedom from other C. perfringens enzymes 
and toxins has allowed many definitive studies to be 
undertaken over the past decade, which are detailed 
later in this article. 
Subsequently the cpa genes from other type A 
strains and types B-E strains of C. perfringenes have 
been isolated and characterised. These cpa genes are 
all chromosomally located close to the origin of 
replication [21). Within the entire open reading frame 
there are nucleotide changes at 56 positions and these 
are distributed with similar frequencies throughout 
the coding region. An unrooted phylogenetic tree 
constructed from the nucleotide sequences within the 
open reading frame (Figure 2) indicates that there are 
several clusters of related genes, but these clusters do 
not represent different biotypes of C. per{ringe11s. 
Related phospholipases C 
Although on the basis of antigenic cross-reactivity 
the C. perfringens et-toxin, C. novyi y-toxin and 
C. bifennentans phospholipases C were thought to be 
structurally related [1 ,22], a full appreciation of these 
relationships awaited the determination of the nucleo-
tide sequences of the encoding genes. The deduced 
amino acid sequences of the clostridial enzymes show 
homology not only with each other but also with the 
Bacillus cereus phosphatidycholine preferring phos-
pholipase C and the Listeria monocytogenes PLC-B [23). 
The enzymes in this group are inactivated by zinc-
chelating agents such as EDTA or o-phenanthroline 
[5,24,25) and have been collectively termed the zinc-
metallophospholipases C [23). On the basis of anti-
genic cross-reactivity with o:-toxin [26) the C. barati 
and C. absonum phospholipases Care also considered 
to be zinc-metallophospholipases C. 
The zinc-metallophospholipases C show differences 
in substrate specificity, for example only some of 
these enzymes are able to efficiently hydrolyse 
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Figure 2. Unrooted phylogram showing the relationship between 
the cpa genes from C. per{ri11gens types A- E. The phylogram was 
generated from a Clustal X sequence alignment and the tree 
constructed using the Neighbour joining method. Bootstrap values 
(from 1000 bootstrap replicates) are shown at the tree nodes. 
sphingomyelin [23]. However, the most striking 
difference in properties is found when the toxicities 
of these enzymes are compared; the C. perfringens 
phospholipase C is a potent toxin (MLD < 0.1 11g/ 
mouse [14]) whereas the C. bifermentans phospholi-
pase C, 8 . cereus PC-PLC and L. monCJjtogenes PLC-B 
are non-toxic (MLD > 10 11g/ mouse [15,25,27]). The 
toxicity of these enzymes can be correlated with their 
haemolytic activity [23], lending support to the 
hypothesis that the hydrolysis of membrane phos-
pholipids is a key event in damage to the host. 
Molecular architecture of ex-toxin 
The crystal structure of recombinant ex-toxin reveals a 
two-domain protein with the amino-terminal domain 
(N-domain) composed from ex-helices and the car-
boxy-terminal domain (C-domain) composed from P-
sheet (Figure 3) [28]. These domains are joined by a 
flexible linker region, by interactions between an N-
domain loop which makes contact with the C-domain 
and by hydrophobic interactions between the adjacent 
faces of the domains. The isolated recombinant N-
domain possesses full phospholipase C activity 
towards phosphatidylcholine and reduced activity 
towards sphingomyelin [29] indicating that the 
phospholipase C active site is Located in this domain. 
The putative active site is located within a cleft which 
is also occupied by three catalytically essential zinc 
ions co-ordinated by the N-terminal tryptophan 
residue, a glutamic acid residue, two aspartic acid 
residues and five histidine residues [28) . Site directed 
mutagenesis of these residues results in proteins 
which are devoid of phospholipase C activity and 
have reduced zinc ion contents (Table 1). Significantly 
these mutated proteins are also devoid of haemolytic 
and lethal activity [30-32], suggesting that the 
phospholipase C active site in the N-domain is 
essential for all activities. 
The exact molecular fold of the C-domain has not 
been seen before in prokaryotic proteins and closely 
resembles the C2-type domains found in eukaryotic 
lipid-metabolishing enzymes such as synaptotagmin, 
human pancreatic lipase an rat phosphatidylinositol 
phospholipase C [33]. The G+ C contents of the N- or 
C-domain coding regions of the cpa gene are 35% and 
30% respectively which is similar to the overall G+ C 
content (24-27%) of C. perfringens DNA [34]. These 
findings, along with the observation that the amino 
acid sequence of the C-domain shows only weak 
sequence homology with the eukaryotic C2 domains 
suggest that the ex-toxin C-domain and the eukaryotic 
C2 phospholipid binding domains are not true 
orthologs (i.e. by descent). 
The function of the C-domain is not fully eluci-
dated . However, several lines of investigation suggest 
that this domain plays a key role in facilitating the 
interaction of ex-toxin wi th membrane phospholipids. 
The B. cereus PC-PLC and the L. monocytogenes PLC-B 
Figure 3. Crystal structure of the C. perfringens ex-toxin show ing the 
N- and C-domains linked by a flexible peptide and the active si te 
zinc ions. The exposed hydrophobic amino acids (Trp 124 and Phe 
334) and proposed locations of bound calcium ions which are 
thought to be required for membrane interaction are also depicted. 
Figure 4. Model showing the interaction of :x-toxin with cell 
membrane phospholip ids (shown with stylised headgroups in pink 
and ta ils groups in grey). The head group of a single phospholipid , 
withd rawn from the outer lea flet of the membrane into the active 
site, is shown in more detai l. The locations of calcium ions which 
might play a role in membrane phospholipid binding are also 
shown. Amino acids which might play a role in calcium ion 
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Table 1. Biological activities of site directed mutants of C. perfringcns ne-toxin 
Proposed function 
Mutation [Reference] Domain of target amino acid 
Wild type 
EDTA-lTeated wild type 
z nh binding W1S [30] N 
HllS [30] N Zn2+ binding 
H68S [30] N Zn2+ binding 
H68G [31] N Zn2+ binding 
H126S [30] N Zn2+ binding 
H126G [31] N Zn2+ binding 
H136S [30] Zn2 ' binding 
H136G [31] N Zn2• binding 
H136A [31] Zn2+ binding 
H148S [30] Zn2• binding 
H148G [31] N Znz. binding 
H148L [31] zn2+ binding 
E152D [32] Zn2+ binding 
E152Q [32] N Zn2+ binding 
E152G [32] Znh binding 
+grea ter than 85% retention of the activity of the wild type toxin. 
- less than 3% retention of activity of the wild type toxin. 
ND: not determined. 
both lack a C-domain [23] and these enzymes are non-
haemolytic and non-toxic [25,27]. In addition, the 
B. cereus PC-PLC is excluded from phospholipid 
monolayers at lateral pressures similar to those 
found in mammalian cells, whereas ex-toxin remains 
active at high membrane lateral pressures [8]. The 
removal of the C-domain from the ex-toxin yields an 
enzymaticaily active N-domain whicl1 lacks the 
haemolytic, liposome disrupting and toxic properties 
of the holotoxin [29,35]. Further, haemolytic and 
liposome disrupting activities are partially restored 
by mixing the isolated N- and C-domains together 
[35,36], presumably because these domains can re-
associate in solution. 
A detailed analysis of the crystal structure has 
suggested a mechanism by which the ex-toxin interacts 
with cell membranes [28). Several exposed hydro-
phobic residues (including Trp214 and Phe334) are 
located on one face of the protein, in the N- and C-
domains, respectively. If this face of the protein is 
docked with a model of the outer leaflet of a 
membrane bilayer then these hydrophobic side chains 
are appropriately positioned to interact with the fatty-
acyl tail groups of the phospholipids (Figure 4). An 
second mechanism of membrane recognition is 
suggested by the functions of the eukaryotic C2-type 
domains mentioned in the previous paragraph. These 
are involved in calcium-mediated phospholipid re-
cognition [33], and the C-domain of ex-toxin might 
therefore play a similar role where the calcium ions 
are partially co-ordinated by acidic amino acid side 
chains and partially by the phosphate groups of 
Activity 
Bound zinc 
pc sph hly let (mol) 

















membrane phospholipids. This model would also 
explain the long-standing observations that calcium 
ions are required for phospholipid recognition and 
haemolytic activity of ex-toxin [3,5,11] but not for the 
phospholipase C activity of the B. cereus PC-PLC [24]. 
On the basis of enzyme kinetic studies it appears that 
the calcium ions first bind loosely to ex-toxin 
(Kct = 12.0 mM) and the protein Ca 1 + complex is then 
able to bind to phospholipid (Kct = 36 ~) [6]. Whilst 
crystallisation of ex-toxin with calcium ions might 
precisely identify the calcium-co-ordinating ligands, 
this has not so far been possible. However, cadmium 
ions (which are molecular mimics of calcium ions) 
have been found bound to regions of the C-domain 
which lie on the membrane-binding face of the 
protein and the mutation of Tyr275 and Asp 269, 
which are strongly implicated in calcium binding, 
results in proteins with reduced activities [37]. 
The combined structural features of exposed hydro-
phobic amino acids and calcium ion co-ordination 
might explain how C'i-toxin interacts with membrane 
phospholipids, and why removal of the C-domain 
abolishes haemolytic activity. However, even allowing 
for the partial insertion of the protein into the 
membrane bilayer it is apparent that the active site 
is still approximately SA from the susceptible bond of 
the phospholipid head group [28) . Various mechan-
isms have been proposed to attempt to explain how 
this might be overcome. It is possible that the protein 
is able to partially retract the target phospholipid from 
the membrane or perhaps the protein undergoes a 
conformational change on membrane binding which 
C. p erfringens ex-toxin 57 
brings the active site into position with the phospho-
lipid head group. Studies to resolve this question are 
currently underway. 
Struct ural var iant s of a-toxin 
The deduced amino acid sequences of ex-toxins from 
15 different strains of proteins show variation at six 
positions (21 %) within the signal sequences, 10 
positions within the N-domain (4.1 %), 3 positions 
within the C-domain (2.7%) and at one position 
within the N- to C-domain linker peptide. Within 
the mature protein, the sequence differences are 
located with equal frequencies in structural elements 
and within loop regions. On the basis of studies with 
purified ex-toxin from strains NCTC8237, 8-6, 
NCIB10691, NCIB10662, NCIB10748 and CER89L43 
these amino acid substitutions do not affect the 
phospholipase C activity [38,39]. Although most of 
the amino acid sequence differences between strains 
are conserved substitutions and do not affect enzy-
matic activity, there is some evidence that they are 
biologically significant. Purified ex-toxin from a type A 
strain (NCTC82387) isolated from a case of gas 
gangrene or from an isolate (CER89L43) from the 
gut of a calf which had died from sudden death 
syndrome had similar enzymatic and toxic specific 
activities [39]. However, the CER89L43 ex-toxin was 
more resistant to the degradation when incubated 
with chymotrypsin [39]. It is possible that this 
protease resistance reflects the different sites of 
production and action of ex-toxin produced in soft 
tissues or in the gut. 
Regulation of expression of the cpa 
gene 
An early observation was that some isolates of 
C. perfringens from cases of gas gangrene produced 
low levels of ex-toxin [40,41], a finding which could not 
be reconciled with the proposed key role of the toxin 
in disease. Differences in the levels of ex-toxin 
production appear to be due to transcriptional 
regulation of cpa [38,42]. Although the possibility that 
cpa expression is upregulated in vivo, has yet to be 
proven major progress has been made in identifying 
the mechanisms of gene regulation in vitro. 
The promoter directing expression of cpa has been 
mapped and shown to contain classical - 10 and -35 
regions, located upstream of the Shine Dalgarno 
region [42]. Although the regulatory si te for cpn has 
yet to be identified, repeated poly-A tracts upstream 
of the -35 region do appear to play a role in cpa 
expression [43,44]. Like many pathogenic bacteria, 
C. perfrillgens is able to regulate gene expression 
(including cpn) via a two component regulatory 
system termed the VirR/VirS system [45,46]. In this 
system it is proposed that VirS acts as a sensor 
histidine kinase, and in response to an as yet 
unidentified environmental signal, phosphorylates 
VirR. On the basis of studies with other bacterial 
two-component response regulators it is proposed 
that the phosphorylated VirR modulates the tran-
scription of target genes [45]. The identification of the 
environmental stimulus which modulates VirR/VirS 
function could certainly provide major new insights 
not only into possibility that the bacterium upregu-
lates the production of ex-toxin in wounds, but also 
that expression of ex-toxin is normally downregulated 
in the healthy gut and upregulated in some disease 
conditions. 
The role of a-toxin in disease 
Identification of ':X-toxin as the ketj virulence factor in gas 
gangrene 
Although C. perfringens is now recognised as the 
causative agent of a variety of diseases of man and 
animals, the bacterium achieved notoriety because of 
its role in gas gangrene. C. perfringens type A strains 
are especially associated with gas gangrene, which 
usually arises as the result of the contamination of a 
traumatic injury site with either spores (which 
germinate within the damaged host tissues) or with 
vegetative cells. Such injuries are especially associated 
with armed conflicts but might also be the conse-
quence of traumatic injuries received by the general 
population during peacetime. Gas gangrene is also an 
occasional consequence of surgery involving the 
intestinal tract, where adjacent tissues become con-
taminated with the intestinal contents [1] . 
The contamination of traumatic wounds is not the 
only pre-requisite for the development of disease. The 
vast majority of traumatic wounds do become con-
taminated with the bacterium [47], but only a small 
proportion of the wounded individuals develop gas 
gangrene. Individuals who develop disease often 
have associated damage to the blood vessels which 
serve the wound site, or obliterative arterial disease, 
both of which render the tissues anoxic and allow the 
growth of the bacterium. The nutrient rich environ-
ment allows rapid growth of the anaerobic bacterium 
and the infection can spread along the lateral planes 
of muscle tissue with remarkable speed to involve the 
entire limb [47,48]. For many years it had been 
suggested that a soluble factor produced by the 
bacterium aided spread of the bacteria [48]. However, 
it was not until relatively recently that ex-toxin was 
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identified as this factor and its role in disease proven 
using two different approaches. First, it was shown 
that inactivation of the cpn gene yielded a 
C. perfringens mutant which was attenuated in the 
murine model of gas gangrene [49,50]. Second, it was 
shown that immunisation of mice with a recombinant 
a-toxoid solidly protected them from experimental 
gas gangrene [51]. 
Does a-toxin play a role 111 other diseases of man and 
animals? 
A number of workers have suggested that a-toxin 
might play a role in non-gangrenous diseases of man 
and animals [52- SS]. Many of these suggestions are 
based on the knowledge that C. perfringens is a 
member of the normal gut flora, and that under some 
conditions overgrowth of the bacterium in the gut 
occurs [52,53,55,56] with the possible production of 
high levels of a-toxin. 
One disease which has been long-associated with 
C. perfringens and a-toxin is necrotic enteritis in 
chickens. The disease has been reproduced in chick-
ens consuming feedstuff containing C. perfringens, 
especially if the feedstuffs were rich in zinc [52,56], 
and in chickens eo-infected with C. perfringens and 
Eimeria brunetti [52]. This finding was attributed to the 
ability of zinc to protect a-toxin from proteolysis by 
trypsin [52,57] and might now be explained by the 
finding that a-toxin is a zinc-metalloenzyme [28]. The 
a-toxin has been especially associated with a fatal 
enteritis in calves [53] and in piglets [54] and this 
disease has been suggested to be the consequence of a 
number of factors; whereas mature animals appear to 
be protected from disease as the result of the 
establishment of a balanced gut flora and the 
generation of a protective antibody response to a-
toxin, preweaned animals do not possess colostrum-
acquired protection against the toxin. 
In man, it has been suggested that a-toxin might 
play a role in some cases of sudden infant death 
syndrome (SIDS) [55,58], and certainly some deaths 
are associated with an increase in the level of 
C. perfringens in the gut. Further evidence comes from 
the finding that a-toxin can be detected in serum 
samples from some SIDS cases, but not in serum 
samples from infants which have died from other 
causes [55]. The a-toxin has also been associated with 
some inflammatory diseases of man, including 
Crohn's disease [59] and rheumatoid arthritis [60). 
The suggestion that a-toxin plays a role in these 
diseases is a t least supported by our knowledge that 
a-toxin can induce the production of inflammatory 
mediators, as a result of activation of the arachidonic 
acid cascade (see below). 
Whilst many of these stud ies have been carefully 
controlled, none provide any conclusive evidence that 
either C. perfringells or a-toxin are the etiological 
factors. An understanding of the etiology of these 
diseases is made difficult because it is uncertain 
whether changes in the level of C. perfringens in the 
gut are a consequence of disease (or of death) rather 
than the true cause of the condition. Clearly it will be 
necessary to establish appropriate models of these 
diseases, and perhaps conduct trails with appropriate 
vaccines before any conclusions can be drawn. 
Molecular mechanisms of disease 
The role of the a-toxin in gas gangrene is complex and 
varied. Although a-toxin is a potent haemolysin, the 
lysis of erythrocytes is only seen after i.v. administra-
tion of toxin in experimental animals (rather than 
after i.m. administration) or in cases of clostridial 
septicaemia [61). Initial suggestions that the toxin 
caused damage to the host by lysing cells [62) have 
been overturned during the past decade by findings 
that the toxin acts in much more subtle and elegant 
ways. Central to these effects is the ability of the toxin 
to hydrolyse phospholipids in host cell membranes 
and to perturb the metabolism of host cells (Figure 5) 
to the advantage of the pathogen and the disadvan-
tage of the host. 
Avoidance of host defence mechanisms 
One of the early histological findings in gangrenous 
tissues was the apparent absence of neutrophils [48), 
in contrast to the appearance of tissues taken from the 
sites of infection with other pathogens of soft tissues. 
More recent studies have shown that in parallel with 
the absence of neutrophils in tissues there is an 
accumulation of neutrophils in the blood vessels 
which serve the site of infection [63). The accumula-
tion of neutrophils appears to be the result of 
upregulation of the intercellular adhesion molecule 1 
(]CAM-1) and endothelial Jeukocyte adhesion mole-
cule 1 (ELAM-1) markers on the surface of endothelial 
cells lining these blood vessels and the enhanced 
production of interleukin 8 (IL-8) by these cells [64). 
Whereas these markers would normally play a role in 
trafficking neutrophils into the tissue spaces, the 
upregulated markers trap neutrophils within the 
blood vessels, preventing trafficking into the tissue 
spaces. Two lines of evidence implicate a-toxin as the 
mediator of these effects. First, it has been shown that 
tissues taken from mice challenged with an a-toxin-
negative mutant of C. perfringens contained large 
numbers of neutrophils in tissue spaces [65). Second, 
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Figure 5. Effects of ex-toxin on the metabolism of a generalised 
cell. 
it has been shown that ICAM-1 and ELAM-1 expres-
sion is upregulated in isolated vascular tissues treated 
with cx-toxin [64]. The molecular mechanism by which 
cx-toxin causes these effects is not yet known. 
Damage to the host 
The outer leaflet of the host cell membrane is rich in 
phosphatidylcholine and sphingomyelin, the pre-
ferred substrates of ex-toxin [5]. Recent research has 
suggested that it is the products of phospholipid 
hydrolysis (diacyglycerol or ceramide, respectively), 
rather than cell membrane damage per se, which are 
responsible for damage to the host. Several lines of 
evidence indicate that, at least in vitro, cells treated 
with ex-toxin respond by producing elevated levels of 
arachidonic acid [66 68] and arachidonic acid meta-
bolites such a thromboxane 82 [671. The general 
activation of the arachidonic acid cascade results in 
the production of thromboxanes, Ieukotrienes and 
prostaglandins [69]. If produced in vivo these mole-
cules could play important roles in generating a local 
inflammatory response and promoting vasoconstric-
tion [69], which might serve to promote anoxia within 
infected tissues. These effects might serve to enhance 
the ability of the bacterium to grow within host 
tissues. 
Diacylglycerol also acts as an important secondary 
messenger within cells, activating protein kinase C 
(PKC) and thereby triggering protein kinase C-
mediated responses [9]. Platelet-activating factor 
(PAF) and prostacyclin production by human en-
dothelial or epithelial cells treated with ex-toxin [66,70] 
is dependent on PKC activation [70,71]. The PAF 
generated might contribute to local inflammatory 
responses. It should also be noted that one of the 
reported effects of ex-toxin is to cause platelet 
aggregation [72] which might be due to the activation 
of the PAF pathway in these cells. 
In another elegant twist of fate, PKC activates 
eukaryotic membrane-bound phospholipases, espe-
cially phospholipases A 21 C and 0 [9,68,73,74]. In 
rabbit erythrocyte membranes treated with ex-toxin it 
has been shown that endogenous PLC is rapidly 
activated, followed later by the activation of PLO 
[9,74]. The hydrolysis of membrane-bound phospho-
lipids by these enzymes further contributes to cell 
damage. The product of PLA2 hydrolysis provides 
further substrate for the arachidonic acid cascade 
whilst PI-PLC hydrolysis of bisphosphatidylinositol 
yields inositol triphosphate (IP3), a potent intracellular 
signalling molecule [75]. One effect if (IP3) is to signal 
the release of stored calcium, mainly from the 
endoplasmic reticulum and in response the calcium 
gates in cell membranes are triggered to open [76]. 
These combined effects might explain the inability of 
muscle cells treated with ex-toxin to respond normally 
[77,78] and the cardiotoxic effects of ex-toxin [79] . 
The effects of o:-toxin might be further potentiated 
by the metabolic status of host cells. A feature of 
gangrenous tissues is the development of profound 
ischaemia, with the resultant development of 
conditions necessary for the growth of C. perfringens. 
UDP-glucose deficiency is a consequence in ischaemic 
cells and a mutation in the UDP-glucose pyropho-
sphorylase gene in Chinese Hamster Fibroblasts 
(resulting in UDP-glucose deficiency), rendered cells 
105 times more sensitive to C. perfringens ex-toxin [80]. 
The molecular basis for this enhanced susceptibility 
has not been fully elucidated . The UDP-glucose 
deficient cells contained normal levels of phosphati-
dylcholine suggesting that alterations to the outer 
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membrane leaflet were not responsible for the 
enhanced sensitivity and the effects of ex-toxin on the 
cells could not be blocked using inhibitors of the 
arachidonic acid cascade or using inhibitors of 
eukaryotic phospholipases [81]. 
Vaccines and antitoxins 
Target populations for vaccination 
Toxoid vaccines can be prepared from crude culture 
filtrates of C. perfringens type A and these vaccines 
have been shown to induce protection against experi-
mental gas gangrene [82- 85]. However, a recurrent 
problem was the preparation of toxoid which was 
immunogenic [86]. The use of anti-toxin for the 
treatment of gas gangrene has also been investigated, 
in some cases with remarkable success. For example, 
in a review of 113 cases of gas gangrene MacLennan 
[87] reported that antiserum, given as two doses 
following wounding, resulted in 75% recovery, 
whereas the use of sulphonamide resulted in only 
21 % recovery. Other workers reported that antiserum 
was of no value in preventing gas gangrene following 
wounding [88,89], which perhaps reflects both the 
difficulties of preparing immunogenic toxoids and the 
requirement to administer antiserum soon after 
wounding. 
Within the civilian population the use of vaccines to 
prevent gas gangrene has received little attention, 
probably because the incidence of disease is relatively 
low and is difficult to predict in individuals. How-
ever, gas gangrene remains a significant problem in 
the elderly, in victims of a traumatic injury and in 
individuals who have undergone surgery on the 
lower gastrointestinal tract [1 ,47]. It may be appro-
priate to immunise these 'at risk' groups. 
Formal toxoid and recombinant vaccines 
Although early studies showed that a formaldehyde 
:x-toxoid could be used to protect mice from experi-
mental gas gangrene, the likely contamination with 
otl1er toxoided proteins makes interpretation of these 
studies d ifficult. The cloning and characterisation of 
the gene encoding ex-toxin has opened up new 
avenues for the production of genetica lly defined 
toxoids, free of other C. perfringens proteins. Two 
approaches to defined vaccines have been proposed. 
The C-domain of :x-toxin is devoid of any enzymatic 
or toxic activity and immunisation of mice with this 
polypeptide induced an antibody response which 
protected against at least 50 MLD of ex-toxin [51]. 
Further studies showed that immunisation with this 
polypeptide induced protection against at least 10 
MLD of C. perfringens type A in a murine model of gas 
gangrene [51). This recombinant vaccine has the 
advantage that it can be produced in f. coli at high 
levels. 
A second approach, which has not been studied, 
would use inactive mutated forms of the protein. A 
number of cpa site directed mutants have been shown 
to express forms of ex-toxin with low levels of 
phospholipase C, haemolytic and lethal activity [30-
32]. In principle, these mutated proteins, or more 
likely doubly mutated to reduce the risk of reversion 
to the wild-type phenotype, could be used as 
vaccines. 
Antigenic architecture of the a-toxin 
The protection afforded by formal-toxoids of ex-toxin 
is assumed to be antibody mediated and over the past 
decade significant progress has been made in under-
standing the antigenic architecture of the protein. 
Several workers have reported the generation and 
characterisation of monoclonal antibodies against the 
ex-toxin [90-92]. However, monoclonal antibodies 
which are capable of neutralising the phospholipase 
C activity are not necessarily effective in neutralising 
the haemolytic and lethal activities of ex-toxin [90- 92]. 
In the case of antibody 3ex4010 the recognised epitope 
was mapped to a hexapeptide within the N-domain 
[90]. These findings fit well with the current hypoth-
esis that the N-domain of the protein contains the 
phospholipase C active site but that the C-domain is 
essential for membrane recognition. Immunisation 
with the C-domain of ex-toxin induced a protective 
antibody response which neutralised all biological 
activities [51]. This might be expected if this antibody 
prevented the membrane-binding event, which is 
crucial for the toxic effects of the ex-toxin. In contrast, 
immunisation with the N-domain induced the pro-
duction of antibody which neutralised phospholipase 
C activity but not haemolytic or lethal activities [51]. 
The reason why antibodies against the N-domain are 
not protective, even though they neutralise the 
phospholipase C activity in vitro is not clear. One 
suggestion is that theN-domain of ex-toxin undergoes a 
conformational change on membrane binding and that 
antibody against this domain is dislodged or no longer 
recognises the membrane-bound form of the toxin. 
Antibody-a-toxin conjugates as 
therapeutics 
Many bacterial toxins have shown promise as 
tumouricidal agents when linked to targeting 
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antibodies. This promoted a study by Chovnick et al 
[93] to examine the potential of the ex-toxin for use in 
this way. The ex-toxin was linked to an anti-TAC 
monoclonal antibody, which is specific fo r the p55 
chain of the human interleukin 2 receptor. The 
conjuga ted toxin was shown to be 103-fold m ore 
potent than ex-toxin towards cultured cells expressing 
the interleukin 2 receptor, and inhibited protein 
synthesis with a 50% inhibitory concentration of 1.8 
ng/ mL. Although these preliminary results looked 
promising this immunotoxin has apparently not been 
investigated further. 
An alternative strategy for the use of an immuno-
toxin based on the ex-toxin has been proposed by 
Carter et al. [94], who exploited the ability of the 
enzyme to lyse liposomes containing the anti-tumour 
drug daunorubicin. In this system, the :t-toxin was 
linked with an antibody to the epidermal growth 
factor receptor which targeted the immunotoxin to the 
tumour cell surface. The subsequent addi6on of 
liposomes containing daunorubicin resulted in drug 
release. Preliminary studies have shown that the use 
of this immunotoxin enhanced the potency of lipo-
some-encapsulated daunorubicin 10-fold when tested 
using cell cultures. When tested in vivo the combined 
effects of the immunotoxin and liposomes containing 
daunorubicin resulted in cessation of growth of A431 
xenografts in nude mice, whereas growth of the 
tumour was unchecked when the immunotoxin or 
daunorubicin liposomes were used alone. 
Conclusions 
There have been two phases of intense research 
activity involving the Clostridium perfringens ex-toxin. 
The first phase started in the late 1930s and continued 
until the mid 1940s and was probably stimulated by 
the high incidence of gas gangrene in wounded 
servicemen. During this period of intense activi ty, 
the ex-toxin was shown to be phospholipase C [3], -
the first time a bacterial toxin had been shown be an 
enzyme and a finding w hich was la ter heralded as a 
landmark in the field of microbiology. Although 
interest in the ex-toxin continued throughout the 
1960s and 70s it was much reduced in level, and 
confined mainly to devising improved methods for 
purifying the p rotein. 
The second phase of in tensive research activity 
which stated in the late 1980s, was kind led by the 
emergence of modern biochemical and recombinant 
DNA techniques. Major progress has been made over 
the past decade in understanding the role of -x-toxin in 
gas gangrene, and in these studies have underpinned 
our knowledge of the roles of other bacterial 
phospholipases in disease [95,96]. However, there 
are still major gaps in our knowledge of the role of ex-
toxin in non-gangrenous diseases of man and animals. 
Many of the diseases of animals for which ex-toxin has 
been suggested to play a role are increasing in 
incidence, especially when there has been a move 
towards reducing the levels of antibiotic additives in 
feedstuffs. It is now timely to examine in detail the 
role of ex-toxin in these d iseases, and to evaluate the 
utility of ex-toxin vaccines to prevent these d iseases. In 
support of these studies it will also be essential to 
identify the mecl1anism of cpa gene regulation with a 
view towards understanding whether some environ-
mental stimuli might upregulate production of the ex-
toxin in the gut or in host tissues. 
Our understanding of the molecular basis of 
toxicity has now progressed to the point that we are 
now able to generate models explaining how the ex-
toxin interacts with cell membranes. However, there 
are still many unanswered questions. What is the 
molecular basis of substrate specificity and how do 
membrane packed phospholipids enter the active 
site? Knowledge of these mechanisms might allow 
the development of inhibitors of the ex-toxin which 
have clinical utility. 
Finally, we have seen the exploitation of the 
properties of the ex-toxin for the development of 
anti-tumour systems. We might expect that other 
workers will find other applications for the wealth of 
knowledge which is now available to us. 
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1. Introduction 
The phospholipases C are an important group of pro-
teins which are produced by many species of bacteria 
including Listeria monocytogenes, Bacillus cereus, Sta-
phylococcus aureus, and many Clostridia spp. (1-4]. Phos-
pholipases C are characterised by the site at which they 
cleave phospholipids (figure 7). The products of hydroly-
sis are a water soluble polar head group which is linked to 
phosphate and a water insoluble hydrocarbon tail linked 
to a glycerol backbone. Phospholipids are often classified 
on the basis of this head group, for example choline is 
present in phosphatidylcholine. The phospholipid tail 
groups can vary with respect to their degree of length and 
degree of saturation. These differences in phospholipid 
structure have profound influences on the efficiency with 
which they are hydrolysed by individual phospholipases 
C, and some bacterial species such as C. novyi, produce 
more than one phospholipase C (5, 6] which catalyse the 
hydrolysis of a range of phospholipids. 
Over the past 50 years, we have gained an understand-
ing of the enzymatic properties of these proteins. More 
recently, with the application of modern molecular bio-
logical techniques, we have gained knowledge of the 
genetic basis of toxin production and the molecular archi-
tecture of some of these proteins. The purpose of this 
review is to draw together the information obtained over 
recent years, with a particular focus on the structure-
function relationships of the clostrid ia phospholipases C. 
2. Clostridial phospholipases C 
The phospholipases C produced by the clostridia have 
attracted attention since the end of World War I, particu-
* Corr~spondenct and rt·1mnrs 
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larly those produced by C. perfringens, C. bifermentans 
and C. novyi. Other clostridia, such as C. sordellii and C. 
paraperfringens (table I) also produce phospholipases C 
(7). However these enzymes are less well characterised. 
The production of these enzymes can be detected by 
the formation of a zone of turbidity surrounding colonies 
grown on agar media containing human ser~ ~hich ~s 
attributed to the hydrolysis of serum phospholip1ds. Thts 
reaction forms the basis of the diagnostic test (the Nagler 
reaction) for C. perfringens [8] . The preferred substrates for 
the C. perfringens enzyme are phosphatidylcholine and 
sphingomyelin. Other clostridial enzymes prefe~ential!y 
cleave other phospholipids. For example, C. novyr a-toxm 
preferentially hydrolyses phosphatidylglycerol and phos-
phatidylethanolamine [9] . The phosphatidylinositol-
preferring phospholipase C (PI-PLC) enzyme produced by 
C. novyi catalyses the hydrolysis of phosphatidylinositol 
but is structurally unrelated to the other clostridial 
enzymes. For the purpose of this review the C. novyi 
~-toxin and PI-PLC will not be considered unless other-
wise stated. 
Some phospholipases C, such as those produced by C. 
perfringens and C. novyi, are haemolytic but only for 
erythrocytes from certain species of animals [9- 11]. These 
phosphol ipases Care also toxic, supporting the suggestion 
of M acFarlane (3] that toxicity and haemolytic activity are 
linked. 
The immature C. perfringens, C. bifermentans and C. 
novyi pho pholipases C, all possess an amino-terminal 
peptide oi 26-28 amino acid residues (a-toxin, 28; Cbp, 
26; C. novyi a-toxin, 28) which corresponds to a post-
translational signal sequence in a-toxin [12]. Al ignment of 
the deduced amino acid sequences of the mature phos-
pholipases C from C. perfringens, C. bifermentans and C. 
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371; C. bifermentans 373, and C. novyi 370 amino acid 
residues) (figure 2). The deduced amino acid sequences of 
the mature C. perfringens and C. bifermentans proteins are 
53% identica l. C. novyi also shares a high degree of amino 
acid identi ty with the C. perfringens (62%) and C. bifer-
mentans (55%) proteins. The crystal structure of C. perfrin-
gens a-toxin shows that the mature protein is organised 
into two domains [13]. The amino-terminal domain has 
phospholipase C activity (14) whi lst the carboxy-terminal 
domain is a ca lcium-dependent putative phospholipid 
binding domain (1 5]. The sequence homology and the 
similarity in length of the C. bifermentans and C. novyi 
enzymes with the C. perfringens enzyme suggest that they 
are also organised into two domain structures. The C. 
bifermentans and C. novyi proteins show 57-68% amino 
acid identity within the putative amino-terminal domains 
and 43-49% within the putative carboxy-terminal 
domains, when compared w ith C. perfringens a-toxin 
(tab le If). 
2.1. C. perfringens a-toxin 
The phospholipase C produced by C. perfringens, 
known as a -toxin, is the best studied of al l of the clostridial 
phospholipases C. C. perfringens is the species of clostridia 
most frequently associated with the d isease gas gangrene 
and the main virulence factor was for many years sus-
1278 
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pected to be a-toxin [16]. The pathologica l fea tures of gas 
gangrene are extensive local ti ssue damage which 
progresses to profound shock [16- 19]. There have been 
many lines of investigation into the precise role of a-toxin 
in gas gangrene but early studies were compl icated by the 
use of preparations which probably con tained other pro-
teins secreted by C. perfringens. Recently the technique of 
reverse genetics was applied to study the pathogenesis oi 
C. perfringens-mediated gas gangrene. The chromosomal 
plc gene was insertionally inactiva ted and the resultant 
strain showed a dramatic reduction in virulence when 
tested in the murine model of gas gangrene (20). Whereas 
only 30% of mice challenged with the wild-type bacte-
rium survived, there were no deaths in the group chal-
lenged with the plc mutant. In comparison w ith the 
wild-type limb swelling, inflammation, muscle necrosis, 
haematuria, and muscle destruction were all markedly 
reduced when mice were challenged with the plc mutant. 
Complementation of the mutant with a recombinant plas-
mid carrying the plc gene restored virulence (20]. This 
study provided proof that a-toxin was an essential viru-
lence factor in gas gangrene. 
The a-toxin is able to hydro lyse phosphatidylcholine 
and sphingomyelin in the presence of calcium ions [21 ]. 
Also in the presence of ca lcium ions the enzyme is 
haemolytic but only towards erythrocytes from some spe-
cies, e.g., human and mouse [1 0]. Erythrocytes from other 
species such as rabbit and horse are not lysed by a-toxin. 
Sheep erythrocytes are only lysed under hot-cold condi-
tions, when the erythrocytes are incubated with a-toxin at 
37 °( and then cooled to 4 ° ( [1 0, 22]. The interaction of 
a-toxin with membrane phospholipids is thought to be a 
key event in the haemolysis of erythrocytes. An explana-
tion for the difference in susceptibility of erythrocytes from 
various animal species could be the different phospholipid 
compositions of the red cell membranes. For example 
sheep erythrocytes contain a high sphingomyelin and low 
phosphatidylcholine rati o (63%: < 1 %) compared with 
human erythrocytes which have a similar phosphatidyl-
choline and sphingomyelin content (39%: 37%) [23, 24]. 
The hydrolysis of membrane phospholipids by a-toxin 
results in the activation of cell pathways which contribute 
to the cytotoxic effect observed. For example, the hydroly-
sis of membrane phospholipids resulting in the accumula-
tion of diacylglycerol can subsequently activate the arachi-
donic acid pathway [25, 26]. The activation of this pathway 
can lead to the production of thromboxane A2 , a potent 
mediator of the inflammatory response [26]. Diacylglyc-
erol is also known to activate protein kinase C and hence 
the hydrolysis of membrane phospholipids by a-toxin 
could also result in the activat ion of this enzyme. Protein 
kinase C may in turn activate eukaryotic cell phospholi-
pases C and D which would increase membrane phospho-
lipid turnover, resulting in extensive cell damage [26, 27]. 
Much less information is known regarding the proper-
ties and mode of action of C. novyi y-toxin. The purifica-
tion of this phospholipase C was final ly achieved in 1975 
and the enzyme was shown to hydrolyse phosphatidyl-
choline, sphingomyelin and lyso-phosphatidylcholine [5]. 
The enzyme was haemolytic for horse but not sheep 
erythrocytes [5]. Haemolysis of horse erythrocytes by C. 
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Table I. The phospholipases C produced by rhe closrridia family. 
Clostridium species Phospholipase C Gene cloned Mol W Substrate specificity 
C. perfringens a-toxin Yes [12. 39.40,4 1] 42.500·' PC,SPH. PS.LPC 
C. biferme/1/ans phospholipase C; Cbp Yes [40] 42.642" PC. SPH 
C. novyi y-toxin No 30.000< PC, SPH, LPC. PE. PS, PG 
PI-PLC Yes [6] 30.000 PI 
(3-toxin No 32.000 PC 
C. sordellii phospholipase C No NR NR 
C. parape1jringens phospholipase C No NR NR 
C. abSOllll/11 phospholipa e C No NR NR 
• calculated from the deduced amino acid sequence of strain NCTC8237 mature protein, b calculated from the deduced amino acid sequence of strain 
ATCC638 mature protem [15], c determined using gel filtration chromatography (19]. PC= phosphatidylcholine; SPH = sphingomyelin; PS = 
phospharidylserine; PI = phospharidylinosirol; LPC = lysophospharidylcholine; PE = phospharidylerhanolamine; PG = phospharidylg lycerol. NR = 
nor reponed . 
novyi y-toxin is reported to parallel phosphatidylcholine-
hydrolysing activity [5). The extracted phospholipids are 
hydrolysed more rapidly than in intact cells. This was also 
the case for C. perfringens a-toxin [5] suggesting that 
access of phospholipid to the enzymes was a factor in 
hydrolysis. Sheep erythrocytes are resistant to C. novyi 
y-toxin and are only hydrolysed by a-toxin under hot-cold 
conditions [5). However C. novyi a-toxin hydrolyses sph-
ingomyelin extracted from erythrocytes to the same extent 
as a-toxin [5]. Therefore differences in the phospholipid 
content of different erythrocytes are not sufficient to pro-
vide a full explanation for the differences in erythrocyte 
susceptibility to lysis by C. perfringens a-toxin or C. novyi 
y-toxin. Therefore other factors must be involved; one of 
which may be the accessibility of the phospholipids in 
membranes to the enzymes. 
3. Structure-function relationships 
3.1. Amino-terminal domain 
The determination of a crystal structure of C. perfrin-
gens a-toxin revealed that it was a two domain protein 
(figure 3) [13) and this has provided important insights into 
the mechanisms involved in toxicity. The putative active 
site is located in the amino-terminal domain and the 
presence of three zinc ions were detected in the active si te 
cleft [1 3). Within this cleft amino acid residues involved in 
coordinating these zinc ions have been identified (resi-
dues Trp 1; His11 ; Asp56 ; His66; His126; Asp130; His136; 
His146; Glu, d [13). These zinc coordinating ligands are 
present in other clostridial phospholipases C, such as C. 
bifermentans and C. novyi. This suggests that the active 
site architecture is similar in each of these enzymes. The 
presence of zinc ions has been identified in other phos-
pholipase C enzymes such as the phosphatidylcholine-
preferring phospholipase C produced by Bac illus cereus 
and L. monocytogenes PLC-B [2, 28, 29). The zinc coor-
dinating residues mentioned above are also conserved in 
these proteins. This group of enzymes has been termed the 
zinc metalloenzymes. 
Chemical modification of the histidine residues with 
diethylpyrocarbonate, post EDTA treatment, abolishes all 
enzyme activity. Enzyme act ivity was not altered without 
Microbes and Infec tion 
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pretreatment with EDTA, suggesting that the zinc ions 
protected the normally susceptible histidine residues [28). 
Site-directed mutagenesis of the zinc-coordinating resi-
dues in a-toxin resu lts in the abolition of the phospholi-
pase C, haemolytic and lethal activities (less than 3% 
retention of activity of the w ild-type toxin) [30-32). Al l of 
these studies confirm the essential role of zinc ions for the 
enzymatic activity of a-toxin and that the phospholipase C 
activity of the amino-terminal domain is essential for all of 
the biological activities of the toxin. 
3.2. Structure-function of the carboxy-terminal domain 
The carboxy-terminal domain of a-toxin has been 
shown to be comprised of eight ~-sheets organised into a 
Greek key fold [13) (figure 3). This structural motif is found 
in phospholipid binding proteins such as synaptotagmin 
and protein kinase C which bind phospholipids in a 
calc ium-dependent manner [33, 34). The carboxy-
terminal domains of the clostridial phospholipases C have 
little amino acid sequence homology with the C2 domains 
of eukaryotic phospholipases C [13). 
3.2. 1. Role of calcium ions with the carboxy-termina/ 
domain 
The carboxy-terminal domains of the clostridial phos-
pholipases C show a high degree of amino acid sequence 
conservation . Moreau [21] showed that calcium ions 
were required for binding of a-toxin to lipid films and one 
of the features of the carboxy-terminal domain is the 
possession of three calcium-binding sites, termed Ca1, 
Ca2 and Ca3 [35) (figure 4). The ligands identified within 
the Ca1 site are Asp269; Glu27 1; Asp273; Asp274 ; and Asp330 
[35). Guillouard et a/ [36] have shown~that the Asp resi-
dues at positions 269 and 336 are important for a-toxin 
activity and that when substituted with Asn the mutated 
proteins showed a 20% reduction in phospholipase C 
activity. The substitution of Asp274 with asparagine did not 
affect lecithinase activity. Each of these mutated proteins 
retained haemolytic act1vity. However, the mutated pro-
teins did show differences in calcium dependency for 
phospholipase C activ ity. Wild-type a-toxin showed full 
phospholipase C activity at 1 .3mM and 5.2mM calcium, 
whereas the aspartic acid mutants Asp269 and Asp336 
required the higher ca lcium concentration for full activity. 
These results suggested that the mutation of the aspartic 
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Figure 2. The deduced amino acid sequences of C. perfringem a-cox in, C. bifermentam Cbp and C. nrwyi y-coxin (PLC).* represents rhe end 
of rhe amino-rerm inal domain of C. perfringem a -roxin (residues 1-246). ** represents rhe srart of rhe carboxy-rerminal domain of C. 
perfringeus a-roxin (residues 256-370). f- ~ highlighrs rhe lysine-rich region in C. petfringem a-roxin (RKRK) and C. biferme11fam Cbp 
(RKER). 
acid residues Asp269 and Asp336 lead to a change in 
calcium dependency for phospholipase C activity. 
The remaining calcium-binding sites Ca2 and Ca3 [13] 
are in close proximity to theCa 1 site (figure 4) and interact 
with highly conserved Asp residues (Ca2, Asp291 , Asp198 
and Ca3, Asp273 , Asp1,J11) (figure 4). All three calcium-
binding sites are located at the putative membrane-binding 
surface of the protein and may therefore be involved in 
binding oi a-toxin to the membrane, allowing the active 
site to be optimally positioned to bind phospholipid [35, 
37]-
1280 
Within the designated Ca 1 site in C perfringens a-toxin 
[35] the amino acid residues Glu271 ; Asp273; Asp2 74 ; and 
Asp3 H• are conserved in C bifermentans Cbp and in C 
novyi a-toxin. The remaining amino acid residues within 
theCa 1 site are not conserved; Asp269 is replaced with Tyr 
in C bifermentans Cbp and Ala in C novyiy-toxin, whilst 
Ala317 is replaced with Asp in both proteins (figure 2). The 
amino acid residue Asplc.'l has been shown to play an 
important role in calcium binding [36] and these changes 
may therefore influence the activity of these enzymes by 
altering their abilities to bind calcium at this site. 
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Table Il. Amino acid sequence identity between the mature C. perfringens, C. bifermentr.ms and C. novyr phospholipases 
C.* 






518% (' 41/2.1•1) 
43.9% (~ .. ,l1_lJ 
53 o/o ('IIH/l7l) 
• Number o( amino acid r('Sidues 1deonc~l Jre showo in brackets. 
The techniques of circular dichroism and intrinsic fluo-
rescence have also shown that the isolated carboxy-
terminal domain of a-toxin binds calcium ions (35]. The 
intrinsic fluorescence of the carboxy-terminal domain 
altered in the presence of calcium ions, inferring that a 
tryptophan residue(s) became less exposed to the environ-
ment following calcium binding. The crystal structure of 
a-toxin reveals that the side chain ofTrp360 lies 4-5A irom 
the designated Ca 1 site and is exposed to the aqueous 
phase [13]. lt is conceivable that this tryptophan residue 
would be sensitive to changes in the environment and 
could relocate to a less polar environment following cal-
Cium ion binding. In the presence of the chromophoric 
chelator, 5-NBAPTA (5' nitro 1 ,2-bls (o-aminophenoxy) 




C. novyi vs C. bifermentans 
58.6 c,. ( 146/"!.49) 
47.5 o/c (:\7/120) 
55 Cf (2111/ 370) 
ethane-N, N,-N', N', -tetra acet1c acid), competitive bind-
rng of Ca1 + to the carboxy-terminal domain was observed 
and a calcium attinity of -200 fJM was determined. The 
data from the CD fluorescence and chelator experiments 
suggested that the carboxv-terminal domain possessed a 
~ingle calcium 1on binding site with an affinity for calcium 
of appro"Ximately 200 fJM (35). In contrast three calcium-
binding s1tes were predicted from the crystal structure of 
a-toxin. Naylor et al. [35] proposed that this discrepancy 
might reflect differences in the conformations of the iso-
lated carboxy-terminal domain compared with the 
carboxy-terminal domain in the holotoxin (crystal struc-
ture). They proposed that the isolated carboxy-terminal 
domain may be partially unfolded and that the change in 
Figure 3. The crystal srruccure of C. perfnngtns a-coxm. The am1no-cerm1nal domam IS represented as a-heltc1es and che carboxy-cerminJI 
doma1n IS dtp1cced as ~-sheers. The incerdomain conneccmg loop becwecn che amino-terminal and carboxy-cerminal domains 1S illuscraced. 
The msec shows che am1no aod residues involved m coordin.uing che chcee zmc ions of che JCt1ve s1ce w1chm che ammo-cermtnal domam. 





structure seen with circular dichroism in the presence of 
Ca 2+ is indicative of correct folding. This phenomenon 
has been reported previously for the C2A domain of the 
phospholipid binding protein synaptotagmin [34). There-
fore the binding of a calcium ion into the Ca1 site (13) 
would induce the complete folding of th1s domain and in 
this case the remaining two calcium-binding sites would 
be undetectable using their methods. 
There are some striking differences in the activity of C. 
perfringens CL-toxin and C. bifermentans Cbp towards dif-
ferent substrates (table Ill) [38]. For example, CL-toxin and 
C. bifermentans Cbp hydrolyse phosphatidylcholine in 
egg yolk or unilamellar liposomes to a similar extent, 
whereas a-toxin was> 1 00-fold more haemolytic than C. 
bifermentans Cbp (15). The a-toxin was tenfold more 
active than C. bifermentans Cbp towards liposomes com-
posed of sphingomyelin. The carboxy-terminal domain is 
thought to pia~ a major role in phospholipid interaction 
Jepson and Tltball 
Figure 4 . The mreracrion of C. perfrin-
gens a-roxtn wtrh membrane phospho-
lipids. The am1no actd residues involved 
in rhts inreracrion are highlighted . The 
pocencial Ca2 -binding sires wt chin che 
carboxy-rerminal domatn are illus-
crared. 
and this interaction plavs a key role in haemolysis. There-
fore it was proposed that differences in the properties of 
the carboxy-terminal domain of a-toxin and Cbp might 
explain the different properties of these enzymes. To inves-
tigate this possibility a hybrid protein was constructed 
comprising the amino-terminal domain of C. bifermentans 
Cbp and the carboxy-terminal domain of C. perfringens 
a-toxin (Nb,(CL) [15). The introduction of the carboxy-
terminal domain of a-toxin resulted in increased 
haemolytic activity, toxicity and activity towards sphingo-
myelin liposornes when LOmpared with activity of C. 
biferment.ms Cbp !table Ill). This suggested that although 
the carboxy-terminal domain played an important role in 
haemolysis, this domain alone did not provoke toxic or 
haemolytic activity to the same extent as a-toxin. There-
fore the amino-terminal domain must also play a role in 
toxicity and haemolytic activity. 
Table Ill. Comparison of activicy of the phospholipases C produced by C. perfringens, C. bifermentans, and C. nOt-'Ji, and 
a constructed hybrid Nb,Ca comprising the amino-terminal domain of C. bifermentans and the carboxy-terminal domain 
of C. perfringem. 
Clostridium species Phosplratidylcholine Sphingomyelin Haemolytic activity Lethalit)' (per mouse) lrydrolysmg activity hydrolysing activity 
- ------ -
C. petfringens a-toxin +++ +++ +++ t flg 
C. btfermemans Cbp +++ ++ ±-' > 10 flg 
C. novyi y-toxin +++ +++ +++b +" 
Hybrid N";C,. +++ +++ ++ 10 flg 
·-- -
-=-:-: ~: .. ondicare ~cci vicy similar eo or less chan rhar of a-cox on respt:crively; ± • weakly hat:molyric for mouse eryrhrocyres; b h~emolyri• for horse 
erythrocytes; T ' lerhailry reponed tor C. hfltmolyttmm amibured ro C. novyi y-roxin 
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4. Interactions between the amino-
terminal and carboxy-terminal domains 
1t has been suggested that interaction between the 
<1mino-terminal domain and carboxy-terminal domain of 
n-toxin occurs via a hydrophobic loop (residues 84- 88, 
WYLAY). This loop is si tuated between the putative active 
site of the amino-terminal domain and the calcium-binding 
sites of the carboxy-terminal domain (figure 3). This loop 
could allow communication between the putative active 
site and the calcium-binding sites during membrane bind-
ing [1 3]. 
5. Membrane interactions 
Interaction with membrane phospholipids is essential 
for the toxic activity of a-toxin and calcium-mediated 
phospholipid binding is one mechanism of membrane 
phospholipid interaction. However other amino acid side 
chains may also play a role in membrane phospholipid 
recognition and a variety of candidate residues have been 
identified in a-toxin [13, 15]. These residues have hydro-
phobic side chains and are located on the membrane-
protein interface. The residues Tyr33 1 and Phe334 are 
replaced by leucine and phenylalanine in C. bifermentans 
Cbp, and by isoleucine and valine in C. novyi y-toxin. lt 
has been suggested that Tyr 331 interacts with the polar 
headgroups of membrane phospholipids promoting bind-
ing to membranes [13]. The replacement of the polar 
residue tyrosine with the non-polar leucine or phenylala-
nine in C. bifermentans Cbp or C. novyi y-toxin respec-
tively, could alter this interaction with membranes. The 
replacement of Phe334 w ith isoleucine or valine with the 
resultant loss of the aromatic ring may alter the interaction 
between enzyme and the phospholipid tail group. The 
limited number of amino acid sequence differences within 
the carboxy-terminal domain could provide an explana-
tion for the differences in activity of the C. perfringens, C. 
bifermentans and C. novyi phospholipases C. 
Residues in the amino-terminal domain might also be 
important for membrane interaction. The side chain of 
residue Trp214 which is located on the membrane interface 
region of the protein, has been suggested to interact with 
the hydrophobic tail groups of the membrane phospholip-
ids [13]. The side chains of the Tyr331 and Phe334 residues 
in the carboxy-terminal domain are also appropriately 
positioned to interact \Nith phospholipid tail groups. This 
residue is conserved in C. bifermentans Cbp and replaced 
with asparagine in C. novyi y-toxin, which may be signifi-
cant. 
6. Conclusions 
This review on the phospholipases C produced by the 
clostridia collates the growing body of information on 
these enzymes. One ot· the landmark events in this field 
was the determination oi the crystal structure of C. perfrin-
gensn-toxin [13]. This structure has provided new insights 
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into the mode of action oi this toxin. lt has for example, 
resulted in the identification of calcium-binding site 
within the carboxy-terminal domain, which supports pre-
vious suggest ions that ca lcium played a key role in et-toxin 
activity. The close structural relationship of the carboxy-
terminal domain of et-toxin with the C2-domains of eukary-
otic phospholipid binding proteins, such as synaptotag-
min and protein kinase C. could provide insights into the 
mechanisms involved in ce ll signalling and calcium-
regulated second messenger systems. There are many key 
questions remaining. What are the precise roles of the 
amino acids thought to be important for membrane inter-
actions and what at a molecular level determines the toxic 
nature of some phospholipases C? These studies will not 
only al low the design of novel anti-toxic drugs, but could 
also allow the exploitation of these enzymes as novel 
therapeutics. 
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INTRODUCTION 
Since the last review of the bacterial phospholipases C 
(106}, several new enzymes have been discovered and the 
application of molecular biological techniques has trans-
formed our knowledge of this important group of proteins. It 
has become apparent that many of the phospholipases Care 
structurally related, and this has revealed new directions for 
the analysis of structure-function relationships. The natural 
function of phospholipases C may be to secure supplies of 
phosphate, and the regulatio n of some phospholipase C 
genes by exogenous phosphate levels supports this hypoth-
esis. The reasons why some phospholipases C are also toxic 
and cytolytic is becoming clearer, and the possible roles of 
some enzymes in the pathogenesis of disease has been 
investigated. In some cases cytolysis may be an important 
mechanism by which toxic effects are elicited, but equa lly 
347 
apparent are the more subtle effects of phospholipases Con 
the metabolism of cells, which could play an important role 
in the disease process. The analysis of the roles of these 
enzymes is further complicated by the complex interactions 
which may occur with other bacterial proteins. 
The interaction of phospholipases C with membrane phos-
pholipids has been exploited in several ways. They can be 
used as probes to explore the phospholipid composition of 
membranes or to mimic the actions of eukaryotic phospho-
lipases C on cell metabolism. Knowledge of the precise 
mechanisms of interaction with membranes may prove use-
ful for delive ring membrane active drugs. Unlike many 
bacterial toxins, internalization of the protein is not required 
for toxicity, and this has attracted at least one group of 
workers to explore the possibility that phospholipase C, 
linked to a suitable antibody, can form the basis of an active 
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FIG. 1. Site of cleavage of the major phospholipids (arrowed) by 
phospholipases C. 
PRODUCTION, PURIFICATION, AND ASSAY OF 
PHOSPHOLIPASES C 
The phospholipases C are characterized by the site of 
cleavage of phospholipids (Fig. 1), which distinguishes them 
from phospholipases A and D, which are also produced by 
some bacteria. For the purposes of this review, sphingomy-
elinases Care also considered members of the phospholipase 
C group. Phospholipases C have been isolated from a wide 
variety of gram-positive and, more recently, gram-negative 
bacteria (Table 1). All of the enzymes are single polypeptide 
proteins which are found in the culture medium, and the 
deduced amino acid sequences of these proteins, where 
known, have revealed typical signal sequences (56, 70, 84, 
115, 118, 129, 130, 139, 166, 175, 181, 192). On solid media 
the production of phosphatidylcholine-hydrolyzing enzymes 
has often been detected as a zone of opalescence surround-
ing colonies grown on an egg yolk emulsion supplemented 
agar, and the neutralization of this effect by specific antisera 
has formed the basis of a diagnostic test for Clostridium 
perfringens (the Nagler reaction). The proteins have been 
purified by a variety of techniques, of which perhaps the 
most elegant use affinity chromatography; a column of 
immobilized egg yolk phosphatidylcholine has been used to 
purify the Bacillus cereus phosphatidylcholine-preferring 
phospholipase C (PC-PLC) (88) and the C. perfringens 
enzyme (162). An alternative procedure for purifying the 
Pseudomonas aeroginosa phospholipase C relies on binding 
to subs tituted ammonium groups on DEAE-Sephacel and 
elution with tetradecyltrimethylammonium bromide (12). 
MIC ROBIO L. REv . 
The act1v11y of phosphol ipases C can be monitored in 
solution by using egg yolk phosphatidylcholine (162, 166) or 
by spectrophotometrically measuring the hydrolysis of chro-
mogenic derivatives of phospholipids such as p-nitrophe-
nylphosphorylcholine (pNPPC) (78), a structural derivative 
of phosphatidylcholine, or N-omegatrinitrophenol-aminolau-
ryl-sphingosylphosphorylcholine (53), a structural derivative 
of sphingomyelin . These chromogenic derivatives may not 
faithfully indicate the true degree of phospholipid hydrolysis 
because of the absence of extended hydrocarbon tails which 
are important for efficient substrate hydrolys is (45), and this 
is reflected in the high K'" value for pNPPC hydrolysis by C. 
perfringens alpha-toxin (78) . Many workers have assumed 
that the hydrolysis of pNPPC was indicative only of hydro-
lysis of phosphatidylcholinc, but this is not the case, and the 
reported hydrolysis of pNPPC by the B. cereus sphingomy-
elinase (121) is not surprising since the head groups of 
phosphatidylcholine and sphingomyelin are identical. This 
result further indicates the importance of hydrocarbon tails 
for correct substrate recognition. A hydrocarbon tail is 
present on the chromogenic substrate dioctanoylthiophos-
phatidylcholine (149), but the head group is significantly 
altered by the chromogen and the use of this substrate may 
yield equally misleading results. A similar argument may be 
applied to the ftuorometric assay recently described by 
Thuren and Kinnunen (164). A more complex procedure for 
measuring phospholipase C activity involves separation of 
phospholipid digestion products by thin-layer chromatogra-
phy (160). For precise measurement of phospholipid diges-
tion, radiolabeled substrates may be used; alternatively the 
release of acid-soluble phosphorous can be measured (88, 
160, 162). Perhaps the method which most closely mimics 
the interaction of the phospholipase C with substrate in-
volves the use of artificial phospholipid bilayers (110), but 
the measurement of phospholipid hydrolysis, especially in 
mixed phospholipid bilayers, can prove complex. 
GRAM-POSITIVE PHOSPHOLIPASES C 
Zinc-Metalloenzymes 
The 8. cereus PC-PLC, C. perfringens alpha-toxin, Clos-
tridium biferment.ans PLC, Listeria monocytogenes PLC-B, 
and Clostridium novyi gamma-toxin form a group of related 
enzymes which contain essential zinc ions and are reversibly 
inactivated by EDTA or o-phenanthroline (54, 64, 76, 143, 
160, 169). It also seems likely that the phospholipases C 
produced from Clostridium absonum and Clostridium ba-
rati, which are antigenically and genetically related to the C. 
perfringens alpha-toxin (112, 171), are also zinc-metallo-
phospholipases C. 
The C. perfringens alpha-toxin and B. cereus PC-PLC are 
the most intensively studied; investigations of the latter were 
prompted by the finding that the C. perfringens enzyme was 
a potent toxin (96, 97, 105) with hemolytic (139, 166), lethal 
(162, 168), dermonecrotic (100), vascular permeabilization 
(158), and platelet-aggregating (114, 157) properties. Specu-
lation that the B. cereus PC-PLC enzyme may have similar 
properties was proved to be unfounded (123), but as a result 
of extensive investigations, this protein has assumed the 
status of a prototype phospholipase C. All of the zinc-
metallophospholipases C are single polypeptides, and B. 
cereus PC-PLC and L. monocytogenes PLC-B are posttrans-
lationally activated by the removal of 14 (70) or 26 (179) 
N-terminal amino acids, respectively. The detection of dif-
ferent molecular size forms of the L. monocytogenes PLC-B 
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TABLE 1. Bacterial phospholipascs C' 
Source of cnzym(.' N•1me Gene cloned Molecular mass Substratc spccificity'' Ion requirements 1-lcmnlysis (Da)" 
B. cereus PC-PLC Yes (56, 70) 28.520 (70) PC. PE, PS (88. 123) Zn';, Ca'' (88, 12.1) - (88) 
SMase Yes ( 189) 34.233 ( 189) SPM (67) Mg'; (67) h" (67) 
Pl-PLC Yes (77) 34.466 (77) PI, LPI (58) None (65) 
B. thuJitlgien•,-iy Pl-PLC Yes (63) 34.515 (6.1) PI, LPI (68, 161) NR NR 
C. bifenrrentans PLC Yes (175) 42.746 (175) NR' NR :t (175) 
C. IIOV)'i -y-Toxin No 30.000 (160) PC. SPM, LPC. PE, Zn 2 -i. Ca:!-.-, Mg> + (160) 
Pl, PG (160) (160) 
PI-PLC No 30.000 ( 159) PI (159) 
C. perfringens a-Toxin Yes (84, ll5, 139, 42,500 ( 176) PC, SPM, PS, LPC Zn2•, Ca2 • (76) + (166) 
166, 175) (76, 162) 
L. monOL')'togenes PLC-A Yes (83, 101) 34,000 (83, 101) PI (101) Non (101) - (83, 101) 
PLC-B Yes (179) 39,000 (179) PC, PE, PS,SPM Zn'• (54) :t (54) 
(54, 179) 
S. aureus 13-Toxin Yes (130) 34.546 ( 130) SPM, LPC (136, Mg,. (136, 186, 187) h (136, 186, 187) 
186, 187) 
PI-PLC No 20,000-30,000 (95) PI, LPI (42) None (66) 
P. aentginosa PLC-H Yes (31) 78,352 (31) SPM, LPC, PC (12, NR + (12, ll8) 
ll8) 
PLC-N Yes (118) 73,455 (ll8) PC, PS (ll8) NR - (ll8) 
P. cepacia PLC Yes (178) 72,000 ( 178) PC, SPM ( 178) NR + (178) 
S. Jraclzijoensis PLC No 18,000 (ll6) PC (ll6) Mg2 • (ll6) NR 
A. ca/coacetius PLC No NR PC, SPM, PE, PS Mg,. (82) - (82) 
(82) 
PLC No NR PC, SPM, PE, PS Mg2 • (81) + (81) 
(81) 
V. tuealyricum PLC No NR pNPPC (39) NR NR 
Leptospira interrogans SMase' No NR SPM, PC (14) Mg2• (14) h (14) 
L. pneumophila PLC No 50,00(}...54,000 (9) PC (9) NR - (9) 
a Numbers in parentheses arc references. 
b Molecular masses have been calculated for the mature exported protein without additional metal ions. 
c PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine; SPM, sphingomyelin; PI, phosphatidylinositol; LPI, lysophosphatidyli· 
nositot; LPG, lysophosphatidytglycerot; PG, phosphatidytgtycerol. 
d h, hot-cold hemolysis on sphingomyelin-rich erythrocytes. 
~ NR, not reported. 
f SMasc. sphingomyelinase. 
in culture fluid suggested that activation occurred after 
export from the cell (179). All of the characterized enzymes 
are able to hydrolyze phosphatidylcholine (54, 110, 123, 
160), and other phospholipids are hydrolyzed with various 
efficiencies; the C. peifringens alpha-toxin, C. novyi gamma-
toxin, and L. monocytogenes PLC-Bare also able to hydro-
lyze sphingomyelin (54, 76, 160, 162, 179). Phosphatidyli-
nositol and phosphatidylglycerol arc additionally hydrolyzed 
by the C. novyi gamma-toxin (160). The reason why some 
enzymes are activated outside of the cell whereas others are 
produced as active enzymes suggests that some of these 
enzymes are potentially toxic to the cell. In this respect it is 
interesting that phosphatidylglyccrol, an important compo-
nent of the bacterial cell membrane, is hydrolyzed by the B. 
cereus PC-PLC but not by C. perfringens alpha-toxin (Table 
1). Ether-linked phospholipids are hydrolyzed with various 
cfficiencics; the B. cereus PC-PLC was able to hydrolyze 
these compounds (45), whereas an ether-linked phosphati-
dylcholine analog was a potent inhibitor of the C. peifrin-
gens enzyme (13S). There is some evidence that subtle 
differences in the active-site architecture arc responsible for 
these substrate preferences: the replacement of zinc ions in 
the active site of the B. cereu.1· PC-PLC with cobalt ions 
enabled the enzyme to hydrolyze sphingomyelin (121). 
The genes encoding some of the zinc-metallophospholi-
pases C have been isolated and characterized (56, 70, 84, 
115, 139, 166, 167, 175, 179), and the gene encoding the C. 
perfringens alpha-toxin has been shown to he chromoso-
m ally located (24). The deduced amino acid sequences of the 
proteins show significant homology up to approximately 
residue 250 (84, 166, 179). After this point the C. peifringens 
alpha-toxin and C. bifennentans PLC possess an additional 
C-terminal domain (Fig. 2). From the observed homologies, 
it seemed likely that the first 250 residues (N-terminal 
domain) encode the phospholipase C activity. This sugges-
tion has recently been proven for the C. peifringens alpha-
toxin, because a truncated form of the protein, correspond-
ing to the B. cereus PC-PLC, retained the phospholipase C 
activity but showed markedly reduced sphingomyelinase, 
hemolytic, and lethal activities (168). The C-terminal do-
mains of the C. peifringens alpha-toxin and C. bifennemans 
PLC appear to confer sphingomyelin-hydrolyzing and hemo-
lytic properties on these enzymes, but only for the C. 
perftingens alpha-toxin does it also confer toxic properties 
on the protein. The nontoxic nature (and low hcmolytic 
activity) of the C. bifennentans enzyme can be explained 
because the turnover rate of the enzyme is much lower than 
that of the C. perfringens alpha-toxin (Table 2), and, indeed, 
this was the reason for the low toxicity of this phospholipase 
proposed by Miles and Miles 45 years ago (104). In support 
of this suggestion, it has been shown that the stoichiometric 
relationship between phospholipase C activity (egg yolk 
phospholipid-hydrolyzing activity [166, 175]) and hcmolytic 
activity {hcmolytic units [166, 175[) is similar for both 
enzymes (1:4.5 and 1 :5.2). The function of the C-terminal 
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FIG. 2. Alignment of the deduced amino acid sequences of the C. perfringens alpha·toxin (166), C. bifennentans phospholipase C (175), 
B. cereus PC·PLC (56), and L. monocytogenes PLC·B (179). Residues known to be involved in the coordination of zinc ions in the B. cereus 
PC-PLC (64) are shaded. 
cation of tyrosine residues abolishes hemolytic, lethal, and 
platelet-aggregating properties of the C. perfringens alpha-
toxin (140). Perhaps significantly, the reported homology 
between the C-terminal domain of the C. perfringens alpha-
toxin and the N terminus of arachidonate-5-lipoxygenase, a 
eukaryotic lipid-metabolizing enzyme, includes five aligned 
tyrosine residucs (168). It seems possible that these hydro-
phobic tyrosine residues are similarly involved in the recog-
nition of hydrocarbon substrates. 
Crystallographic (64) and chemical modification (5, 6, 86, 
87) studies of the B. cereus PC-PLC have provided an insight 
into the molecular architecture of this enzyme and, by 
extrapolation, the possible tertiary structures of homologous 
regions in the other zinc-metallophospholipases C. The 
enzyme is composed of seven helices, forming a twisted 
barrel structure. Three zinc ions, one of which is loosely 
bound, coordinate with amino acids from different helices 
and thus conformationally restrain the molecule. Zinc-coor-
dinating histidine, glutamic acid, tryptophan, and asparagine 
residues are located in similar positions in other zinc-
metallophospholipases C (Fig. 2), an observation which 
provides further confirmation of the relationship of these 
proteins. The importance of histidine residues for zinc 
coordination in the C. perfringens alpha-toxin has been 
confirmed by chemical modification of these residues. The 
inactivation of phospholipase C activity by diethylpyrocar-
bonate could be demonstrated only after EDTA pretreat-
ment, suggesting that the zinc ions also bind to these 
TABLE 2. Properties of the zinc-metallophospholipases C' 
Enzyme C-tcrminal domain 
C. perfringens alpha-toxin Yes 
C. bifennentafL\" PLC Yes 
L- monocytogenes PLC·B No 
B. cereus PC-PLC No 
d Numbers in parentheses arc references. 
h Eyu, egg yolk phospholipid-hydrolyzing units (175). 
··Detected by thin-layer chromatography. 
tJ Hu. hemolytic units (I 75) . 
.. NR. not reponed. 
Phospholipase C Sphingomyclinasc 
activity (Eyu/mg)" activity'" 
252 (175) Yes (139. 168) 
5 (175) NW 
Yes (54) Yes (54) 
Yes (123) Noi (123) 
r Sphingomyelin hydrolysis reported on replacement of zinc ions with cohalt ions ( 121 ). 
~ Weak hemolytic activity has heen reported (89). 
Hemolytic activ? 
(Hu/mg/30 min Lethality (l'g/mouse) 
520,000 (175) 0.03-D.I (175) 
12,000 (175) 1-5 (175) 
0 (54) >25 (54) 
0" >30 (122) 
VoL. 57, 1993 
rcsidues in this protein (169). The protein-stabilizing effect of 
the zinc ions may account for the remarkable thermal 
stability reported for the B. cereus PC-PLC and C. perfrin· 
gens alpha-toxin; either enzyme can survive heating to lOO"C 
for short periods (123, 162). 
The active site of the B. cereus PC-PLC has been tenta-
tively identified by cocrystallizing the protein with phos-
phate ions (64). This study demonstrated phosphate binding 
to all three zinc ions, displacing water molecules in the 
process. A similar involvement of zinc ions in the binding of 
phosphate to Escherichia coli alkaline phosphatase has been 
reported (152), and it has been suggested that this similarity 
may be more than coincidental in two enzymes which 
together form a phosphate retrieval system (59). The archi-
tecture of the active site also revealed features which could 
account for lipid binding; an acidic pocket at one end could 
bind the head group while hydrophobic amino acids line the 
remainder of the active site. 
The clostridial zinc-metallophospholipases C are antigen-
ically related (104, 112, 186). Antigenic cross-reactivity with 
the B. cereus PC-PLC or L. monocytogenes PLC-B has not 
been reported, although, surprisingly, the B. cereus PC-PLC 
has been reported to show antigenic similarity with eukary-
otic phospholipase C (30). Only the C. perfringens alpha-
toxin antigenic structure has been studied in detail (92, 146), 
probably because of the known importance of this toxin in 
disease. It has been reported that a phospholipase C-neutral-
izing monoclonal antibody recognizes a peptide located in 
the N-terminal domain (ARGFAK) but that this antibody 
was less effective in neutralizing hemolytic and lethal activ-
ities (92). Similar results were reported by Sato et al. (142), 
who described other antibodies capable of neutralizing phos; 
pholipase C, hemolytic, and lethal activities. Recent studies 
in this laboratory have shown that whereas antibodies 
against the N-terminal domain neutralize only phospholipase 
C activity, antibodies against the C-terminal domain are 
highly effective in neutralizing haemolytic and lethal activi-
ties as well (180, 185). It is possible that the monoclonal 
antibodies described by Sato et al. (142) also bind to this 
domain. 
When all of these results are considered together, it seems 
likely that phospholipase C activity alone is not sufficient for 
the toxicity of these proteins. The C-terminal domains of the 
C. perfringens alpha-toxin and C. bifennentans enzyme 
confer hemolytic properties on these enzymes; the L. mono-
cytogenes PLC-B has been reported to be weakly hae-
molytic (54), and its activity may be comparable to the weak 
hemolytic activity reported for the B. cereus enzyme (88, 89) 
(Table 2). In the C. perfringens alpha-toxin, removal of this 
domain reduces but does not abolish sphingomyelinase 
activity, whereas hemolytic and lethal activities are not 
detectable (168, 170). It may be that these domains facilitate 
protein interaction with cell membranes and that poor effec-
tiveness of phospholipase C-neutralizing antibodies in neu-
tralizing lethal activity could be explained if the protein 
underwent a conformational change on interaction with 
membranes. 
Sphingomyelinases 
The sphingomyelinases from Staphylococcus aureus and 
B. cereus share many properties. Both enzymes are single 
polypeptides, require magnesium for activity (55, 67, 136, 
189), and cause hot-cold lysis of sphingomyelin-rich eryth-
rocytes (67, 136). In view of this, it is not surprising that a 
comparison of the deduced amino acid sequences (56, 130) 
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revealed 56% similarity over 200 residucs (130). The S. 
aureus sphingomyelinase (beta-toxin) has been the subject of 
intensive studies in past decades, and several reviews on this 
toxin have been written (136, 188, 189). 
Circular dichroism spectrum studies and protein structure 
prediction studies both indicated that the B. cereus protein 
was largely in a beta-sheet conformation (172), and observa-
tions that the enzyme was inactivated by reducing agents 
(189) suggested that the protein may be stabilized by a 
disulfide bridge formed between the two cysteine residues in 
the protein. Magnesium ions have been reported to be 
loosely bound to the B. cereus protein, but their presence 
had little effect on the circular dichroism spectrum, suggest-
ing that the ion(s) did not play a significant structural role 
(172). It has been suggested that the ions, which can be 
substituted for by calcium ions, facilitate substrate binding 
(172). 
It is perhaps surprising that the toxic properties of the S. 
aureus sphingomyelinase have attracted so much attention, 
even though it is between 1 and 0.1% as toxic as the C. 
perfringens alpha-toxin (100, 136), whereas the B. cereus 
enzyme has not been considered in this context. The closely 
related bacterium Bacillus anthracis has also been reported 
to possess hemolytic and phospholipase C activities (35, 
147); although the anthrax toxin is certainly of major signif-
icance in the pathogenesis of disease, it may now be of 
interest to examine the phospholipases C produced by this 
bacterium. 
Phosphatidylinositoi-Hydrolyzing Phospbolipases C 
The phosphatidylinositol phospholipases C (PI-PLCs) 
from B. cere us, Bacillus thuringiensis, and L. monocyto-
genes (PLC-A) show extensive deduced amino acid se-
quence similarity, particularly at theN termini (63, 83, 101). 
Along with the C. novyi PI-PLC, these enzymes have been 
classed as type I enzymes since they are able to hydrolyze 
phosphatidylinositol phosphates but are not membrane as-
sociated (23, 101). Sequence homology has also been re-
ported between the B. cereus PI-PLC and the similarly sized 
Trypanosoma brucei enzyme (77) and between these pro-
teins and eukaryotic PI-PLCs from rats and Drosophila 
species (101). An important feature of the PI-PLCs is their 
ability to cleave the phosphatidylinositol-glycan-ethano-
lamine anchor to which many eukaryotic membrane proteins 
are att~ched (23, 69, 75, 101). Unlike other phospholipases 
C, the Pl-PLCs have not been reported to require divalent 
cations for activity (55, 77, 101). Other than this, little is 
known about structure-function relationships in this group ·or 
enzymes. 
GRAM-NEGATIVE PHOSPHOLIPASES C 
Pseudomonad Phospbolipases C 
The phospholipases C produced by P. aentginosa have 
been the subject of considerable investigation over the past 
decade, and the gene encoding the hemolytic enzyme was 
the first bacterial phospholipase C gene to be cloned (177). 
Later, Ostroff and Vasil reported that the insertional inacti-
vation of the P. aemginosa hemolytic phospholipase C 
(PLC-H) did not completely abolish phospholipase C activ-
ity and thereby identified a second, nonhemolytic phospho-
lipase C (PLC-N) produced by this bacterium (119). Using 
conventional protein purification techniques, Chin and 
Watts (25) also reported that two phospholipases C were 
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produced by a ftecccrot isolate of P. aentginosa but that only 
one of these was hcmolytic; this enzyme has also been 
termed the heat-labile hemolysin by some workers, since 
activity is destroyed by heating to IOO'C (3, 12). PLC-H and 
PLC-N were separable by ion-exchange chromatography 
(25). The genes encoding PLC-H and PLC-N have been 
isolated, and their nucleotide sequences have been deter-
mined (31, 93, 118, 129). pieS, which encodes the PLC-H 
enzyme, and plcN, which encodes PLC-N, are distally 
located on the chromosome (118), and the encoded proteins 
arc of similar molecular weights, but whereas PLC-N is a 
basic protein (pi 8.8), PLC-H is acidic (pi 5.5) (118). Only 
PLC-H is hemolytic for sheep, human, and rabbit erythro-
cytes (12, 118). The protein is posttranslationally modified, 
by one of the pieR gene products via an unknown mecha-
nism, to yield a product with altered charge and greater 
hemolytic activity (144). Neither PLC-H nor PLC-N is able 
to digest phosphatidylethanolamine (118), a major phospho-
lipid component of the prokaryotic cell membrane (1), and it 
has been suggested that a substituted ammonium group on 
the phospholipid is required for binding by PLC-H (12). 
It is interesting to speculate why two phospholipases are 
produced by this organism. The similarity of the deduced 
amino acid sequences (40% identity) suggests that these 
proteins could have risen from an early gene duplication 
event (99%). Since homology is greatest within the N-termi-
nal regions of these proteins, it seems likely that differences 
in the C-terminal regions are responsible for the different 
substrate specificities. The requirement for different en-
zymes, produced by the same organism, to digest different 
phospholipids is not unusual and presumably reflects the 
different roles of these enzymes in the ecology or pathoge-
nicity of the bacterium. Since both enzymes are able to 
digest phosphatidylcholine but only PLC-H can digest sphin-
gomyelin, this difference in substrate specificity must be due 
to differences in recognition of the hydrocarbon tails rather 
than of the head group (which is identical). This contrasts 
with the ability of only PLC-N to hydrolyze phosphatidyl-
serine, which must be due to a difference in the recognition 
of the head group of the phospholipid. 
A DNA fragment which reacted with the P. aernginosa 
plcN or pieS gene probes has been isolated from the related 
pathogen Pseudomonas cepacia and appears to be located 
within a highly variable region of the genome. On expression 
in E. coli, a 72-kDa protein was produced (178). However, 
this gene product alone did not possess phospholipase C 
activity. To generate a phospholipase C (and hemolytic) 
activity, the coexpression of a second gene, located on the 
same DNA fragment and encoding a 22-kDa protein, was 
required. The simple mixing of the two gene products did not 
result in phospholipase C activity (178). This result may 
reflect a mechanism similar to the reported activation of the 
P. aernginosa PLC-H by the pieR gene product. Whether 
the 22-kDa gene product plays a role directly in phospho-
lipase C activity or indirectly by posttranslationally modify-
ing the 72-kDa protein could be resolved by purifying and 
characterizing the active phospholipase C produced by this 
organism. 
A variety of other Pseudomonas species have been re-
ported to produce phospholipases C (106); however, most of 
these species are low-grade pathogens or non pathogens. One 
notable exception is the highly virulent Pseudomonas 
pseudomallei. several strains of which produced large 
amounts of phospholipase C when grown on egg yolk-
containing medium (165). The properties of this enzyme 
await investigation. 
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Legionella Phospholipase C 
There have been several reports of the production of 
phospholipase C by Legionella pneumophila (8-10) and by 
other Legione/la species (43). The enzyme is produced 
cxtraccllularly (43), and the Legionel/a pneumophila enzyme 
has been purified, partially characterized, and shown to 
hydrolyze phosphatidylcholine (9). It is not clear whether 
this enzyme is related to any of the phospholipases described 
above, but it is apparently not a zinc-mctallophospholipase 
C or a phosphatidylinositol-specific enzyme. Zinc ions in-
hibit activity (9), and EDTA stimulates activity severalfold 
(9). The purified protein is not hemolytic for dog erythro-
cytes (9), which arc rich in phosphatidylcholine (113), and 
the hcmolytic activity produced by this bacterium has been 
shown to be due to other moieties, notably the metallopro-
tease and legiolysin (43). The role of this enzyme in the 
pathogenesis of Legionnaires' disease has not been investi· 
gated, but in view of the aerosol route of infection of this 
pathogen, it seems possible that it damages the phospholip-
id-rich lung surfactant in a manner similar to that suggested 
for the P. aemginosa phospholipases C. 
OTHER PHOSPHOLIPASES C 
The production of phospholipases C by a variety of other 
bacteria has been reported, but in most cases these enzymes, 
or their encoding genes, have not been characterized in 
detail. The enzyme produced by Ureaplasma urealyticum 
was unusual in that it appeared to be membrane bound (39), 
and it is not clear from this report whether the protein would 
be surface exposed, which would presumably be a prereq-
uisite for a role in pathogenesis. 
REGULATION OF GENE EXPRESSION 
Phosphate-Regulated Genes 
Both of the phospholipases from P. aernginosa and the B. 
cereus PC-PLC have been reponed to be phosphate regu-
lated (59, 118, 129, 145). The P. aemginosa enzymes are 
induced under low-phosphate conditions, and regulation 
appears to be at the transcriptional level (118, 129, 145). The 
low level of expression ofplcS, cloned into E. coli, has made 
it difficult to determine whether the gene is similarly regu-
lated in this host (93, 129). Other proteins in a P. aemginosa 
putative phosphate-scavenging pathway, such as alkaline 
phosphatase and P; transport proteins, are P; regulated (58); 
PLC-H and PLC-N may form part of a P; regulon (145), 
which would be important for phosphate retrieval from the 
environment. The molecular basis of regulation in P. aem-
ginosa has been partially elucidated by using a variety of 
isogenic mutants. Of particular significance was the finding 
that pleA regulates the expression of both phospholipases C 
and that the gene encodes a homolog of the PhoB regulatory 
protein in E. coli (4). Significantly, a sequence resembling 
the E. coli plw box was located upstream of plcN (4). In 
addition to the regulation of the phospholipascs C by P;. 
several compounds derived from the enzyme product, nota-
bly choline, betaine, and dimethylglycine, can induce phos-
pholipase C production, but the mechanisms of induction of 
PLC-H and PLC-N arc different. Induction of PLC-H was 
independent of P; concentration and PhoB, whereas PLC-N 
induction was seen only under low-P; conditions and re-
quired PhoB (145). Since these product derivatives can also 
act as osmoprotcctants, it has been suggested that induction 
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of phospholipases C can form part of a protective response 
of the bacterium when grown under conditions of high 
osmotic strength (145) . The significance of PLC induction by 
product derivatives in relation to pathogenesis is discussed 
in more detail below. A third mechanism of regulation may 
involve the pieR gene, which is located downstream of pieS, 
and the gene products (PicR1 and PlcR2) may also play a role 
in phosphate regulation of the phospholipases C and other 
phosphate-regulated proteins. Although the deletion of these 
genes in P. aeruginosa results in an increase in phospho-
lipase C activity, production of the enzymes is still phos-
phate repressible (144), suggesting that they are not directly 
involved in phosphate regulation. Perhaps it is more likely 
that the pieR gene products play a role in the export or 
activation of phosphate-regulated proteins (144). 
The B. cereus PC-PLC and sphingomyelinase-encoding 
genes form a cistron. It is known that the products of these 
genes can act synergistically to yield a hemolytic complex 
termed cereolysin A-B (56), suggesting that coexpression of 
these proteins is advantageous to the organism. Whether this 
is because cereolysin A-B plays a particular role in the 
ecology of this organism or whether the coregulation simply 
reflects that phosphatidylcholine and sphingomyelin are 
likely to be found together in the environment awaits inves-
tigation. 
Non-Phosphate-Regulated Genes 
Although production of many of the phospholipases C is 
not regulated by exogenous phosphate levels, other factors 
may control gene expression. The L. monocytogenes plc-A 
promoter contained a 14-bp palindrome within the -35 
promoter region. This motif is characteristic of genes which 
are positively regulated by the pfrA gene product (83, 179), 
and this gene may therefore be coordinately regulated by the 
pfrA gene product along with other virulence determinants 
such as listeriolysin 0, whose gene (hlyA) is located back-
to-back with pleA (83). The L. monocytogenes pleB gene 
was located within an operon which also contained the 
metalloprotease gene (mpl}, the actin-polymerization gene 
(actA) , and the unassigned open reading frames ORF-X, 
ORF-Y, and ORF-Z (179). Control of pleB may be regulated 
since it is known that the gene can be expressed from thempl 
or actA promoters, both of which are regulated by the pfrA 
gene product (179). Transposon mutagenesis into mpl re-
duced PLC-B production significantly, but the total loss of 
pleB expression resulted from disruption of the actA pro-
moter (179). This result can be explained because the operon 
is regulated by the mpl promoter but transcription of pleB 
can also take place from the actA promoter, which is located 
downstream of mpl (179). It is possible that this arrangement 
allows the bacterium to regulate the expression of pleB (and 
actA) partly independently of other pfrA-regulated genes, 
and this may reflect the different roles of these gene products 
in the pathogenesis of listeriosis. 
Studies by Murata et al. (111) and Rood and Cole (137) 
failed to show that environmental phosphate levels also 
affect alpha-toxin production, but it seems unlikely that 
expression of this gene is unregulated, since C. peifringens 
is a normal member of the gut Oora and it seems unlikely that 
large quantities of toxin wo uld be produced by the organism 
in this commensal state. In addition, wide variations in the 
levels of phospholipase C production by different strains 
have been reported (106, 107). Phospholipase C production, 
in vitro, does not correlate with virulence, since some 
clinical isolates produce almost undetectable levels of the 
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e nzyme (106, 171). Some progress has been made in eluci-
dating mechanisms of gene regulation. A possible relation-
ship between environmental iron levels and alpha-toxin 
production by C. peifringens (111) has not been followed up, 
and it is only recently that mechanisms of gene regulation 
have been investigated at a molecular level. Determination 
of mRNA levels in a heat-resistant strain of C. perfringens 
(139) showed that the alpha-toxin gene was expressed con-
stitutively and that production was about threefold higher in 
the stationary phase than in the logarithmic phase. This 
pattern of gene transcription may not be typical, since 
previous reports have indicated that maximal toxin produc-
tion occurs in the logarithmic phase, with a reduction on 
entry into the stationary phase (148). In other type A and 
type B strains, the gene was expressed maximally during the 
logarithmic phase of growth , and it was demonstrated that 
alpha-toxin production is regulated at the transcriptional 
level (191). The mechanisms of regulation have not been 
characterized, but the previously identified A+ T-rich region 
upstream of the -35 promoter region appears to negatively 
regulate expression of the gene (174 ). Deletion of this region 
increased gene expression 10-fold in E. coli and was attrib-
uted to the DNA-bending potential of this region. Whether 
this effect is also seen in C. peifringens awaits investigation, 
but other factors must also regulate gene expression, since it 
has been shown that this region is identical in high- and 
low-producing strains of C. peifringens (191). 
INTERACflON OF PHOSPHOLIPASES C WITH 
PHOSPHOLIPfDS AND MEMBRANES 
Hydrolysis of Membrane Phospholipids 
The interactions of the B. cereus PC-PLC and the C. 
peifringens alpha-toxin with phospholipids and their analogs 
has been studied in some detail. Not surprisingly, interaction 
with the polar head group and also, in the case of the B. 
cereus PC-PLC, the associated carbonyl group appears to be 
important for phospholipid recognition (45). The fatty acyl 
chains also play a significant role in substrate binding and 
must be of sufficient length (greater than six carbons) for 
hydrolysis of phospholipid to take place (45). Presumably, 
hydrophobic side chains close to the active site (64) mediate 
this binding. The ester bonds which link the fatty acyl chains 
also play a major role in the binding of the B. cereus PC-PLC 
to phosphatidylcholine (45) but a less important role in the 
binding of the C. peifringens alpha-toxin (138}. Although 
these ester bonds are considered to be within the interfacial 
region (45), they are presumably less accessible than the 
head group (Fig. 3). These observations could partially 
explain why the C. peifringens alpha-toxin can hydrolyze 
membrane phospholipids whereas hydrolysis by the B. 
cereus PC-PLC is limited. The sphingomyelin molecule 
lacks one of the carbonyl side chains, and one would 
therefore predict that, unlike the C. peifringens alpha-toxin, 
the B. cereus PC-PLC would not be able to hydrolyze this 
molecule. Experimental data confirm this hypothesis to 
some extent, but our observations that a truncated form of 
the C. peifringens alpha-toxin is not able to efficiently digest 
sphingomyelin suggest that there are other parts of the 
sphingomyelin molecule which bind to the active-site region 
(168). The enhancing effect of detergents on activity of the C. 
peifringens alpha-toxin and B. cereus PC-PLC (46, 76) 
appears to be due to phospholipid solubilization (78) or 
solubiliza tio n of the diacylglycerol reaction product (46) 
rather than to an effect on the protein. 
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FIG. 3. Interfacial area of phosphatidylcholine (boxed) in the 
membrane, accessible to phospholipases (adapted from reference 45 
with permission). Charged regions on the phospholipid head group 
are also shown. 
Calcium ions are required for the binding of the C. 
perfr!ngens ~lpha-toxin or the B. cereus PC-PLC to phos-
phattdylchohne films (110), especially at high lateral surface 
p~essures (11), and for the binding of B. cereus sphingomy-
ehnase to erythrocytes (67). Other phospholipases C, such 
as the Legionel/a pneumophila enzyme, have also been 
reported to be stimulated by calcium ions (9) . The most 
commonly cited reason for this effect is that the calcium ion 
binds to the phosphate head group, altering the charge on 
thi~ _region of the phospholipid (11, 173). The ability of 
qumme to enhance phospholipid hydrolysis has been attrib-
uted to a similar mechanism (74). There is some evidence, 
from a kinetic analysis of the hydrolysis of a lysophosphati-
dyl analo~, that the calcium ion binds to the C. peifringens 
alpha-toXln before substrate binding (193). Calcium ions are 
also :equired by numerous other eukaryotic lipid-binding 
protems and enzymes, including intracellular phospholi-
pases C and A2 and snake venom phospholipases A2 (133). It 
seems possible that the calcium ion performs a similar role in 
lipid binding with all of these proteins, although the se-
quence motifs of the suggested calcium-binding domains in 
the eukaryotic phospholipases C (29, 133) do not appear to 
be highly conserved in the prokaryotic phospholipases C. 
Because phospholipids are the major structural compo-
nents of the cell membrane, it seems simple to predict the 
effects of phospholipases C on cells by examining the 
spectrum of phospholipids degraded by the enzyme. Al-
though this rationale may provide a starting point for such 
predictions, it is obvious that other factors are equally 
important in determining the interaction of phospholipases C 
with lipids and membranes. 
It is known that the distribution of phospholipids in the 
cell membrane bilayer is not symmetrical and this asymme-
try can explain why some phospholipases C are cytolytic. 
The outer leaflet is made up mainly of phosphatidylcholine 
and sphingomyelin (Table 3}. Although the potential suscep-
tibility of inner-leanct phospholipids to hydrolysis by S. 
aureus beta-toxin and the 8. cereus sphingomyelinase and 
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TABLE 3. Distributio n o f phospho lipids between the o ute r and 
inner leaflets of the human erythrocy te membrane b ilaye r" 
'C of total m: 
Phospholipid 














PC-PLC has been demonstrated by using erythrocyte ghosts 
(67, 94), phospholipids in the inner leaflet are not normally 
accessible to the phospholipase and movement of phospho-
lipids across the membrane is restricted (27). 
Thus, it seems feasible to propose that the most hemolytic 
phospholipases C preferentially degrade outer-leaflet phos-
pholipids. The C. perfringens alpha-toxin and P. aeruginosa 
PLC-H hydrolyze phosphatidylcholine and sphingomyelin 
and are hemolytic, whereas the structurally related nonhae-
molytic B. cereus PC-PLC and P. aeruginosa PLC-N are not 
able to effectively hydrolyze sphingomyelin. Additional ev-
idence for this hypothesis is provided by reports that the B. 
cereus sphingomyelinase and PC-PLC can act synergisti-
cally to cause hemolysis (56). 
Two exceptions to this rule concern the S. aureus beta-
toxin and the B. cereus sphingomyelinase, which are not 
able to digest phosphatidylcholine. However, the only eryth-
rocytes sensitive to lysis by these enzymes have a high 
proportion of sphingomyelin in the erythrocyte membrane 
(Table 4) (13, 37, 67) and, more specifically, within the outer 
leaflet. Even after sphingomyelin hydrolysis at 37°C, cell 
lysis ensues only when the erythrocytes are cooled (this is 
known as hot-cold hemolysis). Hot-cold hemolysis has also 
been reported when the alpha-toxin acted on sheep erythro-
cytes (162), but hot-only hemolysis was observed when 
mouse erythrocytes (166) or rabbit erythrocytes (110) were 
tested. Since sheep erythrocytes are rich in sphingomyelin 
but almost devoid of phosphatidylcholine (37), it is possible 
that hot-cold lysis is observed when a phospholipase C 
hydrolyzes only the membrane sphingomyelin whereas he-
molysis at 37°C is indicative of hydrolysis of both sphingo-
myelin and phosphatidylcholine. 
The exact mechanism of hot-cold lysis has been attributed 
to the generation of fragile erythrocytes after the cleavage of 
membrane sphingomyelin (13). On cooling, the phase change 
in the membrane lipids may cause stresses which lead to cell 
TABLE 4. Sensitivity of erythrocytes to lysis by 
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~ Hu/ml, hemoly t ic activity expressed as the reciprocal of the dilution 
resulting in 50<:1- lysis of erythrocytes when ex posed to S. auretL\' beta- toxin. 
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lysis. Other treatments, such as EDTA, can also lead to lysis 
of erythrocytes pretreated with 5. attreus beta-toxin at 37°C 
(136), and it seems likely that in this case the chelation of 
metal ions weakened the membrane. Even in the absence of 
EDTA, the reduced membrane-stabi lizing ability of magne-
sium ions at low temperatures (106) can lead to hot-cold 
lysis. 
The appearance of erythrocytes treated with phospholi-
pases C has often revealed electron-dense intralamellar 
droplets, which have been presumed to arise from aggrega-
tion of the ceramide or diglyceride products of phospholipid 
hydrolysis (13, 19, 32, 33, 94, 180). The droplets disappear 
after digestion with pancreat ic lipase (33) or bound lipophilic 
dyes (124}, lending further credence to this suggestion. It has 
been suggested that for erythrocytes treated with S. aureus 
beta-toxin, the appearance of intracellular vesicles is caused 
by the invagination of the inner membrane as a result of the 
shrinking of the sphingomyelin-depleted outer leaflet (94, 
180). However, other workers have suggested that the 
ceramide or diglyceride product remains in the outer leaflet 
and the membrane shape changes to accommodate the 
stresses induced (27). Perhaps the stresses induced on hy-
drolysis of phosphatidylcholine can be accommodated more 
easily than those induced on hydrolysis of sphingomyelin, 
whereas hydrolysis of both phospholipids leads to an ener-
getically unfavourable situation. 
Although the phospholipid composition of the outer leaflet 
undoubtedly influences the outcome of enzyme-membrane 
interaction, other membrane components such as sulfatides 
have been reported to play an additional moderating role in 
C. perfringens alpha-toxin binding (16}, especially at high 
surface pressures (16). This has been attributed to the 
negatively charged head group on the phospholipids (16), 
which could presumably bind the enzyme via sulfatide ions. 
Other workers have shown that proteins can moderate the 
interaction of phospholipases C with membranes. a-Lactal-
bumin bound to lipid monolayers may inhibit phospholipid 
hydrolysis by the C. pelfringens alpha-toxin (62), and the 
increased susceptibility of lipids to hydrolysis by the B. 
cereus PC-PLC in pronase-treated cells has been attributed 
to increased accessibility of the substrate (67). One sug-
gested role of the L. monocytogenes PI-PLC is to remove 
GPI-anchored membrane proteins and enhance the cytolytic 
effect of other membrane-damaging proteins such as listeri-
olysin 0 (101). 
Membrane Lateral Pressure and Phospholipase C Action 
Ultimately, the phospholipase C must gain acces to the 
membrane for phospholipid hydrolysis to take place, and the 
lateral pressure within the membrane reportedly plays a 
significant role in moderating this interaction. The hydrolysis 
of phosphatidylcholine by alpha-toxin, in a phosphatidylcho-
line monolayer or a mixed phosphatidylcholine-cholesterol 
film, could take place at surface pressures up to 40 dynes/cm 
(11) and 35 mN/m ( =35 dynes/cm [ 110]), respectively, which 
is similar to the surface pressure within the erythrocyte 
membrane (31 to 35 mN m [38]). In contrast, nonhemolytic 
phospholipases cannot hydrolyze phospholipid-; at high sur-
face pressures (Table 5). lt seems that some phospholipase 
C can gain access to the membrane more easily than others. 
From studies of the zinc-metallophospholipases C, it is 
tempting to speculate that the C terminus of the C. perfrin-
gens alpha-toxin and C. hifennentans phospholipase C is 
involved in such a role. and this could also explain how this 
domain facilitates interaction with sphingomyelin. This 
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TABLE 5. Hydrolysis of phospholipids in monolayers by 
hemolytic and nonhcmolytic phospholipasesa 
Hemolysis Maximal surface prc!>~urc ar which phospholipid Source of phospholipase Type of human hydrolysis can rake place 
cryrhrocyres (dyne/cm) 
Pig pancreas A2 16.5 
Cabbage D 20.5 
Crotaltts adamantetts A2 23 
B. cereus c 31 
Naja naja Al + 34.8 
Bee venom A2 + 35.3 
S. attreus c + >40 
C. perfringens c + >40 
• Dara from reference 106. 
would certainly explain the weak hemolytic activity of L. 
monocytogenes PLC-B despite its ability to hydrolyze both 
phosphatidylcholine and sphingomyelin (54). 
The precise mechanism by which some phospholipases C 
bind to membranes remains unclear. Presumably these pro-
teins possess hydrophobic regions, and it is possible that a 
conformational change on interaction with the membrane 
surface exposes these regions. Such changes have been 
reported for snake venom phospholipase A2 and Rltizomucor 
mieltei lipase (17, 22), which enable the enzymes to retract 
phospholipids above the membrane surface before cleavage. 
It is not clear whether this enzyme (or other phospholipases 
C) has a similar phospholipid-retracting mechanism or 
whether the protein becomes embedded within the mem-
brane. A conformational change of the C. perfringens alpha-
toxin on phospholipid binding has been previously suggested 
from studies with enzyme inhibitors (138), but presumably 
such a change would be transient when the enzyme inter-
acted with dispersed substrate. On binding to a membrane, 
the conformational change may be attained for longer peri-
ods, and this would explain why a monoclonal antibody 
which neutralizes C. perfringens alpha-toxin phospholipase 
C activity was less effective in neutralizing hemolytic activ-
ity (92). 
All of the studies with purified phospholipases C have 
suggested that only outer-leaflet phospholipids are hydro-
lyzed, and a dearth of information on the interactions of 
phospholipases C with membranes at the molecular level 
makes it difficult to speculate whether these enzymes can 
cross the membrane. However, these studies have all been 
based on the external application of phospholipases C and 
have been colored by studies with extracellular pathogens 
such as C. perfringens. When intracellular pathogens such as 
L. monocytogenes and Legionella pneumophila are consid-
ered, it is apparent that the site of production of the enzymes 
could be within the cell, after escape of the organism from 
the phagolysosome. In these situations it may be more 
appropriate to consider the effects of phospholipases C on 
the inner-leaflet phospholipids. A similar argument can be 
applied to the membrane-localized phospholipase C pro-
duced by U. urealyticum , but in this case it eem pos ible 
that the enzyme also plays a role in the initial stages of entry 
into the host celL 
An additional mechanism which could influence the cyto-
lytic potential of phospholipases C involves the activation of 
the eukaryotic cell phospholipases C by the diacylglycerol 
product of the bacterial enzyme. Since many of these 
eukaryotic phospholipascs C are membrane bound, it is 
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conceivable that these activa ted enzymes contribute to cell 
autolysis. This possibility has yet to be investigated. 
Cell Membrane Repair 
One further consideration which may influence the cyto-
lytic potential of phospholipases is the speed with which the 
cell can repair membrane damage; A TP-depleted erythro-
cytes were more susceptible to cell lysis by alpha-toxin and 
B. cereus PC-PLC, perhaps because of their inability to 
repair membrane damage. Recovery from membrane dam-
age may be quite protracted, taking at least 24 h forS. aureus 
sphingomyelinase-treated lung fibroblast membranes (126). 
Ultimately, cell lysis or extensive membrane damage by 
phospholipases C may reflect the fine balance between cell 
membrane damage and repair (127). An intriguing report by 
Kanfer and Spielvogel (71) suggested that the C. perfringens 
alpha-toxin was able to catalyze the limited formation of 
sphingomyelin from phosphatidylcholine and ceramide. Al-
though this possibility does not appear to have been followed 
up, such a mechanism would presumably result in the 
alteration of the membrane structure. 
SYNERGISTIC AND ANTAGONISTIC EFFECTS 
INVOLVING PHOSPHOLIPASES C 
Only some phospholipases C have been reported to be 
hemolytic and lethal and to have necrotizing activities. 
However, it is now apparent that nonhemolytic phospholi-
pases C can act in conjunction with other proteins to cause 
cell lysis. Individually the B. cereus PC-PLC and sphingo-
myelinases are only weakly hemolytic (56), but, acting 
together, the enzymes are able to cause hemolysis; this 
complex has been termed cereolysin A-B (56). A sirrular 
result has been obtained with the B. cereus PC-PLC and S. 
aureus sphingomyelinase (13, 135). A mechanism to explain 
this result has been proposed, involving the initial degra-
dation of sphingomyelin, with a resultant lowering in 
membrane lateral pressure, which then allows the phosphati-
dylcholine-hydrolyzing enzyme access to susceptible mem-
brane phospholipids (106, 135). 
The CAMP reaction described by Christie et al. (28) 
provides another example of hemolysis occurring as a result 
of interaction between proteins from different bacterial spe-
cies: the initial treatment of erythrocytes with a sphingomy-
elinase resulted in hemolysis only on the addition of a 
second, nonenzyme protein produced by group B strepto-
cocci (termed CAMP factor). Since that discovery, CAMP-
like factors have been reported to be produced by a variety 
of bacteria (48}. Investigation of the molecular biology of the 
CAMP factor has suggested that four regions of the 226-
amino-acid polypeptide, all located in the N-terminal part of 
the molecule, can form amphiphilic helices (48). The lipid-
binding potential of this region has been demonstrated by 
using a 9-kDa CNBr fragment of the CAMP factor (153). It 
has been proposed that CAMP factor interacts with lipids in 
the membrane, which has already been partially destabilized 
by the sphingomyelinase, and this leads to complete mem-
brane destabilization (48). By analogy with the synergistic 
process described in the previous paragraph, it may be the 
case that sphingomyelinase trea tment of erythrocytes leads 
to a lowered membrane lateral pre sure, which then allows 
membrane penetration by the CAMP factor and leads to cell 
lysis . 
Not surprisingly, antagonistic effects between phospholi-
pases C and other prote ins have been less well described. 
MICROIJ IOL. Rev. 
Nevertheless, there are some examples (44, 150). The pre-
treatment of cells with phospholipase D from Corynebacte-
rium haemolyticum, Corynebacterium ovis, or Corynebac-
terium ufcerans reduced their sensitivity to lysis by S. 
aureus sphingomyelinase (150), probably because the prod-
ucts of phospholipase D hydrolysis (phosphatidic acid and/or 
ceramide phosphate) are not suitable substrates for the S. 
aureus enzyme. 
Whether any of these synergistic or antagonistic effects 
are significant in vivo remains open to question, but some 
recent evidence suggests that this may be the case for the 
alpha- and beta-toxins of S. aureus (21). It therefore seems 
pertinent to pursue this line of investigation, which could 
reveal novel pathogenic mechanisms exploited in mixed 
infections. 
EFFECTS OF PHOSPHOLIPASES C ON CELLS OTHER 
THAN ERYfHROCYfES 
Cytotoxicity 
Hemolysis of erythrocytes has often been used to measure 
the cytolytic activity of phospholipases C, but it is apparent 
that some phospholipases C are cytotoxic for other cell 
types. The S. aureus beta-toxin, P. aeruginosa PLC-H, and 
C. perfringens alpha-toxin are the most intensively studied 
in this respect. The beta-toxin shows a marked degree of 
specificity, being cytotoxic for human thrombocytes but not 
leukocytes (182). Platelets were lysed rapidly by this toxin 
(181}. It is not clear whether these differences simply reflect 
differences in sphingomyelin content or accessibility in the 
cell membranes or whether toxicity is elicited by an effect 
other than membrane breakdown. Degradation of membrane 
sphingomyelin in fibroblasts was accompanied by redistribu-
tion of cellular cholesterol away from the cell surface, 
indicating the importance of sphingomyelin as a modulator 
of cholesterol distribution in cells (126). This result may be 
especially significant when considering the roles of sphingo-
myelinases and thiol-activated toxins on cell surfaces. In a 
study with the P. aeruginosa PLC-H, significant cytotoxic 
effects were observed in mouse peritoneal cells and human 
leukocytes (103). The effects of the C. perfringens alpha-
toxin may be more subtle than cell lysis. Nonlethal mem-
brane damage to human diploid fibroblasts was monitored by 
measuring the release of a low-molecular-weight label (ami-
noisobutyric acid) (108, 163), and it is possible that the 
membrane damage in these cells is rapidly repaired, prevent-
ing cell lysis. 
Activation of Arachidonic Acid Cascade 
Several lines of evidence suggest that phospholipases C 
are able to stimulate the arachidonic acid cascade in cells. It 
has been demonstrated that sublytic concentrations of the C. 
perfringens alpha-toxin can lead to limited membrane dam-
age and the accumulation of diacylglycerol in the cell mem-
brane. The diacylglycerol may enter one of two pathways in 
the cell (Fig. 4). In rat aorta cells or colon mucosal cells, the 
arachidonic acid cascade may be activated directly, after 
conversion of diacylglycerol to monoacylglycerol, by intra-
cellular diacylglycerollipase (41, 51). In cells from the small 
intestine, activation appears to take place indirectly after 
stimulation of intracellular phospholipase A2 activity (60, 
61). By whichever mechanism, activation of the arachidonic 
acid cascade by the C. perfringefiS alpha-toxin can lead to 
the production of thromboxane A2, a potent mediator of 
V O L. 57, 1993 






FIG. 4. Effects of bacterial phospholipases C on eukaryotic 
cells. The bacterial phospholipase C is hatched. Enzymes are shown 
in capital letters, and possible effects on eukaryotic cells are boxed. 
E.R., endoplasmic reticulum. 
inflammatory responses (51), or prostaglandins which can 
induce chloride ion secretion in rat colonic cells via activa-
tion of chloride ion channels (41). 
Similar results have been reported with other phospholi-
pases C. The nonhemolyticB. cereus PC-PLC has also been 
reported to both activate the arachidonic acid cascade and 
stimulate prostaglandin formation in several mammalian cell 
types (85). The magnitude of this response is not clear, but in 
view of the proven limited accessibility of cell membrane 
phospholipids to cleavage by this enzyme, it may be much 
lower than that observed with the C. perfringens alpha-
toxin. The P. aeroginosa PLC-H can activate the lipoxyge-
nase and cyclooxygenase pathways in mouse peritoneal 
cells, leading to the product ion of an array of thromboxanes, 
leukotrienes, and prostaglandins (102). Similar results were 
obtained in vitro with mouse peritoneal cells or human 
granulocytes (102). 
The induction of arachidonic acid metabolites by bacterial 
phospholipases C could account for many of the effects 
observed with these toxins in vitro and in vivo. Leukotriene 
C4 and 0 4 (L TC4 and L TD4 ) increase vascular permeability 
and promote the exudation of fluid into the extravascular 
space (141, 182), and these effects have been observed after 
the intradermal administration of purified C. perfringens 
alpha-toxin in the guinea pig (156) and P. aeroginosa PLC-H 
in the mouse (102). The contraction of the isolated rat aorta 
and isolated rat ileum could be attributed to the induced 
production of L TC4 or thromboxane A2 (TXA2) (51). The e 
mechanisms may also be of significance in the aggregation of 
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platelets, which has been reported as an effect of the 
alpha-toxin (114, 157) and P. aemginosa PLC-H (36), since 
the thromboxanes are known to induce platelet aggregation 
(176). The failure of S. aureus beta-toxin to induce platelet 
aggregation (182) would be expected, because the ceramide 
product of sphingomyelin hydrolysis would not serve as a 
substrate for the arachidonic acid pathway. 
It remains to be discovered whether other phospholipases 
C arc able to stimulate the arachidonic acid pathway in cells, 
but this question seems pertinent in view of the potential 
roles of some of these enzymes in the pathogenesis of 
disease. 
Activation of Protein Kinase C 
Several workers have shown that exogenously applied B. 
cereus PC-PLC can elicit mitogenic responses in fibroblasts 
(80) or that C. perfringens alpha-toxin can give selective 
advantages to transformed keratinocyte cells in culture 
(125). It seems possible that the generation of diacylglycerol 
by exogenously applied bacterial phospholipases C mimics 
the effects of normal eukaryotic cell enzymes, where the 
generated diacylglycerol serves as a secondary messenger 
(15). The molecular basis of these effects has not been fully 
elucidated, but it is known that protein kinase C (PKC) can 
be activated by diacyglycerol and/or increased intracellular 
calcium levels (15). Thus it seems possible that bacterial 
phospholipases C activate PKC via the generation of diacyl-
glycerol. Since it has been suggested that PKC can activate 
the eukaryotic cell phospholipases C and D, this pathway 
would serve as a positive-feedback loop. In this respect the 
effect of the bacterial phospholipase C could be considered 
to mimic the effects of hormones and neurotransmitters, 
such as epidermal growth factor, platelet-derived growth 
factor, vasopressin, and the interleukins (47, 126), which 
activate PKC (47). PKC is known to modulate a wide variety 
of cell processes, but Larrodera et al. (80) have shown that 
the mitogenic response elicited by the B. cereus PC-PLC is 
also apparent in PKC down-regulated cells, suggesting that 
the diacylglycerol may activate other pathways. Whatever 
the precise action of the bacterial phospholipases C, it seems 
that the effects observed may be of significance in the 
proliferation of cells and could therefore play a role in 
two-stage carcinogenesis; the effect of C. perfringens alpha-
toxin was shown to be similar to that observed when 
keratinocytes were treated with a phorbol ester tumor pro-
moter (which directly activates PKC), because transformed 
cells were selectively advantaged in cell culture (125). Sim-
ilar conclusions were reached by Diaz-Lavida et al. (40), 
who showed that treatment of fibroblasts with the B. cereus 
PC-PLC (but not the B. thuringiensis PI-PLC) led to in-
creased levels of activated PKC in a manner similar to that 
seen in cells transformed by the ras or src oncogenes. 
NADPH oxidase catalyzes the forma tion of 0 2 - from 
molecular oxygen and therefore plays an important role in 
the respiratory burst of phagocytic cells which is associated 
wi th bacterial killing. It is not known whether PKC can 
activate NADPH oxidase, but it i known that one compo-
nent of NADPH oxidase is a substrate for PKC (7). In this 
context it is s ignificant that the C. perfringens alpha-toxin 
did not affect the viability of polymorphonuclear phago-
cytes, but it was suggested that membrane perturbation 
leads to activation of NADPH oxida e in the cells (154). 
Activation of this enzyme could have explained the produc-
tion of 0 2 - by neu trophils exposed to C. perfringens alpha-
toxin and the B. cereus PC-PLC (155). Such a mechanism 
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TAI3LE fl. Memhranc.:-bound enzymes released by bacterial 
phosphatidy l ino~i tol-spccific phospholipases C' 
Enzyme Source of PI -PLC 
Alkaline phosphatase .. ... .......... .... B. cereus, S. aureus. C. novyi. 
B. tl111ringiensis 
5" -Nucleotida e ...... ... .... ..... .... ... . .5. aureus, C. novyi, 8. tlrur-
ingiensis 
Alkal ine phosphodiesterase I ..... ... 8. thuringiensis 
Acetylcholinestera e ... ..... ... ....... . S. aureus , B. tl111ringiensis 
" Data from reference 66. 
may be of significance in I he pathogenesis of disease caused 
by phospholipase C-producing bacteria, since this event 
would lead to a premature activation of phagocytic cells. The 
extensive vacuolization of neutrophils treated with the P. 
aeruginosa PLC-H was also attributed to lysosomal di s-
charge following a phospholipase C-induced respiratory 
burst (103). If these (and o 1her) phospholipases C acted on 
cells before they contacted bacteria, the resultant respira-
tory burst might subsequently limit the extent of this re-
sponse after ingestion of the bacteria. 
These effects of phospholipases Con PKC activation, with 
the attendant modulation of a variety of cell functions (41), 
require further investigation , especially in the context of the 
possible roles of some bacterial enzymes in pa thogenicity 
and even in the development of tumors. 
Effects on Inositol Triphosphate and Intracellular Calcium 
The hydrolysis of phosphatidylinositol-4,5-bisphosphate 
by phospholipase C yields diacylglycerol and inositol-1,4,5-
triphosphate. The secondary-messenger role of diacylglyc-
erol has been referred to above. Although bacterial phos-
phatidylinositol-hydrolyzing phospholipases C have not 
been shown to increase the levels o f inositol triphosphate in 
eukaryotic cells, there is no reason why this effect could not 
be elicited , especially if the phospholipase C could gain 
access to the inner leaflet of the plasma membrane . Indeed, 
it has been suggested that the L. pneumophila phospholipase 
C could act in this manner (43). One of the clearly defined 
effects of inositol triphosphate and of its derivative inositol 
tetraphosphate {15) is to s timulate the release of calcium 
from the endoplasmic reticulum (15). The a lteration of 
intracellular calcium levels may in turn stimulate calcium 
in~ux across the plasma membrane through calcium gates 
(Ftg. 4). The contraction o f the isolated rat aorta and isolated 
rat ileum has been at tributed to this mechanism (51), and the 
activation of membrane calcium gates (and chloride ions 
channels) may have been responsible for the changes in frog 
muscle resting and action potentials which have previously 
been reponed (18). uch effects may be of significance in 
regulating the blood upply 10 tissues infected with bacteria l 
pathogens. For most pathogens this would be advantageous, 
since access of immune sy tcm cells to the s ite o f infection 
would be re tric ted. For anaerobes, the anoxic conditions 
generated might facilitate g~owth of the o rganism. The role 
of inositol lriphosphate, especia lly in relation to the role of 
diacylglyccrol and arachidonic acid metabolite, , requires 
fu rther investigation. 
Release of Cell Membrane Proteins 
Phosphatidy linositol i~ only a minor component of many 
cell memhrancs, bu l il performs an c sential role in anchor-
ing a va riety of pro1c:ins . The phosphatidylinositol-glycan-
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e1 hanolamine anchor can be cleaved by mcmbrane-activ 
phosphatidylinositol-specific phospholipa. cs C (75 J to re 
lease a variety of cell membrane-bound enzymes (Table 6) 
The report ed increase in blood a lkaline phosphatase level. 
following intravenous admini tration of the B. cereus PI 
PLC (66) suggested that these enzymes elicit similar effect: 
in vivo and in vitro. The significance of these releasee 
enzymes has not been identified , but it seems possible that 
the eukaryotic alkaline phosphatase could be used by the 
bacterium as part o f a phosphate-scavenging pathway. This 
would be especially significant since, as noted above (66), 
the level of P; in the blood is below that required for the 
growth of many bacteria . The phosphatidylinositol phospho-
lipases C have also been reported to moderate the growth of 
cells in tissue culture (66). It is possible that, like the C. 
perfringens alpha-toxin, these enzymes are able to activate 
secondary-messenger pa thways to cause these effects . 
Other Effects 
Other effects of phospholipases Con cell metabolism have 
not been described specifically, but it is worthwhile consid-
ering the central roles of diacylglycerol and inositol triphos-
phate on the s hort-te rm regulation of cell metabolism and the 
secretion and contraction of cells. These second messengers 
may also play a role in longer-term events such as growth 
and perhaps information storage in the brain (15). It seems 
timely to consider the roles of bacterial phospholipases C in 
these contexts rather than simply as agents of cytolysis. 
ROLES OF PHOSPHOLIPASES C IN DISEASE 
C. perfringens Alpha-Toxin 
C. perfringens is the bacterium most frequenily associated 
with gas gangrene in humans (186). The disease usually 
results from the growth of the bacterium in tissues which 
become anoxic either as the result of traumatic damage or 
from obliterative arterial disease in the limbs (187, l88). 
During past armed conflicts, the disease was a major cause 
of death of wounded soldiers (99, 183, 186). It has long been 
suspected that the C. perfringens alpha-toxin plays a key 
role in gas gangrene. However, the precise role of this 
protein in disease and the molecular basis of toxicity have 
not previously been understood. The observation that hemo-
lytic and lethal activities of the alpha-toxin are intimately 
linked has prompted speculation that the role of the toxin in 
the pathogenesis of gas gangrene is simply to cause cytoly-
sis. Hemolysis may occur in tissues close to the focus of 
infection, but the effects may be more subtle in distal tissues. 
The activation of the arachidonic acid cascade and cell 
calcium gates may lead to blood ves el contraction (50. 51). 
Both of these effects would reduce the blood supply 10 
tissues and promote the anoxic condit ions required for the 
further growth of C. perfringens. 
An abnormally high level of C. petfringens in the gut o r 
excessive produc tion of the alpha-toxin has been no ted in 
patients with rheumatoid art hritis (117), and it has also been 
suggested that C. perfringens alpha-toxin-mediated infl am-
matory respo nses play a role in ile it is and Crohn 's disea e 
(60). As described above, the e effects could be elicited , ·ia 
activation of the a rachidonic acid pathway with the produc-
tio n of thromboxanes and leukotri enes. It has also been 
reported tha t a lpha-toxin treatmenl of tissue cultures ca n 
confer selective advantages on transformed cells ( 125). Since 
C. perfringens is a member of I he normal inteslinal flora , and 
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since strains isolated from this source have been shown to 
have the potential to produce phospholipase C, it may be 
appropriate to examine the role of this enzyme in carcinomas 
of the gastrointcstinal tract in more detail. 
L. monocytogenes Phospholipases C 
L. monoeytogenes causes a variety of opportunistic infec-
tions in humans and animals. The pathogencsis of listeriosis 
involves a number of critical steps, including penetration of 
the gut mucosa, dissemination by the vascular system to 
other tissues, establishment of abscesses of infection, and, in 
some cases, passage across the blood-brain barrier to cause 
meningoencephalitis (98, 131, 132). A central feature of the 
pathogenic process is the ability of the organism to enter 
cells, replicate within them, and invade adjacent cells (131, 
132). This process allows the bacterium not only to establish 
foci of infection in tissues but also to evade host phagocyte-
killing mechanisms, even after uptake by these cells (98). It 
is known that listeriolysin 0 plays an important role in 
virulence of the bacterium by permitting escape from ph-
agolysosomes (52, 128), and recent evidence suggests that 
the phospholipases C are also important determinants of 
pathogenicity. The precise interpretation of many studies 
with PLc- mutants is made difficult because of the pleiotro-
pic effects of mutations in these genes (see above). Notwith-
standing these difficulties, several workers have constructed 
PLC-A - and PLc-a- mutants to attempt to elucidate the 
roles of these phospholipases; a pleA mutant of L. monocy-
togenes has been shown to be between 10-fold (101) and 
1,000-fold (23) less virulent in the mouse. The role of PLC-A 
may be most significant after inge tion by professional 
phagocytes; pleA mutants are apparently able to invade liver 
hepatocytes, replicate, and cause a progressive infection in 
mice which have been treated with monoclonal antibody 5C6 
(34). This antibody, which is specific for the type 3 comple-
ment receptor on these cells, prevents the accumulation of 
neutrophils at the site of infection (34). Additional evidence 
for the role of PLC-A in the evasion of phagocyte host 
defenses was reported by Camilli et al. (23), who showed 
that the pleA mutant was able to invade, but did not replicate 
in, mouse peritoneal macrophages. This was suggested to be 
the result of a reduced ability of the bacterium to escape 
from the host cell phagosome (23). It is possible that the 
enzyme removes GPI-anchored host cell membrane proteins 
and that this potentiates the membrane to the damaging 
effects of listeriolysin 0 (101) or PLC-B. 
To study the role of PLC-B in disea e, Vazquez-Boland et 
al. (179) constructed a pleB mutant of L. monocytogenes by 
the insertional inactivation of ple-B. By using in vitro tissue 
culture systems, it was demonstrated that PLC-B did not 
play an important role in the initial infection of J774 macro-
phages, and the pleB mutant was able to lyse the phago ome 
single membrane and escape into the cytoplasm as effec-
tively as the wild-type bacterium did. However, it appeared 
that later in the infection cycle, cell-to-cell spread of the pleB 
mutant was reduced and the bacteria accumulated in the 
resu ltant double membrane vacuolcs. In a plaque assay the 
size of plaques surrounding infected L2 or 3T3 fibroblasts 
wa significantly reduced with the pleB mutant. The role of 
PLC-8 may be to partially disrupt the cell-cell fusion vacu-
ole membrane, but complete disruption may be additionally 
dependent on the action of listcriolysin 0 or PLC-A . 
Thus, both PLC-A and PLC-B appear to play significant 
roles in the pathogcnesis of l isteriosis, perhaps by their 
actions on host cell phagolysosomc membranes. It is also 
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intriguing to speculate that phospholipascs C delivered from 
within infected cells may perturb host cell metabolism in the 
ways suggested above. 
P. aeruginosa Pho pholipases C 
A variety of diseases of humans and animals arc caused by 
P. aeruginosa. Flecccrot is an economically important dis-
ease of sheep; it is characterized by skin lesions and super-
ficial inflammation of the skin. Chin and Watts have reported 
that intradermal inoculation of a hemolytic phospholipase C 
is able to reproduce many of the symptoms of fleecerot in 
sheep (25). This phospholipase C may be similar to that 
reported to induce skin le ions in rabbits (90). In a tudy with 
highly purified PLC-H administered by an intravenous or an 
intraperitoneal route, the enzyme was shown to reproduce 
many of the effects seen with crude cu lture filtrate . Necro-
sis of the liver and kidney was observed, and it was 
concluded that PLC-H was the main lethal toxin produced 
by the bacterium (103). Although this route of administration 
may not be directly relevant to diseases caused by the 
bacterium, it seems likely that phospholipase C is produced 
by the bacterium in vivo. Patients with chronic P. aerugi-
nosa infections show high antibody titers against phospho-
lipase C (57), and sheep which have suffered repeated 
episodes of fleecerot are reported to contain high levels of 
circulating nonneutralizing antibody against phospholipase 
C (25). In the latter case it has therefore been suggested that 
a crude toxoid may not be able to induce protection against 
the disease. 
In humans, P. aeruginosa is an opportunistic pathogen, 
causing disease mainly in debilitated individuals. Lung in-
fections are particularly prevalent in cystic fibrosi patients 
and several lines of evidence indicate that the phospholi-
pases C are produced in vivo; not only has it been shown 
that clinical isolates from the lungs produce phospholipase C 
(12), but also it has been shown that phospholipase C is 
produced when the bacterium is grown in saline bronchial 
washings (90, 91) and that cystic fibrosis patients had circu-
lating antibody against phospholipase C (57). Skin infections 
with P. aemginosa are common in burn patients. and it has 
been shown that partially purified preparations of phospho-
lipase C can reproduce the pathologic changes associated 
with these infections (90, 102). The role of phospholipase C 
in urinary tract infections is not proven, but it may be 
significant that clinical isolates from this site produce higher 
levels of phospholipase C than those isolated from the lungs 
or from blood (12). Since production of the phospholipases C 
(and other proteins such as alkaline phosphatase) is induced 
under low phosphate conditions, it has been sugge ted that 
these enzymes function as part of a phosphate-scavenging 
pathway. Such a phosphate retrieval system ha been sug-
gested to be especially significant in vivo, because it has 
been shown that the level of free pho phate in era from 
humans infected with gram-negative pathogens is uboptimal 
for bacterial growth (184). However, this phosphate retrieval 
system may be of limited significance in P. aemginosa 
infections of the lungs in cystic fibrosis patients. since the 
lung surfactant is phosphate rich. In the lungs the phospho-
lipase C could act by degrading the phospholipid rich lung 
surfactant, enhancing the colonization of tissue. (151) and 
therefore contributing directly to the pathology of disease 
(90, 91). Also, the finding that phospholipascs C arc induced 
under environmental conditions of high osmolarity ( 145) may 
be especially significant in the lungs, where these conditions 
would be found. In this environment the phospholipase C 
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products may be convened into glycine betaine, which can 
be accumulated intracellularly as an osmoprotectant (79). In 
addi tio n to these direct effects of the enzymes on host tissues 
and bacterial metabolism, the abi lity of PLC-H to induce 
leukotricne and thromboxane release from host cells could 
partially explain the inflammatory responses seen in many P. 
aeruginosa infections (102). 
These proposed roles of the phospholipases C in pathoge-
nicity could be investigated by the construction of isogenic 
phospholipase C mutants. pieS mutants of strain PA01, 
grown under phosphate-limiting conditions, showed a 200-
fold increase in 50% lethal dose (LD50) compared with the 
wild-type strain in the mouse burn model (120). pieR mutants 
were also attenuated, and these strains produced greater 
amounts of phospholipase C and hemolysin (120), although 
the relative productio n of PLC-H, PLC-N, and the glycolipid 
hemoiysin was not reported . This apparent enigma indicates 
a role for the pieR gene products in virulence, or the 
regulation of virulence, but the observation that the pieS 
pieR mutant is even more attenuated (10,000-fold increase in 
LD50 compared with the wild type [120)) would suggest that 
the PLC-H does play a significant role in pathogenicity. 
S. aureus Beta-Toxin 
Considerable controversy has been evident over the past 
20 years concerning the toxic properties of beta-toxin, and 
interpretation of data has been made difficult because of the 
likely contamination of many beta-toxin preparations with 
other S. aureus toxins. An attempt to clarify the role of this 
toxin in disease was made by determining the pathogenicity 
of an hlb (beta-toxin-negative) mutant of S. aureus in the 
mouse mammary gland (21). The mutant was recovered in 
significantly lower numbers from the mammary gland, sug-
gesting that this toxin plays a role in virulence. The exact 
mechanism by which the beta-toxin elicits these effects is not 
clear, and, surprisingly, the toxin appeared to stimulate 
neutrophil influx into the site of infection, although increased 
neutrophil killing and epithelial-cell damage was attributed 
to the toxin {21). Epidemiological evidence also suggested 
that the beta-toxin played a significant role in pathogenicity, 
and selection for beta-toxin-producing strains seemed to 
occur in vivo (65). 
RESEARCH AND THERAPEUTIC APPLICATIONS OF 
PHOSPHOLIPASES C 
Vaccines 
Although phospholipases C have been implicated as viru-
lence determinants of several bacterial species, they have 
rarely been inves tigated as vaccine components. In many 
cases this may be because they have been perceived to play 
only a minor role in the disease process . One notable 
exception concerns the C. perfringens alpha-toxin. Because 
this toxin is thought to play a major role in the pathogenesis 
of gas gangrene , various workers have investigated the 
efficacy of a toxoid vaccine in protection against the disease. 
Kameyama et. al. {72) reported that a formaldehyde toxoid 
induced pro tection against C. pe1[ringens-mediated gas gan-
grene, but it is not clear whether the toxoid preparation also 
contai ned o ther C. pelfringens antigens. In a study with a 
mixed C. peifringens-C. septiewn-C. novyi toxoid, sheep 
were found to be almost totally protected (83 to 94 percent ) 
against gas gangrene, even up to 1 year pos tvaccination (20). 
The major problem with such a vaccine is that the time taken 
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for an an tibody response to develop is usually greatly in 
excess of the time taken for symptoms of the disease to 
appear (134}. Such a vaccine would, however, be of great 
use for at-risk groups, particularly if used prior to surgery on 
the lower limbs. 
Membrane Probes and Models for Eukaryotic 
Phospholipases C 
The bacterial phospholipases Care generally readily avail-
able in research quantities and have therefore attracted 
considerable attention as reagents not only for exploring the 
structure of cell membranes, particularly the structure of the 
erythrocyte membrane (2, 27, 49, 180), but also for some 
other novel applications. Some of these earlier studies may 
have yielded equivocal results because of the questionable 
purity of the enzymes used. The production of purified 
phospholipases C by recombinant DNA techniques may 
significantly enhance the utility of these reagents for future 
studies. 
The report that monoclonal antibodies raised against the 
B. cereus PC-PLC also reacted with human monocytic-cell 
phospholipase C (30) indicates that the B. cereus enzyme 
may serve as a readily available model for investigating 
eukaryotic phospholipases C. In particular, the reported 
crystal structure of the B. cereus protein should facilitate the 
design of novel enzyme inhibitors which could have signifi-
cant clinical utility. Various other workers have used the C. 
perfringens alpha-toxin to measure the potency of inhibitors 
of phospholipase C activity (190). Additionally, the bacterial 
phospholipases C could be used to investigate mechanisms 
by which the arachidonic acid pathway and PKC are acti-
vated in mammalian cells (73). In one report exemplifying 
this approach, Parkinson (125) used the C. perfringens 
alpha-toxin to stimulate PKC activity in cells and mimic the 
effect of phorbol ester tumor promoters on cells. 
lmmunotoxins 
AJmost all of the immunotoxios evaluated to date have 
been generated by fusing antibodies with diphtheria toxin, 
ricin, or Pseudomonas exotoxin A. These immunotoxins 
rely on the delivery of the active fragment of the toxin into 
target cells, often an inefficient process, and the subsequent 
inhibition of protein synthesis. The clinical utility of these 
immunotoxins has so far been limited. The fusion of anti-
body with a membrane active toxin could yield an immuno-
toxin with enhanced properties, but the chemical coupling of 
polyclo nal antibody with the C. perfringens alpha-toxin has 
yielded disappointing results (109). Chovnick et al. (26) have 
reported the generation of a hybrid anti-Tac-C. peifringens-
alpha-toxin antibody by fusing cpa with the 5' end of the 
segment encoding VHCH1 from the anti-Tac heavy chain. 
The hybrid toxin retained approximately 50% of the hemo-
lytic activity and retained the ability to recognize the T-cell 
IL-2 receptor. Inhibition of protein synthesis was used to 
measure the activity of the immunotoxin, and the 50% 
inhibitory concentration was found to be 1.8 ng!ml when 
measured against cells expressing the interleukin-2 receptor. 
This potency compared favorably with an anti-Tac-Pseudo-
monas exotoxin A antibody. The utility of such immunotox-
ins remains to be determined, and it is not yet clear whether 
nonspecific hemolytic activity of the alpha-toxin immuno-
toxin in vivo will prove problematic. 
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CONCLUSIONS 
The considerable resurgence of interest in the bacterial 
phospholipases C over recent years can be attributed to 
several factors. Many of the newly characterized enzymes 
such as the L. monocytogenes PLC-A and PLC-B are 
thought to play important roles in the disease process, and 
this has stimulated new interest in phospholipases C such as 
the C. perfringens alpha-toxin which were already thought to 
be determinants of pathogenicity. These studies have re-
vealed that phospholipases C may have varied roles in the 
disease process, ranging from promoting the intracellular 
spread of L. monocytogenes to eliciting toxic and lethal 
effects in C. perfringens-mediated gas gangrene. In general, 
there is a large body of circumstantial data indicating the 
roles of these enzymes in the pathogenesis of disease but 
precious little unambiguous data. In addition, many previous 
studies may have been colored by simply assessing whether 
a phospholipase C was toxic and judging its importance in 
pathogenicity on this basis. The use of defined mutants may 
further clarify the roles of these enzymes in disease, but the 
results of such studies must be interpreted with caution 
because of the complex pleiotropic effects that may be 
associated with such gene deletions . Thus the examination 
of mechanisms of gene regulation must proceed in tandem 
with such gene deletion studies, to enable valid conclusions 
to be drawn from these experiments. 
The finding that eukaryotic phospholipases C can play an 
important role in the regulation of cell metabolism, via the 
generation of secondary messengers, suggested that the 
bacterial phospholipases C may cause similar effects. h is 
apparent that some bacterial phospholipases C elicit toxic 
effects by mimicking the actions of the eukaryotic enzymes 
on host cells. The combined effects on arachidonic acid 
metabolite levels and diacyglycerol and inositol triphosphate 
levels may be to restrict the extent of the immune response 
either by limiting the blood supply to these tissues or by 
"confusing" the phagocytic cells. An additional area which 
merits attention is the possible contribution of bacterial 
phospholipases C to the transformation of eukaryotic cells. 
This effect may be due to the ability of these enzymes to 
activate PKC and may be especially relevant in chronic 
infections (e.g., caused by P. aeruginosa in the lungs) or 
commensal states (e.g., C. peifringens in the gut). 
In spite of the advances over the past decade, the molec-
ular mechanisms by whic h some bacterial phospholipases C 
interact with membranes is till not clear. Much of our 
knowledge concerning the interaction of phospholipases C 
with substrates has been gained by the use of chemically 
modified substratcs, but we cannot unequivocally state why 
some phospholipases C are potent lethal toxins whereas 
others arc apparently non lethal. The comparison of deduced 
amino acid sequences of several phospholipases C has 
provided a basis for examining these differences because 
structurally related enzymes with different tox.icities have 
now been identified. To examine these differences at a mo-
lecular level will require the crystallization of these proteins 
alone and in the presence of substrates. Only then will we be 
able to examine substrate specificities in a rational manner 
and perhaps design enzymes with novel properties. Even at 
this stage, the extrapolation to the interaction of these en-
zymes with membranes will prove challenging, and greater 
emphasis should be placed on the use of synthetic bilayers . 
Many of the studies to date have considered the effects of 
externally applied phospholipases C, but since many phos-
pholipase C-producing bacteria are now known to be intra-
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cellular pathogens, this may not be the most appropriate 
route for investigating the e ffects of these enzymes. The 
prokaryotic enzymes arc generally available in research 
quantities, and the reported antigenic c ross-reactivity o f the 
B. cereus PC-PLC with eukaryotic phospholipase C suggests 
that the bacterial enzyme may serve as a useful model for 
examining eukaryotic enzyme structure-function relation-
ships. In the longer term, the rational design of enzyme 
inhibitors or vaccines with potential therapeu tic use will 
become feasible, and this mus t surely be lhc goal of many 
microbiologists. Such studies will provide an exciting chal-
lenge over the next decade. 
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1. INTRODUCTION 
IPhospholipids are key components of all eukaryotic bi layer 
membranes and it is commonly assumed that these molecules 
serve a scaffolding function for membrane proteins and sep-
arate the intracellular and extracellular em·ironments. 1ore 
recently we have become aware of the role of membrane 
phospholipids and their hydrolytic products in ce ll signalling 
systems (Pelech and \lance 1989; Exton 1990). Membrane 
phospholipids show structura l variation in two ways. T he 
water soluble head group (such as phosphorylcholi ne or phos-
phorylinositol) is linked to a hydrocarbon tail of varying 
length and saturation. Phospholipids with different structures 
lay different roles in cell membranes and in cell s ignalling. 
or example, the outer leaflet of most mammalian cell mem-
ranes is rich in phosphatidy lcholine and sphingomyelin 
vhereas the inner leaflet is rich in phosphatidylenthanolamine 
nd phosphatidylserine (Verkleij e/ al. 1973). Phospha-
idylinosirol sen ·es as a substrare for the intracellular gen-
ration of inositol triphosphate an important signa lling 
olecule, whilst the diac~ lglycerol rail of membrane phos-
holipids serves as a substrate for signalling molecules such as 
eukotr ienes, thromboxancs and prostaglandi ns (Samuelsson 
1983). Gi1·cn these roles, and the 11·idesprcad distribution of 
hospholipids, it is not surprising that ;1 11 ide 1 aricty of 
acteria ha1·c cvoh·ed enz~ mes capable of h~·drol~ sing phos-
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pholipids (Mollby 1978; Titballl 993). T hese phospholipases 
can be grouped according to functional or structural simi-
larities. Knowledge of the site of cleavage of phospholipids 
(Fig. 1) allows the enzymes to be assigned to one of four main 
groups (phospholipases C, 0 , A1 or A2) and of these the 
bacterial phospholipases C are the best characterized group 
(Mollby 1978; Titball 1993). Although the definition of a 
bacterial toxin is increasingly difficu lt, it is generally accepted 
that many of these phospholipases are toxins. Indeed, the 
first bacterial toxin shown to be an enzyme was the ~-toxin 
of Clostridium perji·ingens (MacFarlane and Knight 1941) and 
this finding stimulated extensive interest in this group of 
enzymes during the 1950s and 1960s. It is only recently that 
interest in this group of enzymes has been rekindled. It is the 
advances in our knowledge of the phospholipases C are the 
subject of the remainder of this paper. 
2 . THE PHOSPHOLIPASES C 
Phospholipases C are produced by a wide 1·ariety of patho-
genic and nonpathogen ic bacteria although most attention 
has been focused on the enzymes produced by bacteria which 
are pathogens of man (Titball 1993; Songer 1997). These 
enzymes can be grouped according ro the nature of the pre-
ferred substratc (Fig. 2) and indil'idual enzymes show 1·arying 
abi liti es to hydrol yse other phospholipids. For example, the 
phosphatidylinositol hydrolysing enzymes show a marked 
substrate spccifici ty whereas the phosphatidylcholine pre-
ferring enzymes arc often able to hydrolyse other substrates, 
1285 R.W. TITBALL 
CH3 
I(!) 






0 e 1 ~ Phospholipase 0 
0 - p =0 6... Phospholipase C 
I 
CH2-CH-CH 
I I 2 







0 = C C = O 
Zinc- Gram-negative 
metallophospholipases C phospholipases C 
~--------------~ 
Clostridium perlnngens alpha-to>On 
Clostridium novyi gamma-toxin 
Clostfldlum blfermentans PLC 
Bacillus cereus PC-PLC 
Usleria monocytogenes PC-PLC 
Psuedomonas aerug•nosa PLC·H 
Psuedomonas aerug1nosa PLC-N 
Bacillus pseudomalle• PLC 
Baollus Mallei PLC 
M. tuberculosis M peA 
M tuberetJIOSIS MpcB 
~/ ____________ ~/ 
Staphylococcus aureus beta-toxin 
Bacillus cereus sphingomyelmase [/ 
'--------~ 
~/ ___ ----('/ 
Clostridium novyi PI-PLC 
Bacillus cereus PI-PLC 
Bacillus thuringiensts PI-PLC 
Listeria monocytogenes PI-PLC V 
Fig. 1 Sire of cleavage of 
phosparidylcholine by 
phospholipases At. A2, C and D 
Fig. 2 Grouping uf phosphulipases C. 
according tu amino acid sequence 
similarity 
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albeit with lower efficienc~ . Q,·er the past decade the genes 
encoding some of these phospholipases have been cloned and 
the amino acid sequences of the encoded proteins ha\'C been 
deduced (Titball 1993). The grouping of the phospholipascs 
C according to their amino acid sequence similarity reveals 
that related enzymes also have similar substratc specificitics. 
Three groups of enzymes are re\'ealed by this analysis; many 
of the enzymes which prefer phosphatidyleholine as the sub-
strate are also able to hydrolyse other phospholipids with 
lower efficiencies. In contrast, the sphingomyelin or phos-
phatidylinositol preferring enzymes have a narrow substratc 
specificiry. On the basis of amino acid sequence similarit~ 
the phosphatidyleholine preferring enzymes can be further 
di,·ided into two groups which reflect their Gram-negati,·c 
or Gram-positi,·e origins (Fig. 2). 
3 . ROLES OF PHOSPHOLIPASES C IN THE 
PATHOGENESlS OF DISEASE 
3.1 Invasion and growth 
The invasion of host tissues, and subsequent growth requires 
a variety of somatic and soluble bacterial gene products. 
Whilst it would be unrealistic to propose that phospholipases 
play a universal role in the imasion of and growth in host 
tissues, it is clear that phospholipases do play important and 
sometimes key roles in the establishment of many infections. 
Gas gangrene occurs when Cl. perfringens is able to replicate 
in damaged and anoxic tissues (McNee and Dunn 1917; 
Willis I 969). The initial focus of infection, which is often 
within a deep wound which has also damaged the blood 
supply, is able to develop to rapidly involve an entire limb 
(Me ee and Ounn 1917). To allow the growth of bacteria 
the tissue surrounding the focus of infection must become 
anoxic. In the mouse model of disease the affected limb 
becomes swollen and necrotic with extensive tissue destruc-
tion and muscle necrosis (A wad et al. 1995). Eighty years 
ago it was suggested that a soluble factor produced by Cl. 
perfringms was responsible for these effects (Me cc and 
Dunn 1917). Several early studies showed that a for-
maldehyde toxoid of the ::~-toxin purified from Cl. perfringms 
was able to induce protection against gas gangrene (Boyd 
et al. 1972; Kameyama et al. 1975) but it is likely that these 
preparations also contained small quantities of other toxoided 
proteins making the interpretation of these studies difficult. 
Two recent im·estigations ha,•e demonstrated that the soluble 
factor proposed by Me lee and Ounn ( 19 17) is the ~-toxin. 
Immunization with a genetically engineered o:-toxoid, isolated 
from Eschendua coli, was shown to induce protection against 
gas gangrene in the mouse model without the appearance of 
any signs of tissue damage (\ illiamson and Titball 1993). 
The role of the ~-toxin in promoting im·asion of host tissue~ 
was also confirmed by constructing a defined o:-toxin (plc) 
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mutant from a full~ ,·indent strain of Cl. pe1:{rmgem. The plc 
mutant \\·as not able to c.tusc extensi,·c tissue damage and 
necrosis after inoculation into the hind limbs of mice (.'\. \1 ad 
el al. 1995). The mechanism by 1rhich the a- toxin facilitates 
bacterial growth has not been determined. Howe,·er, it is 
likely that widespread cell damage releases nutrients for bac-
terial growth. In addition, the 7.-toxin is known to cause 
contraction of smooth muscle (Fujii and Sakurai 1989) and 
platelet aggregation (Sugahara eta/. 1976) both of \\·hich 
would reduce the blood supply to affected tissues. 
Phospholipa es C also play important roles in the patho-
genesis of disease caused by intracellular pathogens, especially 
in promoting the e cape of bacteria from phagosomes. This 
possibility is best illustrated by considering the roles of the 
phospholipases C (PI-PLC encoded by pleA and PC-PLC 
encoded by pleB) produced by Listeria monocytogenes (Cam-
illi eta/. 1991; \ ·azquez-Boland eta/. 1992; Smith eta/. 1995). 
Defined pleA and pleB mutants ha1·e been constructed and 
both mutants ha,·e been shown to be attenuated in the mouse 
(Camilli et al. 1991; \'azquez-Boland et al. 1992; Smith elfil. 
1995). The roles of the e enzymes in colonization and growth 
have been investigated u ing tissue culture systems. Although 
the pleA mutant was able to inrade mouse macrophages, it 
was less efficient in escaping from the phagosome and did 
not replicate (Camilli et al. 1991; Smith et al. I 995). In 
contrast, the pleB mutant was still able to escape from the 
phagosome but later in the infection cycle cell-to-cell spread 
of the bacteria was reduced and the bacteria accumulated 
in double membrane ,·acuoles (\'azquez-Boland et al. 1992; 
Smith et al. 1995). Although the individual pleA or pleB 
mutants were two- and 20-fold, respectively, less virulent in 
mice, a double mutant was 500-fold less virulent suggesting 
that these enz~"mes ha,·e overlapping functions during the 
cour e of infection (Smith et a/. 1995). Therefore, it seems 
likely that the Listeria monocytogenes phospholipases C, in 
conjunction with other membrane damaging toxins such as 
listerio lysin 0, play important roles in allowing the patho-
gene is of listeriosis. 
Finally it is worth considering that many of the Gram-
negati,·e bacteria " ·hich produce phospholipases are res-
piratory tract pathogen and production of the Pseudomouns 
aerugiuosa phospholipase C does occur iu vh:o (Granstrom 
et al. 198-f). The effects of phospholipases C in the lung might 
be twofold. First, the lun g surfactant is rich in phos-
phatidylcholine and degradation of the surfactant might allow 
colonization of tissues. econd, the products of phospholipid 
hydrolysis can be comcrrcd to glycine betaine which accumu-
lates "ithin the bacterial cell and IS thought to protect the 
bacterial cell from conditions of high osmolarity found in the 
lung (Landfald and trom 1986; Shortridge et al. 1992). 
The recent identification of tandemly organized genes in 
Mycobacterium tuberculosis Uohansen eta!. 1996), which 
wou ld encode homologues of the Ps. aerugiuosa phos-
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pholipases C ll'ill open nell' a' enues of research "ith this 
pathogen . 
3.2 Evasion of host defence mechanisms 
For many ~cars it had been kno"·n that the 1issucs sur-
rounding the focu~ of infecrion "ith Cl. f1t'l/i-iugens \\ ere 
de,·oid of leukocytes ll'hich instead ap peared ro accumulate 
at the border bet\\ een healthy and diseased tissue {Bryant 
elol. 1993). This is in marked contrast to other bacterial 
infections of soft tissue "here a massi,·e influx of phagocytic 
cells into dise:tsed tissue occurs. The role of the 7.-to.xin in 
this process has been elegantly illustrated using a plc mutant 
of Cl. pet:friugt'lls. :-\fter challenge of mice ll'ith the plc mutant, 
influx of leukocytes ll'as obsen·ed (Ste,·ens elol. 1997) indi-
cating that the 7.-to.\in was responsible for the lack of lcu-
kocyte infiltration. :\ number of pos ibilities might e:>..plain 
this effect. The 7.-toxin is knoll'n to be cause death of leu-
kocytes in cell culture (Titball e/ al. 1993) although it is not 
kno\l'n " ·hether this is due to direct cell lysis or due ro the 
fatal perturbation of leukocyte metabolism. Howe,·er, the 
accumulation of 1eukocytes at the border between diseased 
and healthy tissues suggested that the trafficking of the leu-
kocytes had been affected. This altered trafficking might arise 
from altered patterns ofleukotriene release (Fujii and Sakurai 
1989; Diener e1al. 1991), IL8 and P.-\F production and the 
upregulation of IC.-\.\1 and ECA!\1 markers on endothelial 
cells (Bryant and Stevens 1996; SteYens el al. 1997) in 
response to the 7.-toxi n. 
3.3 Damage to the host 
The ability of phospholipases C to cause cell lysis as a result 
of damage to the cell membrane is \\'ell documented and 
haemolysis of erythrocytes in the laboratory is often used as 
a measure of thi effect. 1-lowe,·er, the large-sca le haemolysis 
of erythrocyte is not a feature of disease involYing phos-
pholipase C producing bacteria. The phospholipases C ca n 
be grouped according to their ability to cause haemolysi "' 
t"ilro (Titball I 993). Whether lysi. of host cells other than 
eryrthocyres occurs iu l"i<·o is an unreso h·ed question . 
Ho\\·ever, it is kno" n thar hydrolysis of membrane pho~­
pholipids by phospholipases C leads to the activation euka-
ryotic cell metabolism "hich resu lts in inflammator~ 
responses. \Vhil. t these responses are <timed at defending the 
host against the pathogen, an exaggera ted response is like!~ 
robe damaging to the host. The ceramide product ofsphingo-
m~ cl in h~ drol~ is can induce signals "hi eh mimic the effect 
of T F o: (Raines <'1111. I 993). The Cl. peji-iugms 7.-toxin 
and Ps. aerugiuoso Plc-H ha\c been ~hown to activate the 
arachidon ic acid cascade in eukar~ otic cells (F ujii and Sakurai 
1989; Gustafson cl al. 1990; .\lc~crs and Berk 1990) leading 
to the production of leukot ricnes, thromboxanes and pro-
staglandins. The production of these mediators might be 
especiall~ important in pulmonar~ infections caused b~ Ps. 
aerugiuosa, where inOammation is one of the hallmarks of 
disease. The exact mechanism by" hich 1his acti,·ation occurs 
is not clear. I lo\\·e, er, the d iac~·gl~ cerol product of pho~­
pholipid hydrolysis can be con\'erted into arachidonic acid 
"hich is a substrate for the arachidonic acid cascade (Fig. J). 
The diacylglycerol might also sene as an intracellular me . -
cnger, and the acti,·:nion of protein kinase C b~ the 7.-to.xin 
has been attributed to this mechanism .. -\et iYated protein 
kinase C is known to acti,·ate endogenous (membrane bound) 
eukaryotic phospholipases :-\.1 and phospatidylinositol phos-
pholipases which generate diacy1glycerol and inositol tri-
phosphate. Inositol triphosphate is kno"·n ro act as a 
secondary mes. enger, further acti\ating protein kinase C and 
leading ro the release of intracellular calcium with the acti-
,·ation of calcium gates. The contraction of isolated frog 
muscle treated \\·ith 7.-tuxin (Boethius e/ al. 1973) and the 
cardiotoxic effects (Asmuth t'llll. 1995) of 7.- tOxin might be 
attributed to this mechanism. 
The ability of bacterial phospholipa es C to cause acti-
vation of eukaryotic membrane bound phospholipases, with 
a resultant positive feedback cascade, has been demonstrated 
in the case of the Cl. perfriugeus 7.-toxin ( akurai et al. 1993, 
1994). It is pos ible that other bacterial phospholipases are 
able to activate host cell phospholipases in this manner and 
this would certainly explain why these enzymes ha\'e such 
profound effect on a \'ariety of host tissues. 
4. INTERACTION OF PHOSPHOLIPASES C 
WITH MEMBRANE PHOSPHOLIPIDS 
4.1 Relationship between membrane lateral 
pressure and hydrolysis of membrane phospholipids 
The event which is central to most of the effects outlined 
abo,·e is the interaction of the pho pholipase C with euka-
ryotic cell membrane phospholipids. Insight into the molec-
ular basis of this interaction has been obtained in several ways. 
lt might be expected that the interaction of a phospholipase C 
requires the partial insertion of the enzyme into the 
membrane. s ing phosphatid~ lcholine monola~ ers (Vloreau 
e/ al. 198H) it was shown Lhat at normal ph~ siological mem-
brane lateral pressures (31 - 25 m l m 1) only haemolytic 
enzymes were able to h~ drol~ se phospholipids "hereas if the 
latera l pressure was reduced the non-haemal~ tic enz~ mes 
were able to hydrolyse phospholipid (.\ lollb~ 1978). This 
finding suggests that the enz~ me must become inserted into 
the membrane for phospholipid h~drol)sis but it is not the 
on I) explanation for the haemol~ tic properties of some phos-
pholipascs C. Other workers ha,·e siHl\1 n that the hydrolysis 
or membrane phosphatidylcholine and ~phingomyelin is 
necessar~ fur haemol~ sis and th e finding that the non-
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Fig. 3 Effects of Clostridium P<'l:fi"ingens 
::>:-toxin on cukarotic cell metabolism 
haemolytic Bacillus cercus PC-PL C and sphingomyelinase arc 
together able to form a haemolytic complc:~. (cerolysin A-B, 
produce both phospholipase C and sphingomyelinase actil·i-
ties Oohansen t'lal. 1996). 
ilmorc et al. 1989) lend suppon to rh is suggestion. In 
onsidering this hypothe is it is 11 orth noting that the head 
roups of phosphatid~ kholine and sphingom~ elin are identi-
·al the difference bet11ecn these molecules I~ ing in the hydro-
arbon tails. 
The suggestion that cnz~ mcs capable of h~ drolysing both 
hospharid~ !choline and sphing-omyelin arc membrane 
tctiYe, .md pia~ imporlant role~ in the parhogcnesis o f disease 
s borne out b~ sc1era l other studies. Of the t110 "related 
' nzymcs produced b~ Ps. at•rugmosa (Ostroff ,., al. 1990), on I ~ 
I ell is ;tblc to h~ tlrul) se both ~ubst rates and this enzyme is 
boug ht tu pl.t~ an important role in rh ~: pathogenesis of 
iscasc. In m~ cobactcrial species, the most 1 indent strains 
4.2 Structures of zinc metallophospholipases C and 
membrane phospholipid hydrolysis 
The zi nc-mctallophospholipasc C group includes haemol~ tic 
anti nonhaemolytic enzymes ll"hich sho11 tliffering abilities 
to hydrolyse sphingomyelin (Table 1 ). :\n alignmenr of the 
deduced ami nu acid sequences of the~c cnz~ mcs re1 cals that 
rcsiducs I 250 sho11 sequence similarit~ (30-60°o). Ho11-
e1er, the Cl. P<'lfi·iugens ~-toxin, C. lllli:J'I i' wxin and Cl. 
/Jifi•rmmtans phospholipase C possess an addition:1 l 120 amino 
acid C-terminal domain (Fig. -1-). The presence of this domain 
can be co rrclatetl ll"ith the abilit~ of the enzyme to cause 
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Table 1 Properties of the 
zincmctallophospholipases C 
Enzyme 
Subsrrate Specificiry Lethality 
PC SPII Haemolysis (LD5fl < I trg) 
Clostridium perFiup,t'll.< !:I.- toxin 
Clostridium rwq•t )'-toxin 
Clostridium /Jifermrullms PLC 
Bartllus rem1.1 PC-PLC 














Clostridium novyi gamma·tOXIn 
Clostnd1um bifermentans PLC 
Bacillus cereus PC·PLC 
usrens monocyrogenes PLC·B 
Fig. 4 Schematic respresenrarion of an alignment of the deduced 
amino acid sequences of the zincmctallophospholipascs C 
haemolysis but not necessarily with the ability of the enzyme 
to hydrolyse sphingomyelin. T o examine the relationship 
between structure and function the indi,•idual - and G-
domains of the a- toxin were produced in E. coli, purified 
and their properties determined. The N-domain retained 
phosphatidylcholine hydrolysing activity but showed reduced 
sphingomyelinase acti ,·ity and was no longer haemolytic or 
toxic (Titball et al. 1991 ). The isolated C-domain did not 
possess any of these activities but mixing the two domains 
together resulted in the partial restoration (5%) of the hae-
molytic activity of the holotoxin (Titball et al. 1993). Similar 
resu lts have been obtained, measuring the cytolytic effects of 
the two domains on CHO cells (Fig. S). 
4.3 Properties of hybrid phospholipases C 
The amino acid sequence of the C-domain of the cc- toxin 
shows 30% identity (Tit ball et al. 1991) with the '- terminal 
sequence of a eukaryotic involved in the arach idonic acid 
Clostnd•um perfnngens 1r===r1 ::=, ='1'10 
u~toxm 
PC SPH HL Y LET 
+ + + + 
+ 
Fig. 5 Properties of Clo.<tmluun per/imp,rns alpha-toxin, Cpa1 H'l or 
Cpam 1;,1 
cascade (human arachidonate- 5-lipoxygenase; HAS 1). The 
H AS I is able to recognize arachidonic acid which , as outlined 
above, is a derivatiYe of the hyd rocarbon tail of phospho-
glycerides. This obsen·ation has lead to the suggestion that 
the similar regions of these proteins are involved in the re-
cognition of fatty acyl chains. In contrast, the C-domain of the 
C. bifermentans phospholi pase C does not show significant 
amino acid sequence homology with the HASl enzyme. To 
determine whether the functions of the Cl. perfringens and 
Cl. bifermentans C-domains were different we constructed 
hybrid proteins (Fig. 6). These hybrid proteins have been 
expressed in E. coli under the control of the cpa promoter . 
Protein isolated from the periplasmic space of the bacteria 
was tested for phosphatidylcholine phospholipase C activity 
and haemolytic acti,·ity against mouse erythrocytes. The 
resul ts, expressed as the ratio of haemolytic activity to phos-
phatidylcholine phospholipase C activity (HU/EYU), indi-
cated that the functions of the two domains are not identical. 
When the Cl. perfringens C-domain replaced the Cl. bifer-
mcntans C-domain the HU/EYU ratio increased . A reciprocal 
effect was seen when the Cl. bifermentans C-domain was fused 
with the Cl. perjri11gens -domain (Fig. 7). 
100 • • • 
90 







0 C'i g 8 .... ~ ~ . . ~ ';' w w w w 8 8 ~ ~ 
Dilution 
Fig. 6 Effect of !X-toxin, Cpa1 z•• or Cpam 170 on tissue culture 
cell viabi lit ~ 
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Clostridium perfrmgens alpha-toxin ~------'------" 
Clostridium bifermentans PLC 
Hybnd NACB 
Hybrid NBCA f .I ~ ! 0 
Fig. 7 Consrruction of hybrid Clostndium perfriugeus/Ciosrrulwm 
bl}ermmtans phospholipascs C 
5 . MOLECULAR STRUCTURE OF THE 
CLOSTRIDIUM PERFRINGENS ex -TOXIN 
An understanding of the interaction of the phospholipases C 
with membrane phospholipids will ultimately be dependant 
on knowledge of the molecular structure of the enzymes. The 
crystal structure of the B. cereus PC-PLC revealed that the 
protein consisted of seven helices which form a twisted barrel 
structure with three zinc ions co-ordinated within the active 
ite cleft. (Hough et al. 1989). This data can be used to 
construct a model of the -domain of the Cl. perfringens ex-
toxin (Fig. 8). Although this models reveals an overall struc-
tural similarity with the B. cereus PC-PLC, there are some 
potentially important differences; helix H2 is absent from the 
Cl. perfringens -domain and the loop below the active site, 
which links the B and C helices, is longer in the 1 -domain 
model. It is possible that this loop in the a-toxin is involved 
in recognition or membrane phospholipids or that it interacts 
with the C-domain. 
The construction of a model of the C-domain, is difficult 
because crystal structures of homologous proteins have not 











Fig. 8 R:nio of haemolytic to phosphatidylcholinc phospholipase 
C activity of hybrid proteins composed from the 1 -and C- domains 
of the Clostrulium pe1ji·i11gens :x-toxin and Clostndium bifermellfiiiiS 
phospholipase C 
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protein, we are determining the crystal structure of the :t-
toxin. We have isolated the ~-toxin from £. coli expressing 
the cloned cpa gene which was originally derived from Cl. 
pe1ji-ingens strains NCTC8237 or CER89 H3. The proteins 
have been purified using ion exchange chromatography (Tit-
ball eta/. 1989; Basak eta!. 1994) with yields of20-30 mg of 
pure protein from each li tre of culture. The proteins have 
been crysta llised in several forms which diffract to resolution 
of up to 1·7 A. Greater structural resolution is obtained with 
crystals derived from the strain CER891-+3 ex-toxin, which 
might be related to the increased resistance of this a-toxin 
to proteolytic degradation (Ginter et n/. 1996). Preliminary 
studies confirm that the protein is composed from two 
domains, with the C-domr~in located rtdjacently to the puta-
tive active site in the -domain. This configuration would 
allow the extended loop in the -domain to interact with the 
C-domain. 
6. SUM MARY 
The phospholipases are a diverse group of enzymes, produced 
by a variety of Gram-positive and Gram-negative bacteria. 
The roles of these enzymes in the pathogenesis of infectious 
disease is equally diverse. It is only recently that molecular 
genetic approaches have allowed data to be obtained which 
indicates the role of these enzymes in the disease process. In 
the case of some pathogens phospholipases play an overriding 
role in disease. Roles for these enzymes have been demon-
sn·ated in the pathogenesis of disease caused by extracellular 
and intracellular pathogens and by disease caused by patho-
gens which enter via the respiratory tract, the intestinal tract 
or after traumatic injury. Some of the mechanisms by which 
phospholipases C affect tissues in vitro or ex vivo are under-
stood but, in the main, the mechanisms by which pho-
spholipases C affect tissues in vivo are not known. 
A key event, which can determine the extent of involve-
ment of phospholipases in the disease process, is the inter-
action of the enzyme with phospholipids in eukaryotic cell 
membranes. Whilst progress has been made in understanding 
the molecular basis of these interactions, the process is far 
from understood. Two theories attempt to explain the reasons 
why only ome phospholipases C are membrane active. In 
general, the membrane active enzymes are able to hydrolyse 
both phosphatidylcholine and sphingomyelin and appear to 
have mechanisms which allow them to interact with mem-
brane phospholipids. The structural differences between 
phosphatidylcholine and sphingomyelin lie within the fatty 
acyl chain/ ester bond region which would be partially embed-
ded in the membrane bilayer. Therefore, then:: may be a 
common explanation for membrane interaction and recog-
nition of botl1 pho pholipid types. 
The value of this information will be several fold. The 
demonstration of the role of these enzymes in disease will 
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Fig. 9 Crystal structure of the B. ureus PC-PC (:\ ) anti molecular model of the N-domain of the a-toxin (B) 
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allow the development of \'accines or therapeutics which 
block the effects of these enzymes. In this context it is worth 
bearing in mind t hat eukaryotic phospholipases C, 11 hich play 
key roles in many inflammatory and autoimmune diseases, 
are the subject of intense study by the pharmaceutical indus-
try. ome of the bacterial toxins are potent cytotoxic agents 
nd this has encouraged some workers to explore the possi-
ility that immunoroxins can be de1 eloped (Chovn ick et al. 
1991 ). Purified recombinant phospholipases C will con tinue 
o be used in the study of cell membranes, and the increasing 
umbers of enzymes with different substrate specilicities will 
nhance their application . 
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Membrane~damaging and cytotoxic 
phospholipases 
Richard W Titball 
SUBSTRATES FOR 
PHOSPHOLIP ASES 
Phospholipids are ubiquitous in biological systems. 
They are key components of biological membranes, and 
derivatives of phospholipids such as diacylglycerol 
and inositol triphosphates serve as messengers within 
cells (Berridge, 1987; Exton, 1990). The generalized 
structure of a glycerolphospholipid (Figure 15.1) 
reveals a polar head group linked via a phosphate 
group and a glycerol backbone to non-polar hydro-
carbon (fatty acyl) tails. The nature of the head group 
can be used to categorize different types of phos-
pholipid. For example, the choline group is present in 
phosphatidylcholine, whilst phosphatidylinositol has 
an inositol sugar head group. 
Sphingolipids (such as sphingomyelin) contain a 
modified glycerol backbone Linked to fatty acyl tails, 
and this entire moiety is called a ceramide. Sphingo-
myelin usually contains a choline head group. 
Within these broad groups, the hydrocarbon tails 
vary with respect to both their length and degree of sat-
uration. The non-polar ta il groups mean that phos-
pholipids a re sparingly soluble in water and the 
majority of phospholipid in eukaryotes is found in cell 
membranes, where it can adopt a bilayer configuration, 
with the tail groups embedded in the membrane and 
the polar head groups exposed on the surface. 
Phospholipases hydrolyse phospholipids, and the 
location of the hydrolysed bond is used to character-
3 10 
ize phospholipases as types A1, A21 C or 0 (Figure 15.1: 
PLA1, PLA21 PLC or PLO; Mollby, 1978). A wide variety 
of assays can be used to measure the activity of these 
enzymes. Colorimetric assays have been described that 
use water-soluble phospholipid derivatives such asp-
nitrophenolphosphorylcholine (pNPPC), in which the 
phosphorylcholine head group is linked to p-nitro-
phenol. (Kurioka and Matsuda, 1976). Since these sub-
strates lack the glycerol backbo ne and the fatty acyl 
tails, they can only serve as substrates for PLCs and 
PLDs. Other solution phase assays use phospholipid 
that has been emulsified with detergen ts to generate 
micelles (Waite, 1987) or use lipoproteins such as egg-
yolk lipoprotein (Waite, 1987). 
All of these assay systems are useful for measuring 
phospholipase activity, but they reveal little about 
the ways in which phospholipases interact with 
membrane phospholipids. Artificial membranes, such 
as monomolecular films, or Liposomes, allow studies 
where the form of the phospholipid more closely 
approximates the cell membrane. However, it is clear 
that even these systems do not faithfully mimic the cell 
membrane, since phospholipases that are active in 
these systems may be inactive towards eukaryotic cells. 
This might be for several reasons; Living cell membranes 
are complex mixtures of different phospholipids and 
proteins, and are able to repair limited damage. In 
addition, there is evidence that cellular metabolism is 
modulated in phospholipase-treated cells and that 
gross effects on cell membranes (e.g. cell lysis) are only 
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FIGURE 15.1 Generalized structure of phospholipids. The entire phosphatidylcholine molecule is shown, along with examples of the dif-
ferences that are seen in other types of phospholipids. Inositol, serine, glycerol or ethanolamine head groups are found in other types of 
phospholipid. In sphingomyeiins, the backbone includes a (CH012, but the CH3 fatty acyl chain is termed a ceramide, and the head group is 
usually choline. In all phospholipids, the fatty acyl tails are typically 16-18 carbon chain lengths, but may be shorter or longer and may be 
unsaturated. The sites of phospholipid cleavage by PLA1, PLA:z, PLC or PLO enzymes are shown arrowed. 
one manifestation of the effect of the enzyme on the 
cell. The eukaryotic cell type most frequently used to 
measure the activity of phospholipases towards 
membranes is the erythrocyte (Mollby, 1978; TitbaU, 
1993), because of its availability and the ease with which 
cell lysis can be measured. 
These different assay systems are of more than 
incidental significance: they can reveal the mechanisms 
by which different enzymes recognize and hydrolyse 
different form s of phospholipids. 
PHOSPHOLIPASES PRODUCED 
BY BACTERIA 
The production of phospholipases by a va riety of 
bacterial species has been reported and many of these 
bacteria are pathogens of humans or of animals. 
These bacterial enzymes can be grouped not only 
according to the site of cleavage of phospholipids (i.e. 
as PLA, PLC or PLO enzymes), but also according to 
the preferred substra te (Table 15.1). 
Perhaps not surprisingly, for those proteins whose 
deduced amino acids sequences are known, this 
classification also leads to the grouping of enzymes 
according to amjno acid sequence homology. Some of 
the bacterial phospholipases are lethal toxins, and this 
might actually be a consequence of their roles in 
scavenging POf-, which is only available in limited free 
amounts in the body. But the fine distinction between 
toxic and non-toxic phospholipases is not discussed 
here - activity towards membrane phospholipids 
might be a better indicator of the potential involvement 
of a phospholipase in disease. This chapter aims to 
consider membrane-ac tive bacterial phospholi pases, 
the roles tha t these enzymes play in the pathogenesis 
of disease, and the molecular basis of membrane 
interactions. 
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TABLE 15.1 Membrane-active bacterial phospholipases: ca tegorized according to site of 
substrate cleavage, substrate specificity and amino acid sequence homology 
PHOSPHOUPASES A 
Vibrionacae phospholi pases A2 
Other phospholipases A2 
PH OSPHOLIPASES C 
Pho;.plrat idylclwlille prejerri11g 
zincmetallophospho lipases 
Gram-negative PLCs 





PHOSPHO LIPASES 0 
Brown recluse spider-related enzymes 
Other phospholipases 0 
Vibrio pnmhacmolyti(U> thermolabile haemolysin 
Vibrio clrolcm phospholipase" 
Aeromonas lrydrnplrila GCAT 
Aero11101W.< snlmomndn GCAT 
Helicobactcr pylort 
Clostridi11111 pc,frinscns a-toxin 
Clostridium 1/ovyi )'toxin 
C/ostridi11m l1ijermmtans PLC 
Clostridium abson11m PLC1' 
Clostridium bamti PLC/> 
Bacill11s cercus PC-PLC 
Listeria monocytogcncs PLC B 
Pseudomonas j/11orc;cm:s PLC 
Pseudomonas aeruginoStl PLC-N 
Pseudom01ws aeruginoStl PLC-H 
Mycobacterium tuberculosis M peA 
Mycobacterium luberculosis MpcB 
Mycobacteriw11 bovis PLC 
Mycobacterium marinum PLC 
Burkho/deria cepacia PLC• 
Burkholderia mallei PLC 
Burkholderia pseudomallei PLC" 
Legionella pneumoplzila PLC/> 
Ureaplasma urealyticum PLCb 
Helicobacter pylori PLCb 
Clostridium novyi /3-toxinb 
Bacillus cereus Smase 
Staplrylococcus aureus /3-toxin 
Leptospira interrogans haemolysin 
Bacillus cereus PI-PLC 
Bacillus tlwringiensis PI-PLC 
Clostridium novyi Pl-PL~ 
Listeria monocytogenes PLC A 








Vibrio damsela haemolysin 
''Assi~ned lo this group on the basis of deduced amino acid sequence homology. Substrilll' 'recificity not fully 
ddt.?rmined . 
1
'A,,tgned to this g roup of tht! basis of DNA hybridization studies and/or studies wi th purified phospholipase. 
l'reci 'e 'ub,trate specificity has ye t to be determined . 
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Phospholipases A 
The production of PLAs by a wide range of bacteria has 
been reported, but many of these enzymes are intracel-
lular or membrane bound and are required for modifi-
cations to bacterial membranes in response to d ifferent 
cultural conditions (Mollby, 1978; Waite, 1987). These 
enzymes are not considered further in this chapter. 
Extracellular PLAs, which in some cases have been 
shown to be haemolytic, are produced by members of 
the Vibriouncne (Fiore et nl., 1997), by Salmouella ucwporl 
(Asnani and Asnani, 1991) and by Helicobacter pylori 
(Ottlecz et nl., 1993). Depending on whether these 
enzymes show specificity for the 1- or 2-acyl position, 
they are classified as phospholipases PLA1 or PLA2. 
The Vibrio pnrnhacmolylicus thermolabile haemolysin is 
reported to be a PLA2 (Shinoda et al.,1991) and shows 
77% similarity to the phospholipase produced by Vibrio 
cholera (Fiore et nl., 1997). These enzymes are also related 
to the glycerophospholipid-cholesterol acyltrans-
ferases (GCAT) produced by Aeromouas salmonicidn (28% 
identity) and Aeromonns hydrophila (26% identi ty) 
(Fiore et al., 1997), which can act as PLA2s in the absence 
of acyl receptors (Thorn ton et al., 1988). 
Phospholipases C 
Gram-positive zincmetallophospholipases C 
All of these enzymes share the properties of being 
inactivated by treatment with compounds capable of 
chelating divalent cations (such as EDTA) and reacti-
vated by zinc ions (Krug and Kent 1984; Gerasimene et 
al., 1985; Geoffroy et al., 1991). The zincmetallo-
phospholipases C have molecular sizes in the range 
29-43 kDa, and a comparison of the deduced amino acid 
sequences of the enzymes produced by the Clostridium 
perfringens (a-toxin; Titball et al., 1989), Clostridiumnovyi 
(y.toxm; Tsutsui et al., 1995), Clostridium bifermentans (PLC; 
Tso and Siebel, 1989), Listeria monocytogenes (PLC-8 or 
PC-PLC; Vazquez-Boland et al., 1992) and Bacillus cereus 
(PC-PLC; Johansen et al., 1988) reveals significant 
homology (29-58%; Titball, 1993; Tsutsui et al., 1995). The 
Clostridium absonum and Clostridium barati are also 
thought to be zincmetallophospholipases C (Nakamura 
et al., 1973; Titball, 1997). The zincmetallophospholipases 
Care all active towards phosphatidyl choline but, apart 
from this, the individual enzymes have different 
activities towards other phospholipids. For example, 
only some of these enzymes a re active towards sphin-
gomyelin (Titball, 1993) and the enzymes also show 
variations in their specific activities, inhibition by 
halides and activa tion by salts (Portnoy et al., 1994). 
These differences provide a unique opportunity to dis-
sect structure-function relationships. 
On the basis of an amino acid sequence alignment, 
the zincmetallophospholipases C can be divided into 
two groups; single-domain proteins and two-domain 
proteins. The single-domain proteins (Listeria 11/0IIO-
cylogclles PLC-Band Bacillus ccreus PC-PLC) consist of 
approximately 250 amino acids, and the crystal struc-
ture of the B. cereus PC-PLC (Hough et al., 1989) 
revealed a seven-helix protein with the putative active 
site located in a cleft w hich was also occupied by three 
zinc ions (Figure 15.2, see colour plate section). 
The two-domain proteins are typically composed 
from 370 amino acids. These proteins are typified by C. 
perjri11gens a-toxin, which has one domain that is 
structurally similar to B. cereus PC-PLC and a second 
domain (carboxy-terminal domain) composed from 
beta-sheet arranged in a Greek key fold and forming a 
so-called 'C2-fold domain' (Naylor et al., 1998). When 
the first domain (amino-terminal domain) of a-toxin 
was produced in E. coli and purified, it was found 
to have PLC activity towards egg yolk lipoprotein 
or detergent solubilized phospholipids, but it was 
devoid of haemolytic activity. Therefore, it appears that 
the amino-terminal domain of a-toxin is a structural 
and functional homologue of the entire B. cereus 
PC-PLC. 
The crystal structures of B. cereus PC-PLC and C. 
perfringens a-toxin have provided insight into the 
locations and roles of the zinc ions. In both proteins, 
three zinc ions are located in the putative active site 
cleft. One of the zinc ions is less firmly bound than 
the others, and it is likely that this is the zinc ion 
removed by EDTA treatment (Hough et al., 1989; 
Titball and Rubidge, 1990; Nagahama et al., 1995). 
Crystallographic analysis of the B. cereus PC-PLC with 
substrate or substrate derivative analogues (tris- and 
3,4-dihexanoyloxybutylphosphorylcholine; Hansen et 
al., 1993a, b) suggests that the zinc ions form part of the 
substrate binding pocket. These zinc ions also play a 
structural role by bridging helices in these proteins, and 
this might explain, in part, the high thermal stability of 
these proteins. The zinc-co-ordinating residues, iden-
tified in the crystal structures of B. cereus PC-PLC 
(Hough et al., 1989) and C. perfringens a-toxin (Naylor 
et al., 1998), are conserved in all of the other zincmet-
allophospholipases for which deduced amino acid 
sequences a re available (Titball, 1993), suggesting that 
these enzymes all have similar active site architectures. 
Site-directed mutagenesis of these residues in C. 
perfringens a-toxin results in proteins devoid of PLC 
activity. Significantly, these mutant proteins were also 
non-haemolytic and non-lethal (Guillouard et al., 
1996; Nagahama et al., 1995, 1997), confi rming that the 
phospholipase activity is essential for all biological 
activities of a-toxin. 
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Until recently it was tho ught that z incmetallophos-
pholipases C were produced only by Gram-positive 
bacteria. The Pseudomonas Jluoresecells PLC is inact·ivated 
by treatment with a zinc-chelating compound 
(o-phenanthro line}, which can be reversed on incuba-
tion with an excess of zinc ions (Crevel et al., 1994; 
Jvanov et al., 1996). The N-terminal amino acid 
sequence of the protein also suggests that the enzyme 
is related to the Gram-positive zincmeta llophos-
pholipases C (Crevel et al., 1994). 
These features, along with the apparent molecular 
mass of the protein (39.5 kDa), suggest that the 
enzyme is a z incmetallophospholipase C and indicate 
that the P. fluorescells enzyme is not related to the 
Pseudomonas aeruginosa PLCs (see below). It is possible 
that the enzymes produced by Pseudomonas schuylkil-
liensis (Arai et al., 1974) and Pseudomonas aureofaciens 
(Sonoki and Ikezawa, 1975), which are also inhibited by 
treatment with EDTA, and have apparent molecular 
sizes of 23 kDa and 35 kDa, respectively, are also 
zincmetallophospholipases, but these enzymes have 
received little attention recently. 
Gram-negative phospholipases C 
There is significant amino acid sequence homology 
between the two PLCs produced by P. aeruginosa (PicH 
encoded by plcH {previously known as pieS) and 
PlcN encoded by plcN; Ostroff et al., 1990) and the 
PLCs produced by Burkholderia pseudomallei and 
Burkholderia mallei (Mack et al., unpublished). On the 
basis of Southern blotting, the PLC produced by 
Burkholderia cepacia also appears to be a member of 
this group of enzymes (Vasil et al., 1990). Although 
PlcH and PlcN show a high degree of overall homology 
(59%; Ostroff et al., 1990), these PLCs differ in their 
properties. PlcH is haemolytic and able to hydrolyse 
phosphatidylcholine and sphingomyelin, whereas 
PlcN is non-haemolytic and able to hydrolyse 
phosphatidylcholine and phosphatidylserine. The 
proteins also have markedly different isoelectric 
points (pi 8.8 for PlcN and pl 5.5 for PlcH). The greatest 
homology between these PLCs occurs in the N-termi-
nal regions, suggesting that the C-termina l regions are 
responsible for the different properties of these proteins 
(Ostroff et al., 1990). 
Expression of P. aerugi11osa PlcH (but not PlcN) 
appears to be dependent on the eo-expression of a pro-
tein (PieR) that is encod ed downstream of plcH and 
forms part of an operon, termed plcHR (Shen et al., 
1987). The function of pieR is not fully elucidated, 
but it is thought either to assist in the export of PlcH 
from the bacterial cell, or to modify post-translational-
ly the structure of PlcH (Cota-Gomez et al., 1997). 
Intriguingly, the deduced amino acid sequence of PieR 
shows sig nificant homology with calmodulin-type 
calcium binding proteins (Cota-Gomez et al., 1997) and 
Ca2+ ions appear to be required fo r activity of PlcH. 
In the case of C. pe1jringens a-toxin, Ca2+ ions are 
required for recognition of membrane phospholipids 
by the protein, and it is possible that the PlcR/Ca2+ com-
plex performs a similar function for PlcH. 
Until recently it was thought that two PLCs were pro-
duced by Mycobacterium tuberculosis (HL-A or MpcA and 
HL-B or MpcB (Leao et al., 1995; Johansen et al., 1996) 
with molecular masses of approximately 56 kDa and 
30-40% amino acid sequence identity with the P. aerug-
inosa PLCs. The genome sequence of M. tuberculosis (Cole 
et al., 1998) reveals that mpcA and mpcB are tandemly 
located and that upstream is a third open reading frame, 
which could encode another PLC (mpcC}. 
Interestingly, part of a PLC-encoding gene (mpcD) is 
located elsewhere on the genome. Only MpcA and 
MpcB have been studied in any detail and the smaller 
sizes of these proteins, in comparison with the 
P aeruginosa enzymes, a re due to several deletions 
w ithin the open reading frame and the absence of the 
C-terminal polypeptide. MpcA expressed as a fusion 
with glutathione-S-transferase in £. coli possessed 
haemolytic activity (Leao et al., 1995), but in M. 
tuberculosis the enzyme is thought to be surface bound 
(Johansen et al., 1996), and this might explain 
the contact-dependent haemolytic activity associated 
with the most virulent strains of M. tuberculosis (Leao 
et al., 1995). 
Other phospholipases C 
The relationship of other Gram-negative PLCs to the 
above enzymes is not known. Many of these enzymes 
a re cell associated and are produced by intracellular 
pathogens, although the significance of this relationship 
awaits clarification. The Legionella pneumophila enzyme 
(Mr 50 000-54 000) requires divalent ca tions, and 
treatment with EDTA abolishes activity (Baine, 1988). 
However, the enzyme is not reactivated by treatment 
w ith Zn2+ ions, suggesting that it is not a zincmetal-
lophospholipase C. The activity of the Ureaplasma ure-
alyticum (De Silva and Quinn, 1987), the oral 
spirochaetes such as Treponema denticola (Siboo et al., 
1989) and Helicobacter pylori (Weitkamp et al., 1993) 
enzymes has only been demonstrated using pNPPC, so 
it is not possible to conclude whether these PLCs are 
phosphatidylcholine-preferring enzymes or are 
sphingomyelinases. 
Sphingomyelinases C 
The head groups of phosphalidylcholine and sphin-
gomyelin are us ually identical, the difference residing 
in the g lycerol and fatty acy l tail groups of Lhe phos-
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pholipid . Some bacte rial phospholipases C show a 
remarkable specificity for sphingomyelin, which must 
reflect their ability to recognize these s tructural differ-
ences. Bacillus ccreus sphingomyelinase (Yamada et al., 
1988; Gilmore cl nl., 1989) and Staphylococcus nureus 
sphingomyelinase (/3- toxin; Projan et nl., 1989) show 
56% amino acid sequence identity over 200 amino acids 
and both have molecular masses of approximately 
39 kDa. Both enzymes require Mi+ or Co2+ ions for 
activity (Gerasimene et nl., 1985; Ikezawa et nl. , 1986). 
The sphingomyel inase produced by Leptospirn inlerro-
gnns is rela ted to the B. cereus and 5. nureus enzymes, 
but appears to be produced as a hig h molecular mass 
form (63 kDa) that is processed a t the C-terminus to 
yield a 39-kDa mature protein (Segers et nl., 1990) 
Pltosplzatidylinositol-hydrolysing enzymes 
Several bacterial enzymes (Mr - 34 000) that are specif-
ic for phosphatidylinositol have been described. These 
enzymes (B. cereus PI-PLC; Kuppe et al., 1989; B. 
thuringiensis PI-PLC; Henner et al., 1988; L. monOCljtogenes 
PLC-A; Leimeister-Wachter et al., 1991; Mengaud et al., 
1991) are all related at the amino acid sequence level 
(Mengaud et al., 1991). They are all type-II PI-PLCs, that 
is they are soluble and are able to hydrolyse phos-
phatidylinositol and glucosyl phosphatidylinositol 
(GPI). It is possible that the 5. aureus PI-PLC (apparent 
Mr20 000-33 000: Ikezawa, 1986) and the C. novyi PI-PLC 
(apparent Mr 30 000: Ikezawa, 1986) are also structurally 
related to the Bacillus and Listeria enzymes. 
Unlike the mammalian enzymes (type-1 enzymes), 
none of the bacterial PI-PLCs reported to date is a met-
alloenzyme - in fact Zn2+, Mi+ or Ca2+ ions inhibit the 
activity of the B. cereus and 5. aureus enzymes (Ikezawa, 
1991; Heinzet al., 1998). Also unlike mammalian PI-PLCs, 
the bacterial enzymes are not able to hydrolyse 
phosphatidylinositol phosphates to generate inosi tol 
triphosphate secondary messengers. The bacterial PI-
PLCs are also distinct from the GPI-PLC produced by 
Trypanosoma brucei, w hich behaves as an integral 
membrane-bound enzyme (Hereld et al., 1988). 
Significant insight into the re lationship between the 
structures and functions of the bacterial (B. cereus PI-
PLC) and mammalian enzymes (rat PI-PLC-81) has 
been obtained by comparing the crystal structures of 
these proteins (Figure 15.3, in colour p late section: 
Heinz et al., 1998). The bacterial enzyme is a single 
domain, which folds as a f3as barrel, with the active site 
located at the C-terminal end in an open cleft (Heinz 
et al., 1998). The crysta l s tructu re of the L. monocytogenes 
PLC-A (Mase r et al., 1997) a lso reveals a si ngle domain 
with very s imilar architecture to the B. cereus enzyme 
- even though these proteins show only 24% 
sequence identi ty. 
The mammalian enzyme also has a f3a~ barrel 
domain, which contains the active site, and a lso has a 
C2-fold domain, a n EF-hand domain and a PH 
domain (Figure 15.3; Heinz et al., 1998). Although the 
active site domain o f the mammalian enzyme shows a 
related topo logy to the entire bacteri al PI-PLC, signif-
icant amino acid sequence identity (26%) is found o nly 
between the N- terminal halves of the catalytic 
domains. On the basis o f amino acid sequence align-
ments, it seems likely that the T brucei enzyme is a sin-
gle-domain protein, w hich is fo lded like the bacteria l 
enzymes (Heinz et al., 1998). The crystal structures of 
these proteins a lso confirm that only the mammalian 
enzymes bind a s ing le catalytically essential Ca2+ ion 
within the active site cleft, and also show that the C2-
fold domain of the mammalian enzymes co-ordina tes 
Ca2+ ions (Heinz et al., 1998). 
Phospholipases D 
The best-studied group of bacterial phospholipases 
D (PLDs) includes the enzymes produced by 
Corynebacterium pseudotuberculosis, Corynebacterium 
ulcerous and Arcanobacterium haemolyticum, which show 
64-97% identity at the amino acid sequence level 
(Songer, 1997) and a re related to the PLO in the venom 
of the brown recluse spider (Truett and King, 1993; 
Songer, 1997). These PLDs are haemolytic only in the 
presence of the cholesterol oxidase of Rhodococcus equi, 
and pretreatment of erythrocytes with C. pseudotuber-
culosis PLO actually renders the cells resistant to lysis 
with C. perfringens a -toxin or 5. aureus /3-toxin (Soucek 
etal.,1971). 
PLOs have also been reported to be produced by a 
variety of other bacteria including Haemophilus influen-
zae, Salmonella typhimurium, Vibrio dnmsela (Waite, 
1987) and M. tuberculosis Oohansen et al., 1996). These 
enzymes have generally no t been well studied, 
although the V. damsela PLO is a haemolysin, which is 
active preferentially towards sphingomyelin, and 
degrades phospholipids in Madin-Oarby canine kidney 
cells (Kothary and Kreger, 1985). As in the C. pseudotu-
berculosis enzyme, treatment of erythrocytes with the 
V. damsela PLO renders them more resistant to lysis with 
S. aureus /3-toxin (Kreger et al., 1987). 
THE MOLECULAR BASIS OF 
SUBSTRATE SPECIFICITY 
One of the striking featu res of the phospholipases is the 
wide va ria tion in substra te specificity of proteins that 
are structurally rela ted. For example, althoug h phos-
phatidylcholine is the preferred substrate for the 
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zincmetallophospholipases, individual enzymes show 
differences in their abilities to hydrolyse other phos-
pholipids. The molecular basis for these differences is 
becoming clearer as crystal structures of these proteins, 
in some cases complexed with substrate analogues, are 
becoming available. 
One of the key mechanisms by which phosp-
holipases recognize (and discriminate between) their 
substrates involves the interaction of the head group 
with the active site. In part the specificity of the enzyme 
for the substrate must reflect the charge on the phos-
pholipid head group and the corresponding charge 
distribution in the active site cleft. Phosphatidylserine 
is the only phospholipid to carry a net negative charge, 
and it may be significant that P. neruginosn PlcN (pl8.8), 
which is a basic protein, is able to hydrolyse this 
phospholipid, whereas PlcH is acidic (pi 5.5) and 
cannot. 
The molecular mechanisms by which phospholipas-
es bind to the head group have been investigated for 
B. cereus PC-PLC (Hanssen et al., 1993a, b) and B. cereus 
PI-PLC (Heinz et al. , 1998). Bacillus cereus PC-PLC 
appears to recognize, primarily, the phosphate moiety 
that displaces water molecules and becomes co-ordi-
nated to the three zinc ions in the active site deft 
(Hansen et al., 1993b). Additional binding occurs via 
hydrogen bonds between various amino acid side-
chains and, especially, the choline head group and the 
carbonyl group (El-Sayed et al. , 1985; Hansen et al., 
1993b). The active site of B. cereus PI-PLC is relatively 
wide, to allow entry of the bulky inositol head group, 
which is recognized primarily via the 4- and 5-hydrox-
yl groups and various polar and charged side-chains of 
amino acids. In fact, the close interactions between 
these hydroxyl groups and the active site explain why 
the enzyme is not able to cleave inositol bisphosphate, 
since the additional phosphate groups cannot be 
accommodated within the active site cleft (Heinz et al., 
1998). 
The importance of the recognition of the fatty acyl tails 
of phospholipids is more variable between different bac-
terial phospholipases. The recognition of substrate by 
the bacterial Pl-PLCs does not appear to be dependent 
on the fatty acyl tail groups, and these enzymes show 
no stereospecificity towards the diacylglycerol moiety 
(Bruznik et al., 1992). In contrast, the fa tty acyl tails a re 
recognized by zincmetallophopholipases such as B. 
cereus PC-PLC and C. pC1fringens a -toxin. The fatty acyl 
tails must be a t least Cc. in length for recognition by B. 
cereus PC-PLC (EI-Sayed et al., 1985), and the recognition 
of phospholipids incorporated into liposomes by C. per-
fringens a-toxin is dependent on the presence of unsa t-
urated fatly acyl tail grou ps that are C,4 or less in length 
(Nagahama et al., 1996). 
Some of these apparent substrate recognition 
events might reflect changes in membrane fluidity, 
especially when liposome assay systems are used . 
Howeve 1~ it is clear that, for some enzymes, recognition 
of this region of phospholipids is a key event; since the 
head groups of sphingomyelin and phosphatidyl-
choline are usually identical (i.e. phosphorylcholine), 
the discrimination of these nwlecules must be 
dependent on recognition of the glycerol backbone and 
fatty acyl tail. 
ROLES OF PHOSPHOLIPASES IN 
DISEASE 
In 1941, pioneering work by MacFarlane and Knight 
showed that a bacterial toxin produced by C. perfringens 
was a PLC (MacFarlane and Knight, 1941). This find-
ing stimulated interest in the roles of PLCs produced 
by other pathogenic bacteria, and we are still dis-
covering the diverse roles of these enzymes in the 
pathogenesis of diseases caused by bacteria. 
Colonization and invasion of host tissues 
Whilst there is no clear evidence that PLCs are 
essential for th.e colonization of host tissues, there 
are several reports that suggest a role for these 
enzymes in this p rocess. 
One barrier to colonization and invasion of the 
respiratory tract is the lung surfactant, which is rich in 
phosphatidylcholine. The degradation of lung surfac-
tant has been demonstrated in vitro using the a-toxin 
from C. perfringens (Holm et al., 1991). Clostridium per-
fringens is not a pathogen of the respiratory tract, but 
there is no reason to suppose that phospholipases pro-
duced by respiratory tract pathogens would not be 
equally effective in degrading the lung surfactant and 
thereby enhancing the coloniza tion of underlying tis-
sues. It is known that the P. aeruginosa PLCs are pro-
duced in vivo, and cystic fibrosis patients develop 
antibody responses to these proteins (Granstrom et al., 
1984). The finding that a tlplcS-LlplcN mutant of P. aerug-
inosa was less able than the wild-type to induce injury 
to alveolar epithelia l cells (Saiman et al., 1992) certain-
ly suggests that the phospholipases do play a role in 
disease of the respiratory tract The P. aeruginosa 
enzymes might play a second role in respiratory tract 
infections by converting phosphatidylcholine to 
choline-betaine, which then accumulates within the 
bacterial cell and acts as a protectant against the high 
osmotic strength environment in the lung (Shortridge 
et al. , 1992). The phospholipases of o ther pathogens of 
the respira tory tract might play similar roles. 
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The suggestion that phospholipases produced by res-
piratory tract pathogens might enhance colonization 
has led to the proposal that these enzymes might also 
play similar roles in the case of pathogens that colonize 
the stomach. For example, it has been suggested that 
the PLA2 produced by H. pylori plays a role in the 
degradation of the phosphatidylcholine-rich stomach 
lining and thereby allows access to underlying tissues 
(Langton and Cesareo, 1992). This suggestion is 
supported by the finding that bismuth sal ts, which are 
often used to treat peptic ulcers, are potent inhibitors 
of the H. pylori PLA2 activity (Ottlecz et al., 1993). The 
phospholipases produced by oral spirochaetes might 
perform similar functions (Siboo et al., 1989) 
A second possible role for phospholipases in the inva-
sion of host tissues arises from a recent study with B. 
cercus PC-PLC, which has shown increased matrix 
metalloprotease production and enhanced perme-
ability of monolayers after treatment of epithelial cell 
cultures with this enzyme (Firth et al., 1997). Whether 
this mechanism also operates in vivo, and with PLCs 
produced by pathogenic bacteria, awaits investiga tion. 
However, if demonstrated, this process could allow the 
release of nutrients on to the epithelial cell surface or 
allow the bacteria to gain access into the body. 
Growth and spread of infection in the host 
The finding that some phospholipases are produced by 
bacteria that are not pathogenic for humans but are 
saprophytes has prompted suggestions that these 
enzymes form part of an enzyme cascade involved in 
phosphate scavenging. The production of the B. cercus 
PLC is induced under low P; conditions, lending weight 
to this suggestion (Guddal et al., 1989). 1t is worth noting 
that the PI-PLCs release GPI-anchored proteins, such 
as alkaline phosphatase and alkaline phosphodiester-
ase, from the surfaces of eukaryotic cells (Ikezawa, 
1986), and it is conceivable that these released enzymes 
contribute to the phosphate-scavenging process. 
In addition to their possible phosphate-scavenging 
functions, some phospholipases appear to play a 
direct role in the spread of infection in the host. Perhaps 
the most dramatic examples of this are seen with gas 
gangrene infections in humans caused by C. perfringens 
and lymphadenitis or lymphangitis in ruminants or 
horses caused by C. pseudotuberculosis. 
The development of gas gangrene is associated with 
two events. Firstly, traumatic injury to soft tissues, such 
as those sustained during road traffic accidents or dur-
ing warfare, allows entry of the bacterium (which is 
present in soil and decaying organic matter) into the 
host (Willis, 1969). Secondly, disruption to the blood 
supply, which might occur following the severing of 
major blood vessels, results in anoxic conditions in tis-
sues necessary for the growth of C. perfringens - an 
anaerobe. [n the mouse model of disease, gas 
gangrene can be caused by the inoculation of a 
large challenge dose of bacteria into the hind limb 
(Williamson and Titball, 1993; Awad et al. , 1995). The 
disease progresses rapidly, wi th spread of the infection 
from the initial focus followed by extensive muscle 
necrosis and swelling of the affected limb and is fata l 
in the majority of animals within 18 h (Awad et al., 
1995). 
For many decades, it was suggested that a-toxin was 
the major virulence determinant associated with the 
spread of the infection from the initial focus into 
adjacent tissues (McNee and Dunn, 1917; MacFarlane 
and Knight, 1941). Evidence that a-toxin played a key 
role in this process was provided when a plc-mutant of 
C. pe1jringens was tested in the murine model with lit-
tle evidence of infection, minimal muscle necrosis 
and no deaths of experimental animals (Awad et al., 
1995). The plc-mutant containing the cloned a-toxin 
gene was as virulent as the wild-type strain (Awad et 
al., 1995). 
The mechanisms by which a-toxin allows the 
spread of the bacterium into previously healthy tissues 
is not fully elucidated. However, the toxin is thought 
to diffuse away from the site of infection into adjacent 
healthy tissues. Here a-toxin might cause changes to 
the microcirculatory system in the limb, which results 
in the anoxic conditions required for growth of the 
bacterium. Certainly, a-toxin induces platelet aggrega-
tion (Ohsaka et al., 1978) and muscle contraction (Fujii 
and Sakurai, 1989), both of which would reduce the 
blood supply to tissues. It seems likely that these effects 
are a result of activation of the arachidonic acid cascade 
and protein kinase C. The toxin might also damage 
healthy cells, allowing the release of nutrients, and 
modulate the immune response, thereby allowing the 
spread of the infection. These effects are discussed in 
more detail below. 
The PLD produced by C. pseudotuberculosis also 
appears to play a key role in the growth and coloniza-
tion of tissues by the bacterium. Studies in sheep 
(Hodgson et al., 1992) or in goats (McNamara et al., 1994) 
have shown that subcutaneous abscesses, which are 
characteristic of infection with a wild-type strain, were 
not apparent in most of the animals challenged with a 
p/d-mutant. In contrast to the C. perfr ingens a-toxin, 
which appears to play a role in reducing the blood 
supply to infected ti ssues, the PLO produced by C. 
pseudotuberculosis causes increased vascular perme-
ability, and this might allow the bacterium to spread 
from the primary si tes of infection to the regional 
lymph nodes, where chronic abscesses become 
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established (Muck.le and Gyles, 1983; McNamara cl al., 
1994). Apart from the haemolytic activity of the 
enzyme, the effects of the C pseudotuberculosis PLO on 
eukaryotic cells are not known. However, since one 
effect of the leukotrienes is to increase vascular 
permeability, it is tempting to speculate that the 
ceramide phosphate product plays a role in activation 
of the arachidonic acid cascade. In this context, it 
may be significant that some PLCs (and perhaps 
eukaryotic membrane PLCs) are able to hydrolyse 
ceramide phosphate to generate diacylglycerol 
(Waite, 1987). 
The PLCs produced by intracellular pathogens also 
play key roles in the spread of the bacterium. Listeria 
monoet;toge11es produces two PLCs; PLC-A is active 
against phosphatidylinositol, whilst PLC-B preferen-
tially hydrolyses phosphatidylcholine (Mengaud et al., 
1991; Leimeister-Wachter et al., 1991; Vazquez-Boland 
et al., 1992). Initial studies with single flplcA (Camilli et 
al., 1991) or flplcB (Vazquez-Boland et al., 1992) 
mutants suggested that these enzymes played a 
minor role, respectively, in the escape of the bacterium 
from the phagosome and the spread of the bacterium 
from cell to cell (Figure 15.4). 
More recent studies have suggested that these 
enzymes have overlapping functions, and a flplcA t:.plcB 
double mutant was 500-fold attenuated in a mouse 
model of disease (Smith et al., 1995). ln cell cultures, the 
double mutant was markedly less effective in escaping 
from the phagosome and in spreading from cell to cell 
(Smith et al., 1995). These findings suggest that the 
enzymes contribute to degradation of the phagosome 














FIGURE 15.4 Roles of the L. monocytogenes PLC-A and PLC-B in 
escape from the primary phagosome and spread from cell to cell. pleA 
mutants are not able to escape from the phagosome a nd therefore 
accumulate within the phagosome. pleB mutants are not able to 
escape from the double-membrane vacuole that form~ when the bac-
teria spread from cell to cell. Re produced from Songcr (1997), wi th 
permission from Elsevier Science Publisher~ Ltd. 
vacuole that forms when bacteria spread from cell to 
cell. It is also worth noting that these effects are further 
potentiated by listeriolysin 0 (Goldfine et al., 1995), 
a pore-forming toxin, which is produced by L. 
monocytogenes. 
Whilst most of this chapter is devoted to the con-
sideration of the roles of phospholipases in the patho-
genesis of diseases of mammalian hosts, it is also worth 
highlighting the possibility that these enzymes play a 
role in diseases of non-mammalian hosts. Perhaps the 
most dramatic example of this is seen in the case of 
the PLCs of P nerugino5n, some strains of which are able 
to infect both mammalian and plant hosts (Rahme et 
nl., 1995). Whilst PlcH is known to play an importan t 
role in disease of mammalian hosts, for example 
in burns infections (Ostroff et nl., 1990; Rahme et al., 
1995) and in respiratory tract infections (Saiman et nl ., 
1992), the enzyme also appears to play a key role in 
growth in plant (Arnbirlopsis thnliana) tissues (Rahme 
et al. , 1995). Whether the enzyme exerts similar effects 
in these markedly different host species awaits 
investigation. 
Other PLCs appear to play less important roles 
in the infection process. The pathological effects 
of wild-type and {3-toxin (Hlb) negative mutants of 
5. aureus were almost identical in the mouse model 
of mastitis and, suprisingly, the level of tissue 
colonization was greater with the Hlb- mutant 
(Brarnley et al., 1989). Whilst this observation suggests 
that {3-toxin does not play a role in disease, it should 
be borne in mind that 5. aureus causes a wide variety 
of different diseases in humans and animals. It seems 
unlikely that the bacterium would retain a gene 
encoding a protein that was not required for survival 
or growth of the bacterium in any niche. Perhaps 
the enhanced colonization levels of the Hlb- mutant of 
5. aureus in the mastitis model indicate the role of 
Hlb in the development of a stable host-pathogen 
relationship. 
Avoidance of host defence mechanisms 
The cytolytic properties of some PLCs extend to cells 
other than erythrocytes, and cytolytic activi ty towards 
host phagocytic cells cultured in vitro has been 
reported (Titball el nl., 1993). There is no evidence that 
lysis of phagocytic cells occurs on a large scale in vivo, 
but there is good evidence that PLCs can modulate the 
host response to infection in more subtle ways, 
thereby allowing the growth of bacteria. The usual host 
response to infection is to mount a dramatic inflam-
matory response with the migration of phagocytes into 
the infected tissues. In contrast, it has been known for 
many years that tissue samples taken from gas 
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gangrenous limbs were devoid of phagocytic cells 
(McNee and Dunn, 1917). This pattern is also seen in 
ti ssues taken h·om mice experimentally infected with 
wild-type C. pc1:fringc11s, but not in tissues taken from 
mice experimentally infected with a l:lplc mutant, 
where there was the expected influx of phagocytes into 
infected ti ssues (Stevens et al., 1997). 
In an elegant study, it was shown that a-toxin caused 
the upregulation of cell adherence markers (!CAM, 
ELAM and p-selectin) on the surface of endothelial 
cells lining blood vessels (Bryant and Stevens, 1996; 
Bunting et al., 1997). In tissues taken h·om mice 
infected with wild-type strains, phagocytic cells 
bound to these markers and accumulated within 
blood vessels serving the site of infection. Therefore, it 
appears that a-toxin causes mis-trafficking of host 
phagocytes, allowing the bacterium to grow in host tis-
sues. Whether other bacterial phospholipases are also 
able to cause host phagocyte mis-trafficking awaits 
investigation. 
Damage to the host 
Early studies with PLCs focused on their cytolytic 
properties, and there was a general assumption that 
these enzymes caused widespread cell lysis in the host. 
Although lysis of erythrocytes does occur in experi-
mental gas gangrene (evidenced as haematuria), there 
is little evidence that extensive haemolysis occurs 
during natural cases of gas gangrene or any other 
diseases involving phospholipase-producing bacteria. 
Rather, it appears that these enzymes damage the host 
by perturbing host cell metabolism. 
Many derivatives of phospholipids act as secondary 
messengers within eukaryotic cells (Exton, 1990). Dia-
cylglycerol, which may be generated after cleavage of 
glycerophospholipids by PLCs, has profound effects on 
cellular metabolism (Exton, 1990). Diacylglcerollipase 
is able to convert diacylglycerol into arachidonic acid, 
which is then able to enter the arachidonic acid cascade 
(Samuelsson, 1983), with the resultant generation of 
prostaglandins, thromboxanes and leukotrienes (Figure 
15.5). Treatment of cultured cells or isolated tissues with 
a variety of phospholipases including C. perfringens a-
toxin (Fujii and Sakurai, 1989; Bunting et al., 1997) or P 
aeruginosa Plc-H (Konig et al. , 1997) result in the gen-
eration of these molecules. The diacylglycerol might 
also activate endogenous protein kinase C, which is 
essential for both short- and long-term effects on cel-
lular metabolism (Nishizuka, 1992; Bunting et al., 
1997). The elevated production of matrix metallopro-
teases by cells treated with B. cereus PC-PLC is also 
thought to be due to activated protein kinase C (Fi rth 
et al., 1997). 
The effects of bacterial phospholipases on 
mammalian cells might be further potentiated as a 
result of activation of endogenous membrane phos-
pholipases and especially phospholipases A21 C and 
D (Gustafson and Tagesson, 1990; Sakurai et al., 
1993; Sakurai et al., 1994; Ochi cl al., 1996). In studies 
with rabbit e rythrocyte membranes, it has been 
shown that endogenous PLC is rapidly activated, 
followed later by the activation of PLO. These activated 
mammalian enzymes might themselves generate 
further substrates for the arachidonic acid cascade. 
The mechanism by which the mammalian phospholi-
pases are activated has been the subject of speculation. 
Some workers have suggested that activated protein 
kinase C is able to activate the mammalian phospholi-
pases, either directly or indirectly (Waite, 1987; 
Exton, 1990; Nishizuka, 1992). An alternative explana-
tion is that the a -toxin mediates the effect via 
activation of GTP-binding proteins, which in turn 
activate mammalian phospholipases (Sakurai et al., 
1994). 
In addition to the further activation of the 
arachidonic acid cascade, mammalian PLCs hydrolyse 
phosphatidylinositol d iphosphate (PIP2) to generate 
the secondary messenger inositol triphosphate (IP3; 
Sakurai et al., 1993). The IP3 would have a variety of 
effects on cells. For example, the release of calcium from 
the endoplasmic reticulum is triggered by IP3, causing 
the opening of calcium gates in the cell membrane (Fujii 
et al., 1986). Boethius et al. (1973) have shown that mus-
cle cells treated with a-toxin become inexcitable, and 
this might explain the cardiotoxic effects of the a-toxin 
(Asmuth et al., 1995). The elevated intracellular calcium 
levels would also contribute to the activation of 
endogenous membrane phospholipases described in 
the previous paragraph. 
The effects of a-toxin on eukaryotic cells might be 
potentiated by the metabolic status of the cells. A muta-
tion in the UDP-glucose pyrophosphorylase gene in 
Chinese hamster fibroblasts, leading to UDP-glucose 
deficiency, rendered cells 105 times more sensitive to 
C. perfringens a-toxin (Flores-Diaz et al., 1997). UDP-glu-
cose deficiency is also a consequence in ischaemic cells. 
Ischaemia would be expected in tissues infected with 
C. perfringens, leading to the suggestion that these 
tissues would be more susceptible to the effects of 
a -toxin. The molecular basis for this enhanced suscep-
tibility has not been fu lly elucidated. However, UDP-
glucose-deficient cells contained normal levels of 
phosphatidylcholine, suggesting that alterations to the 
outer membrane leaflet were not responsible for 
the enhanced sensitivity. Interestingly, these cells 
were not more susceptible to B. cereus PC-PLC, and 
the effects of a-toxin on the cells could not be blocked 
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FIGURE 15.5 Effects of C.pcrfri11ge11s a-toxin on mammalian cell metabolism. Adapted from 1itball (1993), with permission from the American 
Society for Microbiology. 
using inhibitors of the arachidonic acid cascade or 
using inhibitors of eukaryotic phospholipases (Flores-
Dfaz et al., 1998). 
Whils t the above paragraphs discuss the effects of 
glycerophospholipid hydrolysis on cellular metabolism, 
it is becoming apparent that the products of sphin-
golipid hydrolysis (i .e. ceramide) by sphingomye-
linases might a lso modulate cellular me tabolism . 
Although the ability of bacterial enzymes to activate 
these pathways has no t been studied in detail, it is per-
haps worth pointing out that ceramide is thought to 
play an important role in the induction of apoptotic 
responses (Spiegel et al., 1996). 
When viewed together, these e legant studies tend to 
support the hypothesis that the bacterial e nzymes are 
mimicking the effects of the mammalian enzymes 
a nd thereby modulating cellular metabolism to the 
d e triment of the hosl. The effects described above a re 
a ll relative ly short term. IL b abu worth bearing in mind 
that long-term perturbation of cellular messengers such 
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as protein kinase C has been linked with the trans-
formation of cultured cells. Such effects might suggest 
a link between the development of cancers and 





A central feature of phospholipases that play roles in 
the pathogenesis of disease is their ability to interact 
with membranes, whether from outside the cell or from 
inside phagosomes. Bacterial phospholipases vary 
widely in their abi lities to interact with membra ne 
phospholipids, and this has resulted in the suggestion 
that those enzymes that play important roles in the 
pathogenesis of disease can be identifi ed on the basis 
of their haemolytic activity. To some extent this proposal 
is supported by experimental evidence. Of the two 
related PLCs produced by P. aeruginosa PlcH is 
haemolytic and able to induce the release of inflam-
matory mediators from granulocytes, whereas PlcN is 
devoid of both activities (Konig et al., 1997). A similar 
pattern is observed when the properties of the related 
C. perfringens a-toxin and B. cereus PC-PLC are com-
pared; only the C. perfringens a-toxin is haemolytic, able 
to cause release of inflammatory mediators from 
granulocytes (Konig et al., 1997) and lethal when 
administered to animals (Titball et al., 1991). 
The mechanisms that allow some enzymes to 
interact with membrane phospholipids have been the 
subject of various studies and various theories have 
been developed to explain the mode of action of these 
enzymes. One theory proposes that membrane-active 
enzymes have structural features that allow the 
insertion into membranes. A second theory suggests 
that membrane-active enzymes are able to hydrolyse 
both phosphatidylcholine and sphingomyelin. These 
theories are discussed in more detail below. 
Insertion into the membrane bilayer 
It is generally assumed that the surface of the phos-
pholipid bilayer consists of tightly packed head 
groups, which mask the hydrophobic tail groups. This 
model would suggest that the bond susceptible to 
cleavage by the phospholipase is not exposed to the 
aqueous phase. Tn reality, the phospholipids adopt a 
' hockey stick' conformation in the bilaye1~ and the 
susceptible bond might be partially accessible to an 
enzyme in the aqueous phase (Figure 15.6). However, 
even allowing for the ' hockey stick' conformation of 
phospholipids, it is apparent that the active site of the 
enzyme could not be docked with the substrate 
without the phospholipase's either becoming inserted 
into the membrane or having a mechanism that 
allowed retraction of the phospholipid out of the 
membrane. 
Evidence supporting the ' insertion' hypothesis was 
originally reported by van Deenen el al. (1976), who 
measured the activity of phospholipases towards 
phospholipid monolayers maintained at increasing 
lateral pressures. This study (Table 15.2) showed that 
haemolytic phospholipases (such as C. pc1j ri11gens 
a-toxin) were able to insert into monolayers maintained 
at lateral pressures above those found in erythrocytes. 
In contrast, non-haemolytic enzymes (such as B. cercus 
PC-PLC) were able to hydrolyse phospholipids only in 
monolayers maintained at lm"' lateral pressures. 
Surface-exposed hydrophobic amino acids might 
become buried in membranes 
What structural features of phospholipases might 
allow insertion into the membrane? On comparing the 
structures of B. cercus PC-PLC (Hough et al. , 1989) and 
C. perfringens a-toxin (Naylor et al., 1998), it is apparent 
that both enzymes possess structurally similar catalyt-
ic domains, but that only a-toxin has a second domain 
(carboxy-terminal domain). Lf the carboxy-terrninal 
domain is removed from a -toxin, the PLC activity is 
FIGURE 15.6 Space-filling and energy minimized model of d ioc-
lanoyl phospha tidylcholine. The regions of the phospholipid that ar~ 
recognized by the B. ccrrus PC-PLC are ~hown boxed . The charged 
rt>gions on the phosphorylcholine head group a re also ,hown. 
Ad apted from EI-Sayed cl nl. (1985), with pe rmission from Elsevit>r 
Science Publi~hers Ltd . 
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TABLE 15.2 Effect of la teral pressure on the hydrolysis of phospholipids in 
monolayers by different phospholipases 
Source of enzyme Type 
Haemolysis of 
human erythrocytes 
Maximum latera l pressure 
at which hydrolysis 
ceases (dyne cm-1) 
Pig pancreas 
Cabbage 
Crotalus ndnmn11fcus venom 
8. cercus PC-PLC 
























Modified from Mollby (1978), with the permission from Academic Press Ltd. 
retained but haemolytic activity is lost (Titball et 
al., 1991). The possibility that the carboxy-terminal 
domain contains a second active site, responsible for 
membrane phospholipid hydrolysis, appears unlikely, 
since the isolated carboxy-terminal domain does 
not possess haemolytic (or indeed any detectable 
enzymic) activity (Titball et al., 1993). When the two 
domains of a-toxin are mixed together in solution, 
haemolytic activity is restored, confirming that both the 
catalytic domain and the carboxy-terminal domain are 
required for membrane activity (Titball et al., 1993). 
Several regions on the surface of ex-toxin have been 
identified as having possible membrane binding 
functions (Naylor et al., 1998). Trp214 (N-terminal 
domain) Tyr331 and Phe334 (C-terminal domain) are 
surface exposed and are positioned such they could 
interact with the phospholipid tail groups on mem-
brane binding (Figure 15.7, in colour plate section). In 
the B. cereus PC-PLC, Trp214 is replaced with a pair of 
anti parallel helices and Tyr331 and Phe334 are not present, 
since there is no carboxy-domain in this enzyme. Other 
bacterial phospholipases might exploit similar mecha-
nisms to allow insertion into the membrane; the B. 
cereus PI-PLC has a 'ridge' of hydrophobic amino acids, 
which are thought to become inserted into the 
membrane (Heinz et al., 1998). 
C2 domains might be involved in phospholipid 
recognition 
A second mechanism that a llows binding of ex-toxin to 
membranes involves the co-ordination of calcium 
ions by sites formed partially by phospholipid phos-
phate groups and partially by side-chains in the 
carboxy-terminal domain (Guillouard et al., 1997). 
For many years it has been known that calcium ions 
are essential fo r the haemolytic activity of ex-toxin 
(MacFarlane and Knight, 1941) and for the hydrolysis 
of monomolecular fi lms of phosphatidylcholine 
(Bangham and Dawson, 1962; Moreau et al., 1988). 
However, analysis of purified ex-toxin has not revealed 
the presence of bound calcium ions (Guillouard et al., 
1997), suggesting that the calcium binding sites were 
of a low affinity- which would be expected if the Ca2+ 
ions were partially co-ordinated by membrane phos-
pholipid. Although the location of calcium ions in the 
molecule has not been determined, protein crystallized 
in the presence of cadmium ions did reveal potential 
calcium-binding sites in the carboxy-terminal domain 
of ex-toxin (calcium and cadmium have similar charges 
and ionic radii; Naylor et al., 1998). The fold of 
the carboxy-terminal domain, and the ability of this 
region to recognize phospholipids via Ca2+ co-ordina-
tion, confirms that this domain is a 'C2-fold domain'. 
C2-fold domains have not previously been found in 
prokaryotes, and are typically found in proteins that are 
involved in lipid metabolism in higher eukaryotes, such 
as synaptotagmin and phosphatidylinositol-specific 
PLC (Naylor et al., 1998). 
In this context, it is in teresting to note that the 
mammalian PI-PLC-81 has a C2-fold domain (Figure 
15.2), and models suggest that this domain may be 
involved in Ca2+ -mediated interaction wi th the mem-
brane surface (Heinz et al., 1998). The crystal structure 
of mammalian lipoxygenase also reveals anN-terminal 
C2-like domain (Gillmor et al., 1997), and this is reflect-
ed in the earlier observation that the deduced amino 
acid sequences of the C-terminal domain of ex-toxin and 
the N-terminal region of arachidonate-5-lipoxygenase 
showed signi fica nt homology (Titball et al., 1991). 
Although these models can explain how phos-
pholipases become partially inserted into the mem-
brane, they do not fu lly explain how the active 
site of the enzymes is brought into juxtaposition 
with the susceptible bond in the phospholipid. lt is 
possible that the enzymes partially relracl the phos-
pholipid from the membrane; alternat ively, the 
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phospholipase may undergo a conformational 
change, which inserts the active site region into the 
membrane (Blow, 1991). 
Tlze properties of C2 domains vary 
All of the zincmeta llophospholipases C show a one- or 
two-domain organization and, although the two-
domain enzymes are all haemolytic, the specific 
activities of these enzymes are different. This might be 
because the carboxy-terminal domains of different 
enzymes are not structurally identical and have 
different properties. The carboxy-terminal domain of 
the C. bifermentans enzyme shows 50% identity with the 
carboxy-terminal domain of C. pe1jringens a-toxin and 
it is therefore likely to be a C2-fold domain. However, 
the C. bifermentans enzyme is only weakly haemolytic, 
even though the PLC activity is close to that of a-toxin. 
Fusion of the a-toxin carboxy-terminal domain to the 
C. bifermcntans amino-terminal domain significantly 
enhanced the haemolytic activity of the enzyme 
(submitted). Interestingly, the residues identified from 
the model of the a-toxin as playing a key role in 
membrane binding are replaced with a functionally 
different type of amino acid in the C. bifermentans 
C-terminal domain (Naylor et al., 1998). 
Substrate specifi.city and membrane 
phospholipid hydrolysis 
For some years, it was suggested that haemolytic PLCs 
were able to hydrolyse both phosphatidylcholine and 
sphingomyelin, which are major components of the 
outer leaflet of mammalian cell membranes, whereas 
non-haemolytic enzymes were able to hydrolyse only 
one type of phospholipid (Ostroff et al., 1990; Titball, 
1993). For example, the haemolytic P. aeruginosa PlcH 
enzyme can hydrolyse both phosphatidylcholine and 
sphingomyelin, whilst the related P. aeruginosa PlcN 
enzyme is able to hydrolyse only phosphatidylcholine 
and is non-haemolytic (Ostroff et al., 1990). 
One key difference between B. cereus PC-PLC and C. 
perfringens a-toxin is the ability of the latter to hydro-
lyse sphingomyelin a nd phosphatidylcholine (Krug 
and Kent, 1984) whereas the B. cereus enzyme is able to 
hydrolyse only phosphatidylcholine (Otnaess et al., 
1977). Significantly, a mixture of B. cereus PC-PLC and 
B. cereus sphingomyelinase does cause haemolysis, 
and this mixture is termed cereolysin A-B (Gilmore et 
al., 1989). 
How is B. cereus PC-PLC active against erythrocyte 
membranes when combined with a sphingomyelinase, 
when it is apparently not able to insert into membrane 
bilayers? One possibility is that the sphingomyelinase 
enzyme first hyd rolyses sphingomyelin, and that the 
resultant changes in membrane organiza tion (and 
lateral pressure) then allow the phosphatidylcholine 
hydrolysing enzyme to act on membrane phospho-
lipids. Experimental evidence does lend some support 
to this suggestion; sphingomyeli n plays a key structural 
role in the outer leaflet of membranes and erythrocytes 
incubated with B. ccreus (or 5. nu reus) sphingomyelinase 
are not lysed unless they are subsequently exposed to 
a n additional s tress such as cooling below the phase 
transition temperature (termed hot-cold lysis) or 
treatment with divalent cation chelating agents 
(Bernheimer et al., 1974; lkezawa et al., 1986). Viewed 
together, these findings tend to confirm that when 
sphingomyelin and phosphatidylcholine are hydro-
lysed, the cell membrane is sufficiently weakened, 
which results in lysis. 
Membrane,active enzymes may be 
non, haemolytic 
The above findings suggest that haemolytic activity is 
indicative of the hydrolysis of both sphingomyelin and 
phosphatidylcholine, and that haemolytic enzymes (or 
mixtures of enzymes) are able to penetrate membrane 
bilayers. Haemolysis is certainly an extreme measure of 
cell membrane damage and remains a useful indicator 
of the interaction of an enzyme with mammalian cells. 
However, it should not be viewed as the sole indicator 
of membrane phospholipid hydrolysis. As noted 
above, bacterial sphingomyelinases are able to hydro-
lyse membrane sphingomyelin without cell lysis. In 
other cases, non-haemolytic enzymes might act syner-
gistically with other bacterial products to cause 
haemolysis. One example of this synergy is seen with 
the PLCs produced by L. monocytogenes. Although PLC-
A and PLC-Bare considered to be non-haemolytic (or 
at least very weakly haemolytic; Geoffroy et al., 1991), 
they play key roles in disruption of the phagosome and 
the double-membrane vacuole formed during cell-to-
cell spread (SmHh et al., 1995). It is significant that these 
phospholipases appear to act together, and with the 
pore-forming toxin listeriolysin 0, to achieve these 
effects (Goldfine et al., 1995; Smith et al., 1995). 




For many years phospholipases have been used a 
membrane probes- either specifica lly to hydrolyse dif-
feren t classes of phospholipids in membranes or to 
mimic the effects of eukaryotic PLCs. In the past, the 
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use of PLCs in this way has bee n fraught with many 
problems; the enzymes were isolated from bacteria, 
which often produced other membrane-active toxins, 
and the difficulties of isolating ' pure' PLCs mea nt that 
it was difficult to be certain that the effects observed 
were due to the bacterial PLCs. The avai labi lity of 
cloned gene products means that better-de fined 
prepara tio ns of phospholipases a re now available to 
suppo rt these s tud ies. 
Vaccines 
Given the key roles tha t some phospholipases play in 
the pathogenesis of disease, it is not surprising that 
inactiva ted forms of the enzymes have been considered 
as components of vaccines. In this respect, C. pc1frin-
gens a-toxin has attracted most attention, but the toxic 
na ture of this enzyme meant that early vaccination 
studies used forma ldehyde toxoids, prepared from 
a-toxin that was isolated from the supernatant Auid of 
cultures of C. pe1jringens (Evans et nl., 1945; Boyd et nl., 
1972; Kameyama et nl., 1975). Whilst these toxoids did 
induce protection against gas gangrene, it was difficult 
to ensure that the vaccine did not contain other 
toxoided C. perfringens proteins, and therefore to be sure 
that the protective component in the vaccine was 
a-toxoid. 
Several approaches for the generation of genetically 
engineered toxoids have been reported. Site-directed 
mutant forms of the a-toxin with reduced enzymic and 
cytolytic activity have been reported (Nagahama et al., 
1995; Guillouard et al., 1996; Nagahama et al., 1997). 
These mutated proteins could, in principle, be 
developed as vaccines if multiple mutations were 
incorporated to ensure that reversion was an unlikely 
event, and to reduce the activity of the enzyme to a 
negligible level. Alternatively, the carboxy-terminal 
domain of a- toxin, produced using genetic engineer-
ing of E. coli, could be used as a non-toxic vaccine. 
Immunization of mice with this vaccine induced high 
leve ls of antibody, which protected mice against 
experimental gas gangrene cause by C. perfringens 
(Williamson and Titball, 1993). This vaccine might be 
used to pro tect individuals at risk from developing gas 
gangrene, such as the elde rly o r individuals due to 
unde rgo surgica l procedures involving the lower 
gastrointestinal tract. The vaccine has a lso been pro-
posed for the prevention of enterotoxigenic diseases of 
do mestica ted livestock, including necrotic enteritis in 
chickens and sudden dea th disease in calves and piglets 
(Ginter et nl., 1996). 
The finding tha t the C. pseudotu/Jerwlosis PLO p lays 
a key role in the pathogenesis of caseous lymphadenitis 
in sheep and goa ts has prompted suggestions tha t 
eithe r a PLO mutant might itself be used as a vaccine 
(Hodgson cl nl., 1992) or an enzymica lly inactive form 
of the PLO mig ht be used as a compo nent of a subunit 
vaccine (Haynes et nl., 1992). 
The possibility that phoc;pholipases produced by 
other bacteria might be used as component of vaccines 
has yet to be inves tiga ted. Howeve1~ it should be 
borne in mind that, in the case of intracellular 
pathogens, it may be difficult to induce an appropriate 
protective immune response. Furthermore, many of the 
enzymes produced by ex tracellular pathogens d o not 
play the same overriding ro les in the pathogenesis of 
disease as the a-toxin of C. pc1jringcns or the PLO of C. 
pseudotllberclllosis. 
Phospholipase C conjugates 
The ability of phospholipases to damage host cells has 
a ttracted attention as the basis of immunotoxins 
for treating some tumours. The first studies used 
C. perfringens a-toxin linked to an antibody against 
a eukaryotic cell surface ma rker (Chovnick et nl., 
1991). Whilst these immunotoxins showed retention of 
both PLC and antibody-binding activity, the systemic 
toxicity effects were conside red to be too great for 
use of the immunotoxin in humans. A variety of 
approaches has been suggested to resolve this 
problem. One uses the targeting of low doses of the 
immunotoxin to the cancer cell surface, where 
the immunotoxin is then able to cause release of lipo-
some-e ncapsula ted drugs. Studies in 11itro and in vivo 
have confirmed that this approach can be used to 
enhance the activity of liposome-encapsulated anti-
cancer drugs (Carter et nl., 1998) 
Design of therapeutics 
When bacterial phospholi pase~ play key roles in the 
pathogenesis of disease, it i~ feasible that enzyme 
inhibitors could be used to treat these diseases. For 
example, bismuth salts, which can be used to trea t 
gastric and duodenal ulcers, are thoug ht to inactivate 
the H. pylori PLA2, and it ma~· be possible to desig n 
more e ffective enzyme inhibitt1r:'. One limitation of this 
approach is that such inhibitN:' mig ht also be active 
against eukaryotic PLCs and l1 ne report describes 
immunological cross-reacti,·it_,. bet\\·een B. cere11s 
PC-PLC and mammalian pho:'~'ha tidylcholine-prefer­
ring PLCs (Clark el nl., 1 9~t''- The possibi lity that 
prokaryotic a nd eukaryotic ~'hO. pholi pases have 
similar structures or molecular 11h'des of action suggests 
that the bacteria l enzymes mi~ht be u"ed to design and 
test drugs for use against L'uk.u~·otic PLCs or li pid 
binding e nzymes. 
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Such drugs might be used to treat a variety of 
inflammatory diseases in humans. In this respect 
it is interesting to note that the C-terminal domain of 
the C. petf ringcns a-toxin is folded as a C2-domain 
that is found frequently in eukaryotic enzymes such 
as synaptotagmin, phosphatidylinositol PLC and 
arachidonate-5-lipoxygenase (Naylor et al., 1998). 
FUTURE DIRECTIONS FOR 
RESEARCH 
For many years, studies with bacterial phospholipases 
were limited to the enzymes produced by C. perfringens 
and B. cercus. More recently, studies have been carried 
out with phospholipases produced by other pathogens. 
However, there are still many phospholipases produced 
by pathogens that are poorly characterized and for 
which we have not determined their roles in the patho-
genesis of disease. Why are some enzymes membrane 
bound and others exported from the cell and, more 
generally, are the enzymes produced by intracellular 
pathogens specially adapted for this lifestyle? 
In general, the interaction of phospholipases with 
membrane phospholipids is thought to be a key event, 
but we have limited knowledge of how this occurs. 
Haemolysis is an indicator of membrane interaction, but 
the hydrolysis of membrane phospholipids can occur 
without haemolysis. Why are some enzymes active 
towards liposomes but inactive towards erythrocytes? 
Why are mixtures of phosphatidylcholine-hydrolysing 
enzymes and sphingomyelinases haemolytic when the 
individual enzymes are not? Clearly, substrate specificity 
is one of the factors that determines the activity of 
enzymes- but how is this specificity achieved at a mol-
ecular level? In spite of research over the past 10 years, 
we do not fully understand how phospholipases exert 
their many effects on eukaryotic cells. What role do 
eukaryotic enzymes play in these processes? How do 
different enzymes exert different effects on different cell 
types? 
The information that will be derived from these stud-
ies over the next decade is of more than philosophical 
significance. It will allow a variety of new approaches 
to the control of diseases. In some cases, vaccines will 
be devised and enzyme inhibitors could be used to treat 
bacterial diseases. These opportunities provide exciting 
new challenges to investigators in a rapidly expanding 
field . 
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11. MEMBRANE-OAMAGI G TOXINS 
CHAPTER 23 
Bacterial Phospholipases 
R.W. TITBALL and J.I. Rooo 
A. Introduction 
Pioneering work by MACFARLANE and KNIGHT showed for the first time that 
a bacterial toxin - the a-toxin of Clostridium perfringens- also had enzymatic 
activity as a phospholipase C (PLC; MACFARLANE and KNIGHT 1941). This 
finding stimulated great interest not only in the a-toxin but also in the poten-
tially toxic activity of PLC enzymes produced by other bacteria and in the 
mechanisms that control the production of these proteins. In addition to the 
PLCs bacteria have been shown to produce other phospholipases, such as 
phospholipase Os (PLDs) and phospholipase As (PLAs), which differ in the 
site of phospholipid cleavage (Fig. 1). Today, many phospholipases, produced 
by both pathogenic and non-pathogenic bacteria, have been described and 
characterised, but only a few of these enzymes have been shown to be lethal 
toxins. Nevertheless, some of the enzymes considered to be non-toxic have 
been shown to play important roles in the pathogenesis of disease. Recent 
studies have suggested that lethality is a rather crude indicator of the poten-
tial roles of these enzymes in disease and that many of these phospholipases 
appear to exert their effects by allowing the bacteria to colonise the host or 
by perturbing the metabolism of host cells rather than by directly damaging 
the host (TrTBALL 1993; SoNG ER 1997). These findings have challenged the con-
ventional criteria by which a bacterial product is considered to be a toxin. The 
aim of this chapter is to review the broad spectrum of bacterial phospholi-
pases, to discuss the mechanisms by which the expression of phospholipase-
encoding genes are regulated, to examine the ways in which these enzymes 
interact with host cells at a molecular level and to illustrate the ways in which 
bacterial phospholipases contribute to the pathogenesis of disease. 
B. Related Groups of Phospholipases 
Prior to the availability of amino-acid-sequence data, the bacterial phospho-
lipases were grouped according to the site of cleavage of phospholipids- i.e. 
as PLAs, PLCs or PLDs (Fig. 1). However, there were indications that some 
of the bacterial enzymes within these groups are related. For example, antis-
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Fig. l. Site of cleavage of phosphatidylcholine by phospholipases A, C and D. The fatty-
acyl tail groups of the phospholipid are depicted as R 1 and R2 groups 
bifermentans enzyme and with the C. novyi y.toxin. Over the past decade, our 
increased knowledge of the molecular biology of the bacterial phospholipases 
has allowed this structural relationship to be explored and has revealed that 
many of the bacterial enzymes are related and can be grouped according to 
both the site of phospholipid cleavage and the amino-acid-sequence homol-
ogy (Table 1). Not all of these groups of phospholipases will be covered in this 
chapter; rather, we have selected the best-characterised groups of enzymes for 
further discussion. 
I. Zinc Metallophospholipase Cs 
The zinc metallophospholipase Cs are typified by the C. perfringens a-toxin 
and the Bacillus cereus phosphatidylcholine-preferring PLC (PC-PLC). Crys-
tallographic studies (HouGH et al. 1989; NAYLOR et al. 1998) indicate that these 
Tablet. Representative bacterial phospholipases. References cited are for the cloning and nucleotide sequencing of encoding genes or 
for the analysis of purified enzyme 
Source or enzyme Name mass (Da) 
I'LAs 
1/dimlwucr pylori PLA1' 
Vihrio porollae11wlyticu.,· ·n,crmolabilc 
hacnwlysin" 
Zinc mcwllophospholipasc Cs 
Chmridium perfringem a-Toxin' 
C. hifermenll/11.1' PLC' 
c. 11111' \ 'i y-Toxin' 
( . JWftiJit'rfrin~t'll.\" I'LC 
C. absmwm PLC 
Badlllf.v ccreu.,· PC-PLC" 
Luteria mtnu1cywgenes PLC-B' 
f',c' llt/fiiiUmU.\ jflUITt'.\'(.'f!/1\ PLC' 
Gram-negative PLC~ 
~~ IU'fiiJ.,:illfJ,\11 PLC- H1 
PLC-N1 
Burklrolderia ceparia PLC' 
Burklrolderia p.reudomallei PLC 
M yculmcft.'rium tuhercu/osis M PC-Am 
MPC-Bm 
Other PLCs 
Ureaplwmw urealyticum PLC" 
f.c)lit//IC/111 fiiiC/1/IItJfl/ri/11 PLC'' 
\~ rlw/cme PL" 
Sphingomclinase Cs 
8 . cereiLS Smase' 
LeptoJpiru interro~tlll.f Smase' 
Stnpllyltl('tJC(.' II\" llllrt.'lL\ .IJ-toxin' 
PI PLC's 
C. 1/IIVYI PI-PLC' 
13. cereu.\ PI-PLC" 
Molecular Substratc spccificity 
NR I'(' 
45 ~ox PC. LI'C 
42 523 I'C. SI'M.I'S. LI'C 
42 776 NR 
425h2 I'C'. SPM. LI'C PE. PS. PG 
NR NR 
NR NR 
2X 520 I'CI'E.I'S 
27 70<) PC. I' E. PS. SI' M 
:W 51Xl PC. PE. PS 
7X ~52 I'C.SI'M . I.I'C 
73 455 I'C. PS 
72000 PC. SPM 
NR NR 
56 103 PCSI'M 
56 137 PC.SI'M 
NR pNI'PC 
50 IXXI-541XKI I'C 
47 (>()() NR 
34 233 SPM 
41 200 SPM. PC 
34 546 Sf'M . LI'C 
301KXI I' I 
34 460 I'L LPI 




















































Table 1. Continued 
Source of enzyme Name mass (Da) Molecular Substrate specificity Ion requarements Haemolysis 
Bacil111s th11ringiensis PI-PLC 34 515 PI. LPJ NR 
L. monocytogenes PLC-A" 33 532 PI NR 
Phospholipase Os 
Corynebacterium pse11dotuberculosis PLO' 31 109 LPC.SPM NR 
Arcanobacterium laaemolyticum PLO' 31 977 LPC.SPM NR 
V. damsela PLO' 69000 PC,PE.SPM NR + 
C. haemolytic in the presence of cholesterol oxidase from Rlaodococcus equi: la. hot cold haemolysis: LPC.lysophosphatidylcholine: LP/. l)sophosphatidylinositol: M PC. met-
allophospholipase C: NR, not reported: PC, phosphatidylcholine: PE. phosphatidylcthanolaminc: PG. phosphatidylglyccrol: PI. phosphalitlylino<ilnl: PLA . phospholipase A : 
PLC. phospholipase C: PLD. phospholipase D: pNPPC. p-nilrophenylphosphorylcholinc: PS. pho<phalidylscrinc: SF' M. sphingomyelin. 
· ona act. (IW:l). 
• sllti'ODA cl al. ( 1991). 
' TIIIIAI.I. Cl al. ( I 'IX'I). 
''Tso a nu StEUbl. ( I'IX!I). 
' TsUtSll l Cl al. ( IW5). 
' Nt.K•\ MUWA cl al. ( 1973). 
' JOHANSEN Cl al. ( 198ll). 
"VA/.Ulll/-llot .ANO cl al. (1<)92). 
' CWEV~L Cl al. ( l t)CJ4). 
10snon cl al. (I'J'Xl). 
'VASIL cl al. ( 1990). 
' M.-.cK (personal communication). 
•• Joa·oANSbN cl al. ( I W6): Lcao cl a l. ( 1995). 
" DE Sat.VA and OutNN ( 19ll7). 
" BA IN[ ( 19llll). 
• FoowE cl al. (1997). 
'
1 YMtAI>•\ cl al. ( 19HN). 
' SEGERS Cl al. ( 1990). 
' PROlAN Cl al. ( 19ll9). 
' TAGUCII I d al. (1980). 
' KUPI'E Cl a l. ( 1911</). 
' HENN[W Cl al. ( 19&'!). 
• LEIMEISTLR-WACIHER el al. (1991). 
'McNMtARA Cl al. (19\14) . 
' CUE VAS and SONG ER ( 1993 ). 
' KR EGER Cl al. ( 1987) . , 
8 
0 
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Table2. Biologica l activities of site-directed mutants of C perfringens a-toxin 
Mutation Domain Proposed function Activity Bound 
of target amino zinc (mol) 
acid pc sph hly le t 
Wild type + + + + 2 
EDTA-treated NO NO NO 2 
wild type 
WtS·' N Zn2' binding ND 
HlJS·' N Zn2+ binding NO NO 
H68S·' N Zn2• binding NO NO 
H68G" N Znz. binding 2 
Hl26S" N Zn2• binding NO NO 
Hl26Gh N Zn2' binding 2 
H1 36S" N Zn2• binding NO NO 
H136Gh N Zn,. binding 2 
H 136Ab N Zn2+ binding NO 
Hl48S' N Zn2+ binding NO NO 
H148Gh N Zn2+ bindi ng 1 
H148Lh N Zn2• binding ND 
E152D< N Zn2+ binding NO 1.5 
E152Q< N Zn2+ binding NO 1 
E152Gc N Zn2• binding NO 1 
+.greater than 85% retention of the activity of the wild-type toxin; -. less than 3% 
retention of activity of the wild type toxin; EDTA, ethylenediamine tetraacetic acid; 
ND, not determined. 
' GUILLOUARD et al. 1996. 
bNAGAHAMA et al. 1995. 
<NAGAHAMA et al. 1997. 
proteins contain three zinc ions which form part of the putative active sites. 
However, one of these ions is relatively loosely bound, which might explain 
why atomic-absorption spectroscopy indicates that the a-toxin contains only 
two zinc ions (Table 2). It is likely that treatment of the proteins with chelat-
ing agents, such as ethylenediaminetetraacetic acid and o-phenanthroline, 
with the resultant PLC inactivation, also removes this zinc ion (KRUG and 
KENT 1984; HoUGH et al. 1989; TITBALL and RUBIDGE 1990). Crystallographic 
data indicate that the zinc ions are coordinated by histidine, tryptophan and 
glutamic acid side chains in an a-helical domain (HouGH et al. 1989; NAYLOR 
et al. 1998). Confirmation of the roles of these amino acid side chains has been 
obtained by using site-directed mutagenesis to construct mutant forms of the 
C. perfringens a-toxin (Table 2). These mutants were all devoid of PLC activ-
ity toward PC and sphingomyelin, were devoid of haemolytic activity and, for 
those mutants which were evaluated, were non-toxic. This finding suggests that 
all of these activities are dependent on a single active site. The amino acids 
that are involved in zinc-ion coordination are conserved in the C. novyi y- toxin 
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Fig. 2. Cartoon trace of the Clostridium perfringens a-toxin, showing the locations of 
zinc ions. calcium ions and exposed hydrophobic amino acids, which might play a role 
in membrane insertion 
suggesting that the active sites of these enzymes also contain three zinc ions. 
The other members of the zinc-metallophospholipase-C group (C. absonum 
PLC and C. barati PLC; NAKAMlJRA et al.1973) have been assigned on the basis 
of immunological cross-reactivity with the C. perfringens a-toxin and/or the 
ability of zinc-chelating compounds to inactivate these enzymes. 
Although the active-site regions of the different zinc metallophospholi-
pase Cs may be similar, these enzymes differ in that some are single-domain 
proteins whilst others possess an additional C-terminal domain (TITBALL 1993; 
TITBALL et al. 1993). This difference in molecular organisation has been inves-
tigated by comparing the crystal structure of C. perfringens a-toxin (Fig. 2) 
with that of the B. cereus PC-PLC (NAYLOR et al. 1998). TheN-terminal domain 
(the active-site domain) of the a-toxin shows an overall structural similarity 
to the entire B. cereus PC-PLC (TITBALL et al. 1991 ; NAYLOR et al. 1998). The 
additional domain of the C. perfringens a-toxin is in a {3-sheet conformation 
and lies adjacent to the active site. O ne key biological difference between the 
C. perfringens a -toxin and the B. cereus PC-PLC is that the C. pe1jringens 
enzyme is toxic and is able to lyse erythrocytes, suggesting that the C-domain 
plays a key role in this process. In this context, it should be noted that the 
other zinc metallophospholipase Cs that have a C-domain (C. novyi y.toxin 
and C. bifermentans PLC) are also haemolytic. 
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11. Gram-Negative PLCs 
Most studies with enzymes in the gram-negative-PL group have been carried 
out with PLCs from P. aeruginosa. Two re lated enzymes (PLC-N and PLC-H; 
OsTROFF e t a l. 1990) are produced by this bacterium. Both are able to hydrol-
yse PC, but only PLC-H is able to hydro lyse sphingomyelin and is haemolytic 
(OSTROFF e t al. 1990). Liltle is known about the molecular organi at ion of 
these enzymes. a lthough it appears that the PLC-H protein is post-
translationally modified to form the active enzyme by another P. aemginosa 
protein, PieR, which is encoded downstream of p/c f-1 (SHEN e t al. 1987) 
The enzymes produced by P. aeruginosa are now known to be closely 
related to the PLCs produced by a number of o ther bacteria, incl uding 
Mycobacterium tuberculosis (JoHANSEN e t al. 1996; LEAO et al. 1995), Burk-
holderia pseudomallei (Mack, personal communication) and B. cepacia (VASJL 
e t al. 1990). Although the Burholderia enzymes are similar in both size and 
amino acid sequence to the Pseudom onas enzymes, the mycobacterial 
enzymes (MpcA and MpcB) lack a 20-kDa C-terminal region. Another major 
difference between these enzymes is that the Pseudomonas and Burkholderia 
enzymes are exported from the cell, whilst the mycobacterial enzymes appear 
to be cell associated , which might explain why M. tuberculosis has a contact-
dependent haemolytic activity (LEAO et al. 1995). The reason for the differ-
ence in cellular location of the mycobacterial enzymes has yet to be explained, 
but it is worth noting that this bacterium is an intracellular pathogen, whilst 
the other bacteria in this group are extracellular pathogens. 
Ill. Phosphatidylinositol PLCs 
The PLCs that are able to specifically hydrolyse phosphatidylinositol (PI) and 
glycerophosphatidylinositol (GPI) are related and are produced by gram-
positive bacteria. Although the proteins in this group show limited amino-
acid-sequence identity (the B. cereus PI-PLC and the Listeria moncytogenes 
PleA are 24% identical), the crystal structures of these enzymes are similar 
(MosER et al. 1997; H EINZ et al. 1998), suggesting that all of the PI-PLCs have 
a similar architecture. The B. cereus PI-PLC and the L. monocytogenes PleA 
are single-domain proteins, folded as a (,Ba)8-barrel, where the a-helices are 
located outside of an inner ,8-barrel (MosER et al. 1997; HEINZ et al. 1998). The 
active sites of the enzymes are located at the C-terminal ends of the ,8-barrel 
regions. 
The ability of these enzymes to hydrolyse GPI is of particular interest, 
since many eukaryotic cell-surface proteins are linked to GPI phospholipids, 
and cleavage of the PI-glycan-ethanolamine anchor results in the release of 
the protein from the cell surface. The treatment of various eukaryotic cells 
with bacterial PI-PLCs has been shown to release alka line phosphatase, 5' 
nucleotidase, alkaline phosphodiesterase and acetycholinesterase from the cell 
surface (IKEZAWA 1986). TI1is significance of these findings has not been fully 
536 R.W. lTTBALL and J.l. Rooo 
explored, but it seems possible that some of these enzymes might be exploited 
by the bacterium - for example, as components of a phosphate-scavenging 
pathway. 
IV. Phospholipase D 
Whilst a number of bacteria have been shown to produce PLOs, the group of 
enzymes that has been investiga ted in the most detail includes Corynebac-
terium pseudotuberculosis, C. ulcerans and Arcanobacterium haemolyticum 
PLOs (McNAMARA et al. 1995). The bacterial enzymes are 64-97% identical , 
and antibodies against the individual proteins show some cross-neutralisation 
activity against the other enzymes. Intriguingly, these prote ins show amino-
acid-sequence homology with the PLO in brown-recluse-spider venom, espe-
cially at the N-terminus (TRUEIT and KI NG 1993; SoNGER 1997). The bacterial 
enzymes preferentially hydrolyse sphingomyelin and lysophosphatidyleholine 
and cause haemolysis of erythrocytes only in the presence of the Rhodococ-
cus equi cholesterol oxidase. In contrast, treatment of erythrocytes with C. 
pseudotuberculosis PLO renders them resistant to lysis with Staphylococcus 
aureus sphingomyelinase (/3-toxin). Not all bacterial PLOs behave in this way. 
The enzyme produced by Vibrio vulnificus is able to hydrolyse sphingomyelin 
and PC and is haemolytic (KOTHARY and KREGER 1985; KREGER et al. 1987), 
and it seems likely that this enzyme is a member of a distinct group of bacte-
rial PLOs. 
C. Functional and Biological Properties of Phospholipases 
By definition, phospholipases are able to hydrolyse phospholipids, with two 
main types of phospholipid able to serve as substrates. All phospholipids 
possess a water-soluble head group linked to a phosphate group and to 
hydrophobic fatty-acyl tails. The nature of the head group can be quite vari-
able, ranging from charged groups, such as choline, to inositol sugars (Fig. 3). 
Glycerophospholipids, such as PC, phosphatidylserine, PI and phosphatidyl-
glycerol, contain a glycerol backbone linking the fatty-acyl tails to the head 
group. Sphingolipids (sphingomyelins) contain a ceramide moiety (the back-
bone and fatty-acyl tail) linked to the head group. 
The mechanisms by which phospholipases recognise their substrates are 
not well understood. However, the crystal structures of the B. cereus PC-PLC 
(HouGH et al. 1989) and PI-PLC (HEINZ et al. 1998), the C. perfringens a-toxin 
(NAYLOR et al. 1998) and the L. monocytogenes PleA (MosER et al. 1997) all 
reveal an active-site cleft, which is thought to accommodate the head group 
of the phospholipid. The variations in the size and charge of the head group 
might, therefore, be important in determining the specificity of the different 
enzymes. The active site of the B. cereus PI-PLC and the L. monocytogenes 
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on mode (MasER et al. 1997; HEINZ et al. 1998). A number of hydrogen bonds 
are formed between the inositol head group and the side chains of amino 
acids lining the active site. As might be expected, the hydroxyl groups at 
positions 1 and 6 of the inositol ring are accessible to the solvent, and these 
groups are linked to other groups in the natural phospholipid substrate. 
For the B. cereus PC-PLC and the C. perfringens a-toxin, the active-site 
cleft is much narrower (HouGH et al. 1989; NAYLOR et al. 1998), which is in 
accordance with the ability of these enzymes to hydrolyse phospholipids with 
less bulky head groups; indeed, these enzymes are unable to hydrolyse PI sub-
strates. However, in spite of this constraint on the size of the head group, these 
enzymes are able to hydrolyse a remarkably wide range of substrates. For 
example, the B. cereus PC-PLC is reported to be able to hydrolyse PC, phos-
phatidylserine and phosphatidylethanolamine, which suggests that only 
conserved regions of the different head groups are recognised by these 
phospholipases. This suggestion is, to some extent, supported by experimental 
findings that the phosphate moiety of the substrate forms a strong network of 
hydrogen bonds with the three zinc ions, which are found in the active site of 
the protein (HANSEN et al. 1993a, 1993b ). The head group also forms hydro-
gen bonds with the side chains of amino acids lining the active site, and this 
might explain why the enzyme has subtly different activities towards different 
substrates. 
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In eukaryotes, most of the phospholipid is found in cell membranes, where 
it forms a water-impermeable bilayer, with the hydrophobic tail groups 
embedded within the membrane. The phospholipid bilaye r a lso provides a 
matrix for the display of va rious biologically active pro te ins and carbohy-
drates. However. membrane phospholipids pe rform more than a passive role 
in the maintenance of cell function. The products o f phospho li pid hydrolysis, 
especially the fatty-acyl tail groups. are key signalling molecules that modu-
late ce llula r metabolism. Pe rhaps it is no t surprising that many bacte ri al phos-
pholipases a re thought to modulate ce ll me tabolism via the hydrolysis of 
phospholipids and the generation of secondary messenger molecules. 1l1ese 
e ffects are discussed in more detail be low. 
D. Modulation of Eukaryotic Cell Metabolism 
I. Hydrolysis of Membrane Phospholipids 
Many of the bacterial phospholipases that p lay important roles in the patho-
genesis of disease are active towards eukaryotic cells. Erythrocytes are often 
used for these studies, because the effect of the enzyme can easily be mea-
sured in the laboratory as haemolysis. The lysis of these ce lls is thought to be 
due to the degradation of membrane phospholipids, which leads to weaken-
ing of the cell membrane and eventual lysis (TITBALL et al. 1993). Although 
phospholipids in erythrocyte membranes are degraded after treatment with 
phospholipases (COLLEY et al. 1973; SAKURAI et al. 1993, 1994), it not certain 
that the direct action of the bacterial enzyme on membrane phospholipids is 
responsible for cell lysis. One possibility is that the action of the bacterial 
enzyme is to cause activation of endogenous membrane phospholipases, which 
are then responsible for much of the membrane damage. Evidence support-
ing this suggestion has been provided by SAKURAI et al. (1993, 1994) 
who showed that membrane phospholipases C and D are activated in 
rabbit erythrocyte membranes treated with a-toxin and that inhibitors of 
the PLC activity of a-toxin (neomycin and 2-nitro-4-carboxyphenyl-
N,N-diphenylcarbamate) do not inhibit haemolytic activity of the a-toxin. 
Another suggestion is that the limited hydrolysis of the membrane phospho-
lipids leads to the accumulation of the hydrophobic fatty-acyl groups within 
the central region of the membrane bilayer, and that the resultant stresses in 
the membrane result in cell lysis (BowMAN et al. 1971; CoLLEY et al. 1973). 
Several workers have suggested that the haemolytic activity of phospho-
Jipases indicates their toxicity and their likely role in the pathogenesis of 
disease (MAcFARLANE 1955; 0 STROFF e t al. 1990; TITBALL 1993; SoNGER 1997). 
However, it is difficult to define what is meant by a non-haemolytic phospho-
lipase, since the activity of haemolytic enzymes towards e rythrocytes from dif-
ferent species (JouvET-REYNAUD et al. 1988), towards erythrocytes suspended 
in different buffers and even towards erythrocytes of diffe rent ages (LITTLE 
et al. 1981) varies. However, it is generally accepted that phospholipases, which 
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Tablc3. 1l1c relationship between haemolytic activity and the lateral pressure at which 
the hydrolysis of phospholipids ceases in a phospholipid monolayer (Moll by <! I al. 1978) 
Source of enzyme 
Pig pancreas 
Cabbage 
Crotalus adamanteus venom 
Bacillus cereus PC-PLC 
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play important roles in disease, are able to interact with membrane phospho-
lipids, and this might cause lysis of cells. 
The insertion of phospholipases into lipid monolayers was studied by V AN 
DEENEN et al. (1976), who showed that, by increasing the lateral pressure 
within a phospholipid monolayer, it was possible to identify two groups of 
enzymes (Table 3). The enzymes in one group were able to hydrolyse the phos-
pholipid in the monolayer at lateral pressures above those found in typical 
membranes (31-35dyne/cm; Mollby 1978), and enzymes in this group were 
also haemolytic- perhaps a reflection of their ability to be inserted into mem-
brane bilayers. 
Only recently have we gained some insight into the molecular mechanisms 
by which these enzymes interact with membranes. In the case of the C. per-
fringens a-toxin, the crystal structure of the protein has revealed that the 
protein possesses surface-exposed hydrophobic amino acid side chains (Trp214, 
Tyr33, and Phe334) that are positioned on the active-site faces of the N- and 
C-domains of the protein in a way that enables them to interact with the 
hydrophobic tail groups of membrane phospholipids (NAYLOR et al. 1998). In 
addition, the C-domain contains a partial calcium-binding site (GurLLOUARD 
et al. 1997), and a model of the a-toxin docked with a membrane suggests that 
the phosphate head groups of membrane phospholipids provide the additional 
calcium-coordinating ligands (NAYLOR et al. 1998). The C-domain of the a-
toxin shows significant structural homology with calcium-dependent phos-
pholipid-binding domains from mammalian enzymes (Fig. 4) , such as PI-PLC, 
arachidonate-5-lipoxygenase and synaptotagmin (GurLLOUARD et al. 1997· 
NAYLOR et al. 1998). This model is supported by the long-standing observation 
that calcium ions are absolutely required for the activity of the a-toxin (KRUG 
and KENT 1984; MOREAU et al. 1988; NAGAHAMA et al. 1996) and that calcium 
ions have not been detected in purified preparations of the a-toxin (KRUG and 
540 R.W. TITBALL and J.l. Rooo 
.I 
r'?\L ,-!-. 
' \.._~ i\L.. ~0 
Fig. 4. Structural similarity of the C-terminal domain of a-toxin (a) with the lipid-
binding domains of soybean lipoxygenase I (b), synaptotagmin (c) and mammalian 
phosphoinositide-specific phospholipase C COl (d). NAYLOR et al. (1998) 
KENT 1984), probably because of the low affinity of the a-toxin for calcium 
ions in the absence of phospholipid (GuJLLOUARD et al. 1997). The model is 
also supported by a comparison with the crystal structure of the non-
haemolytic B. cereus PC-PLC, which lacks a C-domain (and, therefore, the 
calcium-binding site) and also has amino acids without hydrophobic side 
chains at comparable positions in the a-toxin (NAYLOR et al. 1998; HouGH 
et al. 1989). 
The mechanism by which other phospholipases interact with membrane 
phospholipids are less well understood, and many of these enzymes do not 
require divalent cations, such as calcium, to facilitate the interaction. Never-
theless, it seems likely that at least partial insertion of the enzyme into the 
phospholipid bilayer is required. The active site of the B. cereus PI-PLC is sur-
rounded by a ridge of hydrophobic amino acids, and it is proposed that this 
hydrophobic surface (which has an area of -350A2) becomes inserted into the 
membrane (HEINZ et al. 1998). 
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Many of the early studies with bacterial phospholipases considered that 
haemolysis was the key indicator of activity, and it was suggested that the 
haemolytic enzymes produced by pathogens migh t function by causing lysis of 
host cells. In fact widespread haemolysis is rarely, if ever, encountered in cases 
of disease caused by pathogens that produce phosphol ipases (HOBL et al. 
1993). Nevertheless, phospho lipases do play important and, in some cases, key 
roles in the pa thogenesis of disease, and rece nt studies suggest that these 
enzymes function not by causing wide-scale cell lysis but by causing limited 
hydrolysis of membrane phospholipids, the products of which modulate cell 
metabolism to the detriment of the host and to the benefit of the pathogen. 
Central to this process is the generation of diacylglycerol from glyc-
erophospholipids and ceramide from sphingolipids. Diacylglycerol affects cell 
metabolism in several ways. First, it is able to serve as a substrate for diacyl-
glycerollipase, and the product of this enzyme (arachidonic acid) can, in turn. 
serve as a substrate for the arachidonic-acid pathway (SAMUELSSON 1993). The 
activation of the arachidonic-acid pathway has been reported in cells exposed 
to a variety of phospholipases, including the C. perfringens a-toxin (Fum and 
SAKURAI 1989; GUSTAFSON et al. 1990; BUNTING et al. 1997), the P. aeruginosa 
PLC-H (KoNJG et al. 1997) and the B. cereus PC-PLC (LEVINE et al. 1988). The 
products of the arachidonic-acid pathway include pro-inflammatory mole-
cules, such as the prostaglandins, thromboxanes and leukotrienes, which cause 
vasodilation and bronchonstriction and cause mucus secretion (SAMUELSSON 
1983). A more detailed analysis of the roles of these molecules is beyond the 
scope of this review. However, it is worth pointing out that these molecules 
are also central to the platelet-aggregation pathway, which might explain the 
long-standing observations that some phospholipases cause platelet aggrega-
tion (SuGAHARA et al. 1976; 0HSAKA et al. 1978; CouTrNHO et al. 1988). 
Second, diaycylglycerol can activate protein kinase C (PKC) within cells, 
and the activated PKC is thought to activate eukaryotic membrane-bound 
phospholipases (W AITE 1987; EXTON 1990; NISHIZUKA 1992). These activated 
phospholipases would lead to further hydrolysis of membrane phospholipids, 
and this has lead to the suggestion that haemolysis might actually be an indi-
cation of self-degradation of membrane phospholipids rather than a direct 
effect of the bacterial enzyme on the membrane (SAKURAI e t al. 1993, 1994; 
0CHI e t al. 1996). 
Of equal significance is the ability of the activated eukaryotic phospholi-
pases to generate further substrates for the arachidonic-acid cascade and to 
further activate PKC. Hence, the initial inte raction of the bacterial enzyme 
with the host cell membrane might trigger a positive-feedback loop, which 
leads to the eventual self-destruction of the cell. Of the e ukaryotic phospho-
lipases that might be activated , the PI-PLCs merit specia l consideration , 
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because the inositol triphosphate (I PJ) generated by hydrolysis of inositol 
diphosphate would act as a secondary messenger within the cell. One e ffect 
of IPJ would be to cause the release of calcium from the e ndoplasmic reticu-
lum, and this would. in turn , cause both the opening of calcium ga tes in the 
me mbrane and the contraction of muscle tissues (SAKURAI e t a l. 1990). 
E. Regulation 
1. Regulation of the C. perfringens plc Gene 
The C. pe1jringens a-toxin is encoded by the plc gene, which is some times 
referred to as the cpa gene and is located in a hyper-va riable region of the C. 
pe1jringens chromosome (CoLE and CANARD 1997). Immedia tely upstream of 
the plc promoter, there is a series of poly-A repeat sequences that appear to 
affect the ability of the DNA to bend (ToYONAGA et al. 1992). D eletion of this 
77-bp AT-rich region increases the expression of the plc gene in Escherichia 
coli, suggesting that this region of DNA curvature has a negative regulatory 
role in a-toxin production. However, in C. perfrin.gens, deletion of one or more 
of the dA5~ tracts located within the 77-bp region leads to decreased a-toxin 
production (MATSUSHITA et al. 1996). These results imply that host factors are 
important in plc gene regulation, a conclusion supported by gel-retardation 
studies, which have shown that, in C. perfringens, there is an uncharacterised 
factor that binds within the plc gene (KATAYAMA et al. 1993). 
Other studies have identified a two-component signal-transduction system 
which globally regulates extracellular toxin production in C. pe1jringens 
(LYRrsns et al. 1994; SHIMIZU et al. 1994). Mutation of either the virS or virR 
genes, which encode a sensor histidine kinase and a response regulator, respec-
tively, leads to the complete loss of 6-toxin production and reduced produc-
tion of a-toxin, K-toxin, and other extracellular enzymes. Regulation of this 
system occurs at the transcriptional level (BA-THEIN et al. 1996), but the 
precise mechanism by which the activated VirR protein controls a-toxin pro-
duction is not known. The environmental factors that stimulate the VirS!VirR 
regulatory cascade are also unknown (Rooo and LYRISTIS 1995). 
II. Environmental Control of PLC Production in P aeruginosa 
The PLC-Nand PLC-H PLC enzymes from P aeruginosa are encoded by the 
plcN and plcH (or pieS) genes, respectively. Both genes are induced by phos-
phate starvation, choline or glycine betaine (VASIL et al. 1994). Activation of 
both plcH and plcN in an environment low in inorganic phosphate (Pi) is 
dependent upon a homologue of the E. coli PhoB protein, a response regula-
tor which activates the transcription of the Pi regulon in E. coli. In P aerugi-
nosa, this phoB (or pleA) regulon includes the gene e ncoding alkaline 
phosphatase and the two phospholipases (SHORTRIDGE et al. 1992; V ASIL et al. 
1994). 
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The plcH gene is the first gene in a n operon that also includes two in-
phase overlapping genes, pieR I and plcR2, which e ncode proteins that appear 
to be required for the secre tio n of PlcH (but not PlcN) fro m P. aeruginosa cells 
(COTA-GOMEZ et al. 1997). The plcHR operon has both PhoB-dependent and 
PhoB-independent promo te rs. the la tte r being involved in plcH activa tion 
by the PLC end-product. phosphorylcholine, as well as choline and glycine 
betaine. Choline and glycine be taine a re breakdown products of phosphoryl-
choline and act as osmopro tecta nts a nd pote ntia l carbon, nitrogen a nd e nergy 
sources. A novel catabolite-repression sys tem appears to be involved in the 
osmoprotectant-depende nt regulation of plcH transcription (SAGE and VASI L 
1997). These compounds a lso activate plcN which. since it only has one PhoB-
dependent promoter, requires both PhoB and P, starva tion for choline- and 
glycine-betaine -media ted activa tion (SHORTRIDGE e t al. 1992; VASJL e t al. 1994). 
Choline-induced activatio n o f p lcH requires the orp gene, which encodes a 
putative regulatory protein, and betB, which encodes a betaine-alde hyde dehy-
drogenase, a n enzyme invo lved in the synt hesis of glycine betaine from choline 
(SAGE et al. 1997). 
Ill. Regulation of the Listeria Phospholipases by PrfA 
The Listeria phospholipases PI-PLC and PC-PLC are encoded by the pleA 
and pleB genes, respective ly. These genes are located within a cluster of viru-
lence genes on the L. m onocytogenes chromosome but are encoded on diver-
gently transcribed operons (Fig. 5). The pleB gene is the third gene in an 
operon that includes the mpl gene, the product of which is a zinc metallopro-
tease involved in the post-tra nslational activation of PC-PLC (RAVENEAU et 
al. 1992; PoYART et al. 1993), and the actA gene, which encodes a protein 
involved in host actin polymerisation (SMITH and PoRTNOY 1997). Proximal to 
this operon is the lister iolysin-0 gene, hly, followed by the divergently 
expressed pleA and prfA genes (Fig. 5). The pfrA gene is expressed both from 
prfA pleA hly m pi actA pleB orfX orfZ 
orfY 
Fig.S. Genetic o rganisa tion of the Listeria monocytogenes toxin gene locus. TI1e 
respective genes and their transcriptional orientations are shown by the thick arrows. 
The major transcripts are shown by the thin arrows 
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its own promoter and from the pleA promoter ( MENGAUD et al. L991). It 
encodes a regulatory protein that activates the transcription of all of these 
genes, including pleA and pleB (MENGAUD e t al. 1991; CliAKRABORTY et al. 
1992). It is also autoregulatory. activating its own expression from the pleA 
promoter and repressing transcription from the monocistronic prfA promoter 
(FREITAG et al. 1993; FREITAG and PORTNOY 1994). Other pfrA-regulated genes 
include the inte rnalin operon, in/AB (0RAMSI et al. 1993), in/C (ENGELBRECHT 
et al. 1996) and genes encoding several surface proteins (SOKOLOVIC et a l. 
1993). 
Expression of the prfA regulon is temperature- and growth-phase-
dependent and is activated in minimal essential medium (MENGAUD et al. 1991 ; 
LEIMEISTER-WACHTER et al. 1992; SoKOLOVJC et al. 1993). Higher levels of 
expression of PrfA-regulated genes are observed at 37°C (compared with 
25°C, as expected for an opportunistic pathogen whose virulence genes do not 
need to be expressed in the normal saprophytic environment; LEIMEISTER-
WACHTER et al. 1992). The PrfA protein has sequence similarity to the Crp/Fnr 
family of transcriptional activators (LAMPIDIS et a l. 1994). It contains a 
helix-turn-helix motif, which is commonly found in DNA binding proteins, 
such as the cyclic adenosine monophosphate receptor protein, Cap or Crp, and 
which has been shown to be functionally significant in PrfA-mediated viru-
lence-gene activation (SHEEHAN et al. 1996). PrfA binds to 14-bp regions of 
dyad symmetry, variants of which are found in the promoter regions of all of 
its target genes (FREITAG et al. 1993; DICKNEITE et al. 1998). Differences in the 
regulation of the various PrfA-induced genes probably reflect differences in 
the PrfA-binding sites, which are located at a position 40-41 bases upstream 
of the transcriptional start site (FREITAG et al. 1993; BOHNE et al. 1994; 
DICKNEITE et al. 1998). Binding of PrfA to this PrfA box occurs independently 
of other factors but is more efficient in the presence of Paf (PfrA-activating 
factor; BocKMANN et al. 1996; DICKNEITE et al. 1998). Enhanced Paf synthesis 
or activity occurs in low-iron medium. Note that, independent of any effects 
on the transcription of prfA, expression of the hly and pleA genes is repressed 
in the presence of cellobiose, a plant-cellulose-derived disaccharide (PARK and 
KROLL 1993; KLARSFELD et al. 1994; RENZONI et al. 1997). It has been postu-
lated that repression occurs because the presence of cellobiose signifies that 
the bacterial cells are in a saprophytic environme nt and do not need to 
produce listeriolysin 0 or PI-PLC (PARK and KROLL 1993). 
F. Role in Disease 
I. Gas Gangrene 
D efinitive evidence for the essential role of C. pe1jringens a-toxin in clostridial 
myonecrosis or gas gangrene has come from indepe ndent studies in each of 
our laboratories (WJLLIAMSON and TITBALL 1993; AWAD et al. 1995). Immu-
nization of mice with a recombinant protein which consisted of the C-
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terminal portion (amino acids 247-370) of the a-toxin protected mice aga inst 
at least ten LD uXJ doses of C. perfringens cells (WILLIAMSON and TrrnALL 1993). 
Although this truncated protein was non-functional , antibodies prepared 
against it neutralised both the PLC and haemolytic activity of a-toxin. 
lmmunoprotection was dependent upon the C-terminal component of the a-
toxin, since immunization against an N-terminal de riva tive did not protect 
aga inst the disease. Definitive genetic proof of the essential role of a-toxin in 
gas gangrene has come from studies that involved the construction of an inser-
tionally inactivated chromosomal plc gene (AwAo et a l. 1995). Virulence 
studies carried out in mice showed that isogenic mutants that were unable to 
produce a-toxin were avirulent; virulence could be res tored by providing a 
wild-type copy of the plc gene on a multicopy plasmid. Mice infected with the 
a-toxin-deficient mutants had minimal swelling, muscle destruction, inflam-
mation or necrosis; by contrast, infection with the wild-type or complemented 
strains led to extensive muscle destruction and severe necrosis. Other workers 
have also constructed a chromosomal plc mutant and shown that it had sig-
nificantly reduced virulence in mice (NINOMIYA et al. 1994). 
More recent studies have shown that a-toxin is an important modulator 
of neutrophil migration into infected muscle tissue (STEVENS et al. 1997). One 
of the characteristic and unusual features of C. perfringens-mediated gas gan-
grene is the almost complete absence of polymorphonuclear leucocytes 
(PMNLs) in the infected lesion. Comparative histological examination of 
tissues derived from mice infected with either the wild-type or plc-mutant 
strains has shown that a-toxin prevents the efflux of PMNLs from the blood 
vessels into the muscle tissue, probably by stimulating the production of spe-
cific cell-surface adhesins in the endothelial cells. The net effect is to promote 
the adherence of PMNLs to the vascular endothelium, thereby facilitating the 
spread of the infection by preventing the influx of phagocytic cells into the 
infected tissues. These conclusions are supported by studies which show that 
purified a-toxin positively regulates the expression of the adhesins endothe-
lial leucocyte adehesion molecule 1 and intercellular adhesion molecule 1 on 
the surface of endothelial cells (BRYANT and STEVENS 1996). Studies on cul-
tured human endothelial cells have also revealed enhanced Paf and prostacy-
clin synthesis and P-selectin-mediated neutrophil adhesion in response to 
treatment with purified a-toxin (BuNTING et al. 1997). The C. perfringens 8-
toxin also appears to play a role in preventing PMNL influx into the lesion, 
perhaps in synergy with the a-toxin (AwAD et al. 1995; STEVENS et al. 1997). 
The precise molecular pathways by which a-toxin mediates both its toxic 
effects and its effects on the migration of phagocytic cells are not known. 
However, as already discussed, they are likely to involve the stimulation of 
target cell regulatory cascades by the products of phospholipid hydrolysis, such 
as diacylglycerol. Other studies have shown that Chinese-hamster cell lines 
with a deficiency in their ability to produce uridine diphosphate- glucose 
pyrophosphorylase are hypersensitive to the cytotoxic effects of a-toxin 
although, again, the precise mechanism is not known (FLORES-DIAZ et al. 1997, 
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1998). Finally. studies using purified toxins in rabbits have shown that a-toxin 
causes systemic haemodynamic effects, probably by direct myocardial toxic-
ity, and stimula tes endogenous mediators of systemic shock, such as tumour 
necrosis factor (STEVENS and BRYANT 1997). 
11. P. aeruginosa Infections 
P. aeru.ginoso is the aetiological agent of a va riety of opportunistic infections 
of man and is frequently isolated from the lungs of cystic-fibrosis patients and 
from burn tissues. TI1e bacterium is a lso a pathogen of animals, causing dis-
eases such as fleece rot in sheep, and is a pathogen of plants. causing soft rot 
disease. The bacterium produces a wide variety of exotoxins, including the PLC 
enzymes PLC-H and PLC-N (OsTROFF et al. 1990). TI1ese phospholipases show 
differences in substrate specificity, and only PLC-H is haemolytic. Therefore, 
considerable attention has been focused on PLC-Has the phospholipase most 
likely to play a key role in disease. Antibodies against PLC-H have been 
detected in sera from cystic-fibrosis patients (GRANSTROM et al.1984) and from 
sheep suffering from fleece rot (CHIN and WATTS 1988), indicating that this 
enzyme is produced in vivo. 
The precise roles of the P. aeruginosa phospholipases in the pathogenesis 
of disease have not been determined. The LD50 of PLC-H (pleH) mutants 
grown under phosphate-limited conditions in a mouse burn model is 2.4logs 
greater than that of the wild-type strain (OsTROFF et al. 1989). However, this 
result is difficult to interpret, because mutation of the pieR regulatory gene, 
which is located downstream of pleH, was equally attenuating, even though 
the bacteria produced higher levels of PLC-H. Therefore, it is possible that the 
attenuation seen with the pleH mutant was due to a polar effect on pieR. Sim-
ilarly, the finding that pleH mutants caused less severe disease in Arabidopsis 
thaliana plants (RAHME e t al. 1995) might be due to polar effects on pieR. 
Notwithstanding these results, there are several lines of evidence that 
suggest that the P. aeruginosa phospholipases do play a role in disease. Puri-
fied PLC-H administered intravenously or intraperitoneally caused necrosis 
of liver and kidney tissues, similar to the effects caused by crude culture fil-
trates, a finding which prompted the suggestion that PLC-H was the main exo-
toxin produced by the bacterium (MEYERS et al. 1992). PLC-H administered 
intradermally into sheep has been shown to cause dermal necrosis, with the 
infiltration of leukocytes; this resembled the lesions seen in cases of fleece rot 
(CHIN and WATTS 1988). Pro-inflammatory compounds, such as leukotriene B4 
and histamine, could be responsible for some of these effects, and these com-
pounds are released from human granulocytes treated with PLC-H (KoNIG 
et al. 1996). The effects were further potentiated by the lipase produced by 
P aeruginosa, suggesting that these enzymes might act synergistically in vivo 
(KONIG et al. 1996). 
What role might the PLCs play in disease? One possibility is that the phos-
pholipases form part of a phosphate-retrieval system, which might be impor-
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tant because the level of free phosphate in sera is sub-optimal for the growth 
of Gram-negative pathogens (WEINBERG 1974). The finding that PLC produc-
tion is induced under low-phosphate conditions (PRITCHARD and VASIL 1986; 
OsrROFF et al. 1990; SHORTRIDGE et al. 1992) supports this suggestion. In res-
piratory-tract infections, the enzymes might play additional roles by degrad-
ing lung surfactant (HOLM e t al. 1991), which is rich in PC, to allow the 
bacterium to gain access to unde rlying tissues. Another intriguing possibility 
is that the phospholipases may play a role in the accumulation of choline, 
which then accumulates within the bacterial cell and acts as an osmoprotec-
tant in the lung (LANDFELD and SrROM 1986; SAGE e t al. 1997). 
Ill. The Pathogenesis of Listeriosis 
L. monocytogenes is a food-borne pathogen that causes severe meningitis and 
septicaemia, particularly in elderly or immunocompromised patients, the new 
born and in pregnant women, where it may cause abortion. Pathogenesis is 
primarily dependent on the ability of the organism to survive and replicate in 
macrophages (SHEEHAN et al. 1994 ). L. monocytogenes is an invasive intracel-
lular pathogen that avoids the host immune system by transferring directly 
from one cell to the adjoining cell. This process involves the ActA-mediated 
movement of listeria! cells within and between the mammalian host cells by a 
process of actin polymerisation (TrLNEY and PoRTNOY 1989; SHEEHAN et al. 
1994). After initial entry of L. monocytogenes into the macrophage by phago-
cytosis, the organism escapes the resultant primary phagocytic vacuole, mainly 
because of its ability to produce the pore-forming cytolysin, listeriolysin 0. PI-
PLC also plays a role in the escape of the cells from phagosomes of the 
macrophage, enabling the organism to grow in the cytoplasm of the host cell 
(CAMJLLI et al. 1993).ActA enables the bacteria to move through the host cells 
and into neighbouring cells, forming a membrane-bound protrusion. PC-PLC 
is believed to be important in cell-to-cell spread, probably by hydrolysing 
phospholipids in the cell membrane and enabling the bacteria to escape these 
membrane-bound protrusions (VAZQUEZ-BOLAND et al. 1992). A mutant that 
was unable to produce PC-PLC has been shown to be defective in cell-to-cell 
spread (but not in escape from the primary phagocytic vacuole) and was 20 
times less virulent in mice (SMITH et al. 1995). An equivalent PI-PLC mutant 
had only a twofold reduction in virulence and was not affected in its ability to 
spread directly from one cell to another, although delayed escape from the 
primary vacuole was observed. Double plc mutants unable to produce either 
enzyme are more than 500 times less virulent than the isogenic wild-type strain 
and are severely affected in both intracellular spread and vacuolar escape 
(SMITH et al. 1995). 
Recent virulence studies have also shown that PC-PLC is important in 
cerebral listeriosis in the mouse; when mice are infected with a pleB mutant, 
death is significantly delayed compared with that in wild-type mice (ScHLUTER 
et al. 1998).ln summary, both phospholipases are important in virulence, with 
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PI-PLC required for efficient escape from the primary vacuole and PC-PLC 
required for cell -to-ce ll spread. In epithelial cells, PC-PLC also appears to be 
involved in escape fro m the phagosome, at least in the absence of listerio lysin 
0 , since mutan ts lacking listerio lysin 0 and PC-PLC a re unable to grow intra-
cellularly, unlike mutants lacking listeriolysin 0 and PI-PLC (MARQU IS et al. 
1995). Neither phospholipase appears to be involved on its own in the stimu-
lation of neutrophil adhesion to endothelial cells, a process tha t is presumably 
important in the systemic spread of L. monocytogenes cell s (DREVETS 1998). 
However, even in the absence of cell invasion , Pl-PLC and liste rio lysin 0 act 
syne rgistically to induce endothelial cell signa lling and inflammatory events 
(SmEuus et a l. 1996). It is proposed that pore fo rma tion by listeriolysin 0 is 
required for the uptake of PI-PLC and its subsequent stimula tion of signal-
transductio n pathways in the endothelia l cell. 
IV. Caseous Lymphadenitis in Ruminants 
Caseous lymphadenitis is a disease of the lymphoid tissues of ruminants, par-
ticularly sheep and goats, and is caused by C. pseudotuberculosis. Virulent 
biovars of C. pseudotuberculosis produce a PLO that has been shown to be 
essential for virulence in sheep and goats (HooGSON et al. 1992; McNAMARA 
et al. 1994). The organism appears to be an intracellular pathogen that multi-
plies in the phagolysosomes of neutrophils and macrophages and produces 
abscesses, primarily at the site of infection and in the regional lymph nodes. 
Infection of goats with a C. pseudotuberculosis strain carrying a chromosomal 
pld mutation led to a markedly reduced disease pathology, with minimal dis-
semination of the organism from the primary site of infection and little evi-
dence of abscessation (McNAMARA et al.1994). Using a different chromosomal 
pld mutant, similar results have been obtained in sheep (HooGSON et al.1992) . 
Despite numerous studies on the use of rationally attenuated C. pseudotuber-
culosis strains as vaccines (HooGSON et al. 1992; SIMMONS et al. 1997, 1998), 
very little is known about the role of PLO in the disease process. 
G. Conclusions 
Work with bacterial PLCs during the 1940s founded many principles that were 
then subsequently applied to the study of other bacterial toxins. Perhaps 
because of these early studies, interest in bacterial phospholipases waned 
during subsequent decades, and it was not until the 1990s that there was a 
resurgence of interest in this group of bacterial toxins. Today, a wide variety 
of pathogenic bacteria are known to produce phospholipases and, from the 
early findings that some of these enzymes were toxins, we have developed an 
appreciation of the diversity of roles that these enzymes play in the patho-
genesis of disease. In spite of this knowledge, there are many questions yet to 
be answered. D o these enzymes play a role in the colonisa tion of phospho-
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lipid-rich mucosal surfaces? Why do some pathogens produce several enzymes 
with different properties? What roles do these enzymes play in the role of dis-
eases caused by M. tuberculosis. B. pseudomallei and Helicobacter pylori? At 
a molecular level, we know little about the mechanisms of action of these 
enzymes. How do these enzymes interact with membrane phospholipids, and 
what is the molecular basis of the subtle but important differences in substrate 
speci ficity? Do phospholipases produced by intracellular pathogens play a role 
in modulating cell metabolism to the advantage of the pathogen? How is the 
expression of bacterial phospholipases regulated in the infected tissues? 
Many of the techniques and tools required to answer these questions are 
now avai lable and are being applied to the study of this group of enzymes. 
1l1ese studies are of more then academic interest. Enzymes that play key roles 
in the pathogenesis of disease might be modified to provide vaccines, and 
inhibitors of these enzymes might find places as new anti-bacterial drugs to 
deal with antibiotic-resistant strains of bacterial pathogens. These enzymes 
might also find applications in novel drug-delivery systems, such as that 
described by CARTER et al. (1998). This is a truly exciting time to be working 
in this field. 
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The sequence of 20 amino acids from theN terminus of Clostridium perfringens epsilon-toxin was determined. 
Some differences between this sequence and the previously published sequence (A. S. Bhown and A. F. S. A. 
Habeeb, Biochem. Biophys. Res. Commun. 78:889-896, 1977) were found. A degenerate 23-bp pair 
oligonucleotide probe was designed from the amino acid sequence data and used to isolate a DNA fragment 
containing the gene encoding epsilon-toxin (elx) from C. perfringens type B. The gene encoded a protein with 
a molecular weight of 32,981. Upstream of the gene, promoter sequences which resembled the Escherichia coli 
o-70 consensus sequences were identified. The gene was expressed in E. coli, and the cloned gene product reacted 
with epsilon-toxin-specific monoclonal antibodies and had a molecular weight and isoclectric point similar to 
those of the native protein. Downstream of etx, two overlapping open reading frames were identified. Each 
encoded part of a protein which was homologous to the transposase from Staphylococcus aureus transposon 
Tn400J. Southern hybridization experiments indicated that the etx gene was found only in C. perfringens types 
B and D, the types which produce epsilon-toxin. 
Clostridium perfringens is the causative agent of a wide 
variety of diseases. It has been associated with gas gangrene 
and food poisoning in humans and with a range of severe 
enterotoxemic diseases in many species of domestic animal. 
The bacterium produces up to 17 exotoxins (38) which are 
believed to play a role in pathogenesis , although in most 
cases their activity is poorly understood. The organism is 
grouped into five types (types A, B, C, D, and E) on the basis 
of the production of four major toxins, alpha-, beta-, epsi-
lon-, and iota-toxins (6). Epsilon-toxin is produced by C. 
perfringens types B and D and is responsible for a rapidly 
fatal enterotoxemia in economically important livestock. 
Epsilon-toxin has been purified by a number of indepen-
dent workers, and its physical properties have been studied 
(reviewed in reference 22). It is secreted as a relatively 
inactive prototoxin which, after treatment with trypsin, is 
converted to fully active toxin with the loss of an N-terminal 
peptide (2). The mature toxin is a highly toxic protein with 
lethal , dermonecrotic, and edematic activities (1) . However, 
it is not known how the toxin achieves its effects, although 
some ami no acid residues important for its function have 
been identified. The chemical modification of amino acids 
has suggested that one tryptophan (30), one histidine (32), 
one tyrosine (33) , three or four aspartic or glutamic acid (34), 
and eight lysine (31) residues are essential for the lethal 
activity of the tox in . 
Despite the amount of information known about its phys-
ical properties and its biological activi ties, the mode of 
action of epsilon-toxin is not known, and no enzymatic 
activit y has been attributed to it. In order to investigate its 
activity and to define the physical properties more preci ely , 
we have cloned the gene (etx ) encoding C. perfringens type 
B epsilon-toxin into Escherichia coli. Thi~ approach will also 
allow us to study the antigenicity of the protein and to 
examine the relationship between structure and function . 
* Corresponding author. 
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Eventually, this could enable us to develop synthetic vac-
cines, based on immunogenic peptides or genetically engi-
neered toxoids, which protect livestock against certain 
forms of enterotoxemia. 
MATERIALS AND METHODS 
Enzymes and reagents. Materials for the preparation of 
growth media were obtained from Oxoid Ltd. or Difco 
Laboratories . All enzymes used in the manipulation of DNA 
were obtained from Boehringer Mannheim UK Ltd. and 
used according to the manufacturer's inst ructions. All other 
chemicals and biochemicals were obtained from Sigma 
Chemical Co. Ltd. unless otherwise indicated . Epsilon-
prototoxin, purified from C. perfringens type D (strain 
unknown) was supplied by Wellcome Research Laboratories 
(Beckenham, Kent, United Kingdom) . Anti-epsilon-toxin 
monoclonal antibodies, raised against a toxoid of the protein 
(5, 26). were supplied by D. Percival (Chemical and Biolog-
ical Defence Establishment) or purchased from the Central 
Veterinary Laboratories (Weybridge, Surrey, United King-
dom) . 
Activation of epsilon-prototoxin. Epsilon-prototoxin was 
converted to active toxin with insoluble trypsin-L-1-tosyl-
amide-2-phenylethyl chloromethyl ketone (trypsin-TPCK) 
attached to beaded agarose. Samples (100 IJ-1} containing 
epsilon-prototoxin (up to 50 IJ.g/ml) were incubated with 2.5 
U of trypsin for 1 h at 37°C. The reaction was stopped by 
centrifugation to pellet the trypsin-TPCK . 
Amino acid scquencing. Purified ep ilon-prototoxin was 
converted to toxin with trypsin-TPCK. Samples of the toxin 
(100 pmol) were electroblotted on to a polyvinylidene diflu-
oride membrane [Immobilon-P; Millipore (UK) Ltd.] from a 
denaturing polyacrylamide gel. The N-terminal amino acid 
sequence was determined directly from the blotted protein 
with a gas-phase sequencer (470A; Applied Biosystem ) 
equipped with an on-line phenylthiohydantoin analyzer 
(120A: Applied Biosystems) . 
VoL. 60 , 1992 CLON ING OF THE C. PERFRINGENS EPSILON-TOXI GE E 103 
Bacterial strains and cultivation. C. perfringens strains 
were cultured a naerobicall y at 37"C in a liquid medium 
containing trypticase peptone (3%), yeast extract (0.5%), 
glucose (0.5%), cysteine hydrochloride (0.05%), and sodium 
thioglycolate (0.1%) that was adjusted to pH 7.5 by the 
addition of Na2 HP04 (TPYG broth). For the isolation of 
DNA , cells of C. perfringens were cu ltured in 6-liter vol-
umes of TPYG broth for 18 h and then separated from the 
culture fluid by filtration through a 0.22-~J.m-pore-size mem-
brane. £. coli J M 101 was stored and cultured as described by 
Sambrook et al. (35). 
Preparation of DNA. Chromosomal DNA was isolated 
from strains of C. perfringens, C. botulinum, C. novyi, C. 
bifermentans, C. histolyticum, C. sordel/ii, C. chauvoei, C . 
absonum , £. coli, and Bacillus subtilis by the method of 
Marmur (21). DNA extracted from C. perfringens type B 
strain NCTC 8533 was purified by centrifugation through a 
gradient of cesium chloride (35). Large- and small-scale 
plasmid isolations were performed as described by Sam-
brook et al. (35). Fragments of DNA were isolated from 
agarose gels with DEAE cellulose paper (35). Oligonucleo-
tides were prepared with a DNA synthesizer (200A; Beck-
man Instruments, Inc.). When used in hybridization , the 
oligonucleotides were synthesized without removing the 
final trityl group and then purified with an Oligonucleotide 
Purification Cartridge (Applied Biosystems) according to the 
manufacturer' s instructions. 
Blotting of DNA. After electrophoresis, DNA digested 
with restriction endonucleases was transferred to a nylon 
membrane (Zeta-Probe; Bio-Rad) with a vacuum blotting 
apparatus (Vacugene; Pharmacia LKB Biotechnology) ac-
cording to the manufacturer's instructions. Undigested DNA 
was transferred to a nylon membrane with a slot blotting 
apparatus (Bio-Dot SF; Bio-Rad) according to the recom-
mendations of the manufacturer. 
Hybridization of gene probes. Oligonucleotide probes (10 
pmol) were 5' end labelled by using T4 polynucleotide kinase 
and ["y-32P]ATP (35). The reaction buffer was modified to 
include 1 mM spermidine. Unincorporated ["y-32P)ATP was 
removed by passing the labelled oligonucleotide through a 
Nensorb 20 column [DuPont (UK) Ltd .] according to the 
manufacturer's instructions. Isolated fragments of double-
stranded linear DNA were labelled with [a-32P]dCTP by 
using a random-primed labelling kit (Boehringer Mannheim 
UK). The labelled probes were hybridized to membranes as 
described by Sambrook et al. (35). For oligonucleotide 
probing, the temperature at which hybridization and washing 
took place was 42°C. 
Cloning techniques. Chromosomal DNA from C. perfrin-
gens type B strain NCTC 8533 was digested with restriction 
endonucleases, ligated to 0.1 IJ.g of digested and dephosphor-
ylated pUC18 (Pharmacia LKB Biotechnology) (35) , and 
transformed into £. coli JM101 cells (18). The cells were 
transferred to a nylon membrane (Hybond-N; Amersham 
International plc) by colony blotting as described by Sam-
brook et al. (35). except that after being replica plated , the 
colonies were incubated on L agar containing chloramphen-
icol (100 !J.g/ml) to amplify the plasmid DNA. After the 
membranes were probed with either radioactively labell ed 
oligonucleotides or DNA fragments as described above, 
positive colonies were picked from the original plate and 
subcultured. 
Nucleotide sequencing. C loned DNA fragments which hy-
bridized with etx gene probes were subcloned into bacteri-
ophages Ml3mp18 and Ml3mp19. Templates for sequencing 
single-stranded Ml3 DNA (35) and plasmid DNA (9) were 
produced as described previously. Nucleotide sequencing 
was performed by the dideoxy-chain termination method 
with cloned T7 DNA polymerase (Sequena e ver ion 2.0; 
United States Biochemical Corp.) according to the manufac-
turer's instructions. Nucleotide sequence and derived amino 
acid sequence data were analyzed with DNAstar microcom-
puter soft ware. The amino acid sequences of epsilon-toxin 
and other open reading frames (ORFs) were compared with 
the Protein Information Resource data base of protein se-
quences by using the PROSCAN and AALIGN programs. 
Open reading frames were analyzed with the program 
FRAME (3), which runs on a MicroVAX 3600 computer. 
Preparation of protein from cell cultures.£. coli celllysates 
were prepared by sonicating cells resuspended in deionized 
water at 70% power with three 30-s pulses by using a 
Microson sonicator (Heat Systems Ultrasonics, Inc.). Alter-
natively, lysates were prepared by resuspending pelleted 
cells in deionized water and boiling them for 5 min in an 
equal volume of 2x gel loading buffer (35). £. coli HB101 
cells containing plasmid pSH109 were grown for 16 hat 37°C 
in M9 medium buffered with 0.05 M Tris (pH 7.4) containing 
Proteose Peptone (0.2%), glucose (0.2%), and L-proline (1 
mM). The cells were harvested by centrifugation (5,000 x g, 
10 min, 4°C) and were treated to extract the proteins that 
were located in the periplasmic space or the cytoplasm as 
described by Minton et al. (24). 
Sodium dodecyl sulCate-polyacrylamide gel electrophoresis 
(SOS-PAGE). Proteins were separated in 10 to 15lk poly-
acrylamide gradient gels (Phastsystem; Pharmacia LKB 
Biotechnology) according to the manufacturer's instruc-
tions. 
lsoelectric focusing. Proteins were separated in isoelectric 
focusing gels (pH 3-9; Phastsystem; Pharmacia LKB Bio-
technology) according to the manufacturer' s instructions. 
Western blotting (immunoblotting). Proteins separated by 
SDS-PAGE and isoelectric focusing were capillary blotted 
onto a polyvinylidene ditluoride membrane (lmmobilon-P) 
according to recommendations of Pharmacia LKB Biotech-
nology. Membranes were blocked in 1% BLOITO (35) and 
incubated with monoclonal antibodies specific for epsilon-
toxin (5 , 26) at a dilution of 1/1,000. Protein bands were 
visualized with an anti-mouse immunoglobulin G antibody, 
raised in goats and labelled with colloidal gold , at a dilution 
of 11100 (Auroprobe BLplus; Cambio). 
ELISA. Sandwich enzyme-linked immunosorbent assays 
(ELISAs) to detect epsilon-toxin contained in £ . coli HB101 
cell fractions were performed as previously described (26). 
The capture and detection monoclonal antibodies recognized 
different epitopes on epsilon-toxin . The detection monoclo-
nal antibody was conjugated to horseradish peroxida e. 
Nucleotide sequence accession number. The nucleotide 
sequence of epsilon-toxin gene from C. perfringens ha been 
submitted to GenBank (accession number M80837). 
RESULTS 
Amino acid sequencing of epsilon toxin. Twenty re idues 
were identified from theN terminus of C. perfringens type D 
epsilon-toxin, which could be partially aligned with the 
previously published N-terminal sequence of epsilon-proto-
toxi n starting at Lys-14 (2) (Fig. 1). The homology between 
the two seque nces after residue 20 was poor. although by 
removing Pro-23. residues 24 to 26 can be aligned. 
Design of an oligonucleotide probe for the etx gene. Oligo-
nucleotide probes designed from the previously published 
amino acid sequence of epsilon-prototoxin (2) failed to 
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A KEICBPVSYEMSYKAIYBBVLPPLIZ?Y 
B KASYDNVDTLIEKGRYNTKY 
.... • ... 
mRNA 5 ° GuA GAU ACA UUA AUA GAA AAA GGA 3 ° 
U C U G U G G U 
G G CUA C G 
c c u c 
G 
c 
Probe Sm 5' GTI GAT ACI TTA ATI GAA AAA GG 3 0 
c G G G 
FIG. 1. The N-terminal amino acid sequence of C. petfringens 
type B epsilon-toxin was determined (B) and aligned with the 
sequence of C. perfringens type D epsilon-prototoxin determined by 
Bhown and Habeeb (2) (A). Residue B is Asp or Asn; residue Z is 
Glu or Gin. The site of trypsin cleavage reported by Bhown and 
Habeeb (2) is marked by an arrow. An oligonucleotide, 5m, was 
designed from the amino acid sequence (B) between residues 20 and 
27; I is the base analog, deoxyinosine. 
hybridize to DNA from C. petfringens types 8 and D. An 
oligonucleotide probe, 5m, was therefore designed from the 
new amino acid sequence data between residues 20 and 27 
(Fig. 1). This sequence was of the same sense as mRNA and 
represented a region of minimal cod on degeneracy. In order 
to reduce the redundancy of the oligonucleotide, the neutral 
base deoxyinosine was incorporated where more than two 
codons existed for an amino acid. In the case of Leu, the 
codons ITA and TIG were selected , since they were used 
on approximately 75% of occasions in C. perfringens genes . 
The resulting probe was 23 bp long and 16-fold degenerate 
and hybridized to the noncoding strand of the target se-
quence. 
Hybridization of oligonucleotide Sm to C. perfringens DNA. 
Since the epsilon-toxin used in our sequence analysis was 
purified from an unspecified strain of C. perfringens, it was 
not possible to clone the gene from thi s source. Preliminary 
biochemical and immunological data (not shown) indicated 
that epsilon-prototoxins produced by C. petfringens types 8 
and D were similar in terms of their physical properties, and 
we decided to clone the gene from a type 8 strain. 
DNA from C. perfringens type B strain NCTC 8533 was 
digested with Hindiii or Sau3A and probed with oligonucle-
otide 5m at 42°C. The hybridization temperature was calcu-
lated from the equation described by Suggs et al . (40) and 
allowed one mismatch between the probe and the target 
sequence to occur. Oligonucleotide 5m hybridized to 2.1-kb 
Hindiii and 1.65-kb Sau3A restriction fragments. 
Cloning of the epsilon-toxin gene. A library of Hindiii-
digested c hromosomal DNA from C. perfringens NCTC 
8533 was made in pUC18. After transformation, approxi-
mately 3,000 ampicillin-resistant colonies were obtained and 
were screened by colony hybridization using oligonucleotide 
5m as a probe. Two positive colonies were identified , and 
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FIG. 2. Physical map of C. perfringens type B strain NCTC 8533 
DNA in the region of the etx gene. (A) Clones generated in pUC18. 
(B) Restriction endonuclease digestion sites: A, Accl; H, Hindill ; 
Sa, Sau3A; Se, Seal. (C) ORFs identified. The vertical arrow 
indicates the site of hybridization of oligonucleotide 5m. 
Restriction analysis of the plasmids revealed that pSH103 
consisted of two vector molecules ligated to a 2.1-kb insert 
and that pSH104 contained two Hind Ill fragments with sizes 
of2.1 and 2.2 kb. The fragments were recloned into pUC18. 
One of the recombinant plasmids {pSH105) contained a 
single 2.1-kb Hindiii fragment which hybridized with probe 
5m (Fig. 2A). DNA sequence analysis indicated that this 
fragment did not contain the entire coding region of the 
epsilon-toxin gene. 
By restriction mapping and Southern blotting using oligo-
nucleotide 5m as a probe , a physical map of the DNA in the 
region of the etx gene was obtained (Fig. 2B). The map 
indicated that the 1.65-kb Sau3A fragment recognized by 
probe 5m contained 330 bp upstream of the Hindiii fragment 
cloned into pSH105. This Sau3A fragment was therefore 
large enough to encode the complete etx ORF. 
With the Hindiii insert from pSH105 used as a probe , 
Sau3A fragments in the region of the erx gene were isolated 
from a library of Sau3A-digested DNA from C. perfringens 
type B strain NCTC 8533 by colony hybridization. Four 
positive colonies were identified. Restriction analysis of the 
plasmids isolated from these clones showed that three of 
them (all pSH109) contained the 1.65-kb Sau3A fragment. 
The remaining plasmid (pSHllO) contained a 1.25-kb Sau3A 
fragment located downstream of the erx gene (Fig. 2A). 
Expression of the etx gene in E. coli. To compare the 
physical properties of the cloned and native epsilon-proto-
toxin , cell lysates of £. coli JM101 containing plasmid 
pSH109 or pUC18 were prepared by sonication. Samples of 
the lysates were treated with trypsin-TPCK to activate 
epsilon-prototoxin. The proteins were separated by SOS-
PAGE or isoelectric focusing and analyzed by Western 
blotting with a monoclonal antibody , A5Cl2, which is spe-
cific for epsilon-prototoxin (26) . 
The molecular weights of cloned epsilon-prototoxin and 
epsilon-toxin were estimated to be 33,000 and 29,000, re-
spectively (Fig. 3). Prototoxin and toxin purified from C. 
perfringens type D were found to migrate with similar 
mobilities . These results were confirmed by Western blotting 
with another anti-epsilon-toxin monoclonal antibody pur-
chased from the Central Veterinary Laboratories (5) (data 
not shown). 
The major pis of cloned epsilon-prototoxin and epsi lon-
toxin were estimated to be 8.35 and 5.4, respectively, 
although a minor form with a pi of 5.0 was also present in the 
toxin (Fig. 4). Purified type D epsilon-prototoxin and epsi-
lon-toxin also contained these isoelectric forms , although 
other forms were present as well. 
Proteins with these properties were not found in the cell 
lysates prepared from E. coli containing pUC18. 
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FIG. 3. Western blot of proteins separated by SOS-PAG E (10 to 
15% polyacrylamide gradient gel [Phas tsystem]) and probed with an 
a nti-epsilon-toxin monoclona l antibody, A5C12 (26) . (A) Lanes: 1, 
posi tions of protein molecular weight markers (103); 2 , native 
e psilon-prototoxin; 3, £ . coli and pSH109 cell lysate; 4, £. coli and 
pUC18 cell lysa te . (B) Lanes: 1, native epsilon-prototoxin : 2, 
epsilon-toxin , prepared by treating native epsi lon-prototoxin w~th 
trypsin ; 3, trypsin-treated£. coli a nd pSH109 cell lysate; 4, trypst?-
treated £. coli and pUC18 cell lysate; 5, positions of protem 
molecular weight markers (103). 
Cell lysates of£. coli JM101 containing plasmid pSH109 
were prepared by boiling at various times after inoculation . 
T he lysates were analysed by SDS-PAGE and Western 
blotting with monoclonal antibod y A5C12 (26). The concen-
tration of epsilon-prototoxin in the culture reached a maxi-
mum after approximately 6 h of growth , corresponding to the 
late log phase (data not shown). The level of expression of 
epsilon-prototoxin was estimated to be 5 to 25 JJ.g/ml of cell 
culture from quantitati ve Western blots using purified epsi-
lon-prototoxin as concentration standards (data not shown). 
Site of accumulation of cloned epsilon-toxin in E. coli. 
Plasmid pSH109 was tra nsformed into E. coli HB101, and 
recombinant cell s were fractionated to determine the site of 
accumulation of epsilon-toxin. The results (Table 1) indi-
cated that most of the epsilon-toxin produced was translo-
cated across the cytoplasmic membrane and was accumu-
lated in the periplasmic space. 
Nucleotide sequencing of the etx gene. Restriction frag-
A B 
2 3 4 5 2 3 4 
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F IG. 4. Western blot of proteins separated in an isoelectric 
focusing gel (pH 3-9; Phastsystem) and probed with a n an ti-.e_Psilon-
toxin monoclonal antibody, A5C12 (26) . (A) Lanes: 1, postllons of 
pi marker proteins; 2, epsi lon-toxin , prepared by treating native 
epsilon-pro totoxi n wi th trypsin ; 3 , native epsilon-prototoxin ; 4, £. 
coli a nd pS H109 cell lysate; 5, £. coli a nd pUC18 cell lysate. (B) 
Lanes: 1, trypsin-treated£. coli and pUC18 cell lysate; 2. trypsin-
treated£. coli and pSH109 cell lysate; 3, epsilon-toxin; 4, positions 
of pi protein markers. 
TAB LE 1. S ites of accumulation of cloned epsilon-toxin in 






















" Assayed by sandwich ELISA using monoclonal antibodies specific for 
epsilon-toxin (26). . . 
b Marker enzyme for the periplasmic fraction ; the enzyme actiVIty was 
assayed as described by Torriani (43). . 
< Marker enzyme for the cytoplasmic and membrane-bound fraction: the 
enzyme activity was assayed as described by Miller (23). 
ments from recombinant plasmids pSH105, pSH109, and 
pSH110 were cloned into bacteriophage M13. Ml3 primers 
and synthetic oligonucleotide primers were used to deter-
mine the nucleotide sequence of the cloned DNA. An ORF 
extending from the ATG codon at base 188 to the TAA 
codon at base 1174 and containing a sequence identical to 
oligonucleotide 5m was identified (Fig. 5). The coding region 
had a high A + T content of72.7%, which was consistent with 
the value of 69 to 73% previously reported for C. pe1jringens 
DNA (20). This bias was also reflected in the use of codons 
ending in A or T. For example , the codons GGA (Gly) , UUA 
(Leu), AGA (Arg), and AUA (lie) were used on 87.5, ?3.7, 
60, and 59.1% of occasions, respectively. In companson, 
these codons are used on less than 10% of occasions in E. 
coli (25). 
A purine-rich sequence , GGTGGT (bases 179 to 184), was 
located 4 bp upstream of the initiation codon (Fig. 5) and 
may be a ribosome binding site (36). Hybridization of this 
sequence to the 3' end of 16S rRNA would be energetically 
favo rable (l1G = - 10.2 kcal [ea. -42.7 kJ] (42]). A hexanu-
cleotide stretch , TATATT, was located between bases 120 
and 125 (Fig. 5) and was 83% homologous to the -10 
consensus sequence recognized by the major E. coli and B. 
subtilis a factors (11). Sixteen base pairs upstream of the 
proposed -10 consensus sequence, there was another hexa-
nucleotide stretch, TTGTAT, which was 50% homologous to 
the -35 consensus sequence. Between the proposed - 10 
consensus sequence and the Shine-Dalgarno sequence, there 
was also an AT-rich 10-bp direct repeat, TATAGAAAAA 
(Fig. 5). 
The nucleotide sequence immediately downstream of the 
translation stop codon was examined for the presence of 
transcription termination signals (28). The absence of a 
significant stem-loop structure followed by a poly(T) stretch 
implied that rho-independent termination does not occur. 
However, 11 bp downstream of the stop codon , there wa~ a 
short 11-bp stem-loop structure, incorporating one mts-
match , which may be involved in the termination of tran-
scription (Fig. 5). 
Two short , overlapping ORFs downstream of the erx gene 
were also identified: ORF1 (bases 1360 to 1749) a nd ORF2 
(base 1613 onward) (Fig. 2C and 5) . The nucleotide sequence 
obtained did not include the 3' end of ORF2. The ORFs were 
located on the same strand of DNA as the etx gene. Their 
nucleotide sequences were analysed with the program 
FRAME (3), which predicts ORFs on the basis of their 
nonrandom distribution of G and C bases in each codon 
position. This analysis suggested that the ORFs encode a 
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1 GATCGTTTTTAGTTCTATTTAAATAAACGATTTAATAATAAAAATTTTTAACTTGGGTTTTGTCGTAAATGTTGGAGCTACCCCAATATAATAAAATTTG 
-10 S.O. H K K N L 
2 101 TATATTAAATAATTTTATTTATATTATTTACTTTTTTTAAAAAATATAGAAAAATATAGAAAAATATATTAATGAAAGGGTGGTTTTATGAAAAAAAATC 
V K S L A I A S A V I S I Y S I V N I V S P T N V I A K E I S N T 
3 201 TTGTAAAAAGTTTAGCAATCGCATCAGCGGTGATATCCATCTATTCAATAGTTAATATTGTTTCACCAACTAATGTAATAGCTAAGGAAATATCTAATAC 
V S N E H S K IK A S Y 0 N V 0 T L I E K G R Y N T K vi N Y L K R M 
4 301 AGTATCTAATGAAATGTCCAAAAAAGCTTCTTATGATAATGTAGATACATTAATTGAGAAAGGAAGATATAATACAAAATATAATTACTTAAAGAGAATG 
-------------EKYYPNAHAYFOKVTINPOGNOFYINNPKVELOG 
5 401 GAAAAATATTATCCTAATGCTATGGCATATTTTGATAAGGTTACTATAAATCCACAAGGAAATGATTTTTATATTAATAATCCTAAAGTTGAATTAGATG 
E P S H N Y L E- 0 V Y V G K A L L T N 0 T a a E a K L K S Q S F T 
6 501 GAGAACCA TCAATGAA TT A TCTTGAAGA TGTTT A TGHGGAAAAGCTCTCTT AACT AA TGA T ACTCAACAAGAACAAAAA TT AAAA TCACAA TCA TTCAC 
CKNTOTVTATTTHTVGTSIQATAKFTVPFNETG 
1 601 TTGTAAAAATACTGATACAGTAACTGCAACTACTACTCATACTGTGGGAACTTCGATACAAGCAACTGCTAAGTTTACTGTTCCTTTTAATGAAACAGGA 
VSLTTSYSFANTNTNTNSKEITHNVPSQOILVPA 
8 701 GTATCATTAACTACTAGTTATAGTTTTGCAAATACAAATACAAATACTAATTCAAAAGAAATTACTCATAATGTCCCTTCACAAGATATACTAGTACCAG 
NTTVEVIAYLKKVNVKGNVKLVGaVSGSEWGEI 
9 801 CTAATACTACTGTAGAAGTAATAGCATATTTAAAAAAAGTTAATGTTAAAGGAAATGTAAAGTTAGTAGGACAAGTAAGTGGAAGTGAATGGGGAGAGAT 
PSYLAFPROGYKFSLSOTVNKSOLNEOGTININ 
10 901 ACCTAGHATHAGCTHTCCTAGGGATGGTTATAAATTTAGTTTATCAGATACAGTAAATAAGAGTGATTTAAATGAAGATGGTACTATTAATAHAAT 
GKGNYSAVHGOELIVKVRNLNTNNVQEYVIPVOK 
11 1001 GGAAAAGGAAATTATAGTGCAGTTATGGGAGATGAGTTAATAGTTAAGGTTAGAAATTTAAATACAAATAATGTACAAGAATATGTAATACCTGTAGATA 
K E K S N 0 S N I V K Y R S L S I K A P G I K stp 
12 1101 AAAAAGAAAAAAGTAATGATTCAAATATAGTAAAATATAGGAGTCTTTCTATTAAGGCACCAGGAATAAAATAAGATTATTTATTAGAAGTAAAAATAAG 
13 1201 ATTTTAGTTTTATAGATTAATATTAATTCTAATAAAAACTCTATATAGATTTGTATGTAATCTAATTTTCCTCTTAAAGATAAATTAGACTTTCAAAATT 
-35 -10 :oRF1 start s.o. 
14 1301 AAAACTTTGTAATCTTAAGTCTAATTTGAGAGTGTAAAATAGTCTGTGTAAACTAATAAGATGATATAAHAAATATCATATAAAAGGAGGGTGCACAGA 
15 1401 CTATATCTTATGCCGAAAAAGAATTGATAAAACAACTAATATAGAGACTGCTGAATATGCTCAAAATGTTATTAAAAGTTTATTTGGTGGTTTAAHCAA 
16 1501 CAAATACTTGAAGCTGAAATGGAAGAATATTTAGGATATTTAAAATATGATTATTCAAATAAAAATACTACTGATTCTCGTAATTGGGAAAATGAGAAAA 
:ORF2 start 
17 160 1 CTGTT AAA TTTGA TTT AGA TA TCCCAAGAGA TCGTGAGGGTTCTTTCGAACCACAAA TCGAAAAGAAACA TCAAACT ACT AGAAAGHCAA T AA T AGGGG 
ORF1 end : 
18 1701 GGAGGTATGCGAAAGGCATGTCTACACGAGATATAGCTACTCAAGTTAATGAAATGTACGGCATGGATGTTTCACCTACTTTAATCTCAAATATAACTGA 
19 1801 TAAAATAATACCTTCTATAAAAGAATGGCAATGTAAACCATTAGAAAGTATATATCCTATCG 
FIG. 5. Nucleotide sequence of the DNA fragment encoding epsilon-toxin. The data from bases 1 to 1633 were obtained from both strands 
of the cloned DNA in pSH105 and pSH109; the remaining data were obtained only from the noncoding strand of the pSHllO insert , but three 
Ml3 subclones were sequenced independently. The nucleotide and derived amino acid sequences of the etx gene between the start codon at 
base 188 and the stop codon (stp) at base 1174 are shown . The experimentally determined N-terminal amino acid sequence of epsilon-toxin 
that we obtained is bracketed. The N-terminal peptide of epsilon-prototoxin that is cleaved by trypsin is shown in boldface type. The 
nucleotide sequence of oligonucleotide 5m is indicated with a dashed line. The overlapping ORFs. ORF1 and ORF2, situated downstream of 
the etx gene are shown. Possible Shine-Dalgarno (S.D.) and - 10 and - 35 consensus sequences controlling the transcription and translation 
of the etx gene and ORFl are indicated. Direct repeats and inverted repeats associated with the etx gene are underlined with half-arrows. 
single gene disrupted by a frameshift mutation in the region 
of bp 1680 to 1710 (data not shown). However , none of the 
possible start codon , including AUG, GUG, AUA, ACG 
(37), and UUG (27), was present at the 5' end of ORFl. 
although sequences resembling a Shine-Dalgarno region and 
the £ . coli rr70 - 10 and - 35 consensus sequences were 
identified (Fig. 5). 
Analysis of the derived amino acid sequence. The amino 
acid sequence derived from the erx gene was identical to the 
N-terminal amino acid sequence of epsilon-tox in (a re-
ported here) over 20 residue , starting from Lys (base 323) 
(Fig. 5) . Of the 13 amino acids preceding this residue , 9 were 
a ligned with the previously publi hed N-terminal pro tein 
sequence of e psilo n-pro to tox in (2) , suggesting that Lys (ba e 
284) may be the first residue of the mature , inact ivated 
protein . The 32 amino acids from the start Met to thi~ Ly. 
contained residues characteri tic of a signal pepti de (44), a nd 
plots of the hydropathic pote ntial o f the protein indicated 
that this region consisted of a short. charged N-terminal 
peptide followed by a long hydrophobic core (data not 
hown). 
lf the pro tein is ynthesized with a signal peptide , the 
calculated molecular weight of the exported pro totoxin is 
32,981. The predic ted amino acid composition of epsilon-
prototoxin was comparable to the experimentally deter-
mined amino acid compositions reported previously (16, 29). 
Sakurai and Nagaha ma (29) estimated a higher proportion of 
the residues Ala and Gly, but their prediction of one Trp 
residue agreed with our results . Bhown and Habeeb (2) 
reported that the ingle Cy residue was located in the 
N-tcrminal peptide which is lost after trypsin cleavage. 
whereas we pred ic ted that it occurred in the central regio n of 
the protein (Fig. 5) . 
Computer analysis of the secondary structure of ep ilon-
proto toxin predicted that the protein consisted of 52% 
[3-sheet according to the algorithm of Garnier e t al. (14) a nd 
up to 70% [3- heet according to the Chou and Fasman 
algori thm (10). T his confirmed previous results derived from 
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FIG. 6. Alignment of the amino acids of the ORF1-0RF2 fusion protein (A) and amino acids 1 to 163 of the transposase from S. mtreus 
transposon Tn400/ (8) (8) . The arrow indicates the point of fusion between amino acids derived from ORF1 and ORF2. Double dots indicate 
frequently substituted amino acids, and single dots indicate rarely substituted amino acids. 
circular dichroism and optical rotatory dispersion studies, 
which also indicated that the protein consisted predomi-
nantly of ~-sheet (17). A computer search of the Protein 
Information Resource data base did not reveal significant 
homology (>20%) with any other proteins, so we were 
unable to make further detailed predictions about the struc-
ture or function of epsilon-toxin. 
The nucleotide sequences of ORF1 and ORF2 were fused 
at position 1690 (Fig. 5), on the basis of the assumption that 
a frameshift mutation occurred in the region consisting of bp 
1680 to 1710. The derived amino acid sequence was also 
compared with those in the Protein Information Resource 
data base. It was found to be 24% homologous to the 
transposase from Staphylococcus aureus transposon Tn4001 
(8) , although the C-terminal region of the ORF1-0RF2 fusion 
(position 86 to 166) exhibited a higher degree of homology 
(33%) (Fig. 6) . 
Probing clostridial DNA with the el.x gene. Recombinant 
plasmid pSH109 was digested with restriction enzymes to 
yield either a 1.65-kb Sau3A fragment or a 1.3-kb Hindlli-
Sau3A fragment containing the etx gene (Fig. 2). 
In slot blotting experiments, the etx gene probe hybridized 
strongly to DNA from C. perfringens types B and D only 
(data not shown). Weak hybridization with DNA from E. 
coli JM101 was also seen; this may be due to contamination 
of probe DNA with E. coli chromosomal DNA. The gene 
probe did not hybridize to DNA from C. perfringens types 
A. C, and E . C. botulinum , C. novyi , C. bifermentans, C. 
histolyticum. C. sordellii, C. chauvoei, C. absonum. or B. 
subtilis. 
In Southern blotting experiments with DNA from C. 
pe1:{ringens types B a nd D, the etx gene probe hybridized to 
1.65- or 3.25-kb Sau3A fragments (Fig. 7 A) and 4.5- or 
5.6-kb Xhal fragments (Fig. 78). These results indicated that 
the restncuon profiles of C. perfringens types B and D 
varied in the region of the etx gene, although the fragment 
sizes recognized were not type specific and differed only 
between strains. 
DISCUSSION 
The epsilon-toxin gene from C. pe1:{ringens type B has 
been cloned and expressed in E. coli by using plasmid vector 
pUC18. Expression of the protein was probably controlled 
by an etx promoter, since the gene was not cloned in the 
correct orientation to be expressed from the pUC18 lac 
promoter. Signals potentially controlling transcription and 
translation were identified in the cloned fragment , but be-
cause of the high A+T content of the DNA, caution must be 
exercised in identifying promoter elements. particularly 
those recognized by E. coli a10 and B. subtilis a 43 , merel y by 
sequence inspection. It is possible that the - 10 and - 35 
sequences that we identified were used fortuitously in E. coli 
and that other sequence are used in C. perfringens . The 
function of the 10-bp direct repeat located upstream of the 
proposed ribosome binding site i unknown, although it may 
also be involved in controlling gene expression. 
The gene was expressed at relatively low levels, perhap 
because of instability of the product or inefficient tran crip-
tion and translation. Although product instability has re-
duced the expression of ome clostridial toxins (13), we did 
not detect any degradation products of cloned ep ilon-toxin . 
Bia ed codon usage in clostridial gene has been reported to 
hinder the efficiency of translation in E. coli (15). although 
thi effect would be minimal in a relatively small gene such 
as etx. 
The expressed protein accumulated in the peripla mic 
space of E. coli. sugge ting that it was produced with a signal 
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FIG. 7. Southern blot of C. perfringens type B and D DNA (1to 
3 IL&) digested with Sau3A (A) or Xbal (B). The DNA was probed 
with an [a-32P)dCTP-labelled etx gene probe. (A) Lanes : l , 0.03 IL& 
of plasmid pSH109; 2, blank ; 3, type B strain NCTC 8533 DNA; 4, 
type B strain NCTC 6121 DNA; 5, type B strain CN 8024 DNA; 6, 
type D strain NCTC 8346 DNA. (B) Lanes : 1, type B strain NCTC 
8533 DNA; 2, type B s train NCTC 6121 DNA; 3, type B strain CN 
8024 DNA; 4, type D strain NCTC 8503 DNA; 5, type D strain 
NCTC 8346 DNA. The positions of DNA molecular size marke rs are 
indicated in kilobases. 
peptide which allowed it to cross the cytoplasmic mem-
brane. This was supported by the fact that etx encoded a 
sequence which was structurally similar to a signal peptide; 
also, it is known that the native protein is exported from C. 
perfringens (7). 
We have shown that the cloned type B and native type D 
toxins have similar molecular weights and isoelectric points 
and that they both react with specific monoclonal antibodies. 
The similarity of their properties is supported by the fact that 
the amino acid sequence derived from the cloned type B 
gene is identical to the amino acid sequence of the type D 
toxin that we obtained over 20 residues. The amino acid 
differences in the previously reported sequence of type D 
epsilon-toxin (2) may therefore be due to inaccuracies in 
sequence analysis. This may be partly explained by the fact 
that epsilon-toxin has proved difficult to purify (19) and may 
contain contaminating proteins and breakdown products 
which interfere with sequence analysis. 
The molecular weight of mature epsilon-prototoxin calcu-
lated from the derived amino acid sequence (32,981) agreed 
with our experimentally determined value for the cloned and 
native proteins of 33 ,000. Previously , a range of molecular 
INFECT. IMMUN. 
weights for the protein have been reported (from 23,200 to 
40,500 [22]), although more recent estimates (29, 45) are 
much closer to our value. 
The isoelectric points of epsilon-prototoxin and epsilon-
toxin have been reported to be 8.02 and 5.36, respectively 
(45). The estimated pis of cloned prototoxin (8.35) and toxin 
(5 .4) differ slightly from those of the previous reports but are 
identical to the major pis of the purified proteins from C. 
pe1jringens typeD, which we have determined. Our method 
of estimating the pi is not precise and may account for the 
observed differences. It relies on capillary transfer of the 
proteins to a membrane after isoelectric focusing , and during 
this time, the proteins can migrate away from their isoelec-
tric points. Other isoelectric forms of the type D prototoxin, 
with intermediate pis, were observed. Previously, it has 
been shown that these forms are more toxic than the 
prototoxin but less toxic than the toxin (45), suggesting that 
activation is a multistep process involving sequential re-
moval of short peptides from the N terminus of the proto-
toxin. Minor isoelectric forms of epsilon-toxin, with pis of 
<5.4, were also seen. They may also represent degraded 
forms of the protein , or they may result from posttransla-
tional modifications, such as deamidation or phosphoryla-
tion. Although multiple isoelectric forms of epsilon-toxin 
(rather than epsilon-prototoxin) have not been reported 
previously , micro heterogeneity of bacterial toxins has been 
frequently observed (41). 
Although we were unable to make detailed predictions 
about the structure and function of epsilon-toxin, hydropho-
bicity plots of the protein (not shown) indicated that there 
were no significant hydrophobic stretches, apart from the 
proposed signal peptide. It is therefore unlikely that epsilon-
toxin is a membrane-spanning protein. 
Bhown and Habeeb (2) reported that the trypsin cleavage 
site in epsilon-prototoxin lay between Lys-14 and Ala-15 
(Fig. 1). However, the amino acid sequence data derived 
from the etx gene indicated that the residue preceding Lys-14 
was also Lys. Since trypsin cleaves proteins on the C-ter-
minal side of basic amino acids, this suggested that there 
were two possible sites for cleavage and may explain why we 
found that the N-terminal residue of epsilon-toxin was 
Lys-14 , not Ala-15 as previously described (2). 
Chemical modification studies have suggested that one 
Trp (30) , one His (32), one Tyr (33), three or four Asp or Glu 
(34), and eight Lys (31) residues are essential for the lethal 
activity of epsilon-toxin. From the derived amino acid se-
quence, it was not possible to identify which of the 17 Tyr, 
33 Asp or Glu , and 29 Lys residues in the prototoxin may be 
functionally important. ln contrast, only one Trp residue and 
two His residues were found in the derived amino acid 
sequence, so these amino acids are a natural target for 
studying structure-function relationships of epsilon-toxin. 
The variability of the restriction profiles of C. perfringens 
types B and D in the region of the etx gene may be explained 
by the presence of ORF1-0RF2, which may encode part of 
a transposon , downstream of the gene. Although Southern 
blotting experiments indicate that ORF1-0RF2 is found in all 
of the C. perfringens strains tested (data not shown), regions 
of DNA containing transposons tend to be variable and may 
contain other mobile elements. 
We have shown that the etx gene · is found only in C. 
pe1jringens types B and D, the types which produce epsilon-
toxin. This may suggest that the gene is carried on an 
extrachromosomal element not found in the other types . 
Preliminary results from mapping the genome of C. pelfrin-
gens types 8 and D have indicated that the gene is carried on 
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a large plasmid (> lOO kb) (8a). It is known that C. perfrin-
gens contains a large number of plasmids (39), and there is 
evidence that other C. pe1jringens toxins, including type B 
beta-toxin (12) and type B lambda-toxin (4), are plasmid 
borne. Since etx is present only in the types producing 
epsilon-toxin, the cloned gene will be an important tool for 
classifying C. pe1ji-ingens strains a nd diagnosing some forms 
of enterotoxemia. 
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1. SUMMARY 
The sequence of the epsilon toxin gene of 
Closuidium perfringens type D was determined 
and compared with that of the previously re-
ported type B sequence. It showed two nu-
cleotide changes in the open reading frame, giv-
ing rise to one amino acid substitution. The pro-
mote r sequences were not homologous, and dif-
ferent putative -35 and - 10 regions have been 
identified in each. The sequence information was 
used to develop PC R primers which were specific 
for the epsilon toxin gene. The utility of this 
system for identifying type B or D strains of C. 
perfringens was demonstrated. 
Correspondence to: H.L. Harvard, Che mical and Biological 
De fence Establishment. Porton Down, Salisbury, Wiltshire 
SP4 OJQ, UK. 
2. INTRODUCTION 
The epsilon toxin of Clostridium perfringens is 
produced by type B and type D strains. Type B 
strains produce the major letha l toxins alpha, 
beta, and epsilon, and are responsible for Iamb 
dysentery, and sheep and goat enterotoxaemia. 
Type D strains produce alpha and epsilon major 
toxins, and cause enterotoxaemia in sheep and 
pulpy kidney disease in lambs [ l]. The epsilon 
toxin has been purified from some type D strains, 
and shown experimentally to increase vascular 
pe rmeability in the brain [2], cause kidney' dam-
age [3] and contraction of the ileum [4], and to 
possess cardiovascula r and pressor activities [5). 
Little i known about the mode of action of 
epsilon toxin , and no enzymatic activity has yet 
been assigned to it, but the importance of certain 
amino acid residues for toxicity has been demon-
sti·ated [6- 10]. 
7ll 
The nucleotide seque nce of the epsilon toxin 
gene (etxB) from a Clostridium pe1j ringens type B 
strain. (NCTC 8533) has recently been dete r-
mined. and puta tive promote r sequences identi-
fied [ 11 ]. We considered it impo rtant to charac-
terise the type D toxin e ncoding gene (etxD ), as 
a ll previous studies had used toxin from this 
source. This approach wo uld enable us to de-
ve lop a PC R test which could detect the epsilon 
toxin gene from both bio types. 
3. MATE RIALS AND METHODS 
3. 1. Preparation of DNA 
DNA from C. pe1j ringens type A (NCTC 8237), 
type B (NCTC 612 1. NCTC 8533, C N 8024), type 
C (NCTC 10719, C 883), type D (NCTC 8503, 
NCTC 8346), type E (CN 5063), and Bacillus 
subtilis (NCTC 10452) was pre pa red as described 
previously [ 11]. Recombina nt plasmid DNA 
(pPA26) e ncoding the Bacillus anthracis PA gene, 
was isolated using a standard method [12]. 
3.2. Primers for PCR 
Pa irs of prime rs (generally 15 to 20mers) were 
designed from the published etxB sequence, 
which would allow the open reading frame (ORF) 
of epsilon toxin to be amplified. They were syn-
thesised using an Applied Biosyste ms DNA syn-
thesizer (ABI 392). incorporating biotinylated nu-
cleo tides at the ir 5' ends, whe re appropriate. 
3.3. Polymerase chain reaction (PCR) amplifica-
tion and DNA sequencing of etxD 
Templa te DNA (5 ng), biotinylated and non-
biotinylated primers (2.5 pmol each), dNTPs (0.2 
mM each. Pe rkin-Eime r Cetus), MgCI2 (1.5 mM) 
and T aq polymerase (2.5 units, Boehringer 
Mannheim UK) we re incubated in a LEP (Lumi-
nar Technologies Ltd. UK) the rmal cycle r for 30 
cycles as fo llows: 30 s a t 96°C, 30 s at 40°C, 60 s a t 
73°C. The reaction volume was 0.1 ml. Afte r PC R 
cycling, bio tin tagged DNA product was purified 
using streptavidin-coated Dynabeads ™ (Dynal 
AS, O slo. Norway). Single stranded DNA was 
produced by treating streptavidin bound DNA 
with 0. 1 M NaOH. as descibed by the manufac-
ture r. Dynabead n 1 bound single stranded DNA 
was used directly in dideoxy-chain termina tion 
sequencing (Seque nase 2.0 kit, United States Bio-
chemical Corp.). T he nucleotide seque nce was 
ana lysed and compared wi th etxB using D NA-
STAR software . 
3.4. Inverse PCR 
The DNA sequence of the etxD upstream 
region was obtained by inverse PCR. Brie fl y, to ta l 
DNA fro m stra in NCTC 8346 (1.5 J.L g) was di-
gested with Hind lll (10 un its, Boehringer Mann-
heim UK), a nd hea t treated for 15 min at 70°C. 
The DNA fragments we re circularised by incubat-
ing with DNA ligase (2.5 units. Boehringer 
Mannhe im UK). at I6°C for 16 h in a fina l 
volume o f 50 J ..d . LO J.LI of this ligation reaction 
was the n u ed directly in a PCR reaction with 
appropriate primer . as described above, a nd the 
nucleotide seque nce dete rmined. 
3. 5. PCR typing 
DNA isolated from C. pe1j ringens types A, B, 
C, D or E was used as a te mplate for PCR . DNA 
from B. subtilis and B. anthracis was also tested, 
as these had been shown, by compute r analysis, 
to have some homology ( > 70%) wi th one o f the 
typing primers (see below). The prime rs for this 
work were designed using Primer Detective soft-
ware (Clontech Inc .. USA), and were synthesized 
as described above. Template DNA (5 ng) was 
mixed with primers (2.5 pmol each), dNTPs (0.2 
mM each), MgCI2 (1.5 mM), and Taq polymerase 
(2.5 units) in a tOtal reaction volume of 0.1 ml , 
a nd amplified using a Pe rkin-Elme r PCR system 
(G eneAmp 9600). After de naturing the template 
DNA for 120 s at 96°C, the reaction proceeded 
for 30 cycles as fo llows: 30 s at 96°C, 30 s at 57°C, 
60 s at 73°C. After cycling, PCR reaction prod-
ucts we re visua li ed by agarose gel e lectrophore-
sis and e thid ium bromide staining. 
4. RESU LTS A D DISCUSSION 
4. I. DNA sequence of etx D 
Both strands of the etxD ORF were seque nced 
using prime rs derived from etxB . T he nucleotide 
79 
sequence showed nearly complete homology with 
the etxB sequence. Two nucleotide changes were 
identified at positions + 762 and + 962 (Fig. l). 
The first of these was a silent mutation , with both 
the etx.B and etx.D triplets encoding serine (CAG 
and CGG, respectively). The second change al-
tered the triplet TCf, encoding serine in etxB, to 
TAT which encoded a tyrosine residue in etxD. 
This amino acid substitution is not conservative, 
but previous work showing that the activated 
epsilon toxins from types 8 and D were immuno-
logically cross-reactive and of similar molecular 
etxB CGT T AGTTC ATT AA TAAACGA TT 
etxD TTTTAAAATACAAGTTTTATGATTTTATATAATTTAATCTTGCAATTTAATGCAATTGTAGTAAAA -153 
TAATA AAA TIT AACTTGG T T G CG AAA GT GGA C AC CCAATATAA AAA TTTG 
ATTCCACTCTAAATTTTAATTGCTATTTTATGCCTTCTTAGG~GCCATGGGTGCTAGGCCTATATTA - 81 
A T A A A 
AATAATTTTATTTTTATTATTTACTTTTTTAAAAAAATATAGTAAAATATAGAAAATTATGTTAATGAAAGG -9 
GTGGTTTTATGAAAAAAAATCTTGTAAAAAGTTTAGCAATCGCATCAGCGGTGATATCCATCTATTCAATAG +64 
S.D. m k k n l v k s 1 a i a s a v i s i y s v 
TTAATATTGTTTCACCAACTAATGTAATAGCTAAGGAAATATCTAATACAGTATCTAATGAAATGTCCAAAA +136 
n v s p t n v i a k e i s n t v s n e m s k k 
AAGCTTCTTATGATAATGTAGATACATTAATTGAGAAAGGAAGATATAATACAAAATATAATTACTTAAAGA +208 
a s y d n v d 1 i e k g r y n t k y n y 1 k r 
GAATGGAAAAATATTATCCTAATGCTATGGCATATTTTGATAAGGTTACTATAAATCCACAAGGAAATGATT +280 
m e k y y p n a m a y f d k v i n p q g n d f 
TTTATATTAATAATCCTAAAGTTGAATTAGATGGAGAACCATCAATGAATTATCTTGAAGATGTTTATGTTG +352 
y i n n p k v e 1 d g e p s m n y 1 e d v y v g 
GAAAAGCTCTCTTAACTAATGATACTCAACAAGAACAAAAATTAAAATCACAATCATTCACTTGTAAAAATA +424 
k a 1 1 t n d t q q e q k l k s q 5 f t c k n t 
CTGATACAGTAACTGCAACTACTACTCATACTGTGGGAACTTCGATACAAGCAACTGCTAAGTTTACTGTTC +496 
d t v t a t t t h t v g t s i q a t a k f t v p 
CTTTTAATGAAACAGGAGTATCATTAACTACTAGTTATAGTTTTGCAAATACAAATACAAATACTAATTCAA +568 
f n e t g v s 1 t t s y s f a n t n t n t n 5 k 
AAGAAATTACTCATAATGTCCCTTCACAAGATATACTAGTACCAGCTAATACTACTGTAGAAGTAATAGCAT +640 
e t h n v p s q d l v p a n t t v e v i a y 
ATTTAAAAAAAGTTAATGTTAAAGGAAATGTAAAGTTAGTAGGACAAGTAAGTGGAAGTGAATGGGGAGAGA +712 
l k k V fl V k g 0 V k l V g q V S g 5 e W g e 
A 
TACCTAGTTATTTAGCTTTTCCTAGGGATGGTTATAAATTTAGTTTATCGGATACAGTAAATAAGAGTGATT +784 
p s y l a f p r d g y k f s 1 s d t v n k s d 1 
TAAATGAAGATGGTACTATTAATATTAATGGAAAAGGAAATTATAGTGCAGTTATGGGAGATGAGTTAATAG +856 
n e d g t n i n g k g n y 5 a v m g d e l i v 
TTAAGGTTAGAAATTTAAATACAAATAATGTACAAGAATATGTAATACCTGTAGATAAAAAAGAAAAAAGTA +928 





Fig. I. A comparison of the nucleotide sequences of etxB and etxD. The etxD data were obtained from both strands o f the PCR 
amplified DNA. The sequence of the etxD ORF was generated using a - 15 to +3 primer from the sense strand, and a + 1042 to 
+ 1026 primer from the anti-sense strand of etxB. The upstream sequence o f etxD was obtained by inverse PCR. The 
Shine-Dalgarno region (S.D.) is shown. Possible - 35 and -10 promoter sequences are indicated by double and single underlining, 
respectively. The direct repeat in the etxB upstream region, and the inverted repeat located downstream of both the etxB and etxD 
ORF are indicated by half arrows. Nucleotide and amino acid differences in etxB and etxD are shown . GenBank accession number 
of etxD: M95206. 
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mass [11], suggested that the proteins were al-
most identical. 
4.2. Upstream DNA sequence 
Comparison of the upstream sequences of etxB 
and etxD revealed substantial divergence (Fig. 1). 
Whilst both types shared the same Shine-
Dalgarno sequence [13], there was little other 
homology. The putative -10 promoter sequence 
was identical (TATATT), but was located further 
upstream in etxD (position -87 to - 82). The 
possible - 35 region (TTGACG) of etxD was 
more homologous to the consensus Gram-positive 
promoter (TTGACA) than that of etxB 
(TTGTAT) [14]. We have found that the epsilon 
toxin production by NCTC 8346 is approximately 
ten times greater than that by NCTC 8533. The 
differences in upstream nucleotide sequence may 
account for this variation (unpublished results). 
The Sau3A site present in the upstream region 
of etxB is absent in etxD . This confirms the 
previous finding that the etx gene is found on a 
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type D strain NCTC 8346, than in type 8 strain 
CTC 8533 [ll]. Interestingly, this previous work 
also demonstrated that one of the type 8 strains 
tested (CN8024), showed the same restriction 
fragment polymorphism as the type D strain. This 
suggests that the differences found in the up-
stream sequences are not type-specific. 
The LO-bp repeat identified upstream of etxB 
is a lso absent in etxD , due to two base pair 
changes within this region. The putative 11-bp 
stem loop situated downstream of the ORF is 
identical in both sequences [ll]. 
4.3. Identification of epsilon toxin-encoding strains 
by PCR 
The PCR conditions were optimised using a 
variety of MgC1 2 concentrations (1.5 mM, 3.0 
mM, 4.5 mM and 6 mM), and annealing tempera-
tures (40°C, 45°C, 50°C, 55°C and 57°C). The 
results obtained (Fig. 2) demonstrate that the 
selected primers (EPCR I and EPCR2) clearly 
differentiate between epsilon toxin encoding and 
non-epsilon toxjn encoding strains of C. perfrin-
6 7 8 9 10 11 
Fig. 2. Agarose gel of PCR products: I, C. perfringens type A (NCTC 8237); 2, C. perfringens type B (NCTC 8533); 3, C. perfringens 
type B (CN 8024); 4, C. perfringens type B (NCTC 6121); 5, C. perfringens type C (NCTC 10719); 6, C. perfringens type C (CN 883); 
7, C. pelfringens type D (NCTC 8346); 8, C. perfringens type D (NCTC 8503); 9, C. perfringens type E (CN 5063); 10, B. subtilt1s 
(NCTC 10452), 0.3-kb gene showed 71 % homology with primer EPCR2; 11 , pPA26. a plasmid containing the PA gene of B. 
anthracis, which showed 74% homology with primer EPCR2. Primer EPCRI , 5 '-TACTCATACTGTGGGAACllC-
GATACAAGC-3' (position 447 to 476 of ORF). Primer EPCR2, 5'-CTCATCTCCCATAACTGCACTATAA1TICC-3' (position 
820 to 849 of ORF) yield a PCR product of 403 bp. Lane M represents molecular mass markers. 
gens, under the optimised conditions ( 1.5 mM 
MgC1 2 , and 57°C annealing temperature). 
Screening of the individual PCR primers aga inst 
the EMBL and GENBANK equence databases 
revealed that EPCR2 showed DNA sequence ho-
mology with the B. subtilis 0.3-kb gene (71 %) and 
the B. anthracis PA gene (74%). However, under 
the conditions stated, no PCR product was gener-
ated when these DNAs were used as a template. 
This straightforward and speedy technique allows 
strains from C. perfringens types B and D to be 
differentiated from type A, C and E strains, with-
out recourse to toxicity neutralisation tests in 
animals. 
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The Clostridium perfringens epsilon-toxin 
Dean Payne, E. Diane Williamson and Richard W. Titball 
Defence Evaluation and Research Agency, CBD Porton Down, Salisbury, UK 
The E-toxin is produced by Clostridium perfringens types B and D. The amino acid 
sequences that have been deduced for the toxins in these strains are identical except 
for one amino acid. Of a variety of tissue culture cells tested only Madin-Darby 
canine kidney (MDCK) cells were susceptible to the toxin. In these cells, the toxin 
caused changes in the actin cytoskeleton. An assay for theE-toxin, using MOCK cells, 
has been used to demonstrate the presence of a receptor in rat brain, subsequently 
shown to be a 26 kDa sialoglycoprotein. The MOCK cell assay was also used to show, 
with site-directed mutants, that histidine or tryptophan residues do not play a key 
role in activity of theE-toxin. 
Keywords: Clostridium perfringens, epsilon-toxin, actin cytoskeleton, mutants 
INTRODUCTION 
With the exception of a-toxin and 9-toxins, the tox-
ins produced by Clostridium perfringens are poorly 
characterized and their modes of action are not well 
understood. The E-toxin is one of the major toxins 
produced by types B and D strains of C. perfringens 
and these strains are the aetiological agents of en-
terotoxaemia in sheep, goats, foals and calves [1, 
2]. The disease occurs when animals ingest large 
quantities of starch-rich foodstuffs, allowing growth 
of the bacterium in the intestine and the concomi-
tant production of E-toxin [2]. Such is the economic 
significance of this disease that much of the domes-
ticated livestock in the Western world is vaccinat-
ed using a formaldehyde toxoid [2]. In spite of this, 
little is known about the molecular biology of the 
toxin or its mode of action. The aim of this paper is 
to highlight the progress that has been made in ad-
dressing these questions. 
CLONING AND SEQUENCING OF 
ENCODING GENE 
The gene encoding theE-toxin (etxB) wa originally 
isolated from a type B strain of C. perfringens [3]. 
The open reading frame was predicted to encode a 
311 amino acid protein, preceded by a signal se-
quence which would direct export of the protein 
from C. perfringens. The E-toxin is produced as a 
prototoxin (molecular weight 32 981) which is acti-
vated by proteolytic cleavage [4]. The preferential 
site of cleavage by trypsin followed lys45 [3] . The£-
toxin shows 26% similarity with the Bacillus sphaeri-
cus Mtx3 (mosquitocidal) toxin and 17% similarity 
with the Pseudomonas aeruginosa cytotoxin [4]. Many 
of the B. sphaericus toxins are produced as prototox-
ins which are activated in the insect gut by proteas-
es. 
MODE OF ACTION 
Although the e-toxin is produced in the gut the 
symptoms of £-toxin intoxication in sheep include 
trembling of the hind parts of the body and loss of 
coordination [4], suggesting that the toxin acts on 
the central nervous system [1,5]. Several studies have 
suggested that the toxin acts as a tissue-specific per-
mease. Increased permeability of the brain vascula-
ture is thought to be responsible for the leakage of 
serum protein s and, eventually, erythrocytes, which 
leads to brain oedema [5]. 
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CLOSTRIDIUM PERFINGENS EPSILON-TOXIN 
Some recent studies have provided insight into the 
mechanism of toxicity. A screen of tissue-culture cell 
lines showed that only Madin-Darby Canine Kid-
ney (MDCK) cells showed a response after treatment 
with £-toxin [5]. A cytotoxicity assay using MDCK 
cells was able to detect 15 ng/ml of £-toxin. After 
exposure to the £-toxin, MDCK cells rounded up 
and the cytoplasmic membrane ruptured. These ob-
servations suggest that the toxin has an effect on 
the cytoplasmic membrane. The finding that the£-
toxin shows amino acid sequence homology with 
the Pseudomonas aeruginosa cytotoxin [ 4] lends some 
support to this proposal. However, the direct effect 
of the £-toxin on cell membranes has yet to be dem-
onstrated and recent work has suggested that the 
rounding up of MDCK cells exposed to £-toxin is 
associated with changes to the actin cytoskeleton [6]. 
These changes in the microfilament network, with 
resultant changes in the integrity of the cell; might 
be related to the ability of the toxin to increase vas-
cular pem:eability. 
TISSUE RECEPTORS FOR EPSILON-
TOXIN 
Toxin labelled with 1251 and administered intrave-
nously into mice accumulates mainly in the brain 
1 2 3 4 5 
Fig. 1. Identification of an e-toxin binding protein in rat brain ho-
mogenate. Rat brain homogenate was separated by sodium 
dodecyl sulphate-gel electrophoresis, blotted onto polyvinylidene 
difluoride membrane and the membranes blocked with 5% (weight/ 
vol) skim milk powder in 10 mmol/1 tris-hydroxymethyl-amino meth-
ane, 0.9% weight/vel NaCI, 0.5% (vol/vol) Tween 80, pH 7.2. The 
membranes were stained for glycoproteins (lane 1 ), 
sialoglycoproteins (lane 2) or proteins {lane 3). Membranes were 
also incubated with (lane 4) or without (lane 5) e-toxin (20 11g/ml) 
and, after washing, with polyclonal rabbit anti-e-serum. Horse-
radish peroxidase-labelled goat anti rabbit antibody, which subse-
quently bound to the membrane (arrow), was detected using 
3,3'5,5'-tetramethylbenzidine. The positions of molecular mass 
markers (kDa x 1 03) are shown arrowed at the left of the figure. 
S29 
Table 1. Effect of treatment of rat brain homogenate with glycosi-











(% of control) 
98 ± 8 






24 ± 3 
Results shown are the mean (±SEM) of four determlnations. 
and kidneys and binds preferentially to the lumi-
nal surface of endothelial cells, especially those 
found lining blood vessels in these tissues [7]. The 
high affinity binding of toxin to neural tissues can 
be demonstrated in the laboratory using rat brain 
homogenates or synaptosomal fractions [5,8]. The 
binding was reduced if synaptosomal fractions were 
treated with pronase or neuraminidase suggesting 
that receptor was a sialoglycoprotein. 
Using an immunoblotting technique thee-toxin was 
found to bind predominantly to a 26 kDa sialoglyc-
oprotein in rat brain (Fig. 1). To identify the receptor 
further, rat brain extracts were treated with various 
glycosidases, incubated with e-toxin and the mix-
ture tested in the MDCK cell-culture assay system. 
The activity of the e-toxin was reduced most in ex-
tracts which had been treated with ~-N-acetylglu­
cosaminidase, a-mannosidase, ~-mannosidase and 
a-L-fucosidase (Table 1). These findings suggest that 
the conserved pentasaccharide core found in N-




The chemical modification ofe-toxin suggested that 
one tryptophan and one histidine residue were es-
sential for activity. The protein contains two histi-
dine residues and a single tryptophan residue, and 
to determine whether these amino acids were essen-
tial for activity, site-directed mutants of the e-toxin 
were constructed and expressed in Escherichia coli 
[9]. The trypsin-activated toxins were tested in the 
MDCK tissue-culture assay system and for lethality 
in the mouse model. The results indicated that 
His106, His149 and Trp190 were not essential for 
biological activity. Therefore, the location(s) of ami-
REVIEWS IN MEDICAL MICROBIOLOGY (1997)8 (SUPPL 1) 
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no acids essential for activity of thee-toxin remains 
unknown. 
CONCLUSIONS 
Considerable progress has been made in under-
standing the molecular biology and mode of action 
of the C. perfringms E-toxin. The cloning of the gene 
encoding the E-toxin opens up new possibilities for 
investigating structure-function relationships, espe-
cially using site-directed mutagenesis. The finding 
that E-toxin binds to a 26 kDa N-linked glycopro-
tein in rat brain will allow the receptor for this toxin 
to be fully characterized. Therefore, many of the ba-
sic b uilding blocks for future studies with the toxin 
are now available. Central to any of these studies is 
the availability of a reliable in vitro tissue culture 
assay for the toxin. 
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An assessment of the in vitro toxicology of 
Clostridium perfringens type D s-toxin in 
human and animal cells 
SJ Shortt1 , RW Titball 1 and CD Lindsay*·1 
'Defence Evaluation and Research Agency, CBD Porton Down, Salisbury, Wiltshire SP..J OJQ, UK 
The epithelial Marlin Darby canine kidney (MDCK) cell 
line and 17 human cell lines were examined for sensitivity 
to Clostridium perfringens type D &-toxin. MDCK cells 
were confirmed as being sensitive to the toxin. In addition, 
the Caucasian renalleiomyoblastoma (G-402) human cell 
line was identified as being &-toxin sensitive. Using the 
MTSIPMS assay system the concentration of toxin 
reducing cell culture viability by 50% (LC50) was found to 
be 2 J.tg/ml in MDCK cells. The LC50 for G-402 cells was 
280 J.tg/ml. &-Toxin was found to be rapid acting in MDCK 
cells exposed to a maximum lethal dose of the toxin (40% 
loss of viability after a 0.5 h exposure), but slower acting in 
G-402 cells (40% loss of viability after 1.7 h exposure). 
Photomicrography of toxin exposed cultures indicated 
Introduction 
Clostridium perfringens is a widespread obligate 
anaerobe associated with a range of diseases in 
animals and humans• and can be divided into five 
groups (A, B, C, D and E),Z with e-toxin being 
produced by types Band D only.3 Cl. perfringens e-
toxin is a member of a group of highly toxic 
clostridial toxins, secondary only in potency to 
botulinium and tetanus neurotoxins.• e-toxin is 
normally produced as a relatively inactive proto-
toxin which, after proteolytic hydrolysis and 
conformational changes, becomes cytotoxic.•·n The 
active toxin has a molecular mass of 30 kDa, as 
indicated by previous sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS- PAGE) 
investigations. 7 In the field of veterinary medicine it 
is responsible for a rapidly fatal disease of sheep, 
lambs and occasionally other livestock;8 ·9 charac-
terised by oedema of the brain , lung, heart and 
kidney (also known as 'pulpy kidney' or 'over-
eating disease'). The result of binding between toxin 
and receptors sites in blood vessels at the blood-
•correspondence: CD Lindsay 
Received 14th August 1999: revised 20 December 1999; accepted 
21 December 1999 
necrotic cell death on exposure to e-toxin. Investigations 
using an antibody probe indicated that e-toxin could bind 
to many cell surface proteins in both MDCK, G-402 and a 
toxin insensitive human cell line (CAKl-2). It has 
previously been found that the toxin may bind to the cell 
surface via glycosylated moieties. However, exposing 
MDCK and G-402 cells to e-toxin in the presence of sialic 
acid and several different sugars did not reduce the lethal 
effects of the toxin. 
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brain barrier is a rapid increase in vascular 
permeability resulting in oedema.8 - ' 3 'Pulpy kid-
ney' disease is often associated with a change from a 
poor to a rich diet, accompanied by excessive 
eating,•• which results in large amounts of un-
digested starch-rich food passing into the small 
intestine allowing the proliferation of Cl. perfrin-
gens with subsequent toxin activation.t5 Because 
mortality rates from ' pulpy kidney' disease can 
approach 100%, it is of great economic importance, 
especially when animals are raised under intensive 
stocking regimes. ' 6 As a result, much of the 
domestic livestock in the western world is vacci-
nated using a formaldehyde toxoid. 17 
The use of in vitro cell line cultures to study the 
effects and mechanism of action of the toxin is an 
attractive alternative to animal experiments from 
the perspective of welfare and economic considera-
tions. However, this approach is problematic in the 
case of e-toxin because there are very few appro-
priate in vitro mode ls available. The Madin Darby 
canine kidney (MDCK) cell line has become 
relevant to e-toxin investigations due to the effect 
the toxin has on the kidneys in vivo post exposure 
and to date , only MDCK cells and guinea-pig 
peritoneal macrophages have been identified as 
being susceptible to the effects of r.-toxin in vitro. '" 
This study reports toxicological studies of Cl. 
perfringens t:- toxin in a number of human and 
animal cell lines and the identification of a sensitive 
human cell line. 
Materials and methods 
All growth media and reagents were obtained from 
Sigma Chemical Co. Ltd. (Poole, UK) unless 
otherwise indicated. Disposable cell culture equip-
ment was obtained from BE Thompson (Stock-
bridge, UK). A neutralising murine monoclonal 
antibody to Clostridium perfringens c-toxin was 
supplied by the Central Veterinary Laboratory 
(Surrey, UK). 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl) -2 -(4-sulfophenyl) -2H -tetrazo-
lium; inner salt (MTS) was supplied by Promega UK 
Ltd. (Southampton, UK). Streptavidin biotinylated 
horseradish peroxidase complex (hereafter referred 
to as streptABComplex/HRP) and biotinylated rabbit 
anti-mouse immunoglobulins were supplied by 
DAKO Ltd . (Cambridge, UK). Glacial acetic acid, 
ethanol, methanol, H20 2 and formaldehyde (40%, 
w/v) were supplied by BDH Ltd. (Poole, UK). 
PhastGel 4-15% polyacrylamide gels, SDS buffer 
strips, the PhastSystem separation and PhastTrans-
fer electrophoresis equipment were supplied by 
Pharmacia Biotech (St. Albans, UK). Biotinylated 
SDS- PAGE standards (broad range) and 0.45 .urn 
pore size nitrocellulose membrane were supplied by 
Bio-Rad Laboratories Ltd. The micro BCA protein 
assay kit was supplied by Pierce (Illinois, USA). All 
other chemicals were supplied by Sigma-Aldrich 
Co. Ltd. (Poole, UK). Cl. perfringens type D, 
wildtype e-toxin (hereafter referred to as 6-toxin) 
was supplied by Dr DW Payne, Biomedical Sciences 
Department, DERA, CBD Porton Down, UK. 
Cell culture 
The cell lines KELLY, 1321Nl, TE671, A549, BEAS-
2B, RPMI 2650, 293 , A.704, CAKI-2, 293 N3S, 
MDCK, HGC-2 7, INT 407, SK-PN-DW, HFFF-2, 
and TE 85 were obtained from the European 
Collection of Cell Cultures (Centre for Applied 
Microbiology and Research, Porton Down, Salis-
bury, UK). The SVK-14 line was supplied by Dr J 
Taylor-Papadimitriou, Imperial Cancer Research 
Fund , London. All these lines (with the exception 
of the MDCK line) were of human origin and were 
cultivated in a humidified a tmosphere comprising 
5% C0)95% air at 37 C. in 150 cm" culture flasks 
containing medium supplemented with glutamine 
(2 mM). penicillin (100 units/m!). streptomycin 
(100 lig/m l) and foetal bovine serum (FBS) 10% 
(v/v). The cell lines TE 671. 1321N1, A549, BEAS-
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2B. HFFF-2, SVK-14 and MDCK were cultivated in 
Dulbecco's minimum essential medium (DMEM). 
SK-PN-DW was cu lti va ted in DMEM containing 
non-essential amino acids (NEAA) 1% (v/v). RPMI 
2650, TE 85, HGC-27 and 293 were cultivated in 
Eagle 's minimum essential medium (EMEMJ con-
taining NEAA 1% (v/v). A.704 was cultivated in 
DMEM containing NEAA 1% (v/v) and 1 mM 
Na2HPO •. !NT 407 was cultivated in EMEM without 
NEAA. 293 N3S was cultivated in EMEM Jocklik 's 
modification for suspension cultures. KELLY was 
cultivated in RPMI 1640 medium. CAKI-2 was 
cultivated in McCoy's 5A modified medium. G-
402 was cultivated in McCoy's 5A modified 
medium with FBS 20% (v/v). Cells were subcul-
tured on attaining 80-90% confluency and were 
removed from 150 cm3 flasks by washing the cell 
layer with 10 ml Hank's balanced salt solution 
(HBSS), fo llowed by incubation in 8 ml trypsin 
(0.05%, w/v)/ethylenediaminetetraacetic acid 
(EDTA) (0.02% , w/v) solution for 5-10 min to 
produce a suspension of cells. Cells were sedimen-
ted by centrifuging the suspension for 5 min at 
300 g, 4°C. The cells were re-suspended in the 
required volume of medium for passaging into new 
flasks, or were re-suspended in medium supple-
mented with dimethyl sulphoxide (10%, v/v) for 
storage under liquid nitrogen. Cells were split in 
ratios of 1 : 3 or 1 : 4 when passaging. 
The MTS/PMS cell culture viability assay 
This cytotoxicity assay is based on the conversion of 
the tetrazolium salt, MTS, to a water-soluble 
formazan product by the cytochrome systems of 
viable cells in the presence of the electron-coupling 
agent PMS. The assay was used to determine the 
viability of cells in 96-well microtitre plates as 
described elsewhere. 7 
Exposure of cells to toxin 
A range of serial dilutions of toxin (0-1000 pg/ml) 
was used to determine the concentration at which 
cell viability was reduced by 50% (LC50) compared 
to control cultures (not exposed to toxin) . The cell 
lines were seeded into 96-well plates at densities of 
5 x 10• cells/lOO pl in appropriate media, as in-
dicated previously, and allowed to adhere for 24 h 
at 37°C in an atmosphere of 5% C02/95% air before 
exposure to toxin. Fresh medium containing toxin 
in the range 0-1000 llglml was then added. After 
24 h incubation under the same conditions, the 
medium containing toxin was removed and the 
cultures in the wells washed twice with medium 
(100 pi). 100 1il/wel1 fresh medium was added and 
ce ll viabi lity determ ined by the MTS/PMS assay. 
The results are presented as viability (absorbance 
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measured at 492 nm) of cultures exposed to toxin 
expressed as a percentage of the viability of control 
cells (100%) not exposed to the toxin. The data is 
presented as mean values±standard deviation (s.d.) 
(n=6). 
Effects of pulses of r.- toxin on MDCK, G-402 and 
CAKI-2 cell viability 
Once cytotoxicity had been identified in G-402 
cells and confirmed in MDCK cells, it was 
decided to use a non-sensitive kidney cell line 
(CAKI-2) as a negative control in subsequent 
investigations. The effect of r.-toxin in the three 
cell lines was determined by pulsing them with a 
maximum lethal dose of toxin for periods of up to 
6 h at 37 C under the conditions previously 
described. MDCK cells were therefore exposed 
to 3 ~tg/ml toxin and G-402 and CAKI-2 cells to 
300 pg/ml toxin. The MDCK, G-402 and CAKI-2 
cells had previously been seeded at 5 x 104 cells/ 
100 pl into 96-well plates as before. At the 
appropriate time point, the toxin was removed 
and the wells washed twice with 50 pi medium. 
One hundred ~tl of fresh medium was added and 
an MTS/PMS assay immediately carried out. The 
results are presented as viability (absorbance 
measured at 492 nm) of toxin exposed cultures 
expressed as a percentage of control cells (100% ). 
The data is presented as mean values± standard 
deviation (s.d.) (n=6). Unstained cultures were 
photographed using a 35 mm camera attached to 
an inverted microscope equipped with phase 
contrast optics. 
Protective effects of sugars and sialic acid 
A series of assays were carried out to determine 
whether sugars competitively inhibited interac-
tion of e-toxin with MDCK, CAKI-2 and G-402 
cells. The cell lines were seeded into 96-well 
microtitre plates and incubated for 24 h as 
previously described. A series of sugars (N-
acetyl-D-galactosamine, N-acetyl-glucosamine, L-
mannose, L-fucose) and sialic acid were diluted 
to 3 pg/ml in the appropriate medium. Cultures 
were e ither treated with 100 ~tl medium only, or 
exposed to an LC,.u of toxin in medium, or 
exposed to sial ic acid or sugar in medium on ly, 
or to a particu lar sugar or sialic acid and toxin 
(LC, .. ). The cells were then incubated for a further 
24 h under the condi tions previously described. 
The medium containing the various treatments 
was removed an d the wells washed with 100 ttll 
well of fresh medium. One hundred ttl/well of 
fresh med ium was added to each of the wells and 
cell viability determined by the MTS/PMS assay 
as described above. 
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The resolution of 1:-toxin binding proteins in cell 
m embrane extrocts from MDCK, G-402 nnd CAKI-2 
cell cultures 
Extraction of m e mbranPs from MDCK. G-402 and 
CAKI-2 cell cultures To inves tiga te 1:-toxin bind-
ing, a modification of a technique of membrane 
bound protein extraction was made. '" Briefly, 
medium was removed from the culture flasks and 
the ce ll layer were washed tvvice with PBS (37cC). 
The cells were detached from the flask using a cell 
scraper in the presence of 5 ml of N-[2-hydro-
xyethyl] piperazi ne-N' -[2-ethanesul phonic acid]-
potassium hydroxide (HEPES-KOH) buffer (which 
was comprised of 0.25 M sucrose, 30 mM HEPES, 
3 mM EDTA(Na)2 , 0.1 mM MgCl 2 , 220 mg oL·dithio-
threitol (DTT), 0.1 mM phenylmethylsulphonyl 
fluoride (PMSF), pH 7.5). The cell suspension was 
centrifuged at 900 g for 10 min at 4°C (Beckman CS-
15R centrifuge), followed by removal of the super-
natant and the re-suspension of the cell pellet in 
1 ml fresh HEPES-KOH buffer. The pellet was then 
homogenised (on ice). The homogenate was brought 
to 7.5 ml with HEPES-KOH buffer and centrifuged 
at 9000 g for 15 min at 4°C. The supernatant was 
stored on ice and the pellet re-suspended in 7.5 ml 
HEPES-KOH buffer and centrifuged as before. Both 
supernatants were combined and further centri-
fuged at 50 000 g for 60 m in at 4 oc. The pellets were 
re-suspended in 1 ml buffer and the protein 
concentration was determined using the micro 
BCA protein assay (microtitre plate protocol) from 
Pierce Inc. (IL, USA). The cell membrane extracts 
were aliquotted as 15 ~~~volumes in the SDS sample 
buffer [10 mM Tris-HCl, 1 mM EDT A(Na2) , SDS 
2.5% (w/v), DTT 4% (w/v), bromophenol blue 
0.1% (w/v), pH 8.0] to give a protein concentration 
of 1 mg/ml. The samples were heated at 95°C for 
5 min prior to use . 
Identification of toxin binding proteins by SDS-
PAGE/Western blotting The membrane extracts 
from the MDCK, G-402 and CAKI-2 cell lines were 
electrophoresed on 4 - 15% gels using a loading of 
1 11g protein/lane . The separations were carried out 
at 250 V constant voltage, 10 mA at 15 C, for 1 h. 
Biotinylated standards and samples were run in 
duplicate in adjacent wells throughout the electro-
phoretic analysis. The standards used were myosin , 
200 kDa; {1-galactosidase, 116.25 kDa; phosphory-
lase B, 97.4 kDa ; BSA, 66 .2 kDa; ovalbumin, 
45 kDa; carbonic anhydrase, 31 kDa; trypsin inhi-
bitor, 21.5 kDa: lysozyme, 14.4 kDa and aprotinin, 
6.5 kDa. Separated prote in samples were trans-
ferred onto 0.45 ~~m nitrocellulose membranes 
us ing a semi-dry Phasttransfer e lectrop horetic cell 
and a tris/glycine/methanol transfer buffer (0.025 M 
tris, 0.192 M glycine, methanol 20 % (v/v) respec-
tively, pH 8.3) using a current of 25 mA at 20 V 
constant voltage at 15°C for 1 h . 
Toxin-binding proteins in membrane-bound pro-
tein extracts transferred to 0.45 J.lm nitrocellulose 
membranes were visualised by treating them, in 
sequence, with 50 J.Lg/ml or 100 J.Lglml e-toxin for 
30 min; neutralising murine monoclonal antibody 
to Clostridium perfringens e-toxin (diluted 1: 100 
with PBS/BSA 1% (w/v), hereafter referred to as 
BSA buffer) for 30 min; secondary antibody (bioti-
nylated rabbit anti-mouse immunoglobulins, di-
luted 1: 400 with BSA buffer), for 30 min; 
streptABComplex/HRP for 30 min. These steps 
were interspersed with washing in PBS/tween 20 
0.1% (v/v). After washing with this tween buffer, a 
solution comprised of 32 mg 3,3'-diaminobenzidine 
tetrahydrochloride (DAB)+40 ml PBS+80 J.ll H202 
(30% w/v) was used to visualise the labelled 
antigen. Appropriate controls (i.e. omitting the use 
of toxin or primary antiserum) established that there 
was no non-specific binding to the membrane 
bound proteins. 
Results 
The effect of e-toxin exposure on a range of cell 
lines 
A total of 17 human cell lines as well as the MDCK 
line were screened for sensitivity to e-toxin. Cell 
cultures were exposed to concentrations of up to 
1000 f,lglml of e-toxin. The MDCK cell line was 
confirmed sensitive to the toxin at concentrations of 
greater than 1 J.Lglml, after which point viability 
declined to 20% compared to control cultures 
(Figure 1). The LC50 for e-toxin in the MDCK line 
was found to be 2 J.lg/ml toxin. The G-402 line was 
also found to be adversely affected on exposure to e-
toxin (Figure 1), though viability only declined at 
concentrations in excess of 100 J.lg/ml toxin. At 
300 f,lglml, viability declined to 45% compared to 
that of control cultures. The LC50 for e-toxin in the G-
402 line was found to be 280 J.Lglml toxin. The G-402 
cell line was therefore found to be less sensitive to e-
toxin than the MDCK line. The non-sensitive human 
kidney line, CAKI-2 , is also shown for comparison 
in Figure 1. 
The effect of e-toxin on MDCK, G-402 and CAKI-2 
cells over time 
In experiments carried out to determine the activity 
of e-toxin over a 6 h time course, a marked 
difference in the level of response to a maximum 
lethal dose of the toxin between the MDCK line 
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(exposed to 3 f,lglml toxin) and the G-402 human 
line (exposed to 300 J.Lg/ml toxin) was found (Figure 
2). The viability of MDCK cell cultures exposed to a 
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Figure 1 Effect of e-toxin exposure on a range of cell lines. The 
effect of c-toxin on MDCK ( + ), G-402 (• J and CAKI-2 (.A) cells 
after 24 h exposure to the toxin. Cells were incubated in 96-well 
plates (5 x 104 cells/100 1tl ) for 24 h followed by exposure to 
toxin (0-1000 J~g/ml) for a further 24 h. Cells were incubated 
with 100 1tl DMEM medium only (MDCK cells) or McCoy's 5a 
modified medium only (G-402 and CAKI-2 cells) as controls; or 
DMEM or McCoy's 5a modified medium containing e-toxin (1-
1000 Jl&lml). Viability of the exposed cultures was determined 
by the MTS/PMS assay at 24 h. Viability (absorbance at 492 nm) 
of test wells is expressed as a percentage of control cells (100%). 
Data points represent mean vaJues±s.d. (n= 6) 
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Figure 2 Effect of £-toxin on MDCK ( + ).G-402 !• l and CAKI-2 
(.A) ceUs over time. Cells were incubated in 96-well plates 
(5 x 104 cells/lOO 11l) for 24 h followed by exposure to toxin for 
0-6 h periods. The viability of the exposed cells was 
determined by the MTS/PMS assay at the end of each time 
period. Cells were incubated with DMEM (MOCK cells) or 
McCoy's 5a modified medium (G-402 and CAKI-2 cells) as 
controls, or DIVffiM or McCoy's 5a modified medium containing 
£-toxin. The MDCK cultures were exposed to 3 jjg/ml toxin; G-
402 and CAKl-2 cultures were exposed to 300 pg/ml toxin. 
Viability (as measured by absorbance at 492 nm) of toxin 
exposed cells is expressed as a percentage of control cells 
(100%). Data points represent mean values±s.d. (n=6) 
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maximum lethal dose of ~:-toxin suffered a drop in 
viability of 40% after 0.5 h, increasing to a 80% loss 
of viability after 2 h. G-402 cell cultures exhibited a 
loss of viability of 40% only after 1. 7 h exposure to 
toxin. The more rapid loss of viability over time was 
therefore found in the MDCK cell line. CAKI-2 cell 
cultures tl isplayed no loss of viability during the 
course of Lhe experiment. 
The morphology of cell cultures exposed to a 
maximum lethal dose of e-toxin after 3 b exposure 
to the toxin confirmed these findings. The majority 
of cells in toxin exposed MDCK cultures had either 
rounded up or appeared to have become detached 
from the substratum at 3 h (Figure 3C). Cells in 
toxin exposed G-402 cultures also displayed this 
type of spherical morphology prior to detaching 
from the substratum (Figure 30). though this 
process was not as far advanced at 3 h as it was at 
the same time point in the MDCK cultures. The 
mode of cell death was characteristic of necrosis; no 
apoptotic bodies were seen. 
Protective effects of sugars and sialic acid 
The eo-treatment of MDCK and G-402 cell cultures 
with sugars (N-acetyl-D-galactosamine, N-acetyl-
glucosamine, L-mannose, L-fucose) and sialic acid 
(concentration 3 pg/ml) in the presence of an LC5u of 
e-toxin did not reduce the lethality of the toxin (data 
not shown). 
Identification of toxin binding proteins in 
membrane preparations from CAKI-2, G402 and 
IVIDCK cell lines 
r.-Toxin was found to bind to proteins in cell 
membrane extracts from both sensitive cell lines 
(MDCK and G-402) and the insensitive cell line 
CAKI-2 . As can be seen from Figure 4A, toxin 
binding protein species were resolved from the 
membrane extracts of all three cell lines. A control 
blot is shown in Figure 4B, in which the blot was not 
treated with e-toxin prior to the antibody labelling 
process; no non-specific binding by the antibodies 
is visible. 
In the toxin sensitive MDCK cell line, the major 
toxin binding species was found to have a molecular 
weight of 46 kDa (x in Figure 4A), though minor 
bands of apparent molecular weight above and 
below this figure were resolved. This 46 kDa species 
(y in Figure 4A), and a similar distribution of minor 
bands was also found in G-402 cell cultures though 
Figure 3 The morphology of MOCK and G-402 cells afte r exposure to r.-toxin: MOCK and G-402 control cultures (not exposed to 
toxin) are shown in (A) and (B) respecti vely. Cultures of MOCK and G-402 cells exposed for 3 h to 3 and 300 ,,g/ml of E-toxin are 
shown in (C) and (D) respectively. Phase contrast optics were used ot a magnification of x 200 
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Figure 4 The identification ofr.-toxin binding proteins in CAKl-2, 
G-402 and MDCK cell membrane extracts: Cell membrane extracts 
from CAKJ-2, G-402 and MDCK cell cultures were run on 4 - 15% 
SOS- PAGE gels and the separated membrane proteins including 
biotinylated broad range molecular weight markers were trans-
ferred to a nitrocellulose membrane. The blots were treated with c-
toxin (100 ~tg/ml) (A) or without toxin (B) and the resu lting toxin-
binding proteins resolved using a neutralising anti-toxin mono-
clonal antibody which was subsequent.ly linked to a biotinylated 
secondary antibody. The secondary antibody was labelled with a 
streptABCcomplex/HRP and the labelled toxin binding proteins 
located using DAB. The above figure (A) is of a nitrocellulose blot 
containing toxin labelled membrane proteins from MDCK cells 
(lanes 3,4). G-402 cells (lanes 5,6) and CAKl-2 ce ll s (lanes 7,8). The 
lane numbers are labelled at the bottom of the blots. The major f.-
toxin binding species (46 kDa) has been labelled x, y and z 
respectively for membrane extracts from each cell line. The 
molecular weight standards are in lanes 1 and 2; their molecular 
weights are denoted in kDa. (B) is a control blot, loaded as for (A) but 
not treated with 1:-toxin; it shows no non-specific binding 
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in the G-402 membrane preparations, the 46 kDa 
toxin binding protein and the minor bands appeared 
to be expressed at a lower level than in the MDCK 
line. A toxin binding protein (46 kDa; z in Figure 4A) 
and a similar pattern of minor toxin binding bands to 
that found in MDCK and G-402 cells was also found 
in the membrane preparations from the non-toxin 
sensitive CAKI-2 cell line, though the level of 
expression for the 46 kDa species was intermediate 
between that resolved from the MDCK and G-402 cell 
membrane extracts. The staining intensity of the 
protein bands for all the membrane extracts was 
reduced when the blots were treated with less toxin 
(50 ~tg/ml) . 
Thus, the pattern of toxin binding protein species 
showed both qualitative similarities in terms of 
apparent molecular weight between all three cell 
lines studied, though the apparent level of expres-
sion was quantitatively different between the 
individual lines. 
Discussion 
The MDCK cell line was chosen for these studies 
because of the susceptibility of kidney cells to a-
toxin in vitro and kidneys in vivo. 10•13•18·20 This 
study sought to determine if cultured cell lines of 
human origin were sensitive to e-toxin. A total of 
17 human cell lines from kidney, brain, respira-
tory and intestinal tract, skin and bone sources 
were exposed to the toxin. The MDCK cell line 
was used as a positive control against which to 
confirm the effects of a-toxin in different cell 
lines. It was found that the MDCK cell line bad 
an LC50 of 2 ~tg/ml after 24 h exposure to e-toxin. 
At concentrations above this range, viability 
declined to 20% and remained at this level 
despite increasing the dose of the toxin. In the 
present study, the only other cell line found to 
be sensitive to the toxin was the G-402 cell line. 
Since no human cell line has been reported 
sensitive to date , th.e discovery that the G-402 
kidney line is a- toxin sensitive (over 100-fold less 
so than MDCK cells) is a novel finding, and may 
have implications for in vivo human toxicity. Of 
additional interest is that at concentrations in 
excess of 300 ~tg/ml, the viability of G-402 cells 
did not decline further, suggesting that in both G-
402 and MDCK cell populations there is a toxin 
resistant population. This would favour a toxin-
cell interaction model which involved receptor-
mediated interactions. Lack of, or altered expres-
sion of the required receptor(s) or toxin-binding 
protein(s) at the cell surface, may at least partly 
explain toxin resistance in cells. 
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The differences in relative sensitivity to e-toxin 
alluded to differences in the mode of action 
between the two sensitive cell lines. A non-
sensitive human kidney cell line (CAKl-2) was 
identified in the initial screening study and used 
as a negative control in subsequent experiments. 
Pulsed exposure assays were conducted to further 
probe toxin-cell interactions. MDCK, G-402 and 
CAKI-2 cells were exposed to maximum lethal 
doses of e-toxin for a series of time points from 0-
6 h. MDCK cell viability was found to decline by 
40% after exposure to toxin for 0.5 h. The toxin was 
thus confirmed as being rapid acting in MDCK 
cells.'·21 This was in contrast to the sensitive human 
cell line (G-402) in which viability was reduced by 
40% only after 1. 7 h exposure. This indicated that 
not only was the G-402 cell line considerably less 
sensitive to r.-toxin than the MDCK line, but the 
kinetics associated with the onset of lethal effects 
were also slower, further indicating a different 
mechanism of action between the two sensitive cell 
lines. 
Despite differences in the LCso values and the 
kinetics associated with the onset of effects in the 
sensitive cell lines, the morphology ofMDCK and G-
402 cultures exposed to e-toxin was similar, with 
the cells in both cultures rounding up prior to 
separating from the substratum. Photomicrography 
of toxin exposed cultures indicated that the cell 
lines underwent necrotic cell death on exposure to 
e-toxin. These morphological observations are 
consistent with previous studies by Payne and 
Oyston• and Payne et aJ.n The effect of e-toxin on 
cell membranes has yet to be resolved and recent 
work has indicated that changes in the actin 
cytoskeleton of cells are associated with rounding-
up of MDCK cells exposed to e-toxin.23 The changes 
in the actin cytoskeleton of MDCK cells suggests a 
relationship with the toxin's ability to increase 
vascular permeability. 2• The CAKI-2 line remained 
unaffected by exposure to the toxin in the dose- and 
time-response experiments. 
The mechanism of action of e-toxin was further 
analyzed by determining whether the toxin would 
bind to cell membrane binding proteins. It has been 
speculated that a specific toxin binding receptor is 
required in order to permit the toxin to exert an 
effect on its substrate: for formalinised e-toxin is 
known to moderate the effects of the active toxin in 
vivo.•• In addition, Lindsay26 found that the effects 
of the toxin on MOCK cells were consistent with 
receptor mediated uptake mechanisms. However, 
more recently, Petit et aJ.2' have reported that e-
toxin forms a 155 kDa membrane complex in MDCK 
cells which is correla ted with K+ efflux and 
cyto toxicity. Nagaharna et al. 26 subsequently re-
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ported that r.-toxin forms 17 4 kDa corn plexes in 
MDCK cell membranes but not Vero cell or sheep 
erythrocyte membranes; the same sized complex 
was also resolved in mouse brain homogenates. 
These complexes were associated with K• release. 
These findings still do not explain the nature of the 
interactions which results in very few cell lines 
being sensitive to the toxin. It is tempting to suggest 
that the initial interaction of the cell surface with 
the toxin may involve a toxin binding protein which 
subsequently facilitates the formation of membrane-
located e-toxin complexes. 
However, in the present study, investigations 
using an antibody probe indicated that e-toxin could 
bind to many cell surface proteins in both of the 
sensitive cell lines (MOCK and G-402) , although a 
common major toxin binding protein (46 kDa) in 
cell membrane extracts from the toxin sensitive 
(MDCK and G-402) cell lines was resolved. More e-
toxin appeared to have bound to the major toxin 
binding species in the membrane extracts from the 
MDCK line. In addition , some toxin was also found 
to bind to tviDCK membrane proteins of lower and 
higher molecular weight than that of the main 
46 kDa species. The apparent heterogeneity of e-
toxin binding proteins has been reported elsewhere, 
albeit in rat brain homogenates. '3 ·•• However, in the 
present study, e-toxin was also found to bind to 
similar cell membrane proteins from the non-
sensitive CAKI-2 line, emphasising the lack of a 
clear relationship between toxin binding to proteins 
from cell membrane extracts and sensitivity to e-
toxin. The results of the present study indicate that 
the binding of e-toxin to cell membrane located 
proteins may not be the only prerequisite for 
toxicity. Additional, unresolved factors that med-
iate toxin-cell interactions and sensitivity may be 
required. 
It has been reported elsewhere22 that the 
binding of e-toxin to rat brain homogenates is 
mediated by a 26 kDa sialoglycoprotein; treat-
ment of rat brain homogenates with glycosidases 
(a- and /3-mannosidase, {3-N-acetylglucosamini-
dase and a -L-fucosidase) reduced the lethality 
of e-toxin, suggesting that the relevant sugars 
formed a part of the core structure of the rat 
brain toxin receptor. However, in the present 
study, exposing MDCK and G-402 cells to e-
toxin in the presence of several different sugars 
did not maintain cell viability, suggesting that 
although these sugars may have formed part of 
a toxin binding mechanism, they may not be 
the moieties that the toxin interacts with 
directly at the cell surface receptor. Alterna-
tively, the sugar to toxin molar ratios may have 
been too low. Studies with ricin and abrin have 
indicated that galactose to toxin molar ratios of 
some 10" 2 " are required to protect cells from 
the effec t of toxin. 
ln summary, although the differences in the mode 
of action of f:- toxin between the MOCK and G-402 
cell lines cannot be explained solely on the basis of 
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Production of a non-toxic site-directed mutant 
of Clostridium perlringens e-toxin which 
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A panel of ten site-directed mutants of Clostridium perfringens c-toxin was 
generated. All of the mutated proteins expressed in Escherichia coli were 
recognized in immunoblots by a neutralizing mAb raised against wild-type 
native c-toxin. The cytotoxicity of the site-directed mutated toxins was assayed 
in vitro against MOCK cells. One mutation resulting in loss of activity in the 
assay was identified. This non-toxic protein was derived by substituting a 
proline for the histidine at residue 106 of the toxin. Immunization of mice with 
the non-toxic mutated c-toxin resulted in the induction of a specific antibody 
response and immunized mice were protected against 1000 LD 50 doses of wild-
type recombinant c-toxin. 
Keywords: Clostridium per(ringens, vaccine, e-roxi n, sire-directed mutants 
INTRODUCTION 
e-Toxin is produced by Clostridium perfringens types B 
and D, but not by types A, CorE (Brooks et al., 1957) . 
C. perfringens types Band D have a limited host range, 
being mainly isolated from sheep, occasionally from 
goats and cattle, and rarely from man (Smith & 
Williams, 1984). The bacteria cause lamb dysentery and 
pulpy kidney disease in sheep, with mortality rates as 
high as 100 %, and a re of great economic importance 
where\·er animals are raised intensively (Buxton & 
Fraser, 1977). Neither disease is infectious, but sporadic 
o utbreaks occur when the microbia l balance of the gut is 
disturbed. Pulpy kidney disease is often associated with 
a change from a poor to a rich diet accompanied by 
overeating (Bullen, 1970), causing undigested , starch-
rich food to enter the intestine. The nutritious, anaerobic 
environment produced in the intestine allows the mul-
tiplication of C. per(ringens, which then produces toxins 
(Bullen & Scarisbrick, 1957). The resulting high con-
centrations of <:-toxin produce a rapidly fata l entero-
toxaemia. 
Severn! vaccines exist for the prevention of C. per-
(ringens enterotoxaemia. These vacc ines are based o n 
fo rmaldehyde-treated bacteri al cu lture filtrates or 
Abbrev iat i ons: GE, glutathione 5-transferase-c-toxin fusion protein; GST, 
glutathione $-transferase. 
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whole-cell cultures and confer a high degree of pro-
tection in animals (Stephen & Pietrowski, 1986). How-
ever, the immunogenicity of the e-toxin in the pre-
parations has been reported to be variable and in-
flammatory responses following vaccination to result in 
reduced feed consumption (Stokka et al., 1994). Im-
munity to a single (conformational) epitope on the toxin 
has been shown to be sufficient to protect against 
purified c-toxin and infection with C. perfringens types 
B and D (Percival et al., 1990). 
The etx gene encoding e-toxin is carried on a plasmid 
(Canard et al., 1992). The genes from C. per(ringens 
type B (etxB) and type D (etxD) have been isolated and 
sequenced (Hava rd et al., 1992; Hunter et al., 1992). 
Comparison of the sequences of the etxB and etx D genes 
revealed two nucleotide differences in the ORFs, result-
ing in one amino acid substitution (Havard et al., 1992). 
The cloned etxD gene encoded a protein of Mr of 32981 
(Hunter et al., 1992). Recently, some amino acid 
sequence similarity between e-toxin and a mosquitocidal 
toxin from Bacillus sphaericus has been reported 
(Thanabalu & Porter, 1996). 
The c-toxin is expressed as an inactive protoroxin which 
is preceded by a putative sig na l peptide, resulting in the 
native protein being exported fro m C. per(ringens and 
the recombinant protein accumulating in the periplasmic 
space of Escherichia coli (Bullen & Batty, 1956; Hunter 
et al. , 1992). The prorotoxin is activ:t ted by proteases, 
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suc h as rryp in, causi ng a shift in p i from 8·02 ro 5·36 
(Bhown & Habeeb, 1977; Worrhingron & M ulders, 
1977) . The mature roxin is highl y toxic wirh an LD50 in 
mice of 0·78 ng when admini re red inrravenously 
(H abeeb , 1969), making ir o ne of rhe mos t potent 
bac terial rox ins. The mechani m of roxic iry is nor 
known, bur some amino acid residues which may be 
important for activity have been identified by chemica l 
modification . One tryptophan (Sakurai & Nagahama, 
1985), one histidine (Sakurai & Nagahama, 1987a), one 
ty rosine (Sakurai & Nagahama, 1987b) a nd three or 
four aspartic or glu tamic acid (Sakurai & agaha ma, 
l 987c) residues have bee n shown to be essential fo r the 
le tha l effect of e-roxin. Eight lys ine residues have a lso 
been shown to be important in activity, bur are probably 
involved in maintaining conforma tion rather than being 
integral to an active sire (Sakurai & Nagahama, 1986). 
The purpose of this study was to identify a candida te 
vaccine rhat would protect against e-toxin intoxication, 
and in so doing to further understand the structure-
function relationship of the toxin. To do this, we have 
produced mutated e-toxins with single a mino acid 
changes a nd expressed them in E. coli. We have 
examjned the activity of these mutated proteins both in 
vitro and in vivo. A non-toxic mutated e-toxin was 
eva luated for its a bility to protect mice against e-roxin 
challenge. 
METHODS 
Bacterial strains and plasmids. C. perfringens typeD (NCTC 
8346) was grown in TPYG broth as described previously 
(Percival et al., 1990). E. coli sera ins invcxF' , JM109 and HBlOl 
were grown in Luria broth (LB) or on LB agar plates 
(Sa m brook et nl., 1989), supplemenccJ as req uired with 25 1-1g 
am picillin ml- 1• The plasmids used in this study a re listed in 
T able I. 
Preparation and manipulation of DNA. DNA was isolated 
from C. per{ringens by the method o f Marmur ( 1961). Large-
and sma ll-sca le plasmid isolario ns, restriction enzyme digests, 
blu nt-ending a nd ligarions were performed a described by 
Sambrook et nl. (1989). Restriction endonucleases, T4 DNA 
ligase and sequencing-grade Taq polymerase were obtained 
from Boehringer M annheim. 
Production of site-directed mutations in plasmid pC10. 
Amino acid substitutions we re selected by firsrly considering 
rhe likely surface exposure of the target residue fro m pre-
dictions of secondary structure and hydrophobiciry (D NA-
Sra r). Substitutions which might be permissible were selected 
from the a mino acid exchange matrices devised by Bo rdo & 
Argos (1991). Finally, rhe likely effects of these mutations on 
secondary structure were predicted using the DNASTAR pro-
gram. The site-directed mutants were created under contract 
by Scorgen Biopharmaceuticals, using described methods 
(T aylor et al., 1985a, b; Nakamaye & Ecksrein, 1986 ; Sayers 
et al., 1988). A Hindlii / Avrll fragment was subcloned from 
plasmid pClO into a M13mpl9 veccor as a source of single-
stranded DNA for rhe mutagenesis reaction. Table 2 shows 
the oligonucleorides used in the reactions. The oligonucleo-
rides were annealed to rhe single-stranded template DNA and 
extended using Klenow polymerase in rhe presence of T4 
DNA ligase ro generate mutant hereroduplex molecules. Non-
mutant strands were removed by nicking with restriction 
endonuclease Ncil and exonuclease HI digestion. The mutant 
strands were used as a template to create double-stranded, 
closed circular molecules which were used co transform E. coli 
main HB101. Mutants were identified by DNA sequencing or 
D A hybridization. The presence of a second Hindlll site in 
rhe poly linker of the pBiuescript 11 KS( +)vector made cloning 
of the mutated Hind Ill/ Avrll fragment back into plasmid 
pClO difficult. The strategy employed co circumvent rhis 
Table 1. Vector plasmids used and plasmids constructed in this study 
Plasmid Description• Source 
pBiuescript 11 KS( +) Phagemid cloning vector, lacZa, Ap' Srraragene 
pClO etxD gene from C. per(ringens NCTC 8346 inserted at This study 
Smal site of pBiuescripr, Ap' 
pjSCDEOl Hindlll / Avrll fragment from pClO cloned into This study 
M13mp19 vector, single-stranded template for 
mutagenesis reactions 
pBR322Tox EcoR Jf BamHI fragment from pCIO cloned into This study 
pBR322, Ap' Tee' 
pGEXJx Expression vector for GST, P, •• Ap' Pharmacia 
pHLH2 etxD amplified from pC10 by PCR and cloned into This study 
pGEXJx at BamHI/ EcoRI sires ro produce a 
GST -mature toxin fusion, P,.e Ap' 
pHLH2.1 pHLH2 with Spel sire abolished Th is stud y 
pTrc99A Expression vector with strong promoter, P,., , Ap' Pharmacia 
pTEP7 etxD from pCIO inserted into pTrc99A as a This study 
BamHI-Sall fragment, P"' Ap' 
pTEP7. 1 pTEP7 with Spel ite aboltshed Th is stud y 
~ Ap', ampicill in resistance; Ter', tetracycline resista nce; r, ... , expression o f .:loned protein driven by the 
tac promoter; P,.,., strong trc promoter upstream o f rhe multiple cloning sire. 
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Table 2 - Oligonucleotide primers used to produce site-directed mut ants of ~:-toxin 
Mutation encoded Oligonucleotide primer sequence• 
Wild-type sequence of etxD 5' ACTGCAACTACTACTCATACTGTGGGAACTTCG 3' 
with cod on for histidine-106 
indicated 
Oligonucleotide mutating 5' CGAAGTTCCCACAGTAGAAGTAGTAGTTGCAGT 3' 
hi stidine-106 : serine 
Oligonucleotide mutating 5' CGAAGTTCCCACAGT CGGAGT AGT AGTTGCAGT 3' 
histidine-106: proline 
Oligonucleotide mutating 5' CGAAGTTCCCACAGT AGCAGT AGT AGTTGCAGT 3' 
histidine-106: alanine 
Wild-type sequence for etxD 5' TCAAAAGAAATTACTCA T AATGTCCCTTCACAA3' 
with codon for histidine-149 
indicated 
Oligonucleotide mutating 





Wild-type sequence for etxD 




5' TTGTGAAGGGACATTAGCAGTAATTTCTTTTGA 3' 
5'GTAAGTGGAAGTGAATGGGGAGAGATACCTAGT3' 
Oligonucleotide mutating 5' ACTAGGT ATCTCTCCGTATTCACTTCCACTT AC 3' 
tryptophan-190 : tyrosine 
Oligonucleotide mutating 5' ACTAGGT ATCTCTCCGAATTCACTTCCACTT AC 3' 
tryptophan-190: phenylalanine 
Oligonucleotide mutating 5' ACTAGGTATCTCTCCCAGTTCACTTCCACTTAC 3' 
tryptophan-190: leucine 
Oligonucleotide mutating 5' ACTAGGTATCTCTCCTTTTTCACTTCCACTTAC 3' 
rryptophan-190: lysine 
• The underlined codon in the wild-type sequence indicates the original sequence in etxD and in the 
oligonucleotide the codon it was changed to in o rder to produce the desired mutation . 
problem is illustrated in Fig. 1. A BamHlfEcoR I fragment of 
the e-roxin gene was subcloned into similarly digested vector 
plasmid pBR322 to produce pBR322Tox. This fragment 
contained unique Hindiii and Avrll sires that a llowed the 
mutated gene fragments to be cloned into the pBR322Tox 
construct. The mutated etxD genes in the pBR322Tox' 
constructs were then recovered as EcoRI/ BamHI fragments 
and cloned back into similarly digested pBluescript 11 KS( + ). 
Subcloning of the site-directed mutated e-toxin genes into 
expression vectors. The etxD gene was subcloned from 
plasmid pClO into two expression vectors, pGEX3x and 
pTrc99A to produce pHLH2 and pTEP7, respectively. 
Plasmids pTEP7 and pHLH2 were digested with restriction 
endonuclease Spel, blunt-ended ro abolish the Spel sires and 
religared to produce p lasmids pTEP7.1 and pHLH2.1. A 
Hindlll f £coR! fragment con taining the sire-directed mutation 
was subcloned from a pClO' construct into simila rly digested 
pHLH2.1. A BamHJfCial fragment containing the site-
directed muta tion was subcloned from a pClO' construct inro 
similarl y digested plasmid pTEP7.1. These recombinanr 
plasmids were then electroporared into E. coli strain HB 101. 
Cloning of rhe fragments was confirmed by restoration of the 
Spel sires and subseq uentl y by DNA cquencing. 
Production and purification of e-toxin. Expression of re-
combinanr mutated and wild-type c-roxins was examined by 
SOS-PAGE and immunoblorring (Logan et al., 1991). 
lmmunoblots were probed with a mAb, A5C12, which is 
specific for a neutralizing epirope on the toxin (Percival et al., 
1990). 
Periplasmic fractions were prepared from E. coli strain HB101 
bearing plasmid pTEP7 and its derivatives by the method 
described by Tirball et al. (1989). The e- prororoxin was 
cleaved with bovine pancreatic trypsi n attached ro beaded 
agarose (S igma ). The trypsin-coated beads were washed and 
resuspended in PBS (Dulbecco's formula; Oxoid). Aliquors of 
1 ml of each periplasmic preparation were activated with 4 U 
trypsin for 30 min at 37 °C. 
Glutathione S-tran ferase-e-toxin (GE) fusion protein was 
expressed from plasmid pHLH2 and its derivatives and 
purified by affinity chromatography using glutathione 
Sepha rose 4B according ro the manufacturer's instructions 
(Pharmacia Biorech). 
ative £- toxin was purified from cultures o f C. perfringens 
type D (NCTC 8346) by ammonium su lphate precipitation 
and ion exchange chromatography (Payne et al., 1994) and 
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Mutant genes in pBiuescript 11 KS(+) 
for sequencing and subcloning 
Fig . 1. Diagrammatic representation of the 
strategy employed to subclone the etxD 
gene fragment containing the site-directed 
mutation from the M13mp19-based 
construct pJSCDEOl to produce a construct 
containing the full etxD gene in pBiuescript. 
An Avr11/Hindlll fragment from pJSCDEOl 
was subcloned into similarly digested 
pBR322Tox. An EcoRI/BamHI fragment 
containing the mutated etxD gene was then 
isolated and cloned into pBiuescript 11 KS( + ) 
which had been digested with the same 
restriction enzymes. Direct subcloning of the 
Avr11/Hind lll fragment into pClO, the etxD 
gene in pBiuescript, was not possible due to 
the presence of a second Hindlll site in the 
multiple cloning site (MCS) of pBiuescript. 
The regions represented by cross-hatched 
boxes indicate etxD seq uence and the black 
box within this represents the sequence with 
the mutated codon. 
inactivated by addition of 10 11l 35 % formaldehyde for every 
100 11g roxin. After incubation at 37 °C overnight, the for-
maldehyde was removed by dialysis against PBS. 
Activity of mut ated t oxins in vi tro and in vivo. The e-roxin 
from £ . coli bearing plasmid pTEP7 and its mutants was 
a cri vated with trypsin and screened for cyrotoxicity using 
MOCK cells according ro the method of Payne et al. (1994). 
The significance of the difference in the activity of a mutated 
e-roxin compared with that of the wild-type recombinant 
toxin was assessed by the Student's t-tesr. 
e-Toxin from£. coli bearing plasmid pTEP7 and its mutants 
was purified from periplasmic extracts and activated with 
trypsin. Comparable levels of e-toxin purity were observed in 
immunoblots of a ll preparations. Using published data (Payne 
et al. , 1994}, the ratio o f CT60 (concentration of extract 
required to kill 50% of MOCK cells) ro L050 was calculated 
as 0·006. The CT50 of the activa ted periplasmic extracr from£. 
coli co m.1ining plasmid p TEP7 was determined as 195 ng ml- 1, 
which correspo nded ro a calculated L0 50 of 35 11g kg- •. This is 
lo\\" compared to purified c-roxin due ro th e low purity of the 
periplasmic preparation. Groups of s ix female BALB/c mice 
(Cha rles River Laborarories) were then challenged intra-
,·enously \\"ith 100 11l wild-type and mutated c-toxin peri-
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plasmic extracts diluted in PBS a t a dose (350 11g kg- 1} 
equivalent ro 10 times the calculated L050 of the periplasmic 
extract produced from E. coli containing pTEP7. The animals 
were closely observed during this acute roxicity test and time 
to death was noted. The test was strictly limited to a 24 h 
period and was performed with the approval of the on-site 
animal ethics committee. 
Immune response to mutated t oxins. Groups of 30 mice were 
immunized intra peritoneally with 0·27 nmol each of c-toxoid, 
purified GE fusion protein expressed from plasmid pHLH2, 
purified GE-H106P fusion protein or E-H106P periplasmic 
extract in a 1: 1 emulsion with incomplete Freund's adjuvanr. 
A liquors of the GE fusion protein were frozen at -70 °C until 
just prior to use to ensure chat the fusion did not break down 
to yield active roxin (see Results}. Two control groups were 
included, namely, mice immunized with 0·27 nmol glutathione 
S-cransferase (GST) (Sigma) in incomplete Freund 's adjuvant 
and unimmunized mice. Mice were given booster doses o f 
antigen on days 21 and 35. Ten mice per group, except for the 
E-H106P-immunized mice, were bled on day 48 of the schedule 
and the sera titrated by a modified ELISA procedure in which 
recombinanc wild-type c-toxin and native c-10x in was coa ted 
to the solid phase and the test serum seria lly diluted in 
duplica te on rhe plare. A horseradish-peroxidase-conjugated 
anti-mouse {Pc-specific; Sigma) immunoglobulin antibody 
was used ro derecr bound antibody and plates were developed 
by rhe addition of ABTS substrate (Sigma). Titres of specific 
antibody are presented as rhe final sample dilurion that gave 
an optical density at 414 nm of >0·1 after subtraction of the 
non-specific binding given by pooled serum samples from age-
marched untreated control animals. On day 54 the mice were 
cha llenged in groups of six with lO ro 1000 LD50 doses of 
activated recombinant wild-type e-toxin administered intra-
venously. The mice were observed for 24 hand rimes to death 
noted. Animals surviving for 24 h after toxin administration 
without toxic symptoms were deemed protected. 
RESULTS 
Expression of mutated a-toxin and GE f usion proteins 
in f. coli and their proteolytic cleavage with trypsin 
Mutated e-toxins were produced with amino acid 
substitutions at three positions. The histidine-106 resi-
due was changed to a serine, proline or an alanine. 
Similarly, the histidine-149 residue was changed to a 
serine, proline or alanine. The tryptophan-190 residue 
was changed to a tyrosine, phenylalanine, leucine or 
lysine. 
Genes encoding each mutation in etxD were subcloned 
into each of two constructs based on vector plasmids 
pGEX3x and pTrc99A, designated pHLH2 a nd pTEP7, 
respectively. Expression of the mutated genes &om 
pTEP7 constructs resulted in high levels of e-prototoxin. 
These proteins were designated E. For example, the 
designation E-H106P indicates a mutated e-toxin with 
the histidine residue at position 106 being mutated to a 
proline. Mutant genes in the pHLH2 constructs resulted 
in the e-toxin being expressed as a fusion protein with 
GST. Such GST -e-toxin fusion proteins were designated 
GE, for example, the designation GE-H106P indicates a 
mutated GST -e-toxin fusion protein with the same 
mutation described above. 
In immunoblots of whole-cell lysates of the panel of 
mutated e-toxins or GE fusion proteins expressed in E. 
coli (data not shown), each of the mutants, when probed 
with mAb A5C12, was revealed as a protein of a similar 
size to that of full-length e-toxin or GE fusion protein, 
with the exception of the mutated toxins E-W190K and 
GE-W190K which appeared to be degraded, as only low 
molecular mass bands were seen in the immunoblors. 
The GST fusion proteins were recognized as 57 kDa 
proteins in immunoblots (Fig. 2a), whilst the mutated 
toxins expressed from plasmids based on pTEP7 were 
recognized as bands of approximately 33 kDa in im-
munoblots (F ig. 2b). With the exception of the E-H149P 
mutant toxin, the e-toxin signal sequence resulted in the 
mutated toxins being exported to the periplasmic space 
of E. coli (Fig. 2b). Although there was a band of the 
correct size in immunoblots prepared &om whole cells 
of E. coli expressing the E-H149P mutant toxin, there 
was only a very weak band in the corresponding 
periplasmic preparation (Fig. 2b, lane 3), indicating that 
export, and nor expression, was the cause of low levels 
of this mutated toxin in the periplasm. 
C. perfringens a-toxin mutants 
Trypsin treatment of the periplasmic preparations 
resulted in cleavage of the e-prorotoxin to produce the 
mature e-toxin. This was seen in immunoblots as the 
appearance of two bands of lower molecular mass (Fig. 
2b). In some trypsin-treated samples a faint band 
corresponding to the pro to toxin was visible, for example 
Fig. 2b, lane 10. However, previous studies (data not 
shown) had shown that treatment of the recombinanr 
toxins with trypsin for 30 rnin resulted in the most 
consistent activation of the e-toxin. Heterogeneity of e-
toxin preparations has been reported previously and is 
thought to be due to rhe presence of partially and fully 
proteolytically cleaved forms of the toxin (Worthington 
et al., 1973). The multiple bands we observed probably 
correspond to these partially and fu lly digested forms. 
Extending trypsin treatment of the recombinant e-toxin 
preparations to 2 h (data not shown) resulted in a 
reduction in toxin activity in the in vitro cytotoxicity 
assay. Examination of the same 2 h samples in immuno-
blots showed that the lower band predominated (data 
not shown), and probably reflected tryptic digestion of 
all available sites in the e-toxin molecule. None of the 
bands reacting in immunoblots were due to cross-
reactive epitopes in the E. coli periplasm as there was no 
recognition of any components of the periplasmic 
preparations of E. coli bearing plasmid pTrc99A (data 
not shown). 
Activity of mutated a-toxins in cytotoxicity assay: 
identification of a non-toxic mutant toxin 
The mutated toxins were treated with trypsin and 
assayed for cytotoxicity against MDCK cells (Table 3). 
Three mutated toxin preparations were not toxic to 
MDCK cells (E-W190K, E-W149P and E-H106P). Of 
these, mutated toxin E-W190K had been shown in 
irnmunoblots to be degraded and mutated toxin E-
H149P was not exported into the periplasrnic space. The 
mutation in toxin E-H149A resulted inane-toxin which 
was significantly less active in the cytotoxicity assay 
against MDCK cells than the wild-type recombinanr 
toxin (P < 0·02). The other mutations did not result in 
significant differences in cytotoxicity activity when 
compared to the wild-type recombinant toxin control. 
The cy totox icity of three mutated toxins, E-W190Y, E-
W190L and E-H106S, was compared on days 1, 5 and 44 
to check the stability of the mxins. The mutated toxins 
appeared to be stable at 4 °C over this rime with no 
decrease in their cytotoxic activity (data not shown). 
Activity of selected mutated toxins in mice: the 
mutant toxin E-H106P is non-toxic in vivo 
The GE fusion protein expressed from plasmid pHLH2 
was non-toxic in mice, but was unstable and spon-
taneously degraded to give active toxin upon storage at 
4 °C (data not shown). 
The toxicities of mutant toxins E-H106P, E-H149A, E-
W190Y and E-H106S were determined in groups of six 
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Table 3. In vitro cytotoxicity of periplasmic extracts of e-
toxin site-directed mutants 
Periplasmic extracts of wild-rype and mutated recombinanr e-
toxin were activated with trypsin. Activation and purity were 
determined by immunoblorring. Cytotoxicity was determined 
as the concentration of extract required to kill 50% of MOCK 
cells (CT60). Results are pooled duplicates from three separate 
experiments and are shown as mean CT60 ±SEM. 
Protein preparation Cf;0 (ng ml- 1) ± SEM 
Wild-type e·toxin 400± L89 
E-Hl06A 980±364 
E-H L06P NT 
E-Hl06S 337±63 
E-Hl49A 2267±869'' 
E-H l49P NT 





NT, Nor toxic. 
* E-H 149A showed a significant (P < 0·02) decrease in cyroroxiciry 








Fig. 2. lmmunoblots of the mutated e-toxin 
produced by site-directed mutagenesis 
expressed in E. coli, probed with the 
neutralizing mAb ASC12. The molecular 
mass of the expressed proteins is shown in 
kDa. (a) Mutated toxins produced as fusions 
with GST based on the vector pHLH2 
following purification by affinity 
chromatography on a glutathione 
Sepharose 48 column. Lanes: 1, GE-W190Y; 
2, GE-W190L; 3, GE-H1 49P; 4, GE-H106A; 5, 
GE-H106S; 6, GE-W190K; 7, GE-W190F; 8, 
GE-H149A; 9, GE-H 149S; 10, GE-H106P. (b) 
Periplasmic preparations of the mutated 
toxins expressed from the Ptrc of pTrc99A. 
before and after activation with trypsin. 
Lanes: 1, E-W190Y; 2, E-W190L; 3, E-H149P; 
4, E-H 1 06A; 5, E-H 1 065; 6, E-W190K; 7, E-
W190F; 8, E-H149A; 9, E-H149S; 10, E-H106P. 
Table 4. In vivo activity of periplasmic extracts of 
selected site-directed mutated toxins 
Periplasmic preparation 
E. coli HB101 
E. coli HB10l (pTEP7) 
E. coli HB l01.E-H106S 
E. coli HB10l.E-H106P 
E. coli HB10l.E-H149A 
E. coli HB101.E-W190Y 







NT, Not toxic. No deaths at 24 h post-exposure. 
mice (Table 4). Intravenous administration of 10 LD50 
doses of recombinant toxin expressed from plasmid 
pTEP7 resulted in the death of mice within 
2·48 ± 0·078 min. Similar mean rimes ro death were 
recorded when either mutant roxin E-W190Y or E-
H106S was rested. The E-Hl49A preparation was less 
toxic in mice. Mice receiving rhe mutated toxin E-H106P 
or a periplasmic preparation from E. coli strain HBlO l 
survived for 24 h without showing any signs of an 
intoxication. Therefore, these results in vivo mirrored 
the results in the cytotoxicity assay by confirming that 
C. per(ringens c-roxin murants 
-------------------------------------------------------------------
Table 5. Survival of immunized mice after challenge 
with c-toxin 
Imm unization Challenge Mean time tO death 




Toxoid No deaths 
GE lO No deaths 
GE-H106P No deaths 
E-HI06P o deaths 
None 2·79±0·69 
GST 2·41±0· 16 
Toxoid No deaths 
GE 100 No deaths 
GE-Hl06P No deaths 
E-H 106P No deaths 
None Not tested 




GE One death after 3 h 
GE-H106P One dea th after 3 h 
E-H106P No deaths 
the E-H106P protein was not toxic and that the E-
H149A preparation showed reduced toxicity. 
Immunization with GE and GE-H106P fusion proteins 
induces a specific antibody response 
The induction of a specific immune response against e-
tox in was determined by measuring the a ntibody titres 
in sera from immunized mice. On day 48 of the 
immunization schedule, the mea n IgG titres (in par-
entheses) against purified native e-toxin were recorded 
for mice immunized with GE (1 :69000), e-toxoid 
(1 : 52000), GE-H106P (1: 32000) or GST (undetectable). 
Protection of immunized mice against challenge with 
£-toxin 
Mice immunized with e-toxoid, GE, GE-H106P and E-
H106P were all protected against an intravenous cha l-
lenge w ith 100 L050 doses of e-roxin (Table 5). When the 
challenge dose was increased to 1000 LD50 doses of e-
toxin per mo use, a ll of the e-toxoid-immunized mice, 
and those immunized with the E-H106P preparation, 
survived with no ill -effects. There was o ne death in each 
of the GE-Hl06P- and GE-immunized groups of six 
mice before the experiment was terminated at 24 h after 
challenge. Unimmunized mice and mice immunized with 
GST were not protected against e-toxin inroxicarion . 
DISCUSSION 
c-Toxin i produced by C. perfringens types B a nd D as 
a relatively inactive protoroxin of 311 amino acid wirh 
a molecula r mass o f 32 700 (Worthingron & Mulders, 
1977; Hunter et al., 1992). Proteolytic cleavage results in 
rhe production of the mature toxin (Worrh ington & 
Mulders, 1977; Hunter et al., 1992) . Although exposure 
to the toxin results in rap idly fa ta l disease in sheep and 
goats, the mecha nism of action of rhe toxin is not 
k nown. Although non-toxic, the GE fu ion protein 
encoded by plasmid pHLH2 was nor suitable a a 
vaccine candidate as it was unstab le and spontaneously 
degraded to produce active c-toxin. We, therefore, made 
sire-directed muta tions with the intention of producing 
a stable and non-roxic mutated e-toxin which could be 
considered as a vaccine candidate. 
A panel of ten site-directed mutations in e- roxin was 
produced with amino acid substitutions at three 
positions. Chemical modification experiments had pre-
viously indicated the importance of certain amino acid 
residues for the lethality of e-roxin (Sakurai & Naga-
hama, 1985, 1987a, b, c). The histidine residue appeared 
to be integral to the active site of c-toxin whilst the 
tyrosine and tryptophan residues were necessary for the 
binding site of the toxin. Of the two histidine residues in 
the mature e-toxin protein, histidine-106 was predicted 
to be located midway along a region of P-sheet in a 
weakly hydrophobic environment whereas histidine-149 
was predicted to be located close to a turn region in a 
hydrophilic environment. Residues found most fre-
quently (70% similarity of environment} in place of 
histidine have been reported to be serine, alanine or 
proline (Bordo & Argos, 1991). The chemical modifi-
cation of histidine residues (Sakurai & Nagahama, 
1987a) would lead to cleavage of the imidazole side-
chain with a resultant loss of functionality or dis-
turbance of the secondary structure at this position. Our 
finding that substitution with alanine or serine at 
position 106 o r 149 did not abolish lethal activity 
indicates that the imidazole side-chain does not play a 
role in activity of thee-toxin. However, the mutation of 
residue 149 to an alanine resulted in a significant 
decrease in activity of the recombinant toxin both i11 
vitro and in vivo, which may result from a conforma-
tional change of the protein affecting its activity. From 
the comparison of hydropathy and secondary structure 
plots using DNA STAR software by the meth ods of Garnier 
et al. (1978) and C hou & Fasman (1978), the mutation 
o f either histidine residue to a serine should have caused 
least disruption to the tox in structure. The s ubstitution 
of proline at these positions would be expected to be the 
most likely substitution to cause a local conformational 
change. Although a ll the histidine substitutions resulted 
in stable mutated toxins being expressed, the H149P 
mutation resulted in a pro tein which was not exported 
into the periplasm of E. coli. The subsrirution may have 
disrupted the protein structure, resulting in a con-
fo rmation that could not be efficiently exported into the 
periplasmic space. This supports the suggestion that thi s 
histidine residue is important for rhe correct confor-
mation of the active toxin as indicated by the H149A 
mutation. The mutatio n in c- toxin of H106P resulted in 
a protein that was non-toxic in mice suggesting that a 
structural mo tif in this region is essential for biological 
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activity. lr i poss ible that this mutation caused a gross 
conformationa l change in the protein . However, our 
findings rhar the mutated protein was stable and 
exported into rhe periplasmic space and rhar it induced 
protective immunity suggest that protective epitopes 
within the g ross structure of the protein were unaffected 
by rhe change. 
The single tryptophan residue in t:-toxin, at position 190, 
was pred icted to be located close ro a hydrophil ic turn . 
Tyrosine, phenylalanine, leucine or lysine were the most 
frequentl y observed substitutions for tryptophan in a 
70% similarity environment (Bordo & Argas, 1991). Of 
these mutations, subst itut ion with tyrosine or phenyl-
alanine would retain aromatic side-groups. The finding 
that the W 190L m utation yielded a cytotoxic e-toxin 
indicates that the aromatic side-chain plays no role in 
activity. When predicting the effect of the mutations on 
secondary structure, the substitutions of tryptophan 
with tyros ine or phenylalanine were predicted to be 
conservative substitut ions whilst mutation to lysine or 
leucine should have disrupted the structure, and hence 
activity, more markedly. Of these mutations, W190K 
would be expected to cause the greatest change in 
structure at this position and this may explain the 
instabi lity of this m utant, which was degraded upon 
expressiOn. 
The formaldehyde-treated e-toxoid induced protective 
immunity against challenge with 1000 LD50 doses of 
toxin. The GE and GE-H106P preparations induced 
some protection aga inst 1000 LD50 doses and complete 
protection against 100 LD50 doses. High IgG titres 
against e-toxin were measu red in mice immunized with 
t:- toxoid, GE or GE-H106P 6 d prior to challenge with e-
toxin. The similarity of these ant ibody titres indicates 
rhar most of the B-cell epitopes were conserved between 
the native e-toxin and the wild-type or mutated re-
combinant toxins fused with GST. Of these candidate 
vaccines, the GE fusion protein was not considered to be 
suitable as it degraded on storage to yield active toxin. In 
conrrast, the E-H106P toxin was shown robe non-toxic, 
indicating that the GE-H 106P preparation could not 
yield active toxin if degradation of the fusion protein 
occurred. In addition, the approach of using a GST 
fusion has the advantage of providing the means of 
purification by affinity chromatography. 
In summary, chemical modification studies have pre-
viously identified certain amino acid residues as playing 
a n important role in the activity of t:-toxin. The 
production of a panel of sire-directed muranrs of e-toxin 
has allowed the contribution of these residues to be 
evaluated. One non-toxic mutated toxin was idenrified 
and was evaluated for its a bility to protect mice against 
t:-roxin intoxicatio n . However, further work is required 
to identify other mutations which also result in abo litio n 
of toxic ity of e-roxin. A s ingle codon change would ca rry 
the risk of reversion to fu ll activity, which would be 
unacceptable for a vaccine formulation. Therefore, at 
least o ne further mutation must be inrroduced into the 
toxin to reduce this risk. As a veterinary vacc ine for 
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sheep, lambs a nd ca ttle, rhe non-toxic sire-directed 
murared roxin would have severa l advantages over the 
currently available commercial ,·accine. The recombi-
nant vaccine would be well-defined and standa rdized 
and rhus the immunogeniciry of the vaccine would be 
more uniform than the current vaccines, which are 
produced by formaldehyde treatment of bacterial cul-
ture filtrates or ce ll cultures. In addition, this vaccine 
should be easier and cheaper to produce as it would by-
pass the need to grow large volumes of a dangerous 
pathogen, relying instead on the culture of a labo ratory 
strain of E. coli. Finally, as it can be produced in a highly 
purified form, the mutated e-roxin could be combined in 
the future with other purified vaccine proteins to 
produce a multivalent vaccine formulation to protect 
against a range of animal diseases. 
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Oligonucle?tide probes desi~ned on the basis of the N-t~rminal sequence of Clostridium perjringens beta-toxin 
were used to 1solate the encodmg gene (cpb). The nucleotide sequence of cpb was determined and on the basis 
of DNA hybridization experiments it was shown that the gene is found only in type B and C strains of C. 
perfringens: The deduce~ ~mino acid sequence of the beta-toxin revealed homology with the alpha-toxin, 
gam~a~toxm, and l~ukocadm o~ Sta~hylococcus aureu~. The beta-toxin purified from C. perjringens appeared 
to ex1st m monomer1c and multJmenc forms. Recombmant beta-toxin, produced in Escherichia coli appeared 
to be mainly in the multimeric form. ' 
The etiology of diseases caused by Clostridium perfrin-
gens can be ascribed almost entirely to the potent exotoxins 
produced by the bacterium. Of the major toxins, alpha-toxin 
and epsilon-toxin are associated mainly with disease in 
humans and animals, respectively (17). In contrast, the 
beta-toxin is known to play a major role in the pathogenesis 
of necrotic enteritis in both hosts. In humans, the disease has 
been termed pigbel (12, 14, 15) and has been reported mainly 
in Africa, Southeast Asia, and New Guinea. It has been 
suggested that the disease occurs when the breakdown of 
beta-toxin, produced by C. perfringens in the gut, is pre-
vented by the presence of trypsin-inhibitory compounds in 
the diet. Such trypsin inhibitors often originate from a diet 
rich in sweet potatoes. Necrotic enteritis attributed to beta-
toxigenic C. perfringens has been reported in calves, lambs, 
and pigs (10, 33). Experimental infections when trypsin 
inhibitors are present in the diet have been reported in 
guinea pigs (14), but it is not clear whether the presence of 
dietary trypsin inhibitors is a prerequisite for disease in other 
animals. 
Despite the significant association of beta-toxin with these 
diseases, little is known of the biophysical or molecular 
biological properties of the toxin ; the toxin has been isolated 
in a pure form (21, 23) and shown to be lethal in mice (22) and 
guinea pigs (23). The mode of action of the toxin has not 
been elucidated, but the toxin has been shown to be der-
monecrotic, to induce hemorrhagic necrosis in guinea pig 
intestinal loops (14), and to be cytotoxic for Chinese hamster 
ovary cells (13) . 
To study this toxin in more detail, we planned to isolate 
the encoding gene and determine its nucleotide sequence. 
This approach could facilitate the design of probes for the 
detectio n of the encoding gene and, in the longer term, the 
development of effective prophylactic or therapeutic re-
agents against beta-toxin-mediated diseases. 
• Corresponding author. 
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MATERIALS AND METHODS 
Bacterial strains and cultivation. C. perfringens strains 
were cultured anaerobically at 37°C in a liquid medium 
containing Trypticase peptone (3%), yeast extract (0.5%), 
gl~cose (0.5%), cysteine hydrochloride (0.05%}, and sodium 
th10glycolate (0.1 %) that was adjusted to pH 7.5 by addition 
of Na2HP04 (TPYG broth). For isolation of DNA, C. 
perfringens cells were cultured in 6-liter volumes of TPYG 
broth _ for 18 h and then separated from the culture fluid by 
fiJtratJon through a 0 .22-~J.m-pore-size membrane. Esche-
richia coli JM101 and JM109 were stored and cultured as 
described by Sambrook et al. (25). 
Preparation of DNA. Chromosomal DNA was isolated 
from the bacteria used in this study by the method of 
Marmur (16). DNA extracted from C. perfringens type B 
cz:-rcrc 853~) was p~rified by centrifugation through a gra-
? tent ?f ces1um chlonde (25). Large- and small-scale plasmid 
IsolatJOns were performed as described by Sambrook et al. 
(25). Oligonucleotides were prepared with a Beckman 200A 
DNA synthesizer with the final trityl group left on. The 
oligonucleotides were purified with a cartridge purification 
system (Applied Biosystems). 
N-terminal amino acid sequence of beta-toxin. Beta-toxin 
was purified f~om C. perfringens type C (CN 5386) as 
descnbed prevtously (23). The N-terminal amino acid se-
quence of the toxin was determined independently at the 
U.S. Army Medical Research Ins titute for Infectious Dis-
eases and the Faculty of Pharmaceutica l Sciences, Tokush-
ima ~unri . University, with a gas-phase sequencer (470A; 
Applied. Btosystems) equipped with an on-line phenylthio-
hydantom analyzer (120A; Applied Biosystems). 
Blotting of DNA and hybridization of gene probes. After 
electrophoresis, DNA digested with restriction endonu-
cleases was tran ferred onto a nylon membrane (Hybond-N; 
Arnersham). Undigested DNA wa transferred onto the 
membrane with a slot blot apparatus. Oligonucleotide probes 
(10 pmol) were 5' end labelled (25). Unincorporated 
h·-32P)ATP was removed by passing the labelled ol igonucle-
otide through a Nensorb 20 column [DuPont (UK) Ltd.] in 
Y01 . 61. 199:l 
accordance with the manufacturer's instructions. Isolated 
fra~ments of double-stranded linear DNA were labelled with 
[a- 2 P]dCTP by using a random-primed labelling kit (Boehr-
ingcr Mannheim UK Ltd.). The labelled probes were hybrid-
ized to membranes as described by Sambrook et al. (25). For 
o ligonucleotide probing, the temperature of hybridization 
and washing was 42°C (ClosNH and ClosCOO), 34°C ([3tox3), 
or 40°C ([3tox2). 
Cloning techniques. Two strategies were used to clone 
DNA fragments from C. perfringens type B (NCTC 8533). 
Chromosomal DNA digested with restriction endonuclease 
Sspi was ligated to 0.1 IJ.g of digested and dephosphorylated 
plasmid pUC18 and transformed into£. coli JM101 cells (9). 
Cells were transferred to a nylo n membrane (Hybond-N) by 
colony blotting as described by Sambrook et al. (25), except 
that after replica plating, the colonies were incubated on L 
agar containing chloramphenicol (100 IJ.g/ml) to ampli fy the 
plasmid DNA. 
Chromosomal DNA digested with Hindiii or Sau3A was 
ligated to suitably digested and dephosphorylated Ml3mp18 
(Hindiii) or Ml3mp19 (Sau3A) (Pharmacia LKB Biotech-
nology) , transfected into E. coli XLI-blue (Stratagene), and 
mixed with E. coli JM105 or TG1 cells before inoculation 
onto plates of L agar plus ampicill in (25). The plaques were 
transferred onto a nylon membrane (Hybond-N) as de-
scribed by Sambrook et al. (25). 
After incubation of the membranes with radioactively 
labelled oligonucleotides as described above, colonies or 
plaques which hybridized with the probe were picked from 
the original plate and subcultured. 
Nucleotide sequencing. Single-stranded DNA was prepared 
from M13 clones as described by Sambrook et al. (25). To 
generate single-stranded DNA from plasmid clones , the 
insert DNA fragments were amplified by using the poly-
merase chain reaction (PCR) with one of the oligonucleotide 
primers biotin labelled (Dynal A.S., Oslo, Norway). The 
biotin-labelled strand of DNA was isolated by using strepta-
vidin-coated magnetic beads (Dynabeads; Dynal A.S.). Nu-
cleotide sequencing was performed by the dideoxy-chain 
termination method with cloned T7 DNA polymerase (Se-
quenase Version 2.0; United States Biochemical Corp.) in 
accorda nce with the manufacturer's instructions . 
Alternatively, nucleotide sequencing of the positive s trand 
from Ml3 cloned DNA fragments was performed by isolat-
ing the M13 replicative form {25), which then served as a 
template for use in a Taq polymerase cycle sequencing 
system (GffiCO-BRL). 
Computer analysis of nucleotide and amino acid sequences. 
Nucleotide and deduced amino acid sequence data were 
analyzed with DNAStar computer software. The amino acid 
sequence of Staphylococcus aureus alpha-toxin (8) was 
translated from the nucleotide sequence located in the 
EMBL sequence data base under accession no. X01645 and 
amended by changing the following residues: Gly-25 to Asn, 
AJa-74 to His, Iso-75 to Asn, and Glu-123 to Gin (13a). The 
amino acid sequences of beta-toxin and the individual S. 
aureus toxins were compared by using the PROSCAN and 
AALIGN programs (DNAStar). Multiple sequence align-
ments and comparisons were done with the Cl us tal algorithm 
within the MEGALIGN program (DNAStar). Hydropathy 
(Hopp-Woods algorithm) and surface exposure (Emini algo-
rithm) predictions were done with the appropriate DNAs tar 
programs. 
Expression of beta-toxin in£. coli. A DNA fragment which 
would encode the open reading frame of the beta-toxin and 
the proposed S hine-Dalgarno sequence was ampl ified from 
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C. perfringens NCTC 8533 DNA by using the PCR. Oligo-
nucleotides used in the PCR corrc ponded to nucleotides 316 
to 338, with an add itio nal 5' region that encodes an EcoRI 
s ite (GTCGACGAA TT), and the complementary sequence 
of nucleotides 1335 to 1355, with an additional 5 ' region that 
encodes a Pst! s ite (AAGCTTGGCTGCAG). A DNA frag-
ment was obtained after 35 cycle of amplifica tion (95°C, 15 
s ; 45°C, 15 s; noc, 30 s ; Perkin Elmer 9600 GeneAmp PCR 
System). The fragme nt was purified, digested with EcoRI 
and Pstl , ligated with suitably digested plasmid pUC19, and 
transformed into E. coli JM109 cells as described above. A 
colony con taining the cloned be ta-toxin gene (plasmid 
pBETI) was identified by using the PCR with the o ligonu-
cleotides described above. A cultu re of E. coli containing 
pBETI was grown in L broth (3rC with shaking at 150 rpm) 
to an optical density at 600 nm of 0.5, at which time 
isopropyl-[3-o-thiogalactopyranoside (IPTG) was added to a 
final concentration of 1 mM and the culture was grown for a 
further 18 h. Pe riplasmic and cytoplasmic fractions of these 
cells were prepared as described previously (29). 
SOS-PAGE and Western blotting (immunoblotting). Puri-
fied beta-toxin (100 IJ.g/ml; 23) or extracts from E. coli 
containing pBETI were mixed with sample buffer (4% [wt/ 
vol] sodium dodecyl sulfa te (SOS] , 5% [voVvol] [3-mercap-
toethanol), incubated (5 min, 22 or 1000q, and analyzed 
by SDS-polyacrylarnide gel electrophoresis (PAGE) (0. 1% 
SOS). In some experiments, the separated material was 
transferred onto a polyvinylidene diftuoride membrane (Im-
mobilon P; Millipore Corp.) and the membrane was blocked 
with a 5% (wt/vol) solution of dried skim milk in phosphate-
buffered saline. The membrane was probed with a 1:1,000 
dilution of a mouse anti-beta-toxin monoclonal antibody 
(F154/3-G7), and bound antibody was detected with a horse-
radish peroxidase-labelled anti-mouse immunoglobulin G 
antibody (Sigma) by visualization of the bound antibody with 
a 1-chloro-4-naphthol substrate (25). In some experiments, 
horseradish peroxidase-labelled ho rse anti-C. perfringens 
type B serum (Wellcome Diagnostics) was used to probe the 
membrane directly, with visualization of the bound antibody 
as described above . 
Nucleotide sequence accession number. The nucleotide 
sequence of the beta-toxin gene from C. perfringens has 
been submitted to GenBank and assigned accession no. 
Ll3198. 
RESULTS 
Design of oligonucleotide probes. Four oligonucleotides 
(CiosNH , ClosCOO, [3tox2, and [3tox3) were designed on the 
basis of the experimentally determined N-terminal amino 
acid sequence of beta-toxin . The probes were designed to be 
complementary to the coding ([3tox2 and [3tox3) or noncod-
ing (CiosNH and ClosCOO) strand of the DNA (Fig. 1) and 
were selected from regions where possible codon degener-
acy was minimal (26). To reduce the redundancy of two of 
the oligonucleotides further, the neutral base analog deoxy-
inos ine (26) was incorporated into probe [3tox3 at three 
pos itions and into [3tox2 at two pos itions. The probes were 
also des igned with reference to known codon usage prefer-
ences in C. perfringens (30) and, for ClosNH, ClosCOO, and 
[3tox2. the ability of guanine and thymidine to pair with 
neutral bias. With these s trategies, the probes were reduced 
to 128-fo ld {CiosNH), 64-fold (CiosCOO), 4-fold ([3tox2}, or 
12-fold ([3tox3) degeneracy. 
Hybridization of oligonucleotide probes. DNA from C. 
pelfringens type B (NCTC 8533) was diges ted with Hind Ill , 
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FIG. l. Experimentally determined N-terminal amino acid sequence of beta-toxin (B), showing the possible m RNA that codes for this 
sequence (C). Oligonucleotide probes ClosNH (D), ClosCOO (E), j3tox2 (F), and j3tox3 (G) were designed by taking into account the codon 
usage bias in C. peifringens. To reduce the degeneracy of the j3tox2 and j3tox3 probes further, the neutral-pairing base analog deoxyinosine 
was used at position 3 in the codon for Gly, Thr, and lie. TheN-terminal amino acid sequence of beta-toxin deduced from the experimentally 
determined nucleotide sequence is shown on line A. 
Sau3A, or Sspl, and fragments which hybridized with j3tox2 
or j3tox3 were identified by Southern blotting. The hybrid-
ization temperatures were calculated (26) to be 42°C (probes 
ClosNH and ClosCOO), 40°C (probe j3tox2), and 34°C 
(probe j3tox3). The probes all reacted with a 300-bp Sspl 
fragment, a 700-bp Sau3A fragment, or an 850-bp Hindni 
fragment. In some experiments, probes ClosNH and Clos 
COO reacted with a 1.4-kb Sau3A fragment. On the basis of 
these results, probes ClosNH, ClosCOO, and j3tox2 were 
selected for isolation of the cloned DNA fragments because 
the higher hybridization temperature would minimize non-
specific probe binding. 
Cloning of the beta-toxin-encoding gene. DNA fragments 
generated after Sspl digestion were cloned into plasmid 
pUC18, and approximately 5,000 ampicillin-resistant colo-
nies were screened by hybridization with oligonucleotide 
j3tox2. A single probe-reactive colony was identified, the 
plasmid DNA was isolated (pBET400), and the identity of 
the DNA insert was confirmed by Southern blotting and 
reaction with probe j3tox2. The nucleotide sequence of the 
probe-reactive fragment was determined; this revealed a 
sequence which could encode the N terminus of beta-toxin 
(Fig. lA). Two differences between the experimentally de-
termined and deduced amino acid sequences were observed, 
at positions 5 (threonine-lysine) and 13 (asparagine-lysine). 
To isolate fragments of DNA that encode the remainder of 
the beta-toxin gene, fragments of DNA generated after 
Sau3A or Hindiii digestion were cloned directly into bacte-
riophage M13. Approximately 105 plaques were screened 
from each library, of which 75 and 46%, respectively, 
appeared to contain insert DNA, as judged by inactivation of 
the lacZ gene. Twenty-five plaques which reacted with 
probes ClosNH and ClosCOO were identified, isolated, and 
plaque purified. Examination of the replicative-form DNA 
revea led that two of the Hind Ill clones (pBET2 and pBET4) 
contained a 0.85-kb fragment. A single Sau3A clone 
(pBET26), which contained a 1.4-kb DNA insert , was also 
selected for further characterization. 
Nucleotide sequence determination. The nucleotide se-
quences of clones pBET400, pBET2, and pBET26 were 
determined by us ing a variety of sequencing strategies (Fig. 
2). The nucleotide sequence of the pBET26 DNA insert was 
not determined at the 3' end. The nucleotide sequences of 
the three DNA fragments overlapped, and a total of 1,524 bp 
of the nucleotide sequence was obtained. 
Features of the open reading frame. Examination of the 
nucleotide sequence of the cloned DNA fragments revealed 
the presence of a single open reading frame between nucle-
otides 333 and 1340 (Fig. 2). This open reading frame 
contained regions of DNA homologous with the oligonucle-
otides designed on the basis of the beta-toxin amino acid 
sequence. Comparison of the deduced amino acid sequence 
with the N-terminal amino acid sequence of beta-toxin 
indicated that amino acid Asn-28 corresponded to the start of 
the mature protein. The deduced amino acid sequence 
before this point showed features typical of a signal se-
quence (32); this region was characterized by a central 
hydrophobic domain (Fig. 3) and terminated with an alanine 
residue. Processing of the gene product, on export, would 
yield a protein with a calculated molecular weight of 34,861. 
The predicted isoelectric point of C. perfringens beta-toxin 
(5.5) was similar to previously reported values which had 
been experimentally determined (21, 35). 
The region of DNA that encodes the beta-toxin (cpb) was 
A+T rich (71.5% A+T, which is close to the reported 
composition of C. perfringens DNA [73 to 76% A+ T] [4]). 
A possible Shine-Dalgarno region was located 7 bp up-
stream of the ATG start codon of the cpb gene. This region 
could form a stable bond with the 3' end of the 16S rRNA 
from C. perfringens (tlG = -20.2 kcal [1 cal = 4.184 J ]). The 
region between the putative ribosome-binding site and the 
ATG start codon was composed en tirely of thymidine resi-
dues . No potential promoter sequences were identified be-
eau e of the high A+ T content of the DNA upstream of cpb. 
The nucleotide sequence downstream of cpb contained no 
regions predicted to form stable stem-loop structures which 
were followed by a poly(T) tract, suggesting that rho-
independent termination of transcription did not occur. 
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FIG. 2. Nucleotide sequence of the C. perfringens DNA fragment that encodes beta-toxin. The nucleotide sequence of cpb is shown 
between nucleotides 333 and 1340. The deduced amino acid sequence of be ta-toxin is shown below the coding sequence. The region which 
corresponded to the experimentally de termined N-terminal sequence of beta-toxin is underlined. Also shown are the proposed ribosome-
bindi ng site (RBS) located upstream of the ATG start codon and the TAG stop codon (•). 
Expression ofcpb in£. coli. A DNA fragment which would 
precisely encode the beta-toxin open reading frame and the 
ribosome-binding site was generated from C. perfringens 
NCTC 8533 DNA by us ing a PCR with primers which bound 
upstream and downstream of the gene. The DNA fragment 
was cloned into plasmid pUC19 to generate plasmid pBETI. 
IPTG was added to cultures, and the cells were fractionated 
to determine the location of beta-toxin. The prote ins were 
separated by SOS-PAGE and Western blotted with an anti-
beta-toxin monoclonal antibody. A major reactive protein 
was detected in extracts from the periplasmic space of cells 
containing plasmid pBET7 bu t no t in cells containing pUC19 
alo ne (Fig. 4}. Similar results were obtained when horse 
polyclonal anti-C. perfringens type B serum was used as the 
primary antibody. The appa rent molecular mass of the main 
protein band was 118 kDa, and some immunoreactive bands 
with higher apparent molecular masses were also visible. A 
minor component with an apparent molecular mass of 34 
kDa was also vis ible on We tern blots. When beta-toxin 
purified from C. perfringens (23) was analyzed , two protein 
bands which reacted with the antibody, with sizes similar to 
tho e of the£. coli-expressed proteins, were detected. The 
34-kDa component was the predominant immunoreactive 
form (Fig. 4). Incubation o f the samples in sample buffer, 
without boiling, did no t alter the profile of immunoreactive 
bands. 
Homology of beta-toxin with other proteins. The deduced 
beta-toxin amino acid sequence was screened against the 
Swiss-Prot and PIR data bases with DNAStar computer 
software. We found significant homology with the deduced 
amino acid sequence of S. aureus alpha-toxin (13a) (28% 
similarity), the A, B, and C components of gamma-toxin (6) 
(22, 28, and 18% similarity, respectively), and the S and F 
components of leukocidin (19, 20) (17 and 28% similarity, 
respectively) and leukocidin S (27) (18 and 29% similarity, 
respectively) (Fig. 5). All of these proteins were similar in 
size (286 to 309 amino acids), and alignment of the deduced 
amino acid sequences revealed that 16 amino acids were 
identical and 95 were conservatively substituted. The homol-
ogy between these proteins was weakest at theN termini (to 
residue 52 in Cpb). 
Biophysical properties of beta-toxin and S. aureus alpha-
toxin. In view of the amino acid sequence homology between 
C. perfringens beta-toxin and S. aureus alpha-tox in and the 
fact that bo th are single-component toxins, it was of interest 
to compare the predic ted biophysical properties of these 
proteins. Both proteins were predicted to be composed 
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FIG. 3. Predicted hydropathy (upper trace) and surface exposure 
(lower trace) profiles of the unprocessed forms of C. perfringens 
beta-toxin (A) and S. aureus alpha-toxin (B). Positive values within 
the hydrophilicity plot indicate hydrophilicity, and negative values 
indicate hydrophobicity. The locations of predicted hydrophobic 
and surface-exposed regions are also shown boxed below the 
appropriate traces. The locations of areas of high amino acid 
sequence homology are indicated above the amino acid numbering. 
The hydrophobic region present only in beta-toxin is underlined. 
mainly of a beta-sheet structure (48 and 49%, respectively), 
and circular dichroism studies have previously shown that 
alpha-toxin is composed largely (60%) of a beta-sheet struc-
ture (31). Comparison of the hydropathy and surface expo-
sure profiles revealed little overall similarity between these 
proteins (Fig. 3). To study the structural similarity between 
these proteins in more detail, the hydropathy and surface 
exposure profiles within the highly homologous regions of 
1 2 3 4 
FIG. 4. Analysis of beta-toxin and recombinant beta-toxin by 
SOS-PAGE and Western blotting. Samples of purified beta-toxin (40 
J.Lg/ml; track 2) or extracts from the periplasmic space of £. coli 
containing pBETI (lane 3) or pUC19 (lane 4) were separated by 
SOS-PAGE, Western blotted , and reacted with an anti-beta-toxin 
monoclonal antibody. Prestained molecular size markers (in kilodal-
tons) were in lane 1. 
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these proteins were examined more closely and also com-
pared with the profiles of the colocated regions in LukF and 
HlgB. The N terminus of the region between amino acids 80 
to 102, region 146 to 148, and the C terminus of region 281 to 
290 in Cpb were predicted to be surface exposed, and the 
colocated regions within Hla (Fig. 3), LukF, and HlgB (data 
not shown) were predicted to have similar properties. The 
region between amino acids 159 and 167 in Cpb and the 
colocated regions in Hla (Fig. 3), LukF, and HlgB (data not 
shown) were predicted to be hydrophobic and buried. Other 
regions of amino acid similarity between Cpb and the S. 
aureus toxins showed little structural similarity. The C 
termini of the S. aureus proteins were all predicted to be 
hydrophilic. The C terminus of Cbp was hydrophobic and 
could form a membrane-spanning region. 
Probing of clostridial DNA fot· tbe beta-toxin gene. DNAs 
isolated from C. perfringens types A, B, C, and D were 
hybridized with radiolabelled plasmid pBET400 in a slot blot 
assay. The results (Fig. 6) indicated that the probe hybrid-
ized only with DNAs from C. perfringens types B and C. [n 
other experiments, the probe failed to hybridize to DNA 
isolated from C. botulinum type B, E, or F; C. perfringens 
type E (CN5063); or C. novyi type A (NCTC 538) or D 
(NCTC 8350 or NCTC 9692) (data not shown). 
DISCUSSION 
Three degenerate probes designed on the basis of the 
N-terminal amino acid sequence of purified beta-toxin were 
used to isolate the beta-toxin gene (cpb) from C. perfringens 
NCTC 8533. The deduced N-terminal amino acid sequence 
of beta-toxin did not match the experimentally determined 
sequence precisely, indicating that the proteins from two 
different strains of C. perfringens were not identical. The 
differences observed (Thr-5 to Lys and Asp-13 to Lys) were 
not conservative substitutions. It is unlikely that these 
differences were due to errors in the N-terrninal amino acid 
sequence, since this was determined independently in two 
laboratories. The importance of these residues for the bio-
logical activity of the toxin could not be elucidated, since we 
did not compare the specific toxicities of the proteins. DNA 
hybridization studies revealed that cpb was found only in 
strains of C. perfringens types B and C, and these types are 
associated with beta-toxin production. [t has previously 
been reported that beta-toxin is plasmid encoded (7), and our 
method of isolating bacterial DNA would not have discrim-
inated between chromosomal and plasmid species (ll). 
Beta-toxin is one of the main extracellular products of 
type Band C strains of C. perftingens. Some features of the 
upstream nucleotide sequence suggested that translation of 
cpb mRNA would be efficient: the possible Shine-Dalgarno 
sequence, identified upstream of the ATG start codon, 
would form a highly stable hybrid with the 3' end of the C. 
perfringens 16S rRNA. The intervening seven-nucleotide 
spacing would be optimal for gene expression (34), and the 
unusual poly(T) composition could limit secondary struc-
ture, thus aiding efficient translation (34). The failure to 
identify possible -10 and -35 promoter sequences upstream 
of the ribosome-binding site may be due to the high A+ T 
content of this region. Alternatively, it is possible that the 
gene forms part of a larger operon, but the location of 
translational termination ignals, in all three reading frames, 
upstream of cpb indicated that the 3' end of an open reading 
frame would be located at least 300 bp upstream of cpb. 
Comparison of the start of the beta-toxin N-terminal 
amino acid sequence with the deduced amino acid sequence 



















































































































FIG. 5. Alignment of deduced amino acids sequences of C. perfringens beta-toxin and S. aureus gamma-toxin components, leukocidin 
components, and alpha-toxin. The sequences shown are the processed forms of the following: Cpb, C. perfringens beta-toxin; Hla, S. aureus 
alpha-toxin (l3a); HlgA, HlgB, and HlgC, S. attreus gamma-toxin components A, 8, and C (6); LukS (19) and LukS-R (27), slow components 
of S. aureus leukocidin and leukocidin R; LukF (20) and LukF-R (27), fast components of S. aureus leukocidin and leukocidin R. Identical 
residues (•) and conservative amino acid substitutions (.) are shown below the aligned sequences. 
showed that the first 27 amino acids of the protein could 
encode a signal sequence directing export of the toxin across 
the cell membrane. This result is in accordance with the 
finding that beta-toxin appears in the extracellular fluid in 
cultures of C. perfringens. When allowance was made for 
removal of the signal sequence, cpb would encode a protein 
with a molecular weight of 34,861. Previous workers have 
found that the protein had apparent molecular masses of 20 
to 42 kDa, as determined by gel filtration chromatography or 
SDS-PAGE (22, 23, 35). In this study, we found that 
beta-toxin purified from C. perfringens existed in two forms 
when analyzed by SDS-PAGE and Western blotting: a form 
with a molecular mass of 34 kDa appears to correspond to 
the monomeric gene product, and the high-molecular-mass 
A 
B 
1 2 3 4 5 6 
-
FIG. 6. Hybridization of recombinant plasmid pBET400, which 
encodes part of the beta-toxin gene, with purified pBET400 (Al) and 
DNA isolated from C. perfringens type A (A2, NCTC 8246; AJ, 
NCTC 8237), type 8 (A4, NCTC 8533; A5, NCTC 6121), type C (81, 
NCTC 10719; B2, NCTC 3180; 83, CN 883), type D (84, NCTC 
8346; 85, NCTC 8503), or type E (8 6, CN5063). 
form of the toxin (118 kDa) may be due to oligomerization of 
the toxin. The calculated molecular weight does not corre-
spond to a divisible number of subunits, but this may be due 
to the anomalous migration of the oligomer in SDS-PAGE 
gels. Beta-toxin isolated from the periplasmic space of £. 
coli appeared to be mainly in the high-molecular-weight 
form, and this may be due to the difference in the physio-
chemical environments of the periplasmic space in £. coli 
and the culture extracellular fluid of C. perfringens. 
Previous workers have reported amino acid sequence 
similarity between gamma-toxin and alpha-toxin (6) and 
gamma-toxin and leukocidin or leukocidin R (27). The se-
quence alignment presented here is the first that compares all 
members of this family of proteins, and this will aid future 
studies with these toxins. On the basis of comparisons of 
amino acid sequences of peptides derived from S. aureus 
Pan ton-Va lentine leukocidin (27), it seems likely that the F 
and S components of this toxin also belong to this family of 
proteins. Several regions within the proteins showed high 
degrees of amino acid homology and were predicted to be 
surface exposed, suggesting that they are functionally essen-
tial. Identical amino acids located within these regions would 
be candidates for future investigations of structure-function 
studies with these toxins. Treatment of beta-toxin with thiol-
modifying or oxidizing agents has been reported to abolish 
lethal activity (24), and as there is a single cysteine residue in 
the mature protein this is a candidate residue for future 
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structure-function studies. Several studies have been under-
taken to modify essential ami no acids in S. a11reus alpha-
toxin chemically; arginine, lysine, and histidine residues 
appear to be necessary for biological activity (1), but it is not 
possible to draw conclusions concerning the location or 
s ignificance of these residues in beta-toxin from the compar-
ison of the deduced amino acid sequences. It has been 
proposed that S. aure11s alpha-toxin is composed of two 
domains separated by a glycine-rich hinge region (1). A 
glycine-rich region is present in all of the toxins (positions 
133 to 138 in Cpb), suggesting that this region performs the 
same function in all of these proteins. The C-terminal region 
of alpha-toxin has been suggested to be involved in cell 
binding (2, 3), and although this region was predicted to be 
hydrophilic, it is of interest that the C terminus of beta-toxin 
was predicted to be hydrophobic and potentially membrane 
spanning. 
Both beta-toxin and alpha-toxin are considered to be 
single-component toxins, whereas gamma-toxin and leuko-
cidin require two separate components to elicit cytolytic 
activity. However, alpha-toxin can form membrane-active 
hexamers (18) and in this form it may be appropriate to 
consider it a multicomponent toxin in which all of the 
subunits are identical. It is not clear whether the monomeric 
and oligomeric forms of beta-toxin are toxic, and further 
studies are required to determine the biological properties 
and relationship of the different molecular forms. 
The cytolytic activity of S. aureus alpha-toxin, gamma-
toxin, and leukocidin S against a variety of cell types is well 
characterized (1, 5, 27, 35), and alpha-toxin and gamma-
toxin have been classified as pore-forming cytolysins (28). A 
crude preparation of beta-toxin isolated from the periplasmic 
space of E. coli expressing cpb was not hemolytic for rabbit 
erythrocytes (data not shown), and Jolivet-Raynaud et al. 
(13) have reported that beta-toxin was cytotoxic but not 
cytolytic for Chinese hamster ovary cells and inactive 
against a variety of other cell types. However, some simi-
larities between the toxic properties of alpha-toxin and 
beta-toxin are apparent from other reports. Fifty percent 
lethal doses of 1.87 and 0.68 IJ.g, respectively, for mice have 
been reported (22, 36), and it has been suggested that both 
toxins elicit effects on the central nervous system (1, 13, 17, 
35). 
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The Clostridium perfringens P-toxin 
SOPHIE E.C. LEARY AND RICHARD W. TITBALL 
Defence Evaluation and Research Agency, CBD Porton Down, Salisbury, 
Wiltshire SP4 OJQ, UK 
I. INTRODUCTION 
Clostridium peifringens produces several exotoxins, including four major lethal 
toxins, which play an important part in the pathogenesis of infection of this 
organism. The differential production of the major toxins is also used to classify 
the bacterium into five toxigenic types, A, B, C, D and E. ~-Toxin is produced by 
types B and C, and its association with diseases of domestic livestock has been 
recognized since the early 1930s. 1 It is now recognized as the major virulence 
determinant in enterotoxaemia and necrotic enteritis of a variety of animal 
species, particularly sheep, lambs, calves, piglets and fowl (see Chapter I 0). 
It is also known to cause a similar disease in humans called enteritis necro-
ticans or pig-bel , which is endemic in the Highlands of Papua New Guinea (see 
Chapter 12).2 The conditions leading to the onset of the human disease are 
curious, and are associated with the consumption of under-cooked meat con-
taminated with C. petfringens type C spores by individuals who have a reduced 
level of intestinal proteases resulting from malnourishment, or who consume 
other foods containing protease inhibitors.3 The importance of 13-toxin and the 
role of these contributing factors in causing pig-bel was demon trated u ing a 
guinea-pig model.4 
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The diseases in both humans and animals can be controlled effectively by the 
administration of ~-toxoid, prepared from C. peifringens type C culture filtrates. 
For example, the incidence of pig-bel in children in Papua New Guinea was 
reduced e ightfold by vaccination .5 Despite the significance of the disease in 
veterinary medicine and some human populations, relative ly little is known 
about the biophysical propertie of the toxin, or its mode of action. However, 
the recent application of molecular techniques has yielded further information 
which should contribute significantly to our understanding of this toxin. 
11. MOLECULAR GENETICS 
The gene encoding ~-toxin (cpb) has been isolated and cloned from two C. 
perfringens strains: the type B strain NCTC85336 and the type C strain CPC-
Cph1.7 The DNA sequences of the cloned fragments, which included the cpb 
open reading frame and 332 bp (type B) or 198 bp (type C) upstream, differed by 
only two nucleotides. Both of the changes occurred within the cpb gene, 
although only one affected the amino acid sequence (at position 144 in the 
mature protein) , resulting in the substitution of lysine (type C) for glutamic 
acid (type B).7 
Loss of ~-toxin production by C. peifringens type C strains has been linked to 
the disappearance of a 75 MDa plasmid,8 thus indicating that the gene may be 
plasmid-encoded. This was supported by the observation that a cpb probe 
hybridized only with DNA from the B-toxin-producing types, B and C.6 A 
PCR assay using cpb primers confirmed that the gene was found only in types 
B and C; no cross-reaction was detected with nine other species of Clostridium 
or a range of intestinal pathogenic bacteria.9 A diagnostic polymerase chain 
reaction (PCR) assay also specifically detected the cpb gene in C. petfringens 
strains isolated from cases of necrotic enteritis in piglets.9 
Ill. TOXICITY 
Clostridium perfringens is probably unique not only in terms of the number of 
protein toxins that it produces, but also in terms of their tox icity and lethal 
activity, and ~- and £-toxins are the most potent. The LD50 of purified ~-toxin in 
mice has been reported to be between 0 .3 1 and 12.5 J..tg/kg by the intravenous 
route and between 4.5 and 93.5 !Jglkg when administered intraperitoneall y. 10- 12 
Interesting ly, recombinant ~-toxin expressed in Escherichia coli as a fusion 
with glutathione S-transferase (GST) was nontoxic in mice when administered 
intravenously or intraperitoneally at do es of up to 25 J..tg or I .25 !J.g, respec-
tively, and letha l activity was not re tored after cleavage of the toxin from the 
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carrier protein.7 However, polyclonal antiserum raised against the GST -~-toxin 
fusion neutralized the lethal activity of native ~-toxin in type C culture filtrates, 
indicating that the antigenicity of the recombinant protein was retained. 
IV. BIOLOGICAL PROPERTIES 
Although the gross pathologic effects of f3-toxin in humans and livestock have 
been described, 13· 14 the biological activities underlying these effects are not 
understood. It has been demonstrated that 40-l 00 J..lg of purified ~-toxin causes 
hemorrhagic necrosis and severe destruction of intestinal villi and mucosae in 
guinea-pig intestinal loops, 15 which is similar to the effects caused by type C 
culture filtrates.4 • 15 Parnas 16 also demonstrated that ~-toxin may affect the 
mobility of villi in the intestines of rabbits. Clearly, the ability of ~-toxin to 
induce these types of biological effects in the intestine can be linked to the 
lesions encountered in the natural disease. However, it has also been shown that 
~-toxin has wider effects both in vitro and in vivo. The toxin is known to be 
dermonecrotic in guinea-pigs 11 and it has a number of pharmacological effects. 
Following intravenous inoculation, purified ~-toxin caused an increase in the 
blood pressure of rats, and a corresponding constriction of the arteries. 17• 18 It was 
proposed that this hypertensive effect was caused by the action of toxin on the 
autonomic nervous system and the release of catecholamines. The effect was 
inhibited by the eo-injection of antitoxin and the use of a-adrenergic and gang-
lionic blocking agents. 
The in vitro effects of ~-toxin on cultured cells have been documented to a 
limited extent. Alien 19 reported that the toxin was cytotoxic to primary mono-
cytes from guinea-pigs. Jolivet-Reynaud et al. 15 studied the effects of ~-toxin on 
a number of cell lines, including Vero cells, mouse and human fibroblasts , 
transformed intestine cells, Hep cells and Chinese hamster ovary (CHO) cells. 
Cytotoxic activity was recorded only in CHO cells which had been treated with a 
relatively low dose of the toxin (0.1-10 J..lg), although subsequent cell lysis was 
not observed even after incubation for 5 h. The significance or mechanism of this 
cytotoxic activity is unknown . 
V. PHYSICAL PROPERTIES 
Molecular cloning of the cpb gene indicated that the toxin consisted of a single 
polypeptide chain of 336 amino acids. A signal peptide of 27 amino acids was 
located at the N-terminus, and when thi s fragment was cleaved, the predicted 
molecular mass of the mature protein was approximately 34.9 kDa.6 Previously, 
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the molecular mass of native ~-toxin has been reported to be 20-47.5 
kDa, 10· 15•20•2 1 although when highly purified, it was estimated to be 30-32 
kDa by gel filtration 11 · 12•22 and 40 kDa by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE). 11 The protein purified by Sakurai and 
Fuji i 11 Jacked detectable phospholipase C activity and wa shown to be homo-
genous by native PAGE and SOS-PAGE. In addition, it gave a si ngle pre-
cipitin line with diagnostic C. perfringens types B and C antiserum, and only 
one peak of lethal activity at pH 5.6 was observed after isoelectric focu sing. 
Interestingly, B-toxin purified by the method of Sakurai and Fujii 11 was sub-
sequently shown by Western blotting with an anti ~-toxin monoclonal antibody 
to consist of two forms with molecular masses of approximately 34 and 118 
kDa.6 The 118 kDa form was detected even after boiling in the presence of 
2.5% 2-mercaptoethanol. 
Recombinant ~-toxin purified from the periplasm of E. coli also contained the 
34 and 118 kDa forms, and it was suggested that the smaller component corre-
sponded to the monomeric gene product and the larger component represented an 
oligomer consisting of three to four toxin subunits.6 When recombinant ~-toxin 
was fused to GST, only the monomeric form of the fusion protein with a 
molecular mass of 62 kDa was detected .7 
Sakurai and Duncan 12 showed that the dermonecrotic activity of ~-toxin was 
reduced by 75% after incubating at 50°C for 5 min, indicating that it is relatively 
heat-labile. In addition, they demonstrated that it was sensitive to proteolysis, 
and when treated with trypsin at 37°C, toxin activity was almost completely lost 
within 30 min. The susceptibility of ~-toxin to trypsin digestion would normally 
prevent it from reaching high concentrations in the human intestine and may 
explain why ~-toxin-induced disease is linked to unusual dietary conditions 
affecting the level of intestinal pro teases. 3 
VI. STRUCTURE- FUNCTION RELATIONSHIPS 
In their purification method, Sakurai and Fujii 11 used an affinity column of zinc-
chelate Sepharose to bind ~-toxin, indicatjng that the protein contained exposed 
hi tidine and/or cysteine residues. From the deduced amino acid sequence of the 
mature protein, it is known that the toxin contains four histidine residues at 
positions 85, 175, 293 and 304 and a single cysteine at position 265.6 
Treatment of ~-toxin with thiol-modifying or oxidizing agents, which target 
the s ingle cysteine, abolished dermonecrotic and lethal activity , although this 
reac tion was reversed by reduction.23•24 Thus, it was concluded that cysteine 
may be an essential residue for toxin activity. A similar effect has been reported 
in another family of bacterial toxin , the su lfydryl-acti vated cytolysins, which 
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also contain a single cysteine. However, in three members of this family, 
streptolysin 0, listeriolysin 0, and pneumolysin, site-directed mutagenesis of 
cysteine to alanine yielded mutant toxins that retained at least 75% of the wild-
type haemolytic activity, suggesting that the cysteine was not an essential 
residue.25 It is therefore interesting that when serine was substituted for cysteine 
in P-toxin, and the mutant toxin was expressed in Bacillus subtilis, the protein 
recovered was similar to the native toxin in terms of lethal activity (V. Stein-
p6rsd6ttir, personal communication).26 This preliminary data also suggests that 
cysteine is not an essential residue for P-toxin activity, although this cannot be 
confirmed until the activity of wild-type recombinant toxin, produced in B. 
subtilis, has been tested. In this context, the reason for the nontoxicity of 
recombinant P-toxin purified from E. coli remains unclear.7 
The amino acid sequence of P-toxin was homologous to a family of mem-
brane-active Staphylococcus aureus toxins; the greatest degree of homology 
(28-29%) was observed with a.-toxin, the Fast components of leukocidin and 
leukocidin R, and the HlgB component of gamma-haemolysin (Figure 15.1).6 
Alignment of these toxins also indicated that the amino acid identity was highest 
in the C-terminal two-thirds of the proteins. The S. aureus toxins are cytolytic, 
and the a.-toxin has been shown to achieve its effects by forming membrane-
spanning pores consisting of toxin hexamers.6 Although there is some evidence 
that B-toxin may form oligomers,6 it is unlikely to have cytolytic activity. 
Jolivet-Reynaud et a/. 15 were unable to detect lysis of CHO cells, although 
they did observe cytotoxic activity, and Sakurai and Fujii 11 demonstrated that 
25 Jlg of toxin failed to disrupt mast cells or lysosomes (as shown by the absence 
of extracellular histamine or acid phosphatase, respectively), despite treatment 
for 30 minutes. In addition, recombinant B-toxin was not haemolytic for rabbit 
erythrocytes (unpublished observations).6 
The amino acid sequence homology with S. aureus a.-toxin indicates that P-
toxin is likely to be a ' membrane-active' toxin, but the absence of cytolytic 
activity suggests that it is unable to adopt the conformational changes which are 
predicted to occur in a.-toxin during pore-formation.26 It is possible that the 
toxins interact with the cell membrane in a similar way, perhaps by binding to 
related membrane components, although it is not known how P-toxin achieves its 
effects after these initial stages of membrane interaction. 
VII. FUTURE PERSPECTIVES 
The studies on the molecular biology of P-toxin , which have been carried out over 
the past few years, will now permit a more detailed investigation of structure-
function relationships using site-directed mutants. In addition, a more detailed 
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Figure 15.1 Alignment of the secreted form of Clostridium perfringens P-toxin (Cpb) with the 
secreted forms of Staphylococcus aureus a-toxin (Hia), fast components of leukocidin (LukF) 
and leukocidin R (LukF-R), and gamma-toxin component B (HigB). Identical residues are shown 
below the al igned sequences (* ). 
compari son of the properties of S. aureus a -toxin and C. per.fringens B-toxin 
could provide a fresh insight into the molecular basis of toxicity of both proteins. 
These studies may also result in the development of a second-generati on B-tox in 
vaccine for human and veterinary use, which is both safer and cheaper to produce 
than the current vaccine. 
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SUMMA RY 
Clostridium pe1:(ringens isolates are currently classified into one of five biotypes on the basis of 
the differential production of a-, (J-, e- and t-toxins. Different biotypes are associated with 
different diseases of man and animals. In this study a multiple PCR assay was developed to 
detect the genes encoding these toxins. In addition, detection of the genes encoding the C. 
perfringens enterotoxin and (12-toxin allowed subtyping of the bacteria. C. pet:fringens isolates 
taken from a va riety of animals, including foals, piglets or lambs, were genotyped using this 
assay. Most of the isolates were found to be genotype A and the gene encoding (J-toxin was 
present in 50 % of the isolates genotyped. A significant association between C. petfringens 
possessing the t12-toxin gene and diarrhoea in piglets was identified, suggesting that (12-toxin 
may play a key role in the pathogenesis of the disease. 
INT RO DUCTION 
Clostridium pet:fringens is an important cause of 
enteric disease in both humans and domestic animals 
[1 - 5]. The bacteria produce severa l toxins which play 
key roles in the pathogenesis of disease and are 
classified into five biotypes. designated A- E. on the 
basis of the differential production of alpha- (a-). 
be ta- (/i-). epsilon- (r,-) and iota- (t-) toxins . The :t.-
toxin is produced by all types and, in addition. fl-toxin 
is produced by type B and C strains. r;- tox in is 
produced by type B and D strains. and 1-toxin is 
produced by type E strains. DifTerent biotypes of C. 
pet./i"ingens are associated with ditl'e rent disea cs. For 
• Author fo r corrc,pontknn:. 
example, type C trains have been reported to cause 
enterotoxaemia and necrotic enteritis in sheep, lambs, 
calves, piglets and fowl whilst type D strains are 
thought to cause lamb dysente ry a nd pulpy kidney 
disease in sheep and lambs (1-4]. T ype A st ra ins have 
been associated with gas gangrene and food poisoning 
in humans (4. 5]. 
In addition to the so-called ·major· toxins. there 
are other toxins produced by some strains of C. per-
/i'ingens which m a~ play a role in di ·ease. For example, 
the en terotoxin is important in type A food poisoning 
[6] and is though t to be important in some animal 
diseases [I]. A novel toxin produced by C. pet:fi-ingens, 
termed beta2- (;17.-) toxin . has recentl y been identified 
and it s encoding gene characteriLcd (7]. The /12-toxi n 
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sequence has no significant amino acid sequence 
homology with C. perji·i11ge11s jl-toxin or any other 
known toxin . However. j/2-toxin does have si mi lar 
biologica l ac ti vi ty to ji-toxin , as both a re cytotoxic for 
intes tinal cells and lethal fo r mice [7]. Thus f/2- toxin 
may play a role in disease. Preliminary studies 
suggested that j12-toxin-producing strains of C. 
Jm:fi'i11ge11s are as ociated wi th necrotic enteriti in 
piglets [7] and enterocolitis and typhlocolitis in horse 
[7. 8]. Since enterotoxin and ;12-toxin may play roles 
in disease, it is important to con ider them in any 
typing system. 
The identifica tion of C. pe1fri11gem biotypes has 
traditionally been carried out usi ng an i11 l'it'o toxin 
neutraliza tion test in mice [9]. The difficulties and 
ethical unacceptabi lity of carrying out such tests has 
limited the availability of suitable diagnostic test for 
disease in humans and animals. Whilst antibodies 
against the toxins may be used to identify strains. it is 
known that toxin production is regulated in at least 
some strains (10]. Therefore toxins produced by some 
strains in vico might not be detected when these strains 
are cultured i11 eirro. A genetic test for the presence of 
toxin-encoding genes should be more robust, reliable 
and useful than antibody-based methods and would 
save the unnecessary use of animals. 
We report here the adaptation and testing of a 
multiplex polymerase chain reaction (PCR) assay for 
the simultaneous identification of the C. pe1/ringens a-, 
(1-, e-, t- and (12-toxins and enterotoxin. In addition 
we have used individual PCR assays for these toxin-
encoding genes to genotype C. peJfringens isola ted 
from a va riety of healthy or diseased animals including 
piglets, foa ls and lambs, in order to identify any 
association between the possession of toxin encoding 
genes and disease. 
MATERIALS AND METHODS 
Bacterial reference strains and isolates 
C. pe1fringe11s reference strains were obtained from 
the National Collect ion of Type Cultures or the 
Public Health Laboratory Service Anaerobe Ref-
erence Unit (listed in the text). C. pe1:fi·i11gens isola tes 
tested in the study were obtained from foals, lambs 
and piglets wi th diarrhoea. Contro l isolates were from 
foa ls that were not in contact with diarrhoea cases. 
lambs that were in the same group as the diarrhoea 
cases, and piglets. Isolates were also obtained from an 
alpaca. an elk. a swan. a llama. a horse and calve wi th 
diarrhoea. 
C. pe1ji-i11gc'IIS isolates were cultivated on brain 
heart infusion agar (Oxoid Ltd., UK) in modified 
TPYG broth (50 g/ 1 trypticase peptone, 5 g/1 yeast 
ext ract. 5 g/1 peptone. 5 gj l glucose, 0·5 g/1 cystei ne 
HCI. I g/ 1 sodium thioglycolla te. and di tilled water 
to I 1), and in cooked meat medium (Oxoid) at 37 oc 
under anaerobic conditions. 
Isolation of total DNA 
Cell from overnight 100 ml cultures of modified 
TPYG broth were harve ted by centrifugation a t 
10000 g for 10 min at 4 ac. The cells were washed in 
!Oml of IO x TE buffer pH 7·5, centri fuged and 
resuspended in 2 ml of the same buffer. Lysozyme 
( 10 1tl of 100 mgj ml e lu tion in 0·25 M Tris-HCI, 
pH 8·0) was added and the cells incubated for I h at 
37 °C with agita tion. After addition of 200 pI of I 0% 
(wjv) sodium dodecyl sulphate, the samples were in-
cubated for 10 min at 60 °C, followed by addition of 
20 p i of 0·5 M EDT A and S1d of 20 mgj ml proteinase 
K, and incubation for I h a t 37 °C. 440 Jd of 5 M 
sodium perchlorate was added and the samples were 
incubated for 30 min at 65 oc. The cell lysate was 
extracted with 6 ml of chloroform: isoamyl alcohol 
(24 : I) with agi tation for 30 m in, followed by centri-
fugation at 11 000 g for IS min at 4 °C to separate the 
phases. The upper aqueous layer was recovered and 
the DNA precipitated with just over one volume of 
isopropanol at -20 °C overnigh t. The DNA was 
pelleted, washed wi th 70% ethanol, a llowed to dry, 
and dissolved in 200 pl-l ml TE, pH 8·0. 
Multiplex PCR 
The multiplex PCR reactions each contained 50 ng C. 
pe1ji·ingens template DNA, 62· 5 pmol each cpa primer, 
45 pmol each cpb primer, 55 pmol each erx primer, 70 
pmol each iA primer, 45 pmol each cpe primer (cpa, 
cpb, iA, and cpe primer sequences as described by 
Meer and colleagues [6]), 50 pmol each cpb2 primer 
(5'-AGATTTTAAATATGATCCTAACC-3' and 5'-
CAATACCCTTCACCAAATACTC-3'), d TPs to a 
fina l concentra tion of 0· 1 mr-1. PCR buffer (SO mM 
KC!. 10 mr-1 Tri - HCI. pH 8·3. 2 mM MgCI2), 0· 1% 
T riton X-1 00. 2 units of Taq D A polymerase 
(Roche) and water to 50 ttl DNA was denatured for 
2 min at 95 oc and ampli fied for 35 cycles ( I min at 
94 °C. I min at 55 oe, I min at 72 oc for denaturat ion. 
annealing and extension p hases, respectively), and 
followed by an additional period of extension for 
10 min at 72 oc (model 9600 GeneAmp PCR System ; 
Perkin-Eimer). PCR products were separated by 
electrophoresis in a 2% (w Jv) agarose gel with 0· 5 ttg 
of ethidium bromide/ m!. Twenty pi PCR products 
were subjected to electrophoresis for 45-60 nun at 80 
V. Amplified bands were visualized and photographed 
under UV illumination. 
PCR on colonies 
For PCR analysis of C. perfringens, single colonies 
obtained after overnight cultivation on brain heart 
infusion agar were inoculated into 50 td nuclease-free 
water and boiled for 5 min to lyse the cells. After 
centrifugation at 13000g for 10 s at room tem-
perature, the supernatant fluid was removed and 20 td 
was used in the PCR reaction. Fifty pmol of each 
primer used in a primer pair to amplify a single C. 
perfringens toxin gene was added. All other PCR 
reaction components remain as described above. 
Verification of PCR product 
Verification of the cpb2 PCR product was done by 
DNA sequencing of purified PCR product. The PCR 
product from amplification of cpb2 (567 bp) was 
excised from an aga rose gel and purified using the 
QlAEX II gel extraction kit (Qiagen). DNA sequen-
cing reactions containing the purified PCR product 
and the PCR primers were performed using an 
automated Taq polymerase cycle sequencing protocol 
with ftuorescently labelled dideoxy nucleotides (Ap-
plied Biosystems). The reaction products were ana-
lysed using an automated nucleotide sequencer (Ap-
plied Biosystems model 373A). 
Specificity of multiplex PCR 
50 ng total genomic DNA of C. absonum, C. bifer-
mentans, C. botulinum, C. histolyticum, C. nouyi, C. 
septicum or C. sordel/ii were used in the PCR reactions 
as described above. 
Statistical methods 
The selection of controls was diffe rent for lambs 
compared to foals and piglets. ln the study of 
diarrhoea and faecal soiling in lambs, cases were 
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individually matched with a randomly selected control 
lamb from the same group at the same point in time 
[ 11]. Both culture-positive (for C. per(ringens) a nd 
culture-negative lambs were included in the analysis 
and a McNemar test for matched-pair data [12] was 
used to test for an association between the presence of 
/12-toxin and disease. The samples from foals and 
piglets were all C. pe1ji·ingens culture-positive and 
were not from a matched study including culture-
negative animals. A two-tailed Fisher's exact test [12] 
was used to test for an association between the 
presence of /12-roxin and disease in culture-positive 
animals. 
R ESULTS 
Multiplex PCR of C. perfriugeus 
A multiplex PCR assay to detect the genes for C. 
perfringens a-toxin (cpa), jJ-toxin (cpb), e-toxin (cpe), 
1-toxin (iA), and enterotoxjn (cpe), was recently 
reported [ 13]. PCR products of 324, 196, 655, 446, and 
233 bp, respectively, were obtained. When we used 
this assay it failed to determine correctly the genotype 
of all C. pe1jringens strains (e.g. cpa gene of isolate 
97-6). Therefore the assay was modified by using a 
PCR buffer of pH 8·3 rather than pH 9·0, wl1ich 
allowed the detection of a ll strains. For the detection 
of the gene encoding C. perfringens /12-toxjn (cpb2), 
PCR primers were designed from the reported 
nucleotide sequence of the gene [7]. This PCR. primer 
pair amplified a gene fragment which was of a size 
easily distinguishable from the other gene fragments 
produced in the multiplex PCR (567 bp). The modified 
multiplex PCR assay was used to genotype correctly 
20 C. perfringens reference strains and to detect the 
presence of the enterotoxin and /12-toxin genes in 
these strains. 
The multiplex PCR assay was tested using DNA 
from C. absonum, C. bifermentans, C. botulinum, C. 
histolyticum, C. novyi, C. septicum or C. sordellii. 
None of the reactions produced a 324 bp cpa 
fragment, which was uniquely associated with 
C. perfringens. However, amplification products of 
approx. 580 bp were generated with DNA of C. 
bifermenrans PHLSARU 2825 or C. nouyi NCTC 
9692. These products were amplified using primers for 
cpb and cpe, ra ther than with primers for amplification 
from one of the six C. pe1jringens toxin genes. 
This multiplex PCR assay proved to be successful 
for genotyping C. perfringens from isolated DNA 
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Fig. I . Agarosc gel electrophoresis of the PCR products 
obtained from the multiplex PCR assay for genotyping 
Clostridium pe1}i·ingens and detection of the genes encoding 
enterotoxin and ;11-toxin. PCR products represent amplifi-
ca tio n of cpb ( 196 bp), cpe (233 bp), cpa (324 bp), iA 
(446 bp), cpb:! (567 bp) and etx (655 bp). Lanes: I. DNA 
molecular weight markers; 2, C. pe1ji-ingens CTC 8237 
(genotype A) ; 3, C. perfringem isolate 97- 6 (genot ype A); 4. 
C. pe(fi·ingens PHLSARU 1289 (genotype Ae't!); 5. C. 
perfringens NCTC 528 (genotype Al1t); 6, C. pe1ji-ingens 
NCTC 4964 (genotype 8'12); 7. C. tmfi"ingens NCTC 3227 
(genotype C); 8, C. pe1}i·ingens 1 CTC I 0719 (genotype 
c ,r!); 9, C. pe1ji·ingens CTC 8503 (genotype D); 10. C. 
pe1jringens isola le 294 (genotype Ee/11): 11 , negative control 
(no template DNA). 
(Fig. I), but PCR from bacterial colonies was most 
reliable when the six toxin genes were amplified in 
individual PCR reactions. The latter also ensured that 
amplification of PCR products as a result of cross-
reactivity between primers in the multiplex PCR did 
not occur. 
PCR genotyping 
A total of 140 C. perfringens isolates were genotyped 
using multiple monoplex PCR assays. For 96% of the 
isolates a genotype was determined from colonies, but 
for five isolates no amplification products were found 
in the PCR. 
Foals 
A total of 24 C. pe1jringens iso lates from foals with 
diarrhoea, and a further I 0 control isolates from foals 
without diarrhoea, were genotyped. All isolates 
possessed the cpa gene, but not the cpb, etx or iA 
genes, indicating that they were all genotype A (Table 
I) . These results agreed with previous genotyping of 
these isolates (data not shown) [14]. 
Lambs 
A total of 27 C. petfringens isolates from lambs with 
chronic diarrhoea and 12 control isolates from lambs 
without diarrhoea were genotyped. Twenty-four dis-
ease and 10 control isolates were genotype A, and 3 
disease and 2 control isolates were genotype D, 
possessing the cpa and etx genes (Table 1). For some 
of the isolates, however, lhe genotyping results were 
different to those indicated previously using EUSA 
[J J]. Eleven and six of the isolates genotyped here as 
A (cpn gene only) were types D (cpn and etx) and B 
(cpa, cpb and etx) , respectively by EUSA. Spiking of 
these colony lysates with 25 pmol of plasmid DNA 
encoding the cloned etx gene resulted in amplification 
of the gene, suggesting that these reactions did not 
contain inhibitors of the PCR reaction. Conversely, 
three isolates genotyped as type D here were pre-
viously typed A by ELISA. 
Piglets 
A total of 33 C. petfringens isolates from piglets with 
diarrhoea and 7 control isolates from those without 
diarrhoea were genotyped (Table I). Of the disease 
isolates, 29 were type A (possessing the cpa gene) and 
4 were type C (possessing cpa and cpb genes). All of 
the control isolates were genotype A . These results 
were in agreement with previous genotyping (data not 
shown), except that two of the disease isolates 
genotyped A here were previously genotyped C. 
Other animals 
Twelve C. perfringens isolates from ca lves with 
diarrhoea and five C. perfringens isolates from other 
diseased animals (alpaca, horse, elk, llama, swan) 
were all genotype A (possessing the cpa gene), except 
one ca lf isolate which was genotype E (cpa and iA 
genes) (Table I). 
Associations of disease with genotype A 
All disease and control foal isolates were genotype A, 
and there was no significant difference between the 
presence of genotype A in iso lates from d iseased and 
control piglets. Although only 39 lamb isolates were 
genotyped in this study, a further 126 isolates obtained 
from diseased (55 isolates) and control (71 isolates) 
lambs which were culture-negative for C. pe1ji-ingens 
were included in statistical analyses. When culture-
negative lambs were included in a matched ana lysis, 
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Table I. Geno1_1pe.\ ol lostridium pcrfringens i.w lc11es 
No. of Genotype* 
C. per/i"in~en1 isola te % fl2-positi\ c 
i olates crecned A All" Ae efl" B c C''" D DJ'" De 1 E Ec''" isolates 
Foal disease :24 1:2 10 0 .; 0 0 0 0 0 0 0 0 50 
Foal control 10 5 5 0 0 0 0 0 0 0 0 0 0 50 
Piglet disea e 33 6 :23 0 0 0 0 4 0 0 0 0 0 82 
Piglet control 7 7 0 0 0 0 0 0 0 0 0 0 0 0 
Lamb disease+ :27 17 7 0 0 0 0 0 I :2 0 0 0 33 
Lamb control+ 1:2 4 6 0 0 0 0 0 0 0 2 0 0 67 
Calf disease 12 9 2 0 0 0 0 0 0 0 0 0 I 25 
Other disease s 3 :2 0 0 0 0 0 0 0 0 0 0 40 
• A. B. C, D. E refers to genotype; e refers to presence of the gene encoding enterotoxin: .. ~ refers to presence of the gene 
encoding /12-toxin. 
t Lamb isolates were obtained as part of a matched case control stud y. 
there was a significant as ociation between genotype 
A and diarrhoea (matched odds ratio = 2·30. 95% Cl 
1·11 - 5·05, p =- 0·037). 
Prevalence of cpe in C. perfringens i olates 
The gene encoding C. pe1jringens enterotoxin (cpe) 
was detected in 4 % of isolates genotyped in this 
study. Two foals with diarrhoea and two lambs 
without diarrhoea were cpe-positive. None of the 
piglet isolates were cpe-positive. No significant asso-
ciations between possession of the cpe gene and 
disease in these animals were identified. 
Preralence of cpb2 in C. perfringens isolates 
The gene encoding C. pe1:(ringens f12- toxin (cpb2) was 
present in 50 % of the isolates genotyped. However, 
the prevalence of this gene varied between animal 
isola tes (Table I ). Twenty-seven of the 33 isolates 
(82 % ) from piglets with diarrhoea were positive for 
the cpb2 gene. compared with none of the piglet 
control isolates. strongly uggesting that this gene was 
signi fica ntly as ociated with diarrhoea in piglets (P = 
0·00045). 
The prevalence of the cpb2 gene in C. per(ringens 
was imilar for both disea ed and control isolate 
from foa ls. The Cflh:! gene was more freq uently found 
in con trol isolates than in case isolate from lambs. 
but this association wa not signiticant. The inclusion 
or culture-negati\e lambs revealed a po iti\'e bu t non-
signi fica nt association of cph:! and diarrhoea (matched 
odds ratio. including culture-negati,·e cases and 
controls = 1·33. 95 % C l 0·-16-3·84. P = 0· 79). 
DISCUSSION 
Multiplex PCR assays have recently been used to 
detect the genes encoding the C/os1ridium per.fringens 
a-, fJ- , e- and t-toxins, and enterotoxin and /12-toxin [8. 
13, 15, 16]. In this study. an existing multiplex PCR 
assay [ 13] has been adapted. for the detection of all six 
of these toxin genes. This assay correctly identified C. 
petjringens isolates as genotypes A- E, and further 
subtyped the bacteria on the basis of the enterotoxin 
or /12-toxin genes. This assay is an improvement on 
existing genotyping assays, since it may be used to 
detect all of the genes important in biotyping and 
subtyping C. pe1:(ringens. including atypical isolates 
such as isolate 97- 6. Researchers have not previously 
reported cross-reactivity of other clostridia in C. 
pe~(ringens multiplex PCR assays. Our assay was most 
reliable when used as multiple monoplex PCR assays. 
particularly with lysates of C. per.fringens colonies. 
Our finding that multiplex PCR assay of C. per.fringens 
from colony lysates was less reliable than from purified 
DNA is in keeping with others [1 7] , a lthough recently 
Herholz and colleagues and Kanaka raj and colleagues 
used colony lysa tes in thei r multiplex PC R as~ays (8, 
15]. 
The multiplex PCR and multiple monoplex PCR 
assays were reliable for the genotyping of reference 
strains using either C. per(ringens D A or colony 
ly ates. Only 5 of 140 isolates from animals could not 
be gcnotyred by PCR from colony lysates and 
required the use of extracted D A (14. 15]. 
11 C. perfi·ingens isolates from foa ls were genotype 
A. a genotype which has previously been associated 
with diarrhoea in foals (14]. etherwood and col-
leagues used PCR to analyse C. pl'r(i·ingens associa ted 
66 H. S. Garmory and o thers 
\\ith foal diarrhoea on the basis of ro~session or the 
genes encodi ng .x-, fl-, r.- and 1- toxins as well as fl-
(theta-) toxi n. large a nd small sialidascs. hya luron i-
da c and virulence regu lation, but did not idcn tiry a 
marker for ·ubtyping C. per{i·in,f(ens which was 
associa ted with disease (14). Such a marker may )'C l be 
identified in association wi th diarrhoea in foa l · or 
lambs or o ther animal uch as goa t , ca lves and rowl. 
Most isolate from lambs, piglets and calve were 
al o genotype A, although genotypes D, C and E were 
also identified . C. pe1Fingem type A has previously 
been associa ted with lamb enterotoxaemia and C. 
pet/i-ingens type D has been iden tified as the aetio-
logica l agent of pulpy kidney disease in lambs ( I 4] . 
Recently, a significant association was identified 
between diarrhoea in 2- to 6-month-old lambs and the 
pre ence of C. Jmfringens type A in the faece [ 11]. 
imila rly. type A isolates were associated with 
diarrhoea in the same lambs in thi study. 
However, the genotype of 20 of the lamb i ola tes 
was not the same as the biotype determined usi ng 
ELISAs. For some isolates this might reflect the loss 
of plasrnids known to encode the fl-toxin and ~;- toxin 
[ 18]. while the gene may be si lent in other isola te that 
did not produce detectable e-roxin but posses ed the 
etx gene. These isolate need to be further typed to 
confirm their bio type before associations with disease 
can be studied. 
C. per.fringens types A and C have previously been 
suggested to be the aetiological agents of necrotizing 
enterocolitis and necrotic enteritis (enterotoxaemia) in 
piglets, respectively [1 -4], and that C. pe1:{ringens :x-
toxin and fl- toxin may play key roles in these diseases. 
Here we showed a significant association between C. 
pe1Fingens possessing the gene encoding ;12- toxin 
(cpb2) and diarrhoea in piglets in C. perfi·ingens-
posi tive samples. This association is in agreement wi th 
preliminary epidemiological studies [7] and supports 
the view that ;12- toxin may play a role in enteric 
disease of piglets. 
C. pe1:{i-ingens is a frequent cause of acute entero-
toxaemia in pre-weaned pigs and is reported to be 
increasing in preva lence [19]. Immuniza tion of pre-
weaned pig wi th a C. Jmfringens antitoxin im-
mediately after bi rth provides pro tection agai nst 
disease, but this proced ure i costly and requires 
ex tensive handling o f newborns. Passive protection of 
riglets has abo been achieved by immuniza tion of 
pregnan t gi lls with a C.Jm:/i-ingens type C toxoid [20]. 
However. inwmplete pro tec tio n agai nst disease ha 
been seen in piglets immunized with tyre C strain . 
possibly renectlllg the u ·c of cph.?-negative strains in 
the preparation of vaccincs. 
Although a:,~ocia ti ons between cph.:-posi ti vc C. 
per(ring<'ll.\ and dia rrhoea in foals and lambs were no t 
round in this study. the finding that fi2-toxin is 
associated with piglet enteric disease suggests tha t 
vi ru lence determi nant other than the major tox ins 
may be important in disease. 
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Abstract 
A synthetic gene encoding the He (binding) domain of Clostridium botulinum neurotoxin F (FHc) was expressed in Escherichia 
coli fused to maltose binding protein (MBP). The purified MBP- FHc and FHc isolated after removal of MBP were evaluated in 
mice for their ability to protect against toxin challenge. Balb/c mice developed a protective immune response following 
administration of either protein via the intraperitoneal or intramuscular routes. A comparison of antibody titres and protection 
following single and multiple vaccinations and the effects of dosage are shown. The long term protection afforded by the 
vaccines was also investigated. Ten months following vaccination mice were still protected when challenged with 104 MLD50 
doses of botulinum toxin F. Crown Copyright © 2000 Published by Elsevier Science Ltd. All rights reserved . 
Keywords: FHc subunit; Botulinum; Vaccine 
1. Introduction 
The protein neurotoxins produced by the anaerobic, 
spore forming bacteria Clostridium botulinum and Clos-
fl•idium tetani are the most potent toxins known to 
man (!). Tetanus toxin is commonly produced in 
wounds following germination of C. tetani spores 
which have entered the wound (2]. The toxin causes 
spastic paralysis by blocking neurotransmitter release 
in the inhibitory interneurones of the spinal cord (3]. 
In contrast to tetanus toxin, exposure to the neurotox-
ins produced by strains of C. botulinum (of which 
there are seven serotypes) is usually by ingestion of the 
toxin through food poisoning although there a re rare 
incidents of wound botulism and colonising infections 
o This article is British Crown copyright 2000/ D ERA and is pub-
lished with the permission of the controller of Her Majesty's Station-
ery Office. 
• Corresponding author. Tel. : + 44-19!;0-613903. 
in neonates known as infant botulism [I ,3]. Human 
botulism is commonly associated with toxin types A 
B. E and F. Although tetanus and botulinum toxins 
both act on the nervous system the botulinum toxins 
(BoNT) inhibit the release of acetyl choline at the neu-
romuscular junctions and synapses causing potential 
death by flaccid paralysis. This is in contrast to the 
spastic paralysis produced by tetanus toxin. 
The Clostridial toxins share a number of structural 
and functional characteristics. They are all zinc-endo-
peptidases which act o n the neuroexocytosis macinery 
within their target cells [4]. They consist of a heavy 
chain (MW I 00 kD) and a light chain (MW 50 kD) 
joined by a single disulphide bond. The toxin dimer is 
considered to consist of three functional domains: the 
carboxy-terminal half of the heavy chain binds to the 
target cell, the amino-terminal half of the heavy chain 
is involved with internalisa tion and the light chain 
blocks neurotra nsmitter release (4). 
Botulism ca n be treated with horse-derived anti-tox-
ins a lthough these are only effective if administered 
0264-41 OX/00/$ - see front matter Crown Copyright r' 2000 Published by Elsevier Science Ltd. All rights reserved. 
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prior to binding of the toxin to the target cell. ln ad-
dition these tend to be bivalent (A/ B) o r triva lent (A/ 
B/ E) and therefore do not offer protection against type 
F toxin. A drawback to using hor e-derived anti-toxins 
is the common occurrence of hypersensitivity reactions 
[5]. Botulism is so rare in humans that in the civi lia n 
population only laboratory staff working with the 
organisms and their toxins are considered at sufficient 
risk to justify immunisation. The most widely available 
vaccine for humans is a formalin inactivated pentava-
lent vaccine [6]. This, however, contains only five of 
the seven toxin serotypes (A-E) and therefore does not 
protect against type F toxin. 
lt is apparent, therefore, that the current vaccine 
and anti-toxin therapies are ineffective against botuli-
num serotype F and that a vaccine against this subtype 
is desirable. In order to overcome some of the draw-
backs of the toxoid vaccines (such as cost a nd low 
levels of production with certain serotypes) there is 
now interest in the development of sub-unit vaccines 
against type F toxin and the o ther botulinum toxin 
serotypes. Much of the research in terms of sub-unit 
vaccines for the botulinum toxins is based on the suc-
cess with tetanus toxin. One of the products of papain 
cleavage of tetanus toxin is the 50 kD carboxy term-
inal of the heavy chain known as fragment C. This 
fragment is non-toxic and has been shown to induce 
protective immunity against tetanus [7]. This fragment 
has been expressed in E. coli [8], Saccharomyces cerevi-
siae [9] and Pichia past oris [ 1 0). The equivalent frag-
ment from botulinum toxin A was artificially 
synthesised and expressed in E. coli [11] and more 
recently in Pichia pastoris [12] a nd produced a protec-
tive immune response in mice. 
In this study we constructed a synthetic gene encod-
ing the non-toxic 50 kD carboxyl-terminal fragment 
(He) of botulinum toxin F. This was expressed in E. 
coli as a fusion to maltose binding protein (MBP-
FHc). The fusion protein was cleaved and the FHc 
fragment isolated. The ability of both proteins to elicit 
a protective immune response was investigated. A 
more detailed study into the efficacy of the FHc frag-
ment in protecting against toxin challenge together 
with the type of immune response involved was per-
formed. 
2. Materials and methods 
2.1. Baclerial strains and cloning vectors 
All E. coli strains used in this study were cultured 
on L-agar or in L-broth [ 13]. Where appropriate, the 
culture media were supplemented with ampicillin [13]. 
D A fragments which had been generated using the 
PCR were initially cloned directly into a T-tailed plas-
mid vector (pCRII ; lnvitrogen, Groningen, The Neth-
erlands) and transformed into E. coli strain TG I (F ' 
traD36 laclq delta(lacZ)M 15 proA 1 8 + fsupE del-
ta(hsdM- mcrB )5 (r k'm: McrB- ) thi delta (lac-pro A B)). 
For intermediate cloning steps the assembled synthetic 
gene was cloned into the genera l cloning plasmid vec-
tors pMTL23 [14] or pUC9 (BRL, Bethesda, USA) 
and transformed into E. coli TG I . For expression stu-
dies , the synthetic gene was cloned as an in-frame 
translational fusion with maltose binding protein 
(M BP) in plasmid pMal-c2 (New England Biolabs, 
Hitchin, Hens) or as a translational fusion with gluta-
thione-S-transferase (GST) in plasmid pG EX-3X 
(Pharmacia Biotech, Little Chalfont, Bucks). The 
recombinant plasmids (pFHC206 and pFHC340) were 
expressed in E. coli strain BL21 (D E3; F- ompT [Ion] 
hsc/S8 (r8 -m8 - )) which carries mutations in the ompT 
a nd Ion protease genes. Both the MBP and the GST 
fusion proteins (MBP- FHc a nd GST - FHc) were 
expressed cytoplasmically. 
2.2. Preparation of recombinant Botulinum FHc 
fragment 
A synthetic gene encoding the FHc fragment (13 1 0 
nucleotide base pairs [bp] in length) was constructed as 
four blocks of around 400 bp in length which con-
tained unique restriction sites incorporated in the 5 ' 
and 3' ends of the protein coding sequence. Each 
block (A- D) was constructed from four overlapping 
oligonucleotides, A and B were synthesised using an 
Applied Biosystems DNA synthesiser, model 380B 
(Applied Biosystems,Warrington, UK), C by R and D 
Systems Europe Ltd (Abingdon, UK) and D by Oligos 
Inc. (Orgenon, USA). The oligonucleotides were typi-
cally I 00 base pairs in length and contained regions of 
homology at the 5' and 3' ends to allow annea ling. 
The blocks were then made double stranded and 
further amplified using the PCR with Pfu polymerase 
(Stra tagene corp, Amsterdam,The Netherlands) with 
Mg2 + at a final concentration of 1.5 mM and and 
0.2 mM dNTPs (final concentration). PCR reactions 
were carried out using a Perkin Elmer 9600 thermocy-
cler using thin-walled 0.2 ml tubes and a final reaction 
volume of I 00 111. Cycle conditions as fo llows: 94°C 
for 3 min, (94°C for I min, 42°C for I min, 72°C fo r 
I min) X 30. 72°C for 3 min. Blocks A- D were cloned 
into pCRII and nucleotide sequenced [13]. To correct 
nucleotide sequence errors, DNA restriction endonu-
clease fragments within each block which contained 
the correct sequence were isolated and ligated together 
• to generate the entire block containing the correct 
nucleotide seq uence. The synthetic FHc nucleotide 
sequence has been submit ted to Genbank under the 
accession number AF251281. 
The amplified blocks were digested with the appro-
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priate restnct10n endonucleases (Ndel and Hpal for 
block A; Hpal and Mlul for block B; Mlul and Sp/1 for 
block C and Sp/1 and Xbal for block D) and ligated 
together. The synthetic gene was digested cloned into 
BamHI and Xbal digested plasmid pMTL23 to gener-
ate plasmid pFHC23, and transformed (13] into E. coli 
strain TG I. The nucleotide sequence of the cloned 
fragment was determined (13] to ensure authenticity. 
To generate plasmid pFHC29, the FHc coding region 
was isolated from pFHC23 by digestion with BamHI 
and Xhol and cloned into plasmid pUC9. 
2.3. Insertion of synthetic FHc fragment into E. coli 
expression vectors 
Plasmid pFHC23 was digested with EcoRI and Xbal 
and the excised fragment encoding FHc was cloned 
into suitably digested plasmid pGEX-3X to create 
plasmid pFHC340. Plasmid pFHC29 was digested 
with EcoRI and Xbai and the excised fragment encod-
ing FHc was cloned into suitably digested plasmid 
pMal-c2 to create plasmid pFHC206. The recombinant 
plasmids were transformed [13) into the E. coli strain 
BL21. The nucleotide sequence [13] of the DNA 
encoding the junction between the plasmid encoded 
fusion protein and the FHc was determined. 
2.4. Expression of FHc fusion proteins 
Expression of the FHc fusion proteins was induced 
in cultures using isopropyl-B-o-thiogalactopyranoside 
(IPTG) (0.3 mM) and their production monitored by 
SOS- PAGE and Western blots using anti-MBP (New 
England Biolabs, Hitchin, Herts) or anti-GST anti-
bodies {Pharmacia Biotech, Little Chalfont, Bucks). 
Electrophoresis and semi-dry blotting were carried out 
using a Phastsytem (Pharmacia Biotech, Little Chat-
font, Bucks). 
2.5. Raising of anti-GST- FHc antisera 
GST - FHc was purified using a method based on 
that of Frangioni and Neel (15]. Balb/c mice (6 weeks 
old) were injected intra muscularly (i.m.) with I 0 11g 
GST - FHc in 25% (vfv) alhydrogel in phosphate-buf-
fered saline (PBS). Three doses were given at 14 day 
intervals. Mice were exsanguinated 14 days following 
the final vaccination and sera prepared by removal of 
the clot by centrifugation . The antisera was used for 
the analysis of the purified FHc fragment below. 
2.6. Expression and purification of recombinant FHc 
fu ion protein in E. coli 
Cultures of recombinant E. coli BL21(DE3) contain-
ing pFHC206 were grown in L-broth containing 55 11g/ 
ml ampicillin at 37°C until the absorbance (600 nm) 
was 0.6. IPTG was added to the culture at a final con-
centration of 0.3 mM and growth was continued for a 
further 2.5 h. The cells were harvested by centrifu-
gation (5000 rpm). The cell pellet obtained was frozen 
overnight at -20°C prior to resu pension in lysis buf-
fer (20 mM Tris- HCl/150 mM NaCl/ I mM EDT A 
(pH 8)) containing 300 llgf ml lysozyme (Sigma Chemi-
cal Co, Poole, UK). Cells were lysed on ice for 15 min. 
Benzamidine HCl {1 mM) (Sigma), PMSF 
(0.57 mM)(Sigma, UK) and Triton-X 100 (1 %)(vfv) 
were added and the suspension disintegrated using an 
XL series sonicator with cuphorn attatchment (Heat 
Systems Inc, New York, USA) in the pulse mode for 
three bursts of 30 sec. The resulting lysate was centri-
fuged (15,000 rpm, 30 min, 4°C) and the supernatant 
containing the soluble fraction removed. 
The soluble fraction was mixed with an equal 
volume of column buffer (20 mM Tris-HCl/ 150 mM 
NaCl/ 1 mM DTT/ 1 mM EDTA [pH 7.4)). Amylose 
resin (New England Biolabs, Hitchin, Herts), pre-
washed and equilibrated with column buffer was 
added and the mixture stirred slowly for I h at 4°C. 
The mixture was poured into a disposable chromatog-
raphy column (BioRad, Hemel Hempstead, Herts) and 
non-bound material removed by washing the amylose 
resin with 10 column volumes of column buffer. The 
fusion protein was eluted from the amylose resin with 
maltose (20 mM) in column buffer using approxi-
mately one column volume per fraction. Proteins were 
examined by SOS-PAGE on 10- 15% gradient gels 
(Pharmacia Biotech) and Western blotting. Western 
blots were probed with rabbit anti-MBP (New Eng-
land Biolabs) at a dilution of 1/2000 or mouse anti-
GST - FHc antisera (prepared as described above) at a 
dilution of 1/ 1000. Protein bands were visualised with 
a colloidal gold labelled secondary antibody (Aurop-
robe BLplus, Amersham Life Sciences, Little Chalfont, 
Bucks). 
2.7. Cleavage of FHcfusion protein 
Cleavage of the MBP- FHc (0.5 mgfml) was carried 
out in 150 mM NaCI/ 10 mM MES (pH 6.5) containing 
CaC12 (2 mM). Factor Xa (New England Biolabs) was 
used at a concentration of I 11g per 60 11g of fusion 
protein. Cleavage was carried out at room temperature 
( l6°C) for 18 h. The resulting FHc formed a precipi-
tate which was collected by centrifugation ( 14,000 
rpm, 5 min, 4°C) and resuspended in either 150 mM 
NaCI/ 10 mM Tris- HCI (pH 7.4) for use in inununis-
ation studies or solubilised in 70 mM Na2HP04 pH 9.2 
containing I% CHAPSO (Pierce and Warriner. Che-
ster, UK) for use in ELISAs. The product was ana-
lysed by SOS- PAGE and Western blots as described 
above. 
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2.8. Immunisation of mice 
Six week old female Balb/c mice, raised under 
specific pathogen-free conditions (Charles-River Lab-
oratories, Margate, Kent, UK), were used in this 
study. Groups of six mice received 0.1 ml of MBP-
FHc (10 !lg) or FHc (I 11g) adsorbed to 25% vjv alhy-
drogel (Biofors, Denmark). Mice received either one 
(day 0), two (day 0 and 14) or three (day 0, 14 and 28) 
vaccinations via the i.m. route and were tail bled for 
sera prior to each injection and before toxin challenge. 
In order to determine the minimum protective dose 
groups of five or six mice were immunised (i.m.) with 
two (or three) doses of FHc (day 0 and 14 [and 28]) 
over a dose range of 1.9 ng to I Jlg. Mice were tail 
bled for sera prior to the second or third immunis-
ations and before toxin challenge. 
2.9. Challenge IVith C. botulinum toxin type F 
Mice were challenged with I x 104 MLD50 of C. 
botulinum toxin F (crude or pure) (CAMR, Porton 
Down, Wilts) via the intraperitoneal (i .p.) route. Toxin 
was diluted in 70 mM sodium hydrogen phosphate 
buffer pH 9.2 (pure toxin) or pH 6.5 (crude toxin), 
containing l % (wfv) gelatin (Difco, Detroit). Mice 
were challenged 14 days following their final vacci-
nation. Untreated groups of age matched mice were 
used as controls. In addition extra groups of mice 
were vaccinated with three doses of MBP- FHc (10 !lg) 
or Fhc (I Jlg) and challenged 10 months following the 
final vaccination. 
2.10. M easurement of serum antibody titres 
Blood was sampled from the tail vein prior to each 
vaccination and before toxin challenge. Serum from 
mice in each group was pooled and screened for anti-
bodies specific to botulinum toxin F and FHc by an 
ELISA. Briefly FHc (I 11g/ml in 70 mM Na2HP04) or 
botulinum toxin F (I Jlg/ml in PBS) were coated onto 
microtitre plates. After washing the plates (0. 1% 
Tween-20 in PBS) and blocking non-specific sites (I% 
BSA in PBS) test sera were serially diluted in duplicate 
on the plate. The total Ig titres and the individual ser-
otype of lgG were determined using peroxidase conju-
gates (Harlan Sera-Lab, Crawley, UK) at a dilution of 
I :2000. The antibody titre was estimated as the maxi-
mum dilution of serum giving an absorbance reading 
greater than 0.1 units, after subtraction of the absor-
bance due to non-specific binding detected in control 
sera . Due to trace amounts of uncleaved MBP- FHc 
being present in the cleaved FHc any an ti-MBP titre 
which could effect results was removed by the addition 
of MBP (5 !lg/ml) to sera during the anti FHc ELI-
SAs. Control ELISAs using plates coated with MBP 
(0. 1 Jlg/ml) were carried out to check that no anti-
MBP activity remained. 
3. Results 
3.1. Construction of synthetic FHc fragment for toxin 
type F 
On the basis of deduced amino acid seq uence hom-
ology with the He fragment of tetanus toxin , a DNA 
fragment (1296 bp) was identified which would encode 
432 amino acids at the C-terminus of the heavy chain 
of botulinum toxin F. The native C. botulinum DNA 
fragment had an A + T content of 76%. To enhance 
gene expression in E. coli, a gene encoding the FHc 
was designed to reduce the overall A + T content to 
58% (F ig. I) and to replace codons which were known 
to be found at low frequencies in E. coli genes with 
synonymous codons which are frequently found in 
highly-expressed genes (Table 1). The gene was con-
structed from synthetic oligonucleotides and 371 
nucleotides were changed from the C. botulinum FHc 
encoding sequence. For construction (Fig. 2), the syn-
thetic FHc gene was divided into four blocks, A (N 
terminal end of He fragment) to D (C terminal end of 
He fragment). Each block was around 400 bp in length 
and had unique restiction endonuclease sites incorpor-
ated into the 5' and 3' ends of the coding sequences to 
allow subsequent ligation of the four blocks to each 
other. The complete FHc gene, which would encode a 
polypeptide of 50,232 Da, was created by ligating the 
blocks to each other and cloning into a plasmid vector 
in E. coli. For expression in E. coli, the FHc gene 
cloned was cloned into plasmids pGEX-3X or pMAL-
c2 to generate translational fusions encoding MBP-
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Fig. I. ucleotide composition (% A + D within 100 base pair win-
dow through the original C. botulinum FHc coding region (-• -> and 
through the synthetic gene encoding the botulinum toxin FHc (-11-). 
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Table I 
Codon usage in native and synthetic FHc encoding genes 
Cod on Amino acid Number in native FHc sequence Number in synthetic FHc sequence E. coli highly expressed genes(%) 
TIT phc 17 0 29 
TTC phe 2 19 71 
TTA leu 18 0 3 
TTG lcu 3 0 5 
err leu 2 0 6 
CTC leu 0 I 8 
CTA leu 6 0 
CTG lcu I 29 77 
TCT ser 9 37 32 
TCC ser 0 27 
TCA ser 11 0 5 
TCG ser I 7 
AGT ser 13 0 5 
AGC ser 3 0 24 
TAT tyr 27 2 35 
TAC tyr 3 28 65 
TGT cys 2 0 39 
TGC cys 2 4 61 
TGG trp 8 8 100 
CCT pro 2 I 11 
ccc pro 0 0 2 
CCA pro 4 0 15 
CCG pro 0 5 72 
CAT his 3 0 30 
CAC his 0 3 70 
CAA gin 11 0 19 
CAG gin 2 13 81 
CGT arg I 17 64 
CGC arg 0 I 33 
CGA arg 2 0 
CGG a rg I I 
AGA arg 13 0 I 
AGG arg 2 0 0 
ATT ile 26 I 33 
ATC ile 3 53 66 
ATA ile 25 0 I 
ATG met 4 5 100 
ACT thr 10 20 29 
ACC thr 0 0 53 
ACA thr 10 0 5 
ACG thr I I 13 
AAT asn 59 2 17 
AAC asn 7 64 83 
AAA lys 26 28 79 
AAG lys 2 0 21 
GTT val 11 16 40 
GTC val 0 13 
GTA val 7 2 20 
GTG val 0 27 
GCT ala 4 6 28 
GCC ala 0 0 16 
GCA ala 2 0 24 
GCG ala 0 0 32 
GAT asp 24 0 46 
GAC asp I 25 54 
GAA glu 9 13 75 
GAG glu 4 0 25 
GGT gly 9 24 51 
GGC gly 2 I 43 
GGA gly 13 0 2 
GGG gly 0 4 
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3.1. Production of M BP- FHc in E. coli 
Both GST - FHc and MBP- FHc were expressed in 
E. coli and were identified by their mo lecula r weights 
and their reaction with the antibodies to thei r carrier 
pro tein in Western blots (results not shown). Small 
scale purifica tion of the GST - FHc revealed tha t the 
GST - FHc could o nly be extracted from the E. coli 
using the dena turing detergent N-lauryl sarcosine. The 
resulting pro tein was highly immunogenic but non-
protective (resul ts not shown). 
Therefore the MBP- FHc was chosen for further stu-
dies. The M BP- FHc had a MW of 9 1,300 Da (Fig. 3a) 
and reacted with anti MBP (Fig. 3b) and anti GST-
FHc antibodies (results no t shown) in Western blots. 
The approxima te yield was I mg/1 cul!ure. During 
purifica tion the fragment tended to precipitate out of 
solution and was pa rticula rly sensitive to pH cha nges 
which can occur with T ris buffers a t d ifferent tempera-
tures. All insoluble ma terial was removed prio r to clea-
vage. Digestio n with facto r Xa resulted in 
approximately 90% cleavage and the FHc produced 
(MW 50,000 kDa) (Fig. 3a) precipitated out of sol-
ution. The FHc reacted with anti-GST - FHc (Fig. 3c) 
antisera but not anti-M BP antisera in a Western b lot 
(Fig. 3b). 
3.3. Serum antibody titres 
The serum total lg titres o f vaccinated and control 




anneal oligonucleotides, extend using the PCR, 
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into pGEX-3X 
pFHC340 
l IPTG-induced expression of GST-FHc 
d IPTG-induced l expression of MBP-FHc 
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Fig. 2. Construction. cloning and expression of FHc in £ . coli. The synthetic FHc gene was constructed from four blocks, each of which was 
constructed from four overlapping oligonucleotides which were annealed and made double stranded using the PCR (a). Blocks A- D were cloned 
into plasmid pC RII. nucleotide sequenced and the coding regions excised wi th the indicated restriction c:ndonucleases (b). T he four blocks were 
ligatcd together to generate the synthetic FHc gene (c) and cloned into pMTL23 to generate pl asmid pFHC23 and then into pUC9 to generate 
pFHC29. The FHc coding region was excised from either pFHC23 or pFHC29 and cloned into pGEX-3X or pMal-c2 allowing expression of 
M BP- FHc or GST - FHc fusion proteins (d). 
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Fig. 3. SOS- PAGE gel (a) and Western blots developed with anti-M BP antiserum (b) and anti GST - FHc antiserum (c). Molecular weight mar-
kers (in kD) (lane 1), MBP- FHc (lanes 2 and 4) and FHc (lanes 3, 5 and 6). 
mice against both the FHc subunit or the whole 
toxin were measured. The serum titres obtained in 
mice vaccinated with MBP- FHc (10 J..lg) or FHc 
( l J..lg) are shown in Fig. 4. Titres against the FHc 
subunit were higher than titres against whole toxin 
which were barely measurable with absorbances only 
just above background for aU vaccine doses. Mice 
vaccinated with a single dose of either MBP- FHc 
( 10 J..lg) or FHc (l J..lg) gave titres against FHc which 
were just detectable. Following the second and third 
vaccination titres against the FHc were increased 
reaching a maximum of 12,800 for FHc vaccinated 
and 25,600 for MBP-FHc vaccinated mice (three 
doses). Control experiments using plates coated with 
MBP confirmed that any MBP antibodies had been 













Number of vaccinations 
FHc 
order to determine the nature of the immune re-
sponse to FHc serotyping of the IgG response was 
carried out. The highest titre obtained was for IgG I 
(Fig. 5). 
3.4. Efficacy of the FHc subunit vaccine 
Due to the enhanced sensitivity of the FHc ELISA 
compared to whole toxin ELISA this was used to 
measure titres in the dose-efficacy study. In a prelimi-
nary protection study mice vaccinated with two or 
three doses of MBP- FHc (10 J..lg) or FHc (I J..lg) were 
fully protected against 104 MLD50 pure botulinum 
toxin F (i.p.). However in mice challenged with crude 
botulinum toxin F some symptoms of toxicity were 
observed in mice vaccinated with two doses of MBP-
B 
2 3 
Number of vaccinations 
MBP-FHc 
Fig. 4. Balb/c mice were vaccinated (i.m.) with FHc {I 1-1g) (a) or MBP- FHc (10 1-1&) (b) at 14 day intervals. Total lg titres against botulinum 
toxin F and FHc sub-unit were measured in serum samples taken immediately before vaccination and 14 days following the final boost. 














Totallg lg G1 lg G2a lg G2b lg G3 
Antibody serotype 
Fig. 5. Balb ·c mice were vaccmated (i.m.) with three doses of FHc (I !]g) at 14 day intervals. T itres of total lg and individual lgG serotypes were 
measu red 111 serum samples taken 1-l days followi ng the final boost. 
FHc. These mice exhibited laboured breathing but 
recovered fully within 24 h. All other groups survived 
the challenge with no adverse effects. Control. non-
vaccinated mice sucumbed to the toxin demonstrating 
a typical flaccid paralysis followed by death within 2 h. 
For the dose-response study the titres obtained with 
15000 
12000 
two and three doses of FHc ( 1.9-1000 ng) are shown 
in Fig. 6. A dose- response was seen in both the a nti-
body titre and protective efficacy with increasing FHc 
dose and number of vaccinations (Fig. 6). Two doses 
of 31.2 ng or three of 3.9 ng FHc gave 100% protec-
tion against 104 MLD50 pure toxin but with FHc 
0 2 vaccinatio n s 









3.9 7.8 15.6 31 .2 62.5 250 500 1000 
FHc (ng/dose) 
Fig. 6. Balb/c mice were vaccinated (i.m.) with FHc (3.9- 1000 ng) at day 0,14 {two vaccinations) and 28 (three vaccinations). Total lg titres 
against FHc sub-unit were measured in serum samples taken on day 28 (two vaccinations) and 42 (three vaccinations). The number of survivors 
of a I 04 M LDso i.p. dose of botul inum toxin F are shown above the columns. 
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doses below these there was brea kthrough in protec-
tion. The longevi ty of the protection achieved was 
tested by toxin challenge 10 months after vaccination 
of mice which had received three vaccinations of 
MBP- FHc or FHc. One hundred percent protection 
was maintained. 
4. Discussion 
The botulinum toxins (types A- G) consist of two 
protein chains joined by a disulphide bridge. The light 
chain (50 kDa) is responsible for the intracellular cata-
lytic (toxic) activity and the heavy chain (Hc)(IOO kDa) 
for the binding and internalisation of the toxin into 
the neurone. In particular it is the 50 kDa C-terminal 
domain of the heavy chain which is responsible for the 
binding of the toxin to the neuronal membrane prior 
to internalisation (4]. The botulinum toxins are structu-
rally related to tetanus toxin which is also composed 
from a heavy and a light chain. Previous work with 
tetanus toxin has shown that the isolated carboxy-
terminal fragment of the heavy chain (the He frag-
ment) can be exploited as a highly effective vaccine 
against tetatus toxjn [8- 10]. More recently other 
workers have shown that similar fragments derived 
from botulinum toxins A and B can be exploited as 
vaccines against their respective toxin subtypes 
[ 11 , 12, 16]. On the basis of the structural similarity 
between these toxins and botulinum toxin F we have 
investigated the posibility that the carboxy-terminal 
fragment from the heavy chain of the botulinum F 
toxin can be exploited as vaccine. 
Previous workers have shown that it is important to 
modify the nucleotide sequence of the genes encoding 
the C. tetani He and the C. botulinum type A and B 
toxin He fragments to allow expression of the gene in 
heterologous hosts [8,10- 12,16]. The synthetic gene we 
have designed allowed expression of the FHc polypep-
tide in £. coli by reducing the overall G + C content ro 
a level close to that found in E. coli DNA (51%) [17] 
and by selecting codons found in highly expressed 
genes. In order to further aid gene expression and sub-
sequent purification, the FHc was fused with GST or 
MBP carrier proteins. The MBP- FHc fusion was cho-
sen as the candidate vaccine due partially to its high 
levels of expression and also due to difficulties encoun-
tered during purification of the GST - FHc which 
required strong denaturing conditions for its extraction 
from the cell pellet (results not shown). The GST - FHc 
did, however, give a an excellent (al though non-protec-
tive) immune response and provided antibodie for use 
in Western blots during the purification of the M BP-
FHc a nd subsequent M BP removal. This was necess-
ary since antiserum raised against toxoided type F C. 
botulinum toxin reacts poorly with botulinum toxin 
and was deemed unsuitable for use. 
Mice were vaccinated via the intramuscular route 
with MBP- FHc or FHc u ing a lhydrogel as a n adju-
vant. In order to investigate the immune response ELI-
SAs were carried out initially using whole toxin to 
coat the plates. Antibody titres, however. were low 
(Fig. 4) and the ELISAs were repeated using the FHc 
to coat the plates instead. This resulted in much higher 
titres than toxin coated plates (Fig. 4) and may be due 
to the orientation of the toxin on the plate. It is poss-
ible that with whole toxin the He domain of the toxin 
(hydrophobic) may have a tendency to associate with 
the plate and be shielded from the antibodies by the 
remainder of the toxin. Using FHc to coat the plates 
a lleviated this problem. By using the FHc ELISA it 
was possible to compare the a ntibody titres obtained 
using different doses of the vaccines which would not 
have been detected using toxin coated plates. 
The initial protection study, using two or three 
doses of FHc ( I Jlg) and MBP- FHc (10 Jlg) (i.m.) 
demonstrated that the immune response raised gave 
100% protection against I 04 MLD50 pure botulinum 
toxin F administered i.p. No symptoms of toxicity 
were observed. Protection against the same dose of 
crude botulinum toxin was also seen, although in mice 
vaccinated with two doses of MBP-FHc some symp-
toms of toxicity were observed although the mice 
made a full recovery. A possible reason for this slightly 
less protective effect is that crude toxin is complexed 
to haemagglutinin [ 18] which becomes associated with 
the He domain and may therefore shield the toxin or 
compete with the antisera for binding. 
Following the success of the initial protection studies 
further investigation into the minimum protective dose 
of the FHc vaccine were carried out. MBP- FHc was 
not studied further since the MBP part of the vaccine 
(highly immunogenic) would not be suitable for use in 
a potential human vaccine. For this study we wished 
to determine the efficacy of the vaccine and its re-
lationship, if any, to the observed antibody titres. Two 
or three doses of FHc ranging from 1.9- 1000 ng were 
administered i.m. followed by I 04 M LD50 pure toxin 
challenge 14 days after the final vaccination . Full pro-
tection was seen in mice administered either two 31.2 
ng injections or three 3.9 ng injections of FHc (Fig. 6). 
Below these doses was a decline in the level of protec-
tion achieved. As expected, group antibody titres fol-
lowed a dose-response curve a nd survival against 
toxin challenge was related to the tjtres obtained. 
Group titres of 400 or above gave I 00% protection 
against toxin challenge whereas a titre of 200 protected 
74% of mice. Titres below this gave only 5% . urvival. 
These results indicate that protection is antibody 
mediated. This is in agreement with a similar study by 
Byrne et al. [12] who demonstrated that the He 
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domain of botulinum toxin type A was able to protect 
against type A toxin challenge a nd protection achieved 
was related to a ntibody titres. The hypothesis that pro-
tection against toxin is antibody mediated is reinforced 
by the high titres of the IgG I sub type seen. This is 
consistent with a T H 2 response which involves B lym-
phocyte activation and antibody production and is the 
immune response which would be expected to provide 
protection against bacterial toxins. It is also the 
immune response associated with using alhydrogel as 
an adjuvant. 
We have shown that it is possible to produce a sub-
unit vaccine based on the He binding domain of C. 
botulinum toxin type F which can protect against i.p. 
toxin challenge. This type of vaccine has advantages 
over traditional toxin inactivated vaccines in that it is 
cheaper and less hazardous to produce as it does not 
require containment for its production. The vaccine is 
effective following two doses and produces a long-lived 
immune response which is able to protect against toxin 
challenge I 0 months after vaccination. The yield of 
recombinant protein, however, was low using this ex-
pression system ( I mg/1 of culture). Higher levels of ex-
pression may be achievable using the yeast Pichia 
pas/oris which has been used to successfully express 
the He domains of type A and B botulinum toxins 
[12, 15]. This is currently being investigated. 
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A recombinant vaccine candidate was developed 
that protected mice against botuJinwn neurotoxin se-
rotype F (BoNTF) intoxication. A synthetic gene e n-
coding BoNTF fragment C (rBoNTF(H e) ) was designed, 
constructed, and inserted into a plasmid for expres-
sion in the yeast Pichia pastoris. A total cell protein 
content of 2.9 g was obtained per liter of fermentation 
broth. Recombinant rBoNTF(H e) was purified from the 
soluble yeast extract in two chromatographic steps. 
The process employed Mono S cation exchange chem-
istry followed by Alkyl-Superose hydrophobic interac-
tion chromatography, producing material judged to be 
greater than 98% pure by SDS-PAGE. The recovery of 
purified product from cell extract was estimated to be 
greater than 42%, with a yield of 140 mglkg of cell 
paste. rBoNTF(He) was also purified from the insoluble 
fraction of the yeast cell lysate. Because the fragment 
C in the pellet was 35% of the total insoluble protein, 
only a Mono S cation exchange chromatography step 
was necessary to achieve a purity greate r than 98%. 
Mice that r eceived three injections of 0.2 ,...g of purified 
soluble rBoNTF(He) were completely protected when 
challenged with 1000 mouse ip LD60 of BoNTF toxin. 
Similarly, three doses of 1 ,...g of purified resolubilized 
rBoNTF(He) completely protected mice from a chal-
lenge of5000 mouse ip LD60 ofBoNTF toxin. Individual 
serum antibody ELISA titers of mice injected with 
soluble rBoNTF(He) corre lated with survival as all 34 
mice with ELISA tite r s of 100 or greater s ur-vived toxin 
challenge. The work presented h e r e demons trates tha t 
purified rBoNTF(H e) is able to protect a ga inst a high 
cha llenge dose of neurotoxin. o 2000 Academic Press 
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Botulinum neurotoxins (BoNT2 ) a re the most toxic 
substances known and are the causative agents of the 
disease botulism. These toxins are produced by the 
bacterium Clostrid ium botulinum and can be divided 
into seven serotypes (A-G) which are structurally sim-
ilar , yet an tigenically distinct . BoNT exert their action 
by inhibiting the release of the neurotransmitter ace-
tylcholine at the neuromuscular junction (1- 3), which 
leads to a state of flaccid par alysis . 
Botulinum neurotoxins are translated as a single 
150-kDa polypeptide chain and then posttranslation-
ally nicked, forming a dichain consisting of a 100-kDa 
heavy ch ain and a 50-kDa light chain which remain 
linked by a disulfide bond (4,5). The mechanism of 
nerve intoxication is accomplished through the inter-
play of three key events, each of which is performed by 
a separate portion of the neurotoxin protein. Firs t , the 
carboxy half of the heavy chain (fragment C, or He) is 
required for receptor -specific binding to cholinergic 
nerve cells (6-8). There is evidence suggesting that 
polysialogangliosides (9) could act as receptors for the 
toxins but the data supporting a specific receptor re-
main equivocal (10). After binding, the toxin is inter -
nalized into an endosome through receptor-mediated 
endocytosis (11). The amino-terminal half of the heavy 
chain is believed to participate in the translocation 
mechanism of the ligh t chain across the endosoma l 
membrane (3,12,13). The low-pH environment of the 
endosome may trigger a conformational chan ge in the 
translocation domain, thus forming a channel for the 
light chain. The fi nal event of intoxication involves 
' Abbrevia t ions used: BoNT, botulinu m neurotoxin ; rBoNTF'CH, l, 
recombina nt BoNTF fragment C expressed ft·om a synthetic gene; 
IND, lnvestigationa l New Drug; MWCO, molecular weight cutoff; 
HIC, hydrophobic intera ction chroma tography; MBP, maltose-bind-
ing protein. 
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enzymatic activity of the light chain, a zinc-dependent 
endoprotease (2,14), on key synaptic vesicle proteins 
(2,15-17) necessary for neurotransmitter release. 
Agents that abolish the action of BoNT have been 
investigated since the 1940s. Currently, a pentavalent 
toxoid vaccine against serotypes A-E (18-21), avail-
able under Investigational New Drug OND) status, is 
used to immunize specific populations of at-risk indi-
viduals, i.e., scientists and health care providers who 
handle BoNT and our armed forces, who may be sub-
jected to weaponized forms of the toxin. Though sera-
types A, B, and E are most associated with botulism 
outbreaks in humans, type F has also been diagnosed 
(22- 24). A separate monovalent toxoid vaccine against 
BoNTF is available under IND status (25). Hatheway 
demonstrated that the BoNTF toxoid could protect 
guinea pigs against a homologous challenge (25). Even 
though toxoid vaccines are available, there are numer-
ous shortcomings with their current use and ease of 
production. First, the toxoiding process involves han-
dling large quantities of toxin and thus is dangerous 
and expensive. Second, because the type F toxoid is 
only partially purified (25), it contains a mixture of 
clostridial proteins that may influence immunogenicity 
or reactivity of the vaccine. Third, because the toxoid-
ing process involves the use of formaldehyde, which 
inactivates the toxin, and residual levels of formalde-
hyde (not to exceed 0.02%) are part of the product 
formulation to prevent reactivation of the toxin, the 
vaccine is reactogenic. An additional component of the 
vaccine is the preservative Thimerosal (0.01 %), which 
also increases the reactogenicity of the product. Fi-
nally, the yield of type F toxin produced in clostridial 
culture is low. Wadsworth et al. (26) reported that 
"strains of Clostridium botulinum type F are generally 
poor producers of neurotoxin compared with those of 
types A and B, making purification of this neurotoxin 
difficult." They reported a yield of 101 mg of purified 
type F toxin from 160 L of culture. A second-generation 
recombinant vaccine could alleviate all of these prob-
lems. 
The efforts in our laboratories are focused on devel-
oping recombinant vaccines against the seven sera-
types ofBoNT (27-29), with the goal of Food and Drug 
Administration (FDA) licensure. The recombinant vac-
cine a pproach involves isolating a nontoxic fragment of 
BoNT and evaluating that fragment for safety, immu-
nogenicty, and protective efficacy. This paper describes 
the development of a recombinant vaccine candidate 
that protects against BoNTF intoxication. A synthetic 
gene encoding the fragment C of BoNTF (rBoNTF(H<)) 
was designed, expressed, and purified from the yeast 
Pichia pastoris. The purified antigen was evaluated as 
a vaccine candidate and was shown to protect mice 
against a BoNTF challenge. 
MATERIALS AND METHODS 
Synthesis and Cloning of a Synthetic Gene Encoding 
rBoNTF(H.) 
A synthetic gene encoding a putative fragment C 
region of botulinum neurotoxin serotype F was de-
signed and constructed for expression in Escherichia 
coli (Holley et al. , submitted to Vaccine ). This first 
recombinant BoNTF(HJ , gene was inserted into the 
yeast expression vector, pHILD4 (gift from the Phillips 
Petroleum Co., Bartlesville, OK), at its unique EcoRI 
site. pHILD4 allows easy screening for Pichia transfor-
mants with multiple copies of the transforming DNA. 
pHILD4 is a derivative of the pHILD1 and pHILD2 
plasmid series (lnvitrogen, Carlsbad, CA). Bacterial 
kanamycin resistance gene from pUC-4K (Amersham 
Pharmacia Biotech, Inc., Piscataway, NJ) released as 
Hincii fragment was inserted at the unique Naei site 
in the pBR322-derived region between HIS4 and 3'-
AOXJ of pHILDl. The recombinant construct contain-
ing the rBoNTFCHc) 1 gene was subsequently linearized 
with Sacl and the cassette integrated into the chromo-
somal alcohol oxidase CAOXJ) of P. pastoris strain 
GS115 (30). Yeast transformants expressing the select-
able markers histidine dehydrogenase (31) and amino-
glycoside phosphotransferase 3' (I) (32) were isolated. 
These isolates were further characterized for their abil-
ity to express rBoNTF(Hc) after induction with meth-
anol. 
A second synthetic gene encoding the rBoNTF(Hc) 
fragment was designed and constructed using P. pas-
toris codon usage (33). Briefly, complementary oligonu-
cleotides encoding the amino-terminal region of the 
F(Hc) (423 nucleotides flanked with EcoRI and Pstl 
sites), the central region of the F(Hc) (606 nucleotides 
flanked by Pstl and Sal! sites), and the carboxy-termi-
nal region ofF(Hc) (336 nucleotides flanked by Sal! and 
EcoRI sites) were annealed and cloned into pUC or 
PCR zero-blunt plasmid vectors. After nucleotide se-
quencing, the cloned fragments were excised by the 
appropriate restriction endonucleases, separated by 
agarose gel electrophoresis, and purified. The isolated 
DNA fragments were ligated simultaneously into 
EcoRI digested and dephosphorylated plasmid 
pHILD4. The vector harboring the rBoNTF(HJ 2 gene 
was integrated into the chromosomal AOXJ locus of P. 
pastoris as described above. Transformants expressing 
selectable markers (histidine dehydrogenase and ami-
noglycoside phosphotransferase 3' (I)) were isolated 
and tested for their ability to express rBoNTF(Hc). 
SDS-PAGE, Western Blot, and Protein Assays 
Total protein concentrations were determined by us-
ing the Pierce BCA (bicinchoninic acid) protein assay 
kit with BSA as a standard. The purity of the rBoNT-
FCH<) product was assessed by SDS-PAGE with Novex 
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(San Diego, CA) gel electrophoresis supplies, reagents, 
and protocols and National Institutes of Health (NIH) 
imaging software as previously described (29). Western 
blot assays were used to identify FPLC fractions con-
taining rBoNTF(Hc) as previously described (29) with 
the following changes. The primary antibody used was 
a polyclonal Protein G-Sepharose purified horse anti-
BoNTF antibody incubated at 1 1-1-g/ml for 3 h. The 
secondary antibody used was a horseradish peroxidase 
labeled affinity-purified goat anti-horse IgG (Kirke-
gaard & Perry Laboratories, Gaithersburg, MD) as-
sayed at 1 1-1-g/ml for 2 h. 
Protein Expression 
A stock seed culture of P. pastoris was grown in 
shake flasks containing 0.5 L ofYNB medium (13.4 g/L 
yeast nitrogen base without amino acids, 20 g/L glyc-
erol, and 0.4 mg/L biotin in 100 mM sodium phosphate, 
pH 6.0). Cultures were grown at 30°C until an A 600 of 
20 (6.2 g ofDCWIL) absorbance units was achieved and 
then used to inoculate a 5-L BioFlo 3000 fermentor 
(New Brunswick Scientific, Edison, NJ) containing 2.5 
L of basal-salt medium (1 L ofBSM contains 26.7 ml of 
85% H3P04, 0.93 g ofCaS04 , 18.2 g ofK2S04 , 14.9 g of 
MgS04 • 7H20, 4.13 g of KOH, and 40.0 g of glycerol) 
plus PTM, (1 L ofPTM, contains 6.0 g ofCuS04 · 5H20, 
0.08 g ofNai, 3.0 g ofMnS04 • H 20, 0.2 g ofNa2Mo04 • 
2H20 , 0.02 g of H3B03, 0.5 g of CoC12, 20.0 g of ZnC12, 
65.0 g of FeS04 • 7H20 , 0.2 g of biotin, and 5.0 mL of 
H 2S04) trace mineral salts and 4% glycerol. Dissolved 
oxygen was maintained at 40% and the pH was main-
tained at 5.0 with 30% ammonium hydroxide. After the 
initial glycerol was consumed, 50% (w/v) glycerol was 
added at a rate of 20 g/L/h for 1 h and then decreased 
linearly to 0 g/L/h over 3 h. The medium was enriched 
with 1.5 g ofmethanol/L of medium. Methanol feed was 
started at 4 g/L/h and linearly increased to 9 g/L/h over 
10 h . The methanol feed rate was adjusted by using the 
dissolved oxygen spike method (34). After 10 h of meth-
anol induction, the cells were harvested by centrifuga-
tion at 6000g for 10 min at 4°C with a Beckman JA-10 
rotor (Beckman Instruments, Palo Alto, CA) and then 
stored at - 20°C. A final cell concentration of 59.0 g of 
DCW per liter of fermentation broth was obtained. 
Cell Disruption and Sample Preparation 
Eleven grams of frozen cell paste was resuspended in 
100 ml of 50 mM sodium phosphate, 2 mM EDTA, 1 
mM PMSF, pH 6.8, at 4°C. The suspended cells were 
disrupted by three successive passes through a mi-
crofiuidizer device (Model llOY, Microfluidics Corp., 
Newton, MA) a t 21,000 psi. The temperature of the 
disruptate was kept below 10°C throughout the process 
by cooling the exit line and collection flask with ice. The 
cells were judged to be greater than 95% dis rupted as 
determined by microscopy. The resulting cell lysate 
volume was 105 ml with a protein concentration of 11 
mg/ml. Cellular debris and insoluble proteins were re-
moved by centrifugation at 15,000g for 15 min at 4°C 
with a Sorval SS-34 rotor (Sorval Instruments, New-
ton, CT). The resulting extract was noticeably turbid 
due to the presence of lipids and significant quantities 
of nucleic acids. To remove the polynucleotides, the 
extract was treated with DNase (100 U/ml, Aldrich) 
and ZnCI 2 (2 mM, Aldrich) at room temperature for 30 
min and then dialyzed extensively with 10-kDa molec-
ular weight cutoff(MWCO) Slide-A-Lyzer dialysis cas-
settes (Pierce) in 50 mM sodium phosphate, 2 mM 
EDTA, 1 mM PMSF, pH 6.8, at 4°C. A precipitate 
developed during dialysis that was separated by cen-
trifugation at 15,000g for 15 min at 4°C with a Sorval 
SS-34 rotor. The clarified extract contained 7.8 mg/ml 
of total protein and was used as starting material for 
the FPLC purification of soluble rBoNTF(H.) while the 
pellet was used as starting material for the resolubi-
lized rBoNTF(H.) purification. 
FPLC Purification of Soluble rBoNTF(H.) 
Soluble rBoNTF(Hc) was purified by using a Phar-
macia Model 500 FPLC system (Pharmacia, Uppsala, 
Sweden) with programmed elution and A 280 monitor-
ing. The starting material was loaded onto a Pharma-
cia HR 10/10 Mono S cation exchange column equili-
brated with 50 mM sodium phosphate, 2 mM EDTA, 1 
mM PMSF, pH 6.8 (Buffer A), at a flow rate of2 mVmin 
(150 cm/h). The column was washed with 16 ml (2 bed 
volumes) of Buffer A. Flowthrough and wash were 
collected separately and stored for subsequent analy-
sis. Protein was eluted from the column with a linear 
gradient from 0 to 300 mM NaCl over 80 ml (10 bed 
volumes), then a linear gradient from 300 to 1000 mM 
NaCl over 20 ml (2.5 bed volumes), and then an iso-
cratic gradient at 1000 mM over 10 ml (1.25 bed vol-
umes). Four-milliliter fractions were collected through-
out the linear and isocratic gradients. 
Fractions eluting between 230 and 260 mM NaCl 
were positive for rBoNTF(H.) by Western blot analysis 
and were pooled. The pooled fractions were adjusted to 
1.5 M ammonium sulfate by the slow addition of 2 M 
ammonium sulfate, 50 mM sodium phosphate, 2 mM 
EDTA, 25 mM NaCl, pH 7.5, with stir bar agitation. A 
protein precipitate formed which consisted primarily of 
yeas t proteins with a small amount of rBoNTFCHc) 
product (approximately 10%). The precipitate was re-
moved by centrifuga tion at 6000g for 10 m in at 4 oc 
with a Sorval SS-34 rotor. The supernatant was loaded 
onto a Pharmacia Alkyi- Superose 10/10 hydrophobic 
interaction chromatography (HIC) column equilibrated 
with 1.5 M ammonium sulfate, 50 mM sodium phos-
phate. 2 mM EDTA, 25 mM NaCl, pH 7.5 (Buffer B), at 
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a flow rate of 1 mVmin (75 cm/h). The column was 
washed with 8 ml (1 bed volume) of Buffer B. Protein 
was eluted from the column with a linear gradient of 
decreasing a mmonium sulfate from 1.5 to 0 M over 60 
ml (7.5 bed volumes). Fractions positive by Western 
blot analysis and which only showed a single band by 
SDS-PAGE were pooled and dialyzed extensively in 50 
mM sodium phosphate, 2 mM EDTA, pH 6.8. The 
rBoNTF(Hc) protein eluted from the HIC column at 
0.92 M ammonium sulfate. The product was greater 
than 98% pure as determined by SDS-PAGE. 
FPLC Purification of Resolubilized rBoNTFrHc) 
The cell lysate pellet was resuspended into 20 ml of 
3 M urea, 50 mM sodium phosphate, pH 7.0, and ex-
tracted 15 h at 4°C on a Labquake rotator. The cellular 
components not solubilized by the denaturing buffer 
were removed by centrifugation with a Sorval SS-34 
rotor at 15,000g for 10 min at 4°C. The supernatant 
was dialyzed extensively using 10-kDa MWCO Pierce 
Slide-A-Lyzer dialysis cassettes in Buffer A. A slight 
precipitate formed during the dialysis, which was re-
moved by centrifugation as described above. Western 
blot analysis showed that rBoNTF(Hc) was present 
only in the supernatant , which was estimated to be 
about 35% pure by SDS-PAGE. The supernatant was 
loaded onto a Pharmacia HR 10/10 Mono S cation ex-
change column and separated by the same conditions 
as above. Fractions containing only a single positive 
rBoNTF(Hc) band by SDS-PAGE and Western blot 
analysis were pooled and dialyzed in 50 mM sodium 
phosphate, 2 mM EDTA, pH 6.8, in 10-kDa MWCO 
dialysis cassettes. The final resolubilized rBoNTF(Hc) 
product was judged to be greater than 98% pure as 
determined by SDS- PAGE. 
CD of Purified Soluble and Resolubilized rBoNTF(H) 
Purified soluble and resolubilized rBoNTF(Hc) were 
subjected to CD spectroscopy in a Jasco 600 spectropo-
larimeter (Japan Spectroscopy Co., Tokyo, Japan). Ex-
periments were performed at a concentration of 30 
p.g/ml (0.62 p.M) in a 1-cm path length cell in 10 mM 
sodium phosphate, pH 7.0. Spectra were obtained as an 
average of four accumulations, scanned from 260 to 
200 nm at a scan rate of 10 nm/min with a 2-s response 
and a 1-nm bandwidth. The temperature was main-
tained at 20°C with a Peltier thermocontrol device. 
Mouse Serum ELISA 
Individual mouse serum ELISAs were performed as 
previously described (29) except for the following dif-
ferences. Botulinum neurotoxin serotype F (Langeland 
strain, Food Research Institute, University of Wiscon-
sin , Madison, Wl) was used as the coating antigen and 
the positive control for each assay was a mouse IgG 
monoclonal antibody, 7F8.G2.H3 (35). 
Mouse Inoculations and BoNTF Toxin Challenge 
The efficacy of the purified soluble rBoNTF(H c) was 
determined by injecting groups of five female mice 
(Crl:CD-1, ICR mice (Charles River, NC) weighing 
16- 22 g on receipt) intramuscularly (im) with one, two, 
or three doses of 0.008, 0.04, 0.2, 1.0, or 5.0 p.g of 
rBoNTF(Hc) (diluted in 100 p.l of 0.2% (v/v) Alhydrogel 
(Superfos Biosector, Kvistgaard, Denmark) in 0.9% 
(w/v) saline) per mouse at 14-day intervals. Mice were 
challenged intraperitoneally (ip) 21 days after their 
last rBoNTF<Hc) injection with 1000 mouse ip LD50 
BoNTF toxin complex (Langeland strain) diluted in 
0.2% (w/v) gelatin/0.4% (w/v) sodium phosphate, pH 
6.2, in 100-p.l total volume per mouse. Groups of five 
naive mice were also used as toxin controls. Mice were 
observed daily and deaths were recorded 5 days post-
challenge. Two days before challenge, mice were bled 
retroorbitally and 50 p.l of serum was collected from 
each mouse for ELISA testing. All animal manipula-
tions were in accordance with applicable regulations in 
AAALAC-accredited facilities. 
The purified r esolubilized rBoNTF(Hc) was evalu-
ated for protective efficacy in mice. Groups of 10 male 
mice each received three inoculations of either 1 or 5 p.g 
ofrBoNTF(Hc) (diluted in 100 p.l of0.2% (v/v) Alhydro-
gel in 0.9% (w/v) saline) per mouse at 14-day intervals. 
Mice inocula ted with 1-p.g doses of rBoNTF(HJ were 
challenged with 5000 mouse ip LD50 of BoNTF toxin 
complex while mice inoculated with 5-p.g doses of 
rBoNTF(HJ were challenged with 500,000 mouse ip 
LD 50 of BoNTF toxin complex. 
Statistical Analysis 
The logis tic regression model was used to test asso-
ciations of geometric mean ELISA titers and individual 
titers with survival by using SAS, version 6.10. 
RESULTS 
Cloning and Expression of the Synthetic Genes 
Encoding rBoNTF(Hc) 
A synthetic gene encoding a rBoNTF(Hc) was de-
signed and constructed for expression in E. coli (Holley 
et al., submitted to Vaccine). The recombinant BoNT-
F<Hc)1 gene was expressed in E. coli as a fusion protein 
with maltose-binding protein (MBP), with yields of 1 
mg/L of culture (Holley et al., submitted to Vaccine) . 
The same gene was used for expression studies in the 
yeast P. pastoris. This particular host was chosen be-
cause it could produce high levels of recombinant pro-
teins (36 - 38) and because it lacked endotoxins which 
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would facilitate product development. Intracellular ex-
pression of the antigen was used to avoid potential 
glycosylation of the recombinant protein. The rBoNT-
F(H0)1 gene was modified at its 3' end for insertion into 
the unique EcoRI site of the yeast vector pHILD4. The 
recombinant cassette was integrated into the chromo-
some of P. pastoris and transformants were isolated 
based on their ability to express the selectable markers 
histidine dehydrogenase and aminoglycoside phospho-
transferase 3' (I). Although the various transformants 
generated were able to express the selectable markers, 
no expression ofrBoNTF(H0) as judged by SDS-PAGE 
and blot analysis was observed in these isolates (data 
not shown). 
A second synthetic gene, rBoNTF(Hch, was subse-
quently designed to facilitate expression in P. pastoris. 
Redesigning the gene was intended to lower specific 
regions of the rBoNTF(H0)1 gene in which spikes of 
AT-rich tracts still remained. Previous work had 
shown that rare codons (39) and/or highly enriched AT 
base compositions (40) in clostridial DNA were incom-
patible with optimum expression of clostridial genes in 
E. coli and yeast. The AT base composition in the 
native clostridial BoNTF(H0) DNA averaged 76% while 
rBoNTF(H0)1 averaged 58% and rBoNTF(Hch, 53% 
(Fig. 1). The synthetic gene sequence of rBoNTF(Hch 
and the 432 amino acids it encoded for is shown in Fig. 
2. Unlike the rBoNTF(H0)1 gene, rBoNTF(Hc)2 was ex-
pressed after induction with methanol and yielded the 
expected molecular mass of approximately 50,000 Da 
as judged by SDS-PAGE and Western blot analysis 
(Fig. 4). The deduced molecular mass of the encoded 
polypeptide was 50,250 daltons. 
Expression and Cell Disruption of rBoNTF(Hr) 
in P. pastoris 
Large-scale fermentation conditions and optimal in-
tracellular expression ofrBoNTFCHc) were determined 
for the yeast strain P. pastoris. A microfluidizer device 
was used to disrupt the yeast cells. The cells were 
greater than 95% disrupted as judged by microscopy 
after three passes through the instrument. In compar-
ison, 8-10 passes through a Gaulin homogenizer were 
required to efficiently disrupt the cells in past proto-
cols. SDS-PAGE and Western blot analysis of cell ly-
sate showed that expressed rBoNTFCHc) represented 
< 0.5% of the total protein. As rBoNTFCHc) possessed a 
calculated isoelectric point of 9.1 and presumably in-
teracted trongly with DNA, DNase was added to the 
cell extract in order to digest the polynucleotides and 
facilitate purification. After dialysis, the extract was 
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FIG. 1. (A) AT base content of a putative fragment C region in 
native C. botulinum DNA. (B) Reduction in AT content after the first 
design (rBoNTF(H,),) of the synthetic gene. (C) AT content of the 
final gene design (rBoNTFCH,)2) used to express recombinant rBoN-
TF(H,) in P. pastoris. 
Conventional Purification of rBoNTF(Hr) 
from P. pastoris 
The rBoNTF(H0) protein was purified to homogene-
ity using an FPLC system and two chromatographic 
steps. First, the material was subjected to cation ex-
change chromatography (Fig. 3A). This step was highly 
efficient as most pichia proteins possess isoelectric 
points between pH 5 and 7 and, therefore, pass through 
the column without binding. The first step enriched the 
desired product from < 0.5 to 26% of the total protein 
(Table 1). HIC was used as a second chromatographic 
step (Fig. 3B) and separated proteins based on their 
differences in surface hydrophobicity. It was deter-
mined that neopentyl chemistry provided the appropri-
ate hydrophobic interaction with rBoNTF(H0). Fortu-
nately, when the pool of Mono 8 column fractions was 
diluted with ammonium sulfate, most of the rBoNT-
F(H,.) product remained in solution (approximately 
90%) while significant quantities of pichia proteins 
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EcoRI 
GAA ne AeG ATG Tee TAe Aee AAe GAe AAG ATe eTG ATe nG TAe ne 
M s y T N 0 K I L I L y F 
AAC AAG eTG TAC AAG AAG ATC AAG GAe AAC TCC ATC TTG GAC ATG AGA 
N K L y K K I K 0 N s I L 0 M R 
TAC GAA AAC AAT AAG ne ATe GAe ATC TCC GGT TAC GGT TCe AAC ATC 
y E N N K F I 0 I s G y G s N I 
TCC ATC AAe GGT GAC GTe TAC ATC TAC Tee Aee AAT AGA AAC CAG n e 
s I N G 0 V y I y s T N R N a F 
GGA ATe TAC Tee Tee AAG CCT Tee GAG GTC AAC ATC GCT eAG AAC AAe 
G I y s s K p s E V N I A a N N 
GAC ATC ATC TAe AAe GGA AGA TAC CAG AAC TTC TCC ATG TCC ne TGG 
0 I I y N G R y a N F s M s F w 
GTC CGT ATe eeA AAG TAe ne AAe AAG GTC AAe eTG AAT AAC GAG TAC 
V R I p K y F N K V N L N N E y 
ACC ATC ATe GAe TGC ATC eGT AAC AAT AAC Tee GGA TGG AAG ATe TCC 
T I I 0 c I R N N N s G w K I s 
CTG AAC TAC AAe AAG ATe ATC TGG Aee eTG eAG GAe Aee Gee GGT Aee 
L N y N K I I w T L a 0 T A G N 
AAT eAG AAG nG GTe ne AAe TAC Aee eAG ATG ATe Tee ATe Tee GAe 
N a K L V F N y T a M I s I s 0 
TAe ATe AAC AAG TGG ATe ne GTe Aee ATC Aee AAT AAC eGT nG GGA 
y I N K w I F V T I T N N R L G 
AAe TCe AGA ATe TAe ATe AAe GGT AAe TTG ATe GAC GAG AAG Tee ATe 
N s R I y I N G N L I 0 E K s I 
Tee AAe nG GGT GAC ATC eAC GTe Tee GAe AAe An nG ne AAG ATC 
s N L G 0 I H V s 0 N I L F K I 
GTC GGT TGT AAe GAe Aee eGT TAe GTe GGG ATe CGT TAC ne AAA GTC 
V G e N 0 T R y V G I R y F K V 
ne GAC ACT GAG nG GGT AAG AeC GAG ATe GAG ACC nG TAC TCe GAC 
F 0 T E L G K T E I E T L y s 0 
GAG CeT GAC eeA TCe ATe eTG AAG GAe TTC TGG GGT AAe TAC CTG eTG 
E p 0 p s I L K 0 F w G N y L L 
TAC AAe AAA eGT TAC TAC nG eTG AAe eTG nG CGT ACe GAe AAG TCC 
y N K R y y L L N L L R T 0 K s 
ATC AeC eAG AAe TCe AAC ne TTG AAe ATe AAe eAG CAG AGA GGT GTC 
I T a N s N F L N I N a a R G V 
TAe eAG AAG eeA AAC ATC ne TCC AAe ACe AGA nG TAC Aee GGA GTC 
y a K p N I F s N T R L y T G V 
GAG ne An ATe AGA AAG AAC GGA TCT ACT GAT An TCC AAC ACC GAT 
E F I I R K N G s T 0 I s N T 0 
AAC ne GTe AGA AAG AAC GAT CTG GeT TAC ATe AAC Gn GTe GAC AGA 
N F V R K N 0 L A y I N V V 0 R 
GAT GTe GAA TAC eGT eTG AAC GCC GAT ATC TCT ATe GCe AAA CCT GAA 
0 V E y R L N A 0 I s I A K p E 
AAG ATC ATe AAG eTG ATC eGT ACe TCT AAe TeT AAe AAe TCT CTG GGA 
K I I K L I R T s N s N N s L G 
eAA ATe ATe GTe ATG GAC Tee ATC GGT AAT AAe TGT ACC ATG AAC ne 
a I I V M 0 s I G N N c T M N F 
eAG AAe AAe AAC GGT GGA AAe ATC GGT nG nG GGT ne CAC TCC AAC 
a N N N G G N I G L L G F H s N 
AAe n G GTe GCT TeC TCe TGG TAe TAe AAe AAe ATe CGT AAG AAC ACC 
N L V A s s w y y N N I R K N T 
TCC TCC AAe GGT TGC ne TGG Tee ne ATC TeC AAG GAG CAe GGT TGG 
s s N G c F w s F I s K E H G w 
CAG GAG AAe TAA TAG GAA ne 
a E N ler ter EcoRI 
FIG. 2. Amino acid sequence of a putative fragment C region of botulinum neurotoxin serotype F and the nucleotide sequence of the 
rBoNTF(H,)2 gene. 
salted out. The rBoNTF(Hc) eluted from the HIC col- folded conformation and possesses considerable 
umn at 0.92 M ammonium sulfate in a volume of 3 ml .B-sheet. 
with a protein concentration of 0.52 mg/ml. The recov-
ery of purified product from cell extract was estimated 
Purification of Resolubilized rBoNTF(H) to be greater than 42%, with a yield of 140 mg/kg of cell 
paste (Table 1). The resulting rBoNTF(Hc) was judged Western blot analysis revealed tha t approximately 
to be greater than 98% pure as only a single band was 30- 40% of the total expressed rBoNTF(Hc) was 
detected by SDS- PAGE (Fig. 4) even when modera tely present in the insoluble pellet after cell lysis. To inves-
(4 J.Lg) overloaded. Capillary isoelectric focusing tigate whether th is insoluble protein could be r ecov-
showed the antigen possessed an isoelectric point of9 .4 ered, the pellet was extracted in the denaturan t urea 
(da ta not shown ), which is in reasonable agreement and then dialyzed in nondenaturing buffer. A small 
with the calculated pJ of 9.1. Analysis of the far-UV amount of precipitate formed during the dialysis but 
circular dichroism spectrum (Fig. 5) of the purified conta ined no rBoNTF(Hc) as determined by Western 
antigen showed a positive peak at 233 nm a nd a min- blot . The amount of rBoNTF(H c> resolubilized in the 
imum a t 214 nm. This suggests the molecule is in a dia lyzed extract was about 35% of the total protein. 
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FIG. 3. Purification of rBoNTF(H,) by sequential chromatography. 
(A) Mono S cation exchange chromatography of extract from P. 
pastoris. Proteins were elut.ed with increasing NaCl gradient. Frac-
tions positive for rBoNTF(H,) by West.em analysis were pooled indi-
vidually and subjected to hydrophobic interaction chromatography 
(B) and proteins were eluted with a decreasing ammonium sulfate 
gradient. In both panels, protein monitored by A280 •• , is recorded on 
the left axis and elution conditions are recorded on the right axis, 
with the gradient trace laid over the chromatogram. 
After a single cation exchange chromatography sepa-
ration step, the rBoNTF(H0) was greater than 98% 
pure as judged by SDS-PAGE. The total yield of puri-
fied resolubilized rBoNTF(Hc) was 100 mg/kg of cell 
paste. The conformation of purified resolubilized anti-
gen showed significant {3-sheet as determined by CD 
spectral analysis (Fig. 5). However, the overall fold 
appeared slightly different than that shown by rBoN-
TF(Hc) purified from the cell lysate supernatant. The 
primary difference was the lack of a positive peak at 
233 nm, indicating differences in {3-sheet content. 
Mouse Immunogenicity and Efficacy Studies 
To assess the immunogenicity of the recombinant 
rBoNTF(H0 ), mice were inoculated with either one, 
two, or three doses of purified rBoNTF(Hc) from the 
soluble fraction oflysate at doses ranging from 0.008 to 
5 J.,Lg per mouse. All of the mice, including five naive 
controls, were challenged with 1000 mouse ip LD50 of 
BoNTF toxin. The controls all died within 2-4 h. A 
dose response was observed for groups of mice receiv-
ing different numbers of inoculations (Table 2). A sin-
gle inoculation of 5 J.,Lg protected four of five mice, while 
a dose of0.2 JJ.g or below protected one or no mice. Two 
and three inoculations protected four of five and five of 
five mice at doses of0.2 and 0.04 JJ.g, respectively. At all 
dose levels studied, the number of surviving mice in-
creases with the number of inoculations. 
Serum antibody titers for each individual mouse 
were determined by ELISA, followed by calculation of 
the geometric mean titers for each group in the study. 
Geometric mean titers correlated well with protection 
(Table 2). The three groups with no survivors had 
geometric mean titers below the detection limit of the 
assay (1.4). Similarly, the four groups that showed 
complete protection had geometric mean titers of2.8 or 
greater. Individual mouse antibody titers correlated 
extremely well with protection (Table 3). Only 7 out of 
38 mice survived whose titers were below 100. On the 
other hand, 34 out of 34 survived whose titers were 100 
or greater. One mouse in the study could be classified 
as a "nonresponder." The mouse receiving two injec-
tions at the highest dose level had an antibody titer 
below the detection limit and did not survive the 
BoNTF challenge. The rest of the mice in that partic-
ular group had titers of 1600 or greater. 
The resolubilized antigen was also evaluated for im-
munogenicity and protective efficacy by its ability to 
protect mice from a BoNTF toxin challenge. Mice were 
inoculated three times with either 1 or 5 JJ.g of purified 
TABLE 1 
Purification of Soluble rBoNTF(H ,)• 
Concentration• Protein rBoNTF(H,) Pu1·ity' Fold Recovery 
Step (mg/ml) (m g) (m g) (%) Purification {%) 
Lysate 11 1100 5.6 < 0.5 - 1 
Dialyzed extract 7.8 740 3.7 < 0.5 - 1 66 
Mono S 1.2 9.6 2.5 26 52 45 
Alkyl-Superose 0.52 1.6 1.6 100 200 29 
" Purification is from 11 g of cells weL weight. 
• Total protein concentration was determined by Pierce BCA assay. 
' Purity was estimated by analysis of .individual lanes of SDS- PAGE by pixel densitometry using NIH imaging software. 
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FIG. 4. (A) SDS-PAGE and (B) Western blot of samples at various steps along the rBoNTF(H,J purification. Lanes from both figures are 
identical except lane 1, where SDS-PAGE shows Novex mark 12 wide-range molecular weight markers and Western blot shows Novex See 
Blue prestained molecular weight markers. Lane 2 is the cell lysate, lane 3 is the cell extract, lane 4 is the cell extract after dialysis, lane 
5 is pool of rBoNTF<H,)-positive fractions after Mono S column chromatography, and lane 6 is pool of rBoNTFCH,l-positive fractions after 
hydrophobic interaction chromatography. 
resolubilized rBoNTFCHc). Mice inoculated with 1-J.Lg 
doses were challenged with 5000 mouse ip LD50 of 
BoNTF toxin. Ten of ten mice survived the challenge. 
Because 100% protection was observed with the group 
inoculated with 1-J.Lg doses, the group that received 
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FIG. 5. CD spectra of purified soluble (-) and resolubilized (-) 
rBoNTF(HJ at 30 ~-tg/ml (0.62 ~-tM) in 10 mM sodium phosphate, pH 
7.0, in a 1-cm path length cell. Spectra were the average of four 
accumulations, scanned from 260 to 200 nm at a scan rate of 10 
nm/min with a 2-s response and a 1-nm bandwidth. The temperatw·e 
was maintained at 2o•c using a Peltier thermocontrol device. 
two orders of magnitude greater in order to test the 
limits of the antigen. Therefore, the 5-J.Lg dose group 
was challenged with 500,000 mouse ip LD50 of BoNTF 
toxin. None of the mice survived the challenge; how-
ever, a significant delay in time to death was observed 
TABLE 2 
Survival and Antibody Group ELISA Titers of Mice after 
Inoculation with Purified Soluble rBoNTF(Hc) 
Survival 
(alive/5 Geometric mean 
tested )" ELISA titersb 
Vaccination 
dose (!J.g) l X 2x 3X 1X 2X 3X 
0.008 0' 0 2 1.4 1.4 1.6 :!: 0.3 
0.04 0 1 4 1.4 1.5 :!: 0.3 2.4:!: 0.8 
0.2 1 4 5 1.4 2.1 :!: 0.9 2.9 :!: 1.3 
1.0 2 5 5 1.4 2.8 :!: 0.3 4.3:!: 0.3 
5.0 4 4 5 1.6 :!: 0.3 2.8 :!: 0.9 4.1 :!: 0.5 
• Mice were challenged with 1000 ip LD60 BoNTF loxin 21 days 
after last inoculation. 
b Antibody ELISA titers were measured as the reciprocal of the 
highest dilution having an OD ,06 greater than 0.2 AU after correcting 
for background. Geometric mean ELISA titers were determined by 
taking the geometric mean of the logarithm of the individual titers. 
Standard deviations of the geometric means are also reported. If the 
ELISA titer was determined to be below the detection limit of the 
assay ( < 100), the ELISA titer was arbitrarily assigned a value of 25. 
A geometric mean Liter value of 1.4 means that all ELISA titers 
within that group were below the detection limit. 
' Only four mice were tested within this group. 
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TABLE 3 
Correlation of Individual Antibody ELISA Titer with 
Protection after Inoculation with Purified 
Soluble rBoNTF(H.) 
Individual Survival 
ELISA titer" (alive/total )• ~survival 
< 100 7/38 18.4 
100 ?n 100 
400 4/4 100 
1,600 11111 100 
6,400 3/3 100 
25 ,600 9/9 100 
• Serum was bled ft·om each mouse individually. Titer is reciprocal 
of the highes t dilution having an OD,M greater than 0.2 AU after 
correcting for background. Mice were challenged with 1000 ip LD.., 
BoNTF toxin 21 days a fter last inoculation. 
• The individual antibody titers from three mice were not mea-
sured. Two mice did not offer enough serum and one mouse was not 
challenged. 
(24-48 h). All the control mice succumbed within 2-4 
h after challenge. 
DISCUSSION 
A recombinant vaccine candidate was developed and 
protected mice against botulinum neurotoxin serotype 
F intoxication. The putative receptor-binding domain 
of BoNTF was purified from yeast and shown to be 
efficacious in a mouse model. When purifying a protein 
for the first time, it is important to generate a viable 
means for identifying which fractions contain product. 
If the protein of interest is not an enzyme or does not 
absorb at a unique wavelength, there are still suitable 
assays (for example mass spectrometry) for identifying 
the product. We chose to monitor the purification of 
rBoNTF(Hc) through immunological detection by 
Western blot analysis. However, with various poly-
clonal antibodies against whole type F toxin available 
but without an appropriate positive control, the West-
ern blot results can only be interpreted as ambiguous 
until a purified sample is sequenced or shown to be 
protective. A previous study (25) demonstrated that 
the toxoid antigen needed to be at least partially puri-
fied to be efficacious. The same observation was noted 
with the rBoNTF(Hc) antigen produced in pichia cells 
as the crude cell lysate did not protect mice against a 
BoNTF challenge. 
The initial step in the development of the rBoNT-
F(Hc) vaccine candidate was to design a gene which 
could satisfactorily be expre sed in a pichia host. A 
synthetic gene encoding rBoNTF(Hc) was constructed 
to lower the inherent AT richness of the native clos-
tridial gene and to remove any potentially rare codons. 
Clostridial genes having an AT content in excess of 
65% or having an average AT content but containing 
AT-rich tracts usually contain multiple terminators/ 
polyadenylation signals, which can result in premature 
termination of transcripts when expression is at-
tempted in yeast (41). The synthetic gene in this study 
required two successive rounds of alterations before 
the yeast could properly produce full-length antigen. 
The soluble portion of the cell lysate was purified in 
two conventional chromatographic steps. The ultimate 
objective of this work is to obtain FDA licensure of 
rBoNTF(Hc) as a safe and effective vaccine. Even 
though separations can be accomplished at extremely 
high resolution with affinity chemistry, there remains 
an undesirable effect of hapten leaching from the resin. 
Thus, the separations employed for this purification 
were a cation-exchange step followed by HIC. These 
two steps complemented each other as they provide 
separations based on electrostatic and hydrophobic in-
teractions. The cation-exchange step was particularly 
efficient in increasing the purity ofrBoNTF(Hc). as the 
antigen was estimated to be purified greater than 52-
fold. The efficiency of purification was primarily attrib-
uted to the significant difference in isoelectric points 
between most pichia proteins (p/ values < 7) and 
rBoNTF(Hc) (experimental p/ = 9.4, data not shown) 
and thus, the pichia proteins were removed in the 
column flowthrough. Fortuitously, the precipitate that 
resulted when the cation-exchange pool was treated 
with ammonium sulfate contained mostly pichia pro-
teins and very little rBoNTF(Hc) product. The HIC step 
removed the remaining impurities. The yield of soluble 
rBoNTF(Hc) from the total cell lysate was estimated to 
be greater than 28% with a purity greater than 98%. 
A significant amount of rBoNTF(Hc) product (30-
40%) was identified in the insoluble portion of the cell 
lysate. Also, the antigen was 35% of the total protein 
present in the pellet; in effect, it was more pure than 
the soluble rBoNTF(Hc) was after the ion-exchange 
step. The insoluble product was resolubilized and pu-
rified to homogeneity. The resolubilization was 
performed by resuspending the pellet in urea and sub-
sequently removing the urea by dialyses in nondena-
turing buffer. A single chromatographic step using cat-
ion-exchange chemistry was sufficient to purify the 
resolubilized antigen to greater than 98%. The yield of 
resolubilized product from the total cell lysate was 
estimated to be > 19%. The overall bench-scale yield of 
purified soluble and resolubilized rBoNTF(H c) was es-
timated to be greater than 47%, or 240 mg/kg of the cell 
paste. 
Analysis of CD spectra of both soluble and resolubi-
lizcd product revealed the presence of significant 
f3-sheet, which is in agreement with that predicted for 
rBoNTF(Hc) using an artificial neural network (42) and 
that determined by crystal structure of BoNT serotype 
A (43). However, even though CD revealed that the two 
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antigens possessed similar folds , there were subtle dif-
ferences between the two spectra, suggesting that the 
secondary structures, and hence, tertiary structures, 
were not identical. 
The purified soluble and resolubilized antigens ap-
pear to be in a folded conformation. However, the bot-
tom line with any potential vaccine is the demonstra-
tion of protection. Are the antigens in a conformation 
that will elicit the production of neutralizing antibody? 
To answer this question, mice were inoculated with 
rBoNTFCH.) and subsequently challenged with a high 
level of rBoNTF toxin. The purified soluble rBoNT-
FCHJ completely protected mice receiving three inocu-
lations of 0.2 1-1-g from challenge with 1000 mouse ip 
LD;o of BoNT/F toxin. Analysis of the association of 
dose with survival indicated that dose was associated 
with the odds of surviving (odds ratio = 2.0, meaning 
that the odds of survival increase twofold per unit 
increase in dose with a 95% confidence level from 1.3 to 
3.1). The number of inoculations was also associated 
with survival. Both two inoculations and three inocu-
lations were associated with increased odds of survival 
relative to a single inoculation (5.3-fold with a 95% 
confidence level of 1.2- 23 for two inoculations and 22-
fold with a 95% confidence level of 4.3- 110 for three 
inoculations). It is apparent that a single shot at higher 
doses achieved protection comparable to multiple inoc-
ulations at lower doses. Also, three doses of 1 J.Lg of 
purified resolubilized rBoNTF(H.) completely pro-
tected mice from a challenge of 5000 mouse ip LDso of 
BoNTF toxin, thus demonstrating that refolded rBoN-
TF(H.) from the insoluble fraction of lysate could also 
be a prosperous source of antigen. 
Individual antibody ELISA titer appears to be an 
excellent predictor of mouse survival. If the antibody 
titer of a mouse was 100 or greater, that mouse was 
predicted to, and did, survive a challenge of 1000 
mouse ip LD 50 of BoNTF toxin. 
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The efficacy of ciprofloxacin and doxycycline against experimental 
tularaemia 
P. Russell*, S. M. Eley, M. J . Fulop, D. L. Bell and R. W. Titball 
CBD Po rton D own, Salisbury, Wiltshire SP4 OJ Q, UK 
The efficacy of doxycycline and ciprofloxacin against an experimental tularaemia infection 
was assessed by comparing the median lethal dose (MLD) of Francisella tularensis Schu4 
biotype A strain given intraperitoneally to antibiotic-treated and untreated mice. In untreated 
Porton outbred mice this was <1 cfu. Ciprofloxacin and doxycycline given at 40 mg/kg bd, 
initiated 48 h before infection and continued for 5 days after infection, afforded protection 
against intraperitoneal challenges of 3.7 x 106 cfu and 6.0 x 106 cfu, respectively. Protection 
was reduced when both antibiotics were given over a similar period at a lower dose regimen 
(20 mg/kg bd) to 8.8 x 105 cfu and 3.5 x 102 cfu, respectively. The greater reduction In 
protection offered by doxycycline was a reflection of the higher in-vitro MIC. Protection also 
decreased when the antibiotics were initiated 24 h after challenge. The MLD was 3.2 x 105 cfu 
and 1.6 x 106 cfu for ciprofloxacin and doxycycline respectively given at 40 mg/kg bd and was 
reduced further using the lower dose regimen. Overall, 90% of the deaths occurred following 
the withdrawal of antibiotic, irrespective of the antibiotic dose or type. lt was possible to 
prevent this relapse by extending the antibiotic administration to 10 days after challenge. 
Ciprofloxacin and doxycycline may be useful for treating tularaemia, although the possibility 
of relapse should be considered. 
Introduction 
Tula raemia is a zoono tic disease, confi ned predominantly 
to the cooler regions of the northern hemisphere. There 
are three main biova rs which vary in virulence, geography 
and animal reservoir. The most virulent biovar is Fran-
cisella tularensis biovar tularensis, or type A , which occurs 
in North America, the main reservoir being cottontai l 
rabbits (Sylvilagus spp.). F. udarensis biovar palearctica, 
or type B, generally causes less serious ill ness but has 
a much broader distribution across North America, 
northe rn Euras ia and Japan. and the animal reservoir 
consists of a wider range of species, principally rodents. 
F. tularensis bio var novicida. or type C, is of low virulence 
in both rabbits and man, and appears to be confined to a 
single site in U tah.' 
The disease in humans usua lly occurs fo llowing close 
contact with an infected animal e ithe r via a bite from the 
vector (usually an ixod id tick. mosquito or tabanid fl y) , o r 
th rough handling or ea ting infected carcasses. T he severity 
of the disease depends on the biovar and the ro ute o f 
infection.2-6 The symptomato logy can resemble plague, 
and the primary diagnosis is complicated by the fac t that 
the two diseases share common animal reservoirs, geo-
graphica l distribution and o ften affect the same occupa-
tional groups.5 
The first choice o f therapy for tularaemia is strepto-
mycin.7·H Gentamicin can be used in patients who are 
unable to tolera te streptomycin, and tetracycline or 
ch loramphenicol can be used for non-hospita l cases or 
where streptomycin resistant strains occur.9·10 Strepto-
mycin is o totoxic and not widely available in some 
co untries where the disease occurs. G entamicin is nephro-
toxic and oto toxic. Neither can be given orally. thus they 
are unsuitab le for se lf-administered prophylaxis. U nlike 
plague, human-to-human transmission of tularaemia is 
unknown but prophylaxis may be indicated for asymp-
to ma tic colleagues or companio ns o f a patient who were 
similarly exposed to the disease, fo r example following 
a laboratory accident. Additiona lly, a presumptive mis-
diagnosis o f plague would warrant prophylaxis until 
tularaemia was confirmed. 
Cipro floxacin has been used against experimenta l 
tula raemia (mainly the vaccine stra in, F. tularensis 
*Tel: +4~- 191{0-6 1 3431-!: Fax: +44-191-!0-6 13097. 
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palearctica LVS) and as a clinical trea tment in a few 
instances, principally involving the milder type B 
biovar. 11.12 In-vitro susceptibility studies indica ted that 
stra ins of F. tularensis (types A and B) were sensitive to 
ciproftoxacin. 13 Experimenta l studies in humans a lso 
showed tha t pro phylactic tetracycline was effective in 
preventing pulmonary tularaemiaY 
T his investigation examined the efficacy of cipro-
ftoxacin and doxycycline prophylaxis and therapy in vivo 
against an experimenta l tula raemia infection caused by 
the Schu4 strain of F. tularensis tularensis. 
Materials and methods 
Bacterial strain, culture and storage 
F. tularensis tularensis strain Schu4 was obtained from 
the U S A rmy Medical Research Institute of Infectio us 
Diseases. As this organism is an ACDP category 3 
pathogen, all manipulations with the organism were 
ca rried out in Class 3 safety cabine ts complying to BS5726. 
The bacteria were grown on blood cysteine glucose (BCG) 
agar and modified cysteine partia l hydrolysate (MCPH) 
bro th. F. tularensis used fo r animal challenge was washed 
three times in phosphate-buffe red saline (PBS), resus-
pended in MCPH broth supplemented with 10% glycero l, 
and stored in 0.5 mL aliquots at -70°C. 
F. tularensis used for MIC experiments was stored o n 
Protect beads (TSC Ltd, Heywood, UK). The beads were 
charged according to the manufacturer 's instructions with 
colonies grown on BCG agar fo r 3 days and stored a t 
-70°C. 
A ntibiotic preparation 
Solutions of doxycycline (Sigma, Poole, U K) were 
prepared by dissolving the powder in PBS. Ciprofloxacin 
solutions were prepared by dissolving Ciproxin tablets 
(Bayer, Newbury, U K) in sterile de-ionized water and 
then filtering the solution. T he concentration o f cipro-
floxacin in this solution was measured using a disc 
diffusion assay as previously described.14 
Measurement of M/Cs and MBCs 
The MICs of doxycycline and ciprofloxacin were 
measured for F. tularensis Schu4. MCPH broth was 
inoculated with four o r five beads charged with F. 
tularensis and incuba ted for 3 days a t 37°C. Bo th 
antibiotics we re dissolved in MCPH broth and dilution 
series tha t would give a fi na l concentration range fro m 
0.063 mg/L to 64 mg/L in 100 f..LL aliquo ts were prepared in 
96-we ll microtitre p lates. Each we ll was inoculated with 
approximately 1 X 106 cfu F. tularensis in 100 J..LL T he 
plates were incubated a t 37°C and read visually a t 48 h. 
MBCs were de termined by removing 10 J..LL samples fro m 
wells conta ining supra-MIC levels of antibiotics and 
plat ing them o n BCG agar and incubating for 48 h at 37°C. 
Animals 
Porton outbred mice, obtained in-house, were maintained 
in cages of fi ve animals within a rigid wall isolator (B&B 
Envi ronmenta l, Bo lton, UK) complying to the standards 
laid down in BS5726. They were subjected to a 12 h 
light- 12 h dark cycle and were a llowed to feed and drink 
ad libitum . 
Antibiotic administration 
E ight groups of mice, each conta ining 20-30 animals, we re 
kept in cages of fi ve. All mice in each group received one 
o f the courses of antibio ti cs described in Table II. The 
antibiotics were given twice daily with a 12 h inte rval 
be tween each dose. One group of 30 mice was not given 
antibiotics, in order to de termine the virulence of the 
Schu4 strain. 
Animal challenge and virulence estimation 
T he virulence of F. tularensis Schu4 was determined by 
measuring the median lethal dose (MLD), defined as the 
dose required to kill 50% of a small popula tion of animals 
(25- 30), calculated according to the method of Reed & 
Muench.15 
A nimals were challenged with 0.2 mL of the serial 
dilutions of the F. tularensis suspension by the intra-
per itoneal route. Each subgroup of fi ve mice in each group 
received a different dilution of the suspension. The mice 
were observed for 24 days after challenge (14 days after 
the las t antibiotic administra tion). The prophylaxis groups 
were cha llenged approximately midway between anti-
bio tic doses. 
In addition to the groups described above, two 
unchallenged groups of fi ve mice received either 40 mg/kg 
cipro ftoxacin or 40 mg/kg doxycycline twice daily for 12 
days to determine any toxic effects of the antibiotics. 
A utopsies were carried out within the isolator. Organs 
were bisected and smeared on to BCG agar plates which 
were incuba ted for 3- 5 days a t 37°C. 
Results 
F. tularensis grew slowly in the microtitre plates: MJCs 
could only be read after 48 h incuba tion. MC PH bro th was 
used because the organism will not grow in Isosensi test 
bro th o r Mue lle r- Hinton broth unless it is modified .16 
T he in-vitro MICs of ciprofloxacin and doxycycline for 
F. tularensis Schu4 were 0.063 mg/L and 1.0 mg/L 
respectively. T he MBC of doxycycline for F. tularensis was 
> 8 mg/L. T he MBC of ciprofloxacin was not measured . 
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Untreated control mice were challenged intra-
peritoneally with log dilutions of F. tularensis Schu4 
ranging between 0.1 and 880 cfu (Table I) . The animals 
succumbed to a rapid, sy temic infection, most animals 
showing symptoms between 24 and 48 h following 
challenge. The MLD was calculated to be 0.4 cfu with a 
mean time to death of 104 ± 7 h. Few remarkable gross 
changes were revealed by autopsy, the main feature being 
splenomegaly. F tularensis could be isolated occasionally 
from blood and tissue smears in small numbers. Table I. The virulence of F. tularensis Schu4 (biotype A) 
in the Porton outbred mouse expressed in terms of 
mortality following intraperitoneal challenge 
The groups of mice given ciprofl.oxacin and the 
extended doxycycline prophylaxis (group f: Table II) were 
challenged with log dilutions of F. tularensis ranging from 
8.8 to 8.8 X 106 cfu. The remaining groups of doxycycline-
treated mice were challenged with a series of log dilutions 
ranging between 10 and 107 cfu (Table Ill). 











The performance of the two antibiotics used prophy-
lactically at 40 mg!kg bd was identical; extending the 
length of time of antibiotic administration offered 
complete protection against challenges up to 8.8 x 106 cfu 
(Table 11). Prophylaxis at the lower dose was less effective 
Table 11. The efficacy of ciprofl.oxacin and extended antibiotic prophylaxis against the 
intraperitoneal administration of F. tularer.sis Schu4 challenge to Porton outbred mice 
Mortality (death/group) given indicated antibiotic regimen a 
Challenge dose ( cfu) a b c d e f 
8.8 X 106 4/5 3/5 515 3/5 015 015 
8.8 X 10S 0/5 3/5 3/5 0/5 015 015 
8.8 X 104 015 1/5 015 115 015 015 
8.8 X HP 015 015 2/5 4/5 015 015 
880 0/5 015 0/5 115 nt nt 
88 015 015 015 015 nt nt 
9 015 015 015 0/5 nt nt 
"Antibiotics were administered subcutaneously according to the following regimens: (a) prophylaxis: 40 mg/kg bd 
initiated 48 h before challenge and continued 5 days after challenge; (b) prophylaxis: 20 mglkg bd as in regimen a; 
(c) therapy: 40 mglkg bd initiated 24 h after challenge and continued for 5 days; (d) therapy: 20 mglkg bd as in regimen c; 
(e) extended ciproftoxacin prophylaxis: 40 mglkg bd as in regimen a but antibiotic administration continued for 10 days 
after challenge; (f) extended doxycycline prophylaxis: 40 mglkg bd as in regimen e. nt , not tested. 
Table Ill. The efficacy of doxycycline against the intraperitoneal administration of Francisella 
tularensis Schu4 challenge to Porton out bred mice 
Mortality (death/group) given indicated antibiotic regimena 
Challenge dose ( cfu) a b c d 
107 115 3/5 515 515 
106 015 3/5 015 2/5 
10S 0/5 115 115 3/5 
104 0/5 3/5 115 2/5 
103 015 4/5 115 115 
100 3/5 515 015 115 
10 115 4/5 015 4/5 
"Antibiotic was administered subcutaneously according to the following regimens: (a) prophylaxis: 40 mglkg bd initiated 
48 h before challenge and continued 5 days after challenge; (b) prophylaxis: 20 mglkg bd as in regimen a; (c) therapy: 
40 mglkg bd initiated 24 h after challenge and continued for 5 days; (d) therapy: 20 mglkg bd as in regimen c. 
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in both an tibiotics a lthough the decrease in efficacy was 
greater with doxycycline (Table Ill ). 
Doxycycline therapy a t 40 mg/kg bd was superior to 
equivalen t ciprofloxacin therapy. Therapeutic use of both 
an tibiotics, however, was less effective than prophylaxis. 
with a four-fold and ten-fold decrease in protection for 
doxycycline and ciprofloxacin, respectively. This decreased 
further for the low dose regime ns, and as in the case of 
prophylaxis, the decrease was greater for doxycycline 
(Table lll ). 
Overall, 90% of deaths occurred following the with-
drawal of the antibio tic. The mean time to death was 
markedly consistent among the differe nt antibiotic 
regimens: Mean time to death of prophylactically treated 
mice was 338 .::!:: 10 h (208 h after the last antibio tic 
administration) and the mean time to death for the 
therapy groups was 353 .::!:: 15 h (199 h after the last anti-
biotic administration). The remaining 10% of deaths 
occurred exclusively in the the rapy groups challenged with 
the highest doses of F. tularensis within 48 h, with the 
exception o f two animals which died between 120-128 h 
(2% of the total). Deaths after antibiotic withdrawal were 
prevented by extending the antibiotic administration to 10 
days after challe nge. 
Of the surviving a nimals, 19% were still sick, most of 
these animals being in the extended administra tion groups 
(72% of all the sick anima ls). Autopsy of the survivo rs 
revealed e nlargement of the spleen in most cases. In two 
animals the liver a nd spleen had fused toge ther. Micro-
biological examination of organs from survivors showed a 
variety of results: some plates were clear, others had pure 
culture of F. tularensis, but most were contaminated. 
Discussion 
F. tularensis caused a rapid and systemic disease in the 
Po rton outbred mouse, despite being devoid of a ny 
classical, potent virulence factors, and producing a unique, 
but weak lipopolysaccharide.17 Furthermore, when F. 
tularensis was successfully isolated from autopsy material, 
it only occurred in small numbers. It is difficult to 
comprehe nd how such an apparently benign o rganism can 
cause such severe disease in a murine mode l and in man, 
but the intimate relationship between F. tularensis and 
macrophages underpins the virulent nature of the bac-
terium and contributes to the failure of some antibiotics. 
The difficulty in isolating F. tularensis from biological 
samples , especially from blood, is we ll documented both in 
experimental infections in murine models1R and in clinical 
cases6·19 and would strongly indicate that the organism 
does not survive or multiply extracellularly in vivo. 
However, animal infection s tudies with F. tularensis LVS 
indicate tha t the organism does multiply to considerable 
numbers in the tissues20·21 but is confined within macro-
phages22 and o the r cell types.23 The qualitative sampling 
for F. tularensis by organ or blood smear used in these 
experiments may not be conducive to the survival o f the 
organi m. Cell lysis, occurring post mortem, either in the 
animal or during incubatio n on the BCG agar would 
deprive the organism of the appropriate en vironment to 
survive a nd expose the organi m to a number of non-
specific antimicrobia l metabolites resulting from cell lysis. 
Generally, the protection offered by the two antibiotics 
given at 40 mg/kg bd was identical , corresponding to the 
supra-MIC serum levels ach ieved using this regimen. 
Serum ciprofloxacin concentration exceeded the in-vitro 
MIC at least four-fold for 12 h (> 0.26 .::!:: 0.05 mg/L) and 
the peak conce ntration was almost 50 times the MIC (2.89 
.::!:: 0.14 mg/L). Serum doxycycline remained at least three 
times the in-vitro MIC for 9 h (> 2.58 .::!:: 0.11 mg/L fo r 9 h), 
and exceeded the MIC for 24 h. but never exceeded the 
MBC (unpublished data). The differences in protection at 
the lower dosage probably reflect the fact tha t the regimen 
failed to achieve MIC levels of doxycycline in the serum 
and tissues or resulted in longer periods of sub-MIC levels. 
The in-vitro MICs were identical to the findings of Scheel 
et al. 13 Inexplicably, the low-dose doxycycline therapy 
was more effective than the corresponding prophylaxis 
regimen. 
The occurrence of relapse in these experiments did not 
appear to be related to the size of the challenge dose 
(Tables 11 and Ill), and was particularly marked in 
doxycycline-treated mice given a low challenge dose of 
F. tularensis (Table 11). Relapses were prevented by 
extending the length of time that antibiotics were 
administered, although many animals were sick at the 
end of the experiment with both antibiotics. Unchallenged 
controls given antibiotics for the same period of time did 
not show any signs of ill health , suggesting that sickness 
may be a result of interaction between the bacteria and the 
antibiotic. 
The occurre nce of relapse following withdrawal of anti-
biotic is documented in the treatment of human disease, 
particularly where tetracyclines, including doxycycline, 
have been used.2•9·12 There is less information regarding 
relapse rates for fluoroquinolones because they have not 
been used as widely as te tracyclines.24 Relapse rates were 
identical for both a ntibio tics in the animal model, 
suggesting that relapse could occur following fluoro-
quinolone use in human cases. In a single clinical case, 
relapse occurred with biotype B infection following the 
administration of doxycycline for up to 3 weeks which was 
subseque ntly successfu lly trea ted with ciprofloxacin given 
for 14 days.12 
Relapse is generally accepted to be due to survival in 
intracellular si tes inaccessible to antibiotics, despite both 
ciprofloxacin and doxycycline penetrating into tissues 
a t concentrations higher than corresponding serum 
concentrations (unpublished da ta), and both antibiotics 
are known to pe netrate intracellularly in supra-MIC 
concentrations. In order to survive a nd multiply in a 
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macrophage, F. tularensis resides within an acidified 
vesicle, the low pH being necessary for iron acquisition.22 
Coincidentally, the low pH also prevents the entry of 
ba ophilic antibiotics such as ciproftoxactn and doxy-
cycline. Therapeutic protection may be enhanced by 
encapsulating the ciproftoxacin in liposomes which would 
deliver the antibiotic more efficiently (and possibly more 
rapidly) to intracellular sites_!• 
The difficulties in isolating F. tularensis from autopsy 
material made it difficult to determine whether the anti -
biotics had cleared the organi m from the surviving 
animals. Sterile plates suggest that some animals may have 
successfully cleared F. tularensis. The frequent con -
tamination occurring from autopsy amples was due to the 
use of a highly enriched medium, necessary for such a 
fastidious organism, coupled with its very slow growth 
rate . 
Ciprofloxacin and doxycycline were both effective 
against a severe experimental infection with highly 
virul ent F. tu/arensis. The findings would suggest that 
either antibiotic would be suitable for prophylaxis or 
therapy for tularaemia, although the possibility of relapse 
must be considered. 
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outer membrane protein gene and expression 
in attenuated Salmonella typhimurium 
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Abstract: We have determined the nucleotide sequence of fopA from Francisella rularensis. Using the polymerase chain reaction 
fopA was detected in high and low virulence biotypes of F. tularensis. fopA was stably maintained in pBiuescript in attenuated 
Salmonella typhimurium where FopA was expressed and located in the outer membrane. This recombinant will be su itable for 
studies on the role of FopA in immunity against tularaemia. 
Key words: Francisella tularensis; Outer membrane protein 
Introduction 
Francisella tu/,c:.;zsis is the etiological agent of 
tularaemia, a serious, sometimes fatal disease of 
man. An effective live vaccine strain (LVS) of F. 
tularensis var palaeartica is available, but the 
mechanism by which it induces protection is un-
clear [1]. Expression of a 17 kDa T-cell stimulat-
ing F. tularensis outer membrane lipoprotein in 
attenuated Salmonella typhimurium has recently 
been shown to be insufficient to induce protec-
tion alone [2], and protective immunity against 
tularaemia is thought to depend on both humoral 
and cellular immunity [3]. The dominant antibody 
Correspondence to: D. Leslie, CBDE, Porton Down, Salisbury, 
Wiltshire, SP4 OJQ, UK. 
response to tularaemia is reported to be against 
FopA, a heat-modifiable 43k outer membrane 
protein (omp), and antibody against FopA was 
found in all convalescent sera tested by Bevanger 
et al. [4]. In order to study this protein in more 
detail , we have obtained a clone of fopA from F. 
tularensis for genetic analysis and expression in 
attenuated Salmonella. 
Materials and Methods 
Bacterial strains, plasmids and growth media 
E. coli JMlOl or NM522, S. typhimurium aroA 
SL3261 [5] and S. typhimurium galE r - m + 
LB5010 [6] were maintained as glycerol stock 
cultures and subcultured as required onto L-agar 
or into L-broth [7]. When appropriate, ampicillin 
332 
was added to a final concentration of 50 p.gj ml. 
Broth cultures were normally aerated by shaking 
at 150 rpm in a New Brunswick Environmental 
Shaker. 
Manipulation of DNA 
Plasmid was isolated and, when required, fur-
ther purified by caesium chloride density gradient 
centrifugation using methods described elsewhere 
[7]. Fragments of DNA for subcloning were iso-
lated after electrophoresis through an agarose gel 
onto DEAE cellulose filter paper (Schleicher and 
Schuell) from which they were then eluted [7]. 
Plasmid vector and insert DNA were mixed in a 
ratio of 1 : 3 before DNA ligase (1 U) was added 
to the mixture (total volume 20 p.l). The mixture 
was transformed in E. coli made competent [7] or 
electroporated into S. typhimurium [8] at 1.25 kV, 
25 p.F, 800 ohms using a Bio-Rad Gene Pulser 
system with 0.2 cm electrode gap cuvettes. 
Nucleotide sequencing 
Nucleotide sequences were determined by the 
dideoxy termination method with a 35S dCfP as 
labelled nucleotide either by preparing single 
stranded DNA from pBluescript clones and prim-
ing with synthetic oligonucleotide or by using the 
Strategene Exo-Meth ™ nested-deletion sequenc-
ing system [9]. In either case the reaction prod-
ucts were separated through a 6% polyacrylamide 
sequencing gel [7] and bands visualised after ex-
posure to X-ray film. 
Analysis of nucleotide and amino acid sequence 
data 
Nucleotide and amino acid sequence data were 
analysed using the DNAStar computer programs. 
The hydrophobicity of proteins was calculated 
using the algorithms of Hopp and Woods [10] and 
Kyte and Doolittle [11] with window sizes of 7 
and 9 residues respectively. Structural predictions 
were made using the algorithms of Gamier et al. 
[12] and Chou and Fasman [13]. Nucleotide se-
quences were compared with the GenBank (Los 
Alamos National Laboratory) or EMBL database 
(EMBL, Heidelberg). Deduced amino acid se-
quences were compared with the Protein Identifi-
cation Resource (PIR; NIH, Bethesda, USA) and 
Swiss-prot database (EMBL, Heidelberg). 
Polymerase chain reaction 
Polymerase chain reactions (PCR) were per-
formed in 20-p.l volumes consisting of Boehringer 
Mannheim PCR reaction buffer containing 200 
pg of template DNA, 200 ng of each primer, 200 
p.M dinucleotide triphosphates (Pharmacia/ 
LKB) and 0.5 U Boehringer Mannheim Taq poly-
merase. A Perkin Elmer PE9600 temperature 
cyder was used to denature the reactions for 2 
min at 95°C and perform 35 cycles of denatura-
tion for 30 s at 95°C, annealing for 30 s at 37°C to 
55°C, and extension for 1 min at 72°C. Finally, 
the samples were incubated for 10 min at 72°C to 
complete extension reactions. Products were 
analysed by agarose gel electrophoresis. 
Preparation of antisera 
Rabbit antiserum against F. tularensis biotype 
novicida was kindly donated by Dr. F. Nano, 
University of Victoria, Canada. To prepare anti-
sera against F. tularensis var palaeartica (LVS 
strain), the bacterium was firstly heat-killed (60°C, 
60 rnin). Primary and booster vaccinations con-
taining 0.5 mg of the heat killed bacteria mixed 
with Freund's incomplete adjuvant were inocu-
lated intradermally at six sites. 
Preparation of outer membrane proteins from S. 
typhimurium 
A previously described procedure for the 
preparation of S. typhimurium outer membrane 
proteins [14] was adapted by performing all ma-
nipulations in phosphate buffered saline [7] rather 
than the Tris buffers described, and lysing the 
cells by sonication using a Braun Labsonic Soni-
cator (5 X 30 s bursts with a 16 mm probe at 1500 
W) rather than using the lysis buffer described. 
Bacterial debris was separated by low speed cen-
trifugation (6 000 X g, 5 m in, 4°C) and sarkosyl 
(0.55% w jv, final concentration) added to the 
supernatant. After incubation for 30 min at room 
temperature the membranes were collected by 
centrifugation (40 000 x g, 45 m in, 4°C), the pel-
let resuspended in 10 mM Tris (pH 8 with HCl, 
containing 2% w j v SOS) and recentrifuged at 
100 000 X g for 60 min at 4°C. The pellet was 
resuspended in Tris-SDS buffer and stored at 
-70°C. 
SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting 
E. coli or S. typhimurium with or without plas-
mid pJOl were grown at 37°C in 250-ml Erlen-
meyer flasks containing 100 m! of L-broth supple-
mented with ampicillin (50 J.Lgj ml). After growth 
for 18 h the cells from 1 m! of culture were 
collected after centrifugation (2 m in, 10 000 x g), 
resuspended in 100 J.LI of sample buffer [7] and 
boiled for 5 min. The samples were elec-
trophoresed through SDS-polyacrylamide 10-
15% gradient gels (Pharmacia, Phast System) or 
7.5%, 10% or 12% polyacrylamjde gels (Bio-Rad 
Miniprotean System) and diffusion blotted or 
electroblotted (Bio-Rad Transblot System) onto 
PVDF membrane (lmmobilon P, Mmipore). The 
membranes were reacted with anti-F. tularensis 
L VS serum and bound antibody detected using 
gold labelled goat-anti-rabbit antibody (Jannsen 
Life Science Products) with silver enhancement. 
4. Results and Discussion 
Preparation of fopA clones 
Plasmid pLA68 was kindly supplied by Dr. F. 
Nano (University of Victoria, Canada) and com-
prised pUC8 and a 5.5 kb Sau 3A fragment of 
DNA from F. tularensis var nouicida which en-
coded FopA [15]. The identity of the plasmid was 
confirmed by restriction analysis. Immunoblotting 
demonstrated that FopA produced in E. coli was 
of similar Mr to that from F. tularensis (Fig. 1). A 
2.1-kb Hindiii fragment containing fopA was 
subcloned into pBluescript KS - and KS + 
(Stratagene) to generate plasmids pJO l and 
pML1 respectively. The level of expression of the 
gene from plasmids pLA68 and pJ01 appeared 
similar in immunoblots. 
Nucleotide sequence of fopA 
The complete nucleotide sequence of the 2.1 
kb Hindlll fragment was assembled from unam-
biguous overlapping sequences covering both 
strands of DNA entirely. It contained an open 
reading frame of 1005 nucleotides encoding a 335 
amino acid protein which was deduced to be 
fopA on the basis of size (Fig. 2). In order to 








Fig. l. Comparison of Western blotting patterns of F. tularen-
sis outer me mbrane proteins a nd £. coli containing the fopA 
gene. Whole cell lysa tes from cultures of E. coli NM522 (lane 
1), S. cyphimurium LB5010 (lane 3) or S. cyphimuriwn SL3261 
(lane 5) and from these st rains containing plasmid pJ01 
(lanes 2, 4 and 6) were electrophoresed alongside an F. 
tularensis L VS outer membrane preparation (lane 7; a gift 
from L. Reynolds) through a 10-15% SOS polyacrylamide 
gel. The gel was immunoblotted wi th anti-F. tularensis L VS 
antiserum as primary antibody. The size of prestained molecu-
lar mass standards running in lane 8 is shown in kilodaltons. 
reach the outer membrane, FopA would have to 
be secreted, and the first 23 residues show fea-
tures typical of a bacterial signal sequence [16]. 
After cleavage of this putative signal peptide, 
FopA would be predicted to comprise 313 amino 
acids with a molecular mass of 32 808. This is 
considerably less than the Mr of 42 000 of FopA 
we calculated from SOS-PAGE, but this was not 
surprising as FopA is known to exhibit heat-mod-
ifiable behaviour on SOS-PAGE like some other 
bacterial outer membrane proteins [17- 19]. When 
the outer membrane preparations from recombi-
nants expressing FopA were denatured at various 
temperatures prior to SOS-PAGE, results similar 
to those described by Nano [17] were obtained in 
immunoblots. When samples were denatured at 
60°C or 80°C the Mr of FopA was approximately 
29 000, wruch corresponds well with the calcu-
lated molecular mass, whereas when samples were 
denatured at 100°C the Mr was approximately 
42 000 (not shown). 
Database searches failed to reveal any signifi-
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Fig. 2. Nucleotide sequence of the fopA gene of F. rularensis. 
The deduced amino acid sequence is shown be low the appro-
priate nucleotide sequence. The position of the putative ribo-
some binding site (RBS) is shown underl ined. The putative 
signal sequence for the protein is shown underlined. 
dieted structural characteristics of the deduced 
amino acid sequence are similar to those of other 
bacterial omps [201, in that they consist predomi-
nantly of beta-sheet structure with the only 
strongly hydrophobic region lying within the puta-
tive signal sequence. 
The sequence for several hundred bases up-
stream of the ORF was examined (not shown) 
and found to contain several stretches closely 
resembling the Gram-negative consensus pro-
moter - 10 region [21]. However, this probably 
reflects the high AT content of the DNA (68%), 
and as no strong - 35 homologues were found, 
no putative promote r region was assigned. A con-
sensus type ribosome binding site was found just 
upstream of the putative start codon [22]. 
Verification of the origin of fopA 
The origin of fopA was verified using four 
differe nt PCRs with six 30mer primers designed 
from fopA. Single band products of the correct 
size were produced using template DNA from F. 
tularensis var tularensis strain Schu4, var 
palaearctica strains HN63 and LVS, and var noui-
cida stra in ATCC 15482, but not from E. coli 
JMlOl , suggesting that fopA is present in several 
biotypes of F. tularensis. 
Expression of fopA in attenuated Salmonella ty-
phimurium 
In order to assess the potential for delivering 
Fop A in attenuated Salmonella, pJO 1 was trans-
fer red into S. typhimurium AroA SL3261 via the 
restriction -1 modification + S. typhimurium galE 
LB5010 by e lectroporation [6,5,23]. Expression of 
FopA from the recombinant Salmonella at levels 
approximate ly equal to that in E. coli was veri-
fied by immunoblotting of whole cell extracts 
(Fig. 1). Immunoblots of outer membrane prepa-
rations showed that FopA was located in the 
o uter me mbrane of Salmonella (Fig. 3). pJ01 was 
retained by greater than 90% of S. typhimurium 
over five successive days of subculture with or 
without selective an tibiotics. Expression levels as 
assessed by immunoblotting remained constant 
during this time. 
In summary, we have sequenced fopA from F. 
tularensis and transferred the gene into a ttenu-
2 M 3 4 
-
Fig. 3. Examination of outer membrane proteins of S. ry-
phimurium SLJ261 containing plasmid pBiuescript SK + or 
plasmid pJOl encoding the F. rularensis var novicida FopA. 
Outer membrane proteins were prepared as described in the 
text and analysed by electrophoresis through 10% SDS-poly-
acrylamide gels. Gels were stained with Coomassie blue pro-
tein stain or were immunoblolled using F. tularellSis L VS 
antiserum as the primary antibody. The size of molecular 
mass markers running in lanes M is shown in ki lodaltons. 
ated Salmonella , where it is stable and expresses 
FopA which is found in the outer membrane of 
the recombinant Salmonella in an immunoreac-
tive form. This recombinant should allow further 
studies on the immune response to tularaemia. 
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Role of lipopolysaccharide and a major 
outer membrane protein from 
Francisella tularensis in the induction of 
immunity against tularemia 
Mark Fulop*, Richard Manchee and Richard Titball 
A crude outer membrane preparation from F rancisella tularensis Live Vaccine Srrain 
( L VS) 1ras used to immunize mice. Immunized mice were completely protected from a F. 
tularensis challenge. We evaluated the role of two major outer membrane antigens in the 
induction of protective immunity, namely lipopolysaccharide and an outer membrane 
protein FopA. We presented FopA to the immune system using an aromatic amino 
acid-dependenr Salmonella typhimurium as a vector. Although mice mounted an immune 
response to cloned FopA no significant protection was induced. However, LPS immuni::ed 
mice were completely protected. We conclude that LPS is a major protective antigen 
whereas FopA has a limited or no role in the induction of protective immunity. 
Keywords: Frrmcisella 111/areusis: lipopolysaccharide; outer membrane protein: protective immunity 
Francisella tularensis is the causative agent of tuJaremia 
in man and animals. An attenuated strain is used as 
a vaccine in humans'. This vaccine has significantly 
reduced , but not eliminated, tularemia in laboratory 
personnel exposed to F rularensis2 . However, the nature 
of protective immunity to F. tularensis is unknown and 
protective antigen(s) have not been identified3. F 
tularensis LVS is, however, fully virulent for mice 6 . 
The murine model has been widely used to simula te the 
disease in humans7·8• 
Several membrane proteins from F tularensis L VS have 
been identified and shown to stimulate an immune 
response in human vaccinees9- 11 . The gene encoding the 
protein that elicits the dominant antibody response, 
FopA , has been cloned into Escherichia coli and the 
nucleotide sequence determined 11 . Since FopA is an outer 
membrane protein (OMP) purification and presentation 
to the immune system of the pro tein in a form similar to 
that found in the outer membrane of the living bacterium 
is difficult. a no er al.' ·' showed that the apparent 
molecula r weight of FopA was heat modifiable and 
Bevanger et ai.'T4 proposed that it functions as a porin. 
Recombinant techniques provide means of testing the 
immunogenic significance of a specific protein from a 
pathogenic microorgani ·m. When such techniques are 
used to search for protective antigens of intracellular 
bacteria . attenuated Salmonella is a useful vector 
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because of its ability to colonize livers, spleens, and the 
gut-associated lymphoid tissues15 . We have cloned and 
expressed FopA in the aromatic amino acid-dependent 
S. typhimurium SL 3261 to determine the protein's role 
in protection against F tularensis infection. The cellular 
location of FopA in S. typhimurium is the outer 
membrane. 
In several Gram-negative bacteria lipopolysaccharide 
(LPS) has been shown to be an important protective 
antigen. Exam~les include E. coli16, Shigella flexneri17 
Brucella spp. 1 , Pasteurella multocida 19 and Pseu-
domonas aeruginosa10. In a previous investigation we 
extracted and purified F rularensis LPS, and demon-
st ra ted it possessed a classical 0-side chain that was 
itself immunogenic21 . 
In this study we have evaluated the protection 
afforded by a crude outer membrane preparation from 
F tularensis and have determined the role of the two 
dominant antigens (FopA and LPS) it contains for 
protection aga inst tularemia . 
MATERIALS AND METHODS 
Bacterial strains and culture 
F rularen.Yis L VS was grown on blood cysteine glu-
cose agar and modified cysteine partia l hydrolysate 
broth (MCPH). F tularensis used for animal challenge 
was washed three times in phosphate-buffered sa line 
(PBS). re-suspended in MCPH broth suppleinented with 
I 0% glycerol, and stored in 0.5 m! volumes at - 70°C. S. 
ryphimurium SL 3261 is an aroA his - -derivative of the 
mouse virulen t S. typhimurium SL 1344. S. ryphimurium 
SL 3261 was grown on Luria (L) broth or agar at 37"C. 
Stra ins carrying the ampr gene were cultured in L-broth 
or agar supplemented with 55 llg ml-1 ampicillin. S. 
typhimurium used for a nimal experiments was washed 
three times in PBS, re-suspended in PBS supplemented 
with 10% glycerol, and stored as described above. 
To confirm strains were aroA mutants they were 
grown on minimal media ± aro mix (10 llg mr 1 
p-aminobenzoic acid, 10 llg ml-1 dihydroxybenzoic acid , 
40 llg ml- 1 phenylalanine, 40 llg ml-1 tyrosine, 40 ll g ml- 1 
histidine, and 40 llg ml-1 tryptophan) . 
Construction of FopA expressing S. typhimurium 
The gene encoding FopA was inserted into phagemid 
pBluescript II KS+ (Stratagene Ltd. , Cambridge, UK) 
and transformed into S. typhimurium SL 3261 via the 
restriction deficient, modification proficient S. typhimu-
rium galE LB50 I 0 by electroporation as described 
previously 12 • The plasmid was designated pJOl. 
Antigen preparation 
F tularensis OMPs were prepared by the method 
described by Lambert22 with the modifications described 
by Leslie et a/. 12 Briefly, washed bacteria from 2 I of 
broth culture were disrupted by sonication, treated with 
22% (w/v) sodium N-Jauroyl sarcosinate to solubilize 
the cytoplasmic membrane, and OMPs recovered by 
centrifugation at 40 OOOg. 
F tularensis LPS was extracted by the hot phenol 
method23 and purified using ultracentrifugation and 
treatment with nucleases and proteases as described by 
Fulop et a/.21 The protein content of the LPS prepar-
ation was determined by Farbstoff- Konzenrat reagent 
(BioRad, Watford, UK) and the nucleic acid content 
was determined by addition of ethidium bromide 
and measurement of the UV -induced fluorescence as 
described by Maniatis et a/.24 
Plasmid stability and colonization 
Mice were injected intravenously through the tail vein 
with 4 x 105 c. f. u. , killed 7 or 14 days later by cervical 
dislocation, livers and spleens aseptically removed, and 
homogenised in 10 ml PBS in a Stomacher Lab-Blender 
Model 80 (Seward Medical, London) for 2 min. The 
proportion of ampicillin-resistant bacteria in the organs 
was determined by viable plate counts on L-agar ± 
ampicillin. For some experiments mice were inoculated 
with 4.5 mg ampicillin (Penbriten Injectable sus-
pension POM, SmithKiine Beecham Animal Health) 
subcutaneously for 7 days. 
Immunizations 
BALB/c female mice (6-8 weeks old) were used 
throughout this investigation. Group I received 0.1 ml 
of I mg ml - 1 F. tularensis OMPs in Freund's complete 
adjuvant subcutaneously. Mice were boosted 14 days 
later but with incomplete Freund's adjuvan t replacing 
complete. Group 2 received three 50 pi doses of I mg 
ml - 1 LPS intraperitoneally a t 7-day intervals. Group 
3 received three doses of 0.2 ml of 5 x 107 c. f.u. 
F. tularensis protective antigen: M. Fufop et al. 
S. typhimurium SL3261/pJOI intravenously at 7-day 
intervals and a daily dose of ampicillin subcutaneously 
until 3 days after the last inoculation. Grour 4 were 
inoculated with three doses of 0.2 ml of 5 x 10 c.f.u . S. 
typhimurium SL3261 intravenously at 7-day intervals. 
Control groups received PBS by the corresponding 
route. 
Challenge 
Mice were challenged with various numbers of F. 
tularensis L VS (I x I 0 1 - 2. 5 x I 06) suspended in PBS 
intraperitoneally 8 weeks after their final immunization. 
Mice were observed for 14 days and the median lethal 
dose (L050) determined by the method of Reed and 
Muench25 as described by van Rooyen and Rhodes26. 
Confidence limits (95%) were determined by probit 
analysis as described by Bliss27 and Finner8. Spleens 
from dead mice were aseptically removed, smeared 
onto BCGA supplemented with 55 llg ml - 1 ampicillin, 
and incubated at 37"C. The identity of colonies as F. 
tularensis was confirmed b~ Gram stain and using the 
polymerase chain reaction '-. 
LPS phenotype 
Smooth LPS phenotype was determined by P22 phage 
sensitivit/ 9 and examining LPS profiles on silver-
stained gels30. 
Serum analyses 
Serum from each group was tested for specificity 
against heat-killed F. tularensis LVS and F tularensis 
LPS by indirect enzyme-linked immunosorbent assay 
(ELISA) as described by Fulop et a/.21 For some 
experiments these antigens were treated with sodium 
periodate before coating the microtitre plate as de-
scribed previously31 . The titre was defined as the high-
est serum dilution at which the A414 was higher than 
the mean A414 + three-times the standard deviation of 
preimmune serum. Serum from mice immunized 
with S. typhimurium SL3261 and SL326l/pJO I was 
analysed for F tularensis FopA specificity by immuno-
blotting following SOS-PAGE of the OMPs as de-
scribed by Fulop et a/.1 1 Sera from human vaccinees 
taken six weeks after administration of F tularensis 




The protein profile of the OMP was assessed by 
SOS- PAGE followed by transfer to a PVOF membrane 
a nd staining with total colloidal gold (lane A, Figure 1 ). 
The molecular weights of the major proteins were simi-
lar to those of the sarkosyl insoluble membrane proteins 
from F. tularensis reported by Sjostedt et a/ . .1 2 A major 
protein, with an approximate apparent molecular weight 
of 43 000, corresponded to the molecular weight of 
FopA reported previously12. When inoculated into mice 
the OMP preparation induced an tibody which reacted 
with heat-killed F. 111/arensis and purified LPS in an 
Vaccine 1995 Volume 13 Number 13 1221 
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Figure 1 F. tularens1s LVS OMPs were separated by SOS-PAGE 
and transferred to an lmmobilin-P membrane. Lane A was stained 
with colloidal gold total protein stain; lanes B-D were immunoblotted 
as described in the text using the following serum as the primary 
antibody: lane B S. typhimurium SL3261/pJ01 , lane C S. typhimu-
rium SL3261, and lane D pre-immune serum 
Table 1 The circulating antibody titre resulting from the immuniz-
ation schedules described in the text was determined by indirect 
ELISA against various antigens. Periodate-treated antigens were 
shown to bind to the plate by either protein assay, or labelling with 
digoxigenin and detecting with alkaline phosphatase-labelled anti-
digoxigenin antibodies 
ELISA antigen Immunization Titre 
F. tularensis LPS F. tularensis LPS 1:3200 
F. tularensis OMP 1:6400 
S. typhimurium SL3261 < 1:50 
S. typhimurium SL3261 /pJ < 1:50 
Periodate-treated F. tutarensis LPS < 1:50 
F. tutarens1s LPS 
Periodate-treated heat F. tularensis LPS < 1:50 
killed F. tularensis 
Heat-killed F. tularensis F. tularensis LPS 1:1600 
F. tularensis OMP 1:6400 
S. typhimurium SL3261 1:6400 
S. typhimurium SL3261/pJ01 1:6400 
indirect EUSA (Table 1). The development of antibody, 
which reacted to LPS, showed that the OMP prepara-
tion also contained LPS. 
LPS characterization 
The purified LPS preparation used in this study was 
devoid of detectable nucleic acid and contained less than 
I'Yo (w/w) protein. Mice immunized with LPS developed 
circulating antibody to heat killed F. tulare11sis (Table 1) 
and purified LPS as shown by indirect EUSA. The 
se rum did not react with these antigens after they were 
treated with periodate. 
Immunization with S. typhimurium SL3261/pJOl 
We evaluated the virulence of S. typhimurium SL3261/ 
pJO I compared to S. typhimurium SL3261. After 7 days 
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Figure 2 An indirect ELl SA was performed as described in the text 
using F. tularensis LPS as the antigen. Two sets of paired serum 
from human vaccinees (a and b) were analysed 
we recovered 5.9 x I 01 c. f. u. (S. E. 2.6 x I 02) S. typhimu-
rium SL3261/pJO I from spleen tissue compared to 
2.6 x 105 c.f.u. (S.E. 1.4 x I 04) S. typhimurium SL3261. 
We were concerned that we had selected a rough LPS 
strain during the transformation process and this had 
reduced the virulence of S. typhimuriwn SL3261/pJO I. 
However, S. typhimurium SL3261/pJO I was sensitive to 
phage P22, and examination of whole cell lysates di-
gested with proteinase K by SOS- PAGE followed by 
silver staining showed a banding pattern characteristic 
of smooth LPS. By increasing the inoculating dose 
I 00-fold we restored the number of S. typhinwrium 
SL3261/pJO I recovered from spleen tissue to approxi-
mately the same level asS. typhimurium SL3261. 
The maintenance of pJO I by S. typhimurium SL3261 
in vivo was determined by counting the total number of 
S. typhimurium organisms in spleens on L-agar ± 
ampicillin. Without parenteral administration of ampi-
cillin 3% of bacteria recovered from murine tissues were 
ampicillin resistant 7 days post-inoculation. However. 
90% of the recovered bacteria were ampicillin-resistant 
when the mice were injected daily with ampicillin. Mice 
immunized with S. typhimurium SL3261/pJO I for sub-
sequent challenge received 107 c.f.u. intravenously and 
were inoculated daily with ampicillin. An interval of 8 
weeks between final immunization and challenge en-
sured that the mice had eliminated S. typhimurium33 . 
Our data also showed that S. typhimurium SL3261 ± 
pJO I had been eliminated after 56 days. 
Antibody response to F. tularensis FopA was deter-
mined by immunoblotting. OMPs were separated by 
SOS-PAGE and transferred to a PVOF membrane. The 
membrane was divided into four and probed with serum 
from mice immunized with S. typhimurium SL3261 
± pJOI and preimmune serum. No bands were visible 
using anti-S. typhimurium SL3261 or preimmune serum. 
However, anti-S. typhimurium SL3261/pJO I serum re-
acted to a protein with an approximate molecular weight 
of 43 000 (Figure 1). 
Human erum analysis 
To show that LPS is immunogenic to man when 
presented in viable bacteria, sera from two humans 
vaccinated with F. tularensis LVS were assessed for 
LPS specificity by indirect EUSA (Figure 2). In both 
Table 2 LD50 for mice challenged with F. tularensis LVS following 
various immunization schedules 
Schedule 
F. tularensis OMP 
F. tularensis LPS 















cases an antibody response was detected after a single 
inoculation with the vaccine. 
Protection studies 
Eight weeks after the final immunization, mice were 
challenged intraperitoneally with various numbers ofF 
tularensis LVS and observed for 14 days. The degree of 
protection was determined by calculating the LD50 
(Table 2). S. typhimurium SL3261 and S. typhimurium 
SL3261 /pJOI immunized mice were both significantly 
protected when compared to the control group. How-
ever, the increased protection with S. typhimuriwn 
SL3261/pJO I compared to S. typhimurium SL3261 im-
munized mice was not significant. No deaths were 
recorded with mice immunized with either F tularensis 
LPS or OMPs at the highest challenge dose (1.5 x 106 
c.f. u.). 
DISCUSSION 
The aim of this investigation was to identify the protec-
tive antigen(s) ofF tularensis. Mice immunized with a 
crude OMP preparation were protected against sub-
sequent challenge. This crude preparation was shown to 
contain several major proteins (including FopA) and 
LPS. We evaluated two major antigens in this prepar-
ation for their ability to induce protection against 
F tularensis infection. 
A major proportion of the antibody response against 
protein moieties is directed against Fop A. Bevanger 
et a/. 14 showed that antibodies against FopA were always 
present in human convalescent serum. We sought to 
determine FopA's role as the protective antigen by 
cloning into an aromatic dependent strain of S. typhimu-
rium. Previously we had shown that the cellular location 
for recombinant FopA in S. typhimurium was the outer 
membrane'~. The presentation of Fop A in the outer 
membrane of a live vector is closer to a natural infection 
than presenting the purified protein. The much less 
effective colonization of tissues by S. typhimurium SL 
3261/pJO l unless high inocula were administered sug-
gests that within these ranges of the inoculating dose, a 
fixed proportion of the bacteria can colonize the liver 
and spleen and that increasing the inoculum dose com-
pensates for the impaired colonization ability. Coulson 
et a/:'4 showed a similar effect with the parent plasmid. 
Spontaneous rough LPS mutants or S. typhimurium 
SL3261 have reduced virulence in the mouse·u. It is 
unlikely that this mechanism could have explained our 
results since a ll the bacteria were sensitive to P22 phage 
and examination of the LPS by SOS- PAGE followed by 
F. tularensis protective antigen: M. Fulop et al. 
silver staining revealed a banding profile simiJar to that 
seen with wild-type S. typhimurium SL3261 . 
We had previously shown that without antibiotic 
selective pressure pJO I was maintained by S. typhimu-
rium SL3261 in broth culture'~. However, in this in-
vestigation we have shown that in vivo the plasmid is lost 
without parenteral administration of ampicillin. Mice 
immunized with S. typhimuriwn SL326 llpJO I produced 
antibodies against FopA shown by immunoblot analysis 
indicating that this protein is expressed in vivo. Serum 
from S. typhinwrium SL3261 immunized mice did not 
react with the OMPs from F tularensis. S. typhimurium 
SL326llpJO I immunized mice showed significant pro-
tection when compared to the saline controls. However, 
mice immunized with S. typhimurium SL3261 also 
showed significant protection. The difference in protec-
tion between S. typhimuriwn SL3261 and S. typhimurium 
SL3261/pJO I was not significant. We concluded that 
FopA is not an important protective antigen. It is 
possible that FopA acts synergistically with other anti-
gens to produce an immune response to afford pro-
tection. Sjostedt et a/.7..'6 , who expressed a 17-kDa 
lipoprotein from F tularensis in S. ryphimurium, also 
found the parent strain afforded protection that was not 
significantly lower than the recombinant. These results 
can be explained by the existence of common antigen(s) 
between S. ryphimurium and F tularensis. This was 
shown by the cross-reaction of anti-S. typhimurium 
SL3261 serum to killed F rularensis by EUSA. The 
immune response to these antigens may have a limited 
role in protection. The existence of common protein 
antigens between F tularensis and other Gram-negative 
bacteria such as Yersinia pestis, Brucella spp. , and 
Haemophilus influen:ae has been reportedJ7 0 . It is also 
possible that FopA has protective epitopes that are not 
located on the cell surface and therefore these epitopes 
are hidden from the immune system when presented in 
the S. typhimurium membrane. These protective epitopes 
would presumably be hidden in F. tu/m·ensis and there-
fore not play an important role in the induction of 
immunity. 
A major proportion of the humoral response to 
F. tularensis infections is directed against carbohydrate 
moieties3. The presence of anti-LPS antibodies in mice 
immunized with OMP indicated that LPS was present in 
the crude OMP preparation. Mice immunized with 
purified LPS produced antibodies against LPS as shown 
by ELISA. Presumably the lipid A region adjuvanted 
this preparation. Treatment of heat-killed F tularensis 
LVS or LPS with periodate eliminated their ability to 
react to the serum. This showed that the anti-F. tu/m·en-
sis antibodies in this serum were against carbohydrate 
moieties. When challenged with F. tularensis these mice 
were completely protected. We concluded that the domi-
nant protective antigen in the crude OMP preparation 
was LPS. To ensure that the observed protection in LPS 
immunized mice was specific we allowed 8 weeks to 
elapse before challenge. However, F. tularensis LPS has 
been shown to be an unusual endotoxin because it does 
not induce interleukin-1 or tumour necrosis factor.J 1• We 
have shown in human vaccinees that anti-F. tularensis 
LPS antibodies develop following administration of 
F tularensis L VS. This is in agreement with results 
previously presented on the use of immunoassays for 
the diagnosis of tularemia4~ . The manufacturers of the 
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vaccine recommend that human serum is tested in an 
agglutination assal3 using a non-defined antigen to 
indicate a successful immunization . We propose 
that measurement of circulating LPS antibodies in an 
ELISA may prove to be a more reliable and meaningful 
indicator of successful vaccination. 
Fortier et a/.5 showed that antibodies from mice 
immunized with sub-lethal doses of F tularensis LVS 
passively protected nai·ve mice. Therefore the measure-
ment of the appropriate humoral response should cor-
relate with immunity. It is probable that the protective 
antibodies in that study were directed against LPS. 
However, there is evidence that cell-mediated immunity 
is also involved in the development of protective im-
munity. Leiby et a/.44 significantly reduced the LD50 of 
F tularensis L VS in mice by neutralizing gamma inter-
feron and tumour necrosis factor alpha, and Sjostedt 
et a/.7 increased murine susceptibility to F tularensis 
L VS by administration of cyclosporin A. It is possible 
that the inability ofF tularensis LPS to activate certain 
cytokines is an important defence mechanism. In a 
previous investigation we characterized monoclonal 
antibodies against F tularensis LPS21 • We intend to use 
these to determine the protective epitopes and to inves-
tigate the cell-mediated immune response induced by 
LPS. 
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The stability of plasmids pBR322, pUC19 and pBiuescript and their effect on bacterial colon-
ization of mice was determined. S. typhimurium SL 3261 carrying high copy number plasmids 
colonized spleen and liver tissues poorly compared to low copy number plasmids. After 
inoculation into mice, the stability of the plasmids appeared to be inversely related to the 
plasmid's size and complexity. Mouse-passaging a pBiuescript-based recombinant plasmid 
expressing the Protective Antigen of Bacillus anthracis selected for a mutant S. typhimurium 
strain (designated G3) that colonized at high levels and more stably maintained plasmids than 
S. typhimurium SL 3261. S. typhimurium G3 down-regulated the copy number of CoiE1 
plasmids. The significance of these data for vaccine design is discussed. 
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Introduction 
Aromatic amino acid mutants of Salmonella typhimurium, such as aroA his- S. 
typhimurium SL 3261,1 are effective vaccine strains in mice. This strain has also been 
used as a vaccine vector for the expression of various heterologous antigens.2•3 The 
effective use of S. typhimurium aroA as a vaccine vector is dependent on the bac-
terium colonizing lymphoid tissues with stable and high-level expression of the 
foreign gene. Although chromosomal integration of the foreign DNA has been 
reported,' ·5 it is more common to express the heterologous antigens from plasmid-
borne genes.2·3 To enhance the level of expression of antigens high copy number 
plasmids have been used.6 S. typhimurium SL 3261 expressing plasmid-borne genes 
colonize tissues poorly and the recombinant plasmid may be unstable.7 This has 
often been assumed to be a result of the cloned gene or gene product. However, 
different plasmid vectors may also affectS. typhimurium's ability to colonize tissues. 
In addition the ability of S. typhimurium to maintain plasmids in vivo may also be 
dependent on the type of vector. A lower level of colonization might result in a 
diminished immune response as less antigen may be available for presentation to 
•Author to whom co rrespondence should be addressed. 
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Table 1 Table showing the recovery of S. typhimurium SL 3261 , 
transformed with various plasmids, from murine spleen 7 days post-
inoculation at two doses. 
Inoculating dose Total number of bacteria 
Construct (cfu) in spleen (cfu) 
S. typhimurium 4 X 105 2.6 X 105 
SL 3261 (1.4 X 10') 
S. typhimurium 4 X 105 3.5 X 105 
SL 3261/pBR322 (1.7 X 10') 
S. typhim urium 4 X 105 5.9 X 102 
SL 3261/pBiuescript (2.6 X 102) 
S. typhim urium 4 X 105 6.7 X 102 
SL 3261/pUC19 (7.6 x 101) 
S. typhimurium 5 X 105 1.7 X 101 
SL 3261/pG3 (1 .2 X 101) 
S. typhimurium 5 X 107 2.1 x 105 
SL 3261 /pBiuescript (1 .6 X 10') 
S. typhimurium 5 X 107 5.8 X 10' 
SL 3261/pUC19 (5.4 X 103) 
S. typhimurium 5 X 105 3 X 105 
G3/pBiuescript (3 X 10') 
S. typhimurium 5 X 105 3.8 X 105 
G3/pUC19 (9.8 X 103 ) 
S. typhimurium 5 X 105 3.5 X 105 
G3/pG3 (6.5 X 10') 
The recovery of a mouse-passaged st rain (S. typhimurium G3) transformed with the 
same plasmids is also shown. 
Figures in parenthesis are the standard error. 
the immune system. To investigate this colonization phenomenon we have deter-
mined the effects of different plasmids on colonization by S. typhimurium SL 3261. 
Finally, as mouse-passaging of low-colonizing recombinant S. typhimurium strains 
had been reported to select bacteria with normal colon ization ability/ this effect was 
investigated. 
Results and discussion 
Effect of various plasmids on colonization 
Plasmid p8R322 is a frequently used cloning vector with a copy number of 15-20 per 
cell.8 Plasmid pUC19 is a smaller plasmid with a modified p8R322 origin of rep-
lication9 resulting in a copy number as high as 500-700 per cell .8 Phagemid pBiue-
script 11 KS+ is derived from pUC and contains the f1 phage intergenic region to 
allow the production of single-stranded DNA templates. S. typhimurium SL 3261 , 
transformed with these plasmids, was inoculated intravenously into mice and the 
total number of bacteria in spleen tissue determined at day 7. The results (Table 1) 
indicated that bacteria containing plasmid pBR322 colonized spleen tissue at a level 
similar to that found with S. typhimurium SL 3261 alone. Colonization efficiency was 
reduced 200-fold when plasmids pUC19 or pBiuescript were transformed into S. 
typhimurium SL 3261 . As a preliminary experiment we measured the colonization of 
murine tissue with S. typhimurium SL 3261 and S. typhimurium SL 3261/p0RF1 
(described below) at 3, 7, and 14 days post-inoculation. Colonization levels were not 
significantly different at these time intervals. This confirmed the work of O'Callaghan 
et al. 10 
Spontaneous rough mutants of S. typhimurium SL 3261 have reduced virulence 
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in the mouse.11 lt is unlikely that this mechanism could have explained our results 
since all of the bacteria were sensitive to P22 phage and examination of the LPS by 
SOS-PAGE followed by silver staining revea led a banding profile similar to that seen 
with wild-type S. typhimurium SL 3261 . 
S. typhimurium SL 3261 transformed with pUC19 or pBiuescript, was cured of its 
selectable plasmid and inocu lated into mice. The colonization of spleen tissues 
returned to the same level as S. typhimurium SL 3261. This showed that either the 
virulence plasmid was maintained or it is not important for colonization following 
parenteral inoculation. Recent data by Gulig et af12 support the latter explanation. 
S. typhimurium are phagocytosed by macrophages and survive in this environ-
ment by the production of various proteins which protect them from killing mech-
anisms. 13 lt is possible that the presence of a high copy number plasmid within S . 
typhimurium reduces its ability to adapt to the intracellular environment and resist 
host defence mechanisms. Salas-Vidal et a/.14 reduced the copy number of a pUC8-
derived plasmid in S. typhimurium SL 3261 by insertion of a rop gene. The recovery 
ofthe bacteria from murine tissues increased but the expression ofthe heterologous 
gene producet decreased. lt was suggested that the decreased copy number allowed 
increased colonization, either as a direct effect of copy number or indirectly due to 
the lower level of heterologous gene expression . 
The maintenance of plasmids after inoculation of the bacteria into mice was inves-
tigated. Plasmid pBR322 was stably maintained th roughout the experiment. Plasmid 
pUC19 showed intermediate stabi lity and pBiuescript was unstable (Table 2). The 
relationship between plasmid stability and copy number was also identified by Salas-
Vidal et a/. 14 Turner et a/.,11 using a pBR322 based plasmid, found that 80% of S. 
typhimurium recovered from murine tissues maintained the selectable plasmid. The 
level of colonization was not reported. The increased instability in our experiment of 
the pUC-based phagemid pBiuescript, compared to pUC19, is presumably related to 
the additional genetic material carried by the phagemid. Other workers have ident-
ified the instability of high copy number plasmids as a problem 15 whereas lower 
copy number plasmids have been successfully maintained. 16 
The effect on colonization of inoculating with a larger dose (102 increase) was 
investigated. The number of bacteria colonizing the spleens of mice increased in 
proportion to the increased inoculating dose (Table 1). The relative plasmid stabilities 
for S. typhimurium /pUC19 and for S. typhimurium SL 3261 I pBiuescript were 
similar to stabilities at the low dose. This result suggests that within these ranges of 
inoculating dose, a fixed proportion of the bacteria can colonize the liver and spleen 
and that increasing the inocu lum dose compensates for the impaired colonization 
ability. 
Effects of mouse-passaging a recombinant organism 
Low tissue colonization by recombinant S. typhimurium has been reported byTarkka 
et a/.7 using a pUC18 based plasmid. A mouse-passaged clone recovered from this 
experiment colonised at host strain levels but the plasmid was unstable in vivo 
without antibiotic selection. We set out to repeat this experiment with one of our 
recombinant S. typhimurium stra ins. 
S. typhimurium SL 3261 w as transformed with a pBiuescript-based phagemid 
(p0RF1) which expressed the Protective Antigen of Bacillus anthracis, and inoculated 
into mice. As preliminary experiments had shown that p0RF1 w as unstable in vivo, 
ampicil lin w as administered for 7 days. An ampicillin-resistant colony, designated 
G3, was isolated from the liver on day 14 and used for further studies. Clone G3 was 
cultured in vitro, shown to express Protective Antigen, and contain a plasmid (pG3) 
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Table 2 The percentage recovery of ampicillin resistant bacteria from 
murine spleens 7 days post-inoculation with either S. typhimurium SL 




















+ 'Ampici ll in'= mice received a daily subcutaneous dose of ampicillin. 
NO= Not determined. 
with an identical restriction profile to p0RF1 . S. typhimurium G3 I pG3 colonized 
spleens at similar levels to S. typhimurium SL 3261 (Table 1 ). 
S. typhimurium G3 I pG3 was cured of its selectable plasmid . Plasmids pUC19, 
pBiuescript 11 KS+ and pG3 were transformed into plasmid-cured S. typhimurium G3 
and plasmid pG3 was transformed into S. typhimurium SL 3261 . High colonization 
levels by S. typhimurium G3 containing pUC19 or pBiuescript were observed (Table 
1 ). S. typhimurium SL 3261 lpG3 colonized the spleen at a low level. These results 
indicated that the G3 strain was responsible for the enhanced colonisation of murine 
tissues. The stability of plasmids in S. typhimurium G3 grown in vivo was also 
enhanced (Table 2). 
As it was known that the lower copy number plasmid pBR322 did not affect 
colonization level, one mechanism for the G3 strain's altered colonization and stab-
ility might be its ability to reduce plasmid copy number. To examine this we prepared 
plasmids from standardized culture suspensions of S. typhimurium SL 3261 con-
taining p8R322, pUC19, pBiuescript and pG3, and S. typhimurium G3 containing 
pUC19, pBiuescript and pG3. The copy number of pBiuescript, pUC19 and pG3 were 
all lower in the G3 strain (Fig. 1 ). We also showed by Western blotting that the 
expression of Protective Antigen from pG3 was lower when the copy number was 
reduced. Copy number is usually regulated by the plasmid origin of replication . In 
this case some feature of the G3 strain reduced copy number. Mutations in both 
po/A17 and pcn818 have been shown to reduce the copy number of CoiE1 plasmids 
in E. coli. S. typhimurium G3 may be of use where genes have been cloned into 
pUC-based vectors and colonization and stability problems are encountered. Such 
plasmids could be transformed into the G3 strain and the same advantages as re-
cloning into a low copy number vector gained. 
We have shown the importance of selecting an appropriate plasmid vector for 
recombinant vaccines based on S. typhimurium. Enhancing virulence by animal 
passage yielded a mutant that down-regulated plasmid copy number. 
Materials and methods 
Bacterial strains and p/asmids. S. typhimurium SL 3261 is an aroA his derivative of the 
mouse virulent S. typhimurium SL 1344.1 S. typhimurium G3 is a mouse-passaged derivative 
of S. typhimurium SL 3261 (see below). Plasmids pBR322 and pUC19 were obtained from 
Boehringer Mannheim UK Ltd (Lewes, East Sussex), phagemid pBiuescript 11 KS+ was obtained 
from Stratagene Ltd (Cambridge). and p0RF1 is a pBiuescript-based phagemid expressing the 
Protective Antigen from Bacillus anthracis. 
Electroporation. Prior to use all plasmids were transformed into, and then recovered from, 
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Fig. 1. Effect of different host strains on plasmid copy number. Aliquots of standardized plasmid prep-
arations from S. typhimurium SL 3261 (lanes 1-3 and 7) and strain G3 (lanes 5, 6 and 8) were elec-
trophoresed through a 0.7% agarose gel, ethidium bromide stained, and DNA visualized under UV light. 
The plasmids present are pBR322 (lane 1), pUC19 (lanes 2 and 5), pBiuescript 11 KS+ (lanes 3 and 6) and 
the Protective Antigen-expressing plasmid pORF (lanes 7 and 8). Molecular weight markers were run in 
lane 4. 
the r m+ S. typhimurium LB 5010. Washed S. typhimurium SL 3261 cells were electroporated 
with plasmid using a Gene Pulser (Bio-Rad, Hemel Hempstead; 1.25 kV, 25{tF and 800 ohms) 
and an ampicillin-resistant colony selected. 
Bacterial culture. All S. typhimurium strains were routinely cultured in Luria (L) -broth or 
agar at 37°C. Strains carrying the amp' gene were cultured in L- broth or agar supplemented 
with 55 {tg/ml ampicillin. Bacteria for animal experiments were washed twice in phosphate 
buffered saline, and stored at - 70°C in PBS supplemented with 10% glycerol. 
To confirm strains were aroA mutants they were grown on minimal media ± aro mix (10 
pg/ml p-aminobenzoic acid, 10 pg/ml dihydroxybenzoic acid, 40 pg/ml phenylalanine, 40 ftg/ml 
tyrosine, 40 pg/ml histidine, and 40 Jlg/ml tryptophan). 
Mice. Groups of five 6-8-week-old female BALB/c mice (specific pathogen free) were used 
for all animal experiments. 
Plasmid stability and colonization. Mice were injected intravenously with 4 x 105 CFU, kil led 
by cervical dislocation after 7 days, livers and spleens aseptically removed, and homogenised 
in 10 ml PBS in a Stomacher Lab-Blender Model 80 (Seward Medical, London) for 2 min. The 
proportion of ampicillin-resistant bacteria in the organs was determined by viable plate counts 
on L-agar ± ampicillin. For some experiments mice were inoculated with 4.5 mg ampicillin 
(Penbriten Injectable suspension POM, Smithkline Beecham Animal Health) subcutaneously 
for 7 days. 
Plasmid curing. To obtain a plasmid-cured isolate the bacteria were subcultured twice in L-
broth over 24 hand replica plating used to identify colonies that were ampicillin sensitive. One 
of these colonies was shown not to contain plasmid DNA.8 
LPS phenotype. Smooth LPS phenotype was determined by P22 phage sensitivity19 and 
examining LPS profiles on silver-stained gels.20 
Mouse-passaging. S. typhimurium SL 3261 was transformed with a pBiuescript-based 
phagemid (p0RF1) which expressed the Protective Antigen of Bacillus anthracis. Mice were 
inoculated IV with 5 x 105 bacteria. As it was known that p0RF1 was unstable in vivo, ampi-
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cillin was administered for 7 days. An ampicillin resistant colony was isolated from the liver 
on day 14, designated G3, and used for further studies. 
Plasmid copy number. S. typh imurium SL 3261 containing pBR322, pUC19, pBiuescript and 
pG3 and S. typhimurium G3 containing pUC19, pBiuescript and pG3 were cultured for 18 h 
and adjusted to identical A600 readings. Plasmid DNA was prepared using Qiagen > mini < kit 
columns according to the manufacturer's instructions. To determine relative plasmid copy 
number, plasmid DNA was electrophoresed through 0.7% agarose gels, sta ined with ethidium 
bromide, and visua lised under UV light. 
Protective antigen expression. Whole cel l lysates prepared by resuspending the pellet from 
1.5 ml of culture in 100 Jll of loading buffer and boi ling for 2 min were obtained from stan-
dardized bacterial suspensions. They were separated on 8% SDS-polyacrylamide gels by 
electrophoresis and transferred onto PVDF membrane (fmmobifon-P, Millipore, Watford). The 
PVDF was blocked with 'BLOTIO' [ 1% (w/v) milk powder in PBSJ and B. anthracis Protective 
Antigen was detected with anti-Protective Antigen mouse monoclonal antibodies and horse-
radish peroxidase-labelled anti-mouse antibodies (Sigma). The bands were visualised with 
3,3'-diaminobenzidine (Bio-Rad). 
We thank Prof BAD Stocker, Stanford University, forS. typhimurium SL 3261; Prof G Dougan 
at Imperial College of Science, Technology and Medicine, London, for advice. Ms A Fearn 
assisted with laboratory work and Mr S Eley for support. 
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A RAPID, HIGHLY SENSITIVE METHOD FOR THE DETECTION OF 
FRANC/SELLA TULARENSIS IN CLINICAL SAMPLES USING 
THE POLYMERASE CHAIN REACTION 
MARK FULOP, DARIO LESLIE, AND RICHARD TITBALL 
Chemical and Biological Establishment, Porton Down, Salisbury. Wiltshire. United Kingdom 
Abstract. We have developed a highly sensitive method for detection of Francise/la tularensis in clinical samples 
based on a nested polymerase chain reaction (PCR) for the FopA gene. Mice infected with F. tularensis were killed 
at 24-hr intervals, and the DNA from blood and spleens was extracted by a variety of methods and analyzed by PCR. 
The best method, based on the ability of DNA to bind to silica in the presence of guanidine thiocyanate, yielded 
amplifiable DNA without dilution of the murine tissues samples. Francise/la tLILarensis in infected murine splee ns 
and cu lture-positive blood samples was reliably detected by nested PCR following this extraction procedure. We 
believe this technique has significant advantages over traditional methods for diagnosing F. tularensis infection in 
terms of speed, ease of use, reproducibility, and safety. 
Francisella rularensis is the causative agent of tularemia 
in humans and animals. The species is divided into two sub-
species, namely, F. tularensis subsp. tularensis (type A) and 
F. tularensis subsp. palaearctica (type B). Type A strains, 
confined to Nearctic regions, cause a more serious di sease 
with higher mortality than that caused by type B strains, 
which are of Holarctic distribution. The agent is extremely 
infectious with as few as I 0 organisms capable of causing 
disease in humans.1 
Current methods of diagnosis are unsatisfactory. The 
symptoms of tularemia are not pathognomic and the disease 
is often diagnosed as atypical pneumonia. Blood culture is 
slow (48-72 hr), prone to false-negative results, and repre-
sents a considerable safety hazard to laboratory workers.2 
Measurement of the increase in circulating antibody titer in 
convalescent serum provides important epidemiologic data, 
but is of little value in the management of the di sease. Rapid 
diagnosis of tularemia is particularly important for the se-
lection of appropriate antibiotic therapy. The organism is 
naturally resistant to penici llin , and treatment with antibiot-
ics that cannot penetrate cells, such as gentamicin, fai ls to 
eliminate the bacteria, resulting in relapses of the disease.3 
Because F. tularensis is highly in fectious by the aerosol 
route and causes a severe disease, it is recognized as an 
important biological warfare agent.• Therefore, there is a 
military requirement to rapidly identify this organism. 
The gene encoding the outer membrane protein that elicits 
the dominant antibody response, FopA, has been cloned into 
Escherichia coli and the nucleotide sequence determined.5 
We selected this gene because antibodies to FopA are always 
present in human conva lescent serum6 and, therefore, it is 
well conser ved in the Francise/la genera. We have devel -
oped a polymerase chain reaction (PCR) using primers with 
nucleotide sequences from FopA that are unique to Frcmci-
se/la. 
MATERIALS AND METHODS 
Bacterial strains a nd culture. Francise/la tularensis type 
B strains (HN63 and the Live Vaccine Strain [LVSJ) and F. 
tularensis type A strain Schu 4 were all obtained from the 
U.S. Army Medical Research Institute of Infectious Diseases 
(Fort Detrick , Frederick, MD). Francisella tularensis was 
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grown on blood cysteine glucose agar and modified cysteine 
partial hydrolysate (MCPH) broth. The organisms used for 
mouse challenge were washed three times in phosphate-buf-
fered saline (PBS), resuspended in MCPH broth supple-
mented with I 0% glycerol, and stored in 0.5-ml volumes at 
-70°C. 
Preparation of amplifiable DNA from clinical samples. 
Method I . Mouse spleens were homogenized in 10 ml of 
PBS in a Stomacher Lab-Blender Model 80 (Seward Medi-
cal, London, United Kingdom) for 2 min, the homogenate 
was diluted 1/10, and Gene Releaser (Cambio, Cambridge, 
United Kingdom) was added ~t a dilution ratio of I : I . A 
total of lO f.LI were subjected to the manufacturer's recom-
mended thermal cycle (65°C for 30 sec, 8°C for 30 sec. 65°C 
for 90 sec, 9rc for 180 sec, 8°C for 60 sec, 65°C for 180 
sec, 97°C for 60 sec, 65°C for 50 sec, 80°C for 120 sec, and 
then held at 4°C until subjected to standard PCR). 
Method 2 (based on the method of Boom and others7). 
Organs were homogenized in 2 ml of L6 buffer (8 M gua-
nidine thiocyanate in 0.1 M Tris-HCl, pH 6.4, containing 44 
mM EDTA and 2.6% (v/v) Triton X-100). A total of 100 1-1-l 
of homogenate were added to a reaction vessel containing 
900 f.LI of L6 buffer and 40 f.LI of acidified si lica diatoms 
(Janssen Chimica, Hyde, United Kingdom). The silica dia-
toms were washed twice with L2 buffer (8 M guanidine 
thiocyanate in 0. I M Tris-HCI, pH 6.4 ), twice with ethanol, 
and once with acetone. The pellets were dried at 56°C , I 00 
f.LI of distilled H20 was added, and the DNA was eluted from 
the silica at 56°C for 5 min. The reaction vessels were cen-
trifuged and the DNA was removed and tared at -70°C. 
To determine the relative sensitivity of the two methods, 
spleen and blood were spiked with various numbers of F. 
tularensis before processing and subjected to PCR. 
C hallenge. Mice (BALB/c , 6- 9-weeks old) were kept in 
cages in groups of three within a fl exible film isolator and 
allowed to feed and drink ad libitum. Mice were challenged 
intraperitoneally with 5 X 105 colony-formi ng units (CFU) 
of the LYS strain of F. tularensis suspended in PBS. At 24-
hr intervals, mice were anesthetized with halothane and 
blood was removed by cardiac puncture. Mice were imme-
diately killed by cervical dislocati on and their spleens were 
removed. Fifty microliters of blood were plated onto blood 
cysteine glucose agar. 
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Polymerase cha in reaction. The PCR was performed us-
ing a Perk.in-Eimer (Norwalk, CT) PE9600 thermocycler. 
The thermal cycle was 95°C for 3 min followed by 35 cycles 
of 95°C for 15 se, 55°C for l5 sec, and 72°C for 30 sec. A 
final elongation of 72°C for I 0 m in was followed by storage 
at 4°C until analysis. For each reaction , 20 J..d of reaction 
mixture ( 1.5 JJ.M primers, 300 JJ.M of each dNTP, 4. 125 mM 
MgCI2, and 0.75 U of Boehringer Mannheim (Lewes, United 
Kingdom) Taq polymerase in 1.5X Boehringer Mannheim 
reaction buffer) were added to 10-JJ.l DNA samples. For 
some experiments, the cosolvents dimethylsulfoxide, for-
mamide, or glycerol were added to the PCR master mixture.8 
For the first PCR, the following primer pairs were used: 
FNA8L (sequence CGAGGAGTCTCAATGTAC-
TAAGGTTTGCCC) and FNB2L (sequence CACCATTA-
TCCTGGATATTACCAGTGTCAT), with a predicted prod-
uct s ize of 900 basepairs (bp). The inner (nested pair) prim-
ers were FNA7L (sequence CTTGAGTCTIA-
TGTTTCGGCATGTGAATAG) and FNB IL (sequence 
CC A ACT AA TTGGTTGTACTGTACAGCGAAG), with a 
predicted product size of 409 bp. 
Detection of PCR products. Products were detected by 
ultraviolet (UV)-induced fluorescence following electropho-
resis through 2% agarose and staining with ethidium bro-
mide as described by Sambrook and others.9 
Specificity of primers. All primer pairs were tested 
against a panel of bacterial DNA comprising Clos1ridium 
peifringens type A strain NCTC 8237, type 8 strain NCTC 
8533, type C strain NCTC I 0719, type D strain NCTC 8346; 
C. botulinum undesignated type E strain, undesignated type 
F strain; Bacillus subtilis NCTC I 0412; B. cereus strain 
NCTC 9939; B. anthracis strain Ames; Vibrio cholera strain 
NCTC 8029, strain NCTC 10782; E. coli Kl2 strain JMIOI, 
strain 08:K87:K88ad:Hl9; Pseudomonas aeruginosa strain 
606; P. mallei strain NCTC I 0230; P. pseudomallei strain 
4845 ; Yersinia pestis strain EV76; F. wlarensis strain Schu 
4; F. novicida strain ATCC 15482, and murine DNA. The 
concentration of DNA was estimated by measurement of the 
UV-induced fluorescence following electrophoresis through 
agarose as described above. Purity of extracted DNA was 
determined from the absorbance ratio at 260 nm and 280 
nm. 
RESULTS 
Specificity of the PCR assays. We attempted to amplify 
the FopA targeted sequences from 1-ng samples of DNA 
isolated from F. tularensis LVS and HN63 and the strains 
in the bacterial DNA test panel listed in the Materials and 
Methods. The PCR products of appropriate size were de-
tected from the Francisella-derived DNA but not from any 
of the DNA isolated from the control bacteria. No detectable 
PCR product resu lted from murine DNA. 
Optimization of the PCR. The PCR was optimized for 
maximum product yield by altering the magnesium ion con-
centration and the annealing temperature in reactions using 
purified F. tularensis DNA as template. The optimal an-
nealing temperature was 55°C (range tested 45-60°C) and 
the optimal final magnesium ion concentra ti on was 4.25 mM 
(range tested 1.5-5.5 mM). 
Sen itivity of the PCR using pure culture. Using lim-
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FJGURF I. Detection of Francisella DNA in spiked murine blood 
samples by the polymerase chain reaction (PCR). Francisella mlar-
ensis in 10-fold dilutions were added to murine blood and the DNA 
was extracted according to method #2 as described in the text. The 
DNA was amplified using PCR primers FNA8L and FNB2L (lanes 
A-C, lane D is the negative control). Ten microliters of product from 
the reactions shown in lanes A-C were rearnplified and are shown 
in lanes E-G, respectively. The inner (nested) pair of primers used 
were FNA 7L and FNB I L, lane H is the negative control. The left 
lane is marker DNA. Values arc in basepairs. 
iting dilution of viable F. tularensis LVS, we determined the 
sensitivity of a standard PCR and a nested PCR. The stan-
dard PCR could detect approximately 500 CFU per reaction 
(equivalent to 5 X 10" CFU/ml) whereas the nested PCR 
detected I CFU per reaction (equivalent to I 00 CFU/ml). 
Sensitivity of the PCR with clinical samples. Blood and 
spleen homogenate were spiked with various numbers of F. 
tularensis and processed using methods I and 2 described 
above. Method l required a l 0-fold dilution to eliminate 
PCR inhibition. This resulted in a detection limit of 3 X I 03 
CFU per reaction (equivalent to a total bacterial count in the 
spleen of 3 X 1()3 CFU). Since published data10 indicated 
that the total bacterial count in tularemic spleens is frequent-
ly lower than 3 X 1()6 CFU, we sought an alternative method. 
Method 2 had a detection limit of 5 X 101 CFU per reaction 
(equivalent to 5 X I 04 CFU/spleen). Attempts to improve 
the detection limit by using cosolvents (glycerol, dimethyl-
sulfoxide, and formamide)8 were nor successful. Figure I 
shows that detection was funher enhanced by using a nested 
PCR ( I CFU/reaction, equivalent to I X 102 CFU/ml). 
Detection of F. tularensis from infected tissues. Mice 
were infected with F. tularensis LVS. At 24-hr intervals, 
three mice were killed, their spleens removed, and blood 
samples taken. The infection dose was selected to cause 
death after 3-4 days. Using method 2 followed by standard 
PCR, F. tularensis DNA could be detected in five spleens 
and three blood samples at the height of the tularemic in-
fection . However, using nested PCR, we could detect F. tu-
larensis DNA in all spleen samples and in eight of nine 
blood samples (Figure 2). The PCR-negative blood sample 
was also culture negative. 
DISCUSSION 
Diagnosis of F. tularensis infection is slow, difficult, and 
hazardous using conventional methods. We have developed 
a PCR-based method that overcomes all these problems. The 
molecular basis of F. cularensis pathogenicity is still unclear; 
however, circulating antibodies against FopA are always iso-
lated in convalescent serum,6 suggesting that it is conserved 
in all virulent strains and we selected this gene as a target. 
Primer against the FopA gene allowed single cell detection 
of F. cularensis yet showed no cross-reactions with a range 
of bacterial DNAs in PCRs, nor significant homology with 
other sequences in the nucleic acid sequence databases. 
A previous repon of a study aimed at developing a PCR 
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FIGURE 2. Detection of Francisel/a DNA from infected mice by 
the polymerase chain reaction (PCR). Nine mice were infected wi th 
Francisel/a tularensis Live Vaccine Strain, their blood was removed 
at 24-hr intervals, and subjected to PCR analysis and cullure. Lanes 
B- D = 24 hr; E- G = 48 hr; H- J = 72 hr. Lanes A and K are 
negative controls. All blood was cul ture positive for F. tularensis 
except in lane C. The lowest posi tive blood culture was one colony-
forming unit/f.LI. The left lane is marker DNA. The value on the 
right is in basepairs. 
for F. tularensis used phenol/chloroform to purify DNA 
from infected blood and thus overcome the inhibitory effect 
of hemoglobin. 11 This method requires precipitation of the 
DNA, which is usually an overnight step. We examined rap-
id methods (toLal time less than 45 min) to produce ampli-
fiable DNA. We could purify FranciseLla DNA suiLable for 
PCR using method 2. This method is inexpensive (no pro-
prietary reagents are used), and because all the extraction 
occurs in one vessel it is not prone to cross-contamination. 
We evaluated this diagnostic method by infecting mice 
and examining blood and spleen tissue at vari ous times. 
Francisella tularensis LYS is fully virulent for rn.ice. 12- 14 The 
murine model has been widely used to simulate the disease 
in humans. 10· 15 Using standard PCR, we could detect F. tu-
larensis at the height of the tularemic infection. However, 
using nested PCR, we detected F. rularensis DNA in every 
infected spleen and in eight of nine blood samples . By cul-
turing blood we showed that there were no bacteria present 
in the one PCR-negative sample. Using this method, it is 
possible to diagnose tularern.ia rapidly even in the early 
stages of infection. The development of a nested PCR sig-
nificantly increased the sensitivity from the previous report.11 
Further reductions in the time taken to complete diagnosis 
will occur as PCR technology develops. For example, ther-
mocyclers that can use capillary tubes can significantl y re-
duce the time required for this process . Also, capillary elec-
trophores is reduces the time taken to analyze PCR products. 
We intend to examine these technologies in an effort to pro-
duce a more rapid diagnostic test. 
Authors ' address: Mark Fulop. Dario Leslie, and Richard Titball , 
Chemical and Biological Establishment, Porton Down, Salisbury. 
Willshire, United Kingdom. 
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ABSTRACT 
Francisella tularensis is the etiological agent of tularemia, a serious disease in several North-
ern hemisphere countries. The organism has fastidious growth requirements and is very 
poorly understood at the genetic and molecular levels. Given the lack of data on this or-
ganism, we undertook the sample sequencing of its genome. A random library of DNA frag-
ments from a highly virulent strain (Schu 4) of F. tularensis was constructed and the nu-
cleotide sequences of 13,904 cloned fragments were determined and assembled into 353 
contigs. A total of 1.83Mb of nucleotide sequence was obtained that had a G+C content of 
33.2%. Genes located on plasmids pOMl and pNFLlO, which had been previously isolated 
from low virulence strains of F. tularensis, were absent but all of the other known F. tu-
larensis genes were represented in the assembled data. F. tularensis Schu4 was able to grow 
in the absence of aromatic amino acids and orthologues of genes which could encode en-
zymes in the shikimate pathway in other bacteria were identified in the assembled data. 
Genes that couJd encode all of the enzymes in the purine biosynthetic and most of the en-
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zymes in the purine salvage pathways were also identified. This data will be used to develop 
defined rationally attenuated mutants of F. tularensis, which could be used as replacements 
for the existing genetically undefined live vaccine strain. 
INTRODUCTION 
THE GRAM-NEGATIVE BACrERIUM Francise/la tularensis is the etiological agent of tularemia, a serious dis-ease of humans that occurs in most of the Northern hemisphere, most frequently in Scandinavia. North-
ern America, Japan, and Northern Russ ia (Berdal et al. , 1996; Ohara et al., 1996; Stewan. 1996; Tarnvik 
et al. . 1996). The bacterium is thought to be maintained in the envi ronment in animal hosts such as ground 
squiiTels, hares, voles, or other rodents (Berdal et al., 1996; Tarnvik et al., 1996). There is also evidence 
that the bacterium can persist in water courses, possibly in association with amoebae (Berdal et al., 1996). 
Tularemia in humans can occur in four forms depending on the route of entry of the bacterium into the 
body. The most common forms of the disease are ulceroglandu lar and glandu lar tularemia, which usually 
occur as a consequence of a bite from an insect vector that has previously fed on an infected animal (Ohara 
et al., 1998; Tarn vik et al., 1996). Intestinal tularemia occurs when infected foodstuffs are eaten (Stewart, 
1996) or following the ingestion of bacteria in drinking water (Tarnvik et al., 1996). The occasional cases 
of pneumonic tularemia usually arise from inhalation of dusts in hay barns, which have previously been the 
s ite of residence of infected rodents (S tewart, 1996; Tarnvik et al., 1996). The disease is fata l in approxi-
mately 10% of cases of ulceroglandular tul aremia and 80% of cases of pneumonic tularemia. 
In spite of the medical importance of F. tularensis, very little is known about the bacterium and in par-
ticular how it causes disease. The bacterium is an intracellular pathogen and is difficult to culture in vitro. 
Although previously inc luded in the Pasteurella genus, phylogenetic studies based on J6S rDNA seque nces 
have indicated that F. w/arensis together with Francise/la philomiragia are members of a separate family, 
the Francise/laceae. The family also includes Wolbachia persica (Forsman et al., 1994), a parasite o f in-
sects and worms and an endosymbiont of some ticks (Noda et al., 1997). On the basis of virulence, the 
growth requirement for cyste ine, the presence or absence of capsule, citrulline ureidase activity and the dif-
ferential ability to produce acid from D-g lucose, sucrose, and glycerol, four subspecies of F. tulare11Sis have 
been proposed; subspecies tularensis (also known as type A), subspecies ho/a~·crica (also known as type 
B), subspecies mediaasiarica, and subspecies novicida (Forsman et al. , 1994; Hollis et al., 1989; Morner et 
al., 1993; San trom et al., 1992). 
Tularemia can be prevented in individuals who are likely to come into contact with the bacterium (e.g., 
farmers, veterinarians. and hunters) by prior immunization with the live attenuated vaccine strai n (LVS) 
(Burke, 1977; Sandstrom, 1994). However, the mo lecular basis of attenuation of the LVS strain is not known 
(Sandstrom, 1994) and it has been shown that the degree of attenuation depends on the cultural conditions 
used to prepare the vaccine (Cherwonogrodzky et al., 1994). Attempts to devise improved vaccines again t 
tulare mia, based on outer membrane proteins or lipopolysaccharide, have met with limited success (Fulop et 
al.. 1995; Golovliov et a l. , 1995; Sjostedt et a l., 1992). There are no reports of the identification of genes 
that could be inacti vated to provide rationally attenuated strains. In other pathogens, a wide variety of genes 
have been shown to be targets for inacti vation and the construction of defined attenuated mutants. Of these, 
genes in the shikimate or purine biosynthesis pathways have most frequently been the subject of investiga-
tion (Dougan et al., 1988; Dougan, 1994; Hos ieth and Stacker, 198 1; McFarland and Stocker. 1987; Neuhard 
and ygaard. 1987). Enzyme within these pathway. have not previous ly been reported in F. tularensis. 
Gi, ·en the difficulty in culturing this organism, the paucity of pathogenesis data, and the need to develop 
an effective vacc ine, we initiated a geno me sequencing project with a strain of the most virule nt subspecies 
(wlorellSis). We re port here the construction of a genomic library from F. tularensis strain Schu 4 and the 
results of sample sequenc ing tudies. Thi f> work has provided new ins ights into the genetic makeup o f the 
bacterium and we have used thi data to identify genes that could be targets for inactivation to yield a ra-
tionall y attenuated li ve vaccine against tularemia to replace the current genetically undefined L VS vaccine. 
In the longer term. rationally attenuated mutants will a lso be explo itable fo r the identification of virulence 
determinants of F. tularensis using the !VET system (Mahan et al. , 1993). 
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MATERIALS AND METHODS 
General en-:.ymes and chemicals 
Unless otherwi. e stated, chemicals were obta ined from Sigma Chemical Co. (Poole, UK). enzymes for 
the manipulation of DNA were obtained from BCL Limited (Lewes, UK), and culture media were obtained 
from Oxoid Limited (Basing toke. UK). 
Growth of F. tularensis Schu 4 and isolation of DNA 
F. tularensis subspecies tularensis strain Schu 4 was originally isolated from a human case of tularemia 
(Eigelsbach et al.. I 951 ). A clonal seedstock of the bacterium has recently been shown to have a median 
lethal dose (MLD) in the murine model of disease of less than I cfu (Russel l et al., 1998). Thi seed stock 
culture was used for the preparation of DNA. The bacterium was cultured on blood glucose cysteine agar 
(BCGA; Lab Lemco 3 g· Bacteriological Peptone 20 g; sodium chloride 5 g; Davis Agar 12.5 g; water to 
1000 mL; pH to 8.0 with 10 M NaOH) supplemented with 4% cysteine, 4% histidine, and 10% filtered 
horse blood. Chamberlain's defined medium (CDM) was prepared as described (Chamberlain, 1965) ex-
cept that 0.04 gL -I spermine diphosphate was used in place of spermine phosphate, and tyrosine (0.4 gL -I) 
was omitted as required. To study growth in CDM, bacteria were grown on BCGA plates, then carefully 
removed with a sterile loop and resuspended in CDM from which tyrosine had been omitted. The cells were 
pelleted at 7000 rpm for I 0 minutes, then resuspended in the same medium. Aliquots of 0.5 mL were then 
used to inoculate duplicate flasks of CDM with or without tyrosine. The cultures were incubated at 37°C 
for 48 h with shaking, and the turbidity of the cultures at 600 nm was monitored. 
For the isolation of DNA, F. tu/arensis strain Schu 4 was cu ltured for 18 h at 37oC in 30 mL of modi-
fied casein partial hydrolysate broth (MCPH containing yeast extract, Difco Laboratories Ltd. , West Mole-
sey, UK; 6.25 g/L: casein hydrolysate 12.5 g!L; sodium chloride 6.25 g!L; K2HP04 1.4 g!L; KH2P04 3.3 
g!L; thiamine HCJ 0.001 g!L; cysteine HCL 0.1 g/L pH to 6.7 with 10 M NaOH), supplemented with 5% 
glucose. The bacteria were collected by centrifugation (3000 X g, 10 min), resuspended in 15 mLs of lysing 
solution (10 mM NaCI; 20 mM Tris HCI [pH 8.0]; I mM EDTA and 0.5% [w/v] SOS) containing pro-
teinase K (final concentration I 00 mg/mL) and incubated for 12 h at 50°C. Three mL 5 M sodium per-
chlorate was added to the cleared lysis solution followed by incubation at room temperature for I h. The 
lysate was extracted twice with an equal volume of phenol:chloroform:isoamyl alcohol (25:24: I) and DNA 
in the aqueous phase precipitated by the addition of 2 volumes of ice-cold 95% ethanol. The D A was 
spooled onto a glass rod and resuspended in TE buffer (10 mM Tris-HCL, I mM EDTA) pH 8.0. 
Construction of a random fragment library 
A random fragment library of F. tularensis strain Schu 4 DNA was constructed using previously de-
scribed methods (Fieischmann et al.. 1995). To generate blunt-ended fragments , the sonicated DNA was 
treated with DNA nuclease BAL 31 ( l U, 5 m in, 20°C; Promega Corporation, Southampton, UK). DNA 
fragments ( 1.5-2.0 kb) excised from an agarose gel were cloned into pUC 18/SmaUBAP (A mer ham Phar-
macia Biotech, St. Albans, UK). Purified vector plus in ert DNA was blunt-ended by treatment with T4 
DNA polymerase (9 U; Promega), before self- ligation. The ligated DNA was transformed into Epicurian 
Coli XL2-Blue MRF' uhracompetent cell (Stratagene Ltd, Cambridge, UK). 
Polymerase chain reaction ( PCR) amplification of DNA inserts 
To obtain DNA for nucleotide sequencing, the Escherichia coli clones were individually cultured in 50 
J.LL volumes of L-broth containing ampic illin (50 J.Lg/mL) in microtitre trays. After growth for 18 hat 3rC. 
the cell pellet wa~ resu. pended in I 0 J.LL TE buffer pH 8.0 containing 2.5 mg/mL lysozyme. incubated for 
10 min at 37°C. After boiling for 15 s, lOO J.LL ofTE buffer pH 8.0 was added. The lysate ( J J.LL) was used 
as template DNA in a PCR reaction with MI3 forward (5' GTITTCCCAGTCACGAC 3') and reverse 
primers (5' CAGGAAACAGCTATGAC 3') at final concentrations of I pM/J.LL. The PCR reaction involved 
30 cycles of 90°C I min. 55°C I min, and 72°C I min with a final extension step at 72°C for 10 min. The 
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PCR products were concentrated and desalted us ing Microcon 100 centrifugal filters (M illipore Corpora-
ti on, Bedford. USA) and finally resuspended in 20 J.Ll water. 
Nucle01ide sequencing 
Sequencing reactions were carried out using an AB! 800 Molecular Bio logy LabStation CATALYST (PE 
Applied Biosystems Ltd. Warrington, UK) with dRhodamine dye terminator sequenc ing (PE Applied Biosys-
tems Ltd). Purified PCR products were used as template DNA with the M 13 forward or reverse primers 
(final concentration 0.1 pM) The samples were ethanol precipitated and analyzed using ABI373 or 
ABI377XL nucleotide sequencing systems (PE Applied Biosystems Ltd. Warrington, UK) wi th 5% (w/v) 
polyacrylamide gels. 
Sequence analysis and assembly 
The gels were analyzed using Sequencing Analysis 3.0 software supplied by Applied Biosystems Ltd, UK. A 
first assembly of 13,904 random ABI sequence reads, was done at a statistical -5-fold genome coverage by us-
ing the PHRED/PHRAP base-caller and assembly programs (Ewing and Green, 1998; http://boze man.mbt. 
washington.edu/phrap.docslphrap.html) applying default parameters. The resulting contigs were used to create a 
local database. Initial comparisons of the F. tularensis contiguous sequences with GenBank annotated gene prod-
ucts was carried out using TBLASTN (Altschul et al., 1997). Deduced amino acid sequences were compared 
with the NCBIINR and Swiss-Prot databases using BLASTP (Altschul et al., 1997). Generally, a score of P(n.) < 
1.0 e- 15 was considered to be indicative of a sigrtificant match. Only proteins that revealed sequence similarity, 
after both submissions, were considered as a homolog. The nucleotide sequences analyzed during this work are 
available at the following WWW site: http://www.medmicro.mds.qmw.ac.uk/ftlmain.html. Ln some instances, 
contiguous sequences containing regions of interest within the F. tularensis genome were analyzed in detail with 
DNAStar software (Lasergene, Madison, WI). In these cases, the identification of the protein was also confl.llTled 
by resubrnission of the F. tularensis putative polypeptide to GenBank. Gene and encoded protein names and 
pathway analysis in E. coli, Haemophilus injluenzae, and Bacillus subtilis were performed at the Kyoto Ency-
clopedia of Genes and Genornes intemet site (www.genome.ad.jp/kegg/;Ogata et al. , 1999). 
RESULTS 
Construction of library 
Three libraries were constructed containing randomly fragmented F. tularensis strain Schu4 DNA cloned 
into plasmid pUC18 and transformed into E. coli. When randomly selected c lones were analyzed, between 
80 and 92% of the plasmids were shown to contain insert DNA. The size of these inserts was in the range 
1-2 Kb. Multiple DNA inserts were not detected in any of the plasmids. Jn total , 13,904 nucleotide se-
quences, with an average read length of 740 bp, were obtained providing a total of 10.3 Mb of nucleotide 
sequence data with 0.03% of the nucleotides unassigned. This sequence data should provide an estimated 
five-fold coverage of the F. rularensis genome. The sequences were assembled into 353 larger contigs with 
an average length of 5.2 Kb for the analyses reported be low. The total nucleotide sequence data available 
for analysis after initial assembly was 1.83 Mb with a G +C content of 33.2%. The assembled contigs were 
deposited in a public database (http://www.medmicro.md .qmw.ac.uk/ft/main.html) and analyzed using soft-
ware avai lable through the WWW. 
Confirmation of authenticity of Library 
A complete list of F. tularensis proteins whose sequences had been previously deposited wi th NCBf/Gen-
Bank is shown in Table I . The nucleotide sequence data reported here was analyzed for the pre ence of 
these genes using BLASTX. Of the 34 reported complete F. tularensis proteins, single copies of genes that 
could encode 25 of these proteins (73%) were identified at a P(n) confidence level of < I e- 15. The nine 
genes not identified are all reported to be located on e ither plasmid pOM I , which was isolated from the 
L VS strain of F. tularensis (GenBank accession AF055345), or plasmid pNFLI 0 (Pavlov et al. . 1996) 
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TAuLF. I. l oE T IFICATION oF GENES 1 F. TUI.AR£SSIS STIV\1 Scuu4 
ENCODING PKI!.VIOUSLY I DENTIFIED F. TUI.AR£.\'SIS PROTEI 'S 
Source of reported nucleotide Accession 
Gene desigmuicm ; encoded prolein sequence number 
tRNA nucleotidyltransferase F. 1ularensi.1· subspecies nol"icida Q47907 
(tRNA adenylyltransferase) 
(tRNA cca-pyrophosphorylase) 
w/4 17 kD outer membrane protein F. 111/arensis strain L VS Pl8149 
fopA; 43kD outer membrane protein F. Jularemis subspecies no1·icida AAB00857 
va/A; ABC transporter system F. wlarensis subspecies no1·icida AADI5237 
va/8; ABC transporter system F. wlarensis subspecies 1701·icida AADI5238 
Triosephosphate isomerase F. Ju/arensis strain L VS P96763 
acpA; acid phosphatase F. Jularensis subspecies no1·icida AAB06624 
Copper-zinc superoxide dismutase F. wlarensis strain LVS Q59448 
Ferredoxin F. wlarensis subspecies no1•icida AAB00856 
ftsZ; cell division protein F. Jularensis strain L VS AAC99558 
groEL; subunit of Hsp60 F. Jularensis strain L VS CAA67358 
groES; subunit of Hsp60 F. Jularensis strain L VS CAA67359 
dnaK; DNAK chaperone (Hsp 70) F. wlarensis strain L VS P48205 
dnaJ; part of the DnaK chaperone complex F. llllttrensis strain L VS P48207 
grpE; part of the DnaK chaperon complex F. Jularensis strain L VS P48204 
gyrB; DNA gyrase B F. 1ularensis subspecies holarc/ica AAC 18605 
var japonica 
lpxK; probable tetraacyldi accharide F. 111/arensis subspecies novicida Q47909 
4' -kinase (lipid A 4' -kinase) 
mg/A; macrophage growth locus protein A F. lularensis subspecies novicida AAC29032 
mg/B; macrophage growth locus protein B F. wlarensis subspecies novicida AAC29033 
cca; Cca protein F. lularensis subspecies novicida AAD15236 
23kD macrophage-induced protein F. Jularensis strain L VS CAA70085 
13kD major membrane protein F. wlarensis train LVS Pl8152 
Hypothetical protein IPI F. w/arensis subspecies ho/arclica AACI8606 
var japonica 
Hypothetical 14K protein F. 111/arensis strain L VS A37169 
Unknown protein F. IIIIMensis strain Schu4 AACI2939 
Tetracycline-resi tance proteinb F. Jularensis strain L VS AACI2938 
orj2b F. Jularensis strain L VS AACI2935 
orf3b F. tularensis strain L VS AACI2937 
repAb F. wlarensis strai n L VS AACI2936 
repAc F. 111/arensis subspecies novicida AADI7305 
ph[)C F. tularensis subspecies novicida AADI7306 
doc;C F. tularensis subspecies novicida AADI7307 
orj2c F. tularensis subspecie novicida AAD I7304 
orj2• F. tularensis ubspecies novicida AADI7308 
NF = not found. 
"Probability values as defined by Altschul et al. ( 1997 ). 
bEncoded on plasmid pOM I. 
cEncoded on plasmid pFNL I 0 (Pavlov et al.. 1996). 
BU.ST 
probabili~v 






e - 119 
0.0 






e - 142 3 






e - lls 
se- 67 
e - 133 
se- 67 










which was isolated from F. tularensis var tWI'icida. The G+ C content within the open reading frames of 
the previously sequenced genes was between 31 and 40%. The representation of G or C nucleotides in the 
first. second. and third positions of codons were 49.6, 36.0, and :W.3%. respectively. The F. wlarensis genes 
that were newly identified in this study (Table 2) also had G + C contents of 31-40% and the G or C nu-
29 
T AULE 2. l o E T I FICATION oF T A RGET GE Es FOR T H E Co STRUCTION OF i\ R ATIONAL LY ATTENUATED D ERI VATIVE OF F. TUI.AR ENSIS ST RAIN SCIIU 4 
BLAST 
E. C. Stan Stop Accession probability Origin of 
E. coli gene designation : encoded protein" number Comig Codonb Codonb number l'aluec protein sequence 
Purine biosynthesis and modificmion 
purA (b.t 177): adcnylo~uccinate syntha~e 6.3.4.4 C325 11 265 1255 1 2 14-1565 k 1115 E. mli 
purB (b 113 1 ): adenylsucci nate lyase 4.3.2.2 C250 1973 675 AE00176 le- x' Thermotoga maritima 
1111rC (b247o ): ph(l~phorihosy laminoi mitla.wlesucci no- 6.3.2.6 C343 3402 5714 P38025/Q58 I e-lo~/9e-9R Ambidopsis 
carboxoamide syntase lpurD (b4005); phosphoribo- 6.3.4.13 347 t/w/ iatw/M et hat/IICIJCCIIS 
sylamineglycine Jigased jwmaschii 
pur£ (b0523): pho~phoribo~ylaminoimidazole carboxylase 4. 1.1.2 1 C343 6410 690 1 P72157 se-~7 Pseudomonas aemgino.1a 
purF (b23 12): amidophosphoribosyltransferase 2.4.2. 14 C347 6438 4858 P00496 le-1~7 £. coli 
"" purH ' (b4006)•: phosphoribosylaminoi midazolecarboxamide 2. 1.2.3 C325 11088 10 195 CAA70450. 1 5e- x2 Bacillus cereu.\ )> 
formyltransferase 3.5.4.10 ;;o r 
purH' (b4006)•: phosphoribosylaminoimidazolecarboxamide 2. 1.2.3 C325 10098 9538 P43852 4e -~9 H. injluen:ae Vl Vl 
w formylLransferase 3.5.4.10 0 0 z 
purK (b0522): phosphoribosylaminoimidazole carboxylase 4.1.1.2 1 C343 6905 8002 P72158 2e-57 P. aerugino.w CT1 
A TPase subunit -l 
purL (b2577): phosphoribosylformylglycinamide synthase0 6.3.5.3 C347 4856 1709 P l5254 0 £. coli )> 
purL (b2577): phosphoribosylformylglycinamide synthasec 6.3.5.3 C347 1647 985 P43847 5e- CH 11. injluen:ae r-
purM (b2499): phosphoribosylformylglyci namide cycloligase 6.3.3. 1 C343 2359 3402 P l2043 3e- 7~> B. subtili.1· 
purN (b2500); phosphoribosylglyci namide formyltransferase 2. 1.2.2 C343 5718 6293 P08 179 le-34 £. coli 
purT (b 1849): phosphoribosylglycinamide fonnyltransferase2 2. 1.2.- C34 1 8387 7227 P46927 le -121 Pasteurella lwemolytica 
guaA (b2507); GMP syntahse 6.3.5.2 C299 8328 6778 P44335 Je-IHII H. influen:ae 
guaB' (b2408)1: inosi ne-59-monophosphate dehydrogenase 1. 1. 1.205 C323 > 12996 11938 P0698 1 le - 121 £. coli 
ndk (b2518): nucleoside diphosphate kinase 2.7.4.6 C3 14 4354 3932 Q59636 2e - ~2 P. aerugiun.ltt 
denD (b438~): purine nuc leoside phosphorylase 2.4.2. 1 C262 563 1285 24 15397 le- -'5 B .. wbtilis 
hpt (bO 125)1: hypoxanthine phosphoribosyltransferase 2.4.2.8 C230 > 5400 5176 3046326 4e- 15 Salmonella typhimuritllll 
apt (b0469): aden ine phosphoribosyltransferase 2.4.2.7 C324 3974 3447 BAAI8001 se- 42 Synecluw.,·sti\ Sfl. 
add (bl623)e: adenosine deaminasc 3.5.4.4 C350 17323 166!!2 S7303 1 3c- lx Mycohacteri11111 leprae 
add (b 1623)c: adenosine deaminase 3.5.4.4 C350 16614 16510 S7303 1 3e- :!x M. leprat• 
cmm (h 19!!2): atlcno~i nc monopho~phatc glyco ylase 3.2.2.4 NF NF NF NF 
gpt (b0238): .ranthi11e guani11e p/wsplwribiJ.Iyltra/1.\ferase 2.4.2.22 NF NF NF NF 
gsk (b0477); ino.l·ine-xua/losine kina.1·e 2.7.1.73 NF NF NF NF 
g1111C ChO I 04 )~: guano~inc 5' -monopho~phatc oxidoreductase 1.6.6.8 NF NF F F 
'-'> 
Chorismic acid biosynthe!>is 
amF (b260 I ): phospho-2-dehydro-3-dcoxyheptonate 
aldolase (tyro!>inc sensitive) 
amG (h0754 ): pho~pho-2-dchydro-3-deoxyhcplonalc 
aldolase (phenylalanine sensitive) 
aroH (b 1704 ): phospho-2-dehydro-3-deoxyheptonate 
aldola~e (tryp10phan ~ensi ti ve) 
aroB (b3389): 3-dehydroquinate synLhase 
omD (b 1693): 3-dehydroquinate dehydratase 
cmi£ (b328 1 ): ... hikimate-5-dehydrogenase 
aroK (b3390): shikimate kinase I 
aroL (b0388): shikimate kinase 11 
aroA (b0908): 3-phosphoshikimate 
1-carboxyvinvyltransferase 
aroC (b3239). chorisrnate syntha e 
pABA bio~ynthesis 
pabA (b3360): para-aminobenzoate symhase component 11 
pahB (b 1812). para-aminobenzoate synthase compone111 I 
JlllhC (b I 096): 4-amino-4-deoxychorismate lyase 
Folate biosymhesis 
fol P (b3177) clihydropteroate synthase 
./iJ/C (b23 15) dihydrofolate folypolyglutamate synthetase 
.MA (b0~8) dihydrofolate reductase type I 













































·'The number in parentheses repre~ents the gene designation as indicated by Blattner ( 1997). 
NF NF NF 
11015 P44303 le 110 H. influen:ae 
NF NF Nr 
5276 P07639 le- 74 £.coli 
734 P43878 l e- -'6 Aerti/IIO/Ias .ltilllllllliciclo 
1018 AAC76306 2e- '1 £. wli 
6343 Pl9080 se- 53 £. coli 
NF NF NF 
910 Pl7688 l e- 6J 
4928 Pl2008 le- 13o £. coli 
4245 CABII851 7e - 27 B. subtilis 
4800 AAD07357.1 9e-4~ Helicohacter pylori 
NF NF NF 
1205 AAC68216 le -~3 Chlamydia rrachomatis 
1792 AAC75375 le-H6 £. coli 
599 CABI4099 7e- 37 B .. wbtili.1 
hGcne location., where the location of the initiation of tran~lation codon is larger than the position of the termination codon arc cncotled on the complemcmary .,trand of 
D A. 
"Lowest score match after BLAST X search against NCBI database. probability values as delined by Altschul ( 1997). 
dNucleotide .,equences obtained in this region were reexamined for reliability. The sequences were found to be of high quality from both strands of DNA. 
"A reexamination of the DNA sequences obtained for these regions revealed that sequence information for both strands of DNA w;~s not available. Accordingly. the 
framcshift mutations 1ha1 resull in identity of the~e genes in two reading frames may not be accurate. 
'The coding region rnr the amino terminus for these loci ex tends beyond our current sequence information. 
~'An individual protein coding region for the£. coli GuaC activity was not found. However, this function may be encoded by the putative GuaB protein found in our analy-
~i~ a~ described in the ReMllt. section. 
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cleotidc in the fi rst, second, or third codon posi tion was represented at an average frequency of 50.1 , 35.0. 
and 22.9%, respectively. 
Shikimate pathway proteins 
Our major goal was to assess the genome of F. tularensis for metabolic genes that might be mutagenized 
to create li ve vaccine strains of the organism. The shikimate pathway (Fig. I ) is the common pathway for 
the biosynthesis of chorismate, which is the precursor for the generation of aromatic amino acids, para-
aminobenzoic acid (pABA), 2,3 dihydroxybenzoic acid (DHB}, ubiquinone, and menaquinone (Bentley, 
1990). Although this pathway is functional in many bacteria, some pathogens (e.g., Rickeflsia prowazekii) 
appear to lack all of the necessary genes encoding the chorismate pathway enzymes. In F. tularensis Schu 




















2-amino-4-hydroxy ~ l 
6-hydroll:ymethyl jo/P 





FIG. I. Shikimate pathway as identified in £. coli (Bentley, 1990; Blauner et al .. 1997). Chorismic acid serves as the 
starting poim for the biosynthesi~ o f aromatic amino ac ids. p -aminobe nzoic acid and folic acid. enterochelin and 
ubiquinone and menaquinone. 
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AroE. AroK, AroA, and AroC) in the shikimate pathway (Table 2). The s imilarity of the F. llllarensis pro-
teins with their counterpans in other bacteria varied. The F. tularen.1is AroC showed a high degree of Slln-
ilarity with the E. coli AroC protein (Pn = le - u 0). In contrast the F. tularensis AroE protein showed a 
much lower degree of similarity with the£. coli AroE protein. To confirm that the shikimate pathway ''a!> 
functional. the bacteria were cullured in defined medium (CDM) with and without added tyrosine. F. 111-
/arensis Schu 4 was able to grow in both media (data not shown). 
In £. coli, the first step in the biosynthetic pathway can involve one of three structurally related phos-
pho-2-dehydro-3-deoxyheptonate aldolase enzymes (AroF, AroG, or AroH) as shown in Fig. I. The ex-
pression of the encoding genes is repressible by tyrosine, phenylalanine, or tryptophan. re pectivcly (K,,·ok 
et al., 1995). The data available indicated that in F. tularensis Schu 4, only one gene was present that could 
encode a phospho-2-dehydro-3-deoxyheptonate aldolase enzyme. An analysis of the genome sequence of 
H. influen:ae and B. subtilis revealed that these bacteria also possess only one phospho-2-dehydro-3-de-
oxyheptonate aldolase enzyme. There is similarity between the deduced amino acid sequences of the E. coli 
AroF, AroG, and AroH proteins. but our analysis suggests that, like the H. influenzae protein. the F. 111-
larensis phospho-2-dehydro-3-deoxyheptonate aldolase is most closely related to E. coli AroG. Whether 
the expression of the F. tularensis aroG gene is repressed by phenylalanine is not known. There is also re-
dundancy of the shikimate kinase enzymes (AroK and AroL) in E. coli. ln F. tularensis, a single gene that 
could encode shikimate kinase was identified and a simi lar finding was made when the H. inj711enzae and 
MycobacTerium tuberculosis genomes were analyzed. The encoded protein in all of these bacteria has been 
designated as AroK. 
The attenuation of aro mutants of S. typhimurium is thought to be due to the inability of the bacterium 
to generate pABA and DHB (Hosieth and Stocker, 1981) from chorismate (Fig. I). In E. coli para-aminoben-
zoate synthase convens chorismate and glutamine to 4-amino-4-deoxychorismate (Green et al., 1992). We 
have identified genes (pabA and pabB) which could encode the two components of para-aminobenzoate 
synthase in F. tularensis. Para-aminobenzoic acid also serves as a substrate for the biosynthesis of folate. 
We have not been able to identify a homologue of the pabC gene in F. tularensis. However, an alignment 
of all of the PabC amino acid sequences within GenBank revealed a low level of sequence identity (25'7c). 
We have identified a gene in F. tularensis Schu4 that could encode the FolP protein, required for the bio yn-
thesis of 7 ,8-dihydropteroate from para-aminobenzoate and 6-hydroxymethyl-7 ,8-dihydropterin pyrophos-
phate. Genes that could encode FoiC and FolA. required for the conversion of 7,8-dihydropteroate to fo-
late, were also identified in F. tularensis Schu4. 
Purine biosynthesis pathway proteins 
We analyzed our current DNA sequences for genes that could encode enzymes involved in purine me-
tabolism (Fig 2). Our analysis revealed that the F. tularensis genome was likely to encode all protein nec-
essary for the de novo synthesis of purine nucleotides (Table 2). Potential coding sequences for all of the 
gene products that are neces ary for conver ion of 5-phosphoribo yl-a-1 -pyrophosphate to adeno ine-5 '-
monophosphate (AMP) and guanosine-5 ' -monophosphate (GMP) by E. coli (Fig. 2A) were identified. The 
lowest level of identity (4 1 %) was for the PurN ortholog, which occurred over 87% of the £. coli protein. 
The highest level of imilarity between a complete F. rularensis gene in the de novo purine . ynthesis path-
way was with GuaA. The identity of the Francisella putative protein was 59% over the entire length of the 
H. influen:ae GuaA onholog. strongly indicating a similar function. 
Our DNA sequence analysis indicates that a single open reading frame (ORF) may encode the enzymatic 
activities of the E. coli PurC and PurD proteins (Table 2). The gene designated as purCD would encode a 
polypeptide of 771 amino acids. The predicted amino-terminus of the F. tularensis PurCD contained re idues 
that were 599r identical to 78% of the Arabidopsis thaliana PurC protein, while the carboxy-terminu "a<, 
found to be 44£K identical to the entire M. jannaschii PurD homolog. The E. coli pur C and purD loci en-
code 5 ' -phosphoribosyl-4-(N-succinm:arboxamide)-5-aminoimidazole (SAICAR) synthase and S'phospho-
ribosyl-1-glycinamide (GAR) synthase, respectively (Fig. 2A). To confirm the putative function of the F. 
tularensis PurCD protein, we searched the protein profile Pfam database at hnp://pfam.wu~tl. 
edu/hmrmean:h.shtml/. The search revealed that the putative PurCD protein contained a complete SA ICAR 
:-.yn thase domain from residue 18 to 28 1 and a complete GAR synthase domain from amino acid 328 to 
33 
A phosphoribosylpyrophosphate (PRPP) lpurF 
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FIG. 2. Purine metabolic pathways as 
identified in £. coli (Neuhard and Ny-
gaard 1987: Blattner et al. , 1997) and 
identified in F. wlarensis by genomic 
sequencing and homology searches. 
Gene designations are as reported for E. 
coli loci . (A) The de novo pathway of 
purine biosynthesis. (B) The salvage 
path\\'ay for the scavenging o f pre-
formed nuc leosides. Gene designations 
sho" n in parentheses were not found or 
were not found as a single function pu-
tati,·e ORF in the case of guaC. Because 
everal genes may not be encoded by F. 
tulare11sis. some intermediates may not 
be able to be converted to the next com-
pound in the pathway. These intermedi-
mes are shown in bold print. Our cur-
rent data indicate the F. tularensis does 
not encode guanine phosphoribosyl-
tran<.,ferasc (Gpt) and therefore may not 
b<! able to scavenge xanthi ne as a pre-
cur<.,or for GMP symhesis. However. 
guanine could enter the salvage pathway 
to GMP by the action of hypoxanthine 
phosphoribosyltransfcrase (Hpt). Com-
pound abbrevia tions not defined in the 
figure : R. ribonuclco~ides: dR. deoxyri-
bonuc lcos idcs. 
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750. Thus. individual protein sequence and protein famil y s imilarities suggest that the . ing le prote in en-
coded by F. tularensis could cata lyze both reactions in the de novo synthe is of purines. 
Severa l of the ORFs that encode enzymes in the de noi'O (Fig. 2A) and salvage pathways (Fig. 28) of 
E. coli appear to have frameshifts in our current dataset (Tab le 2). These inc lude purH, purL and add. How-
ever, compared to the £. coli proteins. greater than 75% of the protein coding regions for these ORFs were 
included in our F. tularensis sequence data. Two of the ORFs. guaB and hpT. were incomplete in our cur-
rent assembly of the F. tularensis genome because the amino-terminal coding regions ex tended beyond our 
currelll sequencing data. 
Analysis of our current dataset for enzymes involved in the salvage of purine bases or nucleosides re-
vea led the potential to encode a subset of the proteins necessary to carry out these metabolic reactions 
(Fig. 28). Our analysis revealed coding potential within the F. Tularensis genome for purine nucleoside 
phosphorylase (deaD), hypoxanthine phosphoribosyltransferase (hpT). adenine phosphoribosyltransferase 
(apT), and adenosine deaminase (add) , all of which are necessary to salvage adenine, adenosine, de-
oxyadenosine, or hypoxanthine in E. coli (Fig. 28). However, with our current level of coverage, we were 
not able to identify genes in the F. tularensis genome that would encode guanosine kinase (gsk). xanthine 
guanine phosphoribosyltransferase (gpt}, or amn activities. These latter enzymes are needed for growth of 
E. coli when guanine or xanthine precursors are provided to mutants in the de novo pathway. Thus, our 
results to date suggest that the organism encodes only part of the known salvage pathway that has been 
described in E. coli. Our analysis of the ORF designated gua B also revealed a significant degree of sim-
ilarity with GMP reductase (GuaC). This ORF was originally identified using inosine monophosphate 
(IMP) dehydrogena. e from various organisms as the query against the F. TUiaremis genomic sequences. 
The greatest similarity was with the GuaB protein of E. coli (Table 2). A search using E. coli GuaC as 
the query also matched the same F. tularensis ORF previously identified as guaB. A search of the Pfam 
database with the putmive F. tularensis GuaBC-Iike protein revealed s ignificant similarity between the 
cystathione beta-synthase (CBS) domain (2.9 e - 11 , Bateman, 1997) and the IMP dehydrogenase-GM? re-
ductase (IMPDH) carboxy-terminal domain (7.7e- 125; Zhang et al. , 1999). The similarity of the F. tu-
larensis GuaBC-Iike protein with the CBS and fMPDH domains suggested that the Francisel/a protein 
was most similar to the E. coli GuaB protein. The fact that a search of our genome data also revealed ho-
mology with the same F. tularensis protein and E. coli GuaC is likely due to the fact that both E. coli pro-
teins contain IMPDH domains. These results suggest that the F. tularensis GuaBC-Iike protein may be a 
multi function protein necessary for purine biosynthesis: however, further experimentation wi ll be required 
to clarify the homology data. 
DISCUSSION 
The data reported here provide the first detailed genetic analysis of F. llllarensis. an organism for which 
even the most basic genetic map is absent. A BLAST analysis of nucleotide sequences obtained in this 
study idemified 25 of the 34 previously reported F. tularensis protein . However, the pia mid-encoded genes 
were absent in F. tularensis Schu 4. The e genes were originally identified in F. tularensis subspecie novi-
cida and in the LVS strain. Pulsed-field gel e lectrophoresis analysis of F. Tltlarensis DNA suggests that the 
genome ize i 2 Mb (A. Sjostedt, personal communication. 1990) and the total nucleotide sequence avail-
able ( 1.83 M b) should therefore have provided 92% of the nucleotide sequence of the genome. Our ge-
nomic sequencing re. ults strongly suggest that the plasmid identi fied in other low virulence tra ins of F. 
tularensis are absent in the highly virulent Schu 4 strain. Further tudies are required to demonstrate that 
extrachromosal elements are absent in F. flllarensis stra in Schu 4. However, because F. Tularensis strain 
Schu 4 i. highly virulent. plasmids pOM I and pNFL I 0 cannot contain essenti al virulence genes. 
The nucleotide sequences obtained indicate that the G+C content of the genomic D A i~ :B .2%. which 
is si milar to the G + C content (30-36%) determined using DNA- DNA hybridization studies (Ritter and 
Gerloff. 1966). Our finding that there was a distinct pattern of G and C nucleotide usage in the condons of 
previously repo rted open reading frames suggests that th is analysis might be used to identi fy new open 
reading frames in the F. flllarensis genome sequence. This approach was validated by our find ing that the 
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newly ide ntified genes in the shikimate and purine biosynthesis and salvage pathways also showed this pat-
tern of G or C nucleotide usage. 
The L VS strain of F. tularensis has been widely used to immunize. by scari licat ion, individuals who 
might come into contact with the pathogen (Burke. 1977). The origin of this train is not fully documented. 
but it is thought to originate from two virulent strai ns passaged together in cell culture. When cultured on 
agar two colony forms are visible. on ly one of which is though t to be responsible for induct ion of the pro-
tecti ve re ponse after immunization (Eigelsbach and Downs, 1961 ). Therefore, it is possib le that the L VS 
strain is a mixture of attenuated strains. In the murine model of disease, the LVS strain has been shown to 
be allenuated when given by the subcutaneous route, but to be viru lent (MLD = I cfu) when given by the 
intravenous or intraperitoneal routes (Eikins et al. , 1996). This finding suggests that the L VS strain is sus-
ceptible to the host defence mechanisms that coll ectively constitute the kin-associated lymphoid tissues. 
Bypassing this host defence mechan ism appears to allow the bacterium to coloni ze deep host tissues, such 
as the li ver and spleen, and to establish a lethal infection. Various workers have evaluated surface antigens 
of F. tularensis as components of a subunit vaccine, but a protective antigen has yet to be identified (Fu-
lop et al., 1995: Golovliov et al., 1995; Sjostedt et al. , 1992). An alternative approach to the development 
of a defined vaccine would be to construct a rationally allenuated strain. 
Our finding that F. tularensis strain Schu 4 possessed the genes that cou ld encode shikimate pathway en-
zymes, and that the bacterium was able to grow in a defined medium lacking aromatic amino acids, indi-
cates that the shikimate pathway is functional. Other potential products of this pathway include metabo-
lites, such as DHB and pABA, which are essential for bacterial growth and are not found freely in mammalian 
hosts (Stocker et al., 1983; Hosieth and Stocker, 198 1 ). Because F. rularensis was able to grow in a mini-
mal medium that lacked DHB or pABA, the bacterium must al o be able to synthesize these compounds. 
We have identified putative pabA and pabB genes in F. rularensis that appear to be eo-located. Our failure 
to identify an onhologue of the pabC gene in F. tularensis might reflect the low degree of sequence simi-
larity between other known pabC genes. We have also identified the genes that would be necessary for the 
biosynthesis of folate from pABA. In S. typhimurium DHB is the precursor for the generation of ente-
rochelin (Smith et al., 1984), an iron-chelating compound. lt is possible that F. rularensis might use this 
pathway to generate iron-chelating compounds. However, we have been unable to identify genes in F. ru-
larensis that would encode enzyme (EntA. EntB, EntC, and EntE) in the enterochelin biosynthesis path-
way (data not shown). 
In various pathogenes of man and animals, including S. typhimurium, Salmonella typhi, Shigella flexneri , 
Pasteurella mulrocida, and A. salmonicida, inactivation of genes encoding enzymes involved in the shiki-
mate pathway yields attenuated strains that can be exploited as live vaccines (Cer ini et al.. 1998; Charles 
and Dougan, 1990; Dougan, 1994; Marsden et al. , 1998; Scou et al., 1999; Stocker, 1988). Attenuation ap-
pears to be a result of the impaired abi lity of the bacterium to generate pABA and DHB. The aroA genes 
have been most frequently targeted for the construction of auenuated mutants. but the inactivation of other 
genes such as a roB (Gunel-Ozcan et al. , 1997), aroC (Dougan et al. , 1988), and a roD (Hone et al. . 199 1) 
has also been shown to result in attenuation. The mechanism of allen uation in these pathogens is not fully 
defined and in Yersinia pestis inactivation of the aroA gene did not result in reduced virulence in the mouse 
model of disease (Oyston et al., 1996). When multiple isoforms of shi kimate pathway enzymes are present 
<for example AroF/AroG/AroH and AroK/AroL in E. coli}, the encoding genes may not be ideal targets for 
the construction of attenuated mutants. The aroA. aroC, or aroD genes in F. wlarensis would appear to be 
candidate for inactivation and the construction of a rationally allenuated mutant for use as a vaccine. In 
addition, the finding that single genes, encoding phospho-2-dehydro-3-deoxyheptonate aldolase (AroG) and 
shikimate kinase (AroK), are present in F. rularensis Schu4 suggests that these encoding genes may be tar-
gets for the con. truction of auenuated mutant . 
An alternative strategy for the construction of defined allenuated mutants of F. tularensis could involve 
the mutation or genes in the purine biosynthesis pathway. Mutations that block the de 1/0VO synthesis of 
purines have been shown to auenuate several pathogenic organisms (Brubaker. 1970: Crawford et al.. 1996: 
h anovics et al. . 1968; Jackson et al., 1999: McFarland and Stocker, 1987: o·callaghan et al. , 1988). The 
po~ition in the synthetic pathway where purine synthesis is blocked has a differential influence on the level 
nf attenuation of the pathogen. Specifically, Y. pestis becomes aviru lent when the ability to convert IMP to 
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GMP is blocked (Brubaker. 1970). In contrast. the virulence of Bacillus a111hracis (lvanovics et al.. 1968) 
is not reduced by mutations that block the conversion of IMP to GMP. hut rmher is more sensiti ve to 
mutations that b lock the conversion of IMP to AMP. In the case o f virulence of Salmonella dub/in o r 
S. typhimurium. the inability to convert IMP to AMP a l o appears to be more crucial than synthes is of GMP 
from fMP (McFarland and Stocker, 1987). Mutations that block steps involved in the synthesis of IMP from 
metabolic precursors (Neuhard and Nygaard , 1987) have also been tested. Plague. anthrax. and sa lmone l-
losis all appear to be less sensiti ve to mutations that act before the production of IMP in the purine biosyn-
thetic pathway (Brubaker, 1970: McFarland and Stocker, 1987: O 'Callaghan et al.. 1988). McFarland and 
Stocker ( 1987) have speculated that this may be due to high concentrations of hypoxanthine in blood and 
the ability of the bacteria to obtain purines via the salvage pathway. However, the virulence of Brucella 
melitensis (Crawford et al. , 1996) and M. tuberculosis (Jackson et al. , 1999) is greatly attenuated by muta-
tions that act before the production of IMP. It is clear that different pathogens have different requirements 
for purine precursors that can limit their ability to cause disease. Accordingly, our use of genomic method-
ology will enhance the construction of purine auxotroph and allow a detailed analysis of the effect of these 
mutations on virulence. 
From the above information, it would be difficult to predict which mutations might result in attenuated F. 
tularensis strain that could be suitable for live vaccine development. The best attenuating mutations must 
strike a balance between reducing virulence and stimulation of a protective immune response. The choice of 
a particular auxotrophic mutation to test as a mechanism of attenuation would be expected to be influenced 
by such factors as g rowth rate, life cycle (environment), pathogenesi . and overall metabolic capabi lity of 
the organism. Thus, the evolution of the pathogen would influence how it might be t be attenuated. In fact , 
our results suggest that F. tularensis may have evolved as a genetically compact organism given the genome 
size and our observation that GuaB ' and PurCD appear to encode multifunction proteins. With the informa-
tion gained through genomic sequencing, we may now target specific points in the physiology of F. tularensis 
to construct a genetically defined li ve vaccine strain of the organism. In the longer term, these a ttenuated 
mutants could also form the basis of an lVET system (Mahan et al., 1993) for the identification of putative 
F. tularensis virulence determinants. Such a system would rely on the restoration of the virulent phenotype 
as a result of complementation of the attenuating mutation. The identification of the e virulence determinants 
cou ld also provide novel approaches to the development of vaccines against F. tularensis. 
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Yersinia pestis, the aetiological agent of plague, has in the past caused social 
devastation on a scale unmatched by other infectious diseases. There is still a 
public health problem from plague, with at least 2000 cases reported annually. 
Most of these cases are of the bubonic form. Occasionally bubonic plague 
develops into pneumonic plague, and this form of the disease can spread 
rapidly between susceptible individuals. The recent outbreak of plague in India 
highlighted the potential for plague to explosively re-appear, and modern mass 
transport systems mean that there is the potential for the rapid spread of 
disease. Against this background, there is a need to ensure that vaccines and 
antibiotics are available to prevent and treat the disease. Progress has been 
made in devising a sub-unit vaccine, effective against bubonic and pneumonic 
plague. Antibiotics must be given in the early stages of disease to effect a cure. 
The aetiological agent of plague is the Gram-negative bacterium Yersinia 
pestis. Nowadays, most cases of the disease in man are of the bubonic 
form, which arises following a bite from an infective flea which has 
previously fed on an infected rodent1• From the initial focus of infection, 
the bacterium becomes disseminated into the lymph nodes (often the 
inguinal or femoral lymph nodes) which drain the site of infection. 
These lymph nodes become swollen and tender and the classical feature 
of bubonic plague is the bubo which may reach the size of a hen's egg. 
Often the patient develops a bacteraemia with blood culture counts in 
the range < 10 to 4 x 107 cfu/mF. A second form of the disease, 
septicaemic plague, occurs when there is a bacteraemia without the 
development of buboes. This form of the disease is characterised by an 
elevated temperature, chills, headache, malaise and gastrointestinal 
disturbances 1• Due to the absence of buboes, a diagnosis of plague is 
often delayed and, even with medical intervention, 50% of patients die, 
probably as a result of the induction of the systemic inflammatory 
response syndrome2• The most feared form of plague arises when there 
is colonisation of the alveolar spaces leading to a suppurative 
pneumonia 1• Pneumonic plague results in the production of a highly 
infectious, watery, and bloody sputum which contain viable bacteria. 
Coughing results in the production of airborne droplets containing 
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bacteria, which can be inhaled by susceptible individualsu. The 
pneumonic form of the disease is feared beca use of the rapidity with 
which the disease develops ( 1-3 days), the high mortality rate in infected 
individuals (approaching l 00 %) and the rapid spread of disease from 
man to man 1• 
Incidence of disease 
Past epidemics of plague 
During the last 2000 years, Y. pestis has caused social and economic 
devastation on a scale unmatched by other infectio us diseases or by armed 
conflicts. It is generally considered that there have been three world 
pandemics of plague and credible estimates indicate that together these 
resulted in 200 million deaths2• During these pandemics, the disease 
occurred in both the bubonic and pneumonic forms. The first of these, the 
Justinian plague, occurred during the period AD 542 to AD 750. This 
pandemic is thought to have originated in Central Africa and then spread 
throughout the Mediterranean basin2• The second pandemic started on 
the Eurasian border in the mid-14th century. It is this pandemic which 
resulted in 25 million deaths in Europe and which is often referred to as 
the 'black death'2• This pandemic lasted for several centuries, culminating 
in the Great Plague of London in 1665. The third pandemic started in 
China in the mid-19th century, spread East and West, and caused 12.5 
million deaths in India alone between 1889 and 19504 • 
Current incidence of plague 
626 
World Health Organization (WHO) figures5 indicate that there is still a 
public hea lth problem from plague, especially in Africa, Asia and South 
America 5 and plague, cholera and yellow fever are the only 
internationally quarantinable infectious disease. As a class 1 notifiable 
disease, a ll suspected case must be reported to, and investigated by, 
public health authorities and confirmed cases must be reported to the 
WHO in Geneva, Switzerland6 • During the period 1967-1993, the 
average wor ldwide incidence of plague was 1,666 cases2• Although the 
incidence trend was downwards until 1981 , there has been an apparent 
increase in the incidence of disease over the last decade2·', possibly 
because of more efficient diagnosis and reporting of cases (Fig. 1). Even 
today, many cases of plague are not diagnosed and it is likely that the 
true incidence o f disease i several times the WHO figures. 
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Fig. 1 WHO figures 
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plague worldwide 
during the period 
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total number of cases 
of plague whilst the 
number of deaths due 
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The Indian outbreak of plague in 1994. Despite the high incidence of 
plague in India during the first half of this century, the number of cases 
had declined since 1950, and the last recorded case occurred in 19667• 
However, between August and October 1994 two outbreaks of suspected 
plague occurred, one of bubonic plague in the Beed District of 
Maharashtra State, and the other of pneumonic plague in the city of Surat 
in Gujarat State (Fig. 2). The Surat epidemic caused panic throughout 
India, resulting in a mass exodus of up to half a million people from the 
city, and attracted international media attention. 
At the peak of the epidemic, over 6300 suspected cases were recorded8• 
However, official figures released later indicated that only 876 pre-
sumptive cases of plague were identified (by serological testing for anti-
bodies to F1 antigen of Y. pestis) and there were 54 fatalities8 (Fig. 2). The 
cases were confined to six states in central and western India; none of the 
suspected cases in other states, such as Bihar, Punjab, Rajasthan and West 
Bengal, had positive serological markers for presumptive plague. 
During the outbreaks, one of the major problems was the failure to 
collect systematically clinical samples for analysis. Routine tests to 
confirm a diagnosis of plague were not carried out and pure isolates of Y. 
pestis were not cultured from blood, sputum or autopsy samples. As a 
result, the exact nature of the outbreaks in Maharashtra and Surat has 
provoked controversy and alternative causative agents have been 
proposed9• To address concerns, a team of experts from the WHO visited 
India in October 1994. Although the WHO team was unable to isolate Y. 
pestis from clinical samples, it established that there was clinical, 
epidemiological and serological evidence of an outbreak of plague8• 
In response to the crisis, the Indian government constituted a Technical 
Advisory Committee (TAC) on 9 October, 19949 ' to elucidate the factors 
responsible for rhe current outbreak of plague and its spread'. In clinical 
and environmental studies co-ordinated by rhe TAC, pure Y. pestis was 
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Fig. 2 Map of India 
and its States; where 
relevant, the numbers 
of presumptive cases 
of plague and 
fatalities (in brackets) 
are shown for the 
States. 
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isolated from the sputum of 11 pneumonic plague cases in Surat, and the 
tissues of 6 rodents trapped in Beed and 1 rodent trapped in Surat9. The 
biochemical, genetic and immunological similarity of the Surat and Beed 
isolates suggested that they arose from the same Y. pestis strain and, for the 
first time, provided evidence that the outbreaks were linked9• 
The TAC also conducted studies to identify the events leading up to the 
epidemics. In the Beed District of the Maharashrra State, the seeds of the 
outbreak were laid in October 1993 when the residents of Mamla village 
abandoned their homes in fear of tremors associated with a major 
earthquake in the neighboring districts of Latur and Osmanabad. Large 
quantities of grain remained in the homes, which provided a source of 
food for domestic rats leading to a population explosion and a rodenr 
epizootic of plague9• The initial source of human infection was the wild 
rodenr population located in habitats surrounding the village. During 
August 1994, a heavy flea nuisance and 'rat fall' was reported in the village 
and, shortly afterwards, the first cases of bubonic plague occurred9 • 
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The ongm of the pneumonic plague outbreak in Surat is less well 
understood. Monsoon flooding occurred in the city in the first week of 
September 1994 causing people to leave their homes. Although such 
disruptions to the local ecological balance are known to contribute to 
plague outbreaks, there is no evidence that this occurred in Surat. The 
index case locality of the pneumonic plague outbreak was traced to 
Laxminagar colony in the north of the city and, although the origin of 
the disease remains obscure, the most likely scenario is that an 
individual with pneumonic plague who travelled from the Beed district 
to Surat was the source of the epidemicl·9• 
Animal reservoirs of plague 
Y. pestis is an obligate pathogen which is unable to replicate outside of 
an animal host. In parts of the world where plague is endemic, the 
bacterium persists in 'foci' of infected rodents1•2•10• The observation that 
distinct foci of infection occur at sites throughout the world indicates 
that the bacterium can persist for long periods in some relatively 
resistant (enzootic) animal hosts and their fleas 1•2•10• For this reason it 
would be very difficult, if not impossible, to eradicate Y. pestis 
completely. The bacterium is transferred between animals by fleas and it 
is thought that the bacterium persists in the environment as the result of 
a stable rodent- flea infection cycle. Mice, voles and gerbils have all been 
suggested as enzootic hosts2• The rapid spread of disease occurs when 
epizootic hosts such as the rat, prairie dog, squirrels or mice become 
infected. In the US, prairie dogs or ground squirrels are often the rodent 
reservoir1•2 and a local increase in the number of infected animals is 
considered to be an indication of an increased risk of an outbreak of 
plague2 • In this situation the likelihood of direct infection of man is low, 
but domestic pets, which come into contact with prairie dogs, can 
become infected and then transmit the disease to man either via infective 
fleas even or via the pneumonic route. In the US, there has been an 
increase in the number of human cases of primary pneumonic plague 
especially in veterinarians, following exposure to infected cats2 . 
Changes in the incidence and pattern of disease 
Changes in the patterns o f contact with animal reservoirs 
Where man and rodents are in close proximity, or when the rodent 
population is reduced, as a result of the disease or as a consequence of 
Brit ish M edica/Bulletin 1998;54 (No. 3) 629 
Resurgent/emergent infectious diseases 
rodent control measures, humans and other warm blooded mammals 
serve as alternative hosts for the infective fleas. The increase in plague in 
Vietnam during the Vietnam war has been attributed to deforestation 
which resulted in the movement of animal hosts into areas inhabited by 
man 1• In the US, a new trend in plague epidemiology appears to be 
related to the residential encroachment on former rural areas which 
contain enzootic foci of plague2• This can lead to infection of humans as 
a result of bites by infected fleas or to infection as the result of close 
contact with domestic cats which have become infected2 • In summary, 
any change which results in man encroaching on areas of plague foci or 
which leads to the movement of infective animals hosts into populated 
areas brings with it the risk of an outbreak of plague. 
Potential for spread by mass transport systems 
630 
The spread of plague during the great epidemics can be associated with 
the movement of man or infected animal hosts along trading routes. The 
spread of plague into South Africa and into San Francisco during the 
period 1899 to 1902 is thought to have occurred as a result of the entry 
of infected rats on ships from the Far East10• The potential for the rapid 
spread of plague by mass transport systems (especially air transport) was 
also of concern during the Indian outbreak of plague. This concern is 
related especially to the pneumonic form of the disease because 
individuals with little evidence of serious disease when boarding a long-
haul flight could become infectious during the flight. The spread of 
disease by air transport was controlled by two measures. Firstly, crews 
on flights which originated from or continued through India were 
instructed to pay special attention to passengers with a fever, cough or 
chills and to notify the destination airport of such passengers 11 • In many 
countries, investigations also took place when the flight landed and 
passengers who displayed symptoms which might indicate pneumonic 
plague were placed under the surveillance of the local health 
department 11 • If there was no rise in temperature or the development of 
further symptoms in the following 7 days, the individual was considered 
to be free from plague 11 • If plague could not be excluded as a cause of 
disease, then the individual might have been placed in an isolation 
hospital. There was also concern that an infected individual might have 
transmitted the disease to other travellers. However, the air flow on 
passenger aircraft is downwards and only individuals within 2 m of the 
patient were considered to be at risk of inhaling an infectious dose of the 
bacteria 11 • The possible impact of rapid mass transport systems on the 
spread of infectious disease was amply demonstrated during the Indian 
outbreak of plague and served to heighten our awareness that suitable 
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systems and facilities for the diagnosis and surveillance of individuals 
infected with dangerous pathogens must be maintained. 
Advances in the prevention and treatment of disease 
Current vaccines 
Improved vaccines 
Two types of plague vaccine have been used in man. One of these, the 
killed whole cells vaccine was first produced in 1946 and, over the past 
decade, there have been several commercial suppliers of this type of 
vaccine6• It is generally considered that antibody against the F1 capsular 
antigen is the key protective response induced by these vaccines6• The V 
antigen is also known to induce a protective response against Y. pestis 
but the level of V antigen is low or undetectable in killed whole cells 
vaccines12• There is good epidemiological evidence that the killed whole 
cell vaccine was at least partially effective against bubonic plague. 
During the period 1961-1971, many thousands of Vietnamese civilians 
developed plague but the incidence of disease in immunised US troops 
based in Vietnam was low during this period6• Furthermore, serological 
studies indicated that some immunised individuals were exposed to Y. 
pestis and some developed sub-clinical infections6• Evidence from studies 
in a murine model of disease indicates that the vaccine is less effective 
against pneumonic than bubonic plague and cases of pneumonic plague 
have been reported in vaccinated individuals6•13• The reason for the 
lower efficacy of the vaccine against pneumonic plague is not known, 
but the rapidity with which this form of the disease develops may 
overwhelm the primed host defence mechanisms. 
Over the past few years, a wide variety of antigens from Y. pestis have 
been evaluated as potential components of a sub-unit vaccine 14• The F1 
and V antigens show the greatest potential as components of an 
improved vaccine14• Immunisation of mice with a mixture of the F1 and 
V antigens induced protection against 109 cfu of Y. pestis given by the 
subcutaneous route and also protected mire against at least 100 LD 50 
doses of Y. pestis given by the inhalation route• -. Protection appears to 
be mainly antibody-mediated. When cultured at 37°C, the bacterium 
produces large amounts of the F1 capsule which surrounds bacteria2 and 
antibody against the F1 antigen is thought to opsonise these bacteria . 
The V antigen has been shown to affect the ability of host phagocytic 
cells to produce TNFa. and IFN--y in response to infection2• Antibody 
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Antibiotic therapy 
against the V antigen would allow the host to mount a normal 
inflammatory response which would enable the host phagocytes to clear 
bacteria opsonised by antibody against Fl antigen. The Fl +V antigen 
subunit vaccine shows good promise for development as a replacement 
for the killed whole cell vaccines and this vaccine is currently being 
developed for use in man. 
A variety of antibiotics are effective against bubonic plague and 
antibiotic resistant strains have been reported infrequently2• One notable 
exception involves the recent isolation, from a case of bubonic plague in 
Madagascar, of Y. pestis which was resistant to ampicillin, chlor-
amphenicol, kanamycin, streptomycin, sulfonamide and tetracycline 16• 
Even without the complication of antibiotic resistance, the treatment of 
septicaemic and pneumonic plague is difficult; in the former case 
because diagnosis is often not made at a sufficiently early stage and in 
the latter case because the disease develops so rapidly that many patients 
are already close to death when treatment commences. Streptomycin is 
the drug of choice2 but should be used with care since the ensuing 
bacteriolysis can result in the release of large amounts of endotoxin. 
Tetracycline is often used prophylactically and chloramphenicol used to 
treat plague meningitis2• 
Key points for clinical practice 
632 
Plague is a disease which most medical practitioners will not encounter 
during their working lifetime. However, plague does occur in many 
countries throughout the world and the incidence of disease does not 
appear to be declining. The epidemic potential of the disease is well 
recognised and any suspect case of plague must be reported to the public 
health authorities and confirmed cases of plague must be reported to the 
WHO. Outbreaks of the disease can occur explosively, especially when 
natural disaster strikes an area of the world where endemic plague foci 
already exist. Rapid mass transport systems provide the means for the 
spread of disease to other countries. Pneumonic plague is especially 
feared in this context, since the disease develops rapidly and is readily 
transmissible from man to man. Vaccines might well play a role in the 
control of disease in areas of the world where the disease is endemic but 
antibiotics wi ll continue to play a key role in the control of disease in 
infected individuals arriving in the UK. Such a case of plague will 
Bri t ish Medical Bulletin 1998;54 (No. 3) 
References 
Plague 
certainly require hospita lisation in an isolation ward and measures will 
need to be taken to identify contacts who might have become infected. 
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Laboratory diagnosis of plague 
P. RUSSELJ., M. ELSON, D. WI-IITTI GTO '·M. G REEN, S. M . ELEY 
and R. \V. TITI3ALL 
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Abstract: In response to an outbreak of a plague-like disease in India, the Public 
Health Laboratory Service (PHLS) in the UK distributed adYice on the isolation 
and identification of Yersinia pestis. Some of the procedures outl ined were e,·aluated 
using a number of isolates of Y. pestis, complemented with in-house techniques 
detecting ,·irulence genes or their products. These laboratory investigations are 
limited in that they are either only indicati,·c or they take too long (48 hours or 
more), and thus represent a serious delay to the patient. Successful patient manage-
ment must be based on a case history, and therapy should be started immediately. 
Laboratory diagnosis will subsequently rule out most pathogens which cause simi-
lar infections, yet will still require confi rmation by a reference laboratory. 
Key 1/Jords: Diagnosis, laboratory. Plague. Yersiuia pestis. 
Introduction 
An outbreak of a pneumonic plague-like illness in 
Gujarat, India, in l9H caused sufficient concern for 
some countries to begin a careful scrutiny of travellers 
arriving from affected regions. Yersinia pestis, the causa-
tive organism of plague, was ne,·er isolated, 1•2 and no 
imported disease \\as detected. 
This outbreak, however, coupled with other public 
health 'scares', raised both media and professional aware-
ness to the threa t of importation of exotic diseases, 
especially as the moYement of people to and from en-
demic areas has increased with the m·ailability of cheap 
and rapid air tra\ cl. 
Human plague 
Plague is a disease of rats, transmined from animal to 
animal by a fl ea \'CCtor.3 Human disease occur. when 
conditions permit close contact between humans and 
infected rats. lt is endemic in countries with poor li ving 
and sanitation conditions, and i ~ a threat following man-
made or natu ra l disa~tcr!'. . :\nnually there arc apprm.i -
matcly 2000 cases. principall~ in south-cast Asia, fric.t 
and South America. \\ ith a fe" cases occurring in the 
southern statt:s of the USA.4 111 
Corrcspondcm:c 10. I )r 1'. Ru,,cll . 
The disease presents chiefly as bubonic plague, 
acquired from the bite of an infected flea. The bacteria 
im·ade, and multiply in, the lymph nodes draining the 
region where the bite occurred, giYing rise to swelling 
(the 'bubo') and subsequent septicaemia. If untreated, 
the di ease has a mortality of 50% . Septicaemic plague, 
likewise, will occur following a flea bite, but does not 
present with buboes. As a consequence, the ·more diffi-
cult diagnosis results in h igher mortality.11 
Pneumonic plague arises primarily as a complication of 
bubonic plague, following the haematogenous spread of Y. 
pestis to the lungs. The production of purulent sputum 
means that the disease is highly contagious by aerosol 
transmission. Primary pneumonic plague occurs after 
contact wi th an infected individual or animal: a particular 
concern in the USA is the domestic cat.9•12 The fulminant 
nature of pneumonic plague contributes to the high 
mortality rate of between 50 and IOO~o in untreated cases, 
and this remains high e\'en after antibiotic treatment. 
Rarer p resentations of plague may also occur. Plague 
meningitis usually occurs as a consequence ofim:omplete 
therapy. Cutaneous plague is a loca lised infection at the 
site oft he nca bite, givi ng rise to an eschar. Pharyngeal 
infection ma~ occur follm' ing inhalation or ingestion of 
} ·.pestis, and can gi,·e rise to asymptomatic L-arricrs who 
may act as rescrn>irs during major outbre;~ ks or can 
progress 10 septicaemic disease. En teric plague or 
symptoms associated with gastro-intestinal infection 
23 1 
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may appear in bubonic, scpl icaemic ami pncumontc 
phtguc, and if infected meat is consumed.' ' 
Yersinia pestis 
Vindenr ) ·.pestis expresses a number of vi rulence factors 
encoded on three plasmids <tnd on the chromosome, 
which contri bute to the se1·ere nature of plague. The 
absence of am· one of these 1·irulcncc factors reduces the 
ability of rhe ~>rganism to cause an infection.13 
A 70- 75 kbp plasmid is common to all pathogenic 
Ycrsinin species, and contains a number of genes encod-
ing several 1·irulence f<tctors, whose expression is 
governed by temperature and ca lcium concentration. 
Maximal expression occurs at 37 C in a calcium-free 
environment.1·H(> These virulence factors include the V 
and \V antigens, which arc produced together," and a 
series of proteins formerly known as Ycrsinia outer 
membrane proteins (Yops). This nomenclature belies 
the fact that these proteins are excreted from the 
bacteria; howc1·er, the acronym has been retained. 18 A 
110 kbp plasmid carries the gene encoding the Fraction 
I (Fl ) antigen, a glycoprotein encapsulating the bacter-
ium, which is only produced when the bacterium is 
incubated at 37· C. 11 .19 A 9.5 kbp plasmid encodes a plas-
minogen acti1·aror which has fibrinolytic and coagulase 
activities dependent on the incubation tcmpcraturc.16 
Y pestis can store haemin, which may act as an iron 
resen ·e, and is able to synthesise purines de novo, which 
are generally in short supply within the host. Pesticin is a 
bacteriocin acti1·e against some strains of other Yersinia 
species and some strains of Escherichia coli. 11 
Within a research environment, the genes and the 
respective expression of their virulence factors provide 
useful diagnostic markers to identify Y pestis. These 
techniques, hon·e,·er, require materials and faci lities 
that may not be available readily in a diagnostic labora-
tory. During the Indian outbreak, in readiness for 
imported cases of plague, the Public Health Laboratory 
Service (PllLS) provided a protocol to assist diagnosis, 
based on materials readily available to a diagnostic 
laboraror~. 211 ome of the protocol provided by Pl-:I:LS 
Table I. l rr.<J /1111 p.·.</1< Slr.~in' and hi,IOr~ 
s u,.in Source 
n·as c1·aluarcd, and 1 he obscn·ations from these rests 
and from L he d iagno~l ic techniques '" ai labk in house 
an: discussed. 
Materials and methods 
Bartcrin I stmiw 
) ·. pestis is an Ath isory Commi ttee for Dangerous 
Pathogens (:\ C OP) category 3 pathogen, thus all pro-
cedures n·crc carried our either in a Class 3 safety 
cabinet complying with BS5726, or in a rigid-wall, half-
sui t isolator, designed to similar standards. ):inc strains 
of Y. pestis, held in house or obtained from the US Arm~ 
.\ 1cdical Research Institute of Infectious Diseases 
(C AMRIID), were used in these experiments and 
their origins are summarised in Table I. 
.o\ll stra ins 11·ere maintained on the 'Protect bead' 
storage system25 (Technical Scn·iccs Consulta nts Ltd, 
Heywood, Lanes, U k ) at -80 C and were reco1·ercd 
by placing beads in blood agar base (8:\ 8)-haemin 
broth incubated at 28 C. 
Semi-solid media 
Specific media can be used to identiry· Yeninin species 
and to detect the expression of certain virulence factors. 
Congo red agar25 was used as a routine gr01rth medium 
for purity studies, ,·iable counts and assessing pigmenta-
tion. M agnesium oxalate (.\lagox) agar provided a 
calcium-free em·ironment, and 11·as useful for detecting 
the 70-75 kbp plasmid. Both 1rere prepared in-house 
(Table 2). Plates were streaked with all strains and incu-
bated at 28: C or 37 C. 
PHLS adrice recommended MacConkey agar, des-
oxycholare agar (DC.-\) and the Yersinia-sclective agar 
(Cl. ) .10 The growth characteristics of } ·. pestis ,,·ere 
assessed on .\lacConkey agar Ci\17 and DCA agar 
(Oxoid), and CL agar (Difco). Plates were incubated at 
28 C and 37 C. Escherirliia coli .\ I RE 162 and Salmo11ella 
typ/iimurilllll SL3261 were used as controls to determine 
the effi cacy of the media and for comparison of the 
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Spleen, liver and blood samples were obtained from 
autopsies on vaccinated or infected mice to simulate 
clinical material. These were smeared directly onto the 
different growth media. 
Cram and 11/ay.mn's stains 
Smears of the bacteria from broth culture or spleen 
samples were air-d ried and fixed in absolute methanol 
for 5 min. The smears were stained either with Gram 
sta in or Wayson's stain prepared according to the 
PHLS guidelines.1° For " ·ayson's stain, 0.2 g of basic 
fuchsin and 0.7 g of methylene blue were each dissolved 
in 10 mL of absolute methanol, and added to ZOO mL of 
5% phenol in de-ionised water. Smears were co,·ered in 
the stain for I min and then " ·ashed thoroughly in \Yater. 
Biochemiraltesls 
T he API 20£ identi fication kit ''"as assessed for its utility 
as a diagnostic system. Strips "·ere inoculated, incubated 
and analysed as instructed by the manufacturer. Results 
" ·ere interpreted using Api lab Plus v3.2.2 (bioMerieux 
CK Ltd, Basingstoke, Hants, UK). 
Po(J'IIIemse chain rear/ ion ( PCR) 
Single colonies were picked from agar plates, emulsified 
in 0.5- 1.0 mL sterile, de-ionised water, and boi led for 
15 min. PCR was performed using one pair of :\0-mcr 
oligonucleotide primers ro ampli fy either the } : pes/IS 
plasminogen acti,·ator gene (pag), V antigen gene (/rr / ") 
or the F l antigen gene (a!fl ). 
Simulated 'clinical' material was obtained from 
plague-infected mice used fi>r \accinc cfficac~ testing. 
Li,·er, lung, spleen anJ blood ~amples \\·ere rakcn ar 
;tutopsy. The li,·cr, lung and spleen \\·ere fincl~ cut in 
I 0 mT, ofstcrilc, de-ionised wa tcr, and lmL of rhe result-
ing homogenate boikd for 15 min. In addition, 50 11L of 
\\hole blood \\as added to I mL of sterile, de-ionised 
\\;ltcrand boi led for I) min. 
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Reactions (20 pL) consisted ofBoehringer Mannheim 
PCR buftcr containing 200 ng of each of the appropri.ue 
primers, 200 Jl l11oi /L dinucleo1ide triphosphates and 
0.5 C Boehringer :vtannhcim Thermus aquatims (Taq) 
polymerase. Positi,·e controls contained 200 pg V. pesll~~ 
EV76 template 0:\IA. :\ Perkin-Eimer PE9600 thermal 
cyclcr was used to denature samples for Zmin at 95 C, 
and perfo rm 35 cycles consisting of denaturation for 
15 s at 95 C. annealing for 15 s at 5S'·C, and extension 
for 30 s at 72 C. Extension reactions were completed by 
incubating the samples at n =c fo r 10 min. Products 
were separated by electrophoresis in 0.7% aga rose gel 
containing ethidium bromide (50 Jtg/100 mL gel), and 
analysed under ultra-,·iolct light. 
Results 
Semi-solid media 
On Congo red agar the ,·irulent strains of Y pestis grew 
either as 'bulls-eye' colonies (i. e. a pigmented central 
region " ·ith a pale red or pink or whi te margin) or as 
uniformly pigmented colonies, ranging from dark pink 
to bright red. The intensity of pigmentation increased 
with age, or follo"·ing incubation at {0 C. Single colonies 
could be seen after {8 h incubation and growth "·as opti-
mal at 26-28' (. G ro\\·th did occur at 37°C with no 
differences in pigmentation; howe,·er, with the excep-
tion of strain JAVA./9, the colonies had a 'wetter' 
appearance, and \\·ere more sticky due to the production 
of capsular F l antigen. 
The difference in gro,rth rates at different tempera-
tu res has interesting research appeal, but does not pose 
a significant problem to a diagnostic laboratory, should 
a lower-temperature incubator not be aYa ilable. 
Alternati,·cly, single colonies appeared on plates after 
48 h incubation at room temperature (20-22°C). 
The a,·irulent strain T \\. m1s pigmented, with an 
appearance imi lar to that of the Yirulent strains. 
Avi rulent strains (E\"76 and GB-White) grew as pale pink 
or white colonies that could be seen after{8 h incubation. 
Cultures isolated from autopsy material gre\\· conflu-
ently along the smear line on Congo red agar within {8 h, 
shmYing an intense pigmentation reaction. _A.,·irulent 
isolates from E\"76-,·accinated mice grew confluently, 
but were much paler (light red, pink or " ·hire). 
All the ,·irulent strains tested (GB, 1{39, 1425) gre\\· 
on \ Llgox ;tgar plates incubated at 28 C, but did nor 
gro"·· or sho\\ed reduced gro\\·th , on plates incubated at 
37 C. Strain E\"76 gtT\\ on .\ lagox agar to the same 
degree at both temperatures. 
On .\ l acConkc~ agar, after 2+-+8 h incubation, all 
strains appeared as ,·er~ <;mall t ran~luccnt colonies. The 
colonies of' irulcnt str:tins g:rc\1· larger and were dark 
purple after { H 72 h incubation , irrcspecti\"C of the 
incub:nion temperature. :hirulcnr strains appeared 
/Jr} /Jtnllll"d S11 IIJIJ7: 54 
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slightly pa ler, although the dilfercnces bet\\'ccn pigmen-
tation of \ inllcnt and arirulent strains ,,·ere less marked 
than those seen on Congo red plates. 
Autopsy isolates produced colonies after 2+ h incu-
bation \rhich ,,·ere small and tnmslucent, as described 
above, grmring larger and darker on:r a further 24-
+8 h incubation, irrespective of the incubation 
tempera tun:. 
On DC:\ , gro,,·th \\'as much slower, wi th marginal 
growth at +8 h; single colonies appeared after 72-96 h 
incubation, irrespecti\·e of temperature. On some occa-
sions, there was no grO\nh after 96 h incubation. Both 
rirulent and a\·irulent strains appeared as bright pink 
colonies. :\utopsy samples produced no growth on 
DCA. 
Y pes/is grew as dark purple colonies on Cl agar; 
small colonies appeared 2+-48 h after incubation, and 
grew larger with time. There appeared to be little dilfer-
ence benreen the pigmentation of virulent and avirulent 
strains. Qlantitatirely, the growth of Y. pestis was mark-
edly reduced on CIN agar compared to Congo red agar, 
yielding counts 7.12 ± 2.02% of those obtained on 
Congo red. This difference has implications for research 
studies, but should not present problems in terms of 
diagnosis. 
Stainillg reactions 
Y. pestis was seen as a short, Gram-negati,·e rod showing 
the characteristic bipolar staining reaction ('safety-pin' 
appearance). The organism was seen in large numbers 
in both blood and spleen smears. 
Biochemicallesls 
The API profil e of the strains was compared to the 
:\PIZOE database (Table 3). The biochemical profiles 
of the eight strains were generally similar, although 
odd differences did occur in individual tests, mainly 
in the arirulent strains. The diagnosis in all cases was 
never certain, with warnings of 'presumptive diagno-
sis', 'doubtful profil e' or ' unacceptable profile'. The 
main alternati,·e diagnoses to Y pestis \rere Enlerohac-
/a agf{lomerans, £11Jingel/a amerira na and Erminin 
spectes. 
Po/y memst' d/{/ in l'<'tntion 
The PCR results are shmm in Table 4. Problems were 
encountered \r ith the rcliabilit)' of the l'l~fl and lcrV 
primers, and in the use of clinical material. In some 
experiments the primers did not appear to work at all. 
T he results obtained with the /er V primer were inconsis-
tent, and" ith strain EV76 they contradicted the growth 
characteristics seen on 1\ lagox agar. The pag primer was 
the most consistenr, and benefi ted from being specific 
for Y pes/is . 
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Using the pag primer, there were no problems with 
PCR mixtures generated from colonies picked from 
plates. 'Clinical' samples, however, ga,·e inconsistent 
results. Positi,·e identification was made in 75% of lung 
and 50% ofli,·er homogenates, but was unsuccessful in 
blood and spleen samples. 
Table .f. PCR profiles of selected strains of 11. pestis using primns direc-
ted at fragments of plasminogen acti,·atorgcne ( pag).thc capsular Fraction 
I antigen gene (mjl ) and the V antigen gene (/rrV) 
PCR primers 
S t1~1 i n sample {>ilg cc(/1 /er / . 
GB + + + 
EV76 + + + 
1439 + + + 
l.f2:i + + + 
JA \ :\ 9 + :'\T :'\!T 
T \\. + :\T :'\!T 
I .un[:• + :\T ± 
Li"cr• ± :\T 
Sph:n' :\T 
lli<KKI~ :\T 
•Aninut, anfL<t:h.:ll \\i lh ~lrJin UU 
,T,Illllll',lnl 
Discussion 
In an~ case ,,·here plague is su~pcctetl (i.e. from the case 
histor~ ), priority must be gin~n to the successful treat-
ment anti management of the patient, and the 
protection of contacts by timel~ administrarion of 
antibiotic therapy and proph~ lax is. A case history 
should pay careful attention to recent l'isits to areas 
where plague is endemic, close contact with animals 
(particularly rodcnrs and cats) or with human cases, 
and c1·idcncc of insect bites. The absence of an cschar 
at the bite area is a useful di:1gnostic marker, distin-
guishing plague from tularemia, 11·hich can present as 
a similar disease, and occurs in similar regions within 
the CS:\ .3 Bubonic plague presents with obvious clin-
ical signs. Septicaemic plague and pneumonic plague 
are more subtle, and symptoms occur late in the 
course of the disease. The laboratory tests described 
abo1·c (except PCR) arc indica tii'C of plague, but not 
confirmatory. Other tests should be carried out to 
discount other possible pathogens which gi1·e rise to 
s imilar symptoms. Confi rmation should be sought 
from a reference laboratory. 
Rapid tests include Gram or Wayson staining of bubo 
aspirates, blood, or sputum samples, which will discern 
Gram-positive infections. The characteristic bipolar 
staining ('safety pin') of the organism gives a good indi-
cation of Y. peslis, but is not conclusi1 e.10•26 Burkholderia 
pseudoma!lei, the causative organism of melioidosis, 
gi1·es a similar reaction. Further, some forms of meli-
oidosis can mimic plague, and both diseases share 
common geographic distribution within south-east 
Asia and possibly India.' .27 Fluorescent antibody stain-
ing for the Fl antigen would facilitate diagnosis, but the 
antibody would probably only be al'ailable from a refer-
ence laboratory. 
Results from PCR of ti sue homogenates were 
obtained in 3--+ h, from taking the sample to examining 
the gel. Although highly specific, the reliability of using 
biological isolates is questionab le, and OI'Crall was 
approximately 60°o. lt should be emphasised that no 
attempts 11cre made to optimise the technique, and 
cleaning the sample to reduce interference from proteins 
and nucleic acids from the host tissue may ha1·e 
imprm·ed rcliabili~ . Bubo aspirates and sputum would 
probabl~ contain less cellular material than the homage-
nates used in this stud~ . T .ike the fluorescent Fl antigen, 
rhe primers required arc not 11 id cl~ al'ailablc, and PCR 
as a diagnostic tool is, in many cases, :-.til l being c1·aluated 
and comp:~rcd to e'\isting techniques. 
Other b:lcteriolog-tcal 1 11\Tstigat ions require isola res 
gro11 n from clinical ~am pies. 11 hich usually require -+8 h 
incubation. For a rapid , fulminant disease like plague, 
this represents a dangerous dda~ liu· the patient. 
}'. pes/IS i~ not bstidious in its gnmth requirements 
and 11ill gnm on a 11ide 1 ·aric~ of media, including 
/,a!lllmltll)' t!iag111ms o(plapJll' 23:) 
nutrient agar, albeit slo~rly. The slo~r gr0\1'1 h rate is a 
useful dia~nostic indicator, but not condusi' c. B. ps!'u-
domal!ei gnJ\1 s 11 ithin 12- 2-t h on nutrient agar, 11 hi le 
Fmncisella lufarmsis, a demanding pathogen, takes til'c 
days to gro11· on blood <:ysteine glucose agar. Pigmented 
colonies on Congo red agar are a good indicator of V. 
pcslis, but some ofthe occasional contaminants will also 
grow· as bright red colonies, although usually at a faster 
mtc. 1\lacConkcy agar or DCA 11ill support the growth 
of V pestis, but the lactose reaction should be ignored. 
The accumulation of indicator by the organism, suggest-
ing that it ferments lactose, is a falsc-positi1·e result. 
Growth on Cli\' agar is also a useful diagnostic sign, as 
other Yersiniae rarely cause severe systemic or pulmonary 
disease. Problems arise when plague presents unusually 
with predominant gastro-intestinal symptoms.12 
Isolation of bacteria from blood indicates a poor prog-
nosis as septicaemia appears to be a terminal event in 
experimental infections of mice and in human disease. 
Plague is characterised by the huge numbers of bacteria 
that can be isolated from tissues. Bacterial counts can 
exceed IQS colony-forming units (cfu) per millilitre of 
blood or gram of tissue, hence the confluent growth 
from the organ smears.28 
Biochemically, with the exception of virulence factors 
such as Fl antigen and the low calcium rcspon e, there 
arc no distincti,·e biochemical tests for Y. peslis. 
However, certain reactions will eliminate other possible 
pathogens . .'\case history can help discriminate Y. pes/is 
from the other pos ible pathogens identified by the API 
kit, although identification was neYer certain. If bacteria 
gro~rn on plates are to be examined using fluorescent 
antibody staining of the Fl antigen, then the cultures 
must be incubated at 3JCC to ensure that F l antigen is 
expressed. PCR of single colonies picked from plates 
wa more reliable than PCR of homogenates, particu-
larly 1\ith the pag primer. 
In summary, if plague is suspected from the case 
history, the priori~, must be to treat the patient. 
Laboratory test rake too long and arc only indicati1·e at 
best. Confirmatory tests hould be a1·ailablc from refer-
ence laboratories, particularly in response 10 an outbreak 
such as that in 199-t. Research laboratories ~rhich handle 
Y. pes/is regular!~ can also pro1·ide assi. tance. 
The .unhors 110uld hkc to thank i\ l r C'..olin Cr:tpp and .\lrs .\brgJrct 
.\1orle~ for their tcchnie1l as~ist:tncc in preparing the media u~ed in 
the,c C\pcrimcnt,. 
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Doxycycline or ciproftoxacin prophylaxis and therapy against experimental 
Yersinia pestis infection in mice 
P. Russell, S. M. Eley, D. L. Bell, R. J. Manchee and R. W. Titball 
CBDE Porton Down, Salisbury , Wiltshire SP4 OJQ, UK 
The efficacy of doxycycline and ciprofioxacin against an experimental plague 
infection was assessed by comparing the median lethal dose (MLD) of Yersinia pestis 
in antibiotic-treated and untreated mice. The MLD of Y. pestis GB strain in 
untreated mice by the intra-peritoneal route was 23 cfu. If ciprofioxacin dosage (20 
or 40 mgjkg twice daily) was initiated 48 h before infection, it afforded complete 
protection against an intra-peritoneal challenge of 5.24 x 107 cfu. Ciprofioxacin 
therapy initiated 24 h post-challenge was less protective, the MLD was raised to 
2.0 x 105 and 2.2 x 105 cfu for 40 and 20 mg/kg respectively. Doxycycline dosage 
(40 mgjkg twice daily) initiated 48 h prior to infection raised the MLD to 
1.6 x I Q4 cfu, but other prophylactic and therapeutic regimes were ineffective against 
challenges greater than 6.76 x 102 cfu. Ciprofioxacin may therefore be a useful 
antibiotic to consider for the treatment of plague. 
Introduction 
Since 1948 streptomycin has been the antibiotic of choice for the treatment of 
pneumonic and bubonic plague. The recommended regime is 30 mgfkg body weight 
given intramuscularly in two divided doses per day over 10 days (Butler, 1983). The 
treatment may be complemented with tetracycline, especially if patients are at particular 
risk from the toxic effects of a long course of streptomycin (McCrumb et al. , 1953). The 
severity of plague, however, outweighs the risks of the side-effects of the antibiotic. In 
addition to its toxicity, the major disadvantage of streptomycin is that it can only be 
administered intramuscularly. 
Effective alternatives include tetracycline given orally at a dose of 2-4 g per day 
divided into four doses for 10 days or chloramphenicol, administered intravenously with 
an initial loading dose of 25 mg/kg followed by a 10 day course of 4 g per day in four 
1 g doses. The latter regime is recommended for plague meningitis (Butler, 1979). 
Antibiotics should be given prophylactically to household contacts of patients and 
others who may have been in close contact with a patient (i.e. hunting partners, work 
colleagues, attending medical staff if isolation facilities are unavailable). A 7 day course 
of oral tetracycline, 15 mgjkg per day, or an orally administered sulphonamide, 
40 mg/ kg per day are the regimes advocated for this purpose (Lambert & O'Grady, 
1992). 
The relatively low incidence of plague, particularly in the developed world, and the 
absence of any streptomycin resistance strains of clinical importance has led to a 
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complacent view of the therapy a nd prophylaxis o f plague, hence the lack of change 
since 1948. Plague, however. can suddenly appear. often with devastating consequences. 
Furthermore, the widespread misuse of antibiotics, particularly in endemic regions such 
as South-east Asia, suggests tha t resistance will eventually emerge. 
Butler et al. ( 1976) compared the efficacy of trimethoprim-sulphamethoxazole with 
streptomycin in treating plague patients. and found that although all the patients 
survived , long duration of fever and occurrence of complications were less frequent in 
patients receiving streptomycin. The efficacy of a wider range of antibiotics including 
the "newer" antibiotics such as fluoroquinolones and third generation cephalosporins 
in preventing and trea ting plague infection in animal models has also been investigated 
(Shcherbanyuk et al., 1992; Bonacorsi et al., 1994). 
In the present study the efficacies of doxycycline and ciprofloxacin were evaluated. 
Doxycycline is regarded as the least toxic of the tetracyclines with a long serum half-life 
("' 18 h) which reduces the frequency of administration (Lambert & O'Grady, 1992). 
It has been widely used and is well characterised with regard to long periods of 
administration, as a prophylactic antibiotic and for treating atypical pneumonias. 
Ciprofloxacin is a potent fluoroquinolone which is increasingly being used in clinical 
practice. It has proven effective against other Yersinia species (Hoogkamp-Korstanje, 
1987) and like doxycycline is generally administered once or twice-daily. As both 
antibiotics can be taken orally, they are suitable candidates for prophylactic use as well 
as therapeutic use. 
Materials and methods 
Bacterial strain , storage and culture 
Y. pestis strain GB was used as the challenge stra in. The virulence of the strain was 
confirmed in vitro by determining growth characteristics and detecting virulence 
markers by the polymerase chain reaction (PCR), and in vivo by animal passage. The 
bacteria were stored at - 80°C on a "Protect" bead storage system described previously 
(Russell et al., 1995). 
All challenge cultures were grown in Blood-agar base (BAB) broth, and counts and 
organ isolates grown on Congo red or BAB-haemin agar as previously described 
(Russell et al., 1995). 
Antibiotic preparation 
Solutions of doxycycline (Sigma) were prepared by dissolving the powder in phospha te 
buffered saline. Ciprofloxacin solutions were prepared by dissolving Ciproxin (Bayer) 
tablets in sterile de-ionised water and then filtering the solution. The concentration of 
ciprofloxacin in this solution was measured using a disc diffusion assay. 40 J.ll aliquots 
of a series of dilutions of the ciprofloxacin solution were placed in wells cut from 
lso-sensitest agar covered with lawn cultures of Bacillus subtilis var. niger. The plates 
were incubated for 24 h at 3rC and the zones of inhibition of growth were measured 
and compared to zones of inhibitions measured from a dilution series of a solution of 
pure ciprofloxacin powder kindly supplied by Bayer, UK. The similarity in the diameter 
of the inhibition zones confirmed that the available ciprofloxacin from the tablets was 
as expected. 
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Table I. Efficacy of ciprofloxacin prophylaxis/ therapy administered subcutaneously against an 
intra-peritoneal challenge with virulent Y. pestis . All experiments carried out in Porton-out-
bred mice 
Challenge dose Mortality (death/group) given indicated antibiotic regime 
(multiple MLD) a b c d e f 
2.28 X 106 0/5 0/5 5/5 5/5 nt nt 
2.28 x 105 0/5 0/5 3/5 4/5 nt nt 
2.28 X 104 0/5 0/5 5/5 4/5 nt nt 
2.28 X 103 0/5 0/5 1/5 1/5 nt nt 
2.28 X 102 0/5 0/5 0/5 0/5 5/5 nt 
2.28 X 101 0/5 0/5 0/5 0/5 5/5 nt 
0 nt nt nt nt nt 015 
a, 40 mgfkg ciproftoxcin bd 48 h prophylaxis + 5 days post-challenge; b. 20 mg/kg ciproftoxacin given as 
a above; c, 40 mg/kg ciproftoxacin bd 24 h post-challenge therapy + 5 days; d. 20 mg/kg ciproftoxacin given 
as in c above; e, untreated controls; f, ciproftoxacin toxicity assessment: 40 mg/kg bd for 7 days. nt, Not tested. 
Animal strain 
Porton outbred mice, obtained in-house, were maintained in cages within a rigid wall 
isolator. They were subjected to a 12 h light-dark cycle and were allowed to feed and 
drink ad libitum. Previous studies (Russell et al., 1995) have shown that this strain of 
mice is susceptible to Y. pestis infection, and the median lethal dose (MLD) of Y. pestis 
given intra-peritoneally was 23 cfu as calculated by the method of Reed & Muench 
(1938). 
Antibiotic administration 
Eight groups of mice each containing 25- 35 mice, were kept in cages of five. Antibiotics 
were given sub-cutaneously in 0.1 mL aliquots twice daily according to the regimes 
described in Tables I and 11. 
Table Il. Efficacy of doxycycline prophylaxis/ therapy administered subcutaneously against an 
intra-peritoneal challenge with virulent Y. pestis. All experiments carried out in Porton-out-bred 
mice 
Challenge dose Mortality (death/group) given indicated antibiotic regime 
(multiple MLD) a b c d e f 
2.94 X 105 5/5 5/5 5 5 5/5 nt nt 
2.94 X 104 1/5 5/5 5 5 5/5 nt nt 
2.94 X 103 4/5 5/5 415 5/5 nt nt 
2.94 X 102 3/5 4/5 5/5 5/5 nt nt 
2.94 X 101 2/5 5/5 4 5 5/5 5/5 nt 
0 nt nt nt nt nt 0 5 
a, 40 mg/kg doxycycline bd 48 h prophylaxis + 4 days post-challenge; b. 20 mg/kg doxycycline given as in 
a above; c, 40 mg/kg doxycycline bd 24 h post-challenge therapy + 4 days; d, 20 mg/kg doxycycline given as 
in c above; e, untreated controls; f, doxycycline toxicity assessment: 40 mg/kg bd for 7 days. nt, Not tested. 
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Animal challenge 
Twenty-four hours prior to challenge, BAB broth was inoculated with three or four 
beads charged with Y. pesris from the "'Protect" vials and incubated overnight at 28°C. 
Six to seven hours prior to challenge, 9 mL of fresh broth was inoculated with I mL 
of overnight culture and incubated at 28°C. This subculture was serially diluted and 
0.25 mL aliquots of the higher dilutions plated out on to Congo Red or BAB-Haemin 
agar for colony counting. 
The animals were challenged with 0.1 mL of the serial dilutions of the subculture by 
the intra-peritoneal route. Each sub-group of five mice in each group received a different 
dilution of the subculture. The mice were observed for 20 days after challenge (14 days 
after the last antibiotic administration). Mortality due to Y. pesris was confirmed by 
organ and blood smears on Congo red agar, and organs were also smeared from 
survivors to assess whether or not clearance of the bacteria from the animal had been 
achieved. 
The MLD was measured and the degree of protection calculated by comparing the 
ratio of the MLD following prophylaxis/ treatment to the MLD without 
prophylaxisftrea tment. 
In addition to the groups described above, two groups of five animals not given either 
antibiotic, were challenged to ensure that the Y. pesris had retained its virulence, and 
two unchallenged groups of five mice received either 40 mgfkg ciprofloxacin or 40mgjkg 
doxycycline twice daily for 7 days to determine any toxic effects from the antibiotics. 
Results 
The groups of mice given ciprofloxacin prophylactica lly or therapeutically were exposed 
to log dilutions of Y. pestis ranging from 5.24 x 107 to 5.24 x 10' cfu (Table I) . The 
doxycycline treated groups of mice were exposed to a range of log dilutions from 
6.76 x 106 to 6.76 x 102 cfu (Table II). 
Ciprofloxacin prophylaxis (both doses) afforded complete protection to the mice up 
to the maximum challenge. Therapy was less successful, although the MLD in the mice 
was increased to 2.0 x 105 cfu (8826 x MLD of untreated mice) and 2.2 x 105 cfu 
(9565 x MLD of untreated mice) for 40 and 20 mg/kg respectively. 
The mean times to death of the fata lities in groups of mice given ciprofloxacin 
post-exposure were 51.0 ± 8.21 h for those receiving 40 mgfkg and 54.0 ± 7.77 h for 
those receiving 20 mg/kg. All deaths in both groups occurred either prior to the start 
of therapy or during the time that ciprofloxacin was administered . 
Prophylactic use of doxycycline at 40 mg/ kg increased the MLD to 1.6 x 104 cfu 
(686 x MLD of untreated mice). The prophylactic use of doxycycline at 20 mg/kg and 
the two therapeutic regimes were ineffective at challenges greater than 6. 76 x I 02 cfu 
(29.4 x MLD of untreated mice). 
The mean time to death of the fatalities in the 40 mgfkg doxycycline prophylaxis 
group was 171.8 ± 22.42 h, with 78.6% of the deaths occurring after the antibiotic was 
withdrawn. In the other groups, mean times to death were 74.2 ± 10.39, 62.9 ± 11.10 
and 49.6 ± 4.87 h for 20 mgfkg prophylaxis, 40 mgfkg therapy and 20 mgfkg therapy 
respectively. In each group the majority of deaths occurred during the administration 
period (83.3%, 91 .3% and 96% respectively) . The mean times to death of untreated 
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mice challenged with 5.24 x 103 and 524cfu were 80.8 ± 17.35 and 72.2 ± 9.11 h 
respectively. 
The organs and blood removed from survivors at autopsy were all sterile, irrespective 
of antibiotic and dose regime. Generally, spleens were enlarged, and occasionally, there 
was hepatomegaly. These changes occurred in mice treated with both antibiotics and 
were not related to the size of the challenge or the antibiotic dose. 
Discussion 
Intra-peritoneal injection of virulent Y . pestis results in a widely disseminated , and 
rapidly fatal infection in mice. Although not a ''natural" route of infection, this model 
probably represents a most severe infection, implying that success with an antibiotic 
under these experimental conditions could indicate potential success in the clinical 
environment. 
Ciproftoxacin proved to be effective when used prophylactically. The absence of 
relapse following antibiotic withdrawal and the sterility of organs and blood of 
survivors showed that ciproftoxacin can clear the host of Y. pestis. 
The lower success rate of therapy indicated that 24 h was too long a delay in initiating 
treatment, and the first doses of ciprofloxacin were ineffective in halting the established 
infection in the mice given a high challenge of Y. pestis. This is certainly true in clinical 
practice where delays in differential diagnosis of septicaemic plague (thus delays in 
initiating treatment regimes) are cited as the cause for the high mortality of this form 
of the disease (Butler, 1995). Generally, however, the longer incubation period of the 
various manifestations of plague in man (2-5 days) would mean a longer period for the 
establishment of generalised infection, and more time to initiate therapy (with or 
without positive diagnosis). 
Doxycycline may have been ineffective for two reasons. First, the dose regime used 
may have been too low. The regime was designed to achieve identical tissue and blood 
levels to those achieved in humans. Originally, 40 mg/kg given three times daily was 
proposed. In a previous experiment, five Balb/ C mice were given this regime 48 h prior 
to challenge, and maintained on it for 4! days after challenge. Four out of five mice 
survived a challenge of 5. 78 x 105 cfu (56116 x MLD), but the mice showed 
neurological disturbances which suggested doxycycline toxicity. Second, doxycycline 
has bacteriostatic activity, and affects only actively dividing bacteria . In the 20 mg/kg 
prophylaxis group, the dose may have been insufficient to prevent multiplication of Y. 
pestis . In the therapy groups, the bacteria may have reached sufficient local 
concentrations that by the time the doxycycline was administered, it was ineffective. In 
the 40 mgjkg prophylaxis group. there was some success in treating the infection as the 
MLD was increased and the mean time to death was extended. There was, however, 
a high relapse rate. The antibiotic was probably successful in preventing multiplication, 
but not in killing, the bacteria. The immune system, which would usually kill bacteria 
held in check by a bacteriostatic antibiotic, was ineffective as Y. pestis can express a 
variety of potent virulence factors which enable it to evade the immune cells. As soon 
as the antibiotic was withdrawn, the Y . pestis could multiply and kill the host. 
Subsequent experiments, extending the doxycycline dosing to 7 days post-challenge did 
not reduce mortality. The rate of relapse fell because more mice died during the 
antibiotic administration period . 
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Ciprofloxacin has been shown to be effective against a severe experimental Y. pestis 
infection of mice when used prophylactically. and with some success, when used as a 
therapy. It therefore may be a useful antibiotic to consider when treating plague. 
Doxycycline, however, was of little use against this type of infection . The nature of the 
experimental infection used in this work does not necessarily exclude the clinical use 
of doxycycline against plague, but may indicate that the effectiveness of the a ntibiotic 
may be limited for some forms of the disease. 
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Efficacy of doxycycline and ciproftoxacin against experimental 
Yersinia pestis infection 
P. Russell, S. M. Eley, M. Green, A. J. Stagg, R. R. Taylor, M. Nelson, R. J. Beedham, D. L. Bell, 
D. Rogers, D. Whittington and R.W. Titball 
CBD Porron Down, Salisbury, Wiltshire SP4 OJQ, UK 
The efficacies of ciprofloxacin and doxycycline prophylaxis and therapy were assessed 
against experimental pneumonic plague infections induced by two strains of Yersinia pestis in 
a mouse model. When exposed to an aerosol of Y. pestis strain GB, containing 8.39 x 105 ± 
4.17 x 104 cfu, the retained dose was 7.3 x 103 ± 2.3 x 103 cfu. When exposed to an aerosol of 
Y. pestis strain C0-92, containing 1.86 x 105 ± 7.4 x 103 cfu, the retained dose was 3.4 x 104 ± 
2.6 x 103 cfu. Both strains resulted in a respiratory and systemic infection closely resembling 
human pneumonic plague. Ciprofloxacin prophylaxis and therapy was successful against 
both strains for up to 24 h after challenge, but not after 48 h. Both doxycycline prophylaxis and 
therapy regimens were ineffective against both strains, although strain C0-92 was more 
susceptible In vitro to doxycycline than strain GB and supra-MIC levels were achieved in the 
serum and lungs of the animal. 
Introduction 
Pneumonic plague is a serious complication of systemic 
plague (i.e. bubonic or septicaemic plague) resulting from 
the spread of Yersinia pestis to the lungs. Primary plague 
pneumonia can result from the acquisition of the o rganism 
via aerosols generated in coughing and sneezing. Primary 
disease can also occur after contact with infected animals, 
notably. in recent cases in the USA, the domestic cat.l.2 
In e ither case the disease follows a rapid course and 
is associated with high mortality (~50%) even after 
antibiotic therapy. Treatment is streptomycin 30 mg/kg 
body weight given intramuscularly in two divided doses 
per day over 10 days. The main alternatives a re 
tetracycline given orally or intravenous chloramphenicol. 
Tetracycline is the ant ibiotic of choice for prophylaxis of 
close con tacts.' 
In a previous study the efficacies of prophylactic and 
therapeutic ciprofloxacin and doxycycline were measured 
against a severe systemic plague infection in mice. 
C iprofloxacin was found to be highly effective, while the 
performance of doxycycline was poor.4 In this study the 
efficacies of doxycycline and ciprofloxacin were measured 
against experimental pneumonic infections with two 
strains of Y. pestis. 
Materials and methods 
Bacterial strain, storage and culwre 
Two strains of virulent Y. pestis were used for these 
experiments. Strain GB was recovered from the in-house 
culture collection and was originally isolated from a 
fata lity following laboratory exposure. Strain C0-92 was 
obtained from the US Army Medical Research Institute of 
Infectious Disease (USAM RIID) and was isolated from a 
patient who contracted pneumonic plague from an 
infected cat. The train was cho en for its susceptibility to 
doxycycline in 1·irro (sec below). Both strains were 
ma intai ned o n the ·Protect· bead sy tern as described 
previously.s 
Cha ll enge cu ltures were prepared by inoculating 200 
mL of blood-agar base (BAB) containing 0.4% haemin 
wi th five or six beads. and incubated with shak ing for 48 h 
at 28oC. Viable counts and autopsy isolates were grown on 
Congo Red agar incubated a t 28~ . 
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Antibiotic preparation 
Antibiotics were prepared as descri bed previously.4 
Briefly. doxycycl ine solutions were prepared by dissolving 
the powder (Sigma, Poole, UK) in phosphate buffe red 
saline (PBS). Cipro fl oxacin solutions were prepared 
by dissolving Ciproxin tablets (Baye r. ewbury. U K) 
(containing 250 mg ciprofl oxacin) in sterile, de-ionized 
wate r. Both antibiotic solutio ns were filter sterilized 
before use. 
Animals 
Porton outbred mice, bred in-house, were mainta ined in a 
rigid wall isolator. They were subjected to a 12 h light-12 h 
dark cycle and had free access to food and water. This 
strain of mouse is susceptible to both systemic and pne u-
monic Y. pestis infectio n.4·6 All animal studies were carried 
o ut in accordance with the Scientific Procedures Act 
(Animals) 1986 and the Codes of Practice for the Housing 
and Care of Animals used in Scientific Procedures, 1989. 
D etermination of M !Cs 
The MICs of doxycycline and ciproftoxacin were 
measured for e ight strains of Y. pestis (four virulent 
strains, two avirulent live vaccine strains, an atypica l 
virulent strain and an isogenjc, non-pigmented avirulent 
mutant of strain GB) using a microbroth dilution me thod.7 
The MICs of tetracycline were also measured for com-
parison with doxycycline, as tetracycline is the recom-
mended antibiotic for plague prophylaxis . 
Mueller- Hinton broth was inoculated with fi ve or six 
beads charged with Y. pestis and incubated overnight at 
28°C. All antibiotics were dissolved in Mueller- Hinton 
broth and dilution series to give a final concentration 
range fro m 0.063 mg/L to 64 mg/L in 100 f.l.L a liquots were 
prepared in 96-well microtitre plates. Each well was 
inoculated with approximately 1 X 106 cfu Y. pestis in 100 
f.l.L. The plates were incubated at 28°C and read visually at 
48 h. Minimum bactericidal concentrations (MBCs) were 
measured by streaking a loopful o f medium from wells 
containing the nex t four higher concentrations of anti-
biotic from the MIC on to Congo Red agar. 
Antibiotic administration 
Both antibiotics were used at a dose of 40 mg/kg, given 
twice d aily as a subcutaneous injectio n in 0.1 mL according 
to one of four regimens: a prophylaxis regimen, where 
antibiotics were initiated 48 h be fore challenge and con-
tinued for 5 days after challenge; an immediate or 
supprcs ive therapy regime n with antibiotics initiated 
immediately after cha llenge and continued for 5 d ays; and 
two therapeutic regimens consisting o f a 5 day course of 
antibiotic starting either 24 or 48 h after cha llenge. 
Inhalation challenge 
Aerosols were gene rated by equipment designed aroun, 
the He nderson apparat us contained within a rigid walle• 
isolator fu lly compl ying with the guidance of the Advisor 
Committee on Dangero us Pa thogens on working witl 
aerosols o f Hazard G roup 3 microorgani ms. The equip 
me nt is described fully in Henderson.x Briefly it consists 0 
a Collison spray assembly, a two-fluid atomizer tha 
creates a homogenous aerosol of droplets with a diamete 
of 1.5-3 1-1-m. The aerosol is entrained into a 1.2 m linea 
pipe (the ' piccolo') . 
The humidit y of the aerosol is conditioned within the 
picco lo by mixing the aerosol ai rstream with humidified o 
dehumidified air giving a total fl ow rate through the 
piccolo o f 66 U min. The aerosol stream is then passe< 
through an exposure chambe r whe re the animals are sub 
jected to nose-only exposure. 
In these expe riments 20 mL aliquots of broth cultun 
were prepared and stored o n ice. Three drops of Antifoarr 
289 (Sigma) we re added to the suspension to preven1 
excessive frothing during dissemination prior to placin! 
the culture in a Collison spray assembly. Control experi· 
ments have previously shown that the antifoam did not 
have any de trime ntal effect on either Y. pesris or animal! 
(unpublished data). 
Mice were placed in acrylic tubes that plugged into an 
exposure chamber in groups of 20 and we re exposed to an 
airstream containing an aerosol of Y. pesris generated by 
the Collison spray and conditioned in the Henderson 
apparatus. The aerosol was maintained at consta nt re lative 
humidity (50% ± 2%) and temperature (20°C ± 0.5 %). 
Mice were exposed to the airstream for 10 min. 
The concen tra tion of Y. pesris in the airstream was 
determined by taking samples from the exposure chamber 
using an AGI30 impinger containing fresh BAB- haemin 
broth and antifoam. Impinger samples were plated on 
Congo Red agar, and incubated a t 28°C before counting. 
The re tained dose was measured by homogenizing the 
lungs from ten control animals in PBS and plating the 
homogenate on to Congo Red agar. 
The animals were observed for 14 days after the last 
antibiotic dose had been administered. 
Results 
The MIC o f ciproftoxacin for the tested strains o f Y. pesris 
ranged be tween < 0.063 and 0. 125 mg/L, with the MICs for 
GB and C0-92 be ing 0.125 mg/L and < 0.063 mg/L res-
pective ly. The MICs o f doxycycline and te tracycline were 
ide ntica l and ranged between 1 and 4 mg/L. Strain C0-92 
was one o f two virulent strai ns with an MIC of 1 mg/L 
whilst strain GB had the highest MI C, 4mg/L. The MBC of 
doxycycline fo r both strains was 64 mg/L, whilst the MBC 
o f ciprofloxacin was 0.25 mg/L for strain 0-92 (although 
growth did recur at 1.0 mg/L) and 1.0 mg/L for strain GB. 
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Mice challenged with strain GB were exposed to an 
aerosol containing 8.4 x 105 ::!:: 4.2 X I 04 cfu Y. pestis. The 
mean inhaled dose was 7.3 X I 03 ::!:: 2.3 X lfr' cfu/mouse. 
Those challenged with strain C0-92 were exposed to an 
aerosol of 1.9 X 10~ ::!:: 7.4 x 10"1 cfu. of which 3.4 x 104 ::!:: 
2.6 X 103 cfu were retained in the lungs. 
There was no difference in the progression of disease 
between the two strains of Y. pestis. Few animals showed 
any outward signs of disease. Symptoms, when they did 
occur, appeared 40-45 h a fter exposure. The first deaths 
occurred at 50 h, and the mean time to death in the control 
animals exposed to GB was 64 + 2 h (n = 10) and 55 + 0.9 
h (n = I 0) for strain C0-92 (Table). 
The efficacies of the two antibiotics are summarized in 
the Figure. Differences between the two antibiotics were 
noticeable at 48 h after exposure when all of the doxy-
cycline-treated mice were beginning to show signs of 
infection. These animals deteriorated, 79% of animals 
dying from infection with strain GB and 86% of 
animals dying from C0-92 within the antibiotic admini-
stration period. The mean time to death was significantly 
extended for both strains in all groups except the 48 h 
therapy group, where the delay in treatment was too long 
to have any effect in halting the infection. There was no 
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Table. Comparison of mean times to death of mice treated 
with doxycycline exposed to an aerosol challenge of 
Y. pestis GB and C0-92 (treatments are as described in 







Time to dea th (h) (mean ::!:: .E.) 
train GB strain C0-92 
64::!:: 2 
125 ::!:: 9" 
117 ::!:: 8" 
107::!:: 9" 
74::!:: 5 
55 ::!:: I 




•significantly different from relevant control (P < 0.001 ). 
variation in this group between the two strains (Table). 
Ciprofloxacin completely protected against both strains 
of Y. pestis, the ciprofloxacin-treated mice remaining 
asymptomatic throughout the experiment. Whe re treat-
ment was delayed for 48 h, ciprofloxacin the rapy was 
unsuccessful. 
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Days after challenge 
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Days after challenge 
Figure. Survival curves of mice challenged with aerosolized Y. p estis strain GB and strain C0 -92 and then given ciprofloxacin a nd 
doxycycline: (a) 48 h as prophylaxis then for 5 days after challenge: (b) immediate trea tment on challenge and for 5 days afte r 
challenge: (c) 24 h therapy and 5 days' treatment: (d) 48 h therapy and 5 days ' treatment. In each panel. controls are de noted by 6. 
(stra in G B) and 'V (strain C0 -92): ciprotloxactn regamens vs strains GB and C0-92 are denoted by 0 and 0 respectively: 
doxycycline regimens vs strain GB and C0-92 are denoted by A and T . respective ly. 
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revealed haemorrhagic changes to one or both lungs, 
with clear fluid accumula ting in the thoracic cavity. There 
were no gro s changes to any other organs. a ltho ugh 
Y. pestis could be isolated from liver. sp leen. blood and 
the lungs. Autopsies on surviving ciproftoxacin-treated 
mice showed that all organs examined were free of Y. 
pestis. 
Discussion 
Inhala tion of Y. pestis by mice resulted in an insidious 
infection that followed a rapid course. Symptoms, when 
they did present, occurred very late in the course of the 
infection . In many respects this closely resembled the 
human disease.9 The a utopsy findings suggested the re was 
an initial coloniza tion of the lungs which resulted in 
extensive damage to one or both lungs followed by 
' breakout', when the re was a sudden release of organisms 
from the lungs into the blood stream. When compared 
with an experimental systemic infection, the abse nce of 
spleno megaly indicated that this septicaemic phase was of 
short duration and a terminal event.5 
The an tibiotic dosing regime ns were designed to 
simula te possible clinical exposures to Y. pestis. Prophyl-
axis would be useful for individuals arriving in endemic 
areas at short notice (too short to permit vaccination, 
o r for the vaccine to stimulate an adequate immune 
response). The requirement for immediate treatment 
following challenge could arise if medical staff were 
unexpectedly exposed to a infected individual arriving at a 
care faci lity. The therapeutic regimens were a measure-
ment of how long therapy could be delayed before 
becoming ineffective. 
Ciprofl oxacin was highly e ffecti ve against the two 
strains of Y. pestis given by the aerosol route and was still 
e ffective when administered up to 24 h after exposure. 
Five d ays' trea tme nt was sufficient to clear Y. pestis from 
the anima l, correlating with the very low MIC and low 
MBC of cipro fl oxacin, coupled with the fact that supra-
MIC levels could be maintained in the plasma and lungs 
for 12 h and MBC levels of ciproftoxacin could be main-
tained for 6 h in the lungs and 3 h in the erum (un-
published da ta). At 48 h the disease progression appeared 
to have reached an irreversible phase since the 
administration of antibiotic at thi ti me wa unsuccessful, 
even though some a nima ls were a ymptoma tic at the onset 
of treatment. A similar problem is seen in human disease 
with high mortality even after therapy. u.•J The appearance 
of symptoms in human disease is late and the e mphasis 
must be to initiate therapy on suspicion of plague and not 
to awai t a comprehensive diagno is. As the antibiotic has 
broad-spectrum activity it is like ly to be effective agai nst 
o rgani ms that share sympto mato logy with pneumonic 
plague. 
The reasons why doxycycline was ineffective aga inst 
infection with stra in GB can be related its high MIC and 
MBC in vitro. Strain GB was more resistant to doxycycline 
and te tracycline than the o the r stra ins tested and those 
strains tested by other wo rkers. 10 Peak concentrations of 
doxycycl ine in plasma were only 3.65 ::!:: 0.53 mg/L 
(although levels in some individual animal exceeded 4 
mg/L) and lung concentra tio ns only exceeded 4 mg/kg for 
30 min after the last dose of antibio tic (unpublished data). 
In humans, serum and lung concentrations exceeding the 
MIC can be achieved .11.12 Although supra-M IC levels of 
doxycycline against stra in C0-92 were achieved in the 
plasma and lungs and maintained for 24 h and 9 h res-
pectively (unpublished data), the antibiotic was still in-
e ffective. This is probably due to the bacteriostatic nature 
of doxycycline whereby Y. pestis may readily ' recover' 
from the antibiotic and multiply during periods when 
antibiotic concen trations are close to or below the MIC 
(i.e. the re is no 'post-antibiotic effect'). The high bac-
tericida l concentration can never be achieved in vivo . 
Te tracycl ine has been used clinically to treat or prevent 
pneumonic plague. Although the MICs were similar and 
supra-MIC concentrations are attainable in serum, its 
success may be due to the frequent dosing (four times 
daily) regularly maintaining supra-MIC concentrations. 
Speculative ly, although doxycycline has a long serum half-
life. regimens requiring administration more than the 
usual once or twice daily may prove more effective than 
this study has shown. Whe the r more susceptible strains of 
Y. pestis (i.e. those with MICs < 1 mg/L) could be 
successfully trea ted with doxycycline was not examined. 
Bonacorsi et al. 10 found that doxycycline could stabilize 
the bacterial load in spleens from mice infected with a 
susceptible strain (strain 6/69M with an MIC of 0.5 mg/L) 
but did not examine mortality. The severity of pneumonic 
plague, howeve r, and the rapid progress of infection do 
not permit the physician the luxury of sensitivity tests. As 
strain GB is a human isolate, there is the possibility that 
other strains with simi larly high MICs occur. 
Ciprofloxacin was effective for the prophylaxis and 
the rapy o f pneumonic plague. Coupled with its e ffective-
ness against a severe systemic infection, ciproftoxacin 
wou ld appear to be a suitable candidate antibiotic for the 
treatment of the various different forms of plague. The 
effective ness of doxycycline is questionable but may be 
related to applying a suitab le dosing regimen to maintain 
supra-MIC concentrations in the serum and ti sues. 
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A comparison of Plague vaccine, USP 
and EV76 vaccine induced protection 
against Yersinia pestis in a murine 
model 
P. Russell *, S.M. Eley, S.E. Hibbs, R.J. Manchee, A.J. Stagg and 
R .W. Titball 
The median lethal dose ( M LD) of a pathogenic strain 4 Yersinia pestis 11·as established 
by three routes of administration in three strains of mouse. There 1ras no sign[ficant 
difference bet11·een the M LDs in the different strains of mouse. The MLD by the 
subcutaneous route in Balb/C and an outbred line was approximately 1 c.fu.; 1he MLD 
follo1ring intraperitoneal administration \l'as tenfold higher. There ll'ere significant 
differences in the mean times to death after administration of the challenge by different 
routes. The relatil'e efficacy of a live alfenuated vaccine strain of Y. pestis ( EV76) H'CIS 
compared H'ith that of the formaldehyde-killed vaccine ( Plague vaccine, USP). EV76 
protected against high challenge doses ( up to 5. 75 x 106 MLD ), though immuni:ed 
animals sho11•ed side effecls of varying severity. The killed raccine H'as less effectil•e in 
terms of dose-protection (deaths occurred after challenge ll'ith 4000 MLD ) and sereral of 
the l'accinated animals suffered sub-lethal, plague-related sequelae to the challenge. 
Kc~·words: Yt•r.,iuia pe,ti.': plague: ,·accinc: EV76: Plague vaccine. USP 
Plague is primarily a disease of rodents spread by a flea 
vector!.~ . rn humans, bites from infected fleas lead to the 
bubonic form of the disease.l. Typically, there is an 
incubation period of 2-5 days with sudden headache, 
fever and chills accompanied wi th swelling of the lymph 
nodes ("buboes'') close to the location of the bite. The 
bacteria disseminate widely throughout the body reach-
ing high concentrations in ti ssues. The lungs may 
become involved. leading to secondary pneumonia and 
the consequent risk of human-to-human transmission 
via aerosols generated from sneezing and coughing4 . The 
mortality ra te is high (50'/H ) and remains high even 
after antibiotic therapy2. 
Plague is widespread throughout the world and is 
associated with conditions allowing close contact be-
tween the rodent reservoir and the human population . 
Although ea es of plague do occur in the western world. 
notably in the southern tale of the USA, the condi-
tions leading to outbreaks of plague are usually associ-
ated with developing nations. particularly South-Ea ·t 
Asia and South America. \\'hich c~xrespon<.lingly have 
the largest a nnua l number of cases ' . 
CBDE, Porton Down, Salisbury, Wiltshire SP4 OJQ, UK. *To 
whom correspondence should be addressed. © Crown 
Copyright (1995). (Received 28 September 1994; revised 10 
April 1995; accepted 27 April 1995) 
The vaccine currently used in the USA and in the 
UK is the Plague vaccine. USP (Cutter Biological), a 
formaldehyde-killed preparation of the highly virulent 
195/P strain of Y pestis. It is believed to be effective 
against bubonic plague, but protection is less certain 
against the pneumonic fonn6 •) The problems of the 
vaccine are: production requires special containment; 
the vaccine i expensive: protection is short-term and 
annual boosters are required: the incidence of side-
effect is high. loca l reactions occur in 11- 24% of 
vaccinees and ystemic effect occur 111 4- 1 O'Y., of 
vaccinees 10 
Other vaccine have been ava ilab le. The first killed 
vaccine was developed by Haflkine in India in 1897 and 
was the precursor of the vaccine produced by Cutter. 
The vaccine eau ed severe side-etTects and was discon-
tin ued. altho ugh the HaiTk ine Institute now produces a 
formaldehyde-k illed prepara tton of strain 1 95/P~<. A 
similar vaccine i produced by the Commonwealth 
Serum Labora tories in Awtralia. 
li ve. attenuated vaccine ha · also been used since 
190c u ·ing the avirulent strain of >'. pestis. EV76. This 
strai n 1s not capable of assimilating chromatophores 
such a Congo Red or haemin from artificial media. and 
is described a Pigmentation (Pgm) (Rei's. 7. 8, 11. 12). 
Virulen t strain · ~)r Y. pes! is ;re Pgm'. Although the 
orga nisms in the vaccine could multiply following ad-
ministra tion. and could therefore theoretica lly enhance 
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protection. there appeared to be wide va riation in the 
immunogenicity and virulence between different EV76 
vaccine preparations. The vaccine caused severe side-
effects when u ed and th~re was also the danger of 
reversion to a fully virulent form. A large part of 
the Vietnamese population was vaccinated with EV76 
between I 967 and I 969. although the true effectiveness 
of the programme is not know1;1.'. 
The aim of the present work was to determine the 
suitability of different strain of mice for developing a 
model for measuring the efficacy of vaccines against 
plague. During this study the infectiou dose of a 
vi rulent strain of Yersinia pestis. delivered by several 
routes which mimic natural routes of infection. was 
determined. These data enabled the efficacy of the 
Plague vaccine. USP and EY76 vaccine in the murine 
model to be compared. 
MATERIALS AND METHODS 
Organisms 
The stock of Y. pestis used for the challenge dose in 
these experiments was isolate GB, recovered from a fatal 
human case, which was selected for its known virulence. 
This isolate was derived from strain MP6. Both this 
strain and strain EY76 were reconstituted from freeze-
dried stocks by inoculation into Blood-Agar Base (BAB) 
broth and incubation at 28·c for 24--48 h. Each 
strain was plated out on BAB- haemin agar medium to 
determine purity. 
Detection of virulence marker by growth characteristics 
To ensure that the chosen challenge strain was still 
virulent after prolonged storage and that EY76 had 
retained its avirulence, ,·irulence markers in each strain 
were assessed. 
Pigmentation was determined by growing the strains 
on Difco Heart Infusion agar containing 0.01 % (w/v) 
Congo Red and 0.2'!/o galactose. Aliquots from the broth 
cultures were streaked out on to Congo Red agar and 
incubated at 28"C for 24--48 h and visually checked for 
pigmentation . 
The low calcium response' -'·15 expression of the V and 
W antigens (which implies the presence of the pCD l .lcr 
plasmid) was checked by culturing each strain of Y. 
pestis on magnesium oxalate plates for 24--48 h. The low 
calcium response was revealed by the ability of the 
bacterium to grow at 28·c but not at 37"C. 
Detection of virulence markers by the polymerase chain 
reaction (PCR) 
Single colonies were picked from the Congo Red 
plates. emulsified in 0.5 cm ' steri le, de-ionised water. 
and boiled for I 5 min. The PC Rs were performed using 
one pair of 30-mer oligonucleotide primers to amplify a 
region or either Y. pesti.\ pia ·minogen activator gene 
(PA). V antigen gene or Fraction I (FI) antigen gene. 
Twenty microlitre reac tions consisted of Boehringer 
Mannheim PCR butlCr containing 200 ng or each 
primer. 200 fiM dinucleoude triphosphau.:s (Pharmacia) 
and 0.5 U Boehringer Mannheim TalJ polymerase. 
Posi tive controls contained 200 pg of Y. pestis MP6 or 
EV76 template DNA. !\ Perkin Elmer PE9600 therma l 
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cycler was used to denature samples for 1 min at 95•c 
and performed 35 cycles consisting of denaturation for 
30 s at 95"C. annealing for 30 s at 55"C and extension 
for I min at TJ."C. Finally the samples were incubated 
for I 0 m in at n·c to complete extension reactions. 
Prod ucts were analysed by electrophoresis in l.4'Y., 
agarose gels. 
Virulence ;, t•it•o and animal passage 
Confirmation and maintenance of virulence in GB 
strain was achieved by three passages through Balb/C 
mice. Similarly, avirulence in EV76 was confirmed by a 
single passage. Ten millilitres of BAB broth was inocu-
lated with a single pigmented colony from a Congo Red 
plate and incubated overnight at 28·c. Nine milli litres 
of BAB broth was inoculated with I ml of the over-
night culture and incubated at 28·c for 5- 6 h to 
obtain exponentia lly growing bacteria at a count of 
approximately 10~ colony forming units (c.f.u.) ml· '. 
Mice were kept in cages in groups of five within a 
flexible film isolator and allowed to feed and drink 
ad libitum. Animals were injected subcutaneously with 
0. 1 ml of neat seeded broth. The mice were then 
observed for a period of 14 days. 
Dead mice were autopsied, and spleens and livers 
removed. The organs were bisected and smeared on 
Congo Red plates. A sample of blood was taken from a 
tail cut and also smeared on Congo Red plates. All 
plates were incubated at 28·c for 24--48 h. Ten millilitres 
of BAB broth was inoculated with a single pigmented 
colony from one of the smear plates and the passage 
repeated twice further. 
Pathogen storage 
Colonies of the plague strains were isolated from 
smears from the final animal passage and stored in screw 
cap vials at - 8o·c on a " Protect" bead storage system 
(TSC Ltd, I-leywood, Lancashire, UK). The beads were 
charged according to the manufacturer's instructions 
and kept in storage unti l required. 
Animal cha llenge 
BA B broth was inoculated with three or four beads 
withdrawn from a " Protect" vial containing Y. pestis 
GB train and incubated overnight at 28·c 24 h before 
challenge. In the morning before the challenge, 9 ml of 
fre h BAB broth were inoculated with I ml of the 
overnight culture and incubated for 6- 7 h at 28·c. The 
seeded broth was serially diluted and 0.25 ml aliquots of 
each di lution were plated out on either Congo Red or 
BAB- haemin (0.02'Y,, haemin) plates for counting. 
Systemic virulence was measured by injecting animals 
either subcutaneously or intraperitoneally with 0.1 ml or 
the appropriately di luted culture and observing for 14 
days. Infectivi ty following a mucosal challenge was 
measured by intranasal instillation of 16 Jil of appropri-
ately diluted culture in mice lightly anaesthetized with 
halotha ne (IC I). and observed for 14 days. Mortality 
due to Y. pestis was confirmed by organ and blood 
smears on Congo Red plate . 
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Table 1 Detection of virulence markers in Y. pestis GB strain (the challenge strain) and EV76 (the vaccine strain). The presence of internal 
fragments of the genes encoding the plasminogen activator (pag). fraction 1 (cafg1) antigens and V lcrV antigens was determined using the 
polymerase chain reaction (PCR). Pigmentation was assessed by growrng the organism on Congo Red agar. and low calcium response 
assessed by growth on magnesium oxalate plates. nt = not tested 
Virulence markers 
Y. pestis 
Detected by PCR Growth characteristics 
strain pag caf1 /er V Pigment Ca2 • Free 2a•c 
GB + + + + + 
EV76 + + + 0 + 
Infectivity assays were expressed by the Median 
Lethal Dose (MLD) defined as the dose required to kill 
50% of a population of anima ls. calculated according to 
the method of Reed a nd Muench 14. 
The MLD was measured in two inbred strains [Balb/C 
(Charles River) and NIH/S (Harlan Olac Inc.)] and an 
outbred Porton stra in (bred in-house). 
Immunization 
Mice, immunized with the Plague vaccine. USP, 
were given 0.1 m! of neat vaccine ( 1.8-2.2 x I os 
formaldehyde-killed bacilli) intramuscularly on day 0 
and a booster of identical volume on day 8. The 
mice were then challenged as described above either 
subcutaneously or intranasally with Y. pestis GB 
strain. 
Y. pestis EV76 strain was retrieved from the storage 
beads in the same manner used for the GB strain. Fresh 
BAB broth was seeded with an overnight culture and 
incubated either a t 28 or at 37"C to promote Fl antigen 
expression. Neat seeded broth (0.1 ml) of was adminis-
tered intra muscularly as a single injection on day 0 
(approximately I 0 7 c.f. u.). One group received the 28·c 
cultured bacteria a nd the other the 37•c culture. The 
mice were then challenged subcutaneo usly as described 
above. 
The degree of protection offered by the vaccines 




The GB strain of Y. pestis displayed pigmented 
colonies when grown on Congo Red agar and grew at 
28·c, but not at 37"C. when cultured on magnesium 
oxalate aga r (i .e. thi s strain displayed the low calcium 
response). Interna l fragments from the genes encoding 
the V antigen, F l antigen and plasminogen activator 
were detected using the PC R (Table 1). Strain EV76 did 
not produce pigmented colonies on the Congo Red 
media. A lthough the PCR bowed that the bacteria 
possessed an internal fragment from the gene encodi ng 
the V antigen 1'. l<• the bacteria did not display the low 
calcium response. s uggesting tha t the entire LCR operon 
was no t present . It was non-letha l when passaged 
through mice (Tah/e !) . 
The detection of these virulence markers was repeated 
following storage using the " Protect" system and there 
was no change in virulence ei ther in l'itro or in !•il•o. 
Mortality 
Ca2• Free 37"C Passage 1 Passage 2 Passage 3 
0 5/5 5/5 5/5 
+ 0/5 nl nt 
Table 2 MLD of Y. pestis GB stra1n in three strains of mice by three 



















When Y. pestis strain GB was administered to mice, 
the MLD was lowest by the subcutaneous route, and 
highest by the intranasal route. However, the pa ttern of 
susceptibility to infection by different routes was not 
identical in all strains of mice tested; the NIH/S strain 
a ppeared to be most resistant to subcutaneous challenge 
but most susceptible when challenged via the other 
routes (Table 2). 
PO mice were inoculated subcutaneously with GB 
and sacrificed at various time points after challenge. 
After post mortem. smears of the blood a nd cut surfaces 
of the liver, spleen. kidney. lung and heart were made 
on to Congo Red Agar. No bacteria were detected by 
this method at I. 5. 18 and 36 h post-infection, but the 
liver, spleen and blood samples contained Y. pestis by 
48 h. 
In all cases, animals showed signs of infection within 
14-48 h of challenge with the high doses of Y. pes1is. The 
first deaths occurred within 60 h, irrespective of the 
route and murine strain. The average time-to-death, 
however. varied according to the administra tion route. 
For the intraperitoneal and intranasal ro utes these were 
simila r with little variation between strains. The average 
times to death by the intraperitonea l route were 3 days, 
1- 3 days a nd 3 days for Porion, Ba lb/C and N JH/S, 
respect ively. When administered by the intranasal route, 
the average times were 3 days. 2 days and 2-3 days. 
After subcutaneous challenge the times to death were 
5-6 days. 4 days and 4 da y . respectively (Figure 1). 
Autopsies revealed no consistent changes. In nearly 
all cases the spleen and li ver were enlarged. The appear-
ance of these organs va ried from case to case. The 
spleen was haem;rrhagic. friable and sometimes pale, 
patchy a nd necrotic . The Ji ver sometimes appea red dark 
and haemorrhagic. or pale. speckled and friable. Y. 
pestis could be recovered from the li ver, spleen, lung, 
kidney, heart a nd blood. regardless of the route of 
administra tio n. 
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Figure 1 The mean time to death of the fatalities according to 
challenge route. *=P<0.002. SIC: subcutaneous administration 
of challenge; 1/P: intraperitoneal administration; 1/N: intranasal 
administration 
Table 3 The efficacy of Plague vaccine, USP, administered by the 
intramuscular (i.m.) route against a subcutaneous (s.c .) or intranasal 
challenge with virulent Y. pestis, strain GB. All the experiments were 




Vaccination and (multiple immunized 
challenge procedure MLD) Immunized controls 
Plague vaccine, so 000 2/5 nt 
USP i.m. day 0 and day 8. 5000 0/5 nt 
Challenge s.c. day 16. 500 0/5 nt 
so 1/5 6/6 
5 0/5 5/5 
Plague vaccine, 4 200 000 2/5 nt 
USP i.m. day 0 and day 8. 420 000 3/5 nt 
Challenge s.c. day 34 42 000 2/5 nt 
4200 2/5 5/5 
Plague vaccine. 150 1/5 nt 
USP i.m. day 0 and day 8. 15 1/5 5/5 
Challenge i.n. day 16. 1.5 1/5 3/5 
0.15 0/5 0/5 
Vaccine efficacy 
Both Plague vaccine, USP and EV76 vaccine induced 
protection against a subcutaneous challenge with Y 
pestis strain G B (Tables 3 and 4). With the Plague 
vaccine, USP, two eries of trials were conducted, 
both with the challenge strain growing exponentially. In 
the first trial mice were challenged with multiples of the 
MLD up to 50 000. There \\'as IOO'X, mortality in the 
control groups, treated wi th 5 and 50 M LOs. 1/5 deaths 
in the vaccinated group challenged with 50 M LD, and 
2/5 deaths when challenged \\' ith the highest dose. In the 
second trial (Table 3). in which challenge doses were 
extended from 4200 to 4 200 000 M LD, between 40 and 
60% of the animals died at each do e. There was no 
difference between the protection alforded by Y. pestis 
EV76 grown at 37" to promote expression of the F l 
antigen or at 2s·c. when such promotion does not occur 
(Table 4). Where deat hs did occur the mean time to 
death was extended to between 6 and 8 days in 
Plague vaccine. USP-\'accina ted mice. ten days in EV76 
(370C-grown)-vaccinated mice and four days in mice 
vaccinated with EV76 grown at 2s·c. 
1554 Vaccine 1995 Volume 13 Number 16 
Table 4 The efficacy of Y. pestis EV76 vaccine strain administered 
intramuscularly aga1nst subcutaneous and intranasal challenge with 
wulent Y. pest1s, strain GB. Porton outbred m1ce 
Challenge Mortality (deaths/group) 
dose Non· 
Vaccination and (multiple immun1zed 
challenge procedure MLD) Immunized controls 
Y pestis EV76 28•c -grown 5 750 000 0/5 nt 
i.m. day 0. 575 000 0/5 nt 
Challenge s.c. day 16. 57 500 1/5 nt 
5750 0/5 nt 
575 nt 5/5 
57.5 nt 5/5 
Y. pestis EV76 37"C-grown 5 750 000 0/5 nt 
i.m. day 0. 575 000 1/48 nt 
Challenge s.c. day 16. 57 500 0/5 nt 
5750 0/5 nt 
575 nt 5/5 
57.5 nt 515 
Y. pestis EV76 150 0/5 nt 
i.m. day 0. 15 0/5 5/5 
Challenge i.n. day 16. 1.5 0/5 3/5 
0.15 0/5 nt 
00ne death occurred 6 days following vaccination 
Mice immunized with the Plague vaccine, USP de,·el-
oped local lesions at the site of the injection of the 
challenge including grey/white caseation of the focal 
lymphatic glands. This resembles. at least superficially, 
the lesion caused by Y. pseudotuberculosis when injected 
subcutaneously into normal guinea pigs. This lesion 
would either track to other sites between the dermis and 
the muscle fascia or penetrate the muscle fascia forming 
a lesion between bundles of muscles. In some cases the 
lesions ulcerated and began healing. Fewer lesions (four 
mice only) were seen in mice immunized with Y. pestis 
EV76, and those that did form were generally smaller. 
Mice challenged by the intranasa l route were partially 
protected by the Plague vaccine. USP. and fully pro-
tected by the live vaccine. The challenge series in these 
groups of mice was necessarily restricted by the high 
M LD by this route. and the concomitant difficultie in 
obtaining preparations of the challenge dose at a high 
enough concentration. 
Y. pestis EV76 eau ed side-effects in nearly all of the 
mice. some of the e were evere. There was one death 
attributable to the vaccine. and autopsy revealed 
damage to the spleen, con i ting or purulent abscesses 
over the surface of the org<m and apical necro is. In 
other animals, the vaccine caused paralysis in the in-
jected limb which did not improve over the total tudy 
period . There appeared to be both sensory and motor 
dysfunction. There were no detectable side-e!Tects from 
the Plague vaccine. USP. 
0 1 USS fON 
Y. pes/is strain GB was ori ginal!~ isola ted from a fatal 
human case of plague and thi strain pos ·e. ·ed al l or the 
viru lence factor tes ted for in this ·tudy. Previou · \\'Ork-
er .. have suggested that vi rulence of the bacteria can be 
maintained by repeated passage of the bacteria through 
animals. and can be lost on storaue 1'. Our studies 
suuge ·t that virulence of the bacteria ;an be maintained 
us~~g the Protect R storage sy. tem. Y. pi!slis vaccine 
strain EV76 was attenuated in mrce and. in accordance 
with previous reports. we have found that this strain is 
unable to acq uire haemin 1 '. Our studie also indicate 
that the bacterium also contains other genetic lesions. 
which result in the inability of the bacteria to efTect the 
low calcium response 1 ~ · 1 '1 . The LCR response is regu-
lated by the /er operon 1 ~ · 1 '1 and our finding that the 
bacteria possessed at least a fragment of /er I ' indicates 
that although some components of the /er operon a re 
present the operon is non-functional in this strain. PCR 
revealed that EV76 possessed the gene (cr{(gl) encod ing 
the Fl antigen. and immunoblotting techniques showed 
the expression of this antigen (data not shown). 
A variety of animal models have been proposed for 
investigation of the pathogenesis of plague and the 
efficacy of vaccines. The mouse model has been selected 
in this study. This model may not accurately reflect the 
disease process in man since a murine-specific toxin is 
also produced by Y. pestis10·1 1. However, other animal 
models suffer from the dual drawbacks of high cost and 
the necessary use of adjuvants not licensed for human 
use9; as previously reported. vaccines against Y. pes tis 
have been successfully evaluated m the mouse 
model6· 7·22·2·'. 
Our finding, that the LD50 dose of the bacterium was 
lowest in Balb/C and Porton outbred mice when the 
bacteria were delivered by the subcutaneous route, is not 
surprising since this route most accurately mimics the 
natural route of infection from a flea bite -' · ~4 . After 
colonisation and replication at this site the bacteria 
become more widely dissemi11ated in the body. infecting 
a variety of organs inciuding the spleen, liver and lungs. 
The requirement for this initial phase of multiplication 
in the dermal tissues, before dissemination throughout 
the body, would explain why the time to death was 
significantly greater for bacteria delivered by this route 
rather than by the i.p. or i.n. routes. The relative 
resistance of NIH/S mice to infection by the subcutane-
ous route , and greater sensitivity to i.p. challenge may 
indicate that the initial stages of the infection process are 
different in this strain of mice and would suggest that 
this strain is not suitable as a model for plague. In the 
pneumonic form of plague the bacteria colonise the 
lung tissues and are thought to be transferred directly 
from man to man by snee~zing and coughing4 ·~5 17 . We 
had tested the intranasal route of inoculation with a 
view towards mimicking this route of infection . How-
ever, the infectious dose of the bacteria delivered by 
this route was high. lt is not certain that a true pul-
monary infection was established and the establishment 
of such an infection may require the deposition of small 
aerosol particles, containing Y. pestis, in the lower 
respiratory tract. This would not be achieved by intra-
nasal instillation. 
Both the Plague vaccine, USP and EV76 vaccines 
conferred protection against s.c. challenge with 5 X I o·' 
M LD of r. pestis strain G B. However. at higher chal-
lenge doses only the EY76 vaccine provided complete 
protect ion. In addition. the EY76 vaccine provided 
protection aga inst loca l infection fol lowing challenge. In 
animals immunized " ·i th the Plague vaccine, USP a loca l 
infection \\·as frequently observed fo llowing challenge 
even thou!!h death " ·as prevented . lt has been reported 
that J'. f}(~vtis expresses a va riety of an tigens in ril ·o2x. 
Some of these antigens. including the yaps. are rapidly 
degraded by the plasminogen activator protease in 
Y. pestis vaccines: P Russe/1 et al. 
l'itro~9 ' -' . The live EV76 vaccine would be expected to 
express some or all of these proteins after inoculation 
into mice. Although we have not characterized the 
Plague vaccine. USP, it seems unlikely that this prepa-
ration contained a significa nt proportion of these pro-
teins and this may account for the poorer efficacy of th is 
vaccine. The Plague vaccine, USP does contain the F I 
antigen6 ·10 and our results would suggest that th is anti-
gen cannot. alone, stimulate a fu lly protective response 
against Y. pestis. 
Previous studies have established the efficacy of the 
Plague vaccine. USP. and compared this with va rious 
regimes using attenuated strains of Y. pestis. including 
EV76. both alone and in combination with the killed 
preparation'' 111. These studies have shown that the killed 
vaccine is a poor immunogen in man and animal sub-
jects. and that a proportion of subjects may not sero-
convert6·10·-'4. The data presented here indicate that the 
Plague vaccine, USP, the only licensed vaccine against 
plague, does provide some protection against infection 
with Y. pestis. However. this protection does not extend 
to challenge with high multiplicities of the infectious 
dose. The live EV76 vaccine induces good protection 
against Y. pes tis infection but the vaccine st rain is not 
fully avirulent and can cause disease in the mouse model. 
EV76 grown at 37"C to induce expression of the Fl 
antigen appears to induce a greater protective response 
than that grown at 28oC. in that the time to death is 
greatly extended. Putatively. this is because of the 
presence of Fl antigen in the administered dose, which 
elicits an anti-Fl reaction as part of the primary 
response. A comparison of the immune responses in-
duced by these vaccines. and the effect of the presence 
of Fl antigen in the administered dose, could indicate 
how a more effect ive subunit vaccine, or live vaccine 
could be developed . 
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chapter 
30 Plague 
During the last two millennia, the bacterium Yersinia 
pestis has been responsible for social and economic dev-
astation on a scale unmatched by other infectious dis-
eases or armed conflicts. The first reliable reference is 
to the Justinian plague (AD 542-750), which originated 
in central Africa and spread throughout the Mediterra-
nean Basin. The second pandemic, the Black Death, 
which started on the Eurasian border in the mid- I 4th 
century, may have caused 25 million deaths in Europe 
(25-30% of the population), persisted on the continental 
land mass for several centuries, and culminated in the 
Great Plague of London in I665. The third pandemic 
started in China in the middle of the I 9th century, 
spread east and west, and caused I 0 million deaths in 
India alone. Credible estimates indicate that almost 200 
million deaths could be attributed to plague; which 
swept across Europe in these three major epidemics.1 
The disease occurred in both bubonic and pneumonic 
("black death") forms. The bubonic form spreads as a 
result of transmission of the bacterium from rodents to 
humans via the bites of infective fleas (usually the rat 
flea, Xmopsylla cheopsisl). The close contact of humans 
with infected rats undoubtedly contributed to the spread 
of the disease by this route. In some instances, subse-
quent spread of plague bacilli to the lungs leads to the 
development of the pneumonic form of the disease; 
person-to-person transmission by respirable droplets can 
resu lt in rapid epidemic spread of the disease. 1 It is the 
pneumonic form of"Lhe disease that is most feared and 
that is associated with a mortality rate approaching 
I 00% when untreated.'· 1 For reasons that are not fully 
understOod, epidemics of urban plague have dramatically 
waned, but data from the World Health Organization 
indicate that plague is still a significant public health 
problem, especially in Africa, Asia, and South America 
(Fig. 30- l ).r .. 7 In plague endemic nreas of the world, 
vaccines may be useful in preventing plague in people 
at high risk. Such v;H:cines are also of use in protecting 




Bubonic Pbguc. Bubonic plague is the form of dis-
ease th;lt typica lly occurs after a Il ea that has previously 
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fed on an infected rodent then bites humans. In some 
circumstances, infection occurs via Oj)en wounds that 
are exposed to infected material.~ \Nithin 2 to 6 days of 
infection, the patient develops a fever, headache, and 
chills." Occasionally, lesions develop at the site of inocu-
lation. The classic feature of bubonic plague is the devel-
opment of swollen and tender lymph nodes called buboes, 
from the Greek bubon, meaning groin. (The buboes are 
often located in the inguinal and femoral lymph nodes, 
which drain the original site of infection.~) Bacteremia 
is common in patients with bubonic plague, typically 
resulting in blood culture counts ranging from fewer 
than 10 to 4 X 107 colony-forming units [cfu] per mL.~ 
In many of these cases, there is involvement of the 
gastrointestinal tract, which can cause vomiting, nausea, 
and diarrhea.~ Early intervention during the course of 
disease with antibiotics such as tetracycline, streptOmy-
cin, gentamicin, or chloramphenicol usually leads to 
rapid recovery.9 
Septicemic Plague. The demonstration of a bacter-
emia without evidence of buboes is generally considered 
to be indicative of primary septicemic plague. Clinically, 
the disease appears similar to other gram-negative septi-
cemias, with elevated temperature, chills, headache, mal-
aise, and gastrointestinal disturbances. In the absence of 
aggressive treatment, life-threatening complications of 
the systemic inflammatory response syndrome occur, 
such as disseminated intravascular coagulation and 
bleeding, adult respiratory distress syndrome, shock, and 
organ fai lure. Owing to the absence of buboes, a diagno-
sis of septicemic plague is often delayed, and, even with 
medical intervention at this stage, 50% of patients die.~ 
Pneumonic Plague. Some colonization of pulmonary 
tissues occurs in virtually all untreated fatal cases of 
plague, but most of these patients do not develop a 
transmissible plague pneumoni<1.w H owever, ,,·hen there 
is colonization of the alveolar spaces after a respiratory 
exposure, a suppurative pneumonia develops , and during 
the terminal stages of dtsease there is coughing ~md the 
production of a highly infectious, watery, and bloody 
spumm . Pneumonic plague is the most widely feared 
form of the disease because Y pestis can be spread from 
person to person as respir:nory droplets formed during 
coughing. 111 lnhal:nion of these ;lirborne droplets by sus-
ceptible individuals leads tO the rapid (1-3 tbys) devcl-
Figure 30-1. Worldwide incidence 
of plague, 1970 to 1995. (Data 
from the World Health Organiza-
tion, the Centers for Disease Con-
trol and Prevention, and country 
sources.) 
opment of pneumonic plague.8 The rapidity with which 
the infection spreads between individuals, along with the 
relatively short incubation period, makes control of the 
disease difficult. Antibiotic therapy may be ineffective 
after pulmonary symptoms have developed.4• 8• 9 Pneu-
monic plague is now rare; in the United States, most 
cases are acquired by veterinarians and owners of cats 
that are experiencing a plague pneumonia.4· 5 Neverthe-
less, the potential for pneumonic plague to quickly 
spread in human populations is evident from the reports 
of the great plagues of the Middle Ages. 
Bacteriology 
The etiological agent of plague is Y pestis, a gram-
negative bacterium that is a member of the famj)y 
Enterobacteriaceae. The bacterium is able to grow at 
temperatures between 4 and 40°C and has nutritional 
requirements for L-isoleucine, L-valine, L-methionine, 
L-phenylalanine, and glycine. The species has been sub-
divided into three biovars (o1-ientalis, mediaevalis and anti-
r;w) on the basis of their ability to convert nitrate to 
nitrite and to ferment glycerol; however, all three bio-
vars show similar virulence in animal models.4 The ge-
nus Yeninia also includes Y entn-ocolitica and Y. pseudotu-
bercul~sis species, both of which are pathogens of humans 
but rarely cause disease with a fatal outcome. I. 9 The 
pathogenic differences among these three organisms 
have been shown to be related, in the main , to the 
presence or absence of plasmids that encode virulence 
determinants. All three species contain a 70-kilobase 
(kb) low calcium response (Lcr) plasmid that encodes a 
variety of Yeninin outer membrane peptides (Yops11• 11) . 
The 9.5-kb pesticin plasmid and the 100-kb Tox plas-
mids are present only in Y. pestis. The pia gene on 
the pesticin plasmid encodes a surface-bound protease 
(plasminogen activator}, which has potent fibrinolytic 
activity. 1 Post-translatio na l processing of the pin gene 
product results in the formation of a coagulase enzyme. 
"' Countries reporting plague, 1970-1995 
• Probable foci 
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Although it is possible that many virulence determinants 
are encoded by the Tox plasmid, only the Fl capsular 
antigen has been studjed in detail. The caf operon en-
codes the 17-kd polypeptide Fl antigen (Caf1 13) ; the 
CaflM chaperone, which allows export from the cel1 14; 
and the CaflA polypeptide, which anchors the Fl anti-
gen into the outer membraneY The CaflR regulatory 
protein, which is responsible for the induction of F l 
capsule production at 3 7°C, is also encoded by the caf 
operon.16 
Pathogenesis 
Plague is a zoonosis in which Y pestis is transferred 
most commonly from its animal reservoir (rodents) to 
humans via fleas (Fig. 30- 2). The flea ingests blood-
borne bacteria from the infected rodent, and growth of 
the bacteria leads to blockage of the foregut. T he hemin 
storage system is thought to play an important role in 
the formation of this blockage. 17 The blockage prevents 
digestion of the blood meal, and further ingestion of 
blood leads to regurgitation of bacteria-contaminated 
material. 18 Movement of the fl ea to a new rodent host 
leads to infection of the rodent, and it is thought that 
the bacterium persists in the environment as the result 
of a stable rodent- fl ea infection cycle. H owever, in situa-
tions in which humans and rodents are in close proxim-
ity o r when the rodent population is reduced, either as 
a result of the disease or rodent control measures, hu-
mans and other warm-blooded mammals serve as alter-
native hosts. In this respect, Y pestis differs from the 
other human pathogenic Yersinin species in that it is an 
obligate pathogen. The organism circulates in a "syl-
va tic" form in wild rodent populations, typica lly causing 
a fata l disease in murines and sciurines and a milder, 
subclinical infection in gerbillines and dipod ids. 1v 
Infection of humans usually occurs as the result of a 
bite from an infected Aea. It has been suggested that as 
many as 24,000 bacteria are delivered into the host with 
a single bite.4 The expression of many of the virulence 
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Figure 30-2. Transmission routes of pbguc. Solid lines indicate the usual routes o f transmission, and occasional routes arc shown with dashed 
Iincs. (From Perry RD, Fethcrston JD. l i'I'Sinirt pmt.r-etiologic agent o f plague. Cl in Microbiol Rev I 0:35-66, 1997.) 
genes in Y pestis is upregulated at 3 7°C, and bacteria 
delivered by the flea, where they have been growing for 
several days at ambient temperarures of 28°C or less, do 
not express the Fl antigen or many of the Lcr plasmid 
products that are thought to allow the bacteria to resist 
phagocytosis. Therefore, many of the bacteria that are 
delivered into the host are easily phagocytosed by poly-
morphonuclear leucocytes or monocyres. The bacteria 
within polymorphonuclear leucocytcs are destroyed, but 
those within monocytes survive and express various viru-
lence determinants, thereby allowing growth and even-
rual release from th' monocytes.:11 One such virulence 
determinant is the pH6 antigen, a fibrillar adhesin in-
duced by low pH ·conditions such as those encountered 
in the phagosome, which has a pH of 4.5.: 1 The expres-
sion of the pH6 antigen may facilitate entry into naive 
monocytes or participate in the delivery of Yeniuin-
secreted proteins to monocytes and polymorphonuclear 
leucocytes. Bacteria released from monocytes are resis-
tant to phagocytosis. The Fl capsule might be expected 
to play a key role in avoiding further phagocytosis .~~ 
l Iowever, mutants of Y. pestiJ that are unable to produce 
Fl antigen <1re ~ till able to cause disease in the mouse, 
albeit in 3 more protrncted form .~' Other Yops might 
also play a role in kil ling phagocytic cel ls. For example, 
the YopE. protein is ;t cytotoxin that is transferred into 
host cells after h<JCterinl contact"; the Yopll protein is :1 
ty rosine phosph:nase that has :mtiph:t~ocytic cdl activ-
ity' ~; and the V :mtigen th<tt is exported from the hacu.:-
rial cell has been reported to have a profound immuno-
modulatory effect on cells of the host immune system, 
by down-regulating the production of -y-interferon and 
rumor necrosis factor-a.. H. 11 The expression of Yops is 
further regulated by the environmental calcium concen-
tration, such that maximum expression of these proteins 
occurs at 3 re when the calcium concentration is below 
2.5 mmol (the so-called low calcium response'). These 
are the conditions encountered within the phagosome, 
and int:racellular \' antigen is thought to play a key 
role in the regulation of this response.1r. Under these 
conditions in vitro, however, growth of the bacterium 
virrually ceases. Yop production certainly does occur in 
vi1·o, but, paradoxically, the bacteria are also able to 
grow. Either Yop expression in the mammalian host is 
induced by conditions yet to be identified, or growth in 
vivo is subject to a different regulatory system than that 
which occurs in vitro. 
:\.n ability to proliferate at the site of infection in host 
tissues indicates that the b;tcterium possesses efficient 
iron acquisition systems. The role of the surface-bound 
hemin storage proteins in iron :tcquisi rion is not proven, 
but it is k11own that the bacterium does have an iron 
scl\·enging system based on the ycrsini:tbactin sidcro-
phorc .4 The bacteria become dissemimtted from the site 
of primary infection inro regional lymph nodes that 
drain these tissues. \Vithin the lymph node, further 
~rowth of the b:tncria , accompanied by a m;tssive in-
lhmm:tiOry re:tction, le:tds ro lymph:Hknop:llhy :md the 
form:nion of buboes. Evenru:tlly, the bacteria c ut be 
dissemina ted by the lymphatic system, ga in access to the 
blood stream, and colonize pulmonary tissues, which 
may lead to development of the pneumonic form of the 
disease. Untreated pneumonic plague is almost invari-
ably fatal, but the precise mechanisms that l e;~d to death 
of the host h;tve not been identified. The bacte rium 
does produce a so luble exotoxin ,4 · 11 but thi s exotoxin 
is reported to be active only in murines. Because an 
overwhelming septicemia is a feature of fatal plague 
infection, it seems likely that lipopolysaccharide is re-
sponsible for the systemic inflammatory response syn-
drome and its sequelae, such as disseminated intravascu-
lar coagulation in the terminal stages of the disease. 
Models of Disease and Protection 
Y. pestis causes disease in a wide variety of laboratory 
animals,4• 111 and animal models of the disease in humans 
have been developed using mice, guinea pigs, and other 
primates. Most experimental work has been carried out 
with the mouse model of disease, which has been ac-
cepted as a meaningful indicator of the likely responses 
to infection and protection in humans. However, the 
disease in the mouse model may not faithfully mimic 
disease in humans because of the susceptibility of mice 
to the murine exotox.in.27 Although this limitation might 
be resolved by using the guinea pig model of disease, 
the protracted nantre of the disease in this species4 
suggests that this model is a better indicator of the 
infection that occurs in animal reservoirs. In a compara-
tive study with mice and guinea pigs, it was concluded 
that mice were more suitable for the evaluation of plague 
vaccines,!M and this species is approved by the U.S. Pub-
lic Health Service for the testing of plague vaccines. 
Disease arising from the delivery of Y. pestis by the 
subcutaneous route (median lethal dose [MLD], 1-2 
cfu!?. 30) is considered to mimic bubo nic plague, whereas 
the exposure of mice to the bacteria via aerosols inhaled 
through the nose results in the pneumonic form of the 
disease (MLD, 2 X 104 cfu 10) . The efficacy of currently 
licensed plague vaccines is determined by measuring 
the ability of sera from immunized mice, guinea pigs, 
monkeys, or humans to pro tect mice passively against Y. 
pestis. Serum is injected intravenously into groups of 10 
mice (0.5 mL serum per mouse), and the mice are then 
challenged subcutaneously with I 00 MLD of Y. pestis. 'I. ' 1 
The mouse protection index (MPf) is expressed as the 
percentage mortality of the group of mice (over 14 days) 
di,·ided by the average time to death. MPI values of I 0 
or less are considered to be indicative of protection." 
EPIDEMIOLOGY 
.\lore than 200 mammalian species have been re -
)'Orted to he susceptible.: to infection with Y. pe.fti.f, 4 al-
though rodc nts ;trc considcred to bc the most important 
hosts for the bacterium. Thc observation that distinct 
~l.'ogr<tp h ic:l l foci of infec tion occur indicates that the 
bacterium can persist for long periods in some rclativcly 
f'/,Jguc 7 )7 
(J.., 
rcsist:tnr (enzoot ic) animal hosrs and their flcas (sec Fig. 
.\0-2). 14 llowevcr, rhe nantre of the enzootic host for 
the bacterium has not been clearly demonstrated and 
may even va ry from location to location. Some types of 
mice, voles, and gerbils all have been suggested as enzo-
otic hosts.4 • " The ntpid spread of disease is associated 
with in fection of highly susceptible epizootic hosts such 
as rats, prairie dogs, squirrels, or mice.~ In principle, any 
Ilea that is capable of feeding on these hosts might 
transfer the disease to humans,M but the usual vector in 
epidemic plague is the oriental rat flea (Xmopsylln 
cbeopis). 
Endemic foci of plague occur mainly in semia rid re-
gions of the world (see Fig. 30-1 ). The main foci have 
heen identified in the southwestern {)nited States, the 
fo rmer Soviet Union, South America, South Africa, and 
Asia. ot surprisingly, these are the·"regions of the world 
that report the highest incidence of human plague. Data 
from the \1\Torld Health Organization indicate that the 
average incidence of plague worldwide was 1666 cases 
from 1967 to 19937- 3\ although the trend was downward 
until 1981, there has been an apparent increase in the 
incidence of disease during the 1990s. It is possible that 
this increase is the result of more efficient diagnosis and 
reporting of cases. H owever, the outbreak of disease in 
Surat, India, during 1994, although overstated by the 
press, serves as a reminder that the disease can reappear 
explosively. Serological testing of individuals during this 
outbreak showed that there were 876 presumptive cases 
of plague and 54 fatalities.4 In the United States, a new 
trend in plague epidemiology appears to be re lated to 
the residential encroachment on former rural areas that 
contain enzootic foci. 4 Inhabiting of such areas can lead 
to bites of humans bv infected fleas or to infection as 
the result of close con tact with infected wild rodents or 
other animals (e.g., domestic cats) that have become 
infected. 
PASSIVE IMMUNIZATION 
Early studies showed that serum from human volun-
teers immunized with purified F1 antigen o r with a 
killed whole-cell vaccine could be used in the passive 
protection of mice against a parenteral challenge with 
100 MLD of Y. pestis. '1 Indeed, this is the basis of the 
MPI rest that is used to evaluate the efficacy of killed 
vaccines. More recently, there have been several reports 
that the passive immuniza tion of mice with an tiserum 
<tgainst the V antigen provides protection against paren-
teral challenge with r pestis. "-'~ However, there is no 
antiserum that can be used in humans to prevent o r 
treat pl:tgue. 
ACTIVE IMMUNIZATION 
Killed Whole-Cell Vaccines 
Ki llcd >:pestis o rganisms have been used as a vacci ne.: 
si nce I H97, when \Na ldcmar I laffkine inoculated himself 
with an cxperimcntal vaccine. T he first killed vaccine.: 
7 JS V.Kc ine.s (or Special R1.,J.. CrotJfJ' .1nrl Sclectcrl Gcouraphtcal Are.J' 
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for human use was the Army \'accine, which was pro-
duced in the United Stares in 1946. Improvements to 
this vaccine have led ro rhc plague vaccine, whid1 is 
produced from the virulent I 95/P strain of Y JU'.rtk ''' 
During the 1990s, there h;lve been se,·er;ll commercial 
suppliers of killed whole-cell \'accincs against plague. 
Plague vaccine, which contains timnaldehydc-killed bac-
teria , was formerly manufactured by Currer Laboratories 
but since 1994 has been m;muf<1ctured bv Greer Llbonl-
tories Inc. (P.O. Box 800, Lenoir, · orrh Carolina, 
28645-0800). 1 The killed h<lCteria (strain 195/P) :1re re-
suspended in 0.9% saline ro a concentration of 1.8 X 
109 to 2.2 X 10'1 cells per mL. The vaccine also cont<lins 
traces of growth media components and 0.5% weight 
per volume of phenol as a preservative. T he Greer vac-
cine is given intramuscularly (preferably into the delroid 
muscle) as an initial dose of 1.0 mL and is followed 1 to 
3 months later with a 0.2-mL dose of vaccine and a 
third dose of 0.2 mL after 6 months. Booster doses (0.2 
mL) may be needed at 6-month interva ls< (Table 30-1). 
An alternative killed vaccine is manufactured by the 
Commonwealth Serum Laboratories (CSL Ltd., 45 
Poplar Road, Parkvi lle, 3052, Australia). This vaccine 
contains heat-killed bacteria (Y pestis strain 195/P) that 
are resuspended in saline containing 0.5% weight per 
volume of phenol to a concentration of 3 X I 0'1 organ-
isms per mL. The vaccine is given subcutaneously, and 
the initial course in adults is two 0.5-mL doses of vac-
cine at an interval of I to 4 weeks (sec 1~1 b le 30-1). T he 
vaccine can be administered to chi ldren using modified 
immunization schedules. For example, chi ldren 6 
months to 2 years of age are given three 0.1-mL doses 
of vaccine at intervals of I to 4 weeks (see Table 30-1). 
Live Attenuated Vaccines 
Vaccination of humans has also been achieved using a 
live attenuated vaccine strain of Y pestis (strain EV76). 
This vaccine strain, which was derived from a fully 
virulent strain by in vitro passage,~0 has been used since 
1908, especially in the former Soviet Union and the 
French colonies. At present, however, the vaccine is not 
commercially available. The genetic lesion that resu lts 
.... 
in ;lttCillJ;ltion has not heen defined, but the strain is 
known to be ;1 pigmentation (pgm) mut;lllt. This muta-
tion prevents the bacterium from ;lssimilating hemin• 
and m<~~· also result in a change in ~urEtce prOJ)Crties of 
the bacterium. ' - The recommended dosing regime for 
E 7o is to use 5.8 X I 0'' cfu as ;t priming dose and to 
boost with the killed whole-cell ,·;tccine.4" 41 
Indications for Vaccine Use 
The killed whole-cell ,·accine is recommended for use 
in indi,·idual who arc working- with fully virulent stra ins 
of Y pestis (e.g., researchers~ and labo.ratory workers). 
The vaccine is also indicated for use in personnel who 
are deployed to work in areas where the disease is en-
demic (e.g., mi litary personna l, field workers, and ag-
ricultural consultants), especially if they may be exposed 
to epizootic plague.' The vaccines currently avai lable 
are not suitable for postexposure use, as several months 
are required to complete the primary vaccination sched-
ule. In the case of possible exposure to Y pestis, prophy-
lactic use of antibiotics should be considered, even in 
vaccinees who have completed the full vaccination 
schedule. Vaccination against plague is not a statutory 
requirement for travel to any country. The vaccination 
of populations in plague endemic areas of the world is 
not routinely indicated, because the incidence of disease 
is relatively· low and most cases of disease are of the 
bubonic form, which can be treated with antibiotics. 
Use of the vaccine in the indigenous population might 
be considered in areas where there is recurrent or in-
tense plague activity that cannot be controlled by other 
measures. This situation might arise after natural disas-
ters, especially when there is disruption to sanitation 
systems. Because several months are required to com-
plete the course of vaccination, however, the v<~ccine has 
a limited use in controlling sporadic pl<~gue epidemics. 
Use of the vaccine might be indicated in individuals who 
regularly come into contact with an imals where enzootic 
plague foci are known to be present. ' 
Precautions and Contraindications 
The Greer vaccine should not be used in individuals 
who h<1ve a history of hypersensitivity to any of the 
Table 30-1. SCHEDULES AND DOSAGES OF GREER AND COMMONWEALTH SER UM lABORATORIES 
KillED WHOlE-CEll VACCINES 
VACCINE 
(;rccr 
Commonwealth Scrum l..ihocnoric' 
·one: rn 3 mum hi\ after !ro t.l rt 
f Sox mon1h' .of1cr >i.lrl. 
AGE OF RECIPIENT 
> I H vr 
tJ 1no~] vr 
1- ro rr . 
7- 1 t' H 
> 12 ~· r 
First Dose 
1.0 mL 
0. 1 mL 
0.2 ml. 





0. 1 mL§ 
0.2 mL~ 
0.1 Ill 1.~ 
0.) mL§ 
Third Dose 
0.2 m Lt 
0 .1 ml.§ 






O. l ml.ll 
0.5 mL' 
1/\1 6-month intcrvod, .tftl'f dn't." l, .._-.m lte C\h:ndcd IU 1- to 1 -rc:.ar lll1l'r"\'.ll' Ill du.· t,.' ,hl..' of lndi\tdu.tJ, "ho h.tn . .- rcn .. ' l\l'd thrl'l..' nr more huu .. tcr Jo-.c!l .11 (, . 
uwnth imcrv:d'l. 
~One to 4 wcch .lflt.:r pn.:' 1011, du,c: 
llt\ t ft-rruunh rntcn•.d, .1ftc:r d,.,l.:' \. 
• t\t (,-month intt.:n .rl ' .1f11..-r dn''-' ! . tin''-' L lll l te rnlutol to 0. 1 ml. mll.lllc.: l'lll.rll~ fnr 111dl\ rdu.d, "hu h .l\\.' n.:.u .. trmh tu pn.: ' 11111' do'~.: ' ,,f the ,·.rnrnc:. 
vaccine componc.:nts (c.~ .• bc.:cf protein, soy, casein, sul-
phite, pheno l, or fornl:lldehydc). The safety and efficacy 
of the vaccine in people younger than 18 years or in 
pregnant women <lrc not known. 
RESULTS O F VACCI N ATION 
Immune Responses 
Although Y pestis produces <1 variety of potentially 
protective antigens (including Fl antigen, V antigen 
and other Yops, and lipopolysaccharide), most workers 
consider that antibody against the F l antigen is the 
key protective response induced by killed whole-cell 
vaccines. Although the V antigen is known to also in-
duce a protective response against Y pestis, the level of 
V antigen is low or undetectable in ki lled whole-cell 
vaccinesY There is good experimental evidence that the 
titer of F1 antibody, determined by passive hemaggluti-
nation, does correlate with protection against plague in 
animal models.41 Ninety percent of animals with anti-FI 
passive hemagglutination titers of l2 8 survived challenge 
with 1 X 1 QJ to 5 X I os cfu of }~ pestis, whereas the 
proportions of animals with titers of 3 2 to 64 or 16 that 
survived were 46 and 6%, respectively. Passive immuni-
zation studies with sera obtained from immunized ani-
ma)sJJ or humans4 J also suggest that anti-Fl passive 
hemagglutination titers of 1:128 or greater were protec-
tive. However, the accepted test for demonstrating the 
efficacy of vaccines involves passive immunization of 
mice with sera and the demonstration of an MPI of I 0 
or less. More recent trials with the Greer Laboratories 
vaccine suggest that 55 to 58% of individuals develop 
an antibody response with an MPI of I 0 after two 
vaccinations5; however, even after multiple (an average 
of 5) vaccinations, 8% of individuals fail to develop any 
antibody response. 
Protective Efficacy 
None of the plague vaccines available have been sub-
jected to a randomized , clinically controlled study in 
humans. Although controlled clinical srudies are desir-
able, the sporadic and relatively low incidence of plague 
means that such studies would be difficult to conduct. 
Evidence for the efficacy of killed whole-cell vaccines is 
based mainly on srudies in animals, on evidence that 
they induce antibody in hum;ms that can passively pro-
tect animals, and on data obtained from Vietnam. From 
196 l to 1971 , many thousands of Vietnamese civilians 
developed plague (33 3 cases/ I 0'· person-years of expo-
sure), but the incidence of disease in immunized U.S. 
troops based in Vietnam during this period was low. 
(The total of 8 cases represents I c1se per 10'• person-
years of exposure> +~) Although this difference in the 
incidence of disease mi g-h t bc attributed to different 
exposures of these populations to r pc.l'ti.l', it is worth 
noting that many military personnel developed murine 
typhus, which is also transmitted b~· X. cbeopis. ; further-
mort:, serologica l srudics indicated that some immunized 
Pl.l.~lll' 7;9 
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individuals were exposed ro )~ fJt'.rti.r and dc\·eloped sub-
clinical infecti ons .+~ The cflectivencss of this vaccine 
ag;linst the pneumonic form o( the disease is lllOre ques-
tionable, howeve r, and cases o( pneumonic pbgue have 
been reported in vaccinated individuals."·~' In thc mu-
rine model of disease, immunization wi th the killed 
whole-cell vaccine provided protection against a subcu-
taneous challenge with ) ~ pcsti.1.!'' but not against an 
inhaled challenge with the bacterium.~r. Although these 
data alone do not necessarily indicate the effectiveness 
of the vaccine in humans, when viewed alongside the 
reports previously cited, the overall evidence is that the 
vaccine is better able to protect against bubonic plague 
than against pneumonic plague. Most or these srudies, 
however, have been carried out using fol • stra ins of Y. 
pestis, and the ability of the vaccine to provide protection 
against Fl - strains of Y. pestis, whiob are rarely encoun-
tered in natural infections, has not been tested. 
Immunization of mice with the EV76 strain does 
induce protection against both subcutaneous and inhala-
tion challenges with virulent strains of Y. pestis,lY and in 
this respect the performance of this vaccine is superior 
to the performance of the killed vaccines. The enhanced 
protection offered by the live vaccine might be due to 
three factors . First, it is known that the killed vaccine 
does not contain immunogenic levels of several outer 
membrane proteins such as V antigen42 ; second, it has 
been suggested that the chemical or heat inactivation of 
the bacterium results in structu ral changes in other sur-
face components such as the F I antigenl0 ; third, local 
responses to vaccination with EV76 in mice suggest that 
a limited local infection is initiated and that the duration 
of exposure to the antigenic complement is therefore 
prolonged. The immune response induced by the live 
attenuated vaccine may be more authentic than that 
induced by the killed whole-cell preparations. 
Persistence of Immunity 
There have been few studies to examine the duration 
of immunity to Y. pestis after immunization with killed 
whole-cell vaccines. However, it is generally considered 
that immunity is short lived. Booster immunizations may 
be needed at 6-month intervals to ensure that a protec-
tive response is maintained. 
Side Effects 
The use of killed whole-cell vaccines in humans has 
highlighted the reactogeniciry of the vaccine.•'· ~~ The 
manufacturer of the Cutter vaccine reported that reac-
tions such as malaise, headaches, loca l erythema and 
induration, or mild lymphadenop;Hhy occurred in ap-
proximately I 0% of v;Jccinees; this frequency of side 
effects is reported by other workers.~" Data provided by 
the manufacturer of the Greer vaccine suggest th<lt more 
than I 0% of vaccinees suffcr sidc l:ffects ('1:1ble 30-2). 
Allcrgic reactions, evidenced mainly as urticaria, occur 
infrcquently.~- One study found that the frequency or 
l_ 
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·vaccinccs rccei,·cd the ~cmnd dose 30 doys a.ftcr the first dose. 
side effects was much greater in individuals who had 
previously been immunized with the live EV vaccine.40 
T he safety of the EV76 vaccine has been questioned 
by several workers. Russell and colleagues reported that 
immunization of mice induced severe side effects and 
occasional (approximately l %) fatalities .19 
FUTURE DEVELOPMENTS 
Subunit Vaccines 
Although the killed or attenuated vaccines just de-
scribed have several shortcomings, they do indicate that 
protection against both the bubonic and pneumonic 
forms of the plague is possib le. Work toward the devel-
opmen t of a subunit.,vaccine is supported by two obser-
vations. First , the major ;tntibody response to Y. pestis 
(in sera from either vaccinated or convalescent individu-
als) is known to be directed ag;tinst the Fl antigen.4 '1 
Second, the V antigen has <lttracted attention as a com-
ponent of <l vaccine, '" and the improved performance of 
live vaccines over killed vaccines might be explained by 
the ability of only the live vaccines to induce an antibody 
response to the V <111 ti gen. 4 ~ 
The Fl antigen Clll he produced from cultures of r 
pestis,<~.'! but recent studies have used n:combinant fl 
antigen produced by expressing the m/ operon in Ercbe-
1·itbin w/i bacte ria. " lntr<tperiwneal or intr;tmuscular im-
munization with mrive Fl or rFI antigens adjuv;tntcd 
with alum induced ;ln immune response that protected 
mice against ;l subcutaneous challeng<.: with as many as 
I 0' cFu of viruknt >: fJl'Stis. '"· 4 ! Although the F l antigen 
;llso indun:d pror<.:ction ;tg:tinst inh;t lation chall<:ngc \\'ith 
100 MLD of an Fl · strain of Y. pestix, '" there was 
concern th;H a v:tccine b;ts<.:d solely on the F I amigen 
would not provide protection ag;tinst natural ly occurring 
but virulent f l strains of>: pesti.r. T he production of 
V antigen for vaccmc studtcs has, until recently, been 
difficult. The V antigen is produced at low levels by J: 
prst1:r and readi ly degrades during purification. As a re-
sult, difficulties in preparing the V antigen from this 
source precluded the evaluation of this antigen in active 
immunization studies. The fusion of the gene that en-
codes the V ;mtigen (krV) with a carrier protein such as 
protein A or glut:nhione-s-rransferase allows a high level 
of production of the V antigen in E. coli bacteria. The 
V antigen can be cleaved from the ca rrier protein using 
a site-specific protease such as throm bin o r facto r X.,. 
Immunization of mice in traperitonea lly with either the 
fus ion protein or the V antigen adjuvanted with alum 
induced protection against a subcutaneous challenge 
with 4 X I 06 cfu of Y. pestis.'" A significant advantage 
over the F l an tigen is the ability of the V antigen to 
induce protection against virulent F I - strains of Y pestis 
such as the J ava 9 strain . Protection against 1000 or 
more MLD of either vi ru lent F l + or F l - strains of Y 
pestis given by the inhalation route has been reported.54 
The protection afforded individually by the Fl and V 
antigens was defeated by subcutaneous challenges of 109 
cfu of Y. pestis.42 Protection aga inst this challenge was 
achieved after intraperitoneal immunization with a mix-
ture of the F l and V an tigens.42 T he vaccine also pro-
tected mice against I 00 MLD of Y pestis given by the 
inhalation route (Table 30-3), suggesting that the vac-
cine would provide protection against pneumonic plague 
in humans.46 The advantages of such a combined subunit 
vaccine lie not only with the enhanced level of protec-
tion afforded against disease but also with the ability of 
th e vaccine to confer protection against both F l + and 
F l - strains of Y pestis. 
The mechanism by which this vaccine induces protec-
tive immunity has been the subject of considerable in-
vestigation during the past few years. The F l capsule is 
thought to inhibit phagocytosis of the bacterium by 
Table 30-3. PROTECTION AFFORDED BY KillED 
WHOlE-CEll VACCINE, EV76 VACCINE, OR 
F1- AND V-ANTIGEN SUBUNIT EXPERIMENTAl 
VACCINE AGAINST PARENTERAl OR 




Killed wholc-t·dl v:lcci nc 
1·:\17(, 
Fl + V 
•' J i.·~tt:J Ill B:llhh.· llll l:C. 
l' l<·,tcd in CB.\ note. 
PROTECTION ("'o SURVIVAL) 
AGAINST CHALL ENGE (MLD) 
Subcutaneous 
Rout e 
() ( 10')" 
(,() (2 X 10'')" 
100 (2 X 10'')" 
lOO (1 X 10'')" 
Inhalation Route 
0 (IO')t 
50 (1 X IU')t 
61) (R.5 X I U')t 
100(4 X IO' )t 
E\' /(1, :ltiCIHI.IIcd li\C \',t<...lil\t.' 'tr.un Cl! r {lf"\ll\; Fl + V. ,uhunll \ '.ltC.."IIh.' 
c,:u llt:1111111!! du: Fl .1nd V .uu i!!cll' ,.( J: /""''"· 
preventing C01nplcnH!nt- nH;di,ltcd opsonization.::. '~ 
Therefore, it is possible th;Jt induced antibody against 
the fl antigen opsonizes the bacterium and promott:s 
antibodr-dependenr ce llular cytotoxicity. Some vacci-
nated animals do appear to harbor the pathogen even in 
a mutated fl form . '" The killed whole-cell vaccines 
are less effective than purified Fl antigen in inducing 
high titers of antibody to f I ."'· 4 ! Antibody against the 
V antigen may also be of overriding importance in pro-
tection against plague, and immunization with V antigen 
has been shown to restore the ability of the host to 
produce tumor necrosis factor-a and -y-interferon in 
response to infection.15 Therefore, immunization with 
the V antigen would enable the host to mount a normal 
inflammatory response and thereby enable the host 
phagocytes to clear bacteria opsonized by antibody 
against Fl antigen. 
The FIN antigen subunit vaccine shows good prom-
ise for development as a replacement for the killed 
whole-cell vaccines. A further improvement might be 
achieved by developing an oral or intranasal formu la-
tion. Although the oral delivery of purified Fl antigen 
did not induce an antibody response,>~ microencapsula-
tion of the Fl and V antigens and induction of a protec-
tive response have been achieved and will facilitate intra-
nasal or oral delivery.57 Liposomal encapsulation of the 
plague subunit vaccine offers an alternative approach to 
mucosal delivery.57 Another approach relies on the oral 
delivery of Salmonella typhimw·ium that expresses the Fl 
encoding operon, which induced a high level of protec-
tion against subcutaneous challenge with Y. pestis.sH. 59 
Live Attenuated Vaccines 
The finding that the live EV76 vaccine induces pro-
tection against plague, although its use is accompanied 
by unacceptable side effects, has promoted some studies 
to develop rationally attenuated stra ins of Y pestis as a 
vaccine. \iVork towards this goal has been based on 
the finding that other Gram-negative pathogens can be 
attenuated by the introduction of mutations into genes 
essential for bacterial growth, virulence, or survival in 
the host. Mutations within genes involved in aromatic 
amino acid biosyn thesis have been shown to attenuate a 
variety of pathogens, iududing Y enterocolitica, S. typhi-
1111l1"ium, and Salmo11ella ~vpbi. An fi1'0A mutant of Y pestis 
was not attenuated in mice but was attenuated in guinea 
pigs, which subsequently developed antibodies to the Fl 
and V antigens.'~, Although these guinea pigs were also 
protected against a subsequent challenge with I 07 cfu of 
virulent Y pestis/'11 furtht:r work is needed to determine 
the reason for the species-dependent virulence of the 
nroA mutant before it can be considered for further srud-
tes. 
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Active Immunization with Recombinant V Antigen from 
Yersinia pestis Protects Mice against Plague 
SOPH IE E. C. LEARY,• E. OIANE W ILLIAMSON, KATE F. GRIFFIN, PAUL RUSSELL, 
STEPHEN M. ELEY, AND RICHARD W. TfTBALL 
Chemical and Biological Defence Establishment, Porion Dotvn, 
Salisbury, Wiltshire SP4 OJQ, United Kingdom 
Received 5 December 1994/ Returned for modification 13 February 1995/Accepted 30 April 1995 
The gene encoding V antigen from Yersirzia pestis was cloned into the plasmid expression vector pGEX-SX-2. 
When electroporated into Escherichia coli JM109, the recombinant expressed V antigen as a stable fusion 
prote in with glutathione S-transferase. The glutathione S-transferase-V fusion protein was isolated from 
recombinant E. coli and cleaved with factor Xa to yield purified V antigen as a stable product. Recombinant 
V antigen was inoculated intraperitoneally into mice and shown to induce a protective immune response 
against a subcutaneous challenge with 3.74 x 106 CFU of virulent Y. pestis. Protection correlated with the 
induction of a high titer of serum antibodies and a T-cell response specific for recombinant V antigen. These 
results indicate that V antigen should be a major component of an improved vaccine for plague. 
Plague is a zoonotic infection caused by the bacterium Yer-
sinia pestis and is transmitted among natural animal reservoirs, 
usually by a flea vector. Humans are an occasional host in the 
natural cycle of the disease, and bubonic plague, characterized 
by the swelling of local lymph nodes, may occur fo llowing the 
bite of an infected flea. One of the complications of bubonic 
plague is secondary pneumonia, and in these cases, the disease 
is readily transmitted from person to person by airborne drop-
Jets. 
Plague is endemic in regions of North and South America, 
Africa, China, and Asia (2). The current outbreaks are be-
Lieved to be part of the fourth world pandemic of the disease, 
and there is clearly a need to protect individuals living or 
travelling in areas of endemicity and laboratory workers han-
dling the bacterium. 
A number of vaccines for plague have been developed, in-
cluding the killed Cutte r USP vaccine prepa red in the United 
States and the live a ttenuated EV76 vaccine (8, 9). The Cutter 
USP vaccine was first manufactured in 1942 and consists of a 
formaldehyde-killed preparation of Y pestis derived from a 
viru lent strain (6). The vaccine is believed to be effective 
against bubonic plague, principally because there was a low 
incidence of the disease among inoculated U.S. troops in Viet-
nam (3). However, its ability to protect agai nst pneumonic 
plague is doubtful, and cases of this fo rm of the disease have 
been reported in vaccinated individua ls (8). In addition, local 
side reactions and systemic effects. ranging from mild head-
aches to severe malaise and fever, we re reported in 11 to 24% 
and 4 to 10%, respectively, of the individual inoculated with 
the Cutter USP vaccine (6). The EV76 vaccine was tested 
extensively and used in the former Soviet Union from 1939, 
a lthough its efficacy in evoking an immune response in humans 
is questionable (8. 9). It has been shown that the virulence of 
EV76 differs in several animal species, and nonhuman pri-
mates are particularly susceptible to a chronic infection with 
this strain (I 0). In the Weste rn world. the vaccine is considered 
to be unsu itable for mass vaccinations because of the everity 
of the side effects. 
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The identification of protective subunits of Y pestis cou ld 
enable an improved vaccine against plague to be developed. 
One of the potential protective subunits is V antigen, which is 
believed to have a bifunctional role in Y pestis. It is thought to 
act as a regulator of the low calcium response (14), and it may 
also fu nction as a virulence factor. The latter role was sup-
ported by the early observation that rabbit antiserum raised 
against partially purified V antigen provided passive protec-
tion to mice which had been challenged intraperitoneally with 
100 50% lethal doses (L050) of Y pestis ( 4). This result was 
later confirmed by raising antisera to purified V antigen, and it 
was shown that both monospecific polyclonal antisera (21, 22) 
and a monoclonal anti-V antibody {12, 18) provided passive 
immunity against a 5 to 10 minimum lethal dose intravenous 
challenge with Y pestis KlM. Recently, it was demonstrated 
that polyclonal antisera raised against recombinant V antigen 
or a protein A-V antigen fusio n (PAY) were also partially 
protective against Y pestis KlM (11) . By absorbing the antisera 
with truncates of PAY, it was deduced that at least one pro-
tective epitope lay between amino acids 168 and 275 of V 
antigen ( 11). 
The role of V antigen in virulence is unknown, but Nakajima 
and Brubaker {12) suggested that it may be immunosuppres-
sive, possibly by inhibiting cytokine synthesis, and so prevent 
the infilt ration of host inflammatory cells into infected organs 
(20, 22). The passive protection conferred by anti-V antigen 
serum may therefore be attributed to the neutralization of this 
immunosuppressive activity {12). 
The evidence described above suggested that V antigen 
could induce an immune response which protects against chal-
lenge with Y pestis. Previously, there was a brief report that 
guinea pigs immunized with a V antigen-rich fraction prepared 
from Y pestis were protected aga inst challenge with the bac-
terium (4). To examine this furthe r, we have expressed V 
antigen as a fusion with glutathione S-transferase (GST) in 
Escherichia coli, purified the recombinant protein as a stable 
product, and tested its immunogcnicity in vivo. Our results give 
the first detai led demonstration that V antigen, which is not 
contaminated with other compounds from Yersinia spp., is a 
highly effective protective antige n fo llowing active immuniza-
tion and indicate tha t it should be investigated as a major 
component of an improved vaccine for plague. 
MATERiALS AND METHODS 
Enzymes and rcagcnl s. Materials r\ll. the prcpar:11inn uf l!rtl\\ th media wen.: 
n~laincd from Oxoid Lld. or. Difco Lahoraltlric>. t\11 cnzyn~es u....:d in 1h~ ma-
nopulauon of DNI\ were \\blamed from Buchringcr Mannhcim UK Lld. and used 
a~ descrihcd in !he manuf:oclurcr's instrocloon,. All other chemical' and bin-
chemicals were obtained from Sigma Chemical Cu. unless lllh~mio;c indicated. 
Monuspecific ruhbit polyclonal ami-V and muu'e .omi-G~T sera \\Crc prepared 
byR. Brubakcr (Dep..rlmcnt ?f Microbinlngy. Michigan Stale Uni1c~i1y) and E. 
Wolhamson (Chemocal and Boologocal Defence E>!ablishmenl). re>pcclivcly. 
. Ba~lc~al strains a nd cultivation. Y. fK'.I'ti.l' GIJ was cuhured aerobically al 2x•c 
·~ a l1quod medoum (pH I>.X) containing 15 g o f f>rotcose Pepl<lllC. 2.5 g of liver 
doges!. 5 g of yeas! exlracl. and 5 g of NaC'I per !iter. supplemented with SO ml of 
0.257- hemin dissolved in 0.1 M NaOH (blood ba>e broth).£. mli JM lt)<) was 
cuhurcd and >lUred as described by Sa m brook cl al. ( 17). 
Manipulation of D A. Chromosomal D A was isnlaled from }~ pestis by the 
method o f Marmur (5). The gene encoding V antigen (/crV) was amplifkd frnm 
Y. pestis DNA by PCR with 125 pmol of primers homologous to sequences from 
the 5' and 3' ends of the gene ( 15). The sequences of the 5' primer (V/5'E: 
GAT CGAATTC+ATTAGAGCCTACGAACAA) and the 3' primer (V/J'C: 
GGATCGTCGACTTA"CATAATTACCTCGTGTCA) also included 5' re-
gions encoding !he restriction sites EcoRI :ond S(//1. respective ly. In addition. the 
nucleotides c• and A • were ahered from !he published sequence of /crV ( 15) to 
c~mplc.'e the EcoRI site and include an exlra. tcrmination codon (TAA), rcspcc-
tovely, m the amplified DNA. The PCR pnmers were prepared with a DNA 
synthesize r (model 392: Applied Biosystems). A D A fragment was obtained 
after 30 cycles of amplification (95°C 20 s: 45•c. 20 s: n •c, 30 s I model 96()() 
G.eneAmp PCR system: Perkin-Eimerl). The fragment was purified, digested 
wllh EcoRI and Sail, ligated with suitably digested plasmid pGEX-5X-2. and 
transfor.med into£. coli JM 109 by electroporation ( 17). A colony containing the 
recombonant plasmid (pV~ 1.00) ":as identified by PCR with 30-mer primers (5' 
nucleoudes located al poslloons )4 and 794 11 51) which amplified an interna l 
~gment of the lcrV gene. To confirm the nucleotide sequence of the cloned 
mscrt, sequencing reactions involving pVG 100 and primers designed from the 
lcrV gene ~ere performed with an a~tomated Taq polymerase cycle scquencing 
protocol woth nuorescently labelled d1dcoxy nucleo tides (CATALYST Molecular 
B!ology Labstation; Applied Biosystems). The reaction products were analyzed 
woth an automated DNA sequencer (model 373A: Applied Biosy terns). 
Expression or reeombinant V antigen (rV) in £. CJIIi. Cultures of £. coli 
JM~~/pVGIOO ':'ere grown in LB medium (17) containing 100 IL& of ampicillin 
ml at37"C until the A60<1 was 0.3. lsopropyl -~-o-thiogalactopyranoside ( IPTG) 
was !hen added to the culture to a final concentration of 1 mM. and growth was 
cont1~ued for a further 5 h. Whole-cell lysates of the bacte ria were prepared as 
descnbed by Sambrook et al. ( 17). and expression of the GST-V fusion protein 
wa~ e.xamined by staining 10% sodium dodecyl sulfale (SDS}-polyacrylamide gels 
(M ono-Protean 11; Bio-Rad) with Coomassie brilliant blue R250 and by Western 
blotting (immunoblotting) ( 17}. Western blots were probed with rabbi! anti-V 
scrum at a dilution of 1/4,000 or mouse anti-GST scrum at a dilution of f/1,000. 
and protein bands were visualized with a colloidal gold-labelled secondary anti-
body (Auroprobe BLplus; Cambio). 
Quantifica tion of GST-V fusion protein expression in vitro. Cultures of E. coli 
JMI 09 containing pVGIOO or pGEX-5X-2 were grown as described above. 
On:-milliliter aliquots were removed fro m the cu ltures in the logarithmic and 
stat ionary phases, and !he number of viable cells was determined by inoculating 
the ahquo1s onto L agar con tammg I()() ILg of ampici llin ml - 1• The cells were 
harvested from a second 1-ml aliquot by centrifugation and resuspended in 1 ml 
of phosphate-buffered saline (PBS). The cell suspension was frozen at -20"C for 
I h. thawed, and then sonicated on ice al IO"'o power three times for 30 s each 
(m~el XL2015 sonicator, 3.~-mm Micro1ip probe: Heat Systems Inc.). The 
;;omcates an d a s tandard soluuo n of rV (5 ILg ml - 1) were serially dil uted in PBS 
m~ mocro111er plate and allowed 10 bind overnight at4•c. The quantity of GST-V 
~usoon prolcm 111 each sonicate was determined in a standard enzyme-linked 
om~unosorbenl assay (ELl SA) with rabbit anli-V serum as the primary antibody. 
Antobodies were incubated in 1% skim milk flO"der in PBS. 
Purification of rV. £ . coli JM 109/pVG 100 was gro"n in five 100-ml volumes of 
LB as described above. The cells were harvested by centrifugation and re us-
pended in 3 ml of PBS. After the addition of 80 ILl of lysozyme ( 10 mg ml- 1 ). the 
cell suspension was incubated for 10 min a l 22"C. Tri10n X-lOO "as added to a 
final concentratio n of I%. and I he cells were frozen ( -20' C). thawed, and 
sonicated on ice a1 70% power three limes for 30 s each (model XL2015 
sunicator). The lysed cells were cemrifuged. a nd the supermllant was made up Ill 
30 ml with PBS and mixed with 5 ml of gluta thione Sepharose 4B (Pharmacia 
Biotech). which had been washed three times 11i1h PBS plus 0.1'1 Trilon X- 100. 
TI1e mixture was qirred for 18 h al ~·c. ccmrifuged and washed I\\ ice in 100 ml 
of PBS. and then packed inlo a chrummograph~ column (Poly-Prep: Bio-Rad) a> 
a SW~ slurry. The GST-V fu,ion protein wm. eluted with 10 ml of 50 mM Tris 
(p i I RO) conwining 5 mM reduced glutnlhionc (Pharmacia Bio lcch). After 
Llia\y,is again>! PBS. I he fu,ion prn1cin wa> clca1cd wilh factor Xa ( Bochringcr 
Mannhcim UK Lld.) for IX h a1 n •c al an cnLymc/fu>ion protein rat io uf 
approximate ly I :21 HI hy weight Ckaved GST and excess unci caved GST-V (bul 
nul factor Xa) were removed from 1hc '<olutiun hy aftinily ad,orpliun. a~ de-
'crihcd above. In leave purified rV. 
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. . tmmunit ..ntion \\ilh rV._ ~1x-wc: .: ~-old fcm:.tk llALB/c m•cc. rtii'\Cd under spc-
l"lhC-piitiHlg.c:n-frcc cond11u.1r1' (C'harlc~ Rs'l'l Uthuraturic.:". ~1argatc. Kent. 
United 1-:ongdum) were u>cd in !hi> >llody. 1\ gmup uf lh mice receoved intra-
t'l\!riton,•:tlly" 0.2-ml primary immunizing dm.c o l Ill IL!l of rV. pre,cllled in a 1:1 
w:Hcr-in·<lil emulsion with incomplete Frcund\ adjuvanl. On da~ ' 14 and 34. 
c:tch anomal received hou>ler intrapcril<>neal do:,c,, prepared a' de,crihcd above. 
On da~ 1>-l. six animals were >anificed. and !heir tis.,ues we re removed for 
immunological analy"''· '" described below. The remaining ammab were chal-
knged 1111h Y. fH!Stiv. An untreated control gruup of 16 ag<.:-malched mice wa> 
divided <imil:1rly in10 groups for tissue sampl ing and challenge. In a subsequent 
c.<pcnmcnl 10 determine !he degrc.: of protection against high<.:r challenge doses 
of Y. pe-11.1. groups of five or six rV-immuniLed and control mice \\ere u>cd. 
Measurement or serum antibody titcr. Blood wa~ sampled by cardiac puncture 
frum mic~ aneslhctized intraperi!Uneally wilh a 0. 1-ml cocktail containing 6 mg 
of Domnnr ( orden Lahoratorics) and 27 IL& of ketamine hydrochloride (Kcta-
lar: Parkc-Davis). TI1e samples \\Cre pooled. and !he serum was scpar;o!cd. The 
>oCrum a ntibody 1i1cr was measured by a modified ELISA (23). Briefly. a micro-
! iter plate was coated with rV (5 ILg ml 1 in PBS), and the test sera were serially 
diluted in duplicate on th<.: plate. Bound antibody was detected wilh peroxidase-
la he lied conjugates of a nti-mouse polyvalent immunoglobulin. The 1i1er of spe-
cific amibody was estimated as the maximum dilution of serum giving an absor-
bance reading of greater than 0.1 U. after subtraction of the absorbance due to 
nonspecific binding detected in the control sera. 
Isolation or purified T cells from the spleen. A crude suspension of mixed 
spleen cells was prepared by gen tly grinding the spleen on a fine "ire mesh. The 
cells "ere flushed from the splen ic capsule and connective tissue with 2 ml of 
tissue cuhurc medium (Dulbecco modified Eagle medium IDMEI\.fi with 20 mM 
L-glulamine. 10~. U of penicillin filer - •. and 100 mg of streptomycin I iter 1). A 
populauon of miXed lymphoeytes was separated from the spleen cell suspension 
by den ily gradient centrifugmion on Ficoii-Hypaque (lymphoeyte separation 
medium: ICN Flow). A mixed acridine orange (0.0003% lwt/voli} and ethidium 
bromide (0.001 % lwt/volj) sta in was used to determine the percen1age of viable 
cells in the preparation. 
.The mixed lymphocytes were incubated with sheep anti-mouse immunoglob-
ulin G-coated Dynabeads (M450, Dynal UK) at a ratio of I :3 (numbers of 
cell numbers of beads) for 30 min at 4°C. The Dynabead-linked B cells were 
rcmo1 ed by magnetic separation. and the remaining T cells were resuspended in 
DMEIII. supplemented with antibiotic and 10% (voiJvol) fe tal calf serum (FCS), 
a1 the demed cell density for seeding onto microtiter plates. 
In ,·itro proliferation of crude spleen cells a nd purified T cells against rV. 
Dou~ling dilutions of rV or concanavalin A (positive cont rol) in DMEM (range_ 
0 10 )0 ILg ml- 1) were made in the wells of a micro1i1er plate such 1ha1 0.1 ml 
remained in each well. Negative controls consisted of 0.1 ml of DMEM alone. An 
equal 'olume of the crude spleen cell suspension or purified T -cell suspension 
was seeded into each well at a minimum density of 4.9 x 104 cells and incubated 
for 72 h at 37"C (5% CO:z). One microcurie of i3H]thymidine (imethyf-lHithy-
midinc. 74 GBq mmol- 1; Amersham) in 30 ILl o f DMEM supplemented with 
10'1: FCS was aliquoted into each well. and incubation was continued for 24 h. 
The "ell contents were harvested onto glass fiber filters with a cell harvester 
(Titenek), and discs representing each well were punched from the filler mats 
into 1.5 ml of scintillation fluid (Cytoscinl; ICN Biomedicals Inc.) to measure the 
incorporation of [3 H]1hymidine into cells. The cell stimulation index was calcu-
lated from four replicates as the mean of the counts per minute of the stimulated 
cells di1 ided by the counts per minute of I he negative control cells. 
Challenge with Y. pestis. Groups of 5 10 10 mice from the immunized and 
control gr.oups were challenged subcutaneously with 0.1-ml aliquo1s of Y. pestis 
GB a! , ·aroous cell densities (16}. Strain GB was isolated from a fatal human case 
of plague and has a median lethal dose of < I CFU in BALB 'c mice by the 
ubcu~aneous r?ute (16). The mice were observed for 14 days. and where ap-
propnate. the lime to death was recorded. A postmortem was carried ou1 on all 
animals. The livers and spleens were examined for enlargement To test for the 
presence of Y. fH!Stis, samples of blood. liver, and spleen were also smeared onto 
Congo red agar Hnd incubated at 2s•c for 48 h. 
RESULTS 
Cloning and expression of fer V in £. coli_ The lcrV gene was 
ampli fied by PCR from the chromosomal DNA of Y. pestis GB 
and cloned downstream of the GST gene encoded by the 
plasmid pGEX-SX-2 to form an in-frame fusion. An IPTG-
induced culture of E. coli JMl 09, containing the recombinant 
pia mid pYGIOO, produced a unique protein which wa de-
tected by Western blotting with rabbil anti-V and mouse anti-
GST -era (Fig. I). The molecular weight of this protein was 
determined hy SDS-polyacrylamidc gel electrophoresis (SDS-
PAG E) and was similar to the predicted value of 63.700 for the 
GST-Y fusion . An equivalent protein was not expressed in 
IPTG-induced cultures of E. coli JM 109/pGEX-5 -2. 
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FIG. I. Coomassie brilliant blue R250-stained proteins separated by SOS· 
PAGE ( 10% polyacrylamide gel) (A) and W~stern blots of duplicate gels probed 
with a monospecific rabbit polyclonal anti· V serum (B) o r a mouse polyclonal 
anti-GST serum (C). Lanes: M, positions of protein molecular weight markers 
( 101); I. purified rV; 2. purified GST-V fusion; 3, £ . co/i/pVG 100 cell lysate (plus 
IPTG); 4, E. co/i/pGEX-5X-2 cell lysate {plus IPTG). 
Purification of rV. The GST-V fusion protein was isolated 
from 0.5 I iter of an E. coli JM109/p VG lOO culture and induced 
with IPTG, and rV was cleaved from the carrier protein with 
factor Xa. From the amino acid sequence of the GST-V fusion 
(translated from the nucleotide sequence), it was apparent that 
the residues Gly-lle-Pro-Giy were located downstream of the 
factor Xa cleavage site, and it was predicted that these residues 
were added to the N terminus of rV. When examined by 
SOS-PAGE, Coomassie brilliant blue R250 stained only one 
band in the rV preparation (Fig. lA), and by Western blotting, 
breakdown products of the purified protein were not detected 
with rabbit anti-V serum (Fig. lB). The molecular weight of rV 
was estimated to be 36,000 by SOS-PAGE. 
Quantification of GST-V expression in vitJ·o. To determine 
the level of expression of GST-V in vitro, sonicates were pre-
pared from logarithmic- and stationary-phase cultures of E. 
coli JMJ 09/p VG LOO and analyzed by ELISA with rabbit anti-V 
serum as the primary antibody. Expression of GST-V from 
logarithmic- and stationary-phase cultures occurred at a low 
level ( < 10 f!..g ml - t) without induction with IPTG. However, in 
the presence of IPTG, expression was increased more than 
10-fold, reaching levels of 130 f.l.g ml-t in the logarithmic-
phase culture and 400 f.l.g ml - 1 in the stationary-phase culture. 
This increase in expression was observed despite 4-fold and 
50-fold reductions in the viable cell densities in the logarith-
mic- and stationary-phase cultures, respectively. The GST-V 
fusion protein was not detected by ELISA in cultures of£. coli 
JM109/pGEX-5X-2. 
Titer of serum antibodies in rV-immunized animals. Mice 
were inoculated intraperitoneally with three I 0-f.l.g doses of rV. 
On day 64, blood was sampled from six animals and pooled, 
and the titer of rV-specific serum antibodies was determined. 
lNFECf. IMMUN. 
3.5 • Immune T cells 14.9 x 10' well-
1) 
IZl Immune spleen cells 17.5 x 101 well-1) 
3.0 IZI Control spleen cells {1 x 10° well-
1) 
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FIG. 2. Proliferation of crude spleen cells and purified T c~ll~ . isolated from 
rV-immunizcd or control mice, against rV. The results show the means of four 
replicates + standard errors of the means. 
Immunized animals developed a high titer (1:128,000) of cir-
culating immunoglobulins with specificity for rV. 
ln vitro proliferation of crude spleen cells and purified T 
cells from rV-immunized mice. The ability of the rV antigen to 
stimulate aT-cell response was determined by assaying in vitro 
the proliferation of crude spleen cells and purified T cells upon 
reexposure to rV. Proliferation was observed in both cell pop-
ulations, although the response was greatest in the purified T 
cells, with a peak stimulation index at 25 f.!..& of rV ml - 1 in the 
tissue cu lture medium (Fig. 2). As expected, a significant 26-
fo ld increase in the response to l.S f.l.g of concanavalin A ml- 1 
was also observed in the T-cell popu lation, which confirmed 
the efficiency of the purification process. CeU staining methods 
also indicated that the T-cell population was more than 95% 
pure (data not shown). 
Protection against challenge with Y. pestis. In initial experi-
ments to investigate the protective efficacy of rV, groups of LO 
rV-immunized or control mice were challenged subcutane-
ously with l22 CFU of Y pestis GB. All of the rV-immunized 
animals survived the challenge, although the controls suc-
cumbed with a mean time to death of ll9 ::!::: 4.9 h. Subse-
quently, groups of five rV-immunized mice were challenged 
with Y pestis GB to determine the degree of protection at 
higher doses (Table l). All of the immunized animals were 




TABLE I. Protection of rV-immunized mice against 
challenge with Y. pestis" 
Challenge do~e No. of survivo rs/ Time 10 death 
(CFU) total no. (h)" 
3.74 X 106 5/5 
3.74 X 105 515 
3.74 X 10" 4/5 84 ~ 0 
3.74 X 101 515 
374 5/5 
37.4 0/6 132 ~ 5.7 
" Groups o f five to six rV-immunizcd ~tnd control mice were challenged sub-
cutaneously with a range of doses of Y. pestis GB and observed for !4 days. 
Where necessary. the mean time to death was eMimated. 
• Values arc means ~ sta ndard errors o f the means. 
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visible symptoms for the 14-day observation period. The only 
exception occurred in the group which received 3.74 x 104 
CFU, in which one of five mice died at 84 h postchallenge. This 
mouse was assumed to be less hyperimmune than other ani-
mals in the group. In contrast, all six mice in the control group, 
which received a low dose of Y pestis, succumbed to the chal-
lenge. 
Postmortem analysis of challenged animals. A postmortem 
was conducted on animals challenged with Y pestis either at 
the time of death or after the 14-day observa tion peri od. By 
inoculating tissue samples onto Congo red agar, Y pestis was 
detected in the blood, livers, and spleens of all mice in the 
control groups, which succumbed to the challenge with the 
bacterium, confirming that plague was the cause of death. 
However, tissue samples removed from surviving rY-immu-
nized animals on day 14 postchallenge did not contain Y pestis 
ce lls. There were no visible morphological changes to the livers 
of the rY -immunized mice, although the spleens were enlarged 
in 90% of the animals, indicating that there had been a recent 
acute infection. In the majority of the affected animals (ap-
proximately 80% ), the spleens were only slightly larger than 
normal. Morphological changes to the livers and spleens of the 
control an imals were not observed, mainly because the animals 
succumbed to the infection before these effects were notice-
able. A postmortem was not conducted on the rY-immunized 
mouse which died 84 h after the challenge, because of the onset 
of rigor mortis. 
DISCUSSION 
When extracted from Y. pestis, V antigen degrades during 
the purification process, yielding five antigenic fragments ( I). 
A similar pattern of degradation was observed for recombinant 
V antigen purified from a protease-negative strain of £. coli 
containing the fcrGVH operon ( 11). These observations led to 
the concepts that V antigen may undergo autocata lytic hydro-
lysis or, during purificat ion, become su ceptible to physical 
stress or contaminating proteases ( I , 12). The difficulty in 
obtaining sufficient quantities of the purified protein has hin-
dered a full investigation of the role of V antigen in the reg-
ulation of the low calcium response, viru lence, and in partic-
ular, immunosuppression ( 12). 
In this study, rY was purified in a stable form from the 
cytoplasm of E. coli, thus suggesting that the protein lacks 
au toproteolytic activity. This supports the previous finding that 
V antigen from Yersinia pseudotuberculosis and Yersinia entero-
colitica is not prone to degradation ( 1 ). The fusion of V antigen 
to N-terminal carrier proteins, such as GST or protein A ( ll), 
may also protect the protein from physical or exogenous pro-
teolytic degradation during cell disruption and the initial stages 
of purification. 
We have reported that rY, produced as a GST fusion , is 
expressed at a high level in £. coli ( 400 ~g ml of stationary-
phase culture 1), and that the fusion was easily isolated in one 
step by affin ity chromatography to yield a stable product. 1n 
this respect, our results reflect those of M otin et al. ( ll ), who 
produced a fusion of protein A with a V truncate lacking 67 
amino acids at the N terminus (i.e., PAY). However, the 
GST-V fusion described here can be cleaved specifically with 
the enzyme factor Xa, thus avoiding the need for the stringent 
acid hydrolysis required for the cleavage of PA V ( 11 ), and the 
apparent yield of rY is higher than that indicated by Motin et 
al. ( 11 ). In addition, the product cleaved from GST-V repre-
sents the complete V antigen molecule. Therefore, we have 
developed a means of producing a stab le form of V antigen, 
which can be purified in large quantities and is free from other 
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contaminating Yersinia antigens, thus providing a reliable 
source of the prote in for further investigation of its role in 
virulence and the regulation o f the low calcium response. 
The molecular weight of rY was estimated to be 36,000 by 
SDS-PAGE, which is similar to the values of 37,000 reported 
for native V antigen (1) and 37,200 predicted from the amino 
acid sequence. Recombinant V antigen was also recognized in 
Western blots by monospecific polyclonal antiserum raised 
against native V an tigen, indicating that the antigenicity of the 
recombinant protein had been preserved. 
When used to inoculate mice, purified rY elicited solid pro-
tective immunity against a subcutaneous challenge with up to 
3.74 X 106 CFU of Y. pestis GB. Protection was correlated with 
the induction of a high titer of specific circulating antibodies 
(I: 128,000) in the immunized animals and the induction of a 
significant proliferative response in purified T cells when re-
stimulated with rV in vitro. Thus, we have demonstrated that 
rY is a highly protective immunogen which is able to stimulate 
effectively both serum antibody and T-cell responses. 
The protection offered by active immunization with rY sup-
ports a number of previous studies showing that anti-V serum 
confers passive immunity in mice aga inst low challenge doses 
of 10 minimum lethal doses or 100 LD50 of Y pestis. Passive 
protection was first demonstrated with antisera raised against 
partially purified V antigen (4). Subsequently, improved tech-
niques for the purification of V antigen allowed anti-V sera of 
greater specificity to be developed, and these preparations 
were further purified by absorption with cells and outer mem-
branes from Yersinia species and by isolation of the gamma 
globulin (I , 12, 21). Finally, an unambiguous indication of the 
role of anti-V sera in protection was shown by passively ad-
ministering monoclonal anti-V antigen (12) and polyclonal 
antisera raised against purified PA V ( Ll), although immuni ty 
was not complete in all animals challenged with 10 minimum 
lethal doses. Our results complement these findings by dem-
onstrating the ability of highly purified rY, which is not con-
taminated with other compounds from Yersinia spp., to provide 
protection in an active immunization schedule. In addi tion, 
immunization with rY elicited solid protection aga inst a Y. 
pestis dose of more than 106 median lethal doses, which is 
approximately 104 -fold higher than that shown previously (4, 
11 , 18, 21, 22), and against the highly virulent strain GB ( 16). 
In many protection studies ( ll, 18, 21, 22), the challenge or-
ganism was Y pestis KIM, a nonpigmented mutant, which is 
virulent on ly by intravenous injection (11). 
Although the median lethal dose of Y pestis GB in rY-
immunized mice has not been calculated, rY provided protec-
tion against a challenge dose which was more than I 06-fold 
higher than the median lethal dose of Y pestis GB in nonim-
munized mice ( 16). It may be significant that an equivalent 
decrease of at least 106-fold was observed in the lethality of an 
fcrV-negative mutant of Y. pestis ( 14). The ability of rY to 
induce protective immunity emphasizes the idea that V antigen 
plays an important role in the virulence of Y pestis. 
Russell et al. ( 16) reported that Pon on Outbred mice inoc-
ulated intramuscularly with a single dose of the live vaccine 
strain EY76 were protected against a challenge with 5.75 X 106 
CFU of Y. pestis GB. In contrast, mice which received two 
intramuscular doses of the Cutter USP vaccine were protected 
fully up to a challenge dose of only 5 X 103 CFU (16). We have 
demonstrated that immunization with the subunit rY confers 
at least a similar level of protection against Y. pestis as these 
whole-cell vaccines. Furthermore, rY-immunized mice did not 
display external symptoms of disease, even after challenge with 
the highest dose of Y. pestis, and at postmortem, the only 
indication of infection was a slightly en larged spleen. 
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The absence of Y. pestis in the livers and spleens of vacci-
nated mice and the lack of macroscopic lesions suggested that 
the immune response mounted against rV prevented the bac-
terium from colonizing these organs and forming characteristic 
areas of necrosis (20, 22). fn vivo, Lcr · Y. pestis has been 
shown to suppress the production of the cytokincs tumor ne-
crosis factor alpha and gamma interferon in the tissues of 
infected mice (12). The passive inoculation of monospecific 
polyclonal anti-V sera has been linked to the inhibition of this 
immunosuppressive activity, the promotion of Y. pestis clear-
ance from the liver and spleen, and protection in animals 
challenged with Y. pestis ( 12, 21 , 22). Direct administration of 
exogenous tumor necrosis factor alpha and interferon gamma 
has also been shown to promote clearance of Lcr+ Y. pestis 
from the spleens of infected mice (12). It is possible that the 
absence of Y. pestis in the organs of rV-vaccinated mice, de-
spite the large challenge doses, is due to the effective induction 
of circulating antibodies to V antigen and the consequent de-
velopment of antibacterial responses, which include the pro-
duction of these cytokines. 
Other subunits of Y. pestis which are important in eliciting an 
immune response to plague have been identified. For example, 
a single intramuscular dose of purified Fl capsular antigen 
provided protection against an intraperitoneal challenge with 
105 CFU of Y. pestis (19), and immunization with recombinant 
Salmonella typhimurium aroA expressing Fl protected mice 
against a subcutaneous challenge with approximately 50 CFU 
(13). However, the high degree of protection conferred by rV 
in vaccinated animals indicates that this protein is one of the 
most important immunogenic subunits of Y. pestis. A subunit 
vaccine incorporating rV has some advantages over the current 
whole-cell vaccines: rY is simple to prepare and free from 
other toxic components of Y. pestis. As a result, it is likely to be 
safer and less reactogenic than either the live EV76 vaccine or 
the killed Cutter USP vaccine. 
A requirement of an improved plague vaccine would be to 
induce mucosal and systemic immune responses, since immu-
nity at the lung surface would be an important factor in pro-
tecting against the pneumonic form of plague, which is trans-
missible from person to person. The efficacy of the current 
whole-cell vaccines in protecting against pneumonic plague is 
largely unknown, but because they are administered by paren-
teral routes, they are unlikely to elicit a mucosal immune 
response (7). This is supported by reports of pneumonic plague 
occurring in individuals inoculated with the Cutter USP vac-
cine (8). We are investiga ting a number of delivery systems for 
V antigen which are designed to induce mucosal and systemic 
immune responses. If these delivery systems are able to present 
V antigen effectively and stimulate protective immunity, they 
will form the basis of novel vaccines which have the potential to 
protect against both bubonic and pneumonic plague. 
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The purified recombinant V antigen from Yersinia pestis, expressed in Escherichia coli and adsorbed to 
aluminum hydroxide, an adjuvant approved for human use, was used to immunize outbred Hsd:ND4 mice 
subcutaneously. Immunization protected mice from lethal bubonic and pneumonic plague caused by C092, a 
wild-type Fl + strain, or by the isogenic Fl- strain C12. This work demonstrates that a subunit plague vaccine 
formulated for human use provides significant protection against bubonic plague caused by an Fl- strain 
(C12) or against substantial aerosol challenges from either Fl + (C092) or Fl - (Cl2) Y. pestis. 
Yersinia pestis is the etiological agent of bubonic and pneu-
monic plague. The current plague vaccine USP, which is li-
censed for human use in the United States and the United 
Kingdom, relies on the Y. pestis-specific Fl capsule protein as 
the principal immunogen (26). While indirect evidence sug-
gests that the vaccine was effective in preventing bubonic 
plague in U.S. soldiers in Vietnam, pneumonic cases did occur 
(10, 24). This Formalin-killed, whole-cell vaccine offers little 
protection to guinea pigs and mice (4, 31, 36) or monkeys (30) 
challenged by aerosol with wild-type FJ + Y. pestis and essen-
tially no protection to mice challenged with an Fl - Y. pestis 
strain ( 18, 47). A Formalin-killed, whole-cell preparation sim-
ilar to the plague vaccine USP protected nonhuman primates 
challenged intratracheally from pneumonic plague {16). This 
preparation used the Yreka instead of the 195/P strain of Y. 
pestis which is used in the plague vaccine USP. Whether pro-
tection from pneumonic plague was due to the method of 
challenge or differences in antigen expression of the two strains 
is unknown, but the data suggest that partial protection against 
pneumonic plague by wild-type Y. pestis whole-cell vaccine was 
possible. 
A live, a ttenuated Y. pestis vaccine strain (EV76) has also 
been used as a human vaccine and was recently compared with 
the plague vaccine USP in inbred mice. While the live EV76 
vaccine conferred greater protection against infection with 
wild-type Y. pestis, this vaccine eau ed severe adverse reactions 
in the mice (32). Variabl e virulence of the live vaccine strains 
in animal models and reactogenicity in humans has prevented 
this vaccine from gaining worldwide accepta nce (24, 42). 
Recently. isogenic Fl - strains of Y. pestis were derived from 
fu lly virulent wild-type strains (14. 15, 48) . These Fl • -FI -
isogenic strain pairs were shown collectively to be vi rulen t for 
mice ( I 4, 48) , guinea pigs ( I 4). and African green monkeys 
( 12). These genetically characte rizt:d variants confirmed ear-
lier studies in which phenotypically defined Fl strains were 
• orrcsponding author. M<~iling addrc,s: Bacteriology Division, 
USAMR IID. Ft. Dctrick. Frcdcrick. MD 2 1702-5011. Phone: (301) 
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isolated (8, 43). These findings identified the need for a plague 
vaccine that could protect against Fl - variants, even though 
only one phenorypically Fl - organism has ever been reported 
from a fatal human case (46). Further, passive immunization 
with Fl monoclonal antibodies (2) o r active immunization with 
the recombinant Fl protein (4) protected mice against fatal 
disease; howeve r, Fl - variants were isolated from the spleens 
of some survivors. A vaccine composed of multiple immuno-
gens should reduce the possibility of selecting variants that 
could produce a chronic infection and should protect against 
Fl - strains. 
Burrows and Bacon originally suggested that the V antigen 
of Y. pestis could be an important immunogen (9). Later, Law-
ton et al. (21) demonstrated that polyclonal antiserum contain-
ing V antibody or active immunization with partially purified V 
antigen, could protect against a virulent Y. pestis parenteral 
challenge. More recently, protection obtained by using poly-
clonal monospecific V sera ( 40) or V monoclonal antibodies 
(27, 35) confirmed the ability of V antibody to passively protect 
against a Y. pestis challenge. 
Brubaker e t al. (7) reported the V antigen to be unstable. 
Therefore, they developed a protein A-V fusion protein to 
stabilize the V protein and showed that immunization with this 
fu ion protein was efficacious against an attenuated Y. pestis 
strain that was lethal to mice inocu lated intravenously (28). 
More recently, Lea ry e t al. (22) demonstraled that a recombi-
nam V protein (rV) i not autoproteolytic and, when combined 
with incomplete Freund's adjuvant, protected mice against a 
subcutaneous (s.c.) challenge with I 06 CFU of a virulem wild-
type Y. pestis stra in. These studies uggcsted that the use of rV 
in an improved subunit plague vaccine was feasible against 
bubonic plague from wild-type Y. pe ti ·. 
In thi study, we extended the previous finding that rV pro-
tects against bubonic plague by demonstrating that, when 
combined with an approved-human-use adjuvant to replace 
incomple te Frcund' adjuva nt, rV could protect against an 
F l Y. pestis challenge and also protect against pneumonic 
plague caused by either an Fl or a wild-rype F l • stra in of 
Y. pestis. 
Vo1 . 6-1. J9!J6 
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Bacterial strai ns a nd cullimtion. Th~ Y. pt'\1/,\ " ild-1ypc C092. biovar nricn-
la lis. i,ulatcd dir~c1ly from I he spuiUm of a human ca'c of pneumonic plague 
(13) w;" provided hy T. Oua11. Centcr< for D"case Conlrol and Prevention. Ft. 
Colhn,. Colo. Cl1 i< an Fl isogcnic 'lr:tin de rived hy site-dircclcd mutagenesis 
of lhe Fl MruciUral gene from the C0\12 s1rain (-l8). During the sclcc1inn 
process. I he C l2 slmin wa\ 1wice passaged in mice. S10cks of the two s trains were 
frnz~ n a1 - 70°C in 6ti'h glycerol in id~n1 ica l 'inglc-use ali4uo ts. For challe nge 
sludocs. frozen Slock;, were slreaked onlo lryptosc hlood agar base (Difco Lob-
oralorics, Det roit Mich.J sla ms and incuhaled at 28°C for 2 days. Bacterial cells 
we re harvested from the , )ants in 5 ml of hc:ort in fusion broth (HIB: Difco) and 
adjusted to an A.~., of 1.0 (approximately 10° CFU/ml). For s.c. challenges. the 
suspension was diluted in HIB to variou~ muhiplcs of the 50% lethal doses 
(LD~.,) for C092 (61-. 6,100-. o r 1.200.000 X) and Cl2 (37-. 3.700-, o r 740.000 
X), respectively. and 0.2 ml was injected. For aerosol challenges, 2 ml of 1he 
adjusted slant suspension was used to inoculate nasks containing 100 ml of HI B 
supplemented with 0.2% xylose. The broth cultures were grown for 24 h in a 30°C 
shaker at 10? rpm. centrifuged. washed 1wice with HIB, adjusted to an A1, 211 of 
10.0 (approxomately 10"' CFU/ml), and diluled 10 various mulliples of the LD"'' 
for C092 (59- or 97 1 X) and fo r C l2 (84- or 193X). Ami foam A emulsion (Sigma 
Chemical Company. SI. Lo uis. Mo.) was added to a final concentration of 0.2% 
(voi/Vol) in the bacterial suspension just before the aerosol challenges. 
rV preparation. The expression a nd purificalion of rV was previously de-
scribed (22). Briefly. the lcrV gene encoding the V antigen was amplified from 
Y. JXStis GB DNA by PCR. The amplified product was cloned into the pGEX-
5X-2 plasmid downstream of the glutathione S-1ransferase (GST) gene and 
elcclroporaled into Escltericltio coli JM 109 cells. The recombinant plasmid 
pVGIOO in£. coli JM109 cells produced a GST-V fusion pro te in. The cells were 
lysed and centrifuged. and lite supernalan t was mixed with glutalhione Sepha-
rose 4B. This material was packed into a column, and I he GST-V fusion protein 
was e luted with a Tris bulfer containing glutathione. The fusion protein was 
cleaved with factor X a. Cleaved GST and uncleaved GST-V were separated from 
rV by affinity adsorption . The cslimated molecular weigh1 of purified rV was 
36,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SOS-
PAGE). 
Animal immunizations. Female 8- to 9-weck-old outbred Swiss Webstcr mice 
(Hsd:~D4) we_re obtained from Harlan Sprague Dawley ( lndianapolis, lnd.). 
Expenments w11h ano mals "ere conducted according to the principles set forth in 
the Guide fo r the Care and Use of Laboratory Animals (29). Mice were given 
food and wa1er ad libitum. Mice were immunized s.c. with 10 11g of rV adsorbed 
to an a luminum hydroxide adjuvant (1.3% Alhydrogel, lot no. 4023; Supcrfos 
Boosecto r, Vedbaek. Denmark) on day 0 and again on day 30. The rV in Dul-
becco's phosphate-bulfered sa line (PBS) was gently mixed overnight at 4°C with 
1he aluminum hydroxide adjuvant a nd checked for complete adsorption by as-
saying for residual protein (BCA; Pierce, Rockford, Ill.) after ccn trifuga1ion at 
2,000 x g for 5 min. The concentration of rV was adjusted with PBS to yield a 
final concentration of I 0 11g of rV per 0. 19 mg of aluminum per 0.2-ml dose. 
M~ce were individually identified by transponders with unique numbers (Bio-
Medtc Data Systems. Inc .. Maywood. N.J.). The transponders were injected s.c. 
near the scruff of the neck I week before immunization so I hat the responses of 
~~div~dual _mice_ to immunization and challenge could be determined. This pos-
llove tdc nloficatoon transponder is essentially inert when injected s.c. (5). 
Measurement of serum antibody titers. Blood was obtained from each mouse 
on day 5 1 postimmunizalion. 7 days before Y. JXStis challenge. Mice were ancs-
lhetizcd with a mixture of 5 mg of xylazinc (XYLA-J ECf; Phoenix Pharmaccu-
lical. Inc., St. Joscph. Mo.) per kg. 0.83 mg of acetylpromazine (Fermenla 
Animal Health Co .. Kansas City. Mo.) per kg, and 67 mg of ke tamine hydro-
chloride (Kc1amine: Phoenix Pharmaceutical, I ne.) per kg administered intra-
muscularly. Blood was obtained from 1hc re lro-orbital sinus. Blood was also 
collected by ca rdiac puncture on day 28 postchallenge from the mice 1hat sur-
vived a lethal infection. A separate group of mice was immunized as above but 
were bled on days 13. 29. and 58 postimmunization to measure the sc rum 
antibody ti1ers and to determine 1he V-spccitic immunoglobulin G ( IgG) anti-
bodies in lung lavage fiuid on day 58. Lavage nuid was colleclcd after euthan izing 
I he mice by exposing the 1rachea, inserting and securing an IS-gauge needle, and 
aspirating I ml of PBS lhree limes before lin:ol wit hdrawal. 
Total lgG. lgG I. lgG2a. and lgG2h scrum ;ontibody 1i1crs to the V a ntigen 
were de lermined by using a modification of an e nzyme-linked immunosorbent 
assay (ELISA) (39). Briefl) . 0 .1 f.l.& per we ll of purified rV in ammonium bicar-
hona le buffer. pH 8.8. ""'added 111 96-" cll plates (Linbro: ICN Flow. Horsham. 
l'a.) and air dried. Plates "ae blocked "ilh PBS cuntaining O.l 'i'r bovine scrum 
alhumin (Sigm;o) and 0.05' r gelatin (Difco). 1l1ese plates were washed lhrce 
time, in PBS with 0.31'( Twccn 20. and twofold •erial dilutions of the sample' 
from 1:64010 1:1.310.720 " ere applied in tripl icat~. Afte r 2 it at 3rC. the plale' 
were wa,hcd and a I: UXJO dolu1inn of hor;eradi<h peroxidase-conjugated goal 
.o nlo-mousc lgG (Kirkegaard & Pe rry. G;oithcrshurg. Md.) was applied for I h at 
.H 'C. Plate' w~rc wa,hcd a nd lhe chromogenic •uh,trate 2.2' -azino-bi•(3-elhyl-
hcnzlhiazulinc-6-..,ulfonic acid) (AilTS: Sigma) wa' added. The reaction wa' 
' "'Ppcd al'icr JO min with IWI SOS. and lhe plate' were read al an optical 
ue nsity at 4115 nm (OD~.,,) . To dclerlllllle lgG Mlhci;I\S, goat anti-mou•c lgG I. 
lgG~a. or lgG1h (Sigma) "·"allowed tu rcacl woth 1he hound te<t sera for 1 it 
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<ond a pcrnxoda,e·CllllJUgalcd rahhil anli-gua t lgG ( Sigma) " '" U>Cd tn dctcco the 
isotypc,. 8och of the<e anlihodics wa, U>ed al a maxomum dol11tion of 1 :J.IXJO. 
The endpuonl llt~r was defined as 1~1c highe,t tc\1 'erum doluunn goving a readi ng 
of 2:0. 1 OD uno Is after suhtractong the hack ground from the welh "ithout 
antigen. The results obtained arc expres.,cd a< the gcomclric mean litcr (GMT) 
or log,.. mean !: s tandard deviation ( reciprocal endpoint titcr,). In lhe ea,~ of 
individual liler' of < 640, i.e .. the initia l d ilutonn. the convcntot>n of u'in~ half of 
this value for statistical purposes was u'ed. -
Challenge with Y. 11estis. Groups of 10 immunized and 10 wnlrol mice were 
challenged s.c. with 0.2-ml aliquots of the con or the C l 2 "rain of Y. Pl'Sti,\ at 
various cell concentrations as noted in Rcsu lls. 1l1e s.c. LO,, for adult mice arc 
1.9 and 9.1 CFU. calculated at day 14 po>tinfcction. for C09~ and Cl2. re,pcc-
lively ( 41. 48). 
Mice were exposed to a small-particle aerosol (mass medoan aerosol diameter 
of 1.2 11m) in a modified Henderson exposure system (19) contained \\ithin a 
Class 11 I biological safety cabinet. The aerosol " as ccnerated with a Collision 
nebulize r (23) driven by compressed a ir a1 26 Jb i o~1 with a now rate of 7.5 
lilcr/min. Up to 25 unanesthc lized mice were cha llenged at a time in the nose-
only aerosol exposure system. Mice from 1he various groups were d ivided be-
tween diffcrcnl aerosol exposures to minimize any exposure differences. Mice 
were exposed to I he infectious aerosol for 10 min. The aerosol LD~0 of I he C092 
and C l2 strains for adult mice were 2 x 10~ (4 1) a nd 1.1 X 10~ CFU. calcul:ued 
at day 14, respectively. A sample o f the aerosolized Y. pestis "as collected in 10 
ml of HIB wilh an all-glass impinger during each exposure. The challenge doses 
were assayed by plating dilutions of the collection fluid from the all-glass im-
pingers on sheep blood agar. The inhaled doses were estimated by using Guy-
ton's fomwla ( 17). 
The mice we re observed daily for 28 days. at which lime the survivors were 
anesthetizcd and exsanguina ted by cardiac puncture. a nd the spleens were re-
moved aseplically. we ighed, and titrated for viable Y. pestis cells. Ten percent 
(wi/Vol) spleen homogenates were prepared wilh Ten Brocck homogenizcrs and 
plated onto sheep blood agar plates. 
SDS-PAGE and Western blot (immunoblot) analysis. To determine the syn-
thesis of 1he V antigen, Y. pestis colonies isolated on sheep blood agar plates from 
the spleens of mice that survived I he 28-day observation period were inoculated 
into 5 ml of chemica lly defined thiosulfale-modified Higuchi medi um (38) and 
incubated overnight at 26°C at 150 rpm. The cells were subcultured into fresh 
thiosulfate-modificd Higuchi medium wilhout Ca - 1 to an 00600 of 0.2 with 
shaking fo r 2 h at 26°C and I hen shifted 10 37•c for 6 h to induce the expression 
of V a ntigen. The cultures we re cent rifuged al 5.000 x g for 5 min. and 1he 
pellets were resuspended in PBS. The pellet suspension and the supernalant 
were frozen at - 20"C until assayed. Samples were mixed with an equal volume 
of 2X SOS-PAGE loading bulfer and healed at I00°C for 10 min. Proteins 
were separated on 10 to 20% Tricine gels (Novex. San Diego. Calif.) and lrans-
ferred 10 nitrocellulose membranes. The V protein was detected by Western 
blot with a mouse polygonal monospecific anlibody (provided by G. Andrews. 
USAMRIIO, Ft. Detrick, Frcderick, Md.) to rV and was de1ec1ed by the ECL 
syste m (Amcrsham, Arling1on Heights. Ill.) 
DNA preparation. Overnight cultures of Y. pestis strains were prepared by 
inoculating growth from a sheep blood agar plate into 3 ml of HIB supplemented 
with 0.2% xylose. Plasmid DNA samples were prepared from these cultures by a 
modification of the method described by Kado and Liu (33). After removing 
residual phenol in Insta Mini Prep tubes (5 Prime-3 Prime. Inc .. Boulder. Colo.). 
the aqueous layer was gently extracted with chloroform in the same IUbe. The 
aqueous layer was e1hanol precipitated and rcsuspended in 50 111 of 10 mM 
TRIS, pH 8.0. wilh I mM EDTA. 
PCR. The fo llowing primer pair specific for the ltms locus of Y. pestis was used 
10 confirm the identification of the cells: 5'CCGCCCfGTGCfGTClTC3' (95 
to 22) and 5'CAACACAACCCACGGGG3' (95 to 23). Primer sequences "ere 
designed by using the ltms sequence submitted to GenBank by Lillard et al. 
(GenBank accession number U22837). The reactions con1aoned 1he following 
componems: I 10 2 11g of IOta I DNA. all four dco.,, nucleotid~ triphosphates at 
200 11M each. I X Taq polymerase buffer. 2 ml\1 YfgCJ, . and 2.5 U of Taq 
polymerase (all reagents were from G IBCO BRL Life Technologies. Gaithcrs-
burg, Md.). Samples were denaiUrcd for I mon at 9-I'C before the Taq pol"mcr-
asc was added. Samples were overlaycd wilh a drop of mineral oo l. After a 5-min 
94oC dcnaiUralion cycle, Si!n1ples were subjected to 30 amplifica tion cycles. The 
final cycle ended wilh a 10-min extension period at 70' C. Amplification cvcles 
consisled of a I -m in denaiUration '" 94°C. a 2-min annealing at 65 C, and n 3--min 
extension period ill 70°C. 
Statis tics. Studenl's t tesl, anaiY'i> of vanancc . .ond least ;ignoficanl difference 
tests were used to compare lhe variou' lreatmcnt group> .11 the 0.05 lc\d of 
probahilily (34). 
RESULTS 
Protection aga inst an s.c. cha llenge \\i th Y. pestis. An earlier 
study de monstrated the e ffi cacy of rV combined with incom-
ple te Fre und 's adjuvant aga insl a parenteral challe nge (22). 
We de te rmined the protective efficacy of rV ad o rbed 10 an 
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TABLE I. Survival of Hsd:ND4 mice immunized wi th 
rV and challe nged with Y. pesti~' 
Ch;ollcngc dose" 




Alhydrogel alone, C092, s.c. 
6 1 
6,100 








rV + Alhydrogel, C092, aerosol 
59 
971 
Alhydrogel alone, C092, aerosol 
59 
971 
rV + Alhydrogel, C12, aerosol 
84 
193 


























5.0 = 1.4 
6. 1 = 0.9 
4.8 = 1.3 
7.0 = 0.0 
11.4 ::7.0 
7.2 = 5.5 
5.3 = 1.0 
4.0 = 0.0 
3.3 = 0.5 
3.0 = 0.0 
11.0 = 0.0 
5.0 = 0.0 
3.7 = 0.7 
3.1 = 0.3 
• Female Swiss Wcbster (Hsd:ND4) mice were immunized s.c. with 10 ,...g of 
rV adsorbed to aluminum hydroxide adjuvant (Alhydrogel) or adjuvam alone on 
dar, 0 and 30. The mice were challenged on day 58 post immunization. 
Challenge doses are multiples of the LD50 of the C092 or Cl2 strains as 
indicated. Treatment groups and challenge route arc also indicated. 
'Survived/total inoculated at day 28 post infection. Ratio of survivors to total 
number of inoculated mice was determined at day 28 postinfect ion. 
d Mean time-to-death :!: standard deviation. 
adjuvant approved for human use, aluminum hydroxide, 
against the wild-type Fl ... C092 strain of Y pestis. Groups of 
10 rV-immunized or control mice were challenged s.c. with 
various doses of wild-type, F1 + C092, ranging from 61 to 1.2 X 
106 times the LD50 (61 to 1.2 X 106 LD50) 4 weeks after the 
second immunization (Table 1). All rV-immunized mice sur-
vived challenge with doses of 61 or 6.1 x 103 LD50; 80% of the 
mice survived a challenge of 1.2 X 106 LD50. All control mice, 
except one in the 61 LD50 group, died. This mouse serocon-
verted to rV with a titer of 2,560. 
Because immunization with rV was efficacious against wild-
type Y pestis, we examined the protection afforded by rV 
against Fl - C12, which is incapable of producing the Fl cap-
sular prote in. Mice were challenged with doses ranging from 
37 to 7.4 x 105 LD50 of the nonencapsulated Cl2 strain. All 
rV-immunized mice survived the parenteral challenge of 37 or 
3.7 X 103 LD50, and 90% of the mice survived when challenged 
with 7.4 x 105 LD50. All C l2-challenged control mice died 
except one mouse in the 37 LD~0 group. The surviving control 
mouse had a po tchallenge anti-rV tiler of 1:163,840, indicat-
ing tha t it survived infection. These results demonstrated that 
immunization with rV adsorbed to aluminum hydroxide could 
protecl mice against needle-inoculated plague caused by both 
Fl ' and Fl strains of Y. pestis. 
The spleens from 55 rV-immunized mice which survived an 
s.c. challenge with e ither C0 92 o r C l2 were examined for the 
presence of viable Y. pesris cells at 28 days po tinfection. Ten 
INtlCT. I MMUN. 
percent (wt/vol) spleen homogenates were plated on sheep 
blood agar and examined after 2 days of incubation at 28°C. 
Only 1 of the 55 homogenate examined was po itive for viable 
organisms. This mouse had been infected with 3.7 X IO' LD~0 
of the C12 strain . Its spleen had a bacillary burden of 1.6 X I O.l 
CFU/g of tissue. The one Alhydrogel control mou e that sur-
vived a chall enge dose of 37 LD50 also contained viable Y. pes-
tis on day 28 post infection. The identity of these isolates as Y. 
pesris was confirmed by PCR. These isolates were t ill capable 
of producing the V protein . as determined by Western blo t 
with a monospecific V antiserum. 
While almost a ll mice cleared their infections, increases in 
spleen weight suggested that most of the C092-challenged 
groups had survived an active bacte rial infection. The mean 
spleen weight of the control mice (n = 10) was 0.08 ::!: 0.01 g, 
while spleen weights of the ascending doses of C092-infected 
mice were 0.20 ::!: 0.06 g (P = 0.0066), 0.22 ::!: 0.07 g (P = 
0.0008), and 0.11 ::!: 0.02 g (P = 0.5335), respectively. However, 
no ignificant differences (P ~ 0.05) compared with control 
mice were detected for the spleen weights of the C12-infected 
mice, which were 0.12::!: 0.03 g, 0.16 ::!: 0.03 g, and 0.12::!: 0.03 g 
in ascending dose order, respectively. 
Protection against an aerosol challenge with Y. pestis. Hav-
ing demonstrated the efficacy of rV to protect against needle-
inoculated plague, we challenged mice by aerosol with the 
wild-type, F1 ... C092 or the Fl - C12 strain to determine 
whether immunization with rV was efficacious against pneu-
monic plague (Table 1). Groups of mice were challenged in the 
nose-only aerosol apparatus with either 59 or 971 LD50 of the 
C092 strain. Immunization afforded 90% (9 of 10) protection 
against challenge with 59 LD50 and 100% (10 of 10) protection 
against 971 LD50. The increased survival in the high-dose 
group is not statistically different from the low-dose group and 
most likely re flects the small number of animals in each chal-
lenge group. Mice were similarly protected when challenged 
with the n - strain, C12, with 88% (7 of 8) surviving a chal-
lenge dose of 84 LD50 and 90% (9 of 10) surviving when 
challenged with 193 LD50. Y pestis could not be isolated from 
the spleens of the 35 mice immunized with rV which survived 
e ither a C092 or C12 aerosol challenge. All control mice died. 
Spleen weights of the ascending challenge dose groups for 
the C092-infected mice were 0.15 ::!: 0.05 g (P = 0. 11 82) and 
0.19 ::!: 0.06 g (P = 0.0076), respectively. The spleen weights of 
the ascending challenge dose groups for the C12-infected mice 
were 0.21 ::!: 0.08 g (P = 0.0039) and 0.23 ::!: 0.2 g (P = 0.0009), 
respectively. Immunization with rV was efficacious against 
pneumonic plague, which has a more rapid disease progression 
than bubonic plague in mice. 
Ontogeny and correlation of protection with V a ntibody. A 
group of 10 mice, separate from the mice that were cha llenged, 
were immunized on days 0 and 30 with 10 )..lg of rV adsorbed 
to a luminum hydroxide and assayed for their V-ELISA titers. 
The mice were bled on days I 3, 29, and 58 postimmunization, 
and the JgG, IgG I, lgG2a. and lgG2b V-ELISA titers were 
determined on serum from individual mice. Additionally, lung 
lavage fluid was collected from each mouse on day 58 postim-
munization to de te rmine whether IgG anti-V antibody was 
detectable in the lung. By day 13 postimmunization, 100% 
(n = 10) of the m1ce developed detectable IgG V-ELISA titers 
with a GMT o f 8,317 (Table 2). The tite r increased to 52,780 by 
day 29 and was 640,000 on day 58 post immunization. the day of 
challenge for the o ther groups. The titer of the con tro l gro up 
was < 640, the initial serum dilution tested. The IgG anti-V 
GMT of the lung lavage fluid wa 788 for the immunized mice 
and < 5 for the contro ls. The initial dilution te ted for the 
lavage fluid was I :5. IgG anti-V antibodies were detectable in 
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TABLE 2. Ontogeny of IgG ELISA tit c r~ of 
m ice immunized with rV" 
Day po, timmu· lgG ELISA tit cr 
nization lgG lgGI lgG2a 
13 3.92±0.15 3.23 :t 0.43 2.66 :t 0.29 
29 4.72 :t 0.25 4.52 :t 0.29 3.02 :t 0.40 
5 5.81 :t 0.20 5.79 :t 0.30 4.34 :t 0.17 
lgG2h 
2.66 :t 0.29 
3.26 :t 0.50 
4.34 :t 0.36 
" Ten female S"is' Webste r (Hsd:ND4) mice were immunized s.c. with tO f.l.!\ 
of rV adsorhed to an aluminum hydroxide adjuvant (Aihydrogel) on days U and 
30. Mice "~re bled on days 13. 29. and 58 postimmunization. Lug 111 reciprocal 
endpoint titcr.; were determined for individual mice and the mean :!: standard 
deviation is presented fo r each group of animals. No specific antibodies were 
detected in the sera of control mice. 
all of the lung lavage fluids from rV-immunizcd mice. The IgG 
subclass V-ELISA responses are shown in Table 2. The IgG I 
V-ELISA titer was similar to tota l IgG and predominated over 
IgG2a or IgG2b. 
The IgG rV ELISA antibody titers of 40 rV-immunized mice 
were examined a t day 51 postimmunization. All 40 of the mice, 
including the mice that died, responded to two doses of the 
vaccine. The reciprocal rV titers ranged from 81,920 to 
1,310,720. Total IgG titers and titers of three subclasses of IgG 
were compared in the six mice that died and an equal number 
of mice from the same groups that lived, and these mice had 
similar total IgG V-ELISA titers (Table 3). The serum was 
obtained I week prior to challenge. The GMTs for total IgG, 
IgG2a, and IgG2b of the six mice that died were not statisti-
cally different from the mice that lived. However, the GMTs of 
IgG1 between the survivors and the mice that died were sig-
nificantly different (P = 0.0277) (Table 3). 
While spleen weights were used as one means of determin-
ing the degree of disease caused by the infection, the postchal-
lenge tite r could also be used as an indication of the extent of 
bacterial replication. The pre- and postchallenge IgG ELISA 
GMTs were compared for the group challenged s.c. with 1.2 X 
106 LD50 of the C092 strain. The titers were statistically dif-
ferent (P = 0.01). 
DISCUSSION 
A previous study (22) demonstrated that intraparenteral im-
munization with rV combined with incomplete Freund's ad-
juvant could pro tect inbred mice against a le thal wild-type 
Y pestis infection. In this study we extended this finding by 
demonstrating the efficacy of rV against lethal aerosol infec-
tions with Fl + and Fl - strains of Y pestis. Furthermore, this 
study found that when rV was combined with the human use 
adjuvant a luminum hydroxide, administered s.c., the antigen 
was efficacious. In addition, we showed tha t a reduced, two-
do e , immunization schedule provides significant protection. 
This study was conducted with outbred mice, which may be tter 
mimic the genetic variability in the human population. 
Previous studies demo nstra ted a clear role for antibody to 
the V antigen in passive antibody protection tudies (21 , 35, 
40), though the mechanism by which the V antibody prevents 
fatal di ease in not known. A good IgG antibody response to 
the rV adsorbed to aluminum hydroxide developed <IS ea rly as 
13 days postimmuniza tion, and tite rs continued to rise up to 
the time o f cha llenge on day 58 postimmunization. The pre-
dominant lgG subtypc w<1s IgG I. followed by lgG2a and 
IgG2b. This pattern is typical when a luminum hydroxide is 
used as an <1 djuvant with various antigens ( I, 20). When the 
tOtal IgG. lgG I. lgG2a. and lgG2b titers o f the mice that died 
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were compared to those of survivors. o nly the lgG I tite r were 
sta tistica lly different. However, with o nly 6 deaths out of the 98 
immunized and challenged mice, additional studies with a sub-
optimum dose of rV will be needed to corre late V antibody 
titcrs with pro tectio n, as has been do ne with the Y pestis Fl 
antigen (6, 25, 44). 
The fact tha t only I spleen out of the 90 tested at 28 days 
postchallenge contained viable Y pestis cells suggests that im-
munization with rV is effective for inducing clea rance mecha-
nisms for Fl ' as well as Fl - o rganisms from most individuals 
in an outbred population. The only infection that was not 
cleared from an immunized mouse resulted from an s.c. chal-
lenge with the Fl - Cl2 strain. Fl - variants have been isolated 
from animals infected with Fl ' stra ins (2, 9, 43) and have been 
associated with chronic infections. 
In this study, sign ificant increases in group spleen weight 
were not obtained for all of the infected groups of mice, indi-
cating a variable response to the challenge. Bacteremias, organ 
titers, or temperatures of the infected mice were not dete r-
mined in this study but need to be determined to better assess 
the extent of disease in the immunized, challenged outbred 
mice. The ability of rV to prevent death and the establishment 
of a chronic infection in the majority of the surviving mice 
challenged s.c. or by aerosol indicates the value of this im-
munogen as part of any subunit vaccine. However, the ability 
of this immunogen to prevent disease needs to be ascertained. 
It is possible to protect mice from a lethal aerosol wild-type 
Y pestis infection by administering polyclonal, monospecific 
(37) or IgG1 monoclonal antibodies (2) directed against theY 
pestis Fl antigen or by active s.c. immunization with recombi-
nant Fl. These experiments demonstrated that immunization 
at mucosal surfaces is not an absolute requirement fo r protec-
tion against pneumonic plague. This study further supports 
these findings by demonstrating that s.c. immunization with rV 
protected all mice against death from a substantial (971 LD50 
[C092]) aerosol infection. Whether immunization at mucosal 
surfaces could enhance the protection afforded by rV will have 
to await other studies. These results clearly demonstrate for 
the first time that s.c. immunization with rV can be effective 
against a Y pestis inhalation challenge. 
The efficacy of the current licensed plague vaccine. USP, 
against pneumonic plague in humans is unknown. While indi-
rect evidence suggests that the vaccine is effective against bu-
bonic plague (10), individuals immunized with this vaccine 
have still developed pneumonic plague (24). Smith and Pack-
man demonstrated tha t the plague vaccine USP could elicit 
marginal protection in mice challenged by an aerosol of wild-
TABLE 3. M ean log reciprocal a ntibody titcrs of rV-immunized 
m ice which survived or died from a Y. pestis challengeu 
V-ELISA Titer 
Outcome 
lgG• lgGI' lgG2a" lgG2h" 
Death (11 = 6) 5.66 :':: 0. 17 5.56 :t 0.30 4.06 :t 0.70 4.06 :t 0.48 
Survival (11 = 6) 5.76 :':: 0.23 5.91 :t 0.16 4.36 :t 0.44 4.16 = 0.35 
" Female Sw1ss Webster (H'tl: 04) mice were immunized s.c. \\lth 10 f.l.!l of 
rV adsorhcd to an alummum h)dmx >de adjuvant (Aihytlrogcl) on days 0 and JO. 
Mice were hied I wee~ hcfor~ challenge wi th a lethal dose of Y. pt•stis Cl2 or 
C092 e ither hy aerosol or s.c. Si' mice with similar lgG V-ELISA tit as from the 
respective challenge groups were chosen for the suhclas' compari,on. Log, .. 
reciprocal cndpoint titcr' were detcrminctl for individual mice and the mean :;: 
' tandard de' iauun is prc,cntcd for each group of ammals. o spcc1fic rV anti· 
bodies '"' t..: rc.: lktcctcd an \Cnt nl control mice. 
" ot ' tall,tically '>gnificant (I' .:> 11.115). 
' P = 0.0~77. Student·, I tC,t . 
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type plague (36). We confirmed this in the mouse aerosol 
model with the F1 .. C092 strain (4, 31 ). and we showed that 
the plague vaccine USP does not offer protection aga inst the 
Fl Cl2 strain (18). The lack of ignificant protection could be 
due to the subimmunogenic amount of V in the plague vaccine 
USP. Chen et al. (11) were unable to detect antibodies to the 
V protein by using an Ouchtcrlony test. We did not detect V 
antibodies by ELISA in mice that received two s.c. or intra-
muscular immunizations with plague vaccine USP ( 18. 45). We 
were not able to detect the V protein in the plague vaccine 
USP with Western blots by using monospecific V antiserum 
and enhanced chemiluminescence (3). 
Y. pestis strains expressing the Fl antigen are the usual 
phenotype encountered in nature. Therefore , the Fl antigen 
should be included in any vaccine, and it is the principal im-
munogen in the current plague vaccine, USP. Recently, Wil-
liamson et al. (45) demonstrated the feasibility and efficacy of 
a subunit vaccine consisting of Fl and V antigens combined 
with Freund's incomplete adjuvant, which offered better pro-
tection than either antigen alone aga inst an s.c. challenge. Ln 
subsequent work, we also showed that an Fl-Y fusion protein 
protects against an aerosol challenge (18). These results sug-
gest that a subunit vaccine consisting of at least the Fl and V 
antigens should provide better protection against pneumonic 
plague than that shown with V alone, as in this study. 
In conclusion, we demonstrated that rV formulated for hu-
man use can protect against pneumonic as well as bubonic 
plague. This plague vaccine significantly protected mice against 
pneumonic plague caused by either Fl + or Fl - Y. pestis. 
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Regions of Yersinia pestis V Antigen That Contribute to 
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V antigen of Yersinia pestis is a multifunctional protein that has been implicated as a protective antigen, a 
virulence factor, and a regulatory protein. A series of V-antigen truncates expressed as glutathione S-trans-
ferase (GST) fusion proteins (GST-V truncates) have been cloned and purified to support immunogenicity and 
functionality studies of V antigen. Immunization studies with GST-V truncates have identified two regions of 
V antigen that confer protection against Y. pestis 98 (a fully virulent human pneumonic plague isolate) in a 
mouse model for plague. A minor protective region is located from amino acids 2 to 135 (region 1), and a major 
protective region is found between amino acids 135 and 275 (region H). In addition, analysis of lgG titers 
following immunization suggested that the major antigenic region of V antigen is located between amino acids 
135 and 245. A panel of monoclonal antibodies raised against recombinant V antigen was characterized by 
Western blotting against GST-V truncates, and epitopes of most of the monoclonal antibodies were mapped to 
region I or H. Monoclonal antibody 7.3, which recognizes an epitope in region 11, passively protected mice 
against challenge with 12 median lethal doses of Y. pestis GB, indicating that region II encodes a protective 
epitope. This is the first report of a V-antigen-specific monoclonal antibody that will protect mice against a fully 
virulent strain of Y. pestis. The combined approach of passive and active immunization has therefore confirmed 
the importance of the central region of the protein for protection and also identified a previously unknown 
protective region at the N terminus of V antigen. 
The bacterium Yersinia pestis is the causative agent of bu-
bonic plague, a zoonotic infection that is spread from natural 
animal reservoirs via the bite of an infected flea. The bubonic 
form of the disease can develop into a highly infectious pneu-
monic form which is spread from person to person in airborne 
droplets (see reference 17 for a review). Due to the high 
infectivity and mortality of pneumonic plague, there is a need 
to develop vaccines for people living in or travelling to areas in 
which plague is endemic as well as laboratory workers handling 
specimens from plague patients. 
Current plague vaccines are based on whole-cell formula-
tions. The Cutter USP vaccine, which is currently used in the 
Western world, is a suspension of a formal in-fixed viru lent 
strain of Y. pesris (7). Transient side effects associated with the 
administration of this vaccine have been reported (7). Al-
though it is believed to be protective against bubonic plague 
(3), protection against pneumonic plague is doubtful, as vac-
cinated individuals have been infected (8). EV76 is a live at-
tenuated vaccine that has been used extensively in the former 
Soviet Union, but its efficacy has been questioned (9). The 
viru lence of EV76 differs in several animal species, and non-
human primates are particularly susceptible to this strain ( I 0). 
Furthermore, the severity of the side effects of EV76 precludes 
its widespread use as a vaccine in humans. There is therefore 
a need for an improved plague vaccine that gives greater pro-
tection and produces fewer side effects than existing formula-
tions. 
Immunization with purified Y. pestis proteins has been con-
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sidered as an alternative to whole-cell vaccines. 1\vo subunits 
of Y. pesris, fraction 1 (Fl) and V antigen, have been identified 
as vaccine candidates. The F1 protein, which forms a protein 
capsule-like structure on the bacterial surface that is believed 
to inhibit phagocytosis (26), protects mice against subcutane-
ous (s.c.) and aerosol challenge with virulent Y. pestis (l ). Also, 
Fl expressed by an aroA strain of Salmo11ella typhimurium 
given intragastrically to mice has been shown to protect them 
against plague (16). The gene for V antigen (lcrV) is part of the 
lcrGVH operon (18, 19), which is located on a 70-kb low-
calcium response (lcr) plasmid that is common to Y. pestis, 
Yersi11ia pseudotuberculosis, and Yersinia emerocolitica (2). 
Early s tudies implicated V antigen as a protective antigen 
again t plague in guinea pigs (4), and recently highly purified 
recombinant V antigen has been shown to protect mice against 
high challenge doses of Y. pestis GB (5). Similar protection 
given by a truncated form of V antigen fused to protein A 
indicate that the first 67 amino acids of V antigen are not 
necessary for protection against KIM, an attenuated strain of 
Y. pesris ( 14). Passive immunization with polyclonal V-antigen-
specific e rum adsorbed against truncated forms of V antigen 
indicated that the region from amino acids 168 to 275 contains 
at least one protective epitope ( 12). A monoclonal antibody 
(MAh) has also been shown to confer significant protection 
against Y. pesris KIM ( 15). Combined immunization with the V 
and Fl antigens has been shown to give mice higher levels of 
protecuon agai nst plague than e ither subunit a lone (27). The 
protection observed was several orders of magnitude greater 
than th :.J t or the killed Cutter USP vaccine (27). 
Stuuie\ suggest tha t V antigen is also a virulence factor (23) 
that reduces local expression of the host cytokines tumor ne-
cro. is factor alpha and gamma interferon in response to ycr-
~inia in fection ( 14. 15. 25), thus allowing the bacterium to 
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TABLE I. PCR primers usetltn clone regions of V antigen frnm Y. pestt.\ (i ll 































"Th~ 5 and 3 pre lixes denote forward and reverse primers. respectively: the last number indicate' the first o r la>t primer-encoded V-antigen am inn acid. 
" In the sequences. rc,triction site• used fnr cloning arc unde rlined. 
become established. V antigen a lso has a role in the regula tion 
of the low-calcium response ( 11. 18, 23). 
We report here the cloning and purification of trunca ted 
forms of V antigen expressed as glutathione S-transferasc 
(GST) fusion proteins to aid characterization of antigenic and 
protective regions of V antigen. Active immunization with 
GST fusion proteins has identified two distinct immunogenic 
regions. We have also localized the epitopes of V-antigen-
specific MAbs to regions of the protein and identified a pro-
tecti,·e MAb. Both passive- and active-immunization data iden-
tify amino acids 135 to 275 as the major protective region of V 
antigen. 
MATERIALS AND METHODS 
Reagents. Plasmid pGEX-5X-2 and reagents required for GST fusion protein 
production were purchased from Pharmacia Biotech. St. Albans. United King-
dom. Other reagents were purchased from Bochringer unless stated o therwise. 
Bacterial strains and culti\·otion. Esclrericlrin coli JM1 09 was cultured in L 
broth (22) supplemented. if required. with ampicillin at a final concentration of 
50 11!!- ml (LB-Amp). Y. pestis GB was grown aerobically as described previously 
(5). Y. pestis GB is a human pneumonic plague isolate with a median le thal dose 
(MLD) of approximately I CFU given by the s.c. route in BALB/c mice and an 
o utbred mouse s train (21). 
D "A cloning. Chromosomal DNA was isolated by a standard method (6). 
Regions of the lcrV gene. which encodes V antigen ( 19). we re amplified from Y. 
fKSIIS GB DNA by PCR (22). The primers used for PCR arc listed in Table I. A 
BamHI restriction site was introduced at the 5' end of all forward primers to 
facilitate cloning into the BnmHI site of pGEX-5X-2 . . The BnmHI site (GGAT 
CC) of pGEX-SX-2 encodes the last two residucs of glycine (XGG). all of 
isoleucine (ATC). and the first base of a prol ine residue (CXX) o f GST. Codons 
that begin with a C e ncode amino acids leucine. proline, his tidine. glutamine, and 
arginine. The forward primer was therefore designed to encode a region of V 
antigen wi th isoleucine followed by leucine. proline. h istidine. gl utamine. or 
arginine near the desired start site for the truncated protein. The reverse primer 
was de igned to incorporate a stop codon at the desired residue and a restriction 
site compatible with the multiple cloning site of pGEX-5X-2. PCR was per-
fo rmed with a Perkin-Eimer model 9600 GeneAmp PCR system (35 cycles of 
94•c for I min. 60"C for I min. and n•c for 2 min). DNA fragments were 
visualized on !.5'ii: agarose ge ls with a 100-bp ladder as a standard (Pharmacia 
Biotcch). DNA bands of the expected size were excised and purified (Scphaglas 
Band Prep kit : Pharmacia Biotech). PCR products and pGEX-SX-2 digested with 
the appro priate restriction enzymes were liga ted by using T 4 DNA lig:"e and 
tran formed into £. coli JM 109 lly ckctropora tion (22). Ampicillin-resistant 
colonies were screened by PCR for Y. tx•stis DNA of the expected size. Purified 
plasmtd DNA (Qiagcn-tips Maxi-prep: Qiagcn) was digested with re,lriction 
cn~mcs and sequcnccd Jcross the multiple cloning site of pGEX-5X-2 Ill verify 
insertion of the PCR product. 
Purification and ana lysis of recombinan t proteins. GST-V fu,ion proteins 
were purified as previoll, ly described. with some mndilicatinn' (5). flriclly. a 
stat illnary-phase culture cunt:oining E. mli JM Ill~ plus rccnmhinanl plasmid was 
' uncultu red intn !I iter of LI1·Amp. lsnprnpyl-13-u-thiogalactopyrano,i<lc (IPTG) 
wa' .odded to a fin:tl cuncelll r:llion uf 0.5 mM al an optical den,ity :11 I~Kl 11111 of 
IUI. The cu lture w:" &"'"" fm at least a lurthc r S h :ond then harve,ted at 4.51Ml X 
11 ano.J 4' C for 10 mm (Beckman 12-HS centrifuge). l ltc pellet w:o' re•u•pcndcd 
in 5 ml of phu,phatc-buftereo.J 'aline (PBS) and frnten at -2tfC. The cell> were 
th:l\leo.J. and J2U ..,.1 of l~""~mc (Ill mg ml) "·" ao.Jded. After Ill m in at 22•c. 
Tnt\'m .'\- IOU wa~ addcU hl a tlnal cunc~nlntl ton ,,f l rt·. Th..: cell~ were !\Uillcatcd 
for three 30-s bursts. with I min on ice be tween bursts (Braun Lallsonic 2000 
sonicator: large probe. low sening. 70% power). The sonicate was ccmrifuged at 
12,000 X g and 4•c for 30 m in (Beckman J2-HS). and then the supcrnatant was 
mixed with glutathione-Sepharosc 4B (Pharmacia Biotcch) fo r I h at 22•c with 
continuous agitat ion. The glutathione-Sepharosc 4B was pelletcd at 500 x g and 
4•c for 5 m in (Bcckman GS-6R centrifuge) and then washed four times with 10 
volumes of PBS. The matrix was incubated for 30 m in at 2ZOC 11 ith an equal 
volume of I mM glutathione with agitation. The slurry was loaded onto an 
Econo-Pac chromatography column (Bio-Rad). and the eluate was collected. 
The bed was then washed with an equal volume of I mM glutathione. and the two 
eluates were pooled. After analysis by sodium dodecyl sui fate-polyacrylamide gel 
e lectrophoresis (SOS-PAGE) to confirm the presence ofGST fusion protein. the 
sample was dialyzed extensively against PBS. The protein concentration was 
determined by bicinchoninic acid protein assay [Pierce & Warrincr (UK) Lim-
ited] against a bovine serum albumin standard curve. Protein was concentrated 
by centrifugation through a 10.000-molecular-weight CO (10,000-t..IWCQ) mem-
brane (Centriplus: Amicon) as required. 
SOS-PAGE was performed with prccast 12% acrylamide Ready Gels (Bio-
Rad). Proteins were electrobloned onto lmmobilon P membranes (Mil!ipore) 
and probed wi th V-antigen-specific rabbit polyclonal antiserum. lmmunogold-
labelled secondary antibodies were detected with Auroprobe reagents as recom-
mended by the supplier (Cambio, Cambridge, United Kingdom). 
V-antigen-specific polyc!onal antibody. Polyclonal antibody was produced 
from a female New Zealand White rabbit injected with highly purified recom-
bina nt V antigen (rV antigen) (5). The rabbit received three 250-~J.g doses of rV 
antigen in incomplete Freund's adjuvant and PBS intradermally over a 12-week 
period. Scrum was collectetl 21 weeks after the initial dose of rV antigen. 
Immunization with recombinant proteins. Six-week-old fema le BALB/c mice 
reared under specific-pathogen-free conditions (Charles River. Margate, United 
Kingdom) were used in this study. Six animals per group were immunized 
intraperitoncally (i.p.) with 100 ~'-' of rccombinant pro tein in Alhydrogcl (Su-
perfos Biosector a/s. Vedback. Denma rk). Antigen was administe red at a molar 
concentration equivalent to 10 11g of rV antigen (267 pmol), and mice were given 
booster injections on day 21 as for the priming dose. The mice were tail bled, and 
sera were analyzcd fo r V-antigen-spccific immunoglobulin G (lgG) by enzyme-
linked immunosorbent assay prior to challenge. Briclly, a microtitcr pl:lle was 
coated with 100 ..,.1 of rV antigen (5 ILl: of rV a ntigen per ml diluted in PBS). 
After the plates were blocked with I% skim milk powder in PBS. the test scrum 
was serially diluted in duplicate. Horse radish peroxidase conjugates against 
mouse polyvalent lgG and mouse lgG I and lgG2a ( Har!an Sera-lab, Loughbor-
ough. United Kingdom) were used at 1:2.000 as secondary antibodies. lgGI and 
lgG2a secondary antibodies have been shown to be specific for the homologous 
subclass and to have equivalent sensitivities of detection (data not hown). Titers 
were culculated as the maximum dilution of sc rum to give a 414-nm absorbance 
reading 0. 1 U greater than background und arc presented as the reciproc:tl of the 
dilution. 
Challenge with Y. pestis. Groups of six mice were challenged with approxi-
mately 10' or 107 MLD of Y. p<'stis G B (a fully virulent human pneumonic plague 
isolate) in :o 100-..,.t volume hy s.c. injection. Dilutions of the inoculum were 
plated on tu Congo red agar plates uno.J grown for 2 days at 2h .. C I ll enumerate the 
CFU per du-e ( I CFU is equivalen t tu I MLD [2 1l). l11e animal' were closely 
mnnitnred throughout the working day nvcr a 14-day period. The ~ymptoms of 
rlague infection in nu r moc.ld uf infection arc (i) starry nr rulllcd cnat. (ii) 
lethargy. (iii) hunched back. (iv) reluctance 111 move. and (iv) incapaciwncc. In 
our mnllcl tor plague. incapacitated animals that have hccn inuculatcd with Y. 
pc•.wi< G!3 d11 not recover and were therefnre euthanized 111 alk1 iate sull"ering. 
Mnre than')()' r nf the de:oth> reported in thi> ''udy were una ·,i,ted. hu\\evcr. a' 
mm! :onima), died hetween munituring pc rind,. Blnu<.l. liver. :on<.l 'Plccn samples 
fmm a rerrc,entative samrlc nf animal' that ~urvived challenge were streaked 
untn Cnngn red agar plates'" de-.crihec.l ah<we "' chn·k fnr the prc,ence of Y. 
fX'.\(Il. 
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MW 
4 326 63.7 
74 326 55.0 
135 326 47.8 
215 326 38.9 
2 275 57.6 
2 215 50.7 
2 135 41 .9 
135 275 42.3 
135 §: 245 39.0 
186 275 36.6 
FIG. I. Schcmnric rcprcscrHarion of rhc regions of V amigcn expressed as 
C-re rminal GST fu>ion prorcins. The firs! and lasr V-anrigen amino acids a rc 
hown. The predicred molecular weighr (MW) of each GST-V rruncate is ex-
pressed in thousands. 
Passive immunization. Tissue culture supematants from mouse hybridomas 
expressing MAbs were raised against native rV antigen or SDS-dcna tured rV 
antigen. Tissue culture supernatant of MAbs shown below (sec Table 3) was 
provided by T. J. Eastcrbrook, CAMR. Porton Down. Salisbury, Wiltshire, 
United Kingdom. MAb was concentrated from tissue culture superna tant with a 
10,000-MWCO Centriplus concemrator (Am icon) and then diluted to 3.5 mglml 
with PBS. A 100-fl.l volume of MAb was administe red i.p. 24 h prior to s.c. 
challenge with Y. pestis GB. as recommended by George Anderwn. U.S. Army 
Medical Research lnstirute for Infectious Diseases. Ft. Derrick, Md. The chal-
lenge dose was calculated as 12 MLD. as described above. Mice were monitored 
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RESULTS 
Production and purification of G T-V fusion proteins. Re-
gions of the lcrV ge ne (4) were amplified hy PCR from Y. pestis 
GB genomic DNA with primers conta ining restriction enzyme 
sites (Tab le I). The PCR products were digested with restric-
tion enzymes and cloned into pG EX-SX-2 (Pharmacia Bio-
tech). The regions of V antigen cloned into pGEX-SX-2 and 
expressed as a GST fusion protein are shown in Fig. I. Cloned 
regions were chosen on the basis of previous studies (12), the 
availability of cloning sites (see Materials and Methods), and 
computer-generated secondary-structure and antigenicity pre-
dictions for V antigen (DNASTAR software; results not 
shown). GST fusion pro teins purified by affinity chromatogra-
phy were analyzed by SOS-PAGE and Western blotting 
against rabbit polyclonal anti-V-antigen antibody (data not 
shown). Purified proteins were of the predicted molecular 
weight given in Fig. I, and all proteins we re stable, except for 
GST-V3 and GST-V9, which showed some degradation. Al-
though all the proteins reacted with rabbit polyclonal anti-V-
antigen antibody in Western blots, GST-V3 and GST-V9 pro-
duced weaker bands than the other prote ins. 
Antigenicity or GST-Yl to GST-Y9. Mice immunized i.p. 
with GST-V and GST-VI to GST-V9 were ta il bled prior to 
challenge with Y pestis GB. The sera from individual animals 
were pooled, and V-antigen-specific total IgG, IgGl , and 
IgG2a titers were determined by enzyme-linked immunosor-
bent assay (Fig. 2). An anti-V-antigen response was measured 
in all groups. and in all cases the IgG 1 response was at least 
fourfold higher than the IgG2a response. The IgGl isotype in 
the mouse is commonly associated with a cytokine profile in-
dicative of a Th2 response (24). 
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FIG. 2. Antibody tite" of animal> prim to ch:ollcngc. The tgG. lgG I. and t gG~a tote" nf mice ommunized with GST-V rusinn protein arc >hmvn. Equal volumes 
nf scrum frnm imli' idually hied mice were pooled Hnd ana lyzcd in duplicate. The cnrre'f><liiUing prutectoon "\CCn in Tnhlc 2. Rc,ult' :ore c'prcsscu "' the reciprocal 
uf the titcr (mc:H" := 't:onuard crrnl"'o uf the mc:on,). The dotted line inuicate' a rotcr of 50.tXN.I. Trunc.otc> \\ere dcemeu robe highly antigeouc ( titl·r > IOO.tXXI) or 
moderately an tigcnic (ritcr < 5ll.tXKI). 
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TABLE 2. Pm 1cc1ive ellicacy of GST fusion pr01cins 
lmmuniz1ng Ammn acid"! of Challenged,,..., ,,r Survivor\ 
prole in V anligcn \'. fH.''"' Gl3 (11-ILD) per group 
GST-V 4- 326 1.1 / 10' 6/6 
1.1 / 107 6/() 
GST-VI 74-326 1.1 / 10~ li/6 
1.1 / 1(]1 6/6 
GST-V2 135-326 1.1 X 10' 6/6 
1.1 X 107 6/6 
GST-V3 2 15-326 1.1 / 10' 0/6 
1.1 >< 107 0/6 
GST-V4 2-275 1.1 X 10~ 6/6 
1.1 X 107 3/6 
GST-VS 2-213 1.1 X 10' 2/6 
1.1 X 107 0/6 
None (un1reated) None 1.1 X 105 2/6 
1.1 X 107 0/6 
GST-V6 2-135 1.0 X JOS 5/6 
1.0 X 107 ND" 
GST-V7 135-275 1.0 X lOs 5/6 
1.0 X 107 ND 
GST-VS 135-245 1.0 X l OS 0/6 
1.0 X 107 ND 
GST-V9 186-275 1.0 X lOs 0/6 
1.0 X 107 ND 
GST None 1.0 X lOS 0/6 
1.0 X 107 ND 
• ND. nm dclcrmincd. 
truncates containing amino acids 13S to 245. Truncates lacking 
all or part of this region (GST-V3, GST-VS, GST-V6, and 
GST-V9) produced comparatively reduce·d titcrs. which sug-
gests that amino acids 13S to 24S encode a major antigenic 
region. Moderate titers ( < SO,OOO) generated against truncates 
GST-V3, GST-VS. and GST-V6 indicate that regions of V 
antigen other than amino acids 13S to 245 contribute to anti-
genicity but to a lesser extent. 
GST-Vl to GST-VS protection. Six anima ls per immuniza-
tion group were challenged s.c. with approximately 1. 1 x 1 Q-' or 
1.1 x 107 MLD of Y. pes1is GB and observed for 14 days (Table 
2). GST-V-, GST-Vl -, and GST-V2- immunized animals were 
protected at both challenge doses, suggesting that the first 134 
amino acids are not necessary for protection and that the 
N-tcrminal boundary of a protective region lies at amino acid 
13S. GST-V4 provided complete protection aga inst the lower 
dose, indicating that the C-termina l boundary of the protect ive 
region lies at amino acid 27S. Although amino acids 135 to 27S 
clearly contain one or more protective cpi topcs, full protection 
against the higher challenge dose requires amino acids 276 to 
326, as seen from the GST-V2 and GST-V4 protection dat a 
(Table 2). The contribution of am ino acids 135 to 27S to 
protection was confirmed by immunization studies, si nce 
GST-V3 and GST-VS. which contain only part of this region. 
failed to protect fully against ei ther challenge dose. There is 
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therefore an overlap between the most antigenic region of V 
antigen and the region most important for protection. 
GST-V6 to GST-V9 protection. In the previous challenge 
experiment, the use of a lower challenge dose ( 1.1 X I 0' M LD) 
allowed GST-V3 and GST-VS to be distinguished in terms of 
protection. There fore, in order to define further the protective 
regions of V antigen, mice immunized with GST-V6 to 
GST-V9 were challenged with 105 MLD (Table 2). 
GST-V7, GST-V8, and GST-V9 were used to probe the 
central region of the protein. Pa rtial protection was noted only 
in the GST-V7 group, confirming the importance of amino 
acids 13S to 27S for immunity. Truncates GST-VS and GST-
V9, encoding only part of this region, did not confer protection 
on immunized mice, despite the fact that both arc at least 
moderately antigenic. 
Protection against 105 MLD was given by GST-V6 (amino 
acids 2 to 135), indicating that there are o ne or more minor 
protective epitopes at the terminus of V antigen. This is the 
first indication of a protective region a t the te rminus of V 
antigen. The limited protection seen with GST- VS (Table 2) 
supports this observation. 
Mapping MAbs to regions of V antigen. A set of MAbs had 
been raised against rV antigen in PBS, and a second set had 
been raised against SDS-denatured protein. Table 3 shows the 
degree of recognition of selected GST fusion proteins by 
MAbs in Western blotting studies. The MAbs fell into three 
main categories in terms of their binding to truncates. The 
group I MAbs did not recognize V antigen with deletions at the 
N terminus (GST-Vl to GST-V3) but did recognize GST-V4 
and GST-VS, indicating that a significant part of their epitope 
is located within the first 73 amino acids. Group II MAbs 
strongly recognized GST-Vl , GST-V2, and GST-V4 but not 
GST-V3 and GST-VS, which indicates that their epitope is 
located between amino acids 13S and 27S. Previously, the 
epitope of one or more protective antibodies present in poly-
clonal antiserum had been mapped to a similar region (amino 
acids 168 to 27S (12]). The group Ill MAb could not be local-
ized to a region of V antige n on the basis of its recognition 
pattern. · 
Passive protection with MAbs. Representative MAbs from 
group I (MAb 101.3) and group 11 (MAb 7.3) were chosen for 
studies of passive protection against plague. MAb (3SO J..Lg 
each) was administered i.p. to mice 24 h prior to s.c. challenge 
with 12 MLD of Y. pestis GB, and the animals were monitored 
for 16 days. MAb 7.3 provided complete protection when given 
alone or combined with MAb 101.3 (six of six mice in each 
group survived). There was no significant difference in protec-
tion between MAb 101.3 and nonimmune mouse serum (zero 
of six mice in each group survived). rV antigen-specific rabbit 
polyclonal antiserum provided limited protection, with four of 
six animals surviving to the end point. Passive-protection stud-
ies were necessarily performed with a relatively low challenge 
dose (12 MLD) compared with active-immunization chal-
lenges (lOS and 107 MLD). The ability to passively protect 
against a challenge with 10 MLD of Y. pes1is K.JM has been 
reported as significant ( 12). Although M Ab 7.3 may prove to 
he protective against higher challenge doses, protection against 
12 MLD indica tes that we have identified a protective MAh 
that recognizes an cpitope located between am ino acids 135 
and 275. 
01 CUS ION 
A part of a program to analyzc the structure of V antigen 
and relate it to function. we have immunized mice with trun-
cated forms of V antigen expressed as GST fus ion proteins. 
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TABLE 3. Rccognilion of 1runca1c~ hy an1i-V-an1igcn MAbs in Wc~1 .: rn biOI~ 
Rccognolion uf the indicated fusion prntcin" 
MAl> (rccogniliun >i ter' GST-V GST-VI GST-V~ t•ta GST-\'_; G!)T-V4 GST-V5 
(aa 4- 326) (aa 74-326) 135- D>l (aa 1 5-.>~Cl) (2- 275) (aa 2-213) 
Group I (aa 2-7-1) 
109.3' +++ +++ +++ 
107.3' +++ +++ +++ 
102.3' +++ t-+ + 
45.3" +++ + + 
IOI Y +++ - I- ++ + 
17.3" +++ + +I-
108.3'' +++ + 
104.3' +++ +I- -r/- +I- ++ + 
Group 11 (aa 135-275) 
7.3" +++ +++ -+- +++ 
15.3" +++ +++ ++ - +++ 
51.3'1 +++ +++ ++ - + ++ 
47.3 +++ +++ -+- +++ +I-
1.3' +++ +++ -+- ++ 
103.3" +++ ++ ++ + ++ 
13 1.3'1 +++ ++ ++ ++ + 
Group 111 (undefined) 
11.3<1 +++ 
• MAbs arc grouped according to the ir recognition pattern. aa, amino acids. 
b Recognition was assessed qualitatively as s1rong (++ +), moderate ( ++),weak (+ ).equivocal (+I -). or nonexistent (-). Numbers in parentheses indicate amino 
acids of V antigen. 
c MAb was produced from native rV. 
d MAb was produced from denatured rV. 
Immunization with fusion proteins containing amino acids 74 
to 326 (GST-Vl) and 135 to 326 (GST-V2) protected mice 
agajnst 1.1 X 10 MLD of Y. pestis GB, the highest challenge 
dose tested. Protection at this level of challenge compares with 
previously repo rted protection data for V antigen, where mice 
survived a challenge of 2 X 107 MLD of Y. pestis GB but some 
breakthrough occurred at 2 X 108 MLD (27). GST-V2 there-
fore provides a level of protection similar to that of full-length 
rV antigen against s.c. challenge with Y. pestis. TheN terminus 
of a protective region has thus been mapped to amino acid 135. 
This is consistent with previous protection data showing that a 
protein A fusion protein lacking 67 amino acids from the 
N-terminal end of V antigen protected mice against I 04 MLD 
of Y. pestis KJM (14). 
Mice immunized with GST-V4 were completely protected 
aga inst a challenge dose of 1.1 x 105 MLD of Y. pestis GB, but 
there was only 50% survival at the higher challenge dose (1.1 X 
107 MLD). The results indicate that the C terminus of a pro-
tective region lies at amino acid 275. However, the last 5 1 
amino acids are important for protection and may encode 
additional epitopes, or their omission might cause conforma-
tional changes tha t affect immunoge nicity. 
Reduced protection in mice immunized with GST-V3 and 
GST-VS suppo rts the theory that a protective region lies be-
tween amino acids 135 and 275. as these trunca tes contain only 
part o f this regio n. Five of six mice immunized with GST-V7 
were protected against 105 MLD, which confirmed the pre . -
ence o f one or mo re protective epitopes within this central 
region of V antigen. The results agree with I hose of a previous 
passive-p ro tectio n study, in which immune sera adsorhcd with 
truncated fo rm of V antigen were used to protect mice pa -
sive ly agai nst 10 MLD o f Y. pestis KIM (12). Although the 
challenge dose was nccess<t rily low. the results clearly demon-
strated the presence of one or more protective epitopes be-
tween amino acids 168 and 275. 
All of the immunized mice produced either a high 
(> 100.000) or a moderate ( < 50,000) titer of V -antigen-specific 
IgG. All of the truncates containing amino acids 135 to 245 
induced a high titer, whereas those containing none or only 
part of this region had moderate titers, thus suggesting that the 
major antigenic determinants of V antigen are located between 
amino acids 135 and 245. The putative major antigenic region 
the refore overlaps with the major protective region of V anti-
gen. 
Attempts to define further the central protective region in 
this model failed , as GST-V8 and GST-V9 were not protective. 
Analysis of the V-antigen-specific IgG responses shows that 
GST-V8 elicited an antibody response similar to that of 
GST-V. indicating that loss of protection cannot be attributed 
to a reduction in the V-antigen-spccific IgG titer. The results 
indicate that amino acids 135 to 186 encode all or part of one 
o r more protective epitopes or tha t these residues are impor-
tant for the conformation of a more centrally located epitope. 
Combination of the results of this study with the results of 
Motin and coworkers, who localized one or more protective 
cpi10pes to amino acids 168 to 275 (12). suggests that residues 
168 to 186 are crucial for the formation of one or mo re pro-
tective epitopes. Again. these residucs may encode part of the 
cpitope or may be importan t for protein folding. Similar con-
clus ion~ for the role of am ino acids 246 to 275 were drawn on 
the ba is of GST-V9 protection data. It is possible that pro-
tection o ffered by GST-V8 and GST- V9 against plague might 
be distinguished if immunized animals arc challenged with a 
lower dose of Y. pestis. 
ProJection against 105 MLD by active immunization with 
GST-V6 demonstra ted the presence o r a protective region at 
Vo1 . fl5. llJlJ7 
I heN terminu~ (amino acid~ 2 to 135). GST-V5 abo conferred 
a degre..: of protection. A~ GST-V:l lack~ a large portion of the 
central proteciiv..: region. and small deletions within amino 
acids 135 to 275 (Table 2) aboli hed protection against I 05 
MLD. it is likely that protection abo derives from the 
terminal residues of V an ligen. Din·e rence · observed between 
GST-V5 and GST-V6 in the level of pro1..:c1ion might be due 
to differences in the challenge dose ( 1.1 X I O' versus 1.0 X I O' 
MLD). Allernatively, the addition of amino acids 136 to 213 
might mask, destabilize. or all er the conformation of protective 
epitopcs located within the first 135 ami no acids of GST-V5. 
Result of Western blotting experiments suggested that a 
group of MAbs recognized epitopes located wholly or partly 
within the N-lerminal 74 amino acids (group I) and that an-
o ther group recognized epitopes within the central protective 
region (group 11). It is interes ting thal six of the eight MAbs 
that bound to lhe N terminus were generated against nonde-
natured rV antigen. In contrast, six of even MAbs that rec-
ognized an epi topc found between amino acids 135 and 275 
were generated against SDS-denatured rV antigen. Denatur-
ation of rV antigen might alter protein fo lding to such an 
extent that centrally loca1ed 8-cell cpitope were exposed. 
Passive immunization with MAb 7.3 (group 11) resulted in 
protection against an s.c. challenge with 12 MLD of Y pestis 
GB. Thi result confirm the importance of amino acids I 35 to 
275 for protection and indicates the presence of at least one 
protective 8-cell epitope. M Ab I 01.3, a representative of the 
group I MAbs, did not protect against plague. However, other 
group l MAbs, might prove to be protective in this model, 
although preliminary analysis of the an tibodies described in 
Table 3 (except for MAbs 11.3. 102.3. and 131.3) has failed to 
identify any further protective group I or group 11 MAbs (data 
not shown). 
Sequence analysis of the lcrV gene from strains of Y pestis 
and Y pseudotuberculosis showed that V antigen is highly con-
served ( 13). Sequence variability between strains was noted, 
however. between amino acids 177 and 256 of Y pestis KlM V 
antigen. with a highly variable region centered at amino acid 
227 (13). Roggenkamp et al. (20) have recently shown that two 
forms of lcrV exist in yersiniae. One form is found in Y entero-
colitica 08 strains (LcrV-Yen 08), and another form i typi-
cally found in Y pestis, Y pseudowberculosis, and Y enteroco-
litica 03. 09, and 0 5,27 strains (LcrV-Yps). DNA sequencing 
has indicated that the main differences between LcrV-Yen 08 
and LcrV-Yps reside in a hypervariable region (amino acids 
225 to 232). Furthermore, serum raised against LcrV-Yen 08 
and LcrV-Yps passively protected mice against cha ll enge with 
yersiniae, but only if the immunizing V antigen was the same 
group as that derived from the challenge organism (20). The 
investigators attributed the difference in proteclion between 
species to this hypervariable region. sugge ting that it encodes 
a major protective epitope. The proposed location of such an 
epilope is consistent with the active- and passive-immunization 
data presented in this study. 
In summary. the exi tencc of two distinct regions of V anti-
gen that protect mice again t high levels of a fully vi rulent 
strain of Y. pestis has been demonstrated by active immuniza-
tion. The major protective region is located between amino 
<1cids 135 and 275 and overlaps the major antigenic region 
(amino acids 135 1u 245). We have also shown thal a protective 
MAb recognizes an epitope located within this region. Protec-
tion was also conferred by an N-terminal portion of V anligen 
(amino acids :2 to 135). Previous studies have shown that a 
protein A-Y-antigen fusion peptide containing amino acids 68 
to 326 of V antigen ha~ immunosuppressive properties (1-1). 
Amino acids 25 to 40 have also been implicated as important 
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for viru lence function by I he generat ion of nonpolar deletions 
within lcrV of Y. pestis (23). It is therefore possible that two 
regions of V antigen are involved in virulence. Immunization 
with GST-V6 and GST-V7 might generate separalc pools of 
neutralizing anlibodics th<ll reduce the virulence function of V 
antigen. It would therefore be interesting to compare the level 
of protection achieved in mice coimmunized wilh G T-V6 and 
GST-V7 with that of singly immunized animals and to define 
the upper limit of GST-V2 protection. 
Work to identify functionally important regions of V antigen 
is in progress, making use of the truncates and MAbs de cribed 
in this report. A combination of dala describing protective and 
functional properties of V ant igen will assist the development 
of safe and effective new-generation vaccines again t plague. 
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Summary 
Type Ill-mediated translocation of Yop effectors is an 
essential virulence mechanism of pathogenic Yersinia. 
LcrV is the only protein secreted by the type Ill secre-
tion system that induces protective Immunity. LcrV 
also plays a significant role in the regulation of Yop 
expression and secretion. The role of LcrV in the viru-
lence process has, however, remained elusive on 
account of its pleiotropic effects. Here, we show that 
anti-LcrV antibodies can block the delivery of Yop 
effectors into the target cell cytosol. This argues 
strongly for a cr itical role of LcrV in the Yop transloca-
tion process. Additional evidence supporting this role 
was obtained by genetic analysis. LcrV was found to 
be present on the bacterial surface before the estab-
lishment of bacter ia target cell contact. These find-
ings suggest that LcrV serves an important role in the 
initiation of the translocation process and provides 
one possible explanation for the mechanism of LcrV-
induced protective immunity. 
Introduct ion 
V (LcrV) and W were the first antigens to be associated 
with virulence of Yersinia pestis (Burrows and Bacon, 
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1956; 1958). These investigators showed that only strains 
expressing V and W could induce protective immunity to 
plague in the mouse infection model. Lawton et al. (1963) 
raised antibodies against purified preparations of V and W 
and demonstrated that only anti-V antibodies provided pro-
tection against plague in mice. More recent studies (Une 
and Brubaker. 1984; Motin et al. , 1994; Hill et al., 1997) 
have verified that polyclonal antibodies raised against 
highly purified LcrV as well as a monoclonal antibody 
that recognizes the central domain of LcrV conferred pas-
sive protection against experimental infections with Y. pes-
tis and Y. pseudotuberculosis. lt has been established that 
active immunization using LcrV as an antigen can provide 
high levels of protection against up to 107 lethal doses in 
experimental bubonic and pneumonic plague (Leary et al., 
1995; Anderson et al., 1996}. These studies argue for a 
role of LcrV in the virulence of Yersinia , and it has been 
proposed that LcrV acts by suppressing the inflammatory 
response early during infection. This is supported by experi-
ments in which the injection of LcrV in mice suppressed 
the expression of TNF-a and IFN--y and promoted the sur-
vival of LcrV-negative strains of Y. pestis as well as the 
survival of Salmonella and Listeria (Nakajima et al., 1995). 
LcrV has also been shown to delay allograft rejection and 
increase the tolerance to lipopolysaccharides (LPS) in 
mice (Motin et al., 1997; Nedialkov et al., 1997). In addi-
tion, Welkos et al. (1998) showed that LcrV inhibits neutro-
phil chemotaxis in vitro as well as in vivo. 
Initially, LcrV was purified from the culture supernatant, 
suggesting that LcrV was a secreted protein (Law ton et al., 
1963). More recent studies have shown that LcrV also 
localizes to the bacterial cytoplasm (Straley and Brubaker, 
1981) and is also a substrata of the type Ill secretion sys-
tem (Forsberg et al., 1987; Straley, 1988; Bergman et al., 
1991; Skrzypek and Straley, 1995). Type Ill secretion sys-
tems are part of a mechanism for intracellular targeting 
of virulence factors shared by several bacterial pathogens 
(for a review, see Hueck, 1998). These systems enable the 
different pathogens to secrete and inject virulence effectors 
by a bacterium-host cell contact-dependent mechanism. 
In Yersinia , == 20 virulence plasmid-encoded ysc (.Y.ersinia 
§eQretion) genes encode proteins forming a type Il l secre-
tion organelle (Michiels et al., 1991 ; Piano et al., 1991 ; Had-
dix and Straley, 1992; Rimpilainen et al., 1992; Piano and 
Straley, 1993; Allaoui et al., 1994; 1995; Bergman et al., 
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1994; Fields et al., 1994). The proteins secreted by the 
type Ill secretion system in Yersinia are denoted Yops 
( Yersinia outer proteins) and can be divided into at least 
two groups based on their function. Some of the secreted 
proteins are targeted by the system into the host cell and 
are denoted effector proteins; other secreted proteins are 
either required for the translocation of the effector proteins 
across the host cell membrane or are involved in the control 
of this process. The translocated effector proteins include 
YopE, YopH, YopJ, YopM, YopT and YpkA (Rosqvist et 
al., 1994; Sory and Cornelis, 1994; Persson et al., 1995; 
Sory et al., 1995; Boland et al., 1996; Hakansson et al., 
1996a; Schesser et al., 1998; lriarte and Cornelis, 1998; 
Skrzypek et al., 1998). Delivery of Yops into the target 
cell requires YopB, YopD and, in some cases, also TyeA 
(Rosqvist et al., 1991 ; 1994; Hartland et al., 1994; 1996; 
Boland et al. , 1996; Hakansson et al. , 1996b; Francis 
and Wolf-Watz, 1998; lriarte et al., 1998). YopK is not 
required for translocation but has, instead, been sug-
gested to control the translocation process by modulating 
the size of the translocation pore induced by YopB (Holm-
strom et al., 1997). The role of LcrV is less clear but, in 
recent studies (Nilles et al., 1998; Sarker et al., 1998), it 
has been suggested that LcrV has an indirect role in trans-
location, possibly via effects on secretion/deployment 
of YopB and/or YopD. However, genetic evidence for a 
direct role of LcrV in translocation and virulence has been 
impeded by the fact that lcrV mutants are downregulated 
for yop expression (Bergman et al., 1991; Skrzypek and 
Straley, 1995). 
The type Ill secretion system of Yersinia is believed to 
be gated from the outside by the YopN protein (Forsberg 
et al., 1991; Rosqvist et al., 1994; Boland et al., 1996) 
and is opened only after bacterium-host cell contact has 
been established, resulting in induction of Yop expression 
and secretion (Pettersson et al., 1996). Evidence for a role 
of YopN (LcrE in Y. pestis) in gating the secretion system 
comes from the fact that yopN mutants show a constitu-
tive, cell contact-independent expression and secretion of 
Yops (Yother and Goguen, 1985; Forsberg et al., 1991 ; 
Rosqvist et al., 1994; Skrzypek and Straley, 1995; Boland 
et al., 1996). 
One essential virulence function mediated by the type Ill 
targeting system is the ability of Yersinia to resist uptake 
by phagocytes (Rosqvist et al. , 1988; 1990). This activity 
is dependent on two of the translocated effectors, the 
YopE cytotoxin and the YopH protein tyrosine phospha-
tase, which act in concert to block bacterial uptake (Rosq-
vist et al., 1990; Bliska et al., 1991 ). YopH has been shown 
to act downstream of the phagocytic recaptor, probably 
targeting the focal adhesions (Black and Bliska, 1997; 
Persson et al., 1997). As a consequence, YopH can also 
mediate resistance to the uptake of lgG-opsonized bac-
teria via Fe receptors (Fallman et al., 1995). This powerful 
antiphagocytic mechanism is probably the main reason 
why neither effector proteins nor proteins localized to the 
zone of contact between the bacterium and the target cell 
(YopB, YopD, YopK, YopN) can induce protective immunity 
to Yersinia infections (Benner et al. , 1998; Leary et al., 
1999). Another possibility is that none of these proteins 
are accessible to antibodies with the potential to block the 
function of these essential virulence determinants. The 
unique ability of anti-LcrV antibodies to provide protection 
against Yersinia infections prompted us to investigate 
whether the antibodies could act by blocking an essential 
virulence function involving LcrV. 
In this work, we show that LcrV is involved in transloca-
tion and that antibodies to LcrV can block this process. 
Based on our findings, we propose that the passive protec-
tion conferred by anti-LcrV antibodies is mediated by a 
specific inhibition of the translocation of Yop effectors. 
We also show that LcrV is exposed on the bacterial sur-
face before contact between the pathogen and the target 
cell. Based on our findings, we suggest that LcrV functions 
in the initiation of the translocation process. 
Results 
Anti-LcrV antibodies block translocation of Yop 
effectors 
Previous work has established that LcrV is unique among 
the antigens secreted by the type Ill system in that it can 
provide protective immunity to Y. pestis infections (Law ton 
et al., 1963; Motin et al. , 1994; Leary et al. , 1995; 1999; 
Benner et al. , 1998). Together with the fact that Yersinia 
can also block Fe receptor-mediated phagocytosis by pro-
fessional phagocytes (Fallman et al., 1995), this suggested 
to us that one mechanism by which anti-LcrV antibodies 
could mediate protection was via the interference of trans-
location of Yop effectors. To test this hypothesis, we inves-
tigated whether anti-LcrV antibodies could interfere with 
the translocation of Yop effectors. A sensitive assay for trans-
location is to monitor the cytotoxic effect caused by trans-
location of the YopE cytotoxin, which is manifested as a 
typical rounding up of the infected cells. Interestingly, 
cells infected with wild-type Y. pseudotuberculosis treated 
with a monospecific polyclonal anti-LcrV antiserum dis-
played a dramatically decreased cytotoxicity compared 
with cells treated with the preimmune serum (Fig. 1 ). Anti-
sera directed to essential components of the type Ill deliv-
ery system or to effector Yops (YopB, YopD, YopE, YopH, 
YopK, YopM and YopN) were all unable to block YopE-
mediated cytotoxicity on Hela cells infected with wild-
type Y. pseudotuberculosis (Fig. 1; data not shown). In 
addition, a number of monoclonal antibodies (mAbs) direc-
ted to LcrV of Y. pestis were also evaluated in this system. 
Only the protective antibody mAb 7.3 (Fig. 2) affected the 
cytotoxicity, while the other non-protective mAbs had 
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Fig. 1. Anli·LcrV antiserum blocks YopE·medlated cytotoxicity. 
Phase-contrast m1crographs of Infected Hela cells after 3 h of 
Infection us1ng a x 40/ 1.0 Zeiss 011 immers1on lens. Hela cells 
were infected with (A) the wild-type Y. pseudotuberculosts , 
YPIII(piB102), (B) the w1ld-type treated w1th antisera directed to 
LcrV or (C) YopE. 
no eHect on the YopE-mediated cytotoxicity of Y. pestis 
(data not shown). Yop translocation requires intimate bac-
teria-cell contact. Therefore, it was important to exclude 
the possibility that the anti-LcrV antiserum interfered with 
the bacterial binding to the Hela cell surface and thereby 
indirectly aHected the translocation process. We first mea-
sured whether anti-LcrV had an eHect on the bactena-
Hela cell binding by counting the number of cell-associated 
ill 1999 Blackwell Sc1ence Ltd. Molecular Microbtology. 32, 961 - 976 
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bacteria using an immunofluorescence method described 
earlier (Rosqvist et al., 1988). The addition of anti-LcrV 
antiserum had no eHect on the number of cell-associated 
bacteria. Using a multiplicity of infection of 5, on average, 
1.5-2 bacteria per He la cell were bound irrespective of the 
presence or absence of anti-LcrV antiserum. A lcrVwhole-
gene deletion mutant can be transcomplemented by the 
homologous protein PcrV of Pseudomonas aeruginosa 
(see below). The cytotoxic effect induced by the strain 
YPIII{piB19, pLJ33), lcrV(pP18cpcrV+) on Hela cells was 
not inhibited by the addition of anti-LcrV antiserum. As 
PcrV is not recognized by the anti-LcrV antibodies, this 
result demonstrates that the anti-LcrV antibodies inhibit 
the cytotoxicity via a specific interaction with LcrV. These 
results indicate that LcrV is involved in the delivery of Yop 
effectors into the target cell. 
LcrV is involved in translocation 
To provide genetic evidence for a role of LcrV in transloca-
tion, we constructed an in frame deletion mutant of lcrV in 
which codons 10-313 were removed, thereby essentially 
deleting the entire lcrV gene (Fig. 2). Like previously des-
cribed lcrV mutants (Bergman et al., 1991; Skrzypek and 
Straley, 1995), the resulting mutant strain, YPIII(pl819), 
was found to be downregulated for Yop expression (Fig. 
3) and calcium independent for growth at 3rC (Table 1 ). 
In contrast to other calcium-independent mutants, the 
lcrV mutant secreted considerable amounts of all Yops, 
albeit in reduced amounts compared with the wild-type 
strain, when grown in calcium-depleted medium at 3rC. 
The introduction of pT87 (Bergman et al., 1991 ), which 
expressed lcrV under the control of the tac promoter, 
restored the wild-type phenotype with respect to growth 
phenotype (Table 1) as well as Yop expression and secre-
tion (Fig. 3). 
Interestingly, we found that the lcrVmutant, YPIII(pl819), 
was unable to induce a cytotoxic eHect on infected Hela 
cells even after prolonged incubation (Table 1). This was 
found to result from inactivation of lcrV, as the transcomple-
mented strain, YPII I{pl819, pTB7), induced a strong cyto-
toxic effect similar to that of the wild-type strain (Table 1 ). 
One could argue that the inability of YPIII(pl819) to cause 
cytotoxicity on eukaryotic cells was the result of the lower 
levels of Yop expression by the lcrV mutant compared 
with the wild-type strain. it has been shown recently that 
a double yopN, lcrV mutant of Y. pestis was derepressed 
for Yop expression and secretion (Skrzypek and Straley, 
1995). Therefore, we constructed a strain, YPIII{pi882V), 
in which the mutant allele of the lcrV gene (~ 1 0-313} was 
introduced in a yopN background. Also in Y. pseudotuber-
culosis, YopN was found to be epistatic to LcrV, as the 
yopN, lcrVdouble mutant displayed constitutive Yop secre-
tion at 3rC, with only a minor reduction in Yop secretion 
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Fig. 2. Schematic representation of the LcrV protein, the region recognized by mAb 7.3 and the different mutated forms of LcrV. The regions 
showing high homology to PcrV of P. aeruginosa are shown as black boxes, and the level of Identity at amino acid level is depicted above 
each box . 
levels compared with the yopN mutant strain (Fig. 4). How-
ever, in contrast to the yopN mutant strain, the yopN, lcrV 
double mutant strain, YPIII(pi882V), was non-cytotoxic for 
infected He la cells even after prolonged incubation (Table 
1 ). The introduction of pTB7 (P1ac lcrv+ ) in YPIII(piB82V) 
restored the ability to induce a cytotoxic effect on infected 
He la cells (Table 1 ), indicating that LcrV is important for 
translocation. However, one potential problem with this 
interpretation is the fact that the yopN, lcrV double mutant 
showed a reduction in the level of Yop secretion including 
the translocators YopB and YopD. Therefore, we conduc-
ted a genetic analysis of lcrV with the idea of isolating 
mutations that discriminated between Yop regulation and 
translocation. 
It has become evident recently that the type Ill secretion 
machinery and the translocation systems of Yersinia spp. 
and P. aeruginosa are closely related (Yahr et al., 1996; 
1997). Recent studies have shown that the type Ill secretion 
system and the translocation of virulence effectors are 
functionally conserved between these pathogens (Frithz-
Lindsten et al., 1997; 1998). The protein corresponding 
to LcrV in P. aeruginosa, PcrV, is 41 % identical to LcrV 
at the amino acid level, with a region of high homology 
localized in the central part of the protein, where 11 out of 
12 amino acid residues are identical. In addition, the 55 
C-terminal amino acids show 67% identity (Fig. 2). Analo-
gous to the functional complementation by PopB/ PopD of 
yopB/yopO mutants (Frithz-Lindsten et al. , 1998), we found 
that pcrV+ of P. aeruginosa (cloned under the control of 
the tac promoter of pLJ33) could complement the Y. pseudo-
tuberculosis lcrV mutant, YPIII(p1819). Strain YPIII(pl819, 
pLJ33), lcrV(pP1acPCrV+ ), was calcium dependent for 
growth at 3rC (Table 1 ), secreted wild-type levels of 
Yops in medium devoid of calcium (Fig. 5) and induced 
cytotoxicity on Hela cells (Table 1 ). These findings indi-
cate that LcrV and PcrV are very similar with respect to 
their function in spite of the relatively low levels of homol-
ogy at the amino acid level. Based on this, we argued that 
the highly conserved regions could be important for the 
function of the proteins. Therefore, a series of mutations 
were made in lcrV, based on the homologies between the 
two proteins. First, stepwise C-terminal deletions of 10 











Fig. 3. Express1on and secretion of Yaps by the lcrV mutant strain 
YPIII(piB19) (.laa 10-313). (A) Supernatant fractions and (B) 
whole-cell fractions. The indicated strains were grown for 30 min at 
2s•c and for an additional 3 hat 37•c in Ca2 ·•-containing (+ )and 
Ca2 ' -depleted (-) media. The secreted proteins of the culture 
supernatants were precipitated w1th 10% trichloroacetic acid, and 
the supernatant and whole-cell fractions were subjected to SOS-
PAGE, followed by Western blotting using a polyclonal antiserum 
raised against the secreted Yaps. 
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Table 1. Hela cell cytotoxrcity and growth 
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Cytotoxicity on Growth 
Genotype Hela cells phenotype8 
Wild type + CD 
/crV~10-313 Cl 
lcrV, plcrv+ + CD 
yopN + TS 
yopN, lcrV TS 
yopN, lcrV, plcrv+ + NO 
/crV-1218-234 + CD 
Jcrv, ppcrv~ + CD 
lcrV, plcrV296 Cl 
lcrV, plcrV306 Cl 
lcrV, plcrV316 Cl 
YPIII(piB19, pV~160-171) lcrV, plcrVd 160-171 Cl 
YPIII(piB68) yscS Cl 
YPIII{piB82V, pV296) yopN, lcrV, plcrV296 NO 
YPIII(piB82V, pV306) yopN, lcrV, plcrV306 ND 
YPIII(piB82V, pV316) yopN, lcrV, plcrV316 ND 
YPIII(piB82V, pV~160-171) yopN, JcrV. p/crVtl160-171 ND 
a. Strains unable to grow at 37•c without the addition of Ca2 • are defined as calcrum depen-
dent (CD), which is the wild-type phenotype of Y. pseudotuberculosis. Calcium-independent 
(Cl) mutants are able to grow at 37"C, irrespective of the Ca2" concentrations. If the strain 
is unable to grow at 37"C, it is defined as temperature sensitive (TS). 
V316, V306 and V296 (Fig. 2). In addition, the highly con-
served domain in the central part of lcrV was deleted, 
resulting in the protein V 6.160-171 . The mutated forms 
of lcrV were cloned under the control of the tac promoter 
using the vector pMMB66HE and introduced into the lcrV 
mutant strain, YPIII(piB19). However, none of the constructs 
could complement the lcrV mutant with respect to calcium 
phenotype, expression/secretion of Yops or cytotoxicity 
(Table 1; data not shown). In contrast, an in frame deletion 
mutant strain denoted YPIII(pl8119), in which codons 218-
234 of lcrV were removed, displayed a wild-type pheno-
type (Fig. 5, Table 1 ); this region showed high divergence 
between LcrV and PcrV as well as the LcrV proteins of the 
different Yersinia species. This indicated that the regions 
of LcrV and PcrV showing high homology are also of impor-
tance for the function of the proteins. 
As none of the truncated forms of LcrV could restore 
wild-type expression/secretion of Yops, the constructs 
were introduced in the yopN, lcrV double mutant in an 
attempt to discriminate between the effects on regulation 
and translocation. Introduction of the truncated forms of 
LcrV resulted in levels of LcrV and Yop expression/secre-
tion in vitro similar to the full-length LcrV (Fig. 6A). Impor-
tantly, we also verified that the level of Yop expression was 
similar during infection of Hela cells for all these constructs 
(Fig. 68). However, in contrast to the wild-type protein, 
none of the LcrV truncates could complement the transloca-
tion defect of the yopN, lcrV double mutant (Table 1 ). The 
yopN, lcrV double mutant showed a slight reduction in 
secretion of Yops (Figs 4 and 6A) and, therefore, we were 
concerned that the effect on translocation of the lcrVmuta-
tion was caused by an indirect effect of the lcrV mutation 
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on the secretion of the Yops. However, as complementa-
tion of the lcrV mutation by the LcrV truncates results in 
the same level of expression and secretion of Yops, includ-
ing YopB and YopD, as the strain transcomplemented by 
the full-length LcrV (Fig. 6), we can conclude that the 
effects on translocation are mediated by LcrV per se. In 
addition, the regions conserved between LcrV and PcrV 
are important for translocation. These findings were rein-
forced further by the fact that YopH was also translocated 
Ca2+ + + 
YopH,ML. 
r~f~ /' ~ 
YopD,N 
YopE --. 
Fig. 4. Yop secretion by yopN and yopN, JcrV double mutants. 
Strains YPIII(p1B82) (yopN), and YPIII(piB82V) (yopN, lcrV) were 
grown for 30 min at 2s•c and for an additional 3 h at 37"C in 
Ca 2 • -containing ( + ) and Ca 2+ -depleted (-) media. The secreted 
proteins of the culture supernatants were precipitated with 10% 
trichloroacetic acid, and the supernatant and whole-cell fractions 
were subjected to SOS-PAGE. 







Fig. 5. PcrV of P. aeruginosa transcomplements the lcrV mutant 
YPIII(piB19) of Y pseudotuberculosis. The Indicated strains were 
grown for 30 m in at 26•c and for an additional 3 h at 37"C in 
Cah·depleted media. The secreled proteins of the culture 
supernatants were precipitated with 10% trichloroacetic ac1d and 
subjected to SDS-PAGE. Note that Yop secretion levels of the 
lcrV mutanl strain YPIII(piB119) (.laa 218-234) are Similar to 
those of the wild-type strain. 
into Hela cells in a LcrV-dependent manner, as shown by 
immunofluorescence staining followed by confocal laser 
scanning microscopy (CSLM) analysis (Fig. 7). We there-
fore conclude that LcrV is indeed involved in the transloca-
tion process. 
LcrV is surface localized before target cell contact 
As LcrV can be found not only intracellularly, but also in the 
culture medium (Straley, 1988; Bergman et al., 1991 ), we 
asked whether LcrV was translocated into the cytosol 
of the target cell. Hela cells infected with wild-type Y. 
pseudotuberculosis were analysed by immunofluorescence 
staining followed by CLSM using monospecific anti-LcrV 
antibodies. LcrV was found to be associated with the extra-
cellular bacteria, appearing as distinct foci on the bacterial 
surface, while no specific LcrV staining could be detected 
in the Hela cell cytosol (data not shown). Given that translo-
cation of one effector protein can be increased by removing 
the genes encoding the other translocated Yops (Hakans-
son et al., 1996a), we used a genetically engineered mul-
tiple yop mutant strain MYM lacking yopH, yopE, yopM, 
yopK and ypkA (Persson et al.. 1997) to investigate 
whether LcrV translocation could be detected. When the 
spatial localization of LcrV was analysed after infection 
of He la cells with the MYM strain, no LcrV could be detec-
ted in the cytosol of the target cell (data not shown). As 
observed for the wild-type strain, LcrV was only found in 
discrete foci in the vicinity of the bacteria (Fig. 8). Interest-
ingly, most bacteria exhibited a similar staining pattern 
irrespective of whether they were associated with the 
Hela cells or not. This finding is distinct from the staining 
pattern observed for all the other Yops studied so far. In 
these cases, Yops could only be detected after association 
of the bacteria with the target cells. To investigate the local-
ization of LcrV further, different bacterial strains grown in 
calcium-containing media were analysed by CLSM using 
anti-LcrV antibodies. A secretion mutant (yscS), as well 
as a lcrVmutant (YPIII(piB19)) displayed no LcrV staining, 
whereas the wild-type strain showed a staining pattern 
identical to that of bacteria associated with Hela cells 
(Fig. 8). Importantly, as expected for bacteria grown in 
non-inducing conditions (+Ca2+), the yscS mutant expres-
sed LcrV at the same level as the wild-type strain, as veri-
fied by Western blot analysis (Fig. 8). As shown above, 
PcrV of P. aeruginosa can functionally transcomplement 
an lcrV mutant with respect to the regulation, secretion 
and translocation of Yops (Fig. 6; Table 2). However, 
PcrV is not recognized by the LcrV antiserum. As the 












Fig. 6. Expression of LcrV and Yops m vitro and during infection of 
HeLa cells. 
A. The indicated strains were grown for 30min at 26°C and for an 
additional 3h at 37•c in Ca2•-depleted media. The secreted 
proteins of the culture supernatants were precipitated with 10% 
trichloroacetic acid and subjected to SDS- PAGE followed by 
Western blotting using anti-LcrV or anti-YopB antiserum. 
B. Confluent layers of HeLa cells were infected with the Indicated 
strains of Y. pseudotuberculosis. Two hours after the onset of 
infection, the HeLa cells were lysed by the addition of Triton X-100 
to the tissue culture medium to a final concentration of 0.1 %, and 
the number of bacteria in the lysates was determined by viable 
count. The different samples of the entire infected culture (lysed 
cells plus culture medium) were adjusted to contain equal numbers 
of bacteria (about 2 x 106 ) and analysed by Western blotting using 
a polyclonal antiserum ra1sed against LcrV and the secreted Yops. 
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Fig. 7. LcrV is involved in the translocation of YopH. HeLa cells were infected with different strains of Y. pseudotuberculosis, and the 
localization of YopH (green) and the HeLa cell membrane (red) was determined by laser-scanning confocal microscopy. 
A. Wild type, YPIII(pl8102). 
B. lcrV, YPIII(pl819) (aaa 10-313). 
C. yopN, YPIII(pi882) . 
D. yopN, /crV, YPill(pi882V). 
In all cases, cytochaiasin D (0.5 f.Lg ml- 1 final concentration) was added 30 min before infection, and the samples were analysed 3 h (A and C) 
or 5 h (8 and D) after the onset of infection. The HeLa cell membrane was visualized with Texas red-conjugated wheat germ agglutinin and 
YopH by indirect immunofluorescence using an aHinity-purified goat anti· YopH antiserum followed by donkey anti-goat lgG conjugated to 
FITC. The fluorescent Images were collected simultaneously using a confocal laser-scanning microscope equipped with dual detectors and an 
argon/krypton laser. The images were scanned at 0.28 f.Lm pixel size and a pinhole setting of 50 f.Lm. Scale bar= 20 f.Lm. 
a wild-type phenotype, it served as the optimal negative 
control tor the LcrV stainings. As expected, this strain 
was negative for surface-located LcrV (Fig. 8), demonstrat-
ing that the surface staining was specific for LcrV. The sur-
face localization of LcrV was strengthened further by the 
fact that the addition of purified LcrV before the addition 
of anti-LcrV antiserum totally abolished the immunofluor-
escence signal (data not shown). When CLSM was used, 
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the LcrV staining appeared as 1 0-20 discrete spots per 
bacteria (Fig. 8). Increasing the resolution by using immu-
nogold labelling electron microscopy gave a similar result, 
I.e. clusters of immunogold particles were found at discrete 
areas of the bacterial surface. On average 153 ± 57 gold 
particles per bacteria were observed for the wild-type 
strain, whereas only 10 ± 5 gold particles per bacteria 
were seen for the negative control strain (YPIII(p1819, 
968 J. Pettersson et al. 
Fig. 8. LcrV localizes to discrete areas at the bacterial surface. Confocal micrographs of .A) Wild type, YPIII(pl8102), (B) the Wild-type strain 
at higher magnificatiOn, (C) the yscS secretion mutant, YPIII(piB68), and (D) the lcrV mutant transcomplemented w1th pcrv+, YPIII(pl819, 
pLJ33). The stra1ns were Incubated 1n calcium-contalmng medium (MEM) at 37•c. LcrV was visualized by indirect Immunofluorescence using 
an affinity-punfied rabbit ant1-LcrV antiserum followed by donkey anti-rabbit lgG conjugated to FITC (green). The bacterial surface was labelled 
us1ng rabbit antiserum raised against the whole cell of Y. pseudotuberculosis strain YPIII (Virulence plasmid cured) followed by donkey anti-
rabbit lgG conjugated to Cy3 (red) . The fluorescent 1mages were collected using a confocallaser-scanning microscope equipped with argon/ 
krypton laser. The 1mages were scanned at 0 07 iJ.m pixel size and a pinhole setting of 50 iJ.m. Scale bar= 0.5 iJ.m or 1 iJ.m. Inserts show the 
expression levels of LcrV of the wild-type and the yscS mutant stra1ns; whole-cell fractions of the two strains were analysed by Western 
blotting using rabbit anti-LcrV antiserum. Yellow colour indicates eo-localization between LcrV and the bacterial surface. 
pLJ33)) (Fig. 9A). In the LcrV-expressing strain, the gold 
particles were typically found in clusters (around 10-20 
clusters per bacterium) most easily seen at the edges of 
the bacteria. Similar clusters were rarely found (less than 
one per 1 0 bacteria) on the negative control strain. These 
results showed that LcrV was localized to the bacterial sur-
face and suggested to us that LcrV could form or be part of 
a structure on the bacterial surface. Therefore, the wild-
type strain YPIII(piB102) was analysed by thin-section 
immunogold labelling electron microscopy using anti-LcrV 
antiserum. As expected from the results obtained using 
CLSM, only a few clusters of gold particles were associ-
ated with the bacteria when the thin sections (50 nm) were 
analysed, and rarely were more than two clusters per bac-
terial section observed. No specific labelling was observed 
for the JcrV mutant strain, YPIII(piB19), nor for the lcrV 
mutant strain transcomplemented by PcrV, YPIII(piB19, 
pLJ33) (data not shown). Specific LcrV staining could 
usually be seen as one cluster per bacterium per thin sec-
tion (Fig. 9B). Assuming that each bacteria could be 
divided into 20-40 sections and that we rarely found 
more than two clusters per bacterial section, one can esti-
mate that one bacterium could maximally harbour 40-80 
LcrV clusters. As many sections contained one or no clus-
ter, this number is probably overestimated. The number of 
LcrV clusters observed by this method is thus comparable 
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A 
LcrV Per V 
B 
Fig. 9. lmmunogold labelling of LcrV localized on the bacterial surface. Electron micrographs of Y. pseudotuberculosis immunogold labelled 
with the LcrV antiserum. 
A. lmmunogold labelling of whole cells. The antiserum stained the surface of the wild-type strain YPIII(piB102) (LcrV), but there was no 
staining for the negative control, the PcrV-expressing lcrVmutant strain, YPIII(piB19, pLJ33) (PcrV). Scale bars = 500nm 
B. Six different representative ultrathin sections (50nm) of wild-type Y. pseudotuberculosis, YPIII(piB102) immunogold labelled for LcrV. Scale 
bars = 100 nm. 
with the number of LcrV foci estimated from the CLSM 
analysis (Fig. 8) as well as from the electron microscopy 
analysis of whole bacteria (Fig. 9A). From these results, 
we conclude that LcrV is localized in discrete foci that 
are present on the bacterial surface before contact between 
the pathogen and the target cell has been established. 
However, the thin-section EM did not provide results 
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supporting the hypothesis that LcrV is part of an organized 
surface structure. 
Discussion 
One central virulence mechanism of Yersinia is to deliver 
effector proteins into the cytosol of the target cell via the 
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P rac expression vector Furste et al. (1986) 
Fnthz-Lindsten et al. (1998) 
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lcrV cloned under the control of the lac promoter of pMMB66HE 
pTB7 derivative, lcrVtruncated at codon 316 This study 
pTB7 derivative, lcrV truncated at codon 306 
pTB7 derivative, lcrV truncated at codon 296 
pTB7 derivative, aa 160-171 of lcrV deleted 
contact-dependent type Ill secretion system. This process 
requires a number of discrete steps including attachment, 
secretion, translocation and targeting of the different Yop 
effectors. Inactivation of proteins required at any level of 
this process results in avirulence. Given that anti-LcrV 
antibodies mediate protection against Yersinia infections, 
the neutralizing effect of anti-LcrV antibodies could involve 
any of the steps mentioned above. To elucidate the step at 
which anti-LcrV antibodies act, we used the Hela cell 
infection model and were able to show that anti-LcrV anti-
bodies blocked V opE-mediated cytotoxicity. The antibodies 
did not inhibit attachment of the bacteria to the eukaryotic 
cells. Importantly, the anti-LcrV antibodies could not block 
cytotoxicity mediated by a lcrV mutant strain expressing 
PcrV of P. aeruginosa , which can functionally complement 
LcrV. Thus, the anti-LcrV antibodies obstructed the trans-
location process. Interestingly, one monoclonal antibody 
(mAb 7.3), which provides passive protection in experi-
mental animal infections, has been identified (Hill et al., 
1997). This mAb also affected the cytotoxic response, 
while other non-protective mAbs did not. Thus, there is a 
strong correlation between protective immunity and inhibi-
tion of Yop translocation. This finding argues that the LcrV-
mediated humoral immunity against Yersinia infection can 
be accomplished by neutralization of the translocation 
process. LcrV apparently exhibits two virulence functions, 




Therefore, it cannot be excluded that protection could also 
be provided by interference of the immunosuppressing 
activities of LcrV, as suggested by Brubaker and eo-workers 
(Nakajima et al., 1995; Motin et al. , 1997). 
These results suggested to us that LcrV is actually invol-
ved in the translocation process per se. To investigate this 
further, we constructed a non-polar in frame deletion 
mutant of lcrV. This mutant was indeed non-cytotoxic, 
but was also found to be downregulated for Yop expres-
sion and/or secretion, as shown previously for other lcrV 
mutants (Bergman et al., 1991 ; Price et al. , 1991 ; Skrzypek 
and Straley, 1995). Therefore, these results did not allow 
us to conclude that LcrV was involved in translocation. 
To uncouple Yop expression/secretion from translocation, 
the effect of LcrV was studied in a yopN mutant back-
ground. yopN mutants are constitutive for Yop expression 
and secretion, and Straley and colleagues had shown earlier 
that a yopN (/erE) mutation is epistatic to a mutation in lcrV 
(Skrzypek and Straley, 1995). Thus, a double yopN, lcrV 
mutant is derepressed for Yop expression and secretion. 
We confirmed these results and could show further that 
such a mutant was non-cytotoxic, thus unable to translo-
cate YopE. The block in translocation was general, as 
the translocation of YopH was also blocked, as shown by 
immunofluorescence and CLSM. Introduction of /crV in 
trans restored translocation fully, demonstrating the impor-
tance of LcrV in this process. 
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PopS and PopD of P. aeruginosa can functionally com-
plement yopB and yopD mutants of Y. pseudotuberculosis 
(Frithz-Lindsten et al., 1998). This is somewhat unexpected, 
as the corresponding proteins of the two species are only 
about 40% identical. In an attempt to identify functionally 
important domains of LcrV, we investigated whether the 
LcrV homologue of P. aeruginosa, PcrV, could complement 
the lcrV mutant, YPIII(piB19), and this was indeed found 
to be the case. PcrV and LcrV display an overall identity 
of 41% but, interestingly, two regions, amino acids 160-
171 and the 55 C-terminal amino acids, show significantly 
greater similarity (92% and 67% identity respectively) . 
Based on this information, several deletions in lcrV were 
constructed. Deletions in either of these regions abolished 
lcrV function with respect to expression, secretion and 
translocation, i.e. the phenotypes of these mutants were 
indistinguishable from that of the lcrV null mutant. By ana-
lysing the phenotypes of these mutations in a yopN mutant 
background (with constitutive Yop expression and secre-
tion), it was possible to show that these highly conserved 
domains were important for translocation of Yop effectors. 
The fact that the two regions identified as essential for 
LcrV function affect both Yop expression/secretion as well 
as translocation highlights the close link between these 
processes. 
When we analysed the localization of LcrV during infec-
tion of He la cells, we were unable to detect any LcrV in the 
cytosol of the cells; the majority of the LcrV staining was 
found at the zone of contact between the bacteria and 
the eukaryotic cell. Using fractionation of infected cells, 
Nilles et al. {1998) suggested that LcrV was translocated 
into the cytosol of cells. Our results do not exclude the pos-
sibility that small amounts of LcrV are translocated but 
suggest that the majority of LcrV is localized in discrete 
areas of the bacterial surface. However, we could not 
show that LcrV was part of an organized .surface structure. 
Knutton et al. {1998) showed recently that one of the pro-
teins secreted by the type Ill system of enteropathogenic 
Escherichia coli, EspA, forms a fibrillar organelle on the 
bacterial surface, bridging the space between the patho-
gen and the target cell. Similar to LcrV, EspA was found 
to be important for translocation (Knutton et al., 1998). 
In another study, Kubori et al. (1998) isolated structures 
spanning the bacterial envelope and extending out from 
the bacterial surface that contained components of the 
type Ill secretion system encoded by SPI1 of Salmonella 
typhimurium. These structures showed similarities to the 
basal bodies of flagella. The part of the structure facing 
outwards from the bacteria was needle-like in appearance. 
Thus, these three pathogens have surface-localized pro-
teins involved in the translocation of virulence effector pro-
teins. Although the mechanism of translocation is similar 
and functionally conserved (Rosqvist et al., 1995), the struc-
tural appearance of these proteins seems to be different. 
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LcrV is present on the bacterial surface before target cell 
contact. This suggests that LcrV is required during the early 
stages of translocation. Purified LcrV has been shown to 
inhibit the chemotactic migration of neutrophils (Welkos 
et al., 1998) and to suppress IFN--y and TNF-a induction 
(Nakajima et al., 1995), indicating the possibility that LcrV 
can interact with eukaryotic cell receptors. Thus, one poten-
tial role of LcrV could be to sense contact with a target cell 
recaptor to initiate the translocation process. lt is possible 
that the role of LcrV in translocation as well as in immuno-
suppression is mediated via a common recaptor interac-
tion. There are several molecular mechanisms that might 
explain how LcrV promotes translocation. One possibility 
is that LcrV and Yop proteins are positioned at the target 
cell surface by a continuous polymerization process and 
are internalized once the structures contact the eukaryotic 
cell membrane. Another conceivable mechanism is that 
LcrV forms an organelle, which is hollow, allowing other 
proteins to be channelled through this structure. Alterna-
tively, as proposed by Nilles et al. (1998), LcrV could initi-
ate translocation by mediating the correct positioning of 
another component(s) required for the process. These 
authors also observed that translocation was affected by 
mutating lcrV of Y. pestis and suggested that LcrV had an 
indirect role in the translocation process by affecting the 
deployment of the translocator protein YopB. Thus, it is 
possible that the role of the surface-localized LcrV is to 
conduit YopB to the target cell membrane. 
In conclusion, we have shown that LcrV is surface 
localized and has an important role in the delivery of Yop 
effectors into the cytosol of the target cell. This virulence 
mechanism can be . neutralized by antiserum directed 
to LcrV, thereby providing one possible explanation as 
to how anti-LcrV antibodies can provide full protection 
against subsequent Yersinia infections. Thus, increased 
understanding of the molecular mechanism of virulence 
may enable the development of novel treatments against 
infectious agents. 
Experimental procedures 
Bacterial strains, plasmids, growth conditions and 
DNA methods 
The bacterial strains and plasmids used in this study are listed 
in Table 2. E. coli strains were grown in Luria broth (LB) or on 
Luria agar (LA) plates. Yersinia strains were grown in LB or in 
brain-heart infusion (BHI; Oxoid). BHI was supplemented 
with either 2.5mM CaCI2 (BHI +)or SmM EGTA and 20mM 
MgCI2 (BHI -). For solid media, Yersinia selective agar base 
(YSA; Difco), blood agar base (BAB; Oxoid) or LA was used. 
Where appropriate, antibiotics were used at the following con-
centrations: kanamycin (50 J.l.g ml - 1 ) , chloramphenicol (20 J.l.g 
ml- ') and carbenicillin/ampicillin (1 00 J.l.g ml- 1 ). Preparation 
of plasmid DNA, restriction enzyme digests, ligations and trans-
formations into E. coli were performed essentially as described 
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5' -CGA CAG TCT AGA TTA TCT AAT ATG AAA AAG CGA C·3' 
5' ·AT CAC TGA TGG GTT TTG TTC GTA GGC 7'-3 ' 
5' ·AA AAC CCA TCA GTG ATG CAA CGT CTG C·3 ' 
5'-CGA CAG GAG C'l'C GCA AGA GAG TAG AGT TGC T-3' 
5' ·CGA CAG TCT AGA TAA AGG CGG TCA TTA TGA CA·3' 
5 ' -TTT ATC GAT TTC TCG AGA ATT TTG TAC TC-3 ' 
5 ' -TCG AGA AAT CGA TAA AGA ACT TTC TTG AAA-3' 
5' ·CGA CAG GAG CTC GCA AGA GAG TAG .Z\GT TGC T-3' 
5'·GCG CT GGA TCC TCA CAT CAC TGA ATC ATA TTT CTG-3' 
5 ' ·GCG CT GGA TCC TCA GTT CAG TGC TTC AAT AGC TG-3 ' 
5' ·GCG CT GGA TCC TCA TGA TGT AAT ATC AGA CAG CTG-3 ' 
5 ' -CGA CAG GAA TTC TAT GAA ATC TTC CCA TTT TGA T-3 ' 
5 ' ·AT TTC AGC CTC AGC TAA TTC TTC ACG C-3' 


























VF 5 ' -CGA CAG GGA TCC TTA TTT ATC GTC ATC ATC TTT ATA ATC TTT ACC AGA CGT GTC ATC TA·3 ' 1530- 1510 
a. Nucleotides in bold correspond to restriction enzyme sites. Nucleotides in italic are identical to positions from the Y. pseudotuberculosis 
sequence (lcrGVH) given to the right (accession no. M57893). 
by 8ambrook et al. (1989). Plasmids were introduced into 
Yersinia by conjugation as described by Rimpilainen et al. 
(1992). DNA fragments were purified from agarose gels 
using Geneclean (Bio 1 01} according to the manufacturer's 
instructions. 
Construction of plasmids and mutants 
In frame deletions in lcrVwere constructed by allelic exchange 
using the method described by Milton et al. (1996), which 
involves integration and excision of a suicide plasmid carrying 
upstream and downstream DNA of the fragment to be deleted. 
The near full-gene deletion mutant in which codons 10-313 of 
lcrV were removed was constructed as follows: the primer 
pairs LcrV1 and LcrV2 and LcrV3 and LcrV4 (Table 3) were 
used in polymerase chain reaction (PCR} with YPIII(piB102} 
as the template DNA. The resulting amplified fragments U1 
(primers LcrV1 and LcrV2} and D1 (primers LcrV3 and 
LcrV4}, corresponding to about 400 bp upstream and 182 bp 
downstream of the lcrV gene, respectively, were purified by 
preparative agarose gel electrophoresis. The LcrV2 and LcrV3 
primers were designed to contain complementary sequences, 
and a second overlapping PCR using primers LcrV1 and 
LcrV4 and the purified U1 and D1 fragments as the template 
DNA was performed. A 582 bp fragment with the desired dele-
tion was obtained. Primers LcrV1 and LcrV4 contained sites 
for Xbal and Sacl, respectively, and, after restriction enzyme 
digestion and purification, this 582 bp fragment was cloned 
into the suicide vector pDM4 (Milton et al., 1996), yielding 
plasmid pAH70. The plasmid was transformed into E. coli 
817-H..pir, from which it was introduced by conjugation into 
the recipient Yersinia strain YPIII(piB102). Clones with 
pAH70 integrated into piB102 by a single recombination event 
were selected on plates containing chloramphenicol and kana-
mycin. The resulting eo-integrate strain was verified by PCR, 
after which it was subjected to sucrose selection as described 
by Milton et al. (1996}. This procedure selected for a double 
cross-over event in which the integrated suicide plasmid, 
encoding the sacB gene product, was excised from the viru-
lence plasmid. Four chloramphenicol-sensitive clones carry-
ing the desired deletion were identified by PCR, and one of 
these was denoted YPIII(piB19). Analogously, the lcrVmutant 
allele was also introduced into the yopN mutant of Y. pseudo-
tuberculosis, YPIII(piB82}, resulting in a yopN, lcrV double 
mutant denoted YPIII(piB82V). 
The method described above was also used for constructing 
the in frame deletion mutant YPIII(piB119}. Overlapping PCR 
using the U2 and D2 fragments (generated by primer pairs 
V1 + V2 and V3 + V4 with piB 102 as the template DNA} resulted 
in an 800 bp fragment that was cloned into pDM4 yielding 
pAH69. Conjugation of this plasmid into YPII l(piB 1 02} followed 
by allelic exchange resulted in the strain YPIII(piB119}, which 
is devoid of codons 218- 234 of the lcrVgene. YPIII(piB19}, 
YPIII(piB82V) and YPIII(pl8119} were verified by restriction 
analysis and Western blot analysis using an anti-LcrV antiserum. 
Plasmid pLJ33 expressing pcrV+ under the control of the 
tac promoter of pMMB66EH was constructed as follows. The 
pM89 plasmid described by Frithz-Lindsten et al. ( 1998} con-
tains a 5.3 kb fragment of the P. aeruginosa chromosome 
encoding the PcrR, PcrG, PcrV, PcrH, PopB and PopD 
proteins. A 2.8 kb EcoRI-Bg/11 fragment of pM89, containing 
pcrV with flanking genes, was cloned into the vector 
pMMB66EH. The new plasmid was digested with EcoRI and 
Sphl, after which blunt ends were generated, and the larger 
fragment was subjected to preparative gel electrophoresis 
and religated. The resulting plasmid, pLJ33, contains only 
the very 3' end of the pcrG gene, the entire pcrV gene and 
the 5' end of pcrH. pLJ33 was electroporated into the E. coli 
strain 817-H..pir, from where it was introduced by conjugation 
into YPIII(p\819). 
Three C-terminally truncated variants of LcrV with stepwise 
deletions of 1 0 amino acids were constructed as follows. 
BamHI-tailed primers V316, V306 and V296 were used in 
PCR together with the primer V1 and YPIII(pl8102} as tem-
plate. The three fragments were digested with BamHI and 
Xhol (internal site of the fragments} and purified by preparative 
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gel electrophoresis. The fragments encoding truncated forms 
of the C-terminus of LcrV were cloned into pTB7 digested with 
the same enzymes, resulting in plasmids pV316, pV306 and 
pV296. Electroporation of the plasmids into S17-1 >.pir was fol-
lowed by conjugation into YPIII(piB19) and YPIII(piB82V). 
Another derivative of pTB7 in which codons 160-171 were 
removed was constructed. Using YPIII(piB102) as the tem-
plate DNA, fragments U3 (primers G and V 6160) and 03 (pri-
mers V~ 171 and VF) were generated and, again, overlapping 
PCR was used to obtain a 1200 bp fragment containing the 
desired deletion. The mutated region of lcrV was introduced 
into the pTB7 plasmid by digesting the plasmid and the frag-
ment with Clal and Xhol and replacing the wild-type DNA 
with the mutated form. The resulting plasmid, pV6160-171 , 
was electroporated into S 17-1 >.pir from which it was conju-
gated into YPIII(piB19) and YPIII(piB82V). 
MOX test 
The plating frequencies of the different mutant strains under 
high- and low-Ca2+ conditions at 37"C were determined, and 
the subsequent phenotypes were defined as in Table 1 and 
as described previously by Bergman et al. (1991 ). 
Yop expression and analysis 
Overnight cultures of Yersinia strains grown at 26°C were 
diluted (1 :20) in fresh media (BHI ... or BHI - ) containing 0.1% 
Triton X-1 00, grown for 30 m in at 26°C, then shifted to 37°C 
and grown for an additional 3 h. After measuring the 00600 , 
the cells were harvested, and the culture supernatant was col-
lected and filtered (0.45 ILm pore size; Sartorius). The proteins 
from the supernatant were precipitated with trichloroacetic 
acid (TCA) as described previously (Forsberg et al., 1987). 
The samples from the supernatant and the whole bacteria 
were dissolved in SDS sample buffer, and the volume of the 
samples was adjusted in accordance with the 00600 values 
of the bacterial cultures. The proteins were separated by 
SOS-PAGE and analysed by Coomassie blue staining or 
ECL Western blot analysis according to the manufacturer's 
instructions (Amersham). 
Cultivation and infection of HeLa cells 
The Y. pseudotuberculosis strains used to infect HeLa cells 
were grown overnight at 26°C in LB. Overnight culture (30 IJ.I) 
was added to 3 ml of modified Eagle medium (MEM) with 
10% heat-inactivated fetal calf serum without any antibiotics. 
The inoculated MEM cultures were grown for 30 m in at 26°C 
followed by incubation at 37°C for 2 h before infection. Cultiva-
tion and infection of HeLa cells has been described in detail 
elsewhere (Rosqvist et al., 1990). The He La cells were seeded 
(1.0 x 105 per well) in a 24-well tissue culture plate in MEM with 
10% heat-inactivated fetal calf serum and 100 IU ml- 1 penicil-
lin at 37°C in a 5% C02 humidified atmosphere. For immuno-
fluorescence studies, the HeLa cells were grown on 12 mm 
coverslips placed in a 24-well culture plate. Before infection, 
the He La cells were washed extensively, and MEM with 10% 
heat-inactivated fetal calf serum without any antibiotics was 
added. In experiments using cytochalasin D (0.5 IJ.g ml- 1 
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concentration), the drug was added 30 min before infection. 
After infection, the He La cells were centrifuged for 5 m in at 
400 x g to facilitate contact between the bacteria and the 
HeLa cells, followed by continued incubation at 37"C 
Cytotoxicity 
The HeLa cells were infected at a multiplicity of infection 
(MOl) of about 50 bacteria per cell with various strains of Y. 
pseudotuberculosis or with Y. pestis EV76p(pAMS2). When 
the neutralizing effects of various antisera were analysed, the 
antisera (polyclonal whole serum, Western blot titre 1 :4000) 
at different concentrations (1 :100, 1:50, 1:25, 1 :10) were 
added to the bacterial cultures 5 m in before infection, and the 
MOl was reduced to about two bacteria per cell. The infected 
cells were observed every hour by phase-contrast micro-
scopy. A changed morphology, as visualized by rounding up 
of the HeLa cells (see Fig. 1) indicated a cytotoxic response. 
Detection of bacterial adhesion to HeLa cells 
He La cells grown on coverslips ( = 1.0 x 1 05 ) were infected with 
different strains of Y. pseudotuberculosis (about 0.5 x 106 bac-
teria per well). Two hours after infection, the cells were washed 
twice in PBS and fixed in 2% paraformaldehyde for 10 min. The 
cells were then permeabilized with 0.5% Triton X-1 00 in a buf-
fer containing 1 mM EGTA, 4% polyethylene glycol 6000 and 
100 mM piperazine-N,N' -bis(2-ethanesulphonic acid), pH 6.9, 
and processed further for indirect immunofluorescence label-
ling (for details, see Rosqvist et al., 1991) using rabbit anti-
Yersinia antibodies, followed by fluorescein isothiocyanate 
(FITC)-conjugated anti-rabbit antibodies. The specimens were 
examined using fluorescence microscopy. In each experiment, 
200 HeLa cells were counted in randomly selected fields with-
out previewing. 
Immunofluorescence staining 
HeLa cells grown on coverslips (= 1.0x 105 ) were infected with 
different strains of Y. pseudotuberculosis (about 0.5 x 107 bac-
teria per well). At various times after infection, the cell mono-
layers were washed twice in PBS and stained with wheat 
germ agglutinin (WGA) conjugated to Texas red (Molecular 
Probes) (10 IJ.gml- 1 for 10min at 24°C); the WGA-stained 
cells were fixed in 2% paraformaldehyde for 10 min. Unless 
indicated, the cells were then permeabilized with 0.5% Triton 
X-100 in a buffer containing 1 mM EGTA, 4% polyethylene 
glycol 6000 and 100 mM piperazine-N,N' -bis(2-ethanesulpho-
nic acid), pH 6.9, and processed further for indirect immuno-
fluorescence labelling (for details, see Rosqvist et al., 1991) 
using affinity-purified rabbit anti-LcrV antibodies or affinity-
purified goat anti-YopH antibodies, followed by FITC-con-
jugated anti-rabbit antibodies or FITC-conjugated anti-goat 
antibodies. The specimens were finally mounted in a mount-
ing medium containing Citifluor as an antifading agent. The 
specimens were analysed using a CLSM equipped with dual 
detectors and an argon-krypton (Ar/Kr) laser for simulta-
neous scanning of two different fluorochromes (Multiprobe 
2001; Molecular Dynami.cs). Laser power and gain were set 
by using cells labelled with either fluorochrome alone so that 
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there was no cross-over of green to red or red to green chan-
nel. Sets of fluorescent images were acquired simultaneously 
for Texas red (the HeLa cell membrane) and fluorescein-
tagged (LcrV or YopH) markers using a x60/1.3 plan-ape-
chromate Nikon oil immersion lens. Companion images (1 0 
sections with image size 512 x 512) were scanned with either 
0.28 1-Lm or 0.07 1-Lm pixel size and 0.3 1-Lm step size and a 
pinhole setting of 50 f.Lm . 
Electron microscopy 
For immunolabelling of bacteria, overnight cultures of wild-type 
Y. pseudotuberculosis, YPIII(piB102) , or the PcrV-expressing 
lcrV mutant strain, YPII I(piB19,pLJ33), grown at 25•c were 
diluted (1 :20) in fresh media (BHI +), grown for 30 min at 
25•c , then shifted to 37•c and grown for an additional 2 h. 
The cells were washed twice in PBS, fixed for 1 0 m in in 
0.01 % glutaraldehyde, washed again and then applied to 
grids by placing the grids face down on drops of bacterial 
suspension for 5 min. After washing, the grids were placed 
on drops of affinity-purified anti-LcrV serum for 2 h at room 
temperature, washed again and placed on drops of 6 nm 
gold-conjugated anti-rabbit antibodies (1 :50 dilution; Jackson 
lmmunoResearch Laboratories) for 2 hat room temperature. 
After washing in distilled water, the grids were air dried. For 
the thin-section EM, HeLa cells grown in 35 mm Petri dishes 
were infected with different strains of Y. pseudotuberculosis 
(about Sx 107 bacteria per dish). Eighty minutes after infec-
tion, the cell monolayers were washed twice in PBS, fixed 
for 1 0 min in 0.1 % glutaraldehyde, washed again and then 
incubated with affinity-purified anti-LcrV serum for 2 h at 
room temperature. After washing, the samples were incubated 
with gold-conjugated anti-rabbit antibodies (Jackson Immune-
Research Laboratories) for 12 hat 4•c . After thorough wash-
ing, cells were fixed in 3% buffered glutaraldehyde, post-fixed 
in osmium tetroxide, dehydrated in a graded ethanol series 
and embedded in Agar 100 resin (Agar Scientific) . Ultrathin 
sections were contrasted with uranyl acetate and lead citrate 
and examined in a JEOL 100CX transmission electron micro-
scope at 80kV. 
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Abstract 
Yersinia pestis, the causative organism of plague, produces a capsular protein (fraction I or Fl antigen) that is one of the 
major virulence factors of the bacterium. We report here the production , structural and immunological characterisation of a 
recombinant Fl antigen (rF I). The rFI was purified by ammonium sulfate fractionation fo)lowed by FPLC Superose gel 
filtration chromatography. Using FPLC gel filtration chromatography and capillary electrophoresis, we have demonstrated 
that rFJ antigen exists as a multimer of high molecular mass. This multimer dissociates after heating in the presence of SDS 
and reassociation occurs upon the removal of SDS. Using c ircular dichroism, we have monitored the reassocia tion of 
monomeric rFI into a multimeric form. Mice immunised with monomeric or multimeric rFI develop similar immune 
responses, but mice immunised with monomeric rFI were significantly less well protected against a challenge of I X 106 cfu of 
Y. pestis than mice immunised with multimeric rFI (1/7 compared with 5/7). The significance of this result in terms of the 
structure and the function of rFI is discussed. © 1998 Federation of European Microbiological Societies. Published by 
Elsevier Science B.V. All rights reserved. 
Ke_rll'ords : Yersinia p<'slis; Fl antigen; Polypeptide capsule 
I. Introduction 
Yersinia pe.<ifis is the causative agent of plague. a 
disease which is associated with a high level of mor-
tality in man (I). Although the bacterium no longer 
causes pandemics of disease, the WHO estimates that 
there are approximately 3000 cases of plague annu-
ally world-wide. mainly in N. America , S.E. Asia 
and Africa [2] . The fraction I ( F I) antigen is a major 
• Corre·ponding author. Tel. : +44 (1980) 6 13000; 
Fax : +44 (1980) 613284 . 
component of the surface of Y. pestis [I) and forms a 
capsule-like structure which is visible after negative 
staining of bacteria [3J. Production of the 15.5-kDa 
F I subunit is encoded by the cafl gene [4). and the 
cafl M (5] and cafl A [6] genes tha t encode. respec-
tively, a chaperone which a llows export of the Fl 
antigen subunit to the surface and a protein which 
anchors the Fl antigen into the ou ter membrane. 
The Fl subunit is thought to be assembled on the 
surface of the bacterium to form the capsule. The 
production of F I antigen is temperature regulated 
by the product of the cafl R gene [7]. and the induc-
0928-8244/98/$19.00 <&'! 1998 F~tlcration of European Microbiological Societies. Published by Elscvicr Science B. V. /\11 nght' r,·,;cncd. 
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tion of expression at 37°C is thought to be rela ted to 
its role in protecting the bacterium from killing by 
host phagocytic cells [8], possibly by preven ting com-
plement-mediated opsonisation or by di rupting 
phagocytic cell membra nes [9]. The cafl. cafl R, 
cafl M a nd cajJ A genes a re orga nised into the caf 
operon which has previously been cloned and ex-
pressed in Escherichia coli resulting in encapsulated 
bacteria [3]. 
Intramuscular immunisation with rF I, purified 
from £. coli has previously been shown to induce a 
protective immune response against Y. pestis [I 0, 11] 
and a subunit vaccine composed of Y. pestis Fl anti-
gen and recombinant V a ntigen (a secreted Y. pestis 
protein) shows potential as a replacement for the 
current ki lled whole cell vaccine [12,13]. Although 
the killed whole cell vaccine contains sign ificant lev-
els of F I antigen, it is less effective as a vaccine than 
purified F I antigen, leading to the suggestion that 
the partial denaturation of the F I a ntigen results in 
changes to the antigenic structure [ 11 ]. 
A hypothetical model for the macromolecular or-
ganisation of Fl a ntigen from Y. pestis has been 
reported which suggested that the multimeric Fl 
antigen is composed from dimers of Fl antigen 
joined in a single plane [14]. The purpose o f this 
stud y was : to evaluate the physica l state of rFI; to 
investigate the in vitro assembly Q.f rFI monomers; 
a nd to examine whether assembly of the rFI affected 
the degree of protection afforded after immunisation 
with rF I. 
2. Materials and methods 
2. 1. Bac/erial strains and fermentation 
£. coli JM 101 containing plasmid pAH34L, en-
coding the caf operon from Y. pestis strain GB [3]. 
was cultured in L-bro th containing 50 )..lg ml- 1 ka-
namycin [ 15]. Cultures were incubated with shaki ng 
( 170 rpm ) at 37°C for 19 h. 
2.2. Protein assay 
Protein concentration was determined using the 
BCA protein assay method [ 16]. The protein levels 
in column elua tes were monitored at 280 nm. 
2.3. Polyacrylwnide gel eleclruphoresis 
The rFI preparatio ns we re a nalysed by SOS-
PAGE or na tive PAGE (20%, or 8- 25%, gradien t 
gels; PhastSystem, Pharmacia. St. Alba ns. UK ) fol-
lowed by Coomassie blue staining. Gels were 
scanned using a n LKB Bromma ultrascan XI laser 
densitometer. For Western blotting, the proteins 
were tra nsferred on to polyvinylidenediftuoride 
(PVDF) membrane a nd detected using anti-FI 
monoclonal a ntibody (F 138G-I ; American Type 
Culture Collectio n, USA) followed by detectio n of 
bound antibody using goat a nti-mouse IgA- horse-
radish peroxidase conjugate (Sigma, Poole UK). 
Bound antibody was detected using 3,3' -diaminoben-
zidine tetrahyd rochloride substra te. 
2.4. Purification of rFJ 
All buffers contained 0.5 mM phenylmethanesul-
fonyl fluoride (PMSF : Sigma, Poole, UK) added 
from a 0. 1 M stock solution in propa n-2-ol and 
were pre-filtered (0.2 J..lm filter) and degassed before 
use. Water used in chromatographic procedures was 
of Milli-Q standard . 
E. coli JMIOI/pAH 34L was cultured in 3 X I I 
media, as described above. The cultures were centri-
fuged a t 14000 xg for 45 min at 4°C and the cell 
pellet a nd ftocculant layer resuspended in 200 ml 
phospha te-buffered saline (PBS), pH 7.2 and incu-
ba ted with gentle rolling a t room temperature for 
30 min . The resuspension was centrifuged a t 
14 000 Xg for 30 m in and the supernatant was ad-
justed to 50% ammonium sulfate saturation. After 
st irring for I h, the fractiona te was centrifuged a t 
14000 Xg fo r 30 min at 4°C. The ammonium sulfa te 
pellet was resuspended in PBS and dialysed against 
4 X 2 I of the same buffer, overnight. The dialysed 
crude ex tract was centrifuged at 27 000 Xg to remove 
insoluble material, followed by filter sterilisation us-
ing a 0.22-J..lm disposable filter (Amicon, Stonehouse, 
UK). 
Aliquots of 200 J..ll of the dialysed extract were 
applied to an FPLC Superose 12 HR 10/30 column 
that had been previously equilibra ted with PBS. The 
rF I was elu ted with the same buffer at a now ra te of 
0.5 ml min 1• Peak fractions were collected and an-
a lysed for rFI by SDS-PAGE. Native PAG E and 
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Western blolling (using a monoclonal antibody 
raised to Fl ). An enzyme-linked immunosorbent as-
ay wa performed to determine the concentration of 
rFI antigen produced. using purified Fl antigen 
from Y. pes1is as a standard (12). 
2.5. SlruC/ural clwrac/erismion o.f rF/ 
2.5. 1. FPL C mwlysis 
Purified rFI was heated for 10 min at 100°C. At 
0, 2 and 24 h post-cooling on ice, 200-J..ll aliquots 
were loaded onto an FPLC Superose HR 10/30 gel 
filtration column in PBS at a flow rate of 0.5 ml 
min- 1 and the elution profile at 280 nm was re-
corded. The procedure was repea ted in the presence 
of O.J 'Y,, (w/v) SOS. Molecular weight markers were 
loaded to determine the app roximate molecular 
weight of the trea ted rFI samples. These included 
ribonuclease ( 13 kDa). chymotrypsinogen (25 kDa). 
ovalbumin (43 kDa) and BSA (67 kDa) (Pharmacia, 
St. Albans, UK). The void volume of the column 
was determined using Blue dextran. 
2.5.2. Capillary electrophoresis 
SOS dynamic sieving capillary electrophoresis was 
employed to determine the molecular weight of SDS-
treated rF I. Separations were performed using a Bio-
Focus 3000 capillary electrophoresis system (Bio-
Rad Laboratories). Purified rFI and standard pro-
teins (lysozyme. 14.4 k Da: carbonic anhydrase, 
31 kDa: ovalbumin. 45 kDa; serum albumin. 
66.2 k Da: phosphorylase B. 97 k Da : ~-galactosi­
dase. 11 6 kDa: and myosin, 200 kDa). were loaded 
at 100 psi onto a 24 cm x 50 Jlm uncoated fused 
capillary containing SOS dynamic sieving separation 
medium. separations were performed at 15 kY with 
detection by UV absorbance at 220 nm. 
2. 5. 3. Circular dicltrois111 
CD spectra were recorded from 20 accumulative 
scans at 20°C using a Jobin-Yvon CD6 spectrometer 
(Longjumeau. France). Mean residue uelta epsilon 
values (~£) were calculated using concentrations de-
rived from absorption measurements at 280 nm on a 
Cary 4E absorpt ion spectrometer. Samples of rFI in 
25 mM phosphate butler. pH 7.0, were used at a 
concentration or 1.2 mg ml 1. Boi led samples were 
heated in 1.5 ml plastic reaction tubes in a hea ted 
block at 95 I 00°C for I 0 m in, followed by cooling. 
CD spectra wa recorded immediately and at 20 h 
post-boiling. The procedure was repeated in the pres-
ence of 2'Y,, (w/v) SOS. 
2.6. 111111/lllli.wllion ll'illt SDS-!realed a11d tmlremed 
rFI and cltal/enge of illllllllltised mice 
Purified rF I (I mg ml- 1) was diluted in PBS and 
emulsified wi th an equal volume of incomplete 
Freund's adjuvant (IFA) to a final concentration of 
100 Jlg ml- 1. Six- to eight-week-old female BALB/c 
mice, raised under specific-pathogen-free condi tions 
(Charles River Laboratories, UK) were used in this 
study. Mice in group I (11 = 22) each received intra-
muscularly (i.m.) 100 ).11 of SOS treated rFI (10 Jlg). 
A second group of 22 mice, each received i.m. I 00 Jll 
of untreated rFI (10 Jlg). Mice were boosted on 
day 21. On day 64, 13 mice were challenged sub-
cutaneously with 100 Jll aliquots containing 10~ or 
I 06 colony-forming units (cfu) of Y. pestis strain GB 
(the LD.;u dose of strain GB is approximately I cfu 
per mouse (1 7). The remaining mice in each immu-
nisation group were anaesthetised intraperitoneally 
with a 100-J..ll cocktail of Domitor ( orden Labora-
tories, Smith Kline Beecham. Surrey) (6 mg dose- 1) 
and Ketalar (Parke-Davis) (27 Jlg dose- 1): blood 
was then removed by cardiac puncture. A control 
group of age-matched mice were not immunised 
with rFI. 
2. 7. M easuremenl o.f serum anlibo(~l' litres 
Serum antibody titre was measured by a modified 
ELISA [12). Microtitre plates were coa ted with ei ther 
SDS-treated rFI (5 Jlg/ml in PBS containing 0.1% 
(w/v) SOS) or untrea ted rFI (5 pg ml- 1 in PBS). 
Test sera were serially diluted, in duplica te. across 
the plate. Bound antibody was detected with perox-
idase label led conjuga tes of anti-mouse polyva lent 
immunoglobul in . Pooled sera rrom each group 
were tested ror the titre or tota l lgG and isotypes 
lgG1. lgG2.,. lgG2h and lgG:1. The titre or specific 
an tibody was estimated as the maximum dilution 
of scrum giving an absorbance reading a t 414 nm 
or grea ter than 0.1. after subtraction or the absorb-
ance due to non-specific binding detected in the con-
trol sera. 
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2.8. Statistical analysis k D a 
A Student's /-test wa a pplied to determine the 
significance of the difference between treatment 
group means. 
3. Results 
3. 1. Purification of rFI 
The centrifugation of E. coli JM I 0 l/pAH34L cul-
tures resulted in the sedimentation of bacterial cells 
above which a layer of ftocculated material was visi-
ble. In preliminary experiments, this ftocculated ma-
teria l was shown to be mainly rFI. Additional rFI 
could be removed from the surface of the bacterial 
cells by gentle washing in PBS. The rFI was purified 
by ammonium sulfate fractionation followed by 
FPLC Superose gel filtration chromatography, yield-
ing approximately 50 mg of rFI per litre of culture. 
Based on scanning densitometry of SOS-PAGE gels, 
the purified rF I antigen was judged to be at least 
95% pure and the purified protein reacted with a 
monoclonal antibody against the Y. pestis F I antigen 
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Fig. I. Ana lysis of purified rFI a ntigen by SOS-PAG E. Mo lecu-
la r mass ma rker proteins (track I. molecular mass x 10'1 kOa a r-
rowed) a nd purified rFI antigen (track 2) were separated through 
20% homogeno us gels and stained with Coomassie blue R250. In 
some experiments, the gels "ere Western blo tted using anti-Fl 
monoclonal a ntibod y (track 3). 
high molecular weight form, too large to enter the 
gel (data not shown). During FPLC Superose gel 
filtration chromatography. rFI eluted in the void 
volume (6 m!) of the gel filtration column, indicating 
a molecular weight which was higher than the 
molecular weight predicted from the deduced amino 
acid sequence of the caf ! gene ( 15.5 kDa). The 
10 15 
Migration Time (min) 
Fig. 2. Mo lecula r weight detcrmmauon of rFI by SOS dynamic sieving c<t pill<try electrophoresis. Puriticd r l-1 . with bcntoic acid a> an in-
te rn<tl reference was heated fo r 10 mrn <tt I00°C in the presence of O. I'X, (w/v) SOS <tnd then loaded onto a J.J cm X 50 ~I m fused silica 
ca pillary a nd separa ted a t 15 kV. 
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na ture of the high molecu lar weigh t form of rFI was A 10 
investigated using a variety of techniques. 
3.1. Structural charaCierisation 
3.2.1. Analysis of multimeric and monomeric forms of 
rFI 
When rFI was heated to 100°C in the presence of 
O.I'Yo w/v SDS and then ana lysed using Superose gel 
filtra tion chroma tography, the rF I eluted at a vol-
ume of 12 ml indicating a lower molecular weight 
than the untreated rFI. The low molecular weight 
form of rFl antigen was maintained for at least 24 
h a fter cooling to 0°C. When the SDS-treated rFl 
antigen was dialysed against PBS, a return to the 
high mo lecular weight form of rF I antigen was ob-
served. SOS dynamic sieving capillary electrophore-
sis, showed that the molecular weight of the SDS-
treated rF l was 20 kDa (Fig. 2). 
3.2.2. Reassociation of rFI 
lnterconversion of the low and high molecular 
weight forms of rF l could also be achieved by 
heating rF I in the absence of SOS. When a solution 
of the purified rF I antigen, which had been heated 
to 100°C and then cooled, was applied to the 
FPLC Superose column it eluted at a position 
which, on comparison with standard proteins, indi-
cated a molecular weigh t of 20 kOa (Fig. 3A). After 
furt her incubation at 0°C, the rF I antigen eluted 
from the FPLC Superose column at positions which 
indicated multimerisation ; after 2 h the rFI antigen 
eluted as a peak corresponding to the momomeric 
form of Fl a ntigen and also a peak with an apparent 
mo lecular size of 40 kOa (Fig. 38). After 24 h, a 
broad peak was observed which would encompass 
mu !timers in the size range 80-200 000 kOa (Fig. 
3C). 
3.2.3. Circular dichroism 
Secondary structure determination of rFl, using 
Far-UV-CO. gave a signal that i not cha racteristic 
of any of the three common forms of secondary 
structure. and, in fact, was almost a mirror image 
of that expected for random coil. Often, unusual 
D spectra a re due to a strong a romatic residue 
contribution [ 18]. However, rF I has a low aromatic 
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Fig. 3. Conversion of rF I from low 10 high molecular weight 
forms. Purified rF I (0.5 mg ml 1) \\aS heated to 1oo•c for 10 
min. cooled on ice and samples applied 10 a Supcro<c 12 column 
at 0 h (A). 2 h (B) or 24 h (C) post-cooling. 
tryptophan residues). which gives an estimated molar 
ex tinction coefficient of 5 120 M- 1 cm- 1• The spectral 
maximum at 200 nm. normally exists in type 11 ~­
turns. anti-parallel ~-sheet and even short helices 
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lg(j 1i1rcs (logw) when 1~s1ed using 
plalc> coalcd wi lh 
rFI 
5.43 ± 0.15 
5.09 ± 0.32 
SDS-rFI 
5.44±0.28 
5.23 ± 0.44 
Figur~> ,ho"n are mean values from groups o r 6 mice ± S.E.M . 
r 18. 19]: however, the corresponding characteristic 
minima do not appear in rF I. The spectrum ob-
served for rF I could result from P-structure, super-
imposed on a random coil signal. 
After heating in the presence of 25 mM sodium 
phosphate buffer, pH 7.0, the protein exhibited a 
pure random coi l spectrum which returned partially 
to the original signal after 20 h (Fig. 4). When heated 
in SDS the protein adopted a pure a-helical confor-
mation, which was stable. 
3.3 .. 'v/easurement of serum antibody tin·es 
Preliminary studies were undertaken with rFI ( I 
mg ml- 1) , which had been heated for 10 min at 
I 00°C in the presence of I 0% (w/v) SOS, cooled 
and then diluted with PBS and emulsified with 
IFA. to a final concentration of 100 11g mr1 rFI , 
0.2'Y., (w/v) SDS. After incubation at 22°C, samples 
removed and analysed by SOS-PAGE showed tha t 
the rFI mixed with adjuvant remained in the mono-
meri c fo rm for at least 24 h. For immunisation stud-
ies, either rF I (untreated rF I) or rFI which had been 
boiled in 10% SDS and then mixed with adjuvant as 
described above (SDS-treated rFI) were used. 
The induction of antibodies to rFI antigen in mice 
inoculated i.m. with either SDS-treated rFI or un-
treated rFI in IFA was examined on day 64 post-
immunisa tion. The antibody titres in sera from mice 
immunised with rFI or SDS-trea ted rF I were similar 
when tested using ELISA plates coa ted with rFI or 
SDS-treated rFI (Table 1). The distribution of anti-
body across the lgG subclasses was investigated. The 
profile from mice immunised wi th rFI or SDS-
trea ted rFI was similar to that previously reported 
after immunisa tion with F I purified from Y. pes/is 
[13]. wi th an IgG 1 response predominating and lower 




















- - rF1 bolted. SOS 
... /" 
,..---




.. s L-~1~=---~200=----2~1o~--~no~--~2~=---~2~.o--~m 
Wsvelength I nm 
Fig. -l. CD <tnalysis of t reated and untreaied rF I. Each curv, 
represents the average of 20 accumulated spec! ra measured a t ,, 
concentrat ion of 1.2 mg ml- 1 rFI (0.2 mm p<tthlcnglh cell). Th, 
sample comuined 25 mM sodium p hosph<tte. pH 7.0 with and 
without ~·v., w/v SOS.--. rFI unt reated: ..... rFI . IOO"C for~ 
min: - ·· . rFI IOO"C for 5 min followed by incubation at RT fo1 
20 h: (- - - ) rFJ. 100•c fo r 5 min in 1he presence of 2"/., w/' 
SOS. Each spectrum was corrected by subtraction of a compara-
ble blank. The abscissa is in units of & (M- 1 cm- 1) where M i> 
the molar concenlration of amino acid residues. 
3.4. Protection of immunised mice against challenge 
1rith a virulent strain of plague 
To compare the protective efficacy of immunisa-
tion with SDS-treated rFI and untreated rFI , mice 
were challenged with Y. pestis GB strain in the dose 
range I X 105- 1 X 106 cfu . per mouse, by subcutane-
ous injection. All of the mice in the untreated control 
group died following injection with I X 105 cfu (Ta-
ble 2). There were no mortalities in either immunised 
group at this challenge dose. At a cha llenge dose of 
I X lOG cfu, only I of 7 of the mice immunised with 
SDS-treated rFI survived, compared with 5 of 7 
mice given untreated rF I ( 14.29% compared with 
71.42%). 
Table 2 
Pr01cction of mice immunised \\ith rFI or SDS treated rF I 
(SDS-rFI l against challenge with Y. pt!sti., 
Group Challenge dose Number or survivors 
Control 10·· cfu O/o 
rF I 10:, ~fu 61(, 
rF I 10" cru 517 
SDS-rFI Ill'' cfu 6/(1 
DS-rFI 10' ' d'u 117 
J ,\fill<·!' <'I all F/:",\1.\ lilllll/11/lllug•· anti Mediutl ,\/irml>l,>fogl' :!I t i<)IJ8 } !/.I ~~I 219 
4. Di cussion 
We have previously reported the cloning and ex-
pre sion of the Nlj"opcron in£. coli. The rFI antigen 
produced by this bacterium has been u ed in a num-
ber of studies to evaluate this protein as a compo-
nent of an improved vaccine against plague. The 
method reported here for the purification of the 
rFI antigen yielded a protein which was homogene-
ous when analysed by SOS-PAGE. The expression 
of the mf operon, rather than only the C(!fl gene, in 
E. coli, resulted in the export of the rFI an tigen onto 
the surface of the bacterium and avoided the disrup-
tion of bacterial cells to isolate the protein. The rFI 
antigen appeared to be only loo ely bound to the 
surface of the bacterium and could be removed by 
gentle washing of the cells. Whereas Andrews et al. 
[ 11] reported that purified rF I was in a low molec-
ular mass form, we have found that rF I. which we 
isolated from cells, was in a high molecular mass 
fo rm. It is possible that the more complex purifica-
tion procedure described by Andrews et al. (11]. 
which included treatment of bacterial cells with ace-
tone and toluene, resulted in the monomerisation of 
rF I. 
The Fl antigen is known to form a capsule-like 
structure on the surface of Y. pestis and the autoas-
sembly of the F I antigen has been suggested, but this 
is the first detailed study of this process. The gene 
products of the ctif operon include the F I antigen: 
the Cafl M protein which is thought to ac t as a chap-
erone for the F I antigen ; the Cafl A protein which is 
thought to anchor the Fl antigen into the outer 
membrane of the bacterium and the Cafl R protein 
which regulates gene expression. Our findings sug-
gest that in vi tro, the F I antigen is able to assemble 
in to a high molecular weight form and this might 
indicate the mechanism by which the an tigen on 
the surface of the bacterium assembles into high mo-
lecula r weigh t fimbrial-like structures. The primary 
amino acid seq uence of the Fl antigen does not re-
vea l the pre ·ence of cysteme residues which might 
form disullkle bridges. Our finding that the oligo-
meric rF I could be converted to the monomeric 
fonn by hea ting to 100°C. and that SO prevented 
reas ·ocia tion into the multimeric form suggests that 
hydrogen bonds and hydrophobic interac tions play a 
key role in the oligomerisa tion of rFI antigen. 
In addi1ion, ana lysis by circular dichroism shows 
that rF I antigen contains ~-structure. supporting the 
propo. al by Galyov et al. [4]. Jhat Fl antigen had a t 
least 50'!1,, ~-sheet structure. More recently molecular 
modelling of the structure of F I antigen has sug-
gested that the protein adopts main ly a ~-sheet struc-
ture [20]. In our studies. heating rFI for 5 min a t 
l00°C caused loss of all nati,·e secondary structu re, 
with a return to a conformation similar to, but not 
identical to the original, after incubation for 20 h. 
Heating rF I in the presence of SOS resulted in the 
formation of an a-helical rich structure. This is due 
to the amphiphi lic environment of the SOS micelle, 
causing a -helix formation in sequences that do not 
adopt this formation normally. 
Previous workers have shown that oral immunisa-
tion with Salmonella t_rphimuriwn expressing the caf 
operon induced a higher level of protection against 
plague than oral immunisation with S. typhimurium 
expressing only the cafl gene [3.21]. It was suggested 
that this might be due to differences in the protective 
efficacy of monomeric or multimeric forms of the Fl 
antigen [3]. In this study, the treatment of rFI with 
SOS, which was shown to monomerise the rF I. did 
not affect the immunogenicity of the Fl antigen. In 
addition. we were unable to detect a significant dif-
ference in the level of antibody when rF I or SOS-
treated Fl were used to coat ELISA plates. This 
fi nding might indicate that the SOS-treated rFI anti-
gen re-folded when introduced into animals. and 
whilst we cannot discount this possibility, it is clear 
that SDS-treated rFI. although equally immunogen-
ic. was less effective in inducing protection against 
plague. Previous studies with the killed whole cell 
vaccine or purified Fl antigen vaccine have shown 
that antibody titres to F I antigen were higher in 
mice immunised wi th the killed whole cell vaccine 
yet the mice immunised with F l antigen were better 
protected against plague (11 ]. These fi ndings sug-
gested that the F l an tigen in the killed whole cell 
vaccine had been denatured (11] and the breakdown 
of Fl-antigen in this vaccine has been reported [22]. 
These findings are similar to those reported for the 
Vi capsular antigen or Salmonella typhi, where high 
molecular weigh t forms are reported to induce better 
protection than low molecular weigh t forms of the 
antigen [2.\]. 
The peptide 7 -,TSQDGN HQ, 1 has been identi-
J Htil<'r C't al. I FEMS 111111/tlllolllgr aut! ,\1etltm l Micmlullillg r 11 ( /1)'18 ) 1 13 !! I 
fied as the main B-cell epi tope, and on the basis of 
molecula r model ling it has been suggested that this 
epitope is located on a hyd rophilic loop which is 
accessi ble in monomeric or multimeric forms of F I 
an tigen [20]. lt is possible tha t ei ther another region 
of multimeric rFI i re ponsible for a protective im-
mune response or that the affini ty of antibodies gen-
erated against the SDS-treated F l an tigen was lower 
than those genera ted against rF I an tigen. 
It has previously been reported that F I antigen 
purified from Y. peslis will be a compo nent of an 
improved subunit vaccine against Y. pestis and 4/5 
mice immunised with Y. pestis FJ were protected 
against 2 X 105 cfu of Y. pestis given by the s.c. route 
[ 12]. The rF I we have prepared protected 6/6 mice 
against challenge with 10:; cfu o f Y. pes1is. These 
results also extend the findi ngs of Andrews et al. 
[I I] who showed tha t immunisation with rFI antigen 
provided protection against I 00 LD50 doses of Y. 
pestis. The method we have described for purifica-
tion of a highly protective form of Fl antigen will 
facili tate the development of an improved subunit 
vaccine against Y. pes1is. In addition, the results of 
this stud y provide insight into the mechanisms of 
assembly of bacteria l polypeptide capsules. Our find -
ings will now permit further studies to investigate the 
detailed st ructure of the Y. peslis Fl antigen using 
recombinant Fl antigen. 
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Abstract 
In this study. we have determined the limit of protection achievable by immunisation with sub-units of Yersinia pestis 
agai nst the development of plague in an experimental animal model. eo-immunisation with the purified culture-derived F l 
and the recombinant V sub-units afforded a greater level of protection than with either sub-unit alone. The protection given 
by the combined sub-units was several orders of magnitude greater than that afforded by the whole cell killed (Cutter USP) 
vaccine and was equivalent to that achieved by vaccination with EV76. the li ve attenuated Y. pestis vaccine strain. However. 
the combined sub-unit vaccine has clear advantages over the live vaccine in terms of safety of use and absence of 
side-effects. 
Key ... ords: Sub-uni1: Vaccine: Plague 
1. Introduction 
Yersinia pestis is the causative organ ism of plague 
in a wide range of animals and in humans. Bubonic 
plague in man is most commonly acquired from the 
bite of an infected flea and is characterised by the 
swelling of local lymph nodes which form buboes. A 
secondary pneumonia can arise in cases of bubonic 
plague. and in these cases plague can be transmitted 
to other individuals by ai rborne droplets. Pneumonic 
·Corresponding author. Tel. : +44 (1980) 61300: Fax: ++l 
( 19RO) 613284. 
plague. particu larly, is extremely virulent and if there 
is a fail ure to diagnose the disease rapidly and 
initiate antibiotic treatment. there will be a high 
mortality. There is clearly a need to protect individu-
als living or travelling in endemic areas [I] as well as 
medical and laboratory workers handling Y. pestis. 
So far. the vaccines developed for plague have 
been who le cell vaccines. A number of formu lations 
exist. The Cutter USP vaccine is a formaldehyde-
killed suspension of Y. pestis cell s. derived from a 
virulent strain. Local and systemic side-effects, rang-
ing from mi ld headaches to severe malai. e and fever. 
have been reported in 11 - 24% and 4-1 09c. respec-
tively , of individuals vaccinated [2]. Additionally. 
0\12X-X2-Mj95jS.09.50 © 1995 Fcdcrauon of European Microbiological Socicric,. All righrs rc,crved 
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!'>ome ca~e~ of pneumonic plague have been reported 
in vaccinated individuals. indicating a breakthrough 
in protection [3] and inadequate immunity at mucosa l 
'urface!>. A heat-killed formulation. made by CSL 
labora10rie~ in Australia. has also been licensed for 
human use. 
Strain EV76 is a non-pigmented mutant of >'. 
pestis which is sufficiently attenuated to be used as a 
live vaccine [3-5]. The EV76 vaccine was tested 
.!X tensivcly and used in the former Soviet Union 
from 1939. although its efficacy in evoking an im-
mune response in man is questionable [3- 5]. The 
virulence of EV76 differs in several animal species. 
1nd non-human primates are particu larly susceptible 
o a chronic infect ion with this strain [4]. In the 
..Vestem world. the EV76 vaccine is unsuitable for 
nass vaccination due to the severi ty of the side-ef-
·ects experienced. 
Such ~ide-effects. resulting from the use of whole 
:ell vacc ines. might be avoided by the development 
,fan acellu lar vaccine containing protecti ve sub-units 
·rom Y. pestis as immunogens. Two of the candidate 
.ub-units are the F I and V antigens. Fraction I 
mtigen (F I) is the major protein component of the 
·apsule surrounding Y. pestis cells [6]. Fl is only 
ully expressed at 37°C and is believed to confer 
esistance to phagocytosis [7]. High anti-F I titres 
1ave been correlated with survival following plague 
nfection [8.9]. Fl antigen expressed in the aroA 
nutant of Salmonella typhimurium protected mice 
gainst 50 LD50 ' s of viru lent Y. pestis [I 0] and a 
ingle intra-muscular do. e of Fl antigen protected 
gainst a chal lenge of 105 organism [ 11]. 
The V antigen of Y. pestis is a secreted protein 
vhich is thought to act both as a regulatory protein 
nd a~ a virulence factor. Passive immuni ation with 
era raised to partially purified [ 12] and purified 
13-16] V antigen has been shown to protect against 
challenge of up to 100 LD50 's with Y. pestis. 
'revious work in our laboratory has shown that 
ctive intra-peri toneal (i.p) immuni. ation with highly 
·urified recombinant V (rV) antigen protected mice 
gainst a sub-cutaneous (s.c.) challenge in excess of 
o<> LD50 . s [I 7]. 
In this ~tudy. we have purified the Fl antigen 
·om cultured Y. pestis in high yield and with purity 
reater than 90%, and have used it in conjunction 
ith purified rV antigen. in order to determine the 
l imit of protection achievable by immunisation using 
a J..nown dfecti ve route (i.p.) with these sub-unit~ 
individually and in combination. We have also c.om-
parcd the protective efficacy of the EV76 and Cutter 
vaccines when administered by the convent ional in-
tra-muscular (i.m.) route and schedule for human 
use. Further. we have sought evidence of ant i-F I and 
anti-V acti vity induced after i.m. dosing with these 
vaccines in order to identify any deficiencies . 
2. Materials and methods 
2.1. Preparation (~f sub-units 
The V ari.tigen was expressed as a fusion protein 
with glutathione-5-transfera e (GST) in Escherichia 
coli and purified. as previously described [ 17]. The 
Fl antigen was derived from the supematant of Y. 
pestis grown at 37°C in a chemically defined medium 
[ 18] at pH 7.4. F I was precipitated from the cu lture 
supematant by the addition of 40o/c ( w jv) ammo-
nium sulphate and purified by repeated resuspension 
and centrifugation of the precipitated pellet in 20 
mM Tris-HCI. pH 8.0. 
2.2. EV76 and Culler mccines 
Y. pestis strain EV76 was reconstituted from 
freeze-dried stocks held in-house by inoculation into 
Blood-Agar Base (BAB) broth and incubation at 
28°C for 24-48 h. before plating out onto BAB-
haemin media to determine purity. The Cutter USP 
vacci ne was obtained from the Greer Laboratories. 
Lenoir. C. USA. 
2.3. Animals 
Barrier-bred, female 6-week-old Balbjc mice, free 
of mouse pathogens. were obtained from Charles-
Ri ver Laboratories. Margate. Kent. UK. and used 
throughout these studie .. 
2.-i. fmmunisalion u·ith u·lwle cell raccines 
Mice were divided into groups of 5 or 6 for 
immunisa tion. 
Fifty mice received a si ngle intra-muscular (i.m.) 
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do~e of the li\e altenuated vaccine strain EV76 on 
day 0 of the schedule. This dose comprised approxi -
mate ly 107 live Y. pestis ce lls and was delivered in a 
total volume of 0.1 ml. 
A further group of 50 mice was primed i.m. wi th 
0.1 ml of the Culler USP vaccine. This represented a 
one-fifth of the human do e and comprised approxi-
mately 2 X 10 ~ formaldehyde-killed Y. pestis ce ll s. 
This dose was repeated on day 16 of the schedule. to 
effect a booster immunisation. 
2.5. fiiii71Unisatimt ll"ith candidate sub-unit raccines 
Groups of 62 mice received a primary immunis-
ing dose intra-peritoneally (i.p.) of I 0 1-1-g of either V 
antigen or F I antigen, presented in 0.1 ml I: I water-
in-oil emulsion with Freund's incomplete adjuvant 
(FIA. Sigma). Animals were boosted with the respec-
tive antigen, as appropriate, on days 14 (V and Fl 
groups) and 28 (all Fl group and for V a sub-group 
ofl2only). 
A further group of 12 mice was primed and 
boosted on days 0, 14 and 28 with a combination of 
10 1-1-g Fl and 10 1-1-g V, jointly incorporated into the 
aqueous pha e of a I: I water-in-oil emulsion with 
FIA (final volume 0.1 ml per mouse). 
On day 50 of the immunisation schedule. 6 ani-
mals were elected at random from each of the 
treatment groups for subsequent analysis of spleen 
cell responses. Concomitantly. the remaining animals 
in each group were challenged with virulent Y. pestis 
(see below). An untreated control group of age-
matched mice was similarly split and allocated to 
ti ssue sampling or challenge. 
2.6. Measurement f!{ isorype and titre of the antibody 
response 
Antibody titre was measured by a modified ELISA 
procedure as described previously [ 19]. Peroxidase 
conjugates against mou. e polyvalent lg (Sigma). 
mouse IgG 1 (Sera-Lab) and mouse lgG 1" (Sera-Lab) 
were each used at a maximum dilution of I :2000. 
Titre was estimated as the maximum dilution of 
~erum giving an absorbance reading 0.1 units over 
background and was presented a. reciprocal of dilu-
tion X optical densit y (OD) and from this mean titres 
± ~tandard error of mean (SEM) were derived per 
treatment group. 
2.7. Measurement f~{ T-cell responses in citro w Fl 
(//Id \1 
A purified population ofT cells was derived from 
the spleens of immunised animals and pooled by 
treatment group, prior to determining the in vitro 
proliferative response as described previously [ 17]to 
the Fl and V antigens. Proliferation was quantified 
by the incorporation of "1H thymidine into cells and 
the results are presented as mean counts per minute 
(cpm) per treatment group± SEM, calculated from 3 
replicates. 
2.8. Challenge with Y. pestis 
Mice from each of the immuni. ed groups and 
untreated controls were challenged under ACDP Cat-
egory 3 containment. Aliquots of Y. pestis GB strain 
in the dose range (2 X 105-2 X 10 ~) CFU per mouse 
were injected . . c. Strain GB was isolated from a fatal 
human case of plague and has an LD50 of < I CFU 
in Balb/c mice by the s.c. route [20]. The challenge 
inoculum was prepared as previously described at 
28°C [20]. Challenged mice were closely observed 
over a 12-day period for the development of symp-
toms. and where appropriate, time to death (TTD) 
was carefully recorded. Malai. e was noted in ome 
animals as immobility and ruffled coat. Humane 
end-points were strictly observed so that no animal 
became distressed. 
Animals that succumbed to the challenge were 
autopsied. Livers and spleens were scored for en-
largement and any evidence of abnormality was 
noted. Samples of blood, bisected liver and spleen. 
and swabs from the s.c. challenge site. were smeared 
onto Congo Red agar or Yer. inia . elective agar 
(YSA. Oxoid). and the plate. were incubated at 28°C 
and observed for growth after 48 h. 
At the end of the 12-day observation period. 
sur ivors were humanely cu lled and tissues were 
removed for b::~cteriological and gross morphological 
analysis. as above. 
2.9. SDS-PACE and Western b/ouinx analrsis of Y. 
pestis 
Strain GB of Y. p estis , u. ed for challenge. wa~ 
grown in BAB broth at 3rC to simulate conditions 
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in vivo. Subsequently. it was heat-killed prior to 
de termining its an tigenic compos ition by sodium do-
decyl sulphate-po lyacrylamide gel e lectrophoresis 
(SOS-PAGE) and Western bloning. using standard 
protocols [I 0]. The transferred proteins were probed 
with monoclo nal antibod ies (mAbs) to the Fl anti-
gen (FI3G8- I, American Type Tissue Culture Col-
lec tion) or to the V antigen (m Ab I 04, prepared 
under CBDE contract at CAMR). 
2. 10. Statistical analysis 
A Student ' s t-test was applied to determine the 
significance of the difference between treatment 
group means [2 1]. 
3. Results 
3. 1. Antibody titre and immunoglobulin sub-type in 
immunised groups at day 50 
Following a single i.m. dose of the live anenuated 
EV76 vaccine, an imals had developed a high titre of 
antibody specific for the F I antigen and a lower titre 
against V (Fig. I a, b). By comparison. animals that 
had received 2 i.m. doses of the Cuner vaccine had 
an antibody titre to F I but no detectable titre to V 
1ntigen. In contrast, animals given either 3 i.p. dose. 
J f the purified Fl antigen or 2 to 3 i.p. doses of the 
rV antigen had developed high titres of c irculating 
l ntibodies to the respective immunogen. Animal 
. hat had been eo-immunised on 3 occasion with Fl 
tnd V had high antibody titres to both sub-units. 
Analysi of sera for lgG 1 and lgG 2• antibody 
Jirected against the Fl antigen revealed that in all 
mmunisation groups, lgG 1 titre predominated over 
gG2a titre (Fig. l a). Similarly, an lgG 1 titre predom-
nated against V antigen in all immuni. ation group . . 
rabic I 
n vi tro proliferution of T - celb to Fl 
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Fig. I . a . Mean ant i-F I titres of total lg and lgG , ub-classe' in the 
,cr.t of v;~ccinees. Mean value, were derived from at least 6 >erum 
samples per treatment group. b. Mean anti-V titre' of total lg and 
lgG sub-classes in the sera of vacci nee'. Mean value, were 
derived from at least 6 serum 'itmples per treatment group. 
except EV76 (Fig. I b). In thi s gro up. an lgG2, titre 
agai nst V exceeded the V-spec ific lgG I titre . 
3.2. T-ee// responses to Fl and V in EV76- and 
Cutter-caccinated animals 
It was o f interest to know whether animals immu-
nised with the whole cell vaccines had developed 
i reatment group [ 1 H)Thymidine incorporated per well (cpm) 
:V76 9.7 X 10• ce ll ' well 1 
'utter 1.5 X 10' cclb well - 1 
tmreatcd cont ro l 9.4 X 10' well 1 
1.6 J.Lg ml - 1 F l 3.2 J.L£ ml 1 Fl 
I 130 ± 280.6 • 
962.7 ± 17.9 h 
153.7 ± 3. 9 ' h 
891.7 ± 170 ,. 
8 10.5 ± 5.0 J 
5R0.9 ± 102.5 'J 
h Signilic~nt diffcrcnc:c;, P < 0.05. compari,on' bc1wccn trc:nmcnl group,. 
12.5 J.L£ ml 1 F l 
!0 1.1 ± 99.9 ,. 
J()77.5 ± 67.3 I 
.'17!!.3 ± (,I - ~ e I 
601.7 ± 18.1 ~ 
!lO-l ± 25 .1 " 
2(15. I ± I !l.8 ~ " 
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cell-mediated immunity to the Fl and V antigens. A 
maximum proliferative response at the lowest con-
centration of F I tested ( 1.6 J.Lg ml - 1 ) was observed 
in EV76 vaccinees (Table I) and this was Signifi-
cantly different (P < 0.05) from that observed in an 
untreated control group. Cutter vaccinees al o had a 
significant recall response to F I. which peaked at 
12.5 J.Lg ml - 1 Fl. There was no recall response to 
the V antigen in either the EV76- or Cutter-vac-
cinated groups (data not shown). 
3.3. Limir of prorecrion againsr challenge 
In order to compare the protective efficacy of 
immunisation with the V antigen against that pro-
vided by the Cutter and EV76 vaccines, animals 
were immunised with one (EV76) or 2 (Cutter or V 
antigen) doses of vaccine. in compliance with the 
schedule for use in man. The 2-dose regime is the 
recommended priming schedule for the Cutter vac-
cine, whereas the single-dose regime is standard 
practice for a live vaccine. Subsequently. the vacci-
nated animals were challenged s.c. with viru lent Y. 
pesris. 
The protective effect of the Cuuer vaccine was 
completely defeated by 2 X I ox CFU Y. pesris (Ta-
ble 2). By comparison, 4/5 V-immunised animals 
survived a 2 X IOH CFU challenge, but the protective 
effect was lost at 2 X 109 CFU. EV76-vaccinated 
Table 2 




Treaunenl Survivors Mean TTD Skin 
group (h ± SEM) lesion> 
EV76 5/ 5 + 
Cuner o; 5 119±zero + 
V 0/ 5 102±21 
None o;s 6-1 ±Lero 
EV76 
-1/ 5 + 
Cuner 0/ 5 171 ± 12 + 
V 
-1/ 5 I 56± £ero 
EV76 6/ 6 + 
Cuner 1/ 5 160±zcro + 
V 5/ 5 
EV76 6/ 6 + 
Culler 3 / 5 120 ±9 + 
V 
-1 / S 6-1 ± Lcro 









PrOleClive efficacy of candidalc vaccines 
Y. pestis Trcalmcnl Survivors Mean TTD Skin Sick 
chal lenge group (h±SEM) les1ons 
dose (CFU) 
2 X 10 1 Fl +V 5/ S 
Fl 0/5 99±8 
V 0/ 5 102±9 + 
None 0/ 5 64±zero + 
2 X 10 ' FI+V 5/ S 
Fl 
-1/ S 136 ± Ll!rO 
V 5/ S 
1 X 10' None 0/ 5 122± 16 + 
animals survived a cha llenge of 2 X I 09 CFU, but 
developed skin lesions at the .c. challenge site. 
Cutter-vaccinated animal also developed skin le-
sions and general malaise, but V-immunised mice 
had no side-effects. 
Thus the initial comparison of the V sub-unit with 
Cutter and EV76 indicated that the V sub-unit alone 
was more protective than the Cutter vaccine, but not 
as protective a EV76. 
To determine whether a combined sub-unit ap-
proach to immunisation would offer additional pro-
tection equivalent to that afforded by EV76, animals 
made hyperimmune by immunisation i.p. with 3 
doses of either Fl or V or Fl plus V. were chal-
lenged with virulent Y. pesris up to a maximum of 
2 X I 09 CFU (Table 3). The protective effect of 
either sub-unit alone was defeated by a 2 X 109 CFU 
challenge. However, animals eo-immunised with Fl 
and V were fully protected against a challenge of 
2 X 109 CFU and survived without any appearance 
of side-effects or malaise for the 12-day observation 
period. In contrast. untreated age-matched control 
mice all succumbed to this chal lenge dose with a 
mean TTD of 64 h. 
3.4. Wesrern blorring analysis of Y. pesris srrain GB 
Expression of both the F I and V antigen was 
demonstrated by Western bloning in the Y. pesris 
chal lenge strain cultured at 37°C. The Fl antigen 
was clearly visible as a ingle 17.5 k.Da band (Fig. 
2a) while the V antigen wa observed as a 37 kDa 
band (Fig. 2b). 
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Fig. 2. a. Detection of Fl antigen in Y. pestis strain GB after 
Western hloning. Lanes I and 3: Fl antigen: Lanes 2 and 4 : Y. 
pestis strain GB grown at 37"C in BAB broth: Lane S: Molecular 
mass markers. Lane> 3. 4 and S were stained with Coomassie 
blue. Lane>. I and 2 were developed after Western bloning. b. 
Detection of V amigen in Y. pestis strain GB after We; tern 
bloning. Lane I: molecular mass markers: Lanes 2 and 4: Y. pestiJ 
strain GB grown at 37"C in BAB broth; Lanes 3 and S: V antigen. 
Lanes I. 2 and 3 were stained with Coomas>.ie blue. Lanes -I and S 
were developed after Western bloning. 
3.5. Posf-lnortem analysis of clwllenged animals 
On post-mortem, Y. pestis was recovered from 
the blood, li vers and pleen of control mice and of 
immunised mice that had succumbed to disease after 
challenge. This con fim1ed that plague was the cause 
of death in these animals. However, when surviving 
sub-unit immunised mice (n = 49) were sacrificed 
and autopsied at 12 days post-challenge, l iver, blood 
and spleen samples taken together with .c. challenge 
site swabs, were found to be culture-negative for Y. 
pesris, apart from three animals. In one F !-im-
munised mou e challenged with 2 X 107 CFU. Y. 
pesris was recovered from the blood and s.c. inocula-
tion ite. In two V-immunised animals chal lenged 
with 2 X I 0 9 CFU, Y. pestis wa recovered either 
from the spleen or s.c. inoculation site. In contrast, 
no animals immunised with the combined sub-uni ts 
developed skin lesions at the challenge si te and the 
latter was sterile. All combined sub-unit an imals had 
effectively cleared Y. pestis from their spleens. blood 
and livers by day 12. 
In all EV76 and Cuner-immunised urvivors. 
moderate to severe skin lesions had developed at the 
s.c. challenge site during the 12 day observation 
period (Table 2). The lesion consisted of a large (up 
to 8 mm) membrane-sacculated mas containing 
caseous green to white pus. These lesions appeared 
from day 6 post-challenge and no spontaneous reso-
lution was observed. In animals observed for several 
days after the appearance of the lesion, the dermal 
layers broke down. releasing the material which in 
> 90% of cases was culture-positi ve for Y. pesris. 
On po t-mortem. the lesions were observed between 
the dermis and the urface of the muscle fasciae. and 
appeared to track toward the ax illary region. but 
there was no obvious lymph node invol vement. A l-
though inoculation site swabs from these animals 
were predominantly culture-positive for Y. pesris. 
they had effectively cleared the organism from their 
spleens, blood and livers. 
There were no gross morphological changes visi-
ble in the liver of any immunised survivors, al-
though the spleen were enlarged in 80% of animals. 
indicating that there had been a recent acute infec-
tion. 
4. Discussion 
In thi study the limits of protection against Y. 
pestis challenge which are achievable with the whole 
cell Cutter and EV76 vaccines have been compared 
with tho e given by the Fl and V sub-unit antigens. 
Co-immuni ation with F l and V afforded a level of 
protection equivalent to that achievable with EV76, 
and vastly superior to that given by the Cutter vac-
cine. Furthermore. the sub-unit immunised animals 
did not develop any sk in lesion or malaise after 
challenge, in con trast to the Cuner and EV76 vacci-
nee . These results clearly indicate an additive effect 
of Fl and V, signi ficantly improving protection in 
animals immunised wi th the combined sub-unit . 
over and above that seen in an imals immunised with 
either ub-unit alone. 
The Fl and V antigens are vi ru lence factors in Y. 
pestis. Our re ults demonstrate that animals co-im-
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muni~ed with Fl and V de\ clopcd high titres of 
ci rculating antibodie~ to each antigen. We have pre-
viously shown that both the Fl and V antigens arc 
T-cell dependent [I 0.17]. The functional divi~ion of 
eo~- T-ccll~ into Th I and Th : sub-~cts [22] and the 
differential acti vation of Th 11 to Th 1 or Th ~ cells by 
\ accination is manifest by a characteri stic di~tribu­
tion of fgG sub-c l asse~ in the ~era of vacc inee~ 
[23.2~]. The precise vaccine formulation U).Cd influ-
ences the activation of Th sub-~ets [25]. The predom-
inance of the fgG 1 isotype in the sera of sub-unit 
vaccinees indicates that the accompanying T -cell 
respome to both Fl and V presemcd in FIA is 
predominantly of the Th ~ sub-type [26] which is 
associated particularly w ith a humoral re. ponse. Sim-
ilarly. Fl antigen expres ed by either the Culler or 
EV76 vaccine. evoked predominantly a Th ~ re-
spon. e. Although the V antigen expressed by EV76 
induced only low titres. IgG~. predominated impli -
cating a Th 1 response which is characteri . tic of 
cell-mediated immunity [24]. 
Although the exact mechanism of protection in 
animals immunised with the combined sub-units is 
unknown. it is assumed that the induction of humoral 
and ce ll-mediated immunity to each of these viru-
lence factors promoted elimination of the Fl ... V - Y. 
pestis challenge strain. 
The absence of Y. pestis in the ti .. ues of mice 
immunised with Fl and V twelve days after inocula-
tion of a high challenge dose. and the Jack of macro-
scopic lesions. indicated that the colonisation of 
these ti s. ues by the bacteria was limited. thus pre-
venting the formation of necrotic foci characteristic 
of Y. pestis. In vivo. Lcr+ Y. pestis has been shown 
to suppress the production of cytokincs TNFa and 
IF -y in the ti s ues of infected mice [27] and it has 
been proposed [ 14.28]lhat th is suppression prevents 
the infi ltration of host inflammatory cells into in-
fec ted organs. permilling colonisation and the devel-
opment of necrotic lesions. This suppressi ve activity 
ha<> been allributed to the V antigen [ 13. 14.27] and 
\\ e ha\ e prev io u ~ ly observed a rapid clearance of Y. 
fWslis from the organ!> of rV -immunised mice [ 17]. lt 
i~ po~~ ible that inhibit ion of the anti-inflammatory 
acti\ it} of the V antigen wa), a major factor in the 
rapid clearance of Y. pesti.1· from the ti ).suc~ of 
combined sub-unit immunised mice. 
In contrast. ~everc necrotic lesion), at the ~ .c. 
dlallcnge ~i te. ~ome of \vhich were coloni ~ed wi th r. 
fWI'Ii.l. \vcre seen in 1-: V76 and Culler-vaccinated 
mice 12 day' post-chullenge. although the 'ame ani-
mals had cleared the bacteria from their blood. 
~pleens and livers. As before [20] we found evidence 
that strain EV76 possessed both the F I and V viru-
lence factor!-.. although the e\pres,ion of the V anti -
gen appeared 'everel y l imited so that the EV76 
\ accinee~ had minimal anti-V titre and no T -cell 
re~ponse to V . Sim ilarly. Culler vaccinees had no 
antibody titre or T-cell respon!-.e to V . Both EV76 
and Cutter vaccinees had a 'ignificant anti-F I titre 
and T-cell recall response to Fl . It i ~ possible that 
the absence of an immune re~ponse to V in these 
whole cell-vaccinated animab. permitted a localised 
infection with Y. pestis at the challenge site. but that 
the prevalent anti-FI acti vity enwred systemic clear-
ance of the bacteria. 
Although we have found evidence of only a lim-
ited production of V antigen by strain EV76. never-
theless this attenuated vacc ine is protec tive. The 
potential of this li ve vaccine to produce other factors 
e.g. the plasmid-encoded outer membrane proteins 
(Yops) [29] and the pH6 antigen [30]. would un-
doubtedly contribute to its efficacy and provide fur-
ther explanation of the disparity between it and the 
Cutter vaccine. Recently. the YopB from Y. emero-
colitic:a has been implicated in suppression of TNFa 
and it has been proposed that YopB from Y. pestis 
has si milar function [3 1]. 
We have demonstrated that the use of combined 
!-.ub-units has a protective efficacy again. 1 plague 
equivalent or ~uperior to that achievable with the 
existing whole cell vacc ines. but without the deleteri-
ous side-effect~ attendant on the use of the latter. 
Furthermore. the~e sub-unit\ can be produced as 
recombinant protein~. making production of a vac-
cine for plague l c~s ha?ardou'> than i t is at present. 
The effecti ve induction of mucosal a\ we ll a<. 
-.ystemic immunity i!-. an important attribute of an 
improved vaccine for plague. ~ ince immunity at the 
lung surface i' c~sential to protect against the pneu-
monic form of the d i '>ea~e. I f the Fl and V antigen~ 
can be prc\ented to the immune~~ "tem cffecti\·ely to 
induce both mucosal and "Y"temic protecti\e immu-
nity. the!-.e sub-unit!-. wi ll form the basis of no\ el 
\ acci nes. with potential to protect again\t both 
bubonic and pneumonic plague. 
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IISI· VII· R 
A sub-unit vaccine elicits lgG in 
serum, spleen cell cultures and 
bronchial washings and protects 
immunized animals against 
pneumonic plague 
E. Diane Williamson*t, Steve n M. Eley*, Anthony J. Stagg* 
Michae l Green *, Paul Russell* and Richard W . Titball * 
In this study, the protection afforded against aerosolized Yersinia pestis by injection of 
an alhydrogel-adsorbed sub-unit vaccine has been compared with that given by an 
existing killed whole cell vaccine licensed for human use. The sub-unit vaccine 
protected mice against exposure to > !o-' colony-forming units (c.fu.) of virulent 
plague organisms (100 LD{11 doses), whereas the whole cell vaccine provided only 50% 
protection against 1.8 x J(j c.fu. In sub-unit vaccinees, IgG to each of the FJ and V 
antigens contained in the vaccine, was detected in serum, on direct secretion by spleen 
cells and in broncho-alveolar washings (BAL). ln killed whole cell vaccinees, physio-
logically significant levels of IgG to F I only were detectable in equivalent samples. 
Levels of F /-specific IgG in sent m , secreted from spleen cells and in BAL were 
significantly higher (P < 0.01) in sub-unit compared with killed whole cell vaccinees. 
IgA was not detected in BAL from intra-muscularly dosed sub-unit vaccinees and thus 
the protection achieved against inhalational challenge with Yersinia pestis is attributed 
to the induction of systemic immunity to both the Fl and V antigens in the sub-unit 
vaccine. The enhanced protective efficacy of this sub-unit vaccine over an existing 
vaccine has been demonstrated in an animal model of pneumonic plague. © 1997 
Elsevier Science Ltd. 
Keywords: suh-unit vaccine. pneumonic plague. immunological correlates. protection 
The vaccincs currently licensed fo r human use to 
protect against infection with Yersinia pestis, the causa-
tive organism of plague, arc killed whole cell (KWC) 
vaccincs. Although the KWC vaccincs have hcen used 
widely, they have some disadvantages including a signi-
ficant incidence of transient local and systemic side-
effects' and the need for frequent hoosting to maintain 
adequate immunity. More seriously, some cases of 
pneumonic plague have heen reported in vaccinated 
individuals2, indicating that KWC vaccines arc not ahle 
to induce appropriate immunity to coun teract the 
pneumonic form of the disease. In previous stud ie~. 
deficiencies in protective efficacy of a KWC vacc ine 
agains t injected or aerosol challenge have hccn allri-
*DERA (Chemical and Biological Defence Sector), Porion 
Down, Salisbury, Wiltshire SP4 OJQ, UK. tAuthor to whom 
all correspondence should be addressed. (Received 31 
July 1996; revised 8 October 1996; accepted 27 November 
1996) 
buted to their lack of immunogenic levels of the V 
antigen of Y pestis.~.~. 
A combined suh-unit vaccine. comprising the 
Fraction I (F I) and V antigens of Y pestis has recently 
hcen reported·. F I antigen is a temperature-regulated 
capsular protein of Y pestis. the expression of which is 
maximal at 37°C5. The V antigen is a secreted protein 
of wild-type Y pestis. encoded hy a structural gene 
which is induced in vitro under conditions of low 
calcium1' aml which is located within the lcrGVH 
operon7. In combination wi th lc:rh. it has regulatory 
activity in Y pesti.1·7.x and is thought w influence the 
expression and secretion of o ther virulence factors such 
as the Yersinia outer membrane proteins'1. Both the Fl 
and V antigens arc viru lence factors llf Y pestis and as 
such exert ant i-host activity. The Fl antigen has anti-
phagocytic activity' whilst the V antigen exerts a local 
an ti-intlammatory effect th rough the modulation of 
tissue cytokinc levclsm" . which prevents the intil tration 
llf polymorrhonuclcar lcucocytes Ill the site of 
in feet illn ' ~ · "-
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When used as immunogcns in combination. the Fl 
anti V antigens arc additive in the protection they 
induce against parenteral challenge with virulent Y 
pestis anti the level of protection achieved is at least 
three orders of ma9nitudc greater than that afforded 
hy the KWC vaccine . 
Wild-type strains of Y pestis express Fl antigen and 
secrete V antigen and therefore for full protection 
against them a response to both Fl and V is required. 
In the present study. the protective efficacy of the 
Fl +V vaccine has been compared with that of a KWC 
vaccine, against aerosolized Y pestis in an animal 
model. 
MATERIALS AND METHODS 
Vaccines 
The components of the sub-unit vaccine were 
prepared as previously described·'. Briefly. the Fl 
antigen was precipitated from the supernate of Y pestis 
grown at 3rC by the addit ion of 40% (w/v) ammonium 
sulphate and purified by repeated resuspcnsion and 
centrifugation of the pellet in 20 mM Tris- HCI at 
pH 81. The V antigen was produced as a fusion protein 
with glutathione-s-transferase in Escherichia coli, 
cleaved with Factor Xa (Boehringer Mannheim UK 
Ltd) for 18 h at 22°C and purified by affinity absorp-
tion14. The KWC vaccine for plague was purchased 
from the Greer Laboratories, Lcnoir, NC, USA as a 
formaldehyde-killed suspension (2 x 10~ ml 1) of Y 
pestis. 
Animals 
Female 6-wcck-old Porton outbred mice, free of 
mouse pathogens, were used throughout this study. All 
animal experimentation strictly adhered to the 1986 
Scientific Procedures Act and to the Guidance on the 
Operation of the Animals (Scientific Procedures) Act, 
as promulgated by the Home Office in the UK and 
adopted by the ethics committee on an imal experi-
mentation within this research establishment. 
Immunization protocol 
Groups of 24 mice were allocated to one of three 
immunization regimen s, described below. All groups 
received a primary immunization on day I, followed by 
a booster immunization on day 24. On day 34, indivi-
dual animals in each immunization group were blood-
sampled to assay antibody response. On day 60, 18 
animals were removed from each group for aerosol 
challenge. On day 74. the remaining six unchallenged 
animals per group were anaesthetized i.p. with 6 mg of 
Domitor (Norden Laboratories, UK) and 27 Jig of 
Kctalar (Parke-Davics, UK) before collection of blood 
samples by cardiac puncture. Subsequently, individual 
anaesthetized animals were humanely killed by cervical 
dislocation for immunological analysis of the spleen 
and broncho-alvcolar washings (BAL). 
All groups were immunized by the intramuscular 
(i.m .) route. Group I animals were dosed with a 
combination of 10 11g Fl plus 10 Jig V, delivered 
adsorbcd to alhydrogel (251/r v/v) in 100 1d phosphate 
buffered saline (PBS) per animal. 
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Group 2 unimals were dosed with lOO 1d of the 
KWC vaccine. which contained ea 2 x 10~ killed Y 
pestis ce lls. equivalent to one-fifth of the human dose. 
Group 3 animals received alhydrogel alnnc (2:' r'r 
v/v) in 100 pi PBS per animal and served as vehicle 
con trols. 
Tissue-sampling 
Spleens were removed from the six anima ls killed 
per immunization group on day 74 intO ice-cold 
Dulbccco's modified Eagles medium (DMEM. Sigma) 
for immunological analysis. 
At this time-point also, BAL were collected from 
individual animals as follows: an incision was made in 
the neck and the skin and underlying thymus gland 
were dissected away to expose the trachea. Five milli-
litres (5 ml) of an ice-cold lavage medium (0.9% NaCI. 
().05% Twecn 20, 0. 1% NaN3 and I mM phcnylmc-
thylsulfonyl fluoride [PMSF]) were gently injected into 
the trachea by means of an intravenous canula (Abbott 
Ireland Laboratories) and used to inflate the lungs. 
BAL were withdrawn by means of a syringe and 
collected onto ice. 
Analysis of blood samples 
The measurement of isotype and titre of the 
antibody response was performed on scrum samples by 
means of a modified ELISA. Briefly, individual scrum 
samples were aliquotcd to microtitre plates pre-coated 
with either the Fl or V antigens (Spg ml in PBS). 
Binding of serum antibody was detected with peroxi-
dase-labelled secondary antibodies against mouse lgG 
(Harlan-SeraLab, Crawley Down, UK), each used at a 
maximum dilution of I :2000. Antibody titre was 
estimated as the maximum dilution of serum giving an 
. absorbance• I• nm (A414 ""') reading 0. I U over background 
and was presented as ' log 111 antibody titre and from this, 
mean log111 antibody titres±standard error of mean 
(S.E.M.) were derived per immunization group. 
The measurement of lgG sub-class titre was carried 
out on a pooled sample representative of the immuniz-
ation group. Peroxidase-labelled secondary antibodies 
against mouse, IgG~. IgG1: .. lgG1~ and lgG, (Harlan-
ScraLab, Crawley Down, UK) were each used at 
dilution I :2000 and by using them to construct 
standard curves with the respective IgG sub-class 
proteins, were demonstrated to he speci fic and to have 
equivalent sensitivity of detection ( I ng ml 1) for their 
homologous lgG sub-class proteins. Antibody titre was 
derived as before and is presented as a log111 value. 
Analysis of BAL 
Supernatcs were collected from centrifugation of 
BAL samples (20000g, 45 min, 4°C) and were rapidly 
frozen ( - 700C) prior to lyophiliza tion . Lyophili zed 
samples were reconstituted with 200 1d PBS for assay 
of specific IgG and lgA content by ELISA. For detec-
tion of lgA, a peroxidase-labelled anti-mouse l gA 
(Harlan-SeraLab. Crawlcy Down. UK) was used at a 
dilution of I :2000. Antibody titre was derived for 
individual samples as before and is presented as the 
mean log111 antibody titrc ± S.E.M. per immunization 
group. 
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Analysis or antibody secretion by spleen cells 
Spleens were amalgamated hy immunization group, 
prior to the preparation of crude suspensions of spleen 
cells for the determination of quantity aml speciticity of 
antihody secretion in 1·itro , hy means of a modified 
ELISA: sterile microtitre plates (Dynatcch) were 
coated with either Fl or V antigens in PBS (5Jtg m! 1) 
overnight at -l°C, under aseptic conditions. Subse-
quently the plates were blocked with DMEM plus 10% 
foetal calf scrum (FCS) (I h, 3rC). prior to aliquoting 
200 1t1 of the individual spleen cell suspensions derived 
from each treatment group. The cells were double 
diluted on the plate and then allowed to incubate for 
20 h (37°C, 5% C01). The plates were subsequently 
gently washed in PBS ( x 3). PBS+0.02%Twccn 20 
( x 3) with a final 5 min soak in PBS-0.02%Twecn 20, 
prior to the addition of the peroxidase-labelled 
secondary antibody conjugate. Incubation was 
continued for 20 h ( +4°C) prior to automated washing 
( x 4) in PBS-0.02%Tween 20 and addition of a 
soluble peroxidase substrate, 2.2-azino-bis (3-ethylbenz-
thiazoline-6-sulphonic acid) (ABTS). The amount of 
antibody secreted by well was quantified by measuring 
A~ 1 4 nm and the log111 antibody titre was derived. 
Challenge with Y. pestis 
On day 60 of the schedule, 18 animals per immuniz-
ation group were randomly divided into groups of six 
and chal lcn¥ed with an aerosol of an Fl + strain (GB) 
of Y pestis· at dose levels in the range 1.8 x I o-' to 
9.9 x 10~ colony-forming units (c.f.u.). Colonies of 
animal-passaged Y pestis'5 were stored in screw cap 
vials at -80°C on a ' Protect"' bead storage system 
(TSC Ltd, Heywood, UK). Forty-eight hours before 
challenge, beads were removed from toragc and 
placed directly into 250 ml of blood-agar base (BAB) 
broth. This material was incubated at 28°C on a shaker 
rotating at 150 revs min 1• Aerosol particles were 
generated using a Collison spray 'h and conditioned in a 
modified Henderson aerosol apparatus17• Animals were 
placed in a head-only exposure chamber and exposed 
in groups of six (three immunized plus three vehicle 
controls) for 10 min to doses in the range (10"'-105) 
c.f.u. of Y pestis, equivalent to I 0- 1000 LD511 doses. 
The aerosol stream was maintained at 55% relative 
humidity (±4%) and I9°C (±0.5°C). 
During each exposure period. a sample of Y pestis 
was taken directly from the sampling port. using an 
all-glass impingcr (AG 1-30) and plated onto Congo 
Red agar to quantify the available dose of Y pestis 
delivered. One challenged mouse per treatment group 
of six was humanely killed immediately post-challenge, 
in order to determine the c.f.u. of Y pestis present in 
the lungs. Dosage was calculated using the formula: 
Table 1 Development of lgG titres to F 1 and V in serum with time 
Immunization group Mean log,0 antibody titre 
where C, is the c.f.u. ml 1 in impingcr sample: V, is the 
volume of sample fluid in the impinger; T, is the 
duration of sampling time; R is the sampling rate 
(mlmin 1); MMV is the mouse minute respiratory 
volume (Guyton) and T1• is the duration of exposure 
(min). Challenged mice were removed from the 
exposure chamber and returned to their home cages 
within ca tegory 3 containment to recover. Animals 
were closely ohscrvcd over a 14-day period for the 
development of symptoms, and where appropriate. 
time to death (TTD) was carefully recorded. Malaise 
was noted in some animals as immobility and ruffled 
coat. Humane end-points were strict ly observed so that 
no animal became distressed. 
Animals that succumbed to the challenge were 
autopsied. Livers and spleens were scored for enlarge-
ment and any evidence of abnormality was noted. 
Sections of liver, spleen and lungs were smeared onto 
Congo Red agar or Ycrsinia selective agar (YSA, 
Oxoid), and the plates were incubated at 28°C and 
observed for growth after 48 h. At the end of the 
14-day observat ion period, survivors were humanely 
culled and tissues were removed for bacteriological and 
gross morphological analysis, as above. 
Statistical analysis 
A Student's t-test was applied to determine the signi-
ficance of the difference between treatment group 
mcans'x. 
RESULTS 
Antibody titre and immunoglobulin sub-type in serum 
Animals dosed with combined sub-units had 
responded by day 34 with high serum IgG titres to FI 
and to V (Table I) and these were sustained to day 74. 
By comparison, animals given the KWC vaccine had a 
significantly lower (P<O.OI) anti-Fl IgG titre and 
undetectable titres to the V antigen. For both Fl +V 
and KWC vaccinees, the response to Fl was predomi-
nantly an IgG 1 response (Figure la). Similarly the 
response to V observed in sub-unit vaccinees only was 
almost entirely of the IgG, sub-class (Figure !b) . Thus 
for both groups, the ant ibody response to Fl was 
similar in type but differed quantitatively. Minor differ-
ences in the distribution of ant i-FI activity in the other 
IgG sub-classes existed between the groups, with the 
response to Fl +V exceeding that to KWC vaccine for 
all sub-classes. For Fl +V vaccinccs the scrum IgG 
response to V exceeded that to F I. 
Antibody secretion by spleen cells 
At day 74, Fl- and/or V-spccifc antibody secreted hy 
spleen ce lls isolated from the F I+ V treatment group 
could he detected hy means of a modified ELISA 
Ant1-F1 lgG day 34 Anti-V lgG day 34 Anti·F1 lgG day 74 Anti·V lgG day 74 
F1 +V 
KWC vaccine 
5.31 :: 2.1 
4.71 :: 1.9 
5 .31 ± 0 
0 
4.63 ± 1.9 
4.25 ± 1.7 
5 .31 ± 0 
0 
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(Figure .?a and h). The profile of distribution of anti-FI 
and anti -V acro~~ th~.· IgG sub-classes wa~ similar to 
that for scrum. with an IgG, n:sponse predominating. 
The KWC group al~o re~pondcd with a predominant 
IgG, titre to Fl. al though th is was signi fican tly lower 
(P < O.o:n compan.:d \\·ith that of the FI+V group. The 
mean lng10 titre of lgG 1 mea:-.ured to V in the 
cnmhined :-.ub-unit-immunized group wa:-. 2.7 1 and at 
thi~ level pn;dominatcd over that to Fl hy ea fourfold. 
By compa rison. the mean log,,. titre of Ig.G, to V in the 
KWC gmup was < 1.0. 
Antibody titre in BA L 
Negligible levels of IgA wi th specilicity for F I or V 
were determined in BAL from all vaccinees. By 
comparison. mean log11, IgG titres of 2.7 ± 0.2 and 
3 ± 0.1 were detected to F I and V, respectively, in the 
combined sub-uni t group. KWC vaccinees responded 
with a mean log10 IgG titre of 2.4± 0.2 to Fl , although 
this was significantly lower than that of the Fl +V 
group (P < (l.05). but they did not develop an an tibody 
titre to V . 
Protection against challenge 
In ordc r to compare the protective efficacy of 
immunization with combined sub-units. against that 
provided by the KWC vaccine, animals were challenged 
by the inhalational route with virulent Y. pestis 

































( '/ii/J/C' .?). The maximum challenge dose was 
lJ.lJ x I 0 ' c.f.u .. equiva lent to I()()() LJ ) ,,. doses. The 
re:-.ult~ presented compare the surviva l rates for 
irnnwnii'ation groups rccei\ ing the same challenge 
dl>Se:--. 11 alh, drogcl only control anima l~ succumbed 
to a dosage of 2400 c.r.u . with a mean lTD of 
X . .'n _ !l.X day~ and to multiples of th i~ do:--c up to 
l)l)()()() e.f.u. (ea 1000 LD,,. dtN.:s) with a mean TTD of 
4.X ± !l.IX days. Thus incrca:--e in dosage led to a signifi-
can tly shmtened (l> < tl.!ll) TTD. Three of six KWC 
vaccinces survived challenge wi th IXXO c.r.u .. hut none 
survived when the do~age wa~ increased to 43 (){)() c.f.u. 
(ea 100 LD~u dose~) . In contrast. all the Fl + V an imals 
su rvived exposure to Y. pe.\ tis at dosages of I XOO and 
43000 c.l'.u . withou t the development of symptoms in 
the 14-day post-challenge observa tion period. 
Y. f)(!.l'tis was recovered from the sp leens. livers and 
lungs of animals which succumbed to the challenge. At 
14 day!> post-cha llenge. su rvivors in the Fl + V-immu-
nized and in the KWC vaccine groups were humanely 
killed and autopsied for macroscopic and bacteriolog-
ical analysis of their tiss ue~. The spleens. livers and 
lungs from all the animals which had survived 
challenge appeared normal. and Y. pestis was not 
recovered from any of the t issue sections co llected. 
Exposure of animals from each trea tment group to Y. 
pestis was confirmed hy recovery o f Y. pestis from the 










Figure 1 lgG sub-classes 1n serum at day 74 specific for (a) Fl and (b) V. The log,0 titres per immunization group are plotted 
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Thu:-. the:-.e oh\crvation:-. w nlirmetl that ~urviving 
an imals in the ~ uh-unit anti KWC: vaccinated group~ 
had cffl:ctivcly ck:ared Y pe.1ti1· from thl:ir lun~:-.. livl:r:-. 
and ~plce n :-. by day 14 po:-. t-chalkngc. 
DISCUSS ION 
In this study the combined u~e o f Fl and V antigem in 
a ~uh-uni t vaccine administered i.m. has lll:cn lkmon-
stratctl to protect an imals against exposure to aeroso-
lized Y pestis in excc~~ of 10 ' c.f.u. and 100 LD,u tlosl:~. 
In contra~!. a KWC vaccine. currently licensed for 
human use. failed to protect animals against this 
dosage of aerosol izetl Y pestis. 
The combined use of the Fl and V antigen:- in the 
~ub- unit vaccine i~ a pntl:nt inducer of humural and 
cellular immunity. lligh scrum antibody titre~ to Fl 
and V wen.: apparent ;~t 10 day~ after the booster 
immunization and were ~u:-.taincd to the end nf the 
schedu le at day 74. 
As before ' the scrum titre induced to V 11as I log 
higher than that induced to Fl. even though the molar 
ratio o f Fl Ill V in thl: vaccine is 2: I. I n contrast. the 
KW 'vaccine induced ~erum antibmly titres Ill the Fl 
antigen only and these were significantly lower 
(P < !Ull) than the titres induced to FI in the sub-unit 
vaccinees.This pa11crn of response was also observed in 
BAL collected from vaccinees: in F I+ V vaccinecs. the 
anti-V IgG response was significantly higher than the 
2(a) F1-speclfic lgG secreted by spleen cells 
















2(b) V-specific lgG secreted by spleen cells 
2.5 



















Figure 2 lgG sub-classes secreted by spleen cells in vitro at day 74 specific for (a) F1 and (b) V. The log ,0 titres per immunization group 
are plotted 









"Mean time-to-death in days 
















Mean TTO" :: S.E.M. 
5 .t 0.24 
3.7 1 1.4 
4.8 1. 0.2 
4.3 1 0.3 
8.8 I 0.8 
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response to Fl. In KWC vaccinccs, no anti-V response 
was detect a hie in BAL and the response to F I was 
significantly lower than in Fl +V vaccinccs. Although 
ASCs wit h ant i-V activity appeared present in the 
spleens of KWC vaccinccs. their secretory activi ty was 
very low. presumably insufficient 10 register specific 
antibody in scrum or in BAL. Thus the KWC vaccine 
trialled in this study appears unable to induce effective 
anti-V acti vi ty and is also less able to induce anti-F I 
ac tivity than is the purified Fl as immunogen (a t the 
I 0 11g dose level). 
The developmen t of a predominant IgG 1 ti tre to Fl 
and 10 V was observed in scrum and for antibody 
secreted directly by spleen cells derived from F I + V 
vaccinees. An IgG1 titre is indicative of an ongoing Th! 
re ponse'''. which i. the typical response to dosing with 
purified protein antigens in a lhydrogel~0. 
Recently. the appearance of a predominantly IgG 1 
titre in animals immunized s.c. wi th the V an tigen only 
in alhydrogel, has been posi tively correlated with 
enhanced survival against injected and aerosolized 
plague4 • 
It would not be expected to induce mucosal 
immunity by i.m. injection of either vaccine and negli-
gible titres of lgA speci fic for Fl and/or V were 
detected in the BAL of animals which subsequently 
survived the inhalational challenge. However, substan-
tial IgG titres to• FI and V were detectable in BAL, 
which in the absence of IgA, suggests that the develop-
ment of . ystem ic immunity was the key factor in 
protection of the combined sub-unit-immunized group 
against inhalational challenge. The size of the aerosol 
particles produced by the Collison spray equipment is 
in the range 1-3 pm and > 90% of an aero ol of 
particles of this size will reach the alveoli. However, it 
is likely that the remainder of particles in the aerosol 
will be deposited along the entire length of the respira-
tory tract. This would explain why transudated IgG is 
so protective but also suggests that the induction of a 
slgA response in the upper respiratory tract by appro-
priate mucosal immunization would enhance protec-
tion against aerosol challenge and this approach is also 
being pursued11 . -
The combined sub-unit vaccine has clear advantages 
over existing vaccines not only in terms of protective 
efficacy against both aerosol and parenteral challenge.1 
with wild type strains of plague, but also because it will 
protect against challenge with fully virulent FI -
negative mutant strains of Y. p estis. The combined 
sub-unit vaccine also offers advantages with respect to 
safety of use, immunogenic potency and absence of 
observable side-effects. It is currently formulated 
adsorbcd to the adjuvant alhydrogcl, which is already 
approved for human use. 
This sub-unit vaccine has potential as a prophylactic 
against both bubonic and pneumonic plague. 
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A single dose sub-unit vaccine protects against pneumonic plague 
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Ab tract 
In this study. the protection afforded against aerosolised Yersinia pestis by injection of a single dose of an alhydrogel· 
adsorbed sub-unit vaccine has been compared with that given by an existing killed whole cell vaccine licensed for human use. 
The ub-unit vaccine. prepared by admixing F I antigen derived from a Y. pesFis cell culture supernatant with recombinant V 
antigen derived from an £. coli cell lysate, fully protected an outbred strain of mouse against exposure to 106 CFU of virulent 
plague organisms ( I 0~ mou e lethal doses. M LD). In contrast, the whole cell vaccine provided only 16% protection against the 
same level of challenge. Furthermore, sub-unit vaccinees were able to clear the bacteria from their lungs post-challenge whereas 
bacteria were cultured from the lungs of a surviving K WC vaccinee post-challenge. In killed whole cell vaccinees. physiologically 
significant levels of lgG to F I only were detectable and the levels of F !-specific lgG in serum and in broncho-alveolar washings 
were significant ly lower ( p < 0.05) compared with sub-unit vaccinees. In sub-unit vaccinees. an lgG titre to the F I and V 
antigens was detected in serum where it .was significan tly higher (p < 0.05) compared with broncho-a lveolar washings suggesting 
that. at the time of challenge. protection is anributable mainly to the combined circulating lgG titre to the Fl and V sub-units. 
The enhanced protective efficacy of this sub-unit vaccine administered as a single do e compared with an existing vaccine has 
been demonstrated in an out bred animal model of pneumonic plague . .{; 2000 Elsevier Science Ltd. All rights reserved. 
Key,.ords: Single dose vaccine: Sub-unit vaccine: Pneumonic plague: Immunological correlates: Protection 
I . Introduction 
Currently licensed vacci nes for plague are killed 
whole cell (KWC) fo rmulations, prepared by heat or 
forma ldehyde t rea tment of Yersinia pestis, the causa-
tive o rganism of plague. Although these K WC vac-
cines (K WC V ) have been used widely, they have some 
disadva ntages including the need for freq uent boosting 
to establish a nd maintain adequate immunity and a 
ignificant incidence of reporting of tran ient side-
effects (I] as ''ell as the expen e and inconvenience o f 
requiring manufacture under microbio logica l ACDP3 
containment conditio n . Furthermo re . some cases of 
• Corrc~ponding authnr. Td· - 44- 19R0-6 1JOOO: fa x: 44-1980-
61.17-1 1. 
F-111111/ addn•.1.1 del\ ilhamson ,, dcra.g01.uk (C. D. Wdh.11nson). 
pneumonic plague have been reported in vacc inated in-
dividuals (2], which suggests that the K WCV formu-
lation is not able to induce appropriate immunity to 
counteract the pneumonic form of the disease. This in-
dica tion has been sustained by the poor efficacy data 
for KWCVs reported from a number of an ima l studies 
[3- 5]. In o rder to overcome these disad va ntages a nd to 
improve efficacy. particularly agai nst pneumonic pla-
gue. we a nd others are researching an acellular vaccine 
which comprises the Fractio n I (FI) a nd V antigens of 
Y. fJC'Slis (4.6]. 
Whilst ea rly studies utili sed multiple dose o f the 
sub-un its to achieve protective immunity [J] mo re 
recent studies ha ve shown that two intra-muscular 
dose of the combined sub-u nit delivered adsorbed to 
alhydrogel confer protection against pneumonic plague 
in the mouse (4]. This protection was a tt ributed to a 
high level of lgG both systemtcally and in lung washes 
026-1--IIOX 00 S · -,cc fr<)lll 111.1tter • :woo EJ<,cvJcr Science Ltd. All nghh rco;crvcd. 
Pll 5026-1- -11 OX(OOJOO 159 -6 
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[4]. Subsequently, protection against plague in the 
mouse model has been demonstrated to correlate with 
the magnitude of the combined IgG, and specifically 
IgG I sub-class titre to the combined sub-units [5] 
which was maximised by the administ ration of the vac-
cine sub-units in a 2 molar excess of Fl to V. In this 
study also, it was demonstrated that the titre of IgG to 
the combined sub-units declined as dose-level was 
reduced from 10 J..lg down to 0.01 11g of each sub-unit. 
In an independent study, protection against pneu-
monic plague was achieved with a single dose of the 
combined sub-units in the mouse, although these were 
administered in equimolar ratio and no attempt was 
made to assay the functional. level of lgG required in 
the lung to protect against aerosol challenge [7]. 
In the present study we have demonstrated that by 
escalating the dose-level of the vaccine components 
administered in the optimised 2: I molar ratio, a single 
dose of the vaccine is protective in the mouse against 
an aerosol challenge with virulent Y. pestis at a level 
which defeats the existing KWCV. In sub-unit vacci-
nees, the total titre of IgG in the blood significantly 
exeeded that washed from the lungs of vaccinees, indi-
cating that it is the circulating titre of IgG in the 
blood, rather than the local IgG in lung washings, 
which is likely to be critical for protection. 
2. Materials and methods 
2.1. Vaccines 
The components of the sub-unit vaccine were pre-
pared as previously described. Briefly, the F I anrigen 
was precipitated from the supernate of Y. pestis grown 
at 37°C by the addition of 40% (wfv) ammonium sul-
phate and purified by repeated resuspension a nd cen-
trifuga tion of the pellet in 20 mM Tris- HCI a t pH 8 
[3] . The Fl a ntjgen derived by this method, comprised 
a single protein with greater than 90% purity [3]. The 
V antigen was produced as a fusion protein with gluta-
thione-s-transferase in Escherichia coli, cleaved with 
Factor Xa (Boehringer Mannheim UK Ltd) for 18 h 
a t 22°C and purified by affinity absorption (8]. The 
KWC vaccine for plague was purchased from the 
Greer Labora tories, Lenoir, NC, USA as a formal-
dehyde-killed suspension (2 x 109 ml- 1) of Y. pestis. 
2.2. Animals 
Female 6-week-old Porton outbred mice, free of 
mouse pa thogens, were used throughout this study. All 
an imal experimentation strictly adhered to the 1986 
Scientific Procedures Act and to the Guidance on the 
Operation o f the Animals (Scientific Procedures) Act , 
as promulgated by the Home Office in the U K and 
adopted by the eth ics committee on a nimal experimen-
tation wi thin this research e tablishment. 
2.3. Immunisation protocol and immune response 
analysis 
Groups of 24 mice were alloca ted to one of three 
immunisation regimens. described below. All groups 
received a single immunisation on day I, delivered by 
the intra-muscular (i.m.) route. All animals were dosed 
with a total volume of 100 111 divided equally between 
sites in either hind leg. Group I animals were dosed 
with a combination of 75 J..lg Fl plus 75 J..lg V, deliv-
ered adsorbed to 25% (vfv) a lhydrogel (Superfos Bio-
sector, Denmark) in phosphate-buffered saline (PBS). 
Group 2 animals were dosed with one-fifth of the 
human dose of the KWCV, equivalent to 2 x 108 killed 
Y. pestis cells, as used in previous studies [3,4]. Group 
3 animals received 25% (vfv) alhydrogel alone in PBS 
a nd served as vehicle controls. 
Individual animals in each immunisation group were 
blood-sampled to assay antibody response on day 60. 
On day 68, 18 animals were removed at random from 
each group for aerosol challenge and subjected to a 
14-day post-challenge observation. On day 83, to co-
incide with the end of the post-challenge observation 
period, the unchallenged cohort of six immunised ani-
mals per group were anaesthetised i.p. with 6 J..lg of 
Domitor (Smith Kline Beecham, UK) a nd 3 mg of 
Ketalar (Parke-Davies, UK) before collection of blood 
samples by cardiac puncture. Subsequently, individual 
anaesthetised animals were humanely killed by cervical 
dislocation for assay of the spleeen and broncho-alveo-
lar washings (BAL) for IgG content, as previously 
described (4]. 
2.4. Analysis of blood samples 
The measurement of isotype and titre of the a nti-
body response was performed on individual serum 
samples by means of a modified ELISA [4]. Specific 
lgG titre was estimated as the maximum dilution of 
serum giving a n a bsorbance414nm reading 0.1 units 
over background a nd was presented as log10 antibody 
titre a nd from this, mean log10 a ntibody titres ±stan-
dard error of mean (SEM) were derived per immunis-
ation group. 
The mea urement o f lgG sub-class titre was carried 
out on a pooled sample representative of the immunis-
atio n group. as described previously [4]. Antibody titre 
was derived as before as the end-point dilution at 
which the 0.0.4 14 is 0. 1 units over background (4]. 
Subsequently, the reciproca l of the end-point dilution 
was converted to a log10 va lue. Titres to F I a nd V 
were combined by adding the log 10 va lue . 
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2.5. Analysis of BA L 
Broncho-alveo lar lavage was carried out on individ-
ual mice in ice-cold medium ( I mM PMSF/NaCI with 
0.05% vfv Tween 20) and samples were centrifuged 
(20,000 g, 45 min, 4°C) and supcrna tes were collected 
for susbsequent analysis [4] . 
2.6. Analysis of antibody secretion by spleen cells 
Spleens were a malgamated by immunisa tion group, 
in ice-cold DMEM prior to the preparation of suspen-
sions of spleen cells for the determination of qua ntity 
and specificity of antibody secretion in vitro, by means 
of a modified ELISA [4]. The lgG titre is derived as a 
mean log1o antibody titre ± s.e.m. per immunisa tion 
group. 
2.7. Aerosol challenge wirh Y. pestis 
Animals from each immunisation group were ran-
domly divided into groups of six and challenged with 
an aerosol of an Fl + strain (GB) of Y. pestis at dose 
levels in the range 104 to 106 colony-forming units 
(CFU). The challenge inoculum was prepared at 28°C 
as previously described [9] and administered as an 
aerosol [14]. The challenge dose to which animals were 
exposed was calculated from the recovery of Y. pestis 
on an impinger in the exposure chamber. 
Challenged mice were removed from the exposure 
chamber and returned to their home cages within cat-
egory 3 containment to recover. Animals were closely 
observed over a 14-day period for the development of 
symptoms, and where appropriate, time to death 
(TTD) was carefully recorded. Ma laise was noted in 
some animals as immobility and ruffled coat. Humane 
end-points were strictly observed so that no animal 
became distressed. 
Animals that succumbed to the challenge were 
autopsied. Whole blood or sections of liver or spleen 
were smeared onto Congo Red agar or Yersinia selec-
tive agar (YSA, Oxoid), a nd the plates were incubated 
at 28°C and observed for growth after 48 h. At the 
end of the 14-day observation period survivors were 
humanely culled and blood, li vers and spleens were 
removed for bacteriological and gross morphological 
ana lysis, whilst broncho-alveolar lavage was used to 
determine clearance of bacteria from the lungs. 
2.8. Statistical analysis 
A bal<~n ced ana lysis or va riance in a repeated 
measures design was carried out to determine the influ-
ence of trea tment and of sa mpling site on an tibody re-
sponse [10). 
0 20 40 60 80 100 
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Fig. I. Dynamics of serum IgG titre with time. The development of 
lgG titres with specificity for Fl or V with time is shown for each of 
the immunisation groups, following a single dose of vaccine at day 
0. 
3. Results 
3.1 . Antibody titre and immunoglobulin sub-type in 
serum 
Animals given a single dose of the combined sub-
units had responded by day 60 with high serum IgG 
titres to FI and to V and these were sustained and, for 
V, increased to Clay 89 (Fig. 1). By comparison, ani-
mals given a single dose of the K WC vaccine had a 
significantly lower (p < 0.05) anti-FI IgG Litre and un-
detectable titres to the V antigen. For both Fl + V and 
KWC vaccinees, the response to Fl and to V was pre-
dominantly a n IgG 1 response (Table I). Thus for both 
groups the a ntibody response to Fl was similar quali-
tatively but differed quan tita tively. For FI + V vacci-
nees the serum lgG response to V exceeded that to Fl 
by day 89. 
3.2. Antibody secretion by spleen cells and in BAL 
At day 89, Fl- and V-specific lgG secreted by spleen 
cells or into BAL isolated from the Fl +V treatment 
group could a lso be detected. The combined lgG Litre 
per treatment group at each sampling site (BAL, 
serum and spleen), together with the influence of tota l 
Table I 
lsotyping of serum lgG response o n pooled serum samples represen-
ta tive of each treatment group a t day 89 
Isotype 
Log 10 IgG isotype specific for Fl or V 
lgGI titre to Fl 
IgG I titre to V 
IgG2a titre to Fl 
IgG2a titre to V 
IgG2b titre to Fl 
lgG 2b titre to V 
IgG 3 titre to Fl 
lgG3 titre to V 
Treatment group 
Fl + V KWCV 
4. 11 3.8 1 
4.7 1 Negative 
2.90 2.60 
3.8 1 Negative 
2.90 2.60 
3.5 1 Negative 
2.90 2.0 
Negative Nega tive 
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lgG titre on protection against challenge, is shown 
(Fig. 2). In contrast, Fl-specific lgG only was secreted 
by spleen cells or into BAL for the KWCV group. The 
mean log10 titre of anti-Fl IgG in either BAL or se-
creted from spleen was lower in the K WCV group 
compared with the Fl + V group. By comparison, 
mean log10 IgG titres of 1.95 ± 0.1 and 2.45 ± 0.2 were 
detected to Fl and V respectively in BAL from the 
combined sub-unit group. KWC vaccinees responded 
with a mean log10 IgG titre of 1.45 ± 0.23 to Fl in 
BAL, but they did not develop an antibody titre to V. 
IgG was secreted from spleen cells isolated from the 
Fl +V group with a mean log10 IgG for V of 1.62 and 
of 0.7 for Fl , compared with a log10 anti-Fl titre of 
0.48 secreted from KWCV spleen cells. 
3.3. Analysis of variance of lgG titres in BAL and 
serum 
A comparison between treatment groups in terms of 
combined titre to Fl +V, as measured in individual 
animals in serum and in BAL, was achieved by means 
of a balanced analysis of variance (repeated measures 
design). This test indicated that the anti-Fl titre in the 
Fl +V group was significantly greater than the anti-Fl 
titre in the KWCV group (p < 0.05). For either treat-
ment group, the serum anti-Fl titre was significantly 
greater than the anti-Fl titre in BAL (p < 0.05). Thus 
the effect of treatment group on titre to Fl was inde-
pendent of sampling site. In contrast, for the combined 
titre to Fl + V, there was a significant interaction 
between treatment group and sampling site so that 
serum titre in the sub-unit group was significantly 
higher than that of the KWCV group (p < 0.05) and 
the difference was more significant in serum than in 
BAL p < 0.05). The fact that this concentration gradi-
ent exists between serum and BAL for IgG titre to Fl 
and to V argues against a significant local production 
• F1+V SAL 
• KWCVSAL 
• ALHY SAL 
• F1+V SER 
~ DKWCVSER j • ALHY SER 
K • F1+V SPL 
.. 
O KWCVSPL 
• ALHY SPL 
Fig. 2. Influence of lgG tire on protection against Y. pes/is s.c. 
G roup mean lgG titres to Fl + V expressed as log10 value detected in 
broncho-alveolar lavage (BA L), serum and on secretion from spleen 
cells and their correla tion with protection against s.c. challenge of 
immunised mice with Y. pes/is at 107 cfu. 
of IgG to both sub-units in the BAL, at least m the 
absence of an inhalational challenge. 
3.4. Protection against challenge 
In order to compare the protective efficacy of immu-
nisation with combined sub-units, against that pro-
vided by the KWC vaccine, a nimals were challenged 
by the inhalational route with virulent Y. pestis. The 
maximum challenge dose was 106 CFU, equivalent to 
I 04LD50 doses. The results presented compare the sur-
vival rates for immunisation groups receiving the same 
challenge doses (Fig. 3). All alhydrogel only control 
animals succumbed with a mean time to death (TTD) 
of 4 ± 0 days. One of 6 KWC vaccinees survived chal-
lenge with 106 CFU. The mean TTD for this group 
was calculated as 5.6 ± 2.2 days. In contrast, all the 
Fl +V animals survived exposure to Y. pestis at 106 
CFU without the development of symptoms in the 14-
day post-challenge observation period. 
Y. pestis was recovered from the spleens, livers and 
lungs of animals which succumbed to the challenge. At 
14 days post-challenge, survivors in the F l + V-immu-
nised and in the KWC vaccine groups were humanely 
sacrificed and autopsied for bacteriological analysis of 
their tissues. For survivors in the Fl + V-immunised 
group, Y. pestis was not recovered from any of the tis-
sues sampled (blood, spleen, liver, BAL). However Y. 
pestis was recovered from the single survivor in the 
KWC vaccine group and was cultured from blood, sec-
tions of spleen and from BAL. Thus surviving animals 
in the sub-unit group had effectively cleared Y. pestis 
from their lungs, livers and spleens by day 14 post-
challenge whereas the single survivor from the KWC 
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Fig. 3. Survival curves for groups challenged with 106 CFU Y. pestis 
by the aerosol route. The survival of animals in each immunised 
group is plo tted for the 14-days post-challenge with Y. peslis. 
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4. Discussion 
In this study the combined use of Fl and V antigens 
in a sub-unit vaccine administered i.m. as a single dose 
has been demonstrated to protect animals against ex-
posure to aerosolised virulent Y. pestis strain GB, at a 
high dose-level of I 06 CFU or I 04 M LOs. In contrast, 
a single dose of KWCV, currently licensed for human 
use, gave negligible protection to animals against this 
dosage of aerosolised Y. pestis. Furthermore, F I + V 
sub-unit vaccinees were able to clear the bacteria from 
their lungs whereas Y. pestis was cultured from the 
BAL removed from a single survivor in the KWC vac-
cine group. Thus, the F1 + V vaccine, even after a 
single dose, provided a 4-log shift in protection against 
aerosolised Y. pestis, compared with the existing 
licensed vaccine. This level of protection in the mouse 
model against a wild-type strain of Y. pestis is greater 
than that published previously for a single dose sub-
unit vaccine [7]. 
The high level of protection seen with the combined 
sub-unit vaccine is partly attributable to the additive 
protective effect of the sub-units [3] . There is some evi-
dence that Fl has adjuvantising activity on the 
immune response to the eo-administered V antigen and 
that this effect is specific and not due to LPS contami-
nation of either antigen [11]. From the present data it 
can be seen that the titre to Fl develops more quickly 
than the titre to V early in the schedule, but that at 
day 60 after the single dose of vaccine, anti-F 1 titre 
starts to decline. Conversely, the titre to V is slower to 
develop but then continues to rise at day 60 and 
beyond as the titre to Fl starts to decline. Thus the 
two sub-unit proteins complement each other. This 
could be a key factor in the observed protective effi-
cacy of the vaccine, since the combined antibody titre 
to Fl + V has previously been shown to correlate with 
protection [5]. Since the KWCV induces only an anti-
F I titre, then the protective efficacy is much reduced. 
Further, the combined sub-unit vaccine induces anti-
body against two virulence factors, effectively neutra-
lising two virulence mechanisms, as opposed to one for 
the KWCV and thus protective efficacy is enhanced. 
A previous study [5] showed that as the immunising 
dose level of each sub-unit protein was reduced, the 
antibody response declined in a dose-related manner 
and eventually reached non-protective levels. In this 
study we have increased the dose-level of each sub-unit 
antigen 7.5-fold over the previously used maximum 
immunising dose, to 75 J.Lg of each sub-unit antigen 
and we have shown that the protective efficacy was 
enhanced. Further, this increased dose of sub-unit vac-
cine has resulted in full protection again t 104 MLDs 
of aerosolised Y. pestis in a n outbred mouse strain, 
where less consistency might be expected, compared 
with inbred strains used in the earlier study [4]. 
The aerosolisation system used in this study gener-
a tes particles in the range 1- 3 J.Lm diameter and it 
would be expected that > 90% of an aerosol of par-
ticles of this size will reach the a lveoli. Thus it is likely 
that specific lgG present in the deep lung is important 
as a first line of defence against the aerosolised Y. pes-
tis. However IgG titres to Fl + V present in the BAL 
of the unchallenged cohort of sub-unit vaccinees were 
significantly lower than in serum, which argues against 
a significant local production of lgG. It may be that 
either the local production of IgG or an increased 
extravasation of circulating IgG into the lung is 
induced following inhalational challenge with Y. pestis 
or that a combination of these mechanisms operate to 
protect vaccinees against infection. 
This study has demonstrated the feasibility of using 
a single dose sub-unit vaccine to achieve protection 
against a substantial (104 MLDs) inhalational chal-
lenge with virulent Y. pestis in an outbred mouse 
model. This data further demonstrates the potential of 
the combined Fl +V vaccine to be developed as a 
human prophylactic for pneumonic plague, with sig-
nificantly impro'll!d efficacy over existing vaccines. 
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Abstract 
In this study. we have shown that severe combined immunodeficient/beige mice reconsti tuted with hyperimmune Balb/c 
lymphocytes can be used as a model to demonstrate adoptive and pa ive protection against plague infection. Reconstitution of 
severe combined immunodcficient/beige mice was successful in nine out often mice as demonstrated by spleen colonisation and 
sustained circulating immunoglobulin titres. Furthermore. an increase in antibody titre was evident after a booster 
immunisation of reconstituted mice. Presence of circulating antibody correlated with protection against a systemic plague 
challenge and indicated that in reconstituted mice adoptive transfer of a functional immune system had occurred . The severe 
combined immunodelicient/beige mouse was also used to demonstrate passive protection against inhaled and systemic plague 
infection. The reconstituted severe combined immunodeticient/beige mouse model demonstrating protective immunity against 
plague wi ll be further developed to identify the immune cell ubsets responsible for this protection. © 1999 Federa tion of 
European Microbiological Societies. Publish~d by Elsevier Science B.V. All rights reserved . 
Kl'yword" Severe combined immunodcficiem/bcig~ mouse: Plague : Adopth c protection : Passive protection 
I. Introduction 
Yersinia pestis is the causa tive agent of plague in 
mammals. Plague is endemic in certain areas of the 
world with South East Asia currently bc:ing the ma-
jor focus [ I]. Plague is primarily a disease of rodents: 
however. humans arc believed to be at risk of infec-
tion if they come into contact with an infected an i-
mal. ei ther directly or through a bi te from an in-
fected flea vector [2]. The disease can manifest itself 
in several ways depending on the rou te: or entry or 
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the organism into the host. Bubonic and septicaemic 
forms of plague result usually from the bite of an 
infected animal or flea and the other main form of 
the disease is pneumonic plague. a result of the in-
halation of Y. fU!Stis. [3.4]. Whatever the route of 
infection. the disease has a high mortality rate 
( > 50'%) in untreated cases [5]. 
Currently. protective immunity to plague can be 
conferred by immunisa tion with kil led whole cell 
n1ccines. al though the e vaccines may not protect 
against all forms o f the disease [6] . Recently, a new 
improved ubunit vaccine has been developed that 
generates mucosal and systemic immunity conferring 
pro tection aga inst the pneumonic and bubonic forms 
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or plague infeL·tion [7.8]. The subuni t \accinc com-
prises the Fl- and V-antigem. rrom l'ersinia fi('S/is 
admini~taed after adsorption to alhyd rogel. The 
roles of the antigens in plague inrection arc unclear: 
howe,er. it is bdie,ed that the cap ular Fl-antigen 
has <IIHiphagoc) tic acti vit y. whilst the V-antigen ex-
ens an anti-host effect through the modula tion of 
tissue c~ tokine level [9.1 0]. 
An understanding of the mechanism of protective 
immun.:- rcspon ·es afforded by vaccines i essential to 
allow the rational design of new and improved vac-
cines b~ identil"yi ng the key protective elements in 
immunity. These protective immune mechanisms 
can potentially be investigated using the severe com-
bined immunodeficient/beige (SCI D/Bge) mouse 
model. SCI D/Bge mice carry two genetic defects 
that re~ult in a lack of functional murine immune 
ctTector cells. The murine SC l D mutation results in 
a n absence of matu re B- and T-lymphocytes and the 
beige mutation results in defective natural ki ller 
( K) cells. As a re ult of these mutations. the 
SCI D/Bge mouse lacks a functional immune system 
and is able to accept xenografts from a range of 
o ther species, including different strains of mouse 
[ 11]. This process of immune system reconstitution 
can be achieved. for example. after the parenteral 
administ ration of a purified mixed lymphocyte pop-
ulation from a donor animal. Successful reconstitu-
tion of SCID/Bge mice leads to colonisation of lym-
phoid tissues with donor-derived immune cell subsets 
and e tablishes circulating donor immunoglobulins. 
This model offers a powerful tool for analysing the 
protective immune responses afforded by_ vaccines. 
A problem as ociated with the SCID/Bge mouse is 
occasional reversion of the SCID phenotype in a 
small percentage of animals. These mice are termed 
·]eaky' and are normally removed from experiments; 
consequently, it is important that colonies of SCID/ 
Bge mice are regularly screened for leakiness. The 
immunodcfkient status of the SCI D/Bge mouse 
means that specia li sed housing and procedural tech-
niques arc ncce sary in order to prevent infection 
from a possible environmental con taminant. 
In thi:, stud). we have used the SCID/ Bge mouse 
model to invest igate the mechanisms of protective 
immunity to plague conferred by the subunit vac-
cine. Adoptive transfe r of protectin: immunity to 
plague was at tempted by reconstitution of S ID/ 
Bgt: mice with hypcrimmune donor Balb/c lympho 
cytes. ubscq ucntly the immune response to boost in; 
was monitored in these reconstituted mice. Addition 
ally. the ability to protect against plague infcctior 
through passive transfer of antibody only. into nai\< 
SCI D/Bge mice was investigated. 
2. latcrials and methods 
2.1. Mice 
SCl D/Bge mice at 3--4 weeks of age. were supplied 
by CAMR, Porton Down, Salisbury. UK. The ani-
mals were housed and handled aseptically in Hepa 
filtered isolators and fed with sterile food and sterile 
water ad libitum. The absence of murine immuno-
globulin (lg) was screened by ELI SA and mice hav-
ing detectable murine lg levels were excluded from 
experiments. Barrier-bred. female 6-week-old Balb/c 
mice free of mouse pathogens were obtained from 
Charles River Laboratories, Margate. Kent. UK. 
All animal experimentation strictly adhered to the 
I 986 Scientific Procedures Act and to the Guidance 
on the Operation of the Animals (Scienti fic Proce-
dure ) Act , as promulgated by the ethics committee 
on animal experimentation within this research es-
tablishment. 
2.2. Jmmuni.wllion of donor Ba/h/c lilice 
Donor Balb/c mice (11 = 25) were immunised intra-
peritoneally (i.p.) on days 0. 14 and 28 with the 
plague subunit vaccine comprising I 0 1-1g each of 
F I- and V -antigen delivered after overnight adsorp-
tion to 25'!1,, (v/v) alhydrogel (Superfos Biosector. 
Denmark) at 4°C in 100 Jll of phosphate-bu~Tered 
·a line (PBS) per animal. 
2.3. Prepamtion I!( h.t'f}(!riJIInllme lrlilplwcytes and 
.lef/1111 
Hype rimmune lymphocytes and serum were ob-
tained on day 42 from Balb/c mice immunised as 
above. Mice were anaesthetised i.p. [7] bcl"ore collet:-
tion of blood samples by cardiac puncture from 
which sera was collected and pooled. Subsequent!). 
anaesthetised anima ls were humanely killed by eer-
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,·ica l dislocation and lymphocytes were isolated from 
. pleen cell prepa rations afler densi ty centrifugation. 
Th is procedure has previously been shown to yield a 
pure ( > 90'Y,,) population or lymphocytes [ 12). 
:! . ./. Reconl'lilulion mu/ immtmislllion <4 SCID/Bge 
m ice 
CID/Bge mice (n= 10) were reconstituted i.p. 
with I X 107 hyperimmune lymphocytes isolated as 
detailed above (day 0). Reconst ituted SCID/Bge 
mice were immunised 24 h later (day I) with the 
plague subunit vaccine prepared and administered 
as detailed above. A second immunisation wi th the 
same subunit vaccine formulation was administered 
on day Ill . Serial blood samples were ob tained at 
intervals after reconstitution and circulating immu-
noglobulin levels were determined by ELISA. 
2.5. Passil'e !ransfer of !typerinunune serum 
Serum was collected from hyperimmune Balb/c 
mice and untreated control Balb/c mice as detailed 
above. The serum was tit red by EL! SA fo r F 1- and 
V-specific circulating lgG and lgG subclasses. Sub-
sequently, a 500-~1 volume of hyperimmune erum 
was administered i.p. to six SCJD/Bge mice 20 h 
prior to a parenteral cha llenge of Y. pestis strain 
GB. A control group of six SCID/Bge mice received 
500 111 of naive Balb/c serum. In a second experi-
ment. 500 ~I of hyperimmune se rum was adminis-
tered to 10 SCID/Bge mice 2 h prior to an aerosol 
challenge of Y. pes/is strain GB. 
1.6. Anligen-specific EL/SA 
Serum immunoglobulin levels were determined by 
ELISA as previously detailed [13). In brief. micro-
titre plates were coa ted with either F 1- or V -an tigens 
in PBS (5 11g ml - 1) overnight at 4°C. Sub equentl y. 
the plates were blocked using I'X, non fat dry milk 
powder in PBS+0.05'X, Tween 20 (2 h 3JOC). erum 
samples were double diluted on the plate and incu-
bated for I h at 37°C. Binding of serum antibody 
was detected using a peroxidase conjugate against 
mouse polyvalent lg (Sigma) used at a maximum 
di lution of I :5000. Scrum antibody titre was esti-
ma ted as the maximum dilution or serum giving an 
absorbance at 405 nm (A 111~,) reading 0. 1 units over 
background and was presented a. log 111 reciprocal 
antibody titre per sample. The determination of 
lgG subclasses present and their titre wa · a lso deter-
mined for erum amples u ed in all pas ive tran fer 
experiments. Peroxidase-labelled secondary an tibod-
ies agains t mouse, lgG, lgG 1 and lgG2., (Harlan-Ser-
alab) were each used at a maximum dilution of 
I :4000. It has previously been reported that these 
econdary antibodies are specific and have an equiv-
alent sensitivity of detection [8]. 
A modified ELISA was used to analyse antibody 
secretion by spleen cells as fo llows: steri le microtitre 
plates were coa ted with either F 1- or V -antigens in 
PBS (5 ~g ml- 1) overnight at 4°C, under aseptic 
conditions. Subsequently the plates were blocked 
with DM EM plus 20'% (v/v) foetal calf serum 
(FCS) (I h 37°C), prior to aliquoting I 00 ~I of the 
individual spleen cell suspensions. The cells were 
double diluted on the plate and then allowed to in-
cubate for 48 h (5% C02 37°C). The plates were 
subsequently washed in PBS ( X 3), PBS+0.2'X• Tween 
20 prior to the addition of the peroxidase-labelled 
secondary antibody conjugate. Incuba tion was con-
tinued for 20 h ( +4°C) prior to au tomated washing 
(X 4) in PBS+0.2'Yu Tween 20 and addition of a solu-
ble peroxidase substrate, 2,2-azino-bis (3-ethylbenz-
thiazoline-6-sulphonic acid) (ABTS). The amount of 
antibody secreted by well ~as quantified by measur-
ing A~n:; and the log 111 reciprocal antibody titre was 
derived. 
2. 7. Challenge ll'i!ll Y. pes lis 
SCID/Bge mice were challenged under the Advi-
sory Committee for Dangero us Pathogens (ACDP) 
Category 3 containment conditions. Aliquots of Y. 
pes/is GB strain containing approximately 10:1 col-
ony forming units (cfu) were injected subcutaneously 
in a 0.1-ml volume. into reconstituted SCI D/Bge 
mice and control unreconstituted SCID/Bge mice. 
To mvest igatc passive protection again:.t a sys-
temic plague infection. SCI D/Bge mice received ei-
ther hyperimmune scrum or control naive mouse se-
rum as detai led above and were challenged with 
approximately 1 0~' cru or Y. pes/is GB. The challenge 
inoculum was prepared at 28°C as previously de-
·cribed (14]. 
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train GB \\<IS isolated from a fa tal human case or 
plague a nd has an M LD of < 5 cfu in SCI D/Bge 
mice by the subcutaneous route (unpublished data). 
This stra in was deri ved from strain M P6 and is fully 
virulent in Balb/c mice wi th an M LD or I cfu via the 
subcutaneous route and 900 cfu via the respira tory 
route [1 -l). 
A second group of SCI D/Bge mice received hyper-
immune serum prior to a challenge wi th an aerosol 
or Y. pcs1is G B. The inoculum for aerosol challenge 
was prepared as previously described [8]. Aerosol 
particles were generated using a Colli son spray and 
conditioned in a modified Henderson aerosol appa-
ratus. SCID/Bge mice were placed in a head-only 
exposure chamber and exposed for 10 min to a 10" 
cfu dose of Y. pestis. The aero ol stream was main-
tained at 55% relative humidity ( ± 5'X•) and I9°C 
( ± I0 C). During each exposure period, a sample of 
Y. pestis was ta ken directly from the sampling port , 
using an all-glass impinger (AG I-30) and plated onto 
Congo Red aga r to quantify the available dose of Y. 
pes/is delivered. 
Chal lenged mice were observed over a period of 
14 days. Humane end points were strictly observed 
d uring this time so that no animal became distressed . 
At the end of the observa tion period, survivors were 
humanely cu lled and samples of blood, spleen and 
liver were streaked over the surface of Congo Red 
aga r plates. The plates were incubated at 28°C for 48 
h and then observed for the growth of Y. pestis. 
3. Results 
3.1. A.uay of immunoglobulin.\· in recollslitllled 
SCID/Bge mouse sera 
Initial experiments investigated the reconstitution 
of SCID/Bge mice wi th hyperimmune murine lym-
phocytes by determining the ant ibody response to 
both V -antigen and F !-antigen in these mice at va r-
ious time points after reconstitution. Results pre-
sen ted in Table I indica te the log 10 reciprocal serum 
an tibody titres at four time intervals after reconsti-
tution. lt can be seen that an antibody titre to both 
the F l- and V-antigens was demonstrated in 9 out o f 
10 reconstituted SCID/Bge mice at 56 days after re-
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Fig. I. Mean an ti-Fl and anti-V ti t res o f immunoglobulin sub-
classes in the sera u;ed in pas>ive protection c~perimcnts against 
systemic plague challenge. 
successfully reconstituted with donor lymphocytes. 
A second immunisa tion of the same formulation 
subunit vaccine was given on day Ill after reconsti-
tution and it can be seen that on day 123. antigen-
speci fic serum lg levels were recorded at increased 
levels in the remaining reconstituted mice. In the 
single non-responding SCID/Bge mouse (results not 
shown) a second immunisation did not result in de-
tection of a specific antibody response. It can also be 
seen from the results in Table I that the an tibody 
titre to V-antigen was higher than that to F l-an tigen 
and this is typical of the immune response to the 
plague subunit vaccine seen in previous investiga-
tions [7.8). 
Analysis of antibody secretion by spleen cells from 
three reconstituted SCID/Bge mice prior to the boost 
immunisa tion on day Ill demonstrated a low level 
of antibody titre to both the F l- and V-antigens 
indicating the colonisation of spleen tissues with im-
mune antibody secreting cells (results no t shown). 
J.l. Assay l!{ h_rperimmww .1erw11 trsed jin· passil'e 
tmn~fer 
The rrofile of immunoglobulin subclasses present 
in the hyperimmune sera used in passive transfer 
experiments was determined and is represented in 
Figs. I and 2. lt l'an be seen that the predominant 
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Table I 
AnuboJ~ lllr~-., Ill F 1- .1 ntl V-antig.~n' in SCI D/Bg.c 1111c~ at V<~riow. time point' aft~r rccon>tituuon ' 





11. number of SCID/Bgc mice. 
Anti- 1- 1 
3.90±0.09 (11=9) 
3.85 ± 0.04 (11 = 6) 
4.20 ± 0.05 (11 = 6) 
-1.50 ± 0.22 (11 = 6) 
Ant1-V 
4.6-1 ± 0.09 (/I = 9) 
-1 .56 ± ().()9 (11 = 6) 
-1.86 ± 0.06 (11 = 6) 
5.01 (11=6) 
"RccOihtitullon was allcmpted for 10 SCID/I)gc mice and mean antibody titres were Jeterminctl fo r SCID/Bge mice that were succc.sfully 
rcco n,llluted. 
1
' Rccon titutcd SCID/Bgc mice received it boost immunisation \\ith the subunit vaccine for plague on day Ill. 
immunoglobulin subtype for both sera samples 
against both Fl- and V-antigens is lgc.a, with lower 
levels of lgG2,, being recorded. This is indicative of a 
T-cell immune response of a predominantly Th2 
type. Again it can be seen that the antibody titre 
to the V-antigen is greater than to the Fl-antigen 
3.3. Protection against challenge 
Those SCJD/Bge mice that demonstrated an anti-
body titre to Fl- and V-antigens in Table I were 
protected against a systemic challenge dose of 140 
cfu Y. pestis (approximately 30 MLDs) Control on-


















anti F1 titre anti-V titre 
I ig. 2. Mean anti-FI <tnd anti -V titre' ur nnmunoglnbulin sub-
t:has~~~ tn the ~ra used in pa~sivc prolct.:tion experiments a!!ain~t 
acrn,ol pl-.guc cha llenge. 
a mean time to death of 4 days. Furthermore. the 
single mouse that did not show evidence of reconsti-
tution did not survive the challenge. The spleens. 
livers and blood from a sample of su rvivors (n=4) 
collected after the 14-day observation challenge mac-
roscopically appeared normal and Y. pestis was not 
recovered from these tissues indicating that surviving 
mice had cleared the challenge organism. 
The protective effect of passive transfer of hyper-
immune serum against plague challenge can be seen 
in Figs. 3 and 4. Protection was achieved for 5 of 6 
and 7 of I 0 SCI 0/Bge mice against injected chal-
lenge and aerosol challenge, respectively. Y. pestis 
was not recovered from sections of spleen, blood, 
liver and additionally lung samples from aerosol 
challenged mice. in a sample of surviving mice after 
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Fil). 3. Sun i' .11 of SCI Dlllgc mice against ,y,tcmic plague i nl'ct~­
tion alkr pas,ivc translcr or hypcrimnnmc scrum. 
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Fig. -l. Survl\al of SCID/ Bge mtcc aganl'l an inhaled plague 
challenge after passive transfer of h) pcrimmunc scrum. 
that clearance of the challenge organism had oc-
curred. 
4. Oiscu sion 
An understanding of the underlying mechanisms 
of protecti ve immunity mediated by a vaccine is es-
sential in the rational design of new and improved 
vaccines. The work reported here demonstrated that 
reconstitution of SCID/Bge mice with hyperimmune 
Balb/c lymphocytes followed by immunisation with 
the subunit vaccine for plague, allowed a111igen-spe-
cific antibody to be detected for up to 4 months after 
reconstitution. It was apparent in these experiments 
that 9 out of 10 SCID/Bge mice were successfully 
reconstituted. o antibody response was detected 
in the single remaining SClD/Bge mouse, even a fter 
a booster immunisation. This finding that some 
SCl 0/Bge mice do not sho\\' evidence of reconsti tu-
tion concurs with observations by other investiga tors 
[ 15). 
Antibody leve ls in reconstituted mice were shown 
to increase arter a second boost immunisation of 
reconstituted SClD/Bge mice with the subunit vac-
cine ror plague. These resu lts. toge ther wi th the evi-
denct: or antibody secreting ce lls in spleen prepara-
tion~ from reconstituted mice. suggested that donor 
hype rimmune Balb/c lymphocyte · are colonising re-
cipient SCI D/ 13ge mice lymphoid tissues. leading h1 
successful and evidently long-term reconstitution of 
fu nctional immune lymphocytes. 
The protective efiect which this adopti ' c transfer 
of imm une lymphocytes conferred aga inst a systemic 
plague challenge wa clearly demonstrated here. A 
sample or surviving mice showed evidence of com-
plete clearance of challenge organisms at the end or 
the 14-day observation period. lt is evident in the e 
adoptive transfer experiments that the SClD/Bge 
mouse offers a valuable model to investigate the pro-
tective effect of a subunit vaccine for plague. 
The SCID/Bge mouse also offers a good model to 
investigate passive transfer of immunity because the 
mouse has no circulating immunoglobulins allowing 
easier interpretation of any protective efiects. Balb/c 
mice show a predominantly Th2-type immune re-
sponse to the vaccine and this response is typical 
of immunisation with protein antigens in alhydrogel 
[ 16]. It has been shown in this study that passive 
transfer of hyperimmune serum leads to a high de-
gree of protection against injected and inhaled chal-
lenge. This protection suggests that host resistance to 
plague is principa lly mediated by antibody. It is also 
evident that this passive protection aiTorded by anti-
body alone is not complete. aga inst either systemic 
or inhaled challenge and suggests that an additional 
component of the immune system is required for 
complete protection. For this reason. the SCID/Bge 
mouse model used in this study to investigate the 
protection afforded by the subunit vaccine for plague 
will be further developed to examine selective recon-
stitution with immune cell subsets. This will allow an 
assessment of the role of different immune cell subset 
populations in immune protection against plague in-
fection . 
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SUMMARY 
The objective of thi s study was to identify an immunological correlate of protection for a two-
component subunit vaccine for plague, using a mouse mode l. The compone nts of the vaccine are the Fl 
and V antigens of the plague-causing organism, Yersinia pestis. which are coadsorbed to a I hydrogel and 
administered intramuscularly. The optimum molar ratio of the subunits was determined by keeping the 
dose-level of either subunit constant whilst varying the other and observing the e ffect on specific 
antibody titre. A two-fold molar excess of Flto V. achieved by immunizing with 10 llg of each antigen. 
resulted in optimum antibody titres. The dose of vaccine required to protect against an upper and lower 
subcutaneous challenge with Y. pestis was determined by administering doses in the range I 0 llg 
Fl + 10 llg V to 0·0 1 llg Fl + 0·01 llg V in a two-dose regimen. For animals immunized at the l-Jlg dose 
level o r higher with Fl +V, an increase in specific IgG I titre was observed over the 8 months post-boost 
and they were fully protected against a subcutaneous challenge with I 0~ colony-forming units (CFU) 
virulent Y. pestis at this time point. However, immunization with 5 llg o r more of each subunit was 
required to achieve protection against challenge with I 01 CFU Y. pestis. A new finding of this study is 
that the combined titre of the lgGI subclass, developed to Fl plus V, correlated significantly (P<0·05) 
with protection. The titres of lgG l in vaccinated mice which correlated with 90%, 50% and l 0% 
protection have been determined and provide a useful model to predict vaccine efficacy in man. 
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INTRODUCTION 
The ancient disease of plague is still endemic in parts of the world 
and its resurgence from time-to-time. as in the 1994 epidemic in 
India. is feared [ l ]. Existing vaccines licensed for human use to 
protect against infection with Yersinia pestis. the causative organ-
ism of plague. suffer serious drawbacks. These killed whole-cell 
vacc ines have been used for many years, but they are reactogenic. 
require frequent boosting to maintain adequate immunity and there 
is evidence that they do not induce appropriate immunity to protect 
against the pneumonic form of plague [2.3]. A subunit vaccine. 
comprising the Fraction l (FI ) and V antigens of Y. pesris. provides 
superior protection against parenteral and against aerosol challenge 
with virulent Y. pesris 14). Recent studies have shown that multiple 
doses of the single subunits can protect mice against challenge with 
wild-type Y.pesris 15-81. Several sllldies have demonstrated that 
by combining the subunits in a vaccine an additive protective 
effect is achieved [5,9]. A recent s!lldy has demonstrated that 
intramuscular administration of two doses of the combined subunit 
vaccine in mice confers protection against the pneumonic form of 
the disease, and that protection was mediated largely by a high 
level of IgG systemically and in the lung (4). Further. passive 
immunization of severe combined immunodeficient (SCID) mice 
with Fl - and V-spccific lgG conferred protection against s.c. 
challenge with plague [ 10]. 
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Thus evidence is accumulating to indicate that protection 
against plague is antibody-mediated and this would be appropriate 
to counter this predominantly extracellular infection. In an effort to 
determine the operative protective mechanism. an immunologica l 
correlate of protection has been sought in this study. This has 
entailed an optimization of the vaccine formu lation. To this end. 
the optimum molar ratio of the vaccine components and also Lhe 
dose levels of the vaccine requi red to achieve pro tection against an 
escalating challenge with Y. pestis have been investiga ted. This has 
enabled the determination of protecti ve titres and a posi ti ve 
correlation between specific antibody titre of the lgG I subclass to the 
Fl +V subunits and the degree of protection conferred against plague. 
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MATERIALS AND METHODS 
Vaccines 
The components of the subunit vaccine were prepared a~ pre-
viously described 151. Briefly. the Fl ant igen was precipitated 
from the supemace of Y. pestis grown at 37°C hy the addition of 
40% {w/v) ammonium sulphate and purified by repeated resuspen-
sion and centrifugation of the pellet in 20 mM Tris-HCI at 
pH 8 [5]. The V ant igen was produced as a fusion protein 
with glutathione-s-transferase in Escherichia coli. cleaved with 
Factor Xa (Boehringer Mannheim UK Ltd. Lewes. UK) for 18 hat 
22°C and purified by affini ty absorption [5 1. The killed whole-cell 
vaccine for plague was purchased from the Greer Labs (Lenoir. 
NC) as a formaldehyde-killed suspension (2x 109/m l) of Y.pestis. 
Animals 
Female 6-week-old BALB/c mice (Charles River UK Ltd. 
Margate. UK), free of mouse pathogens, were used throughout 
this study. All animal experimentation strict ly adhered to the 1986 
Scientific Procedures Act and to the Guidance on the Operation of 
the Animals (Scientific Procedures) Act, as promulgated by the 
Home Office in the UK and adopted by the e thics comminee on 
animal experimentation within this research establishment 
Blood and tissue sampling 
Serial blood samples were taken through the immunization 
schedule on the stated days for each study by superficial vene-
puncture of the tail veins of six animals per group, selected a t 
random (representing one quarter of each group). Equal aJiquots of 
these individual samples were pooled to determine the group mean 
antibody titre to Fl and V. At the end of the schedule, and 
concomitant with challenge of a cohort of vaccinees, six to eight 
animals per group were anaesthetized intraperitoneally with 6 p.g 
of Domitor (Smith Kline Beecham, UK) and 3 mg of Ketalar 
(Parke-Davies, Pontypool, UK) prior to the collection of a terminal 
blood sample by cardiac puncture. These animals were humanely 
killed by cervical dislocation and their spleens removed and 
amalgamated by group into ice-cold Dulbecco's modified 
Eagle's medium (DMEM; Sigma. Poole, UK) for subsequent 
analysis. 
Analysis of blood samples 
The measurement of isotype and ti tre of the antibody response was 
performed on serum samples by means of a modified ELISA [4). 
Peroxidase conjugates against mouse IgG, IgG I, lgG2a, IgG2b and 
lgG3 (Sera-Lab, Crawley Down, UK) were each used at a max-
imum dilution of I :2000. These secondary antibody conjugates 
have previously been shown to be entirely specific for the homo-
logous lgG subclass and not to be cross-reactive with any hetero-
logous IgG subclass [11]. Antibody titre was estimated as the 
maximum dilution of serum giving an absorbance4 141101 reading 
0·1 units over background and is presented as log 10 of the 
reciprocal of that dilution. From this, mean titres have been derived 
per treatment group. 
Analysis of antibody secretion by .1pleen cells 
Spleens were amalgamated by treatment group. prior to the 
preparation of crude suspensions of spleen cells for the determina-
tion of quantity and spccifici ty of antibody secretion inl'itm. by 
means of a modified ELISA as described previously [41. The 
amount of antibody secreted by a suspension of cells representative 
of each group was quantified by measuring A414,,, and the mean 
log 10 antibody titre was derived:!: s.e.m. 
Purijic(l{ion of splenic T cells 
Lymphocyte' were i~olatcd by densi ty gradient centrifugation 
from the crude spleen cell 'uspensions prepared for each immuni-
zation group. Subsequently. T celb were isolated by immune-
magnetic separation as de,cribed previously 112] for the assay of 
in vitro recall responses 10 F I and V antigens. The in l'itru recall 
response to equimolar amounts (0· 1 nmol) of Fl (3·2 p.g/ml) and 
V (6·3 J.lg/ml) was mea~ured in T cells aliquoted at constant 
di lution into microtitre well ' precoated with autologous peritoneal 
macrophages. Proliferation was quantified by the incorporation of 
3H-thymidine into cells from which the st imulation index (S I) was 
derived as: mean ct- 1 m in - I per treatment group/mean ct- 1 m in -I 
per negative control. The SI was calculated from a minimum of 
three replicates. Control samples were derived by isolation of 
T cells from untreated control groups. 
Challenge with Y. pestis 
On the indicated day of the schedule for each study, the remaining 
animals in each immunization group were random ly divided into 
groups of six and were challenged by the subcutaneous route with 
doses of the Fl + strain (GB) of Y.pestis in the range 105-107 
colony-forming units (CFU). The challenge inoculum was pre-
pared at 28°C as described previously [ 13). Challenged mice were 
closely observed over a 14-day period for the development of 
symptoms, and where appropriate, time to death (TTD) was care-
fully recorded. Malaise was noted in some animals as immobility 
and ruffled coat. Humane end-points were strictly observed so that 
no animal became distressed. Animals that succumbed to the 
challenge were autopsied. Livers and spleens were scored for 
enlargement and any evidence of abnormality was noted. Sections 
of liver, spleen and lungs were smeared onto Congo red agar or 
Yersinia selective agar (YSA; Oxoid. Basingstoke, UK), and the 
plates were incubated at 28°C and observed for growth after 48 h. 
At the end of the 14-day observation period, survivors were 
humanely culled and tissues were removed for bacteriological 
and gross morphological analysis, as above. 
Statistical analysis 
Student 's Hest was applied to determine the significance of the 
difference betv<een treatment group means [ 14]. The technique of 
Probit analysis [15] was applied to investigate the relationship 
between percentage survival against s.c. challenge with Y. pestis 
and the log 10 IgG, and more specifically, lgGI titre to F l and V. 
Further, a comparison of parallel probit slopes generated by the 
individual and combined subunits enabled a determination of the 
potency ratio of the subunits in inducing an lgG and, more 
specifically, an IgG I titre which correlated with protection. 
Dererminmion of optimum molar ratio of subunits 
In previous studies, a 10-J.Ig dose level of each subunit has been 
demonstrated to induce protective immunity against injected and 
inhalat ional challenge with the plague-causing organism, Y. pestis. 
In this study. the optimum molar ratio of one subunit to the other 
was determined by keeping ei ther subunit constant at I 0 p.g and 
varying the dose level o f the other subunit. 
Eight groups of 24 BALB/c mice were immunized with the 
combined subuni ts at various dose levels to achieve a molar ratio of 
Fl :V in the range 0·5-200. as shown in Table I. The subuni ts were 
delivered adsorbed to 25~ (vlv) alhydrogel (Superfos Biosector. 
Frederikssund. Denmark) in 0· 1 ml PBS per animal. Fun her groups 
of24 mice received 0·1 ml a I hydroge l (25% v/v) only and served as 
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Table I. Dctcrmmatoon of optimum molar ratio uf ,ubunit~ 








2·51'£ Fl + IOI'g V 
51'& Fl + IOI'g V 
101'& Fl + IOI'g V 
201'£ Fl + IOI'g V 
Alhydrogel only 
Group 2: Fl constant at 101'&· V<Jry V 
6 IOI'g V+ IOI'g Fl 
7 5!'£ V+ 101'& Fl 
8 ll'g V+ 101'& Fl 
9 0·11'& V+ 101'& Fl 
10 Alhydrogel only 









vehicle controls. Mice in all groups were dosed on a single 
occasion only. in order to observe fine differences in response 
between groups. All doses were delivered intramuscularly, divided 
equally between two injection sites in order to maximize the 
response in the draining lymph nodes. Tail vein blood samples 
were removed from six animals per group on days 45 and 68 of the 
schedule, for the determination of antibody titre. 
Detenninarion of dose level of vaccine required for protection 
Six groups of 24 BALB/c mice were immunized with the com-
bined subunits at doses in the range 101-'g Fl + 101-'g V to 0·01 1-'g 
Fl + 0·01 1-'g V. The subunits were delivered adsorbed to 25% (v/v) 
alhydrogel (Superfos Biosector) in 0·1 ml PBS per animal. A 
funher group of 24 mice was given the killed whole cell vaccine 
(KWCV) comprising 2 x I 0 8 CFU 0·1/ml per mouse. as before [6] 
and this equates to one fifth of the human dose. Group 8 animals 
received 0 ·1 ml alhydrogel (25% v/v) only and served as vehicle 
controls. Mice in all groups were dosed as indicated on day I and 
this dosing was repeated on day 2 1 to achieve a booster immuniza-
tion. All doses were delivered intramuscularly. divided equally 
between two injection si tes. Serial b lood samples were collected on 
days 21. 68 and 168 from six individual animals per group. On day 
240. terminal blood samples were collected from six animals per 
group for antibody titration and spleens were removed for assay of 
B cell antibody secretion by modified ELISA and ofT cell recall 
response to the subunit antigens. At this time point also. the 
remaining 12 animals in each immunization group were randomly 
divided into two groups and were c hallenged by the subcutaneous 
route with either 107 CFU or with 105 CFU of Y. pestis strain GB. 
RESULT 
Determination of optimum molar ratio of subwrits 
Deo·t•lopme/11 of lgG titre oft er o single l'accine dose . The group 
mean logrn lgG titre to Fl. V and the combined titre to F l +V at 
day 45 b shown in Fig. I a.b. From Fig. I a it is clear that when the 
dose leve l of V was held constant at IOJ.'g.thcrc wa' little effect on 
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Fig. 1. Effect of molar ratio of Fl :V on titre at day 45. 
(2·5-20) jlg. In contrasl. it is clear from Fig. I b that when FJ was 
held con tant at 10 !lg there was a large reduction in the total titre 
when the dose level of V was reduced from I 0 1-'g down to 0· I J.'g. 
In the absence of a booster do e, the total titre had not increased 
beyond log,o 8 for any immunization group by day 68 (data not 
shown). Between days 45 and 68, there were increases in the titre 
to V in groups 7 and 8. further illustrating the more gradual 
development of a titre to V. 
From this study. it appeared that the dose level of the V subunit 
was critical and that as long as Fl was present. the precise dose 
level in the range (2·5-20) 1-'g made no significant difference. To 
achieve maximum total titres early in the schedule (by day 45) the 
combination of Fl + V at the 10-1-'g dose level is indicated. This 
represents a molar excess of Fl :V of 2. However, by day 68 the 
differences in response to the dose levels representing molar ratios 
of Fl :V in the range 2-20 (groups 6- 8) had largely been lost. Only 
group 9. given a 200 molar excess of Fl :V. still had not produced a 
total titre in excess o f log 10 6. some 2 logs lower than the other 
groups. 
Determinmion of dose le1·el of vaccine required for protection 
In the second part of this study. to determine the protective dose 
level of vaccine. a two-fold molar excess of Fl :V wa~ adopted for 
each dose level of vaccine trialled in the range I 0 Jl£ F I + I 0 1-'g V 
to 0 ·01 1-'g Fl +0·01 llg V. 
De•·elopmell/ of l t:G titres to Fl mu/ V H'ith time. The devel-
opment of serum lgG litre was measured at intervals throughout 
the immunization 'chedule and is plotted for each dose 
level agaim. t time in Fig. :!. On each of days 2 1. 68. and 168. a 
dose-response eiTel:t was observed with FJ- and V-specitic lgG 
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generally increa,ing a~ the dose leve l of Fl +V increased. At day 
21. th.:: lgG titre to Fl exceeded the lgG titre to V at all dose levels 
(data not l>hown). From day 68 onwards. the lgG titre to V was of 
the ,am.:: order a ' the titre to Fl. and from this time on. the an ti -V 
titre dominated the response. at all close levels. By day 68, a ll 
individuals within each group had responded with an lgG titre to 
Fl and to V, with a standard error which was<3% of the group 
mean . 
In general, for each dose level total lgG titre increased with 
time up to day 168. but by day 240 was in decline. There were two 
exceptions to thi s: first. the total lgG titre in the group receiving 
10 1-1g Fl + 10 1-'g V was maintained constant between days 168 and 
240: and second. the lgG titre induced to the KWCV. which was 
entirely Fl-specific. had declined by more than one log between 
days 21 and 68 and the n remained at this level to day 240. 
Distribwion of lgG titre across subclasses. The distribution of 
Fl- and V-specific lgG titres across the subclasses was measured 
on the corresponding days 2 1-240 (Table 2). From these data it is 
clear that the lgG I titre dominated the response to either antigen on 
all days in a dose-related manner. This pattern was not altered by 
the administration of a booster dose of vaccine on day 21. As 
reported previously [5) the anti-FI response induced by the KWCV 
was also predominantly of the lgG I isotype. 
Persistence of /gGJ titre to (FI +V). When totallgG I titre to 
F I +V was plotted against time for each dose level (Fig. 3), it was 
apparent that titres were elevated above log10 10 and still rising at 
day 240 for the first three dose levels (I 0 pg F I + I 0 pg V, 5 pg 
Fl + 5 pg V and I pg Fl +I 1-1g V) only and were below log 10 10 
and variable for the lower dose levels (0-5 1-'g Fl + 0-5 1-'g V, 0-1 1-1g 
Fl +0·1 pg V and 0-01 pg Fl +0-01 1-1g V). The totallgGI titre 
was maximal for the group receiving the IOpg Fl + I01-1g V dose 
leveL In contrast. the entirely anti-FI lgG I titre induced to the 
KWCV remained at a value around log10 4-0 throughout the 
schedule. not increasing significantly in response to the booster 
dose at day 21. 
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response of T cells isolated at day 240 from each immunization 
group is shown in Fig. 4. A significantly increased SI (P < 0-005) 
was measured for T cells isolated from animal' in the I 0 1-1g 
F I + I 0 pg V group on re-expo. ure to 6-3 ~1g/ml of the V antigen. 
compared with T cells isolated from the negative contro l group. 
However. T cells isolated from this group did not have a sig-
nificantly increased SI on re-introduction of the F I antigen at 
3-2!-'g/ml. No significant proliferation to either Fl or V was 
measured for T cells isolated from animals immunized at any 
other dose level or from the KWCV group. 
In vitro B cell memory response at day 240. The memory 
response of B cells in spleen cell homogenates prepared from 
animals in each immunization group at day 240 was measured by a 
modified ELISA. Antibody secretion by splenic B cells with 
specificity for both the Fl and V antigens was detected after an 
18-h incubation with Fl or V coated to the solid phase. The results 
shown in Fig. 5 indicate the distribution of total titre to (FI + V) 
across the lgG subclasses. for each immunization group. As for 
serum, the predominant subclass was lgG I and as the dose level of 
F l +V was increased from 0·5pg Fl +0-51-'g V to 101-'g 
Fl + I01-1g V. there was a logarithmic increase in the total titre 
of specific IgG I. The predominant isotype secreted by splenic B 
cells from the KWCV group was also lgG I, but with specifici ty for 
the Fl antigen only. 
Protection against subcutaneous challenge. In order to mea-
sure the protective dose level of Fl +V. 12 animals from each 
immunization group were challenged with Y. pestis strain GB by 
the subcutaneous route in the dose range (105-I07 CFU). The 
number of survivors per group at day 14 post-challenge is shown in 
Table 3. Animals immunized with I 0 1-'g Fl + I 0 pg V or with 5 pg 
Fl + 5 pg V withstood a challenge of up to I 07 CFU, but there was 
breakthrough in protection against 107 CFU for animals immu-
nized at dose levels of I 1-1g F I + I pg V. or less. At the 105 CFU 
Y. pestis challenge level, the breakthrough in protection occurred 
amongst vaccinees given 0-5 1-1g Fl + 0·5 1-1g V, or less. Mice 
immunized with the KWCV were fully protected against 
~' ~ ~ ~~ ~ ~ r-~ ~r-~ [% ~ [% ~ [% [% [% 
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% ~ ~ ~ ~ ~ ~ [% 
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Fig. 2. Development of totnl serum lgG titre to (FI +V) with time. 
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T;tble 2. Developmenl of lgG 1i1rc!> 10 Fl and 10 V wilh ume 
Group mean log10 1i1re 10 F l Group mean log 111 1i1re 10 V 
lmmum7alion 
Group Da} lgGI lgG2a lgG2b IgG3 lgGI lgG2a lgG2b lgG3 
IOFI/IOV 2 1 4 ·7 1 3·5 1 3-8 1 4-41 4·1 1 2 2·9 2 
5FI /5V 2 1 4·41 3·5 1 3·5 1 4· 11 4·1 1 Neg 2·9 Ncg 
IFI/IV 21 4 ·11 3·2 3·2 3·2 3-8 1 Neg 2·3 Neg 
0·5FI/0·5V 21 3·5 1 3·2 3·2 3·51 3-8 1 Neg 2 eg 
O·IFI/O· IV 2 1 3·2 2·3 2·6 2·9 J.S l Neg 2 Ncg 
O·OIFI/O·OIV 2 1 3·2 2·3 2·9 2·9 3·5 1 Neg 2 Neg 
KWCV 21 4·4 1 3·2 3·2 3-81 Neg Neg Neg Neg 
IOFI/IOV 168 4·8 1 3·9 3·9 3·9 5·4 1 3·9 4·2 3 
5FI/5V 168 4·81 3-9 3-6 3·9 5·71 3·6 3-9 3 
IFI/IV 168 4-81 3·6 3·3 3·9 5·41 3·3 J.6 3 
0·5FI/0·5V 168 4 ·51 3·6 3·3 3 4-81 3 3·3 3 
0·1 Fl /0· 1 V 168 4·2 3·3 3 3 5· 11 3·6 3·3 3 
0·01 Fl /0·0 1 V 168 4·2 J.3 3·3 3 5· 11 3·6 3·3 3 
KWCV 168 4·2 3 3 3 0 0 0 0 
IOFIIIOV 240 5·41 4·2 3·6 4·5 1 5·71 4·81 4·5 1 3·3 
5FI/5V 240 5· 11 4·51 3·6 3·9 5·71 4·51 4·51 3 
I Fill V 240 5· 11 3·9 3·3 3·6 5·71 3·6 3·9 3 
0·5FI/0·5V 240 4·2 4·2 J.3 3 5·11 3·3 J.9 3 
O·IFI /0· 1 V 240 3·6 3 3 3 5· 11 3 3·3 3 
0·01 Fl/0·01 V 240 4·51 3·6 3·3 3 5·11 3·3 3·3 0 
KWCV 240 4·51 3-3 3 3 0 0 0 0 
Neg. Negative. 
105 CFU Y. pestis. but none survived challenge with 107 CFU, and 
this is approximately equivalent to the protective efficacy of the 
subunit vaccine administered at the 0·1 p.g Fl + 0·1 p.g V dose 
level. Because of the relatively small numbers of animals in each 
challenge group. it was not possible to carry out a statistical 
analysis, so that the minimum protective dose could not be 
precisely determined. 
At day 14 post-challenge, surviving vaccinees were humanely 
killed and autopsied for macroscopic and bacteriological analysis 
of their ti ssues. The spleens. livers and lungs of all the animals in 
the Fl + V-immunized groups appeared nom1al. and Y. pestis was 
not recovered on culture of the tissue sections collected. These 
observations confirmed that surviving animals in the Fl +V-
immunized groups had effectively cleared Y. pestis from the 
blood, liver and spleen by day 14 post-challenge. 
Correlation oftotal lgGJ titre to Fl +V with protection. Probit 
12 
t:1 10 ~ 
!;? 
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Fig. 3. Persislence of scrum lgG I 1i1re 10 (Fl +V) wilh lime. 
analysis was used to investigate the relationship between 
the protection achieved against s.c. challenge with Y. pestis 
by immunization with Fl + V. and the antibody titre induced by 
the vaccine components (Table 3). A significant correla tion 
(P<0·05) was identified between the predominant IgG subclass, 
lgG 1, titre to F 1 + V and the level of protection achie\'ed. From 
this it was possible to correlate the percentage protection with 
IgG 1 titre to the individual and combined subunits (Table 4). 
Thus the log10 IgG 1 titre to Fl +V required to achieve 90% 
protection against challenge was derived as 1 0 ·97 (confidence 
limits 1 0·53- 11 ·97). 
Evidence for synergistic activity between vaccine components. 
Probit analysis was also used 10 compare the potency ratio of the 
vaccine components in terms of the lgG 1 titres induced and 
the level of protection achieved. This was achieved by comparing 
the probit slopes derived for the subunits, having established that 
the slopes were parallel and that their intercepts with the abscissa 
could be used to compare their potency in terms of protective 
efficacies. When the lgG 1 titres induced by Fl and V individually 
were compared. it was c lear that there was no significant difference 
in their contribution to protection against s.c. challenge with 
107 CFU Y. pestis (Table 5). The combined IgG 1 titre 10 Fl + V 
was significantly more protective (P < 0·05) against 107 CFU s.c. of 
Y. pestis than the lgG 1 titre to V (potency ratio 1·87) or to Fl 
(potency ratio 2· 14). If the enhanced protection achieved with the 
combined subunits was due to an additive effec t of the individual 
subunits, then a potency ratio of 2 would be expected. The data 
derived here suggest that the combined subunits had an additive 
e ffect in terms of protective efficacy. over and above the individual 
subunits. 
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Fig. ~- In l"itro T cell recall response at day 2-lO. 
DISCUS 10 
The studies reported in this paper were designed to optimize fully 
the formulation of the recombinant subunit vaccine for pl ague in 
the mouse model. To this end, a dose level of 10 l!g each of Fl and 
V. giving an optimum molar ratio of Fl :V of2, has been identified 
to maximize the IgG titre induced at an early stage of the 
immunization schedule (day 45 or less). This I 0 l!g Fl + I 0 l!g V 
combination induced a durable response for > 8 months. To opti -
mize the early (day 45) immune response to the subunit vaccine it 
has been shown here that the dose level of the V antigen is critical 
and that Fl is equally effecti ve when present within a range of 
concentrations from 2·5J!g up to 20 J!g. This may be because the 
development of an immune response. as evidenced by the appear-
ance of an IgG titre, is slower for the V antigen compared with the 


















first 6 weeks of the two-dose immunization regimen. the Fl antigen 
was the more immunogenic. However, beyond this Lime point, the 
anti -V titre consistently exceeded the ant i-FI titre. These observa-
tions have been made before [4, 12) and may be explained by 
differences in in vivo processing of the subunits which may 
influence the initial response to each as immunogens. 
In this two-dose regimen. the lgG titre to Fl and to V antigens 
developed in a do e-dependent manner with maximum titres to the 
top dose level of IOI!g Fl + IO!!g V. The predominant IgG 
subclass raised to both F I and to V was IgG I and this remained 
so throughout the schedule. The predominantly lgG I titre was 
established after priming and was not altered by boosting a t day 21 . 
The lgG I titre was persistently elevated over the 8 months of the 
study in animals receiving the three upper dose levels of Fl + V. 
This effect was most marked in the I 0 l!g F I + I 0 l!g V group. in 
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Table J. Pn11C.:tu>n "l!·'"h' 'uhnnan ... ou' chall.:ngc "nh )1 ,,.,,,, GB 
Ch:tllcn~c Jn ... l: 
Group lmmuntl.~tton tCI· U ',. I 
IO,..g Fl + JO,..g V 10' 
IO ,..g Fl -;- IOI'g V Ill' 
2 S,..g Fl + 51'£ V 10' 
5i<g F l +51<£ V 10 
J l,..g Fl + l ,..g V 10' 
l,..g Fl + l,..g 10 
, 
.j 0 -5 1-'£ Fl - 0·5tti! V 1 o' 
0 ·51•!! Fl + 0·5 I-'ll V 107 
5 O· IJ.Lg FI +O IJ.LgV 10' 
0· 1 1-'£ Fl -r- 0·1 1-'£ V 10' 
6 0·01 1-'£ Fl +0·01 1-'£ V 10' 
O·OI,..g Fl + 0·01 Nl V 107 
7 KWCV 10' 
KWCV 107 
8 AI hydrogel 10' 
AI hydrogel 107 
primary and booster immunizations. At day 240. there was evi-
dence of a memory B cell re~ponse to Fl and 10 V in all 
immunization groups. The size of Lhe B cell memory response 
correlated wiLh dose level. with a maximum response being 
achieved in the IOI'g Fl + lOJlg V group. At this time point 
also. only the IOJlg F l + IO!lg V group had significant T cell 
memory and this was directed entirely towards the V subuni l. No 
significant T cell memory to the V or Fl subunit was recorded for 
any other group. Previously. animal given 25 Jlg of each subunit in 
a microencapsulated fom1ulation retained a significant T cell 
response to both Fl and V at day 162 1121. h is li kely that the 
recall response is dependent on numbers of T celb recruited on 
initial exposure 10 the subunit amigen. as well a~ on duration of 
exposure. 
The development of an lgG I titre to F 1 and to V wa~ ob~erved 
in vaccinee;,. both in serum and on di rect secretion from spleen 
cells. An lgG l titre is ind icative of an ongoing Th2 respon'e [ 16]. 
Table 4. Determination of titres required to achie1e pcn.:entagc prut~ction 
again~t challenge "ith Y. peui• , ,c. at 107 CFU 
Protectll·~ tnre 
(cunlidencc lunih) 
Percentage protcc:tion lgG I 'pel·ilkn~ mc;1n log 10 lgG I titre 
90 Fl 5·2X 16·08- 4·'1'11 
90 V s n t6·06-~ 57J 
t)(\ I· I +V 10·'17 ( 1197- 10·53) 
'() I- I 4 (1'1 i-194- -1 l6) 
0 V .'i-411 15 55 5 2fiJ 
·o Fl + \' Ill 117 110 4X .. 6J) 
() Fl 4 I h 14-44 1-15) 
0 V 5 Ill l."i 2-1 4 XI I 
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which is the typical response to dosing with purified protein 
antigens in a! hydrogel [ 17]. Recently. the appearance of a pre-
dominantly lgG I titre in animals immunized 5Ubcutaneously with 
the V antigen only in alhydrogel has been positively correlated 
with enhanced survival agai nst injected or aero olized plague (7]. 
Although the KWCV also induced an lgG I respon;e to Fl. it\ 
lower protective efficacy against injected or aerosol challenge may 
be attributed panly to its lower content of Fl amigen. but more 
importantly. to it> deficiency in the V antigen [4.71. 
The total lgG 1 titre to (F 1 + V) correlated with protection. 
Because total lgG I titre has been demonstrated to correlate with 
protection. the titres required for protection against e'calating ... c. 
challenge doses of Y. pesris can be calculated. In combination. the 
subunits were signiticantl y more potent in inducing th.: immuno-
logical correlate of protection ( lgG 1) than the indivitlun l ,uhunit~. 
This suggc,ts that the ,ubunib arc additive in inducing protection. 
HO\ ever, becau,e antit>ody to the individual ~ubunib 'erve, 10 
inhibit very diffcrem vinllem.:e mcchani~m~. the pos~ibilit} tha t the 
subunits are ') nergistic in the protective efficacy they induce 
against Y. pesti.>. cannnt be dismissed. 
This ~tudy ha' identified a valid imtmtnological cwrdatc nf 
protection again'! '.c. 1'. pe.11is. in the mou'c model. Worl. i' 
ongoing 10 determine ''her her Fl- and V -~pecitic lgG I i, the 
only suhcla~' of antibody I'C4Uired for protection agai1N l'.JWHi• 
anti the preci'<: m..:chantsms underlying clcaranc..: of the organi'm 
Tahl~ 5. Cumpar"'"" 111 '.1~.:ine r""""") in term' 11t I;;G I 1mlm·unn .111d 
prot~l.: II H' t.•flicacy 
Fl \ ' 
\ 1-1- V 
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in vacctnec~. However. this ~tudy has idcntilied a correlate of 
protective immunity. the equivalent of which can be sought acros~ 
the ~pecie~ in which the vacci ne i~ trialled. If the correlation of a 
Th2 'uhclas~ of lgG with protection holds true acro~~ the species. 
thi'> wi ll then constitute a surrogate marker of protecti ve immunity 
when the vaccine i~ tria lled in the clinic. 
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Local and systemic immune response to 
a microencapsulated sub-unit vaccine 
for plague 
E. Diane Williamson*§, Gregory J.E. Sharpt, Stephen M. Eley*, 
Peter M. Vesey*i, Teresa C. Peppert, Richard W. Titball* and 
H. Oya Alpart 
Microencapsulated Fl and V sub-unit antigens of Yersinia pestis were used to immunize 
mice intraperitoneally with a combination of 25 j.lg of each of the microencapsulated 
sub-units. The combined microsphere formulation induced both mucosal and systemic 
immunity. There was an additive effect in combining sub-units and the protection afforded 
by the combined microencapsulated antigens was superior to that provided b; the 
administration of any single encapsulated antigen and by the existing whole cell vaccine. 
The protective efficacy of the combined microencapsulated sub-units was further enhanced 
by eo-administering cholera toxin B sub-unit. Microencapsulation of the sub-units offered 
advantages which included depot release of the vaccine in vivo and the facilitation of oral, 
intranasal or inhalational delivery. Therefore, immunization with microencapsulated 
sub-unit antigens was an effective means of generating humoral and cellular responses 
which endowed protective immunity. 
Keywords: microencapsulated vaccine; protective sub-units; plague 
The causative organism of plague in a wide range 
of animals is Yersinia pestis. The vaccines currently 
available for human use comprise heat-killed or 
formaldehyde-killed suspensions of Y. pestis cells or an 
attenuated live strain of Y. pestis (EV76 strain). Strain 
EV76 is a non-pigmented mutant of Y. pestis which is 
sufficiently attenuated to be used as a live vaccine1- 3• 
Although tested and used extensively in the former 
Soviet Union from 1939, the EV76 vaccine is unaccept-
able for use as a vaccine in the Western world due to the 
severity of the side-effects experienced and its question-
able protective efficacy3.4. Whilst injection of whole-cell 
vaccines induced a degree of systemic immunity in man, 
providing some protection against bubonic plague5 there 
was evidence that they did not induce adequate or 
appropriate immunity at mucosal surfaces, particularly 
the lung4 • Furthermore, the killed whole cell vaccines 
induced transient local and systemic side-effects in 
some vaccinees, ranging from mild headaches to severe 
malaise and fever6 . 
A combined sub-unit vaccine for plague which was 
highly efficacious in protecting animals against an 
*DERA (CBD sector), Porton Down, Salisbury, Wiltshire 
SP4 OJQ, UK. t Department of Pharmaceutical and Biologi-
cal Sciences, Aston University, Aston Triangle, Birmingham, 
B4 7ET, UK. tDepartment of Health Sciences, University of 
Sunderland, Sunderland, UK. §To whom correspondence 
should be addressed. (Received 27 February 1996; revised 
28 April 1996; accepted 1 0 May 1996) 
injected challenge with virulent Y. pestis has recently 
been reported7. This vaccine comprised the sub-unit 
antigens Fl and V. Fraction I antigen (Fl) is the major 
protein component of the capsule surrounding Y. pestis 
cells8. The V antigen of Y. pestis is a secreted protein 
which is thought to act both as a regulatory protein 
and as a virulence factor9. Previous work showed 
that immunization of mice with the native F1 antigen 
purified from Y. pestis (nF I) together with purified 
recombinant V (rV) antigen. protected mice against a 
subcutaneous (s.c.) challenge with 1 x I 09 LD50 doses of 
Y. pestis7 and that this level of protection was at least 
three orders of magnitude greater than that afforded by 
the killed whole cell vaccine. 
Previous studies 10- 17 showed that encapsulation of 
various proteins or peptides in biodegradable micro-
spheres composed of poly-DL-lactide (PLA) or poly-DL-
lactide-co-glycolide (DL-PLG) enhanced their systemic 
immunogenicity and made them effective mucosal 
immunogens. MicroencaRsulation conferred a number 
of potential advantages: 8 it prolonged release of the 
vaccine in vivo. reducing the need for boosting the 
immune response 19, it protected the vaccine from harsh 
environments e.g. the stomach in the host, thus permit-
ting the efficient oral delivery of the intact vaccine to 
immunoresponsive tissues 15, and it transformed a solu-
ble protein vaccine into a particulate antigen. thus 
improving uptake into the phagocytic cells of immune-
responsive tissues2° Furthermore, by careful selection of 
sphere size the residence time in the immunoresponsive 
areas of the gut e.g. Peyers patches and other target 
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tissues could be modulated21 , by selecting polymer type, 
the surface characteristics of the spheres e.g. hydro-
phobicity could be modulated and immunogenicity 
enhanced 11 and by eo-dosing with22, or adsorbing 
ligands to the spheres e.g. cholera toxjn B sub-unit 
(CTB), the spheres could be targetted to GM 1 receptors 
on the cells of the gut epithelium and other target 
tissues23·24 . 
In this study, the suitability of the Fl and V sub-units 
for microencapsulation without loss of immunogenicity 
and protective efficacy was investigated. The influence 
of eo-administering CTB on the immune response to 
the microencapsulated sub-units was also investigated 
and the ability of this formulation to induce both 
mucosal and systemic immunity against plague was 
demonstrated. 
MATERIALS AND METHODS 
Preparation of sub-units 
The V antigen was expressed as a fusion protein with 
glutathione-s-transferase (GST) in Escherichia coli. The 
V protein was cleaved from the fusion with Factor Xa 
(Boehringer Mannheim UK Ltd) for 18 h at 22·c and 
recombinant V protein was purified by affinity absorp-
tion, as previously described25. The Fl antigen was 
precipitated from the supernate of Y pestis grown at 
37•c in a chemically defined medium (pH 7.4), by the 
addition of 40% (w/v) ammonium sulphate and purified 
by repeated resuspension and centrifugation of the pellet 
in 20 mM Tris- HCI at pH 87 . 
Microencapsulation of sub-units 
Poly-(L-lactide) (PLA, Polysciences Inc.) of molecular 
weight 2000 D a was used to encapsulate either the Fl or 
V antigens into individual microsphere preparations. 
Microspheres were prepared in batches by means of a 
modification of the single emulsion solvent evaporation 
method described by Beck et a/.19 Briefly, 25 mg of 
the freeze-dried antigen was suspended in 5 ml di-
chloromethane (DCM, Fisons, UK) containing 250 mg 
PLA. This solvent phase was added, with vigorous 
mixing, to an aqueous phase (75 ml) containing 1.5% 
(w/v) of the surfactant polyvinylalcohol (13000-25000 
Da, Aldrich Chemical Co. , Dorset, UK) to form an 
emulsion. The emulsion was stirred until the DCM had 
evaporated, centrifuged (15000g,30 min) and the micro-
spheres were recovered. Subsequently, the microspheres 
were freeze-dried and stored desiccated at 4•c until 
required. The weight of antigen loaded into the spheres 
was determined as a percentage of sphere mass by the 
bicinchoninic acid protein assay27. The spherical struc-
ture was confirmed by scanning electron microscopy 
(Cambridge Instruments Stereoscan 90) and micro-
sphere size was determined by laser diffraction (Malvern 
Instruments Ltd, Mastersizer). 
Animals 
Barrier-bred, pathogen-free female 6-week-old Balb/c 
mice were obtained from Charles-River Laboratories 
UK, and used throughout these studies. 
Immunization 
Dosing with the microencapsulated sub-units was 
carried o ut by the intraperitonea l (i.p.) route in order to 
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assess the potential mucosal immunogenicity, as well as 
the systemic immunogenicity, of the sub-units. The 
killed whole cell vaccine was included in this trial as a 
positive control for the induction of systemic immunity, 
and as such, it was given by the intramuscular (i.m.) 
route recommended for use in man. 
A group of 21 mice received a combination of2S11g of 
each ofPLA-microencapsulated Fl (PLA-FI) and PLA-
microencapsulated V (PLA-V) antigens (Group I) or 
this combination plus 10 11g cholera toxin B sub-unit 
(CTB C-7771 , purified from Vibrio cholerae, Sigma) 
(Group 2). Further groups of 21 mice received 25 11g of 
either PLA-F I or PLA-V (Groups 3 and 4, respectively). 
For dosing, the microencapsulated an tigens were resus-
pended in phosphate-buffered saline (PBS) immediately 
before i.p. injection. The loading of the Fl sub-unit in 
mjcrospheres was 11% (w/w), so that a dose of 25 11-g of 
Fl was delivered in a total mass of 0.22 mg of spheres; 
whilst the w/w loading of the V sub-unit in microspheres 
was 30%, so that a 25 11-g dose of V was contained in 0.08 
mg of spheres. The mean particle diameter of the 
microspheres was 2 f.lm. The required mass of micro-
spheres was re-suspended in 100 11-l PBS per animal for 
injection. Animals were boosted with the respective 
antigen(s), as appropriate, on days 14 and 28. 
A further group of21 mice (Group 5) was primed i.m. 
with 100 11-l of the killed whole cell Greer vaccine 
(purchased from Greer Laboratories, Lenoir, N. 
Carolina). This represented a one-fifth of the human 
dose and comprised ea 2 x 108 formaldehyde-killed Y 
pestis cells. This dose was repeated on day 14 of the 
schedule, to effect a booster immunization, according to 
the schedule recommended for use in man. 
Control groups, each of 21 mice, were untreated 
(Group 6), or received (Group 7) 10 11-g i.p . of CTB in 
100111 PBS. 
Blood and tissue sampling 
Tail vein blood samples were collected from indi-
vidual animals on days 14 and 28. At these time-points 
also, a pooled sample of faecal pellets (FPs) was 
collected from each treatment group during a 0.3 h 
period. On day 45, six animals selected at random from 
each of the treatment groups, were anaesthetized i.p. 
with 6 mg of Domitor (Norden Laboratories) and 27 11g 
of Ketalar (Parke-Davies) before collection of blood 
samples by cardiac puncture. Subsequently, individual 
anaesthetized animals were humanely killed by cervical 
dislocation prior to the collection of gut washings 
and removal of the spleen. For the collection of gut 
washings, a 50 cm length of gut from the upper small 
intestine was removed from each animal into a petri 
dish. The gut was sectioned longitudinally and the 
luminal surface was carefully scraped into 4 ml of 
ice-cold lavage medium (1 mM phenylmethanesulphonyl 
fluoride, 1 mM iodoacetic acid, 0.001% soyabean type 
1- 5 trypsin inhibitor and 10 mM EDTA). 
On day 60, 15 animals were removed from each 
treatment group for challenge with Y pestis, and the 
remaining two animals in each treatment group were 
killed on day 162 for splenectomy. 
Analysis of blood samples 
The measurement of isotype and titre of the serum 
antibody response was performed by means of a 
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modified ELISA26• Briefly, serum samples were 
aliquoted to microtitre plates pre-coated with either the 
Fl or V antigens (5 jig ml - 1 in PBS). Binding of serum 
antibody was detected with peroxidase-labelled second-
ary antibody to mouse polyvalent lg (lgG+IgA+lgM) 
(Sigma), mouse lgG 1 (Sera-Lab, Crawley Down, UK) 
mouse IgG2a (Sera-Lab) and mouse lgA (Sigma), each 
used at a maximum dilution of 1 in 2000. Antibody titre 
was estimated as the maximum dilution of serum giving 
an absorbance reading 0.1 units above background noise 
and was presented as the relative titre (reciprocal of 
dilution x optical density) and from this, mean 
titres± standard error of mean (S.E.M .) were derived 
per treatment group. All samples were tested in 
duplicate. Samples from each of the control groups (6 
and 7) were used to blank all ELISA's. 
Analysis of FPs 
The FP mass collected per treatment group was 
weighed and placed in 5 ml PBS+0.02% (v/v) Tween 20 
at 4"C for 48 h, with gentle agitation. Subsequently, 
samples were centrifuged (1000 revs min - 1, 10 min, 4"C) 
and the supernate was collected and rapidly frozen 
(- 20"C), pending analysis. Supernates were assayed by 
ELISA for determination of lgA titre. The relative titre 
was determined as above and presented as a mean titre 
mg- 1 FP± S.E.M. per treatment group, after subtrac-
tion of the background signal provided by assay of 
samples derived from each of the control groups. 
Analysis of gut washings 
Gut washings were sonicated on ice (30 s, mid-
amplitude, Kontes sonic probe) to extract immuno-
globuJins from mucin and centrifuged (20000g, 45 min, 
4"C). Supernates were separated and rapidly frozen 
( -70"C) prior to lyophilization. Lyophilized samples 
were reconstituted in 200 jil PBS for assay of specific lgA 
content by ELISA and relative titre was determined as 
above. 
Spleens 
Spleens were removed from individual animals into 
ice-cold Dulbeccos Modified Eagles Medium (DMEM) 
and amalgamated by treatment group, prior to the 
preparation of crude suspensions of spleen cells to 
measure antibody secretory activity. A suspension of 
purified T cells was also derived for each treatment 
group, by density gradient separation of lymphocytes 
from spleen homogenates, folJowed by immunomagnetic 
selection of T cells25 to measure the in vitro recall 
response to FI and V antigens. 
Assay of antibody secreted by spleen cells in vitro 
A modified ELISA was used in which sterile micro-
titre plates (Oynatech) were coated with either Fl or V 
antigens in PBS (5 jig ml - 1) overnight at 4"C, under 
aseptic conditions. Subsequently, the plates were 
blocked with DMEM plus 10% (v/v) foetal calf serum 
(FCS) (I h, 37"C), prior to aliquoting 200 jil of the 
individual spleen cell suspensions derived from each 
treatment group. The cells were diluted twofold on the 
plate and incubated for 20 h (37"C, 5% C02). The plates 
were subsequently gently washed in PBS ( x 3), 
PBS+0.02% (v/v) Tween 20 ( x 3) followed by a final 5 
min soak in PBS+0.02% (v/v) Tween 20, prior to the 
addition of the peroxidase-labelled anti-mouse Ig conju-
gate. Incubation was continued for 20 h (+4"C) prior to 
automated washing ( x 4) in PBS+0.02% (v/v) Tween 20 
and addition of a soluble peroxidase substrate 2,2-azino-
bis(3-ethylbenzthiazoline-6-suJphonic acid) (ABTS). 
Following a 20 min incubation colour development was 
quantified by measuring the absorbance at 414 nm 
(Titertek Multiskan MCC, ICN Flow). Spleen cells 
derived from each of the control groups were used to 
blank the ELISA. 
T cell proliferation to Fl and V 
The in vitro recall response to equimolar amounts 
(1.43 nmol) of Fl (25 jig ml - 1) and V (50 jig ml - 1) 
was measured in T celJs aliquoted at constant dilution 
(minimum l x 104 well - 1) into microtitre wells pre-
coated with autologous peritoneal macrophages25. Pro-
liferation was quantified by the incorporation of 
eHJthyrnidine into cells from which the stimulation 
index (SI) was derived as: mean counts per minute 
(c.p.m.) per treatment group/mean c.p.m. per negative 
control. The SI was calculated from a minimum of three 
replicates. Control samples were provided by T -cells 
isolated from each of the control groups. 
Challenge with Y. pestis 
On day 60, the 15 remaining animals in each treat-
ment and in the untreated control group (6) were 
challenged with Y pestis strain GB in the dose range 
2 x 103- 2 x 105 colony forming units (c.f.u.) per mouse. 
Strain GB was isolated from a fatal human case of 
plague and has an LD50 of < 1 c.f.u. in BaJb/c mice by 
the s.c. route28. The challenge inoculum was cultured in 
Blood-Agar Base broth at 28"C28. Mice were challenged 
s.c. with Y pestis and then closely observed over a 
14-day period for the development of symptoms, and 
where possible, time to death (TTD) was recorded. 
Malaise was noted in some animals as immobility and 
ruffled coat; humane end-points were strictly observed 
so that no animal became distressed. Animals which 
succumbed to the challenge were autopsied. Livers and 
spleens were scored by eye for enlargement and any 
evidence of abnormality was noted. Samples of blood, 
sections of liver and spleen, and swabs from the s.c. 
challenge site, were smeared onto Congo Red agar or 
Yersinia selective agar (YSA, Oxoid, UK), and the 
plates were incubated at 28"C and observed for growth 
after 48 h . At the end of the 14-day observation period, 
survivors were killed and tissues were removed for 
bacteriological and gross morphological analysis, as 
above. 
Statistical analysis 
A Student's /-test was applied to determine the sig-
nificance of the difference between treatment group 
means29. 
RESULTS 
Antibody titre in serum 
Animals dosed with PLA-Y (Groups I , 2 and 4) 
responded with the development of a serum antibody 
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Table 1 Development of F1- and V-specific antibody titres (total immunoglobulin) in serum through the immunization schedule 
Serum (relative titre) 
Anti-F1 Anti-V Anti-F1 Anti-V Anti-F1 Anti-V 
lg lg lg lg lg lg 
Group No. Day 14 Day 14 Day 28 Day 28 Day 45 Day 45 
1 1.72±0.14 37.4±3.17 2.1±0.21 563.8±35.75 2.35±0.88 7770±244.4 
2 5.98±2.67 65±2.94 4.2±0.18 599.7±18.55 5.8±0.64 10899±520 
3 0.36±0.01 0 1.82±0.03 0 10.6±0.35 0 
4 0 60.5±4.75 0 179.84±14.93 0 5158±181 
5 406.4±26.7 0.8±0.03 288±19.8 0 3488±486. 12 0 
Table 2 F1- and V-specific antibody titre in FPs and gut washings through the immunization schedule 
FP (relative titre mg-' FP) 
Anti-F1 Anti-V Anti-F1 
lgA lgA lgA 
Group No. Day 14 Day 14 Day 28 
1 0.25±0.17 0.2±0.01 0.38±0.33 
2 0.1±0.04 0.02±0.002 18.43±5.0 
3 0.21±0.13 0 0.2±0.01 
4 0 0.34±0.08 0 
5 0 0 0 
titre to V by day 14. For Groups 1 and 2, this titre had 
increased tenfold by day 28, compared with a threefold 
increase for Group 4 (Table 1). The response to PLA-Fl 
(Groups 1, 2 and 3) was much slower to develop and 
more limited (Table 1) so that by day 28 the serum titre 
to Fl for Groups 1 and 2 was ea lOO-fold less than that 
to V. 
By day 45, however, the PLA-V formulation had 
induced titres 103 to 104-fold higher than the initial titre 
at day 14 (Table 1). In contrast, the anti-Fl titres 
induced by the PLA-FI formulation changed little 
between days 28 and 45; the exception was in Group 3 
where the anti-Fl titre at day 45 was tenfold higher than 
at day 28. Group 2, dosed with combined micro-
encapsulated sub-units plus CTB, had significantly 
increased anti-V titres at day 14 (P<O.OOl), day 28 
(P<O.Ol) a nd day 45 (P<O.Ol), respectively, compared 
with Group 1. Similarly, anti-Fl titres in Group 2 were 
significantly increased compared with Group 1 at day 28 
(P<O.OOl) and day 45 (P<O.Ol). Thus eo-administration 
of CTB enhanced the development of specific antibody 
titres. By comparison, the Greer vaccinees (Group 5) 
developed a substantial a ntibody titre to Fl in serum by 
day 45. This a nti-Fl titre was 102 to 103-fold higher than 
that measured for groups dosed with PLA-Fl; no serum 
antibody titre to V was detectable in these animals. 
Antibody titre in FPs and gut washings 
At days 14 and 28, an lgA titre to either Fl or V was 
detectable in FPs from a ll groups dosed with PLA-Fl or 
PLA-V (Table 2). When gu t washings collected at day 45 
were assayed, IgA titres with V specificity were detected 
in a ll PLA-Y-dosed anima ls whilst anti-Fl lgA titres 
were detected in all PLA-Fl-dosed animals. The anti-F l 
lgA titres were between 5- a nd 20-fold lower than the 
anti-V titres. Although the eo-administration of CTB 
with PLA-Fl and PLA-Y had no positive effect on titres 
in FPs at day 14, by day 28 the anti-FI titre in Group 2 
was significantly increased over that of Group I 
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Gut washings (relative titre) 
Anti-V Anti-F1 Anti-V 
lgA lgA lgA 
Day 28 Day 45 Day 45 
0.28±0.11 0.99±0.62 4.86±0.16 
0.11±0.009 0.36±0.04 8.0±1.47 
0 0.1±0.04 0 
0.03±0.002 0 5.76±0 
0 0 0 
Table 3 F1- and V-specific antibody titre secreted by spleen cells at 
day 45 
Group No. Anti-F1 lg Anti-V lg 
1 0.27±0.05 3.68±0.91 
2 0.11±0.02 3.15±0.08 
3 0.05±0.007 0 
4 0 2.5±0.006 
5 0.35±0.05 0 
(P<O.Ol) . At day 45, animals in Group 2 had a signifi-
cantly increased anti-V titre (P<O.Ol) in gut washings, 
compared with Group 1 animals. No lgA titre to Fl or V 
was detectable in Greer vaccinees through the schedule. 
Antibody secreting cells 
At day 45, Fl- and/or V-specific antibody directly 
secreted by spleen cells in vitro could be detected by a 
modified ELISA (Table 3). In all groups dosed with 
PLA-FI a nd PLA-Y, antibody to both Fl and V was 
detectable, although the response to V predominated. 
By comparison, spleen cells isolated from Greer 
vaccinees secreted antibody with specificity for Fl only. 
eo-administration ofCTB to Group 2 had no significant 
effect on the level of antibody secretion measured 
directly from spleen cells. 
lgG sub-classes induced to microencapsulated Fl and V 
In groups dosed with PLA-Fl and PLA-V, the serum 
response to Fl at day 45 was evenly distributed between 
the lgG 1 and lgG2a sub-classes (Table 4). In contrast, 
the response to V was predominantly of the IgG 1 
sub-class. The serum response to Fl in Greer vaccinees 
was 92% IgG 1• 
Protection against challenge 
In order to compare the protective efficacy of 
immunization with the combined microencapsulated 
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Table 4 Percentage distribution of F1 - and V-specific lgG sub-
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0 64 36 
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Figure 1 T-cell in vitro recall response to F1 and V on day 162. 
Stimulation indices were measured for T-cells isolated from pairs of 
mice derived from treatment Groups 1-5. The stimulation indices 
against F1 and V differed significantly (P<0.01, P<0.001, respect-
ively) between Groups 1 and 2 
sub-units, against that provided by the Greer vaccine, 
mice were challenged s.c. with 2 x 105 LD50 doses28. By 
day 14 post-challenge, there was a 60% survival rate in 
Greer vaccinees and in animals dosed with either 
PLA-F1 or PLA-Y alone (Groups 3 and 4, respectively) 
(Figure 1}. Combination dosing with PLA-F1 and 
PLA-V (Group 1) increased the survival rate to 80%. 
However, dosing with PLA-F l and PLA-Y, admixed 
with CTB (Group 2) resulted in 100% survival. Thus the 
combined microencapsulated formulation, adminjstered 
with CTB, was fully protective against challenge with 
virulent Y. pestis with no observable symptoms of 
plague during the post-challenge observation period. 
T -ceU recall response in vitro to Fl and V 
At day 162, the remaining two animals from each 
group immunized with PLA-F1 and/or PLA-V, had 
recall responses to equimolar amounts of F1 and V, as 
demonstrated by the abi lity of their isolated T-cells to 
proliferate in vitro (Figure 2). In all groups (except 
Group I) immunized with microencapsulated F1 or V, 
the recall response to V predominated with stimulation 
indices of49.24±3.17 and 60.77± 0.39 in Groups 2 and 
4. The recall response to Fl was lower with stimulation 
indices of 6.64 ± I and 16.49 ± 7.22 in Groups 2 and 3. 
Group 2, dosed with PLA-Fl and PLA-Y admixed with 
CTB, had significantly increased recall responses to Fl 
(P<O.OJ) and V (P<O.OO I}, compared with Group I. 
Thus enhanced T-cell recall responses were observed for 
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' I Gl 
.. 
g 
> 60 . , E 3,4,5 ~ 
il 40 3 l ~ 
20 ' 
0 
I J 9 10 11 ll 13 14 
Days 
• Croup I • Group 2 Group 3 
" Group 4 • GroupS Group 6 
Figure 2 Percent survival of immunized Balb/c mice after chal-
lenge at 2x105 c.f.u. Y. pestis strain GB. Mice were immunized i.p. 
with PLA-F1+PLA-V (Group 1); PLA-F1+PLA-V+CTB (Group 2); 
PLA-F1 (Group 3); PLA-V (Group 4); or i.m. with the killed whole cell 
vaccine (Group 5); or were untreated (Group 6) 
animals dosed with PLA-F l +PLA-V administered with 
CTB, even at 5 months after the last immunization. 
Post-mortem analysis of challenged animals 
Microbiological analysis of tissues removed from ani-
mals that succumbed to the challenge confirmed that 
plague was the cause of death, since Y. pestis was 
recovered from the blood, livers and spleens of these 
animals. Animals dosed with the combined microencap-
sulated sub-units, had effectively cleared Y. pestis from 
their tissues by day 14. No gross morphological change 
was noted in organs from these animals on post-
mortem, apart from some enlargement of the spleen, 
indicating that there had been a recent acute infection. 
DISCUSSION 
In this study, eo-immunization with PLA-Fl and 
PLA-V provided superior protection against an injected 
challenge with virulent plague compared with that 
afforded by the existing whole cell Greer vaccine. As 
before, the individual sub-units were less protective than 
the combined sub-units, but a new finding was that 
maximum protection was achieved when the combined 
sub-units were admixed with CTB. 
PLA-F1 and PLA-Y administered i.p. induced a sys-
temic immune response as demonstrated by the existence 
of antibody secreting cells with Fl and V specificity in 
the spleens of microencapsulated sub-unit immunized 
animals at day 45. Circulating antibody titres to the V 
and Fl antigens were also observed in these animals. 
The gradual development of a serum antibody response 
to PLA-Fl and PLA-Y may well reflect the slow depot 
release of these immunogens from microspheres in vivo. 
By day 45, however, substantial anti-V titres were seen 
in animals dosed with PLA-Fl and PLA-Y and these 
predominated over serum titres to Fl. The w/w loading 
of Fl into PLA microspheres was calculated at 11%, 
whereas the loading of V into the PLA-V formulation 
was 30% (w/w). Although a 2.6-fold greater mass of 
PLA-FI was administered a t each dose per animal, to 
compensate for the poorer loading efficiency of PLA-Fl , 
it may be that a proportion of this microsphere mass was 
lost (excreted or excluded) without being taken up by 
antigen-presenting cells (APC) to initiate an immune 
response. 
The distribution of anti-F I and anti-V activitiy in IgG 
sub-classes indicated that the response to PLA-F l was 
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neither clearly Th 1 or Th2, since lgG2a and IgG 1 were 
present in equal proportion, whereas the response 
to PLA-Y was predominantly a Th2 (lgG1) response. 
The amount of encapsulated sub-unit may influence 
the differential activation of Th sub-sets. The anti-FI 
activity induced in response to the killed whole cell 
vaccine was predominantly a Th2 response, indicating 
that sub-units presented in these two particulate 
formulations (killed whole cells and inert microspheres) 
are similarly processed by APC. 
The combined microencapsulated formulation also 
induced a mucosal response. Fl- and V-specific lgA 
titres were detected in the FPs of animals dosed with 
microencapsulated sub-units. The appearance of anti-
body in FPs indicates the involvement of the gut-
associated lymphoid tissue (GAL T) in the immune 
response to the microencapsulated sub-units and this 
was confirmed by the detection of a local production of 
lgA with Fl and V specificity in gut washings from 
PLA-Fl and PLA-Y-dosed animals. 
Thus i.p. immunization with microencapsulated sub-
units effectively induced both systemic immunity and 
local immunity in GALT. Although the normal route by 
which antigen is taken up by the GAL T is via the 
epithelial surfaces of the gut lumen, Peyer's patch (PPs) 
sites of the GAL T can also be accessed via the serosal 
surface if antigen is administered by the i.p. route. Early 
studies by Pierce and Gowans30 suggested the potential 
for i.p. immunization in stimulating an intestinal IgA 
response. These experiments were conducted using 
Freund's complete adjuvant which created antigen 
depots in the mesentery and on the serosa and pre-
sumably allowed antigen access to PPs by establishing 
peritoneal inflammation and increased serosal per-
meability. Histological studies in our laboratories 
showed that when fluorescent latex particles were 
delivered i.p. to rats and mice, the particles appeared in 
the intestinal lamina propria. Furthermore, work by 
Seymour et al. 31 demonstrated that polystyrene particles 
(size range 0.3- 3 ,urn) are able to exit the peritoneal 
cavity to accumulate in diverse tissue locations after i.p. 
administration. Particles were also detected within the 
omentum, mesentery network and gastrointestinal 
mucosa. In this study, a biodegradable microsphere 
formulation incorporating the Fl and V antigens was 
used to produce a similar effect. 
The immunity induced to Fl and V by this formula-
tion, was further enhanced by eo-administration of 
CfB. This study utilized a commercial source of purified 
CTB, which may have contained trace amounts (0.17%) 
of cholera toxin A sub-unit (Cf A). It is difficult to 
isolate the immunopotentiating activity of CTB from the 
known adjuvanticity inherent in traces of the holotoxin 
which may enhance antigen presentation by macro-
phages22 through a sequence of events involving GM 1 
receptor binding of macrophages, followed by ADP-
ribosylation and increased intracellular cAMP-'2. Re-
combinant CTB has not been demonstrated to have 
adjuvant activity as such-'·' but it has been shown to have 
unique immunodominant B-and T-cell epitopes34 which 
confer potent "carrier" effects. CT-containing CfB has 
been demonstrated to have mucosal adjuvanticity 
through its ability to bind mucosal APC35- .H and 
enhanced the transepithelial influx of eo-administered 
vaccine into immunocompetent cells in the nasal mucosa 
leading not only to mucosal immunity but also to 
1618 Vaccine 1996 Volume 14 Number 17/18 
systemic immunity-'5. The results of this study demon-
strated that when CfB was admixed with PLA-FI and 
PLA-V and injected into the peritoneal cavity, it 
enhanced both the mucosal and systemic immune 
response to FI and V. More studies are required to 
probe the membrane and intracellular events which 
occur in mucosal APC exposed to CTB plus micro-
encapsulated vaccine, but clearly the combination of 
PLA-Fl and PLA-V administered together with CTB, 
resulted in maximum protective efficacy against chal-
lenge with virulent Y pestis. Dosing with PLA-F I and 
PLA-V effectively induced a long-lived cell-mediated 
immune response as demonstrated by the significant 
proliferative response of T cells isolated from these 
animals, 5 months after the last immunizing dose. 
Although this analysis was conducted on T-cells isolated 
from only two animals per treatment group, it indicated 
that the specific CMI response induced to each sub-unit, 
was significantly enhanced in animals dosed with 
PLA-Fl and PLA-V adjuvanted with CTB, compared 
with animals dosed with the combined microencapsu-
lated sub-units only. Thus the microencapsulated sub-
units each induced an antibody and cell-mediated 
immune response, with anti-V activity predominant. The 
apparent immunodominance of the V antigen is of 
interest in view of its perceived anti-host and anti-
inflammatory activities in nature-'8-4 1• No anti-V activity 
was observed in any immune response parameter as-
sayed in Greer vaccinees. The fsrotective advantage 
afforded by the V antigen is clear7· 5 and thus lack of the 
V antigen might be regarded as a deficiency in the Greer 
vaccine. The effective induction of mucosal as well as 
systemic immunity is an important attribute of an im-
proved vaccine for plague, since immunity at the lung 
surface is essential to protect against the pneumonic 
form of the disease whilst systemic immunity is required 
to protect against bubonic plague. The identification of 
a microencapsulated formulation in which to deliver the 
sub-unit antigens has significant potential and provides 
the basis for further studies in which local immunization 
e.g. of the GALT and also of the bronchial-associated 
lymphoid tissue is triaJied in order to maximize protec-
tive mucosal immunity against plague. 
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Immunization with Live Recombinant Salmonella typhimurium 
aroA Producing Fl Antigen Protects against Plague 
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An attenuated Salmonella typhimurium strain which expressed the Fl capsular antigen of Yersinia pestis was 
constructed by transformation of S. typhimurium SL326l with plasmid pFGAL2a, a derivative of pUC18 which 
contained the cafl gene without the leader sequence. The recombinant was used to vaccinate mice intragas-
trically and intravenously. The immunity induced was able to protect mice against challenge with a virulent 
strain of plague. Protection correlated with the induction of high titers of immunoglobulin G in serum samples 
and a specific T-cell response. 
Yersinia pestis is the causative organism of plague in a wide 
range of animals and in humans. It is extremely virulent and 
results in a high rate of mortality. Its virulence is due to a 
complex array of factors encoded by both the chromosome and 
three plasmids. These virulence factors include the Lcr genes 
(33), a fibrinolysin (32), and a capsule. 
The vaccines currently available for the prevention of plague 
a re either killed or attenuated whole-cell preparations. They 
are highly heterogeneous with variable endotoxin content and 
cause a range of side effects, making them unsuitable for wide-
spread use (17, 22, 26). Moreover, such vaccines are suitable 
only fo r parenteral delivery, and although they may effectively 
induce systemic immunity, parenteral immunization may not 
be effective as a means of inducing immunity at vulnerable 
mucosal surfaces (20). The identification of protective subunits 
of Y. pestis which could be delivered directly to mucosal sur-
faces to induce protective responses may faci lita te the devel-
opment of an improved vaccine against plague. One such can-
didate subunit is the fraction l (Fl) antigen, which is a major 
component in heterogeneous whole-cell vaccines (9, 36). 
The capsule that surrounds Y. pestis cells is composed of a 
prote in-polysaccharide complex; the purified protein compo-
nent is F1 antigen (2), with a molecular mas of 17.5 kDa (3). 
Fl is fully expressed only at 37°C and is believed to confer 
resistance to phagocytosis, possibly by fo rming aqueous pores 
in the membranes of phagocytic cells (27). The detection of 
antibodies against Fl is the basis of standard serological tests 
for the surveill ance and diagnosis of plague as infected animals 
and patients produce a strong antibody response to this anti-
gen (30, 36). 
The cafl gene tha t encodes Fl antigen has been cloned and 
sequenced previously (12). Intramuscular (i.m.) immunization 
of BALB/c mice with recombinant Fl purified from Esche-
richia coli induced high titers of Fl -specific antibody and con-
ferred protection against parenteral challenge with 105 virulent 
plague bacilli (31 ). Other workers have shown that Fl is im-
munogenic in humans by the subcutaneous route and that the 
human antiserum so derived affords significant passive protec-
tion in mice (23). Purified Fl has been shown not to induce 
protect ive immunity by the intragastric (i.g.) route, a lthough it 
did induce protective immunity by intraperitoneal (i.p.) admin-
• Corresponding author. Phone: 44-980-613320. Fax: 44-980-613284. 
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istra tion in mice (35). The lack of response following oral 
immunization may have been due to either inadequate dosing 
with Fl , resulting in the induction of oral tolerance, or destruc-
tion of the antigen by stomach acid or digestion. 
Attenuated aromatic acid-dependent (aro) Salmonella typlti-
murium stra ins have been well characterized as carriers for 
various heterologous antigens (7, 1 0). These vaccine stra ins are 
capable of colonization of the gut mucosa and can therefore be 
used to deliver foreign antigens directly to gut-associated lym-
phoid tissue, such as Peyer's patches, effectively inducing a 
local mucosal immune response in the gut. Immune stimula-
tion of the gut mucosa allows induction of immunity via the 
common mucosal immune system (4, 19) at o ther distant mu-
cosal sites, particularly the respiratory tract (1, 11). In mice, S. 
typltimurium organisms delivered orally can a lso ach ieve sys-
temic invasion from the mucosal surface of the gut to the 
lamina propria and then via draining mesenteric lymph nodes 
to the liver and spleen (8, 15, 18, 25) with the subsequent 
induction of systemic immunity. 
In this study, the cloned cafl gene was expressed in an aroA 
S. ryphimurium mutant and the resulting construct was assessed 
for the abi li ty to protect mice by the i.g. route against cha llenge 
with a vi rulent plague strain. 
MATERIAL AND METHODS 
Bacterial s trains and culti"ation. Y. pestis MP6 was grown aerobically at 28•c 
in blood agar base broth (pH 6.8) which contai ned the following (in grams per 
liter of distilled water): Proteose Pe pto ne, 15: li\'er digest, 2.5; yeast extract, 5: 
NaCI. 5: supplemented with 80 ml of 0.25% hem in in l/100 N NaOH. S. typhi-
munum SL3261 (13) and LB5010 (18) were kindly provided by B. A. D. Stacker. 
Stamford University. and G. Dougan, Impe rial College, London, United King-
dom, respectively. £. colt JM 109 and S. typhimurium strains were cultured and 
stored as de,cribed by Sambrook et al. (29). 
Cloning of Cll[l. DNA was isolated from Y. pestis by the method of Marmur 
( 16). A DNA fragment that e ncoded the open reading frame of Fl without its 
signal sequence was a mplified by PCR. Oligonucleotides were prep:ored with a 
Beckman 200A DNA synthesizer for use in PCR. Oligonucleotide GA T C 
GAGCfCGGCAGAlTIAACTGCAAGCACC (FI/5'B) correspond• to the 
first 11 bases of cafl immediately following the nucleotide sequence which 
encodes the Fl signal 'equence (underlined) with an additional 5' region which 
encodes a Sac! site (boldface). O hgonucleoudc CAGGTCGAGCI'CGTCGACG 
G1TAGGCTCAAAGTAG (FI/J"A) is complementary to the sequence which 
c ncod~s a putative ' tcm-loop structure downstream of the ea[/ termination 
C<l<lon. to \\ hich a 5' region which encode> Sac! and Acct 'lie' (hold face) ha' 
been added. A DNA fntgmenl '"" obtamcd after 35 cycles of amplifie<llion 
(95 C. 15 s: SO"C, 15 >: 7l C, 30 s) (Pcrkin·Elrncr <J600 GcneAmp PCR >ystcm). 
The fragment wa\ purified, dige"cd with Sac! and Accl. and cloned into pia~· 
m1d pUCIK 10 form an in-frame fu; ion with the initial 17 amino acids of 13-ga· 
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la~ln>idasc. C\prc,'led from. the lac promoter. ll•i> construct was dcs1gnated 
pFGAL2a and tran>furmed m tu£. mh JM 109 hy clcctmporation. Thi> pla~mid 
constn•ct ""' de>ignatcd pFGAL2a. After transformation mtn £ . coh JM l(l<J. the 
plasmid was i~olated, it> authent icity was confi rmed. and the plasmid was elcc-
troporatcd inw S. 1)7Jirimunum LB5011l Plasmid pFGAL2a isolated from S. 
typlrimunum LB5010 wa> clcctropor.lled into S. o·plrimurium SL3261. This con-
Mruct wa.~ de>~gnated S. /)7Jirimunum/pFGAL2a. A culture of £. coli which 
contained the pFGAL2a plasmid wa' grown at 37"C with shnking in Luria hrmh 
which conwined I mM isopropyl-13-o-thiogalactopyranosidc {IPTG) for Ill h. 
Whole-cell ly,a tcs a nd pcriplasmic <1nd cytopla•mic fractions of hactcria were 
prepared as dco;crihed by Sambrook et al. (29). 
Ex11ression of Fl inS. typlrimurium. The pFGAL2a plasmid was isolated by the 
method de cribcd by Sambrook et al. (29). Purified plasmid wns clectropurated 
into S. l)plrimurium LB5010 (r - m'). Modified pFGAL2a was subsequently iso-
lated from LB5010 for e lcctropora tion imo S. typlrimurium SL3261 (aroA Iris). 
The expression of Fl was examined by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SOS-PAGE) and Western blolling (immunoblolling). These 
procedures were performed as described by Hunter et al. ( 14). Purified F l (2 mg 
ml' 1) was produced and purified from bacterial cell culture {3). Blots were 
probed with Fl-specific polyclonal antisera raised in sheep immunized with 
Culler USP vaccine (dose equivalen t to 4 x 10" formaldehyde-killed Y. pestis 
organisms), and bound antibody was detected wi th a horseradish peroxidase-
labelled donkey anti-sheep immunoglobulin G {lgG) a ntibody (Sigma). Alter-
natively, lgA monoclona l antibody (MAb) F1 3G8-1 {American Type Culture 
Collection) or lgG MAb YPFI-11 (U.S. Army Medical Resea rch Institute for 
Infectious Diseases), both specific for native Fl, was used in Western blots. 
Periplasmic and cytoplasmic fractions were prepared for SOS-PAGE and West· 
ern blotting. 
. S .. ?'Pitimunttm cons~ructs were checked for auxotrophic phenotype by the 
mab1hty to grow on m1mmal media which contained histidine without supple-
~cnts of a~om.atic amino acids and for the expression of smooth lipopolysaccha-
nde by lys1s w11h phage P22 before immunization experime nts. 
Quantification or Fl production during in vitro culture. S. typltimurium/ 
pFGAUa and S. typltimurium/pUC I8 constructs were grown in Luria broth 
which conta ined 25 J.Lg of ampicillin ml - 1. The viable cells in each culture were 
enumerated on L-agar which contained 25 J.Lg of ampicillin ml - 1. AJiquots of cells 
removed from culture in stationary or logarithmic phase were treated as follows: 
cells were harvested by centrifugation and resuspended in I ml of phosphate-
buffered saline (PBS). The cell suspension was frozen (-20"C), thawed, and 
sonicated 12 times for 30 s each time (Braun sonicator at maximum power: 
25-mm-diameter probe) on ice. Sonicates were analyzed for Fl content by en-
zyme-linked immunosorbent assay (ELISA). 
Each sample and a sta ndard solution of Fl (10 J.Lg/ml) were doubly diluted in 
PBS across a microtiler plate . After incubation overnight at 4•c, well con te nts 
were removed and replaced with 100 J.LI of blocking solut ion (I% skim milk 
powder in PBS) per well. After blocking for I h at 37"C, the plate was washed 
three times in PBS with 0.02% Tween, and 100 J.LI of mouse polyclonal anti-FI 
serum diluted 1:500 in blocking solution was aliquo ted into each well and incu-
bated for I h at 37"C. The plate was washed, and 100 J.LI of peroKidasc-labelled 
anti-mouse lgG (Sigma) diluted 1:1 ,000 in blocking solution was a liquoted into 
each well. After incubation (I h, 37•q, the pla te was washed five times and 100 
J.LI of 2,2' -azino bis(3-ethylbenzthiazol ine-6-sulfonic acid) substrate (ABTS) (Sig-
ma) was added to each well. The A.,. of the plate was read. From absorbance 
readings, a standard curve was constructed and the concentrations of Fl in 
samples were derived. 
Stability or constructs. For inoculation into mice, bacteria were grown stati-
cally at 37•C O\'ernight in Luria broth which contained 25 J.Lg of ampicillin ml - 1. 
Bacteria were washed and di luted in PBS as required. Five female BALB/c mice 
(supplied and used at 6 weeks of age; Charles River Laboratories) we re inocu-
lated intrav~nously (i.v.) with either 5 X 10' or 5 X 107 S. l)pltimurium/pFGAUa 
cons_truc~s m 100 J.LI o f PBS. Control mice were inoculated similarly with S. 
f)plumuntml pUCI8 constructs. Mice showed no ill effects fo llowing inoculation. 
After 7 days. mice were sacrificed by cervical dislocation and livers and spleens 
were remo"ed. Organs were homogenized in 10 ml of PBS with a s tomacher 
(Seward Medical Ltd.) on maximum setting for 2 min. The homogenate was 
serially diluted in PBS and plated onto L-agar or L-agar which conta ined 25 J.Lg 
of ampicillin ml 1. 
Immunization of mice. Eighteen male BALB/c mice (supplied and used at 6 
weeks of age: <;"harlcs-River Labonuories) were inoculated i.v. on days I, 7, and 
14 with 5 X Ill S. typltimwium/pFGAL2a constructs in 200 J.LI of PBS. An equal 
number of age-matched mice (11 = 18) were dosed i.g. by gavage with approxi-
mate ly 10 111 S. f)pltim urium!pFGAL2a constructs in 200 J.LI of I'BS on days I. 7. 
and 21. Ampicillin trihydrate susp.-nsion {150 mg ml- 1; Penbritin injectable 
suspension POM : SmithKiine Beecham Animal Health) was given suhcutane-
ou,ly for 5 day< (50 J.LI daily) after each inoculation in the hope of stabilizing the 
pla,mid. Control mice were immunized i.v. (11 = If!) and i.g. (n = 18) with S. 
f)phimuntml pUC18, i.m. (11 = 15) "ith Cuuer USP vaccine (dose equivalent to 
4 X 10" orgamsms), or i.p. (11 = 15) with 10 J.Lg of purified Fl in 200 J.LI of a I: I 
emulsion of PBS with incomplete Freund's adjuvant (Sigma). 
Challenge or immunized mice. Si~ weeks after the fina l immunizing du>e. fi\'C 
mice from e.l,·h t.g. and i.v. inoculated and control group were ancsthetizcd i.p. 
\\llh a cucktali of Domitor ( urden u•boratoric') (6 mg do>e 1) and Kctalar 
INFECT. I MMUN. 
(Parke-Davis) (17 IL£ do'e 1). hlood "'" "'mplcd hy cardiac puncture. and then 
the mice "ere sacrificed hy cervical d1,locatio n with remmal of lhcrs and 
spleens. li\'er' "ere homogenized and plated onto 1 -agar 10 confirm that all 
Sttlmonella organi>m' had been cleared. The 11) remaining mice in each group 
were challenged suhcutaneously with a mean doo;c of 51 CFU of Y. pesti< GB per 
mouse. Strain GB \\3\ isolated from a plague patient and has hcen sho"n 10 he 
virulent in mice \\ith a 50rr lethal dose (LD,11) of approximatdy I CFU per 
mouse (21!). 
Analysis or samples. (i) Blood scrum. Scrum samples were screened for an-
tibodies ( lgG and lgA) ~pecific for Fl hy u~ing a modification of the ELISA 
procedure deM:rihed above. Samples" ere aliquotcd into microtiter wells coated 
wi th a con>tant amount of F l in PBS (2 J.L£ ml 1) and serially diluted on plates 
in PBS which contained I% skim milk powder. Afte r incubation for I hat 37•c. 
>amples were rcmo\'cd and the plate was washed before being probed with a 
peroxidase-labelled secondary antihody (Sigma) directed against ei ther mouse 
lgG or mouse lgA. Peroxidase-labelled conjugates were each used at a dilution 
of 1:1.000. The amount of peroxidase-labelled conjugate bound to the plate was 
determined by the addition of ABTS. Serum samples from individual animals 
were screened to determine the titer range: samples were subsequently pooled by 
treatment group to determine the mean titer. The titer was taken as the log10 of 
the final sample dilution that gave an optical density of > 0. 1 after subtraction of 
the nonspecific binding provided by pooled scrum samples from age-matched 
untreated control animals. 
(ii) Spleen cells. A crude suspension of mixed spleen cells was prepared by 
gently grinding each spleen on a fine wire mesh to tease out cells. Cells w'erc 
flushed from the splenic capsule and connective tissue with I ml of tissue culture 
medium (Dulbecco minimal essential medium with 4% 20 mM L-glutamine, Hr' 
U of penicillin liter 1. and 100 mg of streptomycin liter- 1 ). The cell suspension 
was gently washed by centrifugation {10 min. 500 rpm, Jovan), and the cell pellet 
was resuspended in Dulbecco minimal essential medium supplemented with 10% 
feta l bovine serum. A mixed acridine orange (0.0003% lwt/Vol]}-ethidium bro-
mide (0.00 1% IM/vol]) stain was used 10 dete rmine the percentage of viable cells 
in the preparation. 
Assay of spleen cell proliferation in vit ro against Fl antigen. Doubling dilu-
tions of Fl a ntigen in the range of 40 to 0 ~Jog mt · • we re made in the wells of a 
microtiter plate so that 100 J.LI per well remained. Similarly, doubling dilutions of 
a whole-<:ell lysate of S. l)phimurium were made in the range of 50 to 0 J.Lg of 
protein ml - 1. The mitogen concanavalin A (Sigma) was included in the assay in 
the range of 50 to 0 J.LS ml - 1 as a positive control. Equivalent ' 'olumes of medium 
alone provided the negative controls. 
The mixed spleen cell suspension was seeded in 100-J.LI aliquots into each well 
at a minimum cell density of 5 X 10' cells per well (final volume. 200 J.LI per well), 
and incubation was continued for 72 h (37°C; 5<;C C02). Four to 6 h before the 
e nd of incubation. I3 Hithymidine ( I J.LCi) was aliquoted to each well in 10-J.LI 
volumes (methyi-[3Hjthymidine S.A [74 GBq mmol- 11; Amersham). After 72 h, 
the plate was harvested onto glass fiber fillers (Titenek cell harvester), and d iscs 
which represented each microtiter well were punched from filter mats into 1.5 ml 
of scintillation fluid (Cytoscint; ICN Biomedical Inc.) for the measurement of 
incorporated I3Hjthymidine into cells. T he stimulation index is derived as fol-
lows: mean counts per minute of treated cellS/mean counts per minute of con-
trols (four replicates of each). 
RESULTS 
Cloning and expression of cafl. Plasmid pFGAL2a was sta-
bly maintained in the aroA strain S. typhimuriwn SL3261 fol-
lowing repeated subculture in nonselective broth media. In 
Western blots of both E. coli and S. typhimurium SL3261/ 
pFGAL2a, a band (Mn - 19,000) was recognized by both poly-
clonal and monoclonal (IgA) anti-Fl reagents (Fig. I). How-
ever, this band wa not recognized in blots probed with the 
anti-Fl lgG MAb. No equiva lent band was observed for bac-
teria which conta ined only plasmid pUC18. Fl antigen was 
expressed o nly by E. coli JM l09 in the presence of the inducer 
IPTG; however, expression in S. typhinwrium SL3261 was con-
stitutive as the lacl gene which encodes a repressor is absent in 
this strain. In We tern blo ts of periplasmic and cytoplasmic 
Salmonella cell fractions, la rge quantities of Fl were detected 
in the cytoplasm but not in the periplasm. 
Quantification of Fl production in vitro. The production of 
F l antigen by S. ryphimurium SL3261 in vitro was examined. In 
logarithmic growth phase, an S. ryphimun·um/pFGAL2a cu ltu re 
with a viable count of 1.27 X !Ox CFU ml - 1 yie lded 15.92 :t 4.1 
J.lg of Fl ml 1, whereas in sta tionary phase after overnight 
cultu re, 2.36:!: 0.12 mg of Fl ml 1 wa produced by 4.9 x 1011 
CFU ml - 1• Fl was not detected by ELl SA from 1.83 X I O" 
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FIG. I. Analys1s of Fl nnugen and recombmant Fl antigen by SOS-PAGE 
and We~tern bloumg. Samples of purified F I unugcn (lane I) or whole-cell 
lysates of S. trphimunum which con wined pFGAL2a (lane 2) or pUCIS (lane 3) 
were separated by SOS-PAGE. Western bloued, and reacted with un anu-FI 
MAb. Prestained molecular size markers (in kilodaltons) were run in lane ~. 
CFU of S. typhinwriwn/ pUC18 ml- t in log phase or from 1.15 
x 109 CFU ml - 1 in stationary phase after overnight culture. 
Stability of S. typhimurium/pFGAL2a in vivo. Although the 
construct was stable in vitro, it was necessary to determine 
whether S. typhimurium/pFGAL2a was also stable in vivo and 
whether the colonizing ability of S. typhimwium was impaired 
by po session of the plasmid. 
After inoculation with one dose of 5 X I 05 S. typhimurium 
SL326l organisms which contained either pUCI8 or pF 
GAL2a, colonization levels in mice were low. A mean of 7.2 X 
I 02 bacteria was isolated from spleen tissue, and a mean of 1.1 
x l 03 bacteria was isolated from liver tis ue. Of these, only 5% 
of bacteria in spleens and none of the bacteria which had 
colonized livers retained plasmid pFGAL2a and were able to 
grow in the presence of ampicillin. A higher level of coloniza-
tion wa achieved following inoculation with 5 X 107 bacteria 
(Table l). Similar levels of colonization were observed with S. 
1yphimurium organisms which possessed pUC18 or pFGAL2a. 
A large proportion (85%) of bacteria which colonized spleens 
still possessed the pUC18 plasmid. However, the insertion of 
the cafl gene into the plasmid resulted in the plasmid becom-
ing unstable in vivo; only 0.52 to 0.88% of colonizing s.a~m.o­
nella organisms were able to grow in the presence of amptctlltn. 
Therefore, mice immunized subsequently with S. typhimurium/ 
pFGAL2a were dosed with ampicillin for 5 days following each 
inoculation in the hope of stabilizing the plasmid in vivo. 
Antibody titer to Fl in immunized groups. The induction of 
specific antibodies in mice inoculated either i.g. or i.v. with S. 
TABLE I. Stability of plasmids in vivo" 
CFU/organ enumerated on: % 
Plasmid Orgun L-agar + Retaining L·agar 
ampicill in pla>mld 
pUCI8 Liver l.2 X 105 1.6 X 104 13 
Spleen 4.8 X 104 4.1 X LO" 85 
pFGAL2a Liver 8.4 X 104 4.4 X 102 0.52 
Spleen 7.9 X 104 7.0 X 102 0.88 
" Five OALB/c mice were inoculated i.v. with 5 X 107 S. typlumurium organ-
ism> wh1ch comained pFGAL:!a or pUCIS. Livers and spleens were removed 7 
days later and homogemzcd 10 POS hefo re heing plated on L-agar or L-agar wh1ch 
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FIG. 2. Fl-specific tilers of IgG (A) and o f lgG and lgA (B) in pooled sc rum 
samples from immunized ammals 6 weeks after dosing. GAL. S. typlumunum/ 
pFGAUa; PUC. S. t)'fJiumunum/pUCIS. 
typhinnuium/pFGAL2a was examined. This was comp~red 
wi th the antibody response induced by the formaldehyde-killed 
Cutter USP vaccine. 
The titers of Fl-specific IgG in pooled serum samples from 
immunized animals 6 weeks after either i.g. or i.v. dosing with 
S. typhimurium/pFGAL2a are shown in Fig. 2A. These titers 
are compared with the titers in serum induced by parenteral 
immunization with the Cutter USP vaccine and purified Fl. lt 
can be seen that S. typhimwium/pFGAL2a administered i.v. 
was as effective as the Cutter USP vaccine in inducing an 
Fl-specific IgG titer of l: 160. Dosing with S. typhimurium/ 
pFGAL2a i.g. induced a higher titer ~f IgG speci.fi~ for .Fl 
( l :640), indicating that bacteria had achteved syst~m•.c mvast.on 
from the gut mucosa and had induced systemtc tmmunny. 
Thus, i.g. dosing with this Salmonella construct can induce and 
sustain titers of IgG in serum samples equivalent to those 
which result from i.v. dosing. 
A comparison of F !-specific IgG and IgA titers in serum 
samples 6 weeks after i.g. dos ing with S. typhimurium/ 
pFGAL2a (Fig. 28) demonstrated that lgA titers were appr~x­
imately 16-fold lower than lgG titers (1:40 [comp~red wnh 
I :640]). i.v. dosing with S. typhinnuium/pFGAL2a dtd not re-
sult in significant titers of lgA in serum samples after 6 weeks 
(results not shown), nor did i.m. dosing with the Cutter USP 
vaccine. However, i.p. dosing with Fl alone induced the htgh-
est titers of specific antibody (lgA and IgG) in serum amples 
( 1 :2,000 and I: I ,280, respectively), and this may be attribu~ed 
to the relatively high immunizing dose (1 0 ~g) and to the fact 
that of all the parenteral routes, the i.p. route is the only one 
known to induce mucosal immunity. 
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FIG. 3. Spleen ~ell prolifer:uion against Fl antigen, Salmo11ella lysate, and 
concanavalin A (Con A). Fiv<.: mice from each treatment group were hunuoncly 
killed on day 63 of the immunization schedule with the removal of ,pleens. 
Spleen cells were pooled by treatment group and cultured in vitro for 72 h, and 
proliferation was cstimat<.:d by the incorponotion of (3H]thymidine into DNA. 
The stimulation index is derived as follows: mean count> per monutc nf treated 
cciiS/mcun counts per minute uf ~on trois .!: I he standard error of the mean (four 
microtitcr wells). 
Within treatment groups, individuals did not show a great 
variation in an tibody titer. For example, at a sample dilution of 
1:80, the mean optical density at 414 nm ±the standard error 
of the mean from titration of lgG for individual serum samples 
was 0.190 ± 0.003 for the pFGAL2a i.v. group, 0.209 ± 0.015 
for the Cutter i.m. group, and 0.288 ± 0.052 for the Fl i. p. 
group. 
Spleen cell responses in vitro. The ability of the S. ryphi-
murium/pFGAL2a construct to induce a cell-mediated im-
mune (CM I) response was determined by assaying the prolif-
eration of spleen cells in vitro on reexposure to purified Fl. 
Maximum proliferation in response to Fl was observed in 
spleen cells derived from mice dosed i.v. with S. typhimurium/ 
pFGAL2a (Fig. 3). Spleen cells derived from mice dosed with 
Fl (i.p.) and with S. ryphimuriwn/pFGAL2a (i.g.) also prolif-
e rated in response to Fl , but to a lesser extent. Negligible 
proliferation in response to F I was observed in spleen cells 
derived from mice immunized with the Cutter USP vaccine. 
Spleen cells derived from mice immunized either i.g. or i.v. 
with S. ryphimurium/pFGAL2a proliferated in response to the 
Salmonella protein extract, further indicating that there was 
systemic involvement in the immune response after i.g. dosing 
as well as i.v. dosing. The nonspecific proliferative response to 
the T-cell mitogen concanavalin A demonstrated that spleen 
cells derived from all sources had equal potential fo r prolifer-
ating. 
Protection of immunized mice against plague bacterium 
challenge. To determine whether immunization with S. ryphi-
murium/pFGAL2a provided protection against plague infec-
tion, immunized anima ls were challenged subcutaneously with 
50 L050s of a virulent strain of Y pestis. 
Following challenge with Y pestis GB, almost complete pro-
tection was obtained with each vaccine used, but all of the 
negative control mice inoculated with S. typhimuriwn/pUC18 
died within 9 days (Fig. 4) . One of 10 mice immunized with the 
Cutter vaccine died, as did 2 of 8 mice immunized i.p. with 
purified F1 , a ltho ugh their survival was prolonged over that of 
the majority of negative controls. S. typhimurium organisms 
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FIG. 4. Survoval of BALB/c mice following challenge with a virulent plague 
;,train. Mic~ immunozed i.g. (A) or i.v. (B) wllh S. typlumunum organisms which 
comaoned pFGAL2a <• l or pUCIS (0), i.m. with Cuucr USP vaccine (.a.), or i.p. 
wtth purified Fl antogen (+ ) were challenged with 50 LD,11s of Y. pesl/s GB. 
i.g. routes of inoculation, with no observable deterioration in 
the health of survivors of this challenge. 
DISCUSSION 
In this study, we have demonstrated that the cloned cafl 
gene can be expressed in the aroA strain S. typhimurium 
SL3261 and that protect ive immunity was induced in mice by 
this recombinant organism. The construction of plasmid 
pFGAL2a, which ca rries the cafl gene tha t encodes the mature 
Fl protein but not its signal sequence, allowed the expression 
of Fl antigen in both E. coli and S. iyphimurium organisms. 
Recombinant Fl was recognized in Western blots by poly-
clonal antiserum and an lgA MAb, indicating that the recom-
binant antigen has retained at least some of the antigenic 
properties of native Fl. The recombinant protein (M,, 
- 19,000) was larger than purified Fl, reflecting the fact that Fl 
was expressed as a fusion with part of the [3-galactosidase 
protein. Some antigenic differences might be expected because 
of different glycosylation s tates of the molecule expressed in Y 
pestis and S. ryphimurium organisms. Evidence for this was 
provided by the fail ure of the IgG MAb to recognize recom-
binant Fl in Western blots. 
Although plasmid pFGAL2a was maintained stab ly in the 
absence of antibiotic-selective pressure in vi tro, in vivo there 
was a significant reduction in the proportion of bacteria which 
possessed the plasmid after 7 days. The instabil ity of a number 
of plasmids which direct the expression of recombinant anti-
gens in Salmonella organisms has been observed previously 
( 18). As with this construct, the unstable plasmids employed 
strong unregulated promoters and high copy numbers. Several 
approaches for overcoming this problem, including the use of 
low-copy-number plasmids, balanced lethal mutations, and 
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chromosomal integration (10). which bypass the need for an-
tibiotics and allow the removal of the antibiotic resistance 
marker, exist. 
Previous work {31) has indicated that the immunizing dose 
of Fl is critical for protection against plague. In addition, 
repeated dosing with protein antigens at very low or excessively 
high levels can induce tolerance. Immune tolerance has been 
observed previously in mice immunized i.g. with low-level 
doses of Fl (35). Thus, in designing a Salmonella-based Fl 
vaccine, a substantial level of expression of Fl appears to be 
desirable. The inoculating dose of 5 X 107 CFU of S. ryphi-
mwium/pFGAL2a cultured in vitro would have contained 6.3 
1-1-g of Fl, but it is difficult to estimate the subsequent level of 
Fl that this inoculum would have produced in vivo. However, 
the protection observed in mice vaccinated with this construct 
indicates that the expression levels of cloned Fl were sufficient 
to induce protective immunity but avoided the low- or high-
zone tolerance brackets for i.g. dosing. 
The presentation of Fl in a live, attenuated S. typhimurium 
strain has several advantages over the killed vaccine currently 
available and previously used attenuated Y. pesris vaccine 
strains, such as Haffkine and EY76. In studies with live EY76 
{21), excessive adverse reactions were observed and the degree 
of protection it afforded was highly variable between individ-
uals. In addition, strain EY76 was shown to be lethal for 
nonhuman primates and did not elicit a measurable circulating 
antibody response that was significantly better than that in-
duced by the killed vaccine. The killed vaccine has also been 
shown to cause a range of side effects in humans (17, 22, 26), 
and pneumonic plague has been reported in vaccinated indi-
viduals, indicating that it affords incomplete protection (21). 
The S. typhimurium/pFGAL2a construct induced a specific 
anti-Fl response in mice. Six weeks after the last immunizing 
dose, the titers of Fl-specific IgG in samples from animals 
dosed i.g. or i.v. with S. typltimurium/pFGAL2a were measur-
able. The mean titer of lgG in serum samples from mice dosed 
i.v. with recombinant S. ryphinwrium was equivalent to that 
induced by the Cutter USP vaccine. i.g. dosing with the S. 
typhimurium/pFGAL2a construct was as effective as i.v. dosing 
at inducing seroconversion. 
The induction of a mucosal secretory lgA response may be 
a requirement for an improved plague vaccine to protect 
against the highly contagious pneumonic form of plague. Sal-
monella organisms invade the intestinal mucosa by direct in-
teraction with the follicular lymphoid tissues of the gut. It has 
been shown that the multiplication of bacteria in gut-associ-
a ted lymphoid tissue leads to a secretory IgA response (24). 
Salmonella organisms can also induce a CM! response as they 
are able to multiply intracellularly (5). In animals immunized 
i.g. with S. typhimwium/pFGAL2a, Fl-specific lgA was de-
tected in addition to IgG. This lgA titer in serum samples 
probably reflects the level of ecretory lgA production in the 
gut after oral dosing, a lthough the assay of lgA in serum 
samples is only an indirect mea urement of secretory lgA pro-
duction. These data provide preliminary evidence that in ad-
dition to inducing seroconver ion, i.g. dosing with S. ryphi-
murium/pFGAL2a effectively induces mucosal immunity. 
The Cutter-immunized group did not have detectable levels 
of lgA in serum samples; this was expected since i.m. dosing 
does not effectively stimulate mucosal immunity. The existing 
Cutter U P vaccine is deficient in this respect. The fact that 
protection was observed in Cutter-vaccina ted mice in this tudy 
can be attributed to the induct ion of systemic immunity pro-
tective against the parenteral challenge used. 
The induction of a CMI response i a requirement for any 
ideal plague vaccine to be totally elfective. A CM I response 
must be induced to eliminate bacilli from intracellular sites. as 
Y. pesris is able to survive in intracellular locations, such as 
within macrophages and phagolyso omes (6, 34). Spleen cells 
derived from groups immunized with S. ryphimurium/pF 
GAL2a either i.g. or i.v. proliferated significantly when restim-
ulated in vitro with purified Fl antigen, indicating that the 
organism had induced a CM I response. The spleen cell re-
sponses inS. ryphimurium/pFGAL2a groups were greater than 
those in the Cutter- and Fl-immunized groups, indicating that 
the presentation of Fl in a live-vaccine vector stimulated a 
CM! response more effectively than did presentation in the 
killed Culler USP vaccine or as purified soluble protein. Max-
imum proliferation against Fl was ob erved in spleen cells 
derived from mice dosed i.v. with S. typhimurium/pFGAL2a; 
this illustrates how effectively i.v. dosing induces systemic im-
munity by recruiting spleen cells into the immune response. In 
contrast, the i.m. route of immunization required by the Cutter 
USP vaccine was much less effective at inducing a CM! re-
sponse. Dosing with the recombinant i.g. also induced a CMI 
response, indicating systemic invasion of S. l)phimurium/ 
pFGAL2a organisms from the gut mucosa. 
Spleen cells from the S. ryphimurium/pUClB group showed 
little or no response to the Salmonella lysate, and we can only 
speculate on the reasons for this. This spleen cell population 
showed a normal response to concanavalin A, indicating that 
cells were functional and had the potent~al to proliferate in 
response to other antigens. It may be that in the S. ryphi-
murium/pFGAL2a group, Salmonella epitopes were presented 
together with Fl epitopes to T cells, inducing cross-reactive 
T-cell clones. This would not occur with the empty plasmid 
construct. 
Against parenteral challenge with a virulent plague strain, S. 
typhimurium/pFGAL2a groups exhibited 90% protection, as 
did the Cutter group. The group immunized with purified Fl 
showed 75% protection. No protection was seen in the control 
groups vaccinated with the S. ryphinwrium/pUClB construct, 
discounting an earlier suggestion that antigenic determinants 
common to Y. pestis and S. typhimurium could afford a degree 
of nonspecific immunity (31). The possibility of a nonspecific 
influence in the observed protection against plague was mini-
mized by delaying the challenge for 6 weeks after the last 
immunizing dose to allow the clearance of Salmonella organ-
isms (18). 
Thus, we have demonstrated that the Fl antigen of Y. pesris 
is expressed in an attenuated Salmonella strain and that it 
induces 90% protection against challenge by a virulent Y. pesris 
strain. This approach shows potential as the basis for a live 
attenuated oral vaccine, in which there is increased stable 
expression of Fl in conjunction with other antigen . to achieve 
complete protection against Y. pesris. 
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Expression of the Yersinia pestis Capsular Antigen (Fl Antigen) 
on the Surface of an aroA Mutant of Salmonella typhimurium 
Induces High Levels of Protection against Plague 
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The caf operon from Yersinia pestis encoding the structural subun it (cafl ), the molecular chaperone (caflM), 
the outer membrane anchor (cafJA), and the regulatory protein (caflR ) was cloned into Salmonella typlzimurium 
SL3261 aroA. The recombinant Salmonella organisms were encapsulated when cultured a t 37°C but not when 
cultured at 28°C. Oral inoculation of mice with the recombinant Salmonella induced predominantly an 
immunoglobulin G2a response to F l antigen, and isolated T cells showed a recall response to soluble or 
Salmonella-associated Fl antigen. Mice immunized with S. typhimurium SL3261 aroA expressing F l antigen 
intracellularly developed lower antibody responses to Fl antigen and showed a T-cell recall response only to 
Salmonelw-associated FI antigen. Mice immunized orally with two doses of the recombinant Salmonella which 
expressed Fl antigen on the surface were protected against 107 50% lethal doses (LD50) of virulent Y. pestis 
given by the subcutaneous route of challenge., whereas mice immunized with the recombinant Salmonella 
expressing Fl a ntigen intracellula rly were only partially protected against 105 LD50 of Y. pestis. 
Although Yersinia pestis no longer causes pandemics, the 
bacterium is still a public-health problem on the Asian sub-
continent and in the Far East (4). Most cases of disease caused 
by Y. pestis are of the bubonic form, arising following a bite 
from a flea which has previously fed on the blood of an infected 
rodent (4). Some cases of bubonic plague progress to the 
pneumonic form, which can be transmitted from human to 
human, leading to epidemics (8). Currently available vaccines 
which contain heat- or formaldehyde-killed bacteria (19) in-
duce protection against the bubonic form of the disease (23) 
but are reactogenic (18). Immu nity to infection has been cor-
related with the presence of antibody to the capsular F1 anti-
gen (30), and immunization with the F1 antigen induces pro-
tection against the disease in animal models (20, 25, 32). These 
vaccines require repeated immunizations to evoke protective 
immunity and are defeated by a high-level challenge (1, 23, 32). 
The F1 capsule structural subunit is encoded by the cafl gene 
(12), and we previously reported that immunization with Sal-
monella typhinwrium which expressed the cafl gene and accu-
mulated F1 antigen intracellularly resulted in the induction of 
a protective response against Y. pestis (22). However, the re-
combinant plasmid was ret ained in S. typhimuriwn only when 
mice were codosed with ampici ll in. Export and assembly of the 
Fl capsule are directed by the cafJA ( 17) and the cafl M (I 3) 
gene products. These gene form an operon including the cafl 
gene, which is regulated by the cafl R gene product (16). We 
have investigated the po sibility that expression of the caf 
operon in S. typhimuri11111 would result in stable high-level 
expres io n of FI antigen on the surface of the bacterium and 
would provide enhanced immuni ty against Y pestis. 
Construction of S. typhimurium contai ning the caf operon. 
Two DNA fragments, which together included the Y. pestis caf 
operon ( 16, I 7). were amplified by PCR (35 amplificat ion 
• Corresponding author. Phunc: 44-980-6 13320. Fax: 44-980-613284. 
1926 
cycles; 95°C for 15 s, 50°C for 15 s, 72°C for 30 s) (Perkin-
Elmer 9600 GeneAmp PCR system) with Y. pestis MP6 tem-
plate DNA (22) and oligonucleotide primer pair FIOU2 (S'TG 
CCCCGGGAATTCCGAACATAAATCGGTTCAGTGGC 
C3') and M4D (S'GGCGTATTCCTCGCTAGCAATGTTTA 
ACG3') or M3U (S'ATCGTTAAACATTGCTAGCGAGGA 
ATACGCC3') and FIOD2 (S'GATAGATCTGTCGACTGA 
ACCTATTATATTGCITCGCGC3'). The amplified DNA 
fragments were ligated at the unique Nhel site within the caf 
operon and the DNA was cloned into a low-copy-number plas-
mid (pLG339; Kan (28]) to generate plasmid pAH34L. After 
nucleotide sequencing (24} of the cafl open reading frame, the 
deduced amino acid sequence of the cafl gene from strain 
MP6 was shown to be identical to the previously reported 
sequence from strain EV (12). 
The caf operon, expressed in S. typhimurium, results in the 
formation of encapsula ted bacteria. Plasmid pAH34L was pas-
saged through S. typhimurium LB5010 to methylate the DNA 
and was then electroporated into S. typhimurium SL3261. 
Transformants were unable to grow on minimal media without 
supplements of aromatic amino acids, confirming their auxo-
trophic phenotype. Sonicates (22) of S. typhimuriwn SL326L 
pAH34L contained 12.8 1-'-g of FI antigen/108 cells when an 
enzyme-linked immunosorbent assay was performed with pu-
rified F1 antigen from Y. pestis (32) as the standard antigen. 
The reported molecular mass of the F1 antigen is 15.5 kDa 
( 12), and in Western blots (Fig. I) a band with an M, of 16,000. 
which reacted with an FI polyclonal antibody (32). was iden-
tified in Iysates of S. typhimurium SL3261/pAH34L cultured for 
18 h at 37°C in L broth containing kanamycin (50 1-'-g ml - 1). 
Cell extract~ which were nOt boiled in sodium dodecyl su lfate-
polyacrylamide gel e lectrophoresis (SOS-PAGE) buffer prior 
to analy is contained add itional antibody-reactive bands with 
M,s of 32.000, 49.000, 64,000, and 79,000, indicating oligomer-
ization of FJ antigen. Antibody-reactive bands were not iden-
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FIG. I. SOS-PAGE (12% gels) and Western blouing u>ing a murine poly-
clonal Fl anlibody. Blots were developed with n gold-labelled goat anlHllousc 
amibody (Amersham) wilh ,jiver enhancement. Samples analyLcd PO f'l) were 
prepared from 8 x I 0° cells ml 1 of S. typl11m111111111 SL3261 cui lUred at JrC 
(lane 2) and S. typllimurium SL3261/pAH34L cui lUred lll28°C' (lane J) oral 37•c 
(lane ~). all of which were hoiled with an equal volume of SOS-PAGE hulfcr 
before analysiS. Lane 5 comaoned S. typlumum1111 SL3261ipAI-13-II. cell ly,ale 
wh1ch had not been boiled w1th SDS-PAGE hulfer immcdiatdy before analysis. 
Lane I contained molecular weight markers (numbers on lhc lefl are in thou-
sands), and lane 6 contained 22 1-'& of purified Fl nnugen from Y. pesm which had 
been boiled with SOS-PAGE buo·er before analysi>. 
tified in lysates of S. typhimurium SL3261 cultured in L broth 
(Fig. 1). ln Y pestis, Fl capsule biosynthesis is temperature 
regulated t 10, 16), and Fl antigen production was not detected 
in cell lysates of S. ryphimuriwn SL3261/pAH34L which had 
been cultured at 28°C, confirming that the cafl R gene was 
functional in S. typhinwrium SL3261. 
The encapsulated appearance of S. typhimurium SL3261/ 
pAH34L (Fig. 2) after fi lms were stained with India ink (7) was 
similar to the reported appearance of Y. pestis after similar 
staining (3). Confirmation of the surface location of the Fl 
antigen was obtained when cells of S. typhinwrium SL3261/ 
pAH34L fluoresced during an immunofluorescent assay, 
whereas cells of S. ryphimwium SL3261/pFGAL2a (which ex-
presses the Fl antigen intracellularly [22]) did not fluoresce 
(Fig. 3). 
Plasmid stability in vitro and in vivo. Previous workers have 
found difficulty in achteving stable high-level expression of 
heterologous antigens in Salmonella aroA (5, 6, 9, 11, 22). The 
retention of pAH34L by S. typhimwium SL326l was assessed 
by culturing bacteria in L broth without antibiotic at 28 or 37°C 
and plating dilutions onto agar with (for the selection of bac-
terium-containing plasmids) or without kanamycin. Kanamycin 
resistance was retained by 85 or 29% of the bacteria after 
culture for 24 or 72 h, respectively, at 3rC. When bacteria 
were cultured in broth at ~8°C for 72 h, all of the bacteria 
remained kanamycin resistant. Thi!> finding indicated that plas-
mid pAH34L could be segregated efficiently and that plasmid 






FIG. J. Phase-contrast m1cro•cnpy (panel I) and immunoOuorescencc (panel 
2) of bacteria which had adhered to polylclraOuoroclhylcnc-coalcd glass slides 
(Hendlcy-Essex). The slides were incubated for I h at 37"C wnh murine poly-
clonal antibody against punfied Y pestis Fl an11gen (30) (diluted 1:1,000 in 2% 
BLOTIO in PBS (pH 7.21) und were rinsed three limes in PBS (pH 7.2). Nter 
oncubation for I h a1 37"C wnh Ouorcscem isolhiocyanatc-lahclled goal anti-
mouse anubody diluted I: lOO in PBS (pH 7.2) and rinsing of the slide in PBS (pH 
7.2), bacteria were visualized wnh a fluorescence microscope (Lcill Oialux 20). 
(A) S. ryplrimtmum SL3261/pAH3~L; (B) S. typhmwnum SL326l/pFGAL2a, 
wh1ch expresses the Fl antigen onlracellularly (22). 
The in vivo stability of plasmid pAH34L in S. typhimurium 
and the tissue-colonizing ability of the bacteria were deter-
mined after inoculating groups of six female 6-week-old 
BALB/c mice (Charles River Laboratories, Margate, United 
Kingdom) intravenously (i.v.) or intragastrically (i.g.) by 
gavage. The bacteria tsolated from spleens 7 days after in-
oculation were all kanamycin resistant. The numbers of S. 
typhimurium SL3261 and S. typhinwrium SL3261/pAH34L 
organisms recovered from spleens were similar (Table 1), in-
dicating that the Fl antigen did not mask the surface antigens 
required for invasion of host cells. The stability of pAH34L 
after immunization of the mice, compared with the instability 
of the plasmid in vitro, suggests that the surface-expressed Fl 
antigen confers a selective advantage on S. typhimunum 
SL3261 in vivo. 
All of these findings suggest that it will be possible to achieve 
stable high-level expression of Fl antigen in strains of S. typhi 
B 
FIG. 2. S typlllmlmlllll SL3261 (A) and S. typllimurium SL3261/pAil34L (B) cells photogrnphed by light micro>oeopy afler >taining with India ink. 
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TABLE I. Colonization of spleens after i.g. and i.v. dosing" 
Con'>truct (route) 
CFU/splcen enumerated un1': 
L agar L agar + kanamycin 
r;. of organisms 
ret:uning plasmid 
S. ryphimurium SL3261/pAH34L (i.g.) 
S. typhimwium SL3261 (i.g.) 
S. ryphimurium SL326t/pAH34L (i.v.) 
S. ryphimurium SL3261 (i.v.) 
(9.51 :!: :!.3) X l 03 
(5.-19 ± 3.1:!) X IOJ 
(2.01 ± 0.84) X 10' 
(2.27 ± 0.:!) X I~ 
(9.49 :t 2.1) X IOJ 
NA' 






"Inoculation i.g. with 2 X 10" CFU ufS. f)11him111i11m SU261or 5 X Ill" CFU nl S. typilim11n11111 SU261/pAH3~L or i.v. with ox 10~ CFU of S. 1\'flllllmmllm SL3261 
or 5 x JO' CFU of S. typl11m11mmr SL3261/pAH34L). 
• Menns derived from ~ix animal• in each group :!: 'tandard deviations. 
' NA. not applicahle. 
which might be used as vaccine vectors in humans. Since we 
have achieved high-level expression by using a low-copy-num-
ber vector, chromosomal integration of the caf operon should 
allow high-level expression of Fl antigen. 
Surface-expressed Fl antigen induces serum antibody re-
sponses and cell-mediated immunity responses to Fl antigen. 
Groups of 24 mice were immunized twice (at days I and 21) i.g. 
with 2 X !Ox to 5 X IOK CFU of S. typhinwriunz SL3261 or S. 
ryphimurium SL3261 /pAH34L in I 00 f.!. I of phosphate-buffered 
saline (PBS). A further group of 24 mice was immunized with 
S. typhimurium SLJ261/pFGAL2a according to the same pro-
tocol but was dosed with ampicillin (22) to promote retention 
of the plasmid. Antibody against the Fl antigen was not de-
tected in mice immunized with S. typhinwrium (Fig. 4). Ani-
mals immunized with S. typhimurium SL3261/pAH34L showed 
detectable levels of Fl-specific immunoglobulin G (IgG) in 
scrum from day 16, and by day 52 titers of Fl-specific JgG in 
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FIG. 4. Determination of levels of Fl antibody in scrum collected from 
imrnuniLed mice at days 16 to 52 of the experiment. The measurement of lgG 
subclass was performed on individual sample•. Briefly, samples were double 
diluted on rnicrntller plates prccoated with Fl antigen (5 11-g ml 1 in PBS). 
Bound antibody was detected with peroxida,c-lahellcd secondary antibndies 
againsl mouse lgG 'uhclasses (Harlan-Sera Lth, Crmvley Down, Unilcd King-
dom). and for each sample the titcr was recorded as the maximum dilution ol 
sample grving an abM1rhance at 414 nm of 0.1 unil over the background. Ouan-
tilicatrorr of tgG suhcJa,ses in diluted sample\ ( 14) wa, accomplished hy con-
verti ng the absorbance values a l 414 nm to nnnograms of lgG per millilitcr hy 
reference 10 individual standard curves constructed for each lgG subclass protein 
(range. I to 50 ng ml 1) with the homologous secondary muihody conjugate. 
From thi•. mean values (mrcrngrams per milliliter) :!: •tandard error' ol the 
means for lgG I and lgG2a rn ">Crum were denved for each immunrwtrun gruup. 
in serum exceeding that of !gO I by more than 30-fold (384 ::!:: 
32 JJ.g ml -t , compared with 12 ::!:: 4 f.l.g ml - 1). Mice which had 
been immunized with S. typhimurium SL326 1/pFGAL2a 
showed a high level of scrum antibody to Fl antigen at day 44 
which had declined by day 52 to 6::!:: 1.5 JJ.g of Ig02a ml-t and 
1.8 ::!:: 0.2 f.l.g of I gO I ml -t . The failure of S. typhinwrium 
SL3261/pFGAL2a to induce a sustained antibody response 
may be due to the instability of the plasmid encoding the Fl 
antigen in S. ryphimurium in spite of the ampicillin dosing of 
mice. 
The production of Ig02a in the mouse is associated with a 
cytokine profile that is indicative of a Th I cell response (21, 
27), and the predominant Ig02a response in serum suggests 
that a Th I cell response was induced by surface-expressed F l 
antigen. The ability of Salm01zella-delivered vaccine antigens to 
induce predominantly Th I cell responses has been reported by 
other workers (2, 29). 
The in vitro recall response ofT cells isolated and purified 
(32) from the spleens of six animals in each treatment group to 

















FIG. 5. The in vitro reca ll response ofT cells derived on day 52 from mrcc 
immunized wilh S. typlrimwium SU261/pAH34L (bars a and d). S. typ/11111111111111 
SU261/pFGAL2a {bars band c), and S. typlllnlllrilllll SU261 (har' c and f) to a 
whole-cell lysate of S. typilimuri11111 SL3261/pAH34L containtng 0.2 ng of Fl 
antigen ml - 1 (hars u through c) or 50 11-g of ~olublc purifieu Fl :tntigcn ml - 1 
(ha rs d lhrough f) . Incorporation of 'H is shown as values above the background 
levels found when S. typhinwriwn SL3261/pAH34L S. typ/11111111'111111 SU26t/ 
pFGAL2a. and S. typhimurium SL3261 Tccll' were incubated wtth medium only 
(mean = 135 cpm). 
VoL. 65, 1997 
TABLE 2. Survival of control mice and mice previously immunized 
with S. ryplrimuritmt Sl..326l , S. ryphimurium SL3261/pAH34L, or 
S. ryplrimurium SL3261/pFGAL2a after challenge with Y. pestis GB 
Challenge dose No. of Mean time to Immunization mice death:!: SEM (CFU of Y. pestis) 
surviving" (days) 
None 1.2 X lOS 0 3.7:!: 0.3 
1.1 X 107 0 3.2:!: 0.2 
S. typhimurium 
Sl..326l 1.2 X 105 0 5.2:!: 0.5 
1.2 X 107 0 3.7::!:: 0.2 
S. ryplrimurium 
SL3261/pAH34L 1.2 X !Os 6 NAb 
1.2 X 107 6 NA 
S. typhimurium 
SL3261/pFGAL2a 1.2 X lcP 3 7.7:!: 1.7 
1.2 X 107 2 6.5 ::!:: 0.4 
• Each group had six mice. Deaths were recorded up to 14 days postchallenge. 
h NA, not applicable. 
at day 52 (Fig. 5) . A suspension ofT cells (100 fJ.) at 106 ml- 1) 
was introduced into the wells of a microtiter plate, and prolif-
eration was measured, with three replicates, as e HJthymidine 
incorporation into cells. When F1 antigen in solution (6.3 to 
200 f.l.g ml- 1 ~ was used to stimulate T cells, 50 f.l.g of soluble F1 
antigen ml - was required for the maximum response. At this 
concentration of Fl antigen, the proliferative response of T 
cells isolated from mice immunized with S. typhimurium 
SL3261/pAH34L (Fig. 5, bar d) was significantly greater (P < 
0.05) than the response of T cells isolated from mice immu-
nized with S. typhimurium SL3261/pFGAL2a (Fig. 5, bar e) or 
with S. typhimurium SL3261 (Fig. 5, bar f). 
When dilutions of a lysate of S. typlzimurium SL3261/ 
pAH34L (1010 CFU ml- 1) containing 0.04 to 12.3 ng of Fl 
antigen ml - 1 were tested, much lower levels of Fl antigen (0.2 
ng m! - t) were required to promote the maximum proliferation 
of T cells. This suggests that the T-cell recall response was 
provoked by epitopes in both Fl antigen and Salmonella. 
When a lysate containing 0.2 ng of Fl antigen ml - 1 was used, 
the proliferative response ofT cells from mice immunized with 
S. typhimurium SL3261/pAH34L (Fig. 5, bar a) was found to be 
significantly higher (P < 0.001) than the response ofT cells 
from mice immunized with S. typhimurium SL3261 (Fig. 5, bar 
c). 
The ability of the surface-expressed Fl antigen to induce 
humoral and cellular responses which cross-reacted with Fl 
antigen in solution indicated that association of F1 antigen 
with Salmonella is not a requirement for a recall immune 
response. In contrast, T cells from mice immunized with S. 
typhimurium SL3261/pFGAL2a, unlike T cells from mice im-
munized with S. typhirnurium SL3261, proliferated significantly 
(P < 0.05) when ex~osed to 0.2 ng of Fl antigen associated 
with Salmonella m!- , but they did not proliferate significantly 
to 50 tJ.g of soluble Fl antigen ml - 1, indicating the absence of 
a memory T-cell response to soluble F1 antigen. 
Immunization with S. typhimurium expressing surface-
bound Fl induces high-level protection against challenge with 
Y. pestis. The available whole-cell killed vaccines are reacto-
genic in humans ( 18), and in mice they induce only partial 
protection against a subcutaneous challenge with 1.9 x 1 0~ 
CFU of Y. pestis (23). The requirement for the rapid develop-
ment of immunity in susceptible populations precludes the use 
of a killed whole-cell vaccine, which requires at least two prim-
ing immunizations over a period of 6 months and a further 
booster dose within the first year. Several workers have shown 
NOTES 1929 
that antibody against the Fl antigen provides protection 
against parenterally administered Y. pestis (1, 20, 25, 32). How-
ever, even after immunization with 3 intraperi1oneal doses of 
F1 antigen only four of five mice were protected aga inst a 
subcutaneous challenge with 2 X 105 CFU of Y. pestis (32). 
For this study, immunized mice were divided into groups of 
six and challenged subcutaneously a t day 60 with 1.2 x 105 or 
1.2 X 107 CFU of Y. pestis GB. The 50% lethal dose of this 
strain was previously reported to be approximately l CFU (23). 
All of the control mice (unimmunized or immunized with S. 
typhimurium SL3261) died by day 14 (Table 2), and Y. pestis 
was recovered when spleen samples were plated onto Congo 
red agar or Yersinia selective agar (Oxoid). Other workers have 
reported that mice which had been immunized with S. typhi-
murium SL3261 showed low-level protection against infection 
with other bacterial pathogens (11, 26), and we observed an 
increase in time to death compared with that for unimmunized 
mice afterS. typhimurium SL3261-immunized mice were chal-
lenged with Y pestis. Mice immunized with S. typhimurium 
SL3261/pAH34L survived both challenge doses, 1.2 X 105 and 
1.2 X 107 CFU, without the appearance of symptoms of dis-
ease over the course of the experiment (to day 14). In contrast. 
mice immunized with S. typhimurium SL3261/pFGAL2a were 
only partially protected against challenge with the same doses. 
The enhanced protection afforded after immunization with 
S. typhimurium expressing Fl antigen on the surface does not 
appear to be related to the level of expression, since the Fl 
antigen accumulated to a similar level when it was expressed 
intracellularly (22). At the time of challenge, the levels of 
serum antibody to Fl antigen were higher when mice had been 
immunized with S. typltimurium SL3261/pAH34L than with S. 
typhimurium SL3261/pFGAL2a, and it has been shown that the 
titer of antibody in serum to F1 antigen can be correlated with 
the degree of protection against Y pestis (1). The Fl antigen 
has been suggested to confer antiphagocytic properties on Y. 
pestis by interfering with complement-mediated opsonization 
(31). It is known that the lgG2a subclass antibody is a more 
effective opsonin than the lgG 1 subclass antibody (21 ), and this 
may explain the high level of protection seen after immuniza-
tion with Salmonella expressing F1 antigen. This observation 
might also explain why F1 antigen delivered in S. typhimurium 
induces a more protective response than Fl antigen delivered 
in Freund's (32) or Alhydrogel (1) adjuvant, since immuniza-
tion with Fl antigen induces predominantly an IgG 1 response 
(32). 
The oligomerization of Y. pestis Fl antigen has recently been 
reported (I), and the detection, by Western blotting, of mul-
timeric forms of the F1 in crude lysates of S. typhimurium 
SL3261/pAH34L indicated that F1 antigen was assembled into 
oligomers. 1t was recently reported that antigens exported 
from S. cyphimurium are more effective in inducing a protective 
response against listeriosis, possibly because export of the an-
tigen more closely mimics the natural infection ( I 5). It is pos-
sible that the surface expression of Fl antigen in Salmonella 
more closely mimics the natural presentation of F l antigen on 
Y. pestis organisms. The oligomerization of surface-expressed 
Fl antigen might result in the formation of epitopes not 
present in the intracellular monomeric form of F l antigen. In 
support of this possibility it has been reponed that the F I 
antigen in the killed whole-cell vaccine is less effective in in-
ducing protective responst:~ than purified Fl antigen, even 
though the whole-cell vaccines contained greater amounts of 
Fl antigen, a finding which was attributed to a change in the 
conformation of some protective epitopes in the killed whole-
cell vaccincs ( I). 
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Abstract 
Attenuated mutants of Salmonella typhimurium are being evaluated as delivery systems for a variety of heterologous vaccine 
antigens. G ene promoters which are induced in vivo can direct the stable expression of genes encoding these antigens. We have 
investigated the utility of the phoP. ompC, pagC and lacZ gene promoters for expression of the Y. pestis Fl-antigen in S. 
typhimurium SL3261 (aroA ). After i.g. (intragastric) dosing the highest level of spleen colonisation was found with recombinant 
Salmonella expressing FI-antigen from the phoP gene promoter, and this recombinant was most effective in inducing serum and 
mucosal antibody responses. The use of the pagC gene promoter to direct expression of F l-antigen resulted in the induction of 
serum and mucosal antibody responses even though the recombinant Salmonella were unable to colonise spleen tissues 
suggesting that colonisation of these tissues is not essential for the induction of antibody responses. © 2000 Elsevier Science 
Ltd . All rights reserved . 
Keywords: Salmonella; In-vivo promoter; Fl-antigen 
1. Introduction 
Attenuated mutants of Salmonella typhi (e.g. aroA, 
aroC, htrA) are currently being evaluated as live, oral 
vaccines against typhoid fever [1]. These mutants have 
also attracted attention as carriers for guest (vaccine) 
antigens but suitable a nimal models for testing these 
vaccines are not available. In view of this, many 
workers have used Salmonella typhimurium aroA 
expressing guest antigens for investigating the immune 
responses induced after oral vaccination of mice. 
The unregula ted expression o f foreign genes with in 
S. typhimurium can lead to plasmid instability, yet the 
stable expression of the guest antigen in vivo is necess-
ary for presentation of the antigen to immune effector 
cells and the ind uction of a protective response. These 
* Corresponding au thor. Tel.: + 44-1980-61330 1: fax: + 44-1980-
613284. 
effector cells are located primarily in the gut-associated 
lymphoid tissue (GAL T; primarily Peyer's patches and 
mesenteric lymph nodes) or within recticuloendothelial 
tissue (primarily the spleen). One approach to promote 
the stable expression of guest antigens involves the 
chromosomal integration of the heterologous gene. 
H owever, this may reduce the immune responses 
because of gene dosage effects [2]. The bala nced lethal 
system [3,4] relies on the complementation of a letha l 
mutation by a plasmid which also encodes the guest 
antigen. This approach might reduce the selective 
pressure towards plasmid loss. An alternative 
approach involves the use of promoters which are 
induced within the host so that immune effector cells 
a re presented with the guest antigen. Because the gene 
is only expressed after certain envi ronmental cues have 
been recognised, this approach might reduce the selec-
ti ve pressure towards deleting the gene. 
This solu tion to the problem of expression of 
gue, t antigen has a lso been identified by o ther 
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workers. A variety o f antigens have been expressed 
in S. typhimurium from the nirB promoter which is 
upregulated under a naerobic conditions and within 
host cells [5]. ln general guest antigens delivered in 
the nirB promoter system induce superior responses 
than the same antigens delivered from a constitutive 
promoter, possibly because the nirB promoter-driven 
genes were maintained more effectively in the Sal-
monella host strain [6.7). More recently, it has been 
shown that the htrA and osmC promoters can be 
used to direct expression of guest antigens in Sal-
monella [6,8]. However, it is likely that these pro-
moters will not be suited to the expression of a ll 
guest antigens. 
Immunisation with the Fl-antigen of Yersinia pes-
tis has previously been shown to induce an anti-
body-mediated protective response against plague [9] 
and we have previously shown that the Fl-antigen 
can be expressed in S. typhimurium (10,11]. It is 
known that the invasion and spread of S. typhimur-
ium within the host is accompanied by the ex-
pression of different subsets of genes whjch are 
involved in processes such as attachment and inva-
sion, penetration of the epithelium and the infection 
of deep lymphoid tissue. We considered that we 
could exploit the a ntigenic properties of F !-antigen 
to investigate the ways in which different promoters, 
which are induced in the gut or in the phagosomal 
compartment of cells, can be used to induce differ-
ent antibody responses to guest antigens expressed 
in S. typhimurium. 
The OmpR/ EnvZ two component regulatory system 
responds to changes in the osmotic strength and pH 
withjn S. typhimurium [12] . It has been suggested that 
trus system might play a role in allowing the bacterium 
to survive in the gut by regulating the expression of 
outer membrane porins such as OmpC (13- 15]. The 
PhoP/PhoQ two-component regulatory system controls 
virulence properties such as survival within macro-
phages, resistance to host defence antimjcrobial pep-
tides and acid pH, invasion of epithelial cells, the 
formation of spacious vacuoles and the processing and 
presentation of antigens by activated macrophages 
[16- 19], in response to environmental magnesium con-
centration [15]. Over 40 genes are regulated by this sys-
tem in S. typhimurium [20] including the phoP gene, 
which is autoregula ted [21] a nd the pagC gene which 
encodes an envelope protein required for survival in 
the macrophage [22]. 
For this study we have selected three promoters 
(P ompC• P plwP and PJiagd which are induced a t different 
stages in the infection process. a nd compared their ex-
pression to tha t o f the constitutively expressed lacZ 
gene promoter. This approach could a llow the induc-
tion of different immune responses which provide pro-
tection against pathogens which colonise different host 
cell compa rtments. 
2. Materials and methods 
2. 1. Bacterial strains. cultivation and en::_rmes 
Escherichia coli strain J M I 09 and S. typhimurium 
strains LB5010 (r- m + galE}, SL326 1 (aroA) or 
SL 1344 (a mouse-virulent stra in; [23] were cultured on 
L-agar or in L-broth. supplemented with ampicillin 
(50 llg/ml) where appropriate. Enzymes used for DNA 
cloning and amplification procedures were obtained 
from BCL limited (Lewes, Sussex, UK). PCR (poly-
merase chain reaction) reactions were carried out using 
a Perkin Elmer 9600 (P.E. Applied Biosystems, War-
rington, UK) thermal cyder with cycle conditions of 
95°C, 5 min, followed by 50 cycles of 95,C, 5 s; 45cC, 
5 s; 72°C, 5 s, followed by I 0 m in at n ee. 
2.2. Construction of plasmids containing promoters for 
expression of FJ-antigen 
Oligonucleotide primers were designed to amplify 
promoter regions using the PCR (Table 1). The pri-
mers included unique Not/, Xbaf or Spel sites. Regions 
amplified included the -10 a nd -35 regions and 
upstream regulatory binding sites, but excluded the 
Shine- Dalgarno (SO) ribosome binding site. After 
PCR ampljfication of the promoter regions from S. 
typhimurium SLI344 template DNA (or plasmid 
pUC18 template DNA for amplification of the lac pro-
moter), the DNA fragments were purified using Micro-
con LOO centrifugal concentrators (Millipore, Watford, 
UK). The purified DNA fragments were cloned into 
suitable digested plasmid pBluescript SK-, electropo-
rated into E. coli JMlOl and the cloned fragments 
were nucleotide sequenced to ensure their authenticity. 
After digestion of the recombinant plasmids with Sacf 
a nd BssHII and agarose gel electrophoresis, DNA 
fragments containing the promoter regions were puri-
fied using Qiaex (Qiagen Ltd, Crawley, UK) and blunt 
ended using Klenow fragment (24). The authentic pro-
moter sequences were then cloned into plasmid 
pBR322 which had been digested with EcoRI and 
Nrui a nd then blunt ended using Klenow fragment 
[24]. The orientation o f the cloned 0 A fragment in 
the plasmid was determined by analysing, using agar-
ose gel electrophoresis, the DNA fragments obtained 
a fter digestion with Xbal , SspJ or Sty l. 
A DNA fragment which encoded the Cafl open 
reading frame and the ribosome binding site was iso-
la ted after digestion of plasmid pORFJ (10] ,,·ith 
EcoRI followed by blunt ending of the DNA and 
further digestio n with HindJII. The purified DNA frag-
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ment was ligated with promoter plasmids which had 
been digested with Smal and Hindlll. The final recom-
binant plasmids were transformed into E. coli strain 
JMI09. 
2.3. In vitro stability of plasmids within S. typhimurium 
Plasmids were isolated from E. coli [24] and electro-
porated into S. typhimurium SL3261 (aroA) after pas-
sage through S. typhimurium LB50 I 0 to ensure 
methylation of the DNA. The in vitro stability of plas-
mids was determined by culturing the recombinant 
bacteria for 24 h in L-brotb and enumerating bacteria 
cultured on L-agar or L-agar plus ampicillin [24]. 
2.4. In vivo stability of plasmids within S. typhimurium 
The in vivo stability of plasmids was determined by 
inoculating groups of 10 female BALB/c mice orally 
with I x I 09 colony forming units (cfu) of bacteria in 
100 ).11 of PBS, and enumera ting bacteria isolated 11 
days later from homogenised spleen tissue on L-agar 
or L-agar plus ampicillin. In the case of the P pagc-F I 
construct and the S. typhimurium SL3261 control 
strain, bacteria were also cultured from mesenteric 
lymph nodes (10/mouse), each homogenised in 2 ml of 
PBS, or from homogenised liver tissue which was 
removed 11 days after dosing. Bacteria were enumer-
ated as described above. 
2.5. Immunisation and serum collection 
Groups of five or eight female BALB/c mice were 
immunised via intragastric intubation on days 0 and 
14 with I X 109 cells of the Pompc-Fl , PphorFI, Ppagc-
F I or Ptacz-F I constructs, or the control S. typhimur-
ium strain, SL3261 , in 0.1 ml of phosphate-buffered 
saline (PBS). Bacteria were grown statically overnight 
at 37°C. All oral inoculations were carried out with a 
sta inless steel gavage needle without an a naesthetic. 
The inoculum dose was verified by plating serial di-
lutions of each culture on L-agar plates with or with-
Table I 
Oligonucleotide primers used to amplify promoters used in this study" 
Oligonucleotide pair 
5'AAGGAAAAAAGCGGCCGCCGCCCAATACGCAAACCGJ ' 
out ampicillin. On days 21 , 28 and 98 mice were 
anaesthetized by intraperitoneal (i.p.) administration 
of a cocktail of domitor (6 mg per dose) and Ketalar 
(27 mg per dose) and blood was collected by cardiac 
puncture. Mice were then sacrificed by cervical dislo-
ca tion. Blood was allowed to clot at 4°C overnight 
prior to centrifugation (10,000 g , 10 min, 4°C) and the 
serum stored at -20°C until tested. 
2.6. M easurement of antibody levels 
All measurements of antibody levels in individual 
animals were determined in duplicate. For enzyme-
linked immunosorbent assays (ELISAs) to determine 
IgG and lgA titres, 96-well microtiter plates were 
coated overnight at 4°C either with 50 ).11 5 )lg/ml puri-
fied FJ-antigen [25] in PBS or with 50 ).11 6 )lg/ml S. 
typhimurium SL3261 lysate in PBS, prepared as fol-
lows. Bacteria were grown statically overnight at 37"C, 
prior to harvesting and resuspension in PBS to an ap-
proximate concentration of I x 10 10 cfu/ml. Cells were 
heat-killed in a boiling water bath for 30 min, cooled 
on ice and then sonicated on ice for six pulses of 30 s. 
Total protein concentration was determined by a BCA 
protein assay (Pierce and Warriner, Chester, UK). 
Plates were blocked for I h at 37°C with PBS contain-
ing 1% (wfv) skimmed milk powder (BLOTTO). 
Serum, gut and lung wash samples were diluted in 
BLOTTO and 50 ).11 volumes were assayed in duplicate 
in a series of two-fold dilutions. After incubation over-
night at 4°C, plates were washed three times in PBS 
with 0.02% (vfv) Tween 20. Peroxidase-conjugated sec-
ondary antibodies against mouse lgG or lgA (Harlan 
Sera-Lab Ltd, Loughborough, UK), diluted I :2000 in 
BLOTTO were incubated for 1 h at 37°C. The plate 
was washed as previously and lOO ).11 of 2,2'-azino 
bis(3-ethylbenzthiazoline-6-sulfonic acid) substrate 
(ABTS; Sigma, Poole, UK) was added. Antibody titre 
was estimated as the maximum dilution of serum giv-
ing an absorbance reading at 414 nm of 0.1 U above 
background (sera from animals immunised with 
SL3261 alone) . 
Promoter amplified 
Plac 
5' GAATTCACTAGTATTGTTATCCGCTCACAAT 3' 
5' AAGGAAAAAAGCGGCCGCTGACTCTGGTCGACGAACTTA 3' 
5' CTAGTCTAGATGTGTTAACAATAAGAACAGTCTA3' 
5' AAGGAAAAAAGCGGCCGCTAAACAGACATTCAGAAGTGAATG3' 
5' CTAGTCTAGi\ATATGCCTTTATTGCIIIIIIATG 3' 
PphoP 
PompC 
5' AAGGAAAAAAGCGGCCG GTTAACCACTCTTAATAATAATG3' 
S' CTAGACTAGTTACTACTTATTATTTACG 3' 
• Restriction si tes arc shown underlined. 
PpagC 
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To determine IgG 1 or lgG2a concentrations, ELISAs 
were performed essentially as above, except that wells 
were coated with I 0 J.lg/ml anti-mouse IgG (Fah-
specific, Sigma, Poole UK), 5 J.lg/ml purified Fl-anti-
gen in PBS or 6 J.lg/ml S. typhimurium SL3261 lysate. 
Purified IgG 1 or lgG2a (Sigma) and day 98 serum 
samples were diluted in BLOTTO. Peroxidase-labelled 
secondary antibodies against mouse lgG 1 or IgG2a 
were diluted I :4000 in BLOTTO before use. 
2.7. Gut and lung wash samples 
On day 28, gut and lung wash samples were col-
lected. Briefly, gut wash samples were collected by 
resecting a 10 cm length of small intestine and flushing 
with 5 ml of PBS. Samples were sonicated for 0.5 rnin 
prior to centrifugation (12,000 g, 30 mins, 4°C) and 
the supernatant was decanted and lyophilized. 
Broncho-alveolar washings were collected from indi-
vidual animals by injecting 5 m! of chilled lavage med-
ium (0.9% [w/v] NaCI, 0.05% [v/v] Tween 20, 0.1% 
[wfv] NaN3 and I mM phenylmethylsulfonyl fluoride) 
into the trachea using an intravenous canula and 
inflating the lungs. A syringe was used to remove the 
washings, whjch were subsequently centrifuged 
(12,000 g, 30 min, 4°C) prior to lyophilisation of the 
supernatant fluid. Gut and lung wash samples were 
reconstituted in 200 111 sterile water immediately before 
use. 
Peyer's patches were also removed to determine the 
presence of Fl- and Salmonella-specific lgA producing 
cells in the gut. Briefly, a total of eight Peyer's patches 
were removed from five mice in each treatment group 
and pooled. Cells were separated by crushing through 
a cell strainer, washed by centrifugation and resus-
pended in 1.4 mJ of Dulbeccos Modified Eagles Med-
ium (DMEM) plus 10% foetal calf serum (FCS). 
Duplicate samples (100 Ill/well) were then plated onto 
plates previously coated with 5 llgfml Fl or 6 llgfml S. 
typhimurium SL3261 lysate, and blocked with 20% 
FCS in DMEM, and incubated for 48 h at 37°C. 
Plates were washed and incubated for I h with peroxi-
dase-labelled secondary antibody against mouse lgA, 
diluted I :2000 in PBS before use, and developed with 
I 00 1-11 of ABTS. 
3. Results 
3. 1. Selection of promoters 
The promoters for the phoP. pagC and ompC genes 
have previously been mapped and upstream regulatory 
regions identified [21 ,26-28]. For the phoP gene pro-
moter a 139 bp DNA fragment was identified which 
included the phoPpl and phoPp2 gene promoters and 
Ppal 
Fig. I. Recombinant plasmids used to express the Y. pestis Fl anti-
gen (Cafl ) a nd associated ribosome binding site (rbs) from inducible 
promoters (Ptacz shown). Unique restriction sites in the recombinant 
plasmids a re a lso shown. 
80 bp upstream of the -35 site which has been pre-
dicted to form stem loop structures [21]. For the pagC 
gene promoter a 715 bp DNA fragment included 125 
bp upstream of the -35 region (26]. For the ompC 
gene promoter a 371 bp DNA fragment included a 275 
bp region upstream of the - 35 region [27,28]. These 
DNA fragments were amplified from S. typhimurium 
strain SL1344 genomic DNA using the PCR. For com-
parison with a constitutive gene promoter, a 196 bp 
DNA fragment encoding the lacZ gene promoter and 
140 bp upstream of the - 35 region was identified. The 
3' end of all of the DNA fragments terminated before 
the SD regions associated with the genes. These pro-
moters were cloned upstream of the cafl open reading 
frame (encoding the Y . pestis Fl-antigen) and SO 
region in a low copy number vector (pBR322; Fig. 1) 
and the recombinant plasmids (pPompc-FI , pPphorFI , 
pPpagc-FI or pPtac.z-FI) transformed into S. typhimur-
ium SL3261 (aroA ). 
3.2. In vitro stability of plasmids expressing Fl-antigen 
from different promoters in S. typhimurium 
The stability of the different plasmids encoding Fl-
antigen driven from different promoters in S. typhimur-
ium SL3261 was determined after culture of the bac-
teria in L-broth for 24 h (in vitro stability) and 
enumeration of bacteria which grew on L-agar or L-
agar containing amplicillin. The results indicated that 
all of the plasmids were retained by at least 80% of 
the bacteria which had been cultured in vitro (pP ompc-
FI , 83%; pPphorFI , 100%; pPpagc-FI , 98%; pPtacz-
F1 ,95%). 
3.3. Colonisation of host tissues 
The ability of S. ryphimurium SL3261 containing 
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Fig. 2. Colonisation of spleen tissues 11 days after oral dosing with 
S. typhimuriwn SL3261 (SL3261) or S. typhimurium SL3261 contain-
ing plasmids expressing the Fl-antigen from the PhoP gene promoter 
(PphoP), lacZ gene promoter (PiacZ), PagC gene promoter (PpagC) 
or ompC gene promoter (PompC). Bacteria were enumerated on L-
agar (open bars) or L-agar plus ampicillin (hatched bars). Results 
shown are mean values from groups of 10 mice, with SEM values 
shown as bars. 
pPompc-F1, pPphorF I, pPpagc-F1 or pP1acz-FI to 
colonise host tissues was determined by isolating bac-
teria from the spleens of mice 11 days after i.g. (intra-
gastric) dosing (in vivo stability). With the exception 
of the bacteria containing the Ppagc-F1 plasmid and 
the SL3261 control bacteria, ampicillin-resistant bac-
teria could be recovered from all of the spleens isolated 
from orally dosed mice. The in vivo stability of all of 
the plasmids within Salmonella was lower than the 
stability of the plasmids within Salmonella cultured in 
vitro. 
Although mice were dosed orally with similar num-
bers of bacteria there were marked differences in the 
level of colonisation of spleen tissues at day 11 (Fig. 2). 
The highest levels of colonisation were found with bac-
teria containing pPphorFI. Low numbers of Salmo-
nella containing pPpagc-FI were recovered from spleen 
tissues (maximum 50 cfu/spleen) and none of the bac-
terial colonies were ampicillin resistant. To investigate 
why the presence of the pPpagc-FI affected the colo-
nising ability of this Salmonella, a more detailed study 
was undertaken which involved the enumeration of 
bacteria in the liver and in mesenteric lymph nodes 11 
days after oral dosing. The levels of SL3261 containing 
pP pagc-F I isolated from liver tissues were similar to 
those isolated from spleens (data not shown). Whereas 
the mean number of SL3261 isolated from mesenteric 
lymph nodes was 2.2 x 103 cfu, SL3261 containing 
pPpagc-FI could be isolated only at low level (mean 
20 cfu) from these tissues. 
3.4. Serum antibody responses to FI-antigen 
After i.g. dosing with the recombinant Salmonella, 
mice in all groups developed TgG serum antibody to 
the carrier bacterium, which reached a maximum level 
28 days after immunisation and declined by day 98 
(Fig. 3a). In the case of SL3261 expressing PplrorFI , 
the onset of the immune response was delayed. All 
groups of mice developed lgG serum antibody to Fl-
antigen (Fig. 3b), which had reached a peak at day 98. 
There was no significant difference in the peak titres to 
Fl-antigen induced by the different recombinant Sal-
monella. When the isotype of this antibody was deter-
mined on day 98, it was found to be predominantly of 
an lgG23 isotype in all groups of immunised animals 
(Fig. 4), suggesting that a Thl-type response was 
induced. Several other workers have shown that 
recombinant S. typhimuriurn induce a Th 1-type re-
sponse to the guest antigen [29,30]. 
3.5. Mucosal antibody responses to Fl-antigen 
The ability of the different recombinant Salmonella 
to induce a mucosal antibody response after i.g. dosing 
was determined by measuring the levels of circulating 
IgA antibody to F1-antigen or the levels of IgA anti-
body to Fl-antigen in gut or lung wash samples 
(Fig. 5). The results indicated that SL3261 containing 
pPphorFI, pP,acz-Fl or pPpagc-F1 plasmids all 
induced serum IgA antibody to PI-antigen. The induc-
tion of circulating IgA to PI-antigen did not correlate 
with the presence of lgA to Fl-antigen at mucosal sur-
faces . For example, SL3261 /pP1acz-Fl induced high 
levels of serum antibody to Fl-antigen but IgA anti-
body to PI-antigen was not detected in gut or lung 
wash samples. Only SL3261 /pPplrorFl induced an 
IgA antibody response to Pi-antigen in both the gut 
and the lung. 
3.6. Production of IgA by Peyer's patch cells 
To investigate whether Peyer's patch cells had been 
primed to produce lgA, ELISPOT analysis was carried 
out 28 days after immunisation. The results showed 
that the secretion of lgA against F !-antigen was great-
est in Peyer's patch cells isolated from mice which had 
been immunised with SL3261 containing pPpagc-Fl 
(Fig. 6a). Peyer's patch cells taken from mice which 
had been immunised with SL3261 /pPP110r FI also pro-
duced lgA. Cells taken from other groups produced 
only low levels of lgA to Fl-antigen . This pattern of 
response was not reflected in the pattern of production 
of lgA against Salmonella; Peyer's patch cells taken 
from mice which had been immunised with SL3261 / 
pPpagc-FI produced only low levels of antibody lo 
Salmonella. 
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Fig. 3. Antibody responses to S. typhimurium SL3261 (panel a) or Fl-antigen (panel b), determined by ELISA of serum samples taken 21 days 
(open), 28 days (hatched) or 98 days (cross-hatched) after oral dosing with S. typhimurium expressing the Fl -antigen from the phoP. /acZ, page 
or ompe promoters. Results shown are mean values from groups of eight mice, with SEM values shown as bars. 
4. Discussion 
The development of effective vaccines against patho-
gens is dependent not only on the identification of the 
appropriate protective antigens but also on the induc-
tion of an immune response at the site in the body 
which provides maximum protection against disease. 
For some pathogens, serum antibody provides protec-
tion against disease. However, many pathogens enter 
the body at a mucosal surface and protection against 
these diseases might, therefore, be dependent on the in-
duction of mucosal immune responses. The Salmonella 
vaccine vector system is ideally suited to the delivery 
of many vaccine antigens since the vaccine delivery 
mechanism accurately mimics the natural disease, 
entering the body via the gut. 
The promoters used in this study were all selected 
on the basis that they would be induced either in the 
gut or in the phagosomal compartment of host cells 
and were all cloned into a low copy number vector, 
because high copy number plasmids have been shown 
to be unstable in S. typhimurium [31]. The PhoP gene 
would be expected to be expressed at a basal level 
from the PhoPp2 promoter and upregulated in the 
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Fig. 4. Concentrations of lgG 1 (open) and lgG2a (hatched) in serum 
samples taken from mice 98 days after oral immunisa tion wi th S. 
typhimuriwn expressing the Fl-antigen from the phoP. lacZ. page or 
ompe promoters. Results shown are mean values from groups of 
eight mice, with SEM values shown as bars. 
phagosome of host cells as a result of activation of the 
PhoPpl promoter [21]. The PhoP/PhoQ regulatory sys-
tem has been shown to regulate the expression of a 
variety of genes including pagC, and to be important 
for survival in macro phages [ 16, 19]. Genes regulated 
by the PhoP/PhoQ system are also important for the 
virulence of orally delivered bacteria [32]. Expression 
of the ompC gene promoter would also be expected to 
be induced during the early stages of disease, because 
expression of this gene is upregulated under conditions 
of high osmotic strength [12,14], such as those found 
within the gut, under control of the OmpR/EnvZ regu-
latory system [13]. 
We have not measured in vitro the relative strengths 
of the different promoters used in this study, because 
environmental stimuli other than those identified 
above might influence promoter activity. Therefore, it 
is difficult to make meaningful comparisons of the 
strengths of these promoters in vitro. Rather, we have 
relied on in vivo testing of these promoters to identify 
those most suitable for use for the expression of guest 
antigens. Whilst the different plasmids were stably 
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Fig. 5. lgA levels, measured by ELISA, in serum samples (s) or in 
gut (g) or lung (I) washes 28 days after oral immunisation with S. 
typhimurium expressing the Fl-antigen from the phoP. /acZ. page or 
ompe promoters. Results shown are mean values from groups of five 
mice, with SEM values shown as bars. 
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Fig. 6. Induction of FI-specific (a), or S. typhimurium-specific IgA (b) from cells isolated from the Peyer's patches of mice on day 28. Cells were 
cultured on Fl- or S. typhimurium SL3261 lysate-coated plates for 48 hand the level of lgA production assayed. Mice dosed with S. typhimurium 
SL3261 provided the negative control for anti-Fl lgA production, and untreated mice the negative control for anti-Salmonella lgA production. 
Plates were developed with ABTS substrate and results are presented as the absorbance at 410 nm. Results shown a re the mean of duplicate 
assays from Peyer's patch cells pooled from groups of five immunised mice. 
in vitro, this assessment did not provide a good indi-
cation of the stability of the plasmids in bacteria 
which had been delivered to mice by the oral route. 
All of the recombinant Salmonella induced similar 
levels of serum lgG antibody against the whole bacter-
ium and against Fl-antigen. This finding was unex-
pected for bacteria containing pPpagc-FI , since these 
bacteria were unable to invade deep host tissues and 
were recovered only at low levels from mesenteric 
lymph nodes. Since the completion of this work Dun-
stan et al. [33] have reported that the pagC gene pro-
moter can be used to direct expression of the tetanus 
toxjn fragment C in S. typhimuriwn. This recombinant 
proved to be more effective in inducing high levels of 
tetanus toxin antibody than a recombinant in which 
gene expression was directed by the constitutive trc 
promoter, a finding which they attributed to ex-
pression of the pagC promoter directed gene within 
the GALT. 
We have previously shown that protection against 
Y. pestis after immunisation with FI-antigen is anti-
body mediated [9,34]. The levels of serum lgG anti-
body, which developed after immunisation with the 
recombinant Salmonella tested here, are similar to the 
levels of IgG 1 and IgG2a antibody (1.8 and 6 Jlg/ml re-
spectively) which developed after immunisation with 
recombinant Salmonella in which the F ]-antigen was 
expressed from the lac promoter in a high copy num-
ber vector [11]. immunisation with this recombinant 
provided protection against challenge with 50 MLD 
(methan lethal dose) of Y. pestis. However, dosing of 
mice with ampicillin was necessary to ensure mainten-
ance of this recombinant plasmid [35]. 
The recombinant almone/la evaluated here showed 
significant differences in their abilities to induce muco-
sal IgA antibody responses. Serum lgA levels were not 
a good predictor of mucosal lgA levels, in accordance 
with the general findings by other workers that these 
responses are not well correlated [36-38]. After oral 
dosing all of the recombinant Salmonella would have 
entered the body via M-cells, and, if sufficient antigen 
was subsequently presented to immune effector cells, 
then mucosal antibody responses would be expected. 
Our finding that mucosal antibody in the gut was 
induced only after immunisation with recombinant 
Salmonella expressing F !-antigen from the phoP or 
pagC gene promoters suggests that these promoters di-
rected high-level expression of Fl-antigen within 
GALT. Peyer's patch cells taken from mice immunised 
with SL3261/pPpagc-Fl or SL3261 /pPphorFl pro-
duced the highest levels of IgA supporting this sugges-
tion. Immunisation with Salmonella contammg 
pPphorFl also resulted in detectable IgA antibody in 
the lungs. This is in accordance with the finding that 
this recombinant also induced the highest levels of IgA 
in the gut and might indicate tha t the SL3 261 /pPphor 
Fl was more effective than SL3261 /pPpagc-Fl in indu-
cing long-term expression of IgA. 
Although the recombinant containing pPpagc-Fl 
was unable to colonise mesenteric lymph nodes, it is 
possible that it was able to colonise the Peyers patches. 
However, our a ttempts to quantify the numbers of 
bacteria within Peyers patches were hindered by our 
inability to fully homogenise these tissues. 
Therefore, the measurement of the colonisation of 
spleen or liver tissues, as an indicator of vaccine poten-
tial of recombinant Salmonella , may not always be use-
ful. Similar conclusions were reached by Covone et al. 
[2] who showed that effective delivery of the LTK63 
guest antigen to the immune system was effective only 
when the antigen was delivered during the early tage 
of invasion and by McSorley et a l. [6] who bowed 
that recombinant Salmonella expressing glycopro tein 
63 from the osmC promoter were una ble to invade ti s-
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sues beyond the mediastinal lymph nodes, yet induced 
protection against Leishmania major. This might also 
explain why killed Salmonella wi th or without guest 
antigens, which are not able to invade deep host tis-
sues, are able to induce an immune response [30). 
The reasons why bacteria expressing the Fl-antigen 
from the page promoter showed a much reduced abil-
ity to colonise mesenteric lymph nodes and splenic tis-
sues is not clear. It is possible that the additional 
copies of the page promoter and upstream regulatory 
regions titrated out the available PhoP activator within 
the cell, and that this prevented the bacterium from 
responding to the environmental changes encountered 
after uptake by M-cells. However, others have shown 
that Salmonella expressing guest antigens from the 
page gene promoter were able to colonise splenic tis-
sues [33). Alternatively, it is possible that the reduced 
colonisation was a consequence of the high level of ex-
pression of Fl-antigen. Thjs might have placed a meta-
bolic load on the host bacterium which prevented the 
full expression of genes required for survival in the 
host or the Fl antigen might have accumulated to 
toxic levels. Our finding that at 28 days ELISPOT 
analysis showed that Peyer's patch cells taken from 
mice immunised with SL3261/Ppagc-Fl produced high 
levels of lgA antibody to Fl-antigen but low levels to 
Salmonella SL3261 supports the suggestion that high-
level expression of Fl-antigen from the page occurred 
in vivo resulting in death of the recombinant Salmo-
nella. 
Bacterial promoters which are upregulated within 
the phagosomal compartment of host cells clearly have 
a utility for the expression of guest antigens in S. 
typltimurium. These promoter systems may be es-
pecially useful when the induction of a mucosal anti-
body response is important for protection against 
disease. Our findings also suggest that colonisation of 
deep host tissues might not be necessary for the induc-
tion of immune responses after oral immunisation with 
attenuated S. typhimurium expressing guest antigens. If 
this is proven to be the case then it may be possible to 
devise improved vaccine vectors which are rest ricted to 
the host tissues encountered during the early stages of 
the infection process. 
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Expression of an F1 N fusion protein in 
attenuated Salmonella typhimurium and 
protection of mice against plague 
Sophie E. C. Leary*, Kate F. Griffin, Helen S. Garmoryt, 
E. Diane Williamson & Richard W. Titball 
Medical Countermeasures Department, CBD, Porton Down, Salisbun;, Wiltshire SP4 OJQ, U.K. 
(Received January 17, 1997; accepted in revised form April 7, 1997) 
A novel approach to making fusions of F1 and V antigens, which may be incorporated into a live 
recombinant vaccine for plague, was developed. The nucleotide sequences encoding Yersinia 
pestis V antigen (lcrV) and the mature form of F1 antigen (caf1) were amplified by PCR with primers 
which included tails. At the 3' end of caf1 and the 5' end of lcrV, the tails encoded one of three 
six- or eight-amino acid linkers or their complementary sequences. The DNA overlap in each linker 
region was used to prime a second PCR to generate three F1 N fusions, which were cloned into 
pUC18. The resulting plasmids expressed fusion proteins consisting of F1 and V antigens, separated 
by the linkers Gly-Ser-lle-Giu-Giy-Arg, Ser-Aia-Pro-Giy-Thr-Pro or Ser-Aia-Pro-Giy-Thr-Pro-Ser-
Arg. As shown by Western blotting of bacterial cell lysates with anti-V and anti-F1 sera, the level 
of expression and degree of degradation of the three fusion proteins was similar. To investigate 
the immunogenicity of F1N, one of the plasmids, placFV6 which encoded the Gly-Ser-lle-Giu-Giy-
Arg linker, was electroporated into the attenuated Salmonella typhimurium strain SL3261 (aroA). 
Mice receiving two intravenous doses of 5 x 106 cfu SL3261/placFV6 developed serum anti-V and 
anti-F1 lgG titres, with similar lgG1:1gG28 isotype ratios, and T cell responses specific for V and F1 
antigens. Six weeks after vaccination, mice were challenged subcutaneously with 7.4 x 1 02 or 
7.4 x 104 LD50s of Y. pestis strain GB, and a significant degree of protection was demonstrated. 
These results demonstrate the potential of eo-expressing Y. pestis antigens as fusion proteins to 
develop a live recombinant vaccine against plague. © 1997 Academic Press Limited 
Key words: Plague, Yersinia pestis, F1 antigen, V antigen, attenuated Salmonella. 
Introduction 
Plague is endemic in regions of north and south 
America, Africa, China and Asia [1] where it 
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persists primarily in rodent populations and is 
spread by a flea vector carrying blood infected 
with the causative bacterium, Yersinia pestis. Bu-
bonic plague may be transmitted to humans 
following the bite of an infected flea, leading to 
isolated cases of plague or outbreaks in the 
local population; the largest number of cases are 
usually found in developing nations, par-
ticularly in Africa, South-East Asia and South 
© 1997 Academic Press Limited 
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America [2, 3]. Bubonic plague is characterized 
by the sudden onset of fever and the painful 
swelling of lymph nodes ("buboes") close to the 
flea bite, which are a focus of bacterial infection. 
Bacteria disseminate widely from these sites, 
and if the lungs are infected, the disease is 
readily transmitted in aerosols generated by 
sneezing or coughing, leading to outbreaks of 
primary pneumonic plague. 
Provided treatment is prompt, antibiotic ther-
apy is effective against bubonic plague, although 
the mortality rate in cases of pneumonic plague 
remains high. Vaccination provides an al-
ternative means of protection, and is the pre-
ferred option for individuals at higher risk of 
infection, such as those engaged in field work 
in areas with enzootic plague and laboratory 
workers handling the bacterium [2]. In the West-
ern world, the current plague vaccine consists 
of formaldehyde- or heat-killed preparations of 
Y. pestis derived from virulent strains. The vac-
cine induces protection against bubonic plague 
in a murine model [4] and is also believed to 
lessen the incidence and severity of the disease 
in humans; this is supported by the low number 
of cases among inoculated U.S. troops in Viet-
nam [5] . However, its ability to protect against 
pneumonic plague is doubtful, and in rodent 
models, the protection afforded against a lethal 
aerosol challenge of Y. pestis was minimal [6]. 
In addition, side reactions, ranging from mild 
headaches to severe malaise and fever, occur in 
up to 10% of individuals inoculated with the 
vaccine [7, 8]. 
Y. pestis produces many chromosomally- and 
plasmid-encoded virulence markers, including 
pigmentation, plasminogen activator, 10 or 11 
Yops, V antigen and F1 capsule antigen [9, 10]. 
The precise contribution of many of the virulence 
determinants to the pathogenesis of plague is not 
fully understood, and as a result, it is difficult to 
predict the immunogenic potential of candidate 
vaccines. However, the F1 and V antigens have 
been identified as major protective antigens [ 6, 
11], and when eo-inoculated intraperitoneally, 
they have been shown to protect mice against 109 
LDso5 of Y. pestis administered parenterally [12]. 
V antigen is a secreted protein encoded by 
the 70-75 kb plasmid, and was originally iden-
tified as one of the key virulence factors of Y. 
pestis [13, 14]. It is now believed to have a 
bifunctional role, acting as a regulator of the 
low calcium response [15, 16], and apparently, 
as an immunomodulator by inhibiting the pro-
duction of the cytokines, gamma interferon (IFN-
S . E. C. Leary et al. 
y) and tumour necrosis factor alpha (TNF-cx), 
thus preventing the infiltration of host in-
flammatory cells into infected organs [17, 18]. 
F1 antigen is encoded by the 110 kb plasmid and 
is exported to form a capsule around Y. pestis, 
which is believed to prevent phagocytosis by 
host cells [19-21]. 
Attenuated Salmonella typhimurium strains 
have been well characterised as carriers of many 
heterologous antigens and are capable of eli-
citing both systemic and mucosal immune re-
sponses [22], which may be important in 
protecting against bubonic and pneumonic 
plague. Previously, we have expressed F1 an-
tigen intracellularly in Salmonella, and induced 
protection against 50 LDso5 of Y. pestis in 90% of 
mice [23]. To build on this preliminary work 
and enhance protection levels, we have studied 
alternative approaches, including the pro-
duction of recombinant Salmonella which express 
F1 externally as a capsule-like structure [24]. 
This approach was successful in inducing high 
levels of protection against 107 LDso5 of Y. pestis. 
However, it has been shown that mice vac-
cinated with F1 antigen alone were not protected 
against naturally occurring or genetically mut-
ated Fl-negative strains [21]. These mutant 
strains retain their virulence in mice [21] and 
African green monkeys [25], and a human case 
of plague caused by a F1-negative strain has 
been reported [26]. Thus, to provide effective 
protection against plague, it is desirable that 
F1 antigen should be administered with other 
antigens. 
It has been shown that combined dosing with 
F1 and V antigens affords a high degree of 
protection in a murine model of bubonic plague 
[12]. In this study, as a first step towards de-
veloping a live recombinant vaccine for plague, 
we have addressed the problem of eo-expressing 
these antigens in S. typhimurium aroA. Using a 
rapid PCR method, we have developed a novel 
technique for making genetic fusions of F1 and V 
antigens, separated by different peptide linkers. 
One of the F1/V fusions was expressed in Sal-
monella, and the protective immune responses 
were compared with those induced by F1 and 
V antigens eo-immunized as subunits. 
Results 
Cloning of F1 N fusion proteins 
A rapid PCR technique was developed to make 
fusion proteins consisting of the F1 and V an-
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Table 1. PCR primers used to amplify the cafl and lcrV genes. 



















The flanking primers F/5'6 and VG/3'A contain the Sad and Hindiii restriction sites, respectively. In VG/3'A, the 
nucleotide A • was altered from the published sequence of lcrV (Price S. B. et al., 1989) to include an extra termination 
codon (TAG) in the amplified DNA. In the "tinker" primers, the nucleotides encoding the linker peptides or the 
complementary sequences are underlined. For each pair of "tinker" primers, the derived plasmid and encoded linker 
peptide (using single letter codes for the amino acids) are shown. 
tigens of Y. pestis separated by short peptide 
linkers. The technique avoided the need for a 
two-step cloning procedure and could be ad-
apted to fuse any pair of proteins separated by 
a chosen linker region. In this case, the fusion 
proteins were synthesized with one of three 
six- or eight-amino acid linkers. The first linker 
encoded the peptide Gly-Ser-Ile-Glu-Gly-Arg, 
which included a factor Xa cleavage site (Ile-
Glu-Gly-Arg). Previous work with a glutathione 
5-transferase/V antigen fusion, separated by a 
linker containing this sequence, indicated that 
high levels of expression could be achieved, and 
suggested that it may also allow the effective 
synthesis of an F1/V fusion [11]. The remaining 
two linkers were a hexapeptide (Ser-Ala-Pro-
Gly-Thr-Pro) and a related octapeptide (Ser-Ala-
Pro-Gly-Thr-Pro-Ser-Arg). These linkers were 
designed according to principles established by 
Jagusztyn-Krynicka et al. [27], which indicated 
that maximum antigenicity of fusion proteins 
was obtained when the intervening linker con-
sisted of at least six amino acids with two proline 
residues. 
DNA fragments of cafl and LcrV were amp-
lified from Y. pestis GB to include tails at the 3' 
end of cafl and the 5' end of lcrV, which encoded 
one of the three linkers or their complementary 
sequences (Table 1). Annealing of the com-
plementary tails within the linker regions was 
used to prime a second PCR to generate a fusion 
of the cafl and lcrV genes (Fig. 1). After further 
amplification with flanking primers (Table 1) 
and digestion with the appropriate restriction 
enzymes, the gene fusions were cloned down-
stream of the lac promoter in pUC18 to make 
the recombinant plasrnids placFV6, placFV603 
or placFV8 (Table 1). 
The fusion proteins consisted of mature F1 
antigen and V antigen cloned in-frame with 
the vector-encoded LacZ' fragment; thus, the 
complete proteins encoded nine additional 
amino acids at the N-terrninus (Met-Thr-Met-
lle-Thr-Asn-Ser-Ser-Ser), and were expected to 
accumulate in the cytoplasm 
Production of F1 N in vitro 
In initial experiments, the expression of the three 
F1/V fusions was compared in IPTG-induced 
cultures of recombinant E. coli JM109. The final 
~ of the cultures were adjusted so that they 
were equal and the bacterial cells were harvested 
from a 1 rnl sample. The cells were lysed by 
boiling in SDS-PAGE sample buffer, and the 
lysates were examined by SDS-PAGE and West-
em blotting with rabbit anti-V serum. A major 
band, equivalent to a molecular weight of ap-
proximately 54 kDa, and at least six discrete 
degradation products were detected in all of the 
lysates (data not shown, but similar to results 
shown in Fig. 2, lane 2). The intensity of the 
bands in the three lysates was also similar, in-
dicating that the level of protein expression was 
the same (data not shown). 
Because the amino acid sequence of the linker 
in the three F1/V fusions did not affect the level 
of expression or the degree of degradation, only 
one of them, encoded by placFV6, was selected 
to be expressed in the attenuated S. typhimurium 
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Fl/5'B Flink/3 'C Vlink/5'C VG/3'A 
GATCGAGCTC--+ CCTAGGTACCTTCCAGCA AACCAACCATCCATCCAAGGTCC'I'------+ - TTCCAATACC 







is· .... .'L\.t.Q!;MGGATCCATCCAACCTCC,:. 3'1 is· a~CTAGGTACCTTCCAGCAI... 5'1 
'Fusion assembly' PCR: annealing of boxed sequences and ex~ 
Sac! 
r· =-=-~-_,~,-, • 
1 11 1 1 Hindlii 
... ~ill! s!S!i!S!Bm Si!!81i 
'Fusion amplification' PCR: addition I 
of flanking primers and amplification of fusion 
Fl/5'B VG/3'A 
- -
~- ... ' '---
.. --- --- ~ 
GGA TCC ATC GAA GGT CGT 
Cly Ser fie Glu Gly Arg 
Figure 1. Construction of plasmid placFV6. The PCR primers used to amplify the cafl and lcrV genes are 
shown with the sequences of their 5' tails. The tails of primers Fl / 5'B and VG/3'A include the restriction 
sites Sacl and Hindiii, respectively. The tails of primers Flink/3'C and Vlink/ 5'C encode the linker Gly-Ser-
Ile-Glu-Gly-Arg. In addition, the tail of primer Vlink/S'C encodes the 3' end of cafl (underlined). During 
"fusion assembly" PCR, the 26-bp boxed sequences armeal; these sequences include the linker, the 3' end of 
cafl (underlined), the 5' end of lcrV (double underlined) and the nucleotides dA, which are added to the 3' 
ends of PCR prqducts by Taq polymerase (lower case). A similar method, using different "linker" primers, 
was used to construct the plasmids placFV603 and placFV8. 
strain SL3261 and included in immunogenicity 
studies. 
The expression of Fl/V in cultures of S. typhi-
murium SL3261/placFV6 was studied in vitro. A 
unique protein with an approximate molecular 
weight of 54 kDa was expressed, which was 
detected by Western blotting with anti-V poly-
clonal sera, an anti-Fl MAb (Fig. 2), and anti-Fl 
polyclonal sera (data not shown). This protein 
was not detected in cultures of SL3261/pUC19. 
A band of similar intensity was detected after 
Western blotting of SL3261/placFV6 cells cul-
tured in the presence and absence of IPTG, 
indicating that expression in S. typhimurium 
SL3261 was constitutive (Fig. 2); this was due to 
the absence in this strain of the lac! gene which 
encodes the lac repressor protein. 
The anti-V sera also reacted with breakdown 
products of the fusion protein; the smallest de-
tectable fragment was approximately 37 kDa. 
The anti-Fl Mab and polyclonal sera did not 
recognize these fragments, thus suggesting that 
degradation was occurring from theN-terminus 
of Fl/V, and that removal of N-terminal amino 
acids was sufficient to destroy Fl-reactive epi-
topes. 
To determine the level of expression of Fl I V in 
vitro, sonicates were prepared from logarithmic 
and stationary phase cultures of S. typhimurium 
SL3261/ placFV6 grown in the absence of IPTG, 
and analysed by ELlS A using rabbit anti-V 
serum as the primary antibody. Expression of 
Fl/V from logarithmic and stationary phase 
cultures occurred at levels of 25 and 150 f..Lg / ml, 
respectively. Compared with a similar construct, 
SL3261 / pFGAL2a, which carried only the cafl 
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anti-V a nti-Fl 
Figu re 2. Western blot of S. t1jphimurium Sl.3261 cell lysates separated by SOS-PAGE and probed with (a) 
rabbit polyclonal anti-V serum or (b) mouse anti-Fl MAb. Cultures of SL3261/placFV6 or Sl.3261/pUC19 
were grown for 6 h in the presence or absence of IPTG; equivalent numbers of cells were harvested and the 
pellet was resuspended in SOS-PAGE sample buffer. Lane (a)l: purified V; lane (b)l: purified Fl; lane 2: 
SL3261 / placFV6 ( + IPTG); lane 3: SL3261/placFV6 (-IPTG); lane 4: SL3261/pUC19 (-IPTG); M: molecular 
mass markers ( x l<f). 
gene and produced more than 2 mg/ml of F1 in 
stationary phase cultures [23], the quantity of 
F1/V was reduced approximately 15-fold. This 
suggested that the additional synthesis of V 
antigen caused a significant reduction in the 
yield of heterologous protein from S. typhi-
murium SL2361. 
Protective efficacy of F1 N encoded by 
placFV6 
To study the protective efficacy of F1/V, mice 
were inoculated intravenously (i.v.) on days 0 
and 14 with 5 x 106 cfu of S. typhimurium 
SL3261/placFV6. Previously, it had been shown 
that pUC18-based plasmids were segregated in 
vivo; hence, bacterial cells recovered from the 
liver and spleen were plasmid-negative and had 
lost the ability to express heterologous antigen 
[28]. In an attempt to overcome this problem, 
mice receiving SL3261/ placFV6 were dosed with 
the antibiotic, Penbritin, for 5 days after in-
oculation, thus forcing continued selection of 
the ampicillin-resistant plasmid. One week after 
the first dose, bacterial colonization of the spleen 
was determined in groups of five mice; the 
organs were homogenised in PBS and a sample 
was inoculated on to plates of L-agar ± am-
picillin. Despite the inoculation of equivalent 
doses, the proportion of colonies recovered from 
the spleens of mice which received SL3261/ 
placFV6 was much lower than control mice 
which received SL3261 alone (Table 2), sug-
gesting that SL3261/placFV6 had a diminished 
ability to invade and survive in the reticulo-
endothelial system. In addition, only 37% of 
colonies recovered from SL3261/placFV6-vac-
cinated mice retained the recombinant plasmid, 
indicating that, in this case, administration of 
antibiotic had not been completely successful in 
preventing plasmid segregation. 
Eight weeks after the first immunization, 
groups of seven mice which had been vaccinated 
twice with SL3261/placFV6 were challenged 
subcutaneously with 7.4 x 102 or 7.4 x 104 LDso5 
of Y. pestis strain GB and observed for 14 days. 
At both the low and high challenge doses, one 
mouse died, after 320 h and 124 h, respectively 
(Table 3). Some breakthrough in protection was 
also observed in mice immunized with F1 +V 
ip and challenged at the higher dose of 7.4 x 104 
LDso5. This was unusual, because previously, 
solid protection against a challenge with up to 
109 L050s of Y. pestis GB had been observed in 
mice immunized with F1 +V antigens [12]. The 
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Table 2. Colonization of spleens after i.v. inocula tion". 
S. typhimurium Dose cfu Average cfu per spleen ± SEMb Recovery Retaining 
plasmid 
L-agar L-agar + 
ampicillin 
SL3261 / 5 X 106 1.0 X 103 ± 3.8 X 102 ± 0.02% 37% 
placFV6 2.9 X 102 1.4 X 102 
SL3261 5 X 106 1.85 X 107 ± NA 100% NA 
3.57 X 106 
• Five BALB/c mice were inoculated i.v. with 5 x 106 cfu S. h;phimurium SL3261 or a recombinant containing placFV6. 
Mice vaccinated with SL3261/placFV6 were also dosed with ampicillin for 5 days. After 7 days, the spleens were isolated, 
homogenized in PBS and a sample was inoculated on to plates of L-agar or L-agar supplemented with 100 ~tg/ml 
ampicillin. 
b Standard error of the mean. 
NA: not applicable. 
Table 3. Protection of mice against challenge with Y. pestis". 
Group Challenge dose No. of survivors/ Time to dea thb 
LD50 total no. (h) 
SL3261 / placFV6 i.v. 7.4 X 102 6/ 7 320 
7.4 X 104 6/7 124 
SL3261 i.v. 7.4 X 102 0/ 5 97 ± 18 
7.4 X 104 0/ 5 98 ± 19 
F1 + V i.p. 7.4 X 102 7/7 
7.4 X 104 6/7 184 
Control 7.4 X 102 0/ 5 117 ± 5 
7.4 X 104 0/ 5 64 ± 7 
"Groups of five or seven mice were inoculated i.v. with 5 x 106 cfu SL3261/ placFV6 (two doses on days 0 
and 14) or SL3261 (one dose on day 0). On days 0 and 14, groups of five mice were also immunized i.p. 
with a mixture of 10 J.Lg V and 10 J.Lg Fl adsorbed to Alyhydrogel. A control group of five mice was untreated. 
On day 57, immunized and control mice were challenged subcutaneously with 7.4 x 102 or 7.4 x 104 LD50s 
of Y. pestis GB and observed for 14 days. 
b Values are means± standard error of the means. 
reason for the difference is not clear, but may 
be due to the lack of hyperimmunity in one 
mouse. In contrast, there were no survivors in 
the untreated control group, and all mice which 
received SL3261 alone also succumbed to the 
infection relatively quickly with mean times to 
death of 97 ± 18 hat the low dose or 98 ± 19 h 
at the high dose. Mice dosed with either SL3261/ 
placFV6 iv or F1 +V ip which survived the 
challenge remained healthy, and 14 days after 
the challenge, their tissues were clear of Y. pestis 
infection. 
The level of protection induced by SL3261 / 
placFV6 was enhanced in comparison to a pre-
vious study, in which mice were inoculated iv 
with a similar strain, SL3261 / pFGAL2a, ex-
pressing F1 antigen alone [23] . In that study, 
only nine out of ten mice survived a lower 
challenge with 50 L050s of Y. pestis GB. The 
increased protection may be attributed to the 
eo-expression of V antigen in SL3261/ placFV6. 
Similarly, previous work has shown that eo-
immunisation of F1 and V antigens in a subunit 
formulation induces greater protection than was 
observed for either subunit alone [12] . However, 
the level of protection induced by SL3261 / 
placFV6 did not exceed that of recombinant 
SL3261 expressing F1 antigen on the bacterial 
surface [24]. In that case, all mice survived after 
a challenge of 107 cfu Y. pestis GB; the enhanced 
level of protection may be due to the complete 
stability of the recombinant plasmid in vivo, the 
stimulation of more effective immune responses 
by a surface-located antigen, or the induction of 
antigen expression in vivo [24] . 
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Figure. 3. V- and Fl-specific titres of IgG, IgG1 and 
IgG2a. On day 56, prior to challenge, blood was 
sampled from the tail veins of all immunized and 
control mice, pooled and screened by ELISA for IgG, 
IgG 1 and IgG2a specific to V and Fl. The mean relative 
titre of specific antibody was estimated as described 
in the Materials and methods. O: IgG; •: IgGl; • : 
IgG2a. 
Antibody titre and sub-type in immunized 
animals 
On day 56, prior to challenge, blood was col-
lected from the tail veins of immunized and 
control animals. Mice vaccinated with two i.v. 
doses of SL3261/placFV6 developed serum anti-
body responses to both V and Fl antigens, al-
though the mean relative anti-V IgG titre was 
approximately 3-fold greater than the anti-F1 
IgG titre (Fig. 3). In mice immunized with F1 +V 
ip, although the Fl- and V-specific responses 
were approximately 25-fold higher, the anti-V 
IgG titre also exceeded the anti-F1 titre. This 
indicated that V is the immunodominant an-
tigen, whether it is presented in combination 
with Fl as a soluble antigen or in Salmonella. 
Like SL3261/placFV6, F1-specific serum IgG 
titres were also induced by recombinant SL3261 
expressing F1 antigen alone, either intra-
cellularly [23] or on the bacterial surface [24]. 
Because of differences in the assays, it is difficult 
to compare directly the anti-F1 titres stimulated 
by the three constructs, although surface-located 
F1 appeared to induce the greatest response. 
Analysis of the IgG sub-types revealed that 
mice vaccinated with SL3261/placFV6 de-
veloped V- and F1-specific IgG1 responses which 
were approximately two-fold higher than the 
equivalent IgG2., responses (Fig. 3). When the 
anti-Salmonella titres were measured by coating 
plates with lysates of S. typl!imurium SL3261, the 
IgG2a response predominated, giving an IgG1: 
IgG2a ratio of 1:4 (data not shown). It is known 
that Salmonella-based vaccines have the potential 
to elicit Th1-type responses, and in mice, the 
cytokine profile associated with these responses 
may lead to enhanced IgG2• levels. Indeed, 
several workers have used this as a measure of 
antigen-specific Th1-type responses to re-
combinant Salmonella [29-31]. However, 
SL3261/placFV6 induced similar levels of serum 
IgG1 and IgG2• specific for F1 and V antigens, 
although the Salmonella-specific response was 
biased towards IgG2a. In the case of recombinant 
SL3261 expressing surface-located F1 antigen 
[24], the F1-specific IgG1:IgG2a ratio of 1:4 re-
flected the anticipated response, and thus, in-
dicated that the isotype ratio elicited by SL3261/ 
placFV6 was not an intrinsic feature of the im-
mune response to F1 antigen. 
As expected, mice immunized with F1 +V 
adsorbed to Alhydrogel developed a response 
which was much more biased towards the IgG1 
sub-type; the anti-V and anti-Fl ratios of IgG1: 
IgG2a were 210:1 and 31:1, respectively. Such a 
bias is associated with a cytokine profile in-
dicative of a Th2-type immune response, which 
is known to be stimulated by the aluminium-
based adjuvant, Alhydrogel [32]. 
Splenic T-cell responses to V and F1 
Prior to challenge, six mice from each group 
were sacrificed, and the splenic T cells were 
purified. The T cells isolated from mice vac-
cinated with SL3261/placFV6 proliferated ex-
tensively when re-exposed to V antigen in vitro, 
and the mean stimulation index was sig-
nificantly greater than forT cells isolated from 
mice immunized with F1 +V (P < 0.05) or from 
control mice immunized with SL3261 alone (P 
< 0.0001) (Fig. 4). In contrast, the proliferative 
responses of T cells to F1 antigen were much 
reduced in comparison to the responses to V 
antigen. There was also no difference in the 
mean stimulation indices ofT cells isolated from 
SL3261/placFV6- and F1 + V-dosed mice, al-
though the responses were significantly en-
hanced over the controls from SL3261-
vaccinated mice (P < 0.05). Proliferation of 
splenic T cells in vitro in response to F1 antigen 
has also been shown previously for recombinant 
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25 !lg/ml [V] 25 !lg/ml [Fl] 
Figure 4. Proliferation of purified splenic T cells 
against V or F1 antigens. On day 56, six mice from 
groups inoculated with SL3261/placFV6, SL3261 or 
Fl +V were sacrificed and their spleens removed. T 
cells were purified from each group, pooled and 
stimulated in vitro with V or Fl antigens (25 Jlg/ml). 
The proliferative responses were quantified by the 
incorporation of [3H]thymidine and the mean stimu-
lation index was calculated as described in the 
Materials and methods. The results show the mean 
of four replicates ± the standard errors of the means. 
0: SL3261 / placFV6; • :V+Fl; 1?&1: SL3261. 
Salmonella expressing F1 intracellularly [23] or 
on the surface [24]. 
Discussion 
There has been a resurgence of interest in de-
veloping an improved plague vaccine, which 
provides effective protection with limited side 
effects. The most realistic target would be a 
subunit vaccine consisting of purified antigens 
of Y. pestis, and recent studies have focused on 
this possibility [6, 11, 12, 33]. These studies have 
shown that the F1 and V antigens are major 
protective antigens. In addition, protection in a 
murine model of bubonic plague is most effect-
ive when the F1 and V antigens are combined, 
and it has been demonstrated that eo-im-
munization affords solid protection against chal-
lenge with 109 LD50s of Y. pestis [12]. 
In this study, S. typhimurium SL3261 has been 
used as a vaccine vector for the expression of 
Y. pestis antigens. This strain is attenuated by 
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specific mutation of the aroA gene, and has been 
used extensively for the delivery of heterologous 
antigens to the immune system [22]. The prin-
ciple of using live, attenuated bacteria as vaccine 
vectors is well-established, and they may offer 
significant advantages over the parenterally ad-
ministered subunit vaccines described above. 
For example, attenuated S. typhimurium has been 
shown to stimulate a broad range of humoral 
and cell-mediated immune responses when 
delivered orally, intravenously or intraperi-
toneally [29]. In addition, single doses may be 
sufficient to generate long-lived immune re-
sponses due to the persistence of bacteria in the 
tissues. 
Previous studies in which F1 antigen has been 
expressed inS. typhimurium either intracellularly 
[23] or on the surface [24] have demonstrated 
the potential of this approach for inducing pro-
tection against plague. However, experiments 
with naturally occurring or genetically mutated 
Fl-negative strains of Y. pestis have shown that 
these strains retain their virulence in un-
vaccinated or F1-irnmunized mice21. Therefore, 
to provide effective protection against a range 
of virulent Y. pestis strains, it is desirable that a 
future vaccine is not dependent on F1 antigen 
alone. 
To address this problem, we have devised a 
rapid PCR technique for eo-expressing two Y. 
pestis proteins, the F1 and V antigens, as a fusion 
protein in attenuated S. typhimurium aroA. The 
technique enabled a short peptide of any chosen 
sequence to be inserted between the two pro-
teins, thus giving complete flexibility in design 
of the fusion. In this study, the F1 / V fusion was 
synthesized with three different tinkers, Gly-
Ser-lle-Glu-Gly-Arg, Ser-Ala-Pro-Gly-Thr-Pro or 
Ser-Ala-Pro-Gly-Thr-Pro-Ser-Arg, and the effect 
of the tinker on protein expression and break-
down was investigated. No differences were 
observed between the three fusion proteins, and 
in particular, the amount of degradation, ap-
parently from the N-terminus, suggested that 
all of the linkers prevented the protein domains 
from folding correctly. 
To determine the immunogenicity of F1 / V, 
one of the plasmids, placFV6, which encoded 
the Gly-Ser-Ile-Glu-Gly-Arg linker, was trans-
formed into S. typhimurium SL3261 and in-
oculated into mice. In comparison to SL3261, 
bacteria carrying placFV6 were recovered in 
proportionally lower numbers from the spleens 
of vaccinated mice, indicating that they had a 
reduced ability to invade and survive in the 
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reticuloendothelial system. The reason for this 
is not clear, but may be linked to the greater 
metabolic load placed on a bacterium which 
is constitutively expressing a foreign protein. 
Despite the decreased colonization of SL3261/ 
placFV6, two iv doses stimulated protective im-
mune responses to the fusion protein, thus sug-
gesting that the initial amount of the Fl/V fusion 
presented to the immune system may be the 
most important factor in inducing protection 
rather than persistence of the antigen in the 
tissues. 
The immune responses stimulated by SL3261 I 
placFV6 were sufficient to protect 6/7 mice 
against a subcutaneous challenge with 7.4 x 104 
LDso5 of Y. pestis GB. The protective responses 
were characterized by both humoral and cell-
mediated immunity, as shown by the detection 
of F1- and V-specific serum IgG titres, and the 
proliferation of purified splenic T cells when 
exposed to V antigen in vitro. The IgG isotype 
was also determined, because in mice, a bias 
towards IgG2a is indicative of a cytokine profile 
associated with Th1-type responses, which are 
known to be elicited by Salmonella [29]. It is 
therefore interesting that SL3261/placFV6 in-
duced similar titres of antigen-specific IgG1 and 
IgG2a, although the Salmonella-specific response 
was biased in favour of IgG2a. There have been 
other reports that foreign antigens expressed in 
Salmonella have induced approximately equal 
ratios of specific IgG1:lgG2a [34, 35]. This em-
phasizes that the factors determining the nature 
of the immune response to a particular antigen 
are not fully understood, and for example, it 
may be influenced by the mechanism of antigen 
release from the bacterium [36] or the level of 
antigen expression [37]. In comparison to F1 +V-
immunized mice, animals vaccinated with 
SL3261/placFV6 developed only moderate 
serum IgG responses specific for F1 and V an-
tigens, and this suggests that the level of antigen 
expression in vivo may be low, and may offer 
an explanation for the observed IgG isotype 
ratio. 
In summary, the data reported here describe 
the mechanisms of protective immunity stim-
ulated by F1 and V antigens presented as puri-
fied subunits or as a fusion protein in Salmonella. 
The profile of the immune responses to the two 
formulations is different and in particular, when 
compared to purified F1 and V antigens, re-
combinant Snlmonelln stimulated moderate Fl-
and V-specific serum IgG titres, a subtype dis-
tributjon which was only slightly biased towards 
IgG1, and a significantly enhanced T cell recall 
response to V antigen. Despite these differences, 
the majority of mice receiving either formulation 
were protected against challenge with 7.4 x 104 
LDso5 of Y. pestis. 
In earlier studies, it was reported that S. typhi-
murium SL3261 constitutively expressing an in-
tracellular form of F1 antigen induced protection 
against 50 LDso5 Y. pestis in 90% of mice [23]. 
We have demonstrated that eo-expression as a 
fusion with V antigen raised the level of pro-
tection more than 1000-fold, and thus, confirmed 
the importance of immune responses to V an-
tigen in protection. Previous experience with 
Salmonella expressing F1 showed that the level 
of protection could be enhanced by increasing 
plasmid stability in vivo, changing the site of 
antigen of expression in the bacterium, or in-
ducing antigen expression in vivo [24]. Currently, 
we are investigating how these factors may be 
applied to the F1/V fusion protein and in par-
ticular, whether novel in vivo-inducible pro-
moters may be an efficient way of expressing 
the fusion in Salmonella to achieve high levels of 
protection against plague. 
Materials and methods 
Enzymes and reagents 
Materials for the preparation of growth media 
were obtained from Oxoid Ltd or Difco Laborat-
ories. All enzymes used in the manipulation of 
DNA were obtained from Boehringer Mannheim 
UK Ltd and used according to the manu-
facturer's instructions. All other chemicals and 
biochemicals were obtained from Sigma Chem-
ical Co unless otherwise indicated. Polyclonal 
anti-V serum was prepared at CBD from rabbits 
inoculated with recombinant V antigen pre-
sented in Alhydrogel, and mouse anti-Fl IgA 
monoclonal antibody F13G8-1 was was obtained 
from the American Type Culture Collection. The 
F1 and rV antigens were prepared as described 
previously [11,12]. 
Bacterial strains and cultivation 
Yersinia pestis GB was cultured aerobically at 
28°C, as described previously [11]. Salmonella 
n;phimurium SL3261 [38] and LB5010 [39] were 
kindly provided by B. A. D. Stacker, Stamford 
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University, and G. Dougan, Imperial College, 
London, U.K., respectively. Escherichia coli JM109 
and S. typhimurium strains were cultured and 
stored as described by Sambrook et al. [40]. For 
inoculation into mice, cultures of S. typhimurium 
SL3261 were grown statically for 16 h in LB, 
containing 100 J..lg/ml ampicillin, if needed. After 
washing, the cells were resuspended in 10% 
glycerol in phosphate buffered saline (PBS) and 
stored at -70°C. The cell suspensions were 
defrosted and diluted in PBS as required prior 
to injection. To prepare lysates of S. hjphimurium 
for ELISAs, cultures were grown as described 
above, washed in PBS and adjusted to the de-
sired cell density. The cells were heat-killed by 
incubating in a boiling waterbath for 30 min. 
After centrifugation to remove the cell debris, the 
supematant, containing soluble antigens, was 
recovered and used to coat ELISA plates. 
Cloning of F1 N fusion proteins 
Chromosomal DNA was isolated from Y. pestis 
by the method of Marmur [41]. The genes en-
coding F1 antigen (cafl) and V antigen (lcrV) 
were amplified from Y. pestis DNA using PCR 
with 125 pmol of primers (Table 1) homologous 
to sequences from the 5' and 3' ends of the 
genes [42, 43], although for cafl, only the region 
encoding the mature F1 antigen was amplified. 
The sequences of the F1 5' primer and the V 3' 
primer included 5' tails encoding the restriction 
sites Sad and Hindiii, respectively. The F1 3' 
primer and the V 5' primer also included nuc-
leotides encoding six- or eight-amino acid lin-
kers or their complementary sequences. The PCR 
primers were prepared with a DNA synthesizer 
(model 392; Applied Biosystems). DNA frag-
ments were obtained after 30 cycles of am-
plification (96°C, 20 s; 50°C, 20 s; 72°C, 30 s; 
model 9600 GeneAmp PCR System; Perkin 
Elmer) and they were purified from a 1% agarose 
gel using a QIAEX gel extraction kit (QIAGEN 
Ltd, Dorking, U.K.). A "fusion assembly" PCR 
(7 cycles of 94°C, 30 s; 50°C, 30 s; 72°C, 1 min) 
was then carried out in a standard 50 J..l]. reaction 
containing 50 ng of the cafl and lcrV PCR prod-
ucts, supplemented with 5 mM MgC12• Sub-
sequently, 125 pmol of primers F1/5'B and VG/ 
3' A were added to the reaction and the volume 
was increased to 100 J..ll by the addition of stand-
ard PCR reagents. A "fusion amplification" PCR 
was then carried out for 25 cycles (94°C, 30 s; 
55°C 30 s; 72°C, 1 min). The fusion PCR products 
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were digested with Sad and Hindlll, ligated 
with suitably digested pUC18, and the the re-
combinant plasmids were transformed into E. 
coli JM109 by electroporation. Positive colonies 
were identified by PCR using 30-mer primers 
(5' nucleotides located at positions 54 and 794 
[43] which amplified an internal segment of the 
lcrV gene. To confirm the nucleotide sequences 
of the cloned inserts, sequencing reactions con-
taining plasmid and primers designed from the 
cafl and I er V genes were performed using an 
automated Taq polymerase cycle sequencing 
protocol with fluorescently labelled dideoxy 
nucleotides (CATALYST Molecular Biology Lab-
station; Applied Biosystems). The reaction prod-
ucts were analysed using an automated DNA 
sequencer (model 373A; Applied Biosystems). 
Plasmid DNA was extracted and purified 
using a QIAprep kit (QIAGEN Ltd, Dorking, 
U.K.) and electroporated into S. hjphimurium 
strain LB5010 (r- m +). Subsequently, modified 
plasmid was isolated and electroporated into S. 
typhimurium strain SL3261 (aroA his). 
Expression of F1 N fusion proteins in E. 
coli JM1 09 and S. typhimurium SL3261 
Cultures of recombinant E. coli JM109 or S. 
typhimurium SL3261 were grown in LB con-
taining 100 J..lgml ampicillin at 37°C until the 
absorbance (600 nm) was 0.3. In some cases, 
isopropyl-~-D-thiogalactopyranoside (IPTG) 
was then added to the culture to a final con-
centration of 1 mM and growth was continued 
for a further 6 h. Before harvesting the cells, the 
AfiXl of the final cultures were adjusted so that 
they were equal. Whole celllysates of the bac-
teria were prepared as described by Sambrook 
et al. [40] and expression of the F1 / V fusion 
proteins was examined by SDS-PAGE on 10--15% 
gradient gels (Phastsystem, Pharmacia Biotech) 
and Western blotting [40]. Western blots were 
probed with rabbit anti-V serum at a dilution 
of 1/ 2000 or mouse anti-F1 MAb at a dilution 
of 1/500, and respectively, protein bands were 
visualized with a colloidal gold labelled sec-
ondary antibody (Auroprobe BLplus, Cambio) 
or a peroxidase conjugated anti-mouse alpha-
chain specific secondary antibody. 
Quantification of F1 N production in vitro 
Cultures of S. hjphimurium SL3261 containing 
placFV6 or pUC19 were grown as described 
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above. One ml aliquots were removed from the 
cultures in logarithmic and stationary phases, 
and the number of viable cells was determined 
by inoculating on to L-agar containing 100 J.lg/ 
ml ampicillin. Sonicates were prepared from a 
second 1 ml aliquot as described previously [11]. 
The sonicates and a standard solution of rV 
(10 J.lg/ ml) were serially diluted in PBS in a 
microtitre plate and allowed to bind overnight 
at 4°C. The quantity of Fl-Y fusion protein in 
each sonicate was determined in a standard 
ELISA using rabbit anti-V serum as the primary 
antibody. Antibodies were incubated in 1% 
skimmed milk powder in PBS. 
Immunization of mice 
Six week old female Balb I c mice, raised under 
specific pathogen-free conditions (Charles-River 
Laboratories, Margate, Kent, U.K.), were used 
in this study. A group of 25 mice received 0.1 ml 
doses of approxiinately 5 x 106 cfu of SL3261/ 
placFV6 on days 0 and 14 by the intravenous 
(iv) route. To retain placFV6 in vivo, mice were 
also injected subcutaneously (se) with 50 J.!l am-
picillin trihydrate suspension (150 mg/ml; Pen-
britin injectable suspension POM; SmithKline 
Beecham Animal Health) for 5 days after each 
immunisation. In addition, groups of 16-20 mice 
were immunised i.v. on day 0 with a single 0.1 ml 
dose of approximately 5 x 106 cfu of SL3261 or 
intraperitoneally (i.p.) on days 0 and 14 with 
0.1 ml of a mixture of 10 J.lg V and 10 J.lg F1 
adsorbed to Alhydrogel. An untreated group of 
16 age-matched mice was used as a control. 
On day 7, five mice from the groups receiving 
SL3261/placFV6 or SL3261 were sacrificed and 
their spleens were removed. The organs were 
homogenised in 5 ml of PBS with a stomacher 
(Seward Medical Ltd) for 1 min. The homo-
genates were serially diluted in PBS and in-
oculated on to L-agar or L-agar containing 
100 J.lg/ml ampicillin to determine the number 
of bacteria per spleen. 
Challenge with Y. pestis 
On day 57, groups of five or seven mice from the 
immunized and control groups were challenged 
s.c. with 0.1 ml ali~uots of Y. pestis strain GB 
containing 7.4 x 10 or 7.4 x 104 cfu. Strain GB 
was isolated from a fatal human case of plague 
and has a 50% lethal dose of approximately 
1 cfu in Balb/c mice by the s.c. route [4]. The 
mice were observed for 14 days and, where 
appropriate, the time to death was recorded. A 
post-mortem was carried out on all animals 
where possible. To test for the presence of Y. 
pestis, samples of blood, liver and spleen were 
smeared on to Congo Red agar and incubated 
at 28°C for 48 h. 
Measurement of serum antibody subclass 
and titre 
On day 56, blood was sampled from the tail 
vein of immunized and control mice, pooled, 
and screened for antibodies specific to rV and 
F1 by an ELISA. Briefly, rV (5J.lg/ml in PBS) or 
F1 (2J.lg/ml) were coated on to a microtitre 
plate and the test sera were serially diluted in 
duplicate on the plate. The Salmonella-specific 
titres were measured by coating the plates with 
bacterial lysates. The serum titres of lgG, IgG1 
and IgG2a were determined using peroxidase 
conjugates (Harlan Sera-Lab, Crawley, U.K.) at 
a maximum dilution of 1:4000. The secondary 
antibodies were shown to be specific for the 
homologous sub-class and to have an equivalent 
sensitivity of detection (data not shown). The 
titre of specific antibody was estimated as the 
maximum dilution of serum giving an ab-
sorbance reading greater than 0.1 units, after 
subtraction of the absorbance due to non-specific 
binding detected in the control sera. Mean rel-
ative titres were calculated as the reciprocal of 
the dilution x the optical density. The control 
for SL3261/ placFV6 sera was provided by mice 
. immunized with SL3261, and for Fl + V sera by 
untreated mice. 
In vitro proliferation ofT cells 
On day 56, purified suspensions of splenic T cells 
were isolated and pooled from six immunized 
mice, and the in vitro proliferative response to 
rV and F1 antigens was determined, as described 
previously [11]. Briefly, T cells were stimulated 
in microtitre plates with F1 or V antigens (25 J.lg / 
ml) or concanavalin A (4J.lg/ml, positive control) 
diluted in a final volume of 0.2 ml of DMEM. 
Negative controls consisted ofT cells with 0.2 ml 
DMEM alone. Purified T cells were seeded into 
each well at a minimum density of 4 x 104 cells 
and incubated for 72 h at 37°C (5% C02). Pro-
liferation was quantified by the incorporation of 
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[3H] thymidine and the mean stimulation index 
was calculated from four replicates as the mean 
of the counts per minute of the stimulated cells 
divided by the mean of the counts per minute 
of the negative control cells. 
Statistical analysis 
The Student's t-test was used to determine the 
significance of the difference between sample 
group means. 
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Abstract 
The growth of an aroA mutant of Salmonella typhimurium (SL3261) in minimal medium containing 0.5 M NaCI resulted in the 
intracellular accumulation of 2.2 ~mol trehalosefmg total protein. The vacuum drying of these bacteria in the presence of trehalose 
allowed the recovery of 35% of the viable cells that were present before drying. In contrast, bacteria cultured in control medium 
accumulated 0.4 JlmOI trehalose/mg total protein and only 5% of the viable cells were recovered after vacuum drying with 
trehalose. Similar results were obtained when S. typhimurium SL3261 , expressing the vaccine antigen (F)-antigen) of Yersinia 
pestis, was cultured in minimal medium with or without 0.5 M NaCl and dried in the presence of trehalose. Although these results 
indicate the potential for trehalose stabilisation of vaccine strains of S. typhimiurium, growth in minimal medium containing 0.5 
M NaCI resulted in the loss of invasion competence of the bacteria. © 2000 Elsevier Science Ltd. AJJ rights reserved. 
Keywords: Salmonella vaccines; Trehalose; Stabilisation 
1. Introduction 
Attenuated strains of Salmonella have attracted con-
siderable attention not only as live vaccines against 
Salmonella infections [1], but also for the delivery of 
heterologous (guest) an tigens [2,3]. Attenuation of the 
bacteria is achieved by the inactivation of genes re-
quired for growth of the bacterium in the host. These 
attenua ted strains are able to colonise host tissues, 
without causing disease, and offer advantages over 
other vaccines. First. the ability of attenuated strains to 
present self and guest antigens to the immune system in 
a ma nner that mimics natural infections can promote 
protective immune responses. Second, a wide variety of 
guest antigens can be expressed in Salmonella vectors. 
These include genetic toxoids such as the fragment C of 
• Corresponding author. Tel.: +44-1980-6 13301; fax : + 44-1980-
6 1328-1 . 
£-mad addre.\S: rtitball@dera.gov.uk (R.W. Titball). 
1 Present address: Institute of Biotechnology, University of Cam-
bridge. Tennis Court Road. Cambridge CB2 IQT, UK. 
tetanus toxin [4] and the LTK63 derivative of L TB 
toxin [5], bacterial protective antigens such as the F !-
antigen of Yersinia pestis [6] and the P69 antigen of 
Bordete/la pertussis [7], vira l a ntigens such as the herpes 
simplex vi rus glycoprotein D [8], and parasite antigens 
such as the glycoprotein 63 of Leishmania major [9]. 
Attenuated Salmonella vaccines can a lso be given 
orally and, because of the ability of the bacterium to 
colonise both mucosal tissues and deep body tissues, 
they are able to induce systemic a nd mucosal antibody 
responses [10,11]. In addition, these vaccines induce 
cell-mediated immunity, which might play a role in the 
clearance of some pa thogens [I 0, 11 ]. Much work over 
the past decade has been focused on the problem of 
achieving sta ble high-level expression of vaccine anti-
gens in Salmonella , and good progress has been made 
in devising vaccine that induce pro tection against dis-
ease after a single oral do e. Many of these Salmonella-
based vaccines have a use not only in developed 
nations, but also in developing countries where single 
oral dose vaccines offer major advantages over multi-
dose injected vaccincs. 
0264-41 OX/00/$ - sec front matter © 2000 Else vier Science Ltd . All rights reserved. 
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Live bacteria l vaccines also present the challenge of 
their storage and transport without degradation. One 
approach to solve this problem is to ensure that the 
vaccines are stored and distributed at low temperatures 
[I 0, 12). However, this poses additional infras tructural 
requirements and the exposure of the vaccine to ambi-
ent temperatures, even for a short period, can render 
the vaccine useless. 
One approach to the stabilisation of biological mate-
ria ls involves the use of trehalose, which forms an inert 
'glass' a round macromolecules, replacing water 
molecules and preventing oxidation and degradation 
[13 - 15). The stabilisation of biological macromolecules 
often involves their drying in the presence of exoge-
no usly added trehalose [15). However, it has 
been shown that some prokaryotic and eukaryotic 
organisms synthesise trehalose in response to osmotic 
stress, and this might enable them to survive periods 
of desiccation [14, 16, 17]. Indeed, when Escherichia 
coli is induced to produce significant levels of intra-
cellular treha lose, desiccation tolerance is improved 
[1 8]. Furthermore, if such trehalose-induced bac-
teria a re dried from trehalose solutions, such that 
treha lose is present both inside and outside the 
cell, remarkable stability can be obtained: essentially 
no loss of viability after storage at 37°C for 6 weeks 
[19). 
In E. coli, the otsA and otsB genes are responsible 
for trehalose biosynthesis from UDP glucose 
[20). These genes encode trehalose-6-phosphate 
synthase and trehalose-6-phosphate phosphatase, 
respectively. The stabilisation of bacterial vaccines 
by the induction of treha lose biosynthesis and drying 
in the presence of exogenous trehalose has been 
proposed as a method for the long-term storage of 
these vaccines without the need for refrigeration [15). 
Such applications would significantly enhance the util-
ity of these vaccines in areas of the world where trans-
port and storage under refrigerated conditions is 
difficult. We have set out to determine whether vaccine 
strains of S. typhimurium can be stabilised using a 
combination of intracellular and extracellular tre-
halose, and to investigate whether stabilisation using 
this approach affected the immunogenic properties of 
the vaccine. 
2. Methods 
2. 1. Enzymes and chemicals 
Unless otherwise sta ted, chemicals were obtained 
from the Sigma Chemical Company (Poole, UK) and 
enzymes used for the manipulation of DNA were ob-
tained from BCL Ltd (Lewes, U K) 
2.2. Bacterial strains and culture 
E. coli strain J M I 09 a nd S. typhimurium SL3261 
(aroA) were maintained on L-agar [21). S. typhimurium 
strain SL3261 containing plasmid pAH34L, which en-
coded the Y. pestis caf operon [6] was maintained on 
L-agar containing ka na mycin A (20 jlgfml). The geno-
types of these strains are shown in T able I . S. ty-
phimurium SL326 1 was grown aerobica lly, at 37°C in 
I 00 ml volumes of L-broth or minimal medium. The 
defined minima l medium contained: Na2HP04·7H20 . 
12.8 gfl; KH2P04 , 3.0 g/1; NH4Cl, 0.66 g/1; I mM 
MgS04 ; 0.1 mM CaCI2; L-tryptophan, 40 mg/1; L-
phenylalanine, 40 mg/1; p-aminobenzoic acid, I 0 mgjl: 
2,3-dihydroxybenzoic acid, 10 mg/1; L-tyrosine, 40 mg/1: 
L-histidine, 40 mg/1; and o-glucose to a final concentra-
tion of 2.5% (wfv). In addition, the trehalose induction 
medium contained 29.22 g/1 NaCI. S. typhimurium 
SL3261 fpAH34L cells were grown as S. cyphimurium 
SL3261 with the additio n of kanamycin A (20 jlgfml) to 
growth media. The growth of bacterial cultures in 
liquid medium was determined by measuring the optical 
density at 600 nm of the culture (OD 600 n.J· 
2.3. Isolation of DNA encoding the Salmonella typhi 
otsA and otsB genes 
DNA was isolated from S. cyphi strain CT18 using 
the method of Marmur [21). Polymerase chain reaction 
(PCR) primers (5'-GAGACCGITfGTGAGTCTCAA-
3' and 5'-AGCGCCAGCCAGGTAGATGTGTT-3') 
for the amplification of the S. typhi otsA and otsB genes 
were designed from the DNA nucleotide sequence 
flanking the otsBA operon from S. typhimurium SL 1344 
[24]. PCR conditions for the amplification of DNA 
Table I 
Genotypes and origins of bacterial strains used in this study 
Species and strain Genotype Reference 
E. coli JM 109 el4-(mcrA-) recAI endA I [22] 
gyrA96 
thi-1 hsdR 17(rK m it) 
sup E44 re/ A I 
D(lac-pro AB) [F' tra D36 
pro AB 
/aclqZDM 15] 
S . typhimurium aroA DEL 406 hisG46 [23] 
SL326 1 
Derivative of S . 
typhimurium 
SL1344 (mouse virulent) 
S . ryphimurirm1 aroA DEL 406 his G46 [6] 
SL326 1/pAH34L 
Derivative of S . 
typhimurium 
SLI344 containing plasmid 
pAH34L 
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were 30 cycles of 96°C for 30 s; 55°C for 30 s; 72°C for 
30 s. The amplified DNA fragment was nucleotide 
sequenced using primers designed from the S. ty-
phimurium SLI344 otsBA sequence. 
2.4. Nucleotide sequencing 
Sequencing reactions were carried using an AB! 800 
Molecular Biology LabStation CATALYST (PE Ap-
plied Biosystems Ltd, Warrington, UK) with rho-
damine dye terminator sequencing (PE Applied 
Biosystems Ltd). The samples were ethanol precipitated 
and analysed using an ABI 373 nucleotide sequencing 
system (PE Applied Biosystems Ltd) with 6% (w/v) 
polyacrylamide gels. 
2.5. Vacuum drying 
Vacuum drying was carried essentially out as de-
scribed previously [19]. Bacterial cultures (2 x 30 ml) 
were centrifuged at 10 000 x g for 10 min at 4°C. The 
cell pellets were washed and resuspended in 8 ml tre-
ha lose solution (45% wfv in phosphate-buffered saline 
(PBS)) containing 0.1 % (w/v) carboxymethylcellulose 
(Bianose 7HF; Honeywill and Stein Ltd., Sutton, UK) 
Aliquots (300 ~-tl) of the bacterial cell suspensions, at a 
typical cell density of 4 x I 09-8 x 109 cfu/ml, were 
dispensed into 3 ml vials and vacuum dried. The num-
ber of viable bacteria were determined by resuspending 
the contents of three vials in deionised water, and by 
plating triplicate serial dilutions of each onto appropri-
ate agar and enumerating colonies after incubation for 
24 hat 37°C. 
2.6. Determination of intracellular trehalose 
concentration 
One millilitre of bacterial culture was centrifuged at 
10 000 x g for 10 min and the supernatant removed. 
The cell pellet was resuspended in 200 ~-tl of 80% (vfv) 
ethanol and the ceJJ wall was disrupted by incubation at 
80°C for 10 min. The suspension was centrifuged as 
already described and the supernatant extracted twice 
with an equal volume of chloroform. The resu ltant 
aqueous phase was vacuum dried and reconstituted in 
500 ~-tl sterile water before ana lysis. 
The intracellular concentration of treha lose was de-
termined in triplicate using high-pressure liquid chro-
matography (Dionex DX-500), using a Dionex 
CarboPac PA analytical column and electrochemical 
detection (Dionex ED40 pulsed amperometric electro-
chemical detector) . The trehalose concentration was 
determined with reference to calibration standards of 
trehalose, glucose, sucrose and maltose at concentra-
tions from 2.5 ~tM to I mM. 
2. 7. Determination of protein content 
Trehalose concentration was expressed as micromoles 
per milligram of protein. Bacterial cells within a 10 ml 
a liquot of culture were co llected by centrifugation at 
10 000 x g for 10 min. The cell pellet was washed 
and resuspended in 50 mM HEPES, pH 7.2. The 
bacteria l cells were disrupted by sonic disruption (MSE 
W-220F) for a total of 2 min in 20 s bursts at 30 s 
intervals. The protein content of 0.1 ml samples of the 
cell lysate was determined in triplicate using the Brad-
ford assay with bovine serum a lbumin as the standard 
protein. 
2.8. In-vitro invasion assay 
The 1774.2 mouse macrophage line was propagated 
in 24-well cell culture plates in Dubecco's modified 
Eagle's medium (DMEM) growth medium, containing 
foetal bovine serum (10%, vfv) and glutamine (2 mM). 
S. typhimurium cultu res were diluted to 5 x I 06 cfu/ml 
and 200 J..Ll culture was aliquotted into cell culture 
plate wells. The plates were centrifuged at 300 x g for 
30 min at 20°C to accelerate contact of the bacteria 
with the surface of the cell monolayer and incubated at 
37°C for I h in 5% C02/95% a ir. Culture medium was 
removed and the cells washed three times with I ml 
PBS. Fresh DMEM medium (1 ml) containing gen-
tamycin sulphate (final concentra tion, 200 ~-tg/ml) was 
added to each well. The cultures were further incubated 
at 37°C for 1 h in a humidified atmosphere of 5% 
COJ 95% air before washing in PBS as already de-
scribed. The 1774 cells were lysed by the addition of I 
ml PBS containing 1% (vfv) triton X-100. Bacterial cell 
counts were performed by serial dilution of the lysates 
in PBS onto duplicate L-agar plates containing 
kanamycin (50 ~-tg/ml). The percentage internalisation 
of S. typhimurium in 1774 cells was calculated according 
to the equation: (Number of internalised bacteria/origi-
nal inoculum count) x 100. 
2.9. Immunisation of mice IVith trehalose-stabilised 
bacteria 
Trehalose-stabilised lyophilised S. typhimurium 
SL3261 /pAH34L were resuspended in L-broth to a 
density of I x 109 -2 x 109 cfu /ml. S . typhimurium 
SL3261 or S. typhimurium SL326 1/pAH34L were cul -
tured in L-broth or L-broth containing kanamycin, 
respectively, for 18 h at 37°C without shaking. The 
cultures were centrifuged (10 000 x g, 20 min at 4°C) 
and resuspended in L-broth so that the number of 
viable cells was in the range I x 109 - 2 x 109 cfu/ml. In 
some experiments, the trehalose-stabilised cells were 
cultured in L-bro th containing kanamycin for 18 h a t 
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Fig. I. Viability of S. typhimurium SL3261 (a) or S. typhimurium 
SL3261fpAH34L (b) that had been dried in the presence of trehalose 
after storage at 37•c. Before drying, the bacteria had been cultured in 
broth under conditions which induced ( e ) or did not induce ( A) 
trehalose biosynthesis. Results shown are the mean of nine detem1i-
nations, with bars indicating S.E.M. values. 
37°C without shaking and treated as described in the 
previous section. Groups of six female BALB/c mice 
were dosed orally with 100 111 cell suspensions, using an 
oral dosing needle. Eleven days after oral dosing, mice 
were sacrificed by cervical dislocation and the spleens 
removed, weighed, and then homogenised in 5 ml PBS, 
pH 7.2. The number of viable cells in spleens was 
determined by plating suitable dilutions onto L-agar or 
L-agar containing kanamycin. 
2. 10. Measurement of antibody to S. typhimurium 
SL3261 and Y. pestis Fl-antigen 
Blood samples were taken from groups of six mice 11 
days after oral dosing with bacteria . The blood was 
a llowed to clot and serum samples were analysed for 
the presence of antibody to whole cells of S. ty -
phimurium SL326 1 or to purified Y. pestis F l -antigen 
[6]. 
3. Results 
3. I . Presence of trehalose biosynthesis genes in S. 
typhimurium and S. typhi 
We have previously reported the isolation and nucle-
otide sequencing of the otsA and otsB genes from S. 
typhimurium [24].The otsA and otsB genes were am-
plified from genomic DNA isolated from S. typhi strain 
CTI8, using PCR primers that were designed from the 
nucleotide sequences flanking the S. typhimurium otsBA 
operon. The deduced amino acid sequences of the S. 
typhi OtsA and OtsB proteins were, respectively, 99 and 
98% identical with the S. typhimurium proteins, and 88 
and 72% identical with the E. coli proteins. 
3.2. Induction of trehalose biosynthesis in S . 
typhimurium 
When S. typhimurium SL3261 (aroA) was cultured in 
trehalose induction medium, the bacterium accumu-
lated higher levels of trehalose (2.2 Jlmol trehalosefmg 
protein) than when bacteria were cultured under con-
trol conditions (0.4 Jlmol trehalose/mg protein). These 
bacteria were resuspended in a trehalose solution and 
vacuum dried to a water content of 2.8-2.9%. The 
recovery of trehalose-stabilised bacteria immediately af-
ter drying was 35.5%. There was no significant decrease 
in the number of viable cells after storage of the dried 
bacteria after storage for up to 47 days at 37°C (Fig. 
la) . ln contrast, only 4.6% of control bacteria were 
recovered immediately after drying. The number of 
viable cells in the dried cultures declined to 1% after 
storage for 8 days, and continued to decline slowly 
thereafter (Fig. I a). 
3.3. Stability of trehalose-stabilised S. typhimurium 
expressing a guest antigen 
We have previously cloned the operon encoding the 
Y. pestis F (-antigen, into S. typhimurium SL3261 [6], 
and shown that oral dosing with this recombinant 
bacterium induces protection against plague. When this 
bacterium was cultured under the trehalose-inducing 
conditions, the intracellular levels of trehalose were 1.54 
Jlmol trehalose/mg protein. When these bacteria were 
resuspended in trehalose solution and dried, 77% of the 
bacteria present before drying could be recovered after 
growth on L-agar or L-agar containing kanamycin. 
There was no decrease in the number of viable bacterial 
cells after storage of the dried bacteria for up to 47 days 
at 37°C (Fig. I b). Bacteria cultured in control medium 
contained 0.18 JlmOI trehalose;mg protein. By day 8, 
the number of viable cells had declined to less than I% 
of the number of viable cells before drying. 
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3.4. Immunogenicity of trehalose-stahilised S . 
typhimuriwn expressing a guest antigen 
S. typhimurium SL3261 / pAH34L that had been cul-
tured in trehalose induction medium and dried in the 
presence of trehalose was resuspended in L-broth and 
administered orally to a group of six mice. Eleven days 
after dosing, the serum IgG antibody titres to whole S. 
typhimurium cells and to Y. pestis Fl-antigen were 
measured. No an tibody was detected in sera from mice 
that had been immunised with trehalose-stabilised bac-
teria that had been resuspended in L-broth and used for 
oral dosing. 
Antibody (mean titre, I :2676) to S. typhimurium 
SL3261 ce lls was detected in the sera from mice that 
had been immunised with S. typhimurium SL3261 I 
pAH34L, which had been cultured overnight in L-broth 
before dosing. Antibody (mean titre, I: 1686) was also 
detected in the sera from mice that had been immunised 
with trehalose-stabilised bacteria that had been resus-
pended in L-broth and cultured overnight in L-broth 
before dosing. In sera taken from mice in both of these 
immunised groups, similar levels of antibody to Y. 
pestis Fl-antigen were detected (1:6416 and 1:8671 , 
respectively). 
3.5. Invasion of 1 774 macrophage cells 
To determine why the trehalose-stabilised S. ty-
phimurium SL3261/pAH34L cells were unable to induce 
antibody responses after oral dosing, the bacteria were 
incubated with 1774 cells for I h and the proportion of 
bacterial cells internalised within the macrophages de-
tennined. For comparison, trehalose-stabilised bacteria 
and control bacteria that had both been cultured 
overnight in L-broth before use were incubated with 
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Fig. 2. Internalisation of S. ryphimurium SL3261 pAH34 L by J774 
cel ls. (A) bacteria cultured for 18 h in L-broth. ( B) trehalo>t:->la-
bilised bacteria cultured fo r 18 h in L-broth. and (C) treha lose-sta-
bilised bacteria rcsuspendcd in PBS. Results shown arc the mean of 
six determinations, with bars indicating S.D. values. 
1774 cells. The results (Fig. 2) indicated that 22% of the 
trehalose-stabilised bacteria that had been cultured 
overnight in L-broth were able to invade J774 cells, 
compared with 27% of the control bacterial cultures. 
Only 1.6% of the fresh ly resuspended trehalose-sta-
bilised bacteria were internalised by J774 cells. 
4. Discussion 
The loss of immunogenicity of vaccines on storage is 
recognised as one of the problems that compromises 
their utility. This problem is compounded in areas of 
the world where the storage of vaccines under con-
trolled conditions is difficult. One approach to vaccine 
stabilisation involves the addition of trehalose prior to 
drying. This approach has been used to stabilise a 
number of vaccines including tetanus toxoid [25) and 
hepatitis B surface antigen [26]. A further development 
of this technology involves drying in the presence of 
trehalose under controlled conditions, and tlus technol-
ogy (Q-T4sys) has been commercialised [15, 19]. Al-
though these previously reported studies involve 
sub-unit vaccines, trehalose stabilisation of ljve bacte-
rial vaccines has also been proposed. This is the first 
report documenting the stabilisation of a live bacterial 
vaccine using trehalose. 
Lethal damage to bacteria during drying arises from 
damage to cell membranes and denaturation of 
proteins. The da mage to cell membranes is believed to 
arise from phase changes in the membrane phospho-
lipids [ 13,27). Such phase changes are especially com-
mon in membranes that are rich in 
phosphatidylethanolamine, such as the inner membrane 
of S. typhimurium [27]. It is thought that trehalose is 
able to prevent such damaging phase changes by be-
coming associated with phospholipid head groups in 
place of water molecules [27). Similarly, treha lose is 
able to stabilise the structure of proteins by replacing 
water molecules of the 'shell of hydration' [27- 29]. 
Therefore, we considered that, to fully exploit the sta-
bilising properties of trehalose, we would need to en-
sure that trehalose was present both inside and outside 
the bacterial cells. 
Other workers have shown that £. coli that had been 
resuspended in trehalose solution before drying retained 
a hjgher level of viability than control dried bacteria 
[ 18,27 ,30]. r n addition, when trehalose synthesis is in-
duced in E. coli by growth in medium containing high 
sa lt concentrations, improved desiccation tolerance is 
also seen [ 18]. This ugge ts that both extracellular and 
intracellular structures a re sen. itive to de iccation dam-
age. Indeed, when trehalo e is present on both sides of 
cell membranes, a remarkable degree of desiccation 
tolerance is exhibited by E. coli [19]. 
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In £. coli, the trehalose biosynthetic pathway in-
volves treha lo e-6-phospha te synthase, which is en-
coded by the otsA gene, a nd treha lose-6-phosphate 
phosphatase, which is encoded by the orsB gene [20]. 
We have previously demonstrated that homologues of 
the orsA and otsB genes a re present in S. typhimurium, 
and that the induction of this pa thway results in the 
production of trehalo e a nd enhanced resistance to 
desiccation, thermal stress and growth in the presence 
of 400 mM NaCl [24]. In this study, we have shown 
that the orsBA operon is a lso present in S. ryphi, 
suggesting tha t treha lose production can a lso be in-
duced in a ttenuated S. typhi stra ins used as vaccines. 
Our findings confirm that S. typhimurium that con-
tained trehalose intracellularly and extracellularly were 
stabilised in comparison with bacteria that were dried 
in the presence of extracellular trehalose alone. Bacteria 
that were stabilised with intracellular and extracellular 
trehalose could be stored for up to 6 weeks at tempera-
tures up to 37°C, without loss of viability. This finding 
suggests that such trehalose-stabili sed vaccines could be 
stored and transported without the use of a refrigerated 
environment. 
We have previously shown that, in mice, the oral 
administration of S. typhimurium SL3261 expressing the 
Fl-antigen of Y. pestis resulted in the induction of 
protective immunity towards Y. pestis [6]. In this study, 
we have shown that thjs vaccine can be stabi lised by 
culture of the bacteria under conditions that result in 
trehalose induction and drying of these bacteria in the 
presence of trehalose. The growth conditions that were 
used for the induction of trehalose biosynthesis by S. 
typhimurium SL3261 /pAH34L did not result in the loss 
of the recombinant plasmid encoding the F 1-antigen. 
However, these bacteria showed the loss of invasion 
competence in macrophage cell cultures. This might 
explain why these bacteria were unable to colonise mice 
after oral dosing. It is known that invasion competence 
of S. typhimurium is regulated by a va riety of environ-
mental stimuli including ionic strength , magnesium 
concentration and oxygen tension. Our finding suggests 
that the growth conditions used for the induction of 
trehalose biosynthesis resulted in the loss of invasion 
competence. The culture of the trehalose-sta bilised bac-
teria in a complex growth medium resulted in the 
restoration of invasion competence, indicating a pheno-
typic ra ther than a genotypic change in the bacterium . 
These results indica te the potential for treha lose sta-
bilisation of S. typhimurium vaccines, and our fi nding 
that otsA and otsB genes are present in S. typhi suggests 
that this technology might be a pplied to other live 
bacterial vaccines. Several a pproaches might be used to 
a llow the induction of treha lose biosynthesis a nd the 
retention of invasion competence. It is possible tha t the 
reduced invasion competence of the treha lose-stabilised 
bacteria might be overcome by increasing the immunis-
ing dose. Alterna tively, modification of the trehalose 
inductio n medium might allow the induction of inva-
sion competence a nd the biosynthesis of trehalose. Fi-
nally, it is possible that the orsBA operon could be 
expressed in S. typhimurium under the control of a 
promoter that can be induced in a complex growth 
medium. Work is currently underway to evaluate these 
approaches. 
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This study describes a PCR-based approach for the production of a rationally 
attenuated mutant of Yersinia pestis. Degenerate primers were used to 
amplify a fragment encoding 91 ·45% of the aroA gene of Y. pestis MP6 which 
was cloned into pUC18. The remainder of the gene was isolated by inverse PCR. 
The gene was sequenced and a restriction map was generated. The Y. pestis 
aroA gene had 75·9% identity with the aroA gene of Yersinia enterocolitica. 
The cloned gene was inactivated in vitro and reintroduced into Y. pestis strain 
GB using the suicide vector pGP704. A stable aro-defective mutant, Y. pestis 
GB&aroA, was isolated and its virulence was examined in vivo. The mutant was 
attenuated in guinea-pigs and capable of inducing a protective immune 
response against challenge with the virulent Y. pestis strain GB. Unusually for 
an aro-defective mutant, the Y. pestis aroA mutant was virulent in mice, with a 
median dose which induced morbidity or death similar to that of the wild-
type, although time to death was significantly prolonged. 
Keywords: Yersinin put is, aroA 
INTRODUCTION 
Yersinia pestis is the causative organism of bubonic and 
pneumonic plague and results in a high rate of mortality. 
It is capable of infecting man and a wide range of animals, 
with transmission occurring primarily by Aea bites. 
Virulence of the bacterium is due to the expression in vivo 
of a complex array of factors (Straley & Perry, 1995). The 
prevention of plague is based upon vaccination, but 
existing whole-cell plague vaccines produce a range of 
side-effects, making them unsuitable for widespread use 
(Marshal! el al., 1974; Meyer el al., 1974a; Reisman, 1907). 
Candidate subunit vaccines based on the Y. pestis F1 and 
V antigens have been shown to induce protection against 
plague (Oyston et al., 1995; Leary et al., 1995). However, 
Fl -defective mutants of Y. pestis have recently been 
identified which are still virulent (Davis et al., 1996 ; 
Drozdov et al., 1995). A rationally attenuated Y. pestis 
strain would enable the presentation of a wider variety of 
antigens, including F1 and V, to the immune system, thus 
enhancing protective efficacy. The existing whole-cell 
vaccines currently licensed for human use may leave 
vulnerable mucosal surfaces unprotected as they are 
Abbreviations: DHB, dihydroxybenzoic acid ; PABA, para-aminobenzoic 
acid. 
The EMBUGenBank/DDBJ accession number for the sequence reported in 
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administered parenterally and may not effectively induce a 
mucosal immune response (1vicGhee et al., 1992). The 
pneumonic form of plague is highly infectious, due to the 
large numbers of plague bacilli released in aerosols 
(Cowling & Moss, 1994). A live attenuated mutant strain 
would be amenable to oral dosing and thus should 
effectively induce mucosal immunity to protect against 
pneumonic plague. 
Bacteria possess a linear biochemical pathway for the 
synthesis of aromatic amino acids . The aroA gene encodes 
5-enolpyruvylshikimate-3-phosphate synthase, which is 
involved in the conversion of shikimic acid into chorismic 
acid, a common intermediate in the synthesis of severa l 
compounds, including aromatic amino acids, para-amino-
benzoic acid (PABA), 2,3-dihydroxybenzoic acid (DHB) 
and para-h~·droxybenzoic acid. Interruption of this path-
way produces a requirement for PABA and DHB, which 
are not available in mammalian tissues. Therefore the 
bacteria are only capable of limited replication before 
being cleared from the host. 
Attenuated strains of a range of bacterial species ha\'e 
been produced by inactivation of genes in the aromatic 
acid biosynrhetic parhwa y. A romatic-dcpcndent (11aro) 
mutants of .Salmonella, Pasteurella 11111llocitla, Aerolllonas 
sallllonicitla, ) 'rrsinia mlerorolitica, Bortletella pertwsis, Bacillw 
antbracis and Listeria IIIOIIO~)•Iogenes ( lloiseth & Stocker, 
1981 ; Levine et al., 1987; llomchampa el al., 1992 ; 
1847 
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Vaughan et al., 1993; Bowe et al., 1989; Roberrs et al., 
1990; I vins et al., 1990; A lexander et al., 1993) have all 
been shown to be aviru lent and to stimulate p ro tective 
immu nity. Sallllonelfa 1)'/Jhimurium llaroA administered 
o ra ll y to mice was capable o f invasion from the g ut, 
followed by colonization of the Peyer's patches, li ver and 
spleen (i\laskell et al., 1987). Multiplication was self-
limiting and the salmonellae were cleared after a period of 
several wee ks. llowever, Y. enterocolitica t:.aroA could 
establish o n ly a short-lived colonization of the reticulo-
endothelial system and required repeated inocu lations to 
induce immunity (Bowe et al., 1989). 
) '. pestis auxotrophic mutants with a requirement for 
exogenous supplies of amino acids, including phenyl-
a lanine, have been isolated previously and observed to be 
viru lent in m ice (Burrows, 1960, 1963) . H owever, the 
exact mutation to produce phenylalanine dependence was 
not characterized and it is not possible to know whether 
genes other than those involved in the production of this 
aromatic amino acid were expressed no rmally. In this 
stud y, we have constructed a defined isogenic t:.aro mutant 
and tested its stability, immunog enicity and protective 
efficacy in 11ivo. 
METHODS 
Bacteria, plasmids, media and growth conditions. Y. pestis 
laboratorv strain MP6 and the human isolate strain GB were 
routinely· cultured aerobically at 28 °C in Blood Agar Base 
(BAB) broth or on BAB agar. Yersinia selective agar base 
(YSA) was obtained from Oxoid. 
S. typhi11111rim11 SL3261 (Hoiseth & Stocker, 1981) was provided 
by B. A. D. Stocker, Stanford University, CA, USA. 
Escherichia coli S17-i.pir was provided by A. Forsberg, Umea, 
Sweden. S. typhi11111rim11 and E. coli strains were cultured and 
stored as described by Sambrook t l al. (1989). 
Defined media were prepared as described by Straley & Bowmer 
(1986), omitting, when necessary, the aromatic amino acids 
tyrosine, tryptophan and phenylalanine, which were normally 
present at a final concentration of 1 mM, 0·1 mM and 1 mM, 
respectively. For all media, ampicillin was added as required at 
a final concentration of 25 1-1g ml- 1• 
Plasmid pUC1 8 was obtained pre-digested with St11al and pre-
treated with calf intestinal alkaline phosphorylase (Boehringer 
Mannheim). The vectors pGP704 (Miller & Mekalanos, 1988) 
and pNJSOOO (Gri nter, 1983) were kindly provided by M. Tully, 
CAMR, Salisbury, CK, and B. Wren, St Bartholomew's Hos-
pital, London, U K, respectively. 
Preparation and manipulation of DNA. D r A was isolated 
fro m ) ·. pestis by the method of Marmur (1961 ). Large- and 
small-scale plasmid isolations, restriction enzyme digests, blunt-
ending of D A fragments and ligations were perfo rmed as 
described by Sambrook et al. (1989). Restriction endonucleases, 
T4 D A ligase, DNA polymerase I , large frag ment (Klenow 
enzyme), sequencing-g rade Taq polymerase and polynucleoride 
kinase were obtained from Boehringer Mannheim. 
Electroporation. 1::.. coli strains were transformed following 
electroporatio n as described by D ower et al. ( 1988), using a 
Gene Pulser apparatus (Bio -Rad) set at 2·5 k V, 25 1-1F and 800 n. 
Following electroporation, bacteria were incubated at 37 °C for 
I h without selection and then plated omo the appropriate 
selecti,·e media. 
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Bacterial conjugation. Plasmids were introduced into )'. pestis 
by conjugation in a three-way mating (Grinter, 1983), using a Y. 
pestis recipient, a donor strain comprising E. coli S17-A.pir 
containing the plasmid of interest and E. coli S 17-A.pir. pN JSOOO. 
E. coli strains we re grown overnight at 37 °C, with shaking, in 
LB containing the appropriate antibiotic. } ·.pestis strain GB was 
g rown at 28 °C overnight with shaking in BAB. A I ml aliquot 
of each strain was washed in LB and resuspended to 100 1-1! in 
LB. Equal volumes (SO 1-1!) of the three strains were mixed and 
100 1-11 was spo tted onto an L-agar plate. After incubation at 
28 °C fo r 4 h, the bacteria were removed from the plate using a 
sterile swa b and resuspended in 1 ml LB. T he cells were washed 
twice in LB, diluted and plated onto YSA containing 25 1-1g 
ampicillin ml- 1 and incu bated at 28 °C. E. coli was unable to 
grow on the YSA plates as quickly as Y. putis, and g rew very 
palely pink , while the Y. putis colonies were a very dark pink. 
Cloning and sequencing of the aroA gene of Y. pestis. 
Degenerate oligonucleotide primers were designed by com-
parison of the nucleotide sequences of E. coli, S. typhimuriulll, B. 
pertussis arid Y. mltrocolitica. These primers corresponded to 
nucleotides 4-20 (GAATCCCTGACKTT ACA, where K = G 
o r T ) of the E. coli aroA gene, with the complementary primer 
(CACATCGCCATVCGGTG, where V= G, C o r A) cor-
responding to nucleotides 1105- 1121 (Fig. 1 ). Using these 
oligonucleotide primers in PCR (D ybvig et al., 1992), a DNA 
fragment was obtained after 35 cycles of amplification (95 °C, 
15 s; 50 °C, 15 s; 72 °C, 30 s; Perk in El mer 9600 GeneAmp 
PCR System). The fragment was purified , blunt-ended and 
ligated into pUC18 to produce pYPA7. Synthetic oligo -
nucleotide primers were used to sequence the fragment by the 
dideoxy chain-termination method, using a PRISM Ready 
Reaction Dye Terminator Cycle Sequencing kit (Applied 
Biosystems). Samples were loaded on an ABI 373A automated 
DNA sequencer and electrophoresed through a 6% (w /v) gel, 
and chromatograms were analysed using SeqEd (ABI). The 
remaining bases of the aroA gene sequence were obtained by 
inverse PCR (Havard tl al., 1992) fo llowing digestion of whole-
cell Y. pestis DNA with Socii or Cfol. 
Determination of virulence for mice and guinea-pigs. 
BALB/c female mice (6 week old) and female (young, Duncan 
Hartley) guinea-pigs were used throug hout. The median doses 
of the wild-type and mutant strains which induced morbidity or 
death in mice were assessed by subcutaneous injection of groups 
of fi ve animals with serial dilutions of exponential-phase broth 
cultures grown at 28 °C. Humane end-points were strictly 
observed, and animals deemed incapable of survival were 
humanely sacrificed by cen·ical dislocation. The median lethal 
dose which induced morbidity o r death was determined by the 
method of Reed & Muench (1938). 
The virulence of the strains in gu inea-pigs was assessed with 
cultures g rown at 37 °C. Guinea-pigs challenged with 19·1 c.f.u. 
Y . putis strain GB survi,·ing to 21 d were killed by cervical 
dislocation and autopsied. One animal which had been 
challenged with 26·2 c.f.u. G Bfu1roA was also sacrificed, bled by 
cardiac puncture, post-morremed and o rgan smears were made. 
Sera were titrated by ELISA (Oyston et al., 1995) for the 
presence of antibodies to F1 and V antigens. Guinea-pigs 
inoculated with the ora-defective mutant were challenged with 
Y. pestis GB on day 24. Fo urteen days after this second 
inoculation, the g uinea-pigs were sacrificed and examined for 
the presence of internal abscesses. 
Survival of Y. pestis GBa aroA in vivo. Two g roups of 35 mice 
were inoculated subcutaneously with either 7·28 x 103 c.f. u. }/. 
pestis GB or 7·77 x 103 c.f.u. GBt.aroA. At 6, 12, 24, 48,72 and 
96 h, five mice from each g ro up were sacrificed by cervical 
dislocation and spleens "·ere removed and homogenized in 
10 ml PBS (Dulbecco's A recipe ; Oxoid) using a sromacher 
(Seward Medical) on maximum setting for 2 min and diluted in 
PBS. Spleen homogenates were plated in duplicate on Congo 
red and YSA plates ro determine the numbers of plague bacilli 
present. 
Growth of Y. pestis GBL1aroA in defined media. S. typbimuri11111 
SL3261 and }', pestis GB~oroA \\'ere grown overnight in 
defined medium. Aliquots (1 ml) of each were used ro inoculate 
20 ml defined medium. The cultures were grown at 28 °C p·. 
pestis) or 37 °C (5. typbillntrilltll) with shaking and the OD600 was 
monitored at hourly intervals using a Philips PU8800 spectro-
photometer. At stationary phase, a 1 ml aliquot was used to 
inoculate a fresh 20 ml culture, and the process was repeated . 
When SL3261 was nor growing in fresh defined media, 100 11! 
1 mg folate ml-1 was added ro the broth. After a funher 3 h, 
100 pi 1 mg PABA ml- 1 and 1 mg D HB ml- 1 were added and 
the 00600 was monitored. 
RESULTS 
Sequence analysis of the Y. pestis aroA gene 
T he sequence (Fig. 1) contained an open reading frame of 
1275 nucleotides which encoded a protein of 425 amino 
acids. The nucleotide sequence exhibited 75·9% identity 
to the aroA gene of Y. enterocolitica (O'Gaora et al., 1989). 
A high degree of identity was also identified between the 
predicted amino acid sequence of the aroA gene from Y. 
pestis and the aroA genes from E. coli, S. typhin111rium, B. 
pertussis and Y. enterocolitica, which showed 79·5 %, 
79·1 %, 52·2% and 90·1% identity, respectively (Fig. 2). 
When examining the sequence published here, it should 
be borne in mind that it was derived from a PCR product 
rather than a directly cloned gene and may therefore 
contain PCR-introduced errors. To minimize such errors, 
the pooled PCR products of the aroA gene amplified from 
ch romosomal DNA preparations were sequenced three 
times in each direction to confirm the sequence obtained 
from the cloned PCR-deri,·ed gene. 
Construction of the Y. pestis l\aroA mutant 
A restriction map was generated from the sequence of the 
Y . pestis aroA gene. A unique Socii site and two C/al sites 
were identified, allowing the deletion of an internal 293 bp 
fragment. Plasmid p YPA 7 was digested with Clal and 
Socii, blunt-ended and re-ligated. Loss of the 293 bp 
fragment was confirmed by PCR, restriction digests and 
sequencing. The deleted aroA gene fragment was excised 
from pUC18 by digestion \\'ith Sacl and Soli and cloned 
into Sacl/Sall-cut pGP704 ro produce pGPYPt.A 7. The 
plasmid was electroporated into E. coli S17-J.pir, mobilized 
into Y. pestis GB and transconjugants were selected on 
YSA plates containing 25 1-1g ampicillin ml- 1• Colonies 
which appeared on the selective plates resu lted from 
integ ration of pG PYPt.A 7 into the chromosome by a 
single cross-over event. Fi\'e colonies were picked and re-
plated twice on nonselective media before ampicillin-
sensi tive revenants appea red due to a second cross-over 
event. As either the wild-type copy of the gene originally 
present on the Y. pestis chromosome or the plasmid-borne 
mutated gene could have been excised, the deletion was 
confirmed by PCR (Fig. 3). The mutant, strain GBt.aroA, 
was unable to grow on defined media without supple-
aroA mutant of Yersinia pestis 
ments of aromatic amino acids, whereas the wild-type 
grew on both types of media. 
Growth of Y. pestis GBAaroA in defined media 
The growth of S. typbilllllrilllll SL3261 (aroA bis) in defined 
media containing aromatic amino acids and histidine was 
measured. By the third subculture in defined media, the 
culture showed no increase in optical density after 
incubation for up to 24 h at 37 °C. Supplementing the 
media with PABA and DHB, but not folate alone, resulted 
in rapid growth of the organism. Y. pestis GBt.aroA was 
also able to grow in the same batch of media; however, 
repeated subculture did not result in limitation of growth, 
even by the seventh subculture into fresh media. There-
fore, unlike S. typhi111uri11111 SL3261, the aroA-defective Y. 
pestis mutant was not starved of PA BA and DHB in the 
defined media. 
Virulence of Y. pestis GBl\aroA in vivo 
Y. pestis GB was virulent in BALB/c mice, with a median 
dose which induced morbidity or death of approximately 
1 c.f.u., confirming the virulence of this strain observed 
previously (Russell et al., 1995). The median dose of 
GBt.aroA required to produce morbidity or death was 
1·66 c.f. u., but the mean time to death of158·9 ± 8·6 h was 
significantly longer than with strain GB (108·3±7·75 h; 
P < 0·001 ). Y. pestis was isolated from organ smears from 
the mice challenged with GBt.aroA. PCR amplification of 
the aroA gene of the recovered organisms showed that the 
mutant had not reverted to the wild-type. 
Y. pestis infection in guinea-pigs caused a protracted 
disease compared to that seen in mice. T ypically the 
animals appeared ruffled, lost weight and became less 
active. In some cases, there was asymmetrical paralysis of 
the rear limbs, followed by an apparent depression of the 
respiratory rate. The animals were humanely killed at this 
time. Autopsy revealed abscesses in the liver and spleen, 
and the organs were enlarged. Y. pestis GB produced 
disease in guinea-pigs. One animal died within 21 d and 
the livers and spleens of all but one of the remaining 
animals were shown to be covered by abscesses upon 
post-mortem on day 21. The guinea-pigs challenged with 
GBt.aroA all survived to day 21, and autopsy of one 
animal at this time revealed no apparent internal abscesses. 
Serum from the autopsied animal had a specific anti-F1 
antigen titre of 1 : 1600 and an anti-V antigen titre of 
1 :800. Guinea-pigs from both challenge groups had a 
subcutaneous lesion at the site of injection. 
The remaining guinea-pigs which had originally received 
GBt.aroA were challenged with Y. pestis GB (9·26 x 103-
9·26 X 106 c.f.u.). All the animals survived the challenge 
with no apparent ill-effects over 14 d. Post-mortem after 
this interval revealed all the surv iving animals ro be 
healthy, with no internal abscesses. o Y. pestis was 
isolated from smears of livers and spleens. 
Survival of the aro-defective mutant in vivo 
Following subcutaneous inoculation of ) ·. pestis GB or 
GBt.aroA in mice, no bacteria were isolated from the 
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ATGCTGGAATCCCTGACCTTACAACCCATTGCCCTAGTTAATGGCACCGTTAATTTACCTGGTTCGAAGAGTGTCTCTAACCGCGCACTGCTTCTGGC CG 100 
M l E S l T l a P A l V N G T V N l P G S K S V S N R A l l l A 
CGTTGGCCGAAGGGAC CACTCAGTTGAATAACGTGTTAGACAGCGATGACATCCGCCACATGCTCAATGCATTRCAGGCATTAGGGGTGGACTTCCGCCT 200 
A l A E G T T a l N N V L 0 S 0 0 R H M l N A l a R l G V 0 F R l 
TTCTGCTGATCGCACATGCTGTGAGGTTGRTGGTCTGGGGGGGAARTTRGTGGCTGAACRGCCRTTGTCGCTTTTCTTGGGCARTGCCGGCACAGCCATG 300 
S R D R T C C E V D G L G G K L V R E a P L S L F L G N A G T A M 
CGTCCTTTGGCCGCGGTGTTATGTTTGGGTAATAGCGATRTCGTACTGACGGGTGAGCCTCGGATGAAGGAGCGGCCAATTGGCCATTTGGTGGATGCGC 400 
R P L A A V L C L G N S D V L T G E P R M K E R P G H L V D A 
TACGTCAGGGCGGTGCA CAGATCGATTATCTGGAGCAAGAAAATTACCCG CCATTACGTTTACGTGGTGGTTTCCGAGGGGGGGAGTTAACTGTTGATGG 500 
L R a G G A a D Y L E a E N Y P P L R L R G G F R G G E L T V D G 
GCGTGTCTCTAGCCAGTTCCTGACTGCTTTATTGRTGACCGCCCCG CTGGCGGAGCAAGATACGACTATTCGGATTATGGGTGRTCTGGTTTCCRARCCT 600 
R V S S a F L T A L L M T A P L R E a 0 T T R M G D L V S K P 
TATATCGATATTRCTCTG CRCTTGRTGRAAGCATTTGGTATTGA CGTGGGGCATGAGAACTACCAAATTTTCCACAT CAAAGGGGGCCAGACCTACCGCT 700 
---1 
Y I 0 T L H L M K A F G D V G H E N Y a F H K G G a T Y R 
CACCAGGGACTTATTTGGTTGAGGGCGATGCCTCGTCGGCTTCCTACTTCTTAGCGG CTGCGGCTATTAAGGGGGGAACAGTGCGTGTCACTGGTATTGG BOO 
S P G T Y L V E G D A S S A S Y F L A A A A I K G G T V R V T G I G 
CAAGAAAAGTGTACAGGGCG ACACTAAATTTGCCGATGTGTTGGAAAAAATGGGCGCGAAAGTGACGTGGGGGGATGATTATATCGAGTGCAGTCGTGGT 900 
K K S V a G D T K F A D V L E K M G A K V T W G 0 0 Y I E C S R G 
GAATTACAGGGCATTGACATGGATATGAACCACATTCCTGATGCTGCAATGACCATTGCGACTACGGCATTATTTGCCACGGGTCCAACGACGATCCGCA 1000 
E L a G I 0 M 0 M N H I P 0 A A M T A T T A L F A T G P T T I R 
ATATCTACAACTGGCGGGTAAAAGAAA CTGAC CGG CTGACGGCGRTGGCAACCGAGTTGAGAAAAGTAGGTGCTGAAGTGGAAGAGGGGGAAGATTRCAT 1100 
N I Y N W R V K E T 0 R L T A M A T E L R K V G A E V E E G E 0 Y I 
CCGCGTGGTTCCACCCTTG CAGCTAACTGCTGCAGATATTGGTA CCTA CGATGACCACCGTATGGCGATGTGTTTCTCGCTGGTCG CGTTATCAGATAC C 1200 
R V V P P L 0 L T A A 0 G T Y 0 D H R M A M C F S L V A L S D T 
CCCGTGACGATCCTTGACCCGAAATGTA CCGCAAAAACCTTCCCTGATTATTTTGAACAGTTTGCGCGAAAGTGA 1275 
P V T L 0 P K C T A K T F P D Y F E 0 F A R K 
Fig. 1. Nucleotide and deduced amino acid sequences of the aroA gene of Y. pestis. The internal region of the gene 
deleted to generate the inactivated gene in pGPYP~A7 is underlined by a solid bar from base 312 to base 605. Arrows 
under the sequence indicate the bases corresponding to the oligonucleotide primers used to amplify the fragment cloned 
into pUC18 to produce pYPA7. 
blood during the fi rst 24 h . Bacteraemia then increased 
over several days. The spleens of both g roups of mice 
were colonized by 24 h, with numbers o f bacteria 
increasing to over 108 c.f.u . g-1 at the termination o f the 
experiment at 96 h . T he mean rimes ro dea th fo r two 
g roups of fi ve mice challenged with a high dose of 
approximately 7 x 107 c.f. u. of either strain GB o r 
G BllnroA were 82·9 ± 6· 3 h and 11 7·1 ± 9·6 h, respect-
ively. 
DISCUSSION 
O ne of the earliest descriptions of an attenuating mutation 
in a bacterium concerned pu rine dependence of Y. pestis 
(Burrows, 1963). This mutant was generated by classica l 
clonal selection techn iques. Other spontaneous mutants 
of Y. pestis are currenth· available as ,·accines fo r the 
prevention of plague, e.g. strains E \ 76 and Haffk ine. 
However, the exact nature of these attenuations has not 
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been characterized and the side-effects of vaccinating w ith 
these strai ns were sufficiently severe to hospitalize 2 out of 
12 volunteers in one study (Meyer, 1970). Formalin-killed 
whole-cell vaccines are also available, but these are highly 
heterogeneous with va riable endotoxin content and their 
side-effects make them unsuitable fo r general use 
(Marshall et al., 1974 ; Meyer et al., 1974a; Reisman, 1907). 
T he ad vantages of rario nall y attenuated auxotrophic 
strajns of o ther bacterial species have been described 
previously by Clements et al. (1992) and a rationally 
attenuated strain of Y. pestis may overcome some of the 
problems encountered with existing vaccines, since the 
exact nature of the mutatio n is known and the degree of 
attenuation can thus be contro lled (S igwart et al., 1989; 
IacFa rland & Stocker, 1987). 
T he aroA gene has been sequenced from a range of 
bacterial species. This enabled degenerate PCR primers to 
be des igned from regions of identity. This study found a 




















































Fig. 2. Alignment of the deduced amino acid sequences encoded by aroA genes f rom Y. pestis, Y. enterocolitica, E. coli, 




Fig. 3. Amplification of the aroA gene of Y. pestis GB (lane 1), 
Y. pestis GB~aroA (lane 2) and pGPYP6A7 (lane 3). The lengths 
of the bands on the gel are indicated in bp. 
sequence fro m the Y. pestis aroA gene and those from 
o ther species (Fig. 2). The aroA gene in other species o f 
the Enterobacteriaceae has been shown to form parr of an 
o pero n wi th serC, which is loca ted upstream of aroA 
(O'Gaora et al., 1989; Duncan & Coggins, 1986). The 
nucleotide sequence upstream from the aroA gene was 
homologous ro serC of ~'. enteroco/itim (data nor shown). 
Inspection of the sequence of the intergenic reg io n d id 
nor reveal any obvious promoters, suggesting that the 
aro.--l gene of )'. pestis is transcribed as parr of an operon. 
A deletion was produced in the cloned fragment of the 
aroA gene and this was used tO generate the aro-defective 
mutant strain of Y. pestis, GB~aroA. A single copy of the 
aroA gene containing the lesion was confirmed by PCR. 
This avo ided the need for Southern blo ts as the DNA of 
) '. pestis GB is resistant to digestion due to DNA-
methylation systems, including the dam and dcm S)'Stems 
found in o ther enterobacteria (Demidova et al., 1984). 
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Previous work has evaluated the relative susceptibility of 
various animal models to identify a suitable model for the 
evaluation of candidate plague vaccines (Meyer et al., 
1974c). Although various nonhuman primates were 
considered to refl ect most closely the disease in humans, 
mice and guinea-pigs were also identified as being 
susceptible to Y. pestis infection and able to produce an 
immune response upon vaccination. GBL'l.aroA was 
attenuated in g uinea-pigs in vivo. Only 1/15 animals 
appeared sick, there were no dea ths and healthy animals 
appeared to have clea red the bacteria as there were no 
abscesses on their major internal organs. The induced 
immunity after a sing le low dose of the mutant protected 
against homologous challenge with a dose of 
9·26 X 106 c.f.u. of the virulent wild-type strain and 
significant titres of specific anti-Fl and anti-V antibodies 
were detected in sera from immunized animals. High 
antibody titres to Fl antigen and V antigen have been 
shown to correlate with protection against plague (Meyer 
et al., 1974b ; Leary et al., 1995; Motin et al., 1994). 
Surprisingly, the aro-defective mutant was still virulent in 
mice, although the increased time to death of the mice 
would suggest that the rate of growth in vivo was reduced. 
The virulence of GBL'l.aroA in mice contrasts with the 
behaviour of a L'l.aroA mutant of Y. enterocolitica, which 
was no t lethal in the mouse model (Bowe et al., 1989). Y. 
pestis is known to possess additional genetic elements 
encoding a variety of ,-irulence determinants, e.g. unlike 
Y. enterocolitica, Y. pestis produces a toxin which is active 
in mice. This may go some way towards explaining the 
observed host-dependent natu re of the attenuation . The 
inability of the Y. enterocolitica L'l.aroA mutant to cause 
disease was linked with the rapid clearance of the bacteria 
from the reticulo-endothelial system. It has been sug-
gested that this may indicate an increased susceptibility of 
Yersinia to bacterial clearance mechanisms and that 
Yersinia may rely on rapid and overwhelming growth to 
kill mice (Bowe et al., 1989). Our results provide a 
contrasting result ; the LD50 of GBL'l.aroA was similar to 
that of the wi ld-type strain. The ability of the L'l.aroA 
mutant of Y. pestis to grow in vivo also contrasts with 
results obta ined with L'l.m·oA mutants of other bacterial 
species, bu t is supported by the observation that phenyl-
alanine-dependent mutants of Y. pestis are not attenuated 
in mice (Burrows, 1960, 1963). A previous examination of 
host specificity of Brazilian isolates of Y. pestis found that 
low levels of free asparagine were responsible for a 
mouse-vi rulent stra in being nonvi rulent in guinea-pigs 
(Burrows & Gill et, 1971 ). A similar difference in aromatic 
amino acid levels may provide an explanation for the 
attenuation of the Y. pestis L'l.aroA mutant in g uinea-pigs. 
The persistence, but inabilit~· to grow, in reticulo-
endothelial tissues o bserved with S. typhimuri!lm L'l.aroA 
has been attributed to the inability of the bacteri a to 
synthesize PABA and DHB, which are essential for 
g rowth. Our results show that g rowth of S. l)'fJhiiiJIIrium 
L'l.aroA ceased after subculturing thro ugh media lacking 
PABA and D HB, whereas rhe growth of the Y. pestis 
mutant was not limited in the same media. It is therefore 
possible that Y. pestis possesses an alternative biosynthetic 
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pathway which bypassed the mutation o r alternatiYe 
scavenging mechanisms for metabolites. In addition to 
preventing folate production, mutation in the aroA gene 
blocks the synthesis of the iron-chelating sideropho re 
enterochelin in S. typhimurilfm. It is possible that after 
growth in defined media, s tarvation of PABA and OHB 
inhibited enterochelin synthesis in S. typbimuritllll SL3261 
and therefore iron Jjmitation impaired bacte rial mul -
tiplication. Y. pestis possesses a complex system for 
scavenging iron, including iron chelation by the sidero-
phore yersiniabactin and a haemin-uptake pathwa ~­
(Straley & Perry, 1995). It would be expected that 
yersiniabactin synthesis is prevented in GBL'l.aroA, as has 
been shown for the L'l.aroA strain of Y. enterocolitica 
(Heesemann et al., 1993). Although the mutation in the 
aroA gene may have prevented siderophore production in 
Y. pestis, the availability of alternatiYe iron-uptake 
mechanisms may have been the factor that permitted 
growth of GBL'l.aroA in the defined media by bypassing 
the blockage in the siderophore iron-transport system. 
It has been known for some time that different vi rulence 
factors are important in different species; e.g. a classicall~· 
attenuated mutant, Y. pestis EV76, which was classified as 
'harmless' in g uinea-pigs was subsequently shown to be 
virulent in non human primates (Meyer et al., 1974c). Our 
finding that a L'l.aroA mutant is able to cause disease in one 
host animal species while being attenuated in ano ther 
raises the possibility that L'l.aro mutants of o ther bacteria 
may be virulent in alternative animal models. 
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The Response Regulator PhoP Is Important for Survival under 
Conditions of Macrophage-Induced Stress and 
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The two-component regulatory system PhoPQ has been identified in many bacterial species. However, the 
role of PhoPQ in regulating virulence gene expression in pathogenic bacteria has been characterized only in 
Salmo~telfa species. We have identified, cloned, and sequenced PhoP orthologues from Yersinia pestis, Yersinia 
pseudotuberculosis, and Yersinia enterocolitica. To investigate the role of PhoP in the pathogenicity of Y. pestis, an 
isogenic plwP mutant was constructed by using a reverse-genetics PCR-based strategy. The protein profiles of 
the wild-type and phoP mutant strains, grown at either 28 or 37°C, revealed more than 20 differences, indicating 
that PhoP has pleiotrophic effects on gene expression in Y. pestis. The mutant showed a reduced ability to 
survive in J774 macrophage cell cultures and under conditions of low pH and oxidative stress in vitro. The 
mean lethal dose of the phoP mutant in mice was increased 75-fold in comparison with that of the wild-type 
strain, indicating that the PhoPQ system plays a key role in regulating the virulence of Y. pestis. 
Yersinia pestis is the etiological agent of bubonic plague, a 
serious and often fatal disease in humans. The organism is 
usually transmjtted through the bite of an infected flea. Each 
case of plague has public health significance, since patients 
with subsequent pulmonary involvement may act as sources of 
pneumonic plague, a fatal and highly transmissible form of the 
disease (31). The expression of many virulence genes in Y. pes-
tis is upregulated at 37°C. For example, bacteria transmitted 
from a flea, where they have been growing at ambient temper-
atures of 28°C or below, do not express the F1 capsular antigen 
or many of the low-calcium-response plasmid products, which 
are thought to allow the bacteria to resist phagocytosis (6, 31, 
36). Many of the bacteria delivered into the host are phagocy-
tosed by polymorphonuclear leukocytes or macrophages. The 
trafficking of phagocytes to local lymph nodes and the multi-
plication of bacteria within the lymph nodes, give rise to a bubo 
(the characteristic sign of the infection). The bacteria within 
polymorphonuclear lcukocytes are destroyed, but those within 
macrophages survive and express various virulence determi-
nants, allowing their growth and eventual release from the 
macrophages, resulting in a bacteremia (2). Thus, during in-
fection , the bacteria undergo an intracellular phase in phago-
cytic cells and a later ex1racellular phase. This change in the 
site of colonization must involve changes in the biochemical 
makeup of the cell to allow survival and growth in these dif-
ferent environments, and it is likely that the bacteria possess 
mechanisms which allow sensing of environmental changes and 
corresponding modulation of gene expression. 
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The modulation of the ex-pression of virulence determinants 
is a recurrent theme in the pathogenicity of a variety of organ-
isms. This modulation is often controlled at the transcriptional 
level by a twin superfamily of sensor and regulator proteins 
(13, 22, 37). In the case of Salmonella en/erica serovar Typhi-
murium, a two-component regulatory system involving PhoP 
(the transcriptional regulator) and PhoQ (the sensor kjnase) 
has been shown to play a key role in adaptation of the bacteria 
to intracellular environments and for survival within macro-
phages (14, 19, 23). PhoP has been shown to regulate more 
than 40 polypeptides; the PhoP-activated genes are induced 
when Salmonella serovar Typhimurium is in an intracellular 
environment, while other genes are repressed by PhoP in this 
environment. Many of the PhoP-repressed genes are maxj-
mally expressed in extracellular environments encountered by 
Salmonella serovar Typlllmurium, such as during the invasion 
of epithelial cells (4). Therefore, two virulence properties of 
Salmonella serovar Typhimurium, induction of endocytosis by 
epithelial cells and intramacrophage survival, are oppositely 
regulated by the PhoPQ regulon. 
Given the importance of the PhoPQ signal transduction 
system in Salmonella serovar Typhimurium, we set out to de-
termine whether a PhoPQ system is present in pathogenic 
Yersinia and to analyze the genes encoding this system at a 
molecular level. This information has allowed us to construct 
an isogenic Y. pestis phoP mutant and thereby de termine the 
role of the PhoPQ system in survival within macrophages and 
the effect of the phoP mutation on the viru lence of Y. pestis. 
MATERIALS ANU METHODS 
Oacteriat strains, 11lasmids, growth condilions, and chemicals. Bacterial 
'I rains and pla,mid'> u•cd in this study arc lislcd in Table I. Y.tx!>ll.\ was roulincl) 
cultured aerot>ically a1 2s•c in blood agar base {BAB) broth, on BAB agar (30). 
on Congo r~u agar (i ncluding 25 g or heart infusion bruth/htcr) (33), or on 
\'e•~inia elcc1ivc ag:tr (Oxoid, l.lasingstoke. United Kingdom). Defined media 
were prepared as dco,cribcd by S1ralcy and Buwmer (39). &drericlria coli slrain~ 
\\efC cuhurcd and ,lored as described by Sambrook et al. (34). All chemical' 
were purchased rrum Sigma-Aidrich (Poolc. United Kingdom) . Ampicillin and 
lctracycline "ere u•cd :11 final concentration' or 55 and 20 iJ.g/ml . rcspec1ivel~ 
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TABLE I. Bacteria l strains and plasmids used in this study" 
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Virule nt wild-type s train, bv. oricntalis 
Y. pestis GB phoP muta nt 
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pUC19 containing 262-bp PCRDOP gene fragment of Y. pseudowberculosis phoP 
pUC19 plus 4-kb Drnl chromosomal fragment containing phoP 
pUC19 and 1.5-kb Sspl chromosomal fragment containing phoP 
pSA2 with 31-bp de letio n in phoP 
Donor p lasmid fo r conjugation; Ap' Sue', pSAI Xbai-Pvuii fragme nt contain ing 
the mutated phoP gene cloned into Xba l-Smal pCVD442 
• Abbreviations: Ap'. ampicillin resistant; Tet', tetracycline resistant: Sue', sucrose sensitive. 
Unless otherwise stated. plasmid and genomic extractions, restriction enzyme 
digestions, DNA ligations. and transformations into £. coli were performed by 
standard procedures (34) using enzymes provided by Promega Ltd. (Southamp-
ton, United Kingdom) or Boehringer Mannheim (I.-ewes, United Kingdom). 
PCR and cloning procedures. Oligonucleotide primers used for PCR are 
summarized in Table 2. The Y. pestis, Yersinia pseudowberculosis, and Yersinia 
enterocolitica phoP gene fragments were amplified using PCR with degenerate 
oligonucleotide primers (PCRDOP) (42) with primers P3 and P4. based on 
known PhoP sequence data for£. coli and Salmonella serovar Typhimurium (27). 
The PCR was performed with 40 cycles of 1 min at 94•c, 1 min at40"C, and I min 
at n•c. The 262-bp products were digested with Pstl and Hindll l, ligated into 
similarly digested pUC19, and transformed in £. coli XL2-Biue MRF' cells 
(Stratagene Europe, Amsterdam, The Netherlands). The cloned fragments were 
sequcnced using the dideoxynucleotide chain termination method with an Ap· 
plied Biosystems (Warrington, United Kingdom) PRISM sequencing kit, and the 
data were compared with other PhoP sequences using BLASTX software (1). 
To determine the entire phoP sequence, the cloned Y. pseudomberculosis plroP 
gene fragment was used with Southern blotting to identify a 4-kbp Drnl fragment 
and a 1.5-kbp Sspl fragment from digests of Y. pseudomberculosis chromosomal 
DNA. The fragments were isolated from a SeaPiaque GTG agarose gel (Flow-
gen. Sillingboume, United Kingdom), ligated into pUCI9/Sma i/BAP (Amer-
sham Pharmacia Biotech. St. Albans, United Kingdom), and transformed into£. 
coli XL2-Biuc MRF' cells to generate plasmids pDA5 and pSA2, respectively. 
The nucleotide sequences of these cloned fragments allowed the design of 
primers P41 and P42, which were used to amplify a 1.5-kb product containing the 
entire Y. pestis or Y. pseudowberculosis phoP genes. Both PCR products were 
purified through S-300HR (Amersham Pharmacia Biotech) and nucleotide se-
quenced. The complete plroP gene sequences from Y. pestis and Y. pseudowber-
culosis were determined from sequence data from three independent PCR re-
actions. 
A 31-bp deletion and unique Bglll site were engineered into thephoP gene in 
plasmid pSA2, using inverse-PCR mutagenesis ( IPCRM) (10, 43), with primers 
P9 and PlO. Fifty picograms of alkali-denatured pSA2 was added to a PCR 
mixrure containing primers P9 and PlO and subjected to PCR with 40 cycles of 
I m in at 94•c, 1 m in at50"C. and 4 min at n•c. PCR products were digested with 
Bglll, self ligated, and transformed into £. coli XL2-Biue MRF' to generate 
plasmid pSAil. Primers P27 and ?24, which flank the deletion site, were used to 
screen for mutants by PCR. using I fJ. I of boi led cell supernatant added to a 
standard reaction mixture, which was subjected to 40 cycles of I min at 94•c, I 
min at so•c, and I min at n•c. 
Construction of a Y. pestis p/rQP mutant. Plasmid DNA from pSAII was 
digested with Xbal and Pvull , and the excised fragment containing the mutated 
Y. pseudowberculosis phoP gene was ligated with pCVD442, which had been 
previously digested with Xbal and Smal. This ligation was electroporated into£. 
coli CC118 Apir cells to form pSAl2. pSAl2 was introduced into Y. pestis strain 
GB by conjugation in a three.way mating (25), using a Y. pestis GB wild-type 
recipient, £ . coli CC118 Apir pSAI2. and£. coli S17 >.pir pNJ5000 ( 18). Equal 
volumes (50 fJ.I) of the three strains were mixed, and 100 f.ll was spoiled onto an 
L agar plate. After incubation (28"C for 8 h), the bacteria were recovered. 
resuspended in 1 ml of Luria-Bertani (LB) broth. washed twice in LB broth, and 
TABLE 2. Oligonuclcolides used for PCR 
Primer I'CR method Strand Sequence (5'-J")".h 
P3 PC RDOP + AATCTGCAGYTNMGNCAYCAYYTNAANGT 
P4 PC RDOP CCAAGCTTNARNACYTCNACYTTPTCYTG 
P9 IPCRM + CCAGATCTGGATGGCTTAAGCCTTATC 
PlO I PCRM AAAGATCTTATCTGGGCCATGTTCCTG 
P24 p/roP specific ACTTTATCTTGCCAGCTTT 
P27 phoP specific + CGCGTTGTTGCGT CA CCAT 
P41 phoP amplification + ACCTATCACCAGATATTGGCGTG 
P42 plroP amplification CCCATCATCATTCTACTGATGTGCG 
" Underlined nuclcotides represent l'st1 (P3). Hind lll ( P4), and Bg/11 ( P9 and PlO) restriction endonuclease sites. 
1
' R = A or G: Y = Cor T: M = A or C: N = A. C, G. or T. 
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FIG. I. Comparison of the deduced PhoP amino acid sequences of Y. pestis, Y. pseudotuberculosis (Y. ptb). Y. mterocolitica (Y. e/11), E. coli. and Salmonella serovar 
Typhimurium (S. typlrm), aligned by using Clustal V multiple sequence aUgnment software. Identical amino acids (e ). conserved changes (1). and the essential aspartic 
acid residue (•) are shown. 
cultured on Yersinia selective agar containing ampicillin at 28"C. Individual 
ampicillin-resistant Y. pestis colonies were inoculated into BAB broth, grown 
overnight at 28•c, and plated onto BAB agar or BAB agar supplemented with 
5% (wt/vol) sucrose (9). Sucrose-tolerant revertants occurred at a rate of I in 3 X 
10", a nd these colonies were screened using PCR with primers P27 and P24, 
followed by digestion of the PCR product with Bgfll . An ampicillin-sensitive Y. 
pestis plroP double-crossover mutant, termed SAI2.2, was identified and used for 
further studies. 
Survival following envi ronmental stresses and exposure to dcfenslos. The 
elfect of low pH, high osmolarity, and oxidative stress on Y. pestis was determined 
as described by Badger and Miller (3). Y. pestis wild-type and plroP mutant strains 
were grown overnight al 2s•c, and the cells were pelleted and resuspended 
appropriately. For oxidativc stress experiments, cells were incubated for l h at 
28"C in l5 mM H20 2 in deionized water. For high-osmolarity stress, cells were 
incubated in 2.4 M NaCl in deionized water for l h at 28°C. For low-pH stress, 
cells were incubated in LB broth. adjusted to pH 3 with HCJ, for 5 min at ambient 
temperature (22"C). Control bacteria were incubated in sterile phosphate-bulf-
e red saline (PBS) (pH 7.4). After exposure, the bacteria were pelleted at 
12,000 X g fo r 5 min at 22•c. resuspended in 0.9% (wt/vol) NaCl, and enumer-
ated after growth at 28•c for 48 h on Congo red agar. All survival experiments 
were repeated in triplicate. 
Survival in J774 macrophage cell cultures. Y. pestis cells from 1-ml volumes of 
an 18-h culture grown at 2s•c were diluted with 9 ml of PBS, centrifuged at 
10,000 X g for 10 m in at 22•c, and resuspended in 10 ml of PBS. The number of 
viable cells was determined after culturing dilutions of the cell suspensions on 
Congo red agar. 1774 macrophage cells were seeded at a density of 5 x lOS ml - 1 
in Dulbecco's modified essential medium (Sigma-Aidrich) into 24-well tissue 
culture dishes and cultured until confluent. The tissue culture medium was 
removed. 150 ,.,.1 (106 cells) o ft he bacterial suspension in PBS was added, a nd the 
cells were incubated at 37"C for 30 min. 1l1e suspension above the cell monolayer 
was removed. and the cells were washed three times with PBS. One milliliter of 
2% Ll 5 medium (Sigma-Aldrich) containing 10 (.lg of gentamicin/m! was added. 
and the cells were incubated for 30 min at 37"C. The cells were washed twice with 
PBS, and I ml of 2'< Ll5 medium containing 2 (.lg of gentamicinlml was added 
to the cell . The cells were incubated at 37"C. and at 'arious time points the 
growth medium wa. removed. the cells were washed with PBS. and 200 J.LI of 
0. 1% sodium deoxycholate was added to the cells. which were lysed by aspiration 
The lysate was diluted in PBS. and the number of viable cells was determined 
after growth at 2s·c for 48 h on Congo red agar. Duplicate sample;, were taken 
at all time points. and the assay was repeated four times. 
20 gel electrophoresis. Protein profiles of Y. pestis wild-type and fJhoP mutant 
strains were compared by two-dimensional (20) gel clectrophorcsi;,. Bacteria 
were grown for 6 h at 28°C or 37"C in BAB broth. Cells were washed once with 
PBS and then boiled for 10 m in in a 0.1% (wt/vol) sodium dodecyl sulfate (SDS) 
solution. Cellular debris was removed by centrifugation, and then the proteins 
were concentrated using Am icon Centriplus concentrators (Millipore. Watford. 
United Kingdom) and stored at - 20"C. Culture supernatants were treated with 
protease inhibitors (Complete; Roche Diagnostics Ltd., Lewes. United King-
dom), 9 mM urea, 65 mM dithiothreitol. and 2% (vol/vol) Triton X-100 to obtain 
completely denatured and reduced proteins. Proteins were separated using 20 
gel electrophoresis as described by Gorget al. (17). Lmmobiline dry strips pH 4-7 
linear (18 cm; Amersham Pharmacia Biotech) were rehydrated with each protein 
sample (30 to 40 ,.,.g) as recommended by the manufacturers. lsoelectric focusing 
was carried out for 44,900 V · h at 20"C. After equilibration, horizontal SOS 
electrophoresis was carried out using Excel Gel SOS, with a gradient of 12 to 
14% T (Amersham Pham1acia Bio tech) at 15'C. The separated proteins were 
then visualized by a silver staining method (21). Molecular weight standards 
(Bio-Rad, Hemel Hempstead, United Kingdom) were also applied to the gel. 
Determination or virulence in mice. The median lethal doses (MLD) of the Y. 
pestis wild-type and phoP mutant were assessed by subcutaneous injection of 
groups of five female 6-week-old BALB/c mice (Charles River Laboratories. 
Margatc. United Kingdom) with se rial dilutions of exponential-phase broth 
cultures grown at 28' C (33). Humane endpoints were strictly observed, and 
animals deemed incapable of survival were humanely killed by cervical disloca-
tion. Times to humane death (typically 3 to 5 days) were recorded, and the MLD 
of the phoP mutant was determined by the method of Reed and Muench (32) . 
Nucleotide sequence accession numbers. The nucleotide sequence~ of the Y. 
pestis and Y. pseudotuberculosis plwP genes have been submitted to the EMBL 
database under accession numbers Y0875 and X66587. respectively. 
RESULTS 
Analysis of the Y. pestis phoP gene. PCRDOP experiments 
consistently amplified a single band o f 262 bp from Y. pes1is 
(GB), Y. pseudotuberculosis (YPlllpiBI), and Y. enterocolilica 
(8081 ). Southern blot analysis with the 262-bp Y. pseudotuber-
culosis phoP gene fragment used as a probe against Y. pseudo-
tuberculosis chromosomal DNA digested with Dra l and Ssp l 
revealed single hybridization bands of 4.0 and 1.5 kb, respec-
tively (data not shown). These chromo omal fragments were 
cloned into pUC18 and scquenccd. These sequence data a l-
lowed the design of PCR primers and the subsequent ampli-
fication of the entire phoP genes from both Y. pestis and Y. 
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FIG. 2. Survival of Y. pestis wild-type (GB) and phoP mutant (SAI2.2) strains after uptake by 1774 macrophages. Results shown are the means of dupl icate 
determinations in two separate experiments. with standard errors. 
pseudotuberculosis. Sequence analysis of amplified 1.5-kbp se-
quences revealed the presence of a phoQ orthologue 5 bp 
downstream of phoP (data not shown). ThephoP open reading 
frame encoded a protein with an M, of 25,586. The deduced 
amino acid sequence of the Y. pestis PhoP was aligned with 
reported sequences of PhoP from E. coli and Salmonella sero-
var Typhimurium and with the PhoP sequence from Y. pseudo-
tuberculosis and Y. enrerocolitica, using the Clustal V multiple 
sequence alignment software (Fig. 1). The Y. pestis PhoP re-
vealed 99.6, 99.5, 94.2, and 93.3% similarity and 99.1, 98, 82.3, 
and 80.4% identity to the respective Y. pseudotuberculosis, Y. 
enterocolitica , E. coli, and Salmonella serovar Typhimurium 
counterparts. The Y. pestis PhoP contained the conserved as-
partate (D) residue at position 51, which is the likely site of 
phosphorylation by PhoQ. Analysis of the Y. pestis (C092) 
genome sequence recently released by the Sanger Centre 
(http://www.sanger.ac.uk/Projects/Y _pestis/) revealed a single 
copy of the phoP gene and confirmed the presence of the phoQ 
gene immediately downstream of phoP. 
Construction of the Y. pestis phoP mutant. An isogenic Y. 
pestis phoP mutant was constructed by allelic replacement us-
ing the Y. pseudowberculosis phoP gene, which had a deletion 
of the conserved aspartate residue at position 51 that is re-
quired for phosphorylation of response regulatOrs. There was 
sufficient homology between the phoP genes from Y. pseudo-
tuberculosis and Y. pestis to allow recombination to occur be-
tween the Y. pseudotuberculosis gene carried by pSAI2 and the 
gene on the Y. pesTis chromosome. T he mutation was con-
firmed by PCR and subsequent digestion of the PCR product 
to show the presence of the unique Bglli site within the am-
plified region that was absent in the wild-type gene. Further 
confirma tion that the second crossover event had occurred was 
the loss of the ampicill in resistance gene marker in the newly 
constructed mutant. 
Contribution of PhoP to surviva l under stresses. The effect 
of the phoP mutation o n the phenotype was examined by 
subjecting the mutant and wild-type strains to a range of en-
vironmental stresses. The mutation in phoP rendered the bac-
teria slightly more sensitive to low pH and oxidative killing 
(P < 0.1, using the Student t test with unpaired sets) and sig-
nificantly more sensitive to high osmolarity (P < 0.05, using the 
Student t test with unpaired sets). 
Survival in J774 macrophages. 1774 macrophage cell cul-
tures were infected with either Y. pestis GB or Y. pestis SAI2.2. 
After incubation to allow uptake of bacteria, the extracellular 
bacteria were killed with gentamjcin. At 0, 1, 3, or 5 h postin-
fection, infected cells were lysed, and the number of viable 
bacteria within the cells was determined. The results showed 
that in the case of both the wild-type and the phoP mutant 
strains, the number of viable bacteria declined during the first 
hour (Fig. 2). However, whereas 34% of the wild-type bacteria 
were ki lled by macrophages 5 h postinfection, 81% of the phoP 
mutants had been killed by this time. 
Protein expression by a Y. pestis phoP mutant. The protein 
expression profiles of Y. pestis wild-type and phoP mutant 
strains grown in BAB broth at both 28 and 37°C were studied 
(Fig. 3 and 4). The 2D patterns of both strains at both tem-
peratures investigated are highly similar and comparable. Only 
obvious differences recognizable by visual evaluation are re-
ported. 
Virulence of the phoP mutant in mice. The Y. pestis phoP 
mutant was less virulent in mice than the wild-type strain. The 
reported MLD for the G B wild-type strain is 1 CFU (33). The 
phoP mutant was determined to have an MLD of 75 CFU. 
DISCUSSION 
Many pathogenic bacteria colonize a variety of niches wi th-
in the host, and the differential expression of bacterial genes 
is necessary to allow the bacterium to survive and prolife rate 
in these diffe re nt e nviro nments. T he rapid adaptation of 
pa thogens to these different niches is often achieved via two-











YERSINIA PESTIS phoP MUTANT 3423 
A B 
5.5 7 4 5.5 7 
FIG. 3. 20 gel electrophoresis protein expression profiles for the Y. pestis wild-type strain (a) and Y. pestis plwP muwnt strain (b) grown at 28"C. Dilfercnces in 
protein cxpres!>ion ure highlighted (0). Mr, molecular weights in thousands. 
component regulatory systems. which enable changes in the 
environment to be detected and thus regulate bacterial gene 
expression accordingly. One such system is the PhoPQ regulon, 
which has been characterized for E. coli and Salmonella sero-
var Typhimurium. In this system, PhoQ senses changes in the 
environment, which results in autophosphorylation of a histi-
dine residue and the subsequent phosphorylation of an aspar-
tate residue in PhoP, which is then able to coordinate gene 
expression. Different sets of genes are differentially regulated 
by this system. The Salmonella serovar Typhimurium PhoPQ 
regulon plays a central role in the regulation of several deter-
minants that are required to be differentially expressed during 
infection (13, 14, 23). The pleiotropic role for the PhoPQ regu-
lon in Salmonella serovar Typhimurium has been confirmed by 
mutational analysis of phoP and is related to several pheno-
typic changes, including deficiency in epithelial cell invasion 
(4), increased susceptibility to ca tionic peptides ( 12) and low 
pH (28), reduced survival rates in macrophages ( 11 ), and al-
tered presentation of antigens ( 41 ). 
Hybridization studies have suggested that PhoPQ is widely 
distributed among enteric bacteria ( 19), but only the Salmo-
nella serovar Typhimurium and E. coli genes have been char-
acterized in detail. Ln this study, we have shown that a PhoPQ 
signal transduction system operates in Y. pesris. Alignment of 
the deduced amino acid sequences of the Y. pestis PhoP with 
those from Salmonella serovar Typhimurium and E. coli re-
vealed extensive amino acid identity. Given the amino acid 
similarity between the Y. pestis and Salmonella serovar Typhi-
murium PhoP proteins (93.3%) and the identification of a 
PhoQ orthologue downstream, we are confident that the equiv-
alent Y. pestis plwP gene was characterized in this study. 
Both Y. pestis and Salmonella serovar Typhimurium are ca-
pable of surviving and multiplying in one of the most hostile 
environments bacterial pathogens encounter, the phagolyso-
somes within macrophages (38). Following phagocytosis of 
bacteria, macrophages induce a series of events in an attempt 
to kill the pathogen. In our studies, macrophages were infected 
at 37°C with bacteria which had been cultured at 2s•c to mimic 
the events which would follow delivery of the bacteria into the 
host via a flea. Thus, these bacteria may not initially be pro-
tected from phagocyte killing. This may explain why the num-
ber of wild-type and phoP mutant bacteria initially declined 
after infection of macrophages. However, 5 h after infection of 
macrophages, it was clear that the phoP mutant had been killed 
much more efficiently than the wild-type strain. 
Mechanisms of macrophage killing include the generation of 
reactive oxygen intermediates and the acidification of the 
phagolysosome (2). The phoP locus of Salmonella serovar Ty-
phimurium is essential for virulence and survival within mac-
rophages ( 15, 28). Exposing the Y. pestis phoP mutant to a 
range of environmental stresses which might be encountered in 
the macrophage showed it to be more sensitive to oxidative 
stress and low pH than the wild-type strain. Another environ-
mental signal that has been shown to be important in moder-
ating the expression of the PhoP/PhoQ signal transduction 
system is levels of Mi+ ions ( 16). ln low-Mg2+ -ion environ-
ments, PhoP has been shown to regu late high-affinity magne-
sium transporters ( 16). Preliminary data suggest that a similar 
system may be operating in Y. pestis, since the PhoP mutant 
was unable to grow on Mi + -depleted solid medium, in con-
trast to the wild-type strain (P. Oyston, unpubl ished obseJva-
tion). A further important role for PhoP in the virulence of 
Sulmunella serovar Typhimurium is that PhoP seems to indi-
rectly play a role in lipid A modification (20). Analysis of 
wi ld-type and PhoP mutant polysaccharides on Tricine gels 
reveal no differences in their respective lipopolysaccharide 
profiles. However, further ophisticated analysis of the PhoP 
mutant lipid A composition and structure is required before 
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FIG. 4. 20 gel electrophoresis protein expression pro tiles for the Y. pesus wild-type strain (A) and Y. pestis plroP mutam (B) grown at 37•c. Differences in protein 
expression are highlighted (0). Mr. molecular wc1ght in thousands. 
firm conclusions on the possible role of PhoP on lipid A mod-
ification in Y. pestis can be made. 
Numerous differences were observed between the total pro-
tein profiles of Y. pestis wild-type and phoP muta nt strains 
which had been cultured in vitro, indicating that the PhoPQ 
system has pleiotropic effects on gene expression. Protein spots 
that are a bsent in the phoP mutant but present in the wild type 
probably represent proteins whose expression is activated by 
PhoP. Thus, mutation of the phoP gene results in these genes 
not being expressed . Conversely, protein spots absent in the 
wild type but present in the phoP mutant are probably proteins 
whose expression is normally repressed by PhoP. Therefore, in 
the phoP mutant strain these proteins are expressed. The ab-
sence of a large number of phoP-activated proteins observed 
when the cells were grown at 37°C was surprising. However, 
the pi range of proteins examined was restricted to 4 to 7 in 
order to obtain comparable, reproducible gels. Thus, changes 
in the expression of alkaline proteins would not have been 
observed. The molecular and biochemical characterization of 
these phoP-activated and repressed proteins could provide in-
sight into the mechanisms by which Y. pestis survives the in-
creased temperature encountered when it is transmitted from 
fleas to humans and how the pathogen avoids macrophage 
killing and causes disease. 
Rationally attenuated strains of a wide range of bacteria 
have been produced by inactivation of genes of various biosyn-
thetic pathways, such as aro, pur, gal, and cya (7, 26, 30, 35). 
Inactivation of the genes encoding response regulators, such as 
PhoP and OmpR, has been shown to be attenuating for Sal-
monella serovar Typhimurium (8, l4). Whereas the inactiva-
tion of phoP in Salmonella serovar Typhimurium is severely 
a ttenuating ( 12, 14, 27), the mutation in Y. pestis is only par-
tially attenuating. The differences in orders of magnitude of 
virulence between the Salmonella PhoP and Yersinia PhoP in 
murine infection models suggest possible differences in the 
roles of PhoP in these organisms. This may be a reflection of 
the fact that PhoP regulates different sets of loci in these 
species. Alternatively, this may be explained by the different 
sites occupied by the bacteria in vivo. Salmonella serovar Ty-
phimurium is primarily an intracellular pathogen. By contrast, 
Y. pestis is dependent on an initial intracellular phase, followed 
by the widespread growth of bacteria extracellularly ( 40). 
Therefore, the influence of the mutation of phoP, rendering an 
organism more sensitive to oxidative stress and extremes of 
pH, would have a larger impact on the intracellular Salmonella 
and would thus be more attenuating than for the transiently 
intracellular Y. pestis. Detailed knowledge of virulence-associ-
ated genes aids in the design of novel live vaccines. A Salmo-
nella enterica serovar Typhi phoP-attenuated mutant has been 
shown to be effective in human volunteers (24). Although the 
Y. pestis phoP is only partially attenuating, the method used to 
prepare the Y. pestis phoP mutant in this study did not rely on 
the incorporation of an antibiotic resistance marker. Thus, it 
should be possible to graduate attenuation further in Y. pestis 
by the introduction of further mutations in key genes. The 
mutation of phoP in combination with the mutation of other 
genes could produce a Y. pestis strain with potential as a live 
vaccine candidate. 
In conclusion, we have identified, cloned, and sequenced a 
PhoPQ orthologue from Y. pestis and constructed an isogenic 
mutant. Characterization of the phoP mutant has shown that 
the PhoPQ two-component regulatory system plays a role in 
the intracellular survival of Y pestis similar to that of its or-
thologue in Salmonella serovar Typhimurium. However, due 
to the predominantly extracellular location of Y pestis during 
infection, the effect of a phoP mutation on virulence is weaker 
VOL 68,2000 
than with Salmonella species. Of greater interest is the number 
of proteins that appear to be activated by the PhoPQ system at 
28oc and repressed at 37°C, suggesting an important role for 
this two-component regulatory system in the survival of Y. pes-
tis in the flea and/or during transmission. 
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Abstract 
The HtrA stress response protein has been shown to play a role in the virulence of a number of pathogens. For some organisms. l11rA 
mutants are attenuated in the animal model and can be used as live vaccines. A Yersinia pestis htrA orthologue was identified, cloned and 
sequenced, showing 86% and 87% similarity to Escherichia coli and Salmonella typhimurium HtrAs. An isogenic Y. pestis l11rA mutant was 
constructed using a reverse genetics approach. In contrast to the wild-type strain, the mutant failed to grow at an elevated temperature of 
39°C, but showed only a small increase in sensitivity to oxidative stress and was only partially attenuated in the animal model. However. the 
mutant exhibited a different protein expression profile to that of the wild-type strain when grown at 28•c to simulate growth in the 
flea . ~ 2000 Federation of European Microbiological Societies. Published by Elsevier Science B. V. All rights reserved. 
Keyll'ords: HtrA : lsogenic mutant: Pathogenesis: Stress response: Yersinia pes/is 
1. Introduction 
Yersinia pestis is the etiological agent of bubonic plague, 
a zoonotic infection transmitted from natural animal res-
ervoirs to man usually through the bite of an infected tlea. 
Bubonic plague can develop into the pneumonic form of 
the disease, which has a high mortality rate and is highly 
infectious ( I]. Recent o utbreaks of plague, plus the identi-
fication of a multidrug-resistant strain of Y. pestis in Ma-
dagascar (2,3], have served as timely reminders that this 
organism still poses a significant public-health problem. 
In order to survive a nd establish infection, bacteria have 
to be able to urvive a range of hostile host environments. 
For example. for transmission via a flea bite, Y. pestis 
must firs t adjust to an increase in temperatu re from 
28°C in the tlea to 37°C in the mammalian host, then 
• Corresponding author Tel. : +44 (171) 927 2288: 
Fa~ : +44 ( 171) 636 8739. E-mail : brendan.\\ren(!t lshtm.ac.uk 
1 Pre~ent addr~ss Ac.u.kmic D~partmcnt of Surgery. St. Ba rtholo· 
me\\ ·s and the Royal Londc'n School of Medicine a nd Dentistry. White-
chapel. London. UK 
respond to host defence mechanisms. surviving oxidative 
stress, low pH and host defensins. Altho ugh the Yersinia 
outer membrane proteins (Yops) and other plasmid-bo rne 
genes play a vital role in virulence and in the inhibition of 
phagocytosis [4,5], chromosomal determinants also play a 
role in the pathogenicity of this organism (6]. 
The high temperature response protein (HlrA), a lso 
known as DegP, has been identified as a virulence factor 
in a number of organisms a nd several l11rA mutant of 
Gram-negative pathogens a re attenuated and act as live 
vaccines [7]. HtrA is essential for the surviva l of Escheri-
chia coli at temperatures higher than 3rC. but this is 
not the case fo r Salmonella typhimurium [8]. However, 
S. typhimurium HtrA is essential for resistance to oxidative 
stress and survival in macrophages [8]. In contrast to 
£. coli and S. 1yphimurium, Brucella aborrus and Yeninia 
enrerocolitica htrA mutant s are sen itive to both high 
temperature and oxidative tress [9.10]. S. typhimurium, 
B. aborrus and Y. entemcoliTica IHrA mutants ha\'e all 
been shown to have reduced viru lence compared to the 
wild-type st rains [9.11. 12]. Immunisation of mice with 
S. typhimurium a nd Y. enterocoliticu IurA mutants can 
induce protection against ubsequent challenge with \ iru-
lent wild-type strain (9, 11 ]. 
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Table I 
Bacterial strains and plasmid' u'cd in thi' study 
----------------------------------------------------------------------Strain/plasmid Relevant eh a racteristics Source/rclcrcncc 
Strains 




\ '1rulcnt 1\lld-typc strain. b101ar oncnwhs 
1'. 1'<'.<ti.1 GB IurA mutant 
[14] 
This \ tUd) 
XU-Biue MRF' 





S l7 l..pir pNJ5000 
Plasmids 





Ap' . Sue'. suicide vector 






plJC I9 plus 1.3-kb PCRDOP gene fragment of Y. pc.,ti.l' IurA 
pYHA I wi th 53-bp deletion in lttrA 
This study 
This study 
This study pY HA3 Donor plasmid for conjugation: Ap' Sue' pYHA2 Xha l-Pwll fragment 
containing the mutated IurA gene cloned into Xbal-Smal pCVD442 
Abbreviations: Ap' . ampicillin resistant : Tet'. tetracycline resistant: Sue'. >Ucrose sensitive. 
This stud y describes the iden tifica tio n and initia l cha r-
acterisation of a Y. pesris HtrA ortho logue. 
2. Materials and methods 
2. 1. Bacterial s lrains, plasmids and grou·th conditions 
Bacterial stra ins and plasmids used in this study a re 
listed in Table I. Y. pesris was routinely cultured aerobi-
cally at 28°C in blood aga r base (BA B) bro th. on BAB 
agar [ 13], o n Congo red aga r [ 14] o r on Yersinia selective 
aga r (YSA) (Oxoid, Basingstoke, U K). Defined media 
were prepa red as described p reviously (1 5]. E. coli strains 
were cultured and stored as described by Sambrook et al. 
[ 16]. Ampicillin and tetracycline were used a t fina l concen-
tra tio ns o f 25 mg 1- 1 and 20 mg 1- 1• respectively. 
2.2. DNA manipulations 
Unless o therwise sta ted, plasmid and chromosomal 
DNA extractions, restricti on enzyme digests, DNA liga-
Table 2 
Oligonucleotides used for PCR 
Name PCR method Strand Sequence (5'-3')·' 
HI O PCRDOP + GAAC~GCAGTATATGAARAARACNACh 
H9 PCRDOP CTT ·' -.;GCTTNCC JA TYTGNGCNGCNGGb 
Hl4 IPCRM + TGAG . .; ~CTAGTGGTTTGAATGTGGAAA 
Hl3 IPCRM TGAG . .; ~CTCGA T ;..GCTACGGTA T AA TC 
H22 IurA spcc1fic + GTA-~~;~TGAGCGATGGCCG 
H23 IurA specific ~CAT::~GTGCCAGAATAGC 
·'Underlined nucleotide\ n:prc,ent P.1t l ( H 10). 1/indll I (H9) and Bglll 
(11 14 and H 13) r~,triction ~ndonuclca>~ >i tcs. 
hDcgcncr;llc oligonucleotidcs b<~ scd on amino adds I to 5 of S. trplti-
murium HtrA (HIO) and 44 ~ to 447 1H9). R = A or G : Y =C or T : 
D = A.Gor T : '= A. C.G,H· T. 
tions and transforma tio ns into E. coli were perfo rmed by 
standa rd procedu res [ 16]using enzymes supplied by Prom-
ega (Southampto n, UK) or Boehringer Mannheim (Lewes, 
UK). All chemicals were purchased fro m Sigma-Aldrich 
(Poole, UK). The oligonucleotide primers used for PC Rs 
a re summarised in Table 2. 
2.3. Amplification and sequencing of the hrr A gene 
fragmen t 
The Y. pestis l11rA gene fragment was amplified by PC R 
with degenerate oligonucleotide primers [1 7]. Primers H 10 
and H9. based on HtrA sequence da ta from E. coli and 
S. lyphimurium, were used to identify and clone a Y. pesris 
htrA, as described previously (17]. A clone (pYH AI ) was 
sequenced by the dideoxynucleotide cha in termina tion 
method with a PRISM@ sequencing kit (Applied Biosys-
tems, Wa rrington, UK ) and the data compared with 
known Ht rA sequences using BLASTX software (18]. 
The complete sequence of the Y. pestis hrrA gene was 
determined using the ligation anchor PC R method [9]. 
2.4. Construct ion of Y. pesris l11rA mutant 
A 53-bp deletio n and unique Bgll l site was enginee red 
into the IurA gene fragment in pYHA I by inverse PC R 
mutagenesis ( I PC R M) using primers H 14 and H 13 as de-
scribed previously [19,20], fo rming pYHA2. pY HA2 \\·as 
digested with Xho l and Pl•ttl l. and the fragment contain-
ing the mutated IurA gene was ligated into the suicide 
vecto r pCV D442 [2 1]. previou ·ly digested with Xba l and 
S mu t. The ligated plasmid wa electropora ted into E. coli 
CC II 8 A.pir cells to form pYHA3. E. coli CC I I8 1-pir 
pY HA3 was introduced into the wild-type Y. pesris G B 
recipient by conjugation using a tri-cross mating proce-
dure as described previously [9], to produce ampicillin-re-
K. William.f l'l al. / FEAtS /llit'rohiolox.1· L£'1/c•rs I H6 ( 2000 I 2/f/ !86 28J 
sistant merodiploid transconjugants. A single ampicillin-
resistant transconjugant was selected, plated onto BA B 
agar supplemented with 10% w/v sucrose and grown at 
28°C for 2 days. Grid plates were picked in duplicate 
onto BAB ·ucrose agar and Congo red agar. The BAB 
sucrose plates were incubated at 28°C for 2 days, whilst 
the Congo red plates were incubated at 39°C for 2 days. 
Colonies which failed to grow at 39°C were screened by 
PCR using primers H22 and H23, followed by digestion of 
the resulting PCR product with Bglll, to confirm incorpo-
ration of the defined deletion into the htrA gene. 
2.5. in vitro stress experiments 
To determine the effect of oxidative stress on Y. pestis, 
overnight stationary phase cells were incubated at 37°C 
for I h in the presence of 40 mM H202. To determine 
the number of viable bacteria after exposure to oxidative 
stress, the cells were pelleted and resuspended in PBS and 
appropriate dilutions plated on Congo red agar and incu-
bated at 28°C for 2 days. Experiments were performed in 
triplicate. The statistical significance of experimental data 
was determined using the unpaired Student's t-test per-
formed with the InStal Statistical Package (Sigma). 
2.6. Determination of virulence in mice 
The median lethal doses (MLD) of the wild-type and 
htrA mutant strains which induced morbidity or death in 
mice, were assessed by subcutaneous injection of groups of 
five female 6 weeks old BALB/c mice (Charles River Lab-
oratories, Margate, UK) with serial dilutions of exponen-
tial phase broth cultures grown at 28°C (14]. Humane 
endpoints were strictly observed and animals deemed in-
capable of survival were humanely killed by cervical dis-
location. Times to death were recorded and the MLD of 
the htrA mutant determined by the method of Reed and 
Muench (22]. 
2. 7. Two-dimensional SDS- PAGE analysis 
Y. pestis wild-type and /lirA mutant strains were grown 
for 6 h at 28°C in BAB broth. Cells were washed once 
with PBS then boiled for I 0 m in in a I 0% v/v Triton X-
I 00 solution. Cellular debris was removed by centrifuga-
tion and the protein superna tant retained. Proteins were 
concentrated using Amicon Centriplus concentrators 
(Millipore, Watfo rd, UK) and stored a t - 20°C. Proteins 
were separa ted u ing two-dimensional (20) SOS PAGE 
as described by Gorg et al. [23]. lmmobiline Dry Strips 
pH 3- 10 N L (1 8 cm ; Amersham Pha rmacia Biotech, t. 
Albans, UK) were rehydrated with each protein sample 
(40 J..Lg) as recommended by the manufacturers. lsoelectric 
focusing was performed for 44 900 volt hour- 1 at 20°C. 
After equilibration. horizontal SOS electrophoresis was 
ca rried out using Excel Gel SOS. grad ient 12 14'!1,, T 
(Amersham Pharmacia Biotech) at I 5°C. The separated 
proteins were then visualised by silver staining [24]. Mo-
lecular mass standards (Bio-Rad, Hemel Hempstead. UK) 
were also applied to each gel. 
3. Results 
3.1. Construction and characterisation of a Y. pestis htrA 
1111/tant 
PCROOP experiments consistently amplified a single 
band of approximately I .3 kb, which represents 90% of 
the Y. pestis htr A sequence. The nucleotide sequences of 
htrA clones from two independent PCROOP experiments 
were determined and found to be identical. The remainder 
of the htrA gene sequence was obtained by ligation anchor 
PCR. The Y. pestis HtrA orthologue revealed extensive 
amino acid similarity with the respective Y. enterocolitica 
(95%), E. coli (85%) and S. typhimurium (86%) counter-
parts. These data strongly suggest the identification and 
cloning of the Y. pestis GB htrA gene. 
A Y. pestis l11r A mutant was constructed by allelic re-
placement as summarised previously (9]. The Y. pestis htrA 
cloned gene fragment was mutated by TPCRM with a 59-
bp deletion [I 9,20] . Typically, tri-cross mating experiments 
resulted in 40 ampicillin-resistant Y. pestis merodiploid 
transconjugants per ml of donor strain E. coli CC I I 8 
A.pir pYHA3. After growth on BAB sucrose agar, su-
crose-resistant, ampicillin-sensitive colonies were identi-
fied. Two putative htrA mutants were identified through 
their inability to grow at 39°C. The double-crossover mu-
tation at the htrA locus was confirmed by PCR analysis 
(data not shown). One of these, termed YHA7, was used 
for further study. The htrA mutant appeared identical to 
the wild-type strain when grown at 28°C on Congo red 
agar, but produced smaller colonies when grown at 37°C 
(data not shown). 
Table 3 
Determinatio n of virulence of )' J>l!.\11.\ wild-type and htrA mutant in 
mice 
Strain C hallenge dose De;tths Mean ttd·' (days) 
Wild-type 10• CFU 515 5.4 ± 0.29 
10' C F U 515 5.6 ± 0.48 
101 Fl 515 6.8 ± 0.5 1 
10 CF 515 8.4 ± I.OJ 
I C FU 115 7 + /ei'O 
hilA mutan t I 0" Cf- U 4/5 7.25 ± 0.29 
10' F 515 7 9 ± 0.4 
101 CFU 515 8 .4 ± 0.51 
10 CFU 115 8.0 ± LCI'O 
FU 0/5 
·'Time to d ea th . 
















Fig. I. 2D gel electrophoresis pauerns o f proteins isola ted from (A) Y. Jll!.llis wild-type. (B) htr.-1 mutant. grown in BAB broth for 6 h at 28"C. with 
the respective boxed areas enlarged. 
3.2. in t•itro srress experimenr.1· 
Survival rates of Y. pestis wild-type and /lirA mutant 
strains after exposure to oxidative stress were examined. 
The l11rA mutant showed a reduced surviva l rate 
(82 ± 6.9%) compared to that of the wi ld-type 
(98.1 ± 9.1'%). Statistica l analysis showed the difference in 
the surviva l rates to be not quite significant (P = 0.071 ). 
3.3. Experimenwl infection of 8~ LB/c mice 
The Y. pestis GB wild-type strain was more virulen t in 
mice than the htrA mutant (Table 3). The M LD values 
were calculated to be 2.5 CFU fo r the wild-type strain 
and 30 CFU for the mutant. The MLD value for the 
GB stra in compares with the previous estimate of I CFU 
[14], confirming the virulence of the wi ld-type strain . At 
1\ IVillwms <'t a/ I r£.1/S ,\1itrohwlt•~:•· utters 1116 0000) 281 !86 285 
the higher infection doses (I 02 • I 0·1 and I 0~). the mean 
time to death was longer for the mutant than the wild-
type. 
3. 4. T11 ·o-dimensional SDS- P AGE analysis 
To investigate whether HtrA protease plays a role in the 
degradation of cellular proteins, proteins expressed by 
Y. pes1is wild-type and f11rA mutant when grown in vit ro 
at 28°C were ana lysed by 20 gel electrophoresis and silver 
staining. Many more proteins were identified in the cell 
lysates of the fllrA mutant (Fig. I B) compared to the 
cell lysate of the wild-type strain (Fig. lA). Most notably, 
many acidic (pl < 5) high molecular mass ( > 43 kDa) 
proteins were present in the cell lysate from the f11rA 
mutant. 
4. Discussion 
The current plague vaccines are either heat- or forma lin-
killed bacteria and the primary immunogen is the capsular 
Fl antigen protein. Although the e whole cell vaccines 
protect against the bubonic form of plague, their efficacy 
against the pneumonic form is doubtful [14). Furthermore, 
these vaccines produce a range of side effects, require re-
petitive immunisations and are defeated by a high-level 
challenge, making them unacceptable for widespread use 
[25,26). Several bacterial f11rA mutants are attenuated and 
are excellent live vaccine candidates [7). Therefore. we 
sought to investigate the role of HtrA in the virulence of 
Y. pestis. 
Bacterial stress response proteins play a vital role in the 
adaptation of organisms to their changing environment 
and thus to bacterial survival and colonisation of the 
host. Primarily an extracellular bacterium, Yersinia species 
must be able to resist killing and clearance by the host's 
defences. Although the Y. pestis f11rA mutant exhibited 
increased sensitivity to oxidative stress, the effect was far 
greater in both Y. enterocolitica and S. 1yphimurium htr A 
mutants [8,9). However. bacterial oxidative stress is a com-
plex phenomenon and mutation of genes other than /lirA 
can result in decreased tolerance to oxidative stress [27). 
The Y. pestis htrA mutant was only marginally attenu-
ated for virulence in BA LB/c mice; a 15-fold increase in 
M LD. In contrast, the S. typhimuriwn htrA mutant exhib-
its a I 0 000-fold incrca~e in the LD50 [8). This may be 
because HtrA performs different roles in these two species. 
Alternatively, this may be explained by the different sites 
occupied by the bacteria in vivo. S. lyphimuriwn is primar-
ily an intracellular pathogen. whilst Y. pestis is dependent 
on an initial intracellular phase followed by \\'ldespread 
ex tracellular growth [28]. 
Due to the reduced IurA phenotype ob. erved at 37°C. 
we investigated protein expression profi les using 20 SOS-
PAGE at 28°C to simulate growth in the Oea. The htrA 
mutant did posse sa different protein expression profile to 
that of the wild-type strain. To da te, protein profiles for 
!11rA mutants in other bacterial species have not been 
studied. Whole cell lysates of the IurA mutant grown in 
vit ro at 28°C contained additional proteins, compa red to 
the wild-type strain. It is thus likely that HtrA plays a role 
in protein degradation in bacteria growing at 28°C. as well 
as at 37°C. Recently, in Lacwcoccus lactis, Poquet et al. 
have demonstrated that HtrA is the sole extracellular pro-
tease used in degrading abnormal exported proteins and 
propose that it is totally responsible for the housekeeping 
of exported proteins [29]. If the Y. pestis HtrA has a cen-
tral role in protein degradation, this wou ld explain the 
multiple differences in the expression profiles between the 
mutant and wild-type strains. 
How a hn-A muta tion confers attenuation in bacterial 
pathogens is not yet fully understood. The chief role of 
HtrA is to degrade aberrant proteins in the cytoplasm, a 
role that would be diminished in a f11rA mutant, leading 
to the accumulation of misfolded proteins [7]. One hypoth-
esis is that these proteins accumulate to toxic levels when 
HtrA is non-functional [7]. Another hypothesis for the 
attenuation of htr A mutants is the inability to survive in 
macrophages due to increased sensitivity to oxidative 
stress [7). Both mechanisms could play a role in Y. pestis 
survival, however the importance of HtrA for Y. pestis 
virulence in mammalian hosts appears to be reduced. 
probably due to the significance of the Yop response 
and the different sites occupied in vivo compared to other 
enteric pathogens. 
Detailed knowledge of virulence-associated genes aid in 
the design of novel live vaccines. Live vaccines are pre-
ferred over killed vaccines because they evoke both a cel-
lular and a humoral immune response. It should be 
stressed that the method used for mutant construction in 
this study does not incorporate an antibiotic-resistance 
marker, a stumbling block frequently encountered when 
constructing mutants in ACDP Category 3 organisms. 
This method can also be used to produce additional mu-
tations in the Y. pestis f11rA mutant. Recently, a S. typhi 
htrA aroA aroC mutant has shown good promise as a live, 
oral single-dose typhoid vaccine [30). The mutation of 
htrA in combination with the mutation of other genes 
could produce a Y. pestis st rain with potential as a live 
vaccine candida te. 
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The pH 6 Antigen of Yersinia p estis Binds to ~ 1 -Linked 
Galactosyl Residues in Glycosphingolipids 
DEAN PAYNE, DAVID TATHAM, E. DIANE WILLIAMSON, 
AND RICHARD W. TITBALL * 
Defence Evaluation and Research Agem.y, CBD Ponon Down, Porton Down, 
Salisbwy, Wiltshire SP4 OJQ, United Kingdom 
Received 13 April 1998/Returned for modification 15 May 1998/Accepted 11 June 1998 
The Yersinia pestis pH 6 antigen was expressed by, a nd purifi ed from, Escherichia coli containing cloned psa 
genes. By an enzyme-linked immunosorbence-based assay, purified pH 6 antigen bound to gangliotetraosyl-
ceramide (GMlA), gangliotriaosylceramide (GM2A), and lactosylceramide (LC) (designations follow the 
nomenclature of L. Svennerholm (J. Neurochem. 10:6 13- 623, 1963]) . Binding to GM1A, GM2A, and LC was 
saturable, with 50% maximal binding occurring a t 498 ± 4, 390, and 196 ± 3 nM, respectively. Thin-layer 
chromatography (TLC) overlay binding confirmed that purified pH 6 antigen bound to GM lA, GM2A, and LC 
and a lso revealed binding to hydroxylated galactosylceramide. Intact E. coli cells wh ich expressed the pH 6 
antigen had a specifici ty similar to that of pur ified pH 6 in the TLC overlay assay except that nonhydroxyla ted 
galactosylceramide was also bound. The binding patterns observed indicate that the presence of fH-Iinked 
ga lactosyl res idues in glycosphingolipids is the minimum determinant required for binding of the pH 6 antigen. 
Members of the yersiniae express a range of adhesins termed 
YadA, Ail, invasin, and pH 6 antigen which are associated with 
virulence ( l4, 16). Other virulence attributes include a range of 
outer membrane proteins termed Yops. Some synergism may 
exist between the adhesins and Yops of the ycrsiniae since it 
has been found that adherence mediated by YadA is a prereq-
uisite for the entry of at least two of the Yops (YopE and 
YopH) into eukaryotic cells (16). Yersinia pestis is a gram-neg-
ative facultative intracellular parasite and is the causative agenr 
of plague. The pH 6 antigen is the only known putative adhesin 
expressed by Yersinia pestis. Expression of the pH 6 antigen, on 
the surface of the bacterium, is induced when the bacteria are 
grown between pH 5 and 6.7 and between 35 and 4l°C (13). 
These conditions are encountered in the phagolysome, and 
synthesis at this site in macrophages has been demonstrated 
(13). The pH 6 antigen expressed on bacteria released from 
these macrophages might facilitate the colonization of other 
cell types and might also contribute to the delivery of Yops into 
these cells, by promoting bacterium-host cell contact (16). 
The pH 6 antigen was first identified as a virulence deter-
minant when derivatives of Y. pestis lacking the pH 6 antigen 
showed reduced virulence in mice ( l). Structurally, the pH 6 
antigen was found to consist of PsaA, a subunit protein , which 
assembles to form homopolymeric fibrillar structures on the 
bacterial surface (6, 7). A cosmid containing a 42-kbp DNA 
fragment which encodes PsaA and accessory loci necessa•y for 
pH 6 antigen biosynthesis (pDG I) has previously been cloned 
and expressed in Escherichia coli (6, 7). E. coli organisms ex-
pressing the pH 6 antigen have been shown to produce fibrillar 
structures which appear identical to those produced by Y. pestis 
expressing pH 6 antigen, and the fibrillar structures from both 
bacteria reacted with antiserum against the pH 6 antigen (6). 
Y. pesris cells, E. coli cells expressing the pH 6 antigen, and 
crude potassium isothiocyanate extracts of bacterial cells ex-
pressing the pH 6 antigen were all found to agglutinate eryth-
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shire SP4 OJQ, United Kingdom. Phone: 1980 6 13103. Fax: 0980 6 13284. 
E-mail: I 00655.2360@compusclve.com. 
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rocytes from a range of species (2). The pH 6 antigen has been 
reported to bind to several human immunoglobu lin G sub-
classes by acting as a bacterial Fe receptor (18). 
This study examined the binding specificities of the pH 6 
antigen of Y. pestis for a range of purified glycosphingolipids. 
The approach used was based on the binding pattern observed 
with both purified and cell-bound pH 6 antigen. It is suggested 
that the binding specificity observed in vi tro reflects the recep-
tor specificity in vivo. 
E. coli HBlOl containing pDG I has previously been shown 
to express the pH 6 antigen (7). The pH 6 antigen structural 
gene (psaA) and a putative chaperone (psaB) are found within 
the cloned DNA fragment (6) and are expressed from the 
Y. pestis gene promoter (7). E. coli HB lO 1 cells with or without 
pDGl were grown with shaking (185 rpm) at 37°C in Luria-
Bertanj broth e ither supplemented or not supplemented with 
LOO IJ.g of ampicillin per ml. Only E. coli HB101 cells contain-
ing pDG l were able to cause the agglutination of sheep eryth-
rocytes (2.5% vol/vol) in phosphate-buffered saline (PBS; 8 g 
of NaCI per !iter, 0.2 g of KCI per !iter, 1.1 5 g of Na2 HP04 per 
I iter, 0.2 g of K.H2P04 per !iter (pH 7.l]) after 2 h of incubation 
at 4°C in a microtiter tray assay. Aliquots of culture were taken 
at various time points, and their optical densities at 600 nm 
(OD600) and their levels of expression of the pH 6 antigen were 
determined ( L 1 ). Maximum expression (equivalent to 272 IJ.g/ 
ml of culture) occurred during early stationary phase. 
Crude pH 6 antigen extracts were prepared from cells of 
E. coli HBIOl containing pDGI with crude KSCN as potas-
sium isothiocyanate the chaotropic agent (2). The extract was 
dialyzed against distilled water and mixed overnight at 4°C with 
ammonium sulfate (50% final concentration), and the precip-
itated material was pelleted by centrifugation at 5,000 X g fo r 
I 0 m in at 4°C before being exhaustively dialyzed against PBS. 
The minimal concentration of pH 6 antigen at this stage of 
preparation causing hemagglutination was 6.25 IJ.g/ml. 
The pH 6 antigen was further purified by isoelectric precip-
itation. The preparation described above was adjusted to pH 
5.8 by the dropwise addition of 5 M HCI and incubated over-
night with gentle stirring at 4°C. The resultant precipitate was 
pelleted by low-speed centrifugation and washed three times in 
4546 NOTES 
A 8 
FIG. I. SOS-PAGE of purified pH 6 amigen (5 IJ.g). Arrowheads on the right 
ind ica te molecular masses of marker proteins in k.ilodaltons. Track A contains 
purified pH 6 antigen. and track B contains molecular mass m<~rkcn •. 
PBS (pH 5.8) before fina lly being resuspended in PBS (pH 
7. 1). The minimal concentration of the final preparation of pH 
6 antigen that caused hemagglutination was 4.7 ::!:: 0.9 JJ.g/ml 
(mean ::!:: the standard error of the mean). 
pH 6 antigen, which was not boiled prior to analysis by so-
dium dodecyl sui fate (SDS)-polyacrylamide gel electrophoresis 
( I 0 or 15% acrylamide gels) and stained with Coomassie blue, 
appeared as a single band which migrated with a molecular 
mass of > 100 kOa and did not enter the runn ing gel. When 
samples were boiled prior to analysis, a predominant band with 
a molecular mass of 15 kDa was observed and was recognized 
by antiserum raised against pH 6 antigen (Fig. 1). The higher-
molecular-mass bands did not react with pH 6 antiserum. N-
terminal sequence analysis was carried out on Coomassie blue-
stained (30 s) blots of SDS-polyacrylamide gels loaded with 
INFECf. l MMUN. 
6 JJ.g of puri fied pH 6 antigen per lane. With a model 476A 
sequencer (Applied Biosystems Inc., Warrington, United King-
dom), the 15-kDa band had an N-terminal sequence of STVIN 
SKDVS. This sequence was in agreement with the previously 
reported N-terrninal amino acid sequence of PsaA, the struc-
tural subunit of the pH 6 antigen (6). 
The pH 6 antigen is known to be able to agglutinate eryth-
rocytes from a range of species (2). As few as 4.1 x 107 cells of 
E. coli HBI 01 containing pOGI were able to cause agglutina-
tion of sheep erythrocytes (2.5%, vol/vol, in PBS), indicating 
that the pH 6 antigen is surface exposed. No hemagglutination 
was visible with tO to cells of E. coli HB lO I. o-Mannose-specific 
adhesins are expressed by many gram-negative bacteria, in-
cludi ng E. coli and Salmonella typhimurium (3, 15). Hemagglu-
tination by E. coli containing pDG I was unaffected by the 
presence of I%, wt/vol, o-mannose. Hemagglutination was sta-
ble over a pH range of 4 to 10, indicating that the adhesin 
would be functional in a range of intracellular and extracellular 
environments. Hemagglutination of sheep erythrocytes by the 
purified pH 6 antigen was resistant to heating up to 80°C, 
above which temperature they rapidly pelleted. However, on 
cooling and remixing, stable erythrocyte mats were formed 
once again. Pretreatment of sheep erythrocytes with a range of 
proteases (10 mg of Aspergillus 01yzae protease per ml, 10 mg 
of bovine pancreatic protease per ml, 5 mg of trypsin per ml, 
1 mg of Streptomyces caespitosus per ml, and I mg of Strepto-
myces griseus protease per ml) fo r l h at 37oC (4) had no effect 
on the abili ty of the pH 6 antigen to agglutinate them, indi-
cating that protein was unlikely to be an important component 
of the pH 6 receptor structure. Pretrea tment of erythrocytes 
(5%, vol/vol, in PBS plus I mM glycine) with sodium metape-
riodate (10 mM) for 20 min at 22°C, which disrupts saccharide 
structures containing neighboring hydroxyl residues, had no 
effect on hemagglutioation by the pH 6 antigen ( 4, 12). 
The abili ty of purified pH 6 antigen to bind to 15 glycosphin-
TABLE I. Ability of va rious glycosphingolipids to recognize the pH 6 a ntigen 
Result of binding after 
Structure of glycosphingolipid" sepannion by TLC with: Name or designation of glycosphingolipid0 
pH 6 an tigen E. colilpDG I 
GaiBI-ICer (hydroxylated fatty acids) 
GalB I-ICcr (nonhydroxylated fatly acids) 
Gal~ l-ICer 
GaiB 1-4Glc~ 1-1 Cer 
GaiNAc~ I-4GaiB 1 -4Gic~ 1- 1 Cer 
GalB I-3GaiNAc~ I-4GaiB 1-4Glc~ 1-1 Cer 
Gala-4Ga1B I-4Gic~ 1- 1 Ccr 
GaiNAc~ I-3Gala I-4GaiB l-4Glc~ 1-1 Cer 
GalNAc~ I -3GalNAc~ 1-3Gala I-4Ga1B 1-4Gic~ 1-1 Cer 
GaiB 1 -3GaiNAc~ I-4Ga i3-+2NeuAc)~ I -4Glc~ 1- 1 Cer 
Ga lNAc~ I-4Ga1(3+-2NeuAc)lli -4Gic~ 1-1 Ccr 
NcuAca 1-3Ga1B I -4Glc~ 1- ICer 
NeuAca2-3GaiB 1 -3GaiNAc~ l-4Gal(3+-2aNcuAc)lli -4Gic~ 1- 1 Ccr 
GalB I-3GaiNAc~ I-4Gal(3+-2aNeuAc8+-2cx.NeuAc)lli -4Glc~ 1- 1-Cer 
Gal NAc~ I -4Ga1(3-+2NeuAc8<-2aNeuAc)lli2-4G lc~ 1-1 Cer 
NeuAoo2-8NeuAca2-3GaiB I-4Glc~ 1-1 Cer 
NeuAca2-8NeuAoo2-3GaiB 13GaiNAc~ I-4Gai(3+-2NeuAc8+-2aNeuAc) 
~ I -4G ic~ l - 1 Ccr 
NcuAca2-3GalB I-3GaiNAcJ3l-4Gal(3lli -4Gic~ 1-1 Cer 











( Forssman glycolipid) 









" Abbreviations for gangliosides follow the nomenclature system of Svennerholm ( 17). 
r Purified glycosphingolipids and enzymes were ohtained from Sigma Chemical Co. (Poole. United Kingdom). 
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golipids (Table I) was determined in two independent ex-
periments, each involving quadriplicatc assays based on a 
solid-phase enzyme-linked immunosorbcnt assay (ELISA) ac-
cording to the method of Paync et al. (I 0). Briefly, glycosphin-
golipids (0.1 mg!ml) were suspended in methanol and the wells 
of a 96-wcll microtiter plate (Dynatceh Immulon 2) were coat-
ed with 50-f.ll aliquots. The wells were blocked with 2% bovine 
serum albumin (BSA) in PBS for 2 hat room temperature and 
then washed twice with the same buffer. Purified pH 6 antigen 
was adjusted to 10 f.lg/ml in PBS- 1% (wt/vol) skimmed-milk 
powder (PBS-blotto), and 100-f.ll a liquots were added to mi-
crotiter plate wells. After incubation at 37oC for I h and wash-
ing in 0.02% Tween 20-PBS, bound pH 6 antigen was detected 
with rabbit anti-pH 6 serum in combination with a goat anti-
rabbit horseradish peroxidase conjugate and with 2,2' -azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid) as the chromogenic 
substrate (8). The 0041 4 of the microtiter tray wells were mea-
sured, and an increase of 0.1 over the 0041 4 of the control 
wells was considered to indicate binding. Of the glycosphingo-
lipids tested (Table l ), only lactosylccramide (LC), gangliotri-
aosylceramide (GM2A), and gangliotetraosylceramide (GMlA) 
bound the pH 6 antigen (designations used are according to 
the terminology of Svennerholm [17]). The binding of the pH 
6 antigen to GM1A, GM2A, and LC was saturable, and 50% 
binding occurred at 498 ± 4 nM (GMlA), 390 nM (GM2A), 
and 196 ± 3 nM (LC). Glycolipids containing sialic acid resi-
dues (gangliosides) either bound poorly or were unable to bind 
purified pH 6 antigen. 
Differences between LC, GM1A, and GM2A are confined to 
the nonreducing ends of their oligosaccharide chains. The bind-
ing of the pH 6 antigen to LC is reduced by the addition of a 
GalNAc residue (e.g., in GM2A), and the binding is further 
reduced when a 13-galactose (Gall3) residue is added to GM2A 
(e.g., in GM1A). To confirm the specificity of purified pH 6 
antigen, GMlA was sequentially degraded from its nonreduc-
ing end. Wells containing immobilized glycosphiogolipid were 
sequentially treated (1 h, 37°C) with 0.5 U of 13-galactosidase 
(in 10 mM Tris-1.7 M (NH4 hS04-10 mM MgC12 (pH 7.3)], 
and the wells were washed three times with PBS and then 
treated (1 h, 3rC) with 0.1 U of N-acetylgalactosaminidase (in 
5 mM sodium citrate-100 mM KH2P04 [pH 3.7]) to remove 
galactose and then N-acetylgalactosamine residues (10). The 
wells were washed three times with PBS and then blocked for 
1 h at room temperature with 200 f.ll of 2% BSA in PBS per 
well. The plate was washed twice with the BSA-PBS buffer, and 
100 IJ.l of purified pH 6 antigen was added (10 f.lg/ml in PES-
blotto). After incubation, bound pH 6 antigen was detected as 
described above. Removal of the Gall3 residue from GMlA 
increased binding by 45%. The further removal of GalNAc 
resulted in a 91% increase in binding over the binding of 
GM lA. The c results supported the direct binding studies and 
indicated tha t the affi nity of the pH 6 antigen for glycosphin-
golipids is in the order LC > GM2A > GM1A (Fig. 2). 
Eighteen glycosphingolipids were tested for the ability to 
bind purified pH 6 antigen by thin-layer chromatography 
(TLC) analysis (Table 1). Glycosphingolipids were separated 
with silica G60 (Merck Ltd., Leicester, United Kingdom) with 
chloroform-methanol-distilled water (60:35:8, vol/vol/vol) as 
the solvent. Glyco phingolipid on control plates were visual-
ized by spraying the plates with p-anisaldehyde-sulfuric acid-
ethanol (5:5:90, vol/vol/vol) and heating them at ll0°C for I 0 
min. Test TLC plate::. were washed twice by immersion with 3% 
polyvinylpyrrolidone in accta te-bu!fcrcd saline (ABS; 0.1 M 
sodium acetate, 0.2c-0 CaC11 [pH 7.2]) before being incubated 
either with or without purified pH 6 antigen (0.5 IJ.g/ml in 
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FIG. 2. GMIA was sequcntially treated "ith bovine 13-galactosidase (13-Gal) 
and then N-acctylgalactosaminidase (N-AG). The ability of purified pH 6 antigen 
to bind to the products of enzymatic treatment, i.e., GM2A and LC, was deter· 
mined by ELISA. and results were compared with the binding of the pH 6 
antigen to GM 1 and GM lA. Results arc means ::!:: standard e rrors of duplicates. 
ABS. Bound material was visualized with rabbit anti-pH 6 
antiserum as described above except that a mixture of 3,3'-
diaminobenzidine (3.3 mM) and urea hydrogen peroxide (7.4 
mM) in 0.06 M Tris buffer was used as the chromogenic sub-
strate. GMlA, GM2A, and LC a ll bound to the purified pH 6 
antigen. 1n addition, galactosylceramide with hydroxylated 
fatty acids but not galactosylceramide with nonhydroxylated 
fatty acids or glucosylceramide bound the pH 6 antigen. 
The 18 glycosphingolipids were also tested for the ability to 
bind E. coli expressing the pH 6 antigen (Table 1). Glycosphin-
golipids were prepared, eparated, and visualized as described 
above. Binding was determined after the incubation for 2 h at 
37°C of ABS suspensions (2 X 109 cells/ml) of E. coli HB 101 
either with or without the pDGI plasmid. Binding was visual-
ized as described above and observed only with £. coli con-
taining the pDG 1 plasmid. Specificity was similar to that of 
purified pH 6 antigen except that galactocerebrosides contain-
ing both hydroxylated and nonhydroxylated fatty acids were 
recognized. The degree of hydroxylation of the ceramide por-
tion of glycosphingolipid has been demonstrated previously to 
affect binding characte ristics (9), and the results found in this 
study are in agreement with this concept. It seems that the 
absence of a hydroxyla tcd fatty acid chain alters the presenta-
tion of the a ttached galactose residue in such a way as to 
prevent binding of the purified pH 6 antigen but not of the pH 
6 antigen which is expressed on the cell surface. lt is possible 
that other E. coli cell surface components contribute to this 
altered conformation of the pH 6 antigen and therefore to the 
a ltered binding properties. 
The role of the pH 6 an tigen in the pa thogenesis of infec-
tions caused by Y. pes1is is not known (7). For many years it has 
been assumed that the pH 6 antigen allows the bacteria to bind 
to host cell . The data we present here indicate that the only 
common saccharide moiety of glycosphingolipids found to bind 
the pH 6 antigen i 131-linked ga lactose (Ga ll3l ), which is 
hypo thesized to represent the minimum receptor structure of 
the pH 6 amigen. However. as has been noted with o ther 
adhesin systems, the pre~ence of the minimum reccptor struc-
ture in glycosphingolipids does not neces ·a rily corre late wi th 
-1548 NOTES 
binding (5). Thus. despite containing Gal~ I in their oligosac-
charide sequence. globoside, the Forssman glycolipid, GM I, 
GM2, GM3, GDia, GDib, GD2, GD3, GQib, and GTib do 
not bind or bind poorly to the pH 6 antigen. The inability of the 
pH 6 antigen to bind to gangliosides may have been attribut-
able in part to charge repulsion between the sialosyl groups on 
the ganglioside and the negative charge on the pH 6 antigen 
(pi 5.8) at physiological pH. However, this is unlikely to apply 
to either globoside or the Forssman glycolipid since neither 
contains sialic acid residues. Our findings also indicate that the 
hyd rm.:ylation status of fatry acid chains present in the cer-
amide portion is critical for the binding of the pH 6 antigen. 
The glycosphingolipids recognized by the pH 6 antigen are 
common and are likely to be fou nd on a range of host cell 
types. Accordingly, the receptor specificity of the pH 6 antigen 
is unlikely to play a direct role in cell tropism associated with 
the pathogenesis of Y. pestis. It seems more likely tha t the site 
and timing of the expression of pH 6, rather than its specificity, 
are important in determ ining which cells are bound by Y. pestis. 
In this respect, it is interesting that expression of the pH 6 
antigen is induced only in acidic environments such as those 
found within abscesses (buboes or lesions in the liver and 
spleen) of animals infected with Y. pestis (13). It is known that 
Y. pestis cells are released from these environments, and a role 
for the pH 6 antigen might be in maximizing the colonization 
of na ive macrophages o r other nearby host cells. 
We thank L. Lindler (Waiter Reed Army Institute of Research, 
Washington, D.C.) for the provision of pDG I. 
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Yersinia outer proteins (YOPS) E, K and N are 
antigenic but non-protective compared to V 
antigen, in a murine model of bubonic plague 
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The pathogenic Yersiniae produce a range of virulence proteins, encoded by a 70 kb plasmid, 
which are essential for infection, and also form part of a contact-dependent virulence mechanism. 
One of these proteins, V antigen, has been shown to confer a high level of protection against 
parenteral infection with Y. pestis in murine models, and is considered to be a protective antigen. 
In this study, the protective efficacy of V antigen has been compared in the same model with that 
of other proteins (YopE, YopK and YopN), which are part of the contact-dependent virulence 
mechanism. Mice immunised with two intraperitoneal doses of V antigen or each of the Yops, 
administered with either Alhydrogel or interleukin-12, produced high antigen-specific serum lgG 
titres. As shown in previous studies, V + Aihydrogel was fu lly protective, and 5/5 mice survived a 
subcutaneous challenge with 90 or 9 x 103 LD50 's of Y. pestis GB. In addition, these preliminary 
studies also showed that V+ IL-12 was partially protective: 4/5 or 3/5 mice survived a challenge 
with 90 or 9 x 103 LD50's, respectively. In contrast, none of the mice immunised with the Yops 
survived the challenges, and there was no significant delay in the mean time to death compared 
to mice receiving a control protein. These results show that using two different vaccine regimens, 
Yops E, K and N, failed to elicit protective immune responses in a murine model of plague, whereas 
under the same conditions, V antigen was fully or partially protective. © 1999 Academic Press 
Key words: V antigen, LcrV, Yaps, Yersinia, plague, interleukin-12. 
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Introduction 
The current vaccine for plague consists of a 
killed whole cell preparation of Y. pestis 195/P, 
and although it confers moderate protection in 
murine models of bubonic plague, it is relatively 
ineffective against pneumonic infection [1, 2]. 
Furthermore, up to 24% of individuals reported 
local side effects after receiving the vaccine, and 
up to 10% suffered more severe systemic effects 
[3]. There is now interest in developing a new 
plague vaccine, with enhanced protection and 
reduced side effects, consisting only of purified 
protein subunits. V antigen (also called LcrV) 
and a second Y. pestis-specific protein, F1 an-
tigen, have been tested as candidate vaccine 
antigens, and it has been shown that they pro-
vide a high level of protection against ex-
perimental plague [4-7], especially when used 
in combination [9, 10]. 
Although a new plague vaccine consisting of 
purified F1 and V antigens has been shown to 
be effective in animal models against wild-type 
strains of Y. pestis [2, 9, 10], additional proteins 
may enhance its protective efficacy in particular 
circumstances. First, a multi-component subunit 
vaccine may improve the protection offered 
against mutant, but virulent strains, such as F1-
negative derivatives [11]. Second, it may be more 
effective in humans where individuals may not 
develop an immune response to one of the sub-
units. Finally, such a vaccine may be more pro-
tective against strains which carry antigenic 
variants of one of the subunits. The effect of 
variation was illustrated recently in Y. entero-
colitica, where serotype-dependent variants of V 
antigen were shown to be protective only against 
strains of the same type [12]. 
Yersinia pestis is known to express numerous 
virulence factors, including plasminogen ac-
tivator, pH6 antigen, and Yersinia outer proteins 
(Yaps) [13], which may be useful components of 
a new subunit vaccine for plague. In this study, 
we have carried out a preliminary assessment 
of the protection afforded by some Yaps against 
experimental plague. Evidence that an immune 
response directed against Yaps may contribute 
to protection comes from two sources. First, it 
has been demonstrated that all Yaps, with the 
exception of YopJ, are essential for systemic 
infection in the mouse model [14], and second, 
antibodies directed against some of these 
plasmid-encoded proteins have been detected 
in the sera of humans and animals recovering 
from Yersinin infections [7, 15-19]. 
S. E. C. Leary et al. 
The protective efficacies of Yaps E, K and N 
were tested in a murine model of bubonic 
plague, and compared to the known im-
munogenicity of V antigen. All of these proteins 
are encoded by the 70 kb pCD1 virulence 
plasmid and are exported from the bacterium 
by a secretion machinery which in Yersinin is 
called Ysc [14]. They also form part of a contact-
dependent virulence mechanism common to tl1e 
pathogenic Yersiniae, which results in the direct 
transfer of five or six effector Yaps [20-28] into 
the host cell where they disrupt the cellular 
responses normally allowing phagocytic uptake. 
A key feature of the contact-dependent virulence 
mechanism is the requirement for intimate inter-
action between the bacterium and a target 
eukaryotic cell [14, 20] . 
The role of V antigen in contact-dependent 
virulence is complex. It has been shown in vitro 
to act inside the bacterial cell as a positive reg-
ulator of low calcium response (LCR) genes 
which are involved in this virulence mechanism 
[29, 30], and it is required for the secretion/ 
deployment of other contact-dependent vir-
ulence proteins, specifically Yaps B and D [31, 
32]. More recently, it has been proposed that V 
antigen plays a direct role in the translocation 
of effector Yaps from the bacterium into the host 
eukaryotic cell, and that it is exposed on the 
bacterial surface prior to contact between the 
pathogen and the target cell [33]. Direct anti-host 
effects, involving modulation of the immune 
response to the invading pathogen, have also 
been attributed to V antigen [5, 34, 35], although 
currently, it is not clear how these activities are 
related to its role in contact-dependent virulence. 
More discrete roles have been characterised 
for the other Yaps used in this study. YopN (also 
called LcrE) is located at the bacterial surface 
[36], where it is believed to act as a sensor protein 
which blocks the Ysc secretion machinery until 
contact has been established between the bac-
terium and host cell [20, 23]. YopK has been 
shown to localise at the zone of contact between 
the pathogen and the target cell, and it is thought 
to modulate the size of a YopB-induced pore in 
the eukaryotic cell membrane, which is believed 
to allow translocation of the effector Yaps [37, 
38]. The effector protein YopE is transferred 
directly into the target cell by a polarised mech-
anism where it mediates the disruption of the 
host cell actin rnicrofilament structure [20, 39]. 
Thus, the evidence indicates that the functions 
of V antigen, YopN and YopK are achieved, at 
least partly, as extracellular proteins, which may 
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be located on the bacterial surface (V and YopN) 
or at the point of contact between the bacterium 
and host cell (YopK). In addition, the direct anti-
host effects of V antigen possibly indicate that 
it may also act as a soluble mediator. It is known 
that an anti-V immune response is protective in 
experimental plague, thus supporting a model 
in which it plays an extracellular role in virulence 
[4-7], and therefore, it is possible that an immune 
response to Yops Nand K may also be protective. 
In contrast, effector Yops, such as YopE, which 
act inside the eukaryotic cell, may be hidden 
from immune cell recognition and/ or neut-
ralisation by antibodies. This possibility is sup-
ported by other studies which have shown that 
the effector Yops M and Hare non-protective in 
murine models of bubonic plague [7, 40]. 
To test this idea, a well-characterised model 
was used to compare the immunogenicity of V 
antigen with Yops E, K and N. In this model, 
mice were immunised with proteins adsorbed to 
the aluminium hydroxide adjuvant, Alhydrogel. 
In addition, the immune responses and pro-
tective efficacies were compared using another 
regimen, in which the proteins were ad-
ministered with the cytokine, IL-12. 
The use of Alhydrogel as an adjuvant is known 
to stimulate Th2-mediated immunity [41], and 
in mice the production of cytokines indicative 
of Th2 type T helper responses is associated 
with an antibody profile where the IgG1 isotype 
predominates [42]. This pattern of antibody re-
sponse is typical when aluminium hydroxide 
has been used with various antigens [43, 44]. In 
contrast, IL-12 is considered to be a Th1 type 
cytokine [ 45] and it is known to promote the 
development of Th1 cells and to contribute to 
the proliferation of Th1 cells in response to 
antigen [46] . Further, IL-12 has been used as an 
adjuvant to promote protective immune re-
sponses to a particular antigen [47, 48] . Th1-
mediated immunity in mice is marked by an 
antibody response in which the IgG2a sub-type 
predominates [42], and hence, the use of IL-12 
as an adjuvant may be expected to modify the 
antibody responses to V antigen and the Yops, 
compared to Alhydrogel. 
Results 
Development of serum lgG responses in 
mice immunised with V antigen and Yops 
Balb/c mice were immunised i.p. on days 0 and 
21 with V antigen, YopE, GST-YopK or YopN. 
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The antigen-specific serum IgG titres induced 
by the proteins were measured at 2, 4 and 6 
weeks after the second immunisation [Fig. l(a), 
(b)]. V antigen induced a high antibody re-
sponse, when presented with either Alhydrogel 
or IL-12, and the responses were induced rap-
idly, reaching peak levels after 2-4 weeks. GST-
YopK also elicited rapid antibody responses. 
In contrast, the response to YopN + Alhydrogel 
peaked at 4 weeks, and for YopE and YopN +IL-
12, the titres only reached their highest measured 
value at 6 weeks post-immunisation. 
Of the proteins adsorbed to Alhydrogel, the 
highest antigen-specific IgG titre at 6 weeks 
post-immunisation was induced by V antigen. 
However, at the same time point, the highest 
antibody response to antigen administered with 
IL-12 occurred in mice receiving GST-YopK; the 
mean relative titre was approximately 3-fold 
higher than in mice receiving V. The lowest 
antibody response to antigen presented with 
Alhydrogel or IL-12 occurred in mice receiving 
YopN and YopE, respectively; compared to the 
V groups, the mean relative titres to YopN and 
YopE were approximately 18-fold and 4-fold 
lower, respectively. 
Despite some differences in the antigen-spe-
cific IgG titres and in the rapidity of the response, 
these data show that all of the immunised pro-
teins were antigenic. 
lgG isotype responses in the serum of 
mice immunised with V antigen or Yops 
At 6 weeks post-immunisation, the serum re-
sponses were further characterised by meas-
uring the antigen-specific titre of the IgG sub-
types, IgG1 and IgG2a. The induction of high 
serum antibody responses to V, particularly of 
the IgG1 sub-type, has been correlated with 
protection against plague in a murine model of 
infection [2, 6, 9]. 
When administered with Alhydrogel, V an-
tigen, YopE and YopN elicited the typical re-
sponse, and the mean relative IgG1 titres were 
at least 20-fold greater than the IgG2a titres [Fig. 
2(a)]. In contrast, GST-YopK elicited similar lgG1 
and IgG2a titres. In the presence of lL-12, only 
GST-YopK induced the typical pattern of IgG 
isotypes, showing an approximately 60-fold 
greater IgG2a titre relative to IgG1 [Fig. 2(b)]. 
However, in comparison to the IgG1 responses 
when adsorbed to Alhydrogel, administration 
of V or YopE with IL-12 resulted in a reduction 
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V YopE GST-YopK YopN 
Figure 1. Antibody responses of mice immunised with V antigen or Yaps in the presence of Alhydrogel (a) 
or IL-12 (b). Mice (n =5) were immunised twice with V, YopE, GST-YopK or YopN. At 2 (. ), 4 (0) and 6 
weeks(~) after the last immunisation, sera from each group were collected, pooled, and the antigen-specific 
IgG titres were measured by ELISA. The results are expressed as mean relative titres. 
of the mean relative IgG1 titres of 12- and 148-
fold, respectively. Therefore, the balance of the 
Th cell response appeared to have been changed 
by dosing these proteins with IL-12. In mice 
receiving YopN, the IgG1 and IgG2a responses 
were similar irrespective of whether the protein 
was administered with Alhydrogel or IL-12. 
The significance of these results in providing 
evidence of Th1- or Th2-mediated immune re-
sponses should be interpreted cautiously. Con-
firmation requires measurement of the Th1- and 
Th2-associated cytokines produced by T cells in 
response to antigen stimulation in vitro. How-
ever, it is clear that for V antigen, YopE and 
GST-YopK, the pattern of IgGl and IgG2a re-
sponses were altered in the presence of IL-12 
compared to Alhydrogel. 
Protection of Yops against challenge with 
Y. pestis 
To evaluate the Yops as potentia l vaccine an-
tigens using the two dosing regimens described, 
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YopE GST-YopK YopN 
Figure 2. Antibody responses of mice immunised with V antigen or Yaps in the presence of Alhydrogel (a) 
or IL-12 (b). Mice (n =5) were immunised twice with V, YopE, GST-YopK, or YopN. Six weeks after the last 
immunisation and immediately prior to challenge, sera from each group were collected, pooled, and the 
antigen-specific IgG (. ), IgGl (D) and IgG2a (~)titres were measured by ELISA. The results are expressed 
as mean relative titres. 
their protective efficacy was compared with V 
antigen in a well-characterised murine model of 
bubonic plague. Mice immunised with V, YopE, 
YopN, GST-YopK or the control protein, GST, in 
the presence of either Alhydrogel or IL-12, were 
challenged 6 weeks after the second dose with 
a fully virulent strain of Y. pestis. At this time 
point, the antigen-specific serum IgG titres had 
peaked, but not diminished more than 4-fold, 
in 5 of the challenge groups [Fig. 1(a), (b)]. For 
the remaining three groups, the highest serum 
IgG response was measured at 6 weeks post-
immunisation. 
When challenged subcutaneously with 90 or 
9 x 103 LD50's of Y. pestis, there were no survivors 
in the group immunised with the Yops, but 
mice immunised with V were either fully pro-
tected ( + Alhydrogel) or partially protected ( + 
IL-12) against the same challenge doses (Table 
1). Surviving mice showed no external signs of 
illness. Furthermore, for GST-YopK and YopN, 
there was no significant delay in the mean time to 
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Table 1. Protection of V- and Yop-immunised mice against challenge with Y. pestis. Mice were immunised 
hvice with V antigen, YopE, GST-YopK, YopN or the control protein, GST, in the presence of either Alhydrogel 
or IL-12. Six weeks after the second dose, the mice (n =5) were challenged s.c. with 90 or 9 x 103, LD50's of 
Y. pestis GB and observed for 14 days. Where appropria te, the mean time for mice to reach a humane end-
point was recorded. SEM = standard error of the mean. 
Challenge dose Time to end-point 
(h±SEM) Group LD50 No. of survivors 
90 5/5 V+ Alhydrogel 
9 X HP 5/ 5 
V+ IL-12 90 4/ 5 
9 X 103 3/ 5 
177±0 
141 ±84 
102± 16 90 0/5 YopE + Alhydrogel 
9 X 103 0/5 86±6* 
87±9** 
77±7 
90 0/ 5 YopE + fL-12 
9 X 103 0/ 5 
90 0/ 5 GST-YopK + Alhydrogel 
9 X 103 0/ 5 
124± 12 
71±15 










90 0/ 5 GST-YopK + IL-12 
9 X 103 0/5 
90 0/ 5 YopN + Alhydrogel 
9 X 103 0/ 5 
90 0/ 5 YopN +fL-12 
9 X 103 0/ 5 
90 0/ 5 GST + Alhydrogel 
9 X 103 0/ 5 
GST + IL-12 90 0/ 5 
9 X 103 0/ 5 
*Time to death significantly delayed (P<O.OS) compared to equivalent GST control. 
**Time to death significantly reduced (p<0.05) compared to equivalent GST control 
death compared to the controls, which received 
GST (Table 1). 
For mice immunised with YopE, some in-
consistent changes in the mean time to death 
were observed. Mice immunised with 
YopE + Alhydrogel displayed a significant delay 
in the mean time to death after challenge with 
9 x 103 LD50's of Y. pestis compared to the control 
group (GST + Alhydrogel: P<O.OS) (Table 1). 
H owever, when challenged with a lOO-fold 
lower dose of Y. pestis, there was no significant 
delay in the mean time to death (Table 1). This 
is surprising, since any limited protection eli-
cited by YopE should be most pronounced in 
mice challenged with the lowest dose of Y. pestis. 
At this stage, it is difficult to interpret these 
conflicting results, and their resolution may de-
pend on challenging greater numbers of im-
munised animals with intermediate and lower 
doses of bacteria. 
Contrary to eliciting protective immune re-
sponses, immunisation with YopE + IL-12 res-
ulted in a significant reduction in the mean time 
to death after challenge with 90 LD50's of Y. 
pestis, compared to the control group (GST + IL-
12: P<O.OS) (Table 1). However, in mice chal-
lenged w ith a lOO-fold higher dose of Y. pestis, 
there was no difference in the mean time to 
death, compared to the control group (Table 1). 
Again, the variation in the response to YopE + IL-
12 may only be resolved by challenging larger 
numbers of immunised animals. 
Discussion 
In murine models of plague, many previous 
studies have shown that V antigen is an effective 
immunogen [4-7, 9, 49] and thus, it has been 
proposed as a component of a new improved 
subunit vaccine for plague [2, 9, 10]. 
ln this study, the solid protection achieved by 
immunisa tion wi th two doses of V+ Alhydrogel 
was expected, because in previous experiments 
this formulation has protected 80% of mice 
against systemic challenge with 106 LD50 's of Y. 
pestis C092 [6], and 100% of mice against a 
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higher challenge with 107 LDso's of Y. pestis GB 
[SO]. Indeed, i.J.1 several other studies m which V 
antigen has been administered with mcomplete 
Freund's adjuvant or Titermax [4, 9, 49], solid 
protection in mice agamst bubonic plague has 
been achieved following challenges of between 
105 and 107 LD50's, and it has been described as 
a protective antigen. Hence, the breakthrough m 
protection afforded by V+ IL-12 at the relatively 
low challenge doses of 90 and 9 x 103 LD50's of 
Y. pestis merits further mvestigation. 
Passive immunisation studies have dem-
onstrated the importance of V-specific antibodies 
m conferrmg protection against experimental 
plague [51-53], and in active immunisations, 
protection is correlated with high anti-V IgG 
titres, particularly of the IgGl isotype [2, 6, 9]. 
It is possible that the breakthrough m protection 
afforded by V +IL-12 may be due to a relative 
decrease m the V-specilic serum IgG and IgG1 
responses at the time of challenge; compared to 
mice receivmg V+ Alhydrogel, the pooled anti-
V serum IgG and IgG1 titres were reduced 6- and 
12-fold, respectively. In particular, the marked 
decrease m the pooled IgGl titre m the presence 
of IL-12 may support this idea, although further 
studies measurmg individual titres m larger 
groups of mice are required to substantiate it. 
The precise mechanism of anti-V-mediated 
protection agamst experimental plague is un-
known. Opsonisation is unlikely to be an effect-
ive means of bacterial clearance, because YopH 
mediates resistance to phagocytosis of IgG-
opsonised bacteria via Fe receptors [54] . Al-
ternatively, it has been proposed that anti-V sera 
may neutralise a direct virulence function of V 
antigen in which the host inflammatory response 
is suppressed. In this model, evidence suggests 
that levels of the pro-inflammatory cytokines, 
TNFcx and IFNy, are reduced [5] and neutrophil 
chemotaxis is inhibited [35]. Active im-
munisation with V antigen allowed restoration 
of cytokme synthesis and the onset of a normal 
inflammatory response to mediate bacterial 
clearance [5]. More recently, V antigen has also 
been shown to play an important role in a 
contact-dependent virulence mechanism. Spe-
cifically, the protein is required for the efficient 
secretion/ deployment of the translocator , YopB 
and perhaps YopD, from the bacterium [31, 32]. 
Further, it has been shown that V antigen plays 
a direct role in the translocation of effector Yops 
from the bacterium into the host eukaryotic cell, 
and that this function is neutralised in vitro by 
anti-V sera [33]. Hence, more than one virulence 
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function of V antigen may be inhibited by anti-
V sera. 
The study described here was motivated by 
the need to evaluate other Yersinin protems 
which may enhance the efficacy of a new subunit 
vaccme for plague. The role of V antigen i.J.1 a 
contact-dependent virulence mechanism led us 
to compare the immunogenicity of this protei.J.1 
with some other essential components of the 
mechanism, specifically Yops E, K and N. Al-
though this is a prelimmary study i.J.1 that the 
vaccine dose, schedule and means of ad-
ministration were limited, it was demonstrated 
that Yops E, K and N were antigenic, but non-
protective agamst relatively low challenge doses 
m a well-characterised murme model of plague 
mfection. This was shown for two different vac-
erne regimens. The only indication of limited 
protection was m mice immunised with 
YopE + Alhydrogel, when the mean time to 
death was significantly delayed by ap-
proximately one day; this effect was seen only 
in the group challenged with the higher, and 
not the lower, dose of Y. pestis. In contrast, the 
immune responses to V antigen, administered 
with Alhydrogel or IL-12, were sufficient to 
promote survival of all or most of the mice. This 
observation is of particular importance when 
comparmg the immunogenicities of the proteins 
adsorbed to Alhydrogel. As described pre-
viously, administration of V antigen with this 
adjuvant is known to protect against high doses 
of Y. pestis in a murine model [6, 50]. 
The evidence presented here for the failure of 
Yops E, K and N to protect agamst experimental 
plague is m agreement with other studies m 
which YopM [7] and YopH [40] were non-pro-
tective against challenges with F1-positive, LCR-
positive strains of Y. pestis. Polyclonal anti-Yop 
serum was also shown to be ineffective m pro-
vidmg passive protection agamst plague m a 
mouse model [55]. Although it is possible that 
m this study, the vacci.J.1e regimens stimulated 
inappropriate immune responses to mduce pro-
tection, it is also possible that during infection, 
some Yops are hidden from immune cell re-
cognition and/ or neutralisation by antibodies. 
In particular this could be envisaged for YopE, 
a translocated effector protem; studies of cells 
infected with Yersinia have shown that the trans-
loca tion mechanism is polarised and that very 
little YopE is secreted to the extracellular milieu 
[20]. The requirement for intimate contact be-
tween the bacterial and host cells may also make 
some Yops, mcludmg YopK, which localise at 
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the zone of cell-cell contact [37] inaccessible to 
antibodies. At this stage, it is difficult to explain 
why surface-located YopN, a putative sensor 
of cell contact, failed to induce non-protective 
immune responses. It is possible that before 
intimate cell contact occurs, other Yetsinin pro-
teins mask YopN, thus shielding it from immune 
recognition, or that antibodies raised against a 
soluble form of YopN may be ineffective in 
neutralising surface-bound protein. 
Although more extensive studies are required, 
these data suggest that among the virulence 
factors secreted by the contact-dependent mech-
anism, V antigen may be unique in that its 
function (or functions) can be neutralised ef-
fectively by antibodies. To explore this idea fur-
ther, it is also necessary to evaluate the 
imrnunogenicity of other secreted Yops which 
appear to localise at the zone of contact between 
the bacterium and target cell. Yops B and 0, 
which are essential for the translocation of ef-
fector Yops [14] may be of particular importance. 
In this respect, it is interesting that a preliminary 
report indicated that YopD may offer some lim-
ited protection in mice against challenge with a 
virulent strain of Y. pestis [40]. 
In summary, although YopE, GST-YopK and 
YopN elicited strong humoral responses, it is 
clear from the challenge experiments, that unlike 
V antigen, these proteins are unable to induce 
sufficient protective immune responses in a mur-
ine model of bubonic plague to promote survival 
of the host. This was demonstrated using two 
vaccine regimens, in which the proteins were 
immunised in the presence of Alhydrogel or IL-
12. Hence, compared to V antigen, Yops E, K 
and N may only be of limited use in a subunit 
vaccine for plague. 
Materials and methods 
Preparation of purified proteins 
YopE and YopN were purified from culture 
supernatants of a strain of Yersinia pseudo-
tuberculosis mutated for the genes encoding sev-
eral of the highly expressed Yops (yopBDEHM) 
and over-expressing one of the Yop proteins 
from a high copy-number plasmid. Strain YPIII 
(piB29BDEHM) was constructed by integration 
of the suicide plasmid pSEB601S into strain 
YPIII(piB29ME) [24] which is mutated for the 
yopEHM genes. pSEB601S [38] contains a part 
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of the yopB gene with an in frame deletion. 
Integration of pSEB601S by homologous re-
combination resulted in a strain lacking not only 
a functional yopB gene, but also yopD expression 
was abolished since yopD is located downstream 
of the yopB gene. pSEB601S was introduced 
into strain YPill(piB29ME) by conjugation as 
previously described [56]. Plasmid pAF19 [57] 
which encodes yopE and its chaperone yerA-
(sycE) was introduced into strain YPIII-
(piB29BDEHM) to yield a strain which highly 
over-produced YopE. Similarly, plB575 which 
encodes yopN [58], was introduced into YPITI-
(piB29BDEHM) to give a strain which over-
produced YopN. 
The different strains were grown in calcium 
depleted media to allow maximal expression 
and secretion of Yops as previously described 
[58]. The over-produced proteins could be col-
lected as filaments from the culture supernatants 
and these filaments were dissolved in 2% SOS 
and the respective proteins were purified to 
homogeneity by gel filtration using FPLC. 
V antigen and YopK were purified from re-
combinant Escherichia coli as fusions with glu-
tathione S-transferase (GST). The cloning of V 
antigen, its purification and cleavage from the 
carrier protein, and the cloning and purification 
of GST-YopK have been described previously [ 4, 
56]. 
The control protein, GST, was purified by 
affinity chromatography using glutathione Se-
pharose 4B (Pharmacia Biotech), according to 
manufacturer's instructions. 
Animals 
Six week old female Balb I c mice, raised under 
specific pathogen-free conditions (Charles-River 
Laboratories, Margate, Kent, U.K.), were used 
in this study. 
Immunisation with V antigen and Yops 
On days 0 and 21, groups of 5 mice were im-
munised intraperitoneally (i.p.) with 0.1 ml of V 
antigen, YopE, YopN, GST-YopK or control GST 
(3.5 nmol in PBS) either adsorbed to Alhdrogel 
or mixed w ith 0.5 ug of murine IL-12 (a gift 
from Mr Mike Mulqueen, Roche Discovery U.K. 
Welwyn, U.K.). The approximate mass of each 
protein equivalent to 3.5 nmol is 18 J.lg (V), 10 J.lg 
(YopE), 13 J.lg (YopN), 18 J.lg (GST-YopK) and 
lmmunogenicity of Yersinia outer proteins 
10 !lg (GST). The dose of IL-12 used in the im-
munisations had been shown in previous studies 
with other antigens to be effective in inducing 
immune responses in mice [47, 48, 59]. 
Measurement of serum antibody titre 
At 2, 4 and 6 weeks after the second immunising 
dose, blood was sampled from the tail vein of 
5 mice in each group; equal volumes from each 
individual were pooled and the serum was sep-
arated. A group of five naive mice were used to 
obtain control serum. The antigen-specific serum 
IgG titre was determined by ELlS A. Each antigen 
(S!lg/ml in PBS) was coated on to a microtitre 
plate and the test sera were serially diluted in 
duplicate or triplicate on the plate. The titres of 
IgG, IgG1 or IgG2a were determined using anti-
mouse peroxidase conjugates (Harlan Sera-Lab, 
Crawley, U.K.) at a dilution of 1:4000. The sec-
ondary antibodies were shown to be specific 
for the homologous sub-class and to have an 
equivalent sensitivity of detection (data not 
shown). The titre of specific antibody was es-
timated as the maximum dilution of serum giv-
ing an absorbance reading greater than 0.1 units, 
after subtraction of the absorbance due to non-
specific binding detected in the control sera. 
Relative titres were calculated as the reciprocal 
of the dilution x the optical density, and the 
mean represented the average of duplicate val-
ues for each pool. 
Challenge with Y. pestis 
Under P3 containment, groups of 5 immunised 
mice were challenged subcutaneously (s.c.) with 
90 or 9 x 103 LD50 doses of Y. pestis GB, as pre-
viously described [1]. Strain GB was isolated 
from a fatal human case of plague and has a 
median lethal dose (MLD) of <1 cfu in Balb I c 
mice by the s.c. route [1]. The mice were observed 
for 14 days and when the animals reached the 
terminal stage of disease, they were culled by 
cervical dislocation. The terminal stage of dis-
ease was defined as the point when the animals 
displayed pile-erection, a hunched posture and 
no inclination to move. Previous studies had 
shown that mice displaying these symptoms 
never recovered from the infection. The time to 
reach this stage was recorded. 
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Lipopolysaccharide (LPS) extracted from eight strains of Yersinia pestis, which had been cultured 
at 28 or 37°C, reacted equally well, in Western blots, with four monoclonal antibodies generated 
against the LPS from a single strain of Y pestis cultured at 28°C. LPS was extracted and purified 
from Y pestis strain GB, which had been cultured at 28°C. When the LPS was analysed by SOS-
PAGE and MALDI-TOF mass spectrometry it was found to be devoid of an 0-antigen. The LPS 
possessed activity of 2.7 endotoxin units/ng in the Limulus amoebocyte lysate assay. The LPS 
stimulated the production of TNFcx and IL-6 from mouse macrophages, but was less active in these 
assays than LPS isolated from Escherichia coli strain 0111. Y pestis LPS, either alone or with 
cholera toxin B subunit, was used to immunize mice. Either immunization schedule resulted in the 
development of an antibody response to LPS. However, this response did not provide protection 
against 100 MLD of Y pestis strain GB. 
Key words: Yersinia pestis, lipopolysaccharide, LPS, characterization. 
Introduction 
The genus Yersinia contains 11 species of bac-
teria, three of which (Yersinia pestis, Y. pseudo-
tuberculosis and Y. enterocolitica) are pathogenic 
to humans [1]. Plague, caused by Y. pestis, can 
occur in the bubonic, septicaemic or pneumonic 
form. The bubonic form of the disease is a 
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consequence of the delivery of bacteria into a 
susceptible host from a flea which has previously 
fed on an infected host. Y. enterocolitica causes 
a gastro-enteritis characterized by diarrhoea and 
invasive involvement of the mesenteric lymph-
atics. Y. pseudotuberculosis can cause a similar 
enteric disease in humans, characterized by diar-
rhoea, mesenteric lymphadenopathy and symp-
toms of appendicitis. 
Lipopolysaccharide (LPS) is an integral com-
ponent of the outer membrane of Gram-negative 
bacteria and is composed of three domains. The 
50 
lipid-A, which is the major amphipathic 
molecule in the outer membrane [2], is linked 
to the core oligosccharide and the 0-antigen 
polysaccharide. The 0 -antigen is amongst the 
most polymorphic of known structures [3]. The 
LPS from Y. pseudotuberculosis or Y. enterocolitica 
has been shown to contain lipid-A, core oligo-
saccharide and 0-antigen. In contrast, the LPS 
from Y. pestis contains lipid-A bound to the 
core oligosaccharide by 3 deoxy-D-manno-
octulosonic acid (KDO) [-±]. However, purified 
LPS is not reported to contain an 0 -antigen 
[5-7]. 
Little is known about the properties of Y. 
pestis LPS. The lethal dose of LPS in mice is 
reported to be 5-10 mg, and pyrexia was in-
duced in rabbits after the i.v. injection of 71-lg/ 
kg [7]. Like the LPS from other Gram-negative 
bacteria, the LPS from Y. pestis caused a de-
crease in liver glycogen, a decrease in plasma 
glucose and an increase in blood urea nitrogen 
when injected into mice by the i.p. route [8]. It 
is also reported that immunization with Y. pestis 
LPS conjugated to Shigella dysenteriae outer 
membrane proteins resulted in the de-
velopment of antibody to LPS, but this was not 
sufficient to provide protection against Y. pestis 
infection [7]. In another study, LPS was isolated 
from Y. pestis as a complex with proteins. When 
the complex was used to immunize mice it 
failed to induce protection against a challenge 
of 1000 LD50 of Y. pestis [9]. 
The generalized host response to bacterial 
LPS involves several cytokines, predominantly 
TNFcx, IL-6 and IL-l. A previous study has 
shown that IL-l is produced in response to Y. 
pestis LPS [10]. However, the ability of Y. pestis 
LPS to stimulate the production of TNFcx and 
IL-6 is not known. TNFcx is a proinflammatory 
cytokine which induces septic shock and fever 
(11], both of which are responses to bacterial 
infection. Septic shock induced by LPS can be 
mimicked by the administration of TNFcx, in-
dicating the key role of this cytokine in this 
response. LPS is also known to induce the release 
of the acute phase proteins [12], which are pro-
duced by the liver in response to a bacterial 
infection or tissue injury. These responses appear 
to be mediated by IL-6 which is produced by 
mononuclear phagocytes in response to LPS (13] . 
The aims of this study were to characterize 
the LPS isolated from Y. pestis cultured at 28°C 
with a view towards understanding the role of 
this molecule in the initial stages of the patho-
genesis of bubonic plague. 
J. L. Prior et al. 
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Figure 1. SOS-PAGE analysis of LPS isolated from Y. 
pestis strain GB cultured at 28°C (lane 1), S. typhi-
murium strain L6511 (possessing 0-antigen) (lane 2), 
S. typhimurhtm strain Ra TV119 (lacking 0-antigen) 
(lane 3), S. minnesotn strain Re 595 (lacking 0-antigen 
and core oligosaccharide except the 3-deoxy-0-
manno-2-octulosonic acid residues) (lane 4). 
Results 
LPS purification 
The phenol chloroform petroleum ether (PCPE) 
extraction method was used to purify LPS from 
Y. pestis strain GB cultured at 28°C, producing 
a yield of 0.6% (35 mg from 6 g dry weight of 
cells). One mg of this preparation contained less 
than 7.8 ·11g of protein. When analysed by SOS-
PAGE and silver stained, one intensely stained 
band was visible (Fig. 1). This material migrated 
with a similar mobility to LPS isolated from an 
Ra mutant of Salmonella hjphimurium (Fig. 1). Y. 
pestis strain GB grown at 28°C was used to 
produce a proteinase K min.ipreparation (proK 
miniprep) of LPS which gave a similar band 
pattern to that produced by the PCPE extraction. 
Monoclonal antibodies against Y. pestis 
LPS 
Four monoclonal antibodies were generated, 
which reacted with purified LPS, from Y. pestis 
strain GB. These monoclonal antibodies also 
reacted with LPS isolated from seven other 
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Figure 2. Reactivity of 2FIB101.3 in an lmmuno-blot 
to proK Minipreps of LPS isolated from eight strains 
of Y. pestis which had been cultured at 28°C or at 
37°C. (a) Y. pestis strain GB grown at 28°C (lane 1), 
Y. pestis strain GB grown at 37°C (lane 2), Y. pestis 
strain EV76 grown at 28°C (lane 3), Y. pestis strain 
EV76 grown at 37°C (lane 4), Y. pestis strain C092 
grown at 28°C (lane 5), Y. pestis strain C092 grown 
at 37°C (lane 6), Y. pestis strain 1255 grown at 28°C 
(lane 7) or Y . pestis strain 1255 grown at 37°C (lane 
8). (b) Y. pestis strain TW grown at 28°C (lane 1), Y. 
pestis strain TW grown at 37°C (lane 2), Y. pestis 
strain Java9 grown at 28°C (lane 3), Y. pestis strain 
Java9 grown at 37°C (lane 4), Y. pestis strain 195/P 
grown at 28°C (lane 5), Y. pestis strain 195/ P grown 
at 37°C (lane 6), Y. pestis strain EVAA grown at 28°C 
(lane 7) or Y. pestis strain EVAA grown at 37°C (lane 
8). 
strains of Y. pestis which had been cultured at 
28 or 37°C. Fig. 2(a) and (b) show the reactivity 
of one of the monoclonal antibodies, 3 Fill 1.3, 
with the LPS extracted from eight strains of Y. 
pestis grown at 28 or 37°C. There were small 
differences in the mobility of LPS from bacteria 
which had been cultured at the different tem-
peratures and this is more pronounced in some 
of the Y. pestis strains than others. 
The monoclonal antibodies were further 
screened in an irnrnuno-blot with proteinase 
K minipreparations of Y. pestis strain GB, Y. 
pseudotuberculosis strain 8580, Y. pseudo-
tuberculosis strain 1779, Y. enterocolitica 10598, Y. 
enterocolitica 10461, E. coli strain 0111, all of these 
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Figure 3. MALDI-TOF trace of LPS isolated from Y. 
pestis strain GB which had been cultured at 28°C. 
bacteria were grown at 37 or 28°C. All of the 
monoclonal antibodies cross reacted with Y. 
pseudotuberculosis strain 8580 and one of the 
monoclonal antibodies, 2FIB102.3, cross reacted 
with Y. pseudotuberculosis strain 1779. 
When the monoclonal antibodies were 
screened in an ELISA with whole cells they 
reacted with Y. pestis strain GB cultured at 28 
or 37°C. None of the monoclonal antibodies 
cross reacted with Y. pseudotuberculosis strain 
8580, Y. pseudotuberculosis strain 1779, Y. entero-
coliticn 10598, Y. enterocolitica 10461 and E. coli 
strain 0111 all of which had been cultured at 
37°C. 
Mass spectrometry 
LPS purified from Y. pestis strain GB was ana-
lysed by Matrix-assisted laser desorption time-
of-flight (MALDI-TOF) mass spectrometry in the 
mass range m/z 9000-2000. A major cluster of 
signals were present near m/z 3000 (Fig. 3). 
No significant signals were observed above m/z 
3400. The observed signals are in the mass range 
predicted for molecules containing lipid A plus 
the core oligosaccharide, but lacking an 0-
antigen. For a complete LPS molecule containing 
10-18 repeat units a mass range of m/z 
11000-19 000 would be expected. The mass spec-
trometry analysis did not show the presence of 
RNA or DNA. 
Biological activity of Y. pestis LPS 
LPS, purified from Y. pestis strain GB, was tested 
for activity using the Limulus amoebocyte lysate 
assay. The assay compared activity of the Y. 
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Figure 4. (a) TNFcx production by mouse macro-
phages stimulated by SO llg of Y. pestis LPS (ill3) or 
SO llg of E. coli strain 0111 LPS (. ). (b) IL-6 pro-
duction by mouse macrophages stimulated by SO 1-1g 
of Y. pestis LPS (ill3) or SO llg of E. coli strain 0111 LPS 
(. ). For each of these data sets three times the SO 
are included for each time point. In each case this is 
less than 0.1% of the absorbance value. Each data 
point was assayed in triplicate. 
pestis LPS with the activity of LPS purified from 
E. coli. The LPS purified from Y. pestis had an 
activity of 8.85 EU I pmol compared to the E. coli 
LPS which had an activity of 183.6 EU I pmol. 
LPS purified from Y. pestis which had been 
cultured at 28°C was added to murine macro-
phage cell cultures and the release of selected 
J. L. Prior et al. 
cytokines in cell culture fluid was measured at 
intervals up to 32 h using an ELISA. 
TNFcx was detected in cell culture supernatant 
fluid 4 h after the addition of E. coli strain 0111 
LPS or Y. pestis strain GB LPS. At all time points 
after 4 h the level of TNFcx in the cell culture 
fluid was higher from macrophages stimulated 
with E. coli strain 0111 LPS than from macro-
phages stimulated with Y. pestis strain GB LPS 
[Fig. 4(a)]. The amount of TNFcx produced by 
the cells stimulated by the addition of E. coli 
LPS rose to a peak at 26 h and then declined. 
The cells which were exposed to Y. pestis LPS 
produced increasing amounts of cytokine until 
a plateau was reached by 26 h. 
A similar assay was carried out where levels 
of IL-6 in culture supernatants were measured 
using an ELlS A. IL-6 was detected 7 h after the 
addition of LPS. At every time point the levels 
of IL-6 produced by cells stimulated with E. coli 
LPS were greater than from cells stimulated with 
Y. pestis LPS [Fig. 4(b)]. The cytokine levels 
produced by cells stimulated by E. coli LPS 
increased until a plateau was reached at the end 
of the experiment. The cytokine levels produced 
by the cells stimulated with Y. pestis LPS de-
creased after 30 h. 
Immune response to Y. pestis LPS 
To investigate whether antibody against Y. pestis 
LPS could provide protection against an ex-
perimental bubonic plague infection, groups of 
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Figure 5. Time to death of mice immunized with 
10 pg of LPS and 10 llg of CTB, 10 1-1g of LPS or 10 ~tg 
of CTB. 
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six mice were immunized with purified LPS, 
LPS + cholera toxin B subunit (CTB) or CTB 
alone. Serum samples were taken from mice 14 
days after the final immunization and the level 
of antibody against immobilized bacteria de-
termined. Mice immunized with 10 ~tg of LPS 
and 10 ~g of CTB had a mean IgM titre of 
1:3280 and a mean IgG titre of 1:2360. In each 
case these titres were higher than those achieved 
by immunization with LPS alone, which were 
1:1688 for IgM and 1:289 for total IgG. The mice 
were challenged with 100 median lethal doses 
(MLD) of Y. pestis strain GB which had been 
cultured at 28°C. All of the challenged mice died 
within 6 days (Fig. 5). There was no significant 
difference in the time to death of the mice im-
munized with LPS and CTB or LPS alone, corn-
pared with mice in the control group that had 
been immunized with CTB alone (Fig. 5). 
Discussion 
LPS plays an important role in the modulation 
of the host's response to invading bacteria and 
is capable of initiating many of the biochemical 
responses in the host associated with death from 
Gram-negative bacteremia [14, 15]. The com-
plement cascade is part of the host response and 
is triggered by the presence of lipid-A-core and 
0-antigen, generating the membrane attack com-
plexes (MAC). In some bacteria the presence of 
an 0-antigen is thought to stop the integration 
of the MAC into the cell membrane and therefore 
stop the formation of pores that lead to cell 
death. Pathogenic bacteria without an 0-antigen 
are generally sensitive to complement [16] and 
therefore attenuated. For example, a mutant of 
Y. enterocolitica 0:3 lacking an 0-antigen was 50-
fold less virulent than the wildtype [17]. Some 
pathogenic bacteria poses a truncated 0-antigen 
but are still protected from the activity of com-
plement. Others, like some members of the 
Neisseria species, express polysaccharide com-
ponents that downregulate complement ac-
tivation [18]. The LPS of Y. pestis is reported to 
lack an 0-antigen [5-7], but the bacterium is still 
able to invade its host, and it is reported that 
despite the lack of an 0-antigen the LPS is still 
able to withstand the action of complement [19]. 
Most cases of plague are the consequence of 
a bite from a flea which has previously fed on 
an infected host. Culture of bacteria at 28°C 
is considered to result in bacteria which are 
phenotypically similar to those bacteria con-
stituting the infective dose [1]. In this study we 
have shown by mass spectrometry that the LPS 
isolated from Y. pestis strain GB cultured at 28°C 
lacks an 0-antigen. We have previously shown 
that LPS isolated from different strains of Y. 
pestis which had been cultured at 28 or 37°C 
appeared identical by SOS-PAGE (Prior et al., 
unpublished results). The monoclonal anti-
bodies used in this study reacted with a single 
band on an immuno-blot, confirming the ab-
sence of an 0-antigen from Y. pestis LPS. The 
LPS from eight strains of Y. pestis, which had 
been cultured at 28°C, reacted equally well with 
the monoclonal antibodies suggesting the LPS 
from different strains share regions of similar 
structure. The rnonoclonal antibodies also re-
acted with LPS isolated from Y. pestis, which 
had been cultured at 37°C, suggesting that the 
LPS isolated from Y. pestis cultured at 28 or 37°C 
contains an identical binding epitope(s). 
The activity of LPS is traditionally measured 
using the LAL assay, which involves the binding 
of an antimicrobial peptide to the bacterial LPS. 
Differences in the activity of LPS in this assay 
may be due to differences in the structure of 
lipid-A or differences in the solubility of the 
LPS. In this work we have shown that the LPS 
extracted from Y. pestis has a significantly lower 
activity when compared to E. coli LPS. These 
results agree with the finding that Y. pestis cells 
and Y. pseudotuberculosis cells cultured at 37°C 
(i.e. lacking an 0-antigen) are more resistant to 
polymyxin B than Y. enterocolitica [20]. These 
findings suggest that Y. pestis and Y. pseudo-
tuberculosis may be more resistant to cationic 
peptides involved in phagocytic killing. 
IL-l, IL-6 and TNFa all play key roles in the 
host response to LPS [21-23]. The LPS of Y. pestis 
has previously been shown to be as effective in 
stimulating IL-l production from monocytes as 
the LPS from Salmonella typhimurium or from 
Shigella Jlexneri [10]. However, prior to this study 
the effects of LPS on the production of TNFa 
and IL-6 by immune effector cells were not 
known. TNFa is a proinflamma tory cytokine 
which induces septic shock and fever, both of 
which are associated with bacterial infection. 
Traditionally, the pyrogenicity of LPS was meas-
ured in the rabbit. However, the discovery that 
IL-6 is an endogenous pyrogen involved in the 
stimulation of acute-phase proteins, and induces 
a monophasic fever in rabbits after i.v. injection 
[24], enables the use of a cell culture assay in 
place of the rabbit model. The amount of lL-6 
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produced by macrophages activated by LPS is 
a measure of its ability to induce the release of 
acute phase proteins [25]. The LPS from Y. pestis 
can stimulate macrophages to produce TNFcx 
and IL-6. However, the level of production was 
significantly lower than that induced by E. coli 
LPS. These results suggest that the LPS present 
on Y. pestis delivered from the flea is likely to 
induce a lower level of cytokine stimulation in 
vivo compared to LPS from other Gram-negative 
bacteria. This may be advantageous to the bac-
terium as this would promote the avoidance of 
cellular host defence mechanisms. 
Immunization with LPS derived from a range 
of pathogenic bacteria including Salmonella hjphi-
murium and Actinobacilus pleuropneumoniae has 
been shown to induce protection against Sal-
monellosis and porcine pleuropneumonia, re-
spectively [26, 27]. In many cases the antibodies 
recognize the 0-side chain, but protective anti-
bodies that recognize the core of LPS have been 
reported [14, 28]. 
Previous work has shown that immunization 
of mice with LPS isolated from bacteria cultured 
at 37°C resulted in an antibody response which 
did not protect mice from challenge with Y. 
pestis [7]. In this study we have immunized mice 
with LPS isolated from bacteria cultured at 28°C. 
Although antibody against LPS developed, the 
immunized animals were not protected against 
a challenge with 100 MLDs of Y. pestis. In studies 
with other bacteria, LPS vaccines which have 
achieved good immune responses and/ or pro-
tection against challenge are frequently com-
posed of the 0-antigen component conjugated 
to a carrier protein [29-31]. The carrier protein 
is necessary to convert the typical immune re-
sponse to LPS from a T-cell-independent to a 
T-cell-dependent response and thus to establish 
cellular memory for the LPS. In this study we 
attempted to achieve this effect by eo-
administration of LPS and the protein CTB, a 
strategy previously shown to work for o ther 
antigens [32-34]. Although this strategy in-
creased the antibody titres induced to LPS, it 
did not lead to the development of protective 
immunity. 
Materials and Methods 
Chemicals and enzymes 
All chemicals and enzymes used in this study 
were obtained from the Sigma Chemical Corn-
J. L. Prior et al. 
pany (Poole, U.K.) or from Roche Diagnostics 
(Lewes, U.K.). The LPS .from S. minnesota and S. 
hjphimurium were obtained from Sigma Chem-
ical Company. 
Purification of LPS 
LPS was extracted using an adapted method 
based on the PCPE method by Gal an os [35]. 
Instead of using a homogenizer, a pestle and 
mortar were used to mix the bacteria with the 
extraction mixture. After washing with ether the 
extracted LPS was dried in a fume hood rather 
than under a vacuum. The proK miniprep were 
produced according to the method of Chart [36]. 
Mass spectrometry 
MALO I-TOF MS was performed using a Per-
septive Biosystems Voyager Elite mass spec-
trometer (Foster City, CA, U.S.A.) with Delayed 
Extraction. Native LPS was dissolved in 90% 
dimethylformamide in water and aliquots 
(0.5 ~) of the resulting solution were analysed 
using a matrix of a saturated solution of 2,5-
dihydrobenzoic acid in 70% acetonitrite, 30%, 
0.1% aqueous trilluoroacetic acid. Insulin B chain 
was employed as an external calibrant. 
Culture of bacteria 
Bacteria used in this study were Y. pestis strains 
1255 (CAMR culture collection), 195/ p (CBD 
culture collection), C092 (human isolate from 
Colorado, CBD culture collection), EV76 (CBD 
culture collection), EVAA (Russian vaccine 
strain, CBD culture collection), GB (human isol-
ate, CBD culture collection), Java9 (Fl-negative, 
Indonesian isolate, CBD culture collection) and 
Tjiwidej (37) (CBD culture collection). Y. pseudo-
tuberculosis strain NCTC 8580 and NCTC 1779, 
Y. enterocolitica NCTC 10598 and NCTC 10461 
and E. coli 0111. Bacteria were cultured at 28 
or 37°C as required. All Y. pestis strains were 
cultured on blood base II agar (BABII, Oxoid, 
Basingstoke, U.K., 40 g/1). When agar plates 
were used, hemin was added (0.25% w /v hemin 
in 10 mM sodium hydroxide, filter sterilized and 
8 ml added/lOO ml of agar). Y. pestis colonies 
appeared pigmented on this growth medium. 
All other bacteria strains were grown on nutrient 
agar (Oxoid, Basingstoke, U.K.). 
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Production of monoclonal antibodies 
Four monoclonal antibodies were produced by 
immunizing CBA x BALB/ c mice three times 
with a crude surface preparation from Y. pestis 
strain 1255 grown at 37°C. An i.v. boost was 
given 3 days prior to fusion. Spleen cells were 
fused with P3-X63-Ag8-clone 6.5.3 cells (Amer-
ican Typed Culture Collection CRL 1580). 
The cell culture supematant from clones pro-
duced by this fusion was initially screened by a 
direct ELISA with Y. pestis strain 1255 heat-killed 
whole cells. Bacteria were bound to the plate in 
a carbonate/bicarbonate antigen binding buffer 
overnight at 4°C. Positive wells were expanded 
and cloned by limiting dilution. The resulting 
monoclonal antibodies were isotyped using a 
commercially available kit (Gibco, Uxbridge, 
U.K.). LPS was purified from Y. pestis strain GB 
by a phenol, chloroform petroleum ether method 
[35] and used to screen the monoclonal anti-
bodies. 
Immune-blotting 
The monoclonal antibodies were also screened 
in an immune-blot with LPS proteinase K mini-
preparations (proK mini prep) [36] from eight 
different strains of Y. pestis grown at 28 or 37°C. 
For each proK mini prep a 32 mg/ ml suspension 
of bacteria was digested and 10 ~ of the sus-
pension was used for each lane of a gel. Electro-
phoresis was carried out on 12.5% 
polyacrylamide gels which were produced by a 
method based on Laemmli [38] and immune-
blotted using a semi-dry transfer system. After 
blocking with 5% BSA overnight and washing 
three times for 5 min in 0.1% BSA, blots were 
probed with hybridoma cell culture supematant 
diluted to 1:50 in 0.1% BSA for 1-2h at room 
temperature. This was followed by three 5 min 
washes in 0.1% BSA then an anti-species horse-
radish peroxidase labelled antibody (Harlan 
Seralab, Loughborough, U.K.) diluted to 1:5000 
in 0.1% BSA and applied for 1-2 h. The blot was 
then washed twice for 5 min in 0.1% BSA and 
twice for 5 min in PBS. The substrate 3,3'-di-
arninobenzidine tetrahydrochloride (DAB) was 
used as suggested by the Sigma Chemical Com-
pany until colour developed. 
Quantification of LPS 
Quantitation of LPS assumed that 1 mol of LPS 
carries 4 mol of 3-hydroxytetradecanoic acid. 
LPS in phosphate buffered saline was dried 
under nitrogen and an internal standard added 
(10 nmole C15:0). Hydrolysis in 1 M methanolic 
HCl at 80°C for 14-16 h yielded fatty acid methyl 
esters, the reagent being removed under a stream 
of nitrogen. Fatty acid methyl esters were dis-
solved in chloroform, washed several times with 
water and dried under nitrogen. Analyses were 
performed by gas chromatography coupled to 
mass spectrometry (GC-MS) on a Fisons MD800 
instrument (Micromass UK Ltd, Manchester, 
U.K.). Samples were dissolved in hexanes 
prior to on-column injection on a RTX-5 
(30 m x 0.25 mm, Restek Corporation, Belleforte, 
PA, U.S.A.) column at 90°C. The oven was held 
at 90°C for 1 min before being increased to 130°C 
at a rate of 50°C/min, held at 130°C for 1 rnin, 
then increased to 250°C at a rate of 5°C/min. 
Cytokine release assay 
The J774 mouse macrophage cell line was used 
for cytokine release assays. Cells were cultured 
in Dulbecco's Modified Eagle's Medium 
(DMEM) with 10% foetal calf serum, penicillin 
(100 units/ml), streptomycin (100 !lg/ml) and 
glutamine (2 mM). Fifty 11g of LPS in phosphate 
buffered saline (PBS; pH 7.2) was added to a 
well of a 24 well cell culture plate containing 
3 x 105 cells. As a positive control 50 11g of E. coli 
0111, LPS (Sigma Chemical Company) in PBS 
was used. As a negative control 50 111 of PBS 
was used. Fifty Ill samples were removed from 
the wells at time 0, 4, 7, 23, 26, 30 and 32 h. For 
the measurement of TNFcx or IL-6 commercially 
available kits (R & D Systems, Abingdon, U.K.) 
were used. Samples were diluted in culture 
media and PBS (1:1). 
Limulus amoebocyte lysate assay 
Activation of Limulus amoebocyte lysate was 
determined using the Coatest endotoxin test 
kit according to the manufacturer's instructions 
(Quadratech, Epsom, U.K.). Samples were di-
luted 10- 6 or 10- 5 in distilled water prior to 
analysis. 
Immunization with LPS and protection 
studies 
The ability of Y. pestis LPS to protect BALB/ c 
mice from a Y. pestis challenge was determined 
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by irnmuruzmg groups of six female BALB/c 
mice (Charles River Laboratorie, Kent, U.K.) by 
the i.p. route with LPS purified by the PCPE 
method from Y. pestis strain GB grown at 28°C 
on BAB II media. On each dosing occasion, mice 
were given 10 J.lg of purified LPS in PBS alone 
or LPS in PBS with 10 1-1g of CTB. The mice 
received six immunizations, each 21 days apart. 
They were challenged 46 days after the last 
immunization with 100 cfu of Y. pestis strain GB 
by the subcutaneous route, delivered in 0.1 ml. 
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Population genetic studies suggest that Yersinia pestis, the cause of plague, is a clonal pathogen that has 
recently emerged from Yersinitl psewlotuberculosi. Plasmid acquisition is likely to ha-.e been a key element in 
this evolutionary leap from an enteric to a flea-transmitted systemic pathogen. However, the origin of Y. 
pestis-specific plasmids remains obscure. We demonstrate specific plasmid rearrangements in dil'erent Y. pestis 
strains which distinguish Y. pestis bv. Orientalis strains from other biovars. We also present evidence for 
plasmid-associated DNA exchange between Y. pe#is and the exclusively human pathogen Stzlnwnella etiUriCG 
serovar Typbl. 
Yersinia pestis is primarily a rodent pathogen and is usuaUy 
transmitted subcutaneously by the bite of an infected flea (13 ). 
The microorganism can spread to the regional lymph nodes of 
infected rodents and humans, where local replication can cause 
a swelling, or bubo (55). Subsequent bacteremia may some-
times result in pulmonary infection (secondary pneumonic 
plague) and direct respiratory spread (55). There are historical 
data suggesting that epidemic plague has on occasion been the 
leading cause of death in humans-a third of the population of 
Europe may have died in the 14th century during the second 
pandemic of plague known as the Black Death (79). The third 
pandemic resulting from the Hong Kong outbreak of 1894 
killed miUions of people (mainly in Asia) in the early years of 
the 20th century (55). Currently, most plague cases are re-
ported from developing countries in Africa and Asia such as 
Madagascar, Tanzania, and Vietnam (75). Plague continues to 
have a high mortality rate: 20% of the 200 annual confirmed or 
presumptive cases (95% bubonic) in Madagascar (16) and 6 
out of 19 cases in a recent series from the United States (18) 
were fatal infections. However, most of the countries reporting 
plague currently have much higher disease burdens associated 
with other infectious agents, including the exclusively human 
pathogen Salmonella en/erica serovar Typhi (53). 
The factors influencing the rise and fall of plague epidemics 
remain obscure (34 ), and it is vital to understand the genetic 
basis of the origins and evolution of such a potentially devas-
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tating pathogen as Y. pestis. The enteric pathogen Yersinia 
pseudotuberculosis is so closely related to Y. pestis in terms of 
chromosomal DNA hybridization that they could be classified 
as subspecies (5). On the basis of sequence analysis of multiple 
housekeeping genes, it has been proposed (1) that Y. pestis is a 
clone which has recently evolved from Y. pseudotuberculosis. 
Within the Y. pestis clone, distinct biovars (Antiqua, Medieva-
lis, and Orientalis) have been associated with the three histor-
icaUy recognized pandemics (20). These biovars have been 
shown to be phylogenetically distinct by analysis of DNA re-
striction fragment polymorphisms (1) and ribotyping (29). It 
has been suggested that Y. pestis. bv. Orientalis has emerged 
most recently (1). 
A role for key Y. pestis-specific gene mutations in evolution 
from Y. pseudotuberculosis was suggested by demonstration of 
increased virulence of Y. pseudotuberculosis for mice to a level 
comparable with that of Y. pestis when mutated in the chro-
mosomal inv and plasmid-locatedyadA loci (61). These genes 
are intact open reading frames (ORFs) in Y. pseudotuberculosis 
but not in Y. pestis strains (61, 67). Conversely, introduction of 
a functional Y. pseudotuberculosis yadA gene into Y. pestis 
caused a significant decrease in virulence (61). However, the 
hypervirulent Y. pseudotuberculosis mutants were later found 
not to be isogenic with the wild-type strains (31), suggesting 
that the two single gene mutations were not the only factors 
involved. 
The most obvious additional genetic complement present in 
2586 
Y. pestis compared with Y. pseudotuberculosis is in the form of 
plasmids. Both Y. pestis and Y. pseudotuberculosis possess a 
70-kb plasmid (pCDl in Y. pestis and pffil in Y. pseudotuber-
culosis) which encodes the Yop virulon, a type Ill secretion 
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TABLE l. Bacterial strains used in this study" 












bv. Orientalis pfra 
bv. Orientalis pfra 
bv. Orientalis 
M. C. Chu, NCID" 
M. C. Chu, NCID 
M. C. Chu, NCID 
M. C. Chu, NCID 
M. C. Chu, NCID 
M. C. Chu, NCID 
M. C. Chu, NCID 
M. C. Cbu, NCID 




bv. Or:ientalis pFra 
bv. Orientalis pfra 
bv. Orientalis pfra 
bv. Orientalis pFra 
bv. Or:ieotalis pFra 
bv. Orieotalis pFra 
bv. Orientalis pFra 
bv. Orientalis pfra 
bv. Orieotalis 
P. Oyston, CBDE (21) 
P. Oyston, CBDE (51) 




bv. Orieotalis pfra 
bv. Medievalis pMTl 
bv. Medievalis pFra 
bv. Antiqua pfra 
P. Oyston, CBDE 
M. C. Chu, NCID 
M. C. Chu, NCID 
M. C. Chu, NCID 
S. enterica serovar Typhi CT18 pHCMlpHCM2 J. Wain, Centre for Tropical Diseasesd 
• The presence of pFra/pMTl was demonstrated by cafl PCR (52). 
• NCID, National Ccntcr for Infectious Diseases, Fort CoUins, Colo. 
< CBDE, Chemical & Biological Defence Establishment, Porton Down. United Kingdom. 
J The Centre for Tropical Diseases is in Ho Chi Minh City, Vietnam. 
system essential for virulence in many hosts (9, 55). In addi-
tion, Y. pestis usually possesses two further plasmids which 
encode a variety of potentially virulence-associated determi-
nants. A 9.5-kb plasmid called pPCPl in Y. pestis KIM strains 
(alternatively known as pPst) encodes the plasminogen activa-
tor Pla (55). A 100- to 110-kb plasmid called pMTl in KIM 
strains (alternatively known as pFra) encodes the murine toxin 
Ymt and the Fl capsular protein (55). 
The key difference between Y. pseudotuberculosis and Y. 
pestis is the latter's capacity to colonize the flea and be trans-
mitted to mammalian hosts by a subcutaneous route of infec-
tion. The chromosomal hms locus that is required (33) for 
blockage of the flea midgut by Y. pestis to maximize onward 
transmission is also present in Y. pseudotuberculosis (11). How-
ever, the Y. pestis-specific pMTl or pFra plasmid encodes a 
murine toxin, which is apparently essential for flea colonization 
(35), and the F1 capsular antigen, which is an important pro-
tective immunogen although it is not essential for virulence in 
mammalian hosts (25). The Pia protease encoded by the 
pPCPl or pPst plasmid is required (70) by some strains of Y. 
pestis for systemic spread after subcutaneous injection into a 
mammalian host. It seems likely that acquisition of these two 
plasmids was an essential step in the evolution ofY. pestis from 
Y. pseudotuberculosis. However, the limited sequence similarity 
between the Y. pestis plasmids (37, 42) and other bacterial 
plasmids gives few clues about their origin and capacity for 
mobility. In an elfort to understand the pathogenicity and evo-
lution of Y. pestis, we have undertaken the genome sequencing 
of this devastating pathogen, and plasmid DNA sequence com-
parison is an important application of these data. Genetic 
diversity of plasmids exceeds that of host chromosomes, largely 
due to a higher rate of recombination (6), and genetic variation 
associated with biovar emergence may be more easily revealed 
in plasmids than in the homogeneous chromosomal back-
ground (1). 
Our data provide supporting evidence for the emergence of 
Y. pestis bv. Orientalis after biovars MedievaLis and Antiqua. 
We present data demonstrating the common ancestry of more 
than 50% of the Y. pestis pMTl/pFra plasmid and a cryptic 
plasmid from a recent clinical isolate of S. enterica serovar 
Typhi, another species of Enterobacteriaceae which is an exclu-
sively human pathogen. 
MATERIALS AND ME11IODS 
Bacterial strains. The bacterial strains used in this study arc listed in Table 1. 
DNA l.ibnry constructioo and sequencing. A single colony of Y. pestis C0-92 
was picked from Congo red agar and grown overnight at 2H"C in BAB broth (50). 
A single colony of Salmonella enterica serovar Typhi Crt8 was picked from Luria 
agar and grown overnight at 37"C in Luria broth. Total DNA was isolated as 
described previously (51). Random shotgun libraries of each genome were con-
structed and sequcnccd as previously described (54). 
Sequence annotation and analysis. The DNA was compared with sequences in 
the EMBL database using BLASlN and BLASTX (2). Transfer RNAs were 
predicted with tRNAscan-SE (43). Potential coding sequences (CD&) were 
predicted using ORPHEUS (26) and GUMMER (64) and also stop-to-Slop 
prediction; the results were combined The predicted protein sequences were 
searched against a noorcduodant protein database using WUBLASTP and 
FAST A The complete six-frame translation was used to search PROSITE, and 
the predicted proteins were compared against the PP AM ( 4) database of protein 
domain hidden Markov models. The results of all these analyses were assembled 
u~ing the Artemis sequence viewer (63). Plasmids were defined as separate 
contiguous sequences from analysis of shotgun sequence data with no plasmid 
manipulations (separation o r specific cloning). Statistical analysis of the fre-
quem:y of occurrence of Chi seque nces was pcdormed using the RMES package 
(Unite de Biomctric, INRA, Jouy-en-Josas, France (http://www· bia.inra.fr/J/AB/ 
gcnomc/RMES/wclcomc.html)) to rank the number of O!i and Chi comple ment 
sequences against the frequency of occurrence of all octamcrs and their com-
plements on one plasmid sequence strand 
PCR. Reaction mixtures (20 ILl) we re prepared with 1 U of Taq polyme rase 
(Rochc Mole cular Biochcmicals, Lcwcs, United Kingdom), I X Taq polymerase 
buffer (tu mM Tris-HQ (pH 1!.3). 50 mM KC! , 1.5 mM MgCI:J. 0.2 mM (each) 
dcaxynuclcosidc triphosphate and 0.2 j.lM (each) p rimer. DNA was obtained by 
boiling a single colony in 21Xl j.i.l of distilled water for 5 min. using 1 ILl of 
supcrnatant for the PCR template. For the l.lJ1!3-bp amplicon. primer P12 l 
(5'-CCGITCfACATCATCCATA-3') and prime r P221 (5'-ITATGGCfGGC 
AAATCfGA-3') were used. PCR conditions we re 94°C for I min and 25 cycles 
of 94°C fo r 30 s. 57SC for 30 s. a nd 7Z'C for 1 min. and then 7TC for 10 min. 
Fo r the t.H65-bp amplicon, primer P126 (5 '-GTTGAGCAITAGCGAGACC· 














AG. 1. ISJIJO..associated deletion in pFra of Y. pestis C0-92 compared with Y. pestis KIMS pMTl (GenBank accession no. AF053947) and S. 
entmcu serovar Typhi Cfl8 plasmid pHCM2. A region of 6,668 bp present in KIM5 is shown above the corresponding region in C0-92, which 
laclcs this insertion. Thick black lines above and below the two Y. pestis plasmids and linked to them by dotted lines indicate the regions of pHCM2 
showing more than 95% identity to the adjacent Y. pestis sequence. Locations of PCR primers for the reactions shown in Fig. 2 are indicated by 
arrowheads. Numbers shown at an angle to the horizontal correspond to base-pair locations in the labeled plasmid. In one KIM5 sequence 
(GenBank accession no. AF074611), the regions shown on either side of this ISJOO copy are separated by 24 kb due to lSJOO recombination. 
3' ) and primer P226 (5'-CTACCGCAITACI'CCACfC-3') were used. PCR 
conditions were \WC for 1 m in and 25 cycles of CJ4' C for 30 s. 1\0'C for 30 s, and 
Tl'C for 1 min. and then 77:'C for 10 min. 
Nucleotide teq,_ce ~~«e~sioa oumben. The annotated Y. pe.rti.r plasmid se-
quences have been deposited in EMBL under accession numbers AL11T1.11 
(pFra), AL1171H9 (pYV), and AL10996CJ (pPst). The scqucnoca of S. muriCJJ 
scrovar l)pbi Cl111 and the plasmid pHCM2 arc available from the Sangcr 
Centre (htty.//www .sangcr .ac.uk/Projccts/S _ typhi). 
RESULTS 
Y. pestis interbiovar comparisons. The plasmid sequences 
obtained for Y. pestis C0-92 were compared with those previ-
ously reported for Y. pestis KIMS. Y. pestis C0-92 is a recent 
clinical isolate of Y. pestis bv. Orientalis from a fatal case of 
primary plague pneumonia in the United States (21). Y. pestis 
KIM is a laboratory-passaged bv. Medievalis strain originally 
isolated in the Middle East (Kurdistan Iran man) (55). Two of 
the Y. pestis C0-92 plasmids, pPst and pCD1, show minor 
differences from their counterparts in Y. pestis KIMS. More 
extensive rearrangements and indels were seen for pMTl/pFra 
(Fig. 1; see Fig. 3). 
pPst. The 9,612-bp pesticin plasmid pPst showed two single-
base-pair differences (one insertion and one deletion) and a 
single 2-bp insertion compared with the previously reported 
9,610-bp KlM5 plasmid pPCP1 (GenBank accession no. 
AF053945) (37). All changes involved intergenic homopoly-
meric base-pair tracts. Only the single-base-pair differences 
were adjacent to a coding region: an insertion and a deletion 20 
and 40 bp, respectively, upstream of the psi gene encoding 
pesticin. Neither involved the promoter or any proposed reg-
ulatory site (59). One 5-bp direct repeat flanking the ISJOO 
insertion site in both the pPst and pPCP1 plasmids was also 
found, together with the next 5 bp of downstream sequence 
adjacent to one side of an ISJOO insertion in Y. pestis bv. 
Medievalis KIM pMTI and Y. pestis bv. Oriental is pFra (data 
not shown), suggesting that ISJOO interplasmid recombination 
bad occurred before divergence of these biovars. 
pCDl. Three of the four clusters of insertion elements iden-
tified in the 70,305-bp Y. pestis C0-92 pCD1 plasmid showed 
deletions or insertions compared with the two previously re-
ported Y. pestis KlM5 sequences. These were 70,504 (37) and 
70,509 (56) bp, respectively (the 5-bp indel accounting for the 
size difference between the two KIM sequences is not deleted 
from the C0-92 sequence). The major difference between the 
two KIM sequences and the C0-92 sequence was the location 
of the ISJOO insertion elemenL In both biovars it was nested 
within another insertion element in a cluster of mobile genetic 
elements, but in the case of C0-92 it was inserted into a 
degenerate IS2J-Iike element between :rye£ and :rycH instead 
of a degenerate ISDJ-like element betweenyscM andyopH as 
in Y. pestis KIMS. In both cases, the ISJOO insertion site was 
flanked by a direct repeat of 5 bp. The absence of ambiguities 
on sequence assembly suggests that all copies of pCD1 in the 
cells of the colony used to make the sequence library had the 
same ISJOO insertion site, distinct from that in KIM5 strains. 
However, PCR with primers from ISJOO and both sets of flank-
ing sequences gave products with the Y. pestis bv. Orientalis 
strains listed in Table 1 (data not shown), and we were unable 
to assign strain or biovar specificity to the pCD1 ISJOO inser-
tion site. Another insertion site for ISJOO in pCD1 from Y. 
pestis bv. Orientalis strain EV76 has previously been demon-
strated (GenBank accession no. X78302) (data not shown). 
A 212-bp deletion of a partial IS285 sequence between yopD 
and yopM, apparently following recombination between two 
3-bp direct repeats (located at 18,852 bp in C0-92), accounted 
for most of the difference in size between the KIM5 sequences 
and those of C0-92. It was located within one of three re-
peated sequences (R1-3) (60) forming part of an IS element 
which have apparently recombined to invert the yopM region in 
Y. enterocolitica pYVe227 (38) with respect to that in Y. pestis 
and Y. pseudotuberculosis. The deletion extended the length of 
R1 in Y. pestis C0-92 from 189 to 264 bp. 
There were four other minor differences in non-insertion 
sequence ORFs from the KlM5 pCD1 sequences: three single-
base-pair substitutions changing a single amino acid and an 
11-bp insertion extending the Syc-like ORF7 reported up-
stream of ypkA (56) and rendering this ORF in C0-92 (ORF 
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1. 73c) identical to that upstream of ypkA in Y. pseudotubercu-
losis pilll (28). There were no differences in the gene order in 
pCDl between KIMS and C0-92 other than the insertion 
sequence transposition. The point mutation in yadA which 
distinguishes Y. pestis pCD1 fro m its homologues in Y. entero-
colitica and Y. pseudotuberculosis (56) was present. 
pFra. The 96,210-bp Y. pestis C0-92 pFra plasmid contained 
two ISIOO elements present as inverted repeats, as described 
for pMTl in KIM5 (37, 42). Deletions of 2,109 and 2,606 bp in 
C0-92 pFra compared with the pubUshed KIMS pMT1 se-
quences were also found, corresponding to regions adjacent to 
an ISIOO element (Fig. 1; see Fig. 3). In one of the published 
pMTl sequences (GenBank accession no. AF053947) (37), 
these regions flanked a single ISIOO element with a 5-bp direct 
repeat at the site of insertion and together with that element 
formed a single insertion of 6,669 bp compared with the C0-92 
sequence (Fig. 1). In the other published KIM5 sequence 
(GenBank accession no. AF074611) (42), each was adjacent to 
a different ISIOO copy, neither of which was flanked by a direct 
repeat. This reflected a previously reported inversion of the 
24-kb region between the two ISIOO copies in one KlM5 se-
quence compared with the other (37, 42). One of the two IS lOO 
copies was inserted in a different location in C0-92 (bp 57267 
to 59220) compared with the two KlM5 sequences (Fig. 1; see 
Fig. 3). Other differences in gene order between the two KIM5 
sequences and C0-92 could be accounted for by insertion of 
this lSIOO copy into a DNA polymerase ill gene followed by 
recombination with the other ISIOO sequence, inverting a 
37-kb region in C0-92 (see Fig. 3). 
In addition, a 63-bp deletion was detected in C0-92 pFra 
compared with the KIMS pMT1 sequences, apparently follow-
ing recombination between 12-bp imperfect direct repeats, re-
sulting in the fusion of two unidentified KIMS ORFs (068739 
and 068738 in one KIMS sequence [37], Y1032 and Y1033 in 
the other [42]) to form ORF 1.22c. There were 12 sites showing 
differences with both KIMS sequences. Four of these were 
conservative single-base-pair substitutions in coding regions, 
four were 1- or 2-bp indels in noncoding sequence, and four 
were single-base-pair substitutions in coding regions changing 
one or two amino acids. There were 12 sites where the C0-92 
sequence showed identity with one but not both KIM5 se-
quences (i.e., KIMS polymorphisms were as common as inter-
biovar differences). These comprised three single-base-pair 
substitutions (one conservative, two in noncoding regions), 
eight single-base-pair indels (three in noncoding regions), and 
one 5-bp polymorphism in a noncoding region. There were no 
differences in any known virulence-related factors. 
PCR with primers internal to the two large deletions yielded 
no specific amplicons with a variety of Y. pestis bv. OrientaUs 
strains, but they were present (Fig. 2) in a Y. pestis bv. Antiqua 
strain and a Y. pestis bv. MedievaUs strain unrelated to KIM, 
suggesting that this deletion could be biovar specific. In addi-
tion to previously reported homologies, BLASTN searching 
showed that most of this deleted region (apart from the ISIOO 
sequence) was present in pHCM2, one of two plasmids present 
in a multidrug-resistant strain of S. enterica serovar Typhi 
C fl8 which originated in Vietnam (http://www.sanger.ac.uk/ 
Projects/S_typhi). This plasmid also harbored 60 bp of the 
63-bp deletion. 
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FIG. 2. PCR for ISJOO-flanking regions from Y. pestis KIM5 pMTl 
(bv. Medievalis) showing absence in Y. pestis bv. Orientalis strains and 
presence in other biovar Medievalis and Antiqua strains. DNA frag-
ment sizes are given in base pairs. (A) PCR with primers P12L and 
P221. (B) PCR with primers P226 and Pl26. Lanes: 1, strain All22; 2, 
PEXU2; 3, Harbin 35; 4, PB6; 5, F361/66; 6, Nepal 516; 7, 15-91; 8, 
16-34; 9, AZ94-0666; 10, ZE94-2122; 11, TWS; 12, C0-92; 13, GB; 14, 
JAVA 9; 15, 195P; C, KIM (control); M, molecular weight marker. 
Additional text labels indicate lanes containing DNA templates from 
Y. pestis bv. Anriqua (An) and bv. Medievalis (Me) strains. All other 
numbered lanes contain DNA from Y. pestis bv. Orientalis strains. A 
0.9% agarose gel was used. The digital image was obtained with Gel-
Doe (Bio-Rad) and was cropped and resized in Adobe Photoshop. 
pFra and pHCM2 comparison. More than 52% of pFra 
from Y. pestis C0-92 was highly similar to pHCM2 (Table 2). 
Because some of the shared DNA sequence was in regions 
absent in Y. pestis bv. Orientalis strains, the percentage of 
KIM5 pMT1 resembling pHCM2 was higher than that of 
C0-92 pFra at 56.2%, with 57.6% of pHCM2 showing simi-
larity with pMTl. More than 90% of the similar regions 
showed more than 96% DNA identity. The G+C content of 
the regions in common (51.9%) was closer to the overall S. 
enterica serovar Typhi G+C content of 52.05% than the Yer-
sinia background level of 47.6%, while the unique regions of 
both plasmids showed a lower G+ C content. 
Sixty-two ORFs in Y. pestis C0-92 pFra had their closest 
homologue outside Y. pestis in predicted ORFs in pHCM2. For 
a further four predicted ORFs in pHCM2, homologues in the 
region of Y. pestis KIMS pMTl were absent in C0-92 (Fig. 1). 
The DNA sequences sharing significant homology between 
pFra and pHCM2 included those encoding the repA gene (42) 
and the surrounding iteron-based replication control system in 
the ori region (Fig. 3). pFra encodes a parABS-like system 
(ORFs 1.68c and 1.67c) (Fig. 3) resembling that of bacteria-
phages Pl and P7 (42) which is functional in Escherichia coli 
(78), but this region is absent in pHCM2. The partial repeats of 
fragments of the S. enterica serovar Typhimurium parAE loci 
previously noted ( 42) adjacent to the murine toxin gene in Y. 
pestis KIMS pMT1 and the adjacent resolvase homologue were 
present in C0-92 (ORF 1.70) but not in pHCM2. Neither 
pFra/pMTl nor pHCM2 had an obvious set of transfer or 
mobilization genes. 
There is only one significant segment of low G+C compo-
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TABLE 2. Overall sequence features of pFra, pMTl , and pHCM2 
Chromosomal G+ C (%) 
Plasmid size (bp) 
Plasmid G + C (%) 
Pan~ meters 
Proportion of plasmid with cross-species similarity(%) 
G +C content of plasmid regions with cross-species similarity(%) 









Value for plasmid or specific host" 
Y.pemt .'i. tnurica scrovar 




59.6 526 (pFra) 
56.2 (pMT1) 
51.9 51.9 
47.8 49.1 non-pFra 
48.9 non-pMTl 
Number of Chi and Chi complement sites on one plasmid sequence strand 
Expected" Chi frequency (in same length sequence of random base order) 
Probability" (rank) of random Chi occurrence in plasmid based on 
19 
296 
< 10-JII (1) 
20 32 
3.06 3.36 
< 10- 44 (1) <10-116 (1) 
dinucleotide frequency 
• Unless otbcnrilc apcci1icd. nucleotide scquena:s as listed in Materials and Methods. 
"GcnBank aca:ssion no. ARlS3947. 
< Calculated from the base composition of the sequence ( 41 ). 
J Determined using R"MES software for a word length of 11, Le., ranking 65,536 posstble difercnt octanucle01idcs (23). 
sition in the regions common to pFra/pMT1 and pHCM2 This 
is adjacent to an IS200-like sequence, IS1541, in pFra (Fig. 3) 
and contains the pFra ORF 1.34 with no significant similarity 
on BlAST searching other than in pHCM2. The blocks of 
sequence similarity between pFra and pHCM2 occur in the 
same order in both plasmids. Most of the sequence present in 
Y. pestis KIM5 but not in Y. pt!Siis C0-92 is present in pHCM2, 
and there are no inversions of any homologous sequence in 
pHCM2 compared with Y. pestis KIMS, while there is one such 
inversion in C0-92, reflecting the 37-kb inversion compared 
with KIMS (Fig. 3). 
Repeated elements. The three insertion elements encoded 
by pFra (Two ISIOO copies and a single IS1541) were outside 
the regions of sequence similarity with pHCM2 (Fig. 3). No 
insertion elements were apparent in the pHCM2 sequence. 
The E. coli Chi site GCfGGTGG and the complement CCA 
CCAGC occur 19 times in pFra (Table 2) and are restricted to 
the regions also found in pHCM2 (Fig. 3). This sequence is not 
found in the other two Y. pestis plasmids. The R'MES program 
(23) showed it to be the most overrepresented of the 65,536 
possible octanucleotides in pFra, pMTl, and pHCM2 (Table 
2), based on the dinucleotide composition of each plasmid. A 
novel 57-bp imperfect repeat is present upstream of three 
unidentified ORFs in both pHCM2 and pFra (data not shown). 
Another five copies of this repeat are present between uniden-
tified ORFs in pHCM2. These repeat sequences were not 
found elsewhere in the Y. pestis or S. en/erica serovar Typhi 
genome sequence and were not deposited in GenBank. They 
do not show the palindromic symmetry typical of integrons or 
super integrons (62). 
DISCUSSION 
Y. pestis biovar-associated plasmid di~erences. The most 
obvious differences between the Y. pestis C0-92 and KIM5 
plasmid sequences were those related to recombination be-
tween ISIOO elements or ISIOO transposition. No IS-related 
transposition differences were apparent in C0-92 pPst com-
pared with KIM pPCP1 despite the presence of an IS/00 se-
quence, possibly due to the limited number of potential inser-
tion sites in this small plasmid. A 24-kb inversion between two 
ISIOO copies in pMTl was previously noted on comparison of 
two sequences of the same strain of Y. pestis KIM5 (37, 42). 
From the loss of direct repeats flanking ISJOO in one of these 
sequences, this inversion can be attnbuted to ISIOO recombi-
nation, presumably during 30 years of laboratory storage (8) or 
during the E. coli subcloning of Y. pestis plasmids that was 
carried out to obtain the KIM plasmid sequences (37, 42). 
Laboratory strains of bacteria that are stored for many years 
are particularly subject to IS-related rearrangements ( 48). In 
contrast, Y. pestis C0-92 is a recent clinical isolate (1992) (21) 
with fewer laboratory passages, and the genomic shotgun 
method employed in this study did not require subcloning of 
the entire pFra plasmid, reducing the scope for in vitro rear-
rangement that could influence sequence results. 
The deletions we have detected adjacent to one of the ISIOO 
elements in Y. pestis C0-92 pFra compared to KIM pMTl 
(Fig. 1) are demonstrable in other Y. pestis bv. Orientalis 
strains but not in those of Y. pestis bv. Antiqua or Medievalis 
(Fig. 2). Consistent biovar-specific deletions are unlikely to be 
in vitro phenomena. These deletions are largely responsible for 
the 4.8-kb difference in size between Y. pestis C0-92 pFra and 
KIM5 pMTl. It is well recognized that pFra differs in size in 
strains of different origins (24). In particular, the pFra of two 
Y pestis bv. Orientalis strains has previously been noted on 
restriction mapping to be 3 kb smaller than the pFra of two Y. 
pestis bv. Antiqua strains (57). However, not only is this se-
quence present in Y. pestis bv. Medievalis and Antiqua strains, 
but most of it forms part of the pFra plasmid-related sequence 
which is encoded by the S. en/erica serovar Typhi plasmid. This 
suggests that the interbiovar difference is indeed due to a 
unique deletion in Y. pestis bv. Orientalis pFra strains rather 
than an insertion in Y pestis bv. Medievalis and Antiqua 
strains. This is consistent with a reported Orientalis-specific 
chromosomal point mutation (11) and supports phylogenetic 
analysis based on restriction patterns on chromosomal hybrid-
ization with IS/00, which suggested that this biovar had arisen 
after the other two (1). The definition of these deleted seg-
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FIG. 3. Comparison of theY. pestis C0-92 pFra plasmid (A) with Y. pestis KIMS pMTl (GenBank accession no. AFOS3947) (B) and S. enJericu 
serovar Typhi Cf18 pHCM2 (C). Numbers on the horizontal scales are base pairs. Numbers on the vertical scale correspond to the plasmid GC 
percentage determined on a 200-bp wind<7N shown graphically along the top of each panel. The three numbers shown in each panel correspond 
to the mean percent GC for the whole plasmid and regional maxima and minima. Each panel contains the same features in the following order 
below the GC percentage graph. (i) Selected ORFs are shown as labeled blocks. Those transcribed to the right are shown above those transcribed 
to the left ORF block shades are coded as follows: black, insertion sequence or phage related; dark gray, plasmid or DNA replication; light gray, 
non-DNA metabolism; white, virulence related. ORF abbreviations: DNA pol, DNA polymerase DI alpha subuoit; int, phage integrase; caflR, F1 
capsular operon and regulatory genes; ymt, murine toxin. (ii) Arrowheads corresponding to the location of E. coli au sequences are shown. Those 
pointing to the right are 5 '-GCTGGTGG-3', and those to the left are 5'-CCACCAGC-3'. (ill) Qear blocks in panels A and B correspond to 
regions of theY. pestis plasmid sequence with sequence identity to S. entericu serovar Typhi pHCM2. The grey shading between the clear blocks 
corresponds to regions of theY. pestis plasmids with no sequence identity to pHCM2. In panel C, the clear blocks represent regions of S. enJericu 
serovar Typhi pHCM2 with sigoi6cant sequence identity toY. pestis (pFra and pMTl). The dark gray blocks represent regions with no sequence 
identity with Y. pestis pFralpMTl. This figure is based on Artemis (63) views of individual annotated plasmid sequences arranged in a composite 
image using Adobe Photoshop. 
ments offers the first plasmid-based test for Y. pestis biovar 
differentiation by molecular means. 
Horizontal DNA transfer between YersiniD and other Entero-
btu:Urioceae. Salmonella species are clearly distinct from Yer-
sinia species in 16S rRNA (15, 72) and other sequenced loci 
( 46). Therefore, the presence of such a high degree of se-
quence identity on a potentially mobile element implies recent 
horizontal genetic exchange. There is some evidence of chro-
mosomal DNA exchange between S. enJerica serovar Typhi-
murium and Yersinia species other than Y. pestis. Intervening 
sequences of 100 bp in the rrl genes (23S rRNA genes) of 
highly pathogenic Yersinia enJeroco/itica strains are more 
closely related to sequences inS. enJerica serovar Typhimurium 
than those of other Yersinia strains (68). This intervening se-
quence is not present in Y. pestis (68) or S. enJerica serovar 
Typhi (44). 
Short regions of similarity in nonstructural genes have been 
reported between the virulence-associated plasmids of S. en-
terica serovar Dublin and Y. pseudotuberculosis (40). Numerous 
short stretches of pMT1 (maximum length, 1,150 bp) over a 
30-kb region have been previously noted to show high levels of 
DNA similarity with other plasmid and DNA sequences (42). 
The ISJOO and IS285 insertion sequences found on Y. pestis 
plasmids and in particular pFra are present in the enteropatho-
genic E. coli adherence factor plasmid (74 ). IS285 incorporates 
a 117-bp region with more than 76% identity to the gene 
encoding the 38-amino-acid enteroaggregative E. coli heat-
stable enterotoxin 1 {EASTl) which is found in a variety of 
diarrhea-associated E. coli strains (76). The 225-amino-acid 
ORF pMT1.64c is 89% identical to a 227-arnino-acid ORF 
from the virulence plasmid of E. coli 0157:H7 (12). 
The region of pFra/pMTl forming a mosaic of DNA iden-
tities and insertion sequences is also the region that encodes 
the known Y. pestis virulence-associated factors (capsule and 
the murine toxin). Interestingly, these genes have already been 
noted to be composed of a lower GC percentage than the 
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remainder of the plasmid ( 42) and the Y. pestis host. Strikingly, 
similarity to the pHCM2 plasmid is almost absent from this 
region, apart from the ISJOO-Oanking sequence not present in 
Y. pestis bv. Orientalis strains. 
The overrepresentation of the canonical E. coli Chi se-
quence seen on pHCM2 and the corresponding regions of 
pFra has not previously been reported for naturally occurring 
plasmids. R'MES analysis of the 23 complete plasmid se-
quences from Enterobacteriaceae represented on the Entrez 
Genomes database (http://www.ncbi.nlm.nih.gov:80/PMGifs/ 
Genomes/eub_p.html) revealed only one further plasmid with 
a similar degree of Chi overrepresentation: S. en/erica serovar 
Typhi plasmid pR27 (66) contains Chi as the 4th most'over-
represented octanucleotide. This plasmid shows extensive se-
quence similarity to pHCM1, the other plasmid present in S. 
entmca serovar Typhi CT18 (http://www.sanger.ac.uk/Projects/ 
S_typhi) in which Chi is the 5th most overrepresented oc-
tanucleotide. The contrasting complete absence of Chi se-
quences in the other two Y. pestis plasmids and the virulence-
associated regions of pFra is intriguing. In E. coli, Chi 
sequences regulate the different functions of the RecBCD 
complex (exonuclease-recombinase) in repairing double-
stranded breaks in host DNA and destroying foreign DNA 
cleaved by host endonucleases (71, 73). Different sequences 
may fulfill the function of Chi sequences in different bacterial 
hosts (71 ), and the presence of a specific Chi sequence in 
plasmid genes may be a signature of origin from a specific 
bacterial genome. Phylogenetic analysis suggests that multiple 
horizontal transfers of chromosomal bacterial genes to plas-
mids commonly occur ( 47), and these genes would necessarily 
include the respective specific bacterial Chi sequence, because 
Chi sequences tend to be in coding DNA (41). RecBCD-
induced recombination due to Chi sequences may promote the 
survival of horizontally transferred DNA between closely re-
lated bacteria (32). It has been suggested that Chi sequences 
overlapping the start codons of plasmid replication proteins 
may promote recombination in replicon evolution (49). None 
of the Chi sequences identified in pFra or pHCM2 overlap 
start codons in this way. Related Enterobacteriaceae may use 
the same Chi sequence; e.g., S. enterica serovar Typhimurium 
has RecBCD-Iike enzymes active at E. coli Chi sites ( 45). 
Specific Chi sequence activity in Yersinia species and S. enterica 
serovar Typhi remains to be determined. 
pFra is known to integrate into the Y. pestis chromosome 
(58), and the plasmid regions shared with pHCM2 contain Chi 
sequences and apparent metabolic genes (cobS and cobT) not 
found on plasmids in other organisms. Another recently de-
scribed Y. pestis plasmid containing ORFs highly homologous 
to E. coli chromosomal genes (22) does not contain Chi se-
quences. The pia gene on pPst encodes a serine protease whose 
amino acid sequence is 70% identical (69) to those of products 
of chromosomal genes from E. coli and S. enlerica serovar 
Typhimurium. 
Homologous recombination between identical sequence on 
the plasmid and the chromosome (e.g., copies of ISJOO) is the 
suggested mechanism for the observed phenomenon of chro-
mosomal integration of pFra (58). Other site-specific integra-
tion processes may have been functional in the acquisition of 
chromosomal genes by pFra and pHCM2. A predicted aspar-
agine tRNA gene is present in the pHCM2-specific region at 
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one boundary of the sequence common to both plasmids (Fig. 
3) upstream of an integrase gene. tRNA genes are known to be 
integration sites of pathogenicity islands in the bacterial chro-
mosome (30), and the Yersinia high-pathogenicity island is 
apparently inserted into an asparagine tRNA (10). There are 
no direct repeats of portions of the tRNA gene elsewhere in 
pHCM2 to suggest a currently excisable pathogenicity island. 
The integrase, cobS, and cobT genes are also present in pFra 
with no obvious interrupted genes at the boundaries of shared 
sequence in either plasmid. 
Mechanism of transfer. A transferable plasmid, piPI202, 
conferring multiple drug resistances has recently been found in 
a clinical Y. pestis isolate (27). This 150-kb plasmid has an 
Inc6-C origin of replication (unlike pFra and pHCM2). Al-
though there are no obvious mobilization genes on the pFra/ 
pMT1 plasmid, cointegration (19) with another conjugative 
plasmid (27) or an ori-T-independent method of transfer, such 
as that mediated by the Constin element SXT from Vibrio 
cholerae (36), remain possibilities. The presence of endoge-
nous transducing phages in Y. pestis has not been demonstrated 
(55), but phage genes are represented on the common regions 
of pFra and pHCM2 Both Y. pestis and S. enlerica serovar 
Typhi are among the seven species not known to be naturally 
competent which contain homologues of the HP0333 gene 
involved in natural transformation in Helicobacter pylori (3). 
They may have been naturally competent in the past or require 
specific conditions to show this property. Recently it has been 
shown that genes on another nonconjugative plasmid (E. coli 
p0157) may be transferred from E. coli to other enteric bac-
teria via membrane vesicles (77). This has not been shown for 
SalmoneUa or Yersinia species. 
Whatever the mode or direction of transfer, extensive re-
combination with chromosomal or other plasmid DNA has 
occurred in at least one of the new hosts after the transfer 
event to achieve the sharp delineations observed between plas-
mid regions common to both replicons and those unique to 
each plasmid (Fig. 3). Of the two plasmids, pFra shows more 
mosaicism, evidenced by variability in G+C composition and 
Chi sequence distribution, suggesting that it has recombined 
more than pHCM2, probably due to the presence of multiple 
insertion sequences. This implies that pFra originally resem-
bled pHCM2 even more closely than it does now. The G+C 
composition of the regions common to both plasmids is much 
closer to the S. en/erica serovar Typhi chromosomal back-
ground than that of Y. pestis, and insertion sequences present 
in pFra are found elsewhere in Y. pestis and not in pHCM2 or 
the S. enlerica serovar Typhi chromosome, suggesting that any 
direct transfer was from S. enterica serovar Typhi to Y. pestis or 
Y. pseudotuberculosis and not in the other direction. Experi-
ments are planned to search for conjugative plasmids related 
to pFra and pHCM2 in other S. typhi strains. The source for 
the virulence-related and lifestyle-specific genes on the unique 
portions of Y. pestis pFra remains obscure, but the G + C con-
tent and other sequence features (lack of Chi sequences) sug-
gest an origin outside Enterobacteriaceae. 
Date of plasmid transfer. The opportunities for direct con-
tact between S. en/erica serovar Typhi and Y. pestis are limited. 
Host adaptation limits typhoid fever to humans and a few 
higher primates (39). Although Y. pestis is invasive for epithe-
lial cells in vitro (17) and by the oral route in animal models 
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{14), it does not colonize the gut {14) and has a restricted 
capacity for survival in the environment (55). This would con-
fine contact between the two organisms to a dually infected 
human host or the gut of a flea vector which had fed on 
multiple hosts. Y. pseudotuberculosis however, is, a gastrointes-
tinal pathogen with a wide host range likely to bring it into 
contact with Salmonella species in the environment or verte-
brate gut. Like Y. pestis, S. en/erica serovar Typhi is homoge-
nous in population genetic analysis (65), forming only two 
clones. However, unlike the Y. pestis relationship with Y. 
pseudotuberculosis, phylogenetic analysis does not place it as a 
typical subclone of another S. en/erica serovar (7, 65)-there 
are distinct serovar Typhi-specific polymorphisrns not faUing 
within the allelic variation seen within other currently identi-
fiable Salmonella serovars. The very recent origin proposed for 
theY. pestis clone {1,500 to 20,000 years ago) {1) is not there-
fore applicable to S. enterica serovar Typhi, and it is likely to 
have been in existence before Y. pestis. 
The presence of most of the pFra biovar-specific deletion in 
the cryptic S. en/erica serovar Typhi plasmid pHCM2 suggests 
that horizontal transfer of the plasmid occurred before emer-
gence of the Orientalis biovar or involved a non-Orientalis 
biovar, which would be unusual in Vietnam. Plague arrived in 
Vietnam during the third pandemic in 1898, and most current 
isolates reported are Y. pestis bv. Orientalis, although some Y. 
pestis bv. Medievalis strains have been reported from the High-
Plateaux {T. Mai, A Guiyoule, D. Vinh, D. Tuyet, D. Thung, 
and E. Carniel, Ned. Tidjschr. Med. Microbial. 6, Suppl. II, 
Abstr. P-70, 1998). The simplest route for direct plasmid trans-
fer would be between an ancestral Y. pseudotuberculosis strain 
that gave rise to Y. pestis and an S. enterica serovar Typhi strain. 
The degree of identity retained by the plasmids is compatible 
with the hypothesis {1) that pFra plasmid acquisition and Y. 
pestis emergence could have been as recent as 2,000 years ago. 
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Abstract 
Burkholderia pseudomaflei. the causative agent of the 
disease melioidosis, is widely distributed throughout the 
tropical countries of the world. This Gram-negative bacillus 
lives freely in soil and water and usually enters susceptible 
hosts via cuts and abrasions. Melioidosis affects both 
animals and humans, has a diverse range of symptoms 
and in the acute septicaemic form can be fatal. In endemic 
areas such as Thailand, B. pseudomalleiinfection is a major 
cause of hospitalisation and the popularity of world-wide 
travel has led to increased numbers of cases being reported 
in non-endemic areas such as Europe and North America. 
Introduction 
Burkholderia pseudomallei, formerly Pseudomonas 
pseudomallei, is a Gram-negative, motile, non spore-
forming bacillus, 0.4 - 0.6 mm in width and 2 - 5 mm in 
length. The bacteria exhibit a characteristic bipolar staining 
and are seen singly, in pairs or very occasionally in chains 
( 1 ). The organism grows aerobically in many simple media 
and will grow under strictly anaerobic conditions in a 
complex medium containing nitrate. The range of organic 
compounds which may be used as sole sources of carbon 
and energy is exceptionally wide, making B. pseudomallei 
one of the most nutritionally versatile members of the 
genus, Burkho/deria. The form and colour of growth on 
solid media is highly variable and colonies can range in 
structure from rough to mucoid and in colour from cream 
to bright orange (2). No colonial type appears particularly 
associated with virulence (3), however it has been 
suggested that virulence may be dependent on the 
presence of the capsular antigen {4,5). B. pseudoma/lei 
has been shown to secrete an abundant slime layer made 
up of polysaccharides. This layer has been termed the 
"glycocalyx" and it is thought that bacterial cells may live 
and divide within it , protected from unfavourable 
environmental factors (6). This capsule has also been 
demonstrated in vivo (7). 
B. pseudomallei is a free-living organism that causes the 
potentially fatal disease melioidosis. Cases of melioidosis 
are considered rare in the Western world (8) but in the 
1960's, a large number of cases were reported in soldiers 
who became ill after returning home from the Vietnam War 
(9,1 0). With improvements in diagnostic techniques the 
number of reported cases in developing countries is 
increasing ( 11 ). The number of reported cases in travellers 
to equatorial regions has also increased (12-14}. 
Transmission 
In endemic areas (Figure 1 ), B. pseudomalfei infection 
usually occurs as a consequence of soli and water 
17~ 
contamination of skin abrasions in endemic areas. 
Ingestion, nasal instillation and inhalation are other possible 
routes of infection (3,15). Human to human transmission 
has only been reported once. This case involved a patient's 
wife who had raised haemagglutination titres to B. 
pseudomalleithat indicated recent infection. The woman's 
infection was most likely the result of sexual contact as 
she had no apparent contact with a source of B. 
pseudomallei other than the patient (16}. 
Arthropod-borne infection does not occur naturally but 
experimentally the disease can be transmitted by the rat 
flea (Xenopsylla cheopsis) and by the mosquito (Aedes 
aegypt1) ( 17). There are several reported cases of 
laboratory acquired infection. One occurred after sonication 
of supposed B. cepacia isolates (18). This suggests that 
aerosols of the organisms are infectious to humans, 
although the infective dose is unknown. 
Disease 
B. pseudomafleicauses disease in humans and in a variety 
of animals {Table 1) including dolphins, sheep, pigs and 
goats (27-29). An outbreak of the disease at a Paris zoo 
in the mid 1970's caused the death or slaughter of a number 
of animals and two fatal human cases (30). In humans, 
the incubation period is normally 2-3 days, but there are 
reports of the disease developing 6-26 years after exposure 
( 11 ). 
The clinical spectrum of melioidosis is extremely diverse, 
consisting of four forms of disease : acute fulminant 
septicaemia, sub-acute illness, chronic infection and sub-
clinical disease. The disease may be localised or 
disseminated and virtually any organ may be affected. 
Depending on whether the disease is acute or chronic, 
melioidosis can mimic other bacterial infections including 
typhoid, malaria , tuberculosis and septicaemia from other 
common bacterial organisms (19,20). 
The importance of early diagnosis and treatment has been 
stressed in the management of acute, septicaemic 
melioidosis. However, symptoms are so varied and the 
demise of the patient so rapid that unless a clinician is 
alert to the possibility of a B. pseudomallei infection, the 
disease may be wrongly diagnosed (11 ). The acute 
septicaemic form is usually associated with an underlying 
disease or condition such as diabetes, alcoholism or 
immunodeficiniecy and despite current antibiotic regimes 
still carries a high mortality rate (50-75%) (21}. 
Tissue lesions apparent during the progression ol 
melioidosis have been shown to contain large numbers of 
The Infectious Disease Review - for the medical, veterinary & environmental professions Vol I No 3 
Figure 1: World map showing areas endemic for B. pseudomallei 
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infiltrating cells, mainly macrophages many of which 
contained phagocytosed bacilli (22). Most of the bacillary 
cells were surrounded by an electron dense substance and 
had a clear halo between the substance and the cell wall 
(23). Following uptake, ingested B. pseudoma/lei escape 
from the vacuoles, possibly as a result of bacterium-
mediated vacuolar membrane damage (24). 
Each clinical case of melioidosis may represent the 
outcome of one of three possible processes: primary 
infection, re-infection or re-activation of latent disease. 
Primary infection appears almost inevitable in children in 
north-east Thailand where approximately 80% of the 
population have developed antibodies to B. pseudomallei 
by the age of 4 years. Nearly all these infections appear to 
be asymptomatic or sub-clinical. In most cases, adult 
melioidosis must result from re-infection or re-activation of 
latent infections (25). Serological studies in Malaysia also 
found a high incidence of antibodies to B. pseudomallei, 
presumably due to mild, unrecognised or inapparent 
infections (26). 
Pathogenesis. 
The pathogenesis of melioidosis is poorly understood, and 
although several putative virulence determinants have been 
identified they are poorly characterised. B. pseudomallei 
is reported to produce several toxic factors. Culture filtrates 
were found to contain both toxic and proteolytic activity 
and a heat stable molecule with classical endotoxin activity 
(31 ,32). Further characterisation showed the presence of 
a heat-labile exotoxin (33) which is thought to suppress 
cellular immune functions (34). 
Putative extracellular virulence determinants include the 
thermolabile toxin and a 36KDa protease (35) . 
Metalloproteases have been identified in many bacterial 
species and are thought to play a role in disease 
pathogenesis (36). Cell-associated virulence determinants 
include pili and the extracellular polysaccharide (37). The 
flagellae of B. pseudomallei have been considered to be a 
potential virulence determinant. However, non-motile 
mutants are reported to be fully virulent in the diabetic rat 
model of disease (38). Lipopolysaccharide (endotoxin) has 
also been considered in the pathogenesis of the disease, 
however its toxicity is reported to be low (39). B. 
pseudomallei has been shown to be resistant to the 
bactericidal activity of normal human serum. 11 has been 
suggested that resistance to serum bactericidal killing is 
an important viru lence determinant in Gram-negative 
bacteria (40). The production of haemolysin appears to be 
linked to bacterial cell density; well isolated colonies of B. 
pseudomallei appear to be non haemolytic, however 
smaller colonies which are at a higher density are 
haemolytic (41, 42). 
Survival in the environment. 
B. pseudomallei is a free-living bacterium in the soil and 
water of the tropics from 20°N to 20°S of the equator (Figure 
1 ), and is found especially in Africa. the Indian subcontinent, 
Iran, Northern Australia and Central and South America. 
Sporadic reports have indicated the presence of B. 
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pseudomalleiin Hong Kong, Hawaii, Fiji, Haiti, Puerto Rico, 
France and North America (28,43). The disease is an 
important cause of human morbidity and mortality in 
northern Thailand and this may be true throughout south-
east Asia (44). In Australia, melioidosis causes a smaller 
number of human infections but among livestock the 
disease has important economic and public health 
implications (45). 
The ease with which B. pseudoma/leican be isolated from 
the environment is markedly influenced by the conditions; 
reasonably high temperatures, increased humidity and 
consistent rainfall allows for the accumulation of stagnant 
pools and muddy water courses, thus increasing isolation 
rates of B. pseudomallei (46,47). Bacteria and water are 
thought to be electrostatically attracted to clay particles 
which then retain some of the moisture that would normally 
descend into the water table. During the rainy season the 
water table rises to the surface, carrying with it bacteria 
which then multiply in the favourable conditions (Figure 2). 
lt is possible that in this way the organism is well adapted 
to survive in areas experiencing a long, dry season (48,49). 
A more recent study has shown that B. pseudomallei has 
survived in the environment in temperate south-west 
Western Australia causing disease over a 25 year period 
(29). 
B. pseudomallei in Australian soil survived for up to 30 
months in samples stored in their original collecting bags 
on a shaded shelf in the laboratory at ambient temperature 
(50). In laboratory tests, bacteria maintained in soil samples 
with more than 40% water were still viable after 726 days 
(51) and the organism has been reported to survive in tap 
water for 44 days (49). 
Different biotypes. 
Previous reports in the literature suggest that certain B. 
pseudomallei isolates are avirulent for animals (52) and it 
has been shown that the avirulent strains differ from the 
virulent strains in their ability to assimilate L-arabinose 
(53,54). The lipopolysaccharide of virulent and avirulent 
strains of B. pseudomalleiis antigenically indistinguishable 
(55). However, monoclonal antibodies have been reported 
which bind only to a high molecular weight component 
present only on the surface of B. pseudomallei strains which 
were unable to assimilate L-arabinose (Ara·) (56). The 
identity of these cell surface antigens awaits investigation. 
Differences have also been found in the 16s rRNA gene 
sequences from virulent and avirulent strains and it has 
been suggested that the group of avirulent strains may 
consti tute a new species. B. thailandensis (57). 
Detection and diagnosis. 
Several methods have been developed for the recovery of 
B. pseudomalleifrom soil and water samples including the 
inoculation of animals (58) and the use of various types of 
selective culture media (59-64). 1t has been suggested 
that B. pseudoma/lei can survive nutrient starvation by 
forming vtable but non-culturable cells which would aid its 
long term survival in the environment (65). 
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Table 1. Infection with B. pseudomal/ei 
Animal species Reporting Country 
Sheep, goats and pigs 
Dolphins 






Britain (imported from the Philippines) 
Indonesia 
Pig Madagascar 
Goats and pigs 
Horses and mules 
Horses 





Table 2: Reported antibiotic sensitivities of B. pseudomal/ei (11, 44) 







ofloxacin 8.0- 12.5 
chloramphenicol 16.0-25.0 
kanamycin 32.0-50.0 
nalidixic acid 50.0 
amikacin 64.0- 100.0 
Microbiological detection kits such as the Microbact 24E, 
API 20NE and the Minitek system have been used for the 
routine identification of B. pseudomallei isolates (66-68). 
A latex agglutination test has been developed using 
polyclonal rabbit serum, which when evaluated was 1 00% 
sensitive and specific for the identification of B . 
pseudomallei, a second test has been developed using a 
monoclonal antibody which detected 74 different B. 
pseudomalleistrains (69,70). Cultures of B. pseudomaflei 
have, in the past. been routinely "sniffed" to detect the 
characteristic earthy odour, however, in 1992 a 
recommendation was made to prohibit this test to reduce 
the risk of laboratory acquired !nfection (71 ). 
Serum specimens can be screened by indirect 
haemagglutination (IHA) test. The IHA test is sensitive. 
with false positives occurring infrequently, however sera 
from culture-positive patients were sometimes non-reacti\(e 
in the IHA suggesting that false negative reactions may 
occur in culture-negative patients with sub-clinical 
melioidosis (72). Indirect fluorescence assays have been 
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Antibiotic MICgo (j.Lg/ml) 
ceftazidime 0.4 - 8.0 
piperacillin 1.0- 1.6 
amoxicillin- 1.0 - 8.0 
clavulanic acid 
doxycycline 4.0 
cefotaxime 6.5- 16.0 
cefoperazone 12.5 





developed for specific lgG and lgM antibodies (lgG-IFA 
and lgM-IFA). Sub-clinical melioidosis can be distinguished 
from active infection with the lgM-IFA. High titres of lgM-
IFA antibody with appropriate signs and symptoms are 
indicative of clinical melioidosis (73). Direct 
immunofluorescence has also been used and is reported 
to be both sensitive and specific. This technique is believed 
to give a confident diagnosis of melioidosis within two hours 
of admission to hospital providing appropriate samples are 
available (74). Enzyme linked immunosorbent assay 
(ELISA) based methods have been developed to detect 
antibodies to B. pseudomalfei in underlying sub-clinical 
infections (75-77). 
DNA probes have been developed for the rapid and specific 
identification of B. pseudomallei. Sermswan et a/ 
developed a specific DNA probe for B. pseudomaflei(based 
on the sequence of 1.5Kb chromosomal DNA) which in 
Southern blot hybridisation could detect 1.5 ng of genomic 
DNA (78). Oligonucleotide probes have also been 
·developed for use in the polymerase chain reaction (PCR) 
The Infectious Disease R.:vi.:w- for the medical. veterinary & environmental poofcssoons Vol I No 3 
for the amplification of specific DNA sequences. These 
probes have been based on the 23S rRNA gene sequence, 
16S rRNA gene sequence or chromosomal DNA 
sequences. PCR-based reactions have ranged in 
delectability from trace amounts of DNA to 1 o• cells and 
have been used to detect B. pseudomalle1 in both clinical 
and soil samples (64,79-82). Trials carried out in Australia 
found the PCR assays to be useful in identifying B. 
pseudomallei in environmental samples, however, there 
were a number of false positives in clinical samples and 
because of this PCR is not used in the routine diagnosis of 
B. pseudomallei infection (83). 
Treatment. 
No vaccine currently exists for B. pseudoma/lei. Avirulent 
strains of B. pseudomallei have been used to vaccinate 
animals prior to respiratory challenge with variable results 
(52,84). More recently both the lipopolysaccharide and 
the flagellin proteins of B. pseudomallei have been identified 
as possible candidates for use as protective immunogens 
(37,85). lt has been reported that an acellular vaccine has 
been used successfully in captive marine mammals to 
protect against B. pseudomallei infection. The vaccine 
contains protein and polysaccharide (1 :3), induces high 
levels of specific antibodies and has significantly reduced 
mortality (27). 
Early positive laboratory diagnosis and early appropriate 
chemotherapy (Table 2) are essential for the successful 
management of melioidosis. If these prerequisites are met 
then the prognosis of this disease is good and fatalities 
are limited to those patients who present with an 
overwhelming, fulminating septicaemia which cannot be 
controlled with current medical treatments (86). 
In Thailand, where melioidosis is an endemic disease, the 
conventional treatment regimen for B. pseudoma/lei 
infections was a combination of chloramphenicol, 
doxycycline and cotrimoxazole (87). The fluoroquinolone 
antibiotics were found to be inappropriate for the treatment 
of melioidosis (88). Trials carried out in the 1980s 
recommended ceftazidime as the antibiotic of choice to 
replace the use of high doses of chloramphenicol , 
doxycycline, trimethoprim sulphamethoxazole and 
sometimes kanamycin (89,90). Ceftazidime, widely used 
as a single drug treatment against P. aeruginosa 
septicaemia, is safe, well tolerated and highly active against 
B. pseudomallei in vitro and its use in the treatment of 
melioidosis has halved the mortality of severe cases (91 ). 
The case fatality rate is still high (" 40%) with an increasing 
number of reports of resistance to currently used drug 
treatments (92,93). In this respect, studies indicate that 
the newer carbapenem antibiotics may be useful (94). 
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In Vitro Susceptibilities of Burkholderia mallei in Comparison 
to Those of Other Pathogenic Burkholderia spp. 
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The in vitro antimicrobial susceptibilities of isolates of Burkholderia mallei to 16 antibiotics were assessed 
and compared with the susceptibilities of Burkholderia pseudomallei and Burkholderia cepacill. The antibiotic 
susceptibility profile of B. mallei resembled that of B. pseudomallei more closely than that of B. cepacia, which 
corresponds to their similarities in terms of biochemistry, antigenicity, and pathogenicity. Ceftazidime, imi· 
penem, doxycycline, and ciproftoxacin were active against both B. mallei and B. pseudomallei. Gentamicin was 
active against B. mallei but not against B. pseudomallei. Antibiotics clinically proven to be effective in the 
treatment of melioidosis may therefore be effective for treating glanders. 
Burkholderia mallei is the causative agent of glanders, a rare 
disease of equines which can be transmitted to humans with 
fatal consequences. The incidence of the disease has declined 
worldwide, and it has disappeared in the Western world as the 
use of equines for work and transport has declined; neverthe-
less, cases do still occur in Asia, Africa, South America, and 
Central America (19, 21). As a consequence of its declining 
incidence, very little reference is made to the disease in mod-
ern microbiology texts, and data regarding antibiotic suscepti-
bility, particularly susceptibility to modern antibiotics, are lim-
ited, with most of the published work appearing in Russian 
literature (1 , 5, 6, 16, 18). The in vitro antibiotic susceptibilities 
of a number of strains of B. mallei were measured and com-
pared to those of two other medically important Burklwlderia 
species. Burkholderia pseudomallei is an opportunistic environ-
mental pathogen, inhabiting soil, stagnant water, and rice pad-
dies, that causes melioidosis, a major cause of human morbid-
ity and mortality in certain areas of the tropics (9, 15). B. 
pseudomallei and B. mallei are similar, in that they share mor-
phological, biochemical, and antigenic characteristics, and 
their disease manifestations are similar. Burkholderia cepacia is 
also an opportunistic environmental pathogen, and though it is 
virtually nonpathogenic in healthy patients, it causes respira-
tory infection in cystic fibrosis patients and occasionally noso-
comial infection in patients in intensive care units (14). 
All antibiotic powders used in this study were obtained from 
Sigma Chemical Co. (Poole, Dorset, United Kingdom), with 
the exception of ceftazidime (Giaxo, Uxbridge, Middlesex, 
United Kingdom), ciprofloxacin (Bayer UK, Newbury, United 
Kingdom), and azithromycin (Pfizer, Sandwich, Kent , United 
Kingdom). All antibio tics were prepared and stored in accor-
dance with National Committee for Clinical Laboratory Stan-
dards (NCCLS) guidelines (20). For imipenem, Primaxin 
(Merck Sharp & Dohme, Hoddesdon, Hertfordshire, United 
Kingdom), which contains both imipenem and cilastatin (1: 1, 
wt/wt), was used. For amoxicillin-clavulanic acid, Augmentin 
tablets (Beecham Research, Welwyn Garden City, Hertford-
• Corresponding author. Mailing address: CBD Port on Down, Salis-
bury. Wilts SP4 OJQ, UniJed Kingdom. Phone: 00 44 1980 613438. Fax: 
00 44 1980 613097. 
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shire, United Kingdom) were crushed, dissolved in water, and 
then filtered. Although NCCLS guidelines indicate that par-
enteral preparations should not be used for susceptibility test-
ing, the Augmentin tablets and Primaxin powder were used 
because they were available in-house at the time of the study. 
As this work had no implications for patients per se, and with 
the susceptibilities of B. pseudomallei and B. cepacia to imi-
penem and amoxicillin-clavulanic acid previously reported (11, 
24), useful comparisons could be made. It was assumed that 
cilastatin alone had no activity against any of the test organ-
isms. Ten strains of B. mallei were obtained from the American 
Type Culture Collection (ATCC), and a further seven strains 
were a kind gift from C. Wray at Central Veterinary Labora-
tories, Weybridge, United Kingdom. Clinical and environmen-
tal strains of B. pseudomallei were obtained from the National 
Collection of Type Cultures and the London School of Hy-
giene and Tropical Medicine, and one strain was a kind gift 
from P. Maynard at Blackburn Royal Infirmary, Blackburn, 
United Kingdom. All B. cepacia strains came from the ATCC 
and the National Collection of Type Cultures. Strains were 
stored at -80°C either in glycerol or on Protect beads (TSC 
Ltd., Heywood, Lancashire, United Kingdom). Bacteria were 
recovered prior to the experiment by either placing the glycerol 
stock in Mueller-Hinton broth or placing five or six beads in 
Mueller-Hinton broth and then incubating the cultures stati-
cally at 37•c for 24 h ( 48 h for B. mallei). All procedures with 
B. mallei and B. pseudomallei were carried out within biosafety 
level 3 containment. 
A microtiter plate dilution method in accordance with NC-
CLS guidelines was used (20). Briefly, 96-well microtiter plates 
containing antibiotics ranging in concentration from 0.063 to 
64 mg!liter were prepared in advance and stored at -2o•c 
except for plates containing imipenem and ampicill in, which 
were freshly made on the day of the experiment. An inoculum 
of approximately 5 X 105 CFU/ml (determined by using Mc-
Farland standard 5) in I 00 J..LI was made from overnight or 48-h 
cultures in Mueller-Hinton broth and was added to all wells. 
Plates were incubated at 37°C for 18 to 20 h. Because of the 
organism's slow-growing nature, it was necessary to incubate B. 
mallei plates for 36 h before reading the MICs. 
Escherichia coli A TCC 25922 and Staphylococcus aureus 
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TABLE I . Compa ra livc MICs o f selected a ntibio tics fo r Burkholderia spp. 
MIC (fJ.g/ml) of antimicrobia l ngent for' : 
Antimicrobial agent 8. mallei B. pseudomallei B. cepacia 
Range 50% 90% Range 50% 90% Rnnge 50% 90'if. 
Ampicillin 1-> 64 > 64 > 64 32-> 64 64 > 64 0.125-> 64 > 64 >64 
Pipe racillin 4-16 8 16 2-4 4 4 1- > 64 8 >64 
Amoxicillin-clavulanic acid 1-8 4 8 4-8 8 8 0.25->64 > 64 >64 
Cefuroxime 8->64 > 64 >64 32->64 64 > 64 4-> 64 64 > 64 
Ccftazidime 2-16 4 8 2->64 2 > 64h 1-64 2 64 
Imipenem 0.125-0.25 0.25 0.25 0.5-1 0.5 1 1- 16 8 16 
Chloramphenicol 1-> 64 64 > 64 4-16 8 16 4-64 8 64 
Doxycycline 0.125-4 0.5 2 0.5-1 0.5 I 0.125-32 16 32 
Ofloxacin 0.5-S 2 8 1-S 4 8 0.25-8 2 8 
C iprofloxacin 0.25-S I 8 0.5-4 2 4 0.125-4 0.5 4 
Gentamicin 0.063-0.5 0.25 0.5 0.125-64 32 64 0.5->64 > 64 > 64 
Azithromycin 0.25-16 I 4 1->64 64 > 64 0.5-> 64 64 > 64 
Rifampin 1- 16 8 16 4-16 8 16 0.125-> 32 8 32 
Sulfame thoxazole 1->64 64 > 64 16->64 16 > 64 4->64 > 64 >64 
Trimethoprim 0.125-64 8 32 4-> 64 16 >64 0.125-64 1 > 64 
Co-trimoxazole 0.063->64 16 > 64 4-> 64 16 > 64 0.25->64 4 >64 
• 50% and 90%, MICs at which 50 and 90% of the isolates were inhibited, respectively. 
b One strain (a clinical isolate) was resistant. 
ATCC 29213 (National Collection of Industrial and Marine 
Bacteria, Aberdeen, Scotland) were used as quality control 
standards. All MICs were within the range specified in refer-
ence 2. 
The antibiotic susceptibility of B. mallei was similar to that of 
B. pseudomallei, with resistance to a number of antibiotics 
(Table 1). All strains of both organisms appeared to be sensi-
tive to imipenem and doxycycline, whi le most strains were 
susceptible to ceftazidime, ciproftoxacin, and piperacillin. B. 
mallei was additionally sensitive to gentamicin, and some 
strains were sensitive to azithromycin. Azithromycin, imi-
penem, ceftazidime, and gentamicin showed good bactericidal 
activity at concentrations close to their respective MICs. 
Although B. pseudomallei is also an environmental organ-
ism, it differs from B. cepacia in that it can cause disease in 
apparently healthy individuals (15). The organism does share a 
number of characteristics with B. mallei, including, it appears, 
antibiotic sensitivities. The in vitro MICs suggest that imi-
penem, doxycycline, ciproftoxacin, piperacillin, and ceftazi-
dime may be useful in the treatment of both melioidosis and 
glanders (Table 1). 
Clinical experience with melioidosis, however, has shown 
that despite good in vitro activity, an antibiotic may be inef-
fective, in particular, ftuoroquinolone therapy trials have been 
disappointing (7, 10). Additionally, the choice of antibiotic 
depends on the presentation of the disease. Doxycycline, for 
example, is used alone for localized infection (12) and in com-
bination with chloramphenicol for disseminated disease (8. 
21). Co-trimoxazole is also recommended, but resistance to it 
is now common (21) and was evidenced by some of the strains 
used in this study. Ceftazidime is the favored antibiotic for 
therapy of systemic disease (23), however, resistant strains are 
beginning to appear (11). A clinical isolate from a patient 
treated with ceftazidime was found to be resistant to the anti-
biotic (Table 1), although it is not clear whether resistance 
arose during treatment. Jmi penem was highly effective in vitro. 
which concurs with the findings of Smith et al. (22). who sug-
gest that carbapenem antibiotics may be suitable candidates 
for therapy. Piperacillin may also be a suitable future candi-
date, particularly as concentrations in serum exceeding lOO 
~g/ml can be achieved (13). 
The similarities between the two pathogens and their respec-
tive diseases suggest that the antibiotics that seem effective 
against melioidosis in vitro and are furthermore proven clini-
cally would be effective against glanders. Additionally, the low 
in vitro MICs of gentamicin and azithromycin indicate that 
these two antibiotics may also be suitable for use in the treat-
ment of glanders. These MICs must be interpreted carefully as 
B. pseudomallei is an intracellular pathogen (17) and B. mallei 
is likely to share its pathogenic mechanism. Although the MIC 
of gentamicin is low, the antibiotic does not penetrate intra-
cellularly. ln the case of azithromycin, the excellent intracel-
lular penetration by the antibiotic (cellular/extracellular ratio, 
> 7,000) (13) makes this a possible candidate antibiotic for 
treating glanders, and possibly melioidosis, even in cases 
caused by strains that require a high MIC of the antibiotic. The 
contrasting susceptibility of B. mallei and resistance of B. 
pseudomallei (with the exception of one strain) to gentamicin 
may in addition have some utility in a diagnostic test to distin-
guish between the two organisms. 
The similarities between B. mallei and B. pseudomallei ex-
tend to their in vitro antibiotic susceptibilities. Antibiotics use-
ful in the treatment of melioidosis may therefore be useful in 
treating glanders, although the dis{Jarity between in vitro sus-
ceptibili ty and clinical success in the treatment of melioidosis 
should also be considered for glanders. 
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Comparison of efficacy of ciproftoxacin and doxycycline against 
experimental melioidosis and glanders 
P. Russell*, S. M. Eley, J. Ellis, M. Green, D. L. Bell, D. J. Kenny and R. W. Titball 
CBD Porton Down, Salisbury, Wiltshire SP4 OJQ. UK 
Melioidosis and glanders are caused by the closely related species Burkho/deria pseudomallei 
and Burkholderia mallei, respectively. Whereas melioidosis is a significant cause of morbidity 
In south-east Asia, glanders is extremely rare. The efficacies of ciprofloxacin and doxycycline 
were assessed against a strain of B. pseudomallei and a strain of B. mallei which were suscep-
tible to both antimicrobials in vitro. Porton outbred mice and Syrian hamsters were given 
40 mg/kg of either doxycycline or clprofloxacln twice dally by se Injection according to one 
of three regimens: dosing starting 48 h before challenge and continuing for 5 days post-
challenge; 5 days' therapy starting Immediately after challenge; 5 days' therapy starting 24 h 
after challenge. Mice were challenged lp with B. pseudomallei 4845 and hamsters were chal-
lenged ip with B. mallei 23344. Antimicrobial efficacy was determined by the shift In the median 
lethal dose (MLD). Clprofloxacin prophylaxis and immediate therapy both raised the MLD of B. 
pseudomalleito 4 x 106 cfu from 19 cfu In untreated animals, but therapeutic clprofloxacln only 
raised the MLD to 180 cfu. The results for doxycycline were similar. Ciprofloxacln prophylaxis 
raised the MLD of B. mallei 23344 to 4.6 x 105 cfu compared with 4 cfu in untreated controls. 
Immediate therapy raised the MLD to 7.0 x 104 cfu and therapy raised the MLD to 1.6 x 103 cfu. 
All regimens of doxycycline protected hamsters against challenges of up to 2 x 107 cfu. Despite 
using a susceptible strain of B. pseudomallei, neither antimicrobial was effective when used 
therapeutically. The timely administration of either antimicrobial, however, was effective In pre-
venting symptomatic Infection. Doxycycline was the superior of the two antlmlcrobials against 
experimental glanders although relapse did occur In treated animals approximately 4-5 weeks 
after challenge. 
Introduction 
Melioidosis and glanders are caused by the closely related 
species Burkholderia pseudoma/lei and Burkholderia mallei. 
Whereas melioidosis is an important cause of mortality and 
morbidity in south-east Asia, northern Australia and the 
Indian sub-continent, glanders is extremely rare and is 
generally confined to equine disease in some parts of the 
Middle East. Asia and South America.u 
As a consequence, the antimicrobial susceptibilities of 
B. pseudoma/lei have been scrutinized·'-s and the anti-
microbial therapy of melioidosis is well established.5·6 The 
use of fluoroquinolones for treating melioidosis has gener-
ally been precluded because of high in vitro MICs for some 
strains of B. pseudomallei. which exceed levels that can 
be achieved in serum.45 Ciprofloxacin , either alone or in 
combination. has been used in the treatment of melioidosis 
despite this contra-indication 7·8 on the basis that cipro-
floxacin can penetrate phagocytic cells where B. pseudo-
mallei resides, to achieve concentrations 4-12 times the 
extracellular concentration.9·10 Thus, with serum levels of 
2-3 mg/L achievable by standard oral dosing, theoretically, 
intracellular concentrations of up to 20 mg/L should be 
attained. 11 Furthermore, serum levels of 9 mg/L can be 
achieved by iv infusion, albeit for short periods. 11 A second 
consideration is that, perhaps fluoroquinolones may be 
useful for immediate therapy or as prophylaxis for individ-
uals known to have been exposed, or at high risk of expo-
sure, to melioidosis, particularly as there is no current 
means of immunoprophylaxis. 
The scarcity of glanders in the latter half of this century 
means there is scanty knowledge of the antimicrobial 
susceptibility of B. mallei. particularly to modern anti-
microbials, with the few references in recent microbiology 
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literature principally from Russian sources. 12- 18 Likewise, 
the efficacy in vivo of modern antirnicrobials is not well 
known. Recent studies suggest that the susceptibility of 
B. mallei to ciprofloxacin is similar to that of B. pseudo-
mallei in vitro. 19 Additionally, B. pseudomallei and B. mallei 
are very similar with respect to their antigenicity, bio-
chemistry and, very likely, in their pathogenicity, particu-
larly with respect to intracellular survival.20 The arguments 
promoting the use of ciprofloxacin for melioidosis would 
therefore apply to glanders but, at the same time, its poor 
performance in clinical studies should also be considered. 
Doxycycline is used alone in the treatment of localized 
melioidosis, and in combination with other antimicrobials5 
for systemic disease, thus it may have some utility as a 
prophylactic or immediate treatment for melioidosis. 
Additionally, like ciprotloxacin it can penetrate intra-
cellularly and is effective against a wide variety of intra-
cellular pathogensY In previous experiments doxycycline 
showed good in vitro activity against B. ma/lei.19 
The efficacies of ciprotloxacin and doxycycline prophy-
laxis and immediate therapy were measured against experi-
mental melioidosis in a murine model and experimental 
glanders in a hamster modeL 
Materials and methods 
Challenge strains, storage and culture 
Both organisms are classified by the Advisory Committee 
on Dangerous Pathogens (ACDP) as category 3 patho-
gens, thus all bacteriological procedures were carried out in 
Class 3 safety cabinets complying with BS5726. 
B. pseudomallei NCTC 4845 and B. mallei ATCC 23344 
were used as the challenge strains for melioidosis and 
glanders, respectively. Both species were stored at -80°C 
on a 'Protect' bead storage system (TSC Ltd, Heywood, 
Lancashire, UK) until required. Challenge cultures and 
counts were grown on nutrient agar or nutrient broth and 
in vitro antimicrobial susceptibility studies were carried out 
using Mueller-Hinton broth. 
Antimicrobial preparation 
For the in vitro experiments, doxycycline (Sigma, Poole, 
UK) and ciprotloxacin (Bayer, Newbury, UK) powders 
were dissolved in de-ionized water to give stock solutions 
of 10 mg/L. Solutions for administration were prepared 
freshly each day by dissolving doxycycline powder in phos-
phate-buffered saline and Ciproxin tablets (Bayer) in de-
ionized water then filter sterilizing the solutions. 
In vitro antimicrobial susceptibility testing 
Bacteria were recovered by placing five to six 'Protect' 
beads into Mueller-Hinton broth (Oxoid, Basingstoke, 
UK). and incubating the cultures statically at 37°C for 24 h 
for B. pseudomallei and 48 h for B. mallei. A microtitre 
plate dilution method in accordance with NCCLS guide-
lines was used.22 Briefly, 96-well microtitre plates contain-
ing each antimicrobial ranging in dilution from 0.063 mg/L 
to 64 mg/L were prepared in advance and stored at - 20°C. 
An inoculum of approximately 5 X 105 cfu/mL (determined 
using McFarland standard 5) in 100 f.!.L was made from 
overnight or 48 h cultures in Mueller-Hinton broth and 
was added to all wells. Plates were incubated at 37°C for 
18-20 h. Because of its slow-growing nature it was neces-
sary to incubate B. mallei plates for 36 h before reading the 
MJC. 
Escherichia coli ATCC 25922 and Staphylococcus 
aureus ATCC 29213 (NCIMB, Aberdeen, UK) were used 
as quality control standards. 
Animal models 
All animal studies were carried out in accordance with the 
Scientific Procedures Act (Animals) 1986 and the Codes 
of Practice for the Housing and Care of Animals used in 
Scientific Procedures, 1989. 
Female Porton outbred mice (bred in-house) and Syrian 
hamsters Lakeview strain (Charles River, Margate, UK) 
were used for experimental melioidosis and glanders, 
respectively. Mice were maintained in cages of five animals, 
and hamsters kept in pairs within a rigid-wall half-suit 
isolator complying to BS5726. They were subjected to a 
12 h light-12 h dark cycle and had free access to food and 
water. Both mice and hamsters were given commercial 
rodent diet, the hamsters were additionally given sup-
plements of sunflower seeds once weekly. 
In previous studies, the nitrile rubber gloves worn with 
the half-suit have provided adequate protection against 
accidental bites from mice during husbandry and pro-
cedures. Although the Lakeview strain of Syrian hamster is 
noted for its docility, industrial puncture-resistant Kevlar 
gloves were worn over the nitrile rubber gloves as a 
precaution when handling infected hamsters. 
Antimicrobial administration 
Both antirnicrobials were used at a dose of 40 mg/kg body 
weight, given twice daily at 12 h intervals by se injection in 
0.1 mL in mice and in 0.2 mL in hamsters according to one 
of three regimens: a prophylaxis regimen, where antimicro-
bials were initiated 48 h before challenge and continued for 
5 days following challenge; an immediate or suppressive 
therapy with antimicrobials administered immediately 
after challenge and continued for 5 days; and a therapeutic 
regimen consisting of a 5 day course of antimicrobials 
starting 24 h after challenge. 
Two further groups of mice challenged with B. pseudo-
mallei were given the prophylaxis regimen as described 
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except that the antibiotics were continued for 10 days after 
challenge. 
Animal challenge and virulence estimation 
The virulence of each pathogen was determined by 
measuring the median le thal dose (MLD), defined as the 
dose required to kill 50% of a small population of animals 
(25-30) calculated according to the method of Reed & 
Muench.23 Antimicrobial efficacy was measured by com-
paring the MLD of treated animals with the MLD in 
untreated controls. 
Challenge cultures of B. pseudomallei and B. mallei were 
prepared by recovering the appropriate 'Protect' beads 
into nutrient broth and incubating for 24 hand 48 h, respec-
tively. 
Mice, in groups of five, were challenged with 0.1 mL of 
serial dilutions of the B. pseudomallei suspension by ip 
injection and observed for 35 days after challenge. Ham-
sters, in groups of four , were challenged with 0.2 mL of 
serial dilutions of B. mallei suspension by the ip route and 
were observed for 23 days after challenge. Eight hamsters 
given immediate treatment with doxycycline and ~ight 
hamsters receiving the doxycycline 24 h therapy regtmen 
were kept for 5 weeks post-challenge for further studies. 
In both animal models, the prophylaxis groups were chal-
lenged approximately midway between antimicrobial 
doses. 
Once the signs and symptoms of each of the infections 
had been characterized, humane end-points were observed 
wherever practicable. Autopsies were carried out in the 
isolator. Organs were bisected and smeared on to nutrient 
agar which was incubated for 24 h or 48 b at 37°C for 
B. pseudomallei and B. mallei, respectively. Identification 
of colonies growing on the plates were confirmed by poly-
merase chain reaction (PCR). 
PCR 
Single colonies were picked into 200 f-LL deionized water 
and boiled for 5 min. DNA was amplified using oligo-
nucleotide primers complementary to the 16S rRNA-
encoding genes of B. pseudomallei and B. mallei. PCR 
amplification was carried out by adding 18 f..LL of the 
following mix: 1 X PCR buffer (Boehringer-Mannheim, 
Mannheim, Germany); 0.2 mM PCR nucleotide mix 
(Boehringer-Mannheim), 180 ng of both 3 ' and 5' o ligo-
nucleotide primers, 5% (v/v) dimethylsulphoxide (DMSO) 
and 0.5 U Taq polymerase (Boebringer-Mannheim) to 
2 f-LL of the colony suspension. Amplification was carried 
out in a Perkin-Eimer thermal cyder (Perkin-Eimer Cetus, 
Warrington, UK) under the following conditions: 30 cycles 
of 95°C for 30 s, sooc for 1 m in and 72°C for 1 m in followed 
by 10 min extension time at 72°C. The PCR products were 
analysed by agarose gel e lectrophoresis and the product 
band visualized by ethidium bromide staining on a 2% 
T AE ( 40 mM Tris-acetate, 1 mM EDT A) gel. 
Results 
In vitro susceptibility 
Both B. pseudomallei 4845 and B. mallei 23344 were 
susceptible or moderately susceptible to ciprotloxacin and 
doxycycline in vitro, with B. pseudomallei inhibited by 
2.0 mg/L ciprofloxacin and 1.0 mg/L doxycycline, and B. 
mallei inhibited by 1.0 mg/L ciprotloxacin and 0.25 mg/L 
doxycycline. 
In vivo susceptibility of B. pseudomallei 
Control mice were challenged intraperitoneally with a 
series of log dilutions ranging from 0.3 cfu to 2.9 X 103 cfu 
B. pseudomallei, which resulted in a disseminated and 
rapidly fatal infection. Animals became sick within 24-48 h 
post-challenge indicated by non-specific symptoms such as 
piloerection, with animals given the higher concentrations 
of B. pseudomallei succumbing within 96 h post-chaLieng~. 
Autopsy revealed very few gross changes although bactena 
could be isolated from liver , spleen, lungs and blood. In 
animals succumbing later there was marked splenomegaly 
and, occasionally, hepatomegaly. Numerous small absces-
ses developed in the spleen and pancreas, and less fre-
quently in the liver. The MLD feLl to 111 cfu within 7 days 
following challenge, decreasing further over the course of 
3 weeks to a final MLD of20 cfu (Figures 1 and 2). Autopsy 
of surviving animals revealed no gross changes and the 
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Figure 1. Survival curve of animals challenged ~ith B. pseudo-
mallei NCTC 4845 by ip injection and trea ted wtth 40 mg/kg bd 
ciproftoxacin given subcutaneously: (i) e, 48 h prophylaxis and 
continued fo r S days post-challenge; (ii) 0, 48 h prophylaxis and 
continued fo r 10 days post-challenge; (iii) .&. , S day therapy 
starting immediately after challenge; (iv) +, S day therapy 
starting 24 h after challenge; (v) • , untreated controls. 
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Figure 2. Survival curve of animals challenged with B. pseudo-
mallei NCTC 4845 by ip injection and treated with 40 mglkg bd 
doxycycline given subcutaneously: (i) e, 48 h prophylaxis and 
continued for 5 days post-challenge; (ii) 0 , 48 h prophylaxis and 
continued for I 0 days post-challenge; (iii) .A, 5 day therapy 
starting immediately after challenge; (iv) +, 5 day therapy 
starting 24 h after challenge; (v) • . untrea ted controls. 
Treated mice were chaiJenged with a series of log dilu-
tions ranging from 180 cfu to 1.8 X 107 cfu B. pseudomallei. 
There was little difference between the efficacy of the two 
antimicrobials. Prophylactic or immediate use of either 
agent protected against 1 x 107 cfu bacteria whilst the anti-
microbial was administered. A few animals relapsed over 
the course of 5 weeks, the most dramatic occurring in the 
doxycycline prophylaxis group, between 11 and 21 days 
post-challenge. At the end of the experiment, however, the 
MLDs were substantially higher than the controls, varying 
between 1.4 x 106 cfu and 4.6 X 106 cfu (Figures 1 and 2). 
Autopsy of survivors revealed splenomegaly in a minority 
of animals although not to the degree observed in the con-
trols, and abscesses were present in some cases. B. pseudo-
mallei could be isolated from the organs of some animals 
including those with no apparent gross changes. 
The therapeutic use of either antimicrobial delayed the 
course of infection, but over 5 weeks provided minimal 
protection wjth the final MLD for ciprofioxacin of 180 cfu 
and for doxycycline of 640 cfu (Figures 1 and 2). 
In vivo susceptibility of B. mallei 
Hamsters were challenged intra peritoneally with a series of 
log dilutions ranging from 0.3 cfu to 2.9 X 107 cfu B. mallei. 
The infection followed a very rapid course characterized by 
distinctive symptoms. Within 24-48 h the animals became 
subdued. and less active. The initial sign of disease was the 
production of a watery discharge from the eyes which 
turned purulent. Later signs included swelling of the limbs 
and palpable crepi tus from the pleura. All fatalities/humane 
end-points occurred within 7 days following infection 
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Figure 3. Survival curve of animals challenged with B. mallei 
ATCC 23344 by ip injection and treated with 40 mglkg bd cipro-
floxaci n given subcutaneously: (i) e , 48 h prophylaxis and con-
tinued for 5 days post-challenge: (ii) A , 5 day therapy starting 
immediately after challenge; (iii) +. 5 day therapy starting 24 h 
after challenge; (iv) • . untreated controls. 
megaly being the dominant feature, occasionally with 
abscesses occurring in both the spleen and the pancreas. 
Prophylactic ciprofloxacin and immediate ciprofloxacin 
treatment protected animals against challenges of up to 
2.9 X 107 cfu for 18 days followed by a sudden relapse 
resulting in the MLDs falling to 4.6 X 105 cfu and 7 X 
104 cfu, respectively, at the end of the experiment (Figure 
3). Autopsy of the fatalities revealed an enlarged spleen 
containing one or two large abscesses. Autopsy of surviving 
animals generally revealed splenomegaly with an occa-
sional abscess from which B. mallei could be isolated. 
When ciprofloxacin therapy was started, eight animals 
given the highest challenges presented with signs of the dis-
ease. Two animals deteriorated despite treatment , three 
animals remained stable with no further deterioration but 
no marked improvement and three animals improved. 
With the exception of the two early cases, animals survived 
challenges of up to 2.9 x 107 cfu for 11 days. R elapses 
occurred between 11 and 18 days initially in those animals 
that had presented with symptomatic disease. Relapses in 
the lower challenge groups occurred from 18 days until the 
end of the experiment and the final MLD at 23 days post-
challenge was 1.6 X 103 cfu (Figure 3). Autopsy fi ndings of 
fatalities and surviving animals were identical to those of 
the other regimens. 
All regimens of doxycycline protected hamsters against 
challenges of up to 2.9 X 107 cfu with no relapses observed 
during the 23 day experimental period. including the 
improvement of eight symptomatic hamsters in the thera-
peutic group. Autopsy of survivors revealed splenomegaly 
in some animals although no B. mallei were recovered. 
Relapse did occur, however, in the animals that were 
retained, with disease reappearing in four of the eight 
hamsters given immediate therapy and one of the animals 
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receiving the therapeutic regimen 28-31 days after chal-
lenge. Autopsies revealed numerous abscesses in the spleen. 
liver and pancreas from which B. mallei was isolated. 
Discussion 
Both B. pseudomal/ei and B. mallei given intraperitoneally 
caused a rapidly invasive and lethal infection in their 
respective animal models reproducing the fulminant sys-
temic infection similar to that occurring in human melio-
idosis and glanders. However, melioidosis and glanders 
have other clinical presentations, including chronic absces-
sic infection or a quiescent infection that may take several 
years to become symptomatic.2·24·25 The animal models 
reported here can be manipulated to reproduce chronic 
infections. In experimental melioidosis, a chronic abscessic 
infection in mice can result in some animals following a 
subcutaneous challenge or by using different murine 
strains such as C57B6 inbreds or Swiss-Webster outbreds 
(unpublished data). B. mallei infection in Balb/C, C57B6 
and Swiss-Webster outbred mice leads to a chronic, non-
lethal disease and chronic, fatal disease with a high MLD in 
Porton outbred mice (unpublished data). In these experi-
ments the acute model was of interest, arguably represent-
ing the 'worse case ' infection, which if prevented by 
ciprofloxacin or doxycycline may also inhibit the estab-
lishment of chronic disease. Furthermore, many cases of 
melioidosis present as acute disease although it may be 
unclear whether the infection is recent or represents an 
acute 'crisis' in patients who may have harboured sub-
clinical infections over a long period of time. 
An interesting fea ture of disease in the animal models 
was the involvement of the pancreas as a site of abscesses, 
particularly noticeable in the hamster model. Both B. pseu-
domallei and B. cepacia have been reported to bind with 
insulin26 which may indicate an abili ty to bind to insulin 
receptors, which would account fo r pancreatic involve-
ment. Furthermore diabetes mellitus is a common predis-
posing factor in human disease, although it is not clear in 
some cases of chronic disease whether B. pseudomallei 
causes the diabetes, or underlying diabetes results in symp-
tomatic disease. Pancreatic disease in human melioidosis, 
however, is rare5 and the significance in glanders is no t 
known. 
Ciprofl oxacin and doxycycline have been reported to be 
inferior to other antimicrobials alone, or in combination. in 
the treatment of melioidosis in humans and are associated 
with high re lapse rates. 7.8 The cl inical fi ndings were 
mirrored by the results observed in the therapy groups in 
these studies even when the experimental strain was sus-
ceptible o r moderately susceptible to each antimicrobial 
and serum and tissue levels of the antimicrobial exceeded 
the in vitro MI C. The MIC of cipro fl oxacin aga inst B. 
pseudomallei 4845 was typical of 50% of the strains of 
B. pseudomallei tested in a wider study carried out in our 
labora tory19 but low compared with o ther studies:'-4 The 
MIC of doxycycline was the highest measured for all of the 
strains of B. pseudomallei tested in the laboratory19 but 
again low when compared with o ther studies.5 Prophylactic 
and immediate post-exposure use of cipro fl oxacin o r doxy-
cycline provided good pro tection. although the oppor-
tunity fo r prophylaxis or immedia te therapy in clinical 
cases would be confined to situations such as laboratory 
accidents o r precautionary immedia te therapy fo llowing 
traumatic injury in endemic areas. The experiments 
showed tha t the 'window of opportunity', i.e. the time 
between exposure to the pathogen and successful preven-
tion of infection with antimicrobials was less than 24 h fol-
lowing challenge. 
Some relapses did occur with the prophylactic and imme-
diate therapy groups, which could be attributed to a number 
of factors; principally, that the duration of the antimicrobial 
administration was short, although clinically the regimen 
would be extended should prophylaxis be used. The com-
parative pharmacokinetics of each antimicrobial relative to 
the in vitro MIC, and the ability of the bacteria to reside in 
privileged intracellular sites which may be inaccessible to 
the antimicrobials would also be important. 
Extending the administration of doxycycline to 10 days 
post-challenge prevented relapse (fatalities still occurred 
during the administration period), but extending the cipro-
floxacin administration increased the number of relapses. 
The pharmacokinetics of doxycycline were superior with 
respect to eradicating B. pseudomallei compared with 
ciprofloxacin. Doxycycline reached a peak serum concen-
tration of 3.7 mg/L, and serum concentration exceeded the 
MIC for 24 h after dosing. The peak splenic concentration 
was 4.1 mg/kg with levels exceeding 1 mg/kg fo r 9 h. The 
peak serum concentra tion of ciprofloxacin was 2.9 mg/L 
with the MIC exceeded for only 1 h after dosing, and peak 
spleen concentration was 10.3 mg/kg remaining above 
2 mg/kg for 3 h (unpublished data). Despite favourable 
pharmacokinetics, B. pseudomallei was recovered from 
surviving animals from a ll groups, including those given the 
antimicrobials for 10 days. The potential fo r relapse posed 
by these surviving bacteria is difficult to predict from these 
experiments. 
Similarities in the pharmacokinetics of the two anti-
microbials in hamsters accounted fo r the differences 
between the efficacies of doxycycline and ciprofloxacin 
against B. mallei. The strain used was sensit ive to both 
antimicrobials. the MIC for ciprofloxacin was typical of 
50% of strains tes ted, although the MIC for doxycycline 
was one of the lowest. Peak serum concentrations of cipro-
floxacin in the hamster were 2.3 mg/L with the MIC 
exceeded for only 1 h. Splenic concentration reached a 
maximum of 20 mg/kg and remained greater than 1 mg/kg 
for at least 12 h. Serum concentrations of doxycycline 
reached 2.6 mg/L and remained above 0.25 mg/L for a t 
lea t 12 h. Splenic concentra tions reached 8.7 mg/kg and 
remained above 0.25 mg/kg fo r a t least 12 h (unpublished 
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data). As glande rs is such a rare disease the pathogenic 
mechanisms and virulence factors of B. mallei have not been 
subject to the same degree of scrutiny as those of B. pseudo-
mallei. The similarities between the two organisms, how-
ever, are likely to extend to intracellular penetration and 
survival which would account for relapse. Given these 
similarities, the clinical experience in the treatment of 
melioidosis serves as a warning to potential antimicrobial 
regimens against glanders, notably that despite favourable 
pharmacokinetics and apparent susceptibi lity, recurrent 
infection may still occur. 
In these experiments, both antimicrobials demonstrated 
some utility for melioidosis prophylaxis, but were unsuit-
able for therapeutic use, reflecting clinical findings . Poten-
tially doxycycline could be used for the prevention and 
treatment of glanders although the problems encountered 
in treating melioidosis may also apply to glanders. 
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Abstract 
Using primers designed from the nucleotide sequences of live insertion elements identified previously in Burkltolderia cepacia, 
the presence of two insertion sequences (IS406 and IS407) was detected in chromosomal DNA isolated from strains of the 
human pathogen Burkho/deria pseudomal/ei. The IS407 homologue was cloned from B. pseudomal/ei NCTC 4845 and 
nucleotide sequenced to confirm its identity and degree of homology with B. cepacia IS407. A PCR amplification product from 
B. pseudomal/ei NCTC 4845 DNA provided an IS407 probe which was used to determine, by Southern blotting, the number 
and location of copies of IS407 in ten st rains of B. pseudomallei a nd four representatives from three of the live genomovars of 
B. cepacia. © 1998 Published by Elsevier Science B.Y. 
Key ,.ords: Burkholderia pseudomal/ei: Burkltolderia cepacia; Insertion sequence; Detection; Strain variation 
I. Introduction 
Burkholderia cepacia and BurkJwlderia pseudomal-
lei were formally considered to belong to the genus 
Pseudomonas in the y-subclass of the proteobacteria. 
More recently they were re-assigned to the ~-subclass 
of the proteobacteria on the basis of ribosomal ribo-
nucleotide gene sequence data, and other phenotypic 
characteristics. On the basis of the 16S rRNA se-
quence comparisons they were moved into the sepa-
rate genus Burkholderia [1]. New molecula r taxo-
nomic evidence has revealed that environmental 
and clinical isolates presently identified as B. cepacia 
• Corresponding author. Tel. : +44 (1980) 613518; 
Fax : +44 ( 1980) 613284. 
comprise at least five distinct species or genomovars. 
Genomovars 11 and V have recently been renamed 
B. muliivorans and B. vietnamiensis respectively [2]. 
B. cepacia is described as an opportunistic pathogen 
of immunocompromised hosts, pa rticularly those 
with chronic granulomatous disease and cystic fibro-
sis [3]. Although B. cepacia is genera lly considered 
to be ubiquitous and non-pathogenic, culture of 
B. cepacia from the environment is surprisingly diffi-
cult (4] and virulent, multiresistant epidemic strains 
of B. cepacia, particula rly isolates such as J23 15 and 
other genomovar I Il strains, are a major concern to 
individuals with cystic fibrosis [3]. 
B. pseudomallei is the causati ve agent of melioido-
sis and is particularly noted for its ability to cause 
either an acute, often fatal, septicaemia [5.6] ; or re-
0378·10971981$19.00 1998 Published by Elscvicr Science B. V. All rights reserved. 
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maining dormant in the body for many years appar-
ently asymptomatically, yet retaining its ability to 
flare into an acute septicaemia a t any time [7 10]. 
As with B. cepacia, B. pseudomallei taxonomy is still 
in the process of being established and a new avir-
ulen t biotype of this organism has only recently been 
described [ 11). No vaccine ex ists for either of these 
o rgani sms a nd treatment with antimicrobials is pro-
tracted for both diseases because of the natural re-
sistance of both B. pseudomallei and B. cepacia to 
many of the commonly used an tibiotics. Although 
B. pseudonwllei and B. cepacia cause very different 
diseases in man , they are nevertheless taxonomically 
closely related. 
Insertion sequences (IS) have been defined as 'ge-
netic entities which are capable of inserting as dis-
crete, non-permuted DNA segments at many differ-
ent sites in prokaryotic genomes' [12). Their small 
size means that their structura l, regulatory a nd trans-
position genes are well organised and may even over-
lap. rs elements usually integrate into the genome by 
mechanisms essentially independent of DNA se-
quence homology [I 3] and are known to inactivate 
not only the gene into which they have inserted but 
also genes downstream in the same operon. The plas-
ticity of the B. cepacia genome is now well estab-
lished [14] and much of this plasticity has been at-
tributed to the high number and diversity of 
insertion sequences present in the genome, and the 
presence of multiple copies of many of the elements. 
It has been suggested that the biological function of 
insertion sequences, which lack a phenotypic mani-
festation , is the genera tion of a genetic diversity that 
helps drive evolution and that the capacity to intro-
duce a complex regulatory function in a single muta-
tional step is a feature that clearly would increase the 
evolutionary potential of any cell containing such 
elements [ 15]. This research may indicate that the 
genome of B. pseudomal/ei also has the potential to 
rearrange and evolve in this manner. No IS elements 
have previously been identified in B. pseudomal/ei. 
2. Materials and methods 
2. 1. Bac/erial Sfrains and cul!llre 
Escherichia coli J M I 09 (Stra tagene L TO. U K); B. 
pseudomallei NCTC 4845. 708A and E38 (M icrobi-
ology culture collectio n. C BD. Porton Down) 204, 
576. E25, E27. E82 and E8 (courtesy of T. Pitt, 
PH LS. Colindale Avenue, Lo ndo n ). B. cepacia 
J231 5 (Edinburgh/Toronto epidemic st ra in [ 16]. ge-
nomovar Ill ), C l964 (Edinburgh cyst ic fibrosis iso-
late, genomovar I. courtesy of J. G o\'an, Uni,·ersity 
Ed inburgh, U K). Cl 576 (Glasgow cystic fibrosis iso-
la te, epidemic strain, described by Whiteford et al. 
[17]. genomovar 11 , recently renamed B. mul1irorans 
[2]) and C 1962 (non-cystic fibrosi s isolate from a 
brain abscess [18]. genomovar 11 , courtesy of J. Go-
van. University Edinburgh, UK). All organisms were 
cu ltured on LB medium. 
2.2. PCR 
All PCR reactions were performed in a Perkin 
Elmer Cetus Ltd. GeneAmp PCR system 9600 
(Buckinghamshire, UK) according to manufacturer's 
instructions. Primer pairs and reaction conditions 
used for the amplification of IS elements were de-
signed by Tyler et al. [19). 
2.3. Standard genelic 1eclmiques 
Chromosomal DNA was prepared by centri fuging 
30 ml of a 12 h broth cu lture at 3000 X g for I 0 min. 
The pellet was resuspended in 15 ml of lysing solu-
tion (10 mM NaCI, 20 mM Tris-HCI (pH 8.0). I mM 
EDT A and 0.5% (w/v) SOS) containing proteinase K 
a t a fina l concentration of 100 J.lg/ml and incubated 
for 15 h at 50°C. The lysate was washed with an 
equal volume of phenol :chloroform :isoamyl alcohol 
(25 :24: I) with centrifugation at 5000 rpm to sepa-
ra te the phases. The top phase was transferred to a 
separate tube and the DNA precipitated by the ad-
dition of 2 volumes of ice-cold 95% ethanol. The 
DNA was spoiled on to a glass rod and transferred 
to a suitable volume of TE buffer (10 mM Tris-HCI, 
I mM EDT A pH 8.0). 
Chromosomal DNA was prepared from each of 
the bacterial species and digested with Bgnt restric-
tion endonuclease a nd with BamHI a nd Hindlll re-
stricti on endonucleases. None of these enzymes cuts 
within the B. cepacia IS407 encoding DNA. Diges-
tion with restriction enzymes and ligations were per-
formed as described by Sambroo k et al. [20). Di-
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gested chromosomal D A run on a 0.7'X. TAE (40 
mM Tris-acetate. pH 8.3, I mM EDTA) aga rose gel 
was transferred onto a positively charged nylon 
membrane (Bot:h ringer Mannheim. UK) by capillary 
transfer as described by Southern [11]. Specific e-
quences were detected using a dioxygenin labelled 
IS407 PCR product probe, produced according to 
ma nufactu rer' instructions (PCR DIG labelling 
mix, Boehringer Mannheim. UK). 
2. -1. Nucleol ide seque11cing 
Nucleotide sequencing was performed using an au-
tomated DNA seq uencer (Model 373A, Applied Bio-
sy tems Ltd .. UK) according to manufacturer's 
instructions. The gels were analysed using the 373A 
sequencing software supplied by Applied Bio-
systems Ltd .. U K. All sequence data were obtained 
in triplicate, in both the 5'-3' and the 3'-5' direc-
tion. 
3. Results and di cussion 
3.1. ldelll(/icrlliOIT rl !S elements in B. pseudoma//ei 
The PCR was used to determine whether IS402, 
406, IS407. IS408 or IS 1356 elements, isolated pre-
viously from B. cepacia [ 19], could be detected in 
D A isolated from strains of B. pseudoma//ei. The 
insertion clement IS406 could be amplified from all 
strains of B. cepacia tested: however, it could no t be 
detected in two of the ten strains of B. pseudonw//ei 
(E27 and E82). Similarly, IS407 could not be ampli-
fied from the E27 and E82 strains of B. pseudoma//ei, 
although additionally it could not be amplified from 
tWO out of rour B. cepacia strains tested (Table I). 
The apparent absence of IS407 f'rom the E27 and 
E82 trains of B. pseudolllallei, both of which are 
considered to be avirulent in man, is pa rt icularly 
interesting in light of their recent differentiation 
from virulent B. p.1eudonw//ei strains into a new bio-
type on the basis of an a rabinose assimilat ion phe-
notype [11]. The two strains of B. cepacia which 
contained IS407 (C 1576 and J2315) have been asso-
ciated with epidemic outbreak [16, 17]. IS402, IS408 
and IS1356 (which ha~ also been as ociated with 
epidemic ·trains of B. cepacia [19]) were not ampli-
1kb 
500bp 
Fig. I. PCR or chromosomal DNA rrom strams or B. 1111111<'1. B. 
p.wmtlomallet and B. C<'pacw using primers designed agamst 
IS407. 
tied from the ex tracted DNA of any of the B. pseu-
dolllallei strain which were tested. The question of 
whether these two Burkholderia strains share IS406 
and IS407 by horizontal gene transfer, or whether 
they descend from a single microbia l ancestor [22), 
is an impo rtan t one considering the currenL deba te 
on the human haza rds and ecological consequences 
of using strains belonging to B. cepacia genomovar V 
(B. viemanriensis) as soil decontaminants and agricul-
tural biopesticides [3). 
3.2. Nucleo lide sequence of IS elements 
The PCR products (Fig. I) from the amplification 
of the IS407 elements from B. pseudonw//ei CTC 
Table I 
The PCR WitS used to determine the prescnc~ or ab;cncc or 
IS406 and IS407 rrom strains or B. plt•utlonwll<'i and reprcscnta-
ti \'CS rrom B. 1'1'/)IICill 
Stram IS406 IS407 
B. pl<'lltlunwiiPI CTC 4845 + + 
B. pl<'llliumall<'t 708A + + 
B. p.ll'llt!OIIIIIIIl't E38 + + 
B. pseudonwllei MAL6 + + 
B. /1\l'tlllumo//vl }Q.j + + 
8. pseudumallt•t 576 + + 
8. psvutlomallei E25 + + 
B. plt•utlumallel E27 
B. p.lemlomal/,•t E82 
B. pl'l! llliOIIWIIt•t E8 + + 
B. c<'pacw Cl962 (gcnomovar 11) + 
8. t·epada Cl964 (gcnomontr I) + 
B. ct'pada Cl576 tgcnomova r 11 ) + + 
B. cepada 1231 5 (gcnomovar Il l) + + 
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GTATGCCGGTCAAGGAACTGTGCAGGAAGCACG-GGTTCAGTGACGCGTCGTTCT 
: : : : : : : : : : : : : : : : :A: : : : : : : : : : AGCAT: : : : : : : : : : : : : : : : : : : : : : 
::::::::: :: ::::::::::::::::::: : : C:::::::::: :T:::::::::: 
ACACTTGGCGCGCAAAGTTCGGTGGCATGGAAGTCTCGGAAGCCCGCCGGCTCAA 
: : :·: C: : : : : : : : G: : : : : : : : C: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
::::::::: :T: :G::::::: :C: : ::::: :G:::::::::::: : :::::::::: 
orf3 
GGACCTCGAGGTGGAGAATGCCCGGCTGAAGAAACTGCTGGCCGAAGCAATGCTC 
: : : : : : : : : : : : : : : : : : : : : : : :A: : : : : : : : : : : :A: : : : : : : : : : : : : . : : : : 
:A:::::::::::::::::::·::::::::::::::: :A:::::::::::::: ·::: 
orf4 
GATATGGAAGCGTTGAAGGTCGTCGTCAAGGGAAAGCCCTGAGCCCGCAAGCCAA 
::::::::::::::::::: :T:::::::::::: :·::: :T:::::::::::::::: 
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : ·: : : : 
ACGCGAGGCAGTGTCGGCGATTCGGGAGAAGGTCAACATCTCCGAGCGCCGCGCC 
: : ·: .: : :A: : : : : : : T: : : : : : : ·: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : 
::::::A:::: :A:£··:::::·'::::: :G::::: :-::: : ::::::::::::: : ·::::: 
orf2 
TGCCGGCTTGTCGGGCTTTCTCGCAGCGTGCTGCATTACGACGCGAAGCCAGACC 
: : ·:··: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : G: : : : 
: :-=!:: : : : : : : : : : : : : : : : :_ ~ - : : : : : : : : : : : : ·:·: : : : : : : : : : : : : : : : : ~ : : : 
orf3 ~ 
ACGAGAATGAGGTGCTAGCGGCGCGTCTGGTGGAGTTGGCACACGAACGTCGTCG 
: : : : A: : : : : : : : : : : C : : : : :-: : : : : : : : : : : A : : : : : : :. G : : : : : : : : : : . : : : : 






:A:·: : : : : :. : : : : : : : C: : : : : : : : : : : : : : : : : : : : : : : : : : : : ,: : : : : : ~: - ; : : 
:A:::::::::::::::::::·:::::: :A::::::·::::::::::::: .-: ::: ·:::: 
.. _l ?616 CACAAGCGCATCTATCGCC'J'9TACCGTGAGGCAGGGCTGGCTGTGCGGCGCyGTC : 
·:-:·• 48.45 '' : :"' :'""::::::::::::::::: f:::: :···:, ::::::A:::::"-::::::··:· :::: _ : : : : ~: '{: 
J2 315 : : ': : : : :·: : : : : : : : : : : : : -: : : : : : : : :A: : :A: : : : : : : : : : : : : : : : : ·:"' : : : 
orfl 
"1761"6 GCi.AGCGCCAGGGTGTAATGATTGAGCGCGAGCAACTGGCATTGCCGGGCGCGCC 
4 84 5 c: ·= : : : : : : : c: : c: : c: : : ·:··: : : : : : : : : : : :·: : : : : : : : : : : ·: ·= : : : : : :A.: : 
· J2 315 : : ·: : : : : : : : C: : C: : : : : : ::; : : :A: : : : : : : : : : : : : : : : : : : : : : : : :·: C: : 
orf2 
·· 17"if6 cAACGAGGTGTGGTCAATCGATTTCGTGATGGATGCGcTTTCCAACGGCCGGCGC • 
4845 · ::'::::A:::::::::::::·':·::::::: :::::·::::: :'""::::·! i ': :"f : : ·: ·£:::: 
J2 315 : .: : : : :A: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : "! : : : : ~: : : : 
.. 
Fig. 2. Sequence data of the IS407 sequences from B. pseudomal/ei NCTC 4845, B. cepacia 12315 and the published sequence from B. ce-
pacia A TCC 17616. 
4845 and B. cepacia J23 15 were sequenced using the 
amplification primers as sequencing p rimers. The nu-
cleotide sequence showed between 95.7% identity (B. 
cepacia 12315) and 95.0% identity (B. pseudoma/lei 
NCTC 4845) with the published sequence of IS407 
isolated from B. cepacia 17616 (Genbank NID 
G 151305) (Fig. 2). The sequences of the IS407 ho-
mo1ogs from B. pseudomallei NCTC 4845, B. cepacia 
A TCC 1761 6 and B. cepacia 123 15 indicate hetero-
geneity of IS407. 
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Fig. 3. Southern blot of strains of B. pseudomollei and B. cepacia digested with Bgnl using an IS407 probe. 
3.3. Srrain idenrification by Sourhern blotting 
A Southern blot using labelled IS407 as a probe 
was used to determine the number and location of 
copies of the IS in each bacterial chromosome (Figs. 
3 and 4). This probe showed clearly defined bands 
and the patterns obtained could be used to distin-
guish one strain from another. Using DNA digested 
with two separate restriction endonucleases demon-
strated that the number of lS407 elements present 
within the genomes of different bacterial strains 











ranged between 2 and 4 for the B. pseudomallei 
strains, and between 8 and 9 for the strains of B. 
cepacia tested. 
The difference in intensity seen between some of 
the bands in the Southern blot cannot easily be ex-
plained. It could suggest that there are differences in 
the sequences between copies of !S407 with a ge-
nome, or it may suggest that more than one copy 
of the insertion element lies on each restriction frag-
ment. The use of two separate restriction endonu-
cleases did not resolve this issue ; although it has 






















Fig. 4. So uthern blot of strains o f B pseudomallei and B. cepacia digested with BamHI and Hind ill usmg an IS407 probe. 
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ces can be present as multiple, but non-identica l cop-
ies wi thin a genome [1 5). Interestingly. the two 
strains of B. pseudonwllei which were negative for 
both IS406 and IS407 by PCR showed extremely 
fa int bands present by Southern blot using the 
IS407 probe. This could suggest tha t the IS407 probe 
is binding to a fragment of DNA which has some 
identity to IS407 - perhaps even a distant relative of 
this insertion element. The two strains of B. cepacia 
wh ich were nega tive for IS407 by PCR were also 
clea rly negative by Southern blot. 
Although insertion of either IS406 or IS407 into a 
gene would effectively interrupt the function of that 
gene, both IS elements have been shown to contain 
an outward facing o70 like promoter [14,23). This 
may serve to increase the expression of genes down-
stream of the site into which the IS has inserted . 
As a result of this work, B. pseudomal/ei has now 
been shown to contain mobile genetic elements. 
These insertion sequences may serve a role in the 
genetic diversity of this species, as they do for the 
B. cepacia species, perhaps by increasing the level of 
expression of genes downstream of their insertion 
site, or perhaps by direct insertional inactivat ion. 
The incidence of insertion sequences across the B. 
pseudomal/ei species, as well as their diversity and 
locations, would make interesting topics for the fu-
ture, enabling a greater understanding of this species. 
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Conditions were defined for the successful transfor-
mation of the human pathogen Burkholckria pseu-
domallei 4845 by electroporation, using the incQ plas-
mid pKT230. We have obtained frequencies of up to 8 
X 103 transformants per microgram plasmid DNA with 
freshly prepared electrocompetent B. pseudomallei. The 
method also allows for easy and reproducible produc-
tion of frozen cell suspensions which can produce effi-
ciencies up to 2.5 x lQll transform.ants per microgram of 
plasmid DNA. Kanamycin had to be added to the culture 
growth medium at a minimum concentration of 20 p.g 
ml- 1 and a maximum concentration of 50 p.g ml- 1 for the 
bacteria to become electrocompetent. Bacteria grown in 
medium containing a final concentration of 30 p.g ml- 1 
kanamycin produced the highest numbers of trans-
formants, although the transformation frequency at this 
concentration was not as efficient as that at 50 p.g ml- 1• 
Electron microscopy indicated that the kanamycin af-
fects the integrity of the bacterial outer membrane, 
which becomes loose and wrinkled in appearance. The 
electrocompetence does not result in a permanent mor-
phological change. c 1996 Academic Press, Inc. 
Burkholderia pseudomallei is a human pathogen en-
demic in areas 20° north and 20° south of the equator. 
It causes an acute, often fatal , septicemia, or it remains 
dormant in the body for many years while retaining its 
ability to cause an acute septicemia at any time (1 -
4). No vaccine exists for the disease melioidosis and 
treatment is protracted because of the natural resis-
tance of the bacterium to many of the commonly used 
antibiotics. Research on pathogenesis has been ham-
pered by inefficient chemical transformation methods 
which yield up to 102 transformants per microgram of 
1 To whom correspondence should be addressed at Microbiology, 
Chemical and Biological Defence Establishment, Porton Down, Salis-
bury, Wiltshire, SP40JQ UK. Fax: 01980-613284. 
0003-2697/96 $18.00 
Copyright «:> 1996 by Academic Press, Inc. 
All rights of reproduction in any form reserved. 
DNA (5, 6). Electroporation has been used to transform 
the closely related organisms Pseudomonas putida and 
Ps. aeruginosa at frequencies of up to 5.8 X 108 or 9.0 
x 104 transformants J.Lg- 1 DNA (7). An efficient electro-
poration method for B. pseudomallei, which could be 
used for genetic analysis of this pathoi&Jl, has been 
developed. 
MATERIALS AND METHODS 
B. pseudomallei NCTC4845 was used for all the elec-
troporation experiments. Plasmid pKT230 (incQ, 
RSF1010 origin of r eplication, Km', Smr, mob+, 11.9 
kb; 8), is a broad-host-range vector and was provided 
by C. Winstanley, University of Liverpool, United 
Kingdom. Plasmid DNA was isolated from an Esche-
richia coli JM101 using QIAGEN-tip 500 maxi tips (Qi-
agen Ltd., Dorking, UK). B. pseudomallei cells were 
grown in Luria broth (L-broth; 9) without antibiotic, 
or in L-broth supplemented with kanamycin at final 
concentrations ranging between 10 and 50 J.Lg rnl- 1. 
Transformants were selected on Luria broth agar (L-
agar) supplemented with kanamycin (650 J.Lg ml- 1) . 
Preparation of the bacterial cells for electroporation . 
Fifty milliliters ofL-broth was inoculated with B. p seu-
domallei NCTC4845 and incubated for 18 h at 37°C 
with orbital shaking at 150 rpm. Two hundred microli-
ters of this suspension was used to inoculate 250-ml 
flasks containing 100 ml ofL-broth supplemented with 
kanamycin (10 to 50 J.Lg ml- 1 final concentration). The 
cultures were incubated as described above for 18 h or 
until the optical density (600 nm) was between 1.0 and 
1.3. The culture was chilled on ice for 15 min and then 
centrifuged at 3500g for 15 min at 4°C. The pellet was 
gently resuspended in an equal volume of ice-cold 10% 
(w/v) glycerol washing solution and then recentrifuged. 
The washing stage was repeated twice and th e cell pel-
let finally resuspended in 700 J.LI of ice-cold washing 
solution, to a fina l volume of 1.0 ml. The final bacterial 
suspensions were either incuba ted on ice prior to elec-
73 
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FIG. 1. The effect of field strength and kanamycin concentration 
on the numbers of transformants of B. pseudomallei NCTC4845 with 
plasmid pKT230. Bacterial cells (40 J.d) were mixed with 1 JLI of 
plasmid DNA (150 ng J.Ll - 1) in a precooled electroporation cuvette 
(0.2-cm gap; Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). 
Electroporation was performed with a Gene Pulser (Bio-Rad), set to 
discharge a 25-J.tF capacitor through the bacterial cell sample. Initial 
voltages of between 10 and 25 kV (representing field strengths of 
between 5 and 12.5 kV cm- 1) were applied, in conjunction with a 
pulse controller unit (Bio-Rad) set at either 200 or 400 A (predicted 
time constants of 5 and 10 ms, respectively). Immediately after elec-
troporation 900 J.tl of ice-cold sac broth (9) was added. The cells 
were incubated for 1 h at 37•c with orbital shaking at 150 rpm and 
then plated onto L-agar supplemented with kanamycin. Colonies 
were counted after 3 days incubation at 37•c. 
troporation or aliquoted into 50-J . tl volumes and stored 
at - 70°C until use. 
RESULTS 
When B. pseudomallei was cultured in L-broth the 
cell suspension became viscous during washing and 
concentration steps and could not be transformed using 
plasmid pKT230. Frozen and thawed suspensions of 
cells grown in media supplemented with kanamycin at 
final concentrations between 20 and 50 J.Lg ml- 1 could 
be transformed with plasmid pKT230 (Fig. 1). When 
the bacteria were grown in media supplemented with 
kanamycin there was a reduction in cell viability which 
was greatest for cells grown in the presence of 50 J.Lg 
ml- 1 kanamycin (Fig. 2). The highest transformation 
efficiency (8053 transformants J.Lg- 1 DNA) was obtained 
when cells had been cultured in the presence of 30 J.Lg 
ml- 1 kanamycin. This corresponded to a 60% drop in 
cell viability after the preparation stage and a further 
60% drop in viability after the pulse had been delivered 
(i.e., less than 20% of the original culture remained 
viable). If transformation frequencies are calculated as 
the total number of viable transformants per micro-
20 25 30 35 40 45 50 
Concentration of kanamycin (11-9 ml-1) 
FIG. 2. The effect of kanamycin concentration on the viability of 
B. pseudomallei NCTC4845 cultures grown in supplemented L-broth 
and prepared for electroporation. 
gram of DNA, divided by the total number of viable 
electroporated cells (10), then the frequency of transfor-
mation for cells cultured in 30 J.Lg ml- 1 kanamycin was 
3.0 X 10-9• By contrast, the calculated frequency of 
transformation for cells prepared in kanamycin at a 
final concentration of 50 J.Lg ml-1 rose to 7.9 x 10- 4• 
However, the actual viability of the culture is so low 
at this point (0.096%) compared to the viable count 
prior to preparation that the number of transform ants 
has been reduced by 2 logs. 
The highest transformation frequencies were ob-
tained with freshly prepared cell suspensions of bac-
teria cultured in the presence of 30 J.Lg ml- 1 kanamy-
cin (Fig. 3), although the relative frequency of 
10000 b.~~b. 100 
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FIG. 3. The numbers of transformants produced, per microgram 
plasmid DNA, between fresh (~) or frozen (0) B. pseudomallei NCTC 
4845 cells grown in L-broth containing kanamycin at 30 J.tg ml - •. 
The figure includes the viability of fresh cells after the pulse has 
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transformation (per viable cell, per microgram of 
DNA) was lower than that achieved with higher con-
centrations of antibiotic. The optimal electroporation 
conctitions represent a compromise between the effi-
ciency of the plasmid transfer and the fragility and 
consequently reduced viability of the electrocompe-
tent cells. Bacteria were transformed, therefore, at a 
range of applied voltages. The highest transformation 
frequency was obtained with an applied voltage of 
1.4-1.8 kV (field strength 7-9 kV cm- 1). The number 
of viable cells decreased with an increase in the ap-
plied voltage (Fig. 3). 
Plasmid preparations were made from B. pseudomal-
lei transformed with plasmid pKT230; Qiagen tips 
were used to confirm the presence of the plasmid. Sev-
eral Clones were passaged on L-agar without kanamy-
cin and also replica plated onto L-agar with kanamycin 
at 650 f,lg rnl - 1. All clones cultured on unsupplemented 
medium became sensitive to kanamycin by the fourth 
passage, indicating that the plasmid was unstable in 
its absence. Plasmid preparations of clones passaged 
repeatedly on unsupplemented mectia using Qiagen 
tips confirmed that the plasmid had been lost. These 
bacteria were then grown without kanamycin and pre-
pared for electroporation but the bacterial suspensions 
became viscous during the preparation stages and 
could not be electroporated. 
Electron microscopic examination of bacteria, grown 
with or without added kanamycin (30 f.lg ml- 1), showed 
a distinctive morphological difference in the cell mem-
brane (Fig. 4). The membrane of bacteria grown in the 
presence of kanamycin was clearly visible and wrinkled 
in appearance. 
DISCUSSION 
Chemical transformation methods for B. pseudomal-
lei have produced up to 102 transformants per micro-
gram of DNA (5, 6). We report here a method for trans-
formation of B. pseudomallei using electroporation. 
The adctition of kanamycin to growth media used for 
bacterial cultme was essential for electroporation but 
there was no permanent change in phenotype, sug-
gesting that the antibiotic caused a transient change 
in cell wall or cell membrane permeability. This pro-
FIG. 4. Transmission electron micrographs of (a) B. pseudomallei 
4845 wild-type organism; (b and cl B. pseudomallet cells grown m 
the presence of kanamycin at 30 J.l.g ml - 1• Arrows on all three pictures 
point to the bacterial outer membranes. Bacteria for transmission 
electron microscopy were cultured as described above. After fixation 
with 0.075 M sodium cacodylate-buffered 3% glutaraldehyde and sec-
ondary fixation with 0.075 M sodium cacodylate-buffered 1% osmium 
tetroxide, bacteria were processed through to an epoxy resin. Sev-
enty-nanometer sections were cut, stamed w1th lead citratc at room 
temperature, and examined on a JEOL 100 CX electron microscope. 
76 MACK AND TITBALL 
posal is supported by electron microscopic analysis of 
cells cultured in the presence of kanamycin. The effect 
of low levels of antibiotics on bacterial cell morphology 
is well documented. For example, /3-lactam antibiotics 
can cause changes in the structure of a bacterial cell 
wall, and polymyxin can affect a change in the cyto-
plasmic membrane (11). In addition, it has been re-
ported that antibiotics, which directly or indirectly pro-
duce an alteration in protein synthesis, can induce a 
gram-negative bacterium to elongate and assume a 
more fusiform morphology. Exposure of Ps. aeruginosa 
to aminoglycosides has been reported to result in a 
gradual disruption of cytoplasmic integrity and subse-
quently of its function in a series of characteristic alter-
ations which eventually result in cell lysis (12). The 
use of an antibiotic to induce a physical state suitable 
for electrotransformation has been reported for the ac-
tinomycete Rhodococcus rhodochrous, using penicillin 
G (13). What influence the dissociation of the bacterial 
cell membrane has on the capsule of the organism is 
unknown, but it is possible that it is a change in the 
capsule of the organism, caused by the alteration to 
the outer cell membrane, that is facilitating successful 
electrotransformation. This is the first report of the use 
of kanamycin to enhance the transformation of bacte-
rial cells and this technique may be applicable to other 
bacterial species which have previously proved to be 
refractory to transformation. 
Up to 8 X 103 transformants per microgram of trans-
forming DNA was attainable using freshly prepared 
suspensions of B. pseudomallei. Unlike Ps. aeruginosa 
(7), transformation frequencies were not improved by 
increasing the applied voltage above 1.6 kV, possibly 
because of the fragile state induced by the kanamycin. 
The transformation frequencies which are now achiev-
able with B. pseudomallei mean that techniques such 
as transposon mutagenesis and insertional inactiva-
tion of genes are now feasible. Such stuclies may add 
significantly to our understanding of this pathogen. 
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